##fileformat=VCFv4.0
##fileDate=20140603
##source=PharmGKB
##INFO=<ID=PGKB_INDEX,Number=1,Type=Integer,Description="Number of PharmGKB entries associated">
##INFO=<ID=PGKB_GENE,Number=.,Type=String,Description="Gene associated with drug response. HGNC gene symbol, followed by unique PharmGKB identifier for gene in parentheses">
##INFO=<ID=PGKB_DRUG,Number=.,Type=String,Description="Drug or Drugs associated with variant">
##INFO=<ID=PGKB_TYPE,Number=.,Type=String,Description="Type of variant effect associated with drug">
##INFO=<ID=PGKB_EVIDENCE,Number=.,Type=String,Description="Level of evidence for association: 1A=Very High, 1B=High, 2A=Medium-High, 2B=Medium, 3=Low, 4=Very Low">
##INFO=<ID=PGKB_DISEASE,Number=.,Type=String,Description="Associated disease phenotype, where applicable.">
##INFO=<ID=PGKB_TEXT,Number=.,Type=String,Description="Annotation text from PharmGKB">
##INFO=<ID=PGKB_RACE,Number=.,Type=String,Description="Race where association was found">
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO
.	.	ABCB1 *1, ABCB1 *2 (PMID: 11503014)	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG="cytarabine_(PA449177)""daunorubicin_(PA449212)""dexrazoxane_(PA449259)",sunitinib_(PA162372840);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760),Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_diplotype_and_acute_myeloid_leukemia_may_have_a_decreased_response_to_cytarabine_daunorubicin_and_dexarazoxane_as_compared_to_the_*1/*2_(PMID:_11503014)_or_the_*2_(PMID:_11503014)/*2_(PMID:_11503014)_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_to_cytarabine_dexarazoxane_or_daunorubicin_in_patients_with_acute_myeloid_leukemia._""*1/*2_(PMID:_11503014):Patients_with_the_*1/*2_diplotype_and_acute_myeloid_leukemia_may_have_a_decreased_response_to_cytarabine_daunorubicin_and_dexarazoxane_as_compared_to_the_*1/*2_(PMID:_11503014)_or_the_*2_(PMID:_11503014)/*2_(PMID:_11503014)._Other_clinical_and_genetic_factors_may_also_influence_to_cytarabine_dexarazoxane_or_daunorubicin_in_patients_with_acute_myeloid_leukemia._""*2_(PMID:_11503014)/*2_(PMID:_11503014):Patients_with_the_*2_(PMID:_11503014)/*2_(PMID:_11503014)_diplotype_and_acute_myeloid_leukemia_may_have_a_decreased_response_to_cytarabine_daunorubicin_and_dexarazoxane_as_compared_to_the_*1/*2_(PMID:_11503014)_or_the_*1/*1_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_to_cytarabine_dexarazoxane_or_daunorubicin_in_patients_with_acute_myeloid_leukemia._","*1/*1:Patients_with_renal_cell_carcinoma_and_the_ABCB1_*1/*1_may_show_an_increased_response_to_sunitinib_as_compared_to_patients_with_the_ABCB1_*2_(PMID:_11503014)/*2_(PMID:_11503014)_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib._""*1/*2_(PMID:_11503014):Patients_with_renal_cell_carcinoma_and_the_ABCB1_*1/*2_(PMID:_11503014)_diplotype_may_show_an_increased_response_to_sunitinib_as_compared_to_patients_with_the_ABCB1_*2_(PMID:_11503014)/*2_(PMID:_11503014)_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib._""*2_(PMID:_11503014)/*2_(PMID:_11503014):Patients_with_renal_cell_carcinoma_and_the_ABCB1_*2_(PMID:_11503014)/*2_(PMID:_11503014)_diplotype_may_show_a_decreased_response_to_sunitinib_as_compared_to_patients_with_any_other_combination_diplotype_including_but_not_limited_to_ABCB1*1/*1_or_ABCB1_*1/*2_(PMID:_11503014)._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib._";PGKB_RACE=Asian,Asian
.	.	ABCB1 *2 (PMID: 11503014)	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=oxaliplatin_(PA131285527),sunitinib_(PA162372840);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT=*2_(PMID:_11503014)/_*2_(PMID:_11503014):Patients_with_the_ABCB1_*2/*2_diplotype_and_colorectal_cancer_may_have_worse_prognosis_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_other_diplotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.,*2_(PMID:_11503014)/*2_(PMID:_11503014):Patients_with_renal_cell_carcinoma_and_two_copies_of_the_*2/*2_haplotype_may_have_a_decreased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_individuals_with_any_other_diplotype_combination._Other_clinical_or_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_taking_sunitinib.;PGKB_RACE=Asian,Asian
.	.	ABCC2 H12, ABCC2 H2	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC2_(PA116);PGKB_DRUG="atorvastatin_(PA448500)""simvastatin_(PA451363)";PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="H12/H12:Patients_with_the_H12/H12_diplotype_who_are_treated_with_simvastatin_or_atorvastatin_may_be_more_likely_to_switch_to_a_different_drug_or_require_a_lower_dose_as_compared_to_patients_with_the_H2/H2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment_and_risk_of_adverse_drug_events._""H2/H12:Patients_with_the_H2/H12_diplotype_who_are_treated_with_simvastatin_or_atorvastatin_may_be_more_likely_to_switch_to_a_different_drug_or_require_a_lower_dose_as_compared_to_patients_with_the_H2/H2_genotype_or_may_be_less_likely_to_switch_to_a_different_drug_or_require_a_lower_dose_as_compared_to_patients_with_the_H12/H12_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment_and_risk_of_adverse_drug_events._""H2/H2:Patients_with_the_H2/H2_diplotype_who_are_treated_with_simvastatin_or_atorvastatin_may_be_less_likely_to_switch_to_a_different_drug_or_require_a_lower_dose_as_compared_to_patients_with_the_H12/H12_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment_and_risk_of_adverse_drug_events._";PGKB_RACE=White
.	.	APOE E2, APOE E3, APOE E4	.	.	.	.	PGKB_INDEX=6;PGKB_GENE=APOE_(PA55),APOE_(PA55),APOE_(PA55),APOE_(PA55),APOE_(PA55),APOE_(PA55);PGKB_DRUG=atorvastatin_(PA448500),pravastatin_(PA451089),"fluvastatin_(PA449688)""rosuvastatin_(PA134308647)",fenofibrate_(PA449594),warfarin_(PA451906),simvastatin_(PA451363);PGKB_TYPE=NR,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,4,3,3,3;PGKB_DISEASE="Acute_coronary_syndrome_(PA165108401)""Hyperlipidemias_(PA444528)",NR,NR,Hypertriglyceridemia_(PA446120),NR,Myocardial_Infarction_(PA445019);PGKB_TEXT="E2/E2:Patients_with_the_E2/E2_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E2/E4_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""E2/E3:Patients_with_the_E2/E3_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E2/E4_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""E2/E4:Patients_with_the_E2/E4_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""E3/E3:Patients_with_the_E3/E3_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""E3/E4:Patients_with_the_E3/E4_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""E4/E4:Patients_with_the_E4/E4_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","E2/E2:Patients_with_the_E2/E2_genotype_who_are_treated_with_pravastatin_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E2/E4_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""E2/E3:Patients_with_the_E2/E3_genotype_who_are_treated_with_pravastatin_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E2/E4_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""E2/E4:Patients_with_the_E2/E4_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""E3/E3:Patients_with_the_E3/E3_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""E3/E4:Patients_with_the_E3/E4_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""E4/E4:Patients_with_the_E4/E4_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","E2/E2:Patients_with_the_E2/E2_genotype_who_are_treated_with_statins_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""E2/E3:Patients_with_the_E2/E3_genotype_who_are_treated_with_statins_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""E2/E4:Patients_with_the_E2/E4_genotype_who_are_treated_with_statins_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""E3/E3:Patients_with_the_E3/E3_genotype_who_are_treated_with_statins_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_E2/E3_or_E2/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""E3/E4:Patients_with_the_E3/E4_genotype_who_are_treated_with_statins_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_E2/E3_or_E2/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""E4/E4:Patients_with_the_E4/E4_genotype_who_are_treated_with_statins_may_have_a_reduced_response_(a_smaller_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_E2/E3_or_E2/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._","E2/E2:Patients_APOE_E2/E2_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_APOE_E3/E3_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""E2/E3:Patients_APOE_E2/E3_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_APOE_E3/E3_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""E2/E4:Patients_APOE_E2/E4_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_APOE_E3/E3_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""E3/E3:Patients_APOE_E3/E3_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_APOE_E2/E2_E2/E3_or_E2/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""E3/E4:Patients_APOE_E3/E4_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_APOE_E2/E2_E2/E3_or_E2/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""E4/E4:Patients_APOE_E4/E4_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_APOE_E2/E2_E2/E3_or_E2/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.","E2/E2:Patients_with_APOE_E2/E2_genotype_may_require_shorter_duration_of_time_to_reach_a_stable_warfarin_dose_as_compared_to_patients_with_genotype_E3/E3_in_African-American_patients._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""E2/E4:Patients_with_APOE_E2/E4_genotype_may_require_shorter_duration_of_time_to_reach_a_stable_warfarin_dose_as_compared_to_patients_with_genotype_E3/E3_in_African-American_patients._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""E3/E3:Patients_with_APOE_E3/E3_genotype_may_require_longer_duration_of_time_to_reach_a_stable_warfarin_dose_as_compared_to_patients_with_genotype_E2/E2_E4/E4_or_E2/E4_in_African-American_patients._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""E4/E4:Patients_with_APOE_E4/E4_genotype_may_require_shorter_duration_of_time_to_reach_a_stable_warfarin_dose_as_compared_to_patients_with_genotype_E3/E3_in_African-American_patients._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.","E2/E2:Patients_with_the_E2/E2_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E2/E4_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""E2/E3:Patients_with_the_E2/E3_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_(increased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E3/E3_E2/E4_E3/E4_or_E4/E4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment.""E2/E4:Patients_with_the_E2/E4_genotype_who_are_treated_with_simvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._However_patients_with_the_E2/E4_diplotype_who_have_had_a_myocardial_infarction_may_have_an_increased_risk_of_mortality_as_compared_to_other_genotypes_which_may_be_mitigated_by_simvastatin_treatment._Therefore_these_patients_may_actually_benefit_more_from_simvastatin_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""E3/E3:Patients_with_the_E3/E3_genotype_who_are_treated_with_simvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""E3/E4:Patients_with_the_E3/E4_genotype_who_are_treated_with_simvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._However_patients_with_the_E3/E4_diplotype_who_have_had_a_myocardial_infarction_may_have_an_increased_risk_of_mortality_as_compared_to_other_genotypes_which_may_be_mitigated_by_simvastatin_treatment._Therefore_these_patients_may_actually_benefit_more_from_simvastatin_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""E4/E4:Patients_with_the_E4/E4_genotype_who_are_treated_with_simvastatin_may_have_a_reduced_response_(decreased_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_E2/E2_or_E2/E3_genotype._However_patients_with_the_E4/E4_diplotype_who_have_had_a_myocardial_infarction_may_have_an_increased_risk_of_mortality_as_compared_to_other_genotypes_which_may_be_mitigated_by_simvastatin_treatment._Therefore_these_patients_may_actually_benefit_more_from_simvastatin_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._";PGKB_RACE=White,White,NR,NR,Black_or_African_American,White
.	.	CYP1A2 *1A, CYP1A2 *1F	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP1A2_(PA27093),CYP1A2_(PA27093);PGKB_DRUG=caffeine_(PA448710),clozapine_(PA449061);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Abortion_Spontaneous_(PA443227),Schizophrenia_(PA447216);PGKB_TEXT="*1A/*1A:Pregnant_women_with_the_*1A/*1A_(CC__slow_metabolizer)_genotype_who_consume_caffeine_may_have_a_decreased_likelihood_of_spontaneous_abortion_as_compared_to_patients_with_the_*1F/*1F_(AA)_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_spontaneous_abortion._""*1A/*1F:Pregnant_women_with_the_*1A/*1F_(AC__slow_metabolizer)_genotype_who_consume_caffeine_may_have_a_decreased_likelihood_of_spontaneous_abortion_as_compared_to_patients_with_the_*1F/*1F_(AA)_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_spontaneous_abortion._""*1F/*1F:Pregnant_women_with_the_*1F/*1F_(AA__fast_metabolizer)_genotype_who_consume_caffeine_may_have_an_increased_likelihood_of_spontaneous_abortion_as_compared_to_patients_with_the_*1A/*1A_(CC)_or_*1A/*1F_(AC)_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_spontaneous_abortion._","*1A/*1A:Patients_with_the_*1A/*1A_genotype_and_schizophrenia_may_have_a_decreased_risk_for_seizures_when_treated_with_clozapine_as_compared_to_patients_with_the_*1F/*1F_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_for_seizures_when_taking_clozapine.""*1A/*1F:Patients_with_the_*1A/*1F_genotype_and_schizophrenia_may_have_a_decreased_risk_for_seizures_when_treated_with_clozapine_as_compared_to_patients_with_the_*1F/*1F_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_for_seizures_when_taking_clozapine.""*1F/*1F:Patients_with_the_*1F/*1F_genotype_and_schizophrenia_may_have_an_increased_risk_for_seizures_when_treated_with_clozapine_as_compared_to_patients_with_the_*1A/*1A_or_*1A/*1F_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_for_seizures_when_taking_clozapine.";PGKB_RACE=NR,NR
.	.	CYP2A6 *10, CYP2A6 *19, CYP2A6 *1A, CYP2A6 *1B1, CYP2A6 *1X2B, CYP2A6 *2, CYP2A6 *20, CYP2A6 *24A, CYP2A6 *26, CYP2A6 *27, CYP2A6 *4A, CYP2A6 *7, CYP2A6 *9A	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="*10:Individuals_with_two_CYP2A6*10_alleles_or_one_CYP2A6*10_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28A/B)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*19:Individuals_with_two_CYP2A6*19_alleles_or_one_CYP2A6*19_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*1A/*1A:Individuals_with_the_CYP2A6*1A/*1A_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_CYP2A6_*1B1/*1B1_or_*1X2B/*1X2B_genotype_and_an_increased_metabolism_of_nicotine_as_compared_to_patients_carrying_any_combination_of_following_alleles_*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""*1B1/*1B1:Individuals_with_the_CYP2A6*1B1/*1B1_genotype_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_*1A/*1A_genotype_and_an_increased_metabolism_of_nicotine_as_compared_to_individuals_carrying_any_combination_of_following_alleles_*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""*1X2B:Individuals_with_one_or_two_CYP2A6*1X2B_alleles_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_CYP2A6_*1A/*1A_genotype_as_well_as_compared_to_individuals_with_one_ora_combination_of_two_of_the_following_alleles:_*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""*2:Individuals_with_two_CYP2A6*2_alleles_or_one_CYP2A6*2_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""*20:Individuals_with_two_CYP2A6*20_alleles_or_one_CYP2A6*20_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""*24A:Individuals_with_two_CYP2A6*24A_alleles_or_one_CYP2A6*24A_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*26:Individuals_with_two_CYP2A6*26_alleles_or_one_CYP2A6*26_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*27:Individuals_with_two_CYP2A6*27_alleles_or_one_CYP2A6*27_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*4A:Individuals_with_two_CYP2A6*4A_alleles_or_one_CYP2A6*4A_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*7:Individuals_with_two_CYP2A6*7_alleles_or_one_CYP2A6*4A_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._""*9A:Individuals_who_are_homozygous_for_CYP2A6*9A_CYP2A6*1A/*9A_heterozygous_or_carry_one_CYP2A6*9A_allele_in_combination_with_another_poor_metabolizer_allele_(*2_*4A_*7_*9A_*10_*19_*20_*24A_*26_*27_or_*28)_may_have_decreased_metabolism_of_nicotine_as_compared_to_individuals_with_the_*1A/*1A_*1B1/*1B1_or_*1X2B/*1X2B_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine._";PGKB_RACE=NR
.	.	CYP2A6 *15, CYP2A6 *1A, CYP2A6 *21, CYP2A6 *22	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=methoxsalen_(PA450433);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*15:Patients_with_the_CYP2A6_*15_allele_may_have_decreased_enzyme_activity_of_CYP2A6_when_treated_with_methoxsalen_as_compared_to_patients_with_CYP2A6*1A_allele._Other_genetic_and_clinical_factors_may_affect_enzyme_activity_of_CYP2A6._""*1A:Patients_with_the_CYP2A6_*1A_genotype_may_have_increased_enzyme_activity_of_CYP2A6_when_treated_with_methoxsalen_as_compared_to_patients_with_the_CYP2A6*15_*21_*22_alleles._Other_genetic_and_clinical_factors_may_affect_enzyme_activity_of_CYP2A6._""*21:Patients_with_the_CYP2A6_*21_allele_may_have_decreased_enzyme_activity_of_CYP2A6_when_treated_with_methoxsalen_as_compared_to_patients_with_CYP2A6*1A_allele._Other_genetic_and_clinical_factors_may_affect_enzyme_activity_of_CYP2A6._""*22:Patients_with_the_CYP2A6_*22_allele_may_have_decreased_enzyme_activity_of_CYP2A6_when_treated_with_methoxsalen_as_compared_to_patients_with_CYP2A6*1A_allele._Other_genetic_and_clinical_factors_may_affect_enzyme_activity_of_CYP2A6._";PGKB_RACE=NR
.	.	CYP2B6 *1, CYP2B6 *18, CYP2B6 *2, CYP2B6 *22, CYP2B6 *4, CYP2B6 *5, CYP2B6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1_+_*1/*2_+_*1/*5_+_*1/*6_+_*2/*5_+_*2/*6_+_*5/*6_+_*6/*6:Patients_with_the_*1/*1_*1/*2_*1/*5_*1/*6_*2/*5_*2/*6_*5/*6_or_*6/*6_genotype_(analyzed_as_a_group)_may_have_decreased_clearance_of_bupropion_resulting_in_decreased_concentrations_of_hydroxybupropion_(a_metabolite_of_bupropion)_as_compared_to_patients_with_the_*1/*4_*2/*4_*4/*5_or_*4/*6_genotype_(analyzed_as_a_group)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_bupropion_or_hydroxybupropion._""*1/*1_+_*1/*5_+_*1/*22_+_*22/*22:Patients_with_the_*1/*1_*1/*5_*1/*22_or_*22/*22_genotype_(analyzed_as_a_group)_may_have_increased_concentrations_of_hydroxybupropion_(a_metabolite_of_bupropion)_as_compared_to_patients_with_the_*1/*6_*1/*18_*6/*6_or_*6/*18_genotype_(analyzed_as_a_group)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_hydroxybupropion._""*1/*4_+_*2/*4_+_*4/*5_+_*4/*6:Patients_with_the_*1/*4_*2/*4_*4/*5_or_*4/*6_genotype_(analyzed_as_a_group)_may_have_increased_clearance_of_bupropion_resulting_in_increased_concentrations_of_hydroxybupropion_(a_metabolite_of_bupropion)_as_compared_to_patients_with_the_*1/*1_*1/*2_*1/*5_*1/*6_*1/*18_*2/*5_*2/*6_*5/*6_*6/*6_or_*6/*18_genotype_(analyzed_as_a_group)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_bupropion_or_hydroxybupropion._""*1/*6_+_*1/*18_+_*6/*6_+_*6/*18:Patients_with_the_*1/*6_*6/*6_*1/*18_or_*6/*18_genotype_(analyzed_as_a_group)_may_have_decreased_concentrations_of_hydroxybupropion_(a_metabolite_of_bupropion)_as_compared_to_patients_with_the_*1/*1_*1/*4_*1/*5_*1/*22_*2/*4_*4/*5_*4/*6_or_*22/*22_genotype_(analyzed_as_a_group)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_hydroxybupropion._";PGKB_RACE=NR
.	.	CYP2B6 *1, CYP2B6 *4, CYP2B6 *5, CYP2B6 *6, CYP2B6 *7	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG=mirtazapine_(PA450522),mirtazapine_(PA450522);PGKB_TYPE=Other,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depression_(PA447278),Depression_(PA447278);PGKB_TEXT="*1/*1:Patients_with_the_CYP2B6_*1/*1_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*1/*4:Patients_with_the_CYP2B6_*1/*4_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*1/*5:Patients_with_the_CYP2B6_*1/*5_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*1/*6:Patients_with_the_CYP2B6_*1/*6_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*1/*7:Patients_with_the_CYP2B6_*1/*7_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*4/*6:Patients_with_the_CYP2B6_*4/*6_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*5/*5:Patients_with_the_CYP2B6_*5/*5_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*5/*6:Patients_with_the_CYP2B6_*5/*6_genotype_and_depression_may_have_decreased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.""*6/*6:Patients_with_the_CYP2B6_*6/*6_genotype_and_depression_may_have_increased_metabolism_of_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*1/*1_*1/*4_*1/*5_*1/*6_*1/*7_*4/*6_*5/*5_or_*5/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_mirtazapine.","*1/*1:Patients_with_the_CYP2B6_*1/*1_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*1/*4:Patients_with_the_CYP2B6_*1/*4_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*1/*5:Patients_with_the_CYP2B6_*1/*5_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*1/*6:Patients_with_the_CYP2B6_*1/*6_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*1/*7:Patients_with_the_CYP2B6_*1/*7_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*4/*6:Patients_with_the_CYP2B6_*4/*6_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*5/*5:Patients_with_the_CYP2B6_*5/*5_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*5/*6:Patients_with_the_CYP2B6_*5/*6_genotype_and_depression_may_have_a_decreased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.""*6/*6:Patients_with_the_CYP2B6_*6/*6_genotype_and_depression_may_have_an_increased_response_when_treated_with_mirtazapine_as_compared_to_patients_with_the_CYP2B6_*1/*1_*1/*4_*1/*5_*1/*6_*1/*7_*4/*6_*5/*5_or_*5/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_mirtazapine.";PGKB_RACE=NR,NR
.	.	CYP2B6 *1, CYP2B6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1:Patients_with_the_CYP2B6_*1_genotype_who_are_CYP2C19*1/*1_carriers_and_undergoing_percutaneous_coronary_intervention_may_have_a_decreased_but_not_absent_risk_for_high_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_CYP2B6_*5_genotype_who_are_CYP2C19*1/*1_carriers._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""*5:Patients_with_the_CYP2B6_*5_genotype_who_are_CYP2C19*1/*1_carriers_and_undergoing_percutaneous_coronary_intervention_may_have_an_increased_risk_for_high_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_CYP2B6_*1_genotype_who_are_CYP2C19*1/*1_carriers._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=White
.	.	CYP2B6 *1, CYP2B6 *6	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG=efavirenz_(PA449441),ketamine_(PA450144),cyclophosphamide_(PA449165),cyclophosphamide_(PA449165);PGKB_TYPE=Other,Metabolism/PK,Metabolism/PK,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=2A,3,3,3;PGKB_DISEASE=HIV_(PA447230),"Neoplasms_(PA445062)""Pain_(PA445208)",Lymphoma_B-Cell_(PA446304),Leukemia_Lymphocytic_Chronic_B-Cell_(PA446169);PGKB_TEXT="*1/*1:Patients_with_the_CYP2B6_*1/*1_genotype_may_have_increased_metabolism_including_clearance_of_efavirenz_in_people_with_HIV_as_compared_to_CYP2B6_*6/*6._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_efavirenz.""*1/*6:Patients_with_the_CYP2B6_*1/*6_genotype_may_have_increased_metabolism_including_clearance_of_efavirenz_in_people_with_HIV_as_compared_to_CYP2B6_*6/*6._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_efavirenz.""*6/*6:Patients_with_the_CYP2B6_*6/*6_genotype_may_have_decreased_metabolism_including_clearance_of_efavirenz_in_people_with_HIV_as_compared_to_CYP2B6_*1/*6_and_*1/*1._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_efavirenz.","*1/*1:Patients_with_the_CYP2B6_*1/*1_diplotype_and_chronic_pain_or_cancer_may_have_increased_clearance_of_ketamine_as_compared_to_patients_with_the_CYP2B6_*1/*6_and_*6/*6_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_clearance_of_ketamine._""*1/*6:Patients_with_the_CYP2B6_*1/*6_diplotype_and_chronic_pain_or_cancer_may_have_decreased_clearance_of_ketamine_as_compared_to_patients_with_the_CYP2B6_*1/*1_diplotype_and_increased_clearance_of_ketamine_as_compared_to_patients_with_the_*6/*6_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_clearance_of_ketamine._""*6/*6:Patients_with_the_CYP2B6_*6/*6_diplotype_and_chronic_pain_or_cancer_may_have_decreased_clearance_of_ketamine_as_compared_to_patients_with_the_CYP2B6_*1/*6_and_*1/*1_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_clearance_of_ketamine._","*1/*1:Children_with_the_CYP2B6*1/*1_diplotype_and_B-cell_non-Hodgkin's_lymphoma_may_have_increased_clearance_of_cyclophosphamide_as_compared_to_children_with_the_*1/*6_or_*6/*6_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clearance_of_cyclophosphamide.""*1/*6:Children_with_the_CYP2B6*1/*6_diplotype_and_B-cell_non-Hodgkin's_lymphoma_may_have_decreased_clearance_of_cyclophosphamide_as_compared_to_children_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clearance_of_cyclophosphamide.""*6/*6:Children_with_the_CYP2B6*6/*6_diplotype_and_B-cell_non-Hodgkin's_lymphoma_may_have_decreased_clearance_of_cyclophosphamide_as_compared_to_children_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clearance_of_cyclophosphamide.","*1/*1:Patients_with_the_*1/*1_genotype_and_chronic_lymphocytic_leukemia_may_be_more_likely_to_achieve_a_complete_response_but_also_more_likely_to_experience_drug_toxicities_when_receiving_combination_cyclophosphamide_and_fludarabine_treatment_as_compared_to_patients_with_the_*1/*6_or_*6/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_drug_toxicity_when_receiving_cyclophosphamide_and_fludarabine_treatment.""*1/*6:Patients_with_the_*1/*6_genotype_and_chronic_lymphocytic_leukemia_may_be_less_likely_to_achieve_a_complete_response_but_also_less_likely_to_experience_drug_toxicities_when_receiving_combination_cyclophosphamide_and_fludarabine_treatment_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_drug_toxicity_when_receiving_cyclophosphamide_and_fludarabine_treatment.""*6/*6:Patients_with_the_*6/*6_genotype_and_chronic_lymphocytic_leukemia_may_be_less_likely_to_achieve_a_complete_response_but_also_less_likely_to_experience_drug_toxicities_when_receiving_combination_cyclophosphamide_and_fludarabine_treatment_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_drug_toxicity_when_receiving_cyclophosphamide_and_fludarabine_treatment.";PGKB_RACE="Asian""Black_or_African_American",White,NR,NR
.	.	CYP2C19 *1, CYP2C19 *10, CYP2C19 *11, CYP2C19 *13, CYP2C19 *14, CYP2C19 *15, CYP2C19 *16, CYP2C19 *18, CYP2C19 *19, CYP2C19 *22, CYP2C19 *23, CYP2C19 *24, CYP2C19 *25, CYP2C19 *26, CYP2C19 *28, CYP2C19 *9	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1:Patients_with_the_CYP2C19*1_allele_may_have_an_increased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*9_*10_*14_*16_*19_*22_*23_*24_*25_*26_alleles._The_CYP2C19*1_allele_was_found_to_have_an_increased_clearance_of_clopidogrel_as_compared_to_CYP2C19*9_*10_*14_*16_*19_*22_*23_*24_*25_*26_during_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*10:Patients_with_the_CYP2C19*10_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*10_allele_was_found_to_have_a_decreased_clearance_of_clopidogrel_as_compared_to_*1_during_in-vitro_characterization._43%_of_the_clearance_ration_of_*1_for_clopidogrel_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*11_+_*13_+_*15_+_*18_:Patients_with_the_CYP2C19*11*13_*15_*18_allele_may_have_similar_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._No_significant_differences_in_the_clearance_of_clopidogrel_were_found_during_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*14:Patients_with_the_CYP2C19*14_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*14_allele_was_found_to_have_a_decreased_clearance_of_clopidogrel_as_compared_to_*1_during_in-vitro_characterization._56%_of_the_clearance_ratio_of_*1_for_clopidogrel_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*16:Patients_with_the_CYP2C19*16_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*16_allele_was_catalytic_inactive_toward_clopidogrel_during_in-vitro_characterization._11%_of_*1_activity_for_the_substrate_clopidogrel_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*19:Patients_with_the_CYP2C19*19_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*19_allele_was_found_to_have_a_decreased_clearance_of_clopidogrel_as_compared_to_*1_during_in-vitro_characterization._40%_of_the_clearance_ratio_of_*1_for_clopidogrel_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*22:Patients_with_the_CYP2C19*22_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*22_allele_was_catalytic_inactive_toward_clopidogrel_during_in-vitro_characterization._8%_of_*1_activity_for_the_substrate_clopidogrel_were_reported.Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*23:Patients_with_the_CYP2C19*23_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*23_allele_was_found_to_have_a_decreased_clearance_of_clopidogrel_as_compared_to_*1_during_in-vitro_characterization._66%_of_the_clearance_ratio_of_*1_for_clopidogrel_were_reported.Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*24:Patients_with_the_CYP2C19*24_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*24_allele._The_CYP2C19*24_allele_was_catalytic_inactive_toward_clopidogrel_during_in-vitro_characterization._No_activity_for_*24_was_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*25:Patients_with_the_CYP2C19*25_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*25_allele_was_found_to_have_a_decreased_clearance_of_clopidogrel_as_compared_to_*1_during_in-vitro_characterization._27%_of_the_clearance_ratio_of_*1_for_clopidogrel_were_reported.Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*26:Patients_with_the_CYP2C19*26_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*26_allele_was_found_to_have_a_decreased_clearance_of_clopidogrel_as_compared_to_*1_during_in-vitro_characterization._65%_of_the_clearance_ratio_of_*1_for_clopidogrel_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*28:Patients_with_the_CYP2C19*28_allele_may_have_similar_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._Although_an_increased_clearance_of_clopidogrel_compared_to_*1_was_found_during_in-vitro_characterization_the_reported_summarized_it_as_no_effect_on_clearance_compared_to_*1._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.""*9:Patients_with_the_CYP2C19*9_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*9_allele_was_catalytic_inactive_toward_clopidogrel_during_in-vitro_characterization._12%_of_*1_activity_for_the_substrate_clopidogrel_were_reported.Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_clopidogrel.";PGKB_RACE=NR
.	.	CYP2C19 *1, CYP2C19 *10, CYP2C19 *11, CYP2C19 *13, CYP2C19 *14, CYP2C19 *15, CYP2C19 *16, CYP2C19 *18, CYP2C19 *19, CYP2C19 *22, CYP2C19 *23, CYP2C19 *24, CYP2C19 *25, CYP2C19 *26, CYP2C19 *5, CYP2C19 *6, CYP2C19 *8, CYP2C19 *9	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=mephenytoin_(PA450373);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2C19*1_allele_may_have_an_increased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*5_*6_*8_*9_*10_*14_*16_*19_*22_*23_*24_*25_*26_alleles._The_CYP2C19*1_allele_was_found_to_have_an_increased_clearance_of_mephenytoin_and_an_increased_catalytic_activity_as_compared_to_CYP2C19*5_*6_*8_*9_*10_*14_*16_*19_*22_*23_*24_*25_*26_during_in-vitro_characterizations._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*10:Patients_with_the_CYP2C19*10_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*10_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_and_decreased_catalytic_activity_of_CYP2C19_as_compared_to_*1_during_several_in-vitro_characterizations._7%_of_the_clearance_ration_of_*1_for_mephenytoin_was_reported_in_one_study_and_several_studies_report_significant_lower_catalytic_activity._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*11_+_*13_+_*15_+_*18:Patients_with_the_CYP2C19*11_*13_*15_*18_allele_may_have_similar_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._No_significant_differences_in_the_clearance_of_mephenytoin_were_found_during_several_in-vitro_characterizations._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*14:Patients_with_the_CYP2C19*14_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*14_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_as_compared_to_*1_during_in-vitro_characterization._65%_of_the_clearance_ratio_of_*1_for_mephenytoin_was_reported_while_a_separate_study_found_no_differences_in_catalytic_activity_compared_to_CYP2C19*1._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*16:Patients_with_the_CYP2C19*16_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*16_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_and_decreased_catalytic_activity_of_CYP2C19_as_compared_to_*1_during_several_in-vitro_characterizations.The_CYP2C19*16_allele_was_catalytic_inactive_toward_mephenytoin_during_one_in-vitro_characterization_with_4%_of_*1_activity_for_the_substrate_mephenytoin._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*19:Patients_with_the_CYP2C19*19_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*19_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_and_decreased_catalytic_activity_as_compared_to_*1_during_several_in-vitro_characterizations._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*22:Patients_with_the_CYP2C19*22_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*22_allele_was_catalytic_inactive_toward_mephenytoin_during_in-vitro_characterization._No_activity_for_the_substrate_mephenytoin_was_reported_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*23:Patients_with_the_CYP2C19*23_allele_may_have_increased_clearance_of_mephenytoin_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*23_allele_was_found_to_have_an_increased_clearance_of_mephenytoin_as_compared_to_*1_during_one_in-vitro_characterization_study._235%_of_the_clearance_ratio_of_*1_for_mephenytoin_was_reported_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*24:Patients_with_the_CYP2C19*24_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*24_allele._The_CYP2C19*24_allele_was_catalytic_inactive_toward_mephenytoin_during_in-vitro_characterization._No_activity_for_*24_was_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*25:Patients_with_the_CYP2C19*25_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*25_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_as_compared_to_*1_during_in-vitro_characterization._36%_of_the_clearance_ratio_of_*1_for_mephenytoin_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*26:Patients_with_the_CYP2C19*26_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*26_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_as_compared_to_*1_during_in-vitro_characterizations._42%_of_the_clearance_ratio_of_*1_for_mephenytoin_was_reported_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*5:Patients_with_the_CYP2C19*5_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*5_allele_was_catalytic_inactive_toward_mephenytoin_during_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*6:Patients_with_the_CYP2C19*6_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*6_allele_was_catalytic_inactive_toward_mephenytoin_during_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*8:Patients_with_the_CYP2C19*8_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*8_allele_was_found_to_have_decreased_activity_of_CYP2C19_as_compared_to_*1_during_several_in-vitro_characterizations._The_CYP2C19*8_allele_was_catalytic_inactive_toward_mephenytoin_during_one_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.""*9:Patients_with_the_CYP2C19*9_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele._The_CYP2C19*9_allele_was_found_to_have_a_decreased_clearance_of_mephenytoin_and_decreased_activity_of_CYP2C19_as_compared_to_*1_during_several_in-vitro_characterizations._The_CYP2C19*9_allele_was_catalytic_inactive_toward_mephenytoin_during_one_in-vitro_characterization._6%_of_*1_activity_for_the_substrate_mephenytoin_were_reported._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_mephenytoin.";PGKB_RACE=NR
.	.	CYP2C19 *1, CYP2C19 *10, CYP2C19 *11, CYP2C19 *13, CYP2C19 *14, CYP2C19 *15, CYP2C19 *16, CYP2C19 *18, CYP2C19 *19, CYP2C19 *26, CYP2C19 *9	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=omeprazole_(PA450704);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1:Patients_with_two_functional_CYP2C19_(*1/*1)_alleles_may_have_increased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*9_*10_*16_or_*29_allele_when_assayed_with_omeprazole._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.""*10:Patients_with_the_CYP2C19*10_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele_when_assayed_with_omeprazole._The_CYP2C19*10_allele_was_found_to_have_a_decreased_clearance_of_omeprazole_and_decreased_catalytic_activity_of_CYP2C19_as_compared_to_*1_during_in-vitro_characterizations._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.""*11_+_*13_+*14_+*15_+*18:Patients_with_the_CYP2C19*11_*13_*14_*15_or_*18_allele_may_have_similar_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele_when_assayed_with_omeprazole._No_significant_differences_in_activity_towards_omeprazole_or_clearance_of_omeprazole_were_found_during_one_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.""*16:Patients_with_the_CYP2C19*16_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele_when_assayed_with_omeprazole._The_CYP2C19*16_allele_was_found_to_have_a_decreased_activity_towards_omeprazole_and_decreased_clearance_of_omeprazole_as_compared_to_*1_during_one_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.""*19:Patients_with_the_CYP2C19*19_allele_may_have_similar_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele_when_assayed_with_omeprazole_but_the_results_are_inclusive._The_CYP2C19*19_allele_was_found_to_have_an_increased_activity_towards_omeprazole_and_no_differences_in_clearance_of_omeprazole_as_compared_to_*1_during_one_in-vitro_characterization_but_no_differences_in_activity_and_a_decreased_clearance_are_found_in_another_report_._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.""*26:Patients_with_the_CYP2C19*26_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele_when_assayed_with_omeprazole._The_CYP2C19*26_allele_was_found_to_have_a_decreased_activity_towards_omeprazole_and_decreased_clearance_of_omeprazole_as_compared_to_*1_during_one_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.""*9:Patients_with_the_CYP2C19*9_allele_may_have_decreased_enzyme_activity_of_CYP2C19_as_compared_to_patients_with_the_CYP2C19*1_allele_when_assayed_with_omeprazole._The_CYP2C19*9_allele_was_found_to_have_a_decreased_activity_towards_omeprazole_and_decreased_clearance_of_omeprazole_as_compared_to_*1_during_one_in-vitro_characterization._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_omeprazole.";PGKB_RACE=NR
.	.	CYP2C19 *1, CYP2C19 *16, CYP2C19 *2	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=methylphenobarbital_(PA450374);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2C19*1/*1_genotype_may_have_increased_metabolism_of_methylphenobarbital_as_compared_to_patients_with_the_*2/*16_genotype._Other_clinical_and_genetic_factors_may_also_affect_metabolism_of_methylphenobarbital.""*2/*16:Patients_with_the_CYP2C19*2/*16_genotype_may_have_decreased_metabolism_of_methylphenobarbital_as_compared_to_patients_with_the_*1/*1_genotype._Other_clinical_and_genetic_factors_may_also_affect_metabolism_of_methylphenobarbital.";PGKB_RACE=Asian
.	.	CYP2C19 *1, CYP2C19 *17, CYP2C19 *2, CYP2C19 *3, CYP2C19 *4	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=1A;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="*1/*1:Patients_with_the_CYP2C19*1/*1_genotype_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_drug_clearance/metabolism_as_compared_to_patients_with_CYP2C19*2_*3_or_*4_allele_and_a_decreased_drug_clearance/metabolism_as_compared_to_patients_with_CYP2C19*1/*17_or_*17/*17_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*1/*17:Patients_with_the_CYP2C19*1/*17_genotype_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_drug_clearance/metabolism_as_compared_to_patients_with_CYP2C19*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*17/*17:Patients_with_the_CYP2C19*17/*17_(rs12248560)_genotype_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_drug_clearance/metabolism_as_compared_to_patients_with_CYP2C19*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*2:Patients_with_the_CYP2C19*2_allele_(rs4244285)_who_are_treated_with_citalopram_or_escitalopram_may_have_a_decreased_drug_clearance/metabolism_and_decreased_tolerance_especially_in_combination_with_another_no_function_allele_(*2_*3_*4_*6_*8)_(poor_metabolizer_phenotype)_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._Contradictory_findings_reported_no_association_of_CYP2C19_genotype_with_tolerance_also_no_association_with_response_or_remission_are_reported._One_study_reported_an_association_of_poor_metabolizers_with_increased_remission_if_tolerant_to_citaolpram._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*3:Patients_with_the_CYP2C19*3_allele_(rs4986893)_who_are_treated_with_citalopram_or_escitalopram_may_have_a_decreased_drug_clearance/metabolism_and_decreased_tolerance_especially_in_combination_with_another_loss-of-function_allele_(*2_*3_*4_*6_*8)_(poor_metabolizer_phenotype)_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._Contradictory_findings_reported_no_association_of_CYP2C19_genotype_with_tolerance_also_no_association_with_response_or_remission_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*4:Patients_with_the_CYP2C19*4_allele_(rs28399504)_who_are_treated_with_citalopram_or_escitalopram_may_have_a_decreased_drug_clearance/metabolism_and_decreased_tolerance_especially_in_combination_with_another_no_function_allele_(*2_*3_*4_*6_*8)_(poor_metabolizer_phenotype)_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._Contradictory_findings_reported_no_association_of_CYP2C19_genotype_with_tolerance_also_no_association_with_response_or_remission_are_reported._One_study_reported_an_association_of_poor_metabolizers_with_increased_remission_if_tolerant_to_citaolpram._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.";PGKB_RACE=NR
.	.	CYP2C19 *1, CYP2C19 *17, CYP2C19 *2, CYP2C19 *3	.	.	.	.	PGKB_INDEX=5;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=imipramine_(PA449969),clomipramine_(PA449048),amitriptyline_(PA448385),lansoprazole_(PA450180),voriconazole_(PA10233);PGKB_TYPE=Other,NR,"Efficacy""Toxicity/ADR","Efficacy""Metabolism/PK",Other;PGKB_EVIDENCE=2A,2A,1A,2A,2A;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),NR,NR,Gastroesophageal_Reflux_(PA444255),Mycoses_(PA445009);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_diplotype_and_major_depressive_disorder_1)_may_have_lower_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_*1/*2_or_*2/*2_diplotype_2)_may_have_increased_metabolism_of_impramine_as_compared_to_patients_with_the_*2/*3_diplotype_3)_and_may_have_higher_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_*1/*17_or_*17/*17_diplotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""*1/*17:Patients_with_the_*1/*17_diplotype_and_major_depressive_disorder_may_have_decreased_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""*1/*2:Patients_with_the_*1/*2_diplotype_and_major_depressive_disorder_may_have_higher_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""*17/*17:Patients_with_the_*17/*17_diplotype_and_major_depressive_disorder_may_have_decreased_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""*2/*2:Patients_with_the_*2/*2_diplotype_and_major_depressive_disorder_may_have_higher_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_*1/*1_diplotype._For_patients_with_the_CYP2C19_poor_metabolizer_phenotype_(e.g._*2/*2)_decreased_imipramine_clearance_and_increased_plasma_concentrations_are_reported_as_compared_to_patients_with_the_*1/*1_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""*2/*3:Patients_with_the_*2/*3_diplotype_and_major_depressive_disorder_may_have_reduced_metabolism_of_imipramine_as_compared_to_patients_with_the_*1/*1_diplotype._For_patients_with_the_CYP2C19_poor_metabolizer_phenotype_(e.g._*2/*3)_decreased_imipramine_clearance_and_increased_plasma_concentrations_are_reported_as_compared_to_patients_with_the_*1/*1_genotype.The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._","*1/*1:Patients_with_the_CYP2C19*1/*1_genotype_may_have_1)_increased_metabolism_of_clomipramine_as_compared_to_patients_with_CYP2C19*2_and_*3_alleles_2)_increased_plasma_levels_of_clomipramine_as_compared_to_patients_with_the_CYP2C19*17/*17_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._""*17/*17:Patients_with_the_CYP2C19*17/*17_genotype_may_have_decreased_plasma_levels_of_clomipramine_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._""*2:Patients_with_the_CYP2C19*2_allele_may_have_decreased_metabolism_of_clomipramine_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._""*3:Patients_with_the_CYP2C19*3_allele_in_combination_with_a_CYP2C19*2_or_*3_allele_may_have_decreased_metabolism_of_clomipramine_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._","*1/*1:Patients_with_the_CYP2C19*1/*1_genotype_who_are_treated_with_amitriptyline_may_have_increased_metabolism_of_amitriptyline_(decreased_amitriptyline_plasma_concentrations_and_increased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_CYP2C19*2_or_*3_alleles_or_decreased_metabolism_of_amitriptyline_(increased_amitriptyline_plasma_concentrations_and_decreased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_CYP2C19*17/*17_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*17/*17:Patients_with_the_CYP2C19*17/*17_(rs12248560)_genotype_who_are_treated_with_amitriptyline_may_have_increased_metabolism_of_amitriptyline_(decreased_amitriptyline_plasma_concentrations_and_increased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_CYP2C19*1/*1._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*2:Patients_with_the_CYP2C19*2_(rs4244285)_allele_who_are_treated_with_amitriptyline_may_have_decreased_metabolism_of_amitriptyline_(increased_amitriptyline_plasma_concentrations_and_decreased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*3:Patients_with_the_CYP2C19*3_(rs4986893)_allele_who_are_treated_with_amitriptyline_may_have_decreased_metabolism_of_amitriptyline_(increased_amitriptyline_plasma_concentrations_and_decreased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_increased_metabolism_of_and_decreased_response_to_lansoprazole_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_or_*2/*3_or_*3/*3_genotype_and_decreased_metabolism_compared_to_those_with_the_*17/*17_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_ultrarapid_metabolizers_:_*17/*17_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_+_*2/*3_+_*3/*3._One_study_was_conducted_in_children._One_study_found_no_significant_association_between_CYP2C19_genotypes_and_metabolism._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_may_have_increased_metabolism_of_and_decreased_response_to_lansoprazole_as_compared_to_patients_with_the_*2/*2_or_*2/*3_or_*3/*3_genotype_and_decreased_metabolism/increased_response_as_compared_to_patients_with_the_*1/*1_genotype_or_who_are_carriers_of_the_*17_allele._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_ultrarapid_metabolizers_:_*17/*17_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_+_*2/*3_or_*3/*3._One_study_was_conducted_in_children._One_study_found_no_significant_association_between_CYP2C19_genotypes_and_metabolism._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_may_have_increased_metabolism_of_and_decreased_response_to_lansoprazole_as_compared_to_patients_with_the_*2/*2_or_*2/*3_or_*3/*3_genotype_and_decreased_metabolism/increased_response_as_compared_to_patients_with_the_*1/*1_genotype_or_who_are_carriers_of_the_*17_allele._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_ultrarapid_metabolizers_:_*17/*17_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_+_*2/*3_or_*3/*3._One_study_was_conducted_in_children._One_study_found_no_significant_association_between_CYP2C19_genotypes_and_metabolism._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.""*17/*17:Patients_with_the_CYP2C19_*17/*17_genotype_(*17_:_rs12248560)_may_have_increased_metabolism_of_lansoprazole_as_compared_to_children_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_may_have_decreased_metabolism_of_and_increased_response_to_lansoprazole_as_compared_to_patients_with_the_*1/*1_*1/*2*1/*3_genotype_or_carriers_of_a_*17_allele._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_ultrarapid_metabolizers_:_*17/*17_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_+_*2/*3_or_*3/*3._One_study_was_conducted_in_children._One_study_found_no_significant_association_between_CYP2C19_genotypes_and_metabolism._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_may_have_decreased_metabolism_of_and_increased_response_to_lansoprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_*_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_ultrarapid_metabolizers_:_*17/*17_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_+_*2/*3_or_*3/*3._One_study_found_no_significant_association_between_CYP2C19_genotypes_and_metabolism._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_may_have_decreased_metabolism_of_and_increased_response_to_lansoprazole_as_compared_to_patients_with_the_*1/*1_*1/*2*1/*3_genotype_or_carriers_of_a_*17_allele._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_ultrarapid_metabolizers_:_*17/*17_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_+_*2/*3_or_*3/*3._One_study_found_no_significant_association_between_CYP2C19_genotypes_and_metabolism._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lansoprazole.","*1/*1:Patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_may_have_increased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*2_or_*1/*3_diplotypes_(intermediate/heterozygous_extensive_metabolizers)_or_the_CYP2C19*2/*2_*3/*3_or_*2/*3_diplotypes_(poor_metabolizers)_or_may_have_decreased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*17_or_*17/*17_diplotypes_(ultrarapid_metabolizers)._Though_several_studies_have_found_no_association_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*1/*17:Patients_with_the_CYP2C19*1/*17_diplotype_may_have_increased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_the_CYP2C19*1/*2_or_*1/*3_diplotypes_(intermediate/heterozygous_extensive_metabolizers)_or_the_CYP2C19*2/*2_*2/*3_or_*3/*3_diplotypes_(poor_metabolizers_or_may_have_decreased_metabolism_as_compared_to_patients_with_the_CYP2C19*17/*17_diplotype_(ultrarapid_metabolizers)._Several_studies_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*1/*2:Patients_with_the_CYP2C19*1/*2_diplotype_may_have_decreased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_or_the_CYP2C19_*1/*17_or_*17/*17_diplotypes_(ultrarapid_metabolizers)_or_may_have_increased_metabolism_as_compared_to_patients_with_the_CYP2C19*2/*2_*3/*3_or_*2/*3_diplotypes_(poor_metabolizers)._Several_studies_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*1/*3:Patients_with_the_CYP2C19*1/*3_diplotype_may_have_decreased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_or_the_CYP2C19_*1/*17_or_*17/*17_diplotypes_(ultrarapid_metabolizers)_or_may_have_increased_metabolism_as_compared_to_patients_with_the_CYP2C19*2/*2_*3/*3_or_*2/*3_diplotypes_(poor_metabolizers)._Several_studies_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*17/*17:Patients_with_the_CYP2C19*17/*17_diplotype_(ultrarapid_metabolizers)_may_have_increased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_CYP2C19*1/*17_diplotype_(ultrarapid_metabolizers)_CYP2C19*1/*2_or_*1/*3_diplotypes_(intermediate/heterozygous_extensive_metabolizers)_or_the_CYP2C19*2/*2_*2/*3_or_*3/*3_diplotypes_(poor_metabolizers)._Though_several_studies_have_found_no_association_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*2/*2:Patients_with_the_CYP2C19*2/*2_diplotype_may_have_decreased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_the_CYP2C19*1/*2_or_*1/*3_diplotypes_(intermediate/heterozygous_extensive_metabolizers)_or_the_CYP2C19*1/*17_or_*17/*17_diplotypes_(ultrarapid_metabolizers)._Though_several_studies_have_found_no_association_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*2/*3:Patients_with_the_CYP2C19*2/*3_diplotype_may_have_decreased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_the_CYP2C19*1/*2_or_*1/*3_diplotypes_(intermediate/heterozygous_extensive_metabolizers)_or_the_CYP2C19*1/*17_or_*17/*17_diplotypes_(ultrarapid_metabolizers)._Though_several_studies_have_found_no_association_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.""*3/*3:Patients_with_the_CYP2C19*3/*3_diplotype_may_have_decreased_metabolism_of_voriconazole_as_compared_to_patients_with_the_CYP2C19*1/*1_diplotype_(extensive_metabolizers)_the_CYP2C19*1/*2_or_*1/*3_diplotypes_(intermediate/heterozygous_extensive_metabolizers)_or_the_CYP2C19*1/*17_or_*17/*17_diplotypes_(ultrarapid_metabolizers)._Though_several_studies_have_found_no_association_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_voriconazole_and_required_dose.";PGKB_RACE=NR,NR,NR,NR,NR
.	.	CYP2C19 *1, CYP2C19 *17, CYP2C19 *2	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=pantoprazole_(PA450774),"aspirin_(PA448497)""clopidogrel_(PA449053)";PGKB_TYPE=Metabolism/PK,"Efficacy""Toxicity/ADR""Metabolism/PK";PGKB_EVIDENCE=3,2B;PGKB_DISEASE=NR,Stroke_(PA447054);PGKB_TEXT="*1/*1:Healthy_individuals_with_the_CYP2C19_*1/*1_genotype_may_have_increased_metabolism_of_pantoprazole_as_shown_by_a_decreased_area_under_the_concentration-time_curve_(AUC)_as_compared_to_individuals_with_the_*1/*2_(*2_:_rs4244285)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_pantoprazole.""*1/*2:Healthy_individuals_with_the_CYP2C19_*1/*2_genotype_may_have_decreased_metabolism_of_pantoprazole_as_shown_by_an_increased_area_under_the_concentration-time_curve_(AUC)_as_compared_to_individuals_with_the_*1/*2_(*2_:_rs4244285)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_pantoprazole.""*17/*17:Healthy_individuals_with_the_CYP2C19_*17/*17_genotype_may_have_increased_metabolism_of_pantoprazole_as_shown_by_clearance_as_compared_to_individuals_with_the_*1/*1_or_*1/*17_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_pantoprazole.","*1/*1:Patients_with_the_*1/*1_diplotype_may_have_a_decreased_incidence_of_hemorrhage_stroke_and_an_over_all_improved_response_to_clopidogrel_and_aspirin_such_as_increased_platelet_reactivity_as_compared_to_patients_with_the_*1/*2_or_*2/*2_diplotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_patient_response_to_clopidogrel_and_aspirin._""*1/*17:Patients_with_the_*1/*17_diplotype_may_have_a_decreased_incidence_of_hemorrhage_stroke_and_an_over_all_improved_response_to_clopidogrel_and_aspirin_such_as_increased_platelet_reactivity_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*2/*2_diplotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_patient_response_to_clopidogrel_and_aspirin._""*1/*2:Patients_with_the_*1/*2_diplotype_may_have_a_decreased_incidence_of_hemorrhage_stroke_and_an_over_all_improved_response_to_clopidogrel_and_aspirin_such_as_increased_platelet_reactivity_as_compared_to_patients_with_the_*2/*2_diplotypes_but_an_increased_incidence_of_hemorrhage_stroke_and_an_over_all_worse_response_as_compared_to_patients_with_the_*1/*1_*1/*17_or_*17/*17_diplotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_patient_response_to_clopidogrel_and_aspirin._""*17/*17:Patients_with_the_*17/*17_diplotype_may_have_a_decreased_incidence_of_hemorrhage_stroke_and_an_over_all_improved_response_to_clopidogrel_and_aspirin_such_as_increased_platelet_reactivity_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*2/*2_diplotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_patient_response_to_clopidogrel_and_aspirin._""*2/*2:Patients_with_the_*2/*2_diplotype_may_have_an_increased_incidence_of_hemorrhage_stroke_and_an_over_all_worse_response_to_clopidogrel_and_aspirin_such_as_decreased_platelet_reactivity_as_compared_to_patients_with_the_*1/*1_*1/*17_*17/*17_*1/*2_diplotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_patient_response_to_clopidogrel_and_aspirin._";PGKB_RACE=White,NR
.	.	CYP2C19 *1, CYP2C19 *2, CYP2C19 *3, CYP2C19 *4, CYP2C19 *5, CYP2C19 *6, CYP2C19 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=1A;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2C19_alleles_(*1/*1):_1)_may_have_increased_metabolism_of_clopidogrel_and_2)_may_have_a_decreased_but_not_absent_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_one_or_two_CYP2C19_loss-of-function_alleles_(*2_*3_*4_*5_*6_*8)._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""*2:Patients_with_CYP2C19*2_(rs4244285)_allele_in_combination_with_another_loss-of-function_allele_(*2_*3_*4_*5_*6_*8)_or_one_functional_allele_(*1)_may_have_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""*3:Patients_with_CYP2C19*3_(rs4986893)_allele_in_combination_with_another_loss-of-function_(*2_*3_*4_*5_*6_*8)_or_one_functional_allele_(*1)_may_have_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""*4:Patients_with_CYP2C19*4_(rs28399504)_allele_in_combination_with_another_loss-of-function_(*2_*3_*4_*5_*6_*8)_or_one_functional_allele_(*1)_may_have_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""*5:Patients_with_CYP2C19*5_(rs56337013)_allele_in_combination_with_another_loss-of-function_(*2_*3_*4_*5)_or_one_functional_allele_(*1)_may_have_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""*6:Patients_with_CYP2C19*6_(rs72552267)_allele_in_combination_with_another_loss-of-function_(*2_*3_*4_*5_*6_*8)_or_one_functional_allele_(*1)_may_have_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""*8:Patients_with_CYP2C19*8_(rs41291556)_allele_in_combination_with_another_loss-of-function_(*2_*3_*4_*5_*6_*8)_or_one_functional_allele_(*1)_may_have_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.";PGKB_RACE=NR
.	.	CYP2C19 *1, CYP2C19 *2, CYP2C19 *3, CYP2C19 *5, CYP2C19 *6, CYP2C19 *7, CYP2C19 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=mephenytoin_(PA450373);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2C19_alleles_(*1/*1)_may_have_increased_metabolism_of_mephenytoin_compared_to_patients_with_*2/*2_*2/*3_*3/*3_*2/5_*2/*6_and_*2/*7_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*2/*2:Patients_with_two_no_function_CYP2C19_alleles_(*2/*2)_(rs4244285)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*2/*3:Patients_with_two_no_function_CYP2C19_alleles_(*2/*3)_(rs4244285/rs4986893)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*2/*5:Patients_with_two_no_function_CYP2C19_alleles_(*2/*5)_(rs4244285/rs56337013)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*2/*6:Patients_with_two_no_function_CYP2C19_alleles_(*2/*6)_(rs4244285/rs72552267)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*2/*7:Patients_with_two_no_function_CYP2C19_alleles_(*2/*7)_(rs4244285/rs72558186)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*2/*8:Patients_with_two_no_function_CYP2C19_alleles_(*2/*8)_(rs4244285/rs41291556)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.""*3/*3:Patients_with_two_no_function_CYP2C19_alleles_(*3/*3)_(rs4986893)_may_have_decreased_metabolism_of_mephenytoin_compared_to_patients_with_*1/*1_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_metabolism_of_mephenytoin.";PGKB_RACE=NR
.	.	CYP2C19 *1, CYP2C19 *2, CYP2C19 *3	.	.	.	.	PGKB_INDEX=14;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=pantoprazole_(PA450774),icotinib_(PA166114460),rabeprazole_(PA451216),omeprazole_(PA450704),rabeprazole_(PA451216),diazepam_(PA449283),lansoprazole_(PA450180),sertraline_(PA451333),omeprazole_(PA450704),esomeprazole_(PA10075),pantoprazole_(PA450774),omeprazole_(PA450704),rabeprazole_(PA451216),clobazam_(PA10888);PGKB_TYPE=Efficacy,Other,Efficacy,Efficacy,Efficacy,Other,Efficacy,Metabolism/PK,Other,Other,Efficacy,Efficacy,Other,"Efficacy""Metabolism/PK";PGKB_EVIDENCE=3,3,3,2A,2A,3,2A,1A,3,3,3,2A,2A,2A;PGKB_DISEASE=Helicobacter_Infections_(PA166048740),NR,Helicobacter_Infections_(PA166048740),Helicobacter_Infections_(PA166048740),Gastroesophageal_Reflux_(PA444255),NR,Helicobacter_Infections_(PA166048740),Depressive_Disorder_Major_(PA447321),"Gastroesophageal_Reflux_(PA444255)""Peptic_Ulcer_(PA447240)",NR,NR,"Gastroesophageal_Reflux_(PA444255)""Peptic_Ulcer_(PA447240)","Gastroesophageal_Reflux_(PA444255)""Helicobacter_Infections_(PA166048740)",Epilepsy_(PA444065);PGKB_TEXT="*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_decreased_likelihood_of_eradication_when_treated_with_pantoprazole_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin_or_metronidazole._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._However_only_two_studies_assessed_eradication_in_pantoprazole_alone__one_of_these_found_no_significant_results._The_remainder_analyzed_this_outcome_for_pantoprazole_along_with_omeprazole_esomeprazole_or_other_proton_pump_inhibitors._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_decreased_likelihood_of_eradication_when_treated_with_pantoprazole_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_an_increased_likelihood_of_eradication_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin_or_metronidazole._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._However_only_two_studies_assessed_eradication_in_pantoprazole_alone__one_of_these_found_no_significant_results._The_remainder_analyzed_this_outcome_for_pantoprazole_along_with_omeprazole_esomeprazole_or_other_proton_pump_inhibitors._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*1/*3_:Patients_with_the_CYP2C19_*1/*3_genotype_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_decreased_likelihood_of_eradication_when_treated_with_pantoprazole_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_an_increased_likelihood_of_eradication_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin_or_metronidazole._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._However_only_two_studies_assessed_eradication_in_pantoprazole_alone__one_of_these_found_no_significant_results._The_remainder_analyzed_this_outcome_for_pantoprazole_along_with_omeprazole_esomeprazole_or_other_proton_pump_inhibitors._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_pantoprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin_or_metronidazole._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._However_only_two_studies_assessed_eradication_in_pantoprazole_alone__one_of_these_found_no_significant_results._The_remainder_analyzed_this_outcome_for_pantoprazole_along_with_omeprazole_esomeprazole_or_other_proton_pump_inhibitors._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_pantoprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin_or_metronidazole._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._However_only_two_studies_assessed_eradication_in_pantoprazole_alone__one_of_these_found_no_significant_results._The_remainder_analyzed_this_outcome_for_pantoprazole_along_with_omeprazole_esomeprazole_or_other_proton_pump_inhibitors._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_pantoprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin_or_metronidazole._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._However_only_two_studies_assessed_eradication_in_pantoprazole_alone__one_of_these_found_no_significant_results._The_remainder_analyzed_this_outcome_for_pantoprazole_along_with_omeprazole_esomeprazole_or_other_proton_pump_inhibitors._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.","*1/*1:Patients_with_two_functional_CYP2C19_alleles_(*1/*1)_may_have_increased_metabolism_of_icotinib_as_compared_to_patients_with_one_or_two_CYP2C19_loss-of-function_alleles_(*2_or_*3)._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_icotinib.""*1/*2:Patients_with_CYP2C19*2_may_have_may_have_decreased_metabolism_of_icotinib_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_icotinib.""*1/*3:Patients_with_CYP2C19*3_may_have_may_have_decreased_metabolism_of_icotinib_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_icotinib.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_lower_eradication_rate_when_treated_with_rabeprazole_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype_(*2_:_rs4244285__*3_:_rs4986893)._Patients_also_received_various_antibiotics._However_the_majority_of_studies_have_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate_in_patients_taking_rabeprazole._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_(*2_:_rs4244285)_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_rabeprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_various_antibiotics._However_the_majority_of_studies_have_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate_in_patients_taking_rabeprazole._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_(*3_:_rs4986893)_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_rabeprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_various_antibiotics._However_the_majority_of_studies_have_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate_in_patients_taking_rabeprazole._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_(*2_:_rs4244285)_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_rabeprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_various_antibiotics._However_the_majority_of_studies_have_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate_in_patients_taking_rabeprazole._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_(*2_:_rs4244285__*3_:_rs4986893)_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_rabeprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_various_antibiotics._However_the_majority_of_studies_have_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate_in_patients_taking_rabeprazole._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_(*3_:_rs4986893)_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_rabeprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_various_antibiotics._However_the_majority_of_studies_have_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate_in_patients_taking_rabeprazole._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_lower_eradication_rate_when_treated_with_omeprazole_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_omeprazole_as_compared_to_patients_with_the_*1/*1_genotype_and_a_lower_eradication_rate_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_omeprazole_as_compared_to_patients_with_the_*1/*1_genotype_and_a_lower_eradication_rate_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_omeprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori._""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_omeprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_higher_eradication_rate_when_treated_with_omeprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_a_reduced_response_to_rabeprazole_(larger_%_of_time_with_intragastric_pH_<_4.0_and_a_lower_intragastric_pH)_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_significant_associations_between_CYP2C19_genotypes_and_intragastric_pH_measurements._Other_genetic_and_clinical_factors_may_also_influence_response_to_rabeprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_may_have_a_reduced_response_to_rabeprazole_(larger_%_of_time_with_intragastric_pH_<_4.0_and_a_lower_intragastric_pH)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_a_better_response_compared_to_patients_with_the_*1/*1_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_significant_associations_between_CYP2C19_genotypes_and_intragastric_pH_measurements._Other_genetic_and_clinical_factors_may_also_influence_response_to_rabeprazole.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_may_have_a_reduced_response_to_rabeprazole_(larger_%_of_time_with_intragastric_pH_<_4.0_and_a_lower_intragastric_pH)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_a_better_response_compared_to_patients_with_the_*1/*1_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_significant_associations_between_CYP2C19_genotypes_and_intragastric_pH_measurements._Other_genetic_and_clinical_factors_may_also_influence_response_to_rabeprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_may_have_a_better_response_to_rabeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_significant_associations_between_CYP2C19_genotypes_and_intragastric_pH_measurements._Other_genetic_and_clinical_factors_may_also_influence_response_to_rabeprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_may_have_a_better_response_to_rabeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_significant_associations_between_CYP2C19_genotypes_and_intragastric_pH_measurements._Other_genetic_and_clinical_factors_may_also_influence_response_to_rabeprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_may_have_a_better_response_to_rabeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_significant_associations_between_CYP2C19_genotypes_and_intragastric_pH_measurements._Other_genetic_and_clinical_factors_may_also_influence_response_to_rabeprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_(extensive_metabolizers)_receiving_diazepam_for_preoperative_anxiety_may_have_increased_metabolism_of_diazepam_(lower_AUC_and_higher_clearance)_as_compared_to_patients_with_the_poor_metabolizer_phenotype_(*2/*2_or_*2/*3)._Patients_with_the_*1/*1_genotype_may_also_emerge_from_anesthesia_more_rapidly_than_patients_carrying_the_*2_or_*3_alleles_(intermediate_and_poor_metabolizers)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diazepam.""*1/*2:Patients_with_the_CYP2C19_*1/*2_or_*1/*3_genotype_(intermediate_metabolizers)_receiving_diazepam_for_preoperative_anxiety_may_have_increased_metabolism_of_diazepam_(lower_AUC_and_higher_clearance)_as_compared_to_patients_with_the_poor_metabolizer_phenotype_(*2/*2_or_*2/*3)._Patients_with_the_intermediate_metabolizer_phenotype_may_emerge_from_anesthesia_less_rapidly_than_patients_with_the_extensive_metabolizer_phenotype_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diazepam.""*1/*3:Patients_with_the_CYP2C19_*1/*2_or_*1/*3_genotype_(intermediate_metabolizers)_receiving_diazepam_for_preoperative_anxiety_may_have_increased_metabolism_of_diazepam_(lower_AUC_and_higher_clearance)_as_compared_to_patients_with_the_poor_metabolizer_phenotype_(*2/*2_or_*2/*3)._Patients_with_the_intermediate_metabolizer_phenotype_may_emerge_from_anesthesia_less_rapidly_than_patients_with_the_extensive_metabolizer_phenotype_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diazepam.""*2/*2:Patients_with_the_CYP2C19_*2/*2_or_*2/*3_genotype_(poor_metabolizers)_receiving_diazepam_for_preoperative_anxiety_may_have_decreased_metabolism_of_diazepam_(higher_AUC_and_lower_clearance)_as_compared_to_patients_with_the_extensive_(*1/*1)_or_intermediate_(*1/*2_or_*1/*3)_metabolizer_phenotypes._Patients_with_the_poor_metabolizer_phenotype_may_emerge_from_anesthesia_less_rapidly_than_patients_with_the_extensive_metabolizer_phenotype_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diazepam.""*2/*3:Patients_with_the_CYP2C19_*2/*2_or_*2/*3_genotype_(poor_metabolizers)_receiving_diazepam_for_preoperative_anxiety_may_have_decreased_metabolism_of_diazepam_(higher_AUC_and_lower_clearance)_as_compared_to_patients_with_the_extensive_(*1/*1)_or_intermediate_(*1/*2_or_*1/*3)_metabolizer_phenotypes._Patients_with_the_poor_metabolizer_phenotype_may_emerge_from_anesthesia_less_rapidly_than_patients_with_the_extensive_metabolizer_phenotype_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diazepam.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_decreased_likelihood_of_eradication_when_treated_with_lansoprazole_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._Patients_also_received_amoxicillin_and_clarithromycin._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_lansoprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_lansoprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_lansoprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_lansoprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_likelihood_of_eradication_when_treated_with_lansoprazole_as_compared_to_patients_with_the_*1/*1_genotype._Patients_also_received_amoxicillin_and_clarithromycin._Studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Several_studies_found_no_association_between_CYP2C19_genotypes_and_H._pylori_eradication_rate._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_H._pylori_eradication.","*1/*1:Patients_with_the_*1/*1_diplotype_who_are_treated_with_sertraline_may_have_lower_dose-corrected_drug_plasma_concentrations_and_increased_clearance_as_compared_to_patients_with_one_or_two_CYP2C19_no_alleles_(*1/*2_or_*2/*2_*2/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_sertraline.""*1/*2:Patients_with_the_*1/*2_diplotype_who_are_treated_with_sertraline_may_have_increased_clearance_as_compared_to_patients_with_the_*2/*2_or_*2/*3_diplotype_and_a_decreased_clearance_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_sertraline.""*2/*2:Patients_with_the_*2/*2_diplotype_who_are_treated_with_sertraline_may_have_higher_dose-corrected_drug_plasma_concentrations_and_decreased_clearance_as_compared_to_patients_with_the_*1/*1_and_*1/*2_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_sertraline._""*2/*3:Patients_with_the_*2/*3_diplotype_who_are_treated_with_sertraline_may_have_decreased_clearance_as_compared_to_patients_with_the_*1/*1_and_*1/*2_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_sertraline._","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_and_esophageal_reflux_or_peptic_ulcer_disease_may_have_increased_metabolism_of_omeprazole_(lower_mean_metabolic_ratio_of_omeprazole_to_hydroxyomeprazole)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._The_study_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_omeprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_and_esophageal_reflux_or_peptic_ulcer_disease_may_have_increased_metabolism_of_omeprazole_(lower_mean_metabolic_ratio_of_omeprazole_to_hydroxyomeprazole)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._The_study_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_omeprazole.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_and_esophageal_reflux_or_peptic_ulcer_disease_may_have_increased_metabolism_of_omeprazole_(lower_mean_metabolic_ratio_of_omeprazole_to_hydroxyomeprazole)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._The_study_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_omeprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_and_esophageal_reflux_or_peptic_ulcer_disease_may_have_decreased_metabolism_of_omeprazole_(higher_mean_metabolic_ratio_of_omeprazole_to_hydroxyomeprazole)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_study_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_omeprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_and_esophageal_reflux_or_peptic_ulcer_disease_may_have_decreased_metabolism_of_omeprazole_(higher_mean_metabolic_ratio_of_omeprazole_to_hydroxyomeprazole)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_study_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_omeprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_and_esophageal_reflux_or_peptic_ulcer_disease_may_have_decreased_metabolism_of_omeprazole_(higher_mean_metabolic_ratio_of_omeprazole_to_hydroxyomeprazole)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_study_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_omeprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_increased_metabolism_of_esomeprazole_(shorter_time_taken_for_the_blood_concentration_to_drop_to_50%_of_the_peak_plasma_drug_concentration_and_a_shorter_mean_residence_time)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._No_significant_associations_have_been_seen_for_area_under_the_concentration-time_curve_(AUC)_apparent_oral_clearance_(Cl/F)_or_peak_plasma_drug_concentration_(Cmax)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_esomeprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_may_have_decreased_metabolism_of_esomeprazole_(longer_time_taken_for_the_blood_concentration_to_drop_to_50%_of_the_peak_plasma_drug_concentration_and_a_longer_mean_residence_time)_as_compared_to_patients_with_the_*1/*1_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_+_*2/*3_(*2_:_rs4244285__*3_:_rs4986893)._No_significant_associations_have_been_seen_for_area_under_the_concentration-time_curve_(AUC)_apparent_oral_clearance_(Cl/F)_or_peak_plasma_drug_concentration_(Cmax)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_esomeprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_may_have_decreased_metabolism_of_esomeprazole_(longer_time_taken_for_the_blood_concentration_to_drop_to_50%_of_the_peak_plasma_drug_concentration_and_a_longer_mean_residence_time)_as_compared_to_patients_with_the_*1/*1_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_+_*2/*3_(*2_:_rs4244285__*3_:_rs4986893)._No_significant_associations_have_been_seen_for_area_under_the_concentration-time_curve_(AUC)_apparent_oral_clearance_(Cl/F)_or_peak_plasma_drug_concentration_(Cmax)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_esomeprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_may_have_decreased_metabolism_of_esomeprazole_(longer_time_taken_for_the_blood_concentration_to_drop_to_50%_of_the_peak_plasma_drug_concentration_and_a_longer_mean_residence_time)_as_compared_to_patients_with_the_*1/*1_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_+_*2/*3_(*2_:_rs4244285__*3_:_rs4986893)._No_significant_associations_have_been_seen_for_area_under_the_concentration-time_curve_(AUC)_apparent_oral_clearance_(Cl/F)_or_peak_plasma_drug_concentration_(Cmax)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_esomeprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_a_reduced_response_to_pantoprazole_(smaller_%_of_time_with_intragastric_pH_>_4.0_and_a_lower_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_response_to_pantoprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_may_have_a_reduced_response_to_pantoprazole_(smaller_%_of_time_with_intragastric_pH_>_4.0_and_a_lower_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_response_to_pantoprazole.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_may_have_a_reduced_response_to_pantoprazole_(smaller_%_of_time_with_intragastric_pH_>_4.0_and_a_lower_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_response_to_pantoprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_may_have_a_better_response_to_pantoprazole_(greater_%_of_time_with_intragastric_pH_>_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_response_to_pantoprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_may_have_a_better_response_to_pantoprazole_(greater_%_of_time_with_intragastric_pH_>_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_response_to_pantoprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_may_have_a_better_response_to_pantoprazole_(greater_%_of_time_with_intragastric_pH_>_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._One_of_the_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_response_to_pantoprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_a_reduced_response_to_omeprazole_(greater_%_of_time_with_intragastric_pH_<_4.0_and_a_lower_intragastric_pH_during_a_24-hour_time_period_among_other_parameters)_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Two_studies_found_no_association_between_CYP2C19_genotypes_and_intragastric_pH_parameters._Other_genetic_and_clinical_factors_may_also_influence_response_to_omeprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_may_have_a_better_response_to_omeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period_among_other_parameters)_as_compared_to_patients_with_the_*1/*1_genotype_and_a_reduced_response_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Two_studies_found_no_association_between_CYP2C19_genotypes_and_intragastric_pH_parameters._Other_genetic_and_clinical_factors_may_also_influence_response_to_omeprazole.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_may_have_a_better_response_to_omeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period_among_other_parameters)_as_compared_to_patients_with_the_*1/*1_genotype_and_a_reduced_response_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Two_studies_found_no_association_between_CYP2C19_genotypes_and_intragastric_pH_parameters._Other_genetic_and_clinical_factors_may_also_influence_response_to_omeprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_may_have_a_better_response_to_omeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period_among_other_parameters)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Two_studies_found_no_association_between_CYP2C19_genotypes_and_intragastric_pH_parameters._Other_genetic_and_clinical_factors_may_also_influence_response_to_omeprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_may_have_a_better_response_to_omeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period_among_other_parameters)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Two_studies_found_no_association_between_CYP2C19_genotypes_and_intragastric_pH_parameters._Other_genetic_and_clinical_factors_may_also_influence_response_to_omeprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_may_have_a_better_response_to_omeprazole_(smaller_%_of_time_with_intragastric_pH_<_4.0_and_a_higher_intragastric_pH_during_a_24-hour_time_period_among_other_parameters)_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizers_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Two_studies_found_no_association_between_CYP2C19_genotypes_and_intragastric_pH_parameters._Other_genetic_and_clinical_factors_may_also_influence_response_to_omeprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_increased_metabolism_of_rabeprazole_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rabeprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_may_have_increased_metabolism_of_rabeprazole_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_decreased_metabolism_as_compared_to_patients_with_the_*1/*1_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rabeprazole.""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_may_have_increased_metabolism_of_rabeprazole_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_decreased_metabolism_as_compared_to_patients_with_the_*1/*1_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rabeprazole.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_may_have_decreased_metabolism_of_rabeprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rabeprazole.""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_may_have_decreased_metabolism_of_rabeprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rabeprazole.""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_may_have_decreased_metabolism_of_rabeprazole_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._The_majority_of_studies_grouped_genotypes_together_for_analysis_rather_than_compare_individual_genotypes:_homozygous_extensive_metabolizers_:_*1/*1_heterozygous_extensive_metabolizer_:_*1/*2_+_*1/*3_and_poor_metabolizers_:_*2/*2_*2/*3_+_*3/*3_(*2_:_rs4244285__*3_:_rs4986893)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rabeprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_and_epilepsy_may_have_increased_metabolism_of_N-desmethylclobazam_the_principal_metabolite_of_clobazam_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotype._This_increase_in_metabolism_may_lead_to_a_lower_risk_for_adverse_effects_but_also_a_poorer_response_to_treatment._Some_studies_also_show_an_association_with_increased_metabolism_of_clobazam._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_N-desmethylclobazam_and_clobazam._""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_and_epilepsy_may_have_increased_metabolism_of_N-desmethylclobazam_the_principal_metabolite_of_clobazam_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_decreased_metabolism_as_compared_to_patients_with_the_*1/*1_genotype._This_decrease_in_metabolism_may_lead_to_a_higher_risk_for_adverse_effects_but_also_a_better_response_to_treatment._Some_studies_also_show_an_association_with_metabolism_of_clobazam._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_N-desmethylclobazam_and_clobazam._""*1/*3:Patients_with_the_CYP2C19_*1/*3_genotype_and_epilepsy_may_have_increased_metabolism_of_N-desmethylclobazam_the_principal_metabolite_of_clobazam_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotype_and_decreased_metabolism_as_compared_to_patients_with_the_*1/*1_genotype._This_decrease_in_metabolism_may_lead_to_a_higher_risk_for_adverse_effects_but_also_a_better_response_to_treatment._Some_studies_also_show_an_association_with_metabolism_of_clobazam._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_N-desmethylclobazam_and_clobazam._""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_and_epilepsy_may_have_decreased_metabolism_of_N-desmethylclobazam_the_principal_metabolite_of_clobazam_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._This_decrease_in_metabolism_may_lead_to_a_higher_risk_for_adverse_effects_but_also_a_better_response_to_treatment._Some_studies_also_show_an_association_with_decreased_metabolism_of_clobazam._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_N-desmethylclobazam_and_clobazam._""*2/*3:Patients_with_the_CYP2C19_*2/*3_genotype_and_epilepsy_may_have_decreased_metabolism_of_N-desmethylclobazam_the_principal_metabolite_of_clobazam_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._This_decrease_in_metabolism_may_lead_to_a_higher_risk_for_adverse_effects_but_also_a_better_response_to_treatment._Some_studies_also_show_an_association_with_decreased_metabolism_of_clobazam._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_N-desmethylclobazam_and_clobazam._""*3/*3:Patients_with_the_CYP2C19_*3/*3_genotype_and_epilepsy_may_have_decreased_metabolism_of_N-desmethylclobazam_the_principal_metabolite_of_clobazam_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotype._This_decrease_in_metabolism_may_lead_to_a_higher_risk_for_adverse_effects_but_also_a_better_response_to_treatment._Some_studies_also_show_an_association_with_decreased_metabolism_of_clobazam._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_N-desmethylclobazam_and_clobazam._";PGKB_RACE=NR,Asian,NR,NR,NR,Asian,NR,NR,Asian,NR,NR,NR,NR,NR
.	.	CYP2C19 *1, CYP2C19 *2	.	.	.	.	PGKB_INDEX=9;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=venlafaxine_(PA451866),tacrolimus_(PA451578),trimipramine_(PA451791),esomeprazole_(PA10075),tacrolimus_(PA451578),nelfinavir_(PA450606),tamoxifen_(PA451581),bupropion_(PA448687),carisoprodol_(PA448809);PGKB_TYPE=Efficacy,Dosage,Other,Efficacy,Efficacy,Metabolism/PK,"Efficacy""Metabolism/PK",Other,Metabolism/PK;PGKB_EVIDENCE=4,3,2A,3,3,3,3,3,3;PGKB_DISEASE="Depression_(PA447278)""Obsessive-Compulsive_Disorder_(PA447211)",Kidney_Transplantation_(PA165817016),NR,NR,Kidney_Transplantation_(PA165817016),Pancreatic_Neoplasms_(PA445218),Breast_Neoplasms_(PA443560),NR,NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2C19*1/*1_genotype_who_are_treated_with_venlafaxine_may_have_increased_metabolism_of_venlafaxine_as_compared_to_patients_with_the_CYP2C19*2/*2_genotype._However_no_associations_are_found_with_response_or_risk_for_side_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.""*2/*2:Patients_with_the_CYP2C19*2/*2_genotype_who_are_treated_with_venlafaxine_may_have_decreased_metabolism_of_venlafaxine_as_compared_to_patients_with_the_CYP2C19*1/*1_genotype._However_no_associations_are_found_with_response_or_risk_for_side_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_who_underwent_kidney_transplantation_and_are_treated_with_tacrolimus_may_have_lower_tacrolimus_dose-normalized_trough_blood_concentrations_(C0/D)_as_compared_to_patients_with_the_*2/*2_genotype._Please_note_that_this_was_studied_exclusively_in_patients_with_the_CYP3A5_*3/*3_(also_known_as_rs776746_CC)_non-expresser_genotype._Additionally_no_significant_association_was_seen_between_the_donor_kidney_genotype_and_tacrolimus_C0/D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tacrolimus_dose-normalized_trough_blood_concentrations.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_who_underwent_kidney_transplantation_and_are_treated_with_tacrolimus_may_have_lower_tacrolimus_dose-normalized_trough_blood_concentrations_(C0/D)_as_compared_to_patients_with_the_*2/*2_genotype._Please_note_that_this_was_studied_exclusively_in_patients_with_the_CYP3A5_*3/*3_(also_known_as_rs776746_CC)_non-expresser_genotype._Additionally_no_significant_association_was_seen_between_the_donor_kidney_genotype_and_tacrolimus_C0/D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tacrolimus_dose-normalized_trough_blood_concentrations.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_who_underwent_kidney_transplantation_and_are_treated_with_tacrolimus_may_have_higher_tacrolimus_dose-normalized_trough_blood_concentrations_(C0/D)_as_compared_to_patients_with_the_*1/*1_or_*1/*2_genotype._Please_note_that_this_was_studied_exclusively_in_patients_with_the_CYP3A5_*3/*3_(also_known_as_rs776746_CC)_non-expresser_genotype._Additionally_no_significant_association_was_seen_between_the_donor_kidney_genotype_and_tacrolimus_C0/D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tacrolimus_dose-normalized_trough_blood_concentrations.","*1/*1:Patients_with_the_CYP2C19*1/*1_CYP2C9*1/*1_and_CYP2D6*1/*1_combined_diplotypes_may_have_higher_clearance_of_trimipramine_as_compared_to_patients_with_the_CYP2C19*2/*2_or_*1/*2_genotype._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*1/*2:Patients_with_the_CYP2C19*1/*2_diplotype_(intermediate_metabolizers)_may_have_reduced_clearance_of_trimipramine_as_compared_to_patients_with_CYP2C19*1/*1_CYP2C9*1/*1_and_CYP2D6*1/*1_combined_diplotypes._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*2/*2:Patients_with_the_CYP2C19*2/*2_diplotype_(poor_metabolizers)_may_have_reduced_clearance_of_trimipramine_as_compared_to_patients_with_CYP2C19*1/*1_CYP2C9*1/*1_and_CYP2D6*1/*1_combined_diplotypes._Patients_with_the_CYP2C19_poor_metabolizer_phenotype_(such_as_*2/*2)_may_have_an_increased_trimipramine_and_lower_desmethyltrimipramine_plasma_concentrations_as_compared_to_patients_with_the_*1/*1_genotype._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_may_have_a_reduced_response_to_esomeprazole_(lower_%_of_time_with_intragastric_pH_>_4.0_and_a_lower_median_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*1/*2_genotype_(*2_:_rs4244285)._Other_genetic_and_clinical_factors_may_also_influence_response_to_esomeprazole.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_(*2_:_rs4244285)_may_have_a_better_response_to_esomeprazole_(greater_%_of_time_with_intragastric_pH_>_4.0_and_a_higher_median_intragastric_pH_during_a_24-hour_time_period)_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_esomeprazole.","*1/*1:Patients_with_the_CYP2C19_*1/*1_genotype_who_underwent_kidney_transplantation_may_have_a_shorter_post-transplantation_hospital_stay_when_treated_with_tacrolimus_as_compared_to_patients_with_the_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_post-transplantation_hospital_stay.""*1/*2:Patients_with_the_CYP2C19_*1/*2_genotype_who_underwent_kidney_transplantation_may_have_a_shorter_post-transplantation_hospital_stay_when_treated_with_tacrolimus_as_compared_to_patients_with_the_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_post-transplantation_hospital_stay.""*2/*2:Patients_with_the_CYP2C19_*2/*2_genotype_who_underwent_kidney_transplantation_may_have_a_longer_post-transplantation_hospital_stay_when_treated_with_tacrolimus_as_compared_to_patients_with_the_*1/*1_or_*1/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_post-transplantation_hospital_stay.","*1/*1:Patients_with_pancreatic_cancer_and_the_CYP2C19_*1/*1_genotype_may_have_increased_metabolism_of_and_decreased_concentrations_of_nelfinavir_as_compared_to_patients_with_the_*1/*2_genotype._Other_clinical_and_genetic_factors_may_also_contribute_to_metabolism_of_nelfinivir_in_patients_with_pancreatic_cancer._""*1/*2:Patients_with_pancreatic_cancer_and_the_CYP2C19_*1/*2_genotype_may_have_decreased_metabolism_of_and_increased_concentrations_of_nelfinavir_as_compared_to_patients_with_the_*1/*1_genotype._Other_clinical_and_genetic_factors_may_also_contribute_to_metabolism_of_nelfinivir_in_patients_with_pancreatic_cancer._","*1/*1:Women_with_breast_cancer_and_the_CYP2C19_*1/*1_genotype_who_are_treated_with_tamoxifen_may_have_increased_metabolism_and_may_have_an_improved_response_to_tamoxifen_as_compared_to_those_with_the_*2/*2_genotype._Please_note:_There_is_no_evidence_to_support_an_association_between_the_*3_or_*17_allele_and_tamoxifen_metabolism_or_response_as_compared_to_the_CYP2C19_*1_allele_(there_is_some_evidence_for_the_*1A_allele)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_and_response_to_tamoxifen.""*1/*2:Women_with_breast_cancer_and_the_CYP2C19_*1/*2_genotype_who_are_treated_with_tamoxifen_may_have_increased_metabolism_and_may_have_an_improved_response_to_tamoxifen_as_compared_to_those_with_the_*2/*2_genotype._Please_note:_There_is_no_evidence_to_support_an_association_between_the_*3_or_*17_allele_and_tamoxifen_metabolism_or_response_as_compared_to_the_CYP2C19_*1_allele_(there_is_some_evidence_for_the_*1A_allele)Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_and_response_to_tamoxifen.""*2/*2:Women_with_breast_cancer_and_the_CYP2C19_*2/*2_genotype_who_are_treated_with_tamoxifen_may_have_decreased_metabolism_and_worse_response_to_tamoxifen_as_compared_to_those_with_the_*1/*1_or_*1/*2_genotype._Please_note:_There_is_no_evidence_to_support_an_association_between_the_*3_or_*17_allele_and_tamoxifen_metabolism_or_response_as_compared_to_the_CYP2C19_*1_allele_(there_is_some_evidence_for_the_*1A_allele)Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_and_response_to_tamoxifen.","*1/*1:Patients_with_the_*1/*1_diplotype_who_are_administered_bupropion_may_have_decreased_exposure_to_bupropion_as_compared_to_patients_with_the_*1/*2_and_*2/*2_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_bupropion._""*1/*2:Patients_with_the_*1/*2_diplotype_who_are_administered_bupropion_may_have_increased_exposure_to_bupropion_as_compared_to_patients_with_the_*2/*2_diplotypes_and_increased_exposure_as_compared_to_patients_with_the_*1/*1_diplotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_bupropion._""*2/*2:Patients_with_the_*2/*2_diplotype_who_are_administered_bupropion_may_have_increased_exposure_to_bupropion_as_compared_to_patients_with_the_*1/*2_and_*1/*1_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_bupropion._","*1/*1:Healthy_individuals_with_the_*1/*1_genotype_may_not_have_decreased_concentrations_of_carisoprodol_as_compared_to_those_with_the_*1/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_pharmacokinetics_of_carisoprodol_in_an_individual.""*1/*2:Healthy_individuals_with_the_*1/*2_genotype_may_have_increased_concentrations_of_carisoprodol_as_compared_to_those_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_pharmacokinetics_of_carisoprodol_in_an_individual.";PGKB_RACE=NR,White,NR,White,White,NR,"Asian""White",NR,White
.	.	CYP2C19 *1, CYP2C19 *8, CYP2C19 *9	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=lansoprazole_(PA450180);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2C19_alleles_(*1/*1)_may_have_increased_metabolism_of_lansoprazole_as_compared_to_patients_with_one_or_two_CYP2C19_loss-of-function_alleles_(*8*9)._Other_clinical_and_genetic_factors_may_also_affect_metabolism_of_lansoprazole.""*8:Patients_with_the_CYP2C19*8_allele_in_combination_with_another_loss-of-function_allele_(*8*9)_or_one_functional_allele_(*1)_may_have_decreased_metabolism_of_lansoprazole_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_clinical_and_genetic_factors_may_also_affect_metabolism_of_lansoprazole.""*9:Patients_with_the_CYP2C19*9_allele_in_combination_with_another_loss-of-function_allele_(*8*9)_or_one_functional_allele_(*1)_may_have_decreased_metabolism_of_lansoprazole_as_compared_to_patients_with_two_functional_alleles_(*1/*1)._Other_clinical_and_genetic_factors_may_also_affect_metabolism_of_lansoprazole.";PGKB_RACE=NR
.	.	CYP2C8 *1A, CYP2C8 *2, CYP2C8 *3	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C8_(PA125);PGKB_DRUG=pioglitazone_(PA450970);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1A/*1A:Patients_with_*1A/*1A_genotypes_may_have_increased_pioglitazone_metabolism_as_compared_to_patients_with_the_*2_or_*3_alleles._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_and_response_to_pioglitazone.""*2:Patients_with_the_*2_allele_may_have_decreased_pioglitazone_metabolism_as_compared_to_patients_with_*1A/*1A_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_and_response_to_pioglitazone.""*3:Patients_with_the_*3_allele_may_have_decreased_plasma_concentration_and_decreased_clearance_when_exposed_to_pioglitazone_as_compared_to_patients_with_*1A/*1A_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_and_response_to_pioglitazone.";PGKB_RACE=NR
.	.	CYP2C9 *1, CYP2C9 *11, CYP2C9 *2, CYP2C9 *3, CYP2C9 *5, CYP2C9 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_CYP2C9*1/*1_may_have_decreased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*2_*3_*5_*6_or_*11._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*11:Patients_with_CYP2C9*11_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*2:Patients_with_CYP2C9*2_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*3:Patients_with_CYP2C9*3_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*5:Patients_with_CYP2C9*5_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*6:Patients_with_CYP2C9*6_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._";PGKB_RACE=NR
.	.	CYP2C9 *1, CYP2C9 *13, CYP2C9 *2, CYP2C9 *3	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_CYP2C9*1/*1_may_require_less_time_to_achieve_stable_dose_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*2_*3_or_*13._Other_genetic_or_clinical_factors_may_also_influence_the_time_to_achieve_warfarin_stable_dose.""*13:Patients_with_CYP2C9*13_may_require_more_time_to_achieve_stable_dose_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_or_clinical_factors_may_also_influence_the_time_to_achieve_warfarin_stable_dose.""*2:Patients_with_CYP2C9*2_may_require_more_time_to_achieve_stable_dose_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_or_clinical_factors_may_also_influence_the_time_to_achieve_warfarin_stable_dose.""*3:Patients_with_CYP2C9*3_may_require_more_time_to_achieve_stable_dose_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_or_clinical_factors_may_also_influence_the_time_to_achieve_warfarin_stable_dose.";PGKB_RACE=NR
.	.	CYP2C9 *1, CYP2C9 *13, CYP2C9 *3	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=lornoxicam_(PA165958395);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2C9_*1/*1_genotype_and_may_have_increased_metabolism_of_lornoxicam_as_compared_to_patients_with_the_*1/*3_or_*1/*13_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lornoxicam.""*1/*13:Patients_with_the_CYP2C9_*1/*13_genotype_and_may_have_decreased_metabolism_of_lornoxicam_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lornoxicam.""*1/*3:Patients_with_the_CYP2C9_*1/*3_genotype_and_may_have_decreased_metabolism_of_lornoxicam_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_lornoxicam.";PGKB_RACE=Asian
.	.	CYP2C9 *1, CYP2C9 *2, CYP2C9 *3, CYP2C9 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypotension_(PA444584);PGKB_TEXT="*1/*1:Individuals_with_the_*1/*1_genotype_were_less_likely_to_experience_hypotension_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*3_*2/*3_or_*3/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_hypotension_when_receiving_olanzapine.""*1/*2:Individuals_with_the_*1/*2_genotype_were_less_likely_to_experience_hypotension_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*3_*2/*3_or_*3/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_hypotension_when_receiving_olanzapine.""*1/*3:Individuals_with_the_*1/*3_genotype_were_more_likely_to_experience_hypotension_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_*1/*2_or_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_hypotension_when_receiving_olanzapine.""*2/*2:Individuals_with_the_*2/*2_genotype_were_less_likely_to_experience_hypotension_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*3_*2/*3_or_*3/*6_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_hypotension_when_receiving_olanzapine.""*2/*3:Individuals_with_the_*2/*3_genotype_were_more_likely_to_experience_hypotension_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_*1/*2_or_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_hypotension_when_receiving_olanzapine.""*3/*6:Individuals_with_the_*3/*6_genotype_were_more_likely_to_experience_hypotension_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_*1/*2_or_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_hypotension_when_receiving_olanzapine.";PGKB_RACE=White
.	.	CYP2C9 *1, CYP2C9 *2, CYP2C9 *3	.	.	.	.	PGKB_INDEX=7;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG=phenytoin_(PA450947),acenocoumarol_(PA452632),warfarin_(PA451906),warfarin_(PA451906),warfarin_(PA451906),warfarin_(PA451906),sulfonamides_(PA10772);PGKB_TYPE=Toxicity/ADR,Dosage,Dosage,Toxicity/ADR,Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=1B,2A,1A,2A,3,3,3;PGKB_DISEASE=Epilepsy_(PA444065),NR,"Cardiovascular_Diseases_(PA443635)""Heart_Diseases_(PA444368)",Hemorrhage_(PA444417),NR,NR,Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="*1/*1:Patients_with_*1/*1_genotypes_may_have_increased_metabolism_decreased_plasma_concentration_decreased_toxicity_and_decreased_adverse_drug_reactions_when_treated_with_phenytoin_in_epilepsy_when_compared_to_patients_with_*1/*3_*2/*3_*2/*2_or_*3/*3_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*1/*3:Patients_with_*1/*3_genotypes_may_have_decreased_metabolism_increased_plasma_concentration_increased_toxicity_and_increased_adverse_drug_reactions_when_treated_with_phenytoin_in_epilepsy_when_compared_to_patients_with_*1/*1_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*2/*2:Patients_with_*2/*2_genotypes_may_have_decreased_metabolism_increased_plasma_concentration_increased_toxicity_and_increased_adverse_drug_reactions_when_treated_with_phenytoin_in_epilepsy_when_compared_to_patients_with_*1/*1_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*2/*3:Patients_with_*2/*3_genotypes_may_have_decreased_metabolism_increased_plasma_concentration_increased_toxicity_and_increased_adverse_drug_reactions_when_treated_with_phenytoin_in_epilepsy_when_compared_to_patients_with_*1/*1_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*3/*3:Patients_with_*3/*3_genotypes_may_have_decreased_metabolism_increased_plasma_concentration_increased_toxicity_and_increased_adverse_drug_reactions_when_treated_with_phenytoin_in_epilepsy_when_compared_to_patients_with_*1/*1_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.","*1/*1:Patients_with_the_*1/*1_genotype_may_require_a_higher_dose_of_acenocoumarol_as_compared_to_patients_with_the_*1/*2_*1/*3_*2/*2_*2/*3_or_*3/*3_genotypes_although_this_is_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dosage.""*1/*2:Patients_with_the_*1/*2_genotype_may_require_a_higher_dose_of_acenocoumarol_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotypes_and_a_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_*1/*1_genotype_although_this_is_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dosage.""*1/*3:Patients_with_the_*1/*3_genotype_may_require_a_higher_dose_of_acenocoumarol_as_compared_to_patients_with_the_*2/*2_*2/*3_or_*3/*3_genotypes_and_a_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_*1/*1_genotype_although_this_is_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dosage.""*2/*2:Patients_with_the_*2/*2_genotype_may_require_a_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_*1/*1_*1/*2_*1/*3_genotypes_although_this_is_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dosage.""*2/*3:Patients_with_the_*2/*3_genotype_may_require_a_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_*1/*1_*1/*2_*1/*3_genotypes_although_this_is_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dosage.""*3/*3:Patients_with_the_*3/*3_genotype_may_require_a_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_*1/*1_*1/*2_*1/*3_genotypes_although_this_is_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dosage.","*1/*1:Patients_with_the_*1/*1_diplotype_may_require_a_higher_dose_of_warfarin_as_compared_to_patients_with_the_*2_or_*3_CYP2C9_alleles._CYP2C9*1/*1_is_considered_a_fully_functional_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""*1/*2:Patients_with_the_*1/*2_diplotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""*1/*3:Patients_with_the_*1/*3_diplotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""*2/*2:Patients_with_the_*2/*2_diplotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.""*2/*3:Patients_with_the_*2/*3_diplotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""*3/*3:Patients_with_the_*3/*3_diplotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.","*1/*1:Patients_with_CYP2C9*1/*1_may_have_decreased_risk_of_bleeding_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*2_or_*3._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*2:Patients_with_CYP2C9*2_may_have_increased_risk_of_bleeding_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._""*3:Patients_with_CYP2C9*3_may_have_increased_risk_of_bleeding_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin._","*1/*1:Patients_with_CYP2C9*1/*1_may_require_longer_time_to_therapeutic_INR_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*2_or_*3._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_time_to_therapeutic_INR.""*2:Patients_with_CYP2C9*2_may_require_shorter_time_to_therapeutic_INR_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_time_to_therapeutic_INR.""*3:Patients_with_CYP2C9*3_may_require_shorter_time_to_therapeutic_INR_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_time_to_therapeutic_INR.","*1/*1:Patients_with_CYP2C9*1/*1_may_spent_longer_time_in_therapeutic_INR_range_(TTR)_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*2_or_*3._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_time_in_therapeutic_range._""*2:Patients_with_CYP2C9*2_may_spent_less_time_in_therapeutic_INR_range_(TTR)_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_time_in_therapeutic_range._""*3:Patients_with_CYP2C9*3_may_spent_less_time_in_therapeutic_INR_range_(TTR)_when_treated_with_warfarin_as_compared_to_patients_with_CYP2C9*1/*1._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_time_in_therapeutic_range._","*1/*1:Elderly_patients_with_the_*1/*1_genotype_and_Type_II_diabetes_mellitus_who_are_administered_sulfonamides_specifically_sulfonylureas_may_have_a_decreased_risk_of_hypoglycemia_as_compared_to_patients_who_are_heterozygous_or_homozygous_for_the_*2_or_*3_allele._Other_clinical_and_genetic_factors_may_also_affect_the_risk_of_hypoglycemia_in_elderly_patients_administered_sulfonamides._""*1/*2:Elderly_patients_with_the_*1/*2_genotype_and_Type_II_diabetes_mellitus_who_are_administered_sulfonamides_specifically_sulfonylureas_may_have_a_decreased_risk_of_hypoglycemia_as_compared_to_patients_who_are_homozygous_for_the_*2_or_*3_allele_and_an_increased_risk_of_hypoglycemia_as_compared_to_patients_who_are_*1/*1._Other_clinical_and_genetic_factors_may_also_affect_the_risk_of_hypoglycemia_in_elderly_patients_administered_sulfonamides._""*1/*3:Elderly_patients_with_the_*1/*3_genotype_and_Type_II_diabetes_mellitus_who_are_administered_sulfonamides_specifically_sulfonylureas_may_have_a_decreased_risk_of_hypoglycemia_as_compared_to_patients_who_are_homozygous_for_the_*2_or_*3_allele_and_an_increased_risk_of_hypoglycemia_as_compared_to_patients_who_are_*1/*1._Other_clinical_and_genetic_factors_may_also_affect_the_risk_of_hypoglycemia_in_elderly_patients_administered_sulfonamides._""*2/*2:Elderly_patients_with_the_*2/*2_genotype_and_Type_II_diabetes_mellitus_who_are_administered_sulfonamides_specifically_sulfonylureas_may_have_an_increased_risk_of_hypoglycemia_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotypes._Other_clinical_and_genetic_factors_may_also_affect_the_risk_of_hypoglycemia_in_elderly_patients_administered_sulfonamides._""*2/*3:Elderly_patients_with_the_*2/*3_genotype_and_Type_II_diabetes_mellitus_who_are_administered_sulfonamides_specifically_sulfonylureas_may_have_an_increased_risk_of_hypoglycemia_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotypes._Other_clinical_and_genetic_factors_may_also_affect_the_risk_of_hypoglycemia_in_elderly_patients_administered_sulfonamides._""*3/*3:Elderly_patients_with_the_*3/*3_genotype_and_Type_II_diabetes_mellitus_who_are_administered_sulfonamides_specifically_sulfonylureas_may_have_an_increased_risk_of_hypoglycemia_as_compared_to_patients_with_the_*1/*1_*1/*2_or_*1/*3_genotypes._Other_clinical_and_genetic_factors_may_also_affect_the_risk_of_hypoglycemia_in_elderly_patients_administered_sulfonamides._";PGKB_RACE=NR,NR,NR,NR,NR,NR,White
.	.	CYP2C9 *1, CYP2C9 *3, CYP2C9 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=diclofenac_(PA449293);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Individuals_with_the_*1/*1_genotype_may_have_increased_metabolism_of_diclofenac_as_compared_to_individuals_with_the_*1/*3_or_*1/*8_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diclofenac.""*1/*3:Individuals_with_the_*1/*3_genotype_may_have_decreased_metabolism_of_diclofenac_as_compared_to_individuals_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diclofenac.""*1/*8:Individuals_with_the_*1/*8_genotype_may_have_decreased_metabolism_of_diclofenac_as_compared_to_individuals_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_diclofenac.";PGKB_RACE=NR
.	.	CYP2C9 *1, CYP2C9 *3	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG=trimipramine_(PA451791),doxepin_(PA449409);PGKB_TYPE=Other,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2C9*1/*1_CYP2D6*1/*1_and_CYP2C19*1/*1_combined_diplotype_may_have_increased_metabolism_of_trimipramine_as_compared_to_patients_with_the_CYP2C9*3/*3_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*1/*3:Patients_with_the_CYP2C9*1/*3_diplotype_may_have_reduced_metabolism_of_trimipramine_as_compared_to_patients_with_the_CYP2C9*1/*1_CYP2D6*1/*1_and_CYP2C19*1/*1_combined_diplotype_or_may_have_increased_metabolism_of_trimipramine_as_compared_to_patients_with_the_*3/*3_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*3/*3:Patients_with_the_CYP2C9*3/*3_diplotype_may_have_reduced_metabolism_of_trimipramine_as_compared_to_patients_with_the_CYP2C9*1/*1_CYP2D6*1/*1_and_CYP2C19*1/*1_combined_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._","*1/*1:Patients_with_the_CYP2C9*1/*1_genotype_may_have_an_increased_clearance_of_doxepin_as_compared_to_patients_with_the_CYP2C9*3/*3_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin.""*3/*3:Patients_with_the_CYP2C9*3/*3_genotype_may_have_a_decreased_clearance_of_doxepin_as_compared_to_patients_with_the_CYP2C9*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin.";PGKB_RACE=NR,White
.	.	CYP2C9 *1, CYP2C9 *59	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_CYP2C9*1/*1_may_require_significantly_higher_dose_of_warfarin_as_compared_to_patients_with_CYP2C9_*59/*59_or_CYP2C9_*1/*59._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.""*1/*59:Patients_with_CYP2C9*1/*59_may_require_significantly_decreased_dose_of_warfarin_as_compared_to_patients_with_CYP2C9_*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.""*59/*59:Patients_with_CYP2C9*59/*59_may_require_significantly_decreased_dose_of_warfarin_as_compared_to_patients_with_CYP2C9_*1/*1._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.";PGKB_RACE=Asian
.	.	CYP2D6 *10, CYP2D6 *14, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6, CYP2D6 *7	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Dystonia_(PA166048915);PGKB_TEXT="*10:Patients_with_schizophrenia_who_carry_the_*10_allele_may_have_an_increased_risk_for_tardive_dyskinesia_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._However_some_studies_have_found_no_association_with_tardive_dyskinesia._Additionally_some_evidence_suggests_that_this_association_may_only_be_significant_in_males._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions._""*14:Patients_with_schizophrenia_who_carry_the_*14_allele_may_have_an_increased_risk_for_tardive_dyskinesia_or_parkinsonism_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._Note_that_the_*14_allele_has_only_been_assessed_for_this_association_in_combination_with_other_loss-of-function_alleles_(e.g._*3_*4_*5)._Additionally_some_studies_find_no_association_between_loss-of-function_alleles_and_risk_for_tardive_dyskinesia_parkinsonism_or_other_dystonic_disorders._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions.""*3:Patients_with_schizophrenia_who_carry_the_*3_allele_may_have_an_increased_risk_for_tardive_dyskinesia_or_parkinsonism_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._Note_that_the_*3_allele_has_only_been_assessed_for_this_association_in_combination_with_other_loss-of-function_alleles_(e.g._*4_*5)._Additionally_some_studies_find_no_association_between_loss-of-function_alleles_and_risk_for_tardive_dyskinesia_parkinsonism_or_other_dystonic_disorders._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions.""*4:Patients_with_schizophrenia_who_carry_the_*4_allele_may_have_an_increased_risk_for_tardive_dyskinesia_or_parkinsonism_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._Several_studies_assess_this_association_with_*4_in_combination_with_other_loss-of-function_alleles_(e.g._*3_*5)._Additionally_some_studies_find_no_association_between_loss-of-function_alleles_and_risk_for_tardive_dyskinesia_parkinsonism_or_other_dystonic_disorders._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions._""*5:Patients_with_schizophrenia_who_carry_the_*5_allele_may_have_an_increased_risk_for_tardive_dyskinesia_or_parkinsonism_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._Several_studies_assess_this_association_with_*5_in_combination_with_other_loss-of-function_alleles_(e.g._*3_*4)._Additionally_some_studies_find_no_association_between_loss-of-function_alleles_and_risk_for_tardive_dyskinesia_parkinsonism_or_other_dystonic_disorders._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions._""*6:Patients_with_schizophrenia_who_carry_the_*6_allele_may_have_an_increased_risk_for_tardive_dyskinesia_or_parkinsonism_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._Note_that_the_*6_allele_has_only_been_assessed_for_this_association_in_combination_with_other_loss-of-function_alleles_(e.g._*3_*4_*5)._Additionally_some_studies_find_no_association_between_loss-of-function_alleles_and_risk_for_tardive_dyskinesia_parkinsonism_or_other_dystonic_disorders._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions.""*7:Patients_with_schizophrenia_who_carry_the_*7_allele_may_have_an_increased_risk_for_tardive_dyskinesia_or_parkinsonism_when_treated_with_antipsychotics_as_compared_to_patients_with_the_*1/*1_genotype._Note_that_the_*7_allele_has_only_been_assessed_for_this_association_in_combination_with_other_loss-of-function_alleles_(e.g._*3_*4_*5)._Additionally_some_studies_find_no_association_between_loss-of-function_alleles_and_risk_for_tardive_dyskinesia_parkinsonism_or_other_dystonic_disorders._Other_genetic_and_clinical_factors_may_also_influence_antipsychotic-induced_adverse_reactions.";PGKB_RACE=NR
.	.	CYP2D6 *10, CYP2D6 *2	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=methylphenidate_(PA450464);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Attention_Deficit_Disorder_with_Hyperactivity_(PA447197);PGKB_TEXT=*2/*10:Patients_with_the_CYP2D6*2/*10_genotype_may_have_an_increased_risk_for_agitation_and_insomnia_when_treated_with_methylphenidate._However_no_differences_in_the_pharmacokinetics_of_methylphenidate_with_and_without_quinidine_administration_are_reported_in_patients_with_two_functional_vs_one_or_two_non-functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methylphenidate.;PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *100, CYP2D6 *101, CYP2D6 *13, CYP2D6 *2, CYP2D6 *31, CYP2D6 *4, CYP2D6 *5, CYP2D6 *69	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=dextromethorphan_(PA449273);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*5/*13_or_*4/*31_or_*4/*69_or_*5/*100_or_*2/*101_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*2/*101:Patients_with_the_CYP2D6*2/*101_genotype_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*4/*31:Patients_with_the_CYP2D6*4/*31_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*4/*69:Patients_with_the_CYP2D6*4/*69_genotype_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*5/*100:Patients_with_the_CYP2D6*5/*100_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*5/*13:Patients_with_the_CYP2D6*5/*13_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *14, CYP2D6 *1xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Other;PGKB_EVIDENCE=2A;PGKB_DISEASE="Psychotic_Disorders_(PA447215)""Schizophrenia_(PA447216)";PGKB_TEXT="*1:Patients_with_the_*1_allele_may_have_increased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_two_reduced_function_alleles_(*10)_one_reduced_function_and_one_non-functional_(*4_*5_or_*14)_allele_or_two_non-functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*10:Patients_with_the_*10_allele_may_have_decreased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._One_study_found_that_patients_with_the_*10_allele_showed_increased_severity_of_weight_gain_due_to_treatment_with_risperidone_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*14:Patients_with_the_*14_allele_may_have_decreased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*1xN:Patients_with_the_*1XN_allele_may_have_increased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*3:Patients_with_the_*3_allele_may_have_decreased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_the_*1/*1XN_genotype_(ultrarapid_metabolizers)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*4:Patients_with_the_*4_allele_may_have_decreased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)_or_ultrarapid_metabolizers_(*1/*1XN)._Patients_with_the_*4_allele_may_also_respond_better_to_treatment_with_risperidone_as_compared_to_patients_with_the_*1/*1_genotype_though_conflicting_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*5:Patients_with_the_*5_allele_may_have_decreased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)_or_ultrarapid_metabolizers_(*1/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.""*6:Patients_with_the_*6_allele_may_have_decreased_metabolism/clearance_of_risperidone_as_compared_to_patients_with_the_*1/*1XN_genotype_(ultrarapid_metabolizers)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_risperidone.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *14, CYP2D6 *21, CYP2D6 *3, CYP2D6 *36, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=flecainide_(PA449646);PGKB_TYPE=Other;PGKB_EVIDENCE=2A;PGKB_DISEASE=Arrhythmias_Cardiac_(PA443421);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers_may_have_higher_clearance_of_flecainide_as_compared_to_patients_with_non-functional_(*3_*4_*5_*6)_or_reduced_functional_alleles_(*10*17_*40_*41)._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_flecainide.""*10:Patients_with_the_*10_reduced_functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*14:Patients_with_the_*14_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_or_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*21:Patients_with_the_*21_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_or_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*3:Patients_with_the_*3_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_or_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*36:Patients_with_the_*36_reduced_functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*4:Patients_with_the_*4_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_or_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*5:Patients_with_the_*5_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_or_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.""*6:Patients_with_the_*6_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6_*40)_or_reduced_function_allele_(*9_*10_*17_*41)_may_have_lower_clearance_of_flecainide_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_or_intermediate_metabolizers_may_need_lower_dose_of_flecainide_record_ECG_and_monitor_plasma_concentration._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_dose_and_response_to_flecainide.";PGKB_RACE=Asian
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *14, CYP2D6 *2, CYP2D6 *3, CYP2D6 *4, CYP2D6 *41, CYP2D6 *4xN, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=gefitinib_(PA131301952);PGKB_TYPE="Toxicity/ADR""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE="Adenocarcinoma_(PA443265)""Carcinoma_Non-Small-Cell_Lung_(PA443622)";PGKB_TEXT="*1/*1_+_*1/*2_+_*1/*5_+_*1/*10_+_*1/*14_+_*2/*5_+_*2/*10_+_*1/*4_+_*2/*2_+_*2/*4_+_*1/*3_+_*2/*41:Patients_who_are_designated_as_CYP2D6_extensive_metabolizers_and_have_lung_cancer_may_have_a_decreased_risk_for_rash_or_hepatotoxicity_when_treated_with_gefitinib_as_compared_to_patients_designated_as_CYP2D6_poor_metabolizers._Additionally_healthy_individuals_who_are_designated_as_CYP2D6_extensive_metabolizers_may_have_decreased_concentrations_of_gefitinib_as_compared_to_those_who_are_designated_as_CYP2D6_poor_metabolizers._Other_genetic_and_clinical_factors_may_also_influence_risk_for_rash_or_hepatotoxicity_or_concentrations_of_gefitinib._""*1/*10_+_*2/*10_+_*1/*5_+_*5/*10_+_*10/*10:Patients_who_are_designated_as_CYP2D6_poor_metabolizers_and_have_lung_cancer_may_have_an_increased_risk_for_rash_or_hepatotoxicity_when_treated_with_gefitinib_as_compared_to_patients_designated_as_CYP2D6_extensive_metabolizers._Other_genetic_and_clinical_factors_may_also_influence_risk_for_rash_or_hepatotoxicity.""*4/*4_+_*4/*5_+_*3/*4_+_*4/*6_+_*3/*5_+_*4/*4xN:Healthy_individuals_who_are_designated_as_CYP2D6_poor_metabolizers_may_have_increased_concentrations_of_gefitinib_as_compared_to_individuals_designated_as_CYP2D6_extensive_metabolizers._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_gefitinib.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *17, CYP2D6 *1xN, CYP2D6 *2, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *40, CYP2D6 *41, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=codeine_(PA449088);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=1A;PGKB_DISEASE=Pain_(PA445208);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_who_are_treated_with_codeine_may_have_1)_increased_metabolism/clearance_of_codeine_2)_increased_likelihood_of_response_to_codeine_and_3)_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_non-functional_or_reduced_function_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*1/*1XN:Patients_with_more_than_two_copies_of_CYP2D6_functional_alleles_who_are_CYP2D6_ultrarapid_metabolizers_(i.e._a_CYP2D6_activity_score_of_>2.0)_may_have_1)_increased_formation_of_morphine_following_codeine_administration_and_2)_higher_risk_of_toxicity_as_compared_to_patients_with_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers._Patients_who_are_CYP2D6_ultrarapid_metabolizers_should_avoid_codeine_use_due_to_potential_for_toxicity._Alternative_analgesics_such_as_morphine_or_a_non-opioid_should_be_considered._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*1/*2XN:Patients_with_more_than_two_copies_of_CYP2D6_functional_alleles_who_are_CYP2D6_ultrarapid_metabolizers_(i.e._a_CYP2D6_activity_score_of_>2.0)_may_have_1)_increased_formation_of_morphine_following_codeine_administration_and_2)_higher_risk_of_toxicity_as_compared_to_patients_with_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers._Patients_who_are_CYP2D6_ultrarapid_metabolizers_should_avoid_codeine_use_due_to_potential_for_toxicity._Alternative_analgesics_such_as_morphine_or_a_non-opioid_should_be_considered._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*10:Patients_with_the_*10_reduced_functional_allele_in_combination_with_a_non-functional_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_intermediate_metabolizers_should_be_monitored_closely_for_less_than_optimal_response_and_should_be_offered_an_alternative_analgesic_if_required._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*17:Patients_with_the_*17_reduced_functional_allele_in_combination_with_a_non-functional_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_intermediate_metabolizers_should_be_monitored_closely_for_less_than_optimal_response_and_should_be_offered_an_alternative_analgesic_if_required._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*2/*2XN:Patients_with_more_than_two_copies_of_CYP2D6_functional_alleles_who_are_CYP2D6_ultrarapid_metabolizers_(i.e._a_CYP2D6_activity_score_of_>2.0)_may_have_1)_increased_formation_of_morphine_following_codeine_administration_and_2)_higher_risk_of_toxicity_as_compared_to_patients_with_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers._Patients_who_are_CYP2D6_ultrarapid_metabolizers_should_avoid_codeine_use_due_to_potential_for_toxicity._Alternative_analgesics_such_as_morphine_or_a_non-opioid_should_be_considered._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*3:Patients_with_the_*3_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_codeine_use_due_to_lack_of_efficacy._Alternative_analgesics_such_as_morphine_or_a_non-opioid_should_be_considered._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*4:Patients_with_the_*4_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_codeine_use_due_to_lack_of_efficacy._Alternative_analgesics_such_as_morphine_or_a_non-opioid_should_be_considered._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*40:Patients_with_the_*40_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_intermediate_metabolizers_should_be_monitored_closely_for_less_than_optimal_response_and_should_be_offered_an_alternative_analgesic_if_required._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*41:Patients_with_the_*41_reduced_functional_allele_in_combination_with_another_non-functional_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_intermediate_metabolizers_should_be_monitored_closely_for_less_than_optimal_response_and_should_be_offered_an_alternative_analgesic_if_required._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*5:Patients_with_the_*5_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_codeine_use_due_to_lack_of_efficacy._Consider_alternative_analgesics_such_as_morphine_or_a_non-opioid._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.""*6:Patients_with_the_*6_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism/clearance_of_codeine_2)_decreased_likelihood_of_response_to_codeine_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_codeine_use_due_to_lack_of_efficacy._Consider_alternative_analgesics_such_as_morphine_or_a_non-opioid._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *17, CYP2D6 *1xN, CYP2D6 *2, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=desipramine_(PA449233);PGKB_TYPE=Other;PGKB_EVIDENCE=2A;PGKB_DISEASE=Mental_Disorders_(PA447208);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_diplotype_1)_may_have_increased_metabolism_of_desipramine_as_compared_to_patients_with_the_*5/*10_or_*10/*10_diplotype_or_carriers_of_the_*3_*4_or_*5_allele_2)_may_have_reduced_exposure_to_desipramine_as_compared_to_patients_with_*1/*41_*1/*17_*2/*41_*1/*4_or_*41/*41_diplotypes_3)_may_have_reduced_clearance_of_desipramine_and_better_response_to_treatment_as_compared_to_patients_with_the_*2XN_allele._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*1/*17:Patients_with_the_*1/*17_diplotype_may_have_increased_exposure_to_desipramine_as_compared_to_patients_with_*1/*1_*1/*2_or_*2/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*1/*2:Patients_with_the_*1/*2_diplotype_1)_may_have_increased_metabolism_of_desipramine_as_compared_to_patients_with_the_*5/*10_or_*10/*10_diplotype_2)_may_have_reduced_exposure_to_desipramine_as_compared_to_patients_with_*1/*41_*1/*17_*2/*41_*1/*4_or_*41/*41_diplotypes._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*1/*4:Patients_with_the_*1/*4_diplotype_may_have_reduced_metabolism_and_increased_exposure_to_desipramine_as_compared_to_patients_with_*1/*1_*1/*2_or_*2/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*1/*41:Patients_with_the_*1/*41_diplotype_may_have_increased_exposure_to_desipramine_as_compared_to_patients_with_*1/*1_*1/*2_or_*2/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*10/*10:Patients_with_the_*10/*10_diplotype_may_have_reduced_metabolism_of_desipramine_as_compared_to_patients_with_the_*1/*1_or_*1/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*1xN:Patients_with_the_*1XN_allele_may_who_are_treated_with_desipramine_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*2/*41:Patients_with_the_*2/*41_diplotype_may_have_increased_exposure_to_desipramine_as_compared_to_patients_with_*1/*1_*1/*2_or_*2/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*2xN:Patients_with_the_*2XN_allele_may_have_higher_clearance_of_desipramine_and_reduced_response_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*3:Patients_with_the_*3_allele_may_have_reduced_metabolism_of_desipramine_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*4:Patients_with_the_*4_allele_may_have_reduced_metabolism_of_desipramine_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*41/*41:Patients_with_the_*41/*41_diplotype_may_have_increased_exposure_to_desipramine_as_compared_to_patients_with_*1/*1_*1/*2_or_*2/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*5:Patients_with_the_*5_allele_may_have_reduced_metabolism_of_desipramine_as_compared_to_patients_with_the_*1/*1_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._""*5/*10:Patients_with_the_*5/*10_diplotype_may_have_reduced_metabolism_of_desipramine_as_compared_to_patients_with_the_*1/*1_or_*1/*2_diplotype._The_number_of_studies_for_desipramine_pharmacogenomics_is_limited._Since_secondary_amine_tricyclic_antidepressants_have_comparable_pharmacokinetic_properties_see_also_annotations_for_nortriptyline_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_desipramine._";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *17, CYP2D6 *2, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=haloperidol_(PA449841);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="*1:Patients_with_the_*1_allele_may_have_increased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_reduced_function_alleles_(*10)_one_reduced_function_and_one_non-functional_(*3_*4_or_*5)_allele_or_two_non-functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""*10:Patients_with_the_*10_allele_may_have_decreased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._However_an_approximately_equal_number_of_studies_have_found_the_*10_allele_to_not_be_associated_with_decreased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""*17:Patients_with_the_*17_allele_may_have_increased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_non-functional_(*3_*4_or_*5)_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""*2:Patients_with_the_*2_allele_may_have_increased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_reduced_function_alleles_(*10)_one_reduced_function_and_one_non-functional_(*3_*4_or_*5)_allele_or_two_non-functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""*3:Patients_with_the_*3_allele_may_have_decreased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""*4:Patients_with_the_*4_allele_may_have_decreased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""*5:Patients_with_the_*5_allele_may_have_decreased_metabolism/clearance_of_haloperidol_as_compared_to_patients_with_two_fully_functional_alleles_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *18, CYP2D6 *2, CYP2D6 *21, CYP2D6 *44, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG="debrisoquine_(PA452616)""dextromethorphan_(PA449273)""sparteine_(PA452610)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*21_:Patients_with_the_CYP2D6*1/*21_genotype_may_have_a_decreased_metabolism_of_dextromethorphan_as_compared_to_patients_with_the_CYP2D6*1/*2_genotype._Finding_reported_in_case_study_for_*1/*21_subject._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*1/*1_+_*1/*2:Patients_with_the_CYP2D6*1/*1_or_*1/2_genotype_may_have_an_increased_metabolism_of_debrisoquine_or_dextromethorphan_or_sparteine_as_compared_to_patients_with_the_CYP2D6*18/*21_or_*5/*18_or_*1/*21_or_*10/*21_or_*2/*44_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_debrisoquine_or_dextromethorphan_or_sparteine.""*10/*21:Patients_with_the_CYP2D6*10/*21_genotype_may_have_a_decreased_metabolism_of_dextromethorphan_as_compared_to_patients_with_the_CYP2D6*1/*2_genotype._Finding_reported_in_case_study_for_*10/*21_subject._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*18/*21:Patients_with_the_CYP2D6*18/*21_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_debrisoquine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Finding_reported_in_case_study_for_*18/*21_subject._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_debrisoquine.""*2/*44:Patients_with_the_CYP2D6*2/*44_genotype_may_have_a_decreased_metabolism_of_dextromethorphan_as_compared_to_patients_with_the_CYP2D6*1/*2_genotype._Finding_reported_in_case_study_for_*2/*44_subject._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*5/*18:Patients_with_the_CYP2D6*5/*18_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Finding_reported_in_case_study_for_*5/*18_subject._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.";PGKB_RACE=Asian
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *1xN, CYP2D6 *2, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=amitriptyline_(PA448385);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=1A;PGKB_DISEASE="Depressive_Disorder_Major_(PA447321)""Mental_Disorders_(PA447208)""Mood_Disorders_(PA447209)";PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2D6_alleles_who_are_treated_with_amitriptyline_may_have_1)_decreased_nortriptyline_plasma_levels_and_increased_clearance_of_amitryptyline_and_2)_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_CYP2D6_non-functional_alleles_(*3_*4_*5_*6)_or_reduced_function_alleles_and_a_decreased_metabolism_of_amitriptyline_as_compared_to_patients_with_duplication_of_a_functional_CYP2D6_gene._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*10:Patients_with_the_CYP2D6*10_allele_in_combination_with_another_reduced_function_(*10_*41)_or_non-functional_CYP2D6_allele_who_are_treated_with_amitriptyline_may_have_increased_nortriptyline_plasma_levels_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*1xN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_who_are_treated_with_amitriptyline_may_have_1)_an_increased_metabolism_of_amitriptyline_and_2)_decreased_response_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*2/*2:Patients_with_two_functional_CYP2D6_alleles_who_are_treated_with_amitriptyline_may_have_1)_decreased_nortriptyline_plasma_levels_and_increased_clearance_of_amitryptyline_and_2)_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_CYP2D6_non-functional_alleles_(*3_*4_*5_*6)_or_reduced_function_allelesand_a_decreased_metabolism_of_amitriptyline_as_compared_to_patients_with_duplication_of_a_functional_CYP2D6_gene._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*2xN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_who_are_treated_with_amitriptyline_may_have_1)_an_increased_metabolism_of_amitriptyline_and_2)_decreased_response_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*3:Patients_with_the_CYP2D6*3_allele_who_are_treated_with_amitriptyline_may_have_1)_increased_nortriptyline_plasma_levels_and_decreased_clearance_of_amitriptyline_and_2)_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*4:Patients_with_the_CYP2D6*4_allele_who_are_treated_with_amitriptyline_may_have_1)_increased_nortriptyline_plasma_levels_and_decreased_clearance_of_amitriptyline_and_2)_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*41:Patients_with_the_CYP2D6*41_allele_in_combination_with_another_reduced_function_(*10_*41)_or_non-functional_CYP2D6_allele_who_are_treated_with_amitriptyline_may_have_increased_nortriptyline_plasma_levels_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*5:Patients_with_the_CYP2D6*5_allele_who_are_treated_with_amitriptyline_may_have_1)_increased_nortriptyline_plasma_levels_and_decreased_clearance_of_amitriptyline_and_2)_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.""*6:Patients_with_the_CYP2D6*6_allele_who_are_treated_with_amitriptyline_may_have_1)_increased_nortriptyline_plasma_levels_and_decreased_clearance_of_amitriptyline_and_2)_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *1xN, CYP2D6 *2, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=3;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=paroxetine_(PA450801),nortriptyline_(PA450657),tramadol_(PA451735);PGKB_TYPE="Efficacy""Toxicity/ADR""Metabolism/PK","Efficacy""Toxicity/ADR""Metabolism/PK","Dosage""Efficacy""Toxicity/ADR";PGKB_EVIDENCE=1A,1A,1B;PGKB_DISEASE="Depressive_Disorder_Major_(PA447321)""Mental_Disorders_(PA447208)""Obsessive-Compulsive_Disorder_(PA447211)",Depressive_Disorder_Major_(PA447321),Pain_(PA445208);PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_paroxetine_may_have_1)_a_decreased_clearance_of_paroxetine_as_compared_to_patients_with_more_than_2_functional_CYP2D6_alleles_(*1XN_*2XN)_and_2)_an_increased_clearance_of_paroxetine_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)_or_*10/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*1/*1XN:Patients_with_the_CYP2D6*1/*1XN_genotype_(carriers_of_more_than_two_functional_CYP2D6_alleles)_who_are_treated_with_paroxetine_may_have_an_increased_clearance_of_paroxetine_(lower_or_undetectable_drug_plasma_levels)_which_may_effect_response_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*1/*2XN:Patients_with_the_CYP2D6*1/*2XN_genotype_(carriers_of_more_than_two_functional_CYP2D6_alleles)_who_are_treated_with_paroxetine_may_have_an_increased_clearance_of_paroxetine_(lower_or_undetectable_drug_plasma_levels)_which_may_effect_response_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*10/*10_+_*1/*10_:Patients_with_the_*10/*10_or_*1/*10_genotype_who_are_treated_with_paroxetine_may_have_increased_plasma_concentrations/_decreased_clearance_of_paroxetine_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*2:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_paroxetine_may_have_1)_a_decreased_clearance_of_paroxetine_as_compared_to_patients_with_more_than_2_functional_CYP2D6_alleles_(*1XN_*2XN)_and_2)_an_increased_clearance_of_paroxetine_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)_or_*10/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*2/*2XN:Patients_with_the_CYP2D6*1/*1XN_genotype_(carriers_of_more_than_two_functional_CYP2D6_alleles)_who_are_treated_with_paroxetine_may_have_an_increased_clearance_of_paroxetine_(lower_or_undetectable_drug_plasma_levels)_which_may_effect_response_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*3:Patients_with_the_*3_allele_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_who_are_treated_with_paroxetine_may_have_a_decreased_clearance_of_paroxetine_(higher_paroxetine_plasma_concentrations)_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._However_an_association_with_treatment_response_or_severity_of_side_effects_is_not_conclusive._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*4:Patients_with_the_*4_allele_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_who_are_treated_with_paroxetine_may_have_a_decreased_clearance_of_paroxetine_(higher_paroxetine_plasma_concentrations)_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._However_an_association_with_treatment_response_or_severity_of_side_effects_is_not_conclusive._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*5:Patients_with_the_*5_allele_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_who_are_treated_with_paroxetine_may_have_a_decreased_clearance_of_paroxetine_(higher_paroxetine_plasma_concentrations)_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._However_an_association_with_treatment_response_or_severity_of_side_effects_is_not_conclusive._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""*6:Patients_with_the_*6_allele_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_who_are_treated_with_paroxetine_may_have_a_decreased_clearance_of_paroxetine_(higher_paroxetine_plasma_concentrations)_as_compared_to_patients_with_the_CYPD6*1/*1_or_*2/*2_genotype._However_an_association_with_treatment_response_or_severity_of_side_effects_is_not_conclusive._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._","*1/*1:Patients_with_two_functional_CYP2D6_alleles_who_are_treated_with_nortriptyline_may_have_decreased_metabolism_of_nortriptyline_as_compared_to_patients_with_a_duplication_of_a_functional_CYP2D6_gene_and_1)_increased_metabolism_of_nortriptyline_(decreased_nortriptyline_plasma_levels)_2)_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_CYP2D6_non-functional_alleles_(*3_*4_*5_*6)_or_reduced_function_alleles_(*10)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*1/*1xN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_who_are_treated_with_nortriptyline_may_have_an_increased_metabolism_of_nortriptyline_(decreased_nortriptyline_plasma_concentration_and_increased_maximum_plasma_concentration_of_10-hydroxy_nortriptyline)_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*1/*2xN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_who_are_treated_with_nortriptyline_may_have_an_increased_metabolism_of_nortriptyline_(decreased_nortriptyline_plasma_concentration_and_increased_maximum_plasma_concentration_of_10-hydroxy_nortriptyline)_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*2/*2:Patients_with_two_functional_CYP2D6_alleles_who_are_treated_with_nortriptyline_may_have_decreased_metabolism_of_nortriptyline_as_compared_to_patients_with_a_duplication_of_a_functional_CYP2D6_gene_and_1)_increased_metabolism_of_nortriptyline_(decreased_nortriptyline_plasma_levels)_2)_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_CYP2D6_non-functional_alleles_(*3_*4_*5_*6)_or_reduced_function_alleles_(*10)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*3:Patients_with_the_CYP2D6*3_allele_who_are_treated_with_nortriptyline_may_have_1)_decreased_metabolism_of_nortriptyline_(increased_nortriptyline_plasma_levels)_2)_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_or_reduced_function_allele_(*10)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*4:Patients_with_the_CYP2D6*4_allele_who_are_treated_with_nortriptyline_may_have_1)_decreased_metabolism_of_nortriptyline_(increased_nortriptyline_plasma_levels)_2)_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_or_reduced_function_allele_(*10)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*5:Patients_with_the_CYP2D6*5_allele_who_are_treated_with_nortriptyline_may_have_1)_decreased_metabolism_of_nortriptyline_(increased_nortriptyline_plasma_levels)_2)_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_or_reduced_function_allele_(*10)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*5/*10_+_*10/*10:Patients_with_the_CYP2D6*10/*10_or_*5/*10_genotype_who_are_treated_with_nortriptyline_may_have_1)_decreased_metabolism_of_nortriptyline_(increased_nortriptyline_plasma_levels)_2)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""*6:Patients_with_the_CYP2D6*6_allele_who_are_treated_with_nortriptyline_may_have_1)_decreased_metabolism_of_nortriptyline_(increased_nortriptyline_plasma_levels)_2)_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_or_reduced_function_allele_(*10)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.","*1/_*1xN:Patients_with_more_than_two_copies_of_CYP2D6_fully_functional_alleles_who_are_CYP2D6_ultrarapid_metabolizers_(i.e._a_CYP2D6_activity_score_of_>2.0)_may_have_higher_risk_of_toxicity/side_effects_(respiratory_depression_cardiotoxicity_or_nausea)_as_compared_to_patients_with_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers._Patients_who_are_CYP2D6_ultrarapid_metabolizers_should_reduce_tramadol_dose_or_choose_another_drug_(e.g._acetaminophen_NSAID_morphine-not_oxycodone_or_codeine)_due_to_potential_for_toxicity_and_should_be_alert_to_adverse_drug_events._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*1/*1:Patients_with_the_*1/*1_genotype_who_are_treated_with_tramadol_may_have_1)_increased_metabolism_of_tramadol_2)_increased_likelihood_of_response_to_tramadol_and_3)_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_non-functional_or_reduced_function_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*10:Patients_with_the_*10_reduced_function_allele_in_combination_with_a_non-functional_or_another_reduced_function_allele_may_have_decreased_metabolism_of_tramadol_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_tramadol_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*2:Patients_with_the_*2_allele_and_another_fully_functional_allele_who_are_treated_with_tramadol_may_have_1)_increased_metabolism_of_tramadol_2)_increased_likelihood_of_response_to_tramadol_and_3)_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_non-functional_or_reduced_function_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*2/_*2xN:Patients_with_more_than_two_copies_of_CYP2D6_fully_functional_alleles_who_are_CYP2D6_ultrarapid_metabolizers_(i.e._a_CYP2D6_activity_score_of_>2.0)_may_have_higher_risk_of_toxicity/side_effects_(respiratory_depression_cardiotoxicity_or_nausea)_as_compared_to_patients_with_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers._Patients_who_are_CYP2D6_ultrarapid_metabolizers_should_reduce_tramadol_dose_or_choose_another_drug_(e.g._acetaminophen_NSAID_morphine-not_oxycodone_or_codeine)_due_to_potential_for_toxicity_and_should_be_alert_to_adverse_drug_events._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*3:Patients_with_the_*3_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism_of_tramadol_2)_decreased_likelihood_of_response_to_tramadol_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_tramadol_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*4:Patients_with_the_*4_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism_of_tramadol_2)_decreased_likelihood_of_response_to_tramadol_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_tramadol_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*5:Patients_with_the_*5_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism_of_tramadol_2)_decreased_likelihood_of_response_to_tramadol_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_tramadol_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*6:Patients_with_the_*6_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_may_have_1)_decreased_metabolism_of_tramadol_2)_decreased_likelihood_of_response_to_tramadol_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Patients_who_are_CYP2D6_poor_metabolizers_should_avoid_tramadol_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.";PGKB_RACE=NR,NR,NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *2, CYP2D6 *3, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_citalopram_or_escitalopram_may_have_a_decreased_frequency_of_remission_and_an_increased_dose_as_compared_to_patients_with_two_non-functional_alleles_(*3_*4_*5_*6)_or_a_reduced_function_allele_(*10_*17_*41)_and_a_non-functional_allele._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*10:Patients_with_the_CYP2D6*10_allele_in_combination_with_a_non-functional_allele_(*3_*4_*5_*6)_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_frequency_of_remission_and_a_decreased_dose_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*2/*2:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_citalopram_or_escitalopram_may_have_a_decreased_frequency_of_remission_and_an_increased_dose_as_compared_to_patients_with_two_non-functional_alleles_(*3_*4_*5_*6)_or_a_reduced_function_allele_(*10_*17_*41)_and_a_non-functional_allele._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*3:Patients_with_the_CYP2D6*3_allele_in_combination_with_a_non-functional_allele_(*3_*4_*5_*6)_or_a_reduced_function_allele_(*10_*17_*41)_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_frequency_of_remission_and_a_decreased_dose_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*4:Patients_with_the_CYP2D6*4_allele_in_combination_with_a_non-functional_allele_(*3_*4_*5_*6)_or_a_reduced_function_allele_(*10_*17_*41)_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_frequency_of_remission_and_a_decreased_dose_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*41:Patients_with_the_CYP2D6*41_allele_in_combination_with_a_non-functional_allele_(*3_*4_*5_*6)_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_frequency_of_remission_and_a_decreased_dose_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*5:Patients_with_the_CYP2D6*5_allele_in_combination_with_a_non-functional_allele_(*3_*4_*5_*6)_or_a_reduced_function_allele_(*10_*17_*41)_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_frequency_of_remission_and_a_decreased_dose_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""*6:Patients_with_the_CYP2D6*6_allele_in_combination_with_a_non-functional_allele_(*3_*4_*5_*6)_or_a_reduced_function_allele_(*10_*17_*41)_who_are_treated_with_citalopram_or_escitalopram_may_have_an_increased_frequency_of_remission_and_a_decreased_dose_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_the_majority_of_the_studies_reported_contradictory_finding_with_no_association_of_CYP2D6_genotypes_with_drug_clearance_or_differences_in_remission_or_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *2, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=atomoxetine_(PA134688071);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=2A;PGKB_DISEASE=Attention_Deficit_Disorder_with_Hyperactivity_(PA447197);PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_atomoxetine_may_1)_decreased_response__2)_decreased_risk_for_side_effects_such_as_decreased_appetite_tremor_increase_in_pulse_and_diastolic__3)_higher_dose_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._""*1/*2:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_atomoxetine_may_1)_decreased_response__2)_decreased_risk_for_side_effects_such_as_decreased_appetite_tremor_increase_in_pulse_and_diastolic__3)_higher_dose_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._""*10:Patients_with_the_CYP2D6*10_allele_may_have_decreased_clearance_of_atomoxetine_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_no_association_with_differences_in_adverse_event_rates_when_treated_with_atomoxetine_was_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._""*2/*2:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_atomoxetine_may_1)_decreased_response__2)_decreased_risk_for_side_effects_such_as_decreased_appetite_tremor_increase_in_pulse_and_diastolic__3)_higher_dose_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._""*3:Patients_with_the_CYP2D6*3_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_atomoxetine_may_have_1)_increased_response__2)_increased_risk_for_side_effects_such_as_decreased_appetite_tremor_increase_in_pulse_and_diastolic__3)_lower_dose_to_increase_tolerability_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._""*4:Patients_with_the_CYP2D6*4_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_atomoxetine_may_have_1)_increased_response__2)_increased_risk_for_side_effects_such_as_decreased_appetite_tremor_increase_in_pulse_and_diastolic__3)_lower_dose_to_increase_tolerability_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._""*5:Patients_with_the_CYP2D6*5_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_atomoxetine_may_have_1)_increased_response__2)_increased_risk_for_side_effects_such_as_decreased_appetite_tremor_increase_in_pulse_and_diastolic__3)_lower_dose_to_increase_tolerability_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine._";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *2, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=aripiprazole_(PA10026);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1:Patients_with_the_*1_allele_may_have_increased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_reduced_function_alleles_(*10_or_*41)_one_reduced_function_and_one_non-functional_(*3_*4_*5_or_*6)_allele_or_two_non-functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.""*10:Patients_with_the_*10_allele_may_have_decreased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_fully_functional_alleles_(*1_or_*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.""*2:Patients_with_the_*2_allele_may_have_increased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_reduced_function_alleles_(*10_or_*41)_one_reduced_function_and_one_non-functional_(*3_*4_*5_or_*6)_allele_or_two_non-functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.""*4:Patients_with_the_*4_allele_may_have_decreased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_fully_functional_alleles_(*1_or_*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.""*41:Patients_with_the_*41_allele_may_have_decreased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_fully_functional_alleles_(*1_*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.""*5:Patients_with_the_*5_allele_may_have_decreased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_fully_functional_alleles_(*1_or_*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.""*6:Patients_with_the_*6_allele_may_have_decreased_metabolism/clearance_of_aripiprazole_as_compared_to_patients_with_two_fully_functional_alleles_(*1_or_*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aripiprazole.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *2, CYP2D6 *4, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=carvedilol_(PA448817);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Heart_Diseases_(PA444368);PGKB_TEXT="*1/*1:Patients_with_heart_disease_or_healthy_individuals_with_the_CYP2D6_*1/*1_genotype_may_have_increased_clearance_of_carvedilol_as_compared_to_those_with_the_*1/*4_*1/*5_or_*10/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_carvedilol.""*1/*2:Healthy_individuals_with_the_CYP2D6_*1/*2_genotype_may_have_increased_clearance_of_carvedilol_as_compared_to_those_with_the_*10/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_carvedilol.""*1/*4:Patients_with_the_CYP2D6_*1/*4_genotype_and_heart_disease_may_have_decreased_clearance_of_carvedilol_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_carvedilol.""*1/*5:Patients_with_the_CYP2D6_*1/*5_genotype_and_heart_disease_may_have_decreased_clearance_of_carvedilol_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_carvedilol.""*10/*10:Patients_with_heart_disease_or_healthy_individuals_with_the_CYP2D6_*10/*10_genotype_may_have_decreased_clearance_of_carvedilol_as_compared_to_those_with_the_*1/*1_or_*1/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_carvedilol.";PGKB_RACE=Asian
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *3, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=tamoxifen_(PA451581),venlafaxine_(PA451866);PGKB_TYPE=Efficacy,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,2A;PGKB_DISEASE=Breast_Neoplasms_(PA443560),"Depressive_Disorder_(PA447207)""Obsessive-Compulsive_Disorder_(PA447211)";PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_and_Breast_Cancer_who_are_CYP2D6_normal/extensive_metabolizers_or_have_a_CYP2D6_activity_score_of_>50%_may_have_1)_a_decreased_likelihood_of_recurrence_of_breast_cancer_2)_a_decreased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_poor_metabolizer_status_who_have_a_CYP2D6_activity_score_of_50%_or_less._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._""*10:Patients_with_the_*10_allele_and_Breast_Cancer_who_are_CYP2D6_poor_metabolizers_or_have_a_CYP2D6_activity_score_of_50%_or_less_may_have_1)_an_increased_likelihood_of_recurrence_of_breast_cancer_2)_an_increased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_normal/extensive_metabolizer_status_who_have_a_CYP2D6_activity_score_of_>50%._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._""*3:Patients_with_the_*3_allele_and_Breast_Cancer_who_are_CYP2D6_poor_metabolizers_or_have_a_CYP2D6_activity_score_of_50%_or_less_may_have_1)_an_increased_likelihood_of_recurrence_of_breast_cancer_2)_an_increased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_normal/extensive_metabolizer_status_who_have_a_CYP2D6_activity_score_of_>50%._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._""*4:Patients_with_the_*4_allele_and_Breast_Cancer_who_are_CYP2D6_poor_metabolizers_or_have_a_CYP2D6_activity_score_of_50%_or_less_may_have_1)_an_increased_likelihood_of_recurrence_of_breast_cancer_2)_an_increased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_normal/extensive_metabolizer_status_who_have_a_CYP2D6_activity_score_of_>50%._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._""*41:Patients_with_the_*41_allele_and_Breast_Cancer_who_are_CYP2D6_poor_metabolizers_or_have_a_CYP2D6_activity_score_of_50%_or_less_may_have_1)_an_increased_likelihood_of_recurrence_of_breast_cancer_2)_an_increased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_normal/extensive_metabolizer_status_who_have_a_CYP2D6_activity_score_of_>50%._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._""*5:Patients_with_the_*5_allele_and_Breast_Cancer_who_are_CYP2D6_poor_metabolizers_or_have_a_CYP2D6_activity_score_of_50%_or_less_may_have_1)_an_increased_likelihood_of_recurrence_of_breast_cancer_2)_an_increased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_normal/extensive_metabolizer_status_who_have_a_CYP2D6_activity_score_of_>50%._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._""*6:Patients_with_the_*6_allele_and_Breast_Cancer_who_are_CYP2D6_poor_metabolizers_or_have_a_CYP2D6_activity_score_of_50%_or_less_may_have_1)_an_increased_likelihood_of_recurrence_of_breast_cancer_2)_an_increased_risk_of_breast-cancer-related_death_when_treated_with_tamoxifen_as_compared_to_patients_with_a_genotype_conferring_CYP2D6_normal/extensive_metabolizer_status_who_have_a_CYP2D6_activity_score_of_>50%._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tamoxifen_treatment._","*1/*1:Patients_with_the_*1/*1_genotype_who_carry_two_functional_alleles_may_have_1)_increased_metabolism/clearance_of_venlafaxine_2)_increased_tolerance_of_higher_venlafaxine_dose_and_3)_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_non-functional_(*3_*4_*5_*6)_and_reduced_functional_alleles_(*10_*41)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""*10:Patients_with_Depressive_Disorder_and_the_*10_reduced_function_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6)_or_reduced_function_allele_(*10_*41)_may_have_1)_decreased_metabolism/clearance_of_venlafaxine_and_2)_in_combination_with_another_non-functional_may_have_decreased_tolerance_of_higher_venlafaxine_dose_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._In_patients_with_Obsessive-Compulsive_Disorder_no_association_with_treatment_response_was_found._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""*3:Patients_with_Depressive_Disorder_and_the_*3_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6)_or_reduced_function_(*9_*10_*41)_allele_may_have_1)_decreased_metabolism/clearance_of_venlafaxine_and_2)_decreased_tolerance_of_higher_venlafaxine_dose_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._In_patients_with_Obsessive-Compulsive_Disorder_no_association_with_treatment_response_was_found._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""*4:Patients_with_Depressive_Disorder_and_the_*4_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6)_or_reduced_function_allele_(*10_*17_*41)_may_have_1)_decreased_metabolism/clearance_of_venlafaxine_2)_decreased_tolerance_of_higher_venlafaxine_dose_and_3)_increased_risk_for_side_effects_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._In_patients_with_Obsessive-Compulsive_Disorder_an_association_with_decreased_metabolism/clearance_was_confirmed_but_no_association_with_treatment_response_was_found._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""*41:Patients_with_Depressive_Disorder_and_the_*41_reduced_function_allele_in_combination_with_another_non-functional_allele_(*3_*4_*5_*6)_may_have_decreased_tolerance_of_higher_venlafaxine_dose_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._In_patients_with_Obsessive-Compulsive_Disorder_no_association_with_treatment_response_was_found._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""*5:Patients_with_Depressive_Disorder_and_the_*5_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6)_or_reduced_function_allele_(*10_*41)_may_have_1)_decreased_metabolism_of_venlafaxine_and_2)_increased_risk_for_side_effects_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""*6:Patients_with_Depressive_Disorder_and_the_*6_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5_*6)_or_reduced_function_allele_(*10_*41)_may_have_1)_decreased_metabolism_of_venlafaxine_and_2)_increased_risk_for_side_effects_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._";PGKB_RACE=NR,NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=fluvoxamine_(PA449690),risperidone_(PA451257);PGKB_TYPE="Efficacy""Toxicity/ADR""Metabolism/PK",Other;PGKB_EVIDENCE=1A,3;PGKB_DISEASE="Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)""Mental_Disorders_(PA447208)""Obsessive-Compulsive_Disorder_(PA447211)",Schizophrenia_(PA447216);PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_fluvoxamine_may_have_1)_decreased_steady-state_plasma_concentration-to-dose_(C/D)_ratio_as_compared_to_patients_with_the_*1/*5_*1/*10_*5/*10_*10/*10_genotype_2)_decreased_plasma_concentrations_3)_decreased_risk_of_developing_gastrointestinal_side_effects_as_compared_to_patients_with_the_*5/*10_*10/*10_genotype_and_4)_decreased_AUC_Cmax_and_half-life_time_of_fluvoxamine_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(poor_metabolizer_phenotypes)._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fluvoxamine.""*1/*10:Patients_with_the_CYP2D6*1/*10_genotype_who_are_treated_with_fluvoxamine_may_have_increased_steady-state_plasma_concentration-to-dose_(C/D)_ratio_as_compared_to_patients_with_the_*1/*1_genotype._However_contradictory_findings_reporting_no_association_with_fluvoxamine_plasma_concentrations_are_published._Studies_investigation_multiple_antidepressants_including_fluvoxamine_found_no_association_with_side_effects_or_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fluvoxamine.""*1/*5_:Patients_with_the_CYP2D6*1/*5_genotype_who_are_treated_with_fluvoxamine_may_have_increased_steady-state_plasma_concentration-to-dose_(C/D)_ratio_as_compared_to_patients_with_the_*1/*1_genotype._However_contradictory_findings_reporting_no_association_with_fluvoxamine_plasma_concentrations_are_published._Studies_investigation_multiple_antidepressants_including_fluvoxamine_found_no_association_with_side_effects_or_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fluvoxamine.""*10/*10:Patients_with_the_CYP2D6*10/*10_genotype_who_are_treated_with_fluvoxamine_may_have_increased_1)_steady-state_plasma_concentration-to-dose_(C/D)_ratio_or_increased_fluvoxamine_plasma_concentrations_and_2)_risk_of_developing_gastrointestinal_side_effects_as_compared_to_patients_with_the_*1/*1_genotype._However_contradictory_finding_with_no_association_with_plasma_concentrations_or_side_effect_risk_are_reported._Additionally_Studies_investigation_multiple_antidepressants_including_fluvoxamine_found_no_association_with_with_side_effects_or_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fluvoxamine.""*3_+_*4_+_*5_+_*6:Patients_with_two_non-functional_CYP2D6_alleles_(e.g._*3/*3__*4/*4__*4/*6__*4/*5)_(CYP2D6_poor_metabolizer)_who_are_treated_with_fluvoxamine_may_have_increased_AUC_Cmax_and_half-life_time_of_fluvoxamine_(decreased_clearance)_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1)._However_contradictory_findings_are_reported._Studies_investigation_multiple_antidepressants_including_fluvoxamine_found_no_association_with_side_effects_or_response_but_in_one_study_with_a_decreased_dose_for_*4/*4_carrier._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fluvoxamine.""*5/*10:Patients_with_the_CYP2D6*5/*10_genotype_who_are_treated_with_fluvoxamine_may_have_increased_1)_steady-state_plasma_concentration-to-dose_(C/D)_ratio_or_increased_fluvoxamine_plasma_concentrations_and_2)_risk_of_developing_gastrointestinal_side_effects_as_compared_to_patients_with_the_*1/*1_genotype._However_contradictory_finding_with_no_association_with_plasma_concentrations_or_side_effect_risk_are_reported._Additionally_Studies_investigation_multiple_antidepressants_including_fluvoxamine_found_no_association_with_with_side_effects_or_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fluvoxamine.","*1/*1:Patients_with_the_*1/*1_diplotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_increased_metabolism_of_risperidone_compared_to_patients_with_one_or_two_non-functional_or_reduced_function_haplotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*10:Patients_with_the_*10_reduced_function_allele_in_combination_with_a_non-functional_or_another_reduced_function_allele_may_have_decreased_metabolism_of_risperidone_as_compared_to_patients_with_*1/*1_diplotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*3:Patients_with_the_*3_reduced_function_allele_in_combination_with_a_non-functional_or_another_reduced_function_allele_may_have_decreased_metabolism_of_risperidone_as_compared_to_patients_with_*1/*1_diplotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*4:Patients_with_the_*4_reduced_function_allele_in_combination_with_a_non-functional_or_another_reduced_function_allele_may_have_decreased_metabolism_of_risperidone_as_compared_to_patients_with_*1/*1_diplotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*5:Patients_with_the_*5_reduced_function_allele_in_combination_with_a_non-functional_or_another_reduced_function_allele_may_have_decreased_metabolism_of_risperidone_as_compared_to_patients_with_*1/*1_diplotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.""*6:Patients_with_the_*6_reduced_function_allele_in_combination_with_a_non-functional_or_another_reduced_function_allele_may_have_decreased_metabolism_of_risperidone_as_compared_to_patients_with_*1/*1_diplotype_who_carry_two_functional_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tramadol.";PGKB_RACE=NR,NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *3, CYP2D6 *4	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=tolterodine_(PA164746757);PGKB_TYPE=Other;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2D6_alleles_may_have_an_increased_metabolism_of_tolterodine_as_compared_to_patients_with_two_non-functional_(*3_*4)_or_two_reduced_functional_(*10/*10)_CYP2D6_alleles._However_no_association_with_response_is_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_and_response_to_tolterodine.""*10/*10:Patients_with_the_CYP2D6*10/*10_genotype_may_have_an_increased_tolterodine_and_its_active_metabolite_(5-HM)_exposure_as_compared_to_patients_with_the_*1/*1_or_*1/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_tolterodine.""*3:Patients_with_two_non-functional_CYP2D6_alleles_may_have_decreased_metabolism_of_tolterodine_as_compared_to_patients_with_two_functional_CYP2D6_alleles._However_no_association_with_response_is_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_and_response_to_tolterodine.""*4:Patients_with_two_non-functional_CYP2D6_alleles_may_have_decreased_metabolism_of_tolterodine_as_compared_to_patients_with_two_functional_CYP2D6_alleles._However_no_association_with_response_is_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_and_response_to_tolterodine.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *10, CYP2D6 *5	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=lovastatin_(PA450272),mianserin_(PA134687937);PGKB_TYPE=Other,Metabolism/PK;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Depression_(PA447278);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_may_have_increased_metabolism_of_lovastatin_as_compared_to_patients_carrying_the_*5_or_*10_alleles._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_lovastatin.""*1/*10:Patients_with_the_*1/*10_genotype_may_have_decreased_metabolism_of_lovastatin_as_compared_to_patients_with_the_*1/*1_genotype_but_increased_metabolism_of_lovastatin_as_compared_to_patients_with_the_*10/*10_genotype_or_who_are_carrying_the_*5_allele._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_lovastatin.""*10/*10:Patients_with_the_*10/*10_genotype_may_have_decreased_metabolism_of_lovastatin_as_compared_to_patients_carrying_the_*1_allele_but_increased_metabolism_of_lovastatin_as_compared_to_patients_carrying_the_*5_allele._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_lovastatin.""*5/*10:Patients_with_the_*5/*10_genotype_may_have_decreased_metabolism_of_lovastatin_as_compared_to_patients_without_the_*5_allele_but_increased_metabolism_of_lovastatin_as_compared_to_patients_with_the_*5/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_lovastatin.""*5/*5:Patients_with_the_*5/*5_genotype_may_have_decreased_metabolism_of_lovastatin_as_compared_to_patients_carrying_the_*1_or_*10_alleles._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_lovastatin.","*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_mianserin_may_have_an_increased_plasma_concentration_of_S-mianserin_as_compared_to_patients_with_the_CYP2D6*1/*10_or_*5/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mianserin.""*1/*10_+_*5/*10:Patients_with_the_CYP2D6*1/*10_or_*5/*10_genotype_who_are_treated_with_mianserin_may_have_a_decreased_plasma_concentration_of_S-mianserin_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mianserin.";PGKB_RACE=Asian,NR
.	.	CYP2D6 *1, CYP2D6 *10	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=propranolol_(PA451145),propafenone_(PA451131);PGKB_TYPE=Other,Dosage;PGKB_EVIDENCE=4,2A;PGKB_DISEASE=NR,Arrhythmias_Cardiac_(PA443421);PGKB_TEXT="*1:Patients_with_the_CYP2D6*1_allele_may_have_lower_S-propranolol_plasma_concentration_when_treated_with_propranolol_as_compared_to_patients_with_the_CYP2D6*10_allele._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_propranolol.""*10:Patients_with_the_CYP2D6*10_allele_may_have_higher_S-propranolol_plasma_concentration_when_treated_with_propranolol_as_compared_to_patients_with_the_CYP2D6*1_allele._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_propranolol.","*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_propafenone_may_have_1)_increased_metabolism_of_propafenone_2)_decreased_but_not_absent_risk_of_cardiac_arrythmias_and_other_side_effects_as_compared_to_patients_with_the_*10/*10_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_propafenone.""*10/*10:Patients_with_the_CYP2D6*10/*10_genotype_who_are_treated_with_propafenone_may_have_1)_decreased_metabolism_of_propafenone_2)_increased_exposure_to_propafenone_3)_increased_risk_of_cardiac_arrythmias_and_other_side_effects_4)_exaggerated_beta-adrenergic_blocking_activity_as_compared_to_patients_with_*1/*1_genotype._Patients_with_reduced_function_alleles_of_CYP2D6_may_need_to_adjust_dose_in_response_to_plasma_concentration_and_record_ECG_or_select_alternative_drug_(e.g._sotalol_disopyramide_quinidine_amiodarone)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_propafenone.";PGKB_RACE=Asian,Asian
.	.	CYP2D6 *1, CYP2D6 *11, CYP2D6 *12, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5, CYP2D6 *59, CYP2D6 *62, CYP2D6 *7, CYP2D6 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=sparteine_(PA452610);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*4/*11_or_*4/*12_or_*4/*59_or_*5/*7_or_*5/*8_or_*41/*62_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.""*4/*11:Patients_with_the_CYP2D6*4/*11_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.""*4/*12:Patients_with_the_CYP2D6*4/*12_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.""*4/*59:Patients_with_the_CYP2D6*4/*59_genotype_(assigned_as_intermediate_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.""*41/*62:Patients_with_the_CYP2D6*41/*62_genotype_(assigned_as_intermediate_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.""*5/*7:Patients_with_the_CYP2D6*5/*7_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.""*5/*8:Patients_with_the_CYP2D6*5/*8_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_sparteine.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *15, CYP2D6 *4	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG="debrisoquine_(PA452616)""dextromethorphan_(PA449273)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_metabolism_of_dextromethorphan_(probe_drug)_or_debrisoquine_as_compared_to_patients_with_the_CYP2D6*4/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan_or_debrisoquine.""*4/*15:Patients_with_the_CYP2D6*4/*15_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_or_debrisoquine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan_or_debrisoquine.";PGKB_RACE=White
.	.	CYP2D6 *1, CYP2D6 *1xN, CYP2D6 *2, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=imipramine_(PA449969),clomipramine_(PA449048);PGKB_TYPE=Dosage,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=2A,2A;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),"Depressive_Disorder_Major_(PA447321)""Obsessive-Compulsive_Disorder_(PA447211)";PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_and_major_depressive_disorder_1)_may_have_an_increased_metabolism_of_imipramine_2)_may_require_a_higher_dose_of_imipramine_as_compared_to_patients_with_two_non-functional_alleles_(*3_*4_*5_*6)_or_3)_may_have_an_increased_response_4)_may_require_a_lower_dose_as_compared_to_patients_with_a_duplicated_functional_allele_(*1XN_or_*2XN)._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine.""*1xN/*1:Patients_with_the_*1XN/*1_genotype_and_major_depressive_disorder_1)_may_have_a_decreased_response_2)_may_require_a_higher_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_or_*2/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*1xN/*2:Patients_with_the_*1XN/*2_genotype_and_major_depressive_disorder_1)_may_have_a_decreased_response_2)_may_require_a_higher_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_or_*2/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*2/*2:Patients_with_the_*2/*2_genotype_and_major_depressive_disorder_1)_may_have_an_increased_metabolism_of_imipramine_2)_may_require_a_higher_dose_of_imipramine_as_compared_to_patients_with_two_non-functional_alleles_(*3_*4_*5_*6)_or_3)_may_have_an_increased_response_4)_may_require_a_lower_dose_as_compared_to_patients_with_a_duplicated_functional_allele_(*1XN_or_*2XN)._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine.""*2xN/*1:Patients_with_the_*2XN/*1_genotype_and_major_depressive_disorder_1)_may_have_a_decreased_response_2)_may_require_a_higher_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_or_*2/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*2xN/*2:Patients_with_the_*2XN/*2_genotype_and_major_depressive_disorder_1)_may_have_a_decreased_response_2)_may_require_a_higher_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_or_*2/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*3/*3:Patients_with_the_*3/*3_*3/*4_*3/*5_or_*3/*6_genotype_(two_non-functional_alleles)_and_major_depressive_disorder_1)_may_have_a_decreased_metabolism_of_imipramine_and_2)_may_require_a_lower_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_*1/*2_*2/*2_*1xN/*1_*1xN/*2_*2xN/*1_or_*2xN/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*4/*4:Patients_with_the_*4/*4_*4/*3_*4/*5_or_*4/*6_genotype_(two_non-functional_alleles)_and_major_depressive_disorder_1)_may_have_a_decreased_metabolism_of_imipramine_and_2)_may_require_a_lower_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_*1/*2_*2/*2_*1xN/*1_*1xN/*2_*2xN/*1_or_*2xN/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*5/*5:Patients_with_the_*5/*5_*5/*3_*5/*4_or_*5/*6_genotype_(two_non-functional_alleles)_and_major_depressive_disorder_1)_may_have_a_decreased_metabolism_of_imipramine_and_2)_may_require_a_lower_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_*1/*2_*2/*2_*1xN/*1_*1xN/*2_*2xN/*1_or_*2xN/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._""*6/*6:Patients_with_the_*6/*6_*6/*3_*6/*4_or_*6/*5_genotype_(two_non-functional_alleles)_and_major_depressive_disorder_1)_may_have_a_decreased_metabolism_of_imipramine_and_2)_may_require_a_lower_dose_of_imipramine_as_compared_to_patients_with_the_*1/*1_*1/*2_*2/*2_*1xN/*1_*1xN/*2_*2xN/*1_or_*2xN/*2_genotype._The_number_of_studies_for_imipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_doxepin_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dosage_of_imipramine._","*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_clomipramine_may_have_1)_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_the_CYP2D6*4_allele_2)_increased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_as_compared_to_patients_with_a_duplication_of_a_functional_CYP2D6_gene_3)_decreased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*1/*1xN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_may_have_decreased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_when_treated_with_clomipramine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*2/*2:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_clomipramine_may_have_1)_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_the_CYP2D6*4_allele_2)_increased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_as_compared_to_patients_with_a_duplication_of_a_functional_CYP2D6_gene_3)_decreased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*2/*2xN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_may_have_decreased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_when_treated_with_clomipramine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._The_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*3:Patients_with_the_CYP2D6*3_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_clomipramine_may_have_1)_an_increased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_2)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Contradictory_findings_(no_association_with_side_effects_or_differences_in_plasma_concentration)_have_been_reported_for_clomipramine_and_the_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*4:Patients_with_the_CYP2D6*4_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_clomipramine_may_have_1)_an_increased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_2)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Contradictory_findings_(no_association_with_side_effects_or_differences_in_plasma_concentration)_have_been_reported_for_clomipramine_and_the_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*5:Patients_with_the_CYP2D6*5_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_clomipramine_may_have_1)_an_increased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_2)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Contradictory_findings_(no_association_with_side_effects_or_differences_in_plasma_concentration)_have_been_reported_for_clomipramine_and_the_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""*6:Patients_with_the_CYP2D6*6_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_clomipramine_may_have_1)_an_increased_plasma_concentration_of_clomipramine_and_desmethyl_clomipramine_2)_an_increased_risk_for_side_effects_as_compared_to_patients_with_two_functional_CYP2D6_alleles._Contradictory_findings_(no_association_with_side_effects_or_differences_in_plasma_concentration)_have_been_reported_for_clomipramine_and_the_number_of_studies_for_clomipramine_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.";PGKB_RACE=NR,NR
.	.	CYP2D6 *1, CYP2D6 *1xN, CYP2D6 *2, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=doxepin_(PA449409);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_who_carry_two_functional_alleles_may_have_an_increased_metabolism/clearance_of_doxepin_and_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_two_non-functional_(*3_*4_*5)_CYP2D6_alleles_and_a_decreased_metabolism/clearance_of_doxepin_as_compared_to_patients_carrying_more_than_two_copies_of_CYP2D6_functional_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._""*1/*1XN:Patients_carrying_more_than_two_copies_of_CYP2D6_functional_alleles_may_have_an_increased_metabolism/clearance_of_doxepin_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._""*1/*2:Patients_with_the_*1/*2_genotype_who_carry_two_functional_alleles_may_have_an_increased_metabolism/clearance_of_doxepin_and_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_two_non-functional_(*3_*4_*5)_CYP2D6_alleles_and_a_decreased_metabolism/clearance_of_doxepin_as_compared_to_patients_carrying_more_than_two_copies_of_CYP2D6_functional_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._""*1/*2XN:Patients_carrying_more_than_two_copies_of_CYP2D6_functional_alleles_may_have_an_increased_metabolism/clearance_of_doxepin_as_compared_to_patients_with_two_functional_CYP2D6_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._""*3:Patients_with_the_CYP2D6*3_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5)_may_have_a_decreased_metabolism/clearance_of_doxepin_an_increased_risk_for_side_effects_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._""*4:Patients_with_the_CYP2D6*4_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5)_may_have_a_decreased_metabolism/clearance_of_doxepin_and_an_increased_risk_for_side_effects_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._""*5:Patients_with_the_CYP2D6*5_non-functional_allele_in_combination_with_another_non-functional_(*3_*4_*5)_may_have_a_decreased_metabolism/clearance_of_doxepin_an_increased_risk_for_side_effects_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxepin_treatment._";PGKB_RACE=White
.	.	CYP2D6 *1, CYP2D6 *1xN, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=mirtazapine_(PA450522),fluoxetine_(PA449673);PGKB_TYPE="Efficacy""Toxicity/ADR",Metabolism/PK;PGKB_EVIDENCE=2A,3;PGKB_DISEASE=NR,"Depressive_Disorder_Major_(PA447321)""Mental_Disorders_(PA447208)""Mood_Disorders_(PA447209)""Obsessive-Compulsive_Disorder_(PA447211)";PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_who_are_treated_with_mirtazapine_may_have_an_increased_clearance_of_mirtazapine_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)_and_a_decreased_clearance_of_mirtazapine_as_compared_to_patients_with_a_duplication_of_a_functional_CYP2D6_gene._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.""*1/*1XN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_who_are_treated_with_mirtazapine_may_have_an_increased_clearance_of_mirtazapine_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.""*1/*2XN:Patients_with_a_duplication_of_a_functional_CYP2D6_gene_who_are_treated_with_mirtazapine_may_have_an_increased_clearance_of_mirtazapine_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.""*3:Patients_with_the_CYP2D6*3_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_mirtazapine_may_have_a_decreased_clearance_of_mirtazapine_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.""*4:Patients_with_the_CYP2D6*4_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_mirtazapine_may_have_a_decreased_clearance_of_mirtazapine_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.""*5:Patients_with_the_CYP2D6*5_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_mirtazapine_may_have_a_decreased_clearance_of_mirtazapine_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.""*6:Patients_with_the_CYP2D6*6_allele_in_combination_with_another_non-functional_CYP2D6_allele_(*3_*4_*5_*6)_who_are_treated_with_mirtazapine_may_have_a_decreased_clearance_of_mirtazapine_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mirtazapine.","*1/*1:Patients_with_two_functional_CYP2D6_alleles_who_are_treated_with_fluoxetine_may_have_1)_decreased_plasma_concentrations_of_fluoxetine_or_(S)-fluoxetine_and_an_increased_(S)-norfluoxetine/(S)-fluoxetine_ratios_as_compared_to_patients_with_non-functional_CYP2D6_alleles_(*3_*4_*5_*6)_and_2)_an_increased_plasma_concentrations_of_fluoxetine_or_(S)-fluoxetine_and_decreased_(S)-norfluoxetine/(S)-fluoxetine_ratios_and_decreased_but_not_absent_risk_for_early_treatment_discontinuation_as_compared_to_patients_with_more_than_two_functional_CYP2D6_alleles_(*1XN_*2XN).""*1/*1XN:Patients_with_more_than_two_functional_CYP2D6_alleles_who_are_treated_with_fluoxetine_may_have_decreased_plasma_concentrations_of_fluoxetine_or_(S)-fluoxetine_and_increased_(S)-norfluoxetine/(S)-fluoxetine_ratios_and_increased_risk_for_early_treatment_discontinuation_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""*1/*2XN_:Patients_with_more_than_two_functional_CYP2D6_alleles_who_are_treated_with_fluoxetine_may_have_decreased_plasma_concentrations_of_fluoxetine_or_(S)-fluoxetine_and_increased_(S)-norfluoxetine/(S)-fluoxetine_ratios_and_increased_risk_for_early_treatment_discontinuation_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""*3:Patients_with_the_CYP2D6*3_allele_who_are_treated_with_fluoxetine_may_have_decreased_(S)-norfluoxetine/(S)-fluoxetine_ratios_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_contradictory_findings_regarding_the_pharmacokinetic_parameters_and_no_association_with_response_or_side_effects_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""*4:Patients_with_the_CYP2D6*4_allele_who_are_treated_with_fluoxetine_may_have_increased_plasma_concentrations_of_fluoxetine_or_(S)-fluoxetine_and_decreased_(S)-norfluoxetine/(S)-fluoxetine_ratios_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_contradictory_findings_regarding_the_pharmacokinetic_parameters_and_no_association_with_response_or_side_effects_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""*5:Patients_with_the_CYP2D6*5_allele_who_are_treated_with_fluoxetine_may_have_decreased_(S)-norfluoxetine/(S)-fluoxetine_ratios_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_contradictory_findings_regarding_the_pharmacokinetic_parameters_and_no_association_with_response_or_side_effects_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""*6:Patients_with_the_CYP2D6*6_allele_who_are_treated_with_fluoxetine_may_have_increased_plasma_concentrations_of_fluoxetine_or_(S)-fluoxetine_and_decreased_(S)-norfluoxetine/(S)-fluoxetine_ratios_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._However_contradictory_findings_regarding_the_pharmacokinetic_parameters_and_no_association_with_response_or_side_effects_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._";PGKB_RACE=White,NR
.	.	CYP2D6 *1, CYP2D6 *1xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *41, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=galantamine_(PA449726);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Dementia_(PA443853);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*1/*4:Patients_with_the_*1/*4_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*1/*41:Patients_with_the_*1/*41_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*3/*4:Patients_with_the_*3/*4_genotype_and_dementia_may_have_increased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*1/*1_*1/*4_*4/*41_*1/*41_*5/*41_*6/*41_or_*4/*1XN_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*4/*1XN:Patients_with_the_*4/*1XN_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*4/*4:Patients_with_the_*4/*4_genotype_and_dementia_may_have_increased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*1/*1_*1/*4_*4/*41_*1/*41_*5/*41_*6/*41_or_*4/*1XN_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*4/*41:Patients_with_the_*4/*41_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*4/*5:Patients_with_the_*4/*5_genotype_and_dementia_may_have_increased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*1/*1_*1/*4_*4/*41_*1/*41_*5/*41_*6/*41_or_*4/*1XN_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*5/*41:Patients_with_the_*5/*41_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.""*6/*41:Patients_with_the_*6/*41_genotype_and_dementia_may_have_decreased_dose-adjusted_plasma_concentrations_of_galantamine_as_compared_to_patients_with_the_*3/*4_*4/*4_or_*4/*5_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_plasma_concentrations_of_galantamine.";PGKB_RACE=White
.	.	CYP2D6 *1, CYP2D6 *1xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=donepezil_(PA449394);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Alzheimer_Disease_(PA443319);PGKB_TEXT="*1/*1:Patients_with_Alzheimer_Disease_and_the_*1/*1_diplotype_(homozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*1/*1XN:Patients_with_Alzheimer_Disease_and_the_*1/*1xN_diplotype_(ultrarapid_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_extensive_metabolizers_(diplotypes_*1/*3_*1/*4_*1/*5_*1/*6_*1/*1_*4/*1xN_*6/*1xN)_or_poor_metabolizers_(*4/*4_*4/*5)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*1/*3:Patients_with_Alzheimer_Disease_and_the_*1/*3_diplotype_(heterozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*1/*4:Patients_with_Alzheimer_Disease_and_the_*1/*4_diplotype_(heterozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*1/*5:Patients_with_Alzheimer_Disease_and_the_*1/*5_diplotype_(heterozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*1/*6:Patients_with_Alzheimer_Disease_and_the_*1/*6_diplotype_(heterozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*4/*1XN:Patients_with_Alzheimer_Disease_and_the_*4/*1XN_diplotype_(homozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*4/*4:Patients_with_Alzheimer_Disease_and_the_*4/*4_diplotype_(poor_metabolizers)_may_have_reduced_clearance_of_donepezil_as_compared_to_patients_who_are_extensive_metabolizers_(diplotypes_*1/*3_*1/*4_*1/*5_*1/*6_*1/*1_*4/*1xN_*6/*1xN)_or_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Poor_metabolizers_may_also_be_more_likely_to_experience_adverse_events_(though_this_was_not_statistically_significant)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*4/*5:Patients_with_Alzheimer_Disease_and_the_*4/*5_diplotype_(poor_metabolizers)_may_have_reduced_clearance_of_donepezil_as_compared_to_patients_who_are_extensive_metabolizers_(diplotypes_*1/*3_*1/*4_*1/*5_*1/*6_*1/*1_*4/*1xN_*6/*1xN)_or_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Poor_metabolizers_may_also_be_more_likely_to_experience_adverse_events_(though_this_was_not_statistically_significant)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._""*6/*1XN:Patients_with_Alzheimer_Disease_and_the_*6/*1XN_diplotype_(homozygous_extensive_metabolizers)_may_have_increased_clearance_of_donepezil_as_compared_to_patients_who_are_poor_metabolizers_(*4/*4_*4/*5)_or_may_have_decreased_clearance_as_compared_to_patients_who_are_ultrarapid_metabolizers_(*1/*1xN_*1XN/*1XN)._Other_genetic_and_clinical_factors_may_also_influence_donepezil_clearance._";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *1xN	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=ondansetron_(PA450705);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_CYP2D6_extensive_(e.g._*1/*1)_intermediate_(e.g._*4/*10)_or_poor_(e.g._*4/*4)_metabolizer_genotypes_are_more_likely_to_have_an_increased_response_to_ondansetron_as_compared_to_those_with_CYP2D6_ultrarapid_metabolizer_genotypes_(e.g._*1/*1XN)._This_increased_response_leads_to_a_reduced_risk_of_vomiting_after_chemotherapy_or_anesthesia._No_significant_associations_have_been_seen_for_nausea._For_complete_lists_of_metabolizer_genotypes_designated_as_ultrarapid_extensive_intermediate_and_poor_and_explanations_as_to_the_meaning_of_these_designations_please_refer_to_the_papers_listed_under_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_vomiting_after_chemotherapy_or_anesthesia._""*1/*1XN:Patients_with_CYP2D6_ultrarapid_metabolizer_genotypes_(e.g._*1/*1XN)_are_more_likely_to_have_a_decreased_response_to_ondansetron_as_compared_to_any_other_metabolizer_genotype_group_(extensive_-_e.g._*1/*1_intermediate_-_e.g._*4/*10_or_poor_-_e.g._*4/*4)._This_decreased_response_leads_to_a_higher_risk_of_vomiting_after_chemotherapy_or_anesthesia._No_significant_associations_have_been_seen_for_nausea._For_complete_lists_of_metabolizer_genotypes_designated_as_ultrarapid_extensive_intermediate_and_poor_and_explanations_as_to_the_meaning_of_these_designations_please_refer_to_the_papers_listed_under_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_vomiting_after_chemotherapy_or_anesthesia._";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *29	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG="debrisoquine_(PA452616)""dextromethorphan_(PA449273)""metoprolol_(PA450480)";PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_metabolism_of_metoprolol_or_dextromethorphan_or_debrisoquine_compared_to_patients_with_the_*29/*29_genotype._However_the_findings_for_debrisoquine_or_not_consistent._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_metoprolol_or_dextromethorphan_or_debrisoquine.""*1/*29:Patients_with_the_CYP2D6*1/*29_genotype_may_have_an_increased_metabolism_of_metoprolol_or_dextromethorphan_or_debrisoquine_compared_to_patients_with_the_*29/*29_genotype._However_the_findings_for_debrisoquine_or_not_consistent._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_metoprolol_or_dextromethorphan_or_debrisoquine.""*29/*29:Patients_with_the_CYP2D6*29/*29_genotype_may_have_a_decreased_metabolism_of_metoprolol_or_dextromethorphan_or_debrisoquine_compared_to_patients_with_the_*1/*1_or_*1/*29_genotype._However_the_findings_for_debrisoquine_or_not_consistent._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_metoprolol_or_dextromethorphan_or_debrisoquine.";PGKB_RACE=Black_or_African_American
.	.	CYP2D6 *1, CYP2D6 *2xN, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5, CYP2D6 *6	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=oxycodone_(PA450741),trimipramine_(PA451791);PGKB_TYPE="Efficacy""Toxicity/ADR",Other;PGKB_EVIDENCE=2A,2A;PGKB_DISEASE=Pain_(PA445208),NR;PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_who_are_treated_with_oxycodone_may_have_1)_increased_metabolism_of_oxycodone_2)_increased_likelihood_of_response_to_oxycodone_and_3)_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_non-functional_alleles_or_reduced_function_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxycodone.""*1/*2XN:Patients_with_more_than_two_copies_of_CYP2D6_functional_alleles_(CYP2D6_ultrarapid_metabolizers_(i.e._a_CYP2D6_activity_score_of_>2.0)_)_who_are_treated_with_oxycodone_may_have_1)_increased_metabolism_and_response_to_oxycodone_and_2)_higher_risk_of_toxicity/side_effects_as_compared_to_patients_with_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers._Patients_who_are_CYP2D6_ultrarapid_metabolizer_should_avoid_oxycodone_use_(as_well_as_codeine_or_tramadol)_due_to_potential_for_toxicity_and_should_be_alert_to_adverse_drug_events._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxycodone.""*3:Patients_with_the_*3_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_who_are_treated_with_oxycodone_may_have_1)_decreased_metabolism_of_oxycodone_2)_decreased_likelihood_of_response_to_oxycodone_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._However_conflicting_data_on_oxycodone_efficacy_have_been_reported._Patients_who_are_CYP2D6_poor_metabolizers_may_need_to_avoid_oxycodone_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxycodone.""*4:Patients_with_the_*4_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_who_are_treated_with_oxycodone_may_have_1)_decreased_metabolism_of_oxycodone_2)_decreased_likelihood_of_response_to_oxycodone_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._However_conflicting_data_on_oxycodone_efficacy_have_been_reported._Patients_who_are_CYP2D6_poor_metabolizers_may_need_to_avoid_oxycodone_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxycodone.""*5:Patients_with_the_*5_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_who_are_treated_with_oxycodone_may_have_1)_decreased_metabolism_of_oxycodone_2)_decreased_likelihood_of_response_to_oxycodone_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._However_conflicting_data_on_oxycodone_efficacy_have_been_reported._Patients_who_are_CYP2D6_poor_metabolizers_may_need_to_avoid_oxycodone_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxycodone.""*6:Patients_with_the_*6_non-functional_allele_in_combination_with_another_non-functional_or_reduced_function_allele_who_are_treated_with_oxycodone_may_have_1)_decreased_metabolism_of_oxycodone_2)_decreased_likelihood_of_response_to_oxycodone_as_compared_to_patients_with_*1/*1_genotype_who_carry_two_functional_alleles._However_conflicting_data_on_oxycodone_efficacy_have_been_reported._Patients_who_are_CYP2D6_poor_metabolizers_may_need_to_avoid_oxycodone_use_due_to_lack_of_efficacy_and_should_be_alert_to_symptoms_of_insufficient_pain_relief._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxycodone.","*1/*1:Patients_with_the_*1/*1_diplotype_(two_active_CYP2D6_alleles)_and_CYP2C9*1/*1_and_CYP2C19*1/*1_combined_diplotypes_may_have_higher_clearance_of_trimipramine_as_compared_to_patients_with_two_inactive_CYP2D6_alleles_(*3_*4_*5_or_*6)._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*1/*2xN:Patients_with_the_*1/*2XN_diplotype_may_have_reduced_bioavailability_of_trimipramine_as_compared_to_patients_with_two_inactive_CYP2D6_alleles_(*3_*4_*5_or_*6)._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*3/*3:Patients_with_two_non-functional_CYP2D6_alleles_(e.g._*3/*3_*3/*4_*4/*4_*3/*5_or_*3/*6_*5/*5)_1)_may_have_reduced_clearance_of_trimipramine_as_compared_to_patients_with_the_wildtype_CYP2D6_*1/*1_CYP2C9*1/*1_and_CYP2C19*1/*1_combined_diplotypes_2)_may_have_increased_bioavailability_of_trimipramine_as_compared_to_patients_with_the_CYP2D6_*1/*2XN_diplotype._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*4/*4:Patients_with_two_non-functional_CYP2D6_alleles_(e.g._*3/*3_*3/*4_*4/*4_*3/*5_or_*3/*6_*5/*5)_1)_may_have_reduced_clearance_of_trimipramine_as_compared_to_patients_with_the_wildtype_CYP2D6_*1/*1_CYP2C9*1/*1_and_CYP2C19*1/*1_combined_diplotypes_2)_may_have_increased_bioavailability_of_trimipramine_as_compared_to_patients_with_the_CYP2D6_*1/*2XN_diplotype._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*5/*5:Patients_with_two_non-functional_CYP2D6_alleles_(e.g._*3/*3_*3/*4_*4/*4_*3/*5_or_*3/*6_*5/*5)_1)_may_have_reduced_clearance_of_trimipramine_as_compared_to_patients_with_the_wildtype_CYP2D6_*1/*1_CYP2C9*1/*1_and_CYP2C19*1/*1_combined_diplotypes_2)_may_have_increased_bioavailability_of_trimipramine_as_compared_to_patients_with_the_CYP2D6_*1/*2XN_diplotype._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._""*6/*6:Patients_with_two_non-functional_CYP2D6_alleles_(e.g._*3/*3_*3/*4_*4/*4_*3/*5_or_*3/*6_*5/*5)_1)_may_have_reduced_clearance_of_trimipramine_as_compared_to_patients_with_the_wildtype_CYP2D6_*1/*1_CYP2C9*1/*1_and_CYP2C19*1/*1_combined_diplotypes_2)_may_have_increased_bioavailability_of_trimipramine_as_compared_to_patients_with_the_CYP2D6_*1/*2XN_diplotype._The_number_of_studies_for_trimipramine_pharmacogenomics_is_limited._Since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_clomipramine_and_doxepin_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_trimipramine._";PGKB_RACE=NR,NR
.	.	CYP2D6 *1, CYP2D6 *38, CYP2D6 *4, CYP2D6 *5, CYP2D6 *9	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=debrisoquine_(PA452616);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_CYP2D6_enzyme_activity_as_compared_to_patients_with_the_CYP2D6*5/*9_or_*4/*38_genotype._Other_genetic_and_clinical_factors_may_also_influence_CYP2D6_enzyme_activity.""*4/*38:Patients_with_the_CYP2D6*4/*38_genotype_(assigned_as_a_poor_metabolizer_phenotype)_may_have_a_decreased_CYP2D6_enzyme_activity_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_CYP2D6_enzyme_activity.""*5/*9:Patients_with_the_CYP2D6*5/*9_genotype_may_have_a_decreased_CYP2D6_enzyme_activity_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_CYP2D6_enzyme_activity.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *3, CYP2D6 *36, CYP2D6 *4, CYP2D6 *40, CYP2D6 *42, CYP2D6 *4xN, CYP2D6 *56	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=dextromethorphan_(PA449273);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*40/*42_or_*3/*4XN_or_*4XN/*56_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*3/*4xN:Patients_with_the_CYP2D6*3/*4XN_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*40/*42:Patients_with_the_CYP2D6*40/*42_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*4xN/*56:Patients_with_the_CYP2D6*4XN/*56_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.""*4xN/*36_+_*4/*36:Patients_with_the_CYP2D6*4x2/*36_or_*4/*36_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_dextromethorphan_(probe_drug)_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_dextromethorphan.";PGKB_RACE=Black_or_African_American
.	.	CYP2D6 *1, CYP2D6 *3, CYP2D6 *4, CYP2D6 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=timolol_(PA451690);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2D6_alleles_who_are_treated_with_aqueous_timolol_may_have_decreased_exposure_to_timolol_and_less_excerice_heart_rate_reduction_as_compared_to_patients_with_two_non-functional_CYP2D6_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aqueous_timolol.""*3/*3:Patients_with_two_non-functional_CYP2D6_alleles_(e.g.*3/*3_*3/*4_*4/*4_*5/*4)_who_are_treated_with_aqueous_timolol_may_have_increased_exposure_to_timolol_and_greater_excerice_heart_rate_reduction_as_compared_to_patients_with_two_or_one_functional_CYP2D6_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aqueous_timolol.""*3/*4:Patients_with_two_non-functional_CYP2D6_alleles_(e.g.*3/*3_*3/*4_*4/*4_*5/*4)_who_are_treated_with_aqueous_timolol_may_have_increased_exposure_to_timolol_and_increased_excerice_heart_rate_reduction_as_compared_to_patients_with_two_or_one_functional_CYP2D6_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aqueous_timolol.""*4/*4:Patients_with_two_non-functional_CYP2D6_alleles_(e.g.*3/*3_*3/*4_*4/*4_*5/*4)_who_are_treated_with_aqueous_timolol_may_have_increased_exposure_to_timolol_and_increased_excerice_heart_rate_reduction_as_compared_to_patients_with_two_or_one_functional_CYP2D6_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aqueous_timolol.""*5/*4:Patients_with_two_non-functional_CYP2D6_alleles_(e.g.*3/*3_*3/*4_*4/*4_*5/*4)_who_are_treated_with_aqueous_timolol_may_have_increased_exposure_to_timolol_and_increased_excerice_heart_rate_reduction_as_compared_to_patients_with_two_or_one_functional_CYP2D6_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aqueous_timolol.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *3, CYP2D6 *4	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=zuclopenthixol_(PA452629),olanzapine_(PA450688);PGKB_TYPE=Other,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_who_are_CYP2D6_normal/extensive_metabolizers_may_have_increased_metabolism/clearance_of_zuclopenthixol_as_compared_to_patients_with_non-functional_(*3_or*4)_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_zuclopenthixol.""*1/*4:Patients_with_the_*1/*4_genotype_who_are_CYP2D6_intermediate_metabolizers_may_have_decreased_metabolism/clearance_of_zuclopenthixol_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_zuclopenthixol.""*3/*4:Patients_with_the_*3/*4_genotype_who_are_CYP2D6_poor_metabolizers_may_have_decreased_metabolism/clearance_of_zuclopenthixol_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_zuclopenthixol.","*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_a_decreased_but_not_absent_risk_for_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_CYP2D6*1/*3_or_*1/*4_genotype._However_no_associations_with_differences_in_olanzapine_pharmacokinetic_parameters_or_response_are_reported_in_patients_with_two_non-functional_or_with_CYP2D6*10_alleles_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""*1/*3:Patients_with_the_CYP2D6*1/*3_genotype_may_have_an_increased_risk_for_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._However_no_associations_with_differences_in_olanzapine_pharmacokinetic_parameters_or_response_are_reported_in_patients_with_two_non-functional_or_CYP2D6*10_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""*1/*4:Patients_with_the_CYP2D6*1/*4_genotype_may_have_an_increased_risk_for_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._However_no_associations_with_differences_in_olanzapine_pharmacokinetic_parameters_or_response_are_reported_in_patients_with_two_non-functional_or_CYP2D6*10_compared_to_patients_with_two_functional_CYP2D6_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=White,NR
.	.	CYP2D6 *1, CYP2D6 *47, CYP2D6 *49, CYP2D6 *50, CYP2D6 *51, CYP2D6 *54, CYP2D6 *55, CYP2D6 *57, CYP2D6 *72, CYP2D6 *89, CYP2D6 *92, CYP2D6 *93, CYP2D6 *96	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG="bufuralol_(PA166110256)""dextromethorphan_(PA449273)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1:Patients_with_the_CYP2D6*1_allele_may_have_an_increased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*47_or_*49_or_*50_or_*51_or_*54_or_*55_or_*57_or_*72_or_*89_or_*92_or_*93_or_*96_allele._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*47:Patients_with_the_CYP2D6*47_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*47_allele_was_found_to_have_a_drastic_decrease_in_enzymatic_activity_during_in_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*49:Patients_with_the_CYP2D6*49_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*49_allele_construct_was_found_to_have_catalytic_activity_but_less_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*50:Patients_with_the_CYP2D6*50_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*50_allele_construct_was_found_to_have_catalytic_activity_but_less_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*51:Patients_with_the_CYP2D6*51_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*51_allele_was_found_to_have_a_drastic_decrease_in_enzymatic_activity_during_in_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*54:Patients_with_the_CYP2D6*54_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*54_allele_construct_was_found_to_have_catalytic_activity_but_less_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*55:Patients_with_the_CYP2D6*55_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*55_allele_construct_was_found_to_have_catalytic_activity_but_less_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*57:Patients_with_the_CYP2D6*57_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*57_allele_was_found_to_have_a_drastic_decrease_in_enzymatic_activity_during_in_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*72:Patients_with_the_CYP2D6*72_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*72_allele_construct_was_found_to_have_catalytic_activity_but_less_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*89:Patients_with_the_CYP2D6*89_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*89_allele_construct_was_found_to_exhibited_>90%_decreases_in_catalytic_activity_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*92:Patients_with_the_CYP2D6*92_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*92_allele_construct_was_found_to_exhibited_>90%_decreases_in_catalytic_activity_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*93:Patients_with_the_CYP2D6*93_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*93_allele_construct_was_found_to_exhibited_>90%_decreases_in_catalytic_activity_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.""*96:Patients_with_the_CYP2D6*96_allele_may_have_a_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1_allele._The_CYP2D6*96_allele_construct_was_found_to_exhibited_>90%_decreases_in_catalytic_activity_than_CYP2D6*1_during_in-vitro_characterization_with_bufuralol_and_dextromethorphan._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_bufuralol_and_dextromethorphan.";PGKB_RACE=NR
.	.	CYP2D6 *1, CYP2D6 *4	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=pimozide_(PA450965),"citalopram_(PA449015)""escitalopram_(PA10074)""fluoxetine_(PA449673)""fluvoxamine_(PA449690)""paroxetine_(PA450801)""sertraline_(PA451333)","maprotiline_(PA450322)""opipramol_(PA144614922)",vortioxetine_(PA166122595);PGKB_TYPE=Other,Dosage,"Dosage""Toxicity/ADR",Metabolism/PK;PGKB_EVIDENCE=4,3,3,3;PGKB_DISEASE=NR,Depression_(PA447278),Depression_(PA447278),NR;PGKB_TEXT="*1/*1:Patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)_who_are_treated_with_pimozide_may_have_decreased_plasma_concentrations_of_pimozide_as_compared_to_patients_with_two_non-functional_CYP2D6_alleles_(e.g._*4/*4_*3/*4_*4/*5)._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_pimozide.""*4/*4:Patients_with_two_non-functional_CYP2D6_alleles_(e.g._*4/*4_*3/*4_*4/*5)_who_are_treated_with_pimozide_may_have_increased_plasma_concentrations_of_pimozide_as_compared_to_patients_with_two_functional_CYP2D6_alleles_(*1/*1_*1/*2_*2/*2)._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_pimozide.","*1/*1:Patients_with_the_*1/*1_diplotype_and_depression_may_require_a_higher_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirement._""*1/*4:Patients_with_the_*1/*4_diplotype_and_depression_may_require_a_lower_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_*1/*1_genotype_or_may_require_a_higher_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirement._""*4/*4:Patients_with_the_*4/*4_diplotype_and_depression_may_require_a_lower_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirement._","*1/*1:Patients_with_the_CYP2D6*1/*1_and_depression_who_are_treated_with_opipramol_or_maprotiline_or_tricyclic_antidepressants_1)_may_have_a_decreased_but_not_absent_risk_for_side_effects_2)_may_require_an_increased_dose_of_drug_compared_to_patients_with_CYP2D6*4/*4._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_opipramol_or_maprotiline_or_tricyclic_antidepressants_and_risk_of_adverse_effects.""*1/*4:Patients_with_the_CYP2D6*1/*4_and_depression_who_are_treated_with_opipramol_or_maprotiline_or_tricyclic_antidepressants_1)_may_have_an_increased_risk_of_side_effects_2)_may_require_a_decreased_dose_of_drug_compared_to_patients_with_CYP2D6*1/*1_or_1)_may_have_a_decreased_but_not_absent_risk_for_side_effects_2)_may_require_an_increased_dose_of_drug_compared_to_patients_with_CYP2D6*4/*4._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_opipramol_or_maprotiline_or_tricyclic_antidepressants_and_risk_of_adverse_effects.""*4/*4:Patients_with_the_CYP2D6*4/*4_and_depression_who_are_treated_with_opipramol_or_maprotiline_or_tricyclic_antidepressants_1)_may_have_an_increased_risk_of_side_effects_2)_may_require_a_decreased_dose_of_drug_compared_to_patients_with_CYP2D6*1/*1._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_opipramol_or_maprotiline_or_tricyclic_antidepressants_and_risk_of_adverse_effects.","*1/*1:Patients_with_the_CYP2D6_extensive_metabolizer_phenotype_(e.g._*1/*1)_may_have_an_increased_clearance_of_vortioxetine_as_compared_to_patients_with_the_CYP2D6_poor_metabolizer_phenotype_(e.g._*4/*4)._Other_genetic_and_clinical_factors_may_also_influence_patient's_clearance_of_vortioxetine.""*4/*4:Patients_with_the_CYP2D6_poor_metabolizer_phenotype_(e.g._*4/*4)_may_have_a_decreased_clearance_of_vortioxetine_as_compared_to_patients_with_the_CYP2D6_extensive_metabolizer_phenotype_(e.g._*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_patient's_clearance_of_vortioxetine.";PGKB_RACE=White,White,White,NR
.	.	CYP2D6 *1, CYP2D6 *5, CYP2D6 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG="debrisoquine_(PA452616)""sparteine_(PA452610)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_CYP2D6*1/*1_genotype_may_have_an_increased_metabolism_of_debrisoquine_or_sparteine_as_compared_to_patients_with_the_CYP2D6*5/*8_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_debrisoquine_or_sparteine.""*5/*8:Patients_with_the_CYP2D6*5/*8_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_decreased_metabolism_of_debrisoquine_or_sparteine_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_debrisoquine_or_sparteine.";PGKB_RACE=White
.	.	CYP2D6 *20, CYP2D6 *4	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=metoprolol_(PA450480);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT=*4/*20:Patients_with_the_CYP2D6*4/*20_genotype_(assigned_as_poor_metabolizer_phenotype)_may_have_a_very_decreased_enzyme_activity_of_CYP2D6_as_compared_to_patients_with_the_CYP2D6*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_metoprolol.;PGKB_RACE=NR
.	.	CYP2E1 *1A, CYP2E1 *5B	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2E1_(PA129);PGKB_DRUG=Drugs_For_Treatment_Of_Tuberculosis_(PA164712708);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Tuberculosis_(PA445941);PGKB_TEXT="*1A/*1A:Patients_with_the_*1A/*1A_genotype_and_tuberculosis_may_have_a_decreased_risk_for_hepatotoxicity_when_treated_with_antitubercular_agents_as_compared_to_those_with_the_*1A/*5B_genotype._However_multiple_studies_have_shown_contradictory_or_negative_evidence_for_this_association._Other_genetic_and_clinical_factors_such_as_variants_in_the_NAT2_gene_may_also_affect_risk_for_hepatotoxicity_in_patients_taking_antitubercular_agents.""*1A/*5B:Patients_with_the_*1A/*5B_genotype_and_tuberculosis_may_have_an_increased_risk_for_hepatotoxicity_when_treated_with_antitubercular_agents_as_compared_to_those_with_the_*1A/*1A_genotype._However_multiple_studies_have_shown_contradictory_or_negative_evidence_for_this_association._Other_genetic_and_clinical_factors_such_as_variants_in_the_NAT2_gene_may_also_affect_risk_for_hepatotoxicity_in_patients_taking_antitubercular_agents.""*5B/*5B:No_patients_with_this_genotype_were_available_for_analysis_but_patients_with_the_*1A/*5B_genotype_and_tuberculosis_may_have_an_increased_risk_for_hepatotoxicity_when_treated_with_antitubercular_agents_as_compared_to_those_with_the_*1A/*1A_genotype._However_multiple_studies_have_shown_contradictory_or_negative_evidence_for_this_association._Other_genetic_and_clinical_factors_such_as_variants_in_the_NAT2_gene_may_also_affect_risk_for_hepatotoxicity_in_patients_taking_antitubercular_agents.";PGKB_RACE=NR
.	.	CYP3A4 *1, CYP3A4 *1G	.	.	.	.	PGKB_INDEX=3;PGKB_GENE=CYP3A4_(PA130),CYP3A4_(PA130),CYP3A4_(PA130);PGKB_DRUG=tacrolimus_(PA451578),atorvastatin_(PA448500),tacrolimus_(PA451578);PGKB_TYPE=Other,Efficacy,Other;PGKB_EVIDENCE=2A,3,3;PGKB_DISEASE=Organ_Transplantation_(PA133888799),Hyperlipidemias_(PA444528),liver_transplantation_(PA447247);PGKB_TEXT="*1/*1:Patients_with_the_CYP3A4_*1/*1_diplotype_who_underwent_organ_transplantation_may_have_decreased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_*1/*1G_or_*1G/*1G_diplotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_(rs776746)_may_also_influence_metabolism_of_tacrolimus._""*1/*1G:Patients_with_the_CYP3A4_*1/*1G_diplotype_who_underwent_organ_transplantation_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_(rs776746)_may_also_influence_metabolism_of_tacrolimus._""*1G/*1G:Patients_with_the_CYP3A4_*1G/*1G_diplotype_who_underwent_organ_transplantation_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_(rs776746)_may_also_influence_metabolism_of_tacrolimus._","*1/*1:Patients_with_the_*1/*1_diplotype_and_Hyperlipidemia_may_have_a_reduced_response_to_atorvastatin_treatment_(determined_by_a_lower_reduction_in_total_cholesterol)_as_compared_to_patients_with_the_*1/*1G_or_*1G/*1G_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""*1/*1G:Patients_with_the_*1/*1G_diplotype_and_Hyperlipidemia_may_have_a_better_response_to_atorvastatin_treatment_(determined_by_a_higher_reduction_in_total_cholesterol)_as_compared_to_patients_with_the_*1/*1_diplotype_or_may_have_a_reduced_response_to_atorvastatin_treatment_(determined_by_a_lower_reduction_in_total_cholesterol)_as_compared_to_patients_with_the_*1G/*1G_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""*1G/*1G:Patients_with_the_*1G/*1G_diplotype_and_Hyperlipidemia_may_have_a_better_response_to_atorvastatin_treatment_(determined_by_a_higher_reduction_in_total_cholesterol)_as_compared_to_patients_with_the_*1/*1G_or_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","*1/*1:Patients_with_the_CYP3A4_*1/*1_diplotype_undergoing_organ_transplant_who_received_a_donor_liver_with_the_*1/*1_diplotype_may_have_a_decreased_risk_of_acute_cellular_rejection_when_treated_with_tacrolimus_as_compared_to_patients_with_the_*1/*1G_or_*1G/*1G_diplotype_who_received_a_donor_liver_with_the_*1/*1G_or_*1G/*1G_diplotype._Other_genetic_and_clinical_factors_may_also_influence_incidence_of_acute_cellular_rejection.""*1/*1G:Patients_with_the_CYP3A4_*1/*1G_diplotype_undergoing_organ_transplant_who_received_a_donor_liver_with_the_*1/*1G_or_*1G/*1G_diplotype_may_have_an_increased_risk_of_acute_cellular_rejection_when_treated_with_tacrolimus_as_compared_to_patients_with_the_*1/*1_diplotype_who_received_a_donor_liver_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_incidence_of_acute_cellular_rejection.""*1G/*1G:Patients_with_the_CYP3A4_*1G/*1G_diplotype_undergoing_organ_transplant_who_received_a_donor_liver_with_the_*1G/*1G_or_*1/*1G_diplotype_may_have_an_increased_risk_of_acute_cellular_rejection_when_treated_with_tacrolimus_as_compared_to_patients_with_the_*1/*1_diplotype_who_received_a_donor_liver_with_the_*1/*1_diplotype._Other_genetic_and_clinical_factors_may_also_influence_incidence_of_acute_cellular_rejection.";PGKB_RACE=Asian,Asian,Asian
.	.	CYP3A4 *1, CYP3A4 *20, CYP3A4 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A4_(PA130);PGKB_DRUG=paclitaxel_(PA450761);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Ovarian_Neoplasms_(PA445204)";PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_and_breast_or_ovarian_cancer_may_have_a_decreased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_*1/*8_or_*1/*20_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.""*1/*20:Patients_with_the_*1/*20_genotype_and_breast_or_ovarian_cancer_may_have_an_increased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.""*1/*8:Patients_with_the_*1/*8_genotype_and_breast_or_ovarian_cancer_may_have_an_increased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.";PGKB_RACE=NR
.	.	CYP3A4 *1, CYP3A4 *22	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A4_(PA130);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="*1/*1:Patients_with_the_CYP3A4_*1/*1_diplotype_may_have_decreased_plasma_concentrations_of_simvastatin_as_compared_to_patients_with_the_CYP3A4_*1/*22_or_*22/*22_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_simvastatin._""*1/*22:Patients_with_the_CYP3A4_*1/*22_diplotype_may_have_increased_plasma_concentrations_of_simvastatin_as_compared_to_patients_with_the_CYP3A4_*1/*1_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_simvastatin._""*22/*22:Patients_with_the_CYP3A4_*22/*22_diplotype_may_have_increased_plasma_concentrations_of_simvastatin_as_compared_to_patients_with_the_CYP3A4_*1/*1_diplotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_simvastatin._";PGKB_RACE=NR
.	.	CYP3A4 *1, CYP3A4 *4	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A4_(PA130);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hyperlipidemias_(PA444528);PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_diplotype_and_Hyperlipidemia_may_have_a_reduced_response_to_simvastatin_treatment_as_compared_to_patients_with_the_*1/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""*1/*4:Patients_with_the_*1/*4_diplotype_and_Hyperlipidemia_may_have_a_better_response_to_simvastatin_treatment_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._";PGKB_RACE=NR
.	.	CYP3A5 *1A, CYP3A5 *3A, CYP3A5 *6, CYP3A5 *7	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A5_(PA131);PGKB_DRUG=atazanavir_(PA10251);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=2B;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="*1A/*1A:Individuals_with_the_*1A/*1A_genotype_may_metabolize_atazanavir_more_rapidly_as_compared_to_individuals_with_the_one_or_more_copies_of_the_*3A_*6_or_*7_alleles._Please_note:_this_association_is_for_atazanavir_alone_and_not_in_combination_with_ritonavir_which_inhibits_CYP3A5._Other_clinical_and_genetic_factors_may_also_influence_the_rate_of_atazanavir_metabolism._""*3A:Individuals_with_one_*3A_allele_in_combination_with_one_functional_(*1A)_allele_may_metabolize_atazanavir_more_rapidly_as_compared_to_individuals_with_any_combination_of_two_non-functional_alleles_(*3A_*6_or_*7)_alleles_but_may_metabolize_atazanavir_more_slowly_as_compared_to_individuals_with_the_*1A/*1A_genotype._Please_note:_this_association_is_for_atazanavir_alone_and_not_in_combination_with_ritonavir_which_inhibits_CYP3A5._Other_clinical_and_genetic_factors_may_also_influence_the_rate_of_atazanavir_metabolism._""*6:Individuals_with_one_*6_allele_in_combination_with_one_functional_(*1A)_allele_may_metabolize_atazanavir_more_rapidly_as_compared_to_individuals_with_any_combination_of_two_non-functional_alleles_(*3A_*6_or_*7)_alleles_but_may_metabolize_atazanavir_more_slowly_as_compared_to_individuals_with_the_*1A/*1A_genotype._Please_note:_this_association_is_for_atazanavir_alone_and_not_in_combination_with_ritonavir_which_inhibits_CYP3A5._Other_clinical_and_genetic_factors_may_also_influence_the_rate_of_atazanavir_metabolism._""*7:Individuals_with_one_*7_allele_in_combination_with_one_functional_(*1A)_allele_may_metabolize_atazanavir_more_rapidly_as_compared_to_individuals_with_any_combination_of_two_non-functional_alleles_(*3A_*6_or_*7)_alleles_but_may_metabolize_atazanavir_more_slowly_as_compared_to_individuals_with_the_*1A/*1A_genotype._Please_note:_this_association_is_for_atazanavir_alone_and_not_in_combination_with_ritonavir_which_inhibits_CYP3A5._Other_clinical_and_genetic_factors_may_also_influence_the_rate_of_atazanavir_metabolism._";PGKB_RACE=NR
.	.	CYP3A5 *1A, CYP3A5 *3A	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131);PGKB_DRUG=atorvastatin_(PA448500),midazolam_(PA450496),olanzapine_(PA450688),cilostazol_(PA164746334);PGKB_TYPE="Efficacy""Toxicity/ADR",Metabolism/PK,Metabolism/PK,Metabolism/PK;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Myalgia_unspecified_(PA157379134),Neoplasms_(PA445062),NR,NR;PGKB_TEXT="*1A/*1A:Patients_with_the_*1A/*1A_genotype_who_are_treated_with_atorvastatin_may_have_an_increased_response_to_treatment_as_compared_to_patients_with_the_*3A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""*1A/*3A:Patients_with_the_*1A/*3A_genotype_who_are_treated_with_atorvastatin_1)_may_have_an_increased_response_to_treatment_2)_may_have_a_decreased_risk_of_myalgia_and_a_lower_degree_of_muscle_damage_as_compared_to_patients_with_the_*3A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""*3A/*3A:Patients_with_the_*3A/*3A_genotype_who_are_treated_with_atorvastatin_1)_may_have_a_decreased_response_to_treatment_as_compared_to_patients_with_the_*1A/*3A_and_*1A/*1A_genotype_2)_may_have_an_increased_risk_of_myalgia_and_a_greater_degree_of_muscle_damage_as_compared_to_patients_with_the_*1A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","*1A/*1A:Patients_with_the_*1A/*1A_genotype_may_have_increased_metabolism_of_midazolam_as_compared_to_patients_with_the_*3A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_midazolam._""*1A/*3A:Patients_with_the_*1A/*3A_genotype_may_have_increased_metabolism_of_midazolam_as_compared_to_patients_with_the_*3A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_midazolam._""*3A/*3A:Patients_with_the_*3A/*3A_genotype_may_have_decreased_metabolism_of_midazolam_as_compared_to_patients_with_the_*1A/*1A_or_*1A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_midazolam._","*1A/*1A:Individuals_with_the_*1A/*1A_genotype_may_have_increased_area_under_the_curve_(AUC)_of_olanzapine_as_compared_to_Individuals_with_the_*3A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_AUC_of_olanzapine.""*1A/*3A:Individuals_with_the_*1A/*3A_genotype_may_have_increased_area_under_the_curve_(AUC)_of_olanzapine_as_compared_to_Individuals_with_the_*3A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_AUC_of_olanzapine.""*3A/*3A:Individuals_with_the_*3A/*3A_genotype_may_have_decreased_area_under_the_curve_(AUC)_of_olanzapine_as_compared_to_Individuals_with_the_*1A/*1A_or_*1A/*3A_genotype._Other_genetic_and_clinical_factors_may_also_influence_AUC_of_olanzapine.","*1A/*1A:Patients_with_the_CYP3A5_*1/*1_diplotype_may_have_an_increased_metabolism_of_cilostazol_as_compared_to_patients_with_the_CYP3A5_*3/*3_diplotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cilostazol._""*1A/*3A:Patients_with_the_CYP3A5_*1/*3_may_have_an_increased_metabolism_of_cilostazol_as_compared_to_patients_with_the_CYP3A5_*3/*3_diplotype_and_a_decreased_metabolism_of_cilostazol_as_compared_to_patients_with_the_CYP3A5_*1/*1_diplotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cilostazol._""*3A/*3A:Patients_with_the_CYP3A5_*3/*3_may_have_a_decreased_metabolism_of_cilostazol_as_compared_to_patients_with_the_CYP3A5_*1/*1_diplotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cilostazol._";PGKB_RACE=NR,NR,White,Asian
.	.	G6PD A- 202A_376G, G6PD B (wildtype), G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG=rasburicase_(PA10176);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=1A;PGKB_DISEASE="Hemolysis_(PA444411)""Methemoglobinemia_(PA444942)""Protein_Deficiency_(PA445428)";PGKB_TEXT="A-_202A_376G:Male_patients_with_the_A-_202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_rasburicase_may_have_an_increased_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_the_wildtype_B_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""A-_202A_376G/A-_202A_376G:Female_patients_with_the_A-_202A_376G/A-_202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_rasburicase_may_have_an_increased_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_the_wildtype_B/B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-_202A_376G/B_(wildtype)_:Female_patients_with_the_A-_202A_376G/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_rasburicase_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_methemoglobinemia_and_hemolysis_as_compared_to_patients_with_the_A-_202A_376G/A-_202A_376G_or_B/B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_rasburicase_may_have_a_reduced_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_variants_conferring_G6PD_deficiency_(e.g._hemizygous_for_the_A-_or_Mediterranean_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_the_B/B_wildtype_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_rasburicase_may_have_a_reduced_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_genotypes_conferring_G6PD_deficiency_(e.g._homozygous_for_the_A-_or_Mediterranean_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_patients_who_are_hemizygous_for_the_Mediterranean_variant_(rs5030868_allele_A_associated_with_G6PD_deficiency)_who_are_treated_with_rasburicase_may_have_an_increased_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_the_wildtype_B_haplotype_(rs5030868_allele_G)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/B_(wildtype):Female_patients_who_are_heterozygous_for_the_G6PD_Mediterranean_variant_(rs5030868_genotype_AG)_who_are_treated_with_rasburicase_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_patients_who_are_homozygous_for_the_G6PD_Mediterranean_variant_(rs5030868_genotype_AA_associated_with_G6PD_deficiency)_or_homozygous_for_the_B/_B_wildtype_diplotype_(rs5030868_genotype_GG_not_associated_with_G6PD_deficiency)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Female_patients_who_are_homozygous_for_the_G6PD_Mediterranean_variant_(rs5030868_genotype_AA_associated_with_G6PD_deficiency)_who_are_treated_with_rasburicase_may_have_an_increased_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_the_wildtype_B/_B_diplotype_(rs5030868_genotype_GG)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR
.	.	G6PD A- 202A_376G, G6PD B (wildtype), G6PD Mediterranean Haplotype, G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG=chloroquine_(PA448948);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Anemia_Hemolytic_(PA443343);PGKB_TEXT="A-_202A_376G:Male_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_haplotype_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-_202A_376G/A-_202A_376G:Female_patients_with_the_A-202A_376G/A-202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_haplotype_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-_202A_376G/B_(wildtype):Female_patients_with_the_A-202A_376G/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_A-/A-_or_B/B_diplotype._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_haplotype_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_a_reduced_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean_or_A-202A_376G_haplotype_(hemizygous_for_variants_associated_with_G6PD_deficiency)._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_haplotype_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_the_B/B_(wildtype)_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_a_reduced_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean/Mediterranean_or_A-202A_376G/A-202A_376G_diplotype_(homozygous_for_a_variant_associated_with_G6PD_deficiency)._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_haplotype_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Haplotype/Mediterranean_Haplotype:Female_patients_homozygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_a_high_dose_of_chloroquine_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/B_(wildtype):Female_patients_with_the_heterozygous_for_the_G6PD_Mediterranean_variant_who_are_treated_with_a_high_dose_of_chloroquine_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean/Mediterranean_or_B/B_diplotype._Most_studies_show_no_association_with_increased_risk_with_normal_chloroquine_dosage._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_only_one_reported_genotyping_here_we_are_representing_this_association_under_the_Mediterranean_or_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR
.	.	G6PD A- 202A_376G, G6PD B (wildtype)	.	.	.	.	PGKB_INDEX=7;PGKB_GENE=G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469);PGKB_DRUG=methylene_blue_(PA450457),glibenclamide_(PA449782),nitrofurantoin_(PA450640),mefloquine_(PA450348),sulfasalazine_(PA451547),dimercaprol_(PA165958406),chloramphenicol_(PA448927);PGKB_TYPE="Efficacy""Toxicity/ADR",Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3,4,3,3;PGKB_DISEASE="Anemia_Hemolytic_(PA443343)""Hemolysis_(PA444411)""Protein_Deficiency_(PA445428)",Anemia_Hemolytic_(PA443343),"Anemia_Hemolytic_(PA443343)""Hemolysis_(PA444411)",Malaria_(PA444859),Hemolysis_(PA444411),"Hemolysis_(PA444411)""Lead_Poisoning_Nervous_System_Childhood_(PA166048926)","Anemia_Hemolytic_(PA443343)""Hemolysis_(PA444411)";PGKB_TEXT="A-_202A_376G:Male_patients_with_the_A-_202A_376G_haplotype_(hemizygous_for_the_G6PD_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_methylene_blue_1)_may_not_respond_to_treatment_for_methemoglobinemia_2)_may_have_an_increased_risk_of_drug-induced_hemolysis_as_compared_to_patients_with_the_B_haplotype_(wildtype)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methylene_blue_treatment_and_risk_of_hemolysis._""A-_202A_376G/_A-_202A_376G:Female_patients_with_the_A-_202A_376G/A-_202A_376G_haplotype_(homozygous_for_the_G6PD_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_methylene_blue_1)_may_not_respond_to_treatment_for_methemoglobinemia_2)_may_have_an_increased_risk_of_drug-induced_hemolysis_as_compared_to_patients_with_the_B_haplotype_(wildtype)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methylene_blue_treatment_and_risk_of_hemolysis._""A-_202A_376G/B_(wildtype):Female_patients_with_the_A-_202A_376G/B_(wildtype)_haplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_methylene_blue_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_patients_with_the_A-_202A_376G/A-_202A_376G_or_B/B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_who_are_treated_with_methylene_blue_1)_may_be_more_likely_to_respond_to_treatment_for_methemoglobinemia_2)_may_have_a_reduced_risk_of_drug-induced_hemolysis_as_compared_to_patients_with_the_A-_202A_376G_haplotype_(hemizygous_for_the_G6PD_A-_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methylene_blue_treatment_and_risk_of_hemolysis._""B_(wildtype)/_B_(wildtype):Female_patients_with_the_B_(wildtype)/_B_(wildtype)_haplotype_who_are_treated_with_methylene_blue_1)_may_be_more_likely_to_respond_to_treatment_for_methemoglobinemia_2)_may_have_a_reduced_risk_of_drug-induced_hemolysis_as_compared_to_patients_with_the_A-_202A_376G_haplotype_(homozygous_or_heterozygous_for_the_G6PD_A-_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methylene_blue_treatment_and_risk_of_hemolysis._","A-202A_376G:Male_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_A-_variant)_who_are_treated_with_glibenclamide_may_have_an_increased_risk_of_hemolysis_or_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolytic_anemia._""A-202A_376G/A-202A_376G:Female_patients_with_the_A-202A_376G/_A-202A_376G_diplotype_(homozygous_for_the_A-_variant)_who_are_treated_with_glibenclamide_may_have_an_increased_risk_of_hemolysis_or_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/_B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolytic_anemia._""A-202A_376G/B_(wildtype):Female_patients_with_the_A-202A_376G/_B_diplotype_(heterozygous_for_the_A-_variant)_who_are_treated_with_glibenclamide_may_have_an_increased_risk_of_hemolysis_or_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/_B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolytic_anemia._""B_(wildtype):Male_patients_with_the_wildtype_B_haplotype_who_are_treated_with_glibenclamide_may_have_a_reduced_risk_of_hemolysis_or_hemolytic_anemia_as_compared_to_patients_with_the_A-202A_376G_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolytic_anemia._""B_(wildtype)/B_(wildtype):Female_patients_with_the_wildtype_B/_B_diplotype_who_are_treated_with_glibenclamide_may_have_a_reduced_risk_of_hemolysis_or_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/_B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolytic_anemia._","A-202A_376G:Male_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_nitrofurantoin_may_have_an_increased_risk_of_hemolysis_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-202A_376G/A-202A_376G:Female_patients_with_the_A-202A_376G/A-202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_nitrofurantoin_may_have_an_increased_risk_of_hemolysis_as_compared_to_patients_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-202A_376G/B_(wildtype):Female_patients_with_the_A-202A_376G/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_nitrofurantoin_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_patients_with_the_A-202A_376G/A-202A_376G_or_B/B_diplotype._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_nitrofurantoin_may_have_a_reduced_but_not_absent_risk_of_hemolysis_as_compared_to_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""B_(wildtype)/B_(wildtype):Female_patients_with_the_B/B_wildtype_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_nitrofurantoin_may_have_a_reduced_but_not_absent_risk_of_hemolysis_as_compared_to_patients_with_the_A-202A_376G/A-202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._","A-202A_376G:Male_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_G6PD_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_mefloquine_1)_may_have_an_increased_risk_of_pulmonary_damage_2)_may_have_a_similar_risk_of_hemolysis_as_compared_to_patients_with_the_B_haplotype_(wildtype)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mefloquine_treatment_and_risk_of_toxicity._""B_(wildtype):Male_patients_with_the_B_haplotype_(wildtype_associated_with_normal_G6PD_activity)_who_are_treated_with_mefloquine_1)_may_have_a_reduced_risk_of_pulmonary_damage_2)_may_have_a_similar_risk_of_hemolysis_as_compared_to_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_G6PD_A-_variant_associated_with_G6PD_deficiency)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mefloquine_treatment_and_risk_of_toxicity._","A-_202A_376G:Male_patients_with_the_A-_202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_sulfasalazine_may_have_an_increased_risk_of_hemolysis_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""A-_202A_376G/A-_202A_376G:Female_patients_with_the_A-_202A_376G/A-_202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_sulfasalazine_may_have_an_increased_risk_of_hemolysis_as_compared_to_patients_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-_202A_376G/B_(wildtype):Female_patients_with_the_A-_202A_376G/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_sulfasalazine_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_patients_with_the_A-_202A_376G/A-_202A_376G_or_B/B_diplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfasalazine_may_have_a_reduced_risk_of_hemolysis_as_compared_to_patients_with_variants_conferring_G6PD_deficiency_(e.g._hemizygous_for_the_A-_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_the_B/B_wildtype_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfasalazine_may_have_a_reduced_risk_of_hemolysis_as_compared_to_patients_with_genotypes_conferring_G6PD_deficiency_(e.g._homozygous_for_the_A-)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._","A-_202A_376G:Male_children_with_lead_poisoning_and_the_A-_202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_dimercaprol_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_the_A-_G6PD_variant_was_determined_by_electrophoresis_rather_than_genotyping_and_here_is_represented_by_the_A-_202_376G_haplotype_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-_202A_376G/A-_202A_376G:Female_children_with_lead_poisoning_and_the_A-_202A_376G/A-_202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_dimercaprol_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Please_note:_the_A-_G6PD_variant_was_determined_by_electrophoresis_rather_than_genotyping_and_here_is_represented_by_the_A-_202_376G_haplotype_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-_202A_376G/B_(wildtype):Female_children_with_lead_poisoning_and_the_A-_202A_376G/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_dimercaprol_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_children_with_the_A-_202A_376G/A-_202A_376G_or_B/B_diplotype._Please_note:_the_A-_G6PD_variant_was_determined_by_electrophoresis_rather_than_genotyping_and_here_is_represented_by_the_A-_202_376G_haplotype_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype):Male_children_with_lead_poisoning_and_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_dimercaprol_may_have_a_reduced_risk_of_hemolysis_as_compared_to_children_with_the_A-_202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)._Please_note:_the_A-_G6PD_variant_was_determined_by_electrophoresis_rather_than_genotyping_and_here_is_represented_by_the_A-_202_376G_haplotype_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_children_with_lead_poisoning_and_the_B/B_(wildtype)_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_dimercaprol_may_have_a_reduced_risk_of_hemolysis_as_compared_to_children_with_the_A-_202A_376G_diplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)._Please_note:_the_A-_G6PD_variant_was_determined_by_electrophoresis_rather_than_genotyping_and_here_is_represented_by_the_A-_202_376G_haplotype_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._","A-202A_376G:Male_children_with_typhoid_fever_and_the_A-202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_chloramphenicol_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-202A_376G/A-202A_376G:Female_children_with_typhoid_fever_and_the_A-202A_376G/A-202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_chloramphenicol_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""A-202A_376G/B_(wildtype):Female_children_with_typhoid_fever_and_the_A-202A_376G/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_A-_variant)_who_are_treated_with_chloramphenicol_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_children_with_the_A-202A_376G/A-202A_376G_or_B/B_diplotype._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype):Male_patients_with_typhoid_fever_and_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_chloramphenicol_may_have_a_reduced_but_not_absent_risk_of_hemolysis_as_compared_to_patients_with_the_A-202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_typhoid_fever_and_the_B/B_wildtype_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_chloramphenicol_may_have_a_reduced_but_not_absent_risk_of_hemolysis_as_compared_to_patients_with_the_A-202A_376G/A-202A_376G_diplotype_(homozygous_for_the_A-_variant_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_A-_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR,NR,NR,NR,Black_or_African_American,Black_or_African_American,NR
.	.	G6PD A- 202A_376G	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG=pegloticase_(PA165963961);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Hemolysis_(PA444411)""Methemoglobinemia_(PA444942)";PGKB_TEXT=A-_202A_376G:Male_patients_with_the_A-_202A_376G_haplotype_(hemizygous_for_the_A-_variant_associated_with_G6PD_deficiency)_who_are_treated_with_pegloticase_may_have_an_increased_risk_of_methemoglobinemia_and/or_hemolysis_as_compared_to_patients_with_the_wildtype_B_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.;PGKB_RACE="Black_or_African_American""Hispanic_or_Latino"
.	.	G6PD B (wildtype), G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG="sulfamethoxazole_(PA451544)""sulfamethoxazole_and_trimethoprim_(PA10715)""trimethoprim_(PA451788)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hemolysis_(PA444411);PGKB_TEXT="B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_and_an_infection_who_are_treated_with_co-trimoxazole_may_have_a_reduced_but_not_absent_risk_of_hemolysis_as_compared_to_patients_with_variants_conferring_G6PD_deficiency_(e.g._hemizygous_for_the_Canton_variant)._Sulfamethoxazole_seems_to_underlie_the_effect_on_reducing_red_blood_cell_lifespan_rather_than_trimethoprim._Several_studies_find_no_association_with_increased_risk_in_patients_with_G6PD_deficiency._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_the_B/B_(wildtype)_diplotype_(not_associated_with_G6PD_deficiency)_and_an_infection_who_are_treated_with_co-trimoxazole_may_have_a_reduced_but_not_absent_risk_of_hemolysis_as_compared_to_patients_with_variants_conferring_G6PD_deficiency_(e.g._hemizygous_for_the_Canton_variant)._Sulfamethoxazole_seems_to_underlie_the_effect_on_reducing_red_blood_cell_lifespan_rather_than_trimethoprim._Several_studies_find_no_association_with_increased_risk_in_patients_with_G6PD_deficiency._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Canton_Taiwan-Hakka_Gifu-like_Agrigento-like:Male_patients_who_are_hemizygous_for_the_Canton_variant_(associated_with_G6PD_deficiency)_and_an_infection_may_have_an_increased_risk_of_hemolysis_when_treated_with_co-trimoxazole_as_compared_to_patients_with_the_wildtype_B_haplotype_(associated_with_normal_G6PD_enzyme_levels)._Sulfamethoxazole_seems_to_underlie_the_effect_on_reducing_red_blood_cell_lifespan_rather_than_trimethoprim._Several_studies_find_no_association_with_increased_risk_in_patients_with_G6PD_deficiency._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""Canton_Taiwan-Hakka_Gifu-like_Agrigento-like/B_(wildtype):Female_patients_with_the_Canton/B_(wildtype)_diplotype_(heterozygous_for_the_Canton_variant)_and_an_infection_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_co-trimoxazole-induced_hemolysis_as_compared_to_patients_with_the_Canton/Canton_or_B/B_diplotype._Sulfamethoxazole_seems_to_underlie_the_effect_on_reducing_red_blood_cell_lifespan_rather_than_trimethoprim._Several_studies_find_no_association_with_increased_risk_in_patients_with_G6PD_deficiency._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""Canton_Taiwan-Hakka_Gifu-like_Agrigento-like/Canton_Taiwan-Hakka_Gifu-like_Agrigento-like:Female_patients_who_are_homozygous_for_the_Canton_variant_(associated_with_G6PD_deficiency)_and_an_infection_may_have_an_increased_risk_of_hemolysis_when_treated_with_co-trimoxazole_as_compared_to_patients_with_the_wildtype_B_haplotype_(associated_with_normal_G6PD_enzyme_levels)._Sulfamethoxazole_seems_to_underlie_the_effect_on_reducing_red_blood_cell_lifespan_rather_than_trimethoprim._Several_studies_find_no_association_with_increased_risk_in_patients_with_G6PD_deficiency._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.";PGKB_RACE=NR
.	.	G6PD B (wildtype), G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469),G6PD_(PA28469);PGKB_DRUG=sulfadoxine_(PA451540),sulfametopyrazine_(PA164747038),aspirin_(PA448497),sulfametopyrazine_(PA164747038);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=4,4,4,3;PGKB_DISEASE=Hemolysis_(PA444411),Hemolysis_(PA444411),Hemolysis_(PA444411),Hemolysis_(PA444411);PGKB_TEXT="B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfadoxine_may_have_increased_survival_of_red_blood_cells_as_compared_to_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""B_(wildtype)/B_(wildtype):Female_patients_homozygous_for_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfadoxine_may_have_increased_survival_of_red_blood_cells_as_compared_to_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_sulfadoxine_may_have_reduced_survival_of_red_blood_cells_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/B_(wildtype):Female_patients_heterozygous_for_the_G6PD_Mediterranean_variant_who_are_treated_with_sulfadoxine_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_rate_of_red_blood_cell_survival_as_compared_to_patients_with_the_Mediterranean/Mediterranean_or_B/B_genotype._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Female_patients_homozygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_sulfadoxine_may_have_reduced_survival_of_red_blood_cells_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._","B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_increased_survival_of_red_blood_cells_as_compared_to_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""B_(wildtype)/B_(wildtype):Female_patients_homozygous_for_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_increased_survival_of_red_blood_cells_as_compared_to_patients_homozygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_reduced_survival_of_red_blood_cells_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/B_(wildtype):Female_patients_heterozygous_for_the_G6PD_Mediterranean_variant_who_are_treated_with_sulfametopyrazine_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_rate_of_red_blood_cell_survival_as_compared_to_patients_with_the_Mediterranean/Mediterranean_or_B/B_genotype._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Female_patients_homozygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_reduced_survival_of_red_blood_cells_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping._Other_genetic_and_clinical_factors_may_also_influence_red_blood_cell_survival._","B_(wildtype):Male_children_with_the_B_(wildtype)_genotype_(not_associated_with_G6PD_deficiency)_and_systemic_arthritis_who_are_treated_with_a_high_dose_of_aspirin_may_have_a_reduced_risk_of_hemolysis_as_compared_to_children_hemizygous_for_the_G6PD_Mediterranean_variant_(associated_with_G6PD_deficiency)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_children_with_the_B/B_(wildtype)_genotype_(not_associated_with_G6PD_deficiency)_and_systemic_arthritis_who_are_treated_with_a_high_dose_of_aspirin_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_homozygous_for_the_G6PD_Mediterranean_variant_(associated_with_G6PD_deficiency)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_children_hemizygous_for_the_G6PD_Mediterranean_variant_(associated_with_G6PD_deficiency)_with_systemic_arthritis_who_are_treated_with_a_high_dose_of_aspirin_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_with_the_B_(wildtype)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/B_(wildtype):Female_patients_heterozygous_for_the_G6PD_Mediterranean_variant_with_systemic_arthritis_who_are_treated_with_a_high_dose_of_aspirin_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_patients_with_homozygous_for_the_G6PD_Mediterranean_variant_or_B_(wildtype)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Female_children_homozygous_for_the_G6PD_Mediterranean_variant_(associated_with_G6PD_deficiency)_with_systemic_arthritis_who_are_treated_with_a_high_dose_of_aspirin_may_have_an_increased_risk_of_hemolysis_as_compared_to_children_with_the_B/B_(wildtype)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._","B_(wildtype)_:Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_an_increased_survival_of_red_blood_cells_compared_to_patients_with_variants_conferring_G6PD_deficiency_(e.g._hemizygous_for_the_Mediterranean_variant)._Sulfametopyrazine_treatment_does_not_seem_to_affect_hemocrit_level._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_the_B_(wildtype)/B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_an_increased_survival_of_red_blood_cells_compared_to_patients_with_variants_conferring_G6PD_deficiency_(e.g._homozygous_for_the_Mediterranean_variant)._Sulfametopyrazine_treatment_does_not_seem_to_affect_hemocrit_level._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_patients_who_are_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_a_reduced_survival_of_red_blood_cells_as_compared_to_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)._Sulfametopyrazine_treatment_does_not_seem_to_affect_hemocrit_level._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/B_(wildtype):Female_patients_who_are_heterozygous_for_the_Mediterranean_variant_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_effect_on_red_blood_survival_when_treated_with_sulfametopyrazine_as_compared_to_patients_with_the_B/B_(wildtype)_haplotype_or_homozygous_for_the_Mediterranean/Mediterranean_diplotype._Sulfametopyrazine_treatment_does_not_seem_to_affect_hemocrit_level._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham/Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Female_patients_who_are_homozygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_sulfametopyrazine_may_have_a_reduced_survival_of_red_blood_cells_as_compared_to_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)._Sulfametopyrazine_treatment_does_not_seem_to_affect_hemocrit_level._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR,NR,NR,NR
.	.	G6PD B (wildtype), G6PD Mediterranean Haplotype, G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG=ciprofloxacin_(PA449009);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Anemia_Hemolytic_(PA443343);PGKB_TEXT="B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_ciprofloxacin_may_have_a_reduced_risk_of_hemolytic_anemia_as_compared_to_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping_but_reported_the_patient_to_have_Mediterranean_G6PD_deficiency_therefore_here_we_are_representing_this_association_under_the_Mediterranean_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""B_(wildtype)/B_(wildtype):Female_patients_with_the_B_(wildtype)/B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_ciprofloxacin_may_have_a_reduced_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean/Mediterranean_genotype_(homozygous_for_the_Mediterranean_variant_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping_but_reported_the_patient_to_have_Mediterranean_G6PD_deficiency_therefore_here_we_are_representing_this_association_under_the_Mediterranean_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Haplotype/B_(wildtype):Female_patients_with_the_Mediterranean/B_(wildtype)_genotype_(heterozygous_for_the_G6PD_Mediterranean_variant)_who_are_treated_with_ciprofloxacin_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean/Mediterranean_or_B/B_genotype._Please_note:_this_study_did_not_report_genotyping_but_reported_the_patient_to_have_Mediterranean_G6PD_deficiency_therefore_here_we_are_representing_this_association_under_the_Mediterranean_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Haplotype/Mediterranean_Haplotype:Female_patients_homozygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_ciprofloxacin_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping_but_reported_the_patient_to_have_Mediterranean_G6PD_deficiency_therefore_here_we_are_representing_this_association_under_the_Mediterranean_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Dallas_Panama'_Sassari_Cagliari_Birmingham:Male_patients_hemizygous_for_the_Mediterranean_variant_(associated_with_G6PD_deficiency)_who_are_treated_with_ciprofloxacin_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_this_study_did_not_report_genotyping_but_reported_the_patient_to_have_Mediterranean_G6PD_deficiency_therefore_here_we_are_representing_this_association_under_the_Mediterranean_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR
.	.	G6PD B (wildtype), G6PD Mediterranean Haplotype	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG=phenazopyridine_(PA164746899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Anemia_Hemolytic_(PA443343)""Hemolysis_(PA444411)";PGKB_TEXT="B_(wildtype):Male_patients_with_the_B_(wildtype)_haplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_phenazopyridine_may_have_a_reduced_but_not_absent_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean_haplotype_(hemizygous_for_the_Mediterranean_variant_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_Mediterranean_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis.""B_(wildtype)/B_(wildtype):Female_patients_with_the_B/B_wildtype_diplotype_(not_associated_with_G6PD_deficiency)_who_are_treated_with_phenazopyridine_may_have_a_reduced_but_not_absent_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean/Mediterranean_diplotype_(homozygous_for_the_Mediterranean_variant_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_Mediterranean_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Haplotype:Male_patients_with_the_Mediterranean_haplotype_(hemizygous_for_the_Mediterranean_variant_associated_with_G6PD_deficiency)_who_are_treated_with_phenazopyridine_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B_haplotype_(not_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_Mediterranean_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Haplotype/B_(wildtype):Female_patients_with_the_Mediterranean/B_(wildtype)_diplotype_(heterozygous_for_the_G6PD_Mediterranean_variant)_who_are_treated_with_phenazopyridine_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_Mediterranean/Mediterranean_or_B/B_diplotype._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_Mediterranean_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""Mediterranean_Haplotype/Mediterranean_Haplotype:Female_patients_with_the_Mediterranean/Mediterranean_diplotype_(homozygous_for_the_Mediterranean_variant_associated_with_G6PD_deficiency)_who_are_treated_with_phenazopyridine_may_have_an_increased_risk_of_hemolytic_anemia_as_compared_to_patients_with_the_wildtype_B/B_diplotype_(not_associated_with_G6PD_deficiency)._Please_note:_all_studies_reported_an_association_with_G6PD_deficiency_but_did_not_genotype_or_characterize_the_G6PD_variant_here_we_are_representing_this_association_under_the_Mediterranean_variant_which_is_associated_with_G6PD_deficiency_with_the_B_(wildtype)_haplotype_representing_G6PD_non-deficient._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR
.	.	GSTM1 non-null, GSTM1 null	.	.	.	.	PGKB_INDEX=5;PGKB_GENE=GSTM1_(PA182),GSTM1_(PA182),GSTM1_(PA182),GSTM1_(PA182),GSTM1_(PA182);PGKB_DRUG="Drugs_For_Treatment_Of_Tuberculosis_(PA164712708)""ethambutol_(PA164784021)""isoniazid_(PA450112)""pyrazinamide_(PA451182)""rifampin_(PA451250)""streptomycin_(PA451512)","sulfamethoxazole_(PA451544)""trimethoprim_(PA451788)",cisplatin_(PA449014),"cisplatin_(PA449014)""oxaliplatin_(PA131285527)","bleomycin_(PA448645)""dacarbazine_(PA449197)""doxorubicin_(PA449412)""vinblastine_(PA451877)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Efficacy,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3,4,2B,3;PGKB_DISEASE=Tuberculosis_(PA445941),Acquired_Immunodeficiency_Syndrome_(PA443250),"Deafness_(PA443840)""Ototoxicity_(PA162263534)""Testicular_Neoplasms_(PA445828)","Colorectal_Neoplasms_(PA446108)""Uterine_Cervical_Neoplasms_(PA443685)",NR;PGKB_TEXT="non-null/_non-null:Patients_with_the_non-null/_non-null_genotype_(has_two_copies_of_the_GSTM1_gene)_and_Tuberculosis_may_have_a_decreased_risk_of_drug-induced_hepatotoxicity_when_treated_with_an_isoniazid-containing_anti-TB_drug_regimen_as_compared_to_patients_with_the_null/_null_genotype._However_this_association_is_not_seen_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury.""non-null/_null:Patients_with_the_non-null/_null_genotype_(has_one_copy_of_the_GSTM1_gene)_and_Tuberculosis_may_have_a_decreased_risk_of_drug-induced_hepatotoxicity_when_treated_with_an_isoniazid-containing_anti-TB_drug_regimen_as_compared_to_patients_with_the_null/_null_genotype._However_this_association_is_not_seen_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury.""null/null:Patients_with_the_null/null_(has_no_copies_of_the_GSTM1_gene)_genotype_and_Tuberculosis_may_have_an_increased_risk_of_drug-induced_hepatotoxicity_when_treated_with_an_isoniazid-containing_anti-TB_drug_regimen_as_compared_to_patients_with_the_non-null/_null_or_the_non-null/_non-null_genotype._However_this_association_is_not_seen_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury.","non-null/_non-null:Patients_with_the_non-null/_non-null_genotype_(has_two_copies_of_the_GSTM1_gene)_and_AIDs_who_are_treated_with_sulfamethoxazole_and_trimethoprim_may_have_a_reduced_but_not_absent_risk_of_cutaneous_reactions_as_compared_to_patients_with_the_null/null_genotype_combined_with_a_NAT2_slow_acetylator_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_cutaneous_reactions._""non-null/null:Patients_with_the_non-null/_null_genotype_(has_one_copy_of_the_GSTM1_gene)_and_AIDs_who_are_treated_with_sulfamethoxazole_and_trimethoprim_may_have_a_reduced_but_not_absent_risk_of_cutaneous_reactions_as_compared_to_patients_with_the_null/null_genotype_combined_with_a_NAT2_slow_acetylator_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_cutaneous_reactions._""null/null:Patients_with_the_null/null_genotype_(has_no_copies_of_the_GSTM1_gene)_combined_with_a_NAT2_slow_acetylator_genotype_and_AIDs_who_are_treated_with_sulfamethoxazole_and_trimethoprim_may_have_an_increased_risk_of_cutaneous_reactions_as_compared_to_patients_with_the_non-null/null_or_non-null/non-null_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_cutaneous_reactions._","non-null/non-null:Men_with_the_non-null/_non-null_genotype_(has_two_copies_of_the_GSTM1_gene)_and_testicular_cancer_who_are_treated_with_a_cisplatin-containing_regimen_may_have_an_increased_risk_of_hearing_impairment_as_compared_to_patients_with_the_null/null_genotype._No_association_was_seen_with_ototoxicity_in_a_separate_study_of_children_receiving_cisplatin-based_chemotherapy_for_cancer_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._""non-null/null:Men_with_the_non-null/_null_genotype_(has_one_copy_of_the_GSTM1_gene)_and_testicular_cancer_who_are_treated_with_a_cisplatin-containing_regimen_may_have_an_increased_risk_of_hearing_impairment_as_compared_to_patients_with_the_null/null_genotype._No_association_was_seen_with_ototoxicity_in_a_separate_study_of_children_receiving_cisplatin-based_chemotherapy_for_cancer_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._""null/null:Men_with_the_null/null_genotype_(has_no_copies_of_the_GSTM1_gene)_and_testicular_cancer_who_are_treated_with_a_cisplatin-containing_regimen_may_have_a_reduced_but_not_absent_risk_of_hearing_impairment_as_compared_to_patients_with_the_non-null/null_or_non-null/non-null_genotype._No_association_was_seen_with_ototoxicity_in_a_separate_study_of_children_receiving_cisplatin-based_chemotherapy_for_cancer_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._","non-null/non-null:Patients_with_cervical_or_colorectal_cancer_and_the_GSTM1_non-null/non-null_genotype_who_are_treated_with_cisplatin_or_oxaliplatin_may_have_decreased_likelihood_of_disease_free_survival_and_increased_incidence_of_recurrence_as_compared_to_patients_with_the_null/null_genotypes._Other_clinical_and_genetic_factors_may_also_influence_disease_free_survival_and_incidence_of_disease_recurrence_in_patients_who_are_treated_with_platinum_compounds.""non-null/null:Patients_with_cervical_or_colorectal_cancer_and_the_GSTM1_null/non-null_genotype_who_are_treated_with_cisplatin_or_oxaliplatin_may_have_decreased_likelihood_of_disease_free_survival_and_increased_incidence_of_recurrence_as_compared_to_patients_with_the_null/null_genotypes._Other_clinical_and_genetic_factors_may_also_influence_disease_free_survival_and_incidence_of_disease_recurrence_in_patients_who_are_treated_with_platinum_compounds.""null/null:Patients_with_cervical_or_colorectal_cancer_and_the_GSTM1_null/null_genotype_who_are_treated_with_cisplatin_or_oxaliplatin_compounds_may_have_increased_likelihood_of_disease_free_survival_and_decreased_incidence_of_recurrence_as_compared_to_patients_with_the_null/non-null_and_non-null/non-null_genotypes._Other_clinical_and_genetic_factors_may_also_influence_disease_free_survival_and_incidence_of_disease_recurrence_in_patients_who_are_treated_with_platinum_compounds.","non-null/non-null:Patients_with_the_non-null/non-null_genotype_and_Hodgkin_lymphoma_who_are_on_the_ABVD_chemotherapy_regimen_may_have_a_greater_chance_of_achieving_complete_remission_and_a_decreased_risk_of_experiencing_drug_toxicities_as_compared_to_patients_with_the_non-null/null_or_null/null_genotype._Other_genetic_and_clinical_factors_may_also_influence_chance_of_remission_or_risk_of_drug_toxicities_when_treated_with_the_ABVD_regimen.""non-null/null:Patients_with_the_non-null/null_genotype_and_Hodgkin_lymphoma_who_are_on_the_ABVD_chemotherapy_regimen_may_have_a_poorer_chance_of_achieving_complete_remission_and_an_increased_risk_of_experiencing_drug_toxicities_as_compared_to_patients_with_the_non-null/non-null_genotype._Other_genetic_and_clinical_factors_may_also_influence_chance_of_remission_or_risk_of_drug_toxicities_when_treated_with_the_ABVD_regimen.""null/null:Patients_with_the_null/null_genotype_and_Hodgkin_lymphoma_who_are_on_the_ABVD_chemotherapy_regimen_may_have_a_poorer_chance_of_achieving_complete_remission_and_an_increased_risk_of_experiencing_drug_toxicities_as_compared_to_patients_with_the_non-null/non-null_genotype._Other_genetic_and_clinical_factors_may_also_influence_chance_of_remission_or_risk_of_drug_toxicities_when_treated_with_the_ABVD_regimen.";PGKB_RACE=NR,NR,NR,NR,NR
.	.	GSTT1 non-null, GSTT1 null	.	.	.	.	PGKB_INDEX=3;PGKB_GENE=GSTT1_(PA183),GSTT1_(PA183),GSTT1_(PA183);PGKB_DRUG="Drugs_For_Treatment_Of_Tuberculosis_(PA164712708)""ethambutol_(PA164784021)""isoniazid_(PA450112)""pyrazinamide_(PA451182)""rifampin_(PA451250)""streptomycin_(PA451512)",cisplatin_(PA449014),imatinib_(PA10804);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Tuberculosis_(PA445941),"Deafness_(PA443840)""Neoplasms_(PA445062)""Ototoxicity_(PA162263534)",Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171);PGKB_TEXT="non-null/_non-null:Patients_with_the_non-null/_non-null_genotype_(has_two_copies_of_the_GSTT1_gene)_and_Tuberculosis_may_have_a_decreased_risk_of_drug-induced_hepatotoxicity_when_treated_with_an_isoniazid-containing_anti-TB_drug_regimen_as_compared_to_patients_with_the_null/_null_genotype._However_this_association_is_not_seen_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""non-null/_null:Patients_with_the_non-null/_null_genotype_(has_one_copy_of_the_GSTT1_gene)_and_Tuberculosis_may_have_a_decreased_risk_of_drug-induced_hepatotoxicity_when_treated_with_an_isoniazid-containing_anti-TB_drug_regimen_as_compared_to_patients_with_the_null/_null_genotype._However_this_association_is_not_seen_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""null/null:Patients_with_the_null/null_(has_no_copies_of_the_GSTT1_gene)_genotype_and_Tuberculosis_may_have_an_increased_risk_of_drug-induced_hepatotoxicity_when_treated_with_an_isoniazid-containing_anti-TB_drug_regimen_as_compared_to_patients_with_the_non-null/_null_or_the_non-null/_non-null_genotype._However_this_association_is_not_seen_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._","non-null/non-null:Children_with_the_non-null/non-null_genotype_(has_two_copies_of_the_GSTM1_gene)_and_cancer_who_are_treated_with_a_cisplatin-based_chemotherapy_may_have_an_increased_risk_of_hearing_impairment_as_compared_to_children_with_the_null/null_genotype_(no_copies_of_the_GSTM1_gene)._No_association_was_seen_with_severe_hearing_impairment_in_a_separate_study_of_adult_patients_receiving_a_cisplatin-containing_regimen_for_testicular_cancer_treatment_unless_other_genetic_variants_were_taken_into_account._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._""non-null/null:Children_with_the_non-null/null_genotype_(has_one_copy_of_the_GSTM1_gene)_and_cancer_who_are_treated_with_a_cisplatin-based_chemotherapy_may_have_an_increased_risk_of_hearing_impairment_as_compared_to_children_with_the_null/null_genotype_(no_copies_of_the_GSTM1_gene)._No_association_was_seen_with_severe_hearing_impairment_in_a_separate_study_of_adult_patients_receiving_a_cisplatin-containing_regimen_for_testicular_cancer_treatment_unless_other_genetic_variants_were_taken_into_account._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._""null/null:Children_with_the_null/null_genotype_(has_no_copies_of_the_GSTM1_gene)_and_cancer_who_are_treated_with_a_cisplatin-based_chemotherapy_may_have_a_reduced_but_not_absent_risk_of_hearing_impairment_as_compared_to_children_with_the_non-null/non-null_or_non-null/null_genotype._No_association_was_seen_with_severe_hearing_impairment_in_a_separate_study_of_adult_patients_receiving_a_cisplatin-containing_regimen_for_testicular_cancer_treatment_unless_other_genetic_variants_were_taken_into_account._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._","non-null/non-null:Patients_with_GSTT1_non-null/non-null_genotype_may_have_decreased_likelihood_of_imatinib_failure_in_chronic_myeloid_leukemia_patients_as_compared_to_patients_with_genotype_null/null._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_imatinib.""non-null/null:Patients_with_GSTT1_non-null/null_genotype_may_have_decreased_likelihood_of_imatinib_failure_in_chronic_myeloid_leukemia_patients_as_compared_to_patients_with_genotype_null/null._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_imatinib.""null/null:Patients_with_GSTT1_null/null_genotype_may_have_increased_likelihood_of_imatinib_failure_in_chronic_myeloid_leukemia_patients_as_compared_to_patients_with_genotype_non-null/non-null_+_non-null/null._The_risk_of_imatinib_failure_was_increased_further_if_GSTT1del_was_accompanied_by_GSTM1_del._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_imatinib.";PGKB_RACE=NR,NR,NR
.	.	HLA-A *02:01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-A_(PA35055);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*02:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-A*02:01:01:01_allele_may_have_an_increased_risk_for_maculopapular_eruption_when_receiving_carbamazepine_as_compared_to_patients_with_no_HLA-A*02:01:01:01_alleles_or_negative_for_the_HLA-A*02:01:01:01_test._However_one_study_found_a_decreased_risk_for_drug_hypersensitivity_reactions_for_carriers_of_the_HLA-A*02_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-A *02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-A_(PA35055);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*02:01:Patients_with_one_or_two_copies_of_the_HLA-A*02:01_allele_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_when_treated_with_allopurinol_as_compared_to_patients_with_no_HLA-A*02:01_alleles_or_negative_for_the_HLA-A*02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-A *02:07:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-A_(PA35055);PGKB_DRUG=zonisamide_(PA451978);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*02:07:01:Patients_with_one_or_two_copies_of_the_HLA-A*02:07:01_allele_who_are_treated_with_zonisamide_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_as_compared_to_patients_with_no_HLA-A*02:07:01_alleles_or_negative_for_the_HLA-A*02:07:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-A *31:01:02	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-A_(PA35055);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Drug_Hypersensitivity_(PA443936)""Maculopapular_Exanthema_(PA162316739)";PGKB_TEXT=*31:01:02:Patients_with_one_or_two_copies_of_the_HLA-A*31:01:02_allele_who_are_treated_with_carbamazepine_may_have_an_increased_risk_of_hypersensitivity_as_compared_to_patients_with_no_HLA-A*31:01:02_alleles_or_negative_for_the_HLA-A*31:01:02_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-A *33:03	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-A_(PA35055);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Drug_Hypersensitivity_(PA443936)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*33:03:Patients_with_one_or_two_copies_of_the_HLA-A*33:03_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(SCAR)_as_compared_to_patients_with_no_HLA-A*33:03_alleles_or_negative_for_the_HLA-A*33:03_test._This_allele_has_been_shown_to_be_in_linkage_disequilibrium_with_the_HLA-B*58:01_allele_in_some_populations_which_has_a_strong_association_with_allopurinol-induced_SCAR._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-B *13:01:01	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG=phenytoin_(PA450947),dapsone_(PA449211),sulfasalazine_(PA451547),trichloroethylene_(PA166115521);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,2A,3,3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)",Leprosy_(PA444745),drug_reaction_with_eosinophilia_and_systemic_symptoms_(PA166120927),Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*13:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*13:01:01_allele_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_such_as_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_phenytoin_as_compared_to_patients_with_no_HLA-B*13:01:01_alleles_or_negative_for_the_HLA-B*13:01:01_test._However_one_study_found_no_association_between_the_allele_and_adverse_reactions._Other_genetic_and_clinical_factors_may_also_affect_risk_for_severe_cutaneous_adverse_reactions_in_patients_receiving_phenytoin.,*13:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*13:01:01_allele_who_are_treated_with_dapsone_may_have_an_increased_risk_for_dapsone_hypersensitivity_syndrome_as_compared_to_patients_with_no_HLA-B*13:01:01_alleles_or_negative_for_the_HLA-B*13:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.,*13:01:01:Patients_with_the_HLA-B*13:01_allele_may_have_an_increased_risk_of_DRESS_when_treated_with_sulfasalazine_as_compared_to_patients_with_no_HLA-B*13:01_alleles_or_negative_for_the_HLA-B*13:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_sulfasalazine-induced_adverse_reactions.,*13:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*13:01:01_allele_may_have_an_increased_risk_of_hypersensitivity_dermatitis_when_exposed_to_trichloroethylene_as_compared_to_patients_with_no_HLA-B*13:01:01_alleles_or_negative_for_the_HLA-B*13:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_trichloroethylene-induced_adverse_reactions.;PGKB_RACE=Asian,Asian,Asian,Asian
.	.	HLA-B *13:02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*13:02:01:Patients_with_one_or_two_copies_of_the_HLA-B*13:02:01_allele_may_have_an_increased_risk_of_maculopapular_eruption_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*13:02:01_alleles_or_negative_for_the_HLA-B*13:02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *15:02:01	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG=carbamazepine_(PA448785),phenytoin_(PA450947),lamotrigine_(PA450164),oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=1A,1A,3,3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)","Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)",Epilepsy_(PA444065),"Maculopapular_Exanthema_(PA162316739)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*15:02:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:02:01_allele_have_an_increased_risk_of_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*15:02:01_alleles_or_negative_for_the_HLA-B*15:02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.,*15:02:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:02:01_allele_may_have_an_increased_risk_of_Severe_Cutaneous_Adverse_Reactions_such_as_Stevens-Johnson_Syndrome_and_Toxic_Epidermal_Necrolysis_when_treated_with_phenytoin_as_compared_to_patients_with_no_HLA-B*15:02:01_alleles_or_negative_for_the_HLA-B*15:02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_phenytoin-induced_adverse_reactions.,*15:02:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:02:01_allele_may_have_an_increased_risk_for_Stevens-Johnson_Syndrome_or_toxic_epidermal_necrolysis_(SJS/TEN)_when_receiving_lamotrigine_as_compared_to_patients_with_no_HLA-B*15:02:01_alleles_or_negative_for_the_HLA-B*15:02:01_test._However_this_association_has_only_been_found_in_meta-analyses__no_individual_study_has_shown_a_significant_association_between_the_*15:02:01_allele_and_lamotrigine-induced_SJS/TEN._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_lamotrigine-induced_adverse_reactions.,*15:02:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:02:01_allele_may_have_an_increased_risk_of_Stevens-Johnson_Syndrome_(SJS)_or_maculopapular_eruption_(MPE)_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*15:02:01_alleles_or_negative_for_the_HLA-B*15:02:01_test._However_studies_on_SJS_have_been_conducted_in_small_cohorts_or_in_combination_with_other_drugs_and_a_number_of_studies_on_MPE_have_found_negative_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=Asian,Asian,Asian,Asian
.	.	HLA-B *15:05:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=sulfasalazine_(PA451547);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=drug_reaction_with_eosinophilia_and_systemic_symptoms_(PA166120927);PGKB_TEXT=*15:05:01:Patients_with_the_HLA-B*15:05_allele_may_have_an_increased_risk_of_DRESS_when_treated_with_sulfasalazine_as_compared_to_patients_with_no_HLA-B*15:05_alleles_or_negative_for_the_HLA-B*15:05_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_sulfasalazine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *15:11:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*15:11:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:11:01_allele_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_such_as_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*15:11:01_alleles_or_negative_for_the_HLA-B*15:11:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *15:18:01, HLA-B *40:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Stevens-Johnson_Syndrome_(PA445738);PGKB_TEXT=*15:18:01/*40:01:01:Patients_with_the_HLA-B*15:18:01/*40:01:01_genotype_have_an_increased_risk_of_Stevens-Johnson_Syndrome_when_treated_with_oxcarbazepine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-B *15:18:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Stevens-Johnson_Syndrome_(PA445738);PGKB_TEXT=*15:18:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:18:01_allele_have_an_increased_risk_of_Stevens-Johnson_Syndrome_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*15:18:01_alleles_or_negative_for_the_HLA-B*15:18:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *15:19	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*15:19:Patients_with_one_or_two_copies_of_the_HLA-B*15:19_allele_have_an_increased_risk_of_maculopapular_eruption_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*15:19_alleles_or_negative_for_the_HLA-B*15:19_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *15:27:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*15:27:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:27:01_allele_have_an_increased_risk_of_maculopapular_eruption_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*15:27:01_alleles_or_negative_for_the_HLA-B*15:27:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *27:09	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*27:09:Patients_with_one_or_two_copies_of_the_HLA-B*27:09_allele_have_an_increased_risk_of_maculopapular_eruption_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*27:09_alleles_or_negative_for_the_HLA-B*27:09_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *35:01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*35:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*35:01_allele_have_an_increased_risk_of_experiencing_nevirapine-related_adverse_events_when_treated_with_the_drug_as_compared_to_patients_with_no_HLA-B*35:01_alleles_or_negative_for_the_HLA-B*35:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_nevirapine-induced_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-B *35:05:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Exanthema_(PA444109);PGKB_TEXT=*35:05:01:Patients_with_one_or_two_copies_of_the_HLA-B*35:05:01_allele_have_an_increased_risk_of_skin_rash_when_treated_with_nevirapine_as_compared_to_patients_with_no_HLA-B*35:05:01_alleles_or_negative_for_the_HLA-B*35:05:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_nevirapine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *38:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG="peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_(PA444445);PGKB_TEXT=*38:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*38_allele_have_an_increased_likelihood_of_being_a_non-responder_to_therapy_when_treated_with_pegylated_interferon_and_ribavirin_as_compared_to_patients_with_no_HLA-B*38_alleles_or_negative_for_the_HLA-B*38_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pegylated_interferon_and_ribavirin_therapy._Note_that_the_information_in_this_clinical_annotation_refers_to_the_presence_of_any_HLA-B*38_allele._This_clinical_annotation_appears_on_the_HLA-B*38:01:01_allele_page_because_this_was_the_first_*38_allele_discovered.;PGKB_RACE=NR
.	.	HLA-B *38:02:01	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG="carbimazole_(PA164742970)""methimazole_(PA450422)""propylthiouracil_(PA451156)",oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2A,3;PGKB_DISEASE=Graves_Disease_(PA444329),Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*38:02:01:Patients_with_Graves_disease_who_carry_one_or_two_copies_of_the_HLA-B*38:02:01_allele_have_an_increased_risk_of_agranulocytosis_when_receiving_a_thioamide_(carbimazole_methimazole_or_propylthiouracil)_as_compared_to_patients_with_no_HLA-B*38:02:01_alleles_or_negative_for_the_HLA-B*38:02:01_test._There_is_some_limited_evidence_suggesting_that_this_association_may_not_be_significant_in_patients_taking_propylthiouracil._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_thioamide-induced_agranulocytosis.,*38:02:01:Patients_with_one_or_two_copies_of_the_HLA-B*38:02:01_allele_have_an_increased_risk_of_maculopapular_eruption_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*38:02:01_alleles_or_negative_for_the_HLA-B*38:02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=NR,Asian
.	.	HLA-B *39:01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=sulfasalazine_(PA451547);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=drug_reaction_with_eosinophilia_and_systemic_symptoms_(PA166120927);PGKB_TEXT=*39:01:01:01:Patients_with_the_HLA-B*39:01_allele_may_have_an_increased_risk_of_DRESS_when_treated_with_sulfasalazine_as_compared_to_patients_with_no_HLA-B*39:01_alleles_or_negative_for_the_HLA-B*39:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_sulfasalazine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *40:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*40:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*40:01:01_allele_have_a_decreased_risk_of_severe_cutaneous_adverse_reactions_such_as_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*40:01:01_alleles_or_negative_for_the_HLA-B*40:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *44:02:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG="interferon_alfa-2a_recombinant_(PA164779048)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_(PA444445);PGKB_TEXT=*44:02:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*44_allele_have_an_increased_likelihood_of_having_a_sustained_response_to_interferon-alpha_and_ribavirin_therapy_as_compared_to_patients_with_no_HLA-B*44_alleles_or_negative_for_the_HLA-B*44_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_interferon-alpha_and_ribavirin_therapy._Note_that_the_information_in_this_clinical_annotation_refers_to_the_presence_of_any_HLA-B*44_allele._This_clinical_annotation_appears_on_the_HLA-B*44:02:01:01_allele_page_because_this_was_the_first_*44_allele_discovered.;PGKB_RACE=NR
.	.	HLA-B *44:03:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=ticlopidine_(PA451686);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT=*44:03:01:Patients_with_one_or_two_copies_of_the_HLA-B*44:03_allele_have_an_increased_risk_of_toxic_liver_disease_when_treated_with_ticlopidine_as_compared_to_patients_with_no_HLA-B*44:03_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxic_liver_disease.;PGKB_RACE=NR
.	.	HLA-B *46:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*46:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*46:01:01_allele_have_a_decreased_risk_of_Severe_Cutaneous_Adverse_Reactions_such_as_Stevens-Johnson_Syndrome_and_Toxic_Epidermal_Necrolysis_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*46:01:01_alleles_or_negative_for_the_HLA-B*46:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *48:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*48:01:Patients_with_one_or_two_copies_of_the_HLA-B*48:01_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_hypersensitivity_reactions_as_compared_to_patients_with_no_HLA-B*48:01_alleles_or_negative_for_the_HLA-B*48:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-B *48:04	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=oxcarbazepine_(PA450732);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*48:04:Patients_with_one_or_two_copies_of_the_HLA-B*48:04_allele_have_an_increased_risk_of_maculopapular_eruption_when_treated_with_oxcarbazepine_as_compared_to_patients_with_no_HLA-B*48:04_alleles_or_negative_for_the_HLA-B*48:04_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_oxcarbazepine-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-B *51:01:01	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG=phenobarbital_(PA450911),carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Stevens-Johnson_Syndrome_(PA445738),Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*51:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*15:01:01_allele_have_an_increased_risk_of_Stevens-Johnson_Syndrome_when_treated_with_phenobarbital_as_compared_to_patients_with_no_HLA-B*15:01:01_alleles_or_negative_for_the_HLA-B*15:01:01_test.,*51:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*51:01:01_allele_may_have_an_increased_risk_of_carbamazepine-induced_adverse_reactions_as_compared_to_patients_with_no_HLA-B*51:01:01_alleles_or_negative_for_the_HLA-B*51:01:01_test._However_some_studies_find_no_association_between_this_allele_and_adverse_reactions._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian,NR
.	.	HLA-B *56:02	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-B_(PA35056);PGKB_DRUG=phenytoin_(PA450947);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=drug_reaction_with_eosinophilia_and_systemic_symptoms_(PA166120927);PGKB_TEXT=*56:02:Patients_with_one_or_two_copies_of_the_HLA-B*56:02_allele_have_an_increased_risk_of_drug_reaction_with_eosinophilia_and_systemic_symptoms_(DRESS)_when_treated_with_phenytoin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_phenytoin-induced_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-B *57:01:01	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG=abacavir_(PA448004),flucloxacillin_(PA164781042);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=1A,3;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936),drug-induced_liver_injury_(PA166119041);PGKB_TEXT=*57:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*57:01:01_allele_have_an_increased_risk_of_hypersensitivity_to_abacavir_as_compared_to_patients_with_no_HLA-B*57:01:01_alleles_or_negative_for_the_HLA-B*57:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_abacavir-induced_adverse_reactions.,*57:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*57:01:01_allele_have_an_increased_risk_of_drug-induced_liver_injury_when_treated_with_flucloxacillin_as_compared_to_patients_with_no_HLA-B*57:01:01_alleles_or_negative_for_the_HLA-B*57:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_flucloxacillin-induced_adverse_reactions.;PGKB_RACE=NR,NR
.	.	HLA-B *58:01	.	.	.	.	PGKB_INDEX=5;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG=antiepileptics_(PA143485705),allopurinol_(PA448320),lamotrigine_(PA450164),carbamazepine_(PA448785),carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,1A,3,3,3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)","Arthritis_Gouty_(PA446114)""Drug_Hypersensitivity_(PA443936)""Epidermal_Necrolysis_Toxic_(PA444059)""Hyperuricemia_(PA166048814)""Kidney_Failure_Chronic_(PA444684)""Stevens-Johnson_Syndrome_(PA445738)",severe_cutaneous_adverse_reactions_(PA166120929),Maculopapular_Exanthema_(PA162316739),"Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*58:01:Patients_with_one_or_two_copies_of_the_HLA-B*58:01_allele_have_a_decreased_risk_of_Severe_Cutaneous_Adverse_Reactions_such_as_Stevens-Johnson_Syndrome_and_Toxic_Epidermal_Necrolysis_when_treated_with_antiepileptics_as_compared_to_patients_with_no_HLA-B*58:01_alleles_or_negative_for_the_HLA-B*58:01_test.,*58:01:Patients_with_one_or_two_copies_of_the_HLA-B*58:01_allele_have_an_increased_risk_of_Severe_Cutaneous_Adverse_Reactions_such_as_Stevens-Johnson_Syndrome_and_Toxic_Epidermal_Necrolysis_when_treated_with_allopurinol_as_compared_to_patients_with_no_HLA-B*58:01_alleles_or_negative_for_the_HLA-B*58:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.,*58:01:Patients_with_one_or_two_copies_of_the_HLA-B*58:01_allele_have_an_increased_risk_of_hypersensitivity_reactions_such_as_Stevens-Johnson_Syndrome_toxic_epidermal_necrolysis_or_maculopapular_eruption_when_treated_with_lamotrigine_as_compared_to_patients_with_no_HLA-B*58:01_alleles_or_negative_for_the_HLA-B*58:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_lamotrigine-induced_adverse_reactions.,*58:01:Patients_with_one_or_two_copies_of_the_HLA-B*58:01_allele_have_a_decreased_risk_of_maculopapular_eruption_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*58:01_alleles_or_negative_for_the_HLA-B*58:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.,*58:01:Patients_with_one_or_two_copies_of_the_HLA-B*58:01_allele_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_such_as_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*58:01_alleles_or_negative_for_the_HLA-B*58:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.;PGKB_RACE=Asian,NR,NR,Asian,Asian
.	.	HLA-B *59:01:01:01	.	.	.	.	PGKB_INDEX=3;PGKB_GENE=HLA-B_(PA35056),HLA-B_(PA35056),HLA-B_(PA35056);PGKB_DRUG=acetazolamide_(PA448018),carbamazepine_(PA448785),methazolamide_(PA450413);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=4,3,2A;PGKB_DISEASE=Stevens-Johnson_Syndrome_(PA445738),Stevens-Johnson_Syndrome_(PA445738),"Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*59:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*59:01:01:01_allele_may_have_an_increased_risk_of_Stevens-Johnson_Syndrome_when_treated_with_acetazolamide._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_acetazolamide-induced_adverse_reactions.,*59:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*59:01:01:01_allele_may_have_an_increased_risk_of_Stevens-Johnson_Syndrome_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-B*59:01:01:01_alleles_or_negative_for_the_HLA-B*59:01:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions.,*59:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-B*59:01:01:01_allele_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_such_as_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_methazolamide_as_compared_to_patients_with_no_HLA-B*59:01:01:01_alleles_or_negative_for_the_HLA-B*59:01:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methazolamide-induced_adverse_reactions.;PGKB_RACE=Asian,Asian,Asian
.	.	HLA-C *01:02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-C_(PA35057);PGKB_DRUG=methazolamide_(PA450413);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*01:02:01:Patients_with_one_or_two_copies_of_the_HLA-C*01:02:01_allele_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_such_as_Stevens-Johnson_Syndrome_and_toxic_epidermal_necrolysis_when_treated_with_methazolamide_as_compared_to_patients_with_no_HLA-C*01:02:01_alleles_or_negative_for_the_HLA-C*01:02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methazolamide-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-C *03:02	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-C_(PA35057),HLA-C_(PA35057);PGKB_DRUG=allopurinol_(PA448320),allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2B,3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)",Exanthema_(PA444109);PGKB_TEXT=*03:02:Patients_with_one_or_two_copies_of_the_HLA-C*03:02_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_as_compared_to_patients_with_no_HLA-C*03:02_alleles_or_negative_for_the_HLA-C*03:02_test._This_allele_has_been_shown_to_be_in_linkage_disequilibrium_with_the_HLA-B*58:01_allele_in_some_populations_which_has_a_strong_association_with_allopurinol-induced_SCAR._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.,*03:02:Patients_with_one_or_two_copies_of_the_HLA-C*03:02_allele_and_chronic_renal_insufficiency_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_simple_rash_as_compared_to_patients_with_no_HLA-C*03:02_alleles_or_negative_for_the_HLA-C*03:02_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=NR,Asian
.	.	HLA-C *06:02:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-C_(PA35057);PGKB_DRUG=ustekinumab_(PA166048654);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Psoriasis_(PA445451);PGKB_TEXT=*06:02:01:01:Patients_with_one_or_two_copies_of_the_HLA-C*06:02_allele_and_psoriasis_may_have_a_better_response_to_treatment_with_ustekinumab_as_compared_to_patients_with_no_HLA-C*06:02_alleles_or_negative_for_the_HLA-C*06:02_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_with_ustekinumab.;PGKB_RACE=NR
.	.	HLA-C *08:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-C_(PA35057);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Drug_Hypersensitivity_(PA443936)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*08:01:Patients_with_one_or_two_copies_of_the_HLA-C*08:01_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_hypersensitivity_reactions_as_compared_to_patients_with_no_HLA-C*08:01_alleles_or_negative_for_the_HLA-C*08:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-DPB1 *03:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DPB1_(PA35064);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT=*03:01:01:Patients_with_one_or_two_copies_of_the_HLA-DPB1*03:01:01_allele_have_an_increased_risk_of_asthma_when_treated_with_aspirin_as_compared_to_patients_with_no_HLA-DPB1*03:01:01_alleles_or_negative_for_the_HLA-DPB1*03:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_aspirin-induced_asthma.;PGKB_RACE=NR
.	.	HLA-DPB1 *04:01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DPB1_(PA35064);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT=*04:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-DPB1*04:01:01:01_allele_have_a_decreased_risk_of_asthma_when_treated_with_aspirin_as_compared_to_patients_with_no_HLA-DPB1*04:01:01:01_alleles_or_negative_for_the_HLA-DPB1*04:01:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_aspirin-induced_asthma.;PGKB_RACE=NR
.	.	HLA-DQA1 *02:01	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-DQA1_(PA35066),HLA-DQA1_(PA35066);PGKB_DRUG=lapatinib_(PA152241907),"azathioprine_(PA448515)""mercaptopurine_(PA450379)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=Toxic_liver_disease_(PA164925725),"Drug_Toxicity_(PA443937)""Inflammatory_Bowel_Diseases_(PA446116)""Pancreatitis_(PA445220)";PGKB_TEXT=*02:01:Patients_with_one_or_two_copies_of_the_HLA-DQA1*02:01_allele_have_an_increased_risk_of_hepatotoxicity_when_treated_with_lapatinib_as_compared_to_patients_with_no_HLA-DQA1*02:01_alleles_or_negative_for_the_HLA-DQA1*02:01_test._This_allele_is_in_strong_linkage_disequilibrium_with_HLA-DRB1*07:01._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_lapatinib-induced_hepatotoxicity.,*02:01:Patients_with_the_HLA-DQA1*02:01_allele_with_inflammatory_bowel_disease_who_are_treated_with_azathioprine_or_mercaptopurine_may_have_an_increased_risk_of_pancreatitis_as_compared_to_patients_with_no_HLA-DQA1*02:01_alleles_or_negative_for_the_HLA-DQA1*02:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_pancreatitis.;PGKB_RACE=NR,White
.	.	HLA-DQB1 *02:02	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DQB1_(PA35068);PGKB_DRUG=acetaminophen_(PA448015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*02:02:Patients_with_one_or_two_copies_of_the_HLA-DQB1*02:02_allele_who_are_treated_with_acetaminophen_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_as_compared_to_patients_with_no_HLA-DQB1*02:02_alleles_or_negative_for_the_HLA-DQB1*02:02_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_acetaminophen-induced_adverse_reactions.;PGKB_RACE=White
.	.	HLA-DQB1 *05:01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DQB1_(PA35068);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*05:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-DQB1*05:01:01_allele_may_have_a_decreased_risk_for_drug_hypersensitivity_reactions_when_treated_with_nevirapine_as_compared_to_patients_with_no_HLA-DQB1*05:01:01_alleles_or_negative_for_the_HLA-DQB1*05:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_nevirapine-induced_adverse_reactions.;PGKB_RACE=Black_or_African_American
.	.	HLA-DQB1 *05:02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DQB1_(PA35068);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT=*05:02:01:Patients_with_one_or_two_copies_of_the_HLA-DQB1*05:02-HLA-DRB1-*15:02_haplotype_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_as_compared_to_patients_without_this_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_acetaminophen-induced_adverse_reactions.;PGKB_RACE=White
.	.	HLA-DQB1 *06:02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DQB1_(PA35068);PGKB_DRUG=Influenza_vaccines_(PA164712830);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Narcolepsy_(PA445042);PGKB_TEXT=*06:02:01:Patients_with_one_or_two_copies_of_the_HLA-DQB1*06:02_allele_may_be_at_risk_for_developing_narcolepsy_after_receiving_the_vaccination_against_the_H1N1_influenza_virus_as_compared_to_patients_with_no_HLA-DQB1*06:02_alleles_or_negative_for_the_HLA-DQB1*06:02_test._However_this_allele_is_also_associated_with_the_narcolepsy_independent_of_the_H1N1_vaccine_and_it_is_not_evident_from_the_literature_whether_carrying_this_allele_is_associated_with_the_development_of_narcolepsy_specifically_due_to_the_H1N1_vaccine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_developing_narcolepsy.;PGKB_RACE=NR
.	.	HLA-DRB1 *01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT=*01:01:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*01:01:01_allele_have_an_increased_risk_of_nevirapine-induced_adverse_reactions_such_as_fever_rash_or_hepatotoxicity_as_compared_to_patients_with_no_HLA-DRB1*01:01:01_alleles_or_negative_for_the_HLA-DRB1*01:01:01_test._Please_note_that_some_studies_only_examined_whether_patients_had_the_HLA-DRB1*01_type._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_nevirapine-induced_adverse_reactions.;PGKB_RACE=NR
.	.	HLA-DRB1 *03:01:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Maculopapular_Exanthema_(PA162316739);PGKB_TEXT=*03:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*03:01_allele_have_an_increased_risk_for_maculopapular_eruption_when_treated_with_carbamazepine_as_compared_to_patients_with_no_HLA-DRB1*03:01_alleles_or_negative_for_the_HLA-DRB1*03:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_maculopapular_eruption_when_treated_with_carbamazepine.;PGKB_RACE=Asian
.	.	HLA-DRB1 *03:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*03:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*03:01_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_as_compared_to_patients_with_no_HLA-C*03:01_alleles_or_negative_for_the_HLA-C*03:01_test._This_allele_has_been_shown_to_be_in_linkage_disequilibrium_with_the_HLA-B*58:01_allele_in_some_populations_which_has_a_strong_association_with_allopurinol-induced_SCAR._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-DRB1 *07:01:01:01	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-DRB1_(PA35072),HLA-DRB1_(PA35072);PGKB_DRUG=lapatinib_(PA152241907),"azathioprine_(PA448515)""mercaptopurine_(PA450379)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Toxic_liver_disease_(PA164925725),"Drug_Toxicity_(PA443937)""Inflammatory_Bowel_Diseases_(PA446116)""Pancreatitis_(PA445220)";PGKB_TEXT=*07:01:01:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*07:01_allele_have_an_increased_risk_of_hepatotoxicity_when_treated_with_lapatinib_as_compared_to_patients_with_no_HLA-DRB1*07:01_alleles_or_negative_for_the_HLA-DRB1*07:01_test._This_allele_is_in_strong_linkage_disequilibrium_with_HLA-DQA1*02:01._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_lapatinib-induced_hepatotoxicity.,*07:01:01:01:Patients_with_the_HLA-DRB1*07:01_allele_with_inflammatory_bowel_disease_who_are_treated_with_azathioprine_or_mercaptopurine_may_have_an_increased_risk_of_pancreatitis_as_compared_to_patients_with_no_HLA-DRB1*07:01_alleles_or_negative_for_the_HLA-DRB1*07:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_pancreatitis.;PGKB_RACE=NR,White
.	.	HLA-DRB1 *09:01:02	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*09:01:02:Patients_with_one_or_two_copies_of_the_HLA-DRB1*09:01:02_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_hypersensitivity_reactions_as_compared_to_patients_with_no_HLA-DRB1*09:01:02_alleles_or_negative_for_the_HLA-DRB1*09:01:02_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-DRB1 *11:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=Antiinflammatory_agents_non-steroids_(PA164712462);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=anaphylactoid_reaction_(PA166123554);PGKB_TEXT=*11:01:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*11_allele_have_an_increased_risk_of_having_an_anaphylactoid_reaction_when_receiving_nonsteroidal_anti-inflammatory_drugs_(NSAIDs)_as_compared_to_patients_with_no_HLA-DRB1*11_alleles_or_negative_for_the_HLA-DRB1*11_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_experiencing_an_anaphylactoid_reaction_when_receiving_NSAIDs.;PGKB_RACE=White
.	.	HLA-DRB1 *13:02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*13:02:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*13:02-HLA-B*58:01_haplotype_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(SCAR)_as_compared_to_patients_with_no_HLA-DRB1*13:02-HLA-B*58:01_haplotype_or_negative_for_the_HLA-DRB1*13:02-HLA-B*58:01_test._The_HLA-B*58:01_allele_has_been_shown_in_other_studies_to_have_a_strong_association_with_allopurinol-induced_SCAR._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=White
.	.	HLA-DRB1 *14:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT=*14:01:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*14:01:01_allele_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_hypersensitivity_reactions_as_compared_to_patients_with_no_HLA-DRB1*14:01:01_alleles_or_negative_for_the_HLA-DRB1*14:01:01_test._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.;PGKB_RACE=Asian
.	.	HLA-DRB1 *15:02:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=severe_cutaneous_adverse_reactions_(PA166120929);PGKB_TEXT=*15:02:01:Patients_with_one_or_two_copies_of_the_HLA-DRB1*15:02-HLA-DQB1*05:02_haplotype_who_are_treated_with_allopurinol_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_as_compared_to_patients_without_this_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_acetaminophen-induced_adverse_reactions.;PGKB_RACE=White
.	.	HLA-DRB3 *02:02:01:01	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB3_(PA35074);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT=*02:02:01:01:Patients_with_one_or_two_copies_of_the_HLA-DRB3*02:02_allele_have_an_increased_risk_of_agranulocytosis_when_treated_with_clozapine_in_people_with_schizophrenia_as_compared_to_patients_with_no_HLA-DRB3*02:02_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_agranulocytosis.;PGKB_RACE=NR
.	.	HMGCR H2, HMGCR H7	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HMGCR_(PA189);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="H2/H2:Patients_with_the_H2/H2_diplotype_may_have_a_reduced_response_to_simvastatin_(lower_changes_in_LDL-cholesterol_and_ApoB_levels)_as_compared_to_patients_with_diplotypes_that_do_not_include_the_H7_or_H2_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""H2/H7:Patients_with_the_H2/H7_diplotype_may_have_a_reduced_response_to_simvastatin_(lower_changes_in_LDL-cholesterol_and_ApoB_levels)_as_compared_to_patients_with_diplotypes_that_do_not_include_the_H7_or_H2_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment.""H7/H7:Patients_with_the_H7/H7_diplotype_may_have_a_reduced_response_to_simvastatin_(lower_changes_in_LDL-cholesterol_and_ApoB_levels)_as_compared_to_patients_with_diplotypes_that_do_not_include_the_H7_or_H2_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._";PGKB_RACE=Black_or_African_American
.	.	LDLR L5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=LDLR_(PA227);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT=L5:Patients_with_the_L5_allele_may_have_a_decreased_response_to_simvastatin_as_compared_to_patients_without_the_L5_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment.;PGKB_RACE=Black_or_African_American
.	.	NAT2 *12, NAT2 *13, NAT2 *14, NAT2 *4, NAT2 *5, NAT2 *6, NAT2 *7	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=NAT2_(PA18),NAT2_(PA18);PGKB_DRUG=isoniazid_(PA450112),"Drugs_For_Treatment_Of_Tuberculosis_(PA164712708)""isoniazid_(PA450112)";PGKB_TYPE=Other,Toxicity/ADR;PGKB_EVIDENCE=2A,2A;PGKB_DISEASE=Tuberculosis_(PA445941),"Drug_Toxicity_(PA443937)""Hepatitis_Toxic_(PA444442)""Toxic_liver_disease_(PA164925725)""Tuberculosis_(PA445941)";PGKB_TEXT="*12:Patients_with_the_*12_allele_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_have_increased_metabolism_of_isoniazid_as_compared_to_patients_with_two_slow_NAT2_alleles._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._""*13:Patients_with_the_*13_allele_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_have_increased_metabolism_of_isoniazid_as_compared_to_patients_with_two_slow_NAT2_alleles._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._""*14:Patients_with_the_*14_allele_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_decreased_metabolism_of_isoniazid_as_compared_to_patients_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._""*4:Patients_with_the_*4_allele_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_have_increased_metabolism_of_isoniazid_as_compared_to_patients_with_two_slow_NAT2_alleles._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._""*5:Patients_with_the_*5_allele_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_decreased_metabolism_of_isoniazid_as_compared_to_patients_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._""*6:Patients_with_the_*6_allele_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_decreased_metabolism_of_isoniazid_as_compared_to_patients_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._""*7:Patients_with_the_*7_allele_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_decreased_metabolism_of_isoniazid_as_compared_to_patients_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_isoniazid_metabolism_and_clearance._","*12:Patients_with_the_*12_allele_and_Tuberculosis_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_have_a_reduced_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_two_alleles_conferring_a_slow_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""*13:Patients_with_the_*13_allele_and_Tuberculosis_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_have_a_reduced_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_two_alleles_conferring_a_slow_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""*14:Patients_with_the_*14_allele_and_Tuberculosis_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_an_increased_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""*4:Patients_with_the_*4_allele_and_Tuberculosis_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_have_a_reduced_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_two_alleles_conferring_a_slow_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""*5:Patients_with_the_*5_allele_and_Tuberculosis_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_an_increased_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury._""*6:Patients_with_the_*6_allele_and_Tuberculosis_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_an_increased_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury.""*7:Patients_with_the_*7_allele_and_Tuberculosis_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_have_an_increased_risk_of_developing_hepatotoxicity_induced_by_isoniazid-containing_anti-TB_drug_regimens_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_a_rapid_acetylator_phenotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_liver_injury.";PGKB_RACE=NR,NR
.	.	NAT2 *12, NAT2 *13, NAT2 *4, NAT2 *5, NAT2 *6, NAT2 *7	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=NAT2_(PA18);PGKB_DRUG=hydralazine_(PA449894);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="*12:Patients_with_the_*12_allele_and_resistant_hypertension_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_be_less_likely_to_respond_to_hydralazine_treatment_as_compared_to_those_with_two_alleles_conferring_a_slow_acetylator_phenotype_(NAT2*5_*6_*7_*14)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment.""*13:Patients_with_the_*13_allele_and_resistant_hypertension_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_be_less_likely_to_respond_to_hydralazine_treatment_as_compared_to_those_with_two_alleles_conferring_a_slow_acetylator_phenotype_(NAT2*5_*6_*7_*14)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment.""*4:Patients_with_the_*4_allele_and_resistant_hypertension_who_have_a_rapid_or_intermediate_acetylator_phenotype_may_be_less_likely_to_respond_to_hydralazine_treatment_as_compared_to_those_with_two_alleles_conferring_a_slow_acetylator_phenotype_(NAT2*5_*6_*7_*14)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment.""*5:Patients_with_the_*5_allele_and_resistant_hypertension_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_be_more_likely_to_respond_to_hydralazine_treatment_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_an_intermediate_or_rapid_acetylator_phenotype_(e.g._*4_*12_*13)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment._""*6:Patients_with_the_*6_allele_and_resistant_hypertension_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_be_more_likely_to_respond_to_hydralazine_treatment_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_an_intermediate_or_rapid_acetylator_phenotype_(e.g._*4_*12_*13)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment._""*7:Patients_with_the_*7_allele_and_resistant_hypertension_who_have_another_slow_acetylator_NAT2_allele_(e.g._*5_*6_*7_*14)_may_be_more_likely_to_respond_to_hydralazine_treatment_as_compared_to_those_with_one_or_two_NAT2_alleles_conferring_an_intermediate_or_rapid_acetylator_phenotype_(e.g._*4_*12_*13)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment._";PGKB_RACE=NR
.	.	P2RY12 A, P2RY12 F	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY12_(PA134971947);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="A:Patients_with_the_P2RY12_A_genotype_may_have_an_increased_residual_on-clopidogrel_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_P2RY12_F_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""F:Patients_with_the_P2RY12_F_genotype_may_have_a_decreased_residual_on-clopidogrel_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_P2RY12_A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=NR
.	.	P2RY12 H1, P2RY12 H2	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY12_(PA134971947);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="H1/H1:Patients_who_are_carrier_of_the_P2RY12_H1/H1_haplotype_may_have_a_decreased_but_not_absent_risk_for_high_on-clopidogrel_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_who_are_carrier_of_the_P2RY12_H2/H2_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""H2/H2:Patients_who_are_carrier_of_the_P2RY12_H2/H2_haplotype_may_have_an_increased_risk_for_high_on-clopidogrel_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_who_are_carrier_of_the_P2RY12_H1/H1_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=NR
.	.	rs1053129	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteosarcoma_(PA445601);PGKB_TEXT="AA:No_patients_with_the_AA_genotype_were_available_for_analysis_but_patients_with_the_AC_genotype_and_osteosarcoma_who_are_receiving_methotrexate_may_have_a_reduced_risk_for_metastasis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_metastasis_in_patients_receiving_methotrexate.""AC:Patients_with_the_AC_genotype_and_osteosarcoma_who_are_receiving_methotrexate_may_have_a_reduced_risk_for_metastasis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_metastasis_in_patients_receiving_methotrexate.""CC:Patients_with_the_CC_genotype_and_osteosarcoma_who_are_receiving_methotrexate_may_have_an_increased_risk_for_metastasis_as_compared_to_patients_with_the_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_metastasis_in_patients_receiving_methotrexate.";PGKB_RACE=NR
.	.	rs11568315	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=EGFR_(PA7360);PGKB_DRUG=gefitinib_(PA131301952);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="(CA)16/(CA)16:Advanced_non-small-cell_lung_cancer_patients_patients_with_(CA)16/(CA)16_+_(CA)16/(CA)17_genotype_are_more_likely_to_have_better_clinical_response_(increased_response_rate_(RR)_increased_progression-free_survival_(PFS)_and_increased_survival_time)_when_treated_with_gefitinib_as_compared_to_patients_with_(CA)17/(CA)17_genotype._NOTE:The_rs11568315_is_(CA)n_repeat_in_intron_1_of_EGFR._16_or_fewer_CA_repeats_were_considered_short_were_combined_together_and_named_as_(CA)16_and__17_or_more_CA_repeats_were_considered_long_were_combined_together_and_named_as_(CA)17.""(CA)16/(CA)17:Advanced_non-small-cell_lung_cancer_patients_patients_with_(CA)16/(CA)16_+_(CA)16/(CA)17_genotype_are_more_likely_to_have_better_clinical_response_(increased_response_rate_(RR)_increased_progression-free_survival_(PFS)_and_increased_survival_time)_when_treated_with_gefitinib_as_compared_to_patients_with_(CA)17/(CA)17_genotype._NOTE:The_rs11568315_is_(CA)n_repeat_in_intron_1_of_EGFR._16_or_fewer_CA_repeats_were_considered_short_were_combined_together_and_named_as_(CA)16_and__17_or_more_CA_repeats_were_considered_long_were_combined_together_and_named_as_(CA)17.""(CA)17/(CA)17:Advanced_non-small-cell_lung_cancer_patients_patients_with_(CA)17/(CA)17_genotype_are_more_likely_to_have_worse_clinical_response_(decreased_response_rate_(RR)_decreased_progression-free_survival_(PFS)_and_decreased_survival_time)_when_treated_with_gefitinib_as_compared_to_(CA)16/(CA)16_+_(CA)16/(CA)17_genotype._NOTE:The_rs11568315_is_(CA)n_repeat_in_intron_1_of_EGFR._16_or_fewer_CA_repeats_were_considered_short_were_combined_together_and_named_as_(CA)16_and__17_or_more_CA_repeats_were_considered_long_were_combined_together_and_named_as_(CA)17.";PGKB_RACE=NR
.	.	rs12721646	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_nevirapine_may_have_a_decreased_alanine_aminotransferase_levels_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_alanine_aminotransferase_levels.""TC:Patients_with_the_TC_genotype_who_are_treated_with_nevirapine_may_have_an_increased_alanine_aminotransferase_levels_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_alanine_aminotransferase_levels.""TT:Patients_with_the_TT_genotype_who_are_treated_with_nevirapine_may_have_an_increased_alanine_aminotransferase_levels_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_alanine_aminotransferase_levels.";PGKB_RACE=Black_or_African_American
.	.	rs34743033	.	.	.	.	PGKB_INDEX=4;PGKB_GENE=TYMS_(PA359),TYMS_(PA359),"C18orf56_(PA134956204)""TYMS_(PA359)",TYMS_(PA359);PGKB_DRUG="irinotecan_(PA450085)""raltitrexed_(PA131625240)","capecitabine_(PA448771)""fluorouracil_(PA128406956)""Pyrimidine_analogues_(PA164713220)""tegafur_(PA452620)","methotrexate_(PA450428)""pemetrexed_(PA10810)""raltitrexed_(PA131625240)",methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR,"Efficacy""Toxicity/ADR","Efficacy""Toxicity/ADR",Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),"Colorectal_Neoplasms_(PA446108)""Neoplasms_(PA445062)""Pancreatic_Neoplasms_(PA445218)""Rectal_Neoplasms_(PA445503)","Arthritis_Rheumatoid_(PA443434)""Colorectal_Neoplasms_(PA446108)""Neoplasms_(PA445062)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)""Psoriasis_(PA445451)",Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2:Patients_with_the_2R/2R_genotype_and_colorectal_cancer_may_have_a_decreased_risk_of_asthenia_when_treated_with_irinotecan_and_raltitrexed_as_compared_to_patients_with_the_2R/3R_or_3R/3R_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_asthenia.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients_with_the_2R/3R_genotype_and_colorectal_cancer_may_have_an_increased_risk_of_asthenia_when_treated_with_irinotecan_and_raltitrexed_as_compared_to_patients_with_the_2R/2R_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_asthenia.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients_with_the_3R/3R_genotype_and_colorectal_cancer_may_have_an_increased_risk_of_asthenia_when_treated_with_irinotecan_and_raltitrexed_as_compared_to_patients_with_the_2R/2R_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_asthenia.","(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2:Patients_with_the_2R/2R_genotype_may_have_an_increased_risk_for_toxicity_an_increased_survival_time_and_an_increased_response_to_fluoropyrimidine_chemotherapy_regimens_as_compared_to_patients_with_the_2R/3R_or_3R/3R_genotype._However_contradictory_or_non-significant_evidence_exists_for_all_three_of_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_survival_time_and_response.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients_with_the_2R/3R_genotype_may_have_an_increased_survival_time_and_response_as_compared_to_patients_with_the_3R/3R_genotype_and_a_decreased_response_as_compared_to_patients_with_the_2R/2R_genotype_when_receiving_fluoropyrimidine_chemotherapy_regimens._A_SNP_within_the_third_repeat_may_modify_the_actions_of_the_3R_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_survival_time_and_response.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients_with_the_3R/3R_genotype_may_have_a_decreased_but_not_absent_risk_for_toxicity_a_decreased_survival_time_and_a_decreased_response_to_with_fluoropyrimidine_chemotherapy_regimens_as_compared_to_patients_with_the_2R/2R_or_2R/3R_genotype._However_contradictory_or_non-significant_evidence_exists_for_all_three_of_these_associations._In_addition_a_SNP_within_the_third_repeat_may_modify_the_actions_of_the_3R_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_survival_and_response.","(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2:Patients_with_the_2R/2R_genotype_may_have_increased_progression-free_survival_when_treated_with_methotrexate_chemotherapy_regimens_compared_to_patients_with_the_3R/3R_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methotrexate._The_relevance_of_this_genotype_for_toxicity_or_for_efficacy_of_methotrexate_in_inflammatory_disease_is_not_clear.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients_with_the_2R/3R_genotype_may_have_increased_progression-free_survival_when_treated_with_methotrexate_chemotherapy_regimens_compared_to_patients_with_the_3R/3R_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methotrexate._The_relevance_of_this_genotype_for_toxicity_or_for_efficacy_of_methotrexate_in_inflammatory_disease_is_not_clear.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Patients_with_the_3R/3R_genotype_may_have_decreased_progression-free_survival_when_treated_with_methotrexate_chemotherapy_regimens_compared_to_patients_with_the_2R/2R_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methotrexate._The_relevance_of_this_genotype_for_toxicity_or_for_efficacy_of_methotrexate_in_inflammatory_disease_is_not_clear.","(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2:Pediatric_patients_with_the_2R/2R_genotype_and_acute_lymphoblastic_leukemia_may_have_an_increased_risk_for_drug_toxicity_when_treated_with_methotrexate_as_compared_to_patients_with_the_2R/3R_or_3R/3R_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Pediatric_patients_with_the_2R/3R_genotype_and_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_for_drug_toxicity_when_treated_with_methotrexate_as_compared_to_patients_with_the_2R/2R_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity.""(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3:Pediatric_patients_with_the_3R/3R_genotype_and_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_for_drug_toxicity_when_treated_with_methotrexate_as_compared_to_patients_with_the_2R/2R_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity.";PGKB_RACE=White,NR,White,NR
.	.	rs371194629	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-G_(PA35083);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="ATTTGTTCATGCCT/ATTTGTTCATGCCT:Patients_with_colorectal_cancer_and_the_HLA-G_ATTTGTTCATGCCT/ATTTGTTCATGCCT_genotype_may_have_better_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_HLA-G_del/del_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.""del/ATTTGTTCATGCCT:Patients_with_colorectal_cancer_and_the_HLA-G_del/ATTTGTTCATGCCT_genotype_may_have_better_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_HLA-G_del/del_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.""del/del:Patients_with_colorectal_cancer_and_the_HLA-G_del/del_genotype_may_have_a_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_HLA-G_del/ATTTGTTCATGCCT_or_ATTTGTTCATGCCT/ATTTGTTCATGCCT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.";PGKB_RACE=White
.	.	rs45445694	.	.	.	.	PGKB_INDEX=1;PGKB_GENE="C18orf56_(PA134956204)""TYMS_(PA359)";PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2:Patients_with_genotype_(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2_may_have_increased_response_to_methotrexate_in_people_with_Rheumatoid_Arthritis_as_compared_to_patients_who_were_carriers_of_the_a_third_28-bp_repeat_(for_TSER*3/*3TSER*2/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3:Patients_with_genotype_(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3_may_have_decreased_response_to_methotrexate_in_people_with_Rheumatoid_Arthritis_as_compared_to_patients_with_genotype_(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3:Patients_with_genotype_(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3_may_have_decreased_response_to_methotrexate_in_people_with_Rheumatoid_Arthritis_as_compared_to_patients_with_genotype_(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=NR
.	.	rs4646994	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=salvianolic_acid_b_(PA166128370);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Coronary_Disease_(PA443797);PGKB_TEXT="(289BP_ALU)/(289BP_ALU):Patients_homozygous_for_the_289bp_ALU_insertion_(or_"I"_allele)_with_coronary_heart_disease_may_have_a_better_response_to_treatment_with_salvianolate_as_compared_to_patients_with_heterozygous_for_the_I_allele_and_the_del_(or_"D")_allele_or_homozygous_for_the_D_allele._Other_genetic_and_clinical_factors_may_also_influence_response_to_salvianolate.""(289BP_ALU)/del:Patients_heterozygous_for_the_289bp_ALU_insertion_(or_"I"_allele)_and_the_del_(or_"D")_allele_with_coronary_heart_disease_may_have_a_poorer_response_to_treatment_with_salvianolate_as_compared_to_patients_homozygous_for_the_I_allele._Other_genetic_and_clinical_factors_may_also_influence_response_to_salvianolate.""del/del:Patients_homozygous_for_the_del_(or_"D")_allele_with_coronary_heart_disease_may_have_a_poorer_response_to_treatment_with_salvianolate_as_compared_to_patients_homozygous_for_the_289bp_ALU_insertion_(or_"I"_allele)._Other_genetic_and_clinical_factors_may_also_influence_response_to_salvianolate.";PGKB_RACE=Asian
.	.	rs57098334	.	.	.	.	PGKB_INDEX=3;PGKB_GENE=NR,NR,NR;PGKB_DRUG=antidepressants_(PA452229),"fluoxetine_(PA449673)""paroxetine_(PA450801)",sertraline_(PA451333);PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Depression_(PA447278),Depression_(PA447278),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="(CCCACCCGA)12/(CCCACCCGA)12:Patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype_and_depression_who_are_treated_with_antidepressants_1)_may_have_an_increased_risk_of_adverse_drug_reactions_after_switching_treatment_for_the_second_time_2)_may_be_more_likely_to_have_a_lack_of_a_response_to_treatment_as_compared_to_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""(CCCACCCGA)12/C:Patients_with_the_(CCCACCCGA)12/C_genotype_and_depression_who_are_treated_with_antidepressants_1)_may_have_a_reduced_risk_of_adverse_drug_reactions_after_switching_treatment_for_the_second_time_2)_may_be_less_likely_to_have_a_lack_of_a_response_to_treatment_as_compared_to_patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CC:Patients_with_the_C/C_genotype_and_depression_who_are_treated_with_antidepressants_1)_may_have_a_reduced_risk_of_adverse_drug_reactions_after_switching_treatment_for_the_second_time_2)_may_be_less_likely_to_have_a_lack_of_a_response_to_treatment_as_compared_to_patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","(CCCACCCGA)12/(CCCACCCGA)12_:Patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype_and_depression_who_are_treated_with_fluoxetine_or_paroxetine_may_have_a_better_response_to_treatment_as_compared_to_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""(CCCACCCGA)12/C:Patients_with_the_(CCCACCCGA)12/C_genotype_and_depression_who_are_treated_with_fluoxetine_or_paroxetine_may_be_less_likely_respond_to_treatment_as_compared_to_patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_fluoxetine_or_paroxetine_may_be_less_likely_to_respond_to_treatment_as_compared_to_patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","(CCCACCCGA)10:Patients_with_the_(CCCACCCGA)10_allele_and_depression_who_are_treated_with_sertraline_may_have_a_less_response_to_treatment_as_compared_to_patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype._However_contradictory_findings_report_no_association_of_the_(CCCACCCGA)12_allele_and_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""(CCCACCCGA)9:Patients_with_the_(CCCACCCGA)9_allele_and_depression_who_are_treated_with_sertraline_may_have_a_less_response_to_treatment_as_compared_to_patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype._However_contradictory_findings_report_no_association_of_the_(CCCACCCGA)12_allele_and_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CCCACCCGA)12/(CCCACCCGA)12:Patients_with_the_(CCCACCCGA)12/(CCCACCCGA)12_genotype_and_depression_who_are_treated_with_sertraline_may_have_a_better_response_to_treatment_as_compared_to_other_genotypes._However_contradictory_findings_report_no_association_of_the_(CCCACCCGA)12_allele_and_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._";PGKB_RACE=White,Asian,Asian
.	.	rs66554220	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-G_(PA35083);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="ATTTGTTCATGCCT/ATTTGTTCATGCCT:Patients_with_the_ATTTGTTCATGCCT/ATTTGTTCATGCCT_genotype_and_early_stage_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_as_compared_to_patients_with_the_del/del_genotype._This_association_was_not_seen_in_a_separate_study_of_long-term_RA_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""ATTTGTTCATGCCT/del:Patients_with_the_ATTTGTTCATGCCT/del_genotype_and_early_stage_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_as_compared_to_patients_with_the_del/del_genotype._This_association_was_not_seen_in_a_separate_study_of_long-term_RA_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""del/del:Patients_with_the_del/del_genotype_and_early_stage_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_as_compared_to_patients_with_the_ATTTGTTCATGCCT/del_and_ATTTGTTCATGCCT/ATTTGTTCATGCCT_genotype._This_association_was_not_seen_in_a_separate_study_of_long-term_RA_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=NR
.	.	rs71647872	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="A/del:Patients_with_the_A/del_genotype_who_are_treated_with_clopidogrel_may_have_impaired_catalytic_activity_towards_hydrolysis_of_clopidogrel_and_2-oxo-clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""AA:Patients_with_the_A/A_genotype_who_are_treated_with_clopidogrel_may_have_an_average_catalytic_activity_towards_hydrolysis_of_clopidogrel_and_2-oxo-clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_clopidogrel_may_have_impaired_catalytic_activity_towards_hydrolysis_of_clopidogrel_and_2-oxo-clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.";PGKB_RACE=NR
.	.	rs8175347	.	.	.	.	PGKB_INDEX=12;PGKB_GENE=UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420);PGKB_DRUG=irinotecan_(PA450085),"atazanavir_(PA10251)""ritonavir_(PA451260)",raloxifene_(PA451221),SN-38_(PA165110775),nilotinib_(PA165958345),sorafenib_(PA7000),irinotecan_(PA450085),raloxifene_(PA451221),indinavir_(PA449977),clozapine_(PA449061),deferasirox_(PA164760843),carvedilol_(PA448817);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Other,Other,Toxicity/ADR,Toxicity/ADR,Dosage,Efficacy,Toxicity/ADR,Metabolism/PK,Toxicity/ADR,"Dosage""Metabolism/PK";PGKB_EVIDENCE=2A,1A,3,2A,3,4,3,3,3,4,4,3;PGKB_DISEASE=Neoplasms_(PA445062),"HIV_(PA447230)""HIV_Infections_(PA446213)",Osteoporosis_(PA445190),Neoplasms_(PA445062),Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171),Carcinoma_Hepatocellular_(PA444447),Neoplasms_(PA445062),Osteoporosis_(PA445190),HIV_(PA447230),NR,beta-Thalassemia_(PA446432),Heart_Diseases_(PA444368);PGKB_TEXT="(TA)6/(TA)6:Patients_with_the_(TA)6/(TA)6_genotype_(i.e._UGT1A1*1/*1)_and_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_a_decreased_risk_of_neutropenia_diarrhea_or_asthenia_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._Evidence_for_an_association_between_this_genotype_and_neutropenia_is_stronger_than_that_for_diarrhea_or_asthenia_and_some_studies_only_show_significant_associations_with_neutropenia_and_diarrhea_at_medium_and_high_doses_of_the_drug_(>125_mg/m2)._No_significant_associations_have_been_seen_for_nausea_mucositis_infection_overall_gastrointestinal_toxicities_(diarrhea_nausea_vomiting_and_mucositis_combined)_or_tumor_response._One_study_found_a_decreased_risk_of_vomiting_for_this_genotype_and_another_found_a_decreased_risk_of_treatment-related_death_both_compared_to_the_(TA)7/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia_diarrhea_asthenia_vomiting_or_treatment-related_death._""(TA)6/(TA)7:Patients_with_the_(TA)6/(TA)7_genotype_(i.e._UGT1A1*1/*28)_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_an_increased_risk_of_neutropenia_diarrhea_or_asthenia_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_genotype_and_a_decreased_risk_compared_to_those_with_the_(TA)7/(TA)7_(*28/*28)_genotype._Evidence_for_an_association_between_this_genotype_and_neutropenia_is_stronger_than_that_for_diarrhea_or_asthenia_and_some_studies_only_show_significant_associations_with_neutropenia_at_medium_and_high_doses_of_the_drug_(>125_mg/m2)._No_significant_associations_have_been_seen_for_nausea_mucositis_infection_or_tumor_response._One_study_found_a_decreased_overall_survival_time_for_carriers_of_the_(TA)7_allele._One_study_found_an_increased_risk_of_vomiting_for_this_genotype_and_another_found_an_increased_risk_of_treatment-related_death_both_compared_to_the_(TA)6/(TA)6_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_time_and_risk_of_neutropenia_diarrhea_asthenia_vomiting_or_treatment-related_death._""(TA)7/(TA)7:Patients_with_the_(TA)7/(TA)7_genotype_(i.e._UGT1A1*28/*28)_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_an_increased_risk_of_neutropenia_diarrhea_or_asthenia_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_or_(TA)6/(TA)7_(*1/*28)_genotype._Evidence_for_an_association_between_this_genotype_and_neutropenia_is_stronger_than_that_for_diarrhea_or_asthenia_and_some_studies_only_show_significant_associations_with_neutropenia_and_diarrhea_at_medium_and_high_doses_of_the_drug_(>125_mg/m2)._No_significant_associations_have_been_seen_for_nausea_mucositis_infection_overall_gastrointestinal_toxicities_(diarrhea_nausea_vomiting_and_mucositis_combined)_or_tumor_response._One_study_found_a_decreased_overall_survival_time_for_carriers_of_the_(TA)7_allele._One_study_found_an_increased_risk_of_vomiting_for_this_genotype_and_another_found_an_increased_risk_of_treatment-related_death_both_compared_to_the_(TA)6/(TA)6_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_time_and_risk_of_neutropenia_diarrhea_asthenia_vomiting_or_treatment-related_death._","(TA)6/(TA)6:Patients_with_the_(TA)6/(TA)6_(UGT1A1_*1/*1)_genotype_and_HIV_may_have_1)_a_decreased_likelihood_for_hyperbilirubinemia_(up_to_jaundice_range)_2)_a_decreased_risk_for_treatment_discontinuation_when_treated_with_atazanavir_(in_most_studies_boosted_with_low_dose_of_ritonavir)_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atazanavir.""(TA)6/(TA)7:Patients_with_the_(TA)6/(TA)7_(UGT1A1_*1/*28)_genotype_and_HIV_may_have_increased_levels_of_bilirubin_leading_to_an_increased_likelihood_for_hyperbilirubinemia_when_treated_with_atazanavir_(in_most_studies_boosted_with_low_dose_of_ritonavir)_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atazanavir.""(TA)7/(TA)7:Patients_with_the_(TA)7/(TA)7_(UGT1A1_*28/*28)_genotype_and_HIV_may_have_1)_increased_levels_of_bilirubin_leading_to_an_increased_likelihood_for_hyperbilirubinemia_(up_to_jaundice_range)_2)_an_increased_risk_for_treatment_discontinuation_when_treated_with_atazanavir_(in_most_studies_boosted_with_low_dose_of_ritonavir)_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atazanavir.","(TA)6/(TA)6:Women_with_the_(TA)6/(TA)6_genotype_(i.e._UGT1A1*1/*1)_genotype_and_osteoporosis_may_have_decreased_metabolism_of_raloxifene_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._However_an_in_vitro_study_found_an_increased_clearance_of_raloxifene_as_compared_to_the_*1/*28_and_*28/*28_gentoype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_raloxifene.""(TA)6/(TA)7:Women_with_the_(TA)6/(TA)7_genotype_(i.e._UGT1A1*1/*28)_genotype_and_osteoporosis_may_have_decreased_metabolism_of_raloxifene_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._However_an_in_vitro_study_found_a_decreased_clearance_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_raloxifene.""(TA)7/(TA)7:Women_with_the_(TA)7/(TA)7_genotype_(i.e._UGT1A1*28/*28)_genotype_and_osteoporosis_may_have_increased_metabolism_of_raloxifene_as_compared_to_patients_with_the_(TA)6/(TA)7_(*1/*28)_or_(TA)6/(TA)6_(*1/*1)_genotype._However_an_in_vitro_study_found_a_decreased_clearance_of_raloxifene_as_compared_to_patients_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_raloxifene.","(TA)6/(TA)6:Patients_with_the_(TA)6/(TA)6_genotype_and_cancer_may_have_increased_metabolism_of_SN-38_when_treated_with_irinotecan_as_compared_to_patients_with_the_(TA)6/(TA)7_or_(TA)7/(TA)7_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A1._One_in_vitro_study_found_that_patients_with_the_(TA)6/(TA)6_genotype_had_increased_UGT1A1_enzyme_activity_compared_to_those_with_the_(TA)6/(TA)7_or_(TA)7/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_SN-38.""(TA)6/(TA)7:Patients_with_the_(TA)6/(TA)7_genotype_and_cancer_may_have_decreased_metabolism_of_SN-38_when_treated_with_irinotecan_as_compared_to_patients_with_the_(TA)6/(TA)6_genotype_or_increased_metabolism_compared_to_patients_with_the_(TA)7/(TA)7_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A1._One_in_vitro_study_found_that_livers_with_the_(TA)6/(TA)7_genotype_had_decreased_UGT1A1_enzyme_activity_compared_to_livers_with_the_(TA)6/(TA)6_genotype_and_increased_activity_compared_to_livers_with_the_(TA)7/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_SN-38.""(TA)7/(TA)7:Patients_with_the_(TA)7/(TA)7_genotype_and_cancer_may_have_decreased_metabolism_of_SN-38_when_treated_with_irinotecan_as_compared_to_patients_with_the_(TA)6/(TA)7_or_(TA)6/(TA)6_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A1._One_in_vitro_study_found_that_patients_with_the_(TA)7/(TA)7_genotype_had_decreased_UGT1A1_enzyme_activity_compared_to_those_with_the_(TA)6/(TA)6_or_(TA)6/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_SN-38.","(TA)6/(TA)6:Patients_with_the_UGT1A1_(TA)6/(TA)6_genotype_and_chronic_myeloid_leukemia_or_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_of_hyperbilirubinemia_when_treated_with_nilotinib_as_compared_to_patients_with_the_(TA)7/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hyperbilirubinemia.""(TA)6/(TA)7:Patients_with_the_UGT1A1_(TA)6/(TA)7_genotype_and_chronic_myeloid_leukemia_or_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_of_hyperbilirubinemia_when_treated_with_nilotinib_as_compared_to_patients_with_the_(TA)7/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hyperbilirubinemia.""(TA)7/(TA)7:Patients_with_the_UGT1A1_(TA)7/(TA)7_genotype_and_chronic_myeloid_leukemia_or_acute_lymphoblastic_leukemia_may_have_an_increased_risk_of_hyperbilirubinemia_when_treated_with_nilotinib_as_compared_to_patients_with_the_(TA)6/(TA)6_or_(TA)6/(TA)7_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hyperbilirubinemia.","(TA)6/6:Patients_with_the_(TA)6/6_genotype_may_be_associated_with_decreased_risk_of_Hyperbilirubinemia_when_treated_with_sorafenib_in_people_with_hepatocellular_carcinoma_as_compared_to_patients_with_the_(TA)7/6_or_(TA)7/7_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sorafenib.""(TA)6/7:Patients_with_the_(TA)6/7_genotype_may_be_associated_with_increased_risk_of_Hyperbilirubinemia_when_treated_with_sorafenib_in_people_with_hepatocellular_carcinoma_as_compared_to_patients_with_the_(TA)6/6_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sorafenib.""(TA)7/7:Patients_with_the_(TA)7/7_genotype_may_be_associated_with_increased_risk_of_Hyperbilirubinemia_when_treated_with_sorafenib_in_people_with_hepatocellular_carcinoma_as_compared_to_patients_with_the_(TA)6/6_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sorafenib.","(TA)6/(TA)6:Patients_with_the_(TA)6/(TA)6_genotype_(i.e._UGT1A1*1/*1)_with_Neoplasms_who_are_treated_with_irinotecan-based_regimens_may_require_an_increased_dose_of_irinotecan_as_compared_to_patients_with_the_(TA)6/(TA)7_(*1/*28)_or_(TA)7/(TA)7_(*28/*28)_genotype._However_no_association_was_found_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_irinotecan_dose_requirement._""(TA)6/(TA)7:Patients_with_the_(TA)6/(TA)7_genotype_(i.e._UGT1A1*1/*28)_with_Neoplasms_who_are_treated_with_irinotecan-based_regimens_may_require_a_decreased_dose_of_irinotecan_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_genotype._However_no_association_was_found_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_irinotecan_dose_requirement._""(TA)7/(TA)7:Patients_with_the_(TA)7/(TA)7_genotype_(i.e._UGT1A1*28/*28)_with_Neoplasms_who_are_treated_with_irinotecan-based_regimens_may_require_a_decreased_dose_of_irinotecan_as_compared_to_patients_with_the_(TA)6/(TA)6_(*28/*28)_genotype._However_no_association_was_found_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_irinotecan_dose_requirement._","(TA)6/(TA)6:Women_with_the_(TA)6/(TA)6_genotype_(i.e._UGT1A1*1/*1)_genotype_and_osteoporosis_may_have_decreased_hip_bone_mineral_density_when_treated_with_raloxifene_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._Other_genetic_and_clinical_factors_may_also_influence_bone_mineral_density._""(TA)6/(TA)7:Women_with_the_(TA)6/(TA)7_genotype_(i.e._UGT1A1*1/*28)_genotype_and_osteoporosis_may_have_decreased_hip_bone_mineral_density_when_treated_with_raloxifene_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._Other_genetic_and_clinical_factors_may_also_influence_bone_mineral_density._""(TA)7/(TA)7:Women_with_the_(TA)7/(TA)7_genotype_(i.e._UGT1A1*28/*28)_genotype_and_osteoporosis_may_have_increased_hip_bone_mineral_density_when_treated_with_raloxifene_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_or_(TA)6/(TA)7_(*1/*28)_genotype._Other_genetic_and_clinical_factors_may_also_influence_bone_mineral_density._","(TA)6/(TA)6:Patients_with_the_(TA)6/(TA)6_(UGT1A1_*1/*1)_genotype_and_HIV_may_be_at_decreased_risk_for_hyperbilirubinemia_when_treated_with_indinavir_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._However_results_are_contradictory._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_hyperbilirubinemia_when_treated_with_indinavir.""(TA)6/(TA)7:Patients_with_the_(TA)6/(TA)7_(UGT1A1_*1/*28)_genotype_and_HIV_may_be_at_decreased_risk_for_hyperbilirubinemia_when_treated_with_indinavir_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._However_results_are_contradictory._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_hyperbilirubinemia_when_treated_with_indinavir.""(TA)7/(TA)7:Patients_with_the_(TA)7/(TA)7_(UGT1A1_*28/*28)_genotype_and_HIV_may_be_at_increased_risk_for_hyperbilirubinemia_when_treated_with_indinavir_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_or_(TA)6/(TA)7_(*1/*28)_genotype._However_results_are_contradictory._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_hyperbilirubinemia_when_treated_with_indinavir.","(TA)6/(TA)6:In_human_liver_microsomes_the_(TA)6/(TA)6_genotype_was_found_to_result_in_the_increased_formation_of_the_clozapine_metabolite_clozapine_N+-glucuronide_as_compared_to_the_(TA)7/(TA)7_genotype.""(TA)7/(TA)7:In_human_liver_microsomes_the_(TA)7/(TA)7_genotype_was_found_to_result_in_the_decreased_formation_of_the_clozapine_metabolite_clozapine_N+-glucuronide_as_compared_to_the_(TA)6/(TA)6_genotype.","(TA)6/(TA)6:Pediatric_patients_with_major_thalassemia_and_the_(TA)6/(TA)6_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_(TA)6/(TA)7_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_(TA)6/(TA)7_therefore_there_is_no_information_for_patients_with_the_(TA)6/(TA)6_or_(TA)7/(TA)7_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""(TA)6/(TA)7:Pediatric_patients_with_major_thalassemia_and_the_(TA)6/(TA)7_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_(TA)6/(TA)6_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_(TA)6/(TA)7_therefore_there_is_no_information_for_patients_with_the_(TA)6/(TA)6_or_(TA)7/(TA)7_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""(TA)7/(TA)7:Pediatric_patients_with_major_thalassemia_and_the_(TA)7/(TA)7_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_(TA)6/(TA)6_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_(TA)6/(TA)7_therefore_there_is_no_information_for_patients_with_the_(TA)6/(TA)6_or_(TA)7/(TA)7_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.","(TA)6/(TA)6:Patients_with_the_(TA)6/(TA)6_(UGT1A1*1/*1)_genotype_may_have_lower_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._However_this_does_not_appear_to_affect_carvedilol_dosing._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_carvedilol.""(TA)6/(TA)7:Patients_with_the_(TA)6/(TA)7_(UGT1A1*1/*28)_genotype_may_have_higher_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_genotype_or_lower_glucuronidation_as_compared_to_patients_with_the_(TA)7/(TA)7_(*28/*28)_genotype._However_this_does_not_appear_to_affect_carvedilol_dosing._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_carvedilol.""(TA)7/(TA)7:Patients_with_the_(TA)7/(TA)7_(UGT1A1*28/*28)_genotype_may_have_higher_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_(TA)6/(TA)6_(*1/*1)_genotype._However_this_does_not_appear_to_affect_carvedilol_dosing._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_carvedilol.";PGKB_RACE=NR,NR,White,NR,NR,NR,NR,White,NR,NR,NR,NR
.	.	SLC22A1 *1, SLC22A1 *2, SLC22A1 *3, SLC22A1 *4, SLC22A1 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=morphine_(PA450550);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Children_with_the_*1/*1_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_increased_clearance_of_morphine_as_compared_to_children_with_the_*2/*2_*2/*3_*2/*4_*2/*5_or_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*1/*2:Children_with_the_*1/*2_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_increased_clearance_of_morphine_as_compared_to_children_with_the_*2/*2_*2/*3_*2/*4_*2/*5_or_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*1/*3:Children_with_the_*1/*3_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_increased_clearance_of_morphine_as_compared_to_children_with_the_*2/*2_*2/*3_*2/*4_*2/*5_or_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*1/*4:Children_with_the_*1/*4_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_increased_clearance_of_morphine_as_compared_to_children_with_the_*2/*2_*2/*3_*2/*4_*2/*5_or_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*1/*5:Children_with_the_*1/*5_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_increased_clearance_of_morphine_as_compared_to_children_with_the_*2/*2_*2/*3_*2/*4_*2/*5_or_*4/*4_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*2/*2:Children_with_the_*2/*2_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_reduced_clearance_of_morphine_as_compared_to_children_with_the_*1/*2_*1/*3_*1/*4_*1/*5_or_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*2/*3:Children_with_the_*2/*3_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_reduced_clearance_of_morphine_as_compared_to_children_with_the_*1/*2_*1/*3_*1/*4_*1/*5_or_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*2/*4:Children_with_the_*2/*4_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_reduced_clearance_of_morphine_as_compared_to_children_with_the_*1/*2_*1/*3_*1/*4_*1/*5_or_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*2/*5:Children_with_the_*2/*5_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_reduced_clearance_of_morphine_as_compared_to_children_with_the_*1/*2_*1/*3_*1/*4_*1/*5_or_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._""*4/*4:Children_with_the_*4/*4_genotype_scheduled_to_undergo_adenotonsillectomy_may_have_reduced_clearance_of_morphine_as_compared_to_children_with_the_*1/*2_*1/*3_*1/*4_*1/*5_or_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_clearance_of_morphine._";PGKB_RACE=NR
.	.	SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele)	.	.	.	.	PGKB_INDEX=15;PGKB_GENE=SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312),SLC6A4_(PA312);PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257),"olanzapine_(PA450688)""quetiapine_(PA451201)""risperidone_(PA451257)",escitalopram_(PA10074),ondansetron_(PA450705),paroxetine_(PA450801),clomipramine_(PA449048),paroxetine_(PA450801),fluoxetine_(PA449673),fluoxetine_(PA449673),sertraline_(PA451333),fluvoxamine_(PA449690),mirtazapine_(PA450522),citalopram_(PA449015),sertraline_(PA451333),escitalopram_(PA10074);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Efficacy,Efficacy,Efficacy,Toxicity/ADR,Efficacy,Efficacy,"Efficacy""Toxicity/ADR",Efficacy,Efficacy,Toxicity/ADR,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,2A,3,3,3,3,3,3,3,3,3,2A,3,3;PGKB_DISEASE=NR,Drug_Toxicity_(PA443937),"Depression_(PA447278)""Depressive_Disorder_(PA447207)",Alcoholism_(PA443309),"Depressive_Disorder_Major_(PA447321)""Mood_Disorders_(PA447209)",NR,"Depressive_Disorder_Major_(PA447321)""Mood_Disorders_(PA447209)",Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_may_have_an_increased_risk_for_presence_of_sexual_dysfunction_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_or_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_an_association_of_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_with_increased_risk_of_side_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_genotype_may_have_a_decreased_but_not_absent_risk_for_presence_of_sexual_dysfunction_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_an_association_of_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_with_increased_risk_of_side_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype_may_have_a_decreased_but_not_absent_risk_for_presence_of_sexual_dysfunction_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_an_association_of_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_with_increased_risk_of_side_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_olanzapine_quetiapine_or_risperidone_may_have_an_increased_risk_of_side_effects_as_compared_to_patients_with_the_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)(Short/Short)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_adverse_events._""HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_olanzapine_quetiapine_or_risperidone_may_have_an_increased_risk_of_side_effects_as_compared_to_patients_with_the_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_(Short/Short)_genotype_and_increased_response_to_olanzapine_or_risperidone_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_+_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_adverse_events._""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_olanzapine_quetiapine_or_risperidone_may_have_a_reduced_but_not_absent_risk_of_side_effects_as_compared_to_patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_adverse_events.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_escitalopram_may_have_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_escitalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram._Please_note_study_population_is_White_or_Unknown.""_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_escitalopram_may_have_an_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_escitalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram._Please_note_study_population_is_White_or_Unknown.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_escitalopram_may_have_a_decreased_response_or_decreased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_escitalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram._Please_note_study_population_is_White_or_Unknown.","_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_may_have_an_increased_percentage_of_days_abstinent_and_lower_number_of_drinks_per_drinking_day_when_treated_with_ondansetron_as_compared_to_patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_or_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_genotype_may_have_a_decreased_percentage_of_days_abstinent_and_lower_number_of_drinks_per_drinking_day_when_treated_with_ondansetron_as_compared_to_patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype_may_have_a_decreased_percentage_of_days_abstinent_and_lower_number_of_drinks_per_drinking_day_when_treated_with_ondansetron_as_compared_to_patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_paroxetine_may_have_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_paroxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._Please_note_study_population_is_White_Mixed_Population_or_Unknown.""HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_paroxetine_may_have_a_decreased_response_or_decreased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_paroxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._Please_note_study_population_is_White_Mixed_Population_or_Unknown.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_paroxetine_may_have_a_decreased_response_or_decreased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_paroxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._Please_note_study_population_is_White_Mixed_Population_or_Unknown.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Female_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_may_have_increased_clomipramine-induced_prolactin_release_when_exposed_to_clomipramine_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Female_patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_genotype_were_not_studied._But_female_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_may_have_increased_clomipramine-induced_prolactin_release_when_exposed_to_clomipramine_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Female_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype_may_have_a_decreased_clomipramine-induced_prolactin_release_when_exposed_to_clomipramine_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_(Asian_population)_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_paroxetine_may_have_decreased_response_or_decreased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_a_number_of_contradictory_findings_exist_showing_an_increased_response_for_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Further_studies_exist_reporting_no_association_with_the_genotype_and_paroxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele):Patients_(Asian_population)_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_paroxetine_may_have_a_decreased_response_or_decreased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_a_number_of_contradictory_findings_exist_showing_an_increased_response_for_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Further_studies_exist_reporting_no_association_with_the_genotype_and_paroxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_:Patients_(Asian_population)_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_paroxetine_may_have_an_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_a_number_of_contradictory_findings_exist_showing_an_increased_response_for_the_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Further_studies_exist_reporting_no_association_with_the_genotype_and_paroxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_fluoxetine_may_have_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_the_opposite_effect_with_an_association_of_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_and_increased_fluoxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_fluoxetine_may_have_decreased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_or_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_fluoxetine_may_have_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_the_opposite_effect_with_an_association_of_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_and_increased_fluoxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_fluoxetine_may_have_increased_response_and_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_fluoxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_fluoxetine_may_have_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_and_a_decreased_but_not_absent_risk_for_side_effects_as_compared_to_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_fluoxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_fluoxetine_may_have_decreased_response_and_increased_risk_for_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_fluoxetine_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine._","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_sertraline_may_have_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sertraline._""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_sertraline_may_have_a_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sertraline._""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_sertraline_may_have_increased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sertraline.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_fluvoxamine_may_have_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_either_no_association_of_the_genotype_with_fluvoxamine_response_or_the_opposite_effect_with_an_association_of_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_and_increased_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_fluvoxamine_may_have_increased_response_or_increased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_either_no_association_of_the_genotype_with_fluvoxamine_response_or_the_opposite_effect_with_an_association_of_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_and_increased_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_fluvoxamine_may_have_decreased_response_or_decreased_improvement_based_on_HAMD_score_reduction_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_either_no_association_of_the_genotype_with_fluvoxamine_response_or_the_opposite_effect_with_an_association_of_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_and_increased_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_mirtazapine_may_have_increased_risk_of_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mirtazapine.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_mirtazapine_may_have_increased_risk_of_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mirtazapine.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_mirtazapine_may_have_decreased_but_not_absent_risk_of_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mirtazapine.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_citalopram_may_have_increased_response_and_decreased_but_not_absent_risk_for_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_citalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram._""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_citalopram_may_have_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_citalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram._""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_citalopram_may_have_decreased_response_and_increased_risk_for_side_effects_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_citalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram._","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_sertraline_may_have_increased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_sertraline_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sertraline.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_sertraline_may_have_an_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_sertraline_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sertraline.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_sertraline_may_have_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_sertraline_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sertraline.","HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele):Patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_escitalopram_may_have_decreased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_escitalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram._Please_note_study_population_is_Asian.""HTTLPR_long_form_(L_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/HTTLPR_long_form_(L_allele)_genotype_who_are_treated_with_escitalopram_may_have_an_increased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_escitalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram._Please_note_study_population_is_Asian.""HTTLPR_short_form_(S_allele)/HTTLPR_short_form_(S_allele):Patients_with_the_SLC6A4_HTTLPR_short_form_(S_allele)/SLC6A4_HTTLPR_short_form_(S_allele)_genotype_who_are_treated_with_escitalopram_may_have_increased_response_as_compared_to_patients_with_the_SLC6A4_HTTLPR_long_form_(L_allele)/HTTLPR_long_form_(L_allele)_genotype._However_contradictory_findings_exist_reporting_no_association_with_the_genotype_and_escitalopram_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram._Please_note_study_population_is_Asian.";PGKB_RACE=NR,White,White,NR,NR,NR,Asian,Asian,White,Asian,NR,NR,NR,NR,Asian
.	.	SLCO1B1 *12, SLCO1B1 *13, SLCO1B1 *1A	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=conjugated_estrogens_(PA164754789);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*12/*12:Patients_with_the_*12/*12_genotype_may_have_decreased_uptake_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide_as_compared_to_patients_with_the_*1A/*1A_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide._""*13/*13:Patients_with_the_*13/*13_genotype_may_have_decreased_uptake_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide_as_compared_to_patients_with_the_*1A/*1A_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide._""*1A/*12:Patients_with_the_*1A/*12_genotype_may_have_decreased_uptake_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide_as_compared_to_patients_with_the_*1A/*1A_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide._""*1A/*13:Patients_with_the_*1A/*13_genotype_may_have_decreased_uptake_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide_as_compared_to_patients_with_the_*1A/*1A_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide._""*1A/*1A:Patients_with_the_*1A/*1A_genotype_may_have_increased_uptake_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide_as_compared_to_patients_with_the_*12/*12_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_estrone_sulfate_and_estradiol_17beta-d-glucuronide._";PGKB_RACE=NR
.	.	SLCO1B1 *14, SLCO1B1 *1A	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=fluvastatin_(PA449688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="*14/*14:Patients_with_the_*14/*14_may_have_enhanced_lipid-lowering_efficacy_to_fluvastatin_in_elderly_hypercholesterolemic_patients_as_compared_to_patients_with_the_*1A/*14_or_*1A/*1A_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluvastatin.""*14/*1A:Patients_with_the_*14/*1A_may_have_decreased_lipid-lowering_efficacy_to_fluvastatin_in_elderly_hypercholesterolemic_patients_as_compared_to_patients_with_the_*14/*14_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluvastatin.""*1A/*1A:Patients_with_the_*1A/*1A_may_have_decreased_lipid-lowering_efficacy_to_fluvastatin_in_elderly_hypercholesterolemic_patients_as_compared_to_patients_with_the_*14/*14_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluvastatin.";PGKB_RACE=White
.	.	SLCO1B1 *15, SLCO1B1 *18, SLCO1B1 *1A, SLCO1B1 *1B, SLCO1B1 *5, SLCO1B1 *9	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=SLCO1B1_(PA134865839),SLCO1B1_(PA134865839);PGKB_DRUG=rosuvastatin_(PA134308647),atrasentan_(PA143414738);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,4;PGKB_DISEASE=NR,NR;PGKB_TEXT="*15/*15:Patients_with_the_*15/*15_genotype_may_have_increased_exposure_to_rosuvastatin_and_decrease_hepatic_uptake_pf_rosuvastatin_as_compared_to_patients_with_the_*1A/*1A_*1B/*1B_or_*1B/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._""*18/*18:Patients_with_the_*18/*18_genotype_may_have_decreased_hepatic_uptake_of_rosuvastatin_as_compared_to_patients_with_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._""*1A/*1A:Patients_with_the_*1A/*1A_genotype_may_have_decreased_exposure_to_rosuvastatin_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._""*1B/*15:Patients_with_the_*1B/*15_genotype_may_have_decreased_exposure_to_rosuvastatin_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._""*1B/*1B:Patients_with_the_*1B/*1B_genotype_may_have_decreased_exposure_to_rosuvastatin_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._""*5/*5:Patients_with_the_*5/*5_genotype_may_have_decreased_hepatic_uptake_of_rosuvastatin_as_compared_to_patients_with_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._""*9/*9:Patients_with_the_*9/*9_genotype_may_have_decreased_hepatic_uptake_of_rosuvastatin_as_compared_to_patients_with_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_rosuvastatin_pharmacokinetics._","*15/*15:Individuals_with_*15/*15_genotype_may_have_decreased_transport_of_atrasentan_as_compared_to_individuals_carrying_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_atrasentan.""*18/*18:Individuals_with_*18/*18_genotype_may_have_decreased_transport_of_atrasentan_as_compared_to_individuals_carrying_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_atrasentan.""*1A/*1A:Individuals_with_*1A/*1A_genotype_may_have_increased_transport_of_atrasentan_as_compared_to_individuals_carrying_the_*5/*5_*15/*15_*9/*9_or_*18/*18_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_atrasentan.""*1B/*1B:Individuals_with_*1B/*1B_genotype_may_have_increased_transport_of_atrasentan_as_compared_to_individuals_carrying_the_*5/*5_*15/*15_*9/*9_or_*18/*18_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_atrasentan.""*5/*5:Individuals_with_*5/*5_genotype_may_have_decreased_transport_of_atrasentan_as_compared_to_individuals_carrying_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_atrasentan.""*9/*9:Individuals_with_*9/*9_genotype_may_have_decreased_transport_of_atrasentan_as_compared_to_individuals_carrying_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_atrasentan.";PGKB_RACE=Asian,NR
.	.	SLCO1B1 *15, SLCO1B1 *1A, SLCO1B1 *1B	.	.	.	.	PGKB_INDEX=2;PGKB_GENE=SLCO1B1_(PA134865839),SLCO1B1_(PA134865839);PGKB_DRUG=pravastatin_(PA451089),atorvastatin_(PA448500);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=2A,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="*15/*15:Patients_with_the_*15/*15_genotype_may_have_increased_bioavailability_of_pravastatin_as_compared_to_individuals_with_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_pravastatin._""*1A/*15:Patients_with_the_*1A/*15_genotype_may_have_increased_bioavailability_of_pravastatin_as_compared_to_individuals_with_the_*1A/*1A_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_pravastatin._""*1A/*1A:Patients_with_the_*1A/*1A_genotype_may_have_decreased_bioavailability_of_pravastatin_as_compared_to_individuals_with_the_*15/*15_or_*1A/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_pravastatin._""*1B/*1B:Patients_with_the_*1B/*1B_genotype_may_have_decreased_bioavailability_of_pravastatin_as_compared_to_individuals_with_the_*15/*15_or_*1A/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_pravastatin.","*15/*15:Patients_with_the_*15/*15_genotype_may_have_increased_atorvastatin_concentrations_as_compared_to_patients_with_the_*1A/*15_*1B/*15_*1A/*1A_*1A/*1B_or_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_pharmacokinetics._""*1A/*15:Patients_with_the_*1A/*15_genotype_may_have_decreased_atorvastatin_concentrations_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_pharmacokinetics._""*1A/*1A:Patients_with_the_*1A/*1A_genotype_may_have_decreased_atorvastatin_concentrations_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_pharmacokinetics._""*1A/*1B:Patients_with_the_*1A/*1B_genotype_may_have_decreased_atorvastatin_concentrations_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_pharmacokinetics._""*1B/*15:Patients_with_the_*1B/*15_genotype_may_have_decreased_atorvastatin_concentrations_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_pharmacokinetics._""*1B/*1B:Patients_with_the_*1B/*1B_genotype_may_have_decreased_atorvastatin_concentrations_as_compared_to_patients_with_the_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_pharmacokinetics._";PGKB_RACE=NR,Asian
.	.	SLCO1B1 *15, SLCO1B1 *1A, SLCO1B1 *1B, SLCO1B1 *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*15/*1A:Patients_with_the_*15/*1A_genotype_may_have_increased_pharmacokinetic_exposure_(AUC)_of_repaglinide_as_compared_to_patients_with_the_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repaglinide_pharmacokinetics._""*1A/*1A:Patients_with_the_*1A/*1A_genotype_may_have_increased_pharmacokinetic_exposure_of_repaglinide_including_increased_AUC_and_decreased_clearance_of_repaglinide_as_compared_to_patients_with_the_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repaglinide_pharmacokinetics._""*1A/*1B:Patients_with_the_*1A/*1B_genotype_may_have_increased_pharmacokinetic_exposure_of_repaglinide_including_increased_AUC_and_decreased_clearance_of_repaglinide_as_compared_to_patients_with_the_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repaglinide_pharmacokinetics._""*1B/*1B:Patients_with_the_*1B/*1B_genotype_may_have_decreased_pharmacokinetic_exposure_of_repaglinide_including_decreased_AUC_and_increased_clearance_of_repaglinide_as_compared_to_patients_with_the_*1A/*1A_*1A/*1B_*15/*1A_or_*5/*1A_genotype._However_this_genotype_is_not_associated_with_blood_glucose-lowering_effect_of_repaglinide._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repaglinide_pharmacokinetics._""*5/*1A:Patients_with_the_*5/*1A_genotype_may_have_increased_pharmacokinetic_exposure_(AUC)_of_repaglinide_as_compared_to_patients_with_the_*1B/*1B_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repaglinide_pharmacokinetics._";PGKB_RACE=Asian
.	.	SLCO1B1 *15, SLCO1B1 *1B	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=olmesartan_(PA164742950);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*15/*15:Healthy_individuals_with_the_*15/*15_genotype_may_have_increased_plasma_level_of_olmesartan_as_compared_to_individuals_with_SLCO1B1_*1B/*1B_genotype._Patients_with_the_increased_plasma_level_may_have_enhanced_therapeutic_response_to_olmesartan_yet_may_also_be_at_risk_of_dose-dependent_adverse_effects_of_olmesartan._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_and_response_to_olmesartan.""*1B/*15:Healthy_individuals_with_the_*1B/*15_genotype_may_have_increased_plasma_level_of_olmesartan_as_compared_to_individuals_with_SLCO1B1_*1B/*1B_genotype._Patients_with_the_increased_plasma_level_may_have_enhanced_therapeutic_response_to_olmesartan_yet_may_also_be_at_risk_of_dose-dependent_adverse_effects_of_olmesartan._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_and_response_to_olmesartan.""*1B/*1B:Healthy_individuals_with_the_*1B/*1B_genotype_may_have_decreased_plasma_level_of_olmesartan_as_compared_to_individuals_with_SLCO1B1_*15/*15_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_and_response_to_olmesartan.";PGKB_RACE=Asian
.	.	STAT3 CTA, STAT3 TCG, STAT3 TTA	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=STAT3_(PA337);PGKB_DRUG="ethambutol_(PA164784021)""isoniazid_(PA450112)""pyrazinamide_(PA451182)""rifampin_(PA451250)""streptomycin_(PA451512)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Tuberculosis_(PA445941);PGKB_TEXT="CTA/CTA:Patients_with_the_CTA/CTA_diplotype_and_tuberculosis_who_are_treated_with_ethambutol_isoniazid_pyrazinamide_rifampin_and_streptomycin_may_have_an_increased_risk_of_developing_drug_induced_hepatitis_as_compared_to_patients_with_the_TTA/TTA_diplotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug-induced_hepatitis_in_patients_on_an_anti-tuberculosis_drug_regiment._""CTA/TCG:Patients_with_the_CTA/TCG_diplotype_and_tuberculosis_who_are_treated_with_ethambutol_isoniazid_pyrazinamide_rifampin_and_streptomycin_may_have_an_increased_risk_of_developing_drug_induced_hepatitis_as_compared_to_patients_with_the_TTA/TTA_diplotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug-induced_hepatitis_in_patients_on_an_anti-tuberculosis_drug_regiment._""CTA/TTA:Patients_with_the_CTA/TTA_diplotype_and_tuberculosis_who_are_treated_with_ethambutol_isoniazid_pyrazinamide_rifampin_and_streptomycin_may_have_an_increased_risk_of_developing_drug_induced_hepatitis_as_compared_to_patients_with_the_TTA/TTA_diplotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug-induced_hepatitis_in_patients_on_an_anti-tuberculosis_drug_regiment._""TCG/TCG:Patients_with_the_TCG/TCG_diplotype_and_tuberculosis_who_are_treated_with_ethambutol_isoniazid_pyrazinamide_rifampin_and_streptomycin_may_have_an_increased_risk_of_developing_drug_induced_hepatitis_as_compared_to_patients_with_the_TTA/TTA_diplotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug-induced_hepatitis_in_patients_on_an_anti-tuberculosis_drug_regiment._""TCG/TTA:Patients_with_the_TCG/TTA_diplotype_and_tuberculosis_who_are_treated_with_ethambutol_isoniazid_pyrazinamide_rifampin_and_streptomycin_may_have_an_increased_risk_of_developing_drug_induced_hepatitis_as_compared_to_patients_with_the_TTA/TTA_diplotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug-induced_hepatitis_in_patients_on_an_anti-tuberculosis_drug_regiment._""TTA/TTA:Patients_with_the_TTA/TTA_diplotype_and_tuberculosis_who_are_treated_with_ethambutol_isoniazid_pyrazinamide_rifampin_and_streptomycin_may_have_a_decreased_risk_of_developing_drug_induced_hepatitis_as_compared_to_patients_with_the_the_following_diplotypes:_TCG/TTA_TCG/TCG_CTA/TTA_CTA/TCG_or_CTA/CTA_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug-induced_hepatitis_in_patients_on_an_anti-tuberculosis_drug_regiment._";PGKB_RACE=Asian
.	.	TPMT *1, TPMT *10, TPMT *13, TPMT *15, TPMT *19, TPMT *1A, TPMT *24, TPMT *25, TPMT *26, TPMT *27, TPMT *28, TPMT *30, TPMT *31, TPMT *32, TPMT *33, TPMT *34, TPMT *37, TPMT *3D, TPMT *5	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG="mercaptopurine_(PA450379)""thioguanine_(PA451663)";PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_1)_may_have_increased_inactivation_of_thiopurines_due_to_normal_TPMT_activity_and_2)_may_have_a_decreased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_a_non-functional_allele_(e.g._*3D_*5_*10)._Patients_with_the_*1/*1_genotype_may_still_be_at_risk_for_toxicity_when_taking_thiopurine_drugs_and_purine_analogues_based_upon_their_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*1/*1A:Patients_with_the_*1/*1A_genotype_1)_may_have_increased_inactivation_of_thiopurines_due_to_normal_TPMT_activity_and_2)_may_have_a_decreased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_a_non-functional_allele_(e.g._*3D_*5_*10)._Patients_with_the_*1/*1A_genotype_may_still_be_at_risk_for_toxicity_when_taking_thiopurine_drugs_and_purine_analogues_based_upon_their_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*10:Patients_with_the_*10_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*10)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*10)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*13:Patients_with_the_*13_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*13)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*13)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*15:Patients_with_the_*15_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*15)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*15)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*19:Patients_with_the_*19_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*19)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*19)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*24:Patients_with_the_*24_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*24)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*24)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*25:Patients_with_the_*25_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*25)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*25)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*26:Patients_with_the_*26_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*26)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*26)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*27:Patients_with_the_*27_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*27)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*27)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*28:Patients_with_the_*28_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*28)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*28)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*30:Patients_with_the_*30_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*30)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*30)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*31:Patients_with_the_*31_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*31)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*31)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*32:Patients_with_the_*32_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*32)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*32)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*33:Patients_with_the_*33_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*33)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*33)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*34:Patients_with_the_*34_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*34)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*34)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*37:Patients_with_the_*37_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*37)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*37)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*3D:Patients_with_the_*3D_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*3D)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*3D)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*5:Patients_with_the_*5_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_or_*1/*1A_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*5)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*5)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
.	.	TPMT *1, TPMT *11, TPMT *12, TPMT *14, TPMT *16, TPMT *17, TPMT *18, TPMT *1S, TPMT *20, TPMT *21, TPMT *22, TPMT *23, TPMT *6, TPMT *7, TPMT *8, TPMT *9	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG="azathioprine_(PA448515)""mercaptopurine_(PA450379)""purine_analogues_(PA452634)""thioguanine_(PA451663)";PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=4;PGKB_DISEASE="Lupus_Erythematosus_Systemic_(PA444822)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)";PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_1)_may_have_increased_inactivation_of_thiopurines_due_to_normal_TPMT_activity_and_2)_may_have_a_decreased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_a_non-functional_allele_(e.g._*6_*7_*8)._Patients_with_the_*1/*1_genotype_may_still_be_at_risk_for_toxicity_when_taking_thiopurine_drugs_and_purine_analogues_based_upon_their_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*1/*1S:Patients_with_the_*1/*1S_genotype_1)_may_have_increased_inactivation_of_thiopurines_due_to_normal_TPMT_activity_and_2)_may_have_a_decreased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_a_non-functional_allele_(e.g._*6_*7_*8)._Patients_with_the_*1/*1S_genotype_may_still_be_at_risk_for_toxicity_when_taking_thiopurine_drugs_and_purine_analogues_based_upon_their_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*11:Patients_with_the_*11_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*11)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*11)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*12:Patients_with_the_*12_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*12)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*12)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*14:Patients_with_the_*14_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*14)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*14)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*16:Patients_with_the_*16_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*16)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*16)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*17:Patients_with_the_*17_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*17)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*17)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*18:Patients_with_the_*18_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*18)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*18)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*1S/*1S:Patients_with_the_*1S/*1S_genotype_1)_may_have_increased_inactivation_of_thiopurines_due_to_normal_TPMT_activity_and_2)_may_have_a_decreased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_a_non-functional_allele_(e.g._*6_*7_*8)._Patients_with_the_*1S/*1S_genotype_may_still_be_at_risk_for_toxicity_when_taking_thiopurine_drugs_and_purine_analogues_based_upon_their_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*20:Patients_with_the_*20_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*20)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*20)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*21:Patients_with_the_*21_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*21)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*21)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*22:Patients_with_the_*22_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*22)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*22)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*23:Patients_with_the_*23_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*23)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*23)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*6:Patients_with_the_*6_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*6)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*6)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*7:Patients_with_the_*7_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*7)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*7)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*8:Patients_with_the_*8_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*8)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*8)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*9:Patients_with_the_*9_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_decreased_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_*1/*1S_or_*1S/*1S_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*9)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*9)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
.	.	TPMT *1, TPMT *2, TPMT *3A, TPMT *3B, TPMT *3C, TPMT *4	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG="azathioprine_(PA448515)""mercaptopurine_(PA450379)""purine_analogues_(PA452634)""thioguanine_(PA451663)";PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=1A;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_1)_may_have_increased_inactivation_of_thiopurines_due_to_normal_TPMT_activity_and_2)_may_have_a_decreased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_a_non-functional_allele_(e.g._*2_*3A_*3B_*3C_*4)._Patients_with_the_*1/*1_genotype_may_still_be_at_risk_for_toxicity_when_taking_thiopurine_drugs_and_purine_analogues_based_upon_their_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*2:Patients_with_the_*2_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_deficient_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*2/*3A)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*2)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*3A:Patients_with_the_*3A_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_deficient_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3A/*3B)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*3A)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*3B:Patients_with_the_*3B_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_deficient_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*3B/*3C)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*3B)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*3C:Patients_with_the_*3C_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_deficient_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*2/*3C)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*3C)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""*4:Patients_with_the_*4_allele_1)_may_have_decreased_inactivation_of_thiopurines_due_to_deficient_TPMT_activity_and_2)_may_have_an_increased_risk_for_toxicity_when_receiving_thiopurine_drugs_and_purine_analogues_as_compared_to_patients_with_the_*1/*1_genotype._These_effects_may_be_more_pronounced_in_those_who_are_homozygous_for_two_non-functional_variants_(e.g._*2/*4)_than_in_those_who_are_heterozygous_for_the_non-functional_variant_(*1/*4)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
.	.	TPMT *1, TPMT *2, TPMT *3A, TPMT *3C	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG=azathioprine_(PA448515);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Transplantation_(PA134850491);PGKB_TEXT="*1/*1:Patients_with_the_TPMT_*1/*1_genotype_and_heart_transplantation_who_are_treated_with_azathioprine_may_have_a_decreased_but_not_absent_risk_of_severe_rejection_as_compared_to_patients_with_the_TPMT_*1/*2_or_*1/*3A_or_*1/*3C_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_risk_for_organ_rejection.""*1/*2:Patients_with_the_TPMT_*1/*2_genotype_and_heart_transplantation_who_are_treated_with_azathioprine_may_have_an_increased_risk_of_severe_rejection_as_compared_to_patients_with_the_TPMT_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_risk_for_organ_rejection.""*1/*3A:Patients_with_the_TPMT_*1/*3A_genotype_and_heart_transplantation_who_are_treated_with_azathioprine_may_have_an_increased_risk_of_severe_rejection_as_compared_to_patients_with_the_TPMT_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_risk_for_organ_rejection.""*1/*3C:Patients_with_the_TPMT_*1/*3C_genotype_and_heart_transplantation_who_are_treated_with_azathioprine_may_have_an_increased_risk_of_severe_rejection_as_compared_to_patients_with_the_TPMT_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_risk_for_organ_rejection.";PGKB_RACE=NR
.	.	TPMT *1, TPMT *3A, TPMT *3C	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Fatigue_(PA444153);PGKB_TEXT="*1/*1:Individuals_with_the_*1/*1_genotype_may_have_an_decreased_likelihood_of_fatigue_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*3A_or_*1/*3C_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_fatigue_when_receiving_olanzapine.""*1/*3A:Individuals_with_the_*1/*3A_genotype_may_have_an_increased_likelihood_of_fatigue_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_fatigue_when_receiving_olanzapine.""*1/*3C:Individuals_with_the_*1/*3C_genotype_may_have_an_increased_likelihood_of_fatigue_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_fatigue_when_receiving_olanzapine.";PGKB_RACE=White
.	.	UGT1A1 *1, UGT1A1 *28	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A1_(PA420);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Fatigue_(PA444153);PGKB_TEXT="*1/*1:Individuals_with_the_*1/*1_genotype_may_have_a_decreased_likelihood_of_fatigue_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*28_or_*28/*28_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_fatigue_when_receiving_olanzapine.""*1/*28:Individuals_with_the_*1/*28_genotype_may_have_an_increased_likelihood_of_fatigue_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_fatigue_when_receiving_olanzapine.""*28/*28:Individuals_with_the_*28/*28_genotype_may_have_an_increased_likelihood_of_fatigue_when_receiving_olanzapine_as_compared_to_individuals_with_the_*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_fatigue_when_receiving_olanzapine.";PGKB_RACE=White
.	.	UGT1A1 *60	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A1_(PA420);PGKB_DRUG=irinotecan_(PA450085);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT=*60:Patients_who_carried_the_*60_allele_with_colorectal_cancer_may_have_a_poorer_response_when_treated_with_TIROX_(S-1_irinotecan_and_oxaliplatin)_as_compared_to_patients_who_did_not_carry_the_allele._Other_genetic_and_clinical_factors_may_also_influence_response_to_TIROX_treatment.;PGKB_RACE=NR
.	.	UGT1A3 *1, UGT1A3 *2	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A3_(PA37178);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_UGT1A3*1/*1_genotype_may_have_a_decreased_atorvastatin_lactonization_as_compared_to_patients_with_the_UGT1A3*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_metabolism.""*2/*2:Patients_with_the_UGT1A3*2/*2_genotype_may_have_an_increased_atorvastatin_lactonization_as_compared_to_patients_with_the_UGT1A3*1/*1_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_atorvastatin_metabolism.";PGKB_RACE=Asian
.	.	UGT1A6 *1a, UGT1A6 *2a, UGT1A6 *3a, UGT1A6 *4a, UGT1A6 *8	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A6_(PA37181);PGKB_DRUG=valproic_acid_(PA451846);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="*1a/*1a:Pediatric_patients_with_epilepsy_and_the_*1a/*1a_genotype_may_have_decreased_metabolism_of_valproic_acid_and_may_need_a_decreased_dose_of_valproic_acid_when_compared_to_patients_with_any_of_the_following_genotype_combinations:_*1a/*2a*1a/*3a*1a/*4a*1a/*8_*2a/*2a_*2a/*3a_*2a/*4a_*2a/*8_*3a/*3a_*3a/*4a_*3a/*8_or_*4a/*8_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*1a/*2a:Pediatric_patients_with_epilepsy_and_the_*1a/*2a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*1a/*3a:Pediatric_patients_with_epilepsy_and_the_*1a/*3a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*1a/*4a:Pediatric_patients_with_epilepsy_and_the_*1a/*4a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*1a/*8:Pediatric_patients_with_epilepsy_and_the_*1a/*8_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*2a/*2a:Pediatric_patients_with_epilepsy_and_the_*2a/*2a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*2a/*3a:Pediatric_patients_with_epilepsy_and_the_*2a/*3a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*2a/*4a:Pediatric_patients_with_epilepsy_and_the_*2a/*4a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*2a/*8:Pediatric_patients_with_epilepsy_and_the_*2a/*8_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*3a/*4a:Pediatric_patients_with_epilepsy_and_the_*3a/*4a_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""*4a/*8:Pediatric_patients_with_epilepsy_and_the_*4a/*8_genotype_may_have_increased_metabolism_of_valproic_acid_and_may_need_an_increased_dose_when_treated_with_valproic_acid_when_compared_to_patients_with_the_*1a/*1a_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.";PGKB_RACE=Asian
.	.	UGT1A6 *2a	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A6_(PA37181);PGKB_DRUG="irinotecan_(PA450085)""oxaliplatin_(PA131285527)""s_1_(combination)_(PA166115442)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT=*2a:Patients_who_carry_the_*2a_allele_and_have_colorectal_cancer_may_have_an_increased_risk_for_vomiting_when_treated_with_TIROX_(S-1_irinotecan_and_oxaliplatin)_as_compared_to_patients_without_the_*2a_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_for_vomiting_on_TIROX.;PGKB_RACE=NR
.	.	UGT1A7 *3	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A7_(PA37182);PGKB_DRUG="irinotecan_(PA450085)""oxaliplatin_(PA131285527)""s_1_(combination)_(PA166115442)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT=*3:Patients_who_carry_the_*3_allele_and_have_colorectal_cancer_may_have_an_increased_risk_for_vomiting_when_treated_with_TIROX_(S-1_irinotecan_and_oxaliplatin)_as_compared_to_patients_without_the_*3_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_for_vomiting_on_TIROX.;PGKB_RACE=NR
.	.	UGT2B15 *1, UGT2B15 *2	.	.	.	.	PGKB_INDEX=1;PGKB_GENE=UGT2B15_(PA37188);PGKB_DRUG=sipoglitazar_(PA166114434);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="*1/*1:Patients_with_the_*1/*1_genotype_who_are_treated_with_sipoglitazar_may_have_1)_a_worse_response_(as_measured_by_increased_HbgA1c)_and_2)_increased_clearance_as_compared_to_patients_with_the_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sipoglitazar_treatment.""*1/*2:Patients_with_the_*1/*2_genotype_who_are_treated_with_sipoglitazar_may_have_1)_a_worse_response_(as_measured_by_increased_HbgA1c)_and_2)_increased_clearance_as_compared_to_patients_with_the_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sipoglitazar_treatment.""*2/*2:Patients_with_the_*2/*2_genotype_who_are_treated_with_sipoglitazar_may_have_1)_a_better_response_(as_measured_by_decreased_HbgA1c)_and_2)_decreased_clearance_as_compared_to_patients_with_the_*2/*2_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sipoglitazar_treatment.";PGKB_RACE=NR
1	11852300	rs1476413	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=MTHFR_(PA245);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_respond_to_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=NR
1	11854457	rs4846051	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MTHFR_(PA245);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Arthritis_Rheumatoid_(PA443434)""Drug_Toxicity_(PA443937)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_lower_drug_toxicity_score_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methotrexate_induced_toxicity.""AG:Patients_with_the_AG_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_higher_drug_toxicity_score_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_lower_drug_toxicity_score_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methotrexate_induced_toxicity.""GG:Patients_with_the_GG_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_higher_drug_toxicity_score_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methotrexate_induced_toxicity.";PGKB_RACE=Black_or_African_American
1	11854476	rs1801131	T	G	.	.	PGKB_INDEX=10;PGKB_GENE=MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245);PGKB_DRUG=methotrexate_(PA450428),methotrexate_(PA450428),nitrous_oxide_(PA450645),methotrexate_(PA450428),methotrexate_(PA450428),fluorouracil_(PA128406956),capecitabine_(PA448771),"bevacizumab_(PA130232992)""carboplatin_(PA448803)""cisplatin_(PA449014)""cyanocobalamin_(PA451892)""folic_acid_(PA449692)""pemetrexed_(PA10810)","fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)","clozapine_(PA449061)""olanzapine_(PA450688)";PGKB_TYPE=Efficacy,Toxicity/ADR,Toxicity/ADR,"Toxicity/ADR""Metabolism/PK",Efficacy,Toxicity/ADR,Toxicity/ADR,Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3,3,3,3,3,2A,3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Arthritis_Rheumatoid_(PA443434),NR,"Burkitt_Lymphoma_(PA443580)""Lymphoma_Non-Hodgkin_(PA444845)""Lymphoma_T-Cell_(PA446309)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)",Arthritis_Rheumatoid_(PA443434),Neoplasms_(PA445062),Neoplasms_(PA445062),Neoplasms_(PA445062),Colorectal_Neoplasms_(PA446108),"schizoaffective_disorder_(PA166123368)""Schizophrenia_(PA447216)";PGKB_TEXT="GG:Cancer_patients_with_the_GG_genotype_may_have_decreased_event-free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_TT_genotype._However_some_conflicting_or_non-significant_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_event-free_survival.""GT:Cancer_patients_with_the_GT_genotype_may_have_decreased_event-free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_TT_genotype._However_some_conflicting_or_non-significant_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_event-free_survival.""TT:Cancer_patients_with_the_TT_genotype_may_have_increased_event-free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_GG_or_GT_genotype._However_some_conflicting_or_non-significant_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_event-free_survival.","GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_drug_toxicity_and_adverse_events_as_compared_to_patients_with_the_TT_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.""GT:Patients_with_the_GT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_drug_toxicity_and_adverse_events_as_compared_to_patients_with_the_GG_genotype_or_may_have_an_increased_risk_of_drug_toxicity_and_adverse_events_as_compared_to_patients_with_the_TT_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_drug_toxicity_and_adverse_events_as_compared_to_patients_with_the_GG_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.","GG:Patients_with_the_GG_genotype_may_have_higher_homocysteine_levels_after_nitrous_oxide_anesthesia_as_compared_to_patients_with_the_TG_and_TT_genotype.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_homocysteine_levels_after_nitrous_oxide_exposure.""GT:Patients_with_the_TG_genotype_may_have_lower_homocysteine_levels_after_nitrous_oxide_anesthesia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_homocysteine_levels_after_nitrous_oxide_exposure.""TT:Patients_with_the_TT_genotype_may_have_lower_homocysteine_levels_after_nitrous_oxide_anesthesia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_homocysteine_levels_after_nitrous_oxide_exposure.","GG:Patients_with_the_GG_genotype_and_ALL_or_lymphoma_who_are_treated_with_methotrexate_may_have_1)_a_reduced_risk_of_myelosuppression_and_decreased_likelihood_of_red_blood_cell_transfusion_2)_may_have_an_increased_risk_of_mucositis_3)_may_require_a_lower_dose_as_compared_to_patients_with_the_TT_genotype._The_majority_of_studies_find_no_association_with_methotrexate_concentrations_or_toxicity_and_genotypes_of_this_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dosage_and_risk_of_methotrexate-induced_toxicity.""GT:Patients_with_the_GT_genotype_and_ALL_or_lymphoma_who_are_treated_with_methotrexate_may_have_1)_an_increased_risk_of_myelosuppression_2)_may_have_a_reduced_risk_of_mucositis_as_compared_to_patients_with_the_GG_genotype_and_3)_may_require_a_lower_dose_as_compared_to_patients_with_the_TT_genotype._The_majority_of_studies_find_no_association_with_methotrexate_concentrations_or_toxicity_and_genotypes_of_this_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dosage_and_risk_of_methotrexate-induced_toxicity.""TT:Patients_with_the_TT_genotype_and_ALL_or_lymphoma_who_are_treated_with_methotrexate_may_have_1)_an_increased_risk_of_myelosuppression_and_an_increased_likelihood_of_red_blood_cell_transfusion_2)_may_have_a_reduced_risk_of_mucositis_3)_may_require_a_higher_dose_as_compared_to_patients_with_the_GG_genotype._The_majority_of_studies_find_no_association_with_methotrexate_concentrations_or_toxicity_and_genotypes_of_this_variant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dosage_and_risk_of_methotrexate-induced_toxicity.","GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_likelihood_of_clinical_response_but_may_have_a_decreased_response_based_on_Disease_Activity_Score_in_44_joints_improvement_at_6_months_as_compared_to_patients_with_the_TT_genotype._This_association_has_been_contradicted_in_other_studies_including_a_larger_meta-analysis_that_found_no_association_of_this_variant_with_methotrexate_efficacy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""GT:Patients_with_the_GT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_likelihood_of_clinical_response_but_may_have_a_decreased_response_based_on_Disease_Activity_Score_in_44_joints_improvement_at_6_months_as_compared_to_patients_with_the_TT_genotype._This_association_has_been_contradicted_in_other_studies_including_a_larger_meta-analysis_that_found_no_association_of_this_variant_with_methotrexate_efficacy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_decreased_likelihood_of_clinical_response_but_may_have_an_increased_response_based_on_Disease_Activity_Score_in_44_joints_improvement_at_6_months_as_compared_to_patients_with_the_GG_and_GT_genotype._This_association_has_been_contradicted_in_other_studies_including_a_larger_meta-analysis_that_found_no_association_of_this_variant_with_methotrexate_efficacy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.","GG:Patients_with_the_GG_genotype_and_cancer_may_have_a_decreased_risk_of_drug_toxicities_when_receiving_fluorouracil-based_chemotherapy_as_compared_to_patients_with_TT_genotype._This_has_been_contradicted_in_another_study_and_no_association_with_drug_toxicity_found_in_a_third_study._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_fluorouracil-based_chemotherapy.""GT:Patients_with_the_GT_genotype_and_cancer_may_have_a_decreased_risk_of_drug_toxicities_when_receiving_fluorouracil-based_chemotherapy_as_compared_to_patients_with_TT_genotype._This_has_been_contradicted_in_another_study_and_no_association_with_drug_toxicity_found_in_a_third_study._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_fluorouracil-based_chemotherapy.""TT:Patients_with_the_TT_genotype_and_cancer_may_have_an_increased_risk_of_drug_toxicities_when_receiving_fluorouracil-based_chemotherapy_as_compared_to_patients_with_GG_or_GT_genotype._This_has_been_contradicted_in_another_study_and_no_association_with_drug_toxicity_found_in_a_third_study._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_fluorouracil-based_chemotherapy.","GG:Cancer_patients_with_the_GG_genotype_may_have_an_increased_risk_of_drug_toxicities_and_decreased_survival_times_when_receiving_capecitabine-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug_toxicities._""GT:Cancer_patients_with_the_GT_genotype_may_have_an_increased_risk_of_drug_toxicities_as_compared_to_those_with_the_TT_genotype_and_decreased_survival_times_as_compared_to_those_with_the_GG_genotype_when_receiving_capecitabine-based_chemotherapy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug_toxicities.""TT:Cancer_patients_with_the_TT_genotype_may_have_a_decreased_risk_of_drug_toxicities_and_increased_survival_times_when_receiving_capecitabine-based_chemotherapy_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug_toxicities.","GG:Genotype_GG_may_be_associated_with_overall_survival_and_progression_free_survival_in_cancer_patients_treated_with_pemetrexed_and_a_few_other_anticancer_drugs_as_compared_to_genotype_TT._However_contradictory_findings_(better_and_poorer_responses)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_pemetrexed.""GT:Genotype_GT_may_be_associated_with_overall_survival_and_progression_free_survival_in_cancer_patients_treated_with_pemetrexed_and_a_few_other_anticancer_drugs_as_compared_to_genotype_TT._However_contradictory_findings_(better_and_poorer_responses)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_pemetrexed.""TT:Genotype_TT_may_be_associated_with_overall_survival_and_progression_free_survival_in_cancer_patients_treated_with_pemetrexed_and_a_few_other_anticancer_drugs_as_compared_to_genotype_GG_and_GT._However_contradictory_findings_(better_and_poorer_responses)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_pemetrexed.","GG:Patients_with_the_GG_genotype_and_colorectal_cancer_who_are_treated_with_FOLFOX_therapy_(includes_fluorouracil_leucovorin_oxaliplatin)_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_chemotherapy._""GT:Patients_with_the_GT_genotype_and_colorectal_cancer_who_are_treated_with_FOLFOX_therapy_(includes_fluorouracil_leucovorin_oxaliplatin)_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_chemotherapy._""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_who_are_treated_with_FOLFOX_therapy_(includes_fluorouracil_leucovorin_oxaliplatin)_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_GT_and_GG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_chemotherapy._","GG:Patients_with_the_GG_genotype_and_schizophrenia_or_schizoaffective_disorder_may_have_greater_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_when_receiving_clozapine_or_olanzapine.""GT:Patients_with_the_GT_genotype_and_schizophrenia_or_schizoaffective_disorder_may_have_less_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_when_receiving_clozapine_or_olanzapine.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR,NR,NR,NR
1	11856378	rs1801133	G	A	.	.	PGKB_INDEX=16;PGKB_GENE=MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),"CLCN6_(PA26551)""MTHFR_(PA245)",MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245),MTHFR_(PA245);PGKB_DRUG=disulfiram_(PA449376),"folic_acid_(PA449692)""vitamin_b-complex_plain_(PA10505)",pravastatin_(PA451089),benazepril_(PA448561),antipsychotics_(PA452233),nitrous_oxide_(PA450645),methotrexate_(PA450428),methotrexate_(PA450428),methotrexate_(PA450428),"capecitabine_(PA448771)""fluorouracil_(PA128406956)",carboplatin_(PA448803),cyclophosphamide_(PA449165),cisplatin_(PA449014),mercaptopurine_(PA450379),"fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)",pemetrexed_(PA10810);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,"Dosage""Efficacy""Toxicity/ADR",Efficacy,Toxicity/ADR,Efficacy,Toxicity/ADR,"Efficacy""Toxicity/ADR",Toxicity/ADR,"Efficacy""Toxicity/ADR",Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3,3,3,3,3,2A,2A,3,3,3,3;PGKB_DISEASE=Cocaine-Related_Disorders_(PA446878),NR,"Coronary_Artery_Disease_(PA443796)""Myocardial_Infarction_(PA445019)",Hypertension_(PA444552),Schizophrenia_(PA447216),NR,"Arthritis_Juvenile_Rheumatoid_(PA443433)""Arthritis_Psoriatic_(PA446198)""Arthritis_Rheumatoid_(PA443434)""Drug_Toxicity_(PA443937)","Leukemia_(PA444750)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)","Graft_vs_Host_Disease_(PA444320)""Leukemia_(PA444750)""Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171)",Neoplasms_(PA445062),Carcinoma_Non-Small-Cell_Lung_(PA443622),NR,NR,Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Colonic_Neoplasms_(PA443756),"Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_cocaine_dependence_may_have_an_increased_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_disulfiram.""AG:Patients_with_the_AG_genotype_and_cocaine_dependence_may_have_an_increased_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_disulfiram.""GG:Patients_with_the_GG_genotype_and_cocaine_dependence_may_have_a_decreased_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_disulfiram.","AA:Female_patients_with_the_AA_genotype_and_Migraine_who_are_treated_with_folic_acid_and_a_vitamin_b-complex_may_have_an_increased_severity_of_pain_lesser_reduction_in_homocysteine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_severity_of_pain.""AG:Female_patients_with_the_AG_genotype_and_Migraine_who_are_treated_with_folic_acid_and_a_vitamin_b-complex_may_have_a_decreased_severity_of_pain_greater_reduction_in_homocysteine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_severity_of_pain.""GG:Female_patients_with_the_GG_genotype_and_Migraine_who_are_treated_with_folic_acid_and_a_vitamin_b-complex_may_have_a_decreased_severity_of_pain_and_greater_reduction_in_homocysteine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_severity_of_pain.","AA:Patients_with_the_AA_genotype_and_Hypertension_who_are_treated_with_pravastatin_may_have_an_increased_risk_of_nonfatal_myocardial_infarction_and_fatal_coronary_heart_disease_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AG:Patients_with_the_AG_genotype_and_Hypertension_who_are_treated_with_pravastatin_may_have_an_increased_risk_of_nonfatal_myocardial_infarction_and_fatal_coronary_heart_disease_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Hypertension_who_are_treated_with_pravastatin_may_have_a_decreased_risk_of_nonfatal_myocardial_infarction_and_fatal_coronary_heart_disease_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AG_or_GG_genotype._No_significant_differences_in_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_blood_pressure.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AA_genotype._No_significant_differences_in_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_blood_pressure.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AA_genotype._No_significant_differences_in_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_blood_pressure.","AA:Patients_with_the_AA_genotype_treated_with_antipsychotics_may_have_increased_risk_for_metabolic_syndrome_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""AG:Patients_with_the_AG_genotype_treated_with_antipsychotics_may_have_increased_risk_for_metabolic_syndrome_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""GG:Has_average_risk_for_metabolic_syndrome_when_treated_with_antipsychotics._Patients_with_the_GG_genotype_treated_with_antipsychotics_may_have_decreased_risk_for_metabolic_syndrome_as_compared_to_patients_with_the_AA_or_AG_genotype._Patients_with_the_GG_genotype_may_still_be_at_risk_for_adverse_events_when_taking_antipsychotics_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.","AA:Patients_with_the_AA_genotype_who_undergo_elective_surgery_with_nitrous_oxide_anesthesia_may_have_higher_plasma_total_homocysteine_concentrations_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_homocysteine_levels_after_nitrous_oxide_anesthesia.""AG:Patients_with_the_GA_genotype_who_undergo_elective_surgery_with_nitrous_oxide_anesthesia_may_have_higher_plasma_total_homocysteine_concentrations_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_homocysteine_levels_after_nitrous_oxide_anesthesia.""GG:Patients_with_the_GG_genotype_who_undergo_elective_surgery_with_nitrous_oxide_anesthesia_may_have_lower_plasma_total_homocysteine_concentrations_as_compared_to_patients_with_the_GA_of_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_homocysteine_levels_after_nitrous_oxide_anesthesia.","AA:Patients_with_the_AA_genotype_and_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_adverse_events_and_toxicity_as_compared_to_patients_with_the_GG_genotype_(though_this_association_has_not_been_found_in_all_studies)._There_does_not_seem_to_be_a_significant_association_between_this_genotype_and_response_to_methotrexate_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.""AG:Patients_with_the_AG_genotype_and_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_adverse_events_and_toxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_but_not_absent_risk_of_adverse_events_as_compared_to_patients_with_the_AA_genotype_(though_this_association_has_not_been_found_in_all_studies)._There_does_not_seem_to_be_a_significant_association_between_this_genotype_and_response_to_methotrexate_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.""GG:Patients_with_the_GG_genotype_and_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_adverse_events_and_toxicity_as_compared_to_patients_with_the_AA_genotype_(though_this_association_has_not_been_found_in_all_studies)._There_does_not_seem_to_be_a_significant_association_between_this_genotype_and_response_to_methotrexate_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.","AA:Patients_with_the_AA_genotype_and_leukemia_or_lymphoma_who_are_treated_with_methotrexate:_1)_may_have_poorer_response_to_treatment_2)_may_be_at_increased_risk_of_toxicity_3)_may_require_a_lower_dose_of_methotrexate_as_compared_to_patients_with_the_GG_genotype._This_association_has_been_contradicted_or_not_found_in_several_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_and_response_with_methotrexate_treatment.""AG:Patients_with_the_AG_genotype_and_leukemia_or_lymphoma_who_are_treated_with_methotrexate:_1)_may_have_poorer_response_to_treatment_2)_may_be_at_increased_risk_of_toxicity_3)_may_require_a_lower_dose_of_methotrexate_as_compared_to_patients_with_the_GG_genotype_or_may_be_at_decreased_risk_of_toxicity_as_compared_to_patients_with_the_AA_genotype._This_association_has_been_contradicted_or_not_found_in_several_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_and_response_with_methotrexate_treatment.""GG:Patients_with_the_GG_genotype_and_leukemia_or_lymphoma_who_are_treated_with_methotrexate:_1)_may_have_better_response_to_treatment_2)_may_be_at_decreased_risk_of_toxicity_3)_may_require_a_higher_dose_of_methotrexate_as_compared_to_patients_with_the_AA_genotype._This_association_has_been_contradicted_or_not_found_in_several_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_and_response_with_methotrexate_treatment.","AA:Patients_with_the_AA_genotype_and_leukemia_who_undergo_hematopoietic_cell_transplant_and_are_treated_with_methotrexate_may_have_a_decreased_risk_of_Graft_vs_Host_disease_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_Graft_vs_Host_disease_and_efficacy_of_methotrexate_treatment.""AG:Patients_with_the_AG_genotype_and_leukemia_who_undergo_hematopoietic_cell_transplant_and_are_treated_with_methotrexate_may_have_a_decreased_risk_of_Graft_vs_Host_disease_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_Graft_vs_Host_disease_and_efficacy_of_methotrexate_treatment.""GG:Patients_with_the_GG_genotype_and_leukemia_who_undergo_hematopoietic_cell_transplant_and_are_treated_with_methotrexate_may_have_an_increased_risk_of_Graft_vs_Host_disease_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_Graft_vs_Host_disease_and_efficacy_of_methotrexate_treatment.","AA:Cancer_patients_with_the_AA_genotype_may_have_increased_risk_of_drug_toxicities_when_treated_with_fluorouracil-_or_capecitabine-based_therapy_as_compared_to_patients_with_the_AG_or_GG_genotype_however_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicities_when_taking_these_drugs.""AG:Cancer_patients_with_the_AG_genotype_may_have_increased_risk_of_drug_toxicities_when_treated_with_fluorouracil-_or_capecitabine-based_therapy_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_of_drug_toxicities_as_compared_to_patients_with_the_AA_genotype._This_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicities_when_taking_these_drugs.""GG:Cancer_patients_with_the_GG_genotype_may_have_a_decreased_risk_of_drug_toxicities_when_treated_with_fluorouracil-_or_capecitabine-based_therapy_as_compared_to_patients_with_the_AA_or_AG_genotype_however_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicities_when_taking_these_drugs.","AA:Patients_with_AA_genotype_may_have_1)_increased_likelihood_of_response_2)_increased_progression_free_survival_to_carboplatin_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carboplatin.""AG:Patients_with_AG_genotype_may_have_1)_decreased_likelihood_of_response_2)_decreased_progression_free_survival_to_carboplatin_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carboplatin.""GG:Patients_with_GG_genotype_may_have_1)_decreased_likelihood_of_response_2)_decreased_progression_free_survival_to_carboplatin_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carboplatin.","AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_cyclophosphamide_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_cyclophosphamide.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cyclophosphamide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_cyclophosphamide.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cyclophosphamide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_cyclophosphamide.","AA:Patients_with_the_AA_genotype_may_have:_1)_increased_likelihood_of_response_to_chemotherapy_2)_increased_likelihood_of_Drug_Toxicity_when_treated_with_cisplatin_in_cancer_patients_as_compared_to_patients_with_genotypes_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin.""AG:Patients_with_the_AG_genotype_may_have:_1)_decreased_likelihood_of_response_to_chemotherapy_2)_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cisplatin_in_cancer_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin.""GG:Patients_with_the_GG_genotype_may_have:_1)_decreased_likelihood_of_response_to_chemotherapy_2)_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cisplatin_in_cancer_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin.","AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_treatment_interruptions_when_treated_with_mercaptopurine_in_people_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_as_compared_to_patients_with_genotype_GG._However_contradictory_finding_has_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_mercaptopurine.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_treatment_interruptions_when_treated_with_mercaptopurine_in_people_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_as_compared_to_patients_with_genotype_GG._However_contradictory_finding_has_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_mercaptopurine.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_treatment_interruptions_when_treated_with_mercaptopurine_in_people_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_as_compared_to_patients_with_genotype_AA_or_AG._However_contradictory_finding_has_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_mercaptopurine.","AA:Patients_with_genotype_AA_and_colonic_neoplasms_may_have_decreased_response_to_fluorouracil_leucovorin_and_oxaliplatin_(FOLFOX_therapy)_as_compared_to_patients_with_genotypes_AG_and_GG._However_other_studies_showed_as_increased_response_to_oxaliplatin._Studies_also_conflict_as_to_whether_patients_with_AA_genotype_are_at_increased_risk_of_toxicity_such_as_developing_neutropenia_when_taking_oxaliplatin_compared_to_patients_with_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxaliplatin.""AG:Patients_with_genotype_AG_and_colonic_neoplasms_may_have_decreased_response_to_fluorouracil_leucovorin_and_oxaliplatin_(FOLFOX_therapy)_as_compared_to_patients_with_genotypes_GG._However_other_studies_showed_an_increased_response_to_oxaliplatin._Studies_also_conflict_as_to_whether_patients_with_AG_genotype_are_at_increased_risk_of_toxicity_such_as_developing_neutropenia_when_taking_oxaliplatin_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxaliplatin.""GG:Patients_with_genotype_GG_and_colonic_neoplasms_may_have_increased_response_to_fluorouracil_leucovorin_and_oxaliplatin_(FOLFOX_therapy)_as_compared_to_patients_with_genotypes_AA_and_AG._However_other_studies_showed_decreased_response_to_oxaliplatin._Studies_also_conflict_as_to_whether_patients_with_AA_genotype_are_at_increased_risk_of_toxicity_such_as_developing_neutropenia_when_taking_oxaliplatin_compared_to_patients_with_AA_and_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_oxaliplatin.","AA:Patients_with_the_AA_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""AG:Patients_with_the_AG_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_a_longer_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=NR,NR,NR,Asian,NR,NR,NR,NR,NR,NR,Asian,NR,Asian,NR,"Asian""White",NR
1	11857788	rs17421511	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MTHFR_(PA245);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_respond_to_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=NR
1	11906068	rs5065	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NPPA_(PA256);PGKB_DRUG="amlodipine_(PA448388)""chlorthalidone_(PA448970)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE="Cardiovascular_Diseases_(PA443635)""Coronary_Disease_(PA443797)""Stroke_(PA447054)";PGKB_TEXT="AA:Patients_with_Hypertension_and_the_AA_genotype_1)_may_have_an_increased_chance_of_positive_treatment_response_to_amlodipine_as_compared_to_patients_with_the_AG_or_GG_genotype_2)_may_have_lower_chance_of_positive_treatment_response_to_chlorthalidone_as_compared_to_patients_with_the_AG_or_GG_genotype_3)_may_have_an_increased_chance_of_positive_treatment_response_to_amlodipine_compared_to_treatment_with_chlorthalidone._Other_genetic_and_clinical_factors_may_also_influence_response_to_amlodipine_and_chlorthalidone.""AG:Patients_with_Hypertension_and_the_AG_genotype_1)_may_have_a_decreased_chance_of_positive_treatment_response_to_amlodipine_as_compared_to_patients_with_the_AA_genotype_2)_may_have_an_increased_chance_of_positive_treatment_response_to_chlorthalidone_as_compared_to_patients_with_the_AA_genotype_3)_may_have_an_increased_chance_of_positive_treatment_response_to_chlorthalidone_compared_to_treatment_with_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_response_to_amlodipine_and_chlorthalidone.""GG:Patients_with_Hypertension_and_the_GG_genotype_1)_may_have_a_decreased_chance_of_positive_treatment_response_to_amlodipine_as_compared_to_patients_with_the_AA_genotype_2)_may_have_an_increased_chance_of_positive_treatment_response_to_chlorthalidone_as_compared_to_patients_with_the_AA_genotype_3)_may_have_an_increased_chance_of_positive_treatment_response_to_chlorthalidone_compared_to_treatment_with_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_response_to_amlodipine_and_chlorthalidone.";PGKB_RACE=NR
1	11907648	rs5063	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NPPA-AS1_(PA165752124);PGKB_DRUG="bumetanide_(PA448682)""furosemide_(PA449719)""torasemide_(PA451733)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_better_response_to_bumetanide_furosemide_or_torasemide_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_these_drugs.""CT:Patients_with_the_CT_genotype_may_have_a_better_response_to_bumetanide_furosemide_or_torasemide_as_compared_to_those_with_the_TT_genotype_or_a_poorer_response_as_compared_to_those_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_these_drugs.""TT:Patients_with_the_TT_genotype_may_have_a_poorer_response_to_bumetanide_furosemide_or_torasemide_as_compared_to_those_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_these_drugs.";PGKB_RACE=White
1	12252955	rs1061622	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF1B_(PA36610);PGKB_DRUG="infliximab_(PA452639)""Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(including_infliximab_and_rituximab)_as_compared_to_patients_with_the_GT_or_TT_genotype._However_a_study_only_investigating_the_response_to_rituximab_found_no_association_for_G_vs_T_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""GT:Patients_with_the_GT_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(including_infliximab_and_rituximab)_as_compared_to_patients_with_the_GG_genotype._However_a_study_only_investigating_the_response_to_rituximab_found_no_association_for_G_vs_T_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(including_infliximab_and_rituximab)_as_compared_to_patients_with_the_GG_genotype._However_a_study_only_investigating_the_response_to_rituximab_found_no_association_for_G_vs_T_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.";PGKB_RACE=White
1	12267292	rs3397	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF1B_(PA36610);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.";PGKB_RACE=White
1	12268499	rs1061631	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF1B_(PA36610);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.";PGKB_RACE=White
1	20915172	rs532545	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CDA_(PA98),CDA_(PA98);PGKB_DRUG=cytarabine_(PA449177),cytarabine_(PA449177);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Leukemia_Myeloid_Acute_(PA444760)""Neoplasms_(PA445062)",Leukemia_Myeloid_(PA444761);PGKB_TEXT="CC:Patients_with_the_genotype_CC_who_are_treated_with_cytarabine_may_have_reduced_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cytarabine.""CT:Patients_with_the_genotype_CT_who_are_treated_with_cytarabine_may_have_increased_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cytarabine.""TT:Patients_with_the_genotype_TT_who_are_treated_with_cytarabine_may_have_increased_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cytarabine.","CC:Patients_with_the_CC_genotype_and_Myeloid_Leukemia_who_are_treated_with_cytarabine_may_have_an_increased_survival_time_and_a_decreased_risk_of_death_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cytarabine.""CT:Patients_with_the_CT_genotype_and_Myeloid_Leukemia_who_are_treated_with_cytarabine_may_have_a_decreased_survival_time_and_an_increased_risk_of_death_as_compared_to_patients_with_the_CC_genotype_or_may_have_an_increased_survival_time_and_a_decreased_risk_for_death_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cytarabine._""TT:Patients_with_the_TT_genotype_and_Myeloid_Leukemia_who_are_treated_with_cytarabine_may_have_a_decreased_survival_time_and_an_increased_risk_of_death_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cytarabine.";PGKB_RACE=White,White
1	20915531	rs602950	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=CDA_(PA98),CDA_(PA98);PGKB_DRUG=capecitabine_(PA448771),cytarabine_(PA449177);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,4;PGKB_DISEASE=Neoplasms_(PA445062),NR;PGKB_TEXT="AA:Cancer_patients_with_the_AA_genotype_may_have_a_decreased_risk_of_diarrhea_or_dehydration_when_treated_with_capecitabine-based_therapy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea_and_dehydration.""AG:Cancer_patients_with_the_AG_genotype_may_have_an_increased_risk_of_diarrhea_or_dehydration_when_treated_with_capecitabine-based_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea_and_dehydration.""GG:Cancer_patients_with_the_GG_genotype_may_have_an_increased_risk_of_diarrhea_or_dehydration_when_treated_with_capecitabine-based_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea_and_dehydration.","AA:Patients_with_the_AA_genotype_who_are_treated_with_cytarabine_may_have_lower_levels_of_toxicity_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cytarabine-induced_toxicity.""AG:Patients_with_the_AG_genotype_who_are_treated_with_cytarabine_may_have_higher_levels_of_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cytarabine-induced_toxicity.""GG:Patients_with_the_GG_genotype_who_are_treated_with_cytarabine_may_have_higher_levels_of_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cytarabine-induced_toxicity.";PGKB_RACE=NR,NR
1	20915589	rs3215400	TC	T	.	.	PGKB_INDEX=2;PGKB_GENE=CDA_(PA98),CDA_(PA98);PGKB_DRUG=cytarabine_(PA449177),capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,"Neoplasms_(PA445062)""Palmar-plantar_erythrodysaesthesia_syndrome_(PA165966294)";PGKB_TEXT="C/del:Patients_with_the_C/del_genotype_who_are_treated_with_cytarabine_may_have_an_increased_risk_of_drug_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""CC:Patients_with_the_CC_genotype_who_are_treated_with_cytarabine_may_have_a_decreased_but_not_absent_risk_of_drug_toxicity_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_cytarabine_may_have_an_increased_risk_of_drug_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.","C/del:Patients_with_the_C/del_genotype_and_cancer_who_are_treated_with_capecitabine_may_have_a_decreased_likelihood_of_developing_grade_3_hand-foot_syndrome_as_compared_to_patients_with_the_del/del_genotype._This_has_been_contradicted_in_another_(not_statistically_significant)_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_drug_reactions.""CC:Patients_with_the_C/C_genotype_and_cancer_who_are_treated_with_capecitabine_may_have_a_decreased_likelihood_of_developing_grade_3_hand-foot_syndrome_as_compared_to_patients_with_the_del/del_genotype._This_has_been_contradicted_in_another_(not_statistically_significant)_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_drug_reactions.""del/del:Patients_with_the_del/del_genotype_and_cancer_who_are_treated_with_capecitabine_may_have_an_increased_likelihood_of_developing_grade_3_hand-foot_syndrome_as_compared_to_patients_with_the_CC_or_C/del_genotype._This_has_been_contradicted_in_another_(not_statistically_significant)_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_drug_reactions.";PGKB_RACE=NR,NR
1	20915701	rs2072671	A	C	.	.	PGKB_INDEX=2;PGKB_GENE=CDA_(PA98),CDA_(PA98);PGKB_DRUG=cytarabine_(PA449177),gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760),"Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)""Pancreatic_Neoplasms_(PA445218)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_cytarabine_may_have_a_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""AC:Patients_with_the_AC_genotype_who_are_treated_with_cytarabine_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""CC:Patients_with_the_CC_genotype_who_are_treated_with_cytarabine_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.","AA:Patients_with_cancer_and_the_AA_genotype_who_are_treated_with_gemcitabine_may_have_1)_decreased_expression_of_CDA_leading_to_decreased_clearance_of_gemcitabine_and_2)_a_higher_incidence_of_toxicity_events_such_as_neutropenia_and_GI_toxicity_as_compared_to_patients_with_the_CC_genotype._However_current_evidence_is_contradictory._Other_genetic_and_clinical_factors_may_also_influence_gemcitabine's_risk_of_inducing_toxicity.""AC:Patients_with_cancer_and_the_AC_genotype_who_are_treated_with_gemcitabine_may_have_1)_decreased_expression_of_CDA_leading_to_decreased_clearance_of_gemcitabine_and_2)_a_higher_incidence_of_toxicity_events_such_as_neutropenia_and_GI_toxicity_as_compared_to_patients_with_the_CC_genotype._However_current_evidence_is_contradictory._Other_genetic_and_clinical_factors_may_also_influence_gemcitabine's_risk_of_inducing_toxicity.""CC:Patients_with_the_CC_genotype_who_are_treated_with_gemcitabine_may_have_1)_increased_expression_of_CDA_leading_to_increased_clearance_of_gemcitabine_and_2)_a_lower_incidence_of_toxicity_events_including_neutropenia_and_GI_toxicity_as_compared_to_patients_with_the_CC_genotype._However_current_evidence_is_contradictory._Other_genetic_and_clinical_factors_may_also_influence_gemcitabine's_risk_of_inducing_toxicity.";PGKB_RACE=White,NR
1	20931474	rs60369023	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CDA_(PA98),CDA_(PA98);PGKB_DRUG=cytarabine_(PA449177),gemcitabine_(PA449748);PGKB_TYPE=Other,Toxicity/ADR;PGKB_EVIDENCE=4,3;PGKB_DISEASE=NR,"Neoplasms_(PA445062)""Neutropenia_(PA445113)";PGKB_TEXT="AA:Purified_CDA_proteins_with_the_AA_genotype_may_have_decreased_catalytic_activity_when_exposed_to_cytarabine_as_compared_to_those_proteins_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_catalytic_activity_of_the_CDA_protein.""AG:Purified_CDA_proteins_with_the_AG_genotype_may_have_decreased_catalytic_activity_when_exposed_to_cytarabine_as_compared_to_those_proteins_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_catalytic_activity_of_the_CDA_protein.""GG:Purified_CDA_proteins_with_the_GG_genotype_may_have_increased_catalytic_activity_when_exposed_to_cytarabine_as_compared_to_those_proteins_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_catalytic_activity_of_the_CDA_protein.","AA:Patients_with_the_AA_genotype_and_cancer_who_are_treated_with_gemcitabine_1)_may_have_decreased_clearance_of_gemcitabine_2)_may_have_increased_severity_of_Neutropenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_gemcitabine_clearance_and_severity_of_neutropenia.""AG:Patients_with_the_AG_genotype_and_cancer_who_are_treated_with_gemcitabine_1)_may_have_decreased_clearance_of_gemcitabine_2)_may_have_increased_severity_Neutropenia_as_compared_to_patients_with_the_GG_genotype_or_1)_may_have_increased_clearance_of_gemcitabine_2)_may_have_decreased_severity_of_Neutropenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_gemcitabine_clearance_and_severity_of_neutropenia.""GG:Patients_with_the_GG_genotype_and_cancer_who_are_treated_with_gemcitabine_1)_may_have_increased_clearance_of_gemcitabine_2)_may_have_decreased_severity_of_Neutropenia_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_gemcitabine_clearance_and_severity_of_neutropenia.";PGKB_RACE=NR,Asian
1	20945055	rs1048977	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CDA_(PA98);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_cancer_and_the_CC_genotype_may_have_increased_metabolism_of_gemcitabine_as_compared_to_patients_with_the_TT_genotype._However_this_has_been_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_gemcitabine._""CT:Patients_with_cancer_and_the_CT_genotype_may_have_increased_metabolism_of_gemcitabine_as_compared_to_patients_with_the_TT_genotype._However_this_has_been_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_gemcitabine._""TT:Patients_with_cancer_and_the_TT_genotype_may_have_decreased_metabolism_of_gemcitabine_as_compared_to_patients_with_the_CC_genotype._However_this_has_been_contradicted_by_some_studies._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_gemcitabine._";PGKB_RACE=NR
1	22225743	rs2445142	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=HSPG2_(PA29537);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""CG:Patients_with_the_CG_genotype_may_have_increased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics..""GG:Patients_with_the_GG_genotype_may_have_decreased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.";PGKB_RACE=White
1	22227091	rs878949	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=HSPG2_(PA29537);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_TT_genotype._other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_CC_genotype._other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_CC_genotype._other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.";PGKB_RACE=White
1	29139756	rs2236861	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=OPRD1_(PA31942);PGKB_DRUG=opioids_(PA452618);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Opioid-Related_Disorders_(PA445043);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_influence_risk_of_opioid_dependence_when_exposed_to_opioids._""AG:Patients_with_the_AG_genotype_may_have_a_decreased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_GG_genotype_and_an_increased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_influence_risk_of_opioid_dependence_when_exposed_to_opioids._""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_influence_risk_of_opioid_dependence_when_exposed_to_opioids._";PGKB_RACE=White
1	29174946	rs529520	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=OPRD1_(PA31942);PGKB_DRUG=buprenorphine_(PA448685);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Opioid-Related_Disorders_(PA445043);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_opioid-dependent_may_have_a_poorer_response_to_treatment_with_buprenorphine_as_compared_to_patients_with_the_CC_genotype._Literature_evidence_currently_indicates_that_this_finding_is_only_significant_in_women._Other_genetic_and_clinical_factors_may_also_influence_response_to_buprenorphine.""AC:Patients_with_the_AC_genotype_who_are_opioid-dependent_may_have_a_poorer_response_to_treatment_with_buprenorphine_as_compared_to_patients_with_the_CC_genotype_or_a_better_response_as_compared_to_patients_with_the_AA_genotype._Literature_evidence_currently_indicates_that_this_finding_is_only_significant_in_women._Other_genetic_and_clinical_factors_may_also_influence_response_to_buprenorphine.""CC:Patients_with_the_CC_genotype_who_are_opioid-dependent_may_have_a_better_response_to_treatment_with_buprenorphine_as_compared_to_patients_with_the_AA_genotype._Literature_evidence_currently_indicates_that_this_finding_is_only_significant_in_women._Other_genetic_and_clinical_factors_may_also_influence_response_to_buprenorphine.";PGKB_RACE=NR
1	29175373	rs581111	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=OPRD1_(PA31942);PGKB_DRUG=buprenorphine_(PA448685);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Opioid-Related_Disorders_(PA445043);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_opioid-dependent_may_have_a_poorer_response_to_treatment_with_buprenorphine_as_compared_to_patients_with_the_GG_genotype._Literature_evidence_currently_indicates_that_this_finding_is_only_significant_in_women._Other_genetic_and_clinical_factors_may_also_influence_response_to_buprenorphine.""AG:Patients_with_the_AG_genotype_who_are_opioid-dependent_may_have_a_poorer_response_to_treatment_with_buprenorphine_as_compared_to_patients_with_the_GG_genotype._Literature_evidence_currently_indicates_that_this_finding_is_only_significant_in_women._Other_genetic_and_clinical_factors_may_also_influence_response_to_buprenorphine.""GG:Patients_with_the_GG_genotype_who_are_opioid-dependent_may_have_a_better_response_to_treatment_with_buprenorphine_as_compared_to_patients_with_the_AA_or_AG_genotype._Literature_evidence_currently_indicates_that_this_finding_is_only_significant_in_women._Other_genetic_and_clinical_factors_may_also_influence_response_to_buprenorphine.";PGKB_RACE=NR
1	29190138	rs4654327	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=OPRD1_(PA31942);PGKB_DRUG=naltrexone_(PA450588);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Alcoholism_(PA443309);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Alcoholism_may_have_increased_naltrexone-induced_blunting_of_alcohol_stimulation_and_alcohol_craving_when_treated_with_naltrexone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_naltrexone.""AG:Patients_with_the_AG_genotype_and_Alcoholism_may_have_increased_naltrexone-induced_blunting_of_alcohol_stimulation_and_alcohol_craving_when_treated_with_naltrexone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_naltrexone.""GG:Patients_with_the_GG_genotype_and_Alcoholism_may_have_decreased_naltrexone-induced_blunting_of_alcohol_stimulation_and_alcohol_craving_when_treated_with_naltrexone_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_naltrexone.";PGKB_RACE=NR
1	29411250	rs6702335	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=EPB41_(PA27810);PGKB_DRUG="bupropion_(PA448687)""nicotine_(PA450626)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_abstinence_when_treated_with_bupropion_or_nicotine_in_men_with_Tobacco_Use_Disorder_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_bupropion_or_nicotine.""AG:Patients_with_the_AG_genotype_may_have_increased_abstinence_when_treated_with_bupropion_or_nicotine_in_men_with_Tobacco_Use_Disorder_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_bupropion_or_nicotine.""GG:Patients_with_the_GG_genotype_may_have_decreased_abstinence_when_treated_with_bupropion_or_nicotine_in_men_with_Tobacco_Use_Disorder_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_bupropion_or_nicotine.";PGKB_RACE=White
1	32756439	rs1741981	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=HDAC1_(PA29226);PGKB_DRUG=corticosteroids_(PA10832);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_poorer_response_when_treated_with_corticosteroids_either_systemic_or_inhaled_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.""CT:Patients_with_the_CT_genotype_and_asthma_may_have_a_better_response_when_treated_with_corticosteroids_either_systemic_or_inhaled_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_a_better_response_when_treated_with_corticosteroids_either_systemic_or_inhaled_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.";PGKB_RACE=NR
1	45800156	rs3219484	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=MUTYH_(PA31328);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""TT:Patients_with_the_TT_genotype_were_not_studied._Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._";PGKB_RACE=NR
1	46870761	rs324420	C	A	.	.	PGKB_INDEX=2;PGKB_GENE=FAAH_(PA27955),FAAH_(PA27955);PGKB_DRUG="aripiprazole_(PA10026)""clozapine_(PA449061)""haloperidol_(PA449841)""olanzapine_(PA450688)""quetiapine_(PA451201)""risperidone_(PA451257)",methamphetamine_(PA450403);PGKB_TYPE=Toxicity/ADR,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Psychotic_Disorders_(PA447215),Substance-Related_Disorders_(PA446876);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Psychotic_Disorders_who_are_treated_with_aripiprazole_clozapine_haloperidol_olanzapine_quetiapine_or_risperidone_may_have_an_increased_likelihood_of_weight_gain_of_more_than_7%_of_baseline_body_weight_as_compared_to_patients_with_the_CC_genotype._However_this_is_contradicted_in_one_study_with_risperidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment-induced_weight_gain.""AC:Patients_with_the_AC_genotype_and_Psychotic_Disorders_who_are_treated_with_aripiprazole_clozapine_haloperidol_olanzapine_quetiapine_or_risperidone_may_have_an_increased_likelihood_of_weight_gain_of_more_than_7%_of_baseline_body_weight_as_compared_to_patients_with_the_CC_genotype._However_this_is_contradicted_in_one_study_with_risperidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment-induced_weight_gain.""CC:Patients_with_the_CC_genotype_and_Psychotic_Disorders_who_are_treated_with_aripiprazole_clozapine_haloperidol_olanzapine_quetiapine_or_risperidone_may_have_a_decreased_likelihood_of_weight_gain_of_more_than_7%_of_baseline_body_weight_as_compared_to_patients_with_the_AA_or_AC_genotype._However_this_is_contradicted_in_one_study_with_risperidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment-induced_weight_gain.","AA:Men_with_the_AA_genotype_may_have_an_increased_risk_for_dependence_on_methamphetamine_as_compared_to_men_with_the_CC_genotype._Genotype_was_not_associated_with_risk_of_methamphetamine-induced_pyschosis_or_panic_disorder._Other_genetic_and_clinical_factors_may_also_influence_dependence_on_methamphetamine_and_methamphetamine-induced_side_effects._""AC:Men_with_the_AC_genotype_may_have_an_increased_risk_for_dependence_on_methamphetamine_as_compared_to_men_with_the_CC_genotype_or_a_decreased_risk_for_dependence_on_methamphetamine_as_compared_to_men_with_the_AA_genotype._Genotype_was_not_associated_with_risk_of_methamphetamine-induced_pyschosis_or_panic_disorder._Other_genetic_and_clinical_factors_may_also_influence_dependence_on_methamphetamine_and_methamphetamine-induced_side_effects._""CC:Men_with_the_CC_genotype_may_have_a_decreased_risk_for_dependence_on_methamphetamine_as_compared_to_men_with_the_AA_genotype._Genotype_was_not_associated_with_risk_of_methamphetamine-induced_pyschosis_or_panic_disorder._Other_genetic_and_clinical_factors_may_also_influence_dependence_on_methamphetamine_and_methamphetamine-induced_side_effects._";PGKB_RACE=White,Asian
1	46879562	rs2295632	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=FAAH_(PA27955);PGKB_DRUG=opioids_(PA452618);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Children_with_the_GG_genotype_who_are_undergoing_a_tonsillectomy_may_have_a_decreased_risk_for_respiratory_depression_when_treated_with_opioids_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_respiratory_depression.""GT:Children_with_the_GT_genotype_who_are_undergoing_a_tonsillectomy_may_have_an_increased_risk_for_respiratory_depression_when_treated_with_opioids_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_respiratory_depression.""TT:Children_with_the_TT_genotype_who_are_undergoing_a_tonsillectomy_may_have_an_increased_risk_for_respiratory_depression_when_treated_with_opioids_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_respiratory_depression.";PGKB_RACE=White
1	47279175	rs4646487	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP4B1_(PA27119);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
1	47800845	rs4492666	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=CMPK1_(PA162382539);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_solid_tumors_may_have_increased_response_to_gemcitabine_compared_to_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.""AC:Patients_with_the_AC_genotype_and_and_solid_tumors_may_have_increased_response_to_gemcitabine_compared_to_the_AA_genotype_and_decreased_response_to_gemcitabine_compared_to_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.""CC:Patients_with_the_CC_genotype_and_solid_tumors_may_have_a_decreased_response_to_gemcitabine_compared_to_the_AC_and_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=Asian
1	47833213	rs11211524	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=CMPK1_(PA162382539);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_solid_tumors_may_have_increased_response_to_gemcitabine_compared_to_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.""AC:Patients_with_the_AC_genotype_and_solid_tumors_may_have_increased_response_to_gemcitabine_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.""CC:Patients_with_the_CC_genotype_and_solid_tumors_may_have_decreased_response_to_gemcitabine_compared_to_the_AA_and_AC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.";PGKB_RACE=Asian
1	54688516	rs642990	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_for_neutropenia_when_treated_with_gemcitabine_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.""CT:Patients_with_the_CT_genotype_may_have_decreased_risk_for_neutropenia_when_treated_with_gemcitabine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_for_neutropenia_when_treated_with_gemcitabine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.";PGKB_RACE=Asian
1	66058513	rs1137101	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=LEPR_(PA229),LEPR_(PA229),LEPR_(PA229);PGKB_DRUG=simvastatin_(PA451363),simvastatin_(PA451363),valproic_acid_(PA451846);PGKB_TYPE=Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Coronary_Disease_(PA443797),Hyperlipidemias_(PA444528),Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_coronary_heart_disease_may_have_a_reduced_response_to_treatment_with_smaller_increases_in_HDL-C_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AG:Patients_with_the_AG_genotype_and_coronary_heart_disease_may_have_a_reduced_response_to_treatment_with_smaller_increases_in_HDL-C_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_better_response_to_treatment_with_higher_increases_in_HDL-C_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Patients_with_the_GG_genotype_and_coronary_heart_disease_may_have_a_better_response_to_treatment_with_higher_increases_in_HDL-C_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","AA:Patients_with_the_AA_genotype_and_hypercholesterolemia_may_have_a_better_response_to_treatment_with_increased_reductions_in_total_cholesterol_when_treated_with_simvastatin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AG:Patients_with_the_AG_genotype_and_hypercholesterolemia_may_have_a_better_response_to_treatment_with_increased_reductions_in_total_cholesterol_when_treated_with_simvastatin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Patients_with_the_GG_genotype_and_hypercholesterolemia_may_have_a_reduced_response_to_treatment_with_less_reduction_in_total_cholesterol_when_treated_with_simvastatin_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","AA:Patients_with_the_AA_genotype_and_epilepsy_may_have_greater_weight_gain_when_treated_with_valproic_acid_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain._""AG:Patients_with_the_AG_genotype_and_epilepsy_may_have_greater_weight_gain_when_treated_with_valproic_acid_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain._""GG:Patients_with_the_GG_genotype_and_epilepsy_may_have_lower_weight_gain_when_treated_with_valproic_acid_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain._";PGKB_RACE=Asian,NR,Asian
1	66238379	rs12046844	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_a_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_leukopenia.""GA:Patients_with_the_GA_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_AA_genotype_and_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_leukopenia.""GG:Patients_with_the_GG_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_leukopenia.";PGKB_RACE=Asian
1	67685443	rs7518660	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL23R_(PA134935109);PGKB_DRUG=celecoxib_(PA448871);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Colorectal_Neoplasms_may_have_increased_risk_for_Adenoma_when_treated_with_celecoxib_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""AG:Patients_with_the_AG_genotype_and_Colorectal_Neoplasms_may_have_increased_risk_for_Adenoma_when_treated_with_celecoxib_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_but_not_absent_risk_for_Adenoma_when_treated_with_celecoxib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""GG:Patients_with_the_GG_genotype_and_Colorectal_Neoplasms_may_have_decreased_but_not_absent_risk_for_Adenoma_when_treated_with_celecoxib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.";PGKB_RACE=NR
1	71377650	rs11209716	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PTGER3_(PA288);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Cough_(PA443803)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_of_cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cough_when_treated_with_ACE_inhibitors.""CT:Patients_with_the_genotype_have_not_been_studied.""TT:Patients_with_the_TT_genotype_and_hypertension_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_of_cough_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cough_when_treated_with_ACE_inhibitors.";PGKB_RACE=NR
1	71514969	rs7551789	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=PTGER3_(PA288);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AT:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_TT_genotype_or_may_have_decreased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_decreased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
1	78956432	rs3753380	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PTGFR_(PA290);PGKB_DRUG=latanoprost_(PA164774763);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Glaucoma_Open-Angle_(PA444282);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_open_angle_glaucoma_may_have_an_increased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_compared_to_patients_with_genotypes_CT_or_TT._Other_genetic_and_clinical_factors_may_affect_response_to_latanoprost._*Please_note:_One_study_that_reported_this_SNP's_association_with_response_to_latanoprost_compared_the_haplotype_of_rs3753380_C_and_rs3766355_C_versus_rs3753380_T_and_rs3766355_A.""CT:Patients_with_the_CT_genotype_and_open_angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_affect_response_to_latanoprost._*Please_note:_One_study_that_reported_this_SNP's_association_with_response_to_latanoprost_compared_the_haplotype_of_rs3753380_C_and_rs3766355_C_versus_rs3753380_T_and_rs3766355_A.""TT:Patients_with_the_TT_genotype_and_open_angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_affect_response_to_latanoprost._*Please_note:_One_study_that_reported_this_SNP's_association_with_response_to_latanoprost_compared_the_haplotype_of_rs3753380_C_and_rs3766355_C_versus_rs3753380_T_and_rs3766355_A.";PGKB_RACE=Asian
1	78957441	rs3766355	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=PTGFR_(PA290);PGKB_DRUG=latanoprost_(PA164774763);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Glaucoma_Open-Angle_(PA444282);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_open_angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_compared_to_patients_with_genotypes_AC_or_CC._Other_genetic_and_clinical_factors_may_affect_response_to_latanoprost._*Please_note:_this_SNP_was_not_analyzed_alone._A_single_study_reported_its_association_with_response_to_latanoprost_by_comparing_the_haplotype_of_rs3753380_C_and_rs3766355_C_versus_rs3753380_T_and_rs3766355_A.""AC:Patients_with_the_AC_genotype_and_open_angle_glaucoma_may_have_an_increased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_compared_to_patients_with_genotype_AA_and_a_decreased_response_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_affect_response_to_latanoprost._*Please_note:_this_SNP_was_not_analyzed_alone._Only_a_single_study_reported_its_association_with_response_to_latanoprost_by_comparing_the_haplotypes_rs3753380_C_and_rs3766355_C_versus_rs3753380_T_and_rs3766355_A.""CC:Patients_with_the_CC_genotype_and_open_angle_glaucoma_may_have_an_increased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_compared_to_patients_with_genotypes_AA_or_AC._Other_genetic_and_clinical_factors_may_affect_response_to_latanoprost._*Please_note:_this_SNP_was_not_analyzed_alone._Only_a_single_study_reported_its_association_with_response_to_latanoprost_by_comparing_the_haplotypes_rs3753380_C_and_rs3766355_C_versus_rs3753380_T_and_rs3766355_A.";PGKB_RACE=Asian
1	88132380	rs983332	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="GG:Rheumatoid_Arthritis_patients_with_genotype_GG_may_be_more_likely_to_respond_to_TNF_inhibitors_as_compared_with_patients_with_GT_or_TT_genotypes_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Rheumatoid_Arthritis_patients_with_genotype_GT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_genotype_TT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
1	89849574	rs928655	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GBP6_(PA134964409);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Rheumatoid_Arthritis_patients_with_genotype_AA_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Rheumatoid_Arthritis_patients_with_genotype_AG_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Rheumatoid_Arthritis_patients_with_genotype_GG_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
1	92155337	rs12082710	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TGFBR3_(PA36487);PGKB_DRUG=antidepressants_(PA452229);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depression_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""CT:Patients_with_the_CT_genotype_and_depression_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""TT:Patients_with_the_TT_genotype_and_depression_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.";PGKB_RACE=NR
1	95001867	rs3917643	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=F3_(PA158);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Myocardial_Ischemia_(PA446459);PGKB_TEXT="CC:Patients_with_the_CC_genotype_were_not_studied._Patients_with_the_CT_genotype_and_stable_ischemic_heart_disease_may_have_an_increased_response_to_simvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""CT:Patients_with_the_CT_genotype_and_stable_ischemic_heart_disease_may_have_an_increased_response_to_simvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""TT:Patients_with_the_TT_genotype_and_stable_ischemic_heart_disease_may_have_a_reduced_response_to_simvastatin_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._";PGKB_RACE=White
1	97523004	rs12132152	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_for_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.";PGKB_RACE=White
1	97539400	rs76387818	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine._""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_for_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine._""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine._";PGKB_RACE=White
1	97547947	rs67376798	T	A	.	.	PGKB_INDEX=3;PGKB_GENE=DPYD_(PA145),DPYD_(PA145),DPYD_(PA145);PGKB_DRUG=leucovorin_(PA450198),"capecitabine_(PA448771)""fluorouracil_(PA128406956)""tegafur_(PA452620)","bevacizumab_(PA130232992)""capecitabine_(PA448771)""cetuximab_(PA10040)""oxaliplatin_(PA131285527)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,1A,3;PGKB_DISEASE="Colorectal_Neoplasms_(PA446108)""Rectal_Neoplasms_(PA445503)",Neoplasms_(PA445062),"Colorectal_Neoplasms_(PA446108)""Diarrhea_(PA443899)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_were_not_reported_however_patients_with_the_AT_genotype_and_Cancer_who_are_treated_with_regimens_containing_leucovorin_may_have_increased_severity_of_drug_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""AT:Patients_with_the_AT_genotype_and_Cancer_who_are_treated_with_regimens_containing_leucovorin_may_have_increased_severity_of_drug_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""TT:Patients_with_the_TT_genotype_and_Cancer_who_are_treated_with_regimens_containing_leucovorin_may_have_decreased_severity_of_drug_toxicity_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.","AA:Patients_with_the_AA_genotype_and_Cancer_who_are_treated_with_fluoropyrimidine-based_chemotherapy_1)_may_have_complete_DYPD_deficiency_and_decreased_clearance_of_fluoropyrimidine_drugs_2)_may_have_an_increased_risk_and_increased_severity_of_drug_toxicity_in_particular_diarrhea_as_compared_to_patients_with_the_TT_genotype._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine-based_chemotherapy.""AT:Patients_with_the_AT_genotype_and_Cancer_who_are_treated_with_fluoropyrimidine-based_chemotherapy_1)_may_have_partial_DYPD_deficiency_and_decreased_clearance_of_fluoropyrimidine_drugs_2)_may_have_an_increased_risk_and_increased_severity_of_drug_toxicity_in_particular_diarrhea_as_compared_to_patients_with_the_TT_genotype._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine-based_chemotherapy.""TT:Patients_with_the_TT_genotype_and_Cancer_who_are_treated_with_fluoropyrimidine-based_chemotherapy_1)_may_have_increased_clearance_of_the_drug_2)_may_have_a_decreased_but_not_absent_risk_and_reduced_severity_of_drug_toxicity_as_compared_to_patients_with_the_AT_genotype._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine-based_chemotherapy.","AA:Patients_with_the_AA_genotype_may_have_increased_severity_of_Diarrhea_when_treated_with_bevacizumab_capecitabine_cetuximab_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity.""AT:Patients_with_the_AT_genotype_may_have_increased_severity_of_Diarrhea_when_treated_with_bevacizumab_capecitabine_cetuximab_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity.""TT:Patients_with_the_TT_genotype_may_have_decreased_severity_of_Diarrhea_when_treated_with_bevacizumab_capecitabine_cetuximab_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA_or_AT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity.";PGKB_RACE=NR,NR,NR
1	97602994	rs1760217	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG=antineoplastic_agents_(PA452621);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Pancreatic_Neoplasms_(PA445218);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_survival_when_treated_with_antineoplastic_agents_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.""AG:Patients_with_the_AG_genotype_may_have_decreased_survival_when_treated_with_antineoplastic_agents_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.""GG:Patients_with_the_GG_genotype_may_have_increased_survival_when_treated_with_antineoplastic_agents_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.";PGKB_RACE=NR
1	97770920	rs1801160	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE="Toxicity/ADR""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_cancer_may_have_1)_increased_metabolism_of_fluorouracil_and_2)_decreased_risk_for_drug_toxicities_when_treated_with_fluoropyrimidines_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_fluorouracil_or_fluoropyrimidine-induced_toxicities.""CT:Patients_with_the_CT_genotype_and_cancer_may_have_1)_decreased_metabolism_of_fluorouracil_and_2)_increased_risk_for_drug_toxicities_when_treated_with_fluoropyrimidines_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_fluorouracil_or_fluoropyrimidine-induced_toxicities.""TT:Patients_with_the_TT_genotype_and_cancer_may_have_1)_decreased_metabolism_of_fluorouracil_and_2)_increased_risk_for_drug_toxicities_when_treated_with_fluoropyrimidines_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_fluorouracil_or_fluoropyrimidine-induced_toxicities.";PGKB_RACE=NR
1	97862780	rs12022243	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_diarrhea_when_treated_with_capecitabine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine._""CT:Patients_with_the_CT_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_diarrhea_when_treated_with_capecitabine_as_compared_to_patients_with_the_TT_genotype_or_an_increased_risk_for_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine._""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_diarrhea_when_treated_with_capecitabine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine._";PGKB_RACE=White
1	97915614	rs3918290	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)""Pyrimidine_analogues_(PA164713220)""tegafur_(PA452620)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=1A;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_(DPYD_*1/*1)_may_have_decreased_but_not_non-existent_risk_for_drug_toxicity_when_treated_with_fluoropyrimidine_based_chemotherapy_as_compared_to_patients_with_the_CT_or_TT_genotype_(DPYD_*1/*2A_or_*2A/*2A)._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine_based_chemotherapy.""CT:Patients_with_the_CT_genotype_(DPYD_*1/*2A)_may_1)_have_DPYD_deficiency_and_2)_be_at_risk_for_severe_or_even_fatal_drug_toxicity_when_treated_with_fluoropyrimidine_based_chemotherapy_as_compared_to_patients_with_the_CC_genotype_(DPYD_*1/*1)._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine_based_chemotherapy.""TT:Patients_with_the_TT_genotype_(DPYD_*2A/*2A)_may_1)_have_complete_DPYD_deficiency_and_2)_be_at_risk_for_severe_or_even_fatal_drug_toxicity_when_treated_with_fluoropyrimidine_based_chemotherapy_as_compared_to_patients_with_the_CC_genotype_(DPYD_*1/*1)._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine_based_chemotherapy.";PGKB_RACE=NR
1	97915624	rs17376848	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=DPYD_(PA145),DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)",fluorouracil_(PA128406956);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_Drug_Toxicity_when_treated_with_capecitabine_irinotecan_and_fluorouracil_or_capecitabine_fluorouracil_leucovorin_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug_toxicity.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Drug_Toxicity_when_treated_with_capecitabine_irinotecan_and_fluorouracil_or_capecitabine_fluorouracil_leucovorin_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA_or_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug_toxicity.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Drug_Toxicity_when_treated_with_capecitabine_irinotecan_and_fluorouracil_or_capecitabine_fluorouracil_leucovorin_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug_toxicity.","AA:Patients_with_the_AA_genotype_and_cancer_may_have_a_decreased_risk_for_neutropenia_when_treated_with_5-fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neutropenia_when_receiving_5-fluorouracil._""AG:Patients_with_the_AG_genotype_and_cancer_may_have_a_decreased_risk_for_neutropenia_when_treated_with_5-fluorouracil_as_compared_to_patients_with_the_GG_genotype_or_an_increased_risk_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neutropenia_when_receiving_5-fluorouracil._""GG:Patients_with_the_GG_genotype_and_cancer_may_have_an_increased_risk_for_neutropenia_when_treated_with_5-fluorouracil_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neutropenia_when_receiving_5-fluorouracil._";PGKB_RACE=White,NR
1	97981343	rs55886062	A	C,T	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)""Pyrimidine_analogues_(PA164713220)""tegafur_(PA452620)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=1A;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(DPYD_*1/*1)_and_cancer_who_are_treated_with_fluoropyrimidine-based_chemotherapy_may_have_a_decreased_but_not_absent_risk_for_drug_toxicity_as_compared_to_patients_with_the_AC_or_CC_genotype_(DPYD_*1/*13_or_*13/*13)._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine-based_chemotherapy.""AC:Patients_with_the_AC_genotype_(DPYD_*1/*13)_and_cancer_who_are_treated_with_fluoropyrimidine-based_chemotherapy_1)_may_have_a_partial_DYPD_deficiency_2)_may_have_an_increased_risk_and_increased_severity_of_drug_toxicity_as_compared_to_patients_with_the_AA_genotype_(DPYD_*1/*1)._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine-based_chemotherapy.""CC:Patients_with_the_CC_genotype_(DPYD_*13/*13)_and_cancer_who_are_treated_with_fluoropyrimidine-based_chemotherapy_1)_may_have_complete_DYPD_deficiency_2)_may_have_an_increased_risk_and_increased_severity_of_drug_toxicity_as_compared_to_patients_with_the_AA_genotype_(DPYD_*1/*1)._Fluoropyrimidines_are_often_used_in_combination_chemotherapy_such_as_FOLFOX_(fluorouracil_leucovorin_and_oxaliplatin)_FOLFIRI_(fluorouracil_leucovorin_and_irinotecan)_or_FEC_(fluorouracil_epirubicin_and_cyclophosphamide)_or_with_other_drugs_such_as_bevacizumab_cetuximab_raltitrexed._The_combination_and_delivery_of_the_drug_may_influence_risk_for_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_fluoropyrimidine-based_chemotherapy.";PGKB_RACE=White
1	97981395	rs1801159	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=DPYD_(PA145),DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)",fluorouracil_(PA128406956);PGKB_TYPE=Toxicity/ADR,NR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Neoplasms_(PA445062),Colonic_Neoplasms_(PA443756);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_middle-severe_nausea_vomiting_and_white_blood_cell_decreases_in_cancer_patients_treated_with_fluorouracil_as_compared_to_patients_with_the_TT_genotype._Genotype_CC_is_also_associated_with_decreased_clearance_of_fluorouracil._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluorouracil_related_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_middle-severe_nausea_vomiting_and_white_blood_cell_decreases_in_cancer_patients_treated_with_fluorouracil_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluorouracil_related_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_middle-severe_nausea_vomiting_and_white_blood_cell_decreases_in_cancer_patients_treated_with_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluorouracil_related_adverse_events.","CC:CC_genotype_is_not_associated_with_response_to_fluorouracil_in_white_colon_cancer_patients_as_compared_to_TT_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_fluorouracil.""CT:CT_genotype_is_not_associated_with_response_to_fluorouracil_in_white_colon_cancer_patients_as_compared_to_TT_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_fluorouracil.""TT:TT_genotype_is_not_associated_with_response_to_fluorouracil_in_white_colon_cancer_patients_as_compared_to_CC_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_fluorouracil.";PGKB_RACE=NR,White
1	97981421	rs1801158	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG=fluorouracil_(PA128406956);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_fluorouracil-related_toxicity_in_cancer_patients_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluorouracil-related_toxicity.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_of_fluorouracil-related_toxicity_in_cancer_patients_as_compared_to_patients_with_the_CC_genotype._Genotype_CT_is_also_associated_with_decreased_DPYD_activity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluorouracil-related_toxicity.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_fluorouracil-related_toxicity_in_cancer_patients_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluorouracil-related_toxicity.";PGKB_RACE=NR
1	98045449	rs75017182	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Colorectal_Neoplasms_(PA446108)""Neoplasms_(PA445062)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_cancer_may_have_a_decreased_risk_of_drug_toxicity_when_treated_with_capecitabine_and_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity._""CG:Patients_with_the_CG_genotype_and_cancer_may_have_an_increased_risk_of_drug_toxicity_when_treated_with_capecitabine_and_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity._""GG:Patients_with_the_GG_genotype_and_cancer_may_have_an_increased_risk_of_drug_toxicity_when_treated_with_capecitabine_and_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity._";PGKB_RACE=NR
1	98165030	rs115232898	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG=fluorouracil_(PA128406956);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_5-FU-Related_Severe_Toxicity_when_treated_with_fluorouracil_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_risk_of_toxicity_to_fluorouracil.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_5-FU-Related_Severe_Toxicity_when_treated_with_fluorouracil_as_compared_to_patients_with_genotype_TT._Genotype_CT_is_also_associated_with_decreased_DPD_activity._Other_genetic_or_clinical_factors_may_also_influence_risk_of_toxicity_to_fluorouracil.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_5-FU-Related_Severe_Toxicity_when_treated_with_fluorouracil_as_compared_to_patients_with_genotype_CT_or_CC._Other_genetic_or_clinical_factors_may_also_influence_risk_of_toxicity_to_fluorouracil.";PGKB_RACE=Black_or_African_American
1	98165091	rs2297595	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DPYD_(PA145);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Colorectal_Neoplasms_(PA446108)""Drug_Toxicity_(PA443937)""Neoplasms_(PA445062)""Pancreatic_Neoplasms_(PA445218)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_1)_increased_risk_of_severe_toxicity_when_treated_with_fluoropyrimidines_and_2)_decreased_metabolism_of_fluorouracil_as_compared_to_patients_with_the_TT_genotype._However_contradictory_or_negative_results_exist_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patients_chance_of_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_1)_increased_risk_of_severe_toxicity_when_treated_with_fluoropyrimidines_and_2)_decreased_metabolism_of_fluorouracil_as_compared_to_patients_with_the_TT_genotype._However_contradictory_or_negative_results_exist_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patients_chance_of_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_1)_decreased_but_not_absent_risk_of_severe_toxicity_when_treated_with_fluoropyrimidines_and_2)_increased_metabolism_of_fluorouracil_as_compared_to_patients_with_the_CC_or_CT_genotype._However_contradictory_or_negative_results_exist_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patients_chance_of_adverse_events.";PGKB_RACE=White
1	98348885	rs1801265	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=DPYD_(PA145),DPYD_(PA145);PGKB_DRUG=fluorouracil_(PA128406956),fluorouracil_(PA128406956);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_risk_for_drug_toxicities_when_treated_with_fluorouracil_as_compared_to_the_AG_or_GG_genotypes._However_contradictory_and_negative_evidence_for_this_association_exists._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_of_fluorouracil-related_toxicity.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_drug_toxicities_when_treated_with_fluorouracil_as_compared_to_the_AA_genotype._However_contradictory_and_negative_evidence_for_this_association_exists._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_of_fluorouracil-related_toxicity.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_drug_toxicities_when_treated_with_fluorouracil_as_compared_to_the_AA_genotype._However_contradictory_and_negative_evidence_for_this_association_exists._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_of_fluorouracil-related_toxicity.","AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_middle-severe_nausea_and_vomiting_in_Asian_cancer_patients_treated_with_fluorouracil_as_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_fluorouracil-related_toxicity.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_middle-severe_nausea_and_vomiting_in_Asian_cancer_patients_treated_with_fluorouracil_as_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_fluorouracil-related_toxicity.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_middle-severe_nausea_and_vomiting_in_Asian_cancer_patients_treated_with_fluorouracil_as_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_fluorouracil-related_toxicity.";PGKB_RACE=NR,Asian
1	109818530	rs646776	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CELSR2_(PA26394);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_hmg_coa_reductase_inhibitors.""CT:Patients_with_the_CT_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_hmg_coa_reductase_inhibitors.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_hmg_coa_reductase_inhibitors.";PGKB_RACE=NR
1	110280253	rs1799735	TC	T,TCCT	.	.	PGKB_INDEX=2;PGKB_GENE=GSTM3_(PA29024),GSTM3_(PA29024);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)",olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204),NR;PGKB_TEXT="CCT/CCT:Patients_with_the_CCT/CCT_genotype_may_have_decreased_but_not_non-existent_risk_of_side_effects_(thrombocytopenia_anemia_and_neuropathy)_with_cisplatin_and_cyclophosphamide_therapy_as_compared_to_patients_with_the_del/del_or_del/CCT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_events.""CCT/del:Patients_with_the_CCT/del_genotype_may_have_increased_risk_of_side_effects_(thrombocytopenia_anemia_and_neuropathy)_with_cisplatin_and_cyclophosphamide_therapy_as_compared_to_patients_with_the_CCT/CCT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_events.""del/del:Patients_with_the_del/del_genotype_may_have_increased_risk_of_side_effects_(thrombocytopenia_anemia_and_neuropathy)_with_cisplatin_and_cyclophosphamide_therapy_as_compared_to_patients_with_the_CCT/CCT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_events.","CCT/CCT:Individuals_with_the_CCT/CCT_genotype_may_have_increased_clearance_of_olanzapine_as_compared_to_individuals_with_the_CCT/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_olanzapine.""CCT/del:Individuals_with_the_CCT/del_genotype_may_have_decreased_clearance_of_olanzapine_as_compared_to_individuals_with_the_CCT/CCT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_olanzapine.""del/del:Individuals_with_the_del/del_genotype_may_have_decreased_clearance_of_olanzapine_as_compared_to_individuals_with_the_CCT/CCT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_olanzapine.";PGKB_RACE=White,White
1	111857208	rs3818822	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHIA_(PA142672117);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=aspirin-induced_asthma_(PA131285571);PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AG:Patients_with_asthma_and_the_AG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
1	115236057	rs17602729	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=AMPD1_(PA24776),AMPD1_(PA24776);PGKB_DRUG=methotrexate_(PA450428),regadenoson_(PA166129536);PGKB_TYPE="Efficacy""Toxicity/ADR",Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_response_to_methotrexate_as_compared_to_patients_with_the_GG_genotype._This_association_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_CNS_adverse_events_as_compared_to_patients_with_the_GG_genotype._Patients_with_the_AG_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_response_to_methotrexate_as_compared_to_patients_with_the_GG_genotype._This_association_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_risk_of_CNS_adverse_events.""GG:Patients_with_the_GG_genotype_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_response_to_methotrexate_as_compared_to_patients_with_the_AA_genotype._This_association_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.","AA:Patients_with_the_AA_genotype_may_have_a_greater_elevation_in_systolic_blood_pressure_and_a_greater_incidence_of_side_effects_when_given_regadenoson_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_to_regadenoson.""AG:Patients_with_the_AG_genotype_may_have_a_greater_elevation_in_systolic_blood_pressure_and_a_greater_incidence_of_side_effects_when_given_regadenoson_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_to_regadenoson.""GG:Patients_with_the_GG_genotype_may_have_a_lower_elevation_in_systolic_blood_pressure_and_a_lower_incidence_of_side_effects_when_given_regadenoson_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_to_regadenoson.";PGKB_RACE=NR,NR
1	115837709	rs2239622	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NGF_(PA162397475);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment.""AG:Patients_with_the_AG_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment.""GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment.";PGKB_RACE=NR
1	117087779	rs12044852	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CD58_(PA26227);PGKB_DRUG="interferon_beta-1a_(PA450037)""interferon_beta-1b_(PA450039)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Multiple_Sclerosis_(PA444987);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_multiple_sclerosis_may_have_a_better_response_to_treatment_with_interferon_beta_1a/1b_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_interferon_beta_treatment.""AC:Patients_with_the_AC_genotype_and_multiple_sclerosis_may_have_a_better_response_to_treatment_with_interferon_beta_1a/1b_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_interferon_beta_treatment.""CC:Patients_with_the_CC_genotype_and_multiple_sclerosis_may_have_a_poorer_response_to_treatment_with_interferon_beta_1a/1b_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_interferon_beta_treatment.";PGKB_RACE=NR
1	146681425	rs7541245	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=FMO5_(PA28189);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="AA:Patients_with_diabetes_mellitus_and_the_AA_genotype_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_AC_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_have_an_influence_on_response_to_metformin_in_patients_with_diabetes_mellitus._""AC:Patients_with_diabetes_mellitus_and_the_AC_genotype_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_CC_genotypes_and_an_increased_response_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_have_an_influence_on_response_to_metformin_in_patients_with_diabetes_mellitus._""CC:Patients_with_diabetes_mellitus_and_the_CC_genotype_may_have_an_increased_response_to_metformin_as_compared_to_patients_with_the_AA_and_AC_genotypes._Other_clinical_and_genetic_factors_may_also_have_an_influence_on_response_to_metformin_in_patients_with_diabetes_mellitus._";PGKB_RACE=NR
1	154381103	rs12083537	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=IL6R_(PA29835);PGKB_DRUG=tocilizumab_(PA165292659);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_who_are_treated_with_tocilizumab_may_have_decreased_response_to_tocilizumab_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tocilizumab.""AG:Patients_with_the_AG_genotype_and_rheumatoid_arthritis_who_are_treated_with_tocilizumab_may_have_increased_response_to_tocilizumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tocilizumab.""GG:Patients_with_the_GG_genotype_are_not_studied._However_patients_with_the_AG_genotype_and_rheumatoid_arthritis_who_are_treated_with_tocilizumab_may_have_increased_response_to_tocilizumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tocilizumab.";PGKB_RACE=NR
1	154432420	rs4329505	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL6R_(PA29835);PGKB_DRUG=tocilizumab_(PA165292659);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_tocilizumab_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_tocilizumab.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_tocilizumab_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_tocilizumab.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_tocilizumab_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_tocilizumab.";PGKB_RACE=NR
1	155279482	rs2297480	T	G	.	.	PGKB_INDEX=3;PGKB_GENE=FDPS_(PA28075),FDPS_(PA28075),FDPS_(PA28075);PGKB_DRUG=zoledronate_(PA10235),Bisphosphonates_(PA164712563),atorvastatin_(PA448500);PGKB_TYPE=Toxicity/ADR,Efficacy,Other;PGKB_EVIDENCE=3,2B,3;PGKB_DISEASE="Neoplasms_(PA445062)""Osteonecrosis_(PA445187)","Osteoporosis_(PA445190)""Osteoporosis_Postmenopausal_(PA446214)",Coronary_Disease_(PA443797);PGKB_TEXT="GG:Patients_with_genotype_GG_may_have_decreased_likelihood_of_osteonecrosis_when_treated_with_zoledronate_in_people_with_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""TG:Patients_with_genotype_TG_may_have_increased_likelihood_of_osteonecrosis_when_treated_with_zoledronate_in_people_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""TT:Patients_with_genotype_TT_may_have_increased_likelihood_of_osteonecrosis_when_treated_with_zoledronate_in_people_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.","GG:Patients_with_the_GG_genotype_may_have_a_decreased_chance_of_response_to_bisphosphonate_treatment_as_compared_to_patients_with_the_GT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""GT:Patients_with_the_GT_genotype_may_have_an_increased_chance_of_response_to_bisphosphonate_treatment_as_compared_to_patients_with_the_GG_genotypeas_compared_to_patients_with_the_TT_genotype._Patients_with_the_GT_genotype_may_still_be_at_risk_for_non-response_to_bisphosphonate_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""TT:Patients_with_the_TT_genotype_may_have_an_increased_chance_of_response_to_bisphosphonate_treatment_or_may_have_an_increase_in_bone_density_when_treated_with_atorvastatin_as_compared_to_patients_with_the_GG_or_GT_genotype._Patients_with_the_TT_genotype_may_still_be_at_risk_for_non-response_to_bisphosphonate_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.","GG:Patients_with_the_GG_genotype_may_have_decreased_bone_density_when_treated_with_atorvastatin_in_people_with_Coronary_Disease_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_bone_response_to_atorvastatin.""GT:Patients_with_the_GT_genotype_may_have_decreased_bone_density_when_treated_with_atorvastatin_in_people_with_Coronary_Disease_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_bone_response_to_atorvastatin.""TT:Patients_with_the_TT_genotype_may_have_increased_bone_density_when_treated_with_atorvastatin_in_people_with_Coronary_Disease_as_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_and_clinical_factors_may_also_influence_the_bone_response_to_atorvastatin.";PGKB_RACE=White,White,NR
1	155282829	rs11264359	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=FDPS_(PA28075);PGKB_DRUG="atorvastatin_(PA448500)""Bisphosphonates_(PA164712563)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Disease_(PA443797)""Osteoporosis_(PA445190)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_response_to_bisphosphonate_treatment_or_may_have_an_increase_in_bone_density_when_treated_with_atorvastatin_as_compared_to_those_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response._""AG:Patients_with_the_AG_genotype_may_have_a_decrease_in_bone_density_when_treated_with_atorvastatin_as_compared_to_those_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response._""GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_bisphosphonate_treatment_or_may_have_a_decrease_in_bone_density_when_treated_with_atorvastatin_as_compared_to_those_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response._";PGKB_RACE=NR
1	156852463	rs2768759	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK1_(PA31817);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_residual_platelet_aggregation_to_collagen_and_epinephrine_when_treated_with_aspirin_as_compared_to_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AC:No_information_are_provided_for_the_AC_genotype._But_patients_with_the_CC_genotype_may_have_an_increased_residual_platelet_aggregation_to_collagen_and_epinephrine_when_treated_with_aspirin_as_compared_to_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CC:Patients_with_the_CC_genotype_may_have_an_increased_residual_platelet_aggregation_to_collagen_and_epinephrine_when_treated_with_aspirin_as_compared_to_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Black_or_African_American
1	156869714	rs12041331	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=PEAR1_(PA162399233),PEAR1_(PA162399233);PGKB_DRUG=aspirin_(PA448497),"aspirin_(PA448497)""clopidogrel_(PA449053)";PGKB_TYPE=Toxicity/ADR,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3;PGKB_DISEASE=Myocardial_Infarction_(PA445019),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_myocardial_infarction_(MI)_when_treated_with_aspirin_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_for_toxicity_to_aspirin.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_myocardial_infarction_(MI)_when_treated_with_aspirin_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_for_toxicity_to_aspirin.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_myocardial_infarction_(MI)_when_treated_with_aspirin_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_for_toxicity_to_aspirin.","AA:Patients_with_the_AA_genotype_may_have_1)_increased_risk_of_cardiovascular_events_in_patients_undergoing_percutaneous_coronary_intervention_(PCI)_when_treated_with_aspirin_and_clopidogrel_2)_decreased_collagen_induced_platelet_aggregation_after_Aspirin_or_dual_antiplatelet_therapy_(DAPT)_administration_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_and_risk_for_toxicity_to_aspirin_and_clopidogrel.""AG:Patients_with_the_AG_genotype_may_have_1)_increased_risk_of_cardiovascular_events_in_patients_undergoing_percutaneous_coronary_intervention_(PCI)_when_treated_with_aspirin_and_clopidogrel_2)_decreased_collagen_induced_platelet_aggregation_after_Aspirin_or_dual_antiplatelet_therapy_(DAPT)_administration_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_and_risk_for_toxicity_to_aspirin_and_clopidogrel.""GG:Patients_with_the_GG_genotype_may_have_1)_decreased_risk_of_cardiovascular_events_in_patients_undergoing_percutaneous_coronary_intervention_(PCI)_when_treated_with_aspirin_and_clopidogrel_2)_increased_collagen_induced_platelet_aggregation_after_Aspirin_or_dual_antiplatelet_therapy_(DAPT)_administration_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_and_risk_for_toxicity_to_aspirin_and_clopidogrel.";PGKB_RACE=NR,NR
1	156873727	rs12407843	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PEAR1_(PA162399233);PGKB_DRUG=prasugrel_(PA154410481);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_prasugrel_may_have_lower_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""AG:Patients_with_the_AG_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._";PGKB_RACE=Asian
1	156877797	rs77235035	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=PEAR1_(PA162399233);PGKB_DRUG=prasugrel_(PA154410481);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_prasugrel_may_have_lower_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""AC:Patients_with_the_AC_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""CC:Patients_with_the_CC_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._";PGKB_RACE=Asian
1	156879580	rs3737224	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PEAR1_(PA162399233);PGKB_DRUG=prasugrel_(PA154410481);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""CT:Patients_with_the_CT_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_prasugrel_may_have_lower_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._";PGKB_RACE=Asian
1	156881959	rs41273215	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PEAR1_(PA162399233);PGKB_DRUG=prasugrel_(PA154410481);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""CT:Patients_with_the_CT_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_prasugrel_may_have_lower_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._";PGKB_RACE=Asian
1	156882996	rs822441	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=PEAR1_(PA162399233);PGKB_DRUG=prasugrel_(PA154410481);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_prasugrel_may_have_lower_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""CG:Patients_with_the_CG_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._";PGKB_RACE=Asian
1	156883215	rs822442	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=PEAR1_(PA162399233);PGKB_DRUG=prasugrel_(PA154410481);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_prasugrel_may_have_lower_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""AC:Patients_with_the_AC_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._""CC:Patients_with_the_CC_genotype_who_are_treated_with_prasugrel_may_have_higher_levels_of_platelet_aggregation_inhibition_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel_treatment._";PGKB_RACE=Asian
1	159273943	rs2298805	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=FCER1A_(PA28056);PGKB_DRUG="desloratadine_(PA164776964)""mizolastine_(PA166129535)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Urticaria_(PA445999);PGKB_TEXT="AA:Patients_with_genotype_AA_and_urticaria_may_have_increased_response_to_desloratadine_and_mizolastine_compared_to_patients_with_genotypes_AG_or_GG._Other_clinical_and_genetic_factors_also_may_affect_response_to_desloratadine_and_mizolastine._""AG:Patients_with_genotype_AG_and_urticaria_may_have_decreased_response_to_desloratadine_and_mizolastine_compared_to_patients_with_genotype_AA._Other_clinical_and_genetic_factors_also_may_affect_response_to_desloratadine_and_mizolastine._""GG:Patients_with_genotype_GG_and_urticaria_may_have_decreased_response_to_desloratadine_and_mizolastine_compared_to_patients_with_genotype_AA._Other_clinical_and_genetic_factors_also_may_affect_response_to_desloratadine_and_mizolastine._";PGKB_RACE=Asian
1	159684186	rs1417938	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=CRP_(PA120);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=metabolic_syndrome_(PA162370415);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_metabolic_syndrome_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""AT:Patients_with_the_AT_genotype_and_metabolic_syndrome_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""TT:Patients_with_the_TT_genotype_and_metabolic_syndrome_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.";PGKB_RACE=White
1	159684665	rs3091244	G	T,A	.	.	PGKB_INDEX=1;PGKB_GENE=CRP_(PA120);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=metabolic_syndrome_(PA162370415);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_metabolic_syndrome_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_AG_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""AG:Patients_with_the_AG_genotype_and_metabolic_syndrome_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""AT:Patients_with_the_AT_genotype_and_metabolic_syndrome_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_AG_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""GG:Patients_with_the_GG_genotype_and_metabolic_syndrome_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""GT:Patients_with_the_GT_genotype_and_metabolic_syndrome_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.";PGKB_RACE=White
1	160516308	rs6427528	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CD84_(PA26242);PGKB_DRUG=etanercept_(PA449515);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_etanercept_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_etanercept.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_etanercept_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_etanercept.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_etanercept_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_etanercept.";PGKB_RACE=White
1	161184875	rs11587213	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=FCER1G_(PA28057);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_an_increased_risk_for_aspirin_sensitivity_but_patients_with_chronic_urticaria_may_have_a_decreased_risk_for_aspirin_sensitivity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_sensitivity._""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_decreased_risk_for_aspirin_sensitivity_but_patients_with_chronic_urticaria_may_have_an_increased_risk_for_aspirin_sensitivity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_sensitivity._""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_decreased_risk_for_aspirin_sensitivity_but_patients_with_chronic_urticaria_may_have_an_increased_risk_for_aspirin_sensitivity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_sensitivity._";PGKB_RACE=Asian
1	161204538	rs2501873	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I3_(PA391);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_any_allele_of_rs3212198_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_TT_genotype_and_rs3212198_T_allele._The_variant_combination_of_rs2501873_and_rs3212198_explained_1.7%_of_the_overall_interindividual_variability_in_warfarin_dose_requirements_among_one_study_in_a_multivariate_regression_analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""CT:Patients_with_the_CT_genotype_and_any_allele_of_rs3212198_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_TT_genotype_and_rs3212198_T_allele._The_variant_combination_of_rs2501873_and_rs3212198_explained_1.7%_of_the_overall_interindividual_variability_in_warfarin_dose_requirements_among_one_study_in_a_multivariate_regression_analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_and_rs3212198_T_allele_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CT_or_CC_genotype_in_combination_with_any_allele_of_rs3212198._The_variant_combination_of_rs2501873_and_rs3212198_explained_1.7%_of_the_overall_interindividual_variability_in_warfarin_dose_requirements_among_one_study_in_a_multivariate_regression_analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.";PGKB_RACE=Asian
1	161213063	rs11265572	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=liver_transplantation_(PA447247);PGKB_TEXT="GG:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_GG_genotype_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_metabolism_of_tacrolimus.""GT:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_GT_genotype_may_have_decreased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_metabolism_of_tacrolimus.""TT:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_TT_genotype_may_have_decreased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_metabolism_of_tacrolimus.";PGKB_RACE=Asian
1	161479745	rs1801274	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=FCGR2A_(PA28063),FCGR2A_(PA28063),FCGR2A_(PA28063);PGKB_DRUG="adalimumab_(PA10004)""infliximab_(PA452639)","adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)",trastuzumab_(PA451743);PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,2B;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434),Psoriasis_(PA445451),Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_who_are_with_infliximab_may_have_an_increased_response_based_on_European_League_Against_Rheumatism_(EULAR)_criteria_and_show_more_improvement_using_the_Disease_Activity_Score_28_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_infliximab.""GA:Patients_with_the_GA_genotype_and_rheumatoid_arthritis_who_are_with_infliximab_may_have_a_decreased_response_based_on_European_League_Against_Rheumatism_(EULAR)_criteria_and_show_less_improvement_using_the_Disease_Activity_Score_28_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_infliximab.""GG:Patients_with_the_GG_genotype_and_rheumatoid_arthritis_who_are_with_infliximab_may_have_a_decreased_response_based_on_European_League_Against_Rheumatism_(EULAR)_criteria_and_show_less_improvement_using_the_Disease_Activity_Score_28_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_infliximab.","AA:Patients_with_the_AA_genotype_and_psoriasis_may_have_a_lower_psoriasis_body_surface_area_after_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AG:Patients_with_the_AG_genotype_and_psoriasis_may_have_a_lower_psoriasis_body_surface_area_after_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_psoriasis_may_have_a_higher_psoriasis_body_surface_area_after_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.","AA:Patients_with_the_AA_genotype_may_have_increased_response_to_trastuzumab_and_longer_progression-free_survival_in_people_with_Breast_cancer_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_trastuzumab.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_trastuzumab_and_shorter_progression-free_survival_in_people_with_Breast_cancer_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_trastuzumab.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_trastuzumab_and_shorter_progression-free_survival_in_people_with_Breast_cancer_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_trastuzumab.";PGKB_RACE=NR,White,NR
1	161514542	rs396991	A	C	.	.	PGKB_INDEX=7;PGKB_GENE=FCGR3A_(PA28065),FCGR3A_(PA28065),FCGR3A_(PA28065),FCGR3A_(PA28065),FCGR3A_(PA28065),FCGR3A_(PA28065),FCGR3A_(PA28065);PGKB_DRUG=rituximab_(PA451261),cetuximab_(PA10040),"adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)",infliximab_(PA452639),trastuzumab_(PA451743),rituximab_(PA451261),antithymocyte_globulin_(PA164743704);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Other;PGKB_EVIDENCE=2B,2B,3,3,2B,3,3;PGKB_DISEASE="Lymphoma_B-Cell_(PA446304)""Lymphoma_Follicular_(PA444841)""Lymphoma_Large-Cell_Diffuse_(PA446313)""Lymphoma_Non-Hodgkin_(PA444845)",Colorectal_Neoplasms_(PA446108),Psoriasis_(PA445451),Arthritis_Rheumatoid_(PA443434),Breast_Neoplasms_(PA443560),"Arthritis_Rheumatoid_(PA443434)""Neuromyelitis_Optica_(PA445109)",Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Lymphoma_patients_with_the_AA_genotype_who_are_treated_with_rituximab_may_be_less_likely_to_have_tumor_shrinkage_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rituximab.""AC:Lymphoma_patients_with_the_AC_genotype_who_are_treated_with_rituximab_may_be_more_likely_to_have_tumor_shrinkage_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rituximab.""CC:Lymphoma_patients_with_the_CC_genotype_who_are_treated_with_rituximab_may_be_more_likely_to_have_tumor_shrinkage_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rituximab.","AA:Patients_with_the_AA_genotype_with_Colorectal_Cancer_who_are_treated_with_cetuximab_may_have_better_response_and_treatment_outcome_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""AC:Patients_with_the_AC_genotype_with_Colorectal_Cancer_who_are_treated_with_cetuximab_may_have_better_response_and_treatment_outcome_as_compared_to_patients_with_the_CC_genotype_or_may_have_poorer_response_and_treatment_outcome_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""CC:Patients_with_the_CC_genotype_with_Colorectal_Cancer_who_are_treated_with_cetuximab_may_have_poorer_response_and_treatment_outcome_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.","AA:Patients_with_the_AA_genotype_and_psoriasis_may_have_a_higher_psoriasis_body_surface_area_after_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AC:Patients_with_the_AC_genotype_and_psoriasis_may_have_a_lower_psoriasis_body_surface_area_after_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CC:Patients_with_the_CC_genotype_and_psoriasis_may_have_a_lower_psoriasis_body_surface_area_after_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.","AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_may_have_a_better_response_when_treated_with_infliximab_as_compared_to_patients_with_the_CC_genotype._However_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_infliximab.""AC:Patients_with_the_AC_genotype_and_rheumatoid_arthritis_may_have_a_better_response_when_treated_with_infliximab_as_compared_to_patients_with_the_CC_genotype_or_a_poorer_response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_infliximab.""CC:Patients_with_the_CC_genotype_and_rheumatoid_arthritis_may_have_a_poorer_response_when_treated_with_infliximab_as_compared_to_patients_with_the_AA_genotype._However_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_infliximab.","AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_trastuzumab_and_shorter_progression-free_survival_in_people_with_Breast_cancer_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_trastuzumab.""AC:Patients_with_the_AC_genotype_may_have_decreased_response_to_trastuzumab_and_shorter_progression-free_survival_in_people_with_Breast_cancer_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_trastuzumab.""CC:Patients_with_the_CC_genotype_may_have_increased_response_to_trastuzumab_and_longer_progression-free_survival_in_people_with_Breast_cancer_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_trastuzumab.","AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_or_neuromyelitis_optica_may_have_a_poorer_response_to_rituximab_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab._""AC:Patients_with_the_AC_genotype_and_rheumatoid_arthritis_or_neuromyelitis_optica_may_have_a_poorer_response_to_rituximab_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab._""CC:Patients_with_the_CC_genotype_and_rheumatoid_arthritis_or_neuromyelitis_optica_may_have_a_better_response_to_rituximab_as_compared_to_patients_with_the_AA_and_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab._","AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_may_have_decreased_sensitivity_to_antilymphocyte_serum_when_treated_with_antithymocyte_globulin_as_compared_to_patients_with_the_CC_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antithymocyte_globulin.""AC:Patients_with_the_AC_genotype_and_Kidney_Transplantation_may_have_increased_sensitivity_to_antilymphocyte_serum_when_treated_with_antithymocyte_globulin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antithymocyte_globulin.""CC:Patients_with_the_CC_genotype_and_Kidney_Transplantation_may_have_increased_sensitivity_to_antilymphocyte_serum_when_treated_with_antithymocyte_globulin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antithymocyte_globulin.";PGKB_RACE=NR,NR,White,Asian,NR,NR,NR
1	162030688	rs10918594	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NOS1AP_(PA142671259);PGKB_DRUG=verapamil_(PA451868);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Acquired_Long_QT_Syndrome_(aLQTS)_(PA447300);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_but_not_absent_risk_for_QTc_prolongation_during_verapamil_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_QTc_prolongation_risk.""CG:While_patients_with_the_GG_genotype_may_have_an_increased_risk_for_QTc_prolongation_during_verapamil_treatment_as_compared_to_patients_with_the_CC_genotype_it_was_not_shown_conclusively_if_heterzygous_(GC)_individuals_are_affected._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_QTc_prolongation_risk.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_QTc_prolongation_during_verapamil_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_QTc_prolongation_risk.";PGKB_RACE=White
1	162085685	rs10494366	G	T	.	.	PGKB_INDEX=2;PGKB_GENE=NOS1AP_(PA142671259),NOS1AP_(PA142671259);PGKB_DRUG="dolasetron_(PA449390)""granisetron_(PA449809)",verapamil_(PA451868);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Acquired_Long_QT_Syndrome_(aLQTS)_(PA447300);PGKB_TEXT="GG:Patients_with_the_GG_genotype_undergoing_surgery_who_are_exposed_to_dolasetron_or_granisetron_as_part_of_anesthetic_management_may_have_a_decreased_but_not_absent_risk_for_QTc_interval_prolongation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_QTc_interval_prolongation.""TG:Patients_with_the_TG_genotype_undergoing_surgery_who_are_exposed_to_dolasetron_or_granisetron_as_part_of_anesthetic_management_may_have_an_increased_risk_for_QTc_interval_prolongation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_QTc_interval_prolongation.""TT:Patients_with_the_TT_genotype_undergoing_surgery_who_are_exposed_to_dolasetron_or_granisetron_as_part_of_anesthetic_management_may_have_an_increased_risk_for_QTc_interval_prolongation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_QTc_interval_prolongation.","GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_QTc_prolongation_during_verapamil_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_QTc_prolongation_risk.""GT:While_patients_with_the_GG_genotype_may_have_an_increased_risk_for_QTc_prolongation_during_verapamil_treatment_as_compared_to_patients_with_the_TT_genotype_it_was_not_shown_conclusively_if_heterzygous_(GT)_individuals_are_affected._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_QTc_prolongation_risk.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_but_not_absent_risk_for_QTc_prolongation_during_verapamil_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_QTc_prolongation_risk.";PGKB_RACE=White,White
1	162237090	rs10800397	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NOS1AP_(PA142671259);PGKB_DRUG=amiodarone_(PA448383);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Long_QT_Syndrome_(PA444807);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation_when_treated_with_amiodarone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation_when_treated_with_amiodarone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation_when_treated_with_amiodarone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation.";PGKB_RACE=White
1	162244012	rs10919035	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NOS1AP_(PA142671259);PGKB_DRUG=amiodarone_(PA448383);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Long_QT_Syndrome_(PA444807);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation_when_treated_with_amiodarone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation_when_treated_with_amiodarone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation_when_treated_with_amiodarone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_ventricular_arrhythmia_and_QT_prolongation.";PGKB_RACE=White
1	163033691	rs951439	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=RGS4_(PA34375),RGS4_(PA34375);PGKB_DRUG=risperidone_(PA451257),"antipsychotics_(PA452233)""olanzapine_(PA450688)""perphenazine_(PA450882)""quetiapine_(PA451201)""ziprasidone_(PA451974)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_chance_of_response_to_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_chance_of_response_to_risperidone.""CT:Patients_with_the_CT_genotype_may_have_decreased_chance_of_response_to_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_chance_of_response_to_risperidone.""TT:Patients_with_the_TT_genotype_may_have_increased_chance_of_response_to_risperidone_as_compared_to_patients_with_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patients_chance_of_response_to_risperidone.","CC:Patients_with_the_CC_genotype_and_schizophrenia:_1)_may_have_increased_treatment_response_with_perphanzine_and_olanzapine_treatment_2)_may_have_decreased_treatment_response_with_quetiapine_and_ziprasidone_treatment._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_increased_treatment_response_with_olanzapine_as_compared_to_perphenazine._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_increased_treatment_response_with_quetiapine_and_ziprasidone_treatment._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics.";PGKB_RACE=White,Black_or_African_American
1	163039777	rs2661319	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=RGS4_(PA34375);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""CT:Patients_with_the_CT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_CC_genotype_or_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.";PGKB_RACE=Asian
1	163040495	rs2842030	G	T	.	.	PGKB_INDEX=2;PGKB_GENE=RGS4_(PA34375),RGS4_(PA34375);PGKB_DRUG="olanzapine_(PA450688)""perphenazine_(PA450882)",risperidone_(PA451257);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,4;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_schizophrenia_may_be_less_likely_to_have_improvement_in_symptoms_when_treated_with_olanzapine_and_perphanazine_rather_than_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_perphanazine.""GT:Patients_with_the_GT_genotype_and_schizophrenia_may_be_less_likely_to_have_improvement_in_symptoms_when_treated_with_olanzapine_and_perphanazine_rather_than_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_perphanazine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_be_more_likely_to_have_improvement_in_symptoms_when_treated_with_olanzapine_and_perphanazine_rather_than_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_perphanazine.","GG:Patients_with_the_GG_genotype_is_associated_with_better_response_to_risperidone_than_to_perphenazine_quetiapine_and_ziprasidone_treatment_in_people_with_schizophrenia_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Patients_with_the_GT_genotype_may_have_poorer_response_to_risperidone_than_to_perphenazine_quetiapine_and_ziprasidone_treatment_in_people_with_schizophrenia_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_poorer_response_to_risperidone_than_to_perphenazine_quetiapine_and_ziprasidone_treatment_in_people_with_schizophrenia_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=Black_or_African_American,White
1	163113260	rs1056515	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=RGS5_(PA34376);PGKB_DRUG="bevacizumab_(PA130232992)""fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_poorer_response_when_treated_with_FOLFIRI_and_bevacizumab_as_compared_to_patients_with_the_TT_genotype._However_this_result_only_applied_to_tumors_occurring_in_the_right_colon._Other_genetic_and_clinical_factors_may_also_influence_response_to_FOLFIRI_and_bevacizumab.""GT:Patients_with_the_GT_genotype_and_colorectal_cancer_may_have_a_poorer_response_when_treated_with_FOLFIRI_and_bevacizumab_as_compared_to_patients_with_the_TT_genotype._However_this_result_only_applied_to_tumors_occurring_in_the_right_colon._Other_genetic_and_clinical_factors_may_also_influence_response_to_FOLFIRI_and_bevacizumab.""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_a_better_response_when_treated_with_FOLFIRI_and_bevacizumab_as_compared_to_patients_with_the_GG_or_GT_genotype._However_this_result_only_applied_to_tumors_occurring_in_the_right_colon._Other_genetic_and_clinical_factors_may_also_influence_response_to_FOLFIRI_and_bevacizumab.";PGKB_RACE=NR
1	169519049	rs6025	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=F5_(PA159);PGKB_DRUG=hormonal_contraceptives_for_systemic_use_(PA452637);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=Thrombosis_(PA445850);PGKB_TEXT="CC:Patients_with_the_CC_genotype_(normal_Factor_V)_may_have_a_decreased_risk_of_experiencing_thrombosis_when_receiving_oral_contraceptives_as_compared_to_patients_with_the_CT_or_TT_genotype_(carriers_of_Factor_V_Leiden)._Both_Factor_V_Leiden_and_oral_contraceptives_have_been_found_to_independently_increase_the_risk_for_thrombosis_but_together_they_may_have_a_cumulative_effect_on_thrombosis_risk._Other_genetic_and_clinical_factors_may_also_influence_risk_of_thrombosis._""CT:Patients_with_the_CT_genotype_(heterozygote_for_Factor_V_Leiden)_may_have_an_increased_risk_of_experiencing_thrombosis_when_receiving_oral_contraceptives_as_compared_to_patients_with_the_CC_genotype_(normal_Factor_V)._Both_Factor_V_Leiden_and_oral_contraceptives_have_been_found_to_independently_increase_the_risk_for_thrombosis_but_together_they_may_have_a_cumulative_effect_on_thrombosis_risk._Other_genetic_and_clinical_factors_may_also_influence_risk_of_thrombosis._""TT:Patients_with_the_TT_genotype_(heterozygote_for_Factor_V_Leiden)_may_have_an_increased_risk_of_experiencing_thrombosis_when_receiving_oral_contraceptives_as_compared_to_patients_with_the_CC_genotype_(normal_Factor_V)._Both_Factor_V_Leiden_and_oral_contraceptives_have_been_found_to_independently_increase_the_risk_for_thrombosis_but_together_they_may_have_a_cumulative_effect_on_thrombosis_risk._Other_genetic_and_clinical_factors_may_also_influence_risk_of_thrombosis._";PGKB_RACE=NR
1	169700502	rs3917412	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SELE_(PA35640);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colonic_Neoplasms_(PA443756);PGKB_TEXT="CC:Patients_with_CC_genotype_and_Colonic_Neoplasms_may_have_decreased_response_to_capecitabine_leucovorin_oxaliplatin_or_fluorouracil_(FOLFOX_and_CAPOX)_as_compared_to_people_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_leucovorin_oxaliplatin_and_fluorouracil.""CT:Patients_with_CT_genotype_and_Colonic_Neoplasms_may_have_improved_response_to_capecitabine_leucovorin_oxaliplatin_or_fluorouracil_(FOLFOX_and_CAPOX)_as_compared_to_people_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_leucovorin_oxaliplatin_and_fluorouracil.""TT:Patients_with_TT_genotype_and_Colonic_Neoplasms_may_have_improved_response_to_capecitabine_leucovorin_oxaliplatin_or_fluorouracil_(FOLFOX_and_CAPOX)_as_compared_to_people_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_leucovorin_oxaliplatin_and_fluorouracil.";PGKB_RACE=NR
1	171076966	rs2266782	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=FMO3_(PA166);PGKB_DRUG=itopride_(PA152432599);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_metabolism_of_itopride_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_itopride._""AG:The_AG_genotype_has_not_been_evaluated._""GG:Patients_with_the_GG_genotype_may_have_increased_metabolism_of_itopride_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_itopride._";PGKB_RACE=Asian
1	171080080	rs1736557	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=FMO3_(PA166),FMO3_(PA166);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651),rosuvastatin_(PA134308647);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Neoplasms_(PA445062),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","AA:Patients_with_the_AA_genotype_who_are_treated_with_rosuvastatin_may_have_decreased_LDL-C_reduction_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_rosuvastatin_may_have_decreased_LDL-C_reduction_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_rosuvastatin_may_have_increased_LDL-C_reduction_as_compared_to_patients_with_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin.";PGKB_RACE=NR,Asian
1	171083242	rs2266780	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=FMO3_(PA166),FMO3_(PA166);PGKB_DRUG=olanzapine_(PA450688),itopride_(PA152432599);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_increased_dose-adjusted_serum_olanzapine_N-oxide_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.""AG:Patients_with_AG_genotype_may_have_increased_dose-adjusted_serum_olanzapine_N-oxide_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.""GG:Patients_with_GG_genotype_may_have_decreased_dose-adjusted_serum_olanzapine_N-oxide_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.","AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_itopride_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_itopride.""AG:The_AG_genotype_has_not_been_evaluated.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_metabolism_of_itopride_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_itopride.";PGKB_RACE=White,Asian
1	171217691	rs12720462	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=FMO1_(PA165);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_increased_dose-adjusted_serum_olanzapine_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.""AC:Patients_with_AC_genotype_may_have_increased_dose-adjusted_serum_olanzapine_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.""CC:Patients_with_CC_genotype_may_have_decreased_dose-adjusted_serum_olanzapine_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.";PGKB_RACE=White
1	171227216	rs10912675	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=FMO1_(PA165);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nicotine_dependence.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_TT_genotype_and_may_have_a_decreased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nicotine_dependence.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nicotine_dependence.";PGKB_RACE=White
1	171254890	rs7877	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=FMO1_(PA165),FMO1_(PA165);PGKB_DRUG=olanzapine_(PA450688),nicotine_(PA450626);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_CC_genotype_may_have_decreased_dose-adjusted_serum_olanzapine_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.""CT:Patients_with_CT_genotype_may_have_increased_dose-adjusted_serum_olanzapine_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.""TT:Patients_with_TT_genotype_may_have_increased_dose-adjusted_serum_olanzapine_concentrations_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_olanzapine_metabolism.","CC:Patients_with_the_CC_genotype_may_have_a_decreased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nicotine_dependence.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_CC_genotype_and_may_have_a_decreased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nicotine_dependence.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_for_nicotine_dependence_or_heavy_smoking_when_exposed_to_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nicotine_dependence.";PGKB_RACE=White,White
1	186643950	rs4648287	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=PTGS2_(PA293);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_genotype_AA_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""AG:Patients_with_genotype_AG_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_GG_genotype_and_an_increased_risk_of_hypercholesteremia_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""GG:Patients_with_genotype_GG_and_hypertension_may_have_an_increased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=Black_or_African_American
1	186650321	rs20417	C	G	.	.	PGKB_INDEX=3;PGKB_GENE=PTGS2_(PA293),PTGS2_(PA293),PTGS2_(PA293);PGKB_DRUG=rofecoxib_(PA451268),ibuprofen_(PA449957),aspirin_(PA448497);PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=NR,NR,Coronary_Artery_Disease_(PA443796);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_better_pain_relief_response_to_rofecoxib_as_compared_to_patients_with_GG_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rofecoxib.""CG:Patients_with_the_CG_genotype_may_have_poorer_pain_relief_response_to_rofecoxib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rofecoxib.""GG:Patients_with_the_GG_genotype_may_have_poorer_pain_relief_response_to_rofecoxib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rofecoxib.","CC:Patients_with_the_CC_genotype_may_have_decreased_pain_relief_to_ibuprofen_as_compared_to_patients_with_GG_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ibuprofen.""CG:Patients_with_the_CG_genotype_may_have_increased_pain_relief_when_treated_with_ibuprofen_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ibuprofen.""GG:Patients_with_the_GG_genotype_may_have_increased_pain_relief_when_treated_with_ibuprofen_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ibuprofen.","CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Coronary_Disease_when_treated_with_aspirin_as_compared_to_patients_with_the_GG_or_CG_genotype._However_Allele_G_may_be_associated_with_increased_risk_of_Coronary_Disease_in_people_not_taking_aspirin_as_compared_to_allele_C._Other_genetic_and_clinical_factors_may_influence_patient's_response_to_aspirin.""CG:Patients_with_the_CG_genotype_may_have_decreased_risk_of_Coronary_Disease_when_treated_with_aspirin_as_compared_to_patients_with_the_CC_genotype._However_Allele_G_may_be_associated_with_increased_risk_of_Coronary_Disease_in_people_not_taking_aspirin_as_compared_to_allele_C._Other_genetic_and_clinical_factors_may_influence_patient's_response_to_aspirin.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Coronary_Disease_when_treated_with_aspirin_as_compared_to_patients_with_the_CC_genotype._However_Allele_G_may_be_associated_with_increased_risk_of_Coronary_Disease_in_people_not_taking_aspirin_as_compared_to_allele_C._Other_genetic_and_clinical_factors_may_influence_patient's_response_to_aspirin.";PGKB_RACE=White,NR,White
1	186849186	rs12746200	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=PLA2G4A_(PA271);PGKB_DRUG="acetaminophen_(PA448015)""aspirin_(PA448497)""diclofenac_(PA449293)""propionic_acid_derivatives_(PA451140)""Pyrazolones_(PA164713217)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_a_decreased_but_not_absent_risk_of_urticaria_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.""AG:Patients_with_the_AG_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_an_increased_risk_of_urticaria_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.""GG:Patients_with_the_GG_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_an_increased_risk_of_urticaria_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.";PGKB_RACE=NR
1	186947224	rs10157410	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=PLA2G4A_(PA271);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_an_increased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_CG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""CG:Patients_with_the_CG_genotype_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_CC_genotype_and_an_increased_risk_of_hypercholesteremia_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_CG_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=White
1	192781172	rs4606	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=RGS2_(PA34372);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_antipsychotics_with_may_have_an_increased_risk_for_antipsychotic-induced_parkinsonism_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_antipsychotic-induced_parkinsonism.""GC:Patients_with_the_GC_genotype_and_Schizophrenia_who_are_treated_antipsychotics_with_may_have_a_decreased_but_not_absent_risk_for_antipsychotic-induced_parkinsonism_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_antipsychotic-induced_parkinsonism.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_who_are_treated_antipsychotics_with_may_have_a_decreased_but_not_absent_risk_for_antipsychotic-induced_parkinsonism_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_antipsychotic-induced_parkinsonism.";PGKB_RACE=NR
1	196154898	rs1886629	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=KCNT2_(PA38726);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_Bisphosphonates.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_Bisphosphonates.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_Bisphosphonates.";PGKB_RACE=White
1	196659237	rs1061170	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CFH_(PA29261),CFH_(PA29261);PGKB_DRUG=bevacizumab_(PA130232992),"bevacizumab_(PA130232992)""ranibizumab_(PA164746012)";PGKB_TYPE=Dosage,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Macular_Degeneration_(PA134850558),Macular_Degeneration_(PA134850558);PGKB_TEXT="CC:No_patients_with_the_CC_genotype_available_for_analysis.""CT:Patients_with_the_CT_genotype_and_age-related_macular_degeneration_may_require_a_greater_number_of_bevacizumab_injections_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_number_of_injections_of_bevacizumab.""TT:Patients_with_the_TT_genotype_and_age-related_macular_degeneration_may_require_a_fewer_number_of_bevacizumab_injections_as_compared_to_those_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_number_of_injections_of_bevacizumab.","CC:Patients_with_the_CC_genotype_and_macular_degeneration_may_have_a_poorer_improvement_in_visual_acuity_when_treated_with_ranibizumab_or_bevacizumab_as_compared_to_patients_with_the_CT_or_TT_genotype._However_some_studies_have_found_no_association_with_response_to_ranibizumab_or_bevacizumab._Other_genetic_and_clinical_factors_may_also_influence_response_to_ranibizumab_or_bevacizumab.""CT:Patients_with_the_CT_genotype_and_macular_degeneration_may_have_a_greater_improvement_in_visual_acuity_when_treated_with_ranibizumab_or_bevacizumab_as_compared_to_patients_with_the_CC_genotype._However_some_studies_have_found_no_association_with_response_to_ranibizumab_or_bevacizumab._Other_genetic_and_clinical_factors_may_also_influence_response_to_ranibizumab_or_bevacizumab.""TT:Patients_with_the_TT_genotype_and_macular_degeneration_may_have_a_greater_improvement_in_visual_acuity_when_treated_with_ranibizumab_or_bevacizumab_as_compared_to_patients_with_the_CC_genotype._However_some_studies_have_found_no_association_with_response_to_ranibizumab_or_bevacizumab._Other_genetic_and_clinical_factors_may_also_influence_response_to_ranibizumab_or_bevacizumab.";PGKB_RACE=Asian,NR
1	198700442	rs10919563	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PTPRC_(PA34011);PGKB_DRUG="adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)""Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_adalimumab_etanercept_or_infliximab_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_GG_or_AG._However_contradictory_evidence_has_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-TNF_biologics.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_adalimumab_etanercept_or_infliximab_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_AA._However_contradictory_evidence_has_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-TNF_biologics.""GG:Patients_with_the_GG_genotype_may_have_increased_response_to_adalimumab_etanercept_or_infliximab_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_AA._However_contradictory_evidence_has_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-TNF_biologics.";PGKB_RACE=NR
1	201029943	rs1800559	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1S_(PA85);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CT._Please_note:_this_clinical_annotation_is_based_on_two_case_studies_and_there_were_no_individuals_who_were_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Please_note:_this_clinical_annotation_is_based_on_two_case_studies_and_there_were_no_individuals_who_were_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.";PGKB_RACE=NR
1	203098275	rs2228079	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADORA1_(PA24583);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""GT:Patients_with_the_GT_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.";PGKB_RACE=Asian
1	203135452	rs16851030	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="ADORA1_(PA24583)""MYBPH_(PA31352)";PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""CT:Patients_with_the_CT_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.";PGKB_RACE=Asian
1	204124865	rs2368564	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=REN_(PA297);PGKB_DRUG=muraglitazar_(PA162356187);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Diabetes_Mellitus_(PA443886)""Edema_(PA443994)""Hyperlipidemias_(PA444528)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Diabetes_Mellitus_who_are_treated_with_muraglitazar_may_have_an_increased_risk_of_edema_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_edema_when_treated_with_muraglitazar.""CT:No_conclusive_results_were_found_for_patients_with_the_CT_genotype._But_patients_with_the_TT_genotype_and_Diabetes_Mellitus_who_are_treated_with_muraglitazar_may_have_a_decreased_but_not_absent_risk_of_edema_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_edema_when_treated_with_muraglitazar.""TT:Patients_with_the_TT_genotype_and_Diabetes_Mellitus_who_are_treated_with_muraglitazar_may_have_a_decreased_but_not_absent_risk_of_edema_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_edema_when_treated_with_muraglitazar.";PGKB_RACE=NR
1	204516577	rs1563828	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=MDM4_(PA30719);PGKB_DRUG="docetaxel_(PA449383)""epirubicin_(PA449476)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_a_better_response_when_treated_with_docetaxel_and_epirubicin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_docetaxel_and_epirubicin_treatment.""AG:Patients_with_the_AG_genotype_and_breast_cancer_may_have_a_poorer_response_when_treated_with_docetaxel_and_epirubicin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_docetaxel_and_epirubicin_treatment.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_poorer_response_when_treated_with_docetaxel_and_epirubicin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_docetaxel_and_epirubicin_treatment.";PGKB_RACE=NR
1	206946407	rs1800872	T	G	.	.	PGKB_INDEX=2;PGKB_GENE=IL10_(PA29778),IL10_(PA29778);PGKB_DRUG="cyclosporine_(PA449167)""mycophenolate_mofetil_(PA450566)",tacrolimus_(PA451578);PGKB_TYPE=Efficacy,Dosage;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),liver_transplantation_(PA447247);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Kidney_Transplantation_may_have_a_decreased_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection.""GT:Patients_with_the_TG_genotype_and_Kidney_Transplantation_may_have_a_decreased_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection.""TT:Patients_with_the_TT_genotype_and_Kidney_Transplantation_may_have_an_increased_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection.","GG:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_GG_genotype_and_who_are_also_homozygous_for_CYP3A5*3_may_require_increased_doses_of_tacrolimus_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus.""GT:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_GT_genotype_and_who_are_also_homozygous_for_CYP3A5*3_may_require_increased_doses_of_tacrolimus_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus.""TT:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_TT_genotype_and_who_are_also_homozygous_for_CYP3A5*3_may_require_decreased_doses_of_tacrolimus_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus.";PGKB_RACE=White,Asian
1	206946634	rs1800871	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=IL10_(PA29778),IL10_(PA29778);PGKB_DRUG=tacrolimus_(PA451578),tacrolimus_(PA451578);PGKB_TYPE=Dosage,"Dosage""Efficacy";PGKB_EVIDENCE=3,3;PGKB_DISEASE=liver_transplantation_(PA447247),Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_AA_genotype_and_who_are_also_homozygous_for_CYP3A5*3_may_require_decreased_doses_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus.""AG:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_AG_genotype_and_who_are_also_homozygous_for_CYP3A5*3_may_require_increased_doses_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus.""GG:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_GG_genotype_and_who_are_also_homozygous_for_CYP3A5*3_may_require_increased_doses_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus.","AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_a_greater_chance_of_achieving_target_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_a_patient_achieving_target_concentrations_of_tacrolimus.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_may_have_a_lower_chance_of_achieving_target_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_a_patient_achieving_target_concentrations_of_tacrolimus.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_may_have_a_lower_chance_of_achieving_target_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_a_patient_achieving_target_concentrations_of_tacrolimus.";PGKB_RACE=Asian,Asian
1	206946897	rs1800896	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=IL10_(PA29778),IL10_(PA29778);PGKB_DRUG=efavirenz_(PA449441),tacrolimus_(PA451578);PGKB_TYPE=Toxicity/ADR,Dosage;PGKB_EVIDENCE=3,3;PGKB_DISEASE=HIV_Infections_(PA446213),liver_transplantation_(PA447247);PGKB_TEXT="CC:Patients_with_genotype_CC_may_have_decreased_likelihood_of_Drug_Hypersensitivity_when_treated_with_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_efavirenz.""CT:Patients_with_genotype_CT_may_have_decreased_likelihood_of_Drug_Hypersensitivity_when_treated_with_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_efavirenz.""TT:Patients_with_genotype_TT_may_have_increased_likelihood_of_Drug_Hypersensitivity_when_treated_with_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_efavirenz.","CC:No_patients_with_the_CC_genotype_were_present_in_the_population._However_patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_CT_genotype_may_require_an_increased_dose_of_tacrolimus_as_compared_to_patients_who_receive_a_donor_liver_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus._""CT:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_CT_genotype_may_require_an_increased_dose_of_tacrolimus_as_compared_to_patients_who_receive_a_donor_liver_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus._""TT:Patients_undergoing_liver_transplantation_who_receive_a_donor_liver_with_the_TT_genotype_may_require_a_decreased_dose_of_tacrolimus_as_compared_to_patients_who_receive_a_donor_liver_with_the_CT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_dose_of_tacrolimus._";PGKB_RACE=NR,Asian
1	207753621	rs2274567	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CR1_(PA26855);PGKB_DRUG=eculizumab_(PA164776637);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=paroxysmal_nocturnal_hemoglobinuria_(PA166122772);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_paroxysmal_nocturnal_hemoglobinuria_may_have_a_better_response_to_treatment_with_eculizumab_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_eculizumab.""AG:Patients_with_the_AG_genotype_and_paroxysmal_nocturnal_hemoglobinuria_may_have_a_poorer_response_to_treatment_with_eculizumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_eculizumab.""GG:Patients_with_the_GG_genotype_and_paroxysmal_nocturnal_hemoglobinuria_may_have_a_poorer_response_to_treatment_with_eculizumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_eculizumab.";PGKB_RACE=NR
1	209858453	rs846908	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HSD11B1_(PA29476);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_lower_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.";PGKB_RACE=Asian
1	209870916	rs4844880	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=HSD11B1_(PA29476);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_lower_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AT_or_TT_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.""AT:Patients_with_the_AT_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.""TT:Patients_with_the_TT_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.";PGKB_RACE=Asian
1	209875254	rs846910	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HSD11B1_(PA29476);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_lower_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._However_this_was_only_significant_in_patients_who_were_CYP3A5_expressers_(CYP3A5_*1/*1_or_*1/*3)._Other_genetic_and_clinical_factors_such_as_CYP3A5_variants_may_also_influence_concentrations_of_tacrolimus.";PGKB_RACE=Asian
1	226013355	rs1877724	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=EPHX1_(PA27829);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""CT:Patients_with_the_CT_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.";PGKB_RACE=Asian
1	226019633	rs1051740	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=EPHX1_(PA27829),EPHX1_(PA27829),EPHX1_(PA27829);PGKB_DRUG=carbamazepine_(PA448785),phenytoin_(PA450947),"cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Dosage,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2B,3,3;PGKB_DISEASE=Epilepsy_(PA444065),"Congenital_Abnormalities_(PA443223)""Craniofacial_Abnormalities_(PA446836)",Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_may_have_an_increased_dose_of_carbamazepine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""CT:Patients_with_the_CT_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_may_have_an_increased_dose_of_carbamazepine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""TT:Patients_with_the_TT_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_may_have_a_decreased_dose_of_carbamazepine_as_compared_to_patients_with_the_CT_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.","CC:Patients_with_the_CC_genotype_who_use_phenytoin_during_the_first_trimester_of_pregnancy_may_be_less_likely_to_have_a_child_with_a_craniofacial_abnormality_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_having_a_child_with_a_craniofacial_abnormality.""CT:Patients_with_the_CT_genotype_who_use_phenytoin_during_the_first_trimester_of_pregnancy_may_be_more_likely_to_have_a_child_with_a_craniofacial_abnormality_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""TT:Patients_with_the_TT_genotype_who_use_phenytoin_during_the_first_trimester_of_pregnancy_may_be_more_likely_to_have_a_child_with_a_craniofacial_abnormality_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.","CC:Patients_with_the_CC_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_similar_risk_of_grade_1-4_nephrotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_grade_1-4_nephrotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_reduced_but_not_absent_risk_of_grade_1-4_nephrotoxicity_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._";PGKB_RACE=NR,NR,NR
1	226019653	rs1131873	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=EPHX1_(PA27829);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_a_lower_dose_of_warfarin_than_patients_with_the_GG_genotype_however_there_have_been_conflicting_results_regarding_the_association_of_this_SNP_with_warfarin_dose._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose_requirements.""AG:Patients_with_the_AG_genotype_may_require_a_lower_dose_of_warfarin_than_patients_with_the_GG_genotype_however_there_have_been_conflicting_results_regarding_the_association_of_this_SNP_with_warfarin_dose._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose_requirements.""GG:Patients_with_the_GG_genotype_may_require_a_higher_dose_of_warfarin_than_patients_with_the_AA_or_AG_genotype_however_there_have_been_conflicting_results_regarding_the_association_of_this_SNP_with_warfarin_dose._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose_requirements.";PGKB_RACE=White
1	226026406	rs2234922	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=EPHX1_(PA27829),EPHX1_(PA27829),EPHX1_(PA27829);PGKB_DRUG=phenytoin_(PA450947),docetaxel_(PA449383),carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR,Dosage,Dosage;PGKB_EVIDENCE=3,4,2B;PGKB_DISEASE="Congenital_Abnormalities_(PA443223)""Craniofacial_Abnormalities_(PA446836)",Carcinoma_Non-Small-Cell_Lung_(PA443622),Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_exposed_to_phenytoin_during_the_first_trimester_of_pregnancy_may_have_a_decreased_but_not_absent_risk_for_having_a_child_with_a_craniofacial_abnormality_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_person's_risk_for_having_a_child_with_a_craniofacial_abnormality_after_phenytoin_exposure.""AG:Patients_with_the_AG_genotype_who_are_exposed_to_phenytoin_during_the_first_trimester_of_pregnancy_may_have_an_increased_risk_for_having_a_child_with_a_craniofacial_abnormality_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_who_are_exposed_to_phenytoin_during_the_first_trimester_of_pregnancy_may_have_an_increased_risk_for_having_a_child_with_a_craniofacial_abnormality_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","AA:Patients_with_the_AA_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""AG:Patients_with_the_AG_genotype_may_have_decreased_clearance_of_docetaxel_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""GG:Patients_with_the_GG_genotype_may_have_decreased_clearance_of_docetaxel_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.","AA:Patients_with_the_AA_genotype_may_require_a_decreased_dose_of_carbamazepine_as_compared_to_patients_with_the_AG_or_GG_genotype_although_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_dose_of_carbamazepine.""AG:Patients_with_the_AG_genotype_may_require_an_increased_dose_of_carbamazepine_as_compared_to_patients_with_the_AA_genotype_although_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_dose_of_carbamazepine.""GG:Patients_with_the_GG_genotype_may_require_an_increased_dose_of_carbamazepine_as_compared_to_patients_with_the_AA_genotype_although_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_dose_of_carbamazepine.";PGKB_RACE=NR,White,NR
1	230263844	rs2144297	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GALNT2_(PA28537);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_genotype_CC_and_hypertension_may_have_a_smaller_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_genotype_CT_and_TT._Other_clinical_and_genetic_factors_may_also_influence_changes_in_HDL-C_upon_administration_of_atenolol_in_patients_with_hypertension._""CT:Patients_with_genotype_CT_and_hypertension_may_have_a_greater_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_genotype_CC._Other_clinical_and_genetic_factors_may_also_influence_changes_in_HDL-C_upon_administration_of_atenolol_in_patients_with_hypertension._""TT:Patients_with_genotype_TT_and_hypertension_may_have_a_greater_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_genotype_CC_and_CT._Other_clinical_and_genetic_factors_may_also_influence_changes_in_HDL-C_upon_administration_of_atenolol_in_patients_with_hypertension._";PGKB_RACE=Black_or_African_American
1	230294916	rs2144300	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=GALNT2_(PA28537);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_a_greater_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_the_TT_and_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_changes_in_HDL-C_upon_administration_of_atenolol_in_patients_with_hypertension.""CT:Patients_with_the_CT_genotype_and_hypertension_may_have_a_greater_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_changes_in_HDL-C_upon_administration_of_atenolol_in_patients_with_hypertension.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_a_smaller_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_the_CC_and_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_changes_in_HDL-C_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=Black_or_African_American
1	230837044	rs943580	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=AGT_(PA42);PGKB_DRUG=Antiinflammatory_agents_non-steroids_(PA164712462);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acute_coronary_syndrome_(PA165108401);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_acute_coronary_syndrome_when_exposed_to_NSAIDs_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_risk_of_adverse_events_when_taking_NSAIDs.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_acute_coronary_syndrome_when_exposed_to_NSAIDs_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_risk_of_adverse_events_when_taking_NSAIDs.""GG:Patients_with_the_GG_genotype_may_have_decreased_but_not_non-existent_risk_of_acute_coronary_syndrome_when_exposed_to_NSAIDs_as_compared_to_patients_with_the_AA_or_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patients_risk_of_adverse_events_when_taking_NSAIDs.";PGKB_RACE=NR
1	230838331	rs7079	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=AGT_(PA42);PGKB_DRUG=benazepril_(PA448561);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_hypertension_may_have_smaller_decreases_in_systolic_and_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_change_in_systolic_and_diastrolic_blood_pressure.""GT:Patients_with_the_GT_genotype_and_hypertension_may_have_smaller_decreases_in_systolic_and_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_change_in_systolic_and_diastrolic_blood_pressure.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_greater_decreases_in_systolic_and_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_change_in_systolic_and_diastolic_blood_pressure.";PGKB_RACE=Asian
1	230845794	rs699	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=AGT_(PA42),AGT_(PA42),AGT_(PA42);PGKB_DRUG=irbesartan_(PA450084),atenolol_(PA448499),Antiinflammatory_agents_non-steroids_(PA164712462);PGKB_TYPE=Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE="Hypertension_(PA444552)""Hypertrophy_Left_Ventricular_(PA446479)","Hypertension_(PA444552)""Hypertrophy_Left_Ventricular_(PA446479)",NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_have_hypertension_and_left_ventricular_hypertrophy_may_have_a_smaller_decrease_in_left_ventricular_mass_when_treated_with_irbesartan_as_compared_to_patients_with_the_GG_genotype._However_no_significant_association_has_been_seen_between_this_genotype_and_change_in_diastolic_or_systolic_pressure_for_patients_on_irbesartan._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irbesartan_treatment.""AG:Patients_with_the_AG_genotype_who_have_hypertension_and_left_ventricular_hypertrophy_may_have_a_smaller_decrease_in_left_ventricular_mass_when_treated_with_irbesartan_as_compared_to_patients_with_the_GG_genotype._However_no_significant_association_has_been_seen_between_this_genotype_and_change_in_diastolic_or_systolic_pressure_for_patients_on_irbesartan._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irbesartan_treatment.""GG:Patients_with_the_GG_genotype_who_have_hypertension_and_left_ventricular_hypertrophy_may_have_a_greater_decrease_in_left_ventricular_mass_when_treated_with_irbesartan_as_compared_to_patients_with_the_AA_or_AG_genotype._However_no_significant_association_has_been_seen_between_this_genotype_and_change_in_diastolic_or_systolic_pressure_for_patients_on_irbesartan._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irbesartan_treatment.","AA:Patients_with_the_AA_genotype_who_have_hypertension_and_left_ventricular_hypertrophy_may_have_a_smaller_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_patients_with_the_AG_or_GG_genotype._However_no_significant_results_have_been_seen_for_change_in_diastolic_blood_pressure._Additionally_a_different_study_found_no_association_with_change_in_systolic_or_diastolic_blood_pressure_for_this_genotype._Other_genetic_and_clinical_factors_may_also_influence_change_in_blood_pressure.""AG:Patients_with_the_AG_genotype_who_have_hypertension_and_left_ventricular_hypertrophy_may_have_a_greater_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_patients_with_the_AA_genotype._However_no_significant_results_were_seen_for_change_in_diastolic_blood_pressure._Additionally_a_different_study_found_no_association_with_change_in_systolic_or_diastolic_pressure_for_this_genotype._Other_genetic_and_clinical_factors_may_also_influence_change_in_blood_pressure.""GG:Patients_with_the_GG_genotype_who_have_hypertension_and_left_ventricular_hypertrophy_may_have_a_greater_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_patients_with_the_AA_genotype._However_no_significant_results_were_seen_for_change_in_diastolic_blood_pressure._Additionally_a_different_study_found_no_association_with_change_in_systolic_or_diastolic_pressure_for_this_genotype._Other_genetic_and_clinical_factors_may_also_influence_change_in_blood_pressure.","AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_(NSAIDs)_in_people_with_Acute_coronary_syndrome_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_NSAIDs.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_(NSAIDs)_in_people_with_Acute_coronary_syndrome_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_NSAIDs.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_(NSAIDs)_in_people_with_Acute_coronary_syndrome_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_NSAIDs.";PGKB_RACE=White,White,NR
1	230846679	rs11122576	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=AGT_(PA42),AGT_(PA42);PGKB_DRUG="amlodipine_(PA448388)""chlorthalidone_(PA448970)""lisinopril_(PA450242)","amlodipine_(PA448388)""chlorthalidone_(PA448970)""lisinopril_(PA450242)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=4,4;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_for_Coronary_Disease_when_treated_with_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_CC_genotype_who_are_treated_with_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_for_Coronary_Disease.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_for_Coronary_Disease_when_treated_with_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_CT_genotype_who_are_treated_with_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_for_Coronary_Disease.""TT:No_information_were_reported_regarding_patients_with_the_TT_genotype.","CC:Patients_with_the_CC_genotype_may_have_a_decreased_but_not_absent_risk_for_Coronary_Disease_when_treated_with_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_CC_genotype_who_are_treated_with_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_for_Coronary_Disease.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_but_not_absent_risk_for_Coronary_Disease_when_treated_with_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_CT_genotype_who_are_treated_with_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_for_Coronary_Disease.""TT:No_information_were_reported_regarding_patients_with_the_TT_genotype.";PGKB_RACE=Black_or_African_American,White
1	230849872	rs5051	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=AGT_(PA42),AGT_(PA42);PGKB_DRUG=atenolol_(PA448499),"benazepril_(PA448561)""imidapril_(PA452640)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Hypertension_(PA444552),Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_a_smaller_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_patients_with_the_CT_or_TT_genotype._No_significant_change_in_diastolic_blood_pressure_was_seen_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_change_in_systolic_blood_pressure.""CT:Patients_with_the_CT_genotype_and_hypertension_may_have_a_greater_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_patients_with_the_CC_genotype._No_significant_change_in_diastolic_blood_pressure_was_seen_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_change_in_systolic_blood_pressure.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_a_greater_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_patients_with_the_CC_genotype._No_significant_change_in_diastolic_blood_pressure_was_seen_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_change_in_systolic_blood_pressure.","CC:Patients_with_the_CC_genotype_and_hypertension_may_have_a_better_response_to_treatment_with_benazepril_or_imidapril_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril_or_imidapril.""CT:Patients_with_the_CT_genotype_and_hypertension_may_have_a_poorer_response_to_treatment_with_benazepril_or_imidapril_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril_or_imidapril.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_a_poorer_response_to_treatment_with_benazepril_or_imidapril_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril_or_imidapril.";PGKB_RACE=NR,Asian
1	230849886	rs5050	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=AGT_(PA42);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_who_are_treated_with_aspirin_may_have_increased_risk_for_Peptic_Ulcer_Hemorrhage_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""GT:Patients_with_the_GT_genotype_who_are_treated_with_aspirin_may_have_decreased_but_not_absent_risk_for_Peptic_Ulcer_Hemorrhage_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_aspirin_may_have_decreased_but_not_absent_risk_for_Peptic_Ulcer_Hemorrhage_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
1	237028564	rs3768142	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=MTR_(PA31272);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Agranulocytosis_(PA443297);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_may_have_an_increased_risk_of_granulocytopenia_when_treated_with_methotrexate_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_agranulocytosis.""GT:Patients_with_the_GT_genotype_and_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_of_granulocytopenia_when_treated_with_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_agranulocytosis.""TT:Patients_with_the_TT_genotype_and_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_of_granulocytopenia_when_treated_with_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_agranulocytosis.";PGKB_RACE=White
1	237048500	rs1805087	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=MTR_(PA31272),MTR_(PA31272),MTR_(PA31272);PGKB_DRUG=benazepril_(PA448561),"cisplatin_(PA449014)""cyclophosphamide_(PA449165)""dactinomycin_(PA151917012)""doxorubicin_(PA449412)""methotrexate_(PA450428)""vincristine_(PA451879)",methotrexate_(PA450428);PGKB_TYPE=Efficacy,Toxicity/ADR,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Essential_hypertension_(PA447288),Osteosarcoma_(PA445601),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AG_or_GG_genotype._No_significant_differences_in_change_in_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_decrease_in_diastolic_blood_pressure.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AA_genotype._No_significant_differences_in_change_in_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_decrease_in_diastolic_blood_pressure.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AA_genotype._No_significant_differences_in_change_in_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_decrease_in_diastolic_blood_pressure.","AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cisplatin_cyclophosphamide_dactinomycin_doxorubicin_methotrexate_and_vincristine_in_people_with_Osteosarcoma_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_cisplatin_cyclophosphamide_dactinomycin_doxorubicin_methotrexate_and_vincristine.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cisplatin_cyclophosphamide_dactinomycin_doxorubicin_methotrexate_and_vincristine_in_people_with_Osteosarcoma_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_cisplatin_cyclophosphamide_dactinomycin_doxorubicin_methotrexate_and_vincristine.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_cisplatin_cyclophosphamide_dactinomycin_doxorubicin_methotrexate_and_vincristine_in_people_with_Osteosarcoma_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_cisplatin_cyclophosphamide_dactinomycin_doxorubicin_methotrexate_and_vincristine.","AA:Patients_with_the_AA_genotype_may_have:_1)_decreased_likelihood_of_Drug_Toxicity_2)_increased_response_when_treated_with_methotrexate_as_compared_to_patients_with_genotypes_GG._However_contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_may_have:_1)_decreased_likelihood_of_Drug_Toxicity_2)_increased_response_when_treated_with_methotrexate_as_compared_to_patients_with_genotypes_GG._However_contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_may_have:_1)_increased_likelihood_of_Drug_Toxicity_2)_decreased_response_when_treated_with_methotrexate_as_compared_to_patients_with_genotypes_AA_or_AG._However_contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian,NR,NR
1	237990122	rs2819742	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=RYR2_(PA300);PGKB_DRUG=cerivastatin_(PA448897);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Rhabdomyolysis_(PA445549);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_reduced_risk_of_cerivastatin-associated_rhabdomyolysis_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity._""AG:Patients_with_the_AG_genotype_may_have_a_reduced_risk_of_cerivastatin-associated_rhabdomyolysis_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity._""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_of_cerivastatin-associated_rhabdomyolysis_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity._";PGKB_RACE=NR
1	242042301	rs1047840	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=EXO1_(PA27923);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="AA:Patients_with_metastasized_cancer_and_the_AA_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil.""AG:Patients_with_metastasized_cancer_and_the_AG_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GG_genotype_and_worse_response_as_compared_to_people_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil.""GG:Patients_with_metastasized_cancer_and_the_GG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil.";PGKB_RACE=Asian
2	10262920	rs1130609	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=RRM2_(PA299);PGKB_DRUG="cladribine_(PA449027)""cytarabine_(PA449177)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_better_overall_survival_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""GT:Patients_with_the_GT_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_poorer_overall_survival_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""TT:Patients_with_the_TT_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_poorer_overall_survival_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._";PGKB_RACE=Black_or_African_American
2	10263874	rs5030743	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=RRM2_(PA299);PGKB_DRUG="cladribine_(PA449027)""cytarabine_(PA449177)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_a_better_overall_survival_as_compared_to_patients_with_the_GG_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""CG:Patients_with_the_CG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_a_poorer_overall_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""GG:Patients_with_the_GG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_a_poorer_overall_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._";PGKB_RACE=NR
2	11890428	rs10192566	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=LPIN1_(PA30436);PGKB_DRUG=rosiglitazone_(PA451283);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_type_2_diabetes_who_are_treated_with_rosiglitazone_may_have_the_smallest_decrease_in_fasting_plasma_glucose_2-hour_postprandial_glucose_and_HbA1c_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosiglitazone.""CG:Patients_with_the_CG_genotype_and_type_2_diabetes_who_are_treated_with_rosiglitazone_may_have_a_decrease_in_fasting_plasma_glucose_2-hour_postprandial_glucose_and_HbA1c_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosiglitazone.""GG:Patients_with_the_GG_genotype_and_type_2_diabetes_who_are_treated_with_rosiglitazone_may_have_the_largest_decrease_in_fasting_plasma_glucose_2-hour_postprandial_glucose_and_HbA1c_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosiglitazone.";PGKB_RACE=Asian
2	21228827	rs1801701	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=APOB_(PA50);PGKB_DRUG=irbesartan_(PA450084);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertrophy_Left_Ventricular_(PA446479);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_left_ventricular_hypertrophy_may_have_an_increased_response_when_treated_with_irbesartan_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_irbesartan.""CT:Patients_with_the_CT_genotype_and_left_ventricular_hypertrophy_may_have_a_decreased_response_when_treated_with_irbesartan_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_irbesartan.""TT:Patients_with_the_TT_genotype_and_left_ventricular_hypertrophy_may_have_a_decreased_response_when_treated_with_irbesartan_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_irbesartan.";PGKB_RACE=NR
2	21263900	rs1367117	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=APOB_(PA50);PGKB_DRUG=irbesartan_(PA450084);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_irbesartan_may_be_less_likely_to_respond_than_patients_with_the_AG_or_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_who_are_treated_with_irbesartan_may_be_more_likely_to_respond_than_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_who_are_treated_with_irbesartan_may_be_more_likely_to_respond_than_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
2	31247514	rs9679162	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=GALNT14_(PA134920089);PGKB_DRUG="cisplatin_(PA449014)""fluorouracil_(PA128406956)""mitoxantrone_(PA450526)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Hepatocellular_(PA444447)""Neoplasms_(PA445062)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_response_including_decreased_survival_when_treated_with_cisplatin_fluorouracil_and_mitoxantrone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""GT:Patients_with_the_GT_genotype_may_have_decreased_response_including_decreased_survival_when_treated_with_cisplatin_fluorouracil_and_mitoxantrone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TT:Patients_with_the_TT_genotype_may_have_increased_response_including_increased_survival_when_treated_with_cisplatin_fluorouracil_and_mitoxantrone_as_compared_to_patients_with_the_GT_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.";PGKB_RACE=NR
2	31249427	rs12613732	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=GALNT14_(PA134920089);PGKB_DRUG="cisplatin_(PA449014)""fluorouracil_(PA128406956)""mitoxantrone_(PA450526)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Hepatocellular_(PA444447);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_hepatocellular_carcinoma_who_are_treated_with_cisplatin_fluorouracil_and_mitoxantrone_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GT:Patients_with_the_GT_genotype_and_hepatocellular_carcinoma_who_are_treated_with_cisplatin_fluorouracil_and_mitoxantrone_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_TT_genotype_or_may_be_less_likely_to_respond_to_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""TT:Patients_with_the_TT_genotype_and_hepatocellular_carcinoma_who_are_treated_with_cisplatin_fluorouracil_and_mitoxantrone_may_be_less_likely_to_respond_to_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._";PGKB_RACE=NR
2	31578969	rs1594160	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=XDH_(PA37404);PGKB_DRUG=didanosine_(PA449301);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_may_have_an_increased_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""AC:Patients_with_the_AC_genotype_and_HIV_may_have_a_reduced_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_reduced_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.";PGKB_RACE=NR
2	31588561	rs1429376	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=XDH_(PA37404);PGKB_DRUG=didanosine_(PA449301);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_may_have_an_increased_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""AC:Patients_with_the_AC_genotype_and_HIV_may_have_a_reduced_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_reduced_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.";PGKB_RACE=NR
2	38298203	rs1056836	C	G	.	.	PGKB_INDEX=3;PGKB_GENE=NR,CYP1B1_(PA27094),CYP1B1_(PA27094);PGKB_DRUG="docetaxel_(PA449383)""paclitaxel_(PA450761)","cyclophosphamide_(PA449165)""epirubicin_(PA449476)""paclitaxel_(PA450761)","cyclophosphamide_(PA449165)""epirubicin_(PA449476)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=2B,3,3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Prostatic_Neoplasms_(PA445425)",Breast_Neoplasms_(PA443560),Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_prostate_or_breast_cancer_and_the_CC_genotype_may_have_an_improved_response_to_taxanes_as_compared_to_patients_with_the_GG_genotype_however_one_study_has_found_no_association_between_disease_free_survival_and_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_taxanes.""CG:Patients_with_prostate_or_breast_cancer_and_the_CG_genotype_may_have_a_worse_response_to_taxanes_as_compared_to_patients_with_the_CC_genotype_however_one_study_has_found_no_association_between_disease_free_survival_and_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_taxanes.""GG:Patients_with_prostate_or_breast_cancer_and_the_GG_genotype_may_have_worse_response_to_taxanes_as_compared_to_patients_with_the_CG_or_CC_genotype_however_one_study_has_found_no_association_between_disease_free_survival_and_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_taxanes.","CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_a_decreased_chance_of_experiencing_sensory_neuropathy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_sensory_neuropathy._""CG:Patients_with_the_CG_genotype_and_breast_cancer_may_have_a_decreased_chance_of_experiencing_sensory_neuropathy_as_compared_to_patients_with_the_GG_genotype_or_an_increased_chance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_sensory_neuropathy._""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_an_increased_chance_of_experiencing_sensory_neuropathy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_sensory_neuropathy._","CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_a_poorer_response_when_treated_with_cyclophosphamide_epirubicin_and_fluorouracil_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_cyclophosphamide_epirubicin_and_fluorouracil._""CG:Patients_with_the_CG_genotype_and_breast_cancer_may_have_a_better_response_when_treated_with_cyclophosphamide_epirubicin_and_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_cyclophosphamide_epirubicin_and_fluorouracil._""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_better_response_when_treated_with_cyclophosphamide_epirubicin_and_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_cyclophosphamide_epirubicin_and_fluorouracil._";PGKB_RACE=NR,White,NR
2	44066247	rs11887534	G	A,C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG8_(PA24412);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Hypercholesterolemia_(PA444516)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_(measured_by_higher_decreases_in_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._This_may_be_influenced_by_rs3808607_genotype_with_an_increased_response_in_patients_with_the_rs3808607_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""CG:Patients_with_the_CG_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_(measured_by_higher_decreases_in_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._However_this_association_was_not_observed_in_the_majority_of_studies._This_may_be_influenced_by_rs3808607_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_atorvastatin_may_have_a_decreased_response_to_treatment_(measured_by_lower_decreases_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._This_association_may_be_influenced_by_rs3808607_genotype._Several_studies_show_no_association_as_compared_to_the_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._";PGKB_RACE=NR
2	46056049	rs11125035	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=PRKCE_(PA33765);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Esophagitis_when_treated_with_radiotherapy_as_compared_to_patients_with_genotype_TT_or_AT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_radiotherapy.""AT:Patients_with_the_AT_genotype_may_have_decreased_risk_of_Esophagitis_when_treated_with_radiotherapy_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_radiotherapy.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_Esophagitis_when_treated_with_radiotherapy_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_radiotherapy.";PGKB_RACE=NR
2	49189921	rs6166	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=FSHR_(PA28386);PGKB_DRUG="follitropin_beta_(PA449693)""thyrotropin_alfa_(PA164746560)""urofollitropin_(PA451835)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Infertility_Female_(PA444618)""Ovarian_hyperstimulation_syndrome_(PA165108853)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_poorer_response_to_controlled_ovarian_hyperstimulation_when_treated_with_follitropin_beta_thyrotropin_alfa_and_urofollitropin_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_controlled_ovarian_hyperstimulation.""CT:Patients_with_the_CT_genotype_may_have_good_response_to_controlled_ovarian_hyperstimulation_when_treated_with_follitropin_beta_thyrotropin_alfa_and_urofollitropin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_controlled_ovarian_hyperstimulation.""TT:Patients_with_the_TT_genotype_may_have_good_response_to_controlled_ovarian_hyperstimulation_when_treated_with_follitropin_beta_thyrotropin_alfa_and_urofollitropin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_controlled_ovarian_hyperstimulation.";PGKB_RACE=NR
2	51242270	rs12467557	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NRXN1_(PA31786);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment._""AG:Patients_with_the_AG_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment._""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment._";PGKB_RACE="White""Hispanic_or_Latino"
2	51247657	rs10490162	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NRXN1_(PA31786);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment.""CT:Patients_with_the_CT_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment.";PGKB_RACE=White
2	54395259	rs1872328	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ACYP2_(PA24500);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Brain_Neoplasms_(PA443557);PGKB_TEXT="AA:Pediatric_patients_with_brain_tumors_and_the_AA_genotype_may_have_an_increased_risk_of_experiencing_hearing_loss_when_treated_with_regimens_containing_cisplatin_as_compared_to_patients_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hearing-loss_in_pediatric_patients_exposed_to_cisplatin._""AG:Pediatric_patients_with_brain_tumors_and_the_AG_genotype_may_have_an_increased_risk_of_experiencing_hearing_loss_when_treated_with_regimens_containing_cisplatin_as_compared_to_patients_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hearing-loss_in_pediatric_patients_exposed_to_cisplatin._""GG:Pediatric_patients_with_brain_tumors_and_the_GG_genotype_may_have_a_decreased_risk_of_experiencing_hearing_loss_when_treated_with_regimens_containing_cisplatin_as_compared_to_patients_with_the_AA_or_AG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hearing-loss_in_pediatric_patients_exposed_to_cisplatin._";PGKB_RACE=NR
2	65296798	rs7572857	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CEP68_(PA134991391);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.";PGKB_RACE=Asian
2	67973887	rs13432159	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=sertraline_(PA451333);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_experience_a_higher_burden_of_general_side-effects_when_treated_with_sertraline_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_general_side-effects_when_treated_with_sertraline._""GT:Patients_with_the_GT_genotype_and_major_depressive_disorder_may_experience_a_higher_burden_of_general_side-effects_when_treated_with_sertraline_as_compared_to_patients_with_the_TT_genotype_or_a_lower_burden_of_general_side-effects_when_treated_with_sertraline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_general_side-effects_when_treated_with_sertraline._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_experience_a_lower_burden_of_general_side-effects_when_treated_with_sertraline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_general_side-effects_when_treated_with_sertraline._";PGKB_RACE=NR
2	85637837	rs3770102	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=CAPG_(PA26056);PGKB_DRUG=vincristine_(PA451879);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Neurotoxicity_Syndromes_(PA446975)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_an_increased_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._""GT:Patients_with_the_GT_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_an_increased_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._""TT:Patients_with_the_TT_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._";PGKB_RACE=White
2	85777633	rs11676382	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=GGCX_(PA28660);PGKB_DRUG=acenocoumarol_(PA452632);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_need_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_or_CG_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_warfarin.""CG:Patients_with_the_CG_genotype_may_need_decreased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_warfarin.""GG:Patients_with_the_GG_genotype_may_need_decreased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_warfarin.";PGKB_RACE=NR
2	85780131	rs2592551	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GGCX_(PA28660);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Atrial_Fibrillation_(PA443459);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_atrial_fibrillation_may_require_a_higher_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_variations_in_the_VKORC1_and_CYP2C9_genes_may_also_influence_dose_of_warfarin.""AG:Patients_with_the_AG_genotype_and_atrial_fibrillation_may_require_a_higher_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_variations_in_the_VKORC1_and_CYP2C9_genes_may_also_influence_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_and_atrial_fibrillation_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_such_as_variations_in_the_VKORC1_and_CYP2C9_genes_may_also_influence_dose_of_warfarin.";PGKB_RACE=Asian
2	85780536	rs699664	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=GGCX_(PA28660);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_CT_and_TT_genotypes_however_no_association_was_found_in_the_majority_of_studies_and_in_one_study_the_CC_genotype_was_associated_with_an_increased_dose_of_warfarin._Other_clinical_and_genetic_factors_may_also_influence_dose_of_warfarin._""CT:Patients_with_the_CT_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype_however_no_association_was_found_in_the_majority_of_studies_and_in_one_study_the_CT_genotype_was_associated_with_a_decreased_dose_of_warfarin_as_compared_to_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_dose_of_warfarin._""TT:Patients_with_the_TT_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype_however_no_association_was_found_in_the_majority_of_studies_and_in_one_study_the_TT_genotype_was_associated_with_a_decreased_dose_of_warfarin_as_compared_to_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_dose_of_warfarin._";PGKB_RACE=Asian
2	85787341	rs12714145	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Genotype_CC_may_be_associated_with_decreased_dose_of_warfarin_as_compared_to_genotype_TT._However_contradictory_findings_(no_association)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_dose_of_warfain.""CT:Genotype_CT_may_be_associated_with_decreased_dose_of_warfarin_as_compared_to_genotype_TT._However_contradictory_findings_(no_association)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_dose_of_warfain.""TT:Genotype_TT_may_be_associated_with_increased_dose_of_warfarin_as_compared_to_genotype_GG._However_contradictory_findings_(no_association)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_dose_of_warfain.";PGKB_RACE=NR
2	88424066	rs2241883	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=FABP1_(PA27956);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertriglyceridemia_(PA446120);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertriglyceridemia_may_have_an_increased_risk_of_exhibiting_plasma_triglyceride_concentrations_above_the_therapeutic_target_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._No_associations_with_response_to_fenofibrate_or_risk_of_hypercholesterolemia_were_seen._Other_genetic_and_clinical_factors_may_also_influence_plasma_triglyceride_concentrations_in_patients_taking_fenofibrate.""CT:Patients_with_the_CT_genotype_and_hypertriglyceridemia_may_have_an_increased_risk_of_exhibiting_plasma_triglyceride_concentrations_above_the_therapeutic_target_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._No_associations_with_response_to_fenofibrate_or_risk_of_hypercholesterolemia_were_seen._Other_genetic_and_clinical_factors_may_also_influence_plasma_triglyceride_concentrations_in_patients_taking_fenofibrate.""TT:Patients_with_the_TT_genotype_and_hypertriglyceridemia_may_have_a_decreased_risk_of_exhibiting_plasma_triglyceride_concentrations_above_the_therapeutic_target_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_or_CT_genotype._No_associations_with_response_to_fenofibrate_or_risk_of_hypercholesterolemia_were_seen._Other_genetic_and_clinical_factors_may_also_influence_plasma_triglyceride_concentrations_in_patients_taking_fenofibrate.";PGKB_RACE=White
2	102422994	rs4550690	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=MAP4K4_(PA30612);PGKB_DRUG="anastrozole_(PA448432)""exemestane_(PA449563)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_a_decreased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.""CT:Patients_with_the_CT_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_an_increased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_risk_of_bone_fractures_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.""TT:Patients_with_the_TT_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_an_increased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.";PGKB_RACE=Black_or_African_American
2	108994808	rs1402467	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=SULT1C4_(PA162405070);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CG:Patients_with_the_CG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
2	111907691	rs724710	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=BCL2L11_(PA25305);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_cancer_may_have_an_improved_response_when_treated_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_imatinib._""CT:Patients_with_the_CT_genotype_and_cancer_may_have_a_diminished_response_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_genotype_and_an_improved_response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_imatinib._""TT:Patients_with_the_TT_genotype_and_cancer_may_have_a_diminished_response_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_imatinib._";PGKB_RACE=NR
2	113529240	rs11677416	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_as_compared_to_patients_with_the_TT_genotype_or_may_have_decreased_response_to_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_may_have_decreased_response_to_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=NR
2	113590390	rs1143634	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL1B_(PA29808);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._";PGKB_RACE=NR
2	113594387	rs1143627	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL1B_(PA29808);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Cardiovascular_Diseases_may_have_a_risk_for_peptic_ulcer_as_compared_to_patients_with_the_GG_genotype._The_study_did_not_discuss_the_direction_of_the_association_but_it_might_be_a_protective_effect._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_peptic_ulcer.""AG:Patients_with_the_AG_genotype_and_Cardiovascular_Diseases_may_have_a_risk_for_peptic_ulcer_as_compared_to_patients_with_the_GG_genotype._The_study_did_not_discuss_the_direction_of_the_association_but_it_might_be_a_protective_effect._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_peptic_ulcer.""GG:Patients_with_the_GG_genotype_and_Cardiovascular_Diseases_may_have_a_risk_for_peptic_ulcer_as_compared_to_patients_with_the_AG_or_AA_genotype._The_study_did_not_discuss_the_direction_of_the_association_but_it_might_be_an_increased_risk._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_peptic_ulcer.";PGKB_RACE=Asian
2	113594867	rs16944	A	G	.	.	PGKB_INDEX=4;PGKB_GENE=IL1B_(PA29808),IL1B_(PA29808),IL1B_(PA29808),IL1B_(PA29808);PGKB_DRUG="lansoprazole_(PA450180)""omeprazole_(PA450704)""rabeprazole_(PA451216)",pravastatin_(PA451089),"Bisphosphonates_(PA164712563)""clodronate_(PA10239)""etidronic_acid_(PA449548)""risedronate_(PA451255)""tiludronate_(PA451688)",antipsychotics_(PA452233);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Helicobacter_Infections_(PA166048740),NR,Osteitis_Deformans_(PA445172),Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_lower_chance_of_eradication_failure_when_treated_with_lansoprazole_omeprazole_or_rabeprazole_as_compared_to_patients_with_the_GG_genotype._Patients_also_received_amoxicillin_and_clarithromycin._However_several_studies_have_found_no_association_between_rs16944_genotype_and_H._pylori_eradication_in_patients_taking_these_drugs._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.""AG:Patients_with_the_AG_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_a_lower_chance_of_eradication_failure_when_treated_with_lansoprazole_omeprazole_or_rabeprazole_as_compared_to_patients_with_the_GG_genotype._Patients_also_received_amoxicillin_and_clarithromycin._However_several_studies_have_found_no_association_between_rs16944_genotype_and_H._pylori_eradication_in_patients_taking_these_drugs._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.""GG:Patients_with_the_GG_genotype_who_are_infected_with_Helicobacter_pylori_(H._pylori)_may_have_an_increased_chance_of_eradication_failure_when_treated_with_lansoprazole_omeprazole_or_rabeprazole_as_compared_to_patients_with_the_AA_or_AG_genotype._Patients_also_received_amoxicillin_and_clarithromycin._However_several_studies_have_found_no_association_between_rs16944_genotype_and_H._pylori_eradication_in_patients_taking_these_drugs._Other_genetic_and_clinical_factors_may_also_influence_eradication_rate_of_H._pylori.","AA:Patients_with_the_AA_genotype_who_are_treated_with_pravastatin_may_1)_have_increased_IL1B_serum_levels_and_2)_be_less_likely_to_benefit_from_pravastatin_treatment_in_terms_of_improvement_in_coronary_function_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AG:Patients_with_the_AG_genotype_who_are_treated_with_pravastatin_may_1)_have_increased_IL1B_serum_levels_and_2)_be_less_likely_to_benefit_from_pravastatin_treatment_in_terms_of_improvement_in_coronary_function_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_pravastatin_may_1)_have_lower_IL1B_serum_levels_and_2)_be_more_likely_to_benefit_from_pravastatin_treatment_in_terms_of_improvement_in_coronary_function_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","AA:Patients_with_the_AA_genotype_and_Paget's_disease_of_bone_who_are_treated_with_bisphosphonates_may_have_a_decreased_but_not_absent_risk_of_resistance_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistance_to_bisphosphonates.""AG:Patients_with_the_AG_genotype_and_Paget's_disease_of_bone_who_are_treated_with_bisphosphonates_may_have_a_decreased_but_not_absent_risk_of_resistance_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistance_to_bisphosphonates.""GG:Patients_with_the_GG_genotype_and_Paget's_disease_of_bone_who_are_treated_with_bisphosphonates_may_have_an_increased_risk_of_resistance_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistance_to_bisphosphonates.","AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_higher_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._";PGKB_RACE=NR,NR,White,NR
2	113598107	rs4848306	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL1B_(PA29808);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Colitis_Ulcerative_(PA443750)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AG:Patients_with_the_AG_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
2	113602559	rs4849127	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._";PGKB_RACE=NR
2	113874467	rs4251961	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL1RN_(PA29816);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colitis_Ulcerative_(PA443750);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
2	128018063	rs3738948	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ERCC3_(PA27849);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small-cell_lung_cancer_may_have_a_decreased_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_and_non-small-cell_lung_cancer_may_have_a_decreased_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype_and_an_increased_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_an_increased_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.";PGKB_RACE=NR
2	134437959	rs1901440	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_a_decreased_but_not_absent_risk_for_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.""AC:Patients_with_the_AC_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_leukopenia_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_decreased_but_not_absent_risk_for_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.""CC:Patients_with_the_CC_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_leukopenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine.";PGKB_RACE=Asian
2	138746039	rs17583889	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=HNMT_(PA190);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""AC:Patients_with_the_AC_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.";PGKB_RACE=NR
2	138771760	rs1050891	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HNMT_(PA190);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_acetylsalicylic_acid-intolerant_chronic_urticaria_as_compared_to_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_sensitivity.""AG:Patients_with_the_AG_genotype_may_have_a_decreased_risk_of_acetylsalicylic_acid-intolerant_chronic_urticaria_as_compared_to_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_sensitivity.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_risk_of_acetylsalicylic_acid-intolerant_chronic_urticaria_as_compared_to_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_sensitivity.";PGKB_RACE=Asian
2	159851423	rs10497203	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""AC:Patients_with_the_AC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""CC:Patients_with_the_CC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	159899489	rs7582141	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""GT:Patients_with_the_GT_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""TT:Patients_with_the_TT_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	159899913	rs6432512	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""CT:Patients_with_the_CT_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""TT:Patients_with_the_TT_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	159910206	rs264663	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""CT:Patients_with_the_CT_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""TT:Patients_with_the_TT_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	159929431	rs264651	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""AG:Patients_with_the_AG_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity.""GG:Patients_with_the_GG_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	159936391	rs264588	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""AC:Patients_with_the_AC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""CC:Patients_with_the_CC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	159950865	rs264631	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=TANC1_(PA142670838);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""CG:Patients_with_the_CG_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_reduced_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._""GG:Patients_with_the_GG_genotype_and_prostate_cancer_who_are_treated_with_radiotherapy_may_have_an_increased_risk_of_late_stage_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_radiotherapy-induced_toxicity._";PGKB_RACE=NR
2	162997960	rs13429709	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GCG_(PA28606);PGKB_DRUG="clozapine_(PA449061)""olanzapine_(PA450688)";PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_with_clozapine_or_olanzapine_may_have_greater_weight_gain_as_compared_to_patients_with_the_CT_or_TT_genotype._Weight_gain_may_be_higher_in_patients_who_also_have_a_T_allele_at_SNP_rs2268639._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_weight_gain_and_extent_when_treated_with_antipsychotics._""CT:Patients_with_the_CT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_or_olanzapine_may_have_less_weight_gain_as_compared_to_patients_with_the_CC_genotype_or_may_have_greater_weight_gain_as_compared_to_patients_with_the_TT_genotype._Weight_gain_may_be_higher_in_patients_who_also_have_a_T_allele_at_SNP_rs2268639._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_weight_gain_and_extent_when_treated_with_antipsychotics._""TT:Patients_with_the_TT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_or_olanzapine_may_have_less_weight_gain_as_compared_to_patients_with_the_CC_genotype._Weight_gain_may_be_higher_in_patients_who_also_have_a_T_allele_at_SNP_rs2268639._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_weight_gain_and_extent_when_treated_with_antipsychotics._";PGKB_RACE=White
2	166152389	rs17183814	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SCN2A_(PA35004);PGKB_DRUG="antiepileptics_(PA143485705)""carbamazepine_(PA448785)""phenobarbital_(PA450911)""phenytoin_(PA450947)""valproic_acid_(PA451846)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_epilepsy_may_be_less_likely_to_respond_to_antiepileptic_drugs_as_compared_to_patients_with_the_GG_genotype._Please_note__no_association_was_found_in_two_large_cohorts_and_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics._""AG:Patients_with_the_AG_genotype_and_epilepsy_may_be_less_likely_to_respond_to_antiepileptic_drugs_as_compared_to_patients_with_the_GG_genotype._Please_note__no_association_was_found_in_two_large_cohorts_and_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics._""GG:Patients_with_the_GG_genotype_and_epilepsy_may_be_more_likely_to_respond_to_antiepileptic_drugs_as_compared_to_patients_with_the_AG_or_AA_genotype._Please_note__no_association_was_found_in_two_large_cohorts_and_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics._";PGKB_RACE=Asian
2	166168503	rs2304016	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SCN2A_(PA35004);PGKB_DRUG="antiepileptics_(PA143485705)""carbamazepine_(PA448785)""lamotrigine_(PA450164)""oxcarbazepine_(PA450732)""phenytoin_(PA450947)""topiramate_(PA451728)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_epilepsy_who_are_treated_with_antiepileptic_drugs_(such_as_carbamazepine_lamotrigine_oxcarbazepine_phenytoin_topiramate)_may_have_an_increased_risk_of_drug_resistance_as_compared_to_patients_with_the_GG_genotype._Another_study_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptic_drugs.""AG:Patients_with_the_AG_genotype_and_epilepsy_who_are_treated_with_antiepileptic_drugs_(such_as_carbamazepine_lamotrigine_oxcarbazepine_phenytoin_topiramate)_may_have_an_increased_risk_of_drug_resistance_as_compared_to_patients_with_the_GG_genotype._Another_study_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptic_drugs.""GG:Patients_with_the_GG_genotype_and_epilepsy_who_are_treated_with_antiepileptic_drugs_(such_as_carbamazepine_lamotrigine_oxcarbazepine_phenytoin_topiramate)_may_have_a_decreasedbut_not_absent_risk_of_drug_resistance_as_compared_to_patients_with_the_AG_or_AA_genotype._Another_study_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptic_drugs.";PGKB_RACE=Asian
2	166407511	rs7588295	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CSRNP3_(PA164718184);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.";PGKB_RACE=White
2	166892788	rs2298771	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SCN1A_(PA301);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_epilepsy_who_are_treated_with_carbamazepine_may_have_a_decreased_likelihood_of_a_good_response_within_a_15_month_treatment_period_as_compared_to_patients_with_the_TT_genotype._Several_studies_have_found_no_association_with_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_treatment._""CT:Patients_with_the_CT_genotype_and_epilepsy_who_are_treated_with_carbamazepine_may_have_a_decreased_likelihood_of_a_good_response_within_a_15_month_treatment_period_as_compared_to_patients_with_the_TT_genotype._Several_studies_have_found_no_association_with_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_treatment._""TT:Patients_with_the_TT_genotype_and_epilepsy_who_are_treated_with_carbamazepine_may_have_an_increased_likelihood_of_a_good_response_within_a_15_month_treatment_period_as_compared_to_patients_with_the_CC_genotype._Several_studies_have_found_no_association_with_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_treatment._";PGKB_RACE=Asian
2	166909544	rs3812718	C	T	.	.	PGKB_INDEX=4;PGKB_GENE=SCN1A_(PA301),SCN1A_(PA301),SCN1A_(PA301),SCN1A_(PA301);PGKB_DRUG=carbamazepine_(PA448785),carbamazepine_(PA448785),phenytoin_(PA450947),carbamazepine_(PA448785);PGKB_TYPE="Efficacy""Toxicity/ADR",Dosage,Dosage,Metabolism/PK;PGKB_EVIDENCE=3,2B,2B,3;PGKB_DISEASE=Epilepsy_(PA444065),Epilepsy_(PA444065),Epilepsy_(PA444065),Epilepsy_(PA444065);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_epilepsy_who_are_treated_with_carbamazepine_1)_may_be_more_likely_to_respond_to_treatment_2)_may_be_less_likely_to_discontinue_treatment_as_compared_to_patients_with_the_TT_genotype._Please_note__no_association_was_found_in_a_large_cohort_and_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_and_treatment_retention_rate._""CT:Patients_with_the_CT_genotype_and_epilepsy_who_are_treated_with_carbamazepine_1)_may_be_more_likely_to_respond_to_treatment_2)_may_be_less_likely_to_discontinue_treatment_as_compared_to_patients_with_the_TT_genotype._Please_note__no_association_was_found_in_a_large_cohort_and_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_and_treatment_retention_rate._""TT:Patients_with_the_TT_genotype_and_epilepsy_who_are_treated_with_carbamazepine_1)_may_be_less_likely_to_respond_to_treatment_2)_may_be_more_likely_to_discontinue_treatment_as_compared_to_patients_with_the_TT_genotype._Please_note__no_association_was_found_in_a_large_cohort_and_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_and_treatment_retention_rate._","CC:Patients_with_the_CC_genotype_who_are_treated_with_carbamazepine_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_carbamazepine.""CT:Patients_with_the_CT_genotype_who_are_treated_with_carbamazepine_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_carbamazepine.""TT:Patients_with_the_TT_genotype_who_are_treated_with_carbamazepine_may_require_the_highest_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_carbamazepine.","CC:Patients_with_the_CC_genotype_who_are_treated_with_phenytoin_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_phenytoin.""CT:Patients_with_the_CT_genotype_who_are_treated_with_phenytoin_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_phenytoin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_phenytoin_may_require_the_highest_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_phenytoin.","CC:Patients_with_epilepsy_and_the_CC_genotype_may_have_decreased_metabolism_of_carbamazepine_resulting_in_increased_exposure_as_compared_to_patients_with_the_TT_genotype._""CT:Patients_with_epilepsy_and_the_CT_genotype_may_have_decreased_metabolism_of_carbamazepine_resulting_in_increased_exposure_as_compared_to_patients_with_the_TT_genotype._""TT:Patients_with_epilepsy_and_the_TT_genotype_may_have_increased_metabolism_of_carbamazepine_resulting_in_decreased_exposure_as_compared_to_patients_with_the_CC_and_CT_genotypes._";PGKB_RACE=NR,NR,NR,White
2	169041386	rs6749447	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=STK39_(PA38243);PGKB_DRUG=losartan_(PA450268);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_reduction_in_ambulatory_blood_pressure_when_treated_with_losartan_in_men_with_Hypertension_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_losartan.""GT:Patients_with_the_GT_genotype_may_have_decreased_reduction_in_ambulatory_blood_pressure_when_treated_with_losartan_in_men_with_Hypertension_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_losartan.""TT:Patients_with_the_TT_genotype_may_have_increased_reduction_in_ambulatory_blood_pressure_when_treated_with_losartan_in_men_with_Hypertension_as_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_losartan.";PGKB_RACE=White
2	170010985	rs2075252	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=LRP2_(PA30452);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_treated_with_cisplatin_may_have_a_reduced_but_not_non-existent_risk_for_hearing_loss_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_events.""CT:Patients_with_the_CT_genotype_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_events.""TT:Patients_with_the_TT_genotype_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_events.";PGKB_RACE=NR
2	182455994	rs993648	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CERKL_(PA134984780);PGKB_DRUG=iloperidone_(PA161199368);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acquired_Long_QT_Syndrome_(aLQTS)_(PA447300);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_who_are_treated_with_iloperidone_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_either_the_CC_or_the_TT_genotype._It_is_unclear_at_this_time_why_the_heterozygous_genotype_would_confer_a_different_phenotype_than_either_homozygous_genotype.""TT:Patients_with_the_TT_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
2	182543455	rs1801262	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NEUROD1_(PA31564);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="CC:Patients_with_CC_genotypes_may_have_worse_response_for_fasting_and_postprandial_plasma_glucose_in_diabetic_patients_treated_with_repaglinide_when_compared_to_patients_with_CT_+_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""CT:Patients_with_CT_+_TT_genotypes_may_have_better_response_for_fasting_and_postprandial_plasma_glucose_in_diabetic_patients_treated_with_repaglinide_when_compared_to_patients_with_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""TT:Patients_with_CT_+_TT_genotypes_may_have_better_response_for_fasting_and_postprandial_plasma_glucose_in_diabetic_patients_treated_with_repaglinide_when_compared_to_patients_with_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.";PGKB_RACE=Asian
2	185778428	rs1344706	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=ZNF804A_(PA162410599);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics._""AC:Patients_with_the_AC_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics._""CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics._";PGKB_RACE=White
2	201523736	rs10931910	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=AOX1_(PA24842);PGKB_DRUG=nsc697887_(PA166114484);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_solid_tumors_may_have_an_increased_clearance_of_XK469_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_clearance_of_XK469.""GA:Patients_with_the_AG_genotype_and_solid_tumors_may_have_a_decreased_clearance_of_XK469_as_compared_to_patients_with_the_AA_genotype_or_may_have_an_increased_clearance_of_XK469_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_clearance_of_XK469.""GG:Patients_with_the_GG_genotype_and_solid_tumors_may_have_a_decreased_clearance_of_XK469_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_clearance_of_XK469.";PGKB_RACE=White
2	201526330	rs55754655	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=AOX1_(PA24842);PGKB_DRUG=azathioprine_(PA448515);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Inflammatory_Bowel_Diseases_(PA446116);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Inflammatory_Bowel_Disease_who_are_treated_with_azathioprine_may_have_an_increased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_azathioprine.""GA:Patients_with_the_GA_genotype_and_Inflammatory_Bowel_Disease_who_are_treated_with_azathioprine_may_have_a_decreased_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_azathioprine.""GG:Patients_with_the_GG_genotype_and_Inflammatory_Bowel_Disease_who_are_treated_with_azathioprine_may_have_a_decreased_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_azathioprine.";PGKB_RACE=NR
2	204731005	rs4553808	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CTLA4_(PA27006);PGKB_DRUG="bortezomib_(PA10252)""dexamethasone_(PA449247)""melphalan_(PA450354)""prednisone_(PA451100)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_who_are_treated_with_bortezomib_melphalan_and_prednisone_may_have_a_later_onset_of_bortezomib-induced_peripheral_neuropathy_as_compared_to_patients_with_the_GG_genotype._However_no_association_was_found_for_bortezomib_and_dexamethasone_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment-induced_peripheral_neuropathy.""AG:Patients_with_the_AG_who_are_treated_with_bortezomib_melphalan_and_prednisone_may_have_a_later_onset_of_bortezomib-induced_peripheral_neuropathy_as_compared_to_patients_with_the_GG_genotype._However_no_association_was_found_for_bortezomib_and_dexamethasone_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment-induced_peripheral_neuropathy.""GG:Patients_with_the_GG_who_are_treated_with_bortezomib_melphalan_and_prednisone_may_have_an_earlier_onset_of_bortezomib-induced_peripheral_neuropathy_as_compared_to_patients_with_the_AA_or_AG_genotype._However_no_association_was_found_for_bortezomib_and_dexamethasone_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment-induced_peripheral_neuropathy.";PGKB_RACE=NR
2	206474012	rs17626122	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PARD3B_(PA162398721);PGKB_DRUG="fluorouracil_(PA128406956)""oxaliplatin_(PA131285527)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Colorectal_Neoplasms_(PA446108)""Drug_Toxicity_(PA443937)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_fluorouracil_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_fluorouracil_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_fluorouracil_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.";PGKB_RACE=White
2	206652300	rs10932125	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NRP2_(PA31784);PGKB_DRUG=daunorubicin_(PA449212);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=Drug_Toxicity_(PA443937);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_reduced_response_to_daunorubicin_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.""CG:Patients_with_the_CG_genotype_may_have_reduced_response_to_daunorubicin_compared_to_patients_with_the_GG_genotype_or_may_have_increased_response_to_daunorubicin_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.""GG:Patients_with_the_GG_genotype_may_have_increased_response_to_daunorubicin_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.";PGKB_RACE=NR
2	208398929	rs889895	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CREB1_(PA26864);PGKB_DRUG=antidepressants_(PA452229);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_be_less_likely_to_enter_remission_when_treated_with_antidepressants_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_remission_from_major_depressive_disorder._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_be_less_likely_to_enter_remission_when_treated_with_antidepressants_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_remission_from_major_depressive_disorder._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_be_more_likely_to_enter_remission_when_treated_with_antidepressants_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_remission_from_major_depressive_disorder._";PGKB_RACE=NR
2	208473184	rs7569963	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="antidepressants_(PA452229)""citalopram_(PA449015)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_remission_on_anti-depressants_as_compared_to_patients_with_the_GG_genotype._Male_patients_with_the_AA_genotype_and_depression_who_are_treated_with_citalopram_may_have_a_decreased_but_not_absent_risk_of_suicidal_ideation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_remission_on_anti-depressants_as_compared_to_patients_with_the_GG_genotype._Male_patients_with_the_AG_genotype_and_depression_who_are_treated_with_citalopram_may_have_a_decreased_but_not_absent_risk_of_suicidal_ideation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_remission_on_anti-depressants_as_compared_to_patients_with_the_AA_or_AG_genotype._Male_patients_with_the_GG_genotype_and_depression_who_are_treated_with_citalopram_may_have_an_increased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.";PGKB_RACE=NR
2	208494234	rs2952768	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=NR,NR;PGKB_DRUG="buprenorphine_(PA448685)""fentanyl_(PA449599)""meperidine_(PA450369)""morphine_(PA450550)""opioids_(PA452618)""pentazocine_(PA164744326)",opioids_(PA452618);PGKB_TYPE=Dosage,Other;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_opioid_analgesic_requirements_after_surgery_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_opioid_dose_requirement.""CT:Patients_with_the_CT_genotype_may_have_decreased_opioid_analgesic_requirements_after_surgery_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_opioid_dose_requirement.""TT:Patients_with_the_TT_genotype_may_have_decreased_opioid_analgesic_requirements_after_surgery_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_opioid_dose_requirement.","CC:Patients_with_the_CC_genotype_may_have_less_vulnerability_to_severe_drug_dependence_in_patients_with_methamphetamine_dependence_alcohol_dependence_and_eating_disorders_and_a_lower_'Reward_Dependence'_score_on_a_personality_questionnaire_when_treated_with_opioids_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_opioids.""CT:Patients_with_the_CT_genotype_may_have_more_vulnerability_to_severe_drug_dependence_in_patients_with_methamphetamine_dependence_alcohol_dependence_and_eating_disorders_and_a_lower_'Reward_Dependence'_score_on_a_personality_questionnaire_when_treated_with_opioids_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_opioids.""TT:Patients_with_the_TT_genotype_may_have_more_vulnerability_to_severe_drug_dependence_in_patients_with_methamphetamine_dependence_alcohol_dependence_and_eating_disorders_and_a_lower_'Reward_Dependence'_score_on_a_personality_questionnaire_when_treated_with_opioids_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_opioids.";PGKB_RACE=Asian,Asian
2	208507807	rs4675690	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_may_have_decreased_likelihood_of_treatment-emergent_suicidality_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""CT:Patients_with_the_CT_genotype_and_major_depression_may_have_increased_likelihood_of_treatment-emergent_suicidality_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_likelihood_of_treatment-emergent_suicidality_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""TT:Patients_with_the_TT_genotype_and_major_depression_may_have_increased_likelihood_of_treatment-emergent_suicidality_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=NR
2	216185825	rs10197559	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ATIC_(PA25094);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_discontinue_treatment_due_to_toxicity_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicity.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_discontinue_treatment_due_to_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicity.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_discontinue_treatment_due_to_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicity.";PGKB_RACE=NR
2	216190020	rs2372536	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=ATIC_(PA25094);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_symptom_improvement_as_compared_to_patients_with_the_GG_genotype.""CG:Patients_with_the_CG_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_symptom_improvement_as_compared_to_patients_with_the_GG_genotype.""GG:Patients_with_the_GG_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_symptom_improvement_as_compared_to_patients_with_the_CG_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=NR
2	216205167	rs16853826	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ATIC_(PA25094);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_discontinue_treatment_due_to_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicity.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_discontinue_treatment_due_to_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicity.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_discontinue_treatment_due_to_toxicity_as_compared_to_patients_with_the_AA_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicity.";PGKB_RACE=NR
2	216212339	rs4673993	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ATIC_(PA25094);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=NR
2	217070376	rs1051685	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=XRCC5_(PA37425);PGKB_DRUG=thalidomide_(PA451644);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Multiple_Myeloma_(PA444985);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_overall_survival_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.""AG:Patients_with_the_AG_genotype_may_have_increased_overall_survival_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.""GG:Patients_with_the_GG_genotype_may_have_increased_overall_survival_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.";PGKB_RACE=NR
2	234158839	rs10210302	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ATG16L1_(PA134902949);PGKB_DRUG=adalimumab_(PA10004);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Crohn_Disease_(PA443815);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Crohn's_disease_may_have_a_poorer_response_to_treatment_with_adalimumab_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_adalimumab.""CT:Patients_with_the_CT_genotype_and_Crohn's_disease_may_have_a_better_response_to_treatment_with_adalimumab_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_adalimumab.""TT:Patients_with_the_TT_genotype_and_Crohn's_disease_may_have_a_better_response_to_treatment_with_adalimumab_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_adalimumab.";PGKB_RACE=NR
2	234526871	rs1042597	C	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A8_(PA37183);PGKB_DRUG="cyclosporine_(PA449167)""mycophenolate_mofetil_(PA450566)""sirolimus_(PA451365)""tacrolimus_(PA451578)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Kidney_Transplantation_may_have_an_increased_risk_of_diarrhoea_when_treated_with_mycophenolate_mofetil_and_cyclosporine_as_compared_to_patients_with_the_CG_or_GG_genotype._However_no_association_is_reported_for_treatment_with_mycophenolate_mofetil_sirolimus_or_tacrolimus._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_diarrhoea.""CG:Patients_with_the_CG_genotype_and_Kidney_Transplantation_may_have_a_decreased_risk_of_diarrhoea_when_treated_with_mycophenolate_mofetil_and_cyclosporine_as_compared_to_patients_with_the_CG_or_GG_genotype._However_no_association_is_reported_for_treatment_with_mycophenolate_mofetil_sirolimus_or_tacrolimus._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_diarrhoea.""GG:Patients_with_the_CG_genotype_and_Kidney_Transplantation_may_have_a_decreased_risk_of_diarrhoea_when_treated_with_mycophenolate_mofetil_and_cyclosporine_as_compared_to_patients_with_the_CG_or_GG_genotype._However_no_association_is_reported_for_treatment_with_mycophenolate_mofetil_sirolimus_or_tacrolimus._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_diarrhoea.";PGKB_RACE=NR
2	234529643	rs6431558	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A8_(PA37183);PGKB_DRUG=ABT-751_(PA166104276);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_glucuronidation_metabolic_ratios_of_ABT-751_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_ABT-751.""CT:Patients_with_the_CT_genotype_may_have_an_increased_glucuronidation_metabolic_ratios_of_ABT-751_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_ABT-751.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_glucuronidation_metabolic_ratios_of_ABT-751_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_ABT-751.";PGKB_RACE=NR
2	234578428	rs17868320	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=NR,UGT1A9_(PA419);PGKB_DRUG=sorafenib_(PA7000),mycophenolate_mofetil_(PA450566);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Neoplasms_(PA445062),Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_sorafenib-induced_grade_2_diarrhea_when_treated_with_sorafenib_in_cancer_patients_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_sorafenib-induced_grade_2_diarrhea_when_treated_with_sorafenib_in_cancer_patients_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_sorafenib-induced_grade_2_diarrhea_when_treated_with_sorafenib_in_cancer_patients_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.","CC:Patients_with_the_CC_genotype_who_are_treated_with_mycophenolate_mofetil_may_have_1)_no_changes_in_mycophenolic_acid_exposure-related_parameters_and_2)_a_decreased_but_not_absent_risk_of_acute_allograft_rejection_within_3_month_after_transplantation_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil._""TC:Patients_with_the_TC_genotype_who_are_treated_with_mycophenolate_mofetil_may_have_1)_changes_in_mycophenolic_acid_exposure-related_parameters_and_2)_increased_risk_of_acute_allograft_rejection_within_3_month_after_transplantation_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil._""TT:Patients_with_the_TT_genotype_who_are_treated_with_mycophenolate_mofetil_may_have_1)_changes_in_mycophenolic_acid_exposure-related_parameters_and_2)_increased_risk_of_acute_allograft_rejection_within_3_month_after_transplantation_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil._";PGKB_RACE=NR,NR
2	234579892	rs3806598	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=SN-38_(PA165110775);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:In_human_liver_microsomes_the_AA_genotype_was_associated_with_increased_glucuronidation_of_SN-38_as_compared_to_the_AC_or_CC_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_such_as_the_UGT1A1*28_allele_may_also_influence_glucuronidation_of_SN-38.""AC:In_human_liver_microsomes_the_AC_genotype_was_associated_with_decreased_glucuronidation_of_SN-38_as_compared_to_the_AA_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_such_as_the_UGT1A1*28_allele_may_also_influence_glucuronidation_of_SN-38.""CC:In_human_liver_microsomes_the_CC_genotype_was_associated_with_decreased_glucuronidation_of_SN-38_as_compared_to_the_AA_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_such_as_the_UGT1A1*28_allele_may_also_influence_glucuronidation_of_SN-38.";PGKB_RACE=Asian
2	234580305	rs6714486	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=mycophenolate_mofetil_(PA450566);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_an_increased_risk_for_acute_allograft_rejection_within_3_month_after_transplantation_as_compared_to_patients_with_the_TT_genotype._However_only_a_trend_of_associations_or_no_associations_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_allograft_rejection.""AT:Patients_with_the_AT_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_an_increased_risk_for_acute_allograft_rejection_within_3_month_after_transplantation_as_compared_to_patients_with_the_TT_genotype._However_only_a_trend_of_associations_or_no_associations_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_allograft_rejection.""TT:Patients_with_the_TT_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_a_decreased_but_not_absent_risk_for_acute_allograft_rejection_within_3_month_after_transplantation_as_compared_to_patients_with_the_AA_genotype._However_only_a_trend_of_associations_or_no_associations_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_allograft_rejection.";PGKB_RACE=NR
2	234580453	rs3832043	AT	A	.	.	PGKB_INDEX=3;PGKB_GENE=UGT1A9_(PA419),UGT1A9_(PA419),UGT1A9_(PA419);PGKB_DRUG=irinotecan_(PA450085),mycophenolate_mofetil_(PA450566),SN-38_(PA165110775);PGKB_TYPE=Toxicity/ADR,Other,Other;PGKB_EVIDENCE=3,3,2B;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622),Kidney_Transplantation_(PA165817016),Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="T/del:Patients_with_the_T/del_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_or_irinotecan-based_regimens_as_compared_to_patients_with_the_del/del_genotype._However_a_different_study_of_similar_size_found_no_association_between_this_genotype_and_diarrhea._No_significant_results_have_been_seen_when_considering_neutropenia_or_tumor_response._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.""TT:Patients_with_the_T/T_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_or_irinotecan-based_regimens_as_compared_to_patients_with_the_del/del_genotype._However_a_different_study_of_similar_size_found_no_association_between_this_genotype_and_diarrhea._No_significant_results_have_been_seen_when_considering_neutropenia_or_tumor_response._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.""del/del:Patients_with_the_del/del_genotype_and_non-small_cell_lung_cancer_may_have_an_increased_risk_of_diarrhea_when_treated_with_irinotecan_or_irinotecan-based_regimens_as_compared_to_patients_with_the_T/del_or_TT_genotype._However_a_different_study_of_similar_size_found_no_association_between_this_genotype_and_diarrhea._No_significant_results_have_been_seen_when_considering_neutropenia_or_tumor_response._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.","DEL/DEL:Patients_with_the_DEL/DEL_genotype_with_Kidney_Transplantation_may_have_a_decreased_metabolism_of_mycophenolate_mofetil_as_compared_to_patients_with_the_DEL/T_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mycophenolate_mofetil.""DEL/T:Patients_with_the_DEL/T_genotype_with_Kidney_Transplantation_may_have_a_decreased_metabolism_of_mycophenolate_mofetil_as_compared_to_patients_with_the_DEL/DEL_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mycophenolate_mofetil.""TT:Patients_with_the_TT_genotype_with_Kidney_Transplantation_may_have_a_decreased_metabolism_of_mycophenolate_mofetil_as_compared_to_patients_with_the_DEL/DEL_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mycophenolate_mofetil._","T/del:Patients_with_the_T/del_genotype_and_non-small_cell_lung_cancer_may_have_decreased_glucuronidation_of_SN-38_as_compared_to_patients_with_the_TT_genotype_or_increased_glucuronidation_of_SN-38_as_compared_to_patients_with_the_del/del_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A9_into_an_inactive_form_(SN-38G)._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_SN-38.""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_increased_glucuronidation_of_SN-38_as_compared_to_patients_with_the_T/del_or_del/del_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A9_into_an_inactive_form_(SN-38G)._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_SN-38.""del/del:Patients_with_the_del/del_genotype_and_non-small_cell_lung_cancer_may_have_decreased_glucuronidation_of_SN-38_as_compared_to_patients_with_the_TT_or_T/del_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A9_into_an_inactive_form_(SN-38G)._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_SN-38.";PGKB_RACE=Asian,Asian,Asian
2	234580678	rs72551330	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=mycophenolate_mofetil_(PA450566);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Kidney_Transplantation_may_have_an_increased_risk_for_a_diminished_estimated_glomerular_filtration_rate_and_transient_proteinuria_in_the_first_(p=0.07)_and_second_month_(p=0.03)_after_transplantation_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_TT_genotype._Studies_found_no_association_with_increased_risk_for_acute_allograft_rejection_within_3_month_after_transplantation._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil_and_risk_for_acute_allograft_rejection.""CT:Patients_with_the_CT_genotype_and_Kidney_Transplantation_may_have_an_increased_risk_for_a_diminished_estimated_glomerular_filtration_rate_and_transient_proteinuria_in_the_first_(p=0.07)_and_second_month_(p=0.03)_after_transplantation_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_TT_genotype._Studies_found_no_association_with_increased_risk_for_acute_allograft_rejection_within_3_month_after_transplantation._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil_and_risk_for_acute_allograft_rejection.""TT:Patients_with_the_TT_genotype_and_Kidney_Transplantation_may_have_a_decreased_but_not_absent_risk_for_a_diminished_estimated_glomerular_filtration_rate_and_transient_proteinuria_in_the_first_(p=0.07)_and_second_month_(p=0.03)_after_transplantation_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_CC_genotype._Studies_found_no_association_with_increased_risk_for_acute_allograft_rejection_within_3_month_after_transplantation._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil_and_risk_for_acute_allograft_rejection.";PGKB_RACE=NR
2	234581346	rs58597806	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=propofol_(PA451141);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_adverse_effects_when_treated_with_propofol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_propofol.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_adverse_effects_when_treated_with_propofol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_propofol.""GG:Patients_with_the_GG_genotype_may_have_decreased_but_not_non-existent_risk_of_adverse_effects_when_treated_with_propofol_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_propofol.";PGKB_RACE=NR
2	234581834	rs2741049	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=SN-38_(PA165110775);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:In_human_liver_microsomes_the_CC_genotype_was_associated_with_decreased_glucuronidation_of_SN-38_as_compared_to_the_CT_or_TT_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_such_as_the_UGT1A1*28_allele_may_also_influence_glucuronidation_of_SN-38.""CT:In_human_liver_microsomes_the_CT_genotype_was_associated_with_increased_glucuronidation_of_SN-38_as_compared_to_the_CC_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_such_as_the_UGT1A1*28_allele_may_also_influence_glucuronidation_of_SN-38.""TT:In_human_liver_microsomes_the_TT_genotype_was_associated_with_increased_glucuronidation_of_SN-38_as_compared_to_the_CC_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_such_as_the_UGT1A1*28_allele_may_also_influence_glucuronidation_of_SN-38.";PGKB_RACE=Asian
2	234591205	rs11692021	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=irinotecan_(PA450085);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_severe_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_UGT1A1*28_may_also_influence_the_risk_for_neutropenia_in_patients_taking_irinotecan.""CT:Patients_with_the_CT_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_severe_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_TT_genotype_or_a_decreased_risk_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_such_as_UGT1A1*28_may_also_influence_the_risk_for_neutropenia_in_patients_taking_irinotecan.""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_severe_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_such_as_UGT1A1*28_may_also_influence_the_risk_for_neutropenia_in_patients_taking_irinotecan.";PGKB_RACE=NR
2	234601669	rs6759892	T	G	.	.	PGKB_INDEX=3;PGKB_GENE="UGT1A10_(PA37174)""UGT1A6_(PA37181)""UGT1A7_(PA37182)""UGT1A8_(PA37183)""UGT1A9_(PA419)",UGT1A9_(PA419),UGT1A6_(PA37181);PGKB_DRUG=valproic_acid_(PA451846),anthracyclines_and_related_substances_(PA130620651),deferiprone_(PA166118041);PGKB_TYPE=Dosage,Toxicity/ADR,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Epilepsy_(PA444065),NR,beta-Thalassemia_(PA446432);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Epilepsy_who_are_treated_with_valproic_acid_may_require_a_higher_dose_as_compared_to_patients_with_the_TT_and_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_valproic_acid_dose_requirement.""GT:Patients_with_the_GT_genotype_and_Epilepsy_who_are_treated_with_valproic_acid_may_require_a_higher_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_valproic_acid_dose_requirement.""TT:Patients_with_the_TT_genotype_and_Epilepsy_who_are_treated_with_valproic_acid_may_require_a_lower_dose_as_compared_to_patients_with_the_GG_and_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_valproic_acid_dose_requirement.","GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_anthracyclines_and_related_substances._""GT:Patients_with_the_GT_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_anthracyclines_and_related_substances._""TT:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_anthracyclines_and_related_substances._","GG:Patients_with_the_GG_genotype_and_beta-thalassemia_may_have_a_better_response_but_also_an_increased_risk_for_experiencing_adverse_drug_reactions_when_treated_with_deferiprone_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_risk_for_adverse_events_in_patients_receiving_deferiprone.""GT:Patients_with_the_GT_genotype_and_beta-thalassemia_may_have_a_worse_response_but_also_a_decreased_risk_for_experiencing_adverse_drug_reactions_when_treated_with_deferiprone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_risk_for_adverse_events_in_patients_receiving_deferiprone.""TT:Patients_with_the_TT_genotype_and_beta-thalassemia_may_have_a_worse_response_but_also_a_decreased_risk_for_experiencing_adverse_drug_reactions_when_treated_with_deferiprone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_risk_for_adverse_events_in_patients_receiving_deferiprone.";PGKB_RACE=NR,NR,Asian
2	234602191	rs2070959	A	G	.	.	PGKB_INDEX=2;PGKB_GENE="UGT1A10_(PA37174)""UGT1A6_(PA37181)""UGT1A7_(PA37182)""UGT1A8_(PA37183)""UGT1A9_(PA419)",UGT1A6_(PA37181);PGKB_DRUG=valproic_acid_(PA451846),irinotecan_(PA450085);PGKB_TYPE=Dosage,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Epilepsy_(PA444065),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_a_decreased_dose_of_valproic_acid_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patients_dose_requirements.""AG:Patients_with_the_AG_genotype_may_require_an_increased_dose_of_valproic_acid_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_dose_requirements.""GG:Patients_with_the_GG_genotype_may_require_an_increased_dose_of_valproic_acid_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patients_dose_requirements.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_severe_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_UGT1A1*28_may_also_influence_the_risk_for_neutropenia_in_patients_taking_irinotecan.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_severe_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_UGT1A1*28_may_also_influence_the_risk_for_neutropenia_in_patients_taking_irinotecan.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_severe_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_UGT1A1*28_may_also_influence_the_risk_for_neutropenia_in_patients_taking_irinotecan.";PGKB_RACE=Asian,NR
2	234602202	rs1105879	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A6_(PA37181);PGKB_DRUG=valproic_acid_(PA451846);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Epilepsy_who_are_treated_with_valproic_acid_may_require_a_decreased_dose_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_valproic_acid.""AC:Patients_with_the_AC_genotype_and_Epilepsy_who_are_treated_with_valproic_acid_may_require_an_increased_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_valproic_acid.""CC:Patients_with_the_CC_genotype_and_Epilepsy_who_are_treated_with_valproic_acid_may_require_an_increased_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_valproic_acid.";PGKB_RACE=Asian
2	234627248	rs3732219	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A4_(PA37179);PGKB_DRUG=anastrozole_(PA448432);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_glucuronidation_of_anastrozole_as_compared_to_patients_with_the_CT_or_TT_genotype_as_determined_by_in_vitro_assays._Glucuronidation_allows_for_the_elimination_of_xenobiotics_like_anastrozole._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_anastrozole._""CT:Patients_with_the_CT_genotype_may_have_decreased_glucuronidation_of_anastrozole_as_compared_to_patients_with_the_CC_genotype_as_determined_by_in_vitro_assays._Glucuronidation_allows_for_the_elimination_of_xenobiotics_like_anastrozole._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_anastrozole._""TT:Patients_with_the_TT_genotype_may_have_decreased_glucuronidation_of_anastrozole_as_compared_to_patients_with_the_CC_genotype_as_determined_by_in_vitro_assays._Glucuronidation_allows_for_the_elimination_of_xenobiotics_like_anastrozole._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_anastrozole._";PGKB_RACE=NR
2	234627304	rs3732218	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A4_(PA37179);PGKB_DRUG=anastrozole_(PA448432);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_glucuronidation_of_anastrozole_as_compared_to_patients_with_the_GG_genotype_as_determined_by_in_vitro_assays._Glucuronidation_allows_for_the_elimination_of_xenobiotics_like_anastrozole._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_anastrozole.""AG:Patients_with_the_AG_genotype_may_have_decreased_glucuronidation_of_anastrozole_as_compared_to_patients_with_the_GG_genotype_as_determined_by_in_vitro_assays._Glucuronidation_allows_for_the_elimination_of_xenobiotics_like_anastrozole._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_anastrozole.""GG:Patients_with_the_GG_genotype_may_have_increased_glucuronidation_of_anastrozole_as_compared_to_patients_with_the_AA_or_AG_genotype_as_determined_by_in_vitro_assays._Glucuronidation_allows_for_the_elimination_of_xenobiotics_like_anastrozole._Other_genetic_and_clinical_factors_may_also_influence_glucuronidation_of_anastrozole.";PGKB_RACE=NR
2	234627536	rs6755571	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A4_(PA37179);PGKB_DRUG=ABT-751_(PA166104276);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_AA_genotype_were_not_studied._However_patients_with_the_AC_genotype_and_neoplasms_may_have_a_decreased_plasma_predose_concentration_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_ABT-751_metabolism.""AC:Patients_with_the_AC_genotype_and_neoplasms_may_have_a_decreased_plasma_predose_concentration_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_ABT-751_metabolism.""CC:Patients_with_the_CC_genotype_and_neoplasms_may_have_an_increased_plasma_predose_concentration_as_compared_to_patients_with_the_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_ABT-751_metabolism.";PGKB_RACE=NR
2	234627608	rs2011425	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A4_(PA37179);PGKB_DRUG=lamotrigine_(PA450164);PGKB_TYPE=Other;PGKB_EVIDENCE=2B;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_epilepsy_who_are_administered_lamotrigine_may_have_decreased_serum_concentrations_of_lamotrigine_as_well_as_a_worse_response_to_lamotrigine_and_may_need_a_lower_dose_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_response_and_dose_of_lamotrigine._""GT:Patients_with_the_GT_genotype_and_epilepsy_who_are_administered_lamotrigine_may_have_decreased_serum_concentrations_of_lamotrigine_as_well_as_worse_response_to_lamotrigine_and_may_need_a_lower_dose_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_response_and_dose_of_lamotrigine._""TT:Patients_with_the_TT_genotype_and_epilepsy_who_are_administered_lamotrigine_may_have_increased_serum_concentrations_of_lamotrigine_as_well_as_improved_response_to_lamotrigine_and_may_need_a_higher_dose_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_response_and_dose_of_lamotrigine._";PGKB_RACE=Asian
2	234665659	rs4124874	T	G	.	.	PGKB_INDEX=2;PGKB_GENE=UGT1A1_(PA420),UGT1A1_(PA420);PGKB_DRUG=irinotecan_(PA450085),deferasirox_(PA164760843);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,4;PGKB_DISEASE="Lymphoma_(PA444840)""Neoplasms_(PA445062)",Thalassemia_(PA445833);PGKB_TEXT="GG:Cancer_patients_with_the_GG_genotype_who_are_treated_with_irinotecan_may_have_an_increased_risk_of_Neutropenia_as_compared_to_patients_with_the_TT_genotype._However_several_subsequent_studies_have_found_no_association_between_the_GG_genotype_and_neutropenia_diarrhea_or_tumor_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""GT:Cancer_patients_with_the_GT_genotype_who_are_treated_with_irinotecan_may_have_an_increased_risk_of_Neutropenia_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_risk_of_Neutropenia_as_compared_to_patients_with_the_GG_genotype._However_several_subsequent_studies_have_found_no_association_between_the_GT_genotype_and_neutropenia_diarrhea_or_tumor_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.""TT:Cancer_patients_with_the_TT_genotype_who_are_treated_with_irinotecan_may_have_a_decreased_risk_of_Neutropenia_as_compared_to_patients_with_the_GG_genotype._However_several_subsequent_studies_have_found_no_association_between_the_TT_genotype_and_neutropenia_diarrhea_or_tumor_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity.","GG:Pediatric_patients_with_major_thalassemia_and_the_GG_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_TT_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_GT_therefore_there_is_no_information_for_patients_with_the_GG_or_TT_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox._""GT:Pediatric_patients_with_major_thalassemia_and_the_GT_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_TT_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_GT_therefore_there_is_no_information_for_patients_with_the_GG_or_TT_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox._""TT:Pediatric_patients_with_major_thalassemia_and_the_TT_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GT_or_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_GT_therefore_there_is_no_information_for_patients_with_the_GG_or_TT_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox._";PGKB_RACE=NR,NR
2	234665782	rs10929302	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=deferasirox_(PA164760843);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=beta-Thalassemia_(PA446432);PGKB_TEXT="AA:Pediatric_patients_with_major_thalassemia_and_the_AA_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_AA_or_GG_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""AG:Pediatric_patients_with_major_thalassemia_and_the_AG_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_AA_or_GG_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""GG:Pediatric_patients_with_major_thalassemia_and_the_GG_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_AG_or_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_AA_or_GG_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.";PGKB_RACE=NR
2	234667937	rs2003569	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=UGT1A9_(PA419);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_simvastatin_(higher_LDL_lowering_effect)_as_compared_to_patients_withe_the_GG_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_simvastatin.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_simvastatin_(higher_LDL_lowering_effect)_as_compared_to_patients_withe_the_GG_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_simvastatin.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_simvastatin_(higher_LDL_lowering_effect)_as_compared_to_patients_withe_the_AA_or_AG_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_simvastatin.";PGKB_RACE=NR
2	234668570	rs887829	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=UGT1A1_(PA420),UGT1A1_(PA420);PGKB_DRUG=atazanavir_(PA10251),deferasirox_(PA164760843);PGKB_TYPE=Other,Metabolism/PK;PGKB_EVIDENCE=1A,3;PGKB_DISEASE=HIV_(PA447230),beta-Thalassemia_(PA446432);PGKB_TEXT="CC:Patients_infected_with_the_human_immunodeficiency_virus_(HIV)_and_the_CC_genotype_who_are_treated_with_atazanavir_may_have_a_decreased_but_not_absent_risk_of_hyperbilirubinemia_and_bilirubin-related_drug_discontinuation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hyperbilirubinemia_or_drug_discontinuation.""CT:Patients_infected_with_the_human_immunodeficiency_virus_(HIV)_and_the_CT_genotype_who_are_treated_with_atazanavir_may_have_a_decreased_but_not_absent_risk_of_hyperbilirubinemia_and_bilirubin-related_drug_discontinuation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hyperbilirubinemia_or_drug_discontinuation.""TT:Patients_infected_with_the_human_immunodeficiency_virus_(HIV)_and_the_TT_genotype_who_are_treated_with_atazanavir_may_have_an_increased_risk_of_hyperbilirubinemia_and_bilirubin-related_drug_discontinuation_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hyperbilirubinemia_or_drug_discontinuation.","CC:Patients_with_the_CC_genotype_and_beta-thalassemia_may_have_decreased_concentrations_of_deferasirox_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""CT:Patients_with_the_CT_genotype_and_beta-thalassemia_may_have_decreased_concentrations_of_deferasirox_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""TT:Patients_with_the_TT_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.";PGKB_RACE=NR,NR
2	234669144	rs4148323	G	A	.	.	PGKB_INDEX=6;PGKB_GENE=UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420),UGT1A1_(PA420);PGKB_DRUG=irinotecan_(PA450085),SN-38_(PA165110775),indinavir_(PA449977),carvedilol_(PA448817),irinotecan_(PA450085),deferasirox_(PA164760843);PGKB_TYPE=NR,Other,Toxicity/ADR,Other,Other,Toxicity/ADR;PGKB_EVIDENCE=3,2A,3,3,2A,4;PGKB_DISEASE=Neoplasms_(PA445062),Neoplasms_(PA445062),HIV_(PA447230),"Angina_Pectoris_(PA443362)""Heart_Failure_(PA444370)",Neoplasms_(PA445062),beta-Thalassemia_(PA446432);PGKB_TEXT="AA:Patients_with_the_AA_(UGT1A1_*6/*6)_genotype_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_1)_an_increased_risk_of_thrombocytopenia_or_diarrhea_as_compared_to_patients_with_the_GG_(*1/*1)_genotype_and_2)_may_have_decreased_tumor_response_progression-free_survival_or_overall_survival_as_compared_to_patients_with_the_AG_(*1/*6)_or_GG_(*1/*1)_genotype._However_one_study_found_increased_progression-free_survival_or_overall_survival_for_patients_who_carried_the_A_(*6)_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tumor_response_and_survival_and_risk_of_thrombocytopenia_and_diarrhea.""AG:Patients_with_the_AG_(*1/*6)_genotype_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_1)_an_increased_risk_of_thrombocytopenia_or_diarrhea_as_compared_to_patients_with_the_GG_(*1/*1)_genotype_and_2)_may_have_increased_tumor_response_progression-free_survival_or_overall_survival_as_compared_to_patients_with_the_AA_(*6/*6)_genotype._However_some_studies_have_found_no_association_with_diarrhea_tumor_response_progression-free_survival_or_overall_survival_for_this_genotype_as_compared_to_those_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tumor_response_and_survival_and_risk_of_thrombocytopenia_and_diarrhea.""GG:Patients_with_the_GG_(*1/*1)_genotype_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_1)_a_decreased_risk_of_thrombocytopenia_or_diarrhea_as_compared_to_patients_with_the_AA_(*6/*6)_or_AG_(*1/*6)_genotype_and_2)_may_have_increased_tumor_response_progression-free_survival_or_overall_survival_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tumor_response_and_survival_and_risk_of_thrombocytopenia_and_diarrhea.","AA:Patients_with_the_AA_genotype_and_cancer_may_have_decreased_metabolism_of_SN-38_when_treated_with_irinotecan_as_compared_to_patients_with_the_AG_or_GG_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A1._One_in_vitro_study_found_decreased_enzyme_activity_for_the_A_allele_compared_to_the_G_allele._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_SN-38.""AG:Patients_with_the_AG_genotype_and_cancer_may_have_increased_metabolism_of_SN-38_when_treated_with_irinotecan_as_compared_to_patients_with_the_AA_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A1._One_in_vitro_study_found_decreased_enzyme_activity_for_the_A_allele_compared_to_the_G_allele._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_SN-38.""GG:Patients_with_the_GG_genotype_and_cancer_may_have_increased_metabolism_of_SN-38_when_treated_with_irinotecan_as_compared_to_patients_with_the_AA_genotype._SN-38_is_the_active_metabolite_of_irinotecan_and_is_glucuronidated_by_UGT1A1._One_in_vitro_study_found_increased_enzyme_activity_for_the_G_allele_compared_to_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_SN-38.","AA:No_patients_with_this_genotype_were_present_in_the_study._However_patients_with_the_AG_genotype_and_HIV_may_have_an_increased_risk_of_developing_hyperbilirubinemia_during_treatment_with_indinavir_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_hyperbilirubinemia_risk._""AG:Patients_with_the_AG_genotype_and_HIV_may_have_an_increased_risk_of_developing_hyperbilirubinemia_during_treatment_with_indinavir_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_hyperbilirubinemia_risk._""GG:Patients_with_the_GG_genotype_and_HIV_may_have_a_decreased_risk_of_developing_hyperbilirubinemia_during_treatment_with_indinavir_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_hyperbilirubinemia_risk._","AA:Patients_with_the_AA_(i.e._UGT1A1_*6/*6)_genotype_and_angina_or_heart_failure_may_have_decreased_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_GG_(*1/*1)_genotype._UGT1A1_is_responsible_for_the_glucuronidation_of_target_substrates_rendering_them_water_soluble_and_allowing_for_their_biliary_or_renal_elimination._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_carvedilol.""AG:Patients_with_the_AG_(i.e._UGT1A1_*1/*6)_genotype_and_angina_or_heart_failure_may_have_decreased_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_GG_(*1/*1)_genotype_or_increased_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_AA_(*6/*6)_genotype._UGT1A1_is_responsible_for_the_glucuronidation_of_target_substrates_rendering_them_water_soluble_and_allowing_for_their_biliary_or_renal_elimination._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_carvedilol.""GG:Patients_with_the_GG_(i.e._UGT1A1_*1/*1)_genotype_and_angina_or_heart_failure_may_have_increased_glucuronidation_of_carvedilol_as_compared_to_patients_with_the_AA_(*6/*6)_genotype._UGT1A1_is_responsible_for_the_glucuronidation_of_target_substrates_rendering_them_water_soluble_and_allowing_for_their_biliary_or_renal_elimination._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_carvedilol.","AA:Patients_with_the_AA_genotype_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_an_increased_risk_of_neutropenia_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia.""AG:Patients_with_the_AG_genotype_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_an_increased_risk_of_neutropenia_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_of_neutropenia_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia.""GG:Patients_with_the_GG_genotype_with_cancer_who_are_treated_with_irinotecan-based_regimens_may_have_a_decreased_risk_of_neutropenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia.","AA:Pediatric_patients_with_major_thalassemia_and_the_AA_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_GG_or_AA_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""AG:Pediatric_patients_with_major_thalassemia_and_the_AG_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_GG_or_AA_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""GG:Pediatric_patients_with_major_thalassemia_and_the_GG_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_AA_or_AG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_GG_or_AA_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.";PGKB_RACE=Asian,Asian,Asian,Asian,Asian,NR
2	234681416	rs10929303	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=UGT1A_(PA37173),UGT1A_(PA37173),UGT1A1_(PA420);PGKB_DRUG=acetaminophen_(PA448015),acetaminophen_(PA448015),"atazanavir_(PA10251)""ritonavir_(PA451260)";PGKB_TYPE=Toxicity/ADR,Other,Toxicity/ADR;PGKB_EVIDENCE=3,4,3;PGKB_DISEASE=Liver_Failure_Acute_(PA446443),NR,"HIV_(PA447230)""nephrolithiasis_(PA162355520)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.","CC:Human_liver_microsomes_with_the_CC_genotype_may_have_decreased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CT_or_TT_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.""CT:Human_liver_microsomes_with_the_CT_genotype_may_have_increased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CC_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.""TT:Human_liver_microsomes_with_the_TT_genotype_may_have_increased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CC_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.","CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_decreased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir._""CT:Patients_with_the_CT_genotype_and_HIV_may_have_a_decreased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_TT_genotype_and_an_increased_risk_of_nephrolithiasis_as_compared_to_people_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir._""TT:Patients_with_the_CC_genotype_and_HIV_may_have_an_increased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir._";PGKB_RACE=White,White,Asian
2	234681544	rs1042640	G	C	.	.	PGKB_INDEX=3;PGKB_GENE=UGT1A_(PA37173),UGT1A_(PA37173),"UGT1A_(PA37173)""UGT1A1_(PA420)";PGKB_DRUG=acetaminophen_(PA448015),acetaminophen_(PA448015),"atazanavir_(PA10251)""ritonavir_(PA451260)";PGKB_TYPE=Other,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=4,3,3;PGKB_DISEASE=NR,Liver_Failure_Acute_(PA446443),"HIV_(PA447230)""nephrolithiasis_(PA162355520)";PGKB_TEXT="CC:Human_liver_microsomes_with_the_CC_genotype_may_have_decreased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CG_or_GG_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.""CG:Human_liver_microsomes_with_the_CG_genotype_may_have_increased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CC_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.""GG:Human_liver_microsomes_with_the_GG_genotype_may_have_increased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CC_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.","CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.""CG:Patients_with_the_CG_genotype_may_have_a_decreased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.","CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_decreased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_CG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir.""CG:Patients_with_the_CG_genotype_and_HIV_may_have_a_decreased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_GG_genotype_and_an_increased_risk_of_nephrolithiasis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_people_with_HIV_who_are_taking_atazanavir_and_ritonavir.""GG:Patients_with_the_GG_genotype_and_HIV_may_have_an_increased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_CG_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir.";PGKB_RACE=White,White,Asian
2	234681645	rs8330	G	C	.	.	PGKB_INDEX=3;PGKB_GENE="UGT1A_(PA37173)""UGT1A9_(PA419)",UGT1A_(PA37173),"UGT1A_(PA37173)""UGT1A1_(PA420)""UGT1A4_(PA37179)";PGKB_DRUG=acetaminophen_(PA448015),acetaminophen_(PA448015),"atazanavir_(PA10251)""ritonavir_(PA451260)";PGKB_TYPE=Toxicity/ADR,Other,Toxicity/ADR;PGKB_EVIDENCE=3,4,3;PGKB_DISEASE=Liver_Failure_Acute_(PA446443),NR,"HIV_(PA447230)""nephrolithiasis_(PA162355520)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.""CG:Patients_with_the_CG_genotype_may_have_a_decreased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_liver_failure_due_to_unintentional_acetaminophen_overdose.","CC:Human_liver_microsomes_with_the_CC_genotype_may_have_decreased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CG_or_GG_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.""CG:Human_liver_microsomes_with_the_CG_genotype_may_have_increased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CC_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.""GG:Human_liver_microsomes_with_the_GG_genotype_may_have_increased_activity_of_UGT1A_proteins_when_exposed_to_acetaminophen_as_compared_to_human_liver_microsomes_with_the_CC_genotype._SNP_was_specified_as_being_in_the_UGT1A-3'UTR._Other_genetic_and_clinical_factors_may_also_influence_activity_of_UGT1A_proteins.","CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_decreased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_CG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir.""CG:Patients_with_the_CG_genotype_and_HIV_may_have_a_decreased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_GG_genotype_and_an_increased_risk_of_nephrolithiasis_as_compared_to_people_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir.""GG:Patients_with_the_GG_genotype_and_HIV_may_have_an_increased_risk_of_nephrolithiasis_when_treated_with_atazanavir_and_ritonavir_as_compared_to_patients_with_the_CG_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_affect_risk_of_nephrolithiasis_in_patients_with_HIV_who_are_taking_atazanavir_and_ritonavir.";PGKB_RACE=White,White,Asian
2	234683350	rs11563250	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=UGT1A_(PA37173),UGT1A_(PA37173);PGKB_DRUG=bilirubin_(PA166123346),irinotecan_(PA450085);PGKB_TYPE=Metabolism/PK,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_metastatic_colorectal_cancer_may_have_increased_concentrations_of_bilirubin_possibly_indicating_reduced_UGT1A1_activity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_such_as_rs8175347_may_also_influence_bilirubin_concentrations.""AG:Patients_with_the_AG_genotype_and_metastatic_colorectal_cancer_may_have_reduced_concentrations_of_bilirubin_possibly_indicating_increased_UGT1A1_activity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_rs8175347_may_also_influence_bilirubin_concentrations.""GG:Patients_with_the_GG_genotype_and_metastatic_colorectal_cancer_may_have_reduced_concentrations_of_bilirubin_possibly_indicating_increased_UGT1A1_activity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_rs8175347_may_also_influence_bilirubin_concentrations.","AA:Patients_with_the_AA_genotype_and_metastatic_colorectal_cancer_may_have_an_increased_risk_of_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_such_as_rs8175347_may_also_influence_risk_for_neutropenia.""AG:Patients_with_the_AG_genotype_and_metastatic_colorectal_cancer_may_have_a_decreased_risk_of_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_rs8175347_may_also_influence_risk_for_neutropenia.""GG:Patients_with_the_GG_genotype_and_metastatic_colorectal_cancer_may_have_a_decreased_risk_of_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_rs8175347_may_also_influence_risk_for_neutropenia.";PGKB_RACE=NR,NR
2	239105715	rs113095083	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ILKAP_(PA29856);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""CT:Patients_with_the_CT_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_TT_genotype_and_an_increased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""TT:Patients_with_the_TT_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.";PGKB_RACE=White
2	241080132	rs2291767	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=OTOS_(PA134906408);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Cancer_patients_with_the_CC_genotype_may_have_a_decreased_risk_of_ototoxicity_when_treated_with_cisplatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_ototoxicity.""CT:Cancer_patients_with_the_CT_genotype_may_have_a_decreased_risk_of_ototoxicity_when_treated_with_cisplatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_ototoxicity.""TT:Cancer_patients_with_the_TT_genotype_may_have_an_increased_risk_of_ototoxicity_when_treated_with_cisplatin_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_ototoxicity.";PGKB_RACE=NR
2	241531479	rs3792269	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CAPN10_(PA26058);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_diabetes_mellitus_may_have_an_increased_response_when_treated_with_metformin_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_metformin._""AG:Patients_with_the_AG_genotype_and_diabetes_mellitus_may_have_a_decreased_response_when_treated_with_metformin_as_compared_to_patients_with_the_AA_genotypes_and_an_increased_response_to_metformin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_metformin._""GG:Patients_with_the_GG_genotype_and_diabetes_mellitus_may_have_a_decreased_response_when_treated_with_metformin_as_compared_to_patients_with_the_AA_or_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_metformin._";PGKB_RACE=NR
2	241542703	rs5030952	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_undergo_kidney_transplant_may_have_a_decreased_risk_for_new-onset_posttransplant_diabetes_mellitus_(PTDM)_when_treated_with_tacrolimus_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_PTDM._""CT:Patients_with_the_CT_genotype_who_undergo_kidney_transplant_may_have_an_increased_risk_for_new-onset_posttransplant_diabetes_mellitus_(PTDM)_when_treated_with_tacrolimus_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_PTDM._""TT:No_patients_with_the_TT_genotype_were_present_in_the_population._However_patients_with_the_CT_genotype_who_undergo_kidney_transplant_may_have_an_increased_risk_for_new-onset_posttransplant_diabetes_mellitus_(PTDM)_when_treated_with_tacrolimus_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_PTDM._";PGKB_RACE=NR
3	12475557	rs3856806	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PPARG_(PA281);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin_hypersensitivity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_hypersensitivity.""CT:Patients_with_the_CT_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin_hypersensitivity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_hypersensitivity.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_an_increased_risk_for_aspirin_hypersensitivity_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_hypersensitivity._";PGKB_RACE=Asian
3	14187449	rs2228001	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=XPC_(PA37413);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=1B;PGKB_DISEASE="Neoplasms_(PA445062)""Osteosarcoma_(PA445601)""Urinary_Bladder_Neoplasms_(PA443512)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_toxicity_with_cisplatin_treatment_including_hearing_loss_and_neutropenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GT:Patients_with_the_GT_genotype_may_have_an_increased_risk_for_toxicity_with_cisplatin_treatment_including_hearing_loss_and_neutropenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_but_not_non-existent_risk_for_toxicity_with_cisplatin_treatment_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
3	29954690	rs17024608	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=RBMS3_(PA34276);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.";PGKB_RACE=White
3	38766338	rs9825762	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SCN10A_(PA35000);PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Women_with_ovarian_cancer_and_the_CC_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""CT:Women_with_ovarian_cancer_and_the_CT_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""TT:Women_with_ovarian_cancer_and_the_TT_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CC_or_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._";PGKB_RACE=NR
3	45731451	rs2742417	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45731784	rs2251954	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45732515	rs2742421	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""GT:Patients_with_the_GT_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45733430	rs2742423	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_AA_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45734818	rs1969624	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype_or_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45740863	rs2742435	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_AA_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45749722	rs2245705	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_TT_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	45756722	rs2742390	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SACM1L_(PA34925);PGKB_DRUG=bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_have_decreased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_GG_genotype_or_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_have_increased_sexual_side-effects_when_treated_with_bupropion_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_sexual_side-effects.";PGKB_RACE=NR
3	47459679	rs12487736	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=SCAP_(PA162402461),SCAP_(PA162402461);PGKB_DRUG=atorvastatin_(PA448500),simvastatin_(PA451363);PGKB_TYPE=Other,Efficacy;PGKB_EVIDENCE=4,3;PGKB_DISEASE=NR,Hypercholesterolemia_(PA444516);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_atorvastatin_may_have_higher_expression_of_SCAP_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""CT:Patients_with_the_CT_genotype_who_are_treated_with_atorvastatin_may_have_higher_expression_of_SCAP_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_atorvastatin_may_have_reduced_expression_of_SCAP_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","CC:Patients_with_the_CC_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_simvastatin_treatment_as_compared_to_patients_with_the_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""CT:Patients_with_the_CT_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_simvastatin_treatment_as_compared_to_patients_with_the_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""TT:Patients_with_the_TT_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_simvastatin_treatment_as_compared_to_patients_with_the_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._";PGKB_RACE=NR,White
3	49064110	rs11706052	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=IMPDH2_(PA29863),IMPDH2_(PA29863);PGKB_DRUG="cyclosporine_(PA449167)""mycophenolate_mofetil_(PA450566)","mycophenolate_mofetil_(PA450566)""mycophenolic_acid_(PA164748728)";PGKB_TYPE=Efficacy,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_who_are_treated_with_cyclosporine_and_mycophenolate_mofetil_may_have_1)_a_decreased_but_not_absent_risk_of_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_2)_increased_response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant.""GA:Patients_with_the_GA_genotype_and_Kidney_Transplantation_who_are_treated_with_cyclosporine_and_mycophenolate_mofetil_may_have_1)_an_increased_risk_of_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_2)_decreased_response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant.""GG_:Patients_with_the_GG_genotype_and_Kidney_Transplantation_who_are_treated_with_cyclosporine_and_mycophenolate_mofetil_may_have_1)_an_increased_risk_of_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_2)_decreased_response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant.","AA:Patients_with_the_AA_genotype_may_have_1)_a_decreased_but_not_absent_risk_for_acute_rejection_after_kidney_transplantation_as_compared_to_patients_with_the_GA_or_GG_genotype_and_2)_an_increased_incidence_of_lymphopenia_as_compared_to_patients_with_the_GA_genotype._However_the_AA_genotype_influence_is_controversy_discussed_among_different_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""GA:Patients_with_the_GA_genotype_may_have_1)_an_increased_risk_for_acute_rejection_after_kidney_transplantation_and_2)_decreased_incidence_of_lymphopenia_as_compared_to_patients_with_the_AA_genotype_but_the_GA_genotype_influence_is_controversy_discussed_among_different_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_acute_rejection_after_kidney_transplantation_as_compared_to_patients_with_the_AA_genotype_but_the_GG_genotype_influence_is_controversy_discussed_among_different_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_rejection_after_transplantation.";PGKB_RACE=White,NR
3	52258372	rs352139	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TLR9_(PA38010);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Crohn_Disease_(PA443815)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
3	113046640	rs13064411	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=WDR52_(PA134928828);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.";PGKB_RACE=NR
3	113862887	rs963468	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DRD3_(PA27479);PGKB_DRUG=duloxetine_(PA10066);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Anxiety_Disorders_(PA447196);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine_treatment.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine_treatment.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_duloxetine_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine_treatment.";PGKB_RACE=White
3	113876275	rs167771	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DRD3_(PA27479);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Bipolar_Disorder_(PA447199)""Schizophrenia_(PA447216)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_for_extrapyramidal_symptoms_in_psychiatric_patients_receiving_risperidone_as_compared_to_patients_with_the_AG_or_GG_genotype._Patients_with_the_AA_genotype_may_still_be_at_risk_for_toxicity_when_taking_risperidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_for_extrapyramidal_symptoms_in_psychiatric_patients_receiving_risperidone_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_for_extrapyramidal_symptoms_in_psychiatric_patients_receiving_risperidone_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=White
3	113879562	rs167770	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DRD3_(PA27479);PGKB_DRUG=duloxetine_(PA10066);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Anxiety_Disorders_(PA447196);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._""AG:Patients_with_the_AG_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_decreased_response_to_duloxetine_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._""GG:Patients_with_the_GG_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._";PGKB_RACE=White
3	113885395	rs324023	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DRD3_(PA27479);PGKB_DRUG=duloxetine_(PA10066);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Anxiety_Disorders_(PA447196);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._""CT:Patients_with_the_CT_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_decreased_response_to_duloxetine_as_compared_to_patients_with_the_CC_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._""TT:Patients_with_the_TT_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._";PGKB_RACE=White
3	113890815	rs6280	C	T	.	.	PGKB_INDEX=7;PGKB_GENE=DRD3_(PA27479),DRD3_(PA27479),DRD3_(PA27479),DRD3_(PA27479),DRD3_(PA27479),DRD3_(PA27479),DRD3_(PA27479);PGKB_DRUG=paroxetine_(PA450801),risperidone_(PA451257),olanzapine_(PA450688),pramipexole_(PA164742949),clozapine_(PA449061),methylphenidate_(PA450464),quetiapine_(PA451201);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Metabolism/PK;PGKB_EVIDENCE=3,3,3,3,3,3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),Autistic_Disorder_(PA447198),Schizophrenia_(PA447216),Parkinson_Disease_(PA445254),Schizophrenia_(PA447216),Autism_Spectrum_Disorder_(PA153906318),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_a_better_response_when_treated_with_paroxetine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_a_better_response_when_treated_with_paroxetine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_a_reduced_response_when_treated_with_paroxetine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.","CC:Patients_with_the_CC_genotype_may_have_greater_reductions_in_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_indicating_improved_symptoms_and_response_to_risperidone_in_Children_with_Autism_than_TT_homozygotes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_greater_reductions_in_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_indicating_improved_symptoms_and_response_to_risperidone_in_Children_with_Autism_than_TT_homozygotes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_smaller_reductions_in_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_indicating_poorer_response_to_risperidone_in_Children_with_Autism_than_TT_homozygotes_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_greater_positive_symptom_improvement_and_positive_symptom_remission_as_compared_to_patients_with_the_TT_and_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""CT:Patients_with_the_CT_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_reduced_positive_symptom_improvement_and_positive_symptom_remission_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_reduced_positive_symptom_improvement_and_positive_symptom_remission_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.","CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_pramipexole_in_Chinese_patients_with_Parkinson's_disease_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_lower_response_rate_to_pramipexole_in_Chinese_patients_with_Parkinson's_disease_than_TT_allele_carriers._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_better_therapeutic_efficacy_(response_rate_:_60%)of_pramipexole_in_Chinese_patients_with_Parkinson's_disease_compared_to_patiens_carrying_the_C_allele_(response_rate_:13%)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Please_note__this_association_was_not_found_in_a_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine_treatment.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Please_note__this_association_was_not_found_in_a_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine_treatment.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Please_note__this_association_was_not_found_in_a_meta-analysis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine_treatment.","CC:Patients_with_the_CC_genotype_and_autism_spectrum_disorders_may_have_a_better_tolerance_for_methylphenidate_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_tolerability_for_methylphenidate_treatment.""CT:Patients_with_the_CT_genotype_and_autism_spectrum_disorders_may_have_a_poorer_tolerance_for_methylphenidate_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_tolerability_for_methylphenidate_treatment.""TT:Patients_with_the_TT_genotype_and_autism_spectrum_disorders_may_have_a_poorer_tolerance_for_methylphenidate_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_tolerability_for_methylphenidate_treatment.","CC:People_with_CC_genotype_may_have_decreased_clearance_of_quetiapine_compared_with_people_with_genotype_TT._Other_genetic_and_clinical_factors_may_affect_a_person's_clearance_of_quetiapine.""CT:People_with_CT_genotype_may_have_decreased_clearance_of_quetiapine_compared_with_people_with_genotype_TT._Other_genetic_and_clinical_factors_may_affect_a_person's_clearance_of_quetiapine.""TT:People_with_TT_genotype_may_have_increased_clearance_of_quetiapine_compared_with_people_with_genotypes_CC_or_CT._Other_genetic_and_clinical_factors_may_affect_a_person's_clearance_of_quetiapine.";PGKB_RACE=Asian,NR,NR,Asian,White,NR,White
3	113891042	rs324026	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DRD3_(PA27479);PGKB_DRUG=duloxetine_(PA10066);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Anxiety_Disorders_(PA447196);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_decreased_response_to_duloxetine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._""CT:Patients_with_the_CT_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_decreased_response_to_duloxetine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._""TT:Patients_with_the_TT_genotype_and_Anxiety_Disorders_who_are_treated_with_duloxetine_may_have_increased_response_to_duloxetine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_duloxetine._";PGKB_RACE=White
3	119499507	rs1523130	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=memantine_(PA10364);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Dementia_(PA443853);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_dementia_may_have_increased_clearance_of_memantine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_memantine.""CT:Patients_with_the_CT_genotype_and_dementia_may_have_decreased_clearance_of_memantine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_memantine.""TT:Patients_with_the_TT_genotype_and_dementia_may_have_decreased_clearance_of_memantine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_memantine.";PGKB_RACE=NR
3	119500035	rs3814055	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_a_patient's_tacrolimus_concentrations._""CT:Patients_with_the_CT_genotype_may_have_increased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_a_patient's_tacrolimus_concentrations._""TT:Patients_with_the_TT_genotype_may_have_increased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_a_patient's_tacrolimus_concentrations._";PGKB_RACE=Asian
3	119501307	rs2276706	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_repaglinide_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_repaglinide._""AG:The_AG_genotype_did_not_differ_significantly_in_metabolism_of_repaglinide_as_compared_to_patients_with_the_GG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_repaglinide._""GG:Patients_with_the_GG_genotype_may_have_decreased_metabolism_of_repaglinide_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_repaglinide._";PGKB_RACE=Asian
3	119518417	rs2472677	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=NR1I2_(PA378),NR1I2_(PA378);PGKB_DRUG=rifampin_(PA451250),atazanavir_(PA10251);PGKB_TYPE=Other,Metabolism/PK;PGKB_EVIDENCE=4,3;PGKB_DISEASE=NR,"Acquired_Immunodeficiency_Syndrome_(PA443250)""HIV_(PA447230)""nephrolithiasis_(PA162355520)";PGKB_TEXT="CC:Genotype_CC_is_associated_with_higher_CYP3A4_acitvity_induced_by_rifampin_compared_to_genotype_CT_or_TT_in_liver_samples.""CT:Genotype_CT_is_associated_with_lower_CYP3A4_acitvity_induced_by_rifampin_compared_with_genotype_CC_particularly_in_livers_from_male_subjects.""TT:Genotype_TT_is_associated_with_lower_CYP3A4_acitvity_induced_by_rifampin_compared_with_genotype_CC_particularly_in_livers_from_male_subjects.","CC:Patients_with_the_CC_genotype_and_HIV_may_have_decreased_metabolism_of_atazanavir_as_compared_to_patients_with_the_CT_and_TT_genotypes_but_the_genotype_is_not_associated_with_drug_discontinuation._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_atazanavir_in_patients_with_HIV.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_decreased_metabolism_of_atazanavir_as_compared_to_patients_with_the_TT_genotype_and_an_increased_metabolism_of_atazanavir_as_compared_to_patients_with_the_CC_genotype_but_the_genotype_is_not_associated_with_drug_discontinuation._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_atazanavir_in_patients_with_HIV.""TT:Patients_with_the_TT_genotype_and_HIV_may_have_increased_metabolism_of_atazanavir_as_compared_to_patients_with_the_CT_and_TT_genotypes_but_the_genotype_is_not_associated_with_drug_discontinuation._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_atazanavir_in_patients_with_HIV.";PGKB_RACE=White,NR
3	119524091	rs4688040	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_metabolism_of_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_TT_or_GT._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_carbamazepine.""GT:Patients_with_the_GT_genotype_may_have_increased_metabolism_of_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_carbamazepine.""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_carbamazepine.";PGKB_RACE=NR
3	119525497	rs7643645	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_levels_of_the_active_metabolite_of_risperidone_9-hydroxy-risperidone_as_compared_to_those_with_the_GG_genotype._This_variant_does_not_appear_to_affect_levels_of_risperidone._Other_genetic_and_clinical_factors_may_also_influence_levels_of_9-hydroxy-risperidone._""AG:No_information_available._""GG:Patients_with_the_GG_genotype_may_have_decreased_levels_of_the_active_metabolite_of_risperidone_9-hydroxy-risperidone_as_compared_to_those_with_the_AA_genotype._This_variant_does_not_appear_to_affect_levels_of_risperidone._Other_genetic_and_clinical_factors_may_also_influence_levels_of_9-hydroxy-risperidone._";PGKB_RACE=NR
3	119533733	rs6785049	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_cancer_may_have_an_increased_risk_for_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_hypertension_in_patients_receiving_sunitinib._""AG:Patients_with_the_AG_genotype_and_cancer_may_have_an_increased_risk_for_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_as_compare_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_hypertension_in_patients_receiving_sunitinib._""GG:Patients_with_the_GG_genotype_and_cancer_may_have_a_decreased_risk_for_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_hypertension_in_patients_receiving_sunitinib._";PGKB_RACE=NR
3	119534153	rs2276707	C	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_undergoing_kidney_transplantation_may_have_increased_dose-adjusted_trough_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_tacrolimus.""CT:Patients_with_the_CT_genotype_who_are_undergoing_kidney_transplantation_may_have_decreased_dose-adjusted_trough_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_tacrolimus.""TT:Patients_with_the_TT_genotype_who_are_undergoing_kidney_transplantation_may_have_decreased_dose-adjusted_trough_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_tacrolimus.";PGKB_RACE=White
3	119537291	rs3814058	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR1I2_(PA378);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_metabolism_of_repaglinide_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_repaglinide.""CT:The_CT_genotype_did_not_differ_significantly_in_metabolism_of_repaglinide_as_compared_to_patients_with_the_CC_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_repaglinide.""TT:Patients_with_the_TT_genotype_may_have_an_metabolism_of_repaglinide_as_compared_to_patients_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_repaglinide.";PGKB_RACE=Asian
3	119631814	rs6438552	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=GSK3B_(PA29009);PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GA:Patients_with_the_GA_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GA_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=NR
3	119813282	rs334558	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=GSK3B_(PA29009),GSK3B_(PA29009);PGKB_DRUG=lithium_(PA450243),"citalopram_(PA449015)""fluoxetine_(PA449673)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Bipolar_Disorder_(PA447199),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""AG:Patients_with_the_AG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.","AA:Patients_with_the_AA_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluoxetine_and_citalopram_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine_and_citalopram.""AG:Patients_with_the_AG_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluoxetine_and_citalopram_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine_and_citalopram.""GG:Patients_with_the_GG_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluoxetine_and_citalopram_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine_and_citalopram.";PGKB_RACE=NR,Asian
3	124456742	rs1801019	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)""leucovorin_(PA450198)""tegafur_(PA452620)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Drug_Toxicity_(PA443937);PGKB_TEXT="CC:Patients_with_CC_genotype_and_cancer_may_have_an_increased_risk_for_toxicity_(Diarrhea_any_grade_3_adverse_event)_when_treated_with_leucovorin_and_tegafur_or_fluorouracil_and_leucovorin_as_compared_to_patients_with_the_CG_and_GG_genotype._One_study_found_no_association_between_the_CC_genotype_and_risk_of_drug_toxicity_in_patients_administered_capecitabine_and/or_fluorouracil._Other_genetic_and_clinical_factors_may_also_influence_response_to_leucovorin_tegafur_capecitabine_and_fluorouracil.""CG:Patients_with_CG_genotype_and_cancer_may_have_a_decreased_but_not_absent_risk_for_toxicity_(Diarrhea_any_grade_3_adverse_event)_when_treated_with_leucovorin_and_tegafur_or_fluorouracil_and_leucovorin_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_have_been_reported_that_show_the_CG_genotype_may_be_associated_with_increased_risk_for_grade_3_to_4_diarrhea_when_treated_with_fluorouracil_and_leucovorin_compared_to_the_GG_genotype._Another_study_found_no_association_between_the_CG_genotype_and_risk_of_drug_toxicity_in_patients_administered_capecitabine_and/or_fluorouracil._Other_genetic_and_clinical_factors_may_also_influence_response_to_leucovorin_tegafur_capecitabine_and_fluorouracil.""GG:Patients_with_GG_genotype_and_cancer_may_have_a_decreased_but_not_absent_risk_for_toxicity_(Diarrhea_any_grade_3_adverse_event)_when_treated_with_leucovorin_and_tegafur_or_fluorouracil_and_leucovorin_as_compared_to_patients_with_the_CC_genotype._One_study_found_no_association_between_the_GG_genotype_and_risk_of_drug_toxicity_in_patients_administered_capecitabine_and/or_fluorouracil._Other_genetic_and_clinical_factors_may_also_influence_response_to_leucovorin_tegafur_capecitabine_and_fluorouracil.";PGKB_RACE=Asian
3	124458938	rs2291078	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=UMPS_(PA363);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="AA:Patients_with_metastasized_cancer_and_the_AA_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_AT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction._""AT:Patients_with_metastasized_cancer_and_the_AT_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_TT_genotype_and_improved_response_as_compared_to_people_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction._""TT:Patients_with_metastasized_cancer_and_the_TT_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_AT_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction._";PGKB_RACE=Asian
3	124462824	rs3772809	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=UMPS_(PA363);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="AA:Patients_with_metastasized_cancer_and_the_AA_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction.""AG:Patients_with_metastasized_cancer_and_the_AG_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GG_genotype_and_worse_response_as_compared_to_people_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction.""GG:Patients_with_metastasized_cancer_and_the_GG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction.";PGKB_RACE=Asian
3	124462959	rs3772810	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=UMPS_(PA363);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="AA:Patients_with_metastasized_cancer_and_the_AA_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction.""AG:Patients_with_metastasized_cancer_and_the_AG_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GG_genotype_and_worse_response_as_compared_to_people_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction.""GG:Patients_with_metastasized_cancer_and_the_GG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_association_with_this_SNP_did_not_remain_significant_after_Bonferroni_correction.";PGKB_RACE=Asian
3	148414887	rs275651	T	A	.	.	PGKB_INDEX=1;PGKB_GENE="AGTR1_(PA43)""RPL38P1_(PA34742)";PGKB_DRUG=perindopril_(PA450877);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_coronary_artery_disease_who_are_treated_with_perindopril_may_have_an_increased_risk_for_cardiac_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiac_events_when_treated_with_perindopril.""AT:Patients_with_the_TA_genotype_and_coronary_artery_disease_who_are_treated_with_perindopril_may_have_an_increased_risk_for_cardiac_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiac_events_when_treated_with_perindopril.""TT:Patients_with_the_TT_genotype_and_coronary_artery_disease_who_are_treated_with_perindopril_may_have_a_decreased_but_not_absent_risk_for_cardiac_events_as_compared_to_patients_with_the_TA_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiac_events_when_treated_with_perindopril.";PGKB_RACE=White
3	148459309	rs12721226	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=AGTR1_(PA43);PGKB_DRUG=losartan_(PA450268);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_affinity_to_losartan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_losartan.""AG:The_AG_genotype_was_not_studied_in_association_with_affinity_to_losartan.""GG:Patients_with_the_GG_genotype_may_have_an_increased_affinity_to_losartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_losartan.";PGKB_RACE=NR
3	148459395	rs5182	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=AGTR1_(PA43),AGTR1_(PA43);PGKB_DRUG=perindopril_(PA450877),Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=4,4;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_higher_risk_for_cardiac_events_when_treated_with_perindopril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_higher_risk_for_cardiac_events_when_treated_with_perindopril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_reduced_risk_for_cardiac_events_when_treated_with_perindopril_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_and_Hypertension_may_have_decreased_but_not_absent_risk_of_Myocardial_Infarction_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Ace_Inhibitors_Plain.""CT:Patients_with_the_CT_genotype_and_Hypertension_may_have_decreased_but_not_absent_risk_of_Myocardial_Infarction_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Ace_Inhibitors_Plain.""TT:Patients_with_the_TT_genotype_and_Hypertension_may_have_increased_risk_of_Myocardial_Infarction_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Ace_Inhibitors_Plain.";PGKB_RACE=White,NR
3	148459988	rs5186	A	C	.	.	PGKB_INDEX=3;PGKB_GENE=AGTR1_(PA43),AGTR1_(PA43),AGTR1_(PA43);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308),captopril_(PA448780),candesartan_(PA448765);PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Diabetes_Mellitus_Type_2_(PA443890),Heart_Failure_(PA444370);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Coronary_Artery_Disease_may_have_a_decreased_major_cardiovascular_events_rate_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_CC_and_CA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_major_cardiovascular_events.""CA:Patients_with_the_CA_genotype_and_Coronary_Artery_Disease_may_have_an_increased_major_cardiovascular_events_rate_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_major_cardiovascular_events.""CC:Patients_with_the_CC_genotype_and_Coronary_Artery_Disease_may_have_an_increased_major_cardiovascular_events_rate_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_major_cardiovascular_events.","AA:Patients_with_the_AA_genotype_and_type_2_diabetes_may_have_a_decreased_response_when_treated_with_captopril_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_captopril.""AC:Patients_with_the_AC_genotype_and_type_2_diabetes_may_have_an_increased_response_when_treated_with_captopril_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_captopril.""CC:Patients_with_the_CC_genotype_and_type_2_diabetes_may_have_an_increased_response_when_treated_with_captopril_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_captopril.","AA:Patients_with_the_AA_genotype_and_heart_failure_may_have_an_increased_response_when_treated_with_candesartan_as_compared_to_patients_with_the_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_candesartan.""AC:Patients_with_the_AC_genotype_and_heart_failure_may_have_a_decreased_response_when_treated_with_candesartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_candesartan.""CC:No_patients_with_the_CC_genotype_were_present_in_the_study_analysis._However_patients_with_the_AC_genotype_and_heart_failure_may_have_a_decreased_response_when_treated_with_candesartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_candesartan.";PGKB_RACE=NR,NR,White
3	151056598	rs6809699	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY12_(PA134971947);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_treated_with_clopidogrel_may_have_1)_a_stronger_aggregation_2)_increased_risk_of_non-response_as_compared_to_patients_with_the_AC_or_CC_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""AC:Patients_with_the_AC_genotype_and_treated_with_clopidogrel_may_have_1)_an_average_aggregation_2)_decreased_but_not_absent_risk_of_non-response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""CC:Patients_with_the_CC_genotype_and_treated_with_clopidogrel_may_have_1)_an_average_aggregation_2)_decreased_but_not_absent_risk_of_non-response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=NR
3	151056616	rs6785930	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY12_(PA134971947);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_clopidogrel_may_have_an_increased_risk_of_neurological_events_as_compared_to_patients_with_the_GG_genotype._However_no_association_with_differences_in_risk_of_cardiovascular_events_was_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""AG:Patients_with_the_AG_genotype_who_are_treated_with_clopidogrel_may_have_an_increased_risk_of_neurological_events_as_compared_to_patients_with_the_GG_genotype._However_no_association_with_differences_in_risk_of_cardiovascular_events_was_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""GG:Patients_with_the_GG_genotype_who_are_treated_with_clopidogrel_may_have_a_decreased_but_not_absent_risk_of_neurological_events_as_compared_to_patients_with_the_AA_genotype._However_no_association_with_differences_in_risk_of_cardiovascular_events_was_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._";PGKB_RACE=NR
3	151057642	rs2046934	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY12_(PA134971947);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Acute_coronary_syndrome_(PA165108401)""Angina_Pectoris_(PA443362)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_clopidogrel_(_increased_platelet_activation_to_ADP)_as_compared_to_patients_with_the_GG_or_AG_genotype._However_the_majority_of_the_literature_suggests_this_variant_is_not_significantly_associated_with_response_to_clopidogrel._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_clopidogrel.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_clopidogrel_(_increased_platelet_activation_to_ADP)_as_compared_to_patients_with_the_AA_genotype._However_the_majority_of_the_literature_suggests_this_variant_is_not_significantly_associated_with_response_to_clopidogrel._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_clopidogrel.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_clopidogrel_(_increased_platelet_activation_to_ADP)_as_compared_to_patients_with_the_AA_genotype._However_the_majority_of_the_literature_suggests_this_variant_is_not_significantly_associated_with_response_to_clopidogrel._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=NR
3	151090996	rs9859552	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY12_(PA134971947);PGKB_DRUG=cangrelor_(PA165945763);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_more_inhibition_of_platelet_aggregation_with_crangrelor_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cangrelor.""GT:No_information_is_reported_for_the_GT_genotype._However_patients_with_the_TT_genotype_may_have_less_inhibition_of_platelet_aggregation_with_crangrelor_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cangrelor.""TT:Patients_with_the_TT_genotype_may_have_less_inhibition_of_platelet_aggregation_with_crangrelor_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cangrelor.";PGKB_RACE=NR
3	151099741	rs6787801	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=P2RY12_(PA134971947),P2RY12_(PA134971947);PGKB_DRUG=cangrelor_(PA165945763),clopidogrel_(PA449053);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=4,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_lower_ADP-induced_peak_platelet_aggregation_when_exposed_to_cangrelor_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cangrelor.""GT:Patients_with_the_GT_genotype_may_have_lower_ADP-induced_peak_platelet_aggregation_when_exposed_to_cangrelor_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cangrelor.""TT:Patients_with_the_TT_genotype_may_have_higher_ADP-induced_peak_platelet_aggregation_when_exposed_to_cangrelor_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cangrelor.","AA:Patients_with_the_AA_genotype_undergoing_percutaneous_coronary_intervention_who_are_CYP2C19*1/*1_carriers_may_have_a_decreased_but_not_absent_risk_for_high_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""AG:Patients_with_the_AG_genotype_undergoing_percutaneous_coronary_intervention_who_are_CYP2C19*1/*1_carriers_may_have_an_increased_risk_for_high_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""GG:Patients_with_the_GG_genotype_undergoing_percutaneous_coronary_intervention_who_are_CYP2C19*1/*1_carriers_may_have_an_increased_risk_for_high_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=NR,White
3	152553628	rs1065776	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=P2RY1_(PA32868);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Myocardial_Infarction_(PA445019);PGKB_TEXT="CC:Patients_with_CC_genotype_were_not_studied_but_patients_with_the_CT_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_an_aspirin-resistant_phenotype_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported_for_C_allele_carriers._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""CT:Patients_with_the_CT_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_an_aspirin-resistant_phenotype_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""TT:Patients_with_the_TT_genotype_who_are_treated_with_aspirin_may_have_a_decreased_but_not_absent_risk_of_an_aspirin-resistant_phenotype_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._";PGKB_RACE=NR
3	154858685	rs2016848	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MME_(PA30864);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Cough_(PA443803)""Hypertension_(PA444552)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_for_cough_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough_with_ACE_inhibitor_treatment.""AG:Patients_with_the_AG_genotype_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_for_cough_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough_with_ACE_inhibitor_treatment._Patients_with_this_genotype_were_not_studied_directly.""GG:Patients_with_the_GG_genotype_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_for_cough_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough_with_ACE_inhibitor_treatment.";PGKB_RACE=NR
3	159713467	rs568408	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL12A_(PA29784);PGKB_DRUG=mycophenolate_mofetil_(PA450566);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_toxicity_with_mycophenolate_mofetil.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_toxicity_with_mycophenolate_mofetil.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_of_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_toxicity_with_mycophenolate_mofetil.";PGKB_RACE=NR
3	160429869	rs7624766	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_methotrexate_as_compared_to_patients_with_the_AA_genotype_or_may_have_increased_response_to_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian
3	165491280	rs1803274	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=BCHE_(PA25294);PGKB_DRUG=succinylcholine_(PA451522);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=postanesthesia_apnea_(PA166122649);PGKB_TEXT="CC:Patients_with_the_CC_genotype_have_a_decreased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""CT:Patients_with_the_CT_genotype_have_a_decreased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_TT_genotype_and_an_increased_risk_of_post_anesthesia_apnea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""TT:Patients_with_the_TT_genotype_have_an_increased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.";PGKB_RACE=NR
3	165547569	rs28933390	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=BCHE_(PA25294);PGKB_DRUG=succinylcholine_(PA451522);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_have_an_increased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""AC:Patients_with_the_AC_genotype_have_a_decreased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_AA_genotype_and_an_increased_risk_of_post_anesthesia_apnea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""CC:Patients_with_the_CC_genotype_have_a_decreased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_T_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.";PGKB_RACE=NR
3	165548010	rs28933389	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=BCHE_(PA25294);PGKB_DRUG=succinylcholine_(PA451522);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_have_an_increased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""AG:Patients_with_the_AG_genotype_have_an_decreased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_AA_genotype_and_an_increased_risk_of_post_anesthesia_apnea_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""GG:Patients_with_the_GG_genotype_have_a_decreased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_A_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.";PGKB_RACE=NR
3	165548529	rs1799807	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=BCHE_(PA25294);PGKB_DRUG=succinylcholine_(PA451522);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=postanesthesia_apnea_(PA166122649);PGKB_TEXT="CC:Patients_with_the_CC_genotype_have_an_increased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""CT:Patients_with_the_CT_genotype_have_an_increased_risk_of_post_anesthesia_apnea_when_treated_with_succinylcholine_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_risk_of_post_anesthesia_apnea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.""TT:Patients_with_the_TT_genotype_have_a_decreased_risk_of_post_anesthesia_apnea_as_compared_to_patients_with_the_CC_genotype_when_treated_with_succinylcholine._Other_genetic_and_clinical_factors_may_also_influence_risk_of_post_anesthesia_apnea.";PGKB_RACE=NR
3	178913006	rs870995	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=PIK3CA_(PA33308);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_clearance_of_docetaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""AC:Patients_with_the_CA_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_AA_genotype_or_decreased_clearance_of_docetaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.";PGKB_RACE=White
3	183705184	rs3749438	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC5_(PA395);PGKB_DRUG="fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_grade_34_severe_diarrhea_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_grade_34_severe_diarrhea.""AG:Patients_with_the_AG_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_grade_34_severe_diarrhea_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_grade_34_severe_diarrhea.""GG:Patients_with_the_GG_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_a_decreased_but_not_absent_risk_for_grade_34_severe_diarrhea_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_grade_34_severe_diarrhea.";PGKB_RACE=White
3	183708439	rs10937158	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC5_(PA395);PGKB_DRUG="fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_grade_34_severe_diarrhea_as_compared_to_patients_with_the_CT_+_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_grade_34_severe_diarrhea.""CT:Patients_with_the_CT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_a_decreased_but_not_absent_risk_for_grade_34_severe_diarrhea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_grade_34_severe_diarrhea.""TT:Patients_with_the_TT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_a_decreased_but_not_absent_risk_for_grade_34_severe_diarrhea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_grade_34_severe_diarrhea.";PGKB_RACE=White
3	183724072	rs2292997	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_Neutropenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Neutropenia.""AG:Patients_with_the_AG_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_Neutropenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Neutropenia.""GG:Patients_with_the_GG_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_a_decreased_but_not_absent_risk_for_Neutropenia_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Neutropenia.";PGKB_RACE=White
3	186570892	rs2241766	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADIPOQ_(PA134933118);PGKB_DRUG=pioglitazone_(PA450970);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_diabetes_mellitus_may_have_an_increased_response_to_pioglitazone_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_also_influence_response_to_pioglitazone_in_people_with_diabetes_mellitus._*Please_note:_in_the_single_study_referenced_here_there_were_no_individuals_of_genotype_GG.""GT:Patients_with_the_GT_genotype_and_diabetes_mellitus_may_have_an_increased_response_to_pioglitazone_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_also_influence_response_to_pioglitazone_in_people_with_diabetes_mellitus._*Please_note:_in_the_single_study_referenced_here_there_were_no_individuals_of_genotype_GG.""TT:Patients_with_the_TT_genotype_and_diabetes_mellitus_may_have_a_decreased_response_to_pioglitazone_as_compared_to_patients_with_the_GT_genotype._Other_clinical_and_genetic_factors_also_influence_response_to_pioglitazone_in_people_with_diabetes_mellitus._*Please_note:_in_the_single_study_referenced_here_there_were_no_individuals_of_genotype_GG.";PGKB_RACE=Asian
3	194082161	rs11313667	TC	T	.	.	PGKB_INDEX=3;PGKB_GENE=LRRC15_(PA134956867),LRRC15_(PA134956867),LRRC15_(PA134956867);PGKB_DRUG=hydrochlorothiazide_(PA449899),atenolol_(PA448499),metoprolol_(PA450480);PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Hypertension_(PA444552),Hypertension_(PA444552),Hypertension_(PA444552);PGKB_TEXT="C/del:Patients_with_the_C/del_genotype_and_hypertension_may_have_decreased_response_to_hydrochlorothiazide_compared_to_patients_with_genotype_del/del._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_hydrochlorothiazide.""CC:Patients_with_the_CC_genotype_and_hypertension_may_have_decreased_response_to_hydrochlorothiazide_compared_to_patients_with_genotype_del/del._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_hydrochlorothiazide.""del/del:Patients_with_the_del/del_genotype_and_hypertension_may_have_increased_response_to_hydrochlorothiazide_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_hydrochlorothiazide.","C/del:Patients_with_the_C/del_genotype_and_hypertension_may_have_decreased_response_to_atenolol_compared_to_patients_with_genotype_del/del._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_atenolol.""CC:Patients_with_the_CC_genotype_and_hypertension_may_have_decreased_response_to_atenolol_compared_to_patients_with_genotype_del/del._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_atenolol.""del/del:Patients_with_the_del/del_genotype_and_hypertension_may_have_increased_response_to_atenolol_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_atenolol.","C/del:Patients_with_the_C/del_genotype_and_hypertension_may_have_decreased_response_to_metoprolol_compared_to_patients_with_genotype_del/del._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_metoprolol""CC:Patients_with_the_CC_genotype_and_hypertension_may_have_decreased_response_to_metoprolol_compared_to_patients_with_genotype_del/del._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_metoprolol.""del/del:Patients_with_the_del/del_genotype_and_hypertension_may_have_increased_response_to_metoprolol_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_metoprolol.";PGKB_RACE=Black_or_African_American,"Black_or_African_American""White",Black_or_African_American
3	194586088	rs11719165	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_leukopenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia.""CT:Patients_with_the_CT_genotype_and_neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_leukopenia_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_but_not_absent_risk_for_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia.""TT:Patients_with_the_TT_genotype_and_neoplasms_who_are_treated_with_gemcitabine_may_have_a_decreased_but_not_absent_risk_for_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia.";PGKB_RACE=Asian
4	2906707	rs4961	G	T	.	.	PGKB_INDEX=4;PGKB_GENE=ADD1_(PA31),ADD1_(PA31),ADD1_(PA31),ADD1_(PA31);PGKB_DRUG="bumetanide_(PA448682)""furosemide_(PA449719)""torasemide_(PA451733)",hydrochlorothiazide_(PA449899),diuretics_(PA151249535),"furosemide_(PA449719)""spironolactone_(PA451483)";PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,2B;PGKB_DISEASE=NR,"Essential_hypertension_(PA447288)""Hypertension_(PA444552)","Hypertension_(PA444552)""Myocardial_Infarction_(PA445019)",Liver_Cirrhosis_(PA444797);PGKB_TEXT="GG:Healthy_males_with_the_GG_genotype_may_have_a_decreased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_and_torasemide.""GT:Healthy_males_with_the_GT_genotype_may_have_an_increased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_GG_genotype_or_a_decreased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_and_torasemide._""TT:Healthy_males_with_the_TT_genotype_may_have_an_increased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_and_torasemide.","GG:Patients_with_the_GG_genotype_may_have_a_poorer_response_to_hydrochlorothiazide_treatment_as_compared_to_patients_with_the_TT_or_GT_genotype._This_association_has_not_been_found_in_all_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""GT:Patients_with_the_GT_genotype_may_have_a_better_response_to_hydrochlorothiazide_treatment_as_compared_to_patients_with_the_GG_genotype._This_association_has_not_been_found_in_all_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""TT:Patients_with_the_TT_genotype_may_have_a_better_response_to_hydrochlorothiazide_treatment_as_compared_to_patients_with_the_GG_genotype._This_association_has_not_been_found_in_all_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.","GG:Patients_with_the_GG_genotype_and_Hypertension_who_are_treated_with_diuretics_may_have_an_increased_likelihood_of_Myocardial_Infarction_as_compared_to_patients_with_the_GT_or_TT_genotype._However_this_association_was_not_found_in_a_large_cohort_of_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.""GT:Patients_with_the_GT_genotype_and_Hypertension_who_are_treated_with_diuretics_may_have_a_decreased_likelihood_of_Myocardial_Infarction_as_compared_to_patients_with_the_GG_genotype._However_this_association_was_not_found_in_a_large_cohort_of_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.""TT:Patients_with_the_TT_genotype_and_Hypertension_who_are_treated_with_diuretics_may_have_a_decreased_likelihood_of_Myocardial_Infarction_as_compared_to_patients_with_the_GG_genotype._However_this_association_was_not_found_in_a_large_cohort_of_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.","GG:Patients_with_the_GG_genotype_and_Liver_Cirrhosis_who_are_treated_with_furosemide_and_spironolactone_may_be_more_likely_to_respond_to_diuretic_treatment_as_compared_to_patients_with_the_GT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.""GT:Patients_with_the_GT_genotype_and_Liver_Cirrhosis_who_are_treated_with_furosemide_and_spironolactone_may_be_less_likely_to_respond_to_diuretic_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.""TT:Patients_with_the_TT_genotype_and_Liver_Cirrhosis_who_are_treated_with_furosemide_and_spironolactone_may_be_less_likely_to_respond_to_diuretic_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.";PGKB_RACE=White,NR,NR,Asian
4	3006043	rs1024323	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=GRK4_(PA28941),GRK4_(PA28941);PGKB_DRUG=metoprolol_(PA450480),"atenolol_(PA448499)""verapamil_(PA451868)";PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,4;PGKB_DISEASE="Hypertension_(PA444552)""Kidney_Diseases_(PA444682)""Nephrosclerosis_(PA445086)","Coronary_Artery_Disease_(PA443796)""Hypertension_(PA444552)";PGKB_TEXT="CC:In_male_patients_with_the_rs1024323_CC_genotype_and_hypertensive_nephrosclerosis_1)_those_who_also_have_the_rs2960306_TC_or_TT_genotype_may_have_a_reduced_response_to_metoprolol_compared_to_those_with_rs1024323_genotype_CT_and_TT_2)_those_who_also_have_the_rs2960306_GG_genotype_may_have_a_similar_response_to_metoprolol_compared_to_genotype_CT_and_TT._No_association_was_found_in_women_with_hypertensive_nephrosclerosis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol_treatment.""CT:In_male_patients_with_the_rs1024323_CT_genotype_and_hypertensive_nephrosclerosis_1)_those_who_also_have_the_rs2960306_TC_or_TT_genotype_may_have_a_reduced_response_to_metoprolol_compared_to_those_with_rs1024323_genotype_TT_or_better_response_compared_to_those_with_rs1024323_genotype_CC_2)_those_who_also_have_the_rs2960306_GG_genotype_may_have_a_similar_response_to_metoprolol_compared_to_genotype_CC_and_TT._No_association_was_found_in_women_with_hypertensive_nephrosclerosis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol_treatment.""TT:In_male_patients_with_the_rs1024323_TT_genotype_and_hypertensive_nephrosclerosis_1)_those_who_also_have_the_rs2960306_TC_or_TT_genotype_may_have_a_better_response_to_metoprolol_compared_to_those_with_rs1024323_genotype_CT_and_TT_2)_those_who_also_have_the_rs2960306_GG_genotype_may_have_a_similar_response_to_metoprolol_compared_to_genotype_CT_and_TT._No_association_was_found_in_women_with_hypertensive_nephrosclerosis._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol_treatment.","CC:Patients_with_the_CT_genotype_and_hypertension_and_coronory_artery_disease_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_outcomes_when_treated_with_atenolol_or_verapamil_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atenolol_or_verapamil.""CT:Patients_with_the_CT_genotype_and_hypertension_and_coronory_artery_disease_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_outcomes_when_treated_with_atenolol_or_verapamil_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atenolol_or_verapamil.""TT:Patients_with_the_TT_genotype_and_hypertension_and_coronory_artery_disease_may_have_increased_risk_for_adverse_cardiovascular_outcomes_when_treated_with_atenolol_or_verapamil_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atenolol_or_verapamil.";PGKB_RACE=Black_or_African_American,NR
4	3769296	rs61767072	GGGGGCGGGGCCG	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADRA2C_(PA37);PGKB_DRUG=bucindolol_(PA165945764);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Heart_Failure_(PA444370);PGKB_TEXT="GGGGCGGGGCCG/GGGGCGGGGCCG:Patients_with_the_GGGGCGGGGCCG/GGGGCGGGGCCG_genotype_and_heart_failure_may_have_increased_response_to_bucindolol_as_compared_to_patients_with_the_GGGGCGGGGCCG/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bucindolol.""GGGGCGGGGCCG/del:Patients_with_the_GGGGCGGGGCCG/del_genotype_and_heart_failure_may_have_decreased_response_to_bucindolol_as_compared_to_patients_with_the_GGGGCGGGGCCG/GGGGCGGGGCCG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bucindolol.""del/del:Patients_with_the_GGGGCGGGGCCG/GGGGCGGGGCCG_genotype_and_heart_failure_may_have_decreased_response_to_bucindolol_as_compared_to_patients_with_the_GGGGCGGGGCCG/GGGGCGGGGCCG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bucindolol.";PGKB_RACE=NR
4	3769789	rs11269124	G	GGGGGAGCTTTCCCAGAGACCC	.	.	PGKB_INDEX=1;PGKB_GENE=ADRA2C_(PA37);PGKB_DRUG=clonidine_(PA449051);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Liver_Cirrhosis_(PA444797);PGKB_TEXT="GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC:Patients_with_the_GGGG.../GGGG..._genotype_and_liver_cirrhosis_with_refractory_ascites_may_be_less_likely_to_respond_to_treatment_with_clonidine_as_compared_to_patients_with_the_GGGG.../del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clonidine.""GGGGAGCTTTCCCAGAGACCC/del:Patients_with_the_GGGG.../del_genotype_and_liver_cirrhosis_with_refractory_ascites_may_be_more_likely_to_respond_to_treatment_with_clonidine_as_compared_to_patients_with_the_GGGG.../GGGG..._genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clonidine.""del/del:Patients_with_the_del/del_genotype_and_liver_cirrhosis_with_refractory_ascites_may_be_more_likely_to_respond_to_treatment_with_clonidine_as_compared_to_patients_with_the_GGGG.../GGGG..._genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clonidine.";PGKB_RACE=Asian
4	21355883	rs6838116	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNIP4_(PA134893552);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AC_and_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""AC:Patients_with_the_AC_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_CC_genotype_and_less_likely_than_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors._""CC:Patients_with_the_CC_genotype_may_be_less_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AC_and_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors._";PGKB_RACE=NR
4	21385537	rs7675300	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=KCNIP4_(PA134893552);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AC_and_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""AC:Patients_with_the_AC_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_CC_genotype_and_less_likely_than_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""CC:Patients_with_the_CC_genotype_may_be_less_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AC_and_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.";PGKB_RACE=NR
4	21386764	rs16870989	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=KCNIP4_(PA134893552);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AT_and_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""AT:Patients_with_the_AT_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_TT_genotype_and_less_likely_than_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""TT:Patients_with_the_TT_genotype_may_be_less_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AT_and_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.";PGKB_RACE=NR
4	21391194	rs145489027	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=KCNIP4_(PA134893552);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""AG:Patients_with_the_AG_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_GG_genotype_and_less_likely_than_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""GG:Patients_with_the_GG_genotype_may_be_less_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_AG_and_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.";PGKB_RACE=NR
4	21393616	rs1495509	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNIP4_(PA134893552);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_CT_and_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors._""CT:Patients_with_the_CT_genotype_may_be_more_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_TT_genotype_and_less_likely_than_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.""TT:Patients_with_the_TT_genotype_may_be_less_likely_to_experience_ACE_inhibitor_induced_cough_when_taking_ACE_inhibitors_as_compared_to_patients_with_the_CT_and_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_ACE_inhibitor_induced_cough_in_patients_who_are_taking_ACE_inhibitors.";PGKB_RACE=NR
4	35372098	rs437943	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Rheumatoid_Arthritis_patients_with_the_CC_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_TT.""CT:Rheumatoid_Arthritis_patients_with_the_CT_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_TT.""TT:Rheumatoid_Arthritis_patients_with_the_TT_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_CC_or_CT_.";PGKB_RACE=White
4	38139024	rs9852	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TBC1D1_(PA36342);PGKB_DRUG="clozapine_(PA449061)""olanzapine_(PA450688)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_experience_a_greater_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_when_receiving_clozapine_or_olanzapine.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_experience_less_of_a_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_when_receiving_clozapine_or_olanzapine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_experience_less_of_a_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_when_receiving_clozapine_or_olanzapine.";PGKB_RACE=NR
4	42003671	rs1047626	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC30A9_(PA25909);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=aspirin-induced_asthma_(PA131285571);PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AG:Patients_with_asthma_and_the_AG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
4	55972946	rs34231037	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=KDR_(PA30086);PGKB_DRUG=pazopanib_(PA165291492);PGKB_TYPE="Efficacy""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Neoplasms_(PA444685);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Kidney_Neoplasms_may_have_increased_steady_state_levels_of_KDR_possibly_leading_to_increased_metabolism_of_and_decreased_response_to_pazopanib_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_and_response_to_pazopanib._""AG:Patients_with_the_AG_genotype_and_Kidney_Neoplasms_may_have_increased_steady_state_levels_of_KDR_possibly_leading_to_increased_metabolism_of_and_decreased_response_to_pazopanib_as_compared_to_patients_with_the_GG_genotypes._Conversely_patients_with_the_AG_genotype_may_have_decreased_steady_state_levels_of_KDR_and_an_increased_response_to_pazopanib_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_and_response_to_pazopanib._""GG:Patients_with_the_GG_genotype_and_Kidney_Neoplasms_may_have_decreased_steady_state_levels_of_KDR_possibly_leading_to_decreased_metabolism_of_and_increased_response_to_pazopanib_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_and_response_to_pazopanib._";PGKB_RACE=NR
4	55992139	rs2239702	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=KDR_(PA30086);PGKB_DRUG=sorafenib_(PA7000);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_more_favorable_progression-free_survival_and_overall_survival_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sorafenib.""CT:Patients_with_the_CT_genotype_may_have_unfavorable_progression-free_survival_and_overall_survival_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sorafenib.""TT:Patients_with_the_TT_genotype_may_have_unfavorable_progression-free_survival_and_overall_survival_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sorafenib.";PGKB_RACE=Asian
4	56301369	rs1801260	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CLOCK_(PA26609);PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Bipolar_Disorder_may_have_a_decreased_but_not_absent_risk_for_sleep_disturbances_when_treated_with_lithium_as_compared_to_patients_with_the_GG_genotype._No_association_of_the_G_allele_is_found_with_response_to_lithium_as_compared_to_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""GA:Patients_with_the_GA_genotype_and_Bipolar_Disorder_may_have_a_decreased_but_not_absent_risk_for_sleep_disturbances_when_treated_with_lithium_as_compared_to_patients_with_the_GG_genotype._No_association_of_the_G_allele_is_found_with_response_to_lithium_as_compared_to_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_have_an_increased_risk_for_sleep_disturbances_when_treated_with_lithium_as_compared_to_patients_with_the_AA_genotype._No_association_of_the_G_allele_is_found_with_response_to_lithium_as_compared_to_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.";PGKB_RACE=White
4	56331771	rs1522113	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CLOCK_(PA26609);PGKB_DRUG=salbutamol_(PA448068);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.""AG:Patients_with_the_AG_genotype_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.""GG:Patients_with_the_GG_genotype_may_have_decreased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.";PGKB_RACE=NR
4	69536084	rs1902023	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT2B15_(PA37188);PGKB_DRUG=oxazepam_(PA450731);PGKB_TYPE=Other;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="AA:Subjects_with_the_AA_genotype_who_are_treated_with_oxazepam_may_have_a_decreased_oxazepam_oral_clearance_as_compared_to_subjects_with_the_CC_genotype_which_the_study_reports_resulted_in_no_differences_in_pharmacodynamic_measures._Other_genetic_and_clinical_factors_may_also_influence_the_oral_clearance_of_oxazepam.""AC:Subjects_with_the_AC_genotype_who_are_treated_with_oxazepam_may_have_a_decreased_oxazepam_oral_clearance_as_compared_to_subjects_with_the_CC_genotype_which_the_study_reports_resulted_in_no_differences_in_pharmacodynamic_measures._Other_genetic_and_clinical_factors_may_also_influence_the_oral_clearance_of_oxazepam.""CC:Subjects_with_the_CC_genotype_who_are_treated_with_oxazepam_may_have_an_increased_oxazepam_oral_clearance_as_compared_to_subjects_with_the_AA_and_AC_genotype_which_the_study_reports_resulted_in_no_differences_in_pharmacodynamic_measures._Other_genetic_and_clinical_factors_may_also_influence_the_oral_clearance_of_oxazepam.";PGKB_RACE=NR
4	69681936	rs61750900	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_an_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_nicotine.""GT:Patients_with_the_GT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_nicotine.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_nicotine.";PGKB_RACE=NR
4	69696451	rs112561475	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=UGT2B10_(PA37186);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_nicotine.""GA:Patients_with_the_GA_genotype_may_have_an_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_nicotine.""GG:Patients_with_the_GG_genotype_may_have_an_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_nicotine.";PGKB_RACE=NR
4	69961339	rs7438135	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=UGT2B7_(PA361),UGT2B7_(PA361);PGKB_DRUG=morphine_(PA450550),mycophenolate_mofetil_(PA450566);PGKB_TYPE=Metabolism/PK,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_lower_levels_of_morphine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_morphine_concentrations.""AG:Patients_with_the_AG_genotype_may_have_lower_levels_of_morphine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_morphine_concentrations.""GG:Patients_with_the_GG_genotype_may_have_higher_levels_of_morphine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_morphine_concentrations.","AA:Patients_with_the_AA_genotype_and_kidney_transplantation_may_have_decreased_but_not_absent_risk_for_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""AG:Patients_with_the_AG_genotype_and_kidney_transplantation_may_have_increased_risk_for_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_but_not_absent_risk_for_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""GG:Patients_with_the_GG_genotype_and_kidney_transplantation_may_have_increased_risk_for_anemia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.";PGKB_RACE=NR,NR
4	69962078	rs7668258	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=UGT2B7_(PA361);PGKB_DRUG=lamotrigine_(PA450164);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_1)_have_increased_clearance_(CL/F)_and_2)_require_higher_doses_of_lamotrigine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lamotrigine.""CT:Patients_with_the_CT_genotype_may_1)_have_decreased_clearance_(CL/F)_and_2)_require_lower_doses_of_lamotrigine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lamotrigine.""TT:Patients_with_the_TT_genotype_may_1)_have_decreased_clearance_(CL/F)_and_2)_require_lower_doses_of_lamotrigine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lamotrigine.";PGKB_RACE=NR
4	69964271	rs28365062	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=UGT2B7_(PA361);PGKB_DRUG=zidovudine_(PA451954);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_dereased_metabolism_of_zidovudine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_zidovudine_metabolism.""GA:Patients_with_the_GA_genotype_may_have_an_increased_metabolism_of_zidovudine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_zidovudine_metabolism.""GG:Patients_with_the_GG_genotype_may_have_an_increased_metabolism_of_zidovudine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_zidovudine_metabolism.";PGKB_RACE=Black_or_African_American
4	69964338	rs7439366	T	C	.	.	PGKB_INDEX=4;PGKB_GENE=UGT2B7_(PA361),UGT2B7_(PA361),UGT2B7_(PA361),UGT2B7_(PA361);PGKB_DRUG=valproic_acid_(PA451846),efavirenz_(PA449441),"lorazepam_(PA450267)""valproic_acid_(PA451846)",codeine_(PA449088);PGKB_TYPE="Dosage""Efficacy",Other,Efficacy,Dosage;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=NR,HIV_Infections_(PA446213),NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_valproic_acid_as_compared_to_patients_with_TT_or_TC_genotype._The_association_was_found_in_individuals_with_no_disease_and_was_not_reported_in_cohort_of_patients_with_Epilepsy._Other_genetic_and_clinical_factors_may_also_influence_response_to_valproic_acid.""TC:Patients_with_the_TC_genotype_may_have_increased_response_to_valproic_acid_as_compared_to_patients_with_CC_genotype._The_association_was_found_in_individuals_with_no_disease_and_was_not_reported_in_cohort_of_patients_with_Epilepsy._Other_genetic_and_clinical_factors_may_also_influence_response_to_valproic_acid.""TT:Patients_with_the_TT_genotype_may_have_increased_response_to_valproic_acid_as_compared_to_patients_with_CC_genotype._The_association_was_found_in_individuals_with_no_disease_and_was_not_reported_in_cohort_of_patients_with_Epilepsy._Other_genetic_and_clinical_factors_may_also_influence_response_to_valproic_acid.","CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_higher_plasma_concentrations_of_the_drug_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""CT:Patients_with_the_CT_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_higher_plasma_concentrations_of_the_drug_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_lower_plasma_concentrations_of_the_drug_as_compared_to_patients_with_the_CC_and_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.","CC:Healthy_individuals_with_the_CC_genotype_who_are_treated_with_valproic_acid_and_lorazepam_may_have_poorer_responses_in_psychocognitive_function_tests_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_an_individual's_response_to_valproic_acid_and_lorazepam_treatment.""CT:Healthy_individuals_with_the_CT_genotype_who_are_treated_with_valproic_acid_and_lorazepam_may_have_poorer_responses_in_psychocognitive_function_tests_as_compared_to_those_with_the_TT_genotype_or_may_have_better_responses_in_psychocognitive_function_tests_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_an_individual's_response_to_valproic_acid_and_lorazepam_treatment.""TT:Healthy_individuals_with_the_TT_genotype_who_are_treated_with_valproic_acid_and_lorazepam_may_have_better_responses_in_psychocognitive_function_tests_as_compared_to_those_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_an_individual's_response_to_valproic_acid_and_lorazepam_treatment.","CC:Patients_with_the_CC_genotype_may_require_an_increased_dose_of_codeine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_codeine._""CT:No_information_is_available_for_the_CT_genotype._""TT:Patients_with_the_TT_genotype_may_require_a_decreased_dose_of_codeine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_codeine._";PGKB_RACE=Asian,NR,Asian,NR
4	71859193	rs80143932	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=DCK_(PA137);PGKB_DRUG="cytarabine_(PA449177)""idarubicin_(PA449961)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="CC:Patients_with_acute_myeloid_leukemia_and_the_CC_genotype_may_have_an_decreased_response_to_cytarabine_and_idarubicin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_in_patients_administered_cytarabine_and_idarubicin.""CG:Patients_with_acute_myeloid_leukemia_and_the_CG_genotype_may_have_an_increased_response_to_cytarabine_and_idarubicin_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_response_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_in_patients_administered_cytarabine_and_idarubicin.""GG:Patients_with_acute_myeloid_leukemia_and_the_GG_genotype_may_have_an_increased_response_to_cytarabine_and_idarubicin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_in_patients_administered_cytarabine_and_idarubicin.";PGKB_RACE=NR
4	71859352	rs2306744	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DCK_(PA137);PGKB_DRUG="cytarabine_(PA449177)""idarubicin_(PA449961)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="CC:Patients_with_acute_myeloid_leukemia_and_the_CC_genotype_may_have_an_increased_response_to_cytarabine_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_in_patients_administered_cytarabine_and_idarubicin._""CT:Patients_with_acute_myeloid_leukemia_and_the_CT_genotype_may_have_an_increased_response_to_cytarabine_and_idarubicin_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_response_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_in_patients_administered_cytarabine_and_idarubicin._""TT:Patients_with_acute_myeloid_leukemia_and_the_TT_genotype_may_have_an_increased_response_to_cytarabine_and_idarubicin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_in_patients_administered_cytarabine_and_idarubicin._";PGKB_RACE=NR
4	71859622	rs66878317	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=DCK_(PA137);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Purified_DCK_proteins_with_the_AA_genotype_may_have_reduced_clearance_of_gemcitabine_as_compared_to_those_proteins_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_affect_clearance_of_gemcitabine.""AG:Purified_DCK_proteins_with_the_AG_genotype_may_have_increased_clearance_of_gemcitabine_as_compared_to_those_proteins_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_affect_clearance_of_gemcitabine.""GG:Purified_DCK_proteins_with_the_GG_genotype_may_have_increased_clearance_of_gemcitabine_as_compared_to_those_proteins_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_affect_clearance_of_gemcitabine.";PGKB_RACE=NR
4	71893864	rs4694362	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DCK_(PA137);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Pancreatic_Neoplasms_(PA445218);PGKB_TEXT="CC:Patients_with_CC_genotype_and_pancreatic_cancer_who_are_treated_with_gemcitabine_may_have_an_decreased_risk_of_neutropenia_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia_when_treated_with_gemcitabine._""CT:Patients_with_CT_genotype_and_pancreatic_cancer_who_are_treated_with_gemcitabine_may_have_an_decreased_risk_of_neutropenia_compared_to_patients_with_the_TT_genotype_and_increased_risk_of_neutropenia_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia_when_treated_with_gemcitabine._""TT:Patients_with_TT_genotype_and_pancreatic_cancer_who_are_treated_with_gemcitabine_may_have_an_increased_risk_of_neutropenia_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neutropenia_when_treated_with_gemcitabine._";PGKB_RACE=NR
4	74606024	rs4073	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=IL8_(PA29841);PGKB_DRUG=bevacizumab_(PA130232992);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Macular_Degeneration_(PA134850558);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_age-related_macular_degeneration_may_have_a_poorer_response_when_treated_with_bevacizumab_as_compared_to_patients_with_the_AT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bevacizumab.""AT:Patients_with_the_AT_genotype_and_age-related_macular_degeneration_may_have_a_better_response_when_treated_with_bevacizumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bevacizumab.""TT:Patients_with_the_TT_genotype_and_age-related_macular_degeneration_may_have_a_better_response_when_treated_with_bevacizumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bevacizumab.";PGKB_RACE=White
4	74609045	rs1126647	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=IL8_(PA29841);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="AA:Patients_with_renal_cell_carcinoma_and_the_AA_genotype_may_have_a_decreased_likelihood_of_hypertension_when_taking_sunitinib_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_affect_likelihood_of_hypertension_in_renal_cell_carcinoma_patients_who_are_treated_with_sunitinib.""AT:Patients_with_renal_cell_carcinoma_and_the_AT_genotype_may_have_a_decreased_likelihood_of_hypertension_when_taking_sunitinib_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_affect_likelihood_of_hypertension_in_renal_cell_carcinoma_patients_who_are_treated_with_sunitinib.""TT:Patients_with_renal_cell_carcinoma_and_the_TT_genotype_may_have_an_increased_likelihood_of_hypertension_when_taking_sunitinib_as_compared_to_patients_with_the_AA_and_AT_genotype._Other_clinical_and_genetic_factors_may_also_affect_likelihood_of_hypertension_in_renal_cell_carcinoma_patients_who_are_treated_with_sunitinib.";PGKB_RACE=NR
4	74864550	rs352046	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=CXCL5_(PA35573);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Acute_coronary_syndrome_(PA165108401);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Acute_coronary_syndrome_who_are_treated_with_statins_may_have_an_increased_response_to_treatment_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""CG:Patients_with_the_CG_genotype_and_Acute_coronary_syndrome_who_are_treated_with_statins_may_have_a_decreased_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_and_Acute_coronary_syndrome_who_are_treated_with_statins_may_have_a_deceased_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._";PGKB_RACE=NR
4	75329122	rs1353295	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=AREG_(PA24933);PGKB_DRUG="cetuximab_(PA10040)""irinotecan_(PA450085)""panitumumab_(PA162373091)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment._""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment._""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_better_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment._";PGKB_RACE=NR
4	75395312	rs13104811	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=AREG_(PA24933);PGKB_DRUG="cetuximab_(PA10040)""irinotecan_(PA450085)""panitumumab_(PA162373091)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_better_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.";PGKB_RACE=NR
4	75421961	rs9996584	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=AREG_(PA24933);PGKB_DRUG="cetuximab_(PA10040)""irinotecan_(PA450085)""panitumumab_(PA162373091)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_a_better_response_to_anti-EGFR_plus_irinotecan_treatment_as_well_as_a_longer_overall_survival_time_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_AA_genotype_but_a_longer_overall_survival_time_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_well_as_a_shorter_overall_survival_time_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.";PGKB_RACE=NR
4	75422078	rs11942466	C	A	.	.	PGKB_INDEX=2;PGKB_GENE=AREG_(PA24933),AREG_(PA24933);PGKB_DRUG="capecitabine_(PA448771)""radiotherapy_(PA166122986)","cetuximab_(PA10040)""irinotecan_(PA450085)""panitumumab_(PA162373091)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Rectal_Neoplasms_(PA445503),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_rectal_cancer_may_have_a_poorer_response_to_capecitabine-based_chemoradiotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine-based_chemoradiotherapy.""AC:Patients_with_the_AC_genotype_and_rectal_cancer_may_have_a_poorer_response_to_capecitabine-based_chemoradiotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine-based_chemoradiotherapy.""CC:Patients_with_the_CC_genotype_and_rectal_cancer_may_have_a_better_response_to_capecitabine-based_chemoradiotherapy_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine-based_chemoradiotherapy.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_a_poorer_response_to_anti-EGFR_plus_irinotecan_treatment_as_well_as_a_shorter_overall_survival_time_and_progression-free_survival_time_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.""AC:Patients_with_the_AC_genotype_and_colorectal_cancer_may_have_a_better_response_to_anti-EGFR_plus_irinotecan_treatment_as_well_as_a_longer_overall_survival_time_and_progression-free_survival_time_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.""CC:Patients_with_the_CC_genotype_and_colorectal_cancer_may_have_a_better_response_to_anti-EGFR_plus_irinotecan_treatment_as_well_as_a_longer_overall_survival_time_and_progression-free_survival_time_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-EGFR_plus_irinotecan_treatment.";PGKB_RACE=NR,NR
4	76944785	rs56061981	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="CC:Patients_with_chronic_hepatitis_C_genotype_1_and_the_CC_genotype_who_also_carry_the_CT_or_TT_genotype_at_rs12979860_may_have_a_decreased_response_to_peg_interferon_alpha-2a_or_peg_interferon_alpha-2b_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_peginterfon_in_patients_with_chronic_hepatitis_C._""CT:Patients_with_chronic_hepatitis_C_genotype_1_and_the_CT_genotype_who_also_carry_the_CT_or_TT_genotype_at_rs12979860_may_have_an_increased_response_to_peg_interferon_alpha-2a_or_peg_interferon_alpha-2b_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_peginterfon_in_patients_with_chronic_hepatitis_C._""TT:Patients_with_chronic_hepatitis_C_genotype_1_and_the_TT_genotype_who_also_carry_the_CT_or_TT_genotype_at_rs12979860_may_have_an_increased_response_to_peg_interferon_alpha-2a_or_peg_interferon_alpha-2b_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_peginterfon_in_patients_with_chronic_hepatitis_C._";PGKB_RACE=Asian
4	84191031	rs6535454	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=COQ2_(PA142672084);PGKB_DRUG="atorvastatin_(PA448500)""hmg_coa_reductase_inhibitors_(PA133950441)""rosuvastatin_(PA134308647)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Muscular_Diseases_(PA444997);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_statin_intolerance_defined_primarily_as_muscle_symptoms_when_treated_with_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_to_statin.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_statin_intolerance_defined_primarily_as_muscle_symptoms_when_treated_with_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_to_statin.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_statin_intolerance_defined_primarily_as_muscle_symptoms_when_treated_with_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_to_statin.";PGKB_RACE=White
4	84192168	rs4693075	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=COQ2_(PA142672084);PGKB_DRUG="atorvastatin_(PA448500)""hmg_coa_reductase_inhibitors_(PA133950441)""rosuvastatin_(PA134308647)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Muscular_Diseases_(PA444997);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_statin-related_muscle_symptoms_as_compared_to_patients_with_genotype_GG_or_CG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_statin-related_muscle_symptoms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_statin-related_muscle_symptoms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.";PGKB_RACE=White
4	89018670	rs45605536	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG="dasatinib_(PA162372878)""imatinib_(PA10804)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_CC_genotype_may_have_a_decreased_sensitivity_to_dasatinib_or_imatinib_as_compared_to_patients_with_TT_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_or_imatinib._""CT:Patients_with_the_CT_genotype_are_not_studied._But_based_on_in-vitro_experiments_the_T_allele_may_have_an_association_with_increased_sensitivity_to_dasatinib_or_imatinib_as_compared_to_the_C_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_or_imatinib.""TT:Patients_with_TT_genotype_may_have_an_increased_sensitivity_to_dasatinib_or_imatinib_as_compared_to_patients_with_CC_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_or_imatinib._";PGKB_RACE=NR
4	89018678	rs58818712	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG="dasatinib_(PA162372878)""imatinib_(PA10804)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_a_decreased_sensitivity_to_dasatinib_or_imatinib_as_compared_to_patients_with_CC_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_or_imatinib._""AC:Patients_with_the_AC_genotype_are_not_studied._But_based_on_in-vitro_experiments_the_C_allele_may_have_an_association_with_increased_sensitivity_to_dasatinib_or_imatinib_as_compared_to_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_or_imatinib.""CC:Patients_with_CC_genotype_may_have_an_increased_sensitivity_to_dasatinib_or_imatinib_as_compared_to_patients_with_AA_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_or_imatinib._";PGKB_RACE=NR
4	89030841	rs12505410	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_chronic_myelogenous_leukemia_may_have_a_greater_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib._""GT:Patients_with_the_GT_genotype_and_chronic_myelogenous_leukemia_may_have_a_greater_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib._""TT:Patients_with_the_TT_genotype_and_chronic_myelogenous_leukemia_may_have_a_lower_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib._";PGKB_RACE=NR
4	89033527	rs13120400	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=ABCG2_(PA390),ABCG2_(PA390);PGKB_DRUG=methotrexate_(PA450428),imatinib_(PA10804);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Psoriasis_(PA445451),Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_CT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""CT:Patients_with_the_CT_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.","CC:Patients_with_the_CC_genotype_and_chronic_myelogenous_leukemia_may_have_a_greater_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib.""CT:Patients_with_the_CT_genotype_and_chronic_myelogenous_leukemia_may_have_a_greater_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib.""TT:Patients_with_the_TT_genotype_and_chronic_myelogenous_leukemia_may_have_a_lower_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib.";PGKB_RACE=NR,NR
4	89036166	rs41282401	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG="dasatinib_(PA162372878)""imatinib_(PA10804)""nilotinib_(PA165958345)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_CC_genotype_may_have_an_increased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_GG_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._""CG:Patients_with_the_CG_genotype_are_not_studied._But_based_on_in-vitro_experiments_the_C_allele_may_have_an_association_with_increased_sensitivity_to_dasatinib_imatinib_or_nilotinib_as_compared_to_the_G_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib.""GG:Patients_with_GG_genotype_may_have_a_decreased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_CC_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._";PGKB_RACE=NR
4	89042853	rs1061018	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG="dasatinib_(PA162372878)""imatinib_(PA10804)""nilotinib_(PA165958345)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_a_decreased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_GG_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._""AG:Patients_with_the_AG_genotype_are_not_studied._But_based_on_in-vitro_experiments_the_G_allele_may_have_an_association_with_increased_sensitivity_to_dasatinib_imatinib_or_nilotinib_as_compared_to_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib.""GG:_Patients_with_GG_genotype_may_have_an_increased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_AA_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._";PGKB_RACE=NR
4	89052323	rs2231142	G	T	.	.	PGKB_INDEX=10;PGKB_GENE=ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390),ABCG2_(PA390);PGKB_DRUG=simvastatin_(PA451363),fluvastatin_(PA449688),efavirenz_(PA449441),rosuvastatin_(PA134308647),atorvastatin_(PA448500),imatinib_(PA10804),"capecitabine_(PA448771)""fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)",sulfasalazine_(PA451547),sunitinib_(PA162372840),sulfasalazine_(PA451547);PGKB_TYPE=NR,Other,Toxicity/ADR,Efficacy,Other,Metabolism/PK,Efficacy,Efficacy,Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=3,3,4,2B,3,4,3,3,3,3;PGKB_DISEASE=NR,NR,"HIV_(PA447230)""HIV_Infections_(PA446213)","Hypercholesterolemia_(PA444516)""Myocardial_Infarction_(PA445019)",NR,NR,Colorectal_Neoplasms_(PA446108),Arthritis_Rheumatoid_(PA443434),Neoplasms_(PA445062),NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_reduced_exposure_to_simvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_simvastatin._""GT:Patients_with_the_GT_genotype_may_have_reduced_exposure_to_simvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_simvastatin._""TT:Patients_with_the_TT_genotype_may_have_increased_exposure_to_simvastatin_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_simvastatin._","GG:Patients_with_the_GG_genotype_may_have_reduced_exposure_to_fluvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_fluvastatin._""GT:Patients_with_the_GT_genotype_may_have_reduced_exposure_to_fluvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_fluvastatin._""TT:Patients_with_the_TT_genotype_may_have_increased_exposure_to_fluvastatin_as_compared_to_patients_with_the_GT_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_fluvastatin._","GG:Patients_with_the_GG_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_a_reduced_risk_of_abnormal_dreams_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_efavirenz-induced_side_effects.""GT:Patients_with_the_GT_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_an_increased_risk_of_abnormal_dreams_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_efavirenz-induced_side_effects.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_an_increased_risk_of_abnormal_dreams_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_efavirenz-induced_side_effects.","GG:Patients_with_the_GG_genotype_and_who_are_treated_with_rosuvastatin_1)_may_have_lower_plasma_concentrations_of_rosuvastatin_2)_may_have_a_reduced_response_to_treatment_as_determined_by_a_lower_reduction_in_LDL-C_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin_treatment_and_rosuvastatin_pharmacokinetics.""GT:Patients_with_the_GT_genotype_and_who_are_treated_with_rosuvastatin_1)_may_have_lower_plasma_concentrations_of_rosuvastatin_2)_may_have_a_reduced_response_to_treatment_as_determined_by_a_lower_reduction_in_LDL-C_as_compared_to_patients_with_the_TT_genotype_or_1)_may_have_higher_plasma_concentrations_of_rosuvastatin_2)_may_have_a_better_response_to_treatment_as_determined_by_a_higher_reduction_in_LDL-C_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin_treatment_and_rosuvastatin_pharmacokinetics.""TT:Patients_with_the_TT_genotype_and_who_are_treated_with_rosuvastatin_1)_may_have_higher_plasma_concentrations_of_rosuvastatin_2)_may_have_a_better_response_to_treatment_as_determined_by_a_higher_reduction_in_LDL-C_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin_treatment_and_rosuvastatin_pharmacokinetics.","GG:Patients_with_the_GG_genotype_may_have_lower_plasma_concentrations_of_atorvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_pharmacokinetics_of_atorvastatin.""GT:Patients_with_the_GT_genotype_may_have_lower_plasma_concentrations_of_atorvastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_pharmacokinetics_of_atorvastatin.""TT:Patients_with_the_TT_genotype_may_have_higher_plasma_concentrations_of_atorvastatin_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_pharmacokinetics_of_atorvastatin.","GG:Patients_with_the_GG_genotype_and_Neoplasms_might_have_an_increased_metabolism_of_imatinib_as_compared_to_patients_with_the_GT_genotype._Patients_with_GG_genotype_may_have_a_decreased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_TT_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._""GT:Patients_with_the_GT_genotype_and_Neoplasms_might_have_a_decreased_metabolism_of_imatinib_as_compared_to_patients_with_the_GG_genotype._Patients_with_the_GT_genotype_are_not_studied_for_sensitivity_to_imatinib_but_based_on_in-vitro_experiments_the_T_allele_may_have_an_association_with_increased_sensitivity_to_dasatinib_imatinib_or_nilotinib_as_compared_to_the_G_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib.""TT:Patients_with_the_TT_genotype_and_Neoplasms_might_have_a_decreased_metabolism_of_imatinib_as_compared_to_patients_with_the_GG_genotype_based_on_the_finding_of_the_GT_genotype_being_associated_with_decreased_metabolism_as_compared_to_the_GG_genotype._Patients_with_TT_genotype_may_have_an_increased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_GG_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._","GG:Patients_with_the_GG_genotype_and_and_colorectal_cancer_who_are_receiving_FOLFOX/XELOX_regimens_may_have_a_poorer_response_rate_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_chemotherapy_regimens.""GT:Patients_with_the_GT_genotype_and_and_colorectal_cancer_who_are_receiving_FOLFOX/XELOX_regimens_may_have_a_better_response_rate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_chemotherapy_regimens.""TT:Patients_with_the_TT_genotype_and_and_colorectal_cancer_who_are_receiving_FOLFOX/XELOX_regimens_may_have_a_better_response_rate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_chemotherapy_regimens.","GG:Patients_with_the_GG_genotype_and_rheumatoid_arthritis_may_have_a_lower_likelihood_of_achieving_remission_when_treated_with_sulfasalazine_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_sulfasalazine.""GT:Patients_with_the_GT_genotype_and_rheumatoid_arthritis_may_have_an_increased_likelihood_of_achieving_remission_when_treated_with_sulfasalazine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_sulfasalazine.""TT:Patients_with_the_TT_genotype_and_rheumatoid_arthritis_may_have_an_increased_likelihood_of_achieving_remission_when_treated_with_sulfasalazine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_sulfasalazine.","GG:Patients_with_the_GG_genotype_and_cancer_may_have_decreased_exposure_to_sunitinib_and_a_decreased_risk_for_experiencing_drug_toxicities_as_compared_to_patients_with_the_TT_genotype._However_this_association_with_drug_toxicities_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_exposure_to_sunitinib_and_risk_for_drug_toxicities._""GT:Patients_with_the_GT_genotype_and_renal_cell_carcinoma_may_have_decreased_exposure_to_sunitinib_and_a_decreased_risk_for_experiencing_drug_toxicities_as_compared_to_patients_with_the_TT_genotype._However_this_association_with_drug_toxicities_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicities_when_receiving_sunitinib.""TT:Patients_with_the_TT_genotype_and_renal_cell_carcinoma_may_have_increased_exposure_to_sunitinib_and_an_increased_risk_for_experiencing_drug_toxicities_as_compared_to_patients_with_the_GG_or_GT_genotype._However_this_association_with_drug_toxicities_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicities_when_receiving_sunitinib.","GG:Patients_with_the_GG_genotype_may_have_improved_clearance_and_metabolism_of_sulfasalazine_as_compared_to_patients_with_the_GT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_clearance_and_metabolism_of_sulfasalazine.""GT:Patients_with_the_GT_genotype_may_have_improved_clearance_of_sulfasalazine_as_compared_to_patients_with_the_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_clearance_and_metabolism_of_sulfasalazine.""TT:Patients_with_the_TT_genotype_may_have_decreased_clearance_and_metabolism_of_sulfasalazine_as_compared_to_patients_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_clearance_and_metabolism_of_sulfasalazine.";PGKB_RACE=White,White,White,NR,White,NR,NR,NR,NR,Asian
4	89055379	rs17731538	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Psoriasis_(PA445451);PGKB_TEXT="AA:Patients_with_the_AA_genotype_were_not_studied._However_patients_with_the_AG_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_or_severity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_or_severity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_improvement_in_psoriasis_area_or_severity_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=NR
4	89061114	rs2231137	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=ABCG2_(PA390),ABCG2_(PA390);PGKB_DRUG=irinotecan_(PA450085),"dasatinib_(PA162372878)""imatinib_(PA10804)""nilotinib_(PA165958345)";PGKB_TYPE=Toxicity/ADR,Other;PGKB_EVIDENCE=3,4;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CT_or_TT_genotype._No_significant_associations_were_seen_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.""CT:Patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_have_an_increased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype._No_significant_associations_were_seen_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_an_increased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype._No_significant_associations_were_seen_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.","CC:Patients_with_CC_genotype_may_have_a_decreased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_TT_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._""CT:Patients_with_the_CT_genotype_are_not_studied._But_based_on_in-vitro_experiments_the_T_allele_may_have_an_association_with_increased_sensitivity_to_dasatinib_imatinib_or_nilotinib_as_compared_to_the_C_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib.""TT:Patients_with_TT_genotype_may_have_an_increased_sensitivity_to_dasatinib_or_imatinib_or_nilotinib_as_compared_to_patients_with_CC_genotype._The_association_is_based_on_in-vitro_finding_in_K562_cells._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dasatinib_imatinib_or_nilotinib._";PGKB_RACE=Asian,NR
4	89061910	rs2725252	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_chronic_myelogenous_leukemia_may_have_a_lower_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib.""AC:Patients_with_the_AC_genotype_and_chronic_myelogenous_leukemia_may_have_a_greater_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib.""CC:Patients_with_the_CC_genotype_and_chronic_myelogenous_leukemia_may_have_a_greater_chance_of_achieving_major_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib.";PGKB_RACE=NR
4	89079994	rs2231135	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteosarcoma_(PA445601);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_osteosarcoma_may_be_at_decreased_risk_for_mucositis_when_receiving_methotrexate_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_mucositis_in_patients_receiving_methotrexate.""AG:Patients_with_the_AG_genotype_and_osteosarcoma_may_be_at_increased_risk_for_mucositis_when_receiving_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_mucositis_in_patients_receiving_methotrexate.""GG:No_patients_with_the_GG_genotype_were_available_for_analysis_but_patients_with_the_AG_genotype_and_osteosarcoma_may_be_at_increased_risk_for_mucositis_when_receiving_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_mucositis_in_patients_receiving_methotrexate.";PGKB_RACE=NR
4	89096061	rs7699188	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG2_(PA390);PGKB_DRUG="fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_tumor_response_rate_and_increased_risk_of_grade_3-4_nonhematological_toxicity_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_irinotecan_and_leucovorin.""AG:Patients_with_the_AA_genotype_may_have_increased_tumor_response_rate_and_increased_risk_of_grade_3-4_nonhematological_toxicity_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_tumor_response_rate_and_decreased_risk_of_grade_3-4_nonhematological_toxicity_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_irinotecan_and_leucovorin.""GG:Patients_with_the_GG_genotype_may_have_decreased_tumor_response_rate_and_decreased_risk_of_grade_3-4_nonhematological_toxicity_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_irinotecan_and_leucovorin.";PGKB_RACE=White
4	95370805	rs2433320	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=fluoxetine_(PA449673);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_who_are_treated_with_fluoxetine_may_have_decreased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""AG:Patients_with_the_AG_genotype_and_major_depression_who_are_treated_with_fluoxetine_may_have_decreased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""GG:Patients_with_the_GG_genotype_and_major_depression_who_are_treated_with_fluoxetine_may_have_increased_response_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.";PGKB_RACE=Asian
4	100239319	rs1229984	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ADH1B_(PA24571);PGKB_DRUG=ethanol_(PA448073);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_lower_maximal_rate_(Vmax)_of_ethanol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_Vmax_of_ethanol._""CT:Patients_with_the_CT_genotype_may_have_a_lower_maximal_rate_(Vmax)_of_ethanol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_Vmax_of_ethanol._""TT:Patients_with_the_TT_genotype_may_have_a_higher_maximal_rate_(Vmax)_of_ethanol_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_Vmax_of_ethanol._";PGKB_RACE=Asian
4	100260789	rs698	T	C,A	.	.	PGKB_INDEX=1;PGKB_GENE=ADH1C_(PA24572);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_be_more_likely_to_have_a_complete_response_to_treatment_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_be_less_likely_to_have_a_complete_response_to_treatment_as_compared_to_patients_with_the_CC_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_be_more_likely_to_have_a_complete_response_to_treatment_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._";PGKB_RACE=NR
4	100333267	rs729147	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ADH7_(PA24577);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_anthracyclines.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_anthracyclines.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_anthracyclines.";PGKB_RACE=NR
4	100495488	rs1800591	G	T	.	.	PGKB_INDEX=2;PGKB_GENE=MTTP_(PA164742099),MTTP_(PA164742099);PGKB_DRUG=pravastatin_(PA451089),atorvastatin_(PA448500);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Hyperlipoproteinemia_Type_II_(PA444517);PGKB_TEXT="GG:Patients_with_the_GG_genotype_who_are_treated_with_pravastatin_may_be_less_likely_to_benefit_from_treatment_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GT:Patients_with_the_GT_genotype_who_are_treated_with_pravastatin_may_be_more_likely_to_benefit_from_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_pravastatin_may_be_more_likely_to_benefit_from_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","GG:Men_with_the_GG_genotype_and_Hyperlipoproteinemia_Type_II_who_are_treated_with_atorvastatin_may_have_lower_decreases_in_triglyceride_levels_as_compared_to_patients_with_the_TT_genotype._No_association_with_atorvastatin_response_was_seen_in_women._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""GT:Men_with_the_GT_genotype_and_Hyperlipoproteinemia_Type_II_who_are_treated_with_atorvastatin_may_have_lower_decreases_in_triglyceride_levels_as_compared_to_patients_with_the_TT_genotype._No_association_with_atorvastatin_response_was_seen_in_women._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""TT:Men_with_the_TT_genotype_and_Hyperlipoproteinemia_Type_II_who_are_treated_with_atorvastatin_may_have_higher_decreases_in_triglyceride_levels_as_compared_to_patients_with_the_GT_or_GG_genotype._No_association_with_atorvastatin_response_was_seen_in_women._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._";PGKB_RACE=NR,NR
4	105393361	rs4413407	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CXXC4_(PA134992016);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.";PGKB_RACE=NR
4	106114071	rs12505746	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=TET2_(PA162405634);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""AG:Patients_with_the_AG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GG_genotype_and_an_increased_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""GG:Patients_with_the_GG_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._";PGKB_RACE=White
4	107673848	rs1364805	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_GT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma.""GT:Patients_with_asthma_and_the_GT_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_TT_genotypes_and_an_increased_response_as_compared_to_patients_with_a_GG_genotype._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma.""TT:Patients_with_asthma_and_the_TT_genotype_may_have_an_increased_response_to_montelukast_as_compared_to_patients_with_the_GG_and_GT_genotypes_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma.";PGKB_RACE=NR
4	110834110	rs4444903	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=EGF_(PA27664);PGKB_DRUG=cetuximab_(PA10040);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE="Colorectal_Neoplasms_(PA446108)""Rectal_Neoplasms_(PA445503)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_cetuximab_may_have_a_poorer_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cetuximab_treatment.""AG:Patients_with_the_AG_genotype_who_are_treated_with_cetuximab_may_have_a_poorer_response_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_better_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cetuximab_treatment.""GG:Patients_with_the_GG_genotype_who_are_treated_with_cetuximab_may_have_a_better_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cetuximab_treatment.";PGKB_RACE=White
4	123509421	rs6822844	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=IL2_(PA195);PGKB_DRUG=rituximab_(PA451261);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Lupus_Erythematosus_Systemic_(PA444822);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_systemic_lupus_erythematosus_may_be_more_likely_to_respond_to_treatment_with_rituximab_as_compared_to_patients_with_the_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_rituximab.""GT:Patients_with_the_GT_genotype_and_systemic_lupus_erythematosus_may_be_less_likely_to_respond_to_treatment_with_rituximab_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_rituximab.""TT:No_patients_with_the_TT_genotype_were_present_in_the_study._However_patients_with_the_GT_genotype_and_systemic_lupus_erythematosus_may_be_less_likely_to_respond_to_treatment_with_rituximab_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_rituximab.";PGKB_RACE=White
4	123748086	rs1449683	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=FGF2_(PA28115);PGKB_DRUG=fluvoxamine_(PA449690);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_(PA447207);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depressive_disorder_may_have_decreased_response_to_fluvoxamine_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_fluvoxamine.""CT:Patients_with_the_CT_genotype_and_depressive_disorder_may_have_decreased_response_to_fluvoxamine_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_fluvoxamine.""TT:Patients_with_the_TT_genotype_and_depressive_disorder_may_have_an_increased_response_to_fluvoxamine_compared_to_patients_with_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_fluvoxamine.";PGKB_RACE=Asian
4	128657040	rs201279313	TTTA	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC25A31_(PA142670904);PGKB_DRUG="atenolol_(PA448499)""hydrochlorothiazide_(PA449899)""metoprolol_(PA450480)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="TTA/TTA:Patients_with_the_TTA/TTA_genotype_and_hypertension_may_have_increased_response_to_atenolol_hydrochlorothiazide_or_metoprolol_as_compared_to_patients_with_the_TTA/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TTA/del:Patients_with_the_TTA/del_genotype_and_hypertension_may_have_increased_response_to_atenolol_hydrochlorothiazide_or_metoprolol_as_compared_to_patients_with_the_TTA/TTA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""del/del:No_patients_with_del/del_were_studied._However_patients_with_the_del/del_genotype_and_hypertension_may_have_increased_response_to_atenolol_hydrochlorothiazide_or_metoprolol_as_compared_to_patients_with_the_TTA/TTA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=Black_or_African_American
4	149357475	rs5522	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR3C2_(PA242);PGKB_DRUG=enalapril_(PA449456);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_a_lower_reduction_in_diastolic_blood_pressure_when_treated_with_enalapril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril._""CT:Patients_with_the_CT_genotype_and_hypertension_may_have_a_lower_reduction_in_diastolic_blood_pressure_when_treated_with_enalapril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril._""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_a_greater_reduction_in_diastolic_blood_pressure_when_treated_with_enalapril_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril._";PGKB_RACE=Asian
4	154607126	rs4696480	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=TLR2_(PA36550);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colitis_Ulcerative_(PA443750);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AT:Patients_with_the_AT_genotype_and_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
4	154609523	rs1816702	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TLR2_(PA36550);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Crohn_Disease_(PA443815);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Crohn's_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
4	154621946	rs11938228	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=TLR2_(PA36550);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Colitis_Ulcerative_(PA443750)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AC:Patients_with_the_AC_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
4	154624656	rs3804099	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TLR2_(PA36550);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Inflammatory_Bowel_Diseases_(PA446116);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_inflammatory_bowel_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_inflammatory_bowel_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
4	157011923	rs10030044	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="raloxifene_(PA451221)""tamoxifen_(PA451581)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_occurrence_of_breast_cancer_during_SERM_(selective_estrogen_receptor_modulators)_therapy_when_treated_with_raloxifene_or_tamoxifen_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_SERM_therapy.""GT:Patients_with_the_GT_genotype_may_have_increased_risk_of_occurrence_of_breast_cancer_during_SERM_(selective_estrogen_receptor_modulators)_therapy_when_treated_with_raloxifene_or_tamoxifen_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_SERM_therapy.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_occurrence_of_breast_cancer_during_SERM_(selective_estrogen_receptor_modulators)_therapy_when_treated_with_raloxifene_or_tamoxifen_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_SERM_therapy.";PGKB_RACE=NR
4	187004074	rs3775291	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=TLR3_(PA36551),TLR3_(PA36551);PGKB_DRUG=Measles_vaccines_(PA164712887),aspirin_(PA448497);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Asthma_(PA443450);PGKB_TEXT="CC:Children_with_the_CC_genotype_may_have_an_increased_response_to_measles_vaccination_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_measles_vaccination.""CT:Children_with_the_CT_genotype_may_have_a_decreased_response_to_measles_vaccination_as_compared_to_patients_with_the_CC_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_measles_vaccination.""TT:Children_with_the_TT_genotype_may_have_an_increased_response_to_measles_vaccination_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_measles_vaccination.","CC:Patients_with_the_CC_genotype_and_asthma_who_are_treated_with_aspirin_may_have_decreased_but_not_absent_risk_for_Aspirin-Exacerbated_Respiratory_Disease_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CT:Patients_with_the_CT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_Aspirin-Exacerbated_Respiratory_Disease_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_Aspirin-Exacerbated_Respiratory_Disease_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=White,Asian
5	610093	rs924607	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CEP72_(PA142672125);PGKB_DRUG=vincristine_(PA451879);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_of_peripheral_nervous_system_diseases_when_treated_with_vincristine_may_have_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vincristine.""CT:Patients_with_the_CT_genotype_may_have_decreased_but_not_absent_risk_of_peripheral_nervous_system_diseases_when_treated_with_vincristine_may_have_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vincristine.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_peripheral_nervous_system_diseases_when_treated_with_vincristine_may_have_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vincristine.";PGKB_RACE=NR
5	1411855	rs3836790	G	GCACATACCATGCAACATACACACTCAGACA	.	.	PGKB_INDEX=1;PGKB_GENE=SLC6A3_(PA311);PGKB_DRUG=levodopa_(PA450213);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Parkinson_Disease_(PA445254);PGKB_TEXT="CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA_:Patients_with_the_CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA_genotype_and_Parkinson_Disease_who_are_treated_with_levodopa_may_have_increased_response_to_levodopa_as_compared_to_patients_with_the_CACATACCATGCAACATACACACTCAGACA/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_levodopa._""CACATACCATGCAACATACACACTCAGACA/del:Patients_with_the_CACATACCATGCAACATACACACTCAGACA/del_genotype_and_Parkinson_Disease_who_are_treated_with_levodopa_may_have_decreased_response_to_levodopa_as_compared_to_patients_with_the_CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_levodopa._""del/del:Patients_with_the_del/del_genotype_and_Parkinson_Disease_who_are_treated_with_levodopa_may_have_decreased_response_to_levodopa_as_compared_to_patients_with_the_CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_levodopa._";PGKB_RACE=NR
5	7634232	rs1544938	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=ADCY2_(PA24561);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_antipsychotic_drugs.""CG:Patients_with_the_CG_genotype_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_antipsychotic_drugs.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_decreased_response_to_antipsychotics_compared_to_patients_with_the_CC_or_CG_genotypes._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_antipsychotic_drugs.";PGKB_RACE=Asian
5	7649860	rs4702484	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ADCY2_(PA24561);PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Colorectal_Neoplasms_who_are_treated_with_capecitabine_may_have_decreased_progression-free_survival_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine.""CT:Patients_with_the_CT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_capecitabine_may_have_increased_progression-free_survival_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine.""TT:Patients_with_the_TT_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_capecitabine_may_have_increased_progression-free_survival_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine.";PGKB_RACE=NR
5	7870973	rs1801394	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=MTRR_(PA31277),MTRR_(PA31277);PGKB_DRUG="folic_acid_(PA449692)""vitamin_b-complex_plain_(PA10505)",methotrexate_(PA450428);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,2B;PGKB_DISEASE=Migraine_with_Aura_(PA447004),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Female_patients_with_the_AA_genotype_and_Migraine_who_are_treated_with_folic_acid_and_a_vitamin_b-complex_may_have_decreased_severity_of_pain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_severity_of_pain.""AG:Female_patients_with_the_AG_genotype_and_Migraine_who_are_treated_with_folic_acid_and_a_vitamin_b-complex_may_have_decreased_severity_of_pain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_severity_of_pain.""GG:Female_patients_with_the_GG_genotype_and_Migraine_who_are_treated_with_folic_acid_and_a_vitamin_b-complex_may_have_increased_severity_of_pain_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_severity_of_pain.","AA:Pediatric_ALL_patients_with_AA_genotypes_may_have_decreased_likelihood_of_methotrexate_induced_toxicity_(oral_mucositis)_and_decreased_catalytic_activity_of_TYMS_in_lymphoblasts_when_treated_with_methotrexate_as_compared_to_patients_with_the_GG_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methotrexate.""AG:Pediatric_ALL_patients_with_AG_genotypes_may_have_increased_likelihood_of_methotrexate_induced_toxicity_(oral_mucositis)_increased_speed_of_platelet_recovery_and_increased_catalytic_activity_of_TYMS_in_lymphoblasts_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Allele_G_is_not_associated_with_decreased_IQ_in_pediatric_ALL_patients_treated_with_methotrexate._Other_genetic_and_clinical_factors_may_also_influence_response_to_methotrexate.""GG:Pediatric_ALL_patients_with_GG_genotypes_may_have_increased_likelihood_of_methotrexate_induced_toxicity_(oral_mucositis)_and_increased_catalytic_activity_of_TYMS_in_lymphoblasts_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Allele_G_is_not_associated_with_decreased_IQ_in_pediatric_ALL_patients_treated_with_methotrexate._Other_genetic_and_clinical_factors_may_also_influence_response_to_methotrexate.";PGKB_RACE=NR,NR
5	27611431	rs12054895	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_major_depression_who_are_treated_with_citalopram_or_escitalopram_may_have_less_improvement_over_the_first_2_weeks_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""GT:Patients_with_the_GT_genotype_and_major_depression_who_are_treated_with_citalopram_or_escitalopram_may_have_better_improvement_over_the_first_2_weeks_as_compared_to_patients_with_the_GG_genotype_may_have_less_improvement_over_the_first_2_weeks_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.""TT:Patients_with_the_TT_genotype_and_major_depression_who_are_treated_with_citalopram_or_escitalopram_may_have_better_improvement_over_the_first_2_weeks_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.";PGKB_RACE=White
5	37818139	rs2973049	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GDNF_(PA28644);PGKB_DRUG=paroxetine_(PA450801);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_may_have_increased_response_to_paroxetine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""CT:Patients_with_the_CT_genotype_and_major_depression_may_have_decreased_response_to_paroxetine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""TT:Patients_with_the_TT_genotype_and_major_depression_may_have_decreased_response_to_paroxetine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.";PGKB_RACE=Asian
5	37828844	rs2216711	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GDNF_(PA28644);PGKB_DRUG=paroxetine_(PA450801);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Female_patients_with_the_AA_genotype_and_major_depression_may_have_decreased_response_to_paroxetine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""AG:Female_patients_with_the_AG_genotype_and_major_depression_may_have_decreased_response_to_paroxetine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""GG:Female_patients_with_the_GG_genotype_and_major_depression_may_have_increased_response_to_paroxetine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.";PGKB_RACE=Asian
5	40679567	rs4133101	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PTGER4_(PA289);PGKB_DRUG=celecoxib_(PA448871);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Colorectal_Neoplasms_who_are_treated_with_celecoxib_may_have_decreased_but_not_absent_risk_of_gastrointestinal_toxicities_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""CT:Patients_with_the_CT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_celecoxib_may_have_increased_risk_of_gastrointestinal_toxicities_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_but_not_absent_risk_of_gastrointestinal_toxicities_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""TT:Patients_with_the_TT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_celecoxib_may_have_increased_risk_of_gastrointestinal_toxicities_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.";PGKB_RACE=NR
5	52347369	rs1126643	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ITGA2_(PA204);PGKB_DRUG="aspirin_(PA448497)""clopidogrel_(PA449053)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Coronary_Disease_(PA443797)""Myocardial_Infarction_(PA445019)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_more_likely_to_respond_to_treatment_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_CT_or_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.""CT:Patients_with_the_CT_genotype_may_be_less_likely_to_respond_to_treatment_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.""TT:Patients_with_the_TT_genotype_may_be_less_likely_to_respond_to_treatment_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.";PGKB_RACE=NR
5	52351413	rs1062535	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=ITGA2_(PA204),ITGA2_(PA204);PGKB_DRUG=aspirin_(PA448497),"aspirin_(PA448497)""clopidogrel_(PA449053)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Myocardial_Infarction_(PA445019),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Myocardial_Infarction_may_have_an_increased_risk_for_residual_platelet_reactivity_when_treated_with_aspirin_as_compared_to_patients_with_the_GG_genotype_Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AG:Patients_with_the_AG_genotype_and_Myocardial_Infarction_may_have_an_increased_risk_for_residual_platelet_reactivity_when_treated_with_aspirin_as_compared_to_patients_with_the_GG_genotype_Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""GG:Patients_with_the_GG_genotype_and_Myocardial_Infarction_may_have_a_decreased_but_not_absent_risk_for_residual_platelet_reactivity_when_treated_with_aspirin_as_compared_to_patients_with_the_AG_or_AA_genotype_Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.","AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_for_residual_platelet_reactivity_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel_and_aspirin.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_residual_platelet_reactivity_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel_and_aspirin.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_residual_platelet_reactivity_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel_and_aspirin.";PGKB_RACE=NR,NR
5	56127866	rs726501	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MAP3K1_(PA30592);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)""docetaxel_(PA449383)""erlotinib_(PA134687924)""gefitinib_(PA131301952)""paclitaxel_(PA450761)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_overall_survival_due_to_carboplatin_cisplatin_docetaxel_erlotinib_gefitinib_or_paclitaxel_in_people_with_Carcinoma_Non-Small-Cell_Lung_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_carboplatin_cisplatin_docetaxel_erlotinib_gefitinib_or_paclitaxel.""AG:Patients_with_the_AG_genotype_may_have_decreased_overall_survival_due_to_carboplatin_cisplatin_docetaxel_erlotinib_gefitinib_or_paclitaxel_in_people_with_Carcinoma_Non-Small-Cell_Lung_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_carboplatin_cisplatin_docetaxel_erlotinib_gefitinib_or_paclitaxel.""GG:Patients_with_the_GG_genotype_may_have_increased_overall_survival_due_to_carboplatin_cisplatin_docetaxel_erlotinib_gefitinib_or_paclitaxel_in_people_with_Carcinoma_Non-Small-Cell_Lung_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_carboplatin_cisplatin_docetaxel_erlotinib_gefitinib_or_paclitaxel.";PGKB_RACE=NR
5	59736773	rs702553	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=PDE4D_(PA33130);PGKB_DRUG=diuretics_(PA151249535);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Nephrosclerosis_(PA445086);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Nephrosclerosis_may_have_a_higher_baseline_mean_arterial_blood_pressure_when_treated_with_diuretics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.""AT:Patients_with_the_AT_genotype_and_Nephrosclerosis_may_have_a_higher_baseline_mean_arterial_blood_pressure_when_treated_with_diuretics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.""TT:Patients_with_the_TT_genotype_and_Nephrosclerosis_may_have_a_lower_baseline_mean_arterial_blood_pressure_when_treated_with_diuretics_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diuretics.";PGKB_RACE=Black_or_African_American
5	63250851	rs1364043	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=HTR1A_(PA192);PGKB_DRUG="fluvoxamine_(PA449690)""milnacipran_(PA164752812)""paroxetine_(PA450801)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_fluvoxamine_milnacipran_and_paroxetine_in_people_with_major_depression_as_compared_to_patients_with_genotype_TT._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fluvoxamine_milnacipran_and_paroxetine.""GT:Patients_with_the_GT_genotype_may_have_decreased_response_to_fluvoxamine_milnacipran_and_paroxetine_in_people_with_major_depression_as_compared_to_patients_with_genotype_TT._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fluvoxamine_milnacipran_and_paroxetine.""TT:Patients_with_the_TT_genotype_may_have_increased_response_to_fluvoxamine_milnacipran_and_paroxetine_in_people_with_major_depression_as_compared_to_patients_with_genotype_GG_or_GT._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fluvoxamine_milnacipran_and_paroxetine.";PGKB_RACE=Asian
5	63258565	rs6295	C	G	.	.	PGKB_INDEX=4;PGKB_GENE=HTR1A_(PA192),HTR1A_(PA192),HTR1A_(PA192),HTR1A_(PA192);PGKB_DRUG=paroxetine_(PA450801),"antidepressants_(PA452229)""fluvoxamine_(PA449690)""paroxetine_(PA450801)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""sertraline_(PA451333)",fluoxetine_(PA449673),clozapine_(PA449061);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=2B,3,3,3;PGKB_DISEASE=Panic_Disorder_(PA447212),"Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)",Depressive_Disorder_Major_(PA447321),Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_with_panic_disorder_who_are_treated_with_paroxetine_may_have_an_reduced_response_at_4_weeks_of_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""CG:Patients_with_the_CG_genotype_with_panic_disorder_who_are_treated_with_paroxetine_may_have_an_reduced_response_at_4_weeks_of_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""GG:Patients_with_the_GG_genotype_with_panic_disorder_who_are_treated_with_paroxetine_may_have_a_better_response_at_4_weeks_of_treatment_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._","CC:Patients_with_the_CC_genotype_may_have_a_decreased_likelihood_of_response_to_antidepressants_as_compared_to_patients_with_the_GG_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""CG:Patients_with_the_CG_genotype_may_have_a_increased_likelihood_of_response_to_antidepressants_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""GG:Patients_with_the_GG_genotype_may_have_a_increased_likelihood_of_response_to_antidepressants_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.","CC:Patients_with_the_CC_genotype_who_are_treated_with_fluoxetine_may_have_an_increased_response_as_compared_to_patients_with_the_GG_or_GC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""CG:Patients_with_the_CG_genotype_who_are_treated_with_fluoxetine_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""GG:Patients_with_the_GG_genotype_who_are_treated_with_fluoxetine_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.","CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""CG:Patients_with_the_CG_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_clozapine_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.";PGKB_RACE=NR,NR,Asian,NR
5	63261329	rs10042486	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=NR,HTR1A_(PA192);PGKB_DRUG="amisulpride_(PA162565877)""antipsychotics_(PA452233)""olanzapine_(PA450688)""quetiapine_(PA451201)""risperidone_(PA451257)","fluvoxamine_(PA449690)""milnacipran_(PA164752812)""paroxetine_(PA450801)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_antipsychotics_including_amisulpride_olanzapine_quetiapine_and_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_antipsychotics_including_amisulpride_olanzapine_quetiapine_and_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_antipsychotics_including_amisulpride_olanzapine_quetiapine_and_risperidone_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antipsychotics.","CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluvoxamine_paroxetine_or_milnacipran_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluvoxamine_paroxetine_or_milnacipran_may_have_decreased_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluvoxamine_paroxetine_or_milnacipran_may_have_decreased_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=Asian,Asian
5	74615021	rs17671591	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HMGCR_(PA189);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_a_smaller_drop_in_LDL-C_levels_and_rise_in_HDL-C_levels_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment.""CT:Patients_with_the_CT_genotype_and_hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_an_increased_drop_in_LDL-C_levels_and_rise_in_HDL-C_levels_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment.""TT:Patients_with_the_TT_genotype_and_hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_an_increased_drop_in_LDL-C_levels_and_rise_in_HDL-C_levels_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment.";PGKB_RACE=NR
5	74642855	rs17244841	A	T	.	.	PGKB_INDEX=3;PGKB_GENE=HMGCR_(PA189),HMGCR_(PA189),HMGCR_(PA189);PGKB_DRUG=pravastatin_(PA451089),simvastatin_(PA451363),"hmg_coa_reductase_inhibitors_(PA133950441)""pravastatin_(PA451089)""simvastatin_(PA451363)";PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,2A;PGKB_DISEASE=NR,NR,NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_better_response_(a_higher_reduction_in_LDL_and_total_cholesterol)_to_pravastatin_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AT:Patients_with_the_AT_genotype_may_have_a_reduced_response_(less_reduction_in_LDL_and_total_cholesterol)_to_pravastatin_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Patients_with_the_TT_genotype_were_not_studied._Patients_with_the_AT_genotype_may_have_a_reduced_response_(less_reduction_in_LDL_and_total_cholesterol)_to_pravastatin_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","AA:Patients_with_the_AA_genotype_may_have_a_better_response_to_simvastatin_treatment_(a_higher_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_AT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AT:Patients_with_the_AT_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(a_lower_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""TT:Patients_with_the_TT_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(a_lower_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","AA:Patients_with_the_AA_genotype_who_are_treated_with_statins_may_be_more_likely_to_respond_as_compared_to_patients_with_the_AT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_statins.""AT:Patients_with_the_AT_genotype_who_are_treated_with_statins_may_be_less_likely_to_respond_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_statins.""TT:Patients_with_the_TT_genotype_are_too_infrequent_to_have_been_assessed_for_this_response.";PGKB_RACE=NR,NR,NR
5	74648603	rs12654264	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=HMGCR_(PA189);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Colonic_Neoplasms_(PA443756);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_larger_reduction_in_the_risk_of_colon_cancer_when_treated_with_statins_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_colon_cancer_and_response_to_statin_treatment._""AT:Patients_with_the_AT_genotype_may_have_a_higher_reduction_in_the_risk_of_colon_cancer_when_treated_with_statins_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_lower_reduction_in_the_risk_of_colon_cancer_when_treated_with_statins_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_colon_cancer_and_response_to_statin_treatment._""TT:Patients_with_the_TT_genotype_may_have_a_lower_reduction_in_the_risk_of_colon_cancer_when_treated_with_statins_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_colon_cancer_and_response_to_statin_treatment._";PGKB_RACE=White
5	74651084	rs3846662	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HMGCR_(PA189);PGKB_DRUG=simvastatin_(PA451363);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=Cardiovascular_Diseases_(PA443635);PGKB_TEXT="AA:This_intronic_variant_is_associated_with_differential_induction_upon_simvastatin_exposure_of_expression_of_full-length_HMGCR_transcript_versus_alternatively_spliced_transcript_lacking_exon_13_(HMGCRv_1)._In_immortalized_lymphocytes_A/A_homozygotes_exhibit_40%_greater_induction_of_full-length_transcripts_and_20%_less_alternatively_spliced_HMGCRv_1_transcript_relative_to_A/G_or_G/G_subjects._These_differences_may_have_implications_for_simvastatin_efficacy_since_increased_induction_of_the_alternatively_spliced_transcript_is_correlated_with_reduced_percent_response_to_simvastatin.""AG:The_AG_genotype_may_be_associated_with_decreased_induction_of_full-length_transcripts_and_increased_expression_of_spliced_HMGCRv_1_transcript_as_compared_to_AA_genotype.""GG:The_GG_genotype_may_be_associated_with_decreased_induction_of_full-length_transcripts_and_increased_expression_of_spliced_HMGCRv_1_transcript_as_compared_to_AA_genotype.";PGKB_RACE=NR
5	74655498	rs17238540	T	G	.	.	PGKB_INDEX=3;PGKB_GENE=HMGCR_(PA189),HMGCR_(PA189),HMGCR_(PA189);PGKB_DRUG=pravastatin_(PA451089),simvastatin_(PA451363),"atorvastatin_(PA448500)""fluvastatin_(PA449688)""hmg_coa_reductase_inhibitors_(PA133950441)""lovastatin_(PA450272)""pravastatin_(PA451089)""simvastatin_(PA451363)";PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=NR,NR,NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_were_not_studied_however_patients_with_the_GT_genotype_may_have_a_reduced_response_to_pravastatin_treatment_(lower_decreases_in_LDL-cholesterol_and_total_cholesterol)_as_compared_to_patients_with_the_TT_genotype._Several_studies_show_no_association_between_this_variant_and_pravastatin_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GT:Patients_with_the_GT_genotype_may_have_a_reduced_response_to_pravastatin_treatment_(lower_decreases_in_LDL-cholesterol_and_total_cholesterol)_as_compared_to_patients_with_the_TT_genotype._Several_studies_show_no_association_between_this_variant_and_pravastatin_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Patients_with_the_TT_genotype_may_have_a_better_response_to_pravastatin_treatment_(higher_decreases_in_LDL-cholesterol_and_total_cholesterol)_as_compared_to_patients_with_the_GT_genotype._Several_studies_show_no_association_between_this_variant_and_pravastatin_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","GG:Patients_with_the_GG_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(lower_reductions_in_LDL_cholesterol)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""GT:Patients_with_the_GT_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(lower_reductions_in_LDL_cholesterol)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""TT:Patients_with_the_TT_genotype_may_have_a_better_response_to_simvastatin_treatment_(higher_reductions_in_LDL_cholesterol)_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","GG:Patients_with_the_GG_genotype_who_are_treated_with_statins_may_be_less_likely_to_reach_target_LDL_levels_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_statins.""GT:Patients_with_the_GT_genotype_who_are_treated_with_statins_may_be_less_likely_to_reach_target_LDL_levels_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_statins.""TT:Patients_with_the_TT_genotype_who_are_treated_with_statins_may_be_more_likely_to_reach_target_LDL_levels_as_compared_to_patients_with_the_GT_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_statins.";PGKB_RACE=NR,NR,NR
5	75514986	rs11960832	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SV2C_(PA134888452);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_olanzapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_olanzapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine.";PGKB_RACE=White
5	78812909	rs4704559	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HOMER1_(PA134972608);PGKB_DRUG=levodopa_(PA450213);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Parkinson_Disease_(PA445254);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Parkinson's_disease_may_have_an_increased_risk_for_adverse_reactions_including_hallucinations_and_dyskinesia_when_treated_with_levodopa_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_adverse_effects_in_patients_taking_levodopa.""AG:Patients_with_the_AG_genotype_and_Parkinson's_disease_may_have_a_decreased_risk_for_adverse_reactions_including_hallucinations_and_dyskinesia_when_treated_with_levodopa_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_adverse_effects_in_patients_taking_levodopa.""GG:Patients_with_the_GG_genotype_and_Parkinson's_disease_may_have_a_decreased_risk_for_adverse_reactions_including_hallucinations_and_dyskinesia_when_treated_with_levodopa_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_adverse_effects_in_patients_taking_levodopa.";PGKB_RACE=NR
5	79922030	rs1650723	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteosarcoma_(PA445601);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_osteosarcoma_may_have_reduced_severity_of_mucositis_when_receiving_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_mucositis_in_patients_receiving_methotrexate.""CT:Patients_with_the_CT_genotype_and_osteosarcoma_may_have_reduced_severity_of_mucositis_when_receiving_methotrexate_as_compared_to_patients_with_the_TT_genotype_or_increased_severity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_mucositis_in_patients_receiving_methotrexate.""TT:Patients_with_the_TT_genotype_and_osteosarcoma_may_have_increased_severity_of_mucositis_when_receiving_methotrexate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_mucositis_in_patients_receiving_methotrexate.";PGKB_RACE=NR
5	79940143	rs1643650	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_respond_to_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=NR
5	79950163	rs70991108	C	CTGGCGCGTCCCGCCCAGGT	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT:Pediatric_patients_with_the_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_Thrombocytopenia_as_compared_to_pediatric_patients_with_the_TGGCGCGTCCCGCCCAGGT/del_or_del/del_genotype._Adult_patients_with_the_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_hepatic_toxicity_as_compared_to_adult_patients_with_the_TGGCGCGTCCCGCCCAGGT/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""TGGCGCGTCCCGCCCAGGT/del:Adult_patients_with_the_TGGCGCGTCCCGCCCAGGT/del_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_hepatic_toxicity_as_compared_to_patients_with_the_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT_or_del/del_genotype._Pediatric_patients_with_the_TGGCGCGTCCCGCCCAGGT/del_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_Thrombocytopenia_as_compared_to_pediatric_patients_with_the_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""del/del:Adult_patients_with_the_del/del_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_hepatic_toxicity_as_compared_to_patients_with_the_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT_or_TGGCGCGTCCCGCCCAGGT/del_genotype._Pediatric_patients_with_the_del/del_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_Thrombocytopenia_as_compared_to_pediatric_patients_with_the_TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT_or_TGGCGCGTCCCGCCCAGGT/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.";PGKB_RACE=NR
5	79950508	rs1105525	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_event_free_survival_when_treated_with_methotrexate_in_people_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_as_compared_to_patients_with_genotype_TT_or_TC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TC:Patients_with_the_TC_genotype_may_have_decreased_event_free_survival_when_treated_with_methotrexate_in_people_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_may_have_decreased_event_free_survival_when_treated_with_methotrexate_in_people_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=White
5	79950781	rs1650697	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_lung_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity._""AG:Patients_with_the_AG_genotype_and_lung_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity._""GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_when_treated_with_pemetrexed_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity._";PGKB_RACE=NR
5	79951133	rs408626	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Patients_with_acute_lymphoblastic_leukemia_and_the_CC_genotype_may_have_a_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_TT_genotypes_but_may_also_experience_decreased_rates_of_event-free_survival_and_overall_survival_rates_as_compared_to_patients_with_the_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_leukopenia_as_well_as_event-free_survival_and_overall_survival_rates_in_patients_with_acute_lymphoblastic_leukemia._""CT:Patients_with_acute_lymphoblastic_leukemia_and_the_CT_genotype_may_have_a_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_TT_genotypes_but_may_also_experience_increased_rates_of_event-free_survival_and_overall_survival_rates_as_compared_to_patients_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_leukopenia_as_well_as_event-free_survival_and_overall_survival_rates_in_patients_with_acute_lymphoblastic_leukemia._""TT:Patients_with_acute_lymphoblastic_leukemia_and_the_TT_genotype_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_and_CT_genotypes_but_may_also_experience_increased_rates_of_event-free_survival_as_well_as_overall_survival_as_compared_to_patients_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_leukopenia_as_well_as_event-free_survival_and_overall_survival_rates_in_patients_with_acute_lymphoblastic_leukemia._";PGKB_RACE=Asian
5	79951496	rs442767	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=DHFR_(PA143);PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_be_at_increased_risk_for_experiencing_fatigue_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_fatigue_when_receiving_pemetrexed._""GT:Patients_with_the_GT_genotype_and_non-small-cell_lung_cancer_may_be_at_decreased_risk_for_experiencing_fatigue_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_fatigue_when_receiving_pemetrexed._""TT:Patients_with_the_TT_genotype_and_non-small-cell_lung_cancer_may_be_at_decreased_risk_for_experiencing_fatigue_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_fatigue_when_receiving_pemetrexed._";PGKB_RACE=NR
5	82062544	rs1423515	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=salbutamol_(PA448068);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.""AG:Patients_with_the_AG_genotype_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.""GG:Patients_with_the_GG_genotype_may_have_decreased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.";PGKB_RACE=NR
5	82451075	rs1382368	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=XRCC4_(PA37423);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_clearance_of_docetaxel_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""CT:Patients_with_the_CT_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_CC_genotype_or_decreased_clearance_of_docetaxel_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""TT:Patients_with_the_TT_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.";PGKB_RACE=White
5	107586783	rs7706429	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=FBXL17_(PA134920563);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""AG:Patients_with_the_AG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AA_genotype_and_an_increased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""GG:Patients_with_the_GG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.";PGKB_RACE=White
5	107588958	rs4431329	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=FBXL17_(PA134920563);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""AT:Patients_with_the_AT_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_TT_genotypes_and_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""TT:Patients_with_the_TT_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AT_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._";PGKB_RACE=White
5	112201094	rs495794	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SRP19_(PA36124);PGKB_DRUG="citalopram_(PA449015)""fluoxetine_(PA449673)""paroxetine_(PA450801)""sertraline_(PA451333)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_be_less_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_be_less_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_GG_genotype_or_more_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline._";PGKB_RACE=Asian
5	112236297	rs153549	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=REEP5_(PA134882361);PGKB_DRUG="citalopram_(PA449015)""fluoxetine_(PA449673)""paroxetine_(PA450801)""sertraline_(PA451333)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline.""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_GG_genotype_or_less_likely_to_respond_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline.""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_be_less_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline.";PGKB_RACE=Asian
5	112254377	rs153560	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=REEP5_(PA134882361);PGKB_DRUG="citalopram_(PA449015)""fluoxetine_(PA449673)""paroxetine_(PA450801)""sertraline_(PA451333)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_be_less_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_be_less_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_GG_genotype_or_more_likely_to_respond_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_when_treated_with_citalopram_fluoxetine_paroxetine_or_sertraline_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram_fluoxetine_paroxetine_or_sertraline._";PGKB_RACE=Asian
5	131676320	rs1050152	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A4_(PA332);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Gastrointestinal_Stromal_Tumors_(PA151958383)""Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_cancer_may_have_a_better_response_to_treatment_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.""CT:Patients_with_the_CT_genotype_and_cancer_may_have_a_better_response_to_treatment_with_imatinib_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.""TT:Patients_with_the_TT_genotype_and_cancer_may_have_a_poorer_response_to_treatment_with_imatinib_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.";PGKB_RACE=NR
5	131703578	rs2631372	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A5_(PA333);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Gastrointestinal_Stromal_Tumors_(PA151958383);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_gastrointestinal_stromal_tumours_may_have_a_shorter_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.""CG:Patients_with_the_CG_genotype_and_gastrointestinal_stromal_tumours_may_have_a_longer_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.""GG:Patients_with_the_GG_genotype_and_gastrointestinal_stromal_tumours_may_have_a_longer_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.";PGKB_RACE=White
5	131705458	rs2631367	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A5_(PA333);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Gastrointestinal_Stromal_Tumors_(PA151958383);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_gastrointestinal_stromal_tumors_may_have_a_shorter_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib_treatment.""CG:Patients_with_the_CG_genotype_and_gastrointestinal_stromal_tumors_may_have_a_longer_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib_treatment.""GG:Patients_with_the_GG_genotype_and_gastrointestinal_stromal_tumors_may_have_a_longer_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib_treatment.";PGKB_RACE=White
5	131992809	rs1800925	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=IL13_(PA199);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="CC:Patients_with_renal_cell_carcinoma_and_the_CC_genotype_may_have_a_decreased_severity_of_drug-induced_toxicity_when_administered_sunitinib_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_severity_of_drug-induced_toxicity_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib._""CT:Patients_with_renal_cell_carcinoma_and_the_CT_genotype_may_have_a_decreased_severity_of_drug-induced_toxicity_when_administered_sunitinib_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_severity_of_drug-induced_toxicity_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib._""TT:Patients_with_renal_cell_carcinoma_and_the_TT_genotype_may_have_a_decreased_severity_of_drug-induced_toxicity_when_administered_sunitinib_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_severity_of_drug-induced_toxicity_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib._";PGKB_RACE=NR
5	131995843	rs1295686	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL13_(PA199);PGKB_DRUG=Hepatitis_vaccines_(PA164712789);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_at_decreased_risk_for_non-immune_response_to_the_hepatitis_B_vaccine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_in_patients_receiving_the_hepatitis_B_vaccine._""CT:Patients_with_the_CT_genotype_may_be_at_decreased_risk_for_non-immune_response_to_the_hepatitis_B_vaccine_as_compared_to_patients_with_the_TT_genotype_or_at_increased_risk_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_in_patients_receiving_the_hepatitis_B_vaccine._""TT:Patients_with_the_TT_genotype_may_be_at_increased_risk_for_non-immune_response_to_the_hepatitis_B_vaccine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_in_patients_receiving_the_hepatitis_B_vaccine._";PGKB_RACE=Asian
5	132009154	rs2243250	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=IL4_(PA197);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_higher_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CT:Patients_with_the_CT_genotype_and_asthma_may_have_a_higher_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_a_lower_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
5	140012916	rs2569190	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CD14_(PA26188);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colitis_Ulcerative_(PA443750);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AG:Patients_with_the_AG_genotype_and_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
5	147546452	rs9285669	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""AT:Patients_with_the_AT_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_TT_genotype_and_an_increased_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""TT:Patients_with_the_TT_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AT_and_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._";PGKB_RACE=White
5	148206440	rs1042713	G	A	.	.	PGKB_INDEX=9;PGKB_GENE=ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39),ADRB2_(PA39);PGKB_DRUG=corticosteroids_(PA10832),"corticosteroids_(PA10832)""salmeterol_(PA451300)",methacholine_(PA165958382),benazepril_(PA448561),risperidone_(PA451257),"salbutamol_(PA448068)""salmeterol_(PA451300)",isoproterenol_(PA450121),tiotropium_(PA164769056),phenylephrine_(PA450935);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Toxicity/ADR,Efficacy,Other,Efficacy,Dosage;PGKB_EVIDENCE=3,3,3,3,3,2A,4,3,3;PGKB_DISEASE=Asthma_(PA443450),Asthma_(PA443450),Asthma_(PA443450),Essential_hypertension_(PA447288),Schizophrenia_(PA447216),Asthma_(PA443450),NR,Asthma_(PA443450),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_corticosteroids_may_have_an_increased_risk_for_uncontrolled_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids._""AG:Patients_with_the_AG_genotype_and_asthma_who_are_treated_with_corticosteroids_may_have_an_increased_risk_for_uncontrolled_asthma_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_reduced_risk_for_uncontrolled_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids._""GG:Patients_with_the_GG_genotype_and_asthma_who_are_treated_with_corticosteroids_may_have_a_reduced_risk_for_uncontrolled_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids._","AA:Children_with_the_AA_genotype_and_asthma_who_are_treated_with_corticosteroids_and_long_acting_beta-2-agonists_may_have_an_increased_risk_of_exacerbations_as_compared_to_children_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AG:Children_with_the_AG_genotype_and_asthma_who_are_treated_with_corticosteroids_and_long_acting_beta-2-agonists_may_have_an_increased_risk_of_exacerbations_as_compared_to_children_with_the_GG_genotype_or_may_have_a_reduced_risk_of_exacerbations_as_compared_to_children_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Children_with_the_GG_genotype_and_asthma_who_are_treated_with_corticosteroids_and_long_acting_beta-2-agonists_may_have_a_reduced_risk_of_exacerbations_as_compared_to_children_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_poorer_response_when_treated_with_methacholine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methacholine.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_better_response_when_treated_with_methacholine_as_compared_to_patients_with_the_AA_genotype_or_a_poorer_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_better_response_when_treated_with_methacholine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methacholine.","AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AG_or_GG_genotype._No_significant_results_have_been_seen_for_systolic_blood_pressure._Additionally_the_same_study_reported_no_significant_differences_in_systolic_or_diastolic_blood_pressure_between_genotypes_in_a_different_cohort._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_or_systolic_blood_pressure.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AA_genotype._No_significant_results_have_been_seen_for_systolic_blood_pressure._Additionally_the_same_study_reported_no_significant_differences_in_systolic_or_diastolic_blood_pressure_between_genotypes_in_a_different_cohort._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_or_systolic_blood_pressure.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_as_compared_to_patients_with_the_AA_genotype._No_significant_results_have_been_seen_for_systolic_blood_pressure._Additionally_the_same_study_reported_no_significant_differences_in_systolic_or_diastolic_blood_pressure_between_genotypes_in_a_different_cohort._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_or_systolic_blood_pressure.","AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_sexual_adverse_events_when_treated_with_risperidone_in_people_with_Schizophrenia_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_sexual_adverse_events_when_treated_with_risperidone_in_people_with_Schizophrenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_sexual_adverse_events_when_treated_with_risperidone_in_people_with_Schizophrenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.","AA:Children_with_the_AA_genotype_with_asthma_who_are_treated_with_salmeterol_or_salbutamol_may_have_a_decreased_response_to_treatment_(as_measured_by_increased_risk_of_asthma_excerbations_and_lower_quality_of_life_scores)_as_compared_to_children_with_the_GG_genotype._This_association_does_not_seem_to_apply_to_lung_function_measurements_such_as_peak_expiratory_flow_rate_or_FEV1._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AG:Children_with_the_AG_genotype_with_asthma_who_are_treated_with_salmeterol_or_salbutamol_may_have_a_decreased_response_to_treatment_(as_measured_by_increased_risk_of_asthma_excerbations_and_lower_quality_of_life_scores)_as_compared_to_children_with_the_GG_genotype_or_may_have_a_better_response_to_treatment_(as_measured_by_increased_risk_of_asthma_excerbations_and_lower_quality_of_life_scores)_as_compared_to_patients_with_the_AA_genotype._This_association_does_not_seem_to_apply_to_lung_function_measurements_such_as_peak_expiratory_flow_rate_or_FEV1._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Children_with_the_GG_genotype_with_asthma_who_are_treated_with_salmeterol_or_salbutamol_may_have_a_better_response_to_treatment_(as_measured_by_a_decreased_risk_of_asthma_excerbations_and_higher_quality_of_life_scores)_as_compared_to_children_with_the_AA_genotype._This_association_does_not_seem_to_apply_to_lung_function_measurements._This_association_does_not_seem_to_apply_to_lung_function_measurements_such_as_peak_expiratory_flow_rate_or_FEV1._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","AA:Patients_with_the_AA_genotype_may_have_increased_isoproterenol-mediated_desensitization_in_the_vasculature_when_exposed_to_isoproterenol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_isoproterenol.""AG:Patients_with_the_AG_genotype_may_have_increased_isoproterenol-mediated_desensitization_in_the_vasculature_when_exposed_to_isoproterenol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_isoproterenol.""GG:Patients_with_the_GG_genotype_may_have_decreased_isoproterenol-mediated_desensitization_in_the_vasculature_when_exposed_to_isoproterenol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_isoproterenol.","AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_better_response_to_treatment_with_tiotropium_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_tiotropium._""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_poorer_response_to_treatment_with_tiotropium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_tiotropium._""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_poorer_response_to_treatment_with_tiotropium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_tiotropium._","AA:Women_with_the_AA_genotype_who_are_undergoing_cesarean_delivery_may_require_an_increased_dose_of_phenylephrine_as_compared_to_women_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_phenylephrine.""AG:Women_with_the_AG_genotype_who_are_undergoing_cesarean_delivery_may_require_an_increased_dose_of_phenylephrine_as_compared_to_women_with_the_GG_genotype_or_a_lower_dose_as_compared_to_women_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_phenylephrine.""GG:Women_with_the_GG_genotype_who_are_undergoing_cesarean_delivery_may_require_a_lower_dose_of_phenylephrine_as_compared_to_women_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_phenylephrine.";PGKB_RACE=NR,NR,NR,Asian,White,NR,NR,NR,NR
5	148206473	rs1042714	G	C	.	.	PGKB_INDEX=2;PGKB_GENE=ADRB2_(PA39),ADRB2_(PA39);PGKB_DRUG=enalapril_(PA449456),carvedilol_(PA448817);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Hypertrophy_Left_Ventricular_(PA446479),Heart_Failure_(PA444370);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_left_ventricular_hypertrophy_may_have_a_smaller_percent_reduction_in_left_ventricular_mass_index_when_treated_with_enalapril_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_reduction_in_left_ventricular_mass_index._""CG:Patients_with_the_CG_genotype_and_left_ventricular_hypertrophy_may_have_a_greater_percent_reduction_in_left_ventricular_mass_index_when_treated_with_enalapril_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_reduction_in_left_ventricular_mass_index._""GG:Patients_with_the_GG_genotype_and_left_ventricular_hypertrophy_may_have_a_greater_percent_reduction_in_left_ventricular_mass_index_when_treated_with_enalapril_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_reduction_in_left_ventricular_mass_index._","CC:Patients_with_the_CC_genotype_and_heart_failure_may_have_a_poorer_response_to_carvedilol_treatment_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""CG:Patients_with_the_CG_genotype_and_heart_failure_may_have_a_poorer_response_to_carvedilol_treatment_as_compared_to_patients_with_the_GG_genotype_and_a_better_response_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_CG_genotype_may_still_be_at_risk_for_non-response_to_carvedilol_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""GG:Patients_with_the_GG_genotype_and_heart_failure_may_have_a_better_response_to_carvedilol_treatment_as_compared_to_patients_with_the_CC_or_CG_genotype._Patients_with_the_GG_genotype_may_still_be_at_risk_for_non-response_to_carvedilol_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.";PGKB_RACE=White,White
5	148228496	rs11959113	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=fentanyl_(PA449599);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_Postoperative_(PA445210);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_postoperative_pain_may_require_an_increased_dose_when_treated_with_fentanyl_as_compared_to_patients_with_the_AG+GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_required_dose_of_fentanyl.""AG:Patients_with_the_AG_genotype_and_postoperative_pain_may_require_a_decreased_dose_when_treated_with_fentanyl_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_required_dose_of_fentanyl.""GG:Patients_with_the_GG_genotype_and_postoperative_pain_may_require_a_decreased_dose_when_treated_with_fentanyl_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_required_dose_of_fentanyl.";PGKB_RACE=Asian
5	161111174	rs1992647	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GABRA6_(PA28494);PGKB_DRUG="antidepressants_(PA452229)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""AG:Patients_with_the_AG_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_anti-depressant_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""GG:Patients_with_the_GG_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._";PGKB_RACE=Asian
5	161322889	rs2279020	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GABRA1_(PA28489);PGKB_DRUG="carbamazepine_(PA448785)""phenytoin_(PA450947)""valproic_acid_(PA451846)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_phenytoin_or_valproic_acid_may_have_a_decreased_but_not_absent_risk_for_drug-resistance_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-resistance.""GA:Patients_with_the_GA_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_phenytoin_or_valproic_acid_may_have_increased_risk_for_drug-resistance_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-resistance.""GG:Patients_with_the_GG_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_phenytoin_or_valproic_acid_may_have_increased_risk_for_drug-resistance_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-resistance.";PGKB_RACE=Asian
5	161324898	rs2290732	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=GABRA1_(PA28489);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_epilepsy_may_have_increased_retention_rates_when_treated_with_carbamazepine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_retention_rate_of_carbamazepine.""AG:Patients_with_the_AG_genotype_and_epilepsy_may_have_increased_retention_rates_when_treated_with_carbamazepine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_retention_rate_of_carbamazepine.""GG:Patients_with_the_GG_genotype_and_epilepsy_may_have_decreased_retention_rates_when_treated_with_carbamazepine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_retention_rate_of_carbamazepine.";PGKB_RACE=Asian
5	169805956	rs2301149	C	G	.	.	PGKB_INDEX=1;PGKB_GENE="KCNIP1_(PA30041)""KCNMB1_(PA221)";PGKB_DRUG=verapamil_(PA451868);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertensive_coronary_artery_disease_may_have_a_decreased_risk_of_mortality_nonfatal_myocardial_infarction_or_nonfatal_stroke_when_treated_with_verapamil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_blood_pressure_and_response_to_antihypertensives.""CG:Patients_with_the_CG_genotype_and_hypertensive_coronary_artery_disease_may_have_a_decreased_risk_of_mortality_nonfatal_myocardial_infarction_or_nonfatal_stroke_when_treated_with_verapamil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_blood_pressure_and_response_to_antihypertensives.""GG:Patients_with_the_GG_genotype_and_hypertensive_coronary_artery_disease_may_have_an_increased_risk_of_mortality_nonfatal_myocardial_infarction_or_nonfatal_stroke_when_treated_with_verapamil_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_blood_pressure_and_response_to_antihypertensives.";PGKB_RACE=NR
5	169810796	rs11739136	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="KCNIP1_(PA30041)""KCNMB1_(PA221)";PGKB_DRUG=verapamil_(PA451868);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype:_1)_may_have_increased_blood_pressure_2)_increased_risk_for_hypertension_and_3)_slower_control_of_blood_pressure_when_treated_with_verapamil_as_compared_to_patients_with_the_TT_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_blood_pressure_and_response_to_antihypertensives.""CT:Patients_with_the_CT_genotype:_1)_may_have_decreased_blood_pressure_2)_decreased_risk_for_hypertension_and_3)_faster_control_of_blood_pressure_when_treated_with_verapamil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_blood_pressure_and_response_to_antihypertensives.""TT:Patients_with_the_CT_genotype:_1)_may_have_decreased_blood_pressure_2)_decreased_risk_for_hypertension_and_3)_faster_control_of_blood_pressure_when_treated_with_verapamil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_blood_pressure_and_response_to_antihypertensives.";PGKB_RACE=NR
5	170215638	rs10036156	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GABRP_(PA28503);PGKB_DRUG="antidepressants_(PA452229)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._";PGKB_RACE=Asian
5	174866091	rs11746641	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="bupropion_(PA448687)""nicotine_(PA450626)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_an_increased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.""GT:Patients_with_the_GT_genotype_may_have_an_increased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.";PGKB_RACE=White
5	174870150	rs4532	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=DRD1_(PA147),DRD1_(PA147);PGKB_DRUG=lithium_(PA450243),"dextroamphetamine_(PA449269)""methylphenidate_(PA450464)";PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=4,3;PGKB_DISEASE=Bipolar_Disorder_(PA447199),Attention_Deficit_Disorder_with_Hyperactivity_(PA447197);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Bipolar_Disorder_may_have_a_decreased_response_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""CT:Patients_with_the_CT_genotype_and_Bipolar_Disorder_may_have_a_decreased_response_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TT:Patients_with_the_TT_genotype_and_Bipolar_Disorder_may_have_an_increased_response_to_lithium_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.","CC:Patients_with_the_CC_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_an_increased_severity_of_social_withdrawal_or_nausea_when_treated_with_methylphenidate_or_dextroamphetamine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_social_withdrawal_or_nausea_in_patients_receiving_methylphenidate_or_dextroamphetamine._""CT:Patients_with_the_CT_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_decreased_severity_of_social_withdrawal_or_nausea_when_treated_with_methylphenidate_or_dextroamphetamine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_social_withdrawal_or_nausea_in_patients_receiving_methylphenidate_or_dextroamphetamine._""TT:Patients_with_the_TT_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_decreased_severity_of_social_withdrawal_or_nausea_when_treated_with_methylphenidate_or_dextroamphetamine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_social_withdrawal_or_nausea_in_patients_receiving_methylphenidate_or_dextroamphetamine._";PGKB_RACE=White,White
5	174876002	rs2168631	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="bupropion_(PA448687)""nicotine_(PA450626)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.""AG:Patients_with_the_AG_genotype_may_have_an_increased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.";PGKB_RACE=White
5	174883052	rs11749035	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="bupropion_(PA448687)""nicotine_(PA450626)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.""CT:Patients_with_the_CT_genotype_may_have_an_increased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.""TT:Patients_with_the_TT_genotype_may_have_an_increased_likelihood_of_smoking_abstinence_within_slow_nicotine_metabolizers_when_exposed_to_bupropion_or_nicotine_replacement_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bupropion.";PGKB_RACE=White
5	176836532	rs1801020	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=F12_(PA161);PGKB_DRUG=Enzymes_(PA164712734);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Stroke_(PA447054);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_have_had_a_stroke_may_have_a_decreased_risk_of_in-hospital_death_when_treated_with_tissue_plasminogen_activator_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_in-hospital_death.""AG:Patients_with_the_AG_genotype_who_have_had_a_stroke_may_have_a_decreased_risk_of_in-hospital_death_when_treated_with_tissue_plasminogen_activator_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_in-hospital_death.""GG:Patients_with_the_GG_genotype_who_have_had_a_stroke_may_have_an_increased_risk_of_in-hospital_death_when_treated_with_tissue_plasminogen_activator_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_in-hospital_death.";PGKB_RACE=White
5	179220638	rs730012	A	C	.	.	PGKB_INDEX=2;PGKB_GENE=LTC4S_(PA235),"LTC4S_(PA235)""MGAT4B_(PA30783)";PGKB_DRUG=aspirin_(PA448497),montelukast_(PA450546);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=Urticaria_(PA445999),Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_aspirin_may_have_a_decreased_but_not_absent_risk_of_urticaria_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.""AC:Patients_with_the_AC_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_urticaria_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.""CC:Patients_with_the_CC_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_urticaria_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.","AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_montelukast_may_have_an_increased_risk_of_asthma_exacerbations_as_compared_to_patients_with_the_AC_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma_exacerbations_with_montelukast_treatment.""AC:Patients_with_the_AC_genotype_and_asthma_who_are_treated_with_montelukast_may_have_a_decreased_but_not_absent_risk_of_asthma_exacerbations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma_exacerbations_with_montelukast_treatment.""CC:Patients_with_the_CC_genotype_and_asthma_who_are_treated_with_montelukast_may_have_a_decreased_but_not_absent_risk_of_asthma_exacerbations_as_compared_to_patients_with_the_AA_genotype._However_this_difference_was_not_statistically_significant._This_may_be_related_to_the_relatively_low_frequency_of_CC_homozygotes_(11%)_in_the_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma_exacerbations_with_montelukast_treatment.";PGKB_RACE=NR,White
5	180030313	rs307821	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=FLT4_(PA28183);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="AA:Patients_with_the_AA_genotype_were_not_studied._However_patients_with_the_AC_genotype_and_Renal_Cell_Carcinoma_who_are_treated_with_sunitinib_may_have_reduced_progression-free_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.""AC:Patients_with_the_AC_genotype_and_Renal_Cell_Carcinoma_who_are_treated_with_sunitinib_may_have_reduced_progression-free_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.""CC:Patients_with_the_CC_genotype_and_Renal_Cell_Carcinoma_who_are_treated_with_sunitinib_may_have_increased_progression-free_survival_as_compared_to_patients_with_the_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.";PGKB_RACE=NR
5	180051003	rs307826	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=FLT4_(PA28183);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="CC:Patients_with_the_CC_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_Renal_Cell_Carcinoma_who_are_treated_with_sunitinib_may_have_reduced_progression-free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.""CT:Patients_with_the_CT_genotype_and_Renal_Cell_Carcinoma_who_are_treated_with_sunitinib_may_have_reduced_progression-free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.""TT:Patients_with_the_TT_genotype_and_Renal_Cell_Carcinoma_who_are_treated_with_sunitinib_may_have_increased_progression-free_survival_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.";PGKB_RACE=NR
6	3010390	rs1143684	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NQO2_(PA31745);PGKB_DRUG="cyclophosphamide_(PA449165)""doxorubicin_(PA449412)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Breast_Neoplasms_who_are_ER-ve/PR-ve_negative_and_treated_with_cyclophosphamide_and_doxorubicin_may_have_worse_prognosis_(overall_survival_and_progression-free_survival)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_treatment_prognosis.""CT:Patients_with_the_CT_genotype_and_Breast_Neoplasms_who_are_ER-ve/PR-ve_negative_and_treated_with_cyclophosphamide_and_doxorubicin_may_have_worse_prognosis_(overall_survival_and_progression-free_survival)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_treatment_prognosis.""TT:Patients_with_the_CT_genotype_and_Breast_Neoplasms_who_are_ER-ve/PR-ve_negative_and_treated_with_cyclophosphamide_and_doxorubicin_may_have_worse_prognosis_(overall_survival_and_progression-free_survival)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_treatment_prognosis.";PGKB_RACE=NR
6	6318795	rs5985	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=F13A1_(PA162);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Male_patients_with_the_AA_genotype_may_have_an_increased_inhibition_of_FXIII_activation_by_aspirin_as_compared_to_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AC:Male_patients_with_the_AC_genotype_may_have_an_increased_inhibition_of_FXIII_activation_by_aspirin_as_compared_to_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CC:Male_patients_with_the_CC_genotype_may_have_a_decreased_inhibition_of_FXIII_activation_by_aspirin_as_compared_to_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=NR
6	12296255	rs5370	G	T	.	.	PGKB_INDEX=2;PGKB_GENE=EDN1_(PA27614),EDN1_(PA27614);PGKB_DRUG="atenolol_(PA448499)""irbesartan_(PA450084)",muraglitazar_(PA162356187);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Essential_hypertension_(PA447288),"Diabetes_Mellitus_(PA443886)""Edema_(PA443994)""Hyperlipidemias_(PA444528)";PGKB_TEXT="GG:Men_with_the_GG_genotype_and_hypertension_may_have_a_smaller_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_or_irbesartan_as_compared_to_men_with_the_GT_genotype._No_significant_associations_were_seen_for_diastolic_blood_pressure_or_in_women._Other_genetic_and_clinical_factors_may_also_influence_systolic_and_diastolic_blood_pressure_response_to_atenolol_and_irbesartan.""GT:Men_with_the_GT_genotype_and_hypertension_may_have_a_greater_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_or_irbesartan_as_compared_to_men_with_the_GG_genotype._No_significant_associations_were_seen_for_diastolic_blood_pressure_or_in_women._Other_genetic_and_clinical_factors_may_also_influence_systolic_and_diastolic_blood_pressure_response_to_atenolol_and_irbesartan.""TT:No_men_with_the_TT_genotype_were_present_in_the_study_analysis._However_men_with_the_GT_genotype_and_hypertension_may_have_a_greater_decrease_in_systolic_blood_pressure_when_treated_with_atenolol_or_irbesartan_as_compared_to_men_with_the_GG_genotype._No_significant_associations_were_seen_for_diastolic_blood_pressure_or_in_women_(n=2_with_TT_genotype)._Other_genetic_and_clinical_factors_may_also_influence_systolic_and_diastolic_blood_pressure_response_to_atenolol_and_irbesartan.","GG:Patients_with_the_GG_genotype_and_type_2_diabetes_who_are_treated_with_muraglitazar_may_have_a_decreased_but_not_absent_risk_of_edema_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_edema_with_muraglitazar_treatment.""GT:No_conclusive_results_were_found_for_patients_with_the_GT_genotype._But_patients_with_the_TT_genotype_and_type_2_diabetes_who_are_treated_with_muraglitazar_may_have_an_increased_risk_of_edema_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_edema_with_muraglitazar_treatment.""TT:Patients_with_the_TT_genotype_and_type_2_diabetes_who_are_treated_with_muraglitazar_may_have_an_increased_risk_of_edema_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_edema_with_muraglitazar_treatment.";PGKB_RACE=White,NR
6	15573074	rs742105	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DTNBP1_(PA27512);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_may_have_a_decreased_response_to_clozapine_compared_to_patients_with_a_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_may_have_an_increased_response_to_clozapine_compared_to_patients_with_a_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_may_have_an_increased_response_to_clozapine_compared_to_patients_with_a_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.";PGKB_RACE=Black_or_African_American
6	15628102	rs3213207	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DTNBP1_(PA27512);PGKB_DRUG=methamphetamine_(PA450403);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="CC:Patients_with_this_genotype_were_not_studied.""CT:Patients_with_the_CT_genotype_who_are_exposed_to_methamphetamine_may_have_an_increased_risk_for_psychosis_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_psychosis_with_methamphetamine_exposure.""TT:Patients_with_the_TT_genotype_who_are_exposed_to_methamphetamine_may_have_a_decreased_but_not_absent_risk_for_psychosis_as_compared_to_patients_with_the_TC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_psychosis_with_methamphetamine_exposure.";PGKB_RACE=Asian
6	15651132	rs760761	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DTNBP1_(PA27512);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""AG:Patients_with_the_AG_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=White
6	15660871	rs909706	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DTNBP1_(PA27512);PGKB_DRUG=haloperidol_(PA449841);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_may_have_a_reduced_response_to_haloperidol_as_compared_to_patients_with_the_CT_genotype._Results_were_suggestive_of_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_may_have_a_better_response_to_haloperidol_as_compared_to_patients_with_the_the_CC_genotype._Results_were_suggestive_of_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_may_have_a_better_response_to_haloperidol_as_compared_to_patients_with_the_the_CC_genotype._Please_note_while_the_CT_genotype_was_associated_with_suggestively_better_response_to_haloperidol_in_unrelated_schizophrenic_inpatients_no_results_were_shown_for_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.";PGKB_RACE=Black_or_African_American
6	15665209	rs2619538	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=DTNBP1_(PA27512);PGKB_DRUG=methamphetamine_(PA450403);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_for_methamphetamine_psychosis_compared_to_patients_with_the_TT_genotype._Please_note_that_in_the_study_reporting_this_association_there_were_no_subjects_with_the_AA_genotype_but_the_A_allele_was_found_to_be_associated_with_increased_risk._Please_note_the_associated_did_not_remain_significant_after_Bonferroni_correction_and_was_comparing_allele_frequencies_in_healthy_controls_and_those_with_methamphetamine_psychosis_not_comparing_frequencies_in_individuals_exposed_to_methamphetamine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_to_methamphetamine_psychosis.""AT:Patients_with_the_AT_genotype_may_have_an_increased_risk_for_methamphetamine_psychosis_compared_to_patients_with_the_TT_genotype._Please_note_this_associated_did_not_remain_significant_after_Bonferroni_correction_and_was_comparing_allele_frequencies_in_healthy_controls_and_those_with_methamphetamine_psychosis_not_comparing_frequencies_in_individuals_exposed_to_methamphetamine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_to_methamphetamine_psychosis.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_risk_for_methamphetamine_psychosis_compared_to_patients_with_the_AT_genotype._Please_note_this_association_did_not_remain_significant_after_Bonferroni_correction_and_was_comparing_allele_frequencies_in_healthy_controls_and_those_with_methamphetamine_psychosis_not_comparing_frequencies_in_individuals_exposed_to_methamphetamine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_to_methamphetamine_psychosis.";PGKB_RACE=Asian
6	16145325	rs9370867	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=MYLIP_(PA134942677);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_better_LDL-C_responses_and_are_more_likely_to_achieve_LDL-C_levels_of_less_than_130mg/dl_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin.""AG:Patients_with_the_AG_genotype_and_hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_decreased_LDL-C_responses_and_are_less_likely_to_achieve_LDL-C_levels_of_less_than_130mg/dl_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin.""GG:Patients_with_the_GG_genotype_and_hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_decreased_LDL-C_responses_and_are_less_likely_to_achieve_LDL-C_levels_of_less_than_130mg/dl_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin.";PGKB_RACE=NR
6	18130918	rs1142345	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=TPMT_(PA356),TPMT_(PA356),TPMT_(PA356);PGKB_DRUG=cisplatin_(PA449014),"cisplatin_(PA449014)""cyclophosphamide_(PA449165)",mercaptopurine_(PA450379);PGKB_TYPE=Toxicity/ADR,Efficacy,"Dosage""Toxicity/ADR";PGKB_EVIDENCE=3,3,3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Neoplasms_(PA445062)""Ototoxicity_(PA162263534)",Ovarian_Neoplasms_(PA445204),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Children_with_the_CC_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_TT_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""CT:Children_with_the_CT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_TT_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""TT:Children_with_the_TT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_a_decreased_but_not_absent_risk_for_hearing_loss_as_compared_to_children_with_the_TC_or_CC_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.","CC:Patients_with_the_CC_genotype_were_not_studied._Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_reduced_progression-free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_reduced_progression-free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_increased_progression-free_survival_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._","CC:Pediatric_patients_with_the_CC_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_may_experience_increased_GI_toxicity_when_treated_with_mercaptopurine_and_may_require_a_decreased_dose_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_GI_toxicity_and_dose_of_mercaptopurine_in_pediatric_patients_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma.""CT:Pediatric_patients_with_the_CT_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_may_experience_increased_GI_toxicity_when_treated_with_mercaptopurine_and_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotypes._However_they_may_experience_decreased_GI_toxicity_when_treated_with_mercaptopurine_and_may_require_an_increased_dose_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_GI_toxicity_and_dose_of_mercaptopurine_in_pediatric_patients_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma.""TT:Pediatric_patients_with_the_TT_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_may_experience_decreased_GI_toxicity_when_treated_with_mercaptopurine_and_may_require_an_increased_dose_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_GI_toxicity_and_dose_of_mercaptopurine_in_pediatric_patients_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma.";PGKB_RACE=NR,NR,NR
6	18139228	rs1800460	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Children_with_the_CC_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_a_decreased_but_not_absent_risk_for_hearing_loss_as_compared_to_children_with_the_TC_or_TT_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""CT:Children_with_the_TC_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_CC_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""TT:Children_with_the_TT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_CC_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.";PGKB_RACE=NR
6	18139802	rs12201199	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=TPMT_(PA356);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Children_with_the_AA_genotype_and_cancer_may_have_a_lower_but_not_absent_risk_for_hearing_loss_with_cisplatin_treatment_compared_to_children_with_the_TT_genotype._(Alleles_have_been_complemented_to_the_plus_chromosomal_strand)._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""AT:Children_with_the_AT_genotype_and_cancer_may_have_an_increased_risk_for_hearing_loss_with_cisplatin_treatment_compared_to_children_with_the_AA_genotype._(Alleles_have_been_complemented_to_the_plus_chromosomal_strand)._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""TT:Children_with_the_TT_genotype_and_cancer_may_have_an_increased_risk_for_hearing_loss_with_cisplatin_treatment_compared_to_children_with_the_AA_genotype._(Alleles_have_been_complemented_to_the_plus_chromosomal_strand)._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.";PGKB_RACE=NR
6	24503590	rs2760118	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ALDH5A1_(PA24702);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Opioid-Related_Disorders_(PA445043);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_opioid-dependent_may_have_a_better_response_when_treated_with_methadone_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methadone.""CT:Patients_with_the_CT_genotype_who_are_opioid-dependent_may_have_a_poorer_response_when_treated_with_methadone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methadone.""TT:Patients_with_the_TT_genotype_who_are_opioid-dependent_may_have_a_poorer_response_when_treated_with_methadone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_methadone.";PGKB_RACE=White
6	29798642	rs17179108	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-G_(PA35083);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_colorectal_cancer_and_the_CC_genotype_may_have_a_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_CT_genotype._There_were_no_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.""CT:Patients_with_colorectal_cancer_and_the_CT_genotype_may_have_a_better_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_CC_genotype._There_were_no_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.";PGKB_RACE=White
6	29798749	rs1063320	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-G_(PA35083);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_asthma_and_the_CC_genotype_may_have_an_increased_likelihood_of_asthma-related_exacerbations_when_exposed_to_HMG-CoA_reductase_inhibitors_(statins)_as_compared_to_patients_with_the_CG_and_GG_genotypes._Other_clinical_and_environmental_factors_may_also_influence_likelihood_of_asthma-related_exacerbations_in_patients_taking_statins.""CG:Patients_with_asthma_and_the_CG_genotype_may_have_a_decreased_likelihood_of_asthma-related_exacerbations_when_exposed_to_HMG-CoA_reductase_inhibitors_(statins)_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_environmental_factors_may_also_influence_likelihood_of_asthma-related_exacerbations_in_patients_taking_statins.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_likelihood_of_asthma-related_exacerbations_when_exposed_to_HMG-CoA_reductase_inhibitors_(statins)_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_environmental_factors_may_also_influence_likelihood_of_asthma-related_exacerbations_in_patients_taking_statins.";PGKB_RACE=White
6	29798794	rs9380142	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=HLA-G_(PA35083),HLA-G_(PA35083);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)","capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_colorectal_cancer_and_the_AA_genotype_may_have_a_better_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.""AG:Patients_with_colorectal_cancer_and_the_AG_genotype_may_have_a_better_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.""GG:Patients_with_colorectal_cancer_and_the_GG_genotype_may_have_a_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_capecitabine_or_fluorouracil_in_patients_with_colorectal_cancer.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_a_decreased_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_capecitabine_or_fluorouracil._""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_a_decreased_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_capecitabine_or_fluorouracil._""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_an_increased_response_to_capecitabine_or_fluorouracil_as_compared_to_patients_with_the_AA_and_AG_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_capecitabine_or_fluorouracil._";PGKB_RACE=White,White
6	31006855	rs2844665	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="CC:Patients_with_genotype_CC_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""CT:Patients_with_genotype_CT_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""TT:Patients_with_genotype_TT_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._";PGKB_RACE=NR
6	31093587	rs3815087	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PSORS1C1_(PA33919);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_GG_genotype._This_association_was_significant_for_haplotype_analysis_with_other_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""AG:Patients_with_genotype_AG_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_AA_genotype._This_association_was_significant_for_haplotype_analysis_with_other_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.""GG:Patients_with_genotype_GG_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_AA_genotype._This_association_was_significant_for_haplotype_analysis_with_other_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._";PGKB_RACE=NR
6	31134888	rs3130931	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=POU5F1_(PA33545);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="CC:Patients_with_genotype_CC_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""CT:Patients_with_genotype_CT_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.""TT:Patients_with_genotype_TT_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._";PGKB_RACE=NR
6	31136453	rs3130501	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=POU5F1_(PA33545);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_GG_genotype._This_association_was_significant_for_haplotype_analysis_with_other_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""AG:Patients_with_genotype_AG_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_GG_genotype._This_association_was_significant_for_haplotype_analysis_with_other_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""GG:Patients_with_genotype_GG_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_AA_genotype._This_association_was_significant_for_haplotype_analysis_with_other_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._";PGKB_RACE=NR
6	31142245	rs3094188	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=PSORS1C3_(PA33921);PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""AC:Patients_with_genotype_AC_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""CC:Patients_with_genotype_CC_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._";PGKB_RACE=NR
6	31253444	rs9461684	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-C_(PA35057);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_nevirapine_may_have_a_decreased_risk_of_drug-induced_rash_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nevirapine-induced_rash.""CT:Patients_with_the_CT_genotype_and_HIV_infection_who_are_treated_with_nevirapine_may_have_a_decreased_risk_of_drug-induced_rash_as_compared_to_patients_with_the_TT_genotype_or_may_have_an_increased_risk_of_drug-induced_rash_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nevirapine-induced_rash.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_nevirapine_may_have_an_increased_risk_of_drug-induced_rash_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nevirapine-induced_rash.";PGKB_RACE=Asian
6	31407828	rs9469003	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=allopurinol_(PA448320);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Epidermal_Necrolysis_Toxic_(PA444059)""severe_cutaneous_adverse_reactions_(PA166120929)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="CC:Patients_with_genotype_CC_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._""CT:Patients_with_genotype_CT_may_have_an_increased_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions.""TT:Patients_with_genotype_TT_may_have_a_decreased_but_not_absent_risk_of_severe_cutaneous_adverse_reactions_(such_as_Stevens_Johnson_Syndrome_or_Toxic_Epidermal_Necrolysis)_when_treated_with_allopurinol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_allopurinol-induced_adverse_reactions._";PGKB_RACE=NR
6	31448976	rs3099844	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYCSP5_(PA142672032);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acquired_Immunodeficiency_Syndrome_(PA443250);PGKB_TEXT="AA:Female_patients_with_the_AA_genotype_and_acquired_immunodeficiency_syndrome_(AIDS)_may_have_an_increased_risk_of_Stevens-Johnson_syndrome_when_treated_with_nevirapine_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_affect_risk_of_Stevens-Johnson_syndrome_in_patients_treated_with_nevirapine._""AC:Female_patients_with_the_AC_genotype_and_acquired_immunodeficiency_syndrome_(AIDS)_may_have_an_increased_risk_of_Stevens-Johnson_syndrome_when_treated_with_nevirapine_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_risk_of_Stevens-Johnson_syndrome_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_affect_risk_of_Stevens-Johnson_syndrome_in_patients_treated_with_nevirapine._""CC:Female_patients_with_the_CC_genotype_and_acquired_immunodeficiency_syndrome_(AIDS)_may_have_a_decreased_risk_of_Stevens-Johnson_syndrome_when_treated_with_nevirapine_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_affect_risk_of_Stevens-Johnson_syndrome_in_patients_treated_with_nevirapine._";PGKB_RACE=Black_or_African_American
6	31465795	rs3828913	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=MICB_(PA30812);PGKB_DRUG="peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_lower_rate_of_sustained_virological_response_(SVR)_in_hepatitis_C_virus_(HCV)-infected_patients_treated_with_pegylated_interferon_plus_ribavirin_(PEG-IFN/RBV)_therapy_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_PEG-IFN/RBV_therapy.""AC:Patients_with_genotype_AC_may_have_lower_rate_of_sustained_virological_response_(SVR)_in_hepatitis_C_virus_(HCV)-infected_patients_treated_with_pegylated_interferon_plus_ribavirin_(PEG-IFN/RBV)_therapy_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_PEG-IFN/RBV_therapy.""CC:Patients_with_genotype_CC_may_have_higher_rate_of_sustained_virological_response_(SVR)_in_hepatitis_C_virus_(HCV)-infected_patients_treated_with_pegylated_interferon_plus_ribavirin_(PEG-IFN/RBV)_therapy_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_PEG-IFN/RBV_therapy.";PGKB_RACE=Asian
6	31542308	rs1799964	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TNF_(PA435);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Spondylitis_Ankylosing_(PA445724);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ankylosing_spondylitis_may_have_a_poorer_response_when_treated_with_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_TNF-alpha_inhibitors._""CT:Patients_with_the_CT_genotype_and_ankylosing_spondylitis_may_have_a_poorer_response_when_treated_with_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_TNF-alpha_inhibitors._""TT:Patients_with_the_TT_genotype_and_ankylosing_spondylitis_may_have_a_better_response_when_treated_with_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_TNF-alpha_inhibitors._";PGKB_RACE=Asian
6	31542482	rs1799724	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TNF_(PA435);PGKB_DRUG="infliximab_(PA452639)""Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Arthritis_Rheumatoid_(PA443434)""Crohn_Disease_(PA443815)""Psoriasis_(PA445451)""Spondylitis_Ankylosing_(PA445724)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_inflammatory_diseases_may_be_more_likely_to_respond_to_anti-TNFalpha_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._However_both_conflicting_and_non-significant_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_inhibitors._""CT:Patients_with_the_CT_genotype_and_inflammatory_diseases_may_be_less_likely_to_respond_to_anti-TNFalpha_treatment_as_compared_to_patients_with_the_CC_genotype._However_both_conflicting_and_non-significant_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_inhibitors._""TT:Patients_with_the_TT_genotype_and_inflammatory_diseases_may_be_less_likely_to_respond_to_anti-TNFalpha_treatment_as_compared_to_patients_with_the_CC_genotype._However_both_conflicting_and_non-significant_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_inhibitors._";PGKB_RACE=NR
6	31543031	rs1800629	G	A	.	.	PGKB_INDEX=5;PGKB_GENE="LST1_(PA37856)""LTA_(PA30474)""TNF_(PA435)",TNF_(PA435),"LST1_(PA37856)""LTA_(PA30474)""TNF_(PA435)",TNF_(PA435),TNF_(PA435);PGKB_DRUG="cyclosporine_(PA449167)""mycophenolate_mofetil_(PA450566)",atorvastatin_(PA448500),carbamazepine_(PA448785),"adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)""Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366)","ethambutol_(PA164784021)""isoniazid_(PA450112)""pyrazinamide_(PA451182)""rifampin_(PA451250)";PGKB_TYPE=Efficacy,Other,Toxicity/ADR,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,2B,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),Acute_coronary_syndrome_(PA165108401),Hypersensitivity_(PA444546),"Arthritis_Psoriatic_(PA446198)""Arthritis_Rheumatoid_(PA443434)""Crohn_Disease_(PA443815)""Inflammation_(PA444620)""Psoriasis_(PA445451)""Spondylitis_Ankylosing_(PA445724)","Toxic_liver_disease_(PA164925725)""Tuberculosis_(PA445941)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_may_have_an_increased_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection._""AG:Patients_with_the_AG_genotype_and_Kidney_Transplantation_may_have_an_increased_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection._""GG:Patients_with_the_GG_genotype_and_Kidney_Transplantation_may_have_a_decreased_risk_for_biopsy-proven_acute_rejection_(BPAR)_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_biopsy-proven_acute_rejection.","AA:Patients_with_the_AA_genotype_were_not_studied._Patients_with_the_AG_genotype_and_acute_coronary_syndrome_who_are_treated_with_atorvastatin_may_not_have_an_increase_in_lumbar_bone_marrow_density_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""AG:Patients_with_the_AG_genotype_and_acute_coronary_syndrome_who_are_treated_with_atorvastatin_may_not_have_an_increase_in_lumbar_bone_marrow_density_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""GG:Patients_with_the_GG_genotype_and_acute_coronary_syndrome_who_are_treated_with_atorvastatin_may_have_an_increase_in_lumbar_bone_marrow_density_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","AA:Patients_with_the_AA_genotype_may_have_an_increased_chance_of_severe_hypersensitivity_to_carbamazepine_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_response.""AG:There_were_too_few_patients_with_the_AG_genotype_in_this_one_small_study_for_a_conclusion_to_be_drawn.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_non-existent_chance_of_severe_hypersensitivity_to_carbamazepine_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_response.","AA:Patients_with_the_AA_genotype_and_inflammatory_diseases_who_are_treated_with_anti-TNF_therapies_may_be_less_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-TNF_therapy.""AG:Patients_with_the_AG_genotype_and_inflammatory_diseases_who_are_treated_with_anti-TNF_therapies_may_be_less_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype_or_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_inflammatory_diseases_who_are_treated_with_anti-TNF_therapies_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-TNF_therapy.","AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Toxic_liver_disease_when_treated_with_ethambutol_isoniazid_pyrazinamide_and_rifampin_in_people_with_Tuberculosis_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antituberculosis_drugs.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_Toxic_liver_disease_when_treated_with_ethambutol_isoniazid_pyrazinamide_and_rifampin_in_people_with_Tuberculosis_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antituberculosis_drugs.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Toxic_liver_disease_when_treated_with_ethambutol_isoniazid_pyrazinamide_and_rifampin_in_people_with_Tuberculosis_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antituberculosis_drugs.";PGKB_RACE=White,NR,White,NR,Asian
6	31543101	rs361525	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TNF_(PA435);PGKB_DRUG=infliximab_(PA452639);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:No_patients_with_the_AA_genotype_were_available_for_analysis_but_patients_with_the_AG_genotype_may_have_a_poorer_response_to_treatment_with_infliximab_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_infliximab.""AG:Patients_with_the_AG_genotype_may_have_a_poorer_response_to_treatment_with_infliximab_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_infliximab.""GG:Patients_with_the_GG_genotype_may_have_a_better_response_to_treatment_with_infliximab_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_infliximab.";PGKB_RACE=White
6	31546789	rs3093726	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="LST1_(PA37856)""LTB_(PA30475)""TNF_(PA435)";PGKB_DRUG=abacavir_(PA448004);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Drug_Hypersensitivity_(PA443936);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_Increased_risk_of_hypersensitivity_when_treated_with_abacavir_as_compared_to_patients_with_the_TT_genotypes._This_variant_is_a_tagging_SNP_for_HLA-B*5701_for_which_there_is_greater_evidence_of_association_with_abacavir-induced_hypersensitivity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_hypersensitivity_when_treated_with_abacavir_as_compared_to_patients_with_the_TT_genotype._This_variant_is_a_tagging_SNP_for_HLA-B*5701_for_which_there_is_greater_evidence_of_association_with_abacavir-induced_hypersensitivity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_absent_risk_of_hypersensitivity_when_treated_with_abacavir_as_compared_to_patients_with_the_CC_genotype._This_variant_is_a_tagging_SNP_for_HLA-B*5701_for_which_there_is_greater_evidence_of_association_with_abacavir-induced_hypersensitivity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.";PGKB_RACE=Asian
6	31607050	rs750332	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="BAG6_(PA25264)""PRRC2A_(PA25263)";PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_carbamazepine_may_have_an_increased_risk_of_Stevens-Johnson_syndrome_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Stevens-Johnson_syndrome_with_carbamazepine_treatment.""CT:Patients_with_the_CT_genotype_who_are_treated_with_carbamazepine_may_have_an_increased_risk_of_Stevens-Johnson_syndrome_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Stevens-Johnson_syndrome_with_carbamazepine_treatment.""TT:Patients_with_the_TT_genotype_who_are_treated_with_carbamazepine_may_have_a_decreased_but_not_absent_risk_of_Stevens-Johnson_syndrome_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Stevens-Johnson_syndrome_with_carbamazepine_treatment.";PGKB_RACE=Asian
6	31778272	rs2227956	G	A	.	.	PGKB_INDEX=1;PGKB_GENE="HSPA1A_(PA29498)""HSPA1L_(PA29500)""LSM2_(PA25929)";PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_chance_of_severe_hypersensitivity_to_carbamazepine_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_response.""AG:Patients_with_the_AG_genotype_may_have_a_decreased_but_not_non-existent_chance_of_severe_hypersensitivity_to_carbamazepine_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_response.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_non-existent_chance_of_severe_hypersensitivity_to_carbamazepine_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_adverse_response.";PGKB_RACE=White
6	31783755	rs1043620	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=HSPA1L_(PA29500);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_severe_hypersensitivity_when_treated_with_carbamazepine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""CT:Patients_with_the_CT_genotype_may_have_decreased_risk_of_severe_hypersensitivity_when_treated_with_carbamazepine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_severe_hypersensitivity_when_treated_with_carbamazepine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.";PGKB_RACE=White
6	32552095	rs17885382	C	T,A	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DRB1_(PA35072);PGKB_DRUG=asparaginase_(PA448492);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Pediatric_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma_and_the_AA_genotype_may_have_a_decreased_risk_of_hypersensitivity_to_asparaginase_as_compared_to_patients_with_the_AT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_hypersensitivity_to_asparaginase_in_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma._""AT:Pediatric_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma_and_the_AT_genotype_may_have_an_increased_risk_of_hypersensitivity_to_asparaginase_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_affect_risk_of_hypersensitivity_to_asparaginase_in_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma._""TT:Pediatric_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma_and_the_TT_genotype_may_have_an_increased_risk_of_hypersensitivity_to_asparaginase_as_compared_to_patients_with_the_AT_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_hypersensitivity_to_asparaginase_in_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma._";PGKB_RACE=NR
6	32599999	rs9272105	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DQA1_(PA35066);PGKB_DRUG="interferon_beta-1a_(PA450037)""interferon_beta-1b_(PA450039)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_for_developing_neutralizing_anti-IFN-beta_antibodies_(i.e._decreased_risk_of_treatment_failure)_when_treated_with_interferon-beta_therapy_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_interferon-beta_therapy.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_for_developing_neutralizing_anti-IFN-beta_antibodies_(i.e._increased_risk_of_treatment_failure)_when_treated_with_interferon-beta_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_interferon-beta_therapy.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_for_developing_neutralizing_anti-IFN-beta_antibodies_(i.e._increased_risk_of_treatment_failure)_when_treated_with_interferon-beta_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_interferon-beta_therapy.";PGKB_RACE=White
6	32632832	rs9274407	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DQB1_(PA35068);PGKB_DRUG="amoxicillin_(PA448406)""clavulanate_(PA164742987)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Drug_Toxicity_(PA443937);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_drug_induced_liver_injury_in_response_to_amoxicillin_or_clavulanate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_induced_liver_injury.""AT:Patients_with_the_AT_genotype_may_have_increased_risk_of_drug_induced_liver_injury_in_response_to_amoxicillin_or_clavulanate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_induced_liver_injury.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_absent_risk_of_drug_induced_liver_injury_in_response_to_amoxicillin_or_clavulanate_as_compared_to_patients_with_the_AA_or_AT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_induced_liver_injury.";PGKB_RACE=White
6	32681049	rs2647087	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="azathioprine_(PA448515)""mercaptopurine_(PA450379)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Inflammatory_Bowel_Diseases_(PA446116)""Pancreatitis_(PA445220)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_disease_who_are_treated_with_azathioprine_or_mercaptopurine_may_have_a_reduced_but_not_absent_risk_of_pancreatitis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_pancreatitis._""AC:Patients_with_the_AC_genotype_and_inflammatory_bowel_disease_who_are_treated_with_azathioprine_or_mercaptopurine_may_have_an_increased_risk_of_pancreatitis_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_pancreatitis._""CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_who_are_treated_with_azathioprine_or_mercaptopurine_may_have_an_increased_risk_of_pancreatitis_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_pancreatitis._";PGKB_RACE=NR
6	33047612	rs3097671	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DPB1_(PA35064);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=aspirin-induced_asthma_(PA131285571);PGKB_TEXT="CC:Patients_with_asthma_and_the_CC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""CG:Patients_with_asthma_and_the_CG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
6	33048628	rs1042136	A	C,T	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DPB1_(PA35064);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AC:Patients_with_asthma_and_the_AC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""CC:Patients_with_asthma_and_the_CC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE="Asian""White"
6	33048661	rs1042151	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DPB1_(PA35064);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AG:Patients_with_asthma_and_the_AG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
6	33084671	rs3129294	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=HLA-DPB2_(PA35065);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AC:Patients_with_asthma_and_the_AC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""CC:Patients_with_asthma_and_the_CC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
6	33267672	rs1059288	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=TAPBP_(PA36331);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Asthma_may_have_a_lower_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""AG:Patients_with_the_AG_genotype_and_Asthma_may_have_a_higher_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""GG:Patients_with_the_GG_genotype_and_Asthma_may_have_a_higher_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._";PGKB_RACE=Asian
6	33272855	rs2071888	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=TAPBP_(PA36331);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Asthma_may_have_a_higher_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CG:Patients_with_the_CG_genotype_and_Asthma_may_have_a_higher_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""GG:Patients_with_the_GG_genotype_and_Asthma_may_have_a_lower_aspirin-induced_decline_in_forced_expiratory_volume_in_1_s_(FEV1)_after_aspirin_provocation_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._";PGKB_RACE=Asian
6	33283766	rs3130100	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="TAPBP_(PA36331)""ZBTB22_(PA37661)";PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="CC:Patients_with_asthma_and_the_CC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""CT:Patients_with_asthma_and_the_CT_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""TT:Patients_with_asthma_and_the_TT_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
6	35353523	rs6922548	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=PPARD_(PA33557);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
6	35362525	rs7769719	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PPARD_(PA33557);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
6	35369806	rs1883322	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PPARD_(PA33557);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
6	35378778	rs2016520	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PPARD_(PA33557);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
6	35395010	rs3734254	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PPARD_(PA33557);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
6	35542476	rs3800373	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=FKBP5_(PA28162);PGKB_DRUG=antidepressants_(PA452229);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_antidepressants_may_be_less_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_AC_or_CC_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""AC:Patients_with_the_AC_genotype_and_depression_who_are_treated_with_antidepressants_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_antidepressants_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.";PGKB_RACE=NR
6	35589070	rs9380524	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=FKBP5_(PA28162);PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_chance_of_response_to_citalopram_or_ecitalopram_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""AC:Patients_with_the_AC_genotype_may_have_a_decreased_chance_of_response_to_citalopram_or_ecitalopram_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""CC:Patients_with_the_CC_genotype_may_have_an_increased_chance_of_response_to_citalopram_or_ecitalopram_treatment_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.";PGKB_RACE=White
6	35607571	rs1360780	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=FKBP5_(PA28162),FKBP5_(PA28162),FKBP5_(PA28162);PGKB_DRUG="clomipramine_(PA449048)""nefazodone_(PA450603)""paroxetine_(PA450801)""venlafaxine_(PA451866)","antidepressants_(PA452229)""citalopram_(PA449015)""clomipramine_(PA449048)""lithium_(PA450243)""nefazodone_(PA450603)""paroxetine_(PA450801)""venlafaxine_(PA451866)",clozapine_(PA449061);PGKB_TYPE=Toxicity/ADR,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Depression_(PA447278),Depression_(PA447278),Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_paroxetine_venlafaxine_clomipramine_or_nefazodone_have_a_decreased_but_not_absent_risk_of_suicidal_ideation_as_compared_to_patients_with_the_CT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_venlafaxine_clomipramine_or_nefazodone.""CT:Patients_with_the_CT_genotype_and_depression_who_are_treated_with_paroxetine_venlafaxine_clomipramine_or_nefazodone_may_have_an_increased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_venlafaxine_clomipramine_or_nefazodone.""TT:Patients_with_the_TT_genotype_and_depression_who_are_treated_with_paroxetine_venlafaxine_clomipramine_or_nefazodone_may_have_an_increased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_venlafaxine_clomipramine_or_nefazodone.","CC:Patients_with_the_CC_genotype_may_1)_have_decreased_response_to_antidepressants_2)_have_decreased_but_not_absent_risk_for_suicide_ideation_with_paroxetine_venlafaxine_clomipramine_lithium_liothyronine_or_nefazodone_as_compared_to_patients_with_the_CT_or_TT_genotype._However_contradictory_findings_regarding_an_association_of_the_opposite_allele_or_no_association_with_response_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""CT:Patients_with_the_CT_genotype_may_1)_have_increased_response_to_antidepressants_2)_have_increased_risk_for_suicide_ideation_with_paroxetine_venlafaxine_clomipramine_lithium_liothyronine_or_nefazodone_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_regarding_an_association_of_the_opposite_allele_or_no_association_with_response_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""TT:Patients_with_the_TT_genotype_may_1)_have_increased_response_to_antidepressants_2)_have_increased_risk_for_suicide_ideation_with_paroxetine_venlafaxine_clomipramine_lithium_liothyronine_or_nefazodone_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_regarding_an_association_of_the_opposite_allele_or_no_association_with_response_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.","CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_to_clozapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_to_clozapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_decreased_response_to_clozapine_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.";PGKB_RACE=NR,NR,White
6	35669983	rs4713916	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=FKBP5_(PA28162),FKBP5_(PA28162);PGKB_DRUG="antidepressants_(PA452229)""citalopram_(PA449015)""fluoxetine_(PA449673)""mirtazapine_(PA450522)""paroxetine_(PA450801)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""venlafaxine_(PA451866)",corticosteroids_(PA10832);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=2B,3;PGKB_DISEASE="Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)""Mood_Disorders_(PA447209)",Crohn_Disease_(PA443815);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_better_response_to_antidepressants_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant_treatment._""AG:Patients_with_the_AG_genotype_may_have_a_better_response_to_antidepressants_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_reduced_response_to_antidepressants_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant_treatment._""GG:Patients_with_the_GG_genotype_may_have_a_reduced_response_to_antidepressants_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant_treatment._","AA:Patients_with_the_AA_genotype_and_Crohn_Disease_who_are_treated_with_corticosteroids_may_have_an_increased_likelihood_of_responsiveness_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids.""AG:Patients_with_the_AG_genotype_and_Crohn_Disease_who_are_treated_with_corticosteroids_may_have_an_increased_likelihood_of_responsiveness_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids.""GG:Patients_with_the_GG_genotype_and_Crohn_Disease_who_are_treated_with_corticosteroids_may_have_a_decreased_likelihood_of_responsiveness_as_compared_to_patients_with_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids.";PGKB_RACE=NR,White
6	39016636	rs10305420	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=GLP1R_(PA28725);PGKB_DRUG=liraglutide_(PA165958364);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Obesity_(PA445131)""Polycystic_Ovary_Syndrome_(PA445376)";PGKB_TEXT="CC:Women_with_the_CC_genotype_and_obesity_and_polycystic_ovarian_syndrome_(PCOS)_may_have_an_increased_response_to_liraglutide_as_compared_to_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_liraglutide_in_women_with_obesity_and_PCOS.""CT:Women_with_the_CT_genotype_and_obesity_and_polycystic_ovarian_syndrome_(PCOS)_may_have_a_decreased_response_to_liraglutide_as_compared_to_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_liraglutide_in_women_with_obesity_and_PCOS.""TT:Women_with_the_TT_genotype_and_obesity_and_polycystic_ovarian_syndrome_(PCOS)_may_have_a_decreased_response_to_liraglutide_as_compared_to_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_liraglutide_in_women_with_obesity_and_PCOS.";PGKB_RACE=NR
6	39034072	rs6923761	G	A,C	.	.	PGKB_INDEX=1;PGKB_GENE=GLP1R_(PA28725);PGKB_DRUG=liraglutide_(PA165958364);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Obesity_(PA445131)""Polycystic_Ovary_Syndrome_(PA445376)";PGKB_TEXT="AA:Women_with_obesity_and_polycystic_ovarian_syndrome_(PCOS)_and_the_AA_genotype_may_have_an_increased_response_to_liraglutide_as_compared_to_women_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_liraglutide_in_women_with_obesity_and_PCOS.""AG:Women_with_obesity_and_polycystic_ovarian_syndrome_(PCOS)_and_the_AG_genotype_may_have_an_increased_response_to_liraglutide_as_compared_to_women_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_liraglutide_in_women_with_obesity_and_PCOS.""GG:Women_with_obesity_and_polycystic_ovarian_syndrome_(PCOS)_and_the_GG_genotype_may_have_a_decreased_response_to_liraglutide_as_compared_to_women_with_the_AA_and_AG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_liraglutide_in_women_with_obesity_and_PCOS.";PGKB_RACE=NR
6	39050622	rs2268639	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=GLP1R_(PA28725);PGKB_DRUG="clozapine_(PA449061)""olanzapine_(PA450688)";PGKB_TYPE=NR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_rs2268639_AA_genotype_and_Schizophrenia_and_genotype_TT_at_SNP_rs13429709_who_are_treated_with_clozapine_or_olanzapine_may_have_less_weight_gain_as_compared_to_patients_with_the_rs2268639_TT_genotype_and_at_least_one_C_allele_at_SNP_rs13429709._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_weight_gain_and_extent_when_treated_with_antipsychotics._""AT:Patients_with_the_rs2268639_AT_genotype_and_Schizophrenia_and_genotype_TT_at_SNP_rs13429709_who_are_treated_with_clozapine_or_olanzapine_may_have_less_weight_gain_as_compared_to_patients_with_the_rs2268639_TT_genotype_and_at_least_one_C_allele_at_SNP_rs13429709._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_weight_gain_and_extent_when_treated_with_antipsychotics._""TT:Patients_with_the_rs2268639_TT_genotype_and_Schizophrenia_who_also_have_at_least_one_allele_C_at_SNP_rs13429709_who_are_treated_with_clozapine_or_olanzapine_may_have_greater_weight_gain_as_compared_to_patients_with_the_rs2268639_AA_genotype_who_also_have_genotype_rs13429709_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_weight_gain_and_extent_when_treated_with_antipsychotics._";PGKB_RACE=White
6	39325078	rs20455	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=KIF6_(PA134920075);PGKB_DRUG="atorvastatin_(PA448500)""pravastatin_(PA451089)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_AG_or_GG_genotype._Patients_with_the_AA_genotype_may_have_a_poorer_response_to_statin_treatment_than_patients_with_the_GG_or_AG_genotype._However_contradictory_results_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_cardiovascular_events.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_adverse_cardiovascular_events_(myocardial_infarction_and_coronary_heart_diseases)_as_compared_to_patients_with_the_AA_genotype._Statin_treatments_(Pravastatin_or_atorvastatin)_substantially_reduced_that_risk._Patients_with_the_AG_genotype_may_have_a_better_statin_response_than_patients_with_the_AA_genotype._However_contradictory_results_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_cardiovascular_events.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_adverse_cardiovascular_events_(myocardial_infarction_and_coronary_heart_diseases)_as_compared_to_patients_with_the_AA_genotype._Statin_treatment_(Pravastatin_or_atorvastatin)_substantially_reduced_that_risk._Patients_with_the_GG_genotype_may_have_a_better_statin_response_than_patients_with_the_AA_genotype._However_contradictory_results_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_cardiovascular_events.";PGKB_RACE=White
6	43404511	rs9349256	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC10_(PA24392);PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_for_kidney_tubular_dysfunction_when_exposed_to_tenofovir_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_for_kidney_tubular_dysfunction_when_exposed_to_tenofovir_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_for_kidney_tubular_dysfunction_when_exposed_to_tenofovir_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.";PGKB_RACE=NR
6	43736389	rs699947	A	C	.	.	PGKB_INDEX=5;PGKB_GENE=VEGFA_(PA37302),VEGFA_(PA37302),VEGFA_(PA37302),VEGFA_(PA37302),VEGFA_(PA37302);PGKB_DRUG=ranibizumab_(PA164746012),sildenafil_(PA451346),sunitinib_(PA162372840),docetaxel_(PA449383),"bevacizumab_(PA130232992)""capecitabine_(PA448771)""fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)";PGKB_TYPE=Efficacy,Efficacy,Toxicity/ADR,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,3,3;PGKB_DISEASE=Macular_Degeneration_(PA134850558),Erectile_Dysfunction_(PA444606),NR,Breast_Neoplasms_(PA443560),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Macular_Degeneration_who_are_treated_with_ranibizumab_may_have_a_lack_of_early_response_to_treatment_compared_to_patients_with_the_AC_or_CC_genotype._No_association_with_response_was_found_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ranibizumab_treatment._""AC:Patients_with_the_AC_genotype_and_Macular_Degeneration_who_are_treated_with_ranibizumab_may_have_an_early_response_to_treatment_compared_to_patients_with_the_AA_genotype._No_association_with_response_was_found_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ranibizumab_treatment._""CC:Patients_with_the_CC_genotype_and_Macular_Degeneration_who_are_treated_with_ranibizumab_may_have_an_early_response_to_treatment_compared_to_patients_with_the_AA_genotype._No_association_with_response_was_found_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ranibizumab_treatment._","AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_sildenafil_in_men_with_Erectile_Dysfunction_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sildenafil.""AC:Patients_with_the_AC_genotype_may_have_decreased_response_to_sildenafil_in_men_with_Erectile_Dysfunction_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sildenafil.""CC:Patients_with_the_CC_genotype_may_have_increased_response_to_sildenafil_in_men_with_Erectile_Dysfunction_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sildenafil.","AA:Patients_with_the_AA_genotype_may_have_higher_increase_in_systolic_blood_pressure_and_increased_risk_of_developing_grade_3_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sunitinib.""AC:Patients_with_the_AC_genotype_may_have_higher_increase_in_systolic_blood_pressure_and_increased_risk_of_developing_grade_3_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sunitinib.""CC:Patients_with_the_CC_genotype_may_have_lower_increase_in_systolic_blood_pressure_and_decreased_risk_of_developing_grade_3_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sunitinib.","AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_a_longer_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AC:Current_literature_evidence_finds_no_significant_effect_of_the_AC_genotype_on_progression-free_survival_time_in_patients_taking_docetaxel.""CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_a_shorter_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.","AC:Patients_with_colorectal_cancer_and_the_AC_genotype_may_have_a_reduced_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_or_oxaliplatin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_affect_response_to_chemotherapy_in_people_with_colorectal_cancer.""CC:Patients_with_colorectal_cancer_and_the_CC_genotype_may_have_an_improved_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_or_oxaliplatin_as_compared_to_patients_with_the_AC_genotype._Other_clinical_and_genetic_factors_may_also_affect_response_to_chemotherapy_in_people_with_colorectal_cancer.";PGKB_RACE=NR,NR,NR,NR,NR
6	43736415	rs144854329	TGGTCCCACTCTTCCCACA	T	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA:Patients_with_the_GGTC.../GGTC..._genotype_and_breast_cancer_may_have_a_longer_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GGTCCCACTCTTCCCACA/del:Current_literature_evidence_finds_no_significant_effect_of_the_GGTC.../del_genotype_on_progression-free_survival_time_in_patients_taking_docetaxel.""del/del:Patients_with_the_del/del_genotype_and_breast_cancer_may_have_a_shorter_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_GGTC.../GGTC..._genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=NR
6	43736537	rs35864111	T	TG	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="G/del:Current_literature_evidence_finds_no_significant_effect_of_the_G/del_genotype_on_progression-free_survival_time_in_patients_taking_docetaxel.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_longer_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""del/del:Patients_with_the_del/del_genotype_and_breast_cancer_may_have_a_shorter_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=NR
6	43737486	rs833061	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_associated_with_a_higher_increase_in_systolic_blood_pressure_and_increased_risk_of_developing_grade_3_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sunitinib.""CT:Patients_with_the_CT_genotype_may_be_associated_with_a_higher_increase_in_systolic_blood_pressure_and_increased_risk_of_developing_grade_3_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sunitinib.""TT:Patients_with_the_TT_genotype_may_be_associated_with_a_decreased_risk_of_developing_grade_3_hypertension_when_treated_with_sunitinib_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sunitinib.";PGKB_RACE=NR
6	43737794	rs13207351	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_a_longer_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AG:Patients_with_the_AG_genotype_and_breast_cancer_may_have_a_longer_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_shorter_progression-free_survival_time_when_treated_with_docetaxel_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=NR
6	43737830	rs1570360	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=VEGFA_(PA37302),VEGFA_(PA37302),VEGFA_(PA37302);PGKB_DRUG="cyclophosphamide_(PA449165)""docetaxel_(PA449383)",sorafenib_(PA7000),docetaxel_(PA449383);PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425),Carcinoma_Renal_Cell_(PA443624),Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_prostate_cancer_may_have_shorter_progression-free_survival_time_when_treated_with_docetaxel_plus_oral_metronomic_cyclophosphamide_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AG:Patients_with_the_AG_genotype_and_prostate_cancer_may_have_longer_progression-free_survival_time_when_treated_with_docetaxel_plus_oral_metronomic_cyclophosphamide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GG:Patients_with_the_GG_genotype_and_prostate_cancer_may_have_longer_progression-free_survival_time_when_treated_with_docetaxel_plus_oral_metronomic_cyclophosphamide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.","AA:Patients_with_the_AA_genotype_may_have_unfavorable_progression-free_survival_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sorafenib.""AG:Patients_with_the_AG_genotype_may_have_unfavorable_progression-free_survival_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sorafenib.""GG:Patients_with_the_GG_genotype_may_have_more_favorable_progression-free_survival_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sorafenib.","AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_a_better_response_to_docetaxel_treatment_as_compared_to_patients_with_the_GG_genotype._However_contradictory_evidence_exists_when_considering_progression-free_survival._Other_genetic_and_clinical_factors_may_also_influence_response_to_docetaxel.""AG:Patients_with_the_AG_genotype_and_breast_cancer_may_have_a_better_response_to_docetaxel_treatment_as_compared_to_patients_with_the_GG_genotype._However_contradictory_evidence_exists_when_considering_progression-free_survival._Other_genetic_and_clinical_factors_may_also_influence_response_to_docetaxel.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_poorer_response_to_docetaxel_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._However_contradictory_evidence_exists_when_considering_progression-free_survival._Other_genetic_and_clinical_factors_may_also_influence_response_to_docetaxel.";PGKB_RACE=NR,Asian,NR
6	43738350	rs2010963	C	G	.	.	PGKB_INDEX=3;PGKB_GENE=VEGFA_(PA37302),VEGFA_(PA37302),VEGFA_(PA37302);PGKB_DRUG=cyclophosphamide_(PA449165),sorafenib_(PA7000),"bevacizumab_(PA130232992)""pegaptanib_(PA164771236)""ranibizumab_(PA164746012)";PGKB_TYPE=Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425),"Carcinoma_Renal_Cell_(PA443624)""hand-foot_syndrome_(PA166114377)",Choroidal_Neovascularization_(PA446974);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_prostate_cancer_may_have_shorter_progression-free_survival_time_when_treated_with_cyclophosphamide_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_progression-free_survival.""CG:Patients_with_the_CG_genotype_and_prostate_cancer_may_have_longer_progression-free_survival_time_when_treated_with_cyclophosphamide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_progression-free_survival.""GG:Patients_with_the_GG_genotype_and_prostate_cancer_may_have_longer_progression-free_survival_time_when_treated_with_cyclophosphamide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_progression-free_survival.","CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_hand-foot_syndrome_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_GG_or_CG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_hand-foot_syndrome_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_hand-foot_syndrome_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.","CC:Patients_with_the_CC_genotype_and_choroidal_neovascularization_may_have_a_poorer_response_to_anti-VEGF_treatment_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-VEGF_treatment._""CG:Patients_with_the_CG_genotype_and_choroidal_neovascularization_may_have_a_better_response_to_anti-VEGF_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-VEGF_treatment._""GG:Patients_with_the_GG_genotype_and_choroidal_neovascularization_may_have_a_better_response_to_anti-VEGF_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-VEGF_treatment._";PGKB_RACE=NR,Asian,Asian
6	43738977	rs25648	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG="cisplatin_(PA449014)""fluorouracil_(PA128406956)""oxaliplatin_(PA131285527)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Stomach_Neoplasms_(PA445742);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_metastatic_gastric_cancer_who_are_treated_with_platinum-based_chemotherapy_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CT:Patients_with_the_CT_genotype_and_metastatic_gastric_cancer_who_are_treated_with_platinum-based_chemotherapy_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""TT:Patients_with_the_TT_genotype_and_metastatic_gastric_cancer_who_are_treated_with_platinum-based_chemotherapy_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._";PGKB_RACE=NR
6	43742579	rs833069	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG=ranibizumab_(PA164746012);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Macular_Degeneration_(PA134850558);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_macular_degeneration_may_have_greater_decreases_in_central_subfield_macular_thickness_(CSMT)_when_treated_with_ranibizumab_as_compared_to_patients_with_the_TT_genotype._However_no_associations_have_been_seen_when_considering_changes_in_visual_acuity._Other_genetic_and_clinical_factors_may_also_influence_response_to_ranibizumab.""CT:Patients_with_the_CT_genotype_and_macular_degeneration_may_have_greater_decreases_in_central_subfield_macular_thickness_(CSMT)_when_treated_with_ranibizumab_as_compared_to_patients_with_the_TT_genotype._However_no_associations_have_been_seen_when_considering_changes_in_visual_acuity._Other_genetic_and_clinical_factors_may_also_influence_response_to_ranibizumab.""TT:Patients_with_the_TT_genotype_and_macular_degeneration_may_have_greater_increases_in_central_subfield_macular_thickness_(CSMT)_when_treated_with_ranibizumab_as_compared_to_patients_with_the_CC_or_CT_genotype._However_no_associations_have_been_seen_when_considering_changes_in_visual_acuity._Other_genetic_and_clinical_factors_may_also_influence_response_to_ranibizumab.";PGKB_RACE=NR
6	43746169	rs3025000	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG="bevacizumab_(PA130232992)""ranibizumab_(PA164746012)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Macular_Degeneration_(PA134850558);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_macular_degeneration_may_have_a_poorer_response_when_treated_with_bevacizumab_or_ranibizumab_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bevacizumab_or_ranibizumab.""CT:Patients_with_the_CT_genotype_and_macular_degeneration_may_have_a_better_response_when_treated_with_bevacizumab_or_ranibizumab_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bevacizumab_or_ranibizumab.""TT:Patients_with_the_TT_genotype_and_macular_degeneration_may_have_a_better_response_when_treated_with_bevacizumab_or_ranibizumab_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bevacizumab_or_ranibizumab.";PGKB_RACE=NR
6	43752536	rs3025039	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=VEGFA_(PA37302);PGKB_DRUG="bevacizumab_(PA130232992)""capecitabine_(PA448771)""fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_colorectal_cancer_and_the_CC_genotype_may_have_an_improved_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_oxaliplatin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_and_oxaliplatin.""CT:Patients_with_colorectal_cancer_and_the_CT_genotype_may_have_an_improved_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_oxaliplatin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_and_oxaliplatin.""TT:Patients_with_colorectal_cancer_and_the_TT_genotype_may_have_an_improved_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_oxaliplatin_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_bevacizumab_capecitabine_fluorouracil_irinotecan_leucovorin_and_oxaliplatin.";PGKB_RACE=NR
6	43758485	rs6900017	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Women_with_ovarian_cancer_and_the_CC_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""CT:Women_with_ovarian_cancer_and_the_CT_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""TT:Women_with_ovarian_cancer_and_the_TT_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CC_or_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.";PGKB_RACE=NR
6	43762122	rs9369421	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=NR,NR;PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)","carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204),NR;PGKB_TEXT="CC:Women_with_ovarian_cancer_and_the_CC_genotype_may_have_an_improved_response_such_as_longer_survival_times_when_treated_with_carboplatin_and_taxanes_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_survival_time_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""CT:Women_with_ovarian_cancer_and_the_CT_genotype_may_have_an_improved_response_such_as_longer_survival_times_when_treated_with_carboplatin_and_taxanes_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_survival_time_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""TT:Women_with_ovarian_cancer_and_the_TT_genotype_may_have_a_worse_response_such_as_shorter_survival_times_when_treated_with_carboplatin_and_taxanes_as_compared_to_women_with_the_CC_or_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_survival_time_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._","CC:Women_with_ovarian_cancer_and_the_CC_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CT_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""CT:Women_with_ovarian_cancer_and_the_CT_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""TT:Women_with_ovarian_cancer_and_the_TT_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.";PGKB_RACE=NR,NR
6	43763814	rs879825	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="AA:Women_with_ovarian_cancer_and_the_AA_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""AG:Women_with_ovarian_cancer_and_the_AG_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""GG:Women_with_ovarian_cancer_and_the_GG_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_AA_or_AG_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.";PGKB_RACE=NR
6	44194345	rs747199	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC29A1_(PA154);PGKB_DRUG="gemcitabine_(PA449748)""paclitaxel_(PA450761)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_breast_cancer_and_the_CC_genotype_may_have_an_increased_response_to_gemcitabine_and_paclitaxel_as_compared_to_the_patients_with_the_CG_and_GG_genotypes_when_part_of_a_haplotype_with_the_rs760370_A_allele._Other_genetic_and_clinical_factors_may_influence_the_response_to_gemcitabine_and_paclitaxel._""CG:Patients_with_breast_cancer_and_the_CG_genotype_may_have_a_decreased_response_to_gemcitabine_and_paclitaxel_as_compared_to_patients_with_the_CC_genotypes_and_an_increased_response_as_compared_to_patients_with_the_GG_genotype_when_part_of_a_haplotype_with_the_rs760370_A_allele._Other_genetic_and_clinical_factors_may_influence_the_response_to_gemcitabine_and_paclitaxel._""GG:Patients_with_breast_cancer_and_the_GG_genotype_may_have_a_decreased_response_to_gemcitabine_and_paclitaxel_as_compared_to_patients_with_the_CC_and_CG_genotypes_when_part_of_a_haplotype_with_the_rs760370_A_allele._Other_genetic_and_clinical_factors_may_influence_the_response_to_gemcitabine_and_paclitaxel._";PGKB_RACE=Asian
6	44195992	rs9394992	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC29A1_(PA154);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Pancreatic_Neoplasms_(PA445218);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_neutropenia_when_treated_with_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_gemcitabine.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_neutropenia_when_treated_with_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_gemcitabine.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_neutropenia_when_treated_with_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_gemcitabine.";PGKB_RACE=NR
6	44200953	rs760370	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC29A1_(PA154);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_cancer_and_the_AA_genotype_may_have_increased_response_to_gemcitabine_as_compared_to_patients_with_the_AG_and_GG_genotypes._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_response_to_gemcitabine._""AG:Patients_with_cancer_and_the_AG_genotype_may_have_increased_response_to_gemcitabine_as_compared_to_patients_with_the_GG_genotype._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_response_to_gemcitabine._""GG:Patients_with_cancer_and_the_GG_genotype_may_have_decreased_response_to_gemcitabine_as_compared_to_patients_with_the_AG_and_AA_genotypes._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_response_to_gemcitabine._";PGKB_RACE=NR
6	52051033	rs2275913	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL17A_(PA29794);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Colitis_Ulcerative_(PA443750)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AG:Patients_with_the_AG_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
6	52445381	rs6901146	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="anastrozole_(PA448432)""exemestane_(PA449563)";PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_a_decreased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.""CT:Patients_with_the_CT_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_an_increased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_risk_of_bone_fractures_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.""TT:Patients_with_the_TT_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_an_increased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.";PGKB_RACE=NR
6	52668687	rs3957357	A	G	.	.	PGKB_INDEX=2;PGKB_GENE="GSTA1_(PA29016)""GSTA6P_(PA29020)",GSTA1_(PA29016);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)",doxorubicin_(PA449412);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Anemia_(PA443340)""Ovarian_Neoplasms_(PA445204)",Sarcoma_(PA445594);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_for_anemia_when_treated_with_cisplatin_and_cyclophosphamide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_cisplatin_regimens.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_for_anemia_when_treated_with_cisplatin_and_cyclophosphamide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_cisplatin_regimens.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_for_anemia_when_treated_with_cisplatin_and_cyclophosphamide_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_cisplatin_regimens.","AA:Patients_with_the_AA_genotype_and_soft_tissue_sarcoma_may_have_a_longer_progression-free_survival_time_when_treated_with_doxorubicin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AG:Patients_with_the_AG_genotype_and_soft_tissue_sarcoma_may_have_a_shorter_progression-free_survival_time_when_treated_with_doxorubicin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GG:Patients_with_the_GG_genotype_and_soft_tissue_sarcoma_may_have_a_shorter_progression-free_survival_time_when_treated_with_doxorubicin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=NR,NR
6	53392108	rs761142	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=GCLC_(PA28612);PGKB_DRUG=sulfamethoxazole_(PA451544);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_may_have_a_decreased_risk_for_a_drug_hypersensitivity_reaction_when_treated_with_sulfamethoxazole_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_a_drug_hypersensitivity_reaction._""AC:Patients_with_the_AC_genotype_and_HIV_may_have_an_increased_risk_for_a_drug_hypersensitivity_reaction_when_treated_with_sulfamethoxazole_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_a_drug_hypersensitivity_reaction._""CC:Patients_with_the_CC_genotype_and_HIV_may_have_an_increased_risk_for_a_drug_hypersensitivity_reaction_when_treated_with_sulfamethoxazole_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_a_drug_hypersensitivity_reaction._";PGKB_RACE=NR
6	55639028	rs41271330	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=BMP5_(PA25382);PGKB_DRUG=escitalopram_(PA10074);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_escitalopram_may_have_a_decreased_chance_of_response_and_may_require_an_increase_in_dose_during_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.""AG:Patients_with_the_AG_genotype_who_are_treated_with_escitalopram_may_have_a_decreased_chance_of_response_and_may_require_an_increase_in_dose_during_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.""GG:Patients_with_the_GG_genotype_who_are_treated_with_escitalopram_may_have_an_increased_chance_of_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.";PGKB_RACE=White
6	71991816	rs9346455	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_schizophrenia_may_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics.""GT:Patients_with_the_GT_genotype_and_schizophrenia_may_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics.";PGKB_RACE=White
6	73749861	rs9351963	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNQ5_(PA30077);PGKB_DRUG=irinotecan_(PA450085);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_diarrhea_in_people_with_cancer._""AC:Patients_with_the_AC_genotype_and_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype_and_an_increased_risk_of_diarrhea_as_compared_to_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_diarrhea_in_people_with_cancer._""CC:Patients_with_the_CC_genotype_and_cancer_may_have_an_increased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_diarrhea_in_people_with_cancer._";PGKB_RACE=NR
6	78173281	rs130058	T	A	.	.	PGKB_INDEX=2;PGKB_GENE=HTR1B_(PA29549),HTR1B_(PA29549);PGKB_DRUG=paroxetine_(PA450801),"clomipramine_(PA449048)""liothyronine_(PA164778866)""lithium_(PA450243)""nefazodone_(PA450603)""venlafaxine_(PA451866)";PGKB_TYPE=Other,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depression_(PA447278),Depression_(PA447278);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_paroxetine_may_have_an_increased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_TT_genotype._Please_note__alleles_are_complemented_to_the_plus_chromosomal_strand._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_suicidal_ideation._""AT:Patients_with_the_AT_genotype_and_depression_who_are_treated_with_paroxetine_may_have_an_increased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_AA_genotype._Please_note__alleles_are_complemented_to_the_plus_chromosomal_strand._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_suicidal_ideation._""TT:Patients_with_the_TT_genotype_and_depression_who_are_treated_with_paroxetine_may_have_a_decreased_risk_of_suicidal_ideation_as_compared_to_patients_with_the_AA_genotype._Please_note__alleles_are_complemented_to_the_plus_chromosomal_strand._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_suicidal_ideation._","AA:Patients_with_the_AA_genotype_and_Depression_who_are_treated_with_clomipramine_liothyronine_lithium_nefazodone_or_venlafaxine_may_have_an_increased_risk_for_suicidal_ideation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_suicidal_ideation._""AT:Patients_with_the_AT_genotype_and_Depression_who_are_treated_with_clomipramine_liothyronine_lithium_nefazodone_or_venlafaxine_may_have_an_increased_risk_for_suicidal_ideation_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_but_not_absent_risk_for_suicidal_ideation_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_suicidal_ideation._""TT:Patients_with_the_TT_genotype_and_Depression_who_are_treated_with_clomipramine_liothyronine_lithium_nefazodone_or_venlafaxine_may_have_a_decreased_but_not_absent_risk_for_suicidal_ideation_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_suicidal_ideation._";PGKB_RACE=NR,NR
6	78173382	rs11568817	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=HTR1B_(PA29549);PGKB_DRUG=escitalopram_(PA10074);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Anxiety_Disorders_(PA447196);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_anxiety_disorder_who_are_treated_with_escitalopram_may_have_decreased_but_not_absent_risk_of_adverse_cognitive_effects_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_escitalopram._""AC:Patients_with_the_AC_genotype_and_anxiety_disorder_who_are_treated_with_escitalopram_may_have_increased_risk_of_adverse_cognitive_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_escitalopram._""CC:Patients_with_the_CC_genotype_and_anxiety_disorder_who_are_treated_with_escitalopram_may_have_increased_risk_of_adverse_cognitive_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_escitalopram._";PGKB_RACE=White
6	88850100	rs806368	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CNR1_(PA26681);PGKB_DRUG=cocaine_(PA449072);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Cocaine-Related_Disorders_(PA446878);PGKB_TEXT="CC:Individuals_with_the_CC_genotype_may_have_a_decreased_risk_of_cocaine_dependence_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_cocaine_dependence.""CT:Individuals_with_the_CT_genotype_may_have_a_decreased_risk_of_cocaine_dependence_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_cocaine_dependence.""TT:Individuals_with_the_TT_genotype_may_have_an_increased_risk_of_cocaine_dependence_as_compared_to_those_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_cocaine_dependence.";PGKB_RACE=Black_or_African_American
6	88859551	rs806378	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CNR1_(PA26681);PGKB_DRUG="clozapine_(PA449061)""olanzapine_(PA450688)""risperidone_(PA451257)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Autism_Spectrum_Disorder_(PA153906318)""Schizophrenia_(PA447216)";PGKB_TEXT="CC:Patients_with_schizophrenia_or_autism_spectrum_disorder_(ASD)_and_the_CC_genotype_may_have_a_decreased_likelihood_of_weight_gain_as_compared_to_patients_with_the_CT_and_TT_genotypes_when_taking_risperidone_clozapine_or_olanzapine._Other_clinical_and_genetic_factors_may_also_influence_risk_of_weight_gain_in_patients_with_ASD_or_schizophrenia_who_are_taking_risperidone_clozapine_or_olanzapine.""CT:Patients_with_schizophrenia_or_autism_spectrum_disorder_(ASD)_and_the_CT_genotype_may_have_an_increased_likelihood_of_weight_gain_as_compared_to_patients_with_the_CC_genotypes_when_taking_risperidone_clozapine_or_olanzapine._Other_clinical_and_genetic_factors_may_also_influence_risk_of_weight_gain_in_patients_taking_risperidone_clozapine_or_olanzapine.""TT:Patients_with_schizophrenia_or_autism_spectrum_disorder_(ASD)_and_the_TT_genotype_may_have_an_increased_likelihood_of_weight_gain_as_compared_to_patients_with_the_CC_genotypes_when_taking_risperidone_clozapine_or_olanzapine._Other_clinical_and_genetic_factors_may_also_influence_risk_of_weight_gain_in_patients_taking_risperidone_clozapine_or_olanzapine.";PGKB_RACE=NR
6	88872930	rs6454674	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=CNR1_(PA26681);PGKB_DRUG=cocaine_(PA449072);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Cocaine-Related_Disorders_(PA446878);PGKB_TEXT="GG:Individuals_with_the_GG_genotype_may_have_a_decreased_risk_of_cocaine_dependence_as_compared_to_individuals_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_cocaine_dependence.""GT:Individuals_with_the_GT_genotype_may_have_an_increased_risk_of_cocaine_dependence_as_compared_to_individuals_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_cocaine_dependence.""TT:Individuals_with_the_TT_genotype_may_have_an_increased_risk_of_cocaine_dependence_as_compared_to_individuals_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_cocaine_dependence.";PGKB_RACE=Black_or_African_American
6	92412150	rs578427	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_metformin_may_have_decreased_renal_clearance_and_secretion_clearance_of_metformin_but_no_differences_in_the_plasma_metformin_concentration_and_no_association_with_glucose-lowering_effect_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""CT:Patients_with_the_CT_genotype_who_are_treated_with_metformin_may_have_increased_renal_clearance_and_secretion_clearance_of_metformin_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_renal_clearance_and_secretion_clearance_of_metformin_but_no_differences_in_the_plasma_metformin_concentration_and_no_association_with_glucose-lowering_effect_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_metformin_may_have_increased_renal_clearance_and_secretion_clearance_of_metformin_but_no_differences_in_the_plasma_metformin_concentration_and_no_association_with_glucose-lowering_effect_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.";PGKB_RACE=Asian
6	94440604	rs9345389	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Neoplasm_Residual_(PA446714)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_childhood_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_end-of-induction_minimal_residual_disease_(MRD)_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_end-of-induction_minimal_residual_disease_(MRD).""AG:Patients_with_the_AG_genotype_and_childhood_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_end-of-induction_minimal_residual_disease_(MRD)_as_compared_to_patients_with_the_AA_genotype.""GG:Patients_with_the_GG_genotype_and_childhood_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_end-of-induction_minimal_residual_disease_(MRD)_as_compared_to_patients_with_the_AA_genotype.";PGKB_RACE=NR
6	110760008	rs12210538	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A16_(PA134911502);PGKB_DRUG="cyclophosphamide_(PA449165)""doxorubicin_(PA449412)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
6	110763875	rs723685	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A16_(PA134911502);PGKB_DRUG="cyclophosphamide_(PA449165)""doxorubicin_(PA449412)";PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cyclophosphamide_and_doxorubicin.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cyclophosphamide_and_doxorubicin.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cyclophosphamide_and_doxorubicin.";PGKB_RACE=NR
6	110777962	rs6907567	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A16_(PA134911502);PGKB_DRUG="cyclophosphamide_(PA449165)""doxorubicin_(PA449412)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cyclophosphamide_and_doxorubicin.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cyclophosphamide_and_doxorubicin.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cyclophosphamide_and_doxorubicin.";PGKB_RACE=NR
6	110778128	rs714368	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A16_(PA134911502);PGKB_DRUG="doxorubicin_(PA449412)""doxorubicinol_(PA165291922)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_exposure_to_doxorubicin_and_its_metabolite_doxorubicinol_compared_to_patients_with_the_genotype_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_exposure_to_doxorubicin_and_doxorubicinol.""CT:Patients_with_the_CT_genotype_may_have_decreased_exposure_to_doxorubicin_and_its_metabolite_doxorubicinol_compared_to_patients_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_exposure_to_doxorubicin_and_doxorubicinol.""TT:Patients_with_the_TT_genotype_may_have_decreased_exposure_to_doxorubicin_and_its_metabolite_doxorubicinol_compared_to_patients_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_exposure_to_doxorubicin_and_doxorubicinol.";PGKB_RACE=Asian
6	111643838	rs3218592	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=REV3L_(PA34337);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="CC:Patients_with_metastasized_cancer_and_the_CC_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""CT:Patients_with_metastasized_cancer_and_the_CT_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_TT_genotype_and_worse_response_as_compared_to_people_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""TT:Patients_with_metastasized_cancer_and_the_TT_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.";PGKB_RACE=Asian
6	111922503	rs76228616	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=TRAF3IP2_(PA25938);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_developing_Steven-Johnson_Syndrome_(SJS)_and_Toxic_Epidermal_Necrolysis_(TEN)_when_treated_with_nevirapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_nevirapine._""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_developing_Steven-Johnson_Syndrome_(SJS)_and_Toxic_Epidermal_Necrolysis_(TEN)_when_treated_with_nevirapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_nevirapine._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_developing_Steven-Johnson_Syndrome_(SJS)_and_Toxic_Epidermal_Necrolysis_(TEN)_when_treated_with_nevirapine_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_nevirapine._";PGKB_RACE=Black_or_African_American
6	117816128	rs17574269	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=DCBLD1_(PA134903108);PGKB_DRUG="cisplatin_(PA449014)""irinotecan_(PA450085)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Small_Cell_(PA446661);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Small_Cell_Carcinoma_as_compared_to_patients_with_genotype_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cisplatin_and_irinotecan.""AG:Patients_with_the_AG_genotype_may_have_decreased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Small_Cell_Carcinoma_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cisplatin_and_irinotecan.""GG:Patients_with_the_GG_genotype_may_have_decreased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Small_Cell_Carcinoma_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cisplatin_and_irinotecan.";PGKB_RACE=Asian
6	120856203	rs7740004	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=C6orf170_(PA134871908);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_TT_or_AT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_Bisphosphonates.""AT:Patients_with_the_AT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_Bisphosphonates.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_Bisphosphonates.";PGKB_RACE=White
6	121189802	rs2789047	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=vancomycin_(PA451850);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_greater_likelihood_of_experiencing_an_increase_in_serum_creatine_kinase_when_exposed_to_vancomycin_as_compared_with_patients_with_the_AC_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_serum_creatine_kinase_in_patients_taking_vancomycin._""AG:Patients_with_the_AG_genotype_may_have_a_greater_likelihood_of_experiencing_an_increase_in_serum_creatine_kinase_when_exposed_to_vancomycin_as_compared_with_patients_with_the_CC_genotype_and_a_lower_likelihood_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_affect_serum_creatine_kinase_in_patients_taking_vancomycin._""CC:Patients_with_the_CC_genotype_may_have_a_lower_likelihood_of_experiencing_an_increase_in_serum_creatine_kinase_when_exposed_to_vancomycin_as_compared_with_patients_with_the_AA_genotypes._Other_clinical_and_genetic_factors_may_also_affect_serum_creatine_kinase_in_patients_taking_vancomycin._";PGKB_RACE=White
6	131891820	rs2781659	A	G	.	.	PGKB_INDEX=1;PGKB_GENE="ARG1_(PA24947)""MED23_(PA162395499)";PGKB_DRUG=selective_beta-2-adrenoreceptor_agonists_(PA134687887);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_selective_beta-2-adenoreceptor_agonists_may_have_increased_improvement_in_forced_expiratory_volume_(FEV)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_beta-2-adenoreceptor_agonist_treatment.""AG:Patients_with_the_AG_genotype_and_asthma_who_are_treated_with_selective_beta-2-adenoreceptor_agonists_may_have_increased_improvement_in_forced_expiratory_volume_(FEV)_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_improvement_in_forced_expiratory_volume_(FEV)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_beta-2-adenoreceptor_agonist_treatment.""GG:Patients_with_the_GG_genotype_and_asthma_who_are_treated_with_selective_beta-2-adenoreceptor_agonists_may_have_decreased_improvement_in_forced_expiratory_volume_(FEV)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_beta-2-adenoreceptor_agonist_treatment.";PGKB_RACE=White
6	137102365	rs9376230	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=MAP3K5_(PA30601);PGKB_DRUG=hydroxyurea_(PA449942);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Thalassemia_(PA445833);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Thalassemia_may_be_more_likely_to_respond_to_hydroxyurea_treatment_as_compared_to_genotype_AC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AC:Patients_with_the_AC_genotype_and_Thalassemia_may_be_less_likely_to_respond_to_hydroxyurea_treatment_as_compared_to_genotype_CC_or_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CC:Patients_with_the_CC_genotype_and_Thalassemia_may_be_more_likely_to_respond_to_hydroxyurea_treatment_as_compared_to_genotype_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._";PGKB_RACE=NR
6	137105400	rs9483947	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=MAP3K5_(PA30601);PGKB_DRUG=hydroxyurea_(PA449942);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Thalassemia_(PA445833);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Thalassemia_may_be_more_likely_to_respond_to_hydroxyurea_treatment_as_compared_to_genotype_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CT:Patients_with_the_CT_genotype_and_Thalassemia_may_be_less_likely_to_respond_to_hydroxyurea_treatment_as_compared_to_genotype_CC_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""TT:Patients_with_the_TT_genotype_and_Thalassemia_may_be_more_likely_to_respond_to_hydroxyurea_treatment_as_compared_to_genotype_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._";PGKB_RACE=NR
6	138002175	rs6927172	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=TNFAIP3_(PA36593);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Colitis_Ulcerative_(PA443750)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CG:Patients_with_the_CG_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
6	138006504	rs6920220	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TNFAIP3_(PA36593);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_discontinuation_of_methotrexate_in_people_with_Arthritis_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_discontinuation_of_methotrexate_in_people_with_Arthritis_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_discontinuation_of_methotrexate_in_people_with_Arthritis_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.";PGKB_RACE=NR
6	149329267	rs2500535	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=UST_(PA38213);PGKB_DRUG=nortriptyline_(PA450657);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_who_are_treated_with_nortriptyline_may_have_decreased_improvement_of_depression_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_who_are_treated_with_nortriptyline_may_have_decreased_improvement_of_depression_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_who_are_treated_with_nortriptyline_may_have_increased_improvement_of_depression_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.";PGKB_RACE=NR
6	152163335	rs2234693	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ESR1_(PA156);PGKB_DRUG="anastrozole_(PA448432)""letrozole_(PA450196)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_cancer_and_the_CC_genotype_may_have_an_increased_risk_of_musculoskeletal_pain_when_exposed_to_anastrozole_and_letrozole_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_musculoskeletal_pain.""CT:Patients_with_cancer_and_the_CT_genotype_may_have_an_increased_risk_of_musculoskeletal_pain_when_exposed_to_anastrozole_and_letrozole_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_musculoskeletal_pain.""TT:Patients_with_cancer_and_the_TT_genotype_may_have_a_decreased_risk_of_musculoskeletal_pain_when_exposed_to_anastrozole_and_letrozole_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_musculoskeletal_pain.";PGKB_RACE=Asian
6	152163381	rs9340799	A	G	.	.	PGKB_INDEX=4;PGKB_GENE=ESR1_(PA156),ESR1_(PA156),ESR1_(PA156),ESR1_(PA156);PGKB_DRUG=tamoxifen_(PA451581),leflunomide_(PA450192),"conjugated_estrogens_(PA164754789)""medroxyprogesterone_(PA450344)","anastrozole_(PA448432)""letrozole_(PA450196)";PGKB_TYPE=Toxicity/ADR,Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=NR,Arthritis_Rheumatoid_(PA443434),NR,Neoplasms_(PA445062);PGKB_TEXT="AA:The_AA_genotype_carriers_had_smaller_tamoxifen-induced_decrease_in_total_cholesterol_in_postmenopausal_woman_and_tamoxifen-induced_decrease_in_triglycerides_and_increase_in_high_density_lipoprotein_in_premenopausal_women_compared_to_GG_genotype_carriers""AG:The_AG_genotype_carriers_had_smaller_tamoxifen-induced_decrease_in_total_cholesterol_in_postmenopausal_woman_and_intermediate_tamoxifen-induced_increase_in_triglycerides_and_decrease_in_high_density_lipoprotein_in_premenopausal_women_compared_to_GG_genotype_carriers.""GG:The_GG_genotype_carriers_had_larger_tamoxifen-induced_decrease_in_total_cholesterol_in_postmenopausal_woman_compared_to_GA/AA_genotypes_(P=0.03__GG_vs_GA/AA)_and_tamoxifen-induced_increase_in_triglycerides_(P=0.002__gene-dose_effect)_and_decrease_in_high_density_lipoprotein_(P=0.004__gene-dose_effect)_in_premenopausal_women.","AA:Patients_with_the_AA_genotype_may_experience_greater_response_to_leflunomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_leflunomide_particularly_rs2234693.""AG:Patients_with_the_AG_genotype_may_experience_greater_response_to_leflunomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_leflunomide_particularly_rs2234693.""GG:Patients_with_the_GG_genotype_may_experience_decreased_response_to_leflunomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_leflunomide_particularly_rs2234693.","AA:Patients_with_the_AA_genotype_may_experience_1)_smaller_increases_in_spine_bone_mineral_density_when_treated_with_conjugated_estrogens_and_medroxyprogesterone_or_2)_larger_decreases_in_spine_bone_mineral_density_when_untreated_as_compared_to_patient_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_spine_bone_mineral_density.""AG:Patients_with_the_AG_genotype_may_experience_1)_smaller_increases_in_spine_bone_mineral_density_when_treated_with_conjugated_estrogens_and_medroxyprogesterone_or_2)_larger_decreases_in_spine_bone_mineral_density_when_untreated_as_compared_to_patient_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_spine_bone_mineral_density.""GG:Patients_with_the_GG_genotype_may_experience_1)_greater_increases_in_spine_bone_mineral_density_when_treated_with_conjugated_estrogens_and_medroxyprogesterone_or_2)_smaller_decreases_in_spine_bone_mineral_density_when_untreated_as_compared_to_patient_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_spine_bone_mineral_density.","AA:Patients_with_cancer_and_the_AA_genotype_may_experience_increased_risk_of_musculoskeletal_pain_when_exposed_to_anastrozole_and_letrozole_as_compared_to_the_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_risk_of_musculoskeletal_pain._""AG:Patients_with_cancer_and_the_AG_genotype_may_experience_increased_risk_of_musculoskeletal_pain_when_exposed_to_anastrozole_and_letrozole_as_compared_to_the_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_risk_of_musculoskeletal_pain._""GG:Patients_with_cancer_and_the_GG_genotype_may_experience_increased_risk_of_musculoskeletal_pain_when_exposed_to_anastrozole_and_letrozole_as_compared_to_the_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_risk_of_musculoskeletal_pain._";PGKB_RACE=NR,NR,White,Asian
6	152200129	rs9322335	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ESR1_(PA156);PGKB_DRUG="exemestane_(PA449563)""letrozole_(PA450196)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Breast_Neoplasms_may_be_at_decreased_risk_for_bone_mineral_density_loss_when_treated_with_letrozole_and/or_exemestane_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_bone_mineral_density_loss.""CT:Patients_with_the_CT_genotype_and_Breast_Neoplasms_may_be_at_decreased_risk_for_bone_mineral_density_loss_when_treated_with_letrozole_and/or_exemestane_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_bone_mineral_density_loss.""TT:Patients_with_the_TT_genotype_and_Breast_Neoplasms_may_be_at_increased_risk_for_bone_mineral_density_loss_when_treated_with_letrozole_and/or_exemestane_as_compared_to_patients_with_the_CC_and_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_bone_mineral_density_loss.";PGKB_RACE=NR
6	152237468	rs4870061	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ESR1_(PA156);PGKB_DRUG=letrozole_(PA450196);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Women_with_the_CC_genotype_and_breast_neoplasms_may_have_less_bone_mineral_loss_when_taking_letrozole_with_or_without_exemestane_as_compared_to_women_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_letrozole_with_and_without_exemestane.""CT:Women_with_the_CT_genotype_and_breast_neoplasms_may_have_less_bone_mineral_loss_when_taking_letrozole_as_compared_to_women_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_letrozole.""TT:Women_with_the_TT_genotype_and_breast_neoplasms_may_have_greater_bone_mineral_loss_when_taking_letrozole_with_or_without_exemestane_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_letrozole_with_and_without_exemestane.";PGKB_RACE=NR
6	152382382	rs2207396	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ESR1_(PA156);PGKB_DRUG="Alkylating_Agents_(PA164712331)""cisplatin_(PA449014)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_childhood_cancer_who_are_treated_with_Alkylating_Agents_and_cisplatin_may_have_an_increased_risk_of_azoospermia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Alkylating_Agents_and_cisplatin_treatment.""AG:Patients_with_the_AG_genotype_and_childhood_cancer_who_are_treated_with_Alkylating_Agents_and_cisplatin_may_have_an_increased_risk_of_azoospermia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Alkylating_Agents_and_cisplatin_treatment.""GG:Patients_with_the_GG_genotype_and_childhood_cancer_who_are_treated_with_Alkylating_Agents_and_cisplatin_may_have_a_decreased_but_not_absent_risk_of_azoospermia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Alkylating_Agents_and_cisplatin_treatment.";PGKB_RACE=NR
6	154360797	rs1799971	A	G	.	.	PGKB_INDEX=8;PGKB_GENE=OPRM1_(PA31945),OPRM1_(PA31945),OPRM1_(PA31945),OPRM1_(PA31945),OPRM1_(PA31945),OPRM1_(PA31945),OPRM1_(PA31945),OPRM1_(PA31945);PGKB_DRUG="Drugs_used_in_nicotine_dependence_(PA164712720)""nicotine_(PA450626)",ethanol_(PA448073),"alfentanil_(PA448084)""Drugs_used_in_opioid_dependence_(PA164712721)""fentanyl_(PA449599)""heroin_(PA452619)""morphine_(PA450550)""naltrexone_(PA450588)""opioids_(PA452618)""tramadol_(PA451735)",morphine_(PA450550),naloxone_(PA450586),naltrexone_(PA450588),"Analgesics_(PA164712362)""Antiinflammatory_agents_non-steroids_(PA164712462)""Ergot_alkaloids_(PA164712741)""opioids_(PA452618)""sumatriptan_(PA451566)",hydrocodone_(PA449900);PGKB_TYPE=Efficacy,Toxicity/ADR,Metabolism/PK,"Dosage""Efficacy",Efficacy,"Efficacy""Toxicity/ADR",Other,Toxicity/ADR;PGKB_EVIDENCE=3,2B,2B,3,2B,3,3,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),NR,"Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)""Pain_(PA445208)""Pain_Postoperative_(PA445210)",Pain_(PA445208),NR,Alcoholism_(PA443309),Substance_Withdrawal_Syndrome_(PA445768),NR;PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_an_increased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_(transdermal_nicotine_patch)_as_compared_to_patients_with_the_AG_and_GG_genotype._However_contradictory_findings_have_been_reported_with_the_AA_genotype_may_be_associated_with_a_decreased_likelihood_of_smoking_cessation_compared_to_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.""AG:Patients_with_AG_genotype_may_have_a_decreased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_(transdermal_nicotine_patch)_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_have_been_reported_with_the_AG_genotype_may_be_associated_with_an_increased_likelihood_of_smoking_cessation_compared_to_AA_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.""GG:Patients_with_GG_genotype_may_have_a_decreased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_(transdermal_nicotine_patch)_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_have_been_reported_with_the_GG_genotype_may_be_associated_with_an_increased_likelihood_of_smoking_cessation_compared_to_AA_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.","AA:Patients_with_the_AA_genotype_may_have_a_decreased__but_not_absent_severity_of_intoxication_and_a_decreased_response_when_exposed_to_ethanol_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_ethanol_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_severity_of_intoxication_and_an_increased_response_when_exposed_to_ethanol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_ethanol_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_severity_of_intoxication_and_an_increased_response_when_exposed_to_ethanol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_ethanol_response.","AA:Individuals_with_the_AA_genotype_may_experience_increased_efficacy_of_opioids_for_pain_and_opioid_related_drugs_to_treat_addiction_and_may_require_a_decreased_dose_of_opioids_as_compared_to_individuals_with_the_AG_and_GG_genotypes._However_this_has_been_contradicted_in_some_studies._In_some_studies_the_AA_and_AG_genotypes_were_found_to_have_a_increased_efficacy_and_to_require_a_decreased_dose_as_compared_to_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_opioid_drugs._""AG:Individuals_with_the_AG_genotype_may_experience_decreased_efficacy_of_opioids_for_pain_and_opioid_related_drugs_to_treat_addiction_and_may_require_an_increased_dose_of_opioids_as_compared_to_individuals_with_the_AA_genotype._However_this_has_been_contradicted_in_some_studies._In_some_studies_the_AA_and_AG_genotypes_were_found_to_have_a_increased_efficacy_and_to_require_a_decreased_dose_as_compared_to_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dependence_on_opioid_drugs._""GG:Individuals_with_the_GG_genotype_may_experience_decreased_efficacy_of_opioids_for_pain_and_opioid_related_drugs_to_treat_addiction_and_may_require_an_increased_dose_of_opioids_as_compared_to_individuals_with_the_AA_genotype._However_this_has_been_contradicted_in_some_studies._In_some_studies_the_AA_and_AG_genotypes_were_found_to_have_a_increased_efficacy_and_to_require_a_decreased_dose_as_compared_to_the_GG_genotype._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dependence_on_opioid_drugs._","AA:Patients_with_the_AA_genotype_who_are_treated_with_morphine:_1)_may_require_a_lower_dose_as_compared_to_patients_with_the_AG_or_GG_genotype_2)_may_be_more_likely_to_have_an_increased_pain_relief_as_compared_to_patients_with_the_AG_or_GG_genotype_and_neoplasms._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_morphine.""AG:Patients_with_the_AG_genotype_who_are_treated_with_morphine:_1)_may_require_a_higher_dose_as_compared_to_patients_with_the_AA_genotype_2)_may_be_less_likely_to_have_an_increased_pain_relief_as_compared_to_patients_the_AA_genotype_and_neoplasms._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_morphine.""GG:Patients_with_the_GG_genotype_who_are_treated_with_morphine:_1)_may_require_the_highest_dose_as_compared_to_patients_with_the_AG_and_AA_genotype_2)_may_be_less_likely_to_have_an_increased_pain_relief_as_compared_to_patients_the_AA_genotype_and_neoplasms._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_morphine.","AA:Patients_with_the_AA_genotype_who_are_treated_with_naloxone_may_have_lower_cortisol_response_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_naloxone.""AG:Patients_with_the_AG_genotype_who_are_treated_with_naloxone_may_have_increased_peak_cortisol_response_as_compared_to_patients_with_AA_genotype.""GG:Patients_with_the_GG_genotype_who_are_treated_with_naloxone_may_have_increased_peak_cortisol_response_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_naloxone.","AA:Patients_with_the_AA_genotype_who_are_treated_with_naltrexone_may_have_a_decreased_1)_response_to_naltrexone_2)_blunting_of_alcohol_craving_3)_severity_of_intoxication_when_exposed_to_ethanol_and_naltrexone_as_compared_to_patients_with_the_AG_or_GG_genotype._The_association_with_naltrexone_response_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_naltrexone.""AG:Patients_with_the_AG_genotype_who_are_treated_with_naltrexone_may_have_an_increased_1)_response_to_naltrexone_2)_blunting_of_alcohol_craving_3)_severity_of_intoxication_when_exposed_to_ethanol_and_naltrexone_as_compared_to_patients_with_the_AA_genotype._The_association_with_naltrexone_response_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_naltrexone.""GG:Patients_with_the_GG_genotype_who_are_treated_with_naltrexone_may_have_an_increased_1)_response_to_naltrexone_2)_blunting_of_alcohol_craving_3)_severity_of_intoxication_when_exposed_to_ethanol_and_naltrexone_as_compared_to_patients_with_the_AA_genotype._The_association_with_naltrexone_response_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_naltrexone.","AA:Patients_with_the_AA_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics._""AG:Patients_with_the_AG_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics._""GG:Patients_with_the_GG_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AA_and_AG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics._","AA:Patients_with_the_AA_genotype_who_are_receiving_hydrocodone_may_have_a_decreased_risk_for_experiencing_side_effects_including_constipation_dry_mouth_or_respiratory_depression_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_side_effects_when_receiving_hydrocodone.""AG:Patients_with_the_AG_genotype_who_are_receiving_hydrocodone_may_have_an_increased_risk_for_experiencing_side_effects_including_constipation_dry_mouth_or_respiratory_depression_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_side_effects_when_receiving_hydrocodone.""GG:Patients_with_the_GG_genotype_who_are_receiving_hydrocodone_may_have_an_increased_risk_for_experiencing_side_effects_including_constipation_dry_mouth_or_respiratory_depression_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_side_effects_when_receiving_hydrocodone.";PGKB_RACE=White,NR,NR,White,NR,NR,NR,NR
6	154362019	rs510769	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=OPRM1_(PA31945);PGKB_DRUG=amphetamine_(PA448408);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_Stimulation_and_Euphoria_scores_after_amphetamine_exposure_as_compared_to_patients_with_the_TT_genotype.""CT:Patients_with_the_CT_genotype_may_have_increased_Stimulation_and_Euphoria_scores_after_amphetamine_exposure_as_compared_to_patients_with_the_TT_genotype.""TT:Patients_with_the_TT_genotype_may_have_decreased_Stimulation_and_Euphoria_scores_after_amphetamine_exposure_as_compared_to_patients_with_the_CC_or_CT_genotype.";PGKB_RACE=White
6	154411344	rs9479757	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=OPRM1_(PA31945);PGKB_DRUG=opioids_(PA452618);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Opioid-Related_Disorders_(PA445043);PGKB_TEXT="AA:The_AA_genotype_was_only_present_in_one_individual_and_could_not_be_evaluated_for_its_influence_on_risk_of_opioid_dependence_upon_exposure_to_opioids._Other_clinical_and_genetic_factors_may_also_influence_the_risk_of_opioid_dependence_upon_exposure_to_opioids._""AG:Patients_with_the_AG_genotype_may_have_a_decreased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_opioid_dependence_upon_exposure_to_opioids.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_AG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_opioid_dependence_upon_exposure_to_opioids.";PGKB_RACE=White
6	154421057	rs9384179	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=OPRM1_(PA31945);PGKB_DRUG=fentanyl_(PA449599);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_Postoperative_(PA445210);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_post-operative_pain_may_require_an_increased_dose_of_fentanyl_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_dose_of_fentanyl_in_people_with_post-operative_pain._""AG:Patients_with_the_AG_genotype_and_post-operative_pain_may_require_a_decreased_dose_of_fentanyl_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_dose_of_fentanyl_in_people_with_post-operative_pain._""GG:Patients_with_the_GG_genotype_and_post-operative_pain_may_require_a_decreased_dose_of_fentanyl_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_dose_of_fentanyl_in_people_with_post-operative_pain._";PGKB_RACE=Asian
6	154441965	rs558025	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=OPRM1_(PA31945);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment.""AG:Patients_with_the_AG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment.""GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment.";PGKB_RACE=NR
6	154457493	rs544093	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=OPRM1_(PA31945);PGKB_DRUG="carboplatin_(PA448803)""docetaxel_(PA449383)""paclitaxel_(PA450761)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""GT:Patients_with_the_GT_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_may_have_an_increased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._";PGKB_RACE=NR
6	154487421	rs2281617	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=OPRM1_(PA31945);PGKB_DRUG=amphetamine_(PA448408);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_Euphoric_and_Energetic_after_amphetamine_exposure_as_compared_to_patients_with_the_CT_or_TT_genotype.""CT:Patients_with_the_CT_genotype_may_have_decreased_Euphoric_and_Energetic_after_amphetamine_exposure_as_compared_to_patients_with_the_CC_genotype.""TT:Patients_with_the_TT_genotype_may_have_decreased_Euphoric_and_Energetic_after_amphetamine_exposure_as_compared_to_patients_with_the_CC_genotype.";PGKB_RACE=White
6	160113872	rs4880	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=SOD2_(PA36017),SOD2_(PA36017),SOD2_(PA36017);PGKB_DRUG=cyclophosphamide_(PA449165),valproic_acid_(PA451846),paclitaxel_(PA450761);PGKB_TYPE=Efficacy,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2B,4,3;PGKB_DISEASE=Breast_Neoplasms_(PA443560),Epilepsy_(PA444065),Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_increased_survival_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cyclophosphamide.""AG:Patients_with_the_AG_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_a_decreased_survival_as_compared_to_patients_with_the_AA_genotype_or_may_have_increased_survival_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cyclophosphamide.""GG:Patients_with_the_GG_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_a_decreased_survival_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_when_treated_with_cyclophosphamide.","AA:Patients_with_genotype_AA_and_epilepsy_may_have_a_decreased_risk_of_drug_toxicity_when_taking_valproic_acid_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_affect_risk_of_drug_toxicity_when_taking_valproic_acid._""AG:Patients_with_genotype_AG_and_epilepsy_may_have_a_decreased_risk_of_drug_toxicity_when_taking_valproic_acid_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_affect_risk_of_drug_toxicity_when_taking_valproic_acid._""GG:Patients_with_genotype_GG_and_epilepsy_may_have_an_increased_risk_of_drug_toxicity_when_taking_valproic_acid_as_compared_to_patients_with_the_AA_and_AG_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_drug_toxicity_when_taking_valproic_acid._","AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_an_increased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_AG_or_GG_genotype._This_association_was_only_found_in_individuals_who_are_CYP3A4_and_CYP3A5_non-expressers_(CYP3A4_*1/*1_and_CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.""AG:Patients_with_the_AG_genotype_and_breast_cancer_may_have_a_decreased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_AA_genotype._This_association_was_only_found_in_individuals_who_are_CYP3A4_and_CYP3A5_non-expressers_(CYP3A4_*1/*1_and_CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_decreased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_AA_genotype._This_association_was_only_found_in_individuals_who_are_CYP3A4_and_CYP3A5_non-expressers_(CYP3A4_*1/*1_and_CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.";PGKB_RACE=NR,Asian,White
6	160543148	rs12208357	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=tramadol_(PA451735);PGKB_TYPE=NR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_lower_plasma_concentrations_of_O-desmethyltramadol_when_exposed_to_tramadol_in_healthy_individuals_as_compared_to_patients_with_the_TT_genotype._Other_genetic_or_clinical_factors_may_influence_the_response_to_tramadol.""CT:Patients_with_the_CT_genotype_may_have_higher_plasma_concentrations_of_O-desmethyltramadol_when_exposed_to_tramadol_in_healthy_individuals_as_compared_to_patients_with_the_CC_genotype._Other_genetic_or_clinical_factors_may_influence_the_response_to_tramadol.""TT:Patients_with_the_TT_genotype_may_have_higher_plasma_concentrations_of_O-desmethyltramadol_when_exposed_to_tramadol_in_healthy_individuals_as_compared_to_patients_with_the_CC_genotype._Other_genetic_or_clinical_factors_may_influence_the_response_to_tramadol.";PGKB_RACE=NR
6	160551204	rs683369	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE="Efficacy""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_chronic_myeloid_leukemia_may_have_increased_clearance_of_imatinib_as_well_as_increased_event-free_survival_time_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_imatinib_and_event-free_survival_time.""CG:Patients_with_the_CG_genotype_and_chronic_myeloid_leukemia_may_have_decreased_clearance_of_imatinib_as_well_as_decreased_event-free_survival_time_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_imatinib_and_event-free_survival_time.""GG:Patients_with_the_GG_genotype_and_chronic_myeloid_leukemia_may_have_decreased_clearance_of_imatinib_as_well_as_decreased_event-free_survival_time_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_imatinib_and_event-free_survival_time.";PGKB_RACE=NR
6	160557643	rs2282143	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_metformin_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_metformin._""CT:Patients_with_the_CT_genotype_may_have_decreased_clearance_of_metformin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_metformin._""TT:Patients_with_the_TT_genotype_may_have_decreased_clearance_of_metformin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_metformin._";PGKB_RACE=Asian
6	160560845	rs628031	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_metformin_may_have_a_decreased_response_and_increased_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_metformin_may_have_a_decreased_response_and_increased_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_GG_genotype_and_increased_response_and_decreased_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_metformin_may_have_a_increased_response_and_decreased_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.";PGKB_RACE=NR
6	160560880	rs35167514	CA	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=tramadol_(PA451735);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="A/del:Patients_with_the_A/del_genotype_may_have_increased_plasma_concentrations_of_O-desmethyltramadol_when_exposed_to_tramadol_in_healthy_individuals_as_compared_to_patients_with_the_AA_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_clearance_of_tramadol.""AA:Patients_with_the_AA_genotype_may_have_decreased_plasma_concentrations_of_O-desmethyltramadol_when_exposed_to_tramadol_in_healthy_individuals_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_clearance_of_tramadol.""del/del:Patients_with_the_del/del_genotype_may_have_increased_plasma_concentrations_of_O-desmethyltramadol_when_exposed_to_tramadol_in_healthy_individuals_as_compared_to_patients_with_the_AA_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_clearance_of_tramadol.";PGKB_RACE=NR
6	160560882	rs72552763	TGAT	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GAT/DEL:Patients_with_the_GAT/DEL_genotype_who_are_treated_with_metformin_may_have_a_decreased_trough_metformin_steady-state_concentration_as_compared_to_patients_with_the_GAT/GAT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""GAT/GAT:Patients_with_the_GAT/GAT_genotype_who_are_treated_with_metformin_may_have_an_increased_trough_metformin_steady-state_concentration_as_compared_to_patients_with_the_GAT/DEL_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""del/del:Patients_with_the_del/del_genotype_were_not_studied_but_patients_with_the_GAT/DEL_genotype_who_are_treated_with_metformin_may_have_a_decreased_trough_metformin_steady-state_concentration_as_compared_to_patients_with_the_GAT/GAT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.";PGKB_RACE=NR
6	160560899	rs36056065	GGTAAGTTG	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="GTAAGTTG/GTAAGTTG:Patients_with_the_GTAAGTTG/GTAAGTTG_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_increased_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_deldel_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""GTAAGTTG/del:Patients_with_the_GTAAGTTG/del_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_increased_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_deldel_genotype_or_may_have_decreased_but_not_absent_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_GTAAGTTG/GTAAGTTG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""del/del:Patients_with_the_del/del_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_decreased_but_not_absent_risk_for_gastrointestinal_side_effects_as_compared_to_patients_with_the_GTAAGTTG/GTAAGTTG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.";PGKB_RACE=White
6	160572866	rs622342	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A1_(PA329);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_the_GG_genotype_at_rs2289669_who_have_diabetes_may_have_a_better_response_to_metformin_as_measured_by_a_larger_reduction_in_HbA1c_levels_as_compared_to_patients_with_the_CC_genotype_and_the_GG_genotype_at_rs2289669._This_association_is_not_significant_when_compared_to_patients_with_the_CC_genotype_and_the_AG_or_AA_genotype_at_rs2289699._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_reduction_in_HbA1c_levels_with_metformin_treatment.""AC:Patients_with_the_AC_genotype_and_the_GG_genotype_at_rs2289669_who_have_diabetes_may_have_a_poorer_response_to_metformin_as_measured_by_a_smaller_reduction_in_HbA1c_levels_as_compared_to_patients_with_the_AA_genotype._Although_contradictory_information_exists_for_this_association_and_may_be_dependent_on_the_absence_of_an_A_allele_at_rs2289669._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_reduction_in_HbA1c_levels_with_metformin_treatment.""CC:Patients_with_the_CC_genotype_and_the_GG_genotype_at_rs2289669_who_have_diabetes_may_have_a_poorer_response_to_metformin_as_measured_by_a_smaller_reduction_in_HbA1c_levels_as_compared_to_patients_with_the_AA_genotype_and_the_GG_genotype_at_rs2289669._This_association_is_no_longer_significant_in_patients_with_the_CC_genotype_and_the_AG_or_AA_genotype_at_rs2289669._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin_treatment.";PGKB_RACE=White
6	160670282	rs316019	A	C	.	.	PGKB_INDEX=4;PGKB_GENE=SLC22A2_(PA331),SLC22A2_(PA331),SLC22A2_(PA331),SLC22A2_(PA331);PGKB_DRUG=metformin_(PA450395),l-tryptophan_(PA10323),cisplatin_(PA449014),cisplatin_(PA449014);PGKB_TYPE=Other,Other,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=NR,NR,Neoplasms_(PA445062),Ototoxicity_(PA162263534);PGKB_TEXT="AA:No_patients_with_the_AA_genotype_were_seen_in_the_study_population._However_patients_with_the_AC_genotype_may_have_decreased_clearance_of_metformin_as_compared_to_patients_with_the_CC_genotype_however_this_is_contradicted_by_one_study._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_metformin._""AC:Patients_with_the_AC_genotype_may_have_decreased_clearance_of_metformin_as_compared_to_patients_with_the_CC_genotype_however_this_is_contradicted_by_one_study._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_metformin._""CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_metformin_as_compared_to_patients_with_the_AC_genotype_however_this_is_contradicted_by_one_study._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_metformin._","AA:Patients_with_the_AA_genotype_may_have_decreased_clearance_of_L-tryptophan_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AC:Patients_with_the_AC_genotype_may_have_decreased_clearance_of_L-tryptophan_as_compared_to_patients_with_the_CC_genotype_but_an_increased_clearance_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_L-tryptophan_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Patients_with_the_AA_genotype_may_have_reduced_but_not_non-existent_risk_of_nephrotoxicity_in_response_to_cisplatin_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AC:Patients_with_the_AC_genotype_may_have_reduced_but_not_non-existent_risk_of_nephrotoxicity_in_response_to_cisplatin_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_nephrotoxicity_in_response_to_cisplatin_treatment_as_compared_to_patients_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_cisplatin-induced_ototoxicity_as_compared_to_patients_with_AC_or_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_risk_of_toxicity_to_cisplatin.""AC:Patients_with_the_AC_genotype_may_have_increased_risk_of_cisplatin-induced_ototoxicity_as_compared_to_patients_with_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_risk_of_toxicity_to_cisplatin.""CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_cisplatin-induced_ototoxicity_as_compared_to_patients_with_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_risk_of_toxicity_to_cisplatin.";PGKB_RACE=NR,NR,White,NR
6	160872786	rs2076828	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A3_(PA330);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_CG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_metformin.""CG:Patients_with_the_CG_genotype_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_GG_genotype_and_an_increased_response_to_metformin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_metformin.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_CG_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_metformin.";PGKB_RACE=NR
6	161010118	rs10455872	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=LPA_(PA30432);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_and_(according_to_one_study)_a_decreased_risk_of_coronary_artery_disease_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_hmg_coa_reductase_inhibitors._""AG:Patients_with_the_AG_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_and_(according_to_one_study)_a_decreased_risk_of_coronary_artery_disease_as_compared_to_patients_with_the_GG_genotypes_and_a_decreased_response_to_hmg_coa_reductase_inhibitors_and_an_increased_risk_of_coronary_artery_disease_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_hmg_coa_reductase_inhibitors._""GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_hmg_coa_reductase_inhibitors_and_(according_to_one_study)_an_increased_risk_of_coronary_artery_disease_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_hmg_coa_reductase_inhibitors._";PGKB_RACE=NR
6	166579270	rs2305089	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=T_(PA36296);PGKB_DRUG=flunisolide_(PA449661);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_poorer_response_when_treated_with_flunisolide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_flunisolide.""CT:Patients_with_the_CT_genotype_and_asthma_may_have_a_poorer_response_when_treated_with_flunisolide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_flunisolide.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_a_better_response_when_treated_with_flunisolide_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_flunisolide.";PGKB_RACE=White
7	1976457	rs1801368	C	T,G	.	.	PGKB_INDEX=1;PGKB_GENE=MAD1L1_(PA372);PGKB_DRUG="carboplatin_(PA448803)""paclitaxel_(PA450761)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Ovarian_Neoplasms_who_are_treated_with_carboplatin_and_paclitaxel_may_have_higher_biochemical_response_optimal_cytoreduction_and_sensitivity_to_the_treatment_as_compared_to_patients_with_the_TT_or_TC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carboplatin_and_paclitaxel.""TC:Patients_with_the_TC_genotype_and_Ovarian_Neoplasms_who_are_treated_with_carboplatin_and_paclitaxel_may_have_lower_decreased_biochemical_response_cytoreduction_and_sensitivity_to_the_induction_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carboplatin_and_paclitaxel.""TT:Patients_with_the_TT_genotype_and_Ovarian_Neoplasms_who_are_treated_with_carboplatin_and_paclitaxel_may_have_lower_decreased_biochemical_response_cytoreduction_and_sensitivity_to_the_induction_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carboplatin_and_paclitaxel.";PGKB_RACE=NR
7	8007876	rs37973	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GLCCI1_(PA38657);PGKB_DRUG="budesonide_(PA448681)""flunisolide_(PA449661)""fluticasone_propionate_(PA449686)""glucocorticoids_(PA452347)""nedocromil_(PA450601)""triamcinolone_(PA451749)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_better_response_to_inhaled_glucocorticoids_in_asthma_patients_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_glucocorticoids.""AG:Patients_with_the_AG_genotype_may_have_intermediate_increased_risk_of_poor_response_to_inhaled_glucocorticoids_in_asthma_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_glucocorticoids._The_G_allele_is_associated_with_decrease_in_the_expression_of_GLCCI1_gene_and_cells_with_heterozygous_AG_genotype_has_an_intermediate_GLCC1_expression_value.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_poor_response_to_inhaled_glucocorticoids_in_asthma_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_glucocorticoids._The_G_allele_is_associated_with_decrease_in_the_expression_of_GLCCI1_gene_and_cells_with_homozygous_GG_genotype_has_the_lowest_GLCC1_expression_value_compared_to_AA_or_AG.";PGKB_RACE=NR
7	17284577	rs4410790	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=AHR_(PA24641);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_olanzapine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_olanzapine.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_olanzapine.""TT:Patients_with_the_TT_genotype_may_have_decreased_metabolism_of_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_olanzapine.";PGKB_RACE=White
7	20682884	rs17143212	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB5_(PA24387);PGKB_DRUG=haloperidol_(PA449841);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_psychotic_illnesses_may_be_at_a_lower_risk_for_haloperidol-induced_toxicities_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_haloperidol-induced_toxicities.""CT:Patients_with_the_CT_genotype_and_psychotic_illnesses_may_be_at_a_greater_risk_for_haloperidol-induced_toxicities_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_haloperidol-induced_toxicities.""TT:No_patients_with_the_TT_genotype_were_present_but_patients_with_the_CT_genotype_and_psychotic_illnesses_may_be_at_a_greater_risk_for_haloperidol-induced_toxicities_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_haloperidol-induced_toxicities.";PGKB_RACE=NR
7	22760488	rs10499563	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL6_(PA198);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Colitis_Ulcerative_(PA443750)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_inflammatory_bowel_disease_or_specifically_ulcerative_colitis_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
7	22766645	rs1800795	C	G	.	.	PGKB_INDEX=3;PGKB_GENE=IL6_(PA198),IL6_(PA198),IL6_(PA198);PGKB_DRUG=fenofibrate_(PA449594),Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366),"adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)";PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Cardiovascular_Diseases_(PA443635),Psoriasis_(PA445451),Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_have_a_high_risk_of_cardiovascular_disease_may_have_a_better_anti-inflammatory_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_anti-inflammatory_action_of_fenofibrate.""CG:Patients_with_the_CG_genotype_who_have_a_high_risk_of_cardiovascular_disease_may_have_a_better_anti-inflammatory_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_anti-inflammatory_action_of_fenofibrate.""GG:Patients_with_the_GG_genotype_who_have_a_high_risk_of_cardiovascular_disease_may_have_a_poorer_anti-inflammatory_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_anti-inflammatory_action_of_fenofibrate.","CC:Patients_with_the_CC_genotype_and_psoriasis_who_are_treated_with_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_may_have_decreased_response_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""CG:Patients_with_the_CG_genotype_and_psoriasis_who_are_treated_with_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_may_have_decreased_response_as_compared_to_patients_with_CC_genotype_or_may_have_decreased_response_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.""GG:Patients_with_the_GG_genotype_and_psoriasis_who_are_treated_with_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_may_have_decreased_response_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors.","CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_adalimumab_etanercept_or_infliximab_may_have_decreased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_adalimumab_etanercept_or_infliximab.""CG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_adalimumab_etanercept_or_infliximab_may_have_increased_response_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_adalimumab_etanercept_or_infliximab.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_adalimumab_etanercept_or_infliximab_may_have_increased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_adalimumab_etanercept_or_infliximab.";PGKB_RACE=NR,NR,NR
7	30616761	rs1074373	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AC:Patients_with_asthma_and_the_AC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""CC:Patients_with_asthma_and_the_CC_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
7	30699972	rs2270007	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR2_(PA26875);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""CG:Patients_with_the_CG_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=White
7	30716087	rs2267715	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR2_(PA26875);PGKB_DRUG="salbutamol_(PA448068)""selective_beta-2-adrenoreceptor_agonists_(PA134687887)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_salbutamol_in_people_with_Asthma_as_compare_to_patients_with_the_GG_genotype._However_contradictory_finding_has_been_reported._No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_salbutamol_in_people_with_Asthma_as_compare_to_patients_with_the_AA_genotype._However_contradictory_finding_has_been_reported._No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_salbutamol_in_people_with_Asthma_as_compare_to_patients_with_the_AA_genotype._However_contradictory_finding_has_been_reported._No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.";PGKB_RACE=White
7	30718103	rs2284220	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR2_(PA26875);PGKB_DRUG="salbutamol_(PA448068)""selective_beta-2-adrenoreceptor_agonists_(PA134687887)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.""AG:No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.""GG:No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.";PGKB_RACE=White
7	30726777	rs7793837	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR2_(PA26875);PGKB_DRUG="salbutamol_(PA448068)""selective_beta-2-adrenoreceptor_agonists_(PA134687887)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_short-acting_beta2-antagonists_may_have_a_better_response_(increased_acute_bronchodilation)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_short-acting_beta2-antagonists.""AT:Patients_with_the_AT_genotype_and_asthma_who_are_treated_with_short-acting_beta2-antagonists_may_have_a_poorer_response_(decreased_acute_bronchodilation)_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_better_response_(increased_acute_bronchodilation)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_short-acting_beta2-antagonists.""TT:Patients_with_the_TT_genotype_and_asthma_who_are_treated_with_short-acting_beta2-antagonists_may_have_a_poorer_response_(decreased_acute_bronchodilation)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_short-acting_beta2-antagonists.";PGKB_RACE=White
7	30728908	rs255100	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR2_(PA26875);PGKB_DRUG="salbutamol_(PA448068)""selective_beta-2-adrenoreceptor_agonists_(PA134687887)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.""AT:No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.""TT:No_conclusive_results_regarding_the_association_between_this_variant_and_bronchodilator_response.";PGKB_RACE=White
7	31072469	rs34548976	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=adrenergics_inhalants_(PA10405);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:In_pediatric_patients_with_asthma_and_the_CC_genotype_may_have_an_increased_response_to_beta-adrenergic_inhalants_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_such_as_stress_may_also_influence_response_to_beta-adrenergics_in_patients_with_asthma._""CT:In_pediatric_patients_with_asthma_and_the_CT_genotype_may_have_a_decreased_response_to_beta-adrenergic_inhalants_as_compared_to_patients_with_the_CC_genotypes_and_an_increased_response_to_beta-adrenergic_inhalants_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_such_as_stress_may_also_influence_response_to_beta-adrenergics_in_patients_with_asthma._""TT:In_pediatric_patients_with_asthma_and_the_TT_genotype_may_have_a_decreased_response_to_beta-adrenergic_inhalants_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_clinical_and_genetic_factors_such_as_stress_may_also_influence_response_to_beta-adrenergics_in_patients_with_asthma._";PGKB_RACE=NR
7	33060946	rs3750117	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NT5C3A_(PA31802);PGKB_DRUG="cytarabine_(PA449177)""idarubicin_(PA449961)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Leukemia_who_are_treated_with_cytarabine_and_idarubicin_may_have_decreased_but_not_absent_risk_for_induction_failure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin.""AG:Patients_with_the_AG_genotype_and_Leukemia_who_are_treated_with_cytarabine_and_idarubicin_may_have_decreased_but_not_absent_risk_for_induction_failure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin.""GG:Patients_with_the_GG_genotype_and_Leukemia_who_are_treated_with_cytarabine_and_idarubicin_may_have_increased_risk_for_induction_failure_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin.";PGKB_RACE=Asian
7	34150775	rs757639	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="BMPER_(PA142672557)""OCRL_(PA31896)";PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_increased_creatinine_clearance_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.""CT:Patients_with_the_CT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_decreased_creatinine_clearance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.""TT:Patients_with_the_TT_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_decreased_creatinine_clearance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.";PGKB_RACE=NR
7	44580991	rs17655652	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NPC1L1_(PA31699);PGKB_DRUG=pravastatin_(PA451089);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Diabetes_Mellitus_(PA443886)""Hypertension_(PA444552)""Vascular_Diseases_(PA446021)";PGKB_TEXT="CC:Men_with_the_CC_genotype_who_are_treated_with_pravastatin_may_have_a_better_response_to_treatment_(an_increased_reduction_in_LDL-cholesterol)_as_compared_to_men_with_the_CT_or_TT_genotype._Women_with_the_CC_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_to_treatment_(a_decreased_reduction_in_LDL-cholesterol)_as_compared_to_women_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""CT:Men_with_the_CT_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_to_treatment_(a_decreased_reduction_in_LDL-cholesterol)_as_compared_to_men_with_the_CC_genotype._Women_with_the_CT_genotype_who_are_treated_with_pravastatin_may_have_a_better_response_to_treatment_(an_increased_reduction_in_LDL-cholesterol)_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Men_with_the_TT_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_to_treatment_(a_decreased_reduction_in_LDL-cholesterol)_as_compared_to_men_with_the_CC_genotype._Women_with_the_TT_genotype_who_are_treated_with_pravastatin_may_have_a_better_response_to_treatment_(an_increased_reduction_in_LDL-cholesterol)_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._";PGKB_RACE=NR
7	55086755	rs712829	G	T	.	.	PGKB_INDEX=7;PGKB_GENE=EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360);PGKB_DRUG=erlotinib_(PA134687924),topoisomerase_I_inhibitors_(PA150481186),geldanamycin_(PA152031327),Alkylating_Agents_(PA164712331),gefitinib_(PA131301952),erlotinib_(PA134687924),"cetuximab_(PA10040)""irinotecan_(PA450085)""panitumumab_(PA162373091)";PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=4,4,4,4,3,3,3;PGKB_DISEASE=Neoplasms_(PA445062),Neoplasms_(PA445062),Neoplasms_(PA445062),Neoplasms_(PA445062),Neoplasms_(PA445062),Neoplasms_(PA445062),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_be_less_sensitive_to_treatment_with_erlotinib_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_drug_sensitivity.""GT:Patients_with_the_GT_genotype_may_be_more_sensitive_to_treatment_with_erlotinib_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_drug_sensitivity.""TT:Patients_with_the_TT_genotype_may_be_more_sensitive_to_treatment_with_erlotinib_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_drug_sensitivity.","GG:Cancer_patients_with_genotype_GG_may_be_more_likely_to_respond_to_topoisomerase_I_inhibitors_compared_to_patients_with_genotypes_GT_or_TT_(based_solely_on_in_vitro_work)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Cancer_patients_with_genotype_GT_may_be_less_likely_to_respond_to_topoisomerase_I_inhibitors_compared_to_patients_with_genotype_GG_(based_solely_on_in_vitro_work)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Cancer_patients_with_genotype_TT_may_be_less_likely_to_respond_to_topoisomerase_I_inhibitors_compared_to_patients_with_genotype_GG_(based_solely_on_in_vitro_work)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","GG:Patients_with_the_genotype_GG_who_are_treated_with_geldanamycin_may_be_more_likely_to_respond_as_compared_to_patients_with_genotype_GT_or_TT_(based_solely_on_in_vitro_work)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Patients_with_the_genotype_GT_who_are_treated_with_geldanamycin_may_be_less_likely_to_respond_as_compared_to_patients_with_genotype_GG_(based_solely_on_in_vitro_work)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_genotype_TT_who_are_treated_with_geldanamycin_may_be_less_likely_to_respond_as_compared_to_patients_with_genotype_GG_(based_solely_on_in_vitro_work)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","GG:Cancer_cells_with_the_GG_genotype_may_be_more_sensitive_to_Alkylating_agents_than_are_cells_with_genotype_GT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_tumor_response_to_Alkylating_agents.""GT:Cancer_cells_with_the_GT_genotype_may_be_less_sensitive_to_Alkylating_agents_than_cells_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_tumor_response_to_Alkylating_agents.""TT:Cancer_cells_with_the_TT_genotype_may_be_less_sensitive_to_Alkylating_agents_than_cells_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_tumor_response_to_Alkylating_agents.","GG:Patients_with_the_GG_genotype_who_are_treated_with_gefitinib_may_be_less_likely_to_respond_compared_to_a_patient_with_one_or_more_T_alleles._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Patients_with_the_GT_genotype_who_are_treated_with_gefitinib_may_be_more_likely_to_respond_compared_to_such_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_who_are_treated_with_gefitinib_may_be_more_likely_to_respond_compared_to_such_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","GG:Patients_with_the_GG_genotype_and_cancer_who_are_treated_with_erlotinib_may_have_increased_severity_of_Diarrhea_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_Diarrhea_when_treated_with_erlotinib.""GT:Patients_with_the_GT_genotype_and_cancer_who_are_treated_with_erlotinib_may_have_decreased_severity_of_Diarrhea_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_Diarrhea_when_treated_with_erlotinib.""TT:Patients_with_the_TT_genotype_and_cancer_who_are_treated_with_erlotinib_may_have_decreased_severity_of_Diarrhea_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_Diarrhea_when_treated_with_erlotinib.","GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_shorter_overall_survival_time_and_progression-free_survival_time_when_receiving_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_on_anti-EGFR_plus_irinotecan_treatment.""GT:Patients_with_the_GT_genotype_and_colorectal_cancer_may_have_a_longer_overall_survival_time_and_progression-free_survival_time_when_receiving_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_on_anti-EGFR_plus_irinotecan_treatment.""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_a_longer_overall_survival_time_and_progression-free_survival_time_when_receiving_anti-EGFR_plus_irinotecan_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_on_anti-EGFR_plus_irinotecan_treatment.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR
7	55229255	rs2227983	G	A,C,T	.	.	PGKB_INDEX=1;PGKB_GENE=EGFR_(PA7360);PGKB_DRUG=egfr_inhibitors_(PA153561371);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Colorectal_Neoplasms_(PA446108)""Neoplasms_(PA445062)""Pancreatic_Neoplasms_(PA445218)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_but_not_absent_risk_for_rash_when_treated_with_EGFR_inhibitors_such_as_erlotinib_as_compared_to_patients_with_the_GG_genotypes._No_significant_association_is_found_between_this_variant_and_cetuximab_or_panitumumab_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_may_have_a_decreased_but_not_absent_risk_for_rash_when_treated_with_EGFR_inhibitors_such_as_erlotinib_as_compared_to_patients_with_the_GG_genotypes._No_significant_association_is_found_between_this_variant_and_cetuximab_or_panitumumab_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_rash_when_treated_with_EGFR_inhibitors_such_as_erlotinib_as_compared_to_patients_with_the_AA_or_AG_genotypes._No_significant_association_is_found_between_this_variant_and_cetuximab_or_panitumumab_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
7	55249071	rs121434569	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=EGFR_(PA7360);PGKB_DRUG="erlotinib_(PA134687924)""gefitinib_(PA131301952)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2A;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Advanced_non-small-cell_lung_cancer_patients_with_CC_genotype_may_less_likely_develop_acquired_resistance_and_more_likely_have_increased_progression-free_survival_(PFS)_time_when_treated_with_erlotinib_or_gefitinib_compared_to_patients_with_CT_or_TT_genotypes._In_these_studies_patients_who_have_EGFR_activating_mutations_[e.g._L858R_or_exon_19_deletion]_are_treated_with_erlotinib_or_gefitinib._The_T790M_mutation_(rs121434569)_was_not_detected_or_detected_in_very_low_frequency_in_patients_who_remained_sensitive_to_erlotinib_or_gefitinib_treatment_or_in_nonresponders_to_these_drugs._This_is_a_somatic_mutation_occurred_in_one_cell_then_go_for_clonal_expansion_under_some_circumstances._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity.""CT:Advanced_non-small-cell_lung_cancer_patients_with_CT_genotype_may_more_likely_develop_acquired_resistance_and_less_likely_have_increased_progression-free_survival_(PFS)_time_when_treated_with_erlotinib_or_gefitinib_compared_to_patients_with_CC_genotypes._In_these_studies_patients_who_have_EGFR_activating_mutations_[e.g._L858R_or_exon_19_deletion]_are_treated_with_erlotinib_or_gefitinib._The_T790M_mutation_(rs121434569)_was_not_detected_or_detected_in_very_low_frequency_in_patients_who_remained_sensitive_to_erlotinib_or_gefitinib_treatment_or_in_nonresponders_to_these_drugs._This_is_a_somatic_mutation_occurred_in_one_cell_then_go_for_clonal_expansion_under_some_circumstances._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._""TT:Advanced_non-small-cell_lung_cancer_patients_with_TT_genotype_may_more_likely_develop_acquired_resistance_and_less_likely_have_increased_progression-free_survival_(PFS)_time_when_treated_with_erlotinib_or_gefitinib_compared_to_patients_with_CC_genotypes._In_these_studies_patients_who_have_EGFR_activating_mutations_[e.g._L858R_or_exon_19_deletion]_are_treated_with_erlotinib_or_gefitinib._The_T790M_mutation_(rs121434569)_was_not_detected_or_detected_in_very_low_frequency_in_patients_who_remained_sensitive_to_erlotinib_or_gefitinib_treatment_or_in_nonresponders_to_these_drugs._This_is_a_somatic_mutation_occurred_in_one_cell_then_go_for_clonal_expansion_under_some_circumstances._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._";PGKB_RACE=NR
7	55259515	rs121434568	T	G	.	.	PGKB_INDEX=4;PGKB_GENE=EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360),EGFR_(PA7360);PGKB_DRUG=erlotinib_(PA134687924),"carboplatin_(PA448803)""gefitinib_(PA131301952)""paclitaxel_(PA450761)","carboplatin_(PA448803)""docetaxel_(PA449383)""erlotinib_(PA134687924)""gemcitabine_(PA449748)""paclitaxel_(PA450761)",gefitinib_(PA131301952);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=1B,2A,2A,1B;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622),Carcinoma_Non-Small-Cell_Lung_(PA443622),Carcinoma_Non-Small-Cell_Lung_(PA443622),Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="GG:Patients_with_an_activating_somatic_EGFR_mutation_who_have_advanced_non-small-cell_lung_cancer_and_who_are_treated_with_erlotinib_may_be_more_likely_have_increased_response_rate_(RR)_and_increased_progression-free_survival_(PFS)_time_compared_to_patients_who_have_no_somatic_mutation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GG_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""GT:Patients_with_an_activating_somatic_EGFR_mutation_who_have_advanced_non-small-cell_lung_cancer_and_who_are_treated_with_erlotinib_may_be_more_likely_have_increased_response_rate_(RR)_and_increased_progression-free_survival_(PFS)_time_compared_to_patients_who_have_no_somatic_mutation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GT_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome.""TT:Patients_without_an_activating_somatic_EGFR_mutation_who_have_advanced_non-small-cell_lung_cancer_and_who_are_treated_with_erlotinib_may_be_more_likely_have_decreased_response_rate_(RR)_and_decreased_progression-free_survival_(PFS)_time_compared_to_patients_who_have_activating_somatic_mutation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568._Patients_who_have_no_mutation_are_presented_here_as_TT_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome.","GG:Patients_with_an_activating_somatic_EGFR_mutation_are_presented_in_this_annotation_and_effects_of_gefitinib_vs_paclitaxel_plus_carboplatin_were_compared_in_non-small-cell_lung_cancer_patients._Patients_with_an_activating_somatic_EGFR_mutation_had_increased_progression-free_survival_(PFS)_time_and_increased_response_rate_(RR)_when_treated_with_gefitinib_vs_paclitaxel_plus_carboplatin._Genotypes_are_not_compared_in_this_annotation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GG_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""GT:Patients_with_an_activating_somatic_EGFR_mutation_are_presented_in_this_annotation_and_effects_of_gefitinib_vs_paclitaxel_plus_carboplatin_were_compared_in_non-small-cell_lung_cancer_patients._Patients_with_an_activating_somatic_EGFR_mutation_had_increased_progression-free_survival_(PFS)_time_and_increased_response_rate_(RR)_when_treated_with_gefitinib_vs_paclitaxel_plus_carboplatin._Genotypes_are_not_compared_in_this_annotation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GT_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""TT:Patients_who_have_no_activating_somatic_EGFR_mutation_were_NOT_included_in_these_studies_where_this_annotation_is_derived_from._In_this_annotation_and_effects_of_gefitinib_vs_vs_paclitaxel_plus_carboplatin_were_compared_in_non-small-cell_lung_cancer_patients_who_have_somatic_mutation._Genotypes_are_not_compared_in_this_annotation.","GG:Patients_with_an_activating_somatic_EGFR_mutation_are_presented_in_this_annotation_and_effects_of_erlotinib_vs_standard_chemotherapy_[i)_paclitaxel_plus_carboplatin_ii)_cisplatin_plus_gemcitabine_or_docetaxel]_were_compared_in_non-small-cell_lung_cancer_patients._Patients_with_an_activating_somatic_EGFR_mutation_had_increased_progression-free_survival_(PFS)_time_decreased_toxic_effects_and_decreased_serious_adverse_events_when_treated_with_erlotinib_vs_standard_chemotherapy._Genotypes_are_not_compared_in_this_annotation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GG_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""GT:Patients_with_an_activating_somatic_EGFR_mutation_are_presented_in_this_annotation_and_effects_of_erlotinib_vs_standard_chemotherapy_[i)_paclitaxel_plus_carboplatin_ii)_cisplatin_plus_gemcitabine_or_docetaxel]_were_compared_in_non-small-cell_lung_cancer_patients._Patients_with_an_activating_somatic_EGFR_mutation_had_increased_progression-free_survival_(PFS)_time_decreased_toxic_effects_and_decreased_serious_adverse_events_when_treated_with_erlotinib_vs_standard_chemotherapy._Genotypes_are_not_compared_in_this_annotation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GT_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""TT:Patients_who_have_no_activating_somatic_EGFR_mutation_were_NOT_included_in_these_studies_where_this_annotation_is_derived_from._In_this_annotation_and_effects_of_erlotinib_vs_standard_chemotherapy_[i)_paclitaxel_plus_carboplatin_ii)_cisplatin_plus_gemcitabine_or_docetaxel]_were_compared_in_non-small-cell_lung_cancer_patients_who_have_somatic_mutation._Genotypes_are_not_compared_in_this_annotation.","GG:Patients_with_an_activating_somatic_EGFR_mutation_who_have_advanced_non-small-cell_lung_cancer_and_who_are_treated_with_gefitinib_may_be_more_likely_have_increased_response_rate_(RR)_and_increased_progression-free_survival_(PFS)_time_compared_to_patients_who_have_no_somatic_mutation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GG_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""GT:Patients_with_an_activating_somatic_EGFR_mutation_who_have_advanced_non-small-cell_lung_cancer_and_who_are_treated_with_gefitinib_may_be_more_likely_have_increased_response_rate_(RR)_and_increased_progression-free_survival_(PFS)_time_compared_to_patients_who_have_no_somatic_mutation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568_mutation_bearing_patients_are_presented_here_as_GT_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome._""TT:Patients_without_an_activating_somatic_EGFR_mutation_who_have_advanced_non-small-cell_lung_cancer_and_who_are_treated_with_gefitinib_may_be_more_likely_have_decreased_response_rate_(RR)_and_decreased_progression-free_survival_(PFS)_time_compared_to_patients_who_have_activating_somatic_mutation._The_manuscripts_where_this_annotation_derived_from_presented_the_results_according_to_activating_somatic_EGFR_mutation_status_regardless_of_the_mutation_type_therefore_the_rs121434568_(L858R)_exon_19_deletion(s)_and_other_activating_somatic_mutations_were_included_in_mutation_positive_group_and_combined_under_rs121434568._Patients_who_have_no_mutation_are_presented_here_as_TT_genotype._Very_few_of_the_patients_have_more_than_one_type_of_somatic_mutation._None_of_the_studies_mentioned_status_for_heterozygosity_or_homozygocity._Other_genetic_demographic_and_environmental_parameters_may_affect_the_treatment_outcome.";PGKB_RACE=NR,NR,NR,NR
7	55268916	rs2293347	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=EGFR_(PA7360);PGKB_DRUG=fluorouracil_(PA128406956);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Stomach_Neoplasms_(PA445742);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_gastric_cancer_may_have_a_poorer_response_when_treated_with_fluorouracil_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._""CT:Patients_with_the_CT_genotype_and_gastric_cancer_may_have_a_better_response_when_treated_with_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._""TT:Patients_with_the_TT_genotype_and_gastric_cancer_may_have_a_better_response_when_treated_with_fluorouracil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._";PGKB_RACE=NR
7	70738729	rs7794356	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=WBSCR17_(PA38124);PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_an_increased_response_to_montelukast_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_Asthma.""AG:Patients_with_asthma_and_the_AG_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_AA_genotype_and_an_increased_response_to_GG_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_Asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_AA_and_AG_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_Asthma.";PGKB_RACE=NR
7	75615006	rs1057868	C	T	.	.	PGKB_INDEX=4;PGKB_GENE=POR_(PA33532),POR_(PA33532),POR_(PA33532),POR_(PA33532);PGKB_DRUG=tacrolimus_(PA451578),midazolam_(PA450496),cyclosporine_(PA449167),atorvastatin_(PA448500);PGKB_TYPE="Dosage""Toxicity/ADR",Other,Metabolism/PK,Efficacy;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),NR,Kidney_Transplantation_(PA165817016),familial_hypercholesterolemia_(PA166114942);PGKB_TEXT="CC:Patients_with_the_CC_(POR_*1/*1)_genotype_and_Kidney_Transplantation_who_are_treated_with_tacrolimus_1)_may_have_a_decreased_but_not_absent_risk_for_developing_new-onset_diabetes_after_transplantation_2)_in_combination_with_the_CYP3A5_expressors_genotype_*1/*1_or_*1/*3_(rs776746)_may_require_a_decreased_dose_of_tacrolimus_as_compared_to_patients_with_the_CT_and_TT_(*1/*28_and_*28/*28)_genotype_however_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus._""CT:Patients_with_the_CT_(POR_*1/*28)_genotype_and_Kidney_Transplantation_who_are_treated_with_tacrolimus_1)_may_have_an_increased_risk_for_developing_new-onset_diabetes_after_transplantation_2)_in_combination_with_the_CYP3A5_expressors_genotype_*1/*1_or_*1/*3_(rs776746)_may_require_an_increased_dose_of_tacrolimus_as_compared_to_patients_with_the_CC_(*1/*1)_genotype_however_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus._""TT:Patients_with_the_TT_(POR_*28/*28)_genotype_and_Kidney_Transplantation_who_are_treated_with_tacrolimus_1)_may_have_an_increased_risk_for_developing_new-onset_diabetes_after_transplantation_2)_in_combination_with_the_CYP3A5_expressors_genotype_*1/*1_or_*1/*3_(rs776746)_may_require_an_increased_dose_of_tacrolimus_as_compared_to_patients_with_the_CC_(*1/*1)_genotype_however_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus._","CC:Patients_with_the_CC_genotype_may_have_an_decreased_metabolic_ratio_of_midazolam_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported_with_an_increased_metabolic_ratio_of_midazolam_as_compared_to_patients_with_the_CT_genotype_in_CYP3A5*1_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_midazolam.""CT:Patients_with_the_TC_genotype_may_have_a_decreased_metabolic_ratio_of_midazolam_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported_with_a_decreased_metabolic_ratio_of_midazolam_as_compared_to_patients_with_the_CC_genotype_in_CYP3A5*1_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_midazolam.""TT:Patients_with_the_TT_genotype_may_have_an_increased_metabolic_ratio_of_midazolam_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_midazolam.","CC:Patients_with_the_CC_genotype_undergoing_kidney_transplantation_who_are_CYP3A5_nonexpressers_(CYP3A5_*1/*3_or_*3/*3)_and_who_do_not_carry_the_CYP3A4*22_(rs35599367_A)_allele_may_have_increased_trough_concentrations_of_cyclosporine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_and_CYP3A4*22_may_also_influence_cyclosporine_concentrations.""CT:Patients_with_the_CT_genotype_undergoing_kidney_transplantation_who_are_CYP3A5_nonexpressers_(CYP3A5_*1/*3_or_*3/*3)_and_who_do_not_carry_the_CYP3A4*22_(rs35599367_A)_allele_may_have_increased_trough_concentrations_of_cyclosporine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_and_CYP3A4*22_may_also_influence_cyclosporine_concentrations.""TT:Patients_with_the_TT_genotype_undergoing_kidney_transplantation_who_are_CYP3A5_nonexpressers_(CYP3A5_*1/*3_or_*3/*3)_and_who_do_not_carry_the_CYP3A4*22_(rs35599367_A)_allele_may_have_decreased_trough_concentrations_of_cyclosporine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_and_CYP3A4*22_may_also_influence_cyclosporine_concentrations.","CC:Patients_with_the_CC_genotype_(POR_*1/*1)_and_familial_hypercholesterolemia_may_have_a_greater_decrease_in_total_cholesterol_and_low-density_lipoprotein_cholesterol_when_treated_with_atorvastatin_as_compared_to_patients_with_the_CT_(*1/*28)_or_TT_(*28/*28)_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atorvastatin.""CT:Patients_with_the_CT_genotype_(POR_*1/*28)_and_familial_hypercholesterolemia_may_have_a_lower_decrease_in_total_cholesterol_and_low-density_lipoprotein_cholesterol_when_treated_with_atorvastatin_as_compared_to_patients_with_the_CC_genotype_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_response_to_atorvastatin.""TT:Patients_with_the_TT_genotype_(POR_*28/*28)_and_familial_hypercholesterolemia_may_have_a_lower_decrease_in_total_cholesterol_and_low-density_lipoprotein_cholesterol_when_treated_with_atorvastatin_as_compared_to_patients_with_the_CC_genotype_(POR_*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_response_to_atorvastatin.";PGKB_RACE=NR,NR,NR,White
7	80532112	rs7779029	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SEMA3C_(PA35647);PGKB_DRUG=irinotecan_(PA450085);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_severity_of_Neutropenia_when_treated_with_irinotecan_in_people_with_Carcinoma_Non-Small-Cell_Lung_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_toxicity_to_irinotecan.""CT:Patients_with_the_CT_genotype_may_have_increased_severity_of_Neutropenia_when_treated_with_irinotecan_in_people_with_Carcinoma_Non-Small-Cell_Lung_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_toxicity_to_irinotecan.""TT:Patients_with_the_TT_genotype_may_have_decreased_severity_of_Neutropenia_when_treated_with_irinotecan_in_people_with_Carcinoma_Non-Small-Cell_Lung_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_or_clinical_factors_may_also_influence_the_toxicity_to_irinotecan.";PGKB_RACE=Asian
7	86272016	rs274618	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=GRM3_(PA28992);PGKB_DRUG=heroin_(PA452619);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Heroin_Dependence_(PA444460);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.""AT:Patients_with_the_AT_genotype_may_have_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.";PGKB_RACE=Asian
7	86313074	rs1990040	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=GRM3_(PA28992);PGKB_DRUG=heroin_(PA452619);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Heroin_Dependence_(PA444460);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.""AG:Patients_with_the_AG_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_AA_genotype_and_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.";PGKB_RACE=Asian
7	86314420	rs13242038	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=GRM3_(PA28992);PGKB_DRUG=heroin_(PA452619);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Heroin_Dependence_(PA444460);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence._""CT:Patients_with_the_CT_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_TT_genotype_and_an_increased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence._""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence._";PGKB_RACE=Asian
7	86325374	rs724226	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=GRM3_(PA28992),GRM3_(PA28992);PGKB_DRUG=risperidone_(PA451257),heroin_(PA452619);PGKB_TYPE=Efficacy,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Heroin_Dependence_(PA444460);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""AG:Patients_with_the_AG_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.","AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence._""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence._""GG:Patients_with_the_GG_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_when_exposed_to_heroin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence._";PGKB_RACE=NR,Asian
7	86331756	rs2189814	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GRM3_(PA28992);PGKB_DRUG=heroin_(PA452619);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Heroin_Dependence_(PA444460);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_TT_genotype_and_an_increased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_Heroin_Dependence_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_Heroin_Dependence.";PGKB_RACE=Asian
7	86403475	rs6465084	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=GRM3_(PA28992);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_better_response_according_to_the_Brief_Psychiatric_Rating_Scale_(BPRS)_negative_symptoms_subscale_as_compared_to_patients_with_the_AG_or_GG_genotype._However_a_different_study_found_that_the_AA_genotype_was_associated_with_poorer_response_according_to_the_clinical_global_impressions_(CGI)_score_though_this_association_did_not_withstand_correction_for_multiple_testing._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment.""AG:Patients_with_the_AG_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_poorer_response_according_to_the_Brief_Psychiatric_Rating_Scale_(BPRS)_negative_symptoms_subscale_as_compared_to_patients_with_the_AA_genotype._However_a_different_study_found_that_the_AG_genotype_was_associated_with_better_response_according_to_the_clinical_global_impressions_(CGI)_score_though_this_association_did_not_withstand_correction_for_multiple_testing._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_poorer_response_according_to_the_Brief_Psychiatric_Rating_Scale_(BPRS)_negative_symptoms_subscale_as_compared_to_patients_with_the_AA_genotype._However_a_different_study_found_that_the_GG_genotype_was_associated_with_better_response_according_to_the_clinical_global_impressions_(CGI)_score_though_this_association_did_not_withstand_correction_for_multiple_testing._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotic_treatment.";PGKB_RACE=NR
7	86433451	rs1468412	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=GRM3_(PA28992);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_decreased_but_not_absent_risk_for_worsening_of_working_memory_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_worsening_working_memory._""AT:Patients_with_the_AT_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_a_decreased_but_not_absent_risk_for_worsening_of_working_memory_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_worsening_working_memory._""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_antipsychotics_may_have_an_increased_risk_for_worsening_of_working_memory_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_worsening_working_memory._";PGKB_RACE=NR
7	87133366	rs3842	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG=efavirenz_(PA449441);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_CC_genotype_and_HIV_infection_may_have_increased_exposure_to_efavirenz_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_efavirenz_and_patient's_exposure_to_the_drug.""CT:Patients_with_the_CT_genotype_and_HIV_infection_may_have_increased_exposure_to_efavirenz_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_efavirenz_and_patient's_exposure_to_the_drug.""TT:Patients_with_the_TT_genotype_and_HIV_infection_have_decreased_exposure_to_efavirenz_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_efavirenz_and_patient's_exposure_to_the_drug.";PGKB_RACE=NR
7	87138645	rs1045642	A	T,G	.	.	PGKB_INDEX=64;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=talinolol_(PA146123005),atorvastatin_(PA448500),simvastatin_(PA451363),"lamivudine_(PA450163)""lopinavir_(PA450264)""ritonavir_(PA451260)""zidovudine_(PA451954)",tamoxifen_(PA451581),oxaliplatin_(PA131285527),simvastatin_(PA451363),"anthracyclines_and_related_substances_(PA130620651)""taxanes_(PA150481189)",atorvastatin_(PA448500),ondansetron_(PA450705),verapamil_(PA451868),sirolimus_(PA451365),methotrexate_(PA450428),"efavirenz_(PA449441)""nelfinavir_(PA450606)",fexofenadine_(PA449621),"anthracyclines_and_related_substances_(PA130620651)""cytarabine_(PA449177)""doxorubicin_(PA449412)""epirubicin_(PA449476)""idarubicin_(PA449961)",nevirapine_(PA450616),"prednisone_(PA451100)""tacrolimus_(PA451578)",nortriptyline_(PA450657),"lansoprazole_(PA450180)""tacrolimus_(PA451578)",antiepileptics_(PA143485705),carbamazepine_(PA448785),"dexamethasone_(PA449247)""doxorubicin_(PA449412)""vincristine_(PA451879)",rhodamine_123_(PA165110729),capecitabine_(PA448771),paclitaxel_(PA450761),paclitaxel_(PA450761),phenytoin_(PA450947),cyclosporine_(PA449167),digoxin_(PA449319),"cisplatin_(PA449014)""fluorouracil_(PA128406956)",fluorouracil_(PA128406956),dicloxacillin_(PA164749649),phenytoin_(PA450947),clopidogrel_(PA449053),hmg_coa_reductase_inhibitors_(PA133950441),efavirenz_(PA449441),morphine_(PA450550),tacrolimus_(PA451578),imatinib_(PA10804),sorafenib_(PA7000),modafinil_(PA450530),venlafaxine_(PA451866),Selective_serotonin_reuptake_inhibitors_(PA164713257),silibinin_(PA166129539),daptomycin_(PA164768820),morphine_(PA450550),methotrexate_(PA450428),opioids_(PA452618),"omeprazole_(PA450704)""pantoprazole_(PA450774)",codeine_(PA449088),"fentanyl_(PA449599)""methadone_(PA450401)""morphine_(PA450550)""opioids_(PA452618)""oxycodone_(PA450741)""tramadol_(PA451735)",etoposide_(PA449552),phenobarbital_(PA450911),"methylprednisolone_(PA450466)""prednisolone_(PA451096)","atazanavir_(PA10251)""ritonavir_(PA451260)",olanzapine_(PA450688),tacrolimus_(PA451578),tacrolimus_(PA451578),tacrolimus_(PA451578),risperidone_(PA451257),sunitinib_(PA162372840),carbamazepine_(PA448785),vincristine_(PA451879);PGKB_TYPE=Other,Toxicity/ADR,Toxicity/ADR,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Other,Toxicity/ADR,Toxicity/ADR,"Efficacy""Toxicity/ADR",Dosage,Efficacy,Toxicity/ADR,Other,Toxicity/ADR,Metabolism/PK,Efficacy,Efficacy,Efficacy,Other,Toxicity/ADR,Toxicity/ADR,Efficacy,Dosage,Metabolism/PK,Other,Efficacy,Toxicity/ADR,Other,Efficacy,"Efficacy""Toxicity/ADR",Other,Other,Efficacy,"Dosage""Metabolism/PK",Efficacy,Toxicity/ADR,Efficacy,Efficacy,Efficacy,Metabolism/PK,Metabolism/PK,Other,Toxicity/ADR,Other,Efficacy,Toxicity/ADR,Dosage,Metabolism/PK,Efficacy,Toxicity/ADR,Other,Other,Efficacy,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,"Dosage""Metabolism/PK",Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3,3,3,3,2A,3,3,3,3,3,3,2A,3,3,3,3,3,3,4,3,3,3,3,3,2A,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,2A,3,3,3,2B,3,3,3,3,3,3,3,3,3,3,3,3;PGKB_DISEASE=NR,"Coronary_Artery_Disease_(PA443796)""Myalgia_unspecified_(PA157379134)","Hypercholesterolemia_(PA444516)""Myalgia_unspecified_(PA157379134)",HIV_(PA447230),Breast_Neoplasms_(PA443560),Colorectal_Neoplasms_(PA446108),NR,Breast_Neoplasms_(PA443560),Coronary_Artery_Disease_(PA443796),NR,NR,Kidney_Transplantation_(PA165817016),Arthritis_Rheumatoid_(PA443434),HIV_(PA447230),NR,"Breast_Neoplasms_(PA443560)""Leukemia_Myeloid_Acute_(PA444760)""Multiple_Myeloma_(PA444985)",HIV_Infections_(PA446213),"Organ_Transplantation_(PA133888799)""Transplantation_(PA134850491)","Depression_(PA447278)""Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)""Hypotension_(PA444584)","Gastroesophageal_Reflux_(PA444255)""Transplantation_(PA134850491)",Epilepsy_(PA444065),Epilepsy_(PA444065),Multiple_Myeloma_(PA444985),NR,Neoplasms_(PA445062),"Neoplasms_(PA445062)""Neurotoxicity_Syndromes_(PA446975)""Neutropenia_(PA445113)",Breast_Neoplasms_(PA443560),NR,Transplantation_(PA134850491),NR,Esophageal_Neoplasms_(PA444101),Colorectal_Neoplasms_(PA446108),NR,Epilepsy_(PA444065),"Acute_coronary_syndrome_(PA165108401)""Myocardial_Infarction_(PA445019)",NR,HIV_Infections_(PA446213),Pain_(PA445208),Organ_Transplantation_(PA133888799),Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171),"Carcinoma_Renal_Cell_(PA443624)""Hypertension_(PA444552)",Narcolepsy_(PA445042),"Depressive_Disorder_(PA447207)""Narcolepsy_(PA445042)",Depressive_Disorder_(PA447207),NR,NR,Pain_(PA445208),"Burkitt_Lymphoma_(PA443580)""Drug_Toxicity_(PA443937)""Lymphoma_T-Cell_(PA446309)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)""Toxic_liver_disease_(PA164925725)",Opioid-Related_Disorders_(PA445043),Helicobacter_Infections_(PA166048740),NR,Pain_(PA445208),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Epilepsy_(PA444065),Kidney_Transplantation_(PA165817016),HIV_(PA447230),Psychotic_Disorders_(PA447215),Colitis_Ulcerative_(PA443750),Kidney_Transplantation_(PA165817016),Kidney_Transplantation_(PA165817016),Schizophrenia_(PA447216),Carcinoma_Renal_Cell_(PA443624),Epilepsy_(PA444065),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_clearance_of_talinolol_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_talinolol.""AG:Patients_with_the_AG_genotype_may_have_decreased_clearance_of_talinolol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_talinolol.""GG:Patients_with_the_GG_genotype_may_have_decreased_clearance_of_talinolol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_talinolol.","AA:Patients_with_the_AA_genotype_and_Coronary_Artery_Disease_who_are_treated_with_atorvastatin_may_have_a_higher_likelihood_of_developing_myalgia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_atorvastatin-induced_myalgia.""AG:Patients_with_the_AG_genotype_and_Coronary_Artery_Disease_who_are_treated_with_atorvastatin_may_have_a_higher_likelihood_of_developing_myalgia_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_lower_likelihood_of_developing_myalgia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_atorvastatin-induced_myalgia.""GG:Patients_with_the_GG_genotype_and_Coronary_Artery_Disease_who_are_treated_with_atorvastatin_may_have_a_lower_likelihood_of_developing_myalgia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_atorvastatin-induced_myalgia.","AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_reduced_risk_of_developing_myalgia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_myalgia.""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_reduced_risk_of_developing_myalgia_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_higher_risk_of_developing_myalgia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_myalgia.""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_higher_risk_of_developing_myalgia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_myalgia.","AA:Patients_with_the_AA_genotype_and_HIV_may_have_a_decreased_risk_of_virological_failure_when_receiving_highly_active_antiretroviral_therapy_(HAART)_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_virological_failure_on_HAART.""AG:Patients_with_the_AG_genotype_and_HIV_may_have_an_increased_risk_of_virological_failure_when_receiving_highly_active_antiretroviral_therapy_(HAART)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_virological_failure_on_HAART.""GG:Patients_with_the_GG_genotype_and_HIV_may_have_an_increased_risk_of_virological_failure_when_receiving_highly_active_antiretroviral_therapy_(HAART)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_virological_failure_on_HAART.","AA:Women_with_the_AA_genotype_and_breast_cancer_may_have_a_decreased_chance_of_disease_recurrence_when_treated_with_tamoxifen_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_breast_cancer_recurrence.""AG:Women_with_the_AG_genotype_and_breast_cancer_may_have_an_increased_chance_of_disease_recurrence_when_treated_with_tamoxifen_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_breast_cancer_recurrence.""GG:Women_with_the_GG_genotype_and_breast_cancer_may_have_a_decreased_chance_of_disease_recurrence_when_treated_with_tamoxifen_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_breast_cancer_recurrence.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_a_shorter_period_of_recurrence-free_survival_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_a_longer_period_of_recurrence-free_survival_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_did_not_have_a_statistically_significant_different_period_of_recurrence-free_survival_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","AA:Patients_with_the_AA_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_to_treatment_(measured_by_a_higher_reduction_in_total_cholesterol)_compared_to_patients_with_the_GG_genotype._In_another_study_no_association_was_seen._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AG:Patients_with_the_AG_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_to_treatment_(measured_by_a_higher_reduction_in_total_cholesterol)_compared_to_patients_with_the_GG_genotype_or_may_have_a_reduced_response_(measured_by_a_lower_reduction_in_total_cholesterol)_as_compared_to_patients_with_the_AA_genotype._In_another_study_no_association_was_seen._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_simvastatin_may_have_a_reduced_response_to_treatment_(measured_by_a_lower_reduction_in_total_cholesterol)_compared_to_patients_with_the_AA_genotype._In_another_study_no_association_was_seen._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_complete_response_when_treated_with_anthracyclines_and_related_substances_and_taxanes_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines_and_related_substances_and_taxanes.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_complete_response_when_treated_with_anthracyclines_and_related_substances_and_taxanes_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines_and_related_substances_and_taxanes.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_complete_response_when_treated_with_anthracyclines_and_related_substances_and_taxanes_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines_and_related_substances_and_taxanes.","AA:Patients_with_the_AA_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_(as_measured_by_an_increased_reduction_in_LDL-cholesterol_or_total_cholesterol)_compared_to_patients_with_the_GG_genotype._Some_studies_find_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""AG:Patients_with_the_AA_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_(as_measured_by_an_increased_reduction_in_LDL-cholesterol_or_total_cholesterol)_as_compared_to_patients_with_the_GG_genotype._Some_studies_find_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_to_treatment_(as_measured_by_a_lower_reduction_in_LDL-cholesterol_or_total_cholesterol)_as_compared_to_patients_with_the_AG_or_AA_genotype._Some_studies_find_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","AA:Patients_with_genotype_AA_may_have_decreased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_ondansetron_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""AG:Patients_with_genotype_AG_may_have_increased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_treated_with_ondansetron_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""GG:Patients_with_genotype_GG_may_have_increased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_treated_with_ondansetron_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.","AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_verapamil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_verapamil.""AG:Patients_with_the_AG_genotype_may_have_increased_metabolism_of_verapamil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_verapamil.""GG:Patients_with_the_GG_genotype_may_have_decreased_metabolism_of_verapamil_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_verapamil.","AA:Patients_with_the_AA_genotype_who_underwent_kidney_transplantation_may_have_increased_total_and_low-density_lipoprotein_cholesterol_when_treated_with_sirolimus_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_total_and_low-density_lipoprotein_cholesterol_levels._""AG:Patients_with_the_AG_genotype_who_underwent_kidney_transplantation_may_have_increased_total_and_low-density_lipoprotein_cholesterol_when_treated_with_sirolimus_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_total_and_low-density_lipoprotein_cholesterol_levels._""GG:Patients_with_the_GG_genotype_who_underwent_kidney_transplantation_may_have_decreased_total_and_low-density_lipoprotein_cholesterol_when_treated_with_sirolimus_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_total_and_low-density_lipoprotein_cholesterol_levels._","AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_GG_genotype._However_one_study_found_an_increased_risk_of_adverse_drug_events_for_carriers_of_the_A_allele_though_this_was_not_significant_after_multiple_comparison_correction._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_drug_events_when_treated_with_methotrexate.""AG:Patients_with_the_AG_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_GG_genotype_although_one_study_found_that_the_AG_genotype_was_associated_with_an_increased_likelihood_of_GI_toxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_drug_events_when_treated_with_methotrexate.""GG:Patients_with_the_GG_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_AA_or_AG_genotype._However_one_study_found_a_decreased_risk_of_adverse_drug_events_for_carriers_of_the_G_allele_though_this_was_not_significant_after_multiple_comparison_correction._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_drug_events_when_treated_with_methotrexate.","AA:Patients_with_the_AA_genotype_and_HIV_who_are_treated_with_nelfinavir_and_efavirenz:_1)_May_have_increased_CD4-cell_count_as_compared_to_patients_with_the_GA_and_GG_genotype_2)_May_have_increased_virologic_response_as_compared_to_patients_with_the_GA_and_GG_genotype_3)_May_have_an_increased_risk_for_toxicity-related_failure_as_compared_to_patients_with_the_GA_and_GG_genotype_4)_May_have_a_decreased_but_not_absent_risk_of_hepatotoxicity_as_compared_to_patients_with_the_GA_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_response_or_risk_for_toxicity.""AG:Patients_with_the_GA_genotype_and_HIV_who_are_treated_with_nelfinavir_and_efavirenz:_1)_May_have_decreased_CD4-cell_count_as_compared_to_patients_with_the_AA_genotype_2)_May_have_decreased_virologic_response_as_compared_to_patients_with_the_AA_genotype_3)_May_have_a_decreased_but_not_absent_risk_for_toxicity-related_failure_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_response_or_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_and_HIV_who_are_treated_with_nelfinavir_and_efavirenz:_1)_May_have_decreased_CD4-cell_count_as_compared_to_patients_with_the_AA_genotype_2)_May_have_decreased_virologic_response_as_compared_to_patients_with_the_AA_genotype_3)_May_have_a_decreased_but_not_absent_risk_for_toxicity-related_failure_as_compared_to_patients_with_the_AA_genotype_4)_May_have_an_increased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_response_or_risk_for_toxicity.","AA:Healthy_individuals_with_the_AA_genotype_who_are_treated_with_fexofenadine_may_have_lower_plasma_drug_levels_as_compared_to_healthy_individuals_with_the_AG_or_GG_genotype._Another_study_found_no_association_with_fexofenadine_plasma_concentrations._Other_genetic_and_clinical_factors_may_also_influence_plasma_concentrations_of_fexofenadine_and_dose_requirements.""AG:Healthy_individuals_with_the_AG_genotype_who_are_treated_with_fexofenadine_may_have_higher_plasma_drug_levels_as_compared_to_healthy_individuals_with_the_AA_genotype._Another_study_found_no_association_with_fexofenadine_plasma_concentrations._Other_genetic_and_clinical_factors_may_also_influence_plasma_concentrations_of_fexofenadine_and_dose_requirements.""GG:Healthy_individuals_with_the_GG_genotype_who_are_treated_with_fexofenadine_may_have_higher_plasma_drug_levels_as_compared_with_healthy_individuals_with_the_AA_genotype._Another_study_found_no_association_with_fexofenadine_plasma_concentrations._Other_genetic_and_clinical_factors_may_also_influence_plasma_concentrations_of_fexofenadine_and_dose_requirements.","AA:Patients_with_the_AA_genotype_may_have_1)_increased_exposure_to_doxorubicin_metabolites_and_2)_increased_response_to_anthracycline_regimens_as_compared_to_patients_with_the_GG_genotype_however_the_evidence_is_highly_contradictory._Other_genetic_and_clinical_factors_may_also_influence_response_to_anthracycline_regimens.""AG:Patients_with_the_AG_genotype_may_have_1)_decreased_exposure_to_doxorubicin_metabolites_and_2)_decreased_response_to_anthracycline_regimens_as_compared_to_patients_with_the_AA_genotype_however_the_evidence_is_highly_contradictory_and_analysis_of_the_heterozygote_is_limited._Other_genetic_and_clinical_factors_may_also_influence_response_to_anthracycline_regimens.""GG:Patients_with_the_GG_genotype_may_have_1)_decreased_exposure_to_doxorubicin_metabolites_and_2)_decreased_response_to_anthracycline_regimens_as_compared_to_patients_with_the_AA_genotype_however_the_evidence_is_highly_contradictory._Other_genetic_and_clinical_factors_may_also_influence_response_to_anthracycline_regimens.","AA:Patients_with_the_AA_genotype_and_HIV-1_infection_who_are_treated_with_nevirapine_may_have_a_decreased_but_not_absent_risk_for_nevirapine_hepatotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatotoxicity_with_nevirapine_treatment.""AG:While_patients_with_the_AA_genotype_and_HIV-1_infection_who_are_treated_with_nevirapine_may_have_a_decreased_but_not_absent_risk_for_nevirapine_hepatotoxicity_as_compared_to_patients_with_the_GG_genotype_it_is_not_clear_what_the_influence_of_one_A_allele_with_the_G_allele_is._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatotoxicity_with_nevirapine_treatment.""GG:Patients_with_the_GG_genotype_and_HIV-1_infection_who_are_treated_with_nevirapine_may_have_an_increased_risk_for_nevirapine_hepatotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatotoxicity_with_nevirapine_treatment.","AA:Pediatric_patients_with_the_AA_genotype_who_are_treated_with_prednisone_and_tacrolimus_may_have_a_decreased_risk_of_remaining_on_steroids_1_year_after_heart_transplantation_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_remaining_on_steroids_1_year_after_transplantation.""AG:Pediatric_patients_with_the_AG_genotype_who_are_treated_with_prednisone_and_tacrolimus_may_have_a_decreased_risk_of_remaining_on_steroids_1_year_after_heart_transplantation_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_remaining_on_steroids_1_year_after_transplantation.""GG:Pediatric_patients_with_the_GG_genotype_who_are_treated_with_prednisone_and_tacrolimus_may_have_an_increased_risk_of_remaining_on_steroids_1_year_after_heart_transplantation_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_remaining_on_steroids_1_year_after_transplantation.","AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_nortriptyline_may_have_a_higher_likelihood_to_develop_postural_hypotension_as_compared_to_patients_with_the_GG_or_GA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_postural_hypotension_with_nortriptyline_treatment.""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_nortriptyline_may_have_a_decreased_but_not_absent_likelihood_to_develop_postural_hypotension_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_postural_hypotension_with_nortriptyline_treatment.""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_nortriptyline_may_have_a_decreased_but_not_absent_likelihood_to_develop_postural_hypotension_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_postural_hypotension_with_nortriptyline_treatment.","AA:Patients_with_the_AA_genotype_who_are_CYP2C19_extensive_metabolizers_and_are_receiving_tacrolimus_after_renal_transplantation_may_have_decreased_plasma_concentrations_of_(R)-lansoprazole_but_no_significant_differences_in_the_frequency_of_gastroesophageal_symptoms_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_lansoprazole_clearance.""AG:Patients_with_the_AG_genotype_who_are_CYP2C19_extensive_metabolizers_and_are_receiving_tacrolimus_after_renal_transplantation_may_have_increased_plasma_concentrations_of_(R)-lansoprazole_but_no_significant_differences_in_the_frequency_of_gastroesophageal_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_lansoprazole_clearance.""GG:Patients_with_the_GG_genotype_who_are_CYP2C19_extensive_metabolizers_and_are_receiving_tacrolimus_after_renal_transplantation_may_have_increased_plasma_concentrations_of_(R)-lansoprazole_but_no_significant_differences_in_the_frequency_of_gastroesophageal_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_lansoprazole_clearance.","AA:Genotype_AA_may_be_associated_with_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_in_people_with_Epilepsy_in_Asian_as_compared_to_genotype_GG._However_this_finding_has_been_contradicted_with_many_studies_reporting_no_association_between_this_variant_and_response_to_antiepileptics._There's_also_a_report_showing_that_genotype_GG_is_associated_with_increased_likelihood_of_drug-resistance_when_treated_with_antiepileptics_as_compared_to_genotype_AA_in_Caucasian_patients._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_antiepileptics.""AG:Genotype_AG_may_be_associated_with_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_in_people_with_Epilepsy_in_Asian_as_compared_to_genotype_GG._However_this_finding_has_been_contradicted_with_many_studies_reporting_no_association_between_this_variant_and_response_to_antiepileptics._There's_also_a_report_showing_that_genotype_GG_is_associated_with_increased_likelihood_of_drug-resistance_when_treated_with_antiepileptics_as_compared_to_genotype_AA_in_Caucasian_patients._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_antiepileptics.""GG:Genotype_GG_genotype_may_be_associated_with_decreased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_in_people_with_Epilepsy_in_Asian_as_compared_to_genotype_AA._However_this_finding_has_been_contradicted_with_many_studies_reporting_no_association_between_this_variant_and_response_to_antiepileptics._There's_also_a_report_showing_that_genotype_GG_is_associated_with_increased_likelihood_of_drug-resistance_when_treated_with_antiepileptics_as_compared_to_genotype_AA_in_Caucasian_patients._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_antiepileptics.","AA:Patient_with_genotype_AA_may_have_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GG._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_response_to_carbamazepine.""AG:Patient_with_genotype_AG_may_have_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GG._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_response_to_carbamazepine.""GG:Patient_with_genotype_GG_may_have_decreased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_AA._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_response_to_carbamazepine.","AA:Patients_with_the_AA_genotype_may_have_increased_survival_when_treated_with_dexamethasone_doxorubicin_and_vincristine_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_dexamethasone_doxorubicin_and_vincristine.""AG:Patients_with_the_AG_genotype_may_have_increased_survival_when_treated_with_dexamethasone_doxorubicin_and_vincristine_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_dexamethasone_doxorubicin_and_vincristine.""GG:Patients_with_the_GG_genotype_may_have_decreased_survival_when_treated_with_dexamethasone_doxorubicin_and_vincristine_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_influence_the_patient's_response_to_dexamethasone_doxorubicin_and_vincristine.","AA:Genotype_AA_may_be_associated_with_decreased_efflux_of_rhodamine_from_CD56+_natural_killer_cells_when_exposed_to_rhodamine_123_as_compared_to_genotypes_GG._However_contradictory_finding_has_been_reported.""AG:Genotype_AG_may_be_associated_with_decreased_efflux_of_rhodamine_from_CD56+_natural_killer_cells_when_exposed_to_rhodamine_123_as_compared_to_genotypes_GG._However_contradictory_finding_has_been_reported.""GG:Genotype_GG_may_be_associated_with_increased_efflux_of_rhodamine_from_CD56+_natural_killer_cells_when_exposed_to_rhodamine_123_as_compared_to_genotypes_AA_+_AG._However_contradictory_finding_has_been_reported.","AA:Patients_with_AA_genotype_may_have_decreased_risk_of_hand-foot_syndrome_when_treated_with_capecitabine_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_GG._Genotypes_AG_+_GG_are_not_associated_with_decreased_clinical_outcome_when_treated_with_capecitabine_cisplatin_docetaxel_epirubicin_and_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_influence_the_response_to_capecitabine.""AG:Patients_with_AG_genotype_may_have_increased_risk_of_hand-foot_syndrome_when_treated_with_capecitabine_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Genotypes_AG_+_GG_are_not_associated_with_decreased_clinical_outcome_when_treated_with_capecitabine_cisplatin_docetaxel_epirubicin_and_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_influence_the_response_to_capecitabine.""GG:Patients_with_GG_genotype_may_have_increased_risk_of_hand-foot_syndrome_when_treated_with_capecitabine_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Genotypes_AG_+_GG_are_not_associated_with_decreased_clinical_outcome_when_treated_with_capecitabine_cisplatin_docetaxel_epirubicin_and_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_influence_the_response_to_capecitabine.","AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Neutropenia_and_Neurotoxicity_Syndromes_when_treated_with_paclitaxel_in_cancer_patients_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_influence_the_risk_of_adverse_events_to_paclitaxel.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Neutropenia_and_Neurotoxicity_Syndromes_when_treated_with_paclitaxel_in_cancer_patients_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_influence_the_risk_of_adverse_events_to_paclitaxel.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Neutropenia_and_Neurotoxicity_Syndromes_when_treated_with_paclitaxel_in_cancer_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_influence_the_risk_of_adverse_events_to_paclitaxel.","AA:Genotype_AA_may_be_associated_with_decreased_disease_control_rate_and_lower_overall_survival_rate_when_treated_with_paclitaxel_in_Asians_with_metastatic_breast_cancer_as_compared_to_genotype_GG._However_contradictory_findings_have_been_reported_and_no_association_have_been_reported_for_Caucasians._Other_genetic_and_clinical_factors_may_influence_the_response_to_paclitaxel.""AG:Genotype_AG_may_be_associated_with_decreased_disease_control_rate_and_lower_overall_survival_rate_when_treated_with_paclitaxel_in_Asians_with_metastatic_breast_cancer_as_compared_to_genotype_GG._However_contradictory_findings_have_been_reported_and_no_association_have_been_reported_for_Caucasians._Other_genetic_and_clinical_factors_may_influence_the_response_to_paclitaxel.""GG:Genotype_GG_may_be_associated_with_increased_disease_control_rate_and_lower_overall_survival_rate_when_treated_with_paclitaxel_in_Asians_with_metastatic_breast_cancer_as_compared_to_genotype_AG._However_contradictory_findings_have_been_reported_and_no_association_have_been_reported_for_Caucasians._Other_genetic_and_clinical_factors_may_influence_the_response_to_paclitaxel.","AA:Patients_with_genotype_AA_may_have_increased_plasma_drug_levels_of_phenytoin_in_people_with_no_disease_as_compared_to_genotype_GG._However_another_study_reported_no_association_between_this_variant_and_increased_dose_of_phenytoin_in_people_with_Epilepsy._Other_genetic_and_clinical_factors_may_influence_a_patient's_dose_of_phenytoin.""AG:Patients_with_genotype_AG_may_have_increased_plasma_drug_levels_of_phenytoin_in_people_with_no_disease_as_compared_to_genotype_GG._However_another_study_reported_no_association_between_this_variant_and_increased_dose_of_phenytoin_in_people_with_Epilepsy._Other_genetic_and_clinical_factors_may_influence_a_patient's_dose_of_phenytoin.""GG:Patients_with_genotype_GG_may_have_decreased_plasma_drug_levels_of_phenytoin_in_people_with_no_disease_as_compared_to_genotype_AA._However_another_study_reported_no_association_between_this_variant_and_increased_dose_of_phenytoin_in_people_with_Epilepsy._Other_genetic_and_clinical_factors_may_influence_a_patient's_dose_of_phenytoin.","AA:Patients_with_genotype_AA_may_have_increased_intracellular_and_blood_concentrations_of_cyclosporine_in_people_with_Transplantation_as_compared_to_patients_with_genotype_GG._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_concentration_of_cyclosporine.""AG:Patients_with_genotype_AG_may_have_increased_intracellular_and_blood_concentrations_of_cyclosporine_in_people_with_Transplantation_as_compared_to_patients_with_genotype_GG._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_concentration_of_cyclosporine.""GG:Patients_with_genotype_GG_may_have_decreased_intracellular_and_blood_concentrations_of_cyclosporine_in_people_with_Transplantation_as_compared_to_patients_with_genotype_AA_or_AG._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_concentration_of_cyclosporine.","AA:Patients_with_AA_genotype_may_have_decreased_metabolism_and_increased_serum_concentration_of_digoxin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_digoxin.""AG:Patients_with_AG_genotype_may_have_decreased_metabolism_and_increased_serum_concentration_of_digoxin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_digoxin.""GG:Patients_with_GG_genotype_may_have_increased_metabolism_and_decreased_serum_concentration_of_digoxin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_digoxin.","AA:Patients_with_the_AA_genotype_may_have_a_decreased_risk_of_lymph_node_metastases_and_increased_survival_rate_when_treated_with_cisplatin_and_fluorouracil_in_people_with_Esophageal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_patients'_response_to_cisplatin_and_fluorouracil.""AG:Patients_with_the_AG_genotype_may_have_a_decreased_risk_of_lymph_node_metastases_and_an_increased_survival_rate_when_treated_with_cisplatin_and_fluorouracil_in_people_with_Esophageal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_patients'_response_to_cisplatin_and_fluorouracil.""GG:Patients_with_the_GG_genotype_may_have_unfavorable_prognosis_(increased_risk_of_lymph_node_metastases_and_decreased_survival_rate)_when_treated_with_cisplatin_and_fluorouracil_in_people_with_Esophageal_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_patients'_response_to_cisplatin_and_fluorouracil.","AA:Patients_with_AA_genotype_may_have_increased_risk_of_diarrhea_when_treated_with_fluorouracil_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_impact_a_patients_response_to_fluorouracil.""AG:Patients_with_AG_genotype_may_have_increased_risk_of_diarrhea_when_treated_with_fluorouracil_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_impact_a_patients_response_to_fluorouracil.""GG:Patients_with_GG_genotype_may_have_decreased_risk_of_diarrhea_when_treated_with_fluorouracil_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_impact_a_patients_response_to_fluorouracil.","AA:Genotype_AA_may_be_associated_with_decreased_clearance_of_dicloxacillin_when_treated_with_dicloxacillin_and_probenecid_as_compared_to_genotype_GG._however_another_report_showed_no_association_between_this_variant_and_PK_of_dicloxacillin._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_dicloxacillin.""AG:Genotype_AG_may_be_associated_with_decreased_clearance_of_dicloxacillin_when_treated_with_dicloxacillin_and_probenecid_as_compared_to_genotype_GG._however_another_report_showed_no_association_between_this_variant_and_PK_of_dicloxacillin._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_dicloxacillin.""GG:Genotype_GG_may_be_associated_with_increased_clearance_of_dicloxacillin_when_treated_with_dicloxacillin_and_probenecid_as_compared_to_genotype_AG._however_another_report_showed_no_association_between_this_variant_and_PK_of_dicloxacillin._Other_genetic_and_clinical_factors_may_also_influence_the_pharmacokinetics_of_dicloxacillin.","AA:Patients_with_genotype_AA_may_have_decreased_likelihood_of_drug_resistance_when_treated_with_phenytoin_in_African_American_with_Epilepsy_as_compared_to_patients_with_genotype_GG._However_no_association_have_been_found_between_this_variant_and_increased_response_to_carbamazepine_phenobarbital_phenytoin_and_valproic_acid_in_Asians._Other_genetic_or_clinical_factors_may_influence_a_patient's_response_to_phenytoin.""AG:Patients_with_genotype_AG_may_have_increased_likelihood_of_drug_resistance_when_treated_with_phenytoin_in_African_American_with_Epilepsy_as_compared_to_patients_with_genotype_AA._However_no_association_have_been_found_between_this_variant_and_increased_response_to_carbamazepine_phenobarbital_phenytoin_and_valproic_acid_in_Asians._Other_genetic_or_clinical_factors_may_influence_a_patient's_response_to_phenytoin.""GG:Patients_with_genotype_GG_may_have_increased_likelihood_of_drug_resistance_when_treated_with_phenytoin_in_African_American_with_Epilepsy_as_compared_to_patients_with_genotype_AA._However_no_association_have_been_found_between_this_variant_and_increased_response_to_carbamazepine_phenobarbital_phenytoin_and_valproic_acid_in_Asians._Other_genetic_or_clinical_factors_may_influence_a_patient's_response_to_phenytoin.","AA:People_with_AA_genotype_may_have_an_increased_risk_of_major_adverse_cardiovascular_events_(MACE_such_as_cardiovascular_death_myocardial_infarction_or_stroke)_when_treated_with_clopidogrel_in_people_with_Acute_coronary_syndrome_or_myocardial_Infarction_as_compared_to_people_with_genotypes_GG_or_AG._Contradictory_findings_have_been_reported_in_the_literature._Other_genetic_and_clinical_factors_may_also_impact_the_response_to_clopidogrel.""AG:People_with_AG_genotype_may_have_an_increased_risk_of_major_adverse_cardiovascular_events_(MACE_such_as_cardiovascular_death_myocardial_infarction_or_stroke)_when_treated_with_clopidogrel_in_people_with_acute_coronary_syndrome_or_myocardial_Infarction_as_compared_to_people_with_genotypes_GG._Contradictory_findings_have_been_reported_in_the_literature._Other_genetic_and_clinical_factors_may_also_impact_the_response_to_clopidogrel.""GG:People_with_GG_genotype_may_have_decreased_but_not_absent_risk_of_major_adverse_cardiovascular_events_(MACE_such_as_cardiovascular_death_myocardial_infarction_or_stroke)_when_treated_with_clopidogrel_in_people_with_acute_coronary_syndrome_or_myocardial_Infarction_as_compared_to_people_with_genotypes_AA._Contradictory_findings_have_been_reported_in_the_literature._Other_genetic_and_clinical_factors_may_also_impact_the_response_to_clopidogrel.","AA:Patients_with_the_AA_genotype_may_have_increased_serum_creatine_kinase_levels_when_treated_with_hmg_CoA_reductase_inhibitors_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_serum_creatine_kinase_levels._""AG:Patients_with_the_AG_genotype_may_have_decreased_serum_creatine_kinase_levels_when_treated_with_hmg_CoA_reductase_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_serum_creatine_kinase_levels._""GG:Patients_with_the_GG_genotype_may_have_decreased_serum_creatine_kinase_levels_when_treated_with_hmg_CoA_reductase_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_serum_creatine_kinase_levels._","AA:Patients_with_the_AA_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_increased_clearance_of_efavirenz_as_compared_to_patients_with_the_AG_or_GG_genotype._Some_studies_have_shown_no_association_between_this_polymorphism_and_efavirenz_clearance_plasma_concentrations_or_exposure_or_PBMC_concentrations._Other_genetic_and_clinical_factors_may_also_influence_efavirenz_pharmacokinetics._""AG:Patients_with_the_AG_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_increased_clearance_of_efavirenz_as_compared_to_patients_with_the_GG_genotype_and_may_have_reduced_clearance_of_efavirenz_as_compared_to_patients_with_the_AA_genotype._Some_studies_have_shown_no_association_between_this_polymorphism_and_efavirenz_clearance_plasma_concentrations_or_exposure_or_PBMC_concentrations._Other_genetic_and_clinical_factors_may_also_influence_efavirenz_pharmacokinetics._""GG:Patients_with_the_GG_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_reduced_clearance_of_efavirenz_as_compared_to_patients_with_the_AG_genotype._Some_studies_have_shown_no_association_between_this_polymorphism_and_efavirenz_clearance_plasma_concentrations_or_exposure_or_PBMC_concentrations._Other_genetic_and_clinical_factors_may_also_influence_efavirenz_pharmacokinetics._","AA:Patients_with_the_AA_genotype_may_have_increased_pain_reduction_when_treated_with_morphine_in_cancer_patients_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_response_to_morphine.""AG:Patients_with_the_AG_genotype_may_have_decreased_pain_reduction_when_treated_with_morphine_in_cancer_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_response_to_morphine.""GG:Patients_with_the_GG_genotype_may_have_decreased_pain_reduction_when_treated_with_morphine_in_cancer_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_response_to_morphine.","AA:Patients_with_the_AA_genotype_who_are_undergoing_organ_transplantation_may_have_decreased_clearance_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._However_the_vast_majority_of_studies_find_no_association_between_this_SNP_and_clearance_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_clearance_and_dose_of_tacrolimus._""AG:Patients_with_the_AG_genotype_who_are_undergoing_organ_transplantation_may_have_increased_clearance_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype_and_decreased_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_GG_genotype._However_the_vast_majority_of_studies_find_no_association_between_this_SNP_and_clearance_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_clearance_and_dose_of_tacrolimus._""GG:Patients_with_the_GG_genotype_who_are_undergoing_organ_transplantation_may_have_increased_clearance_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_AA_or_AG_genotype._However_the_vast_majority_of_studies_find_no_association_between_this_SNP_and_clearance_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_clearance_and_dose_of_tacrolimus._","AA:Patients_with_the_AA_genotype_and_chronic_myeloid_leukemia_may_have_a_decreased_likelihood_of_achieving_complete_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_GG_genotype._However_this_was_only_significant_in_an_exclusively_Caucasian_population._Additionally_no_significant_results_were_seen_when_considering_major_molecular_response._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_achieving_complete_molecular_response.""AG:Patients_with_the_AG_genotype_and_chronic_myeloid_leukemia_may_have_a_decreased_likelihood_of_achieving_complete_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_GG_genotype._However_this_was_only_significant_in_an_exclusively_Caucasian_population._Additionally_no_significant_results_were_seen_when_considering_major_molecular_response._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_achieving_complete_molecular_response.""GG:Patients_with_the_GG_genotype_and_chronic_myeloid_leukemia_may_have_an_increased_likelihood_of_achieving_complete_molecular_response_when_treated_with_imatinib_as_compared_to_patients_with_the_AA_or_AG_genotype._However_this_was_only_significant_in_an_exclusively_Caucasian_population._Additionally_no_significant_results_were_seen_when_considering_major_molecular_response._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_achieving_complete_molecular_response.","AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_hypertension_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_hypertension_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_hypertension_when_treated_with_sorafenib_in_people_with_Carcinoma_Renal_Cell_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_sorafenib.","AA:Patients_with_genotype_AA_and_narcolepsy_may_have_decreased_response_to_modafinil_compared_to_patients_with_genotype_AG._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_modafinil.""AG:Patients_with_genotype_AG_and_narcolepsy_may_have_increased_response_to_modafinil_compared_to_patients_with_genotypes_AA_or_GG._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_modafinil.""GG:Patients_with_genotype_GG_and_narcolepsy_may_have_decreased_response_to_modafinil_compared_to_patients_with_genotype_AG._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_modafinil.","AA:Patients_with_genotype_AA_and_depressive_disorder_may_have_decreased_response_to_venlafaxine_compared_to_patients_with_genotype_GG._Patients_with_AA_genotype_and_narcolepsy_were_not_found_to_have_different_response_to_venlafaxine_compared_to_patients_with_other_genotypes._Other_clinical_and_genetic_factors_also_may_affect_response_to_venlafaxine.""AG:Patients_with_genotype_AG_and_depressive_disorder_may_have_decreased_response_to_venlafaxine_compared_to_patients_with_genotype_GG._Patients_with_AG_genotype_and_narcolepsy_were_not_found_to_have_different_response_to_venlafaxine_compared_to_patients_with_other_genotypes._Other_clinical_and_genetic_factors_also_may_affect_response_to_venlafaxine.""GG:Patients_with_genotype_GG_and_depressive_disorder_may_have_increased_response_to_venlafaxine_compared_to_patients_with_genotype_AA_or_AG._Patients_with_GG_genotype_and_narcolepsy_were_not_found_to_have_different_response_to_venlafaxine_compared_to_patients_with_other_genotypes._Other_clinical_and_genetic_factors_also_may_affect_response_to_venlafaxine.","AA:Patients_with_the_AA_genotype_and_depressive_disorder_may_have_decreased_response_to_serotonin_reuptake_inhibitors_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_selective_serotonin_inhibitors.""AG:Patients_with_the_AG_genotype_and_depressive_disorder_may_have_decreased_response_to_serotonin_reuptake_inhibitors_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_selective_serotonin_inhibitors.""GG:Patients_with_the_GG_genotype_and_depressive_disorder_may_have_increased_response_to_serotonin_reuptake_inhibitors_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_selective_serotonin_inhibitors.","AA:People_with_genotype_AA_may_have_decreased_exposure_to_silibinin_compared_to_people_with_genotypes_AG_or_GG._Other_clinical_and_genetic_factors_may_affect_a_person's_exposure_to_silibinin.""AG:People_with_genotype_AG_may_have_decreased_exposure_to_silibinin_compared_to_people_with_genotypes_GG._Other_clinical_and_genetic_factors_may_affect_a_person's_exposure_to_silibinin.""GG:People_with_genotype_GG_may_have_increased_exposure_to_silibinin_compared_to_people_with_genotypes_AA_or_AG._Other_clinical_and_genetic_factors_may_affect_a_person's_exposure_to_silibinin.","AA:Patients_with_the_AA_genotype_may_decreased_clearance_of_daptomycin_resulting_in_increased_concentrations_of_the_drug_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_daptomycin.""AG:Patients_with_the_AG_genotype_may_increased_clearance_of_daptomycin_resulting_in_decreased_concentrations_of_the_drug_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_daptomycin.""GG:Patients_with_the_GG_genotype_may_increased_clearance_of_daptomycin_resulting_in_decreased_concentrations_of_the_drug_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_daptomycin.","AA:Patients_with_the_AA_genotype_who_are_treated_with_morphine_may_have_higher_levels_of_morphine-3-glucuronide_formation_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_morphine._""AG:Patients_with_the_AG_genotype_who_are_treated_with_morphine_may_have_lower_levels_of_morphine-3-glucuronide_formation_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_morphine._""GG:Patients_with_the_GG_genotype_who_are_treated_with_morphine_may_have_lower_levels_of_morphine-3-glucuronide_formation_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_morphine._","AA:Patients_with_the_AA_genotype_and_lymphoma_or_leukemia_who_are_treated_with_methotrexate_may_have_increased_concentrations_of_the_drug_and_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicities._""AG:Patients_with_the_AG_genotype_and_lymphoma_or_leukemia_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_of_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicities._""GG:Patients_with_the_GG_genotype_and_lymphoma_or_leukemia_who_are_treated_with_methotrexate_may_have_lower_concentrations_of_the_drug_and_may_have_a_reduced_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_methotrexate-induced_toxicities._","AA:The_AA_genotype_is_not_clearly_associated_with_risk_of_opioid-related_disorder._""AG:Patients_with_the_AG_genotype_may_have_a_greater_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_opioid_dependence_upon_exposure_to_opioids._""GG:Patients_with_the_GG_genotype_may_have_a_decreased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_AG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_opioid_dependence_upon_exposure_to_opioids._","AA:Patients_with_the_AA_genotype_and_acid-related_disorders_with_Helicobacter_pylori_(H._pylori)_infections_may_have_a_higher_chance_of_eradication_when_treated_with_omeprazole_or_pantoprazole_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_H._pylori_infection_eradication.""AG:Patients_with_the_AG_genotype_and_acid-related_disorders_with_Helicobacter_pylori_(H._pylori)_infections_may_have_a_lower_chance_of_eradication_when_treated_with_omeprazole_or_pantoprazole_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_H._pylori_infection_eradication.""GG:Patients_with_the_GG_genotype_and_acid-related_disorders_with_Helicobacter_pylori_(H._pylori)_infections_may_have_a_lower_chance_of_eradication_when_treated_with_omeprazole_or_pantoprazole_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_H._pylori_infection_eradication.","AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_CNS_depression_in_breast-feeding_infants_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine._""AG:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_CNS_depression_in_breast-feeding_infants_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_likelihood_of_CNS_depression_in_breast-feeding_infants_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine._""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_CNS_depression_in_breast-feeding_infants_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_codeine._","AA:Patients_with_the_AA_genotype_may_experience_improved_efficacy_of_fentanyl_methadone_morphine_tramadol_oxycodone_or_other_opioids_and_thus_may_require_a_decreased_dose_those_drugs_as_compared_to_patients_with_the_AG_and_GG_genotypes_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_or_response_to_opioids_or_drugs_used_to_treat_opioid_disorders.""AG:Patients_with_the_AG_genotype_may_experience_decreased_efficacy_of_fentanyl_methadone_morphine_tramadol_oxycodone_or_other_opioids_and_thus_may_require_an_increased_dose_those_drugs_as_compared_to_patients_with_the_the_AA_genotype_and_an_improved_efficacy_and_decreased_dose_of_as_compared_to_patients_with_the_GG_genotype_athough_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_or_response_to_opioids_or_drugs_used_to_treat_opioid_disorders.""GG:Patients_with_the_GG_genotype_may_experience_decreased_efficacy_of_fentanyl_methadone_morphine_tramadol_oxycodone_or_other_opioids_and_thus_may_require_an_increased_dose_those_drugs_as_compared_to_patients_with_the_the_AA_or_AG_genotype_athough_this_is_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_or_response_to_opioids_or_drugs_used_to_treat_opioid_disorders.","AA:Patients_with_the_AA_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_may_have_decreased_metabolism_of_etoposide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_etoposide.""AG:Patients_with_the_AG_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_may_have_decreased_metabolism_of_etoposide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_etoposide.""GG:Patients_with_the_GG_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_may_have_increased_metabolism_of_etoposide_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_etoposide.","AA:Patients_with_genotype_AA_may_have_decreased_likelihood_to_be_phenobarbital_resistant_in_epilepsy_patients_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_phenobarbital._""AG:Patients_with_genotype_AG_may_have_increased_likelihood_to_be_phenobarbital_resistant_in_epilepsy_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_phenobarbital._""GG:Patients_with_genotype_GG_may_have_increased_likelihood_to_be_phenobarbital_resistant_in_epilepsy_patients_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_phenobarbital._","AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_may_have_decreased_but_not_absent_risk_of_Osteonecrosis_when_treated_with_methylprednisolone_and_prednisolone_as_compared_to_patients_with_the_GG_or_GA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_methylprednisolone_and_prednisolone.""AG:Patients_with_the_AG_genotype_and_Kidney_Transplantation_may_have_increased_risk_of_Osteonecrosis_when_treated_with_methylprednisolone_and_prednisolone_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_methylprednisolone_and_prednisolone.""GG:Patients_with_the_GG_genotype_and_Kidney_Transplantation_may_have_increased_risk_of_Osteonecrosis_when_treated_with_methylprednisolone_and_prednisolone_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_methylprednisolone_and_prednisolone.","AA:Patients_with_the_AA_genotype_and_HIV_may_have_decreased_concentrations_of_atazanavir_as_compared_to_patients_with_the_GG_genotypes_although_this_is_contradicted_in_one_study._There_is_no_evidence_that_the_AA_genotype_is_associated_with_hyperbilirubinemia_drug_discontinuation_or_nephrolithiasis._Other_clinical_and_genetic_factors_may_also_influence_the_concentrations_of_atazanavir_in_patients_with_HIV._""AG:Patients_with_the_AG_genotype_and_HIV_may_have_increased_concentrations_of_atazanavir_as_compared_to_patients_with_the_AA_genotypes_although_this_is_contradicted_in_one_study._There_is_no_evidence_that_the_AG_genotype_is_associated_with_hyperbilirubinemia_drug_discontinuation_or_nephrolithiasis._Other_clinical_and_genetic_factors_may_also_influence_the_concentrations_of_atazanavir_in_patients_with_HIV._""GG:Patients_with_the_GG_genotype_and_HIV_may_have_increased_concentrations_of_atazanavir_as_compared_to_patients_with_the_AA_genotypes_although_this_is_contradicted_in_one_study._There_is_no_evidence_that_the_GG_genotype_is_associated_with_hyperbilirubinemia_drug_discontinuation_or_nephrolithiasis._Other_clinical_and_genetic_factors_may_also_influence_the_concentrations_of_atazanavir_in_patients_with_HIV._","AA:Patients_with_the_AA_genotype_and_Psychotic_Disorders_who_are_treated_with_olanzapine_may_have_increased_social_and_clinical_needs_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_olanzapine.""AG:Patients_with_the_AG_genotype_and_Psychotic_Disorders_who_are_treated_with_olanzapine_may_have_decreased_social_and_clinical_needs_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_olanzapine.""GG:Patients_with_the_GG_genotype_and_Psychotic_Disorders_who_are_treated_with_olanzapine_may_have_decreased_social_and_clinical_needs_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_olanzapine.","AA:Patients_with_the_AA_genotype_and_ulcerative_colitis_may_have_a_better_chance_at_achieving_remission_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_ulcerative_colitis_remission.""AG:Patients_with_the_AG_genotype_and_ulcerative_colitis_may_have_a_poorer_chance_at_achieving_remission_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_ulcerative_colitis_remission.""GG:Patients_with_the_GG_genotype_and_ulcerative_colitis_may_have_a_poorer_chance_at_achieving_remission_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_ulcerative_colitis_remission.","AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_and_are_treated_with_tacrolimus_may_have_decreased_risk_of_experiencing_transplant_rejection_as_compared_to_patients_with_the_AG_genotype._However_the_majority_of_studies_find_no_association_between_this_polymorphism_and_risk_for_transplant_rejection._Other_genetic_and_clinical_factors_may_also_influence_risk_of_transplant_rejection.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_and_are_treated_with_tacrolimus_may_have_an_increased_risk_of_experiencing_transplant_rejection_as_compared_to_patients_with_the_AA_or_GG_genotype._However_the_majority_of_studies_find_no_association_between_this_polymorphism_and_risk_for_transplant_rejection._Other_genetic_and_clinical_factors_may_also_influence_risk_of_transplant_rejection.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_and_are_treated_with_tacrolimus_may_have_decreased_risk_of_experiencing_transplant_rejection_as_compared_to_patients_with_the_AG_genotype._However_the_majority_of_studies_find_no_association_between_this_polymorphism_and_risk_for_transplant_rejection._Other_genetic_and_clinical_factors_may_also_influence_risk_of_transplant_rejection.","AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_a_decreased_risk_of_hypokalemia_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hypokalemia.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_may_have_an_increased_risk_of_hypokalemia_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hypokalemia.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_may_have_a_decreased_risk_of_hypokalemia_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hypokalemia.","AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_a_longer_QTc_interval_when_treated_with_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_QTc_interval_in_patients_taking_risperidone.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_a_longer_QTc_interval_when_treated_with_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_QTc_interval_in_patients_taking_risperidone.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_shorter_QTc_interval_when_treated_with_risperidone_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_QTc_interval_in_patients_taking_risperidone.","AA:Patients_with_the_AA_genotype_and_renal_cell_carcinoma_may_have_a_lower_risk_for_adverse_effects_when_treated_with_sunitinib_as_compared_to_patients_with_the_GG_genotype._One_study_found_no_association_between_this_SNP_and_thrombocytopenia_neutropenia_anemia_or_hand-food_syndrome._Other_genetic_and_clinical_factors_may_also_influence_risk_for_sunitinib_toxicities.""AG:Patients_with_the_AG_genotype_and_renal_cell_carcinoma_may_have_a_lower_risk_for_adverse_effects_when_treated_with_sunitinib_as_compared_to_patients_with_the_GG_genotype._One_study_found_no_association_between_this_SNP_and_thrombocytopenia_neutropenia_anemia_or_hand-food_syndrome._Other_genetic_and_clinical_factors_may_also_influence_risk_for_sunitinib_toxicities.""GG:Patients_with_the_GG_genotype_and_renal_cell_carcinoma_may_have_an_increased_risk_for_adverse_effects_when_treated_with_sunitinib_as_compared_to_patients_with_the_AA_or_AG_genotype._One_study_found_no_association_between_this_SNP_and_thrombocytopenia_neutropenia_anemia_or_hand-food_syndrome._Other_genetic_and_clinical_factors_may_also_influence_risk_for_sunitinib_toxicities.","AA:Patients_with_the_AA_genotype_and_epilepsy_may_need_a_decreased_dose_carbamazepine_as_compared_to_patients_with_the_AG_genotype._However_multiple_studies_have_shown_no_association_with_dose_or_concentrations_of_carbamazepine._Other_genetic_and_clinical_factors_may_also_influence_dose_requirements_and_concentrations_of_carbamazepine.""AG:Patients_with_the_AG_genotype_and_epilepsy_may_have_increased_metabolism_of_carbamazepine_and_may_need_an_increased_dose_as_compared_to_patients_with_the_AA_or_GG_genotypes._However_multiple_studies_have_shown_no_association_with_dose_or_concentrations_of_carbamazepine._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_carbamazepine.""GG:Patients_with_the_GG_genotype_and_epilepsy_may_have_decreased_metabolism_of_carbamazepine_and_may_need_a_decreased_dose_as_compared_to_patients_with_the_AG_genotype._However_multiple_studies_have_shown_no_association_with_dose_or_concentrations_of_carbamazepine._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_carbamazepine.","AA:Patients_with_the_AA_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_decreased_likelihood_of_event-free_survival_as_compared_to_patients_with_the_GG_genotype._This_association_was_not_replicated_in_a_second_cohort._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vincristine_treatment._""AG:Patients_with_the_AG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_decreased_likelihood_of_event-free_survival_as_compared_to_patients_with_the_GG_genotype._This_association_was_not_replicated_in_a_second_cohort._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vincristine_treatment._""GG:Patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_an_increased_likelihood_of_event-free_survival_as_compared_to_patients_with_the_AA_genotype._This_association_was_not_replicated_in_a_second_cohort._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vincristine_treatment._";PGKB_RACE=Asian,NR,NR,NR,Asian,Asian,White,White,NR,Asian,Asian,NR,NR,NR,White,NR,NR,NR,NR,Asian,NR,Asian,NR,White,White,NR,NR,NR,NR,NR,NR,NR,NR,Black_or_African_American,NR,NR,NR,White,NR,White,Asian,NR,NR,White,Asian,White,NR,NR,White,White,NR,White,NR,Asian,Asian,NR,NR,NR,NR,NR,Asian,NR,Asian,White
7	87145914	rs72552784	C	T	.	.	PGKB_INDEX=7;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=bisantrene_(PA146096021),calcein_(PA132595336),forskolin_(PA146096022),prazosin_(PA451093),verapamil_(PA451868),vinblastine_(PA451877),paclitaxel_(PA450761);PGKB_TYPE=Other,Other,Other,Other,Other,Other,Other;PGKB_EVIDENCE=4,4,4,4,4,4,4;PGKB_DISEASE=NR,NR,NR,NR,NR,NR,NR;PGKB_TEXT="CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.","CC:Cells_with_the_C_allele_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_alleles.""CT:Cells_with_this_genotype_would_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_genotypes.""TT:Cells_with_the_T_allele_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_alleles.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.","CC:Cells_with_the_CC_genotype_have_normal_ability_to_efflux_fluorescently_labelled_paclitaxel.""CT:Cells_with_the_CT_genotype_have_a_slight_decrease_in_ability_to_efflux_fluorescently_labelled_paclitaxel_compared_to_cells_with_genotype_CC.""TT:Cells_with_the_TT_genotype_have_a_slight_decrease_in_ability_to_efflux_fluorescently_labelled_paclitaxel_compared_to_cells_with_genotype_CC.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR
7	87148328	rs28401781	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="citalopram_(PA449015)""fluoxetine_(PA449673)""paroxetine_(PA450801)""sertraline_(PA451333)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_be_less_likely_to_respond_to_treatment_with_selective_serotonin-reuptake_inhibitors_(SSRIs)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_SSRI_treatment._""CT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_to_treatment_with_selective_serotonin-reuptake_inhibitors_(SSRIs)_as_compared_to_patients_with_the_CC_genotype_or_may_be_less_likely_to_respond_to_treatment_with_selective_serotonin-reuptake_inhibitors_(SSRIs)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_SSRI_treatment._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_to_treatment_with_selective_serotonin-reuptake_inhibitors_(SSRIs)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_SSRI_treatment._";PGKB_RACE=Asian
7	87149922	rs2235067	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""CT:Patients_with_the_CT_genotype_and_Depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_CC_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""TT:Patients_with_the_TT_genotype_and_Depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=White
7	87152103	rs4148740	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""AG:Patients_with_the_AG_genotype_and_Depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_AA_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""GG:Patients_with_the_GG_genotype_and_Depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=White
7	87153585	rs10280101	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""AC:Patients_with_the_AC_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=White
7	87157051	rs7787082	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=clozapine_(PA449061),"amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Depressive_Disorder_(PA447207);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_an_increased_response_when_treated_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_an_increased_response_when_treated_with_clozapine_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_response_when_treated_with_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_decreased_response_when_treated_with_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.","AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_amitryptiline_citalopram_paroxetine_or_venlafaxine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission.""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_amitryptiline_citalopram_paroxetine_or_venlafaxine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission.""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_amitryptiline_citalopram_paroxetine_or_venlafaxine_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission.";PGKB_RACE=Asian,White
7	87160561	rs2032583	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""antidepressants_(PA452229)""citalopram_(PA449015)""fluvoxamine_(PA449690)""paroxetine_(PA450801)""sertraline_(PA451333)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Depression_(PA447278)""Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_antidepressants_1)_may_be_less_likely_to_experience_adverse_effects_2)_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission_and_risk_of_side_effects.""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_antidepressants_1)_may_be_more_likely_to_experience_adverse_effects_2)_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission_and_risk_of_side_effects.""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_antidepressants_1)_may_be_more_likely_to_experience_adverse_effects_2)_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission_and_risk_of_side_effects.";PGKB_RACE=White
7	87160618	rs2032582	A	T,C	.	.	PGKB_INDEX=30;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=simvastatin_(PA451363),atorvastatin_(PA448500),"cytarabine_(PA449177)""daunorubicin_(PA449212)""dexrazoxane_(PA449259)""idarubicin_(PA449961)",simvastatin_(PA451363),"cyclosporine_(PA449167)""mycophenolate_mofetil_(PA450566)",pravastatin_(PA451089),"clomipramine_(PA449048)""lithium_(PA450243)""nefazodone_(PA450603)""paroxetine_(PA450801)""venlafaxine_(PA451866)",verapamil_(PA451868),paclitaxel_(PA450761),anthracyclines_and_related_substances_(PA130620651),"Platinum_compounds_(PA164713176)""taxanes_(PA150481189)","Platinum_compounds_(PA164713176)""taxanes_(PA150481189)",cyclosporine_(PA449167),cyclosporine_(PA449167),"cyclophosphamide_(PA449165)""doxorubicin_(PA449412)",efavirenz_(PA449441),tacrolimus_(PA451578),doxorubicin_(PA449412),"dexamethasone_(PA449247)""doxorubicin_(PA449412)""vincristine_(PA451879)","antiepileptics_(PA143485705)""carbamazepine_(PA448785)",antiepileptics_(PA143485705),digoxin_(PA449319),capecitabine_(PA448771),ondansetron_(PA450705),sunitinib_(PA162372840),sunitinib_(PA162372840),tacrolimus_(PA451578),ritonavir_(PA451260),fluoxetine_(PA449673),"carbamazepine_(PA448785)""phenytoin_(PA450947)""valproic_acid_(PA451846)";PGKB_TYPE=Toxicity/ADR,Efficacy,Efficacy,Efficacy,Efficacy,NR,Toxicity/ADR,Other,Efficacy,Efficacy,Toxicity/ADR,Toxicity/ADR,Efficacy,Dosage,Efficacy,Efficacy,Efficacy,Other,Efficacy,"Dosage""Efficacy",Efficacy,Other,Toxicity/ADR,Efficacy,Efficacy,Toxicity/ADR,"Dosage""Metabolism/PK",Metabolism/PK,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,2A,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,4,3,3,2A,3,3,3,3,3,3;PGKB_DISEASE="Hypercholesterolemia_(PA444516)""Myalgia_unspecified_(PA157379134)",Hypercholesterolemia_(PA444516),Leukemia_Myeloid_Acute_(PA444760),Hypercholesterolemia_(PA444516),Kidney_Transplantation_(PA165817016),Acute_coronary_syndrome_(PA165108401),Depression_(PA447278),NR,"Breast_Neoplasms_(PA443560)""Ovarian_Neoplasms_(PA445204)","Breast_Neoplasms_(PA443560)""Leukemia_Myeloid_Acute_(PA444760)""Multiple_Myeloma_(PA444985)",Ovarian_Neoplasms_(PA445204),Ovarian_Neoplasms_(PA445204),Colitis_Ulcerative_(PA443750),NR,Breast_Neoplasms_(PA443560),HIV_(PA447230),"Colitis_Ulcerative_(PA443750)""Kidney_Transplantation_(PA165817016)",Breast_Neoplasms_(PA443560),Multiple_Myeloma_(PA444985),Epilepsy_(PA444065),Epilepsy_(PA444065),NR,"Colorectal_Neoplasms_(PA446108)""hand-foot_syndrome_(PA166114377)",NR,Carcinoma_Renal_Cell_(PA443624),Carcinoma_Renal_Cell_(PA443624),"Kidney_Transplantation_(PA165817016)""liver_transplantation_(PA447247)",HIV_(PA447230),Depressive_Disorder_(PA447207),Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_reduced_risk_of_developing_myalgia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_adverse_drug_reactions._""AC:Patients_with_the_AC_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_an_increased_risk_of_developing_myalgia_as_compared_to_patients_with_the_AA_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_adverse_drug_reactions._""AT:Patients_with_the_AT_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_reduced_developing_myalgia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_adverse_drug_reactions._""CC:Patients_with_the_CC_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_an_increased_risk_of_developing_myalgia_as_compared_to_patients_with_the_AA_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_adverse_drug_reactions._""TT:Patients_with_the_TT_genotype_and_Hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_reduced_risk_of_developing_myalgia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_simvastatin-induced_adverse_drug_reactions._","AA:Patients_with_the_AA_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""AC:Patients_with_the_AC_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""AT:Patients_with_the_AT_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""CC:Patients_with_the_CC_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","AA:Patients_with_the_AA_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_idarubicin_or_cytrarabine_daunorubicin_and_dexrazoxane_may_have_an_increased_response_as_compared_to_the_AC_AT_CC_CT_or_TT_genotypes._Some_contradictory_evidence_exists_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin_or_cytarabine_daunorubicin_and_dexrazoxane_treatment._""AC:Patients_with_the_AC_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_idarubicin_or_cytrarabine_daunorubicin_and_dexrazoxane_may_have_an_increased_response_as_compared_to_the_CC_CT_or_TT_genotypes._Some_contradictory_evidence_exists_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin_or_cytarabine_daunorubicin_and_dexrazoxane_treatment._""AT:Patients_with_the_AT_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_idarubicin_or_cytrarabine_daunorubicin_and_dexrazoxane_may_have_an_increased_response_as_compared_to_the_CC_CT_or_TT_genotypes._Some_contradictory_evidence_exists_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin_or_cytarabine_daunorubicin_and_dexrazoxane_treatment._""CC:Patients_with_the_CC_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_idarubicin_or_cytrarabine_daunorubicin_and_dexrazoxane_may_have_an_decreased_response_as_compared_to_the_AC_AT_or_AA_genotypes._Some_contradictory_evidence_exists_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin_or_cytarabine_daunorubicin_and_dexrazoxane_treatment._""TT:Patients_with_the_TT_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_idarubicin_or_cytrarabine_daunorubicin_and_dexrazoxane_may_have_an_decreased_response_as_compared_to_the_AC_AT_or_AA_genotypes._Some_contradictory_evidence_exists_for_these_associations._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_idarubicin_or_cytarabine_daunorubicin_and_dexrazoxane_treatment._","AA:Patients_with_the_AA_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AC:Patients_with_the_AC_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AT:Patients_with_the_AT_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""CC:Patients_with_the_CC_genotype_who_are_treated_with_simvastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_AC_AA_TT_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_simvastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_biopsy-proven_acute_rejection_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil._""AC:Patients_with_the_AC_genotype_may_have_an_increased_risk_of_biopsy-proven_acute_rejection_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil._""CC:Patients_with_the_CC_genotype_may_have_a_decreased_but_not_absent_risk_of_biopsy-proven_acute_rejection_at_12_month_post-transplant_when_treated_with_cyclosporine_and_mycophenolate_mofetil_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil._","AA:Patients_with_the_AA_genotype_and_Acute_Coronary_Syndrome_who_are_treated_with_pravastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._This_association_was_not_seen_in_children_with_familial_hypercholesterolemia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AC:Patients_with_the_AC_genotype_and_Acute_Coronary_Syndrome_who_are_treated_with_pravastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_who_do_not_have_the_C_allele._This_association_was_not_seen_in_children_with_familial_hypercholesterolemia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AT:Patients_with_the_AT_genotype_and_Acute_Coronary_Syndrome_who_are_treated_with_pravastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_who_do_not_have_the_C_allele._This_association_was_not_seen_in_children_with_familial_hypercholesterolemia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""CC:Patients_with_the_CC_genotype_and_Acute_Coronary_Syndrome_who_are_treated_with_pravastatin_may_have_a_better_response_(as_measured_by_higher_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_AA_or_TT_genotype._This_association_was_not_seen_in_children_with_familial_hypercholesterolemia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Patients_with_the_TT_genotype_and_Acute_Coronary_Syndrome_who_are_treated_with_pravastatin_may_have_a_reduced_response_(as_measured_by_lower_reductions_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._This_association_was_not_seen_in_children_with_familial_hypercholesterolemia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","AA:Patients_with_the_AA_genotype_and_depression_may_have_an_increased_risk_of_suicidal_ideation_when_treated_with_clomipramine_liothyronine_Lithium_nefazodone_paroxetine_or_venlafaxine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine_liothyronine_Lithium_nefazodone_paroxetine_or_venlafaxine._""AC:Patients_with_the_AC_genotype_and_depression_may_have_an_increased_risk_of_suicidal_ideation_when_treated_with_clomipramine_liothyronine_Lithium_nefazodone_paroxetine_or_venlafaxine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine_liothyronine_Lithium_nefazodone_paroxetine_or_venlafaxine._""CC:Patients_with_the_CC_genotype_and_depression_may_have_a_decreased_but_not_absent_risk_of_suicidal_ideation_when_treated_with_clomipramine_liothyronine_Lithium_nefazodone_paroxetine_or_venlafaxine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clomipramine_liothyronine_Lithium_nefazodone_paroxetine_or_venlafaxine._","AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_verapamil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_verapamil.""AC:Patients_with_the_AC_genotype_may_have_increased_metabolism_of_verapamil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_verapamil.""CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_verapamil_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_verapamil.","AA:Patients_with_the_TT_AT_or_AA_genotype_may_have_increased_response_to_paclitaxel_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paclitaxel._Note_that_rs2032582_is_a_tri-allelic_snp.""AT:Patients_with_the_TT_AT_or_AA_genotype_may_have_increased_response_to_paclitaxel_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paclitaxel._Note_that_rs2032582_is_a_tri-allelic_snp.""CA:Patients_with_the_CA_or_CT_genotype_may_have_increased_response_to_paclitaxel_as_compared_to_the_CC_genotype_but_decreased_response_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paclitaxel._Note_that_rs2032582_is_a_tri-allelic_snp.""CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_paclitaxel_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paclitaxel._Note_that_rs2032582_is_a_tri-allelic_snp.""CT:Patients_with_the_CA_or_CT_genotype_may_have_increased_response_to_paclitaxel_as_compared_to_the_CC_genotype_but_decreased_response_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paclitaxel._Note_that_rs2032582_is_a_tri-allelic_snp.""TT:Patients_with_the_TT_AT_or_AA_genotype_may_have_increased_response_to_paclitaxel_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paclitaxel._Note_that_rs2032582_is_a_tri-allelic_snp.","AA:Patients_with_the_AA_genotype_and_cancer_who_are_treated_with_anthracyclines:_1)_may_have_a_decreased_but_not_absent_risk_for_resistance_as_compared_to_patients_with_the_CC_genotype_2)_may_have_increased_overall_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines.""AC:Patients_with_the_CA_genotype_and_cancer_who_are_treated_with_anthracyclines:_1)_may_have_a_decreased_but_not_absent_risk_for_resistance_as_compared_to_patients_with_the_CC_genotype_2)_may_have_increased_overall_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines.""CC:Patients_with_the_CC_CT_or_TT_genotype_and_cancer_who_are_treated_with_anthracyclines_1)_may_have_an_increased_risk_of_resistance_as_compared_to_patients_with_the_AC_and_AA_genotype_2)_may_have_decreased_overall_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines.","AC:Patients_with_the_AC_genotype_may_have_increased_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens.""CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_non-existent_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens_as_compared_to_patients_with_the_CA_CT_AA_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens.","AA:Patients_with_the_AA_genotype_may_have_increased_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens.""AT:Patients_with_the_AT_genotype_and_cancer_who_are_treated_with_taxanes_and_platinum_therapy_may_have_a_decreased_but_not_absent_risk_for_gastrointestinal_toxicity_as_compared_to_patients_with_the_CA_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_gastrointestinal_toxicity_with_taxanes_and_platinum_therapy.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_gastrointestinal_toxicity_with_taxane_and_platinum_regimens.","AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_resistance_to_cyclosporine_compared_to_patients_with_the_CC_and_CA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_resistance_to_cyclosporine.""AC:Patients_with_the_AC_genotype_may_have_a_decreased_risk_of_resistance_to_cyclosporine_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_resistance_to_cyclosporine.""CC:Patients_with_the_CC_genotype_may_have_a_decreased_risk_of_resistance_to_cyclosporine_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_resistance_to_cyclosporine.","AA:Patients_with_the_AA_genotype_may_have_higher_blood_trough_concentrations_of_cyclosporine_compared_to_patients_with_the_CC_genotype_and_may_require_dose_adjustments._Other_genetic_and_clinical_factors_may_also_influence_cyclosporine_blood_concentrations.""AC:Patients_with_the_AC_genotype_may_have_higher_blood_trough_concentrations_of_cyclosporine_compared_to_patients_with_the_CC_genotype_or_may_have_lower_blood_trough_concentrations_of_cyclosporine_compared_to_patients_with_the_AA_genotype_and_may_require_dose_adjustments._Other_genetic_and_clinical_factors_may_also_influence_cyclosporine_blood_concentrations.""CC:Patients_with_the_CC_genotype_may_have_lower_blood_trough_concentrations_of_cyclosporine_compared_to_patients_with_the_AA_genotype_and_may_require_dose_adjustments._Other_genetic_and_clinical_factors_may_also_influence_cyclosporine_blood_concentrations.","CC:Patients_with_the_CC_genotype_may_have_increased_survival_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_genotypes_patients_with_genotype_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cyclophosphamide_and_doxorubicin.""CT:Patients_with_the_CT_genotype_may_have_decreased_survival_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_genotypes_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cyclophosphamide_and_doxorubicin.""TT:Patients_with_the_TT_genotype_may_have_decreased_survival_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_genotypes_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cyclophosphamide_and_doxorubicin.","AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_emerging_viral_drug_resistance_when_exposed_to_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_the_CC_genotype.This_varaint_is_not_associated_with_plasma_exposure_of_efavirenz._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_efavirenz.""AC:Patients_with_the_AC_genotype_may_have_decreased_likelihood_of_emerging_viral_drug_resistance_when_exposed_to_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_the_CC_genotype.This_varaint_is_not_associated_with_plasma_exposure_of_efavirenz._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_efavirenz.""CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_emerging_viral_drug_resistance_when_exposed_to_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_the_AA_genotype.This_varaint_is_not_associated_with_plasma_exposure_of_efavirenz._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_efavirenz","AA:Patients_with_AA_genotype_may_have_higher_success_rate_in_achieving_short-term_remission_when_treated_with_tacrolimus_in_people_with_Colitis_Ulcerative_as_compared_to_patients_with_CC_or_AC_genotype._The_majority_of_studies_find_no_association_with_dose_of_tacrolimus_in_people_with_transplantations_as_compared_and_genotypes_of_this_SNP._Other_genetic_or_clinical_factors_may_influence_response_and_dose_of_tacrolimus.""AC:Patients_with_AC_genotype_may_have_lower_success_rate_in_achieving_short-term_remission_when_treated_with_tacrolimus_in_people_with_Colitis_Ulcerative_as_compared_to_patients_with_the_AA_genotype._The_majority_of_studies_find_no_association_with_dose_of_tacrolimus_in_people_with_transplantations_as_compared_and_genotypes_of_this_SNP._Other_genetic_or_clinical_factors_may_influence_response_and_dose_of_tacrolimus.""CC:Patients_with_CC_genotype_may_have_lower_success_rate_in_achieving_short-term_remission_when_treated_with_tacrolimus_in_people_with_Colitis_Ulcerative_as_compared_to_patients_with_the_AA_genotype._The_majority_of_studies_find_no_association_with_dose_of_tacrolimus_in_people_with_transplantations_as_compared_and_genotypes_of_this_SNP._Other_genetic_or_clinical_factors_may_influence_response_and_dose_of_tacrolimus.","AA:Patients_with_the_AA_genotype_may_have_decreased_metabolism_of_doxorubicin_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_doxorubicin.""AC:Patients_with_the_AC_genotype_may_have_decreased_metabolism_of_doxorubicin_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_doxorubicin.""CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_doxorubicin_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_doxorubicin.","AA:Patients_with_the_AA_genotype_are_associated_with_increased_overall_survival_when_treated_with_dexamethasone_doxorubicin_and_vincristine_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_the_therapy.""AC:Patients_with_the_AC_genotype_are_associated_with_increased_overall_survival_when_treated_with_dexamethasone_doxorubicin_and_vincristine_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_the_therapy.""CC:Patients_with_the_CC_genotype_are_associated_with_decreased_overall_survival_when_treated_with_dexamethasone_doxorubicin_and_vincristine_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_the_therapy.","AA:Patients_with_genotype_AA_may_have_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_CC._However_contradictory_findings_have_been_reported._Genotype_AA_is_not_associated_with_dose_of_carbamazepine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""AC:Patients_with_genotype_AC_may_have_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_CC._However_contradictory_findings_have_been_reported._Genotype_AC_is_not_associated_with_dose_of_carbamazepine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""CC:Patients_with_genotype_CC_may_have_decreased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_AA._However_contradictory_findings_have_been_reported._Genotype_CC_is_not_associated_with_dose_of_carbamazepine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.","AA:Patients_with_genotype_AA_may_have_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_CC._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.""AC:Patients_with_genotype_AC_may_have_increased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_CC._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.""CC:Patients_with_genotype_CC_may_have_decreased_likelihood_of_drug_resistance_when_treated_with_antiepileptics_and_carbamazepine_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_AA._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.","AA:Patients_with_genotype_AA_may_have_decreased_metabolism_of_digoxin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_digoxin.""AC:Patients_with_genotype_AC_may_have_increased_metabolism_of_digoxin_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_digoxin.""CC:Patients_with_genotype_CC_may_have_increased_metabolism_of_digoxin_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_digoxin.","AA:Patients_with_genotype_AA_may_have_decreased_risk_of_hand-foot_syndrome_when_treated_with_capecitabine_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_capecitabine.""AC:Patients_with_genotype_AC_may_have_increased_risk_of_hand-foot_syndrome_when_treated_with_capecitabine_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_capecitabine.""CC:Patients_with_genotype_CC_may_have_increased_risk_of_hand-foot_syndrome_when_treated_with_capecitabine_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_capecitabine.","AA:Patients_with_genotype_AA_may_have_decreased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_ondansetron_as_compared_to_patients_with_other_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""AC:Patients_with_genotype_AC_may_have_increased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_ondansetron_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""AT:Patients_with_genotype_AT_may_have_increased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_ondansetron_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""CC:Patients_with_genotype_CC_may_have_increased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_ondansetron_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""TT:Patients_with_genotype_TT_may_have_increased_likelihood_of_nausea_and_vomiting_shortly_after_being_treated_with_ondansetron_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.","AA:Patients_with_renal_cell_carcinoma_and_the_AA_genotype_may_have_a_decreased_response_to_sunitinib_as_compared_to_patients_with_the_AC_AT_CC_CT_or_TT_genotypes._There_is_no_association_between_this_SNP_and_overall_or_progression_free_survival._Response_here_refers_to_stable_disease_or_partial_response_and_non-response_to_progressive_disease._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib_in_patients_with_renal_cell_carcinoma._""AC:Patients_with_renal_cell_carcinoma_and_the_AC_genotype_may_have_an_incresed_response_to_sunitinib_as_compared_to_patients_with_the_AA_genotypes._There_is_no_association_between_this_SNP_and_overall_or_progression_free_survival._Response_here_refers_to_stable_disease_or_partial_response_and_non-response_to_progressive_disease._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib_in_patients_with_renal_cell_carcinoma._""AT:Patients_with_renal_cell_carcinoma_and_the_AT_genotype_may_have_an_incresed_response_to_sunitinib_as_compared_to_patients_with_the_AA_genotypes._There_is_no_association_between_this_SNP_and_overall_or_progression_free_survival._Response_here_refers_to_stable_disease_or_partial_response_and_non-response_to_progressive_disease._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib_in_patients_with_renal_cell_carcinoma._""CC:Patients_with_renal_cell_carcinoma_and_the_CC_genotype_may_have_an_incresed_response_to_sunitinib_as_compared_to_patients_with_the_AA_genotypes._There_is_no_association_between_this_SNP_and_overall_or_progression_free_survival._Response_here_refers_to_stable_disease_or_partial_response_and_non-response_to_progressive_disease._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib_in_patients_with_renal_cell_carcinoma._""CT:Patients_with_renal_cell_carcinoma_and_the_CT_genotype_may_have_an_incresed_response_to_sunitinib_as_compared_to_patients_with_the_AA_genotypes._There_is_no_association_between_this_SNP_and_overall_or_progression_free_survival._Response_here_refers_to_stable_disease_or_partial_response_and_non-response_to_progressive_disease._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib_in_patients_with_renal_cell_carcinoma._""TT:Patients_with_renal_cell_carcinoma_and_the_TT_genotype_may_have_an_incresed_response_to_sunitinib_as_compared_to_patients_with_the_AA_genotypes._There_is_no_association_between_this_SNP_and_overall_or_progression_free_survival._Response_here_refers_to_stable_disease_or_partial_response_and_non-response_to_progressive_disease._Other_clinical_and_genetic_factors_may_also_influence_response_to_sunitinib_in_patients_with_renal_cell_carcinoma._","AA:Patients_with_renal_cell_carcinoma_and_the_AA_genotypes_may_have_a_decreased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_patients_with_any_of_the_following_genotypes:_CC_CT_TT_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_treated_with_sunitinib.""AC:Patients_with_renal_cell_carcinoma_and_the_AC_genotypes_may_have_a_decreased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_patients_with_any_of_the_following_genotypes:_CC_CT_TT_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_treated_with_sunitinib.""AT:Patients_with_renal_cell_carcinoma_and_the_AT_genotypes_may_have_a_decreased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_patients_with_any_of_the_following_genotypes:_CC_CT_TT_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_treated_with_sunitinib.""CC:Patients_with_renal_cell_carcinoma_and_the_CC_genotypes_may_have_an_increased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_patients_with_any_of_the_following_genotypes:_AA_AC_AT_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_treated_with_sunitinib.""CT:Patients_with_renal_cell_carcinoma_and_the_CT_genotypes_may_have_an_increased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_patients_with_any_of_the_following_genotypes:_AA_AC_AT_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_treated_with_sunitinib.""TT:Patients_with_renal_cell_carcinoma_and_the_TT_genotypes_may_have_an_increased_risk_of_neutropenia_when_treated_with_sunitinib_as_compared_to_patients_with_any_of_the_following_genotypes:_AA_AC_AT_._Other_clinical_and_genetic_factors_may_also_influence_risk_of_neutropenia_in_patients_with_renal_cell_carcinoma_who_are_treated_with_sunitinib.","AA:Patients_with_the_AA_genotype_who_are_undergoing_organ_transplantation_may_have_decreased_metabolism_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._However_the_majority_of_studies_have_found_no_association_between_this_polymorphism_and_metabolism_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_metabolism_and_dose_of_tacrolimus.""AC:Patients_with_the_AC_genotype_who_are_undergoing_organ_transplantation_may_have_decreased_metabolism_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._However_the_majority_of_studies_have_found_no_association_between_this_polymorphism_and_metabolism_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_metabolism_and_dose_of_tacrolimus.""CC:Patients_with_the_CC_genotype_who_are_undergoing_organ_transplantation_may_have_increased_metabolism_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_AA_AC_CT_or_TT_genotypes._However_the_majority_of_studies_have_found_no_association_between_this_polymorphism_and_metabolism_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_metabolism_and_dose_of_tacrolimus.""CT:Patients_with_the_CT_genotype_who_are_undergoing_organ_transplantation_may_have_decreased_metabolism_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._However_the_majority_of_studies_have_found_no_association_between_this_polymorphism_and_metabolism_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_metabolism_and_dose_of_tacrolimus.""TT:Patients_with_the_TT_genotype_who_are_undergoing_organ_transplantation_may_have_decreased_metabolism_and_dose_requirements_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._However_the_majority_of_studies_have_found_no_association_between_this_polymorphism_and_metabolism_or_dose_of_tacrolimus._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_metabolism_and_dose_of_tacrolimus.","AA:Patients_with_the_AA_genotype_who_are_treated_with_ritonavir_may_have_a_decreased_intracellular/plasma_trough_concentration_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ritonavir.""AC:Patients_with_the_AC_genotype_who_are_treated_with_ritonavir_may_have_a_increased_intracellular/plasma_trough_concentration_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ritonavir.""CC:Patients_with_the_CC_genotype_who_are_treated_with_ritonavir_may_have_a_increased_intracellular/plasma_trough_concentration_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ritonavir.","AA:Patients_with_the_AA_genotype_and_Depressive_Disorder_may_have_increased_response_to_fluoxetine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""AC:Patients_with_the_AA_genotype_and_Depressive_Disorder_may_have_increased_response_to_fluoxetine_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_response_to_fluoxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""CC:Patients_with_the_CC_genotype_and_Depressive_Disorder_may_have_decreased_response_to_fluoxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.","CC:Patients_with_the_CC_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_phenytoin_or_valproic_acid_may_have_decreased_risk_for_non-response_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_for_no_association_of_the_variation_with_response_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_phenytoin_or_valproic_acid.""CT:Patients_with_the_CT_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_phenytoin_or_valproic_acid_may_have_increased_risk_for_non-response_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_risk_for_non-response_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_for_no_association_of_the_variation_with_response_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_phenytoin_or_valproic_acid.""TT_:Patients_with_the_TT_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_phenytoin_or_valproic_acid_may_have_increased_risk_for_non-response_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_for_no_association_of_the_variation_with_response_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine_phenytoin_or_valproic_acid.";PGKB_RACE=NR,NR,NR,White,White,White,NR,Asian,NR,NR,Asian,Asian,White,Asian,NR,NR,NR,Asian,NR,Asian,NR,NR,NR,Asian,Asian,Asian,NR,NR,White,NR
7	87161049	rs4148739	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""citalopram_(PA449015)""fluoxetine_(PA449673)""paroxetine_(PA450801)""sertraline_(PA451333)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Depression_(PA447278)""Depressive_Disorder_Major_(PA447321)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_antidepressants_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants._""CT:Patients_with_the_CT_genotype_who_are_treated_with_antidepressants_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_TT_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants._""TT:Patients_with_the_TT_genotype_and_Depression_who_are_treated_with_antidepressants_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants._";PGKB_RACE=NR
7	87161520	rs11983225	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""CT:Patients_with_the_CT_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""TT:Patients_with_the_TT_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=White
7	87164986	rs10248420	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=clozapine_(PA449061),"amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Depression_(PA447278);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_be_less_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_be_less_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_GG_genotype_or_more_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_be_more_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.","AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=Asian,White
7	87165750	rs2235040	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG="antidepressants_(PA452229)""citalopram_(PA449015)""fluvoxamine_(PA449690)""paroxetine_(PA450801)""sertraline_(PA451333)""venlafaxine_(PA451866)","amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_antidepressants_may_have_a_reduced_risk_of_adverse_effects_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_effects._""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_who_are_treated_with_antidepressants_may_have_a_reduced_risk_of_adverse_effects_as_compared_to_patients_with_the_TT_genotype_or_may_have_an_increased_risk_of_adverse_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_effects._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_antidepressants_may_have_an_increased_risk_of_adverse_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_effects._","CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""CT:Patients_with_the_CT_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""TT:Patients_with_the_TT_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=NR,White
7	87169356	rs12720067	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""CT:Patients_with_the_CT_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_likelihood_of_remission_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.""TT:Patients_with_the_TT_genotype_and_depression_who_are_treated_with_amitriptyline_citalopram_paroxetine_or_venlafaxine_may_have_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_amitriptyline_citalopram_paroxetine_or_venlafaxine.";PGKB_RACE=White
7	87171152	rs4148737	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""methotrexate_(PA450428)""vincristine_(PA451879)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteosarcoma_(PA445601);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_osteosarcoma_may_have_an_increased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CC_genotype_but_an_increased_risk_of_death_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
7	87173667	rs1922242	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG=fluvastatin_(PA449688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_fluvastatin_(a_higher_change_in_LDL-cholesterol_levels)_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""AT:Patients_with_the_AT_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_fluvastatin_(a_lower_change_in_LDL-cholesterol_levels)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""TT:Patients_with_the_TT_genotype_were_not_studied_however_patients_with_the_AT_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_fluvastatin_(a_lower_change_in_LDL-cholesterol_levels)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._";PGKB_RACE=NR
7	87179601	rs1128503	A	G	.	.	PGKB_INDEX=15;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=sirolimus_(PA451365),"cisplatin_(PA449014)""cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""methotrexate_(PA450428)""vincristine_(PA451879)",oxaliplatin_(PA131285527),digoxin_(PA449319),risperidone_(PA451257),cyclosporine_(PA449167),phenytoin_(PA450947),hmg_coa_reductase_inhibitors_(PA133950441),imatinib_(PA10804),rocuronium_(PA164754992),sunitinib_(PA162372840),efavirenz_(PA449441),modafinil_(PA450530),tacrolimus_(PA451578),cytarabine_(PA449177);PGKB_TYPE=Toxicity/ADR,Efficacy,Efficacy,Other,Efficacy,Dosage,Other,Other,Efficacy,Efficacy,Toxicity/ADR,Metabolism/PK,Efficacy,"Dosage""Metabolism/PK",Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3,3,3,3,3,3,4,3,3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),Osteosarcoma_(PA445601),Colorectal_Neoplasms_(PA446108),NR,Autistic_Disorder_(PA447198),Myasthenia_Gravis_(PA445004),NR,NR,Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171),NR,Carcinoma_Renal_Cell_(PA443624),HIV_(PA447230),Narcolepsy_(PA445042),Transplantation_(PA134850491),Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_underwent_kidney_transplantation_may_have_increased_triglyceride_levels_when_treated_with_sirolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_triglyceride_levels._""AG:Patients_with_the_AG_genotype_who_underwent_kidney_transplantation_may_have_decreased_triglyceride_levels_when_treated_with_sirolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_triglyceride_levels._""GG:Patients_with_the_GG_genotype_who_underwent_kidney_transplantation_may_have_decreased_triglyceride_levels_when_treated_with_sirolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_triglyceride_levels._","AA:Patients_with_the_AA_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_GG_genotype_but_an_increased_risk_of_death_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_and_osteosarcoma_may_have_an_increased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_an_increased_overall_survival_period_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_an_increased_overall_survival_period_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_a_decreased_overall_survival_period_when_treated_with_oxaliplatin-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","AA:Patients_with_the_AA_genotype_may_have_increased_serum_concentrations_of_digoxin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_serum_concentrations_of_digoxin.""AG:Patients_with_the_AA_genotype_may_have_increased_serum_concentrations_of_digoxin_as_compared_to_patients_with_the_GG_genotype_or_decreased_serum_concentrations_of_digoxin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_impact_serum_concentrations_of_digoxin.""GG:Patients_with_the_GG_genotype_may_have_decreased_serum_concentrations_of_digoxin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_impact_serum_concentrations_of_digoxin.","AA:Patients_with_the_AA_genotype_may_have_lower_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_indicating_improved_symptoms_and_response_to_risperidone_in_Children_with_Autism_than_patients_with_the_GG_homozygotes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_may_have_lower_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_indicating_improved_symptoms_and_response_to_risperidone_in_Children_with_Autism_than_patients_with_the_GG_homozygotes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_may_have_poorer_response_to_risperidone_in_Children_with_Autism_than_patients_with_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Patients_with_the_AA_genotype_and_Myasthenia_Gravis_may_have_reduced_clearance_of_cyclosporine_and_therefore_may_require_a_decreased_dose_of_cyclosporine_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_and_dose_of_cyclosporine.""AG:Patients_with_the_AG_genotype_and_Myasthenia_Gravis_may_have_altered_clearance_of_cyclosporine_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_and_dose_of_cyclosporine.""GG:Patients_with_the_GG_genotype_and_Myasthenia_Gravis_may_have_increased_clearance_of_cyclosporine_and_therefore_may_require_an_increased_dose_of_cyclosporine_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_and_dose_of_cyclosporine.","AA:Patients_with_the_AA_genotype_who_receive_phenytoin_may_have_increased_plasma_drug_levels_of_phenytoin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.""AG:Patients_with_the_AG_genotype_who_receive_phenytoin_may_have_increased_plasma_drug_levels_of_phenytoin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.""GG:Patients_with_the_GG_genotype_who_receive_phenytoin_may_have_decreased_plasma_drug_levels_of_phenytoin_as_compared_to_patients_with_the_AG_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.","AA:Patients_with_the_AA_genotype_may_have_increased_serum_creatine_kinase_levels_when_treated_with_hmg_CoA_reductase_inhibitors_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_serum_creatine_kinase_levels._""AG:Patients_with_the_AG_genotype_may_have_decreased_serum_creatine_kinase_levels_when_treated_with_hmg_CoA_reductase_inhibitors_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_serum_creatine_kinase_levels._""GG:Patients_with_the_GG_genotype_may_have_decreased_serum_creatine_kinase_levels_when_treated_with_hmg_CoA_reductase_inhibitors_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_serum_creatine_kinase_levels._","AA:Patients_with_the_AA_genotype_and_chronic_myeloid_leukemia_may_have_a_poorer_response_to_imatinib_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib._""AG:Patients_with_the_AG_genotype_and_chronic_myeloid_leukemia_may_have_a_poorer_response_to_imatinib_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib._""GG:Patients_with_the_GG_genotype_and_chronic_myeloid_leukemia_may_have_a_better_response_to_imatinib_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_imatinib._","AA:Patients_with_the_AA_genotype_who_are_placed_under_anesthesia_may_have_an_increased_response_to_rocuronium_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rocuronium._""AG:Patients_with_the_AG_genotype_who_are_placed_under_anesthesia_may_have_a_decreased_response_to_rocuronium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rocuronium._""GG:Patients_with_the_GG_genotype_who_are_placed_under_anesthesia_may_have_a_decreased_response_to_rocuronium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rocuronium._","AA:Patients_with_renal_cell_carcinoma_and_the_AA_genotype_who_are_treated_with_sunitinib_may_have_a_decreased_risk_of_neutropenia_leukopenia_and_diarrhea_as_compared_to_patients_with_the_AG_and_GG_genotypes_although_this_has_been_contradicted_by_some_studies._Other_clinical_and_genetic_factors_may_also_influence_risk_of_toxicity_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib.""AG:Patients_with_renal_cell_carcinoma_and_the_AG_genotype_who_are_treated_with_sunitinib_may_have_an_increased_risk_of_neutropenia_leukopenia_as_compared_to_patients_with_the_AA_genotypes_and_a_decreased_risk_of_diarrhea_as_compared_to_patients_with_the_GG_genotype_although_this_has_been_contradicted_by_some_studies._Other_clinical_and_genetic_factors_may_also_influence_risk_of_toxicity_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib.""GG:Patients_with_renal_cell_carcinoma_and_the_GG_genotype_who_are_treated_with_sunitinib_may_have_an_increased_risk_of_neutropenia_leukopenia_and_diarrhea_as_compared_to_patients_with_the_AA_genotypes_although_this_has_been_contradicted_by_some_studies._Other_clinical_and_genetic_factors_may_also_influence_risk_of_toxicity_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib.","AA:Patients_with_AA_genotype_and_HIV_may_have_decreased_concentrations_of_efavirenz_in_plasma_compared_to_patients_with_AG_or_GG_genotypes._However_this_association_was_not_significant_and_was_not_found_in_another_study_of_plasma_and_PBMCs._Other_clinical_and_genetic_factors_may_affect_efavirenz_concentrations.""AG:Patients_with_AG_genotype_and_HIV_may_have_increased_concentrations_of_efavirenz_in_plasma_compared_to_patients_with_AA_genotype._However_this_association_was_not_significant_and_was_not_found_in_another_study_of_plasma_and_PBMCs._Other_clinical_and_genetic_factors_may_affect_efavirenz_concentrations.""GG:Patients_with_GG_genotype_and_HIV_may_have_increased_concentrations_of_efavirenz_in_plasma_compared_to_patients_with_AA_genotype._However_this_association_was_not_significant_and_was_not_found_in_another_study_of_plasma_and_PBMCs._Other_clinical_and_genetic_factors_may_affect_efavirenz_concentrations.","AA:Patients_with_AA_genotype_and_narcolepsy_may_have_decreased_response_to_modafinil_compared_to_patients_with_AG_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_modafinil.""AG:Patients_with_AG_genotype_and_narcolepsy_may_have_increased_response_to_modafinil_compared_to_patients_with_AA_or_GG_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_modafinil.""GG:Patients_with_GG_genotype_and_narcolepsy_may_have_decreased_response_to_modafinil_compared_to_patients_with_AG_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_modafinil.","AA:Patients_with_the_AA_genotype_who_are_undergoing_organ_transplantation_may_have_increased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._However_the_majority_of_the_literature_evidence_shows_no_association_between_this_variant_and_tacrolimus_concentrations_clearance_or_dose._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_tacrolimus._""AG:Patients_with_the_AG_genotype_who_are_undergoing_organ_transplantation_may_have_increased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_GG_genotype._However_the_majority_of_the_literature_evidence_shows_no_association_between_this_variant_and_tacrolimus_concentrations_clearance_or_dose._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_tacrolimus._""GG:Patients_with_the_GG_genotype_who_are_undergoing_organ_transplantation_may_have_decreased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_or_AG_genotype._However_the_majority_of_the_literature_evidence_shows_no_association_between_this_variant_and_tacrolimus_concentrations_clearance_or_dose._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_tacrolimus._","AA:Patients_with_the_AA_genotype_and_acute_myeloid_leukemia_may_have_a_better_response_when_treated_with_cytarabine_alone_or_in_combination_with_daunorubicin_or_dexrazoxane_as_compared_to_patients_with_the_GG_genotype_however_some_evidence_contradicts_this._Other_genetic_and_clinical_factors_may_also_influence_response_to_cytarabine.""AG:Patients_with_the_AG_genotype_and_acute_myeloid_leukemia_may_have_a_better_response_when_treated_with_cytarabine_alone_or_in_combination_with_daunorubicin_or_dexrazoxane_as_compared_to_patients_with_the_GG_genotype_however_some_evidence_contradicts_this._Other_genetic_and_clinical_factors_may_also_influence_response_to_cytarabine.""GG:Patients_with_the_GG_genotype_and_acute_myeloid_leukemia_may_have_a_poorer_response_when_treated_with_cytarabine_alone_or_in_combination_with_daunorubicin_or_dexrazoxane_as_compared_to_patients_with_the_AA_or_AG_genotype_however_some_evidence_contradicts_this._Other_genetic_and_clinical_factors_may_also_influence_response_to_cytarabine.";PGKB_RACE=NR,NR,Asian,White,NR,Asian,Black_or_African_American,NR,Asian,Asian,Asian,NR,NR,NR,NR
7	87179809	rs2229109	C	T,A	.	.	PGKB_INDEX=9;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=bisantrene_(PA146096021),calcein_(PA132595336),forskolin_(PA146096022),prazosin_(PA451093),verapamil_(PA451868),vinblastine_(PA451877),paclitaxel_(PA450761),"doxorubicin_(PA449412)""methotrexate_(PA450428)""prednisolone_(PA451096)""vincristine_(PA451879)","bleomycin_(PA448645)""cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""prednisone_(PA451100)""rituximab_(PA451261)""vincristine_(PA451879)""vindesine_(PA10232)";PGKB_TYPE=Other,Other,Other,Other,Other,Other,Other,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=4,4,4,4,4,4,4,3,3;PGKB_DISEASE=NR,NR,NR,NR,NR,NR,NR,Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Lymphoma_Non-Hodgkin_(PA444845);PGKB_TEXT="CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.","CC:Cells_with_the_C_allele_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_alleles.""CT:Cells_with_this_genotype_would_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_genotypes_(inferred).""TT:Cells_with_the_T_allele_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_alleles.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.","CC:Cells_with_the_CC_genotype_have_normal_ability_to_efflux_fluorescently_labelled_paclitaxel.""CT:Cells_with_the_CT_genotype_have_a_slight_decrease_in_ability_to_efflux_fluorescently_labelled_paclitaxel_compared_to_cells_with_genotype_CC.""TT:Cells_with_the_TT_genotype_have_a_slight_decrease_in_ability_to_efflux_fluorescently_labelled_paclitaxel_compared_to_cells_with_genotype_CC.","CC:Patients_with_the_CC_genotype_and_acute_lymphoblastic_leukemia_may_have_a_lower_risk_of_relapse_when_treated_with_doxorubicin_methotrexate_prednisolone_and_vincristine_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_relapse.""CT:Patients_with_the_CT_genotype_and_acute_lymphoblastic_leukemia_may_have_a_greater_risk_of_relapse_when_treated_with_doxorubicin_methotrexate_prednisolone_and_vincristine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_relapse.""TT:No_patients_with_the_TT_genotype_were_studied_but_patients_with_the_CT_genotype_and_acute_lymphoblastic_leukemia_may_have_a_greater_risk_of_relapse_when_treated_with_doxorubicin_methotrexate_prednisolone_and_vincristine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_relapse.","CC:Patients_with_the_CC_genotype_and_non-Hodgkin_lymphoma_may_have_a_lower_risk_of_diarrhea_and_vomiting_when_treated_with_R-CHOP_type_regimens_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea_and_vomiting_when_treated_with_R-CHOP_type_regimens.""CT:Patients_with_the_CT_genotype_and_non-Hodgkin_lymphoma_may_have_a_greater_risk_of_diarrhea_and_vomiting_when_treated_with_R-CHOP_type_regimens_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea_and_vomiting_when_treated_with_R-CHOP_type_regimens.""TT:No_patients_with_the_TT_genotype_were_studied_but_patients_with_the_CT_genotype_and_non-Hodgkin_lymphoma_may_have_a_greater_risk_of_diarrhea_and_vomiting_when_treated_with_R-CHOP_type_regimens_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea_and_vomiting_when_treated_with_R-CHOP_type_regimens.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR,NR,NR
7	87180198	rs10276036	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""methotrexate_(PA450428)""vincristine_(PA451879)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteosarcoma_(PA445601);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_osteosarcoma_may_have_an_increased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CC_genotype_but_an_increased_risk_of_death_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
7	87199564	rs2235015	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="amitriptyline_(PA448385)""antidepressants_(PA452229)""citalopram_(PA449015)""paroxetine_(PA450801)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Depression_(PA447278)""Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_amitryptiline_citalopram_paraxetine_or_venlafaxine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission.""AC:Patients_with_the_AC_genotype_and_depression_who_are_treated_with_amitryptiline_citalopram_paraxetine_or_venlafaxine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission.""CC:Patients_with_the_CC_genotype_and_depression_who_are_treated_with_amitryptiline_citalopram_paraxetine_or_venlafaxine_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_remission.";PGKB_RACE=White
7	87229440	rs9282564	T	C	.	.	PGKB_INDEX=8;PGKB_GENE=ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267),ABCB1_(PA267);PGKB_DRUG=bisantrene_(PA146096021),calcein_(PA132595336),forskolin_(PA146096022),prazosin_(PA451093),verapamil_(PA451868),vinblastine_(PA451877),paclitaxel_(PA450761),morphine_(PA450550);PGKB_TYPE=Other,Other,Other,Other,Other,Other,Other,Toxicity/ADR;PGKB_EVIDENCE=4,4,4,4,4,4,4,3;PGKB_DISEASE=NR,NR,NR,NR,NR,NR,NR,NR;PGKB_TEXT="CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_bisantrene_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_calcein_compared_to_cells_with_other_genotypes.","CC:Cells_with_the_C_allele_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_alleles.""CT:Cells_with_the_CT_genotype_would_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_genotypes(inferred).""TT:Cells_with_the_T_allele_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_forskolin_compared_to_cells_with_other_alleles.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_prazosin_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_verapamil_compared_to_cells_with_other_genotypes.","CC:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.""CT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastine_compared_to_cells_with_other_genotypes.""TT:Cells_with_this_genotype_show_no_difference_in_P-glycoprotein_expression_or_ability_to_transport_vinblastinel_compared_to_cells_with_other_genotypes.","CC:Cells_with_the_CC_genotype_have_a_slight_decrease_in_ability_to_efflux_fluorescently_labelled_paclitaxel_compared_to_cells_with_genotype_TT.""CT:Cells_with_the_CT_genotype_have_a_slight_decrease_in_ability_to_efflux_fluorescently_labelled_paclitaxel_compared_to_cells_with_genotype_TT.""TT:Cells_with_the_TT_genotype_have_normal_ability_to_efflux_fluorescently_labelled_paclitaxel.","CC:Children_with_the_CC_genotype_who_are_undergoing_a_tonsillectomy_and_are_treated_with_morphine_may_have_a_longer_hospital_stay_due_to_respiratory_depression_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_respiratory_depression.""CT:Children_with_the_CT_genotype_who_are_undergoing_a_tonsillectomy_and_are_treated_with_morphine_may_have_a_longer_hospital_stay_due_to_respiratory_depression_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_respiratory_depression.""TT:Children_with_the_TT_genotype_who_are_undergoing_a_tonsillectomy_and_are_treated_with_morphine_may_have_a_decreased_chance_of_a_prolonged_hospital_stay_due_to_respiratory_depression_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_respiratory_depression.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR,NR
7	87230193	rs3213619	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_an_increased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=Black_or_African_American
7	87233602	rs4728709	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG=vincristine_(PA451879);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_reduced_but_not_absent_risk_of_grade_1-2_neurotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._""AG:Patients_with_the_AG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_reduced_but_not_absent_risk_of_grade_1-2_neurotoxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_an_increased_risk_of_grade_1-2_neurotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._""GG:Patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_an_increased_risk_of_grade_1-2_neurotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._";PGKB_RACE=White
7	87278760	rs10267099	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_genotype_AA_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""AG:Patients_with_genotype_AG_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_GG_genotype_and_an_increased_risk_of_hypercholesteremia_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""GG:Patients_with_genotype_GG_and_hypertension_may_have_an_increased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=White
7	87346819	rs17160359	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCB1_(PA267);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="GG:Patients_with_metastasized_cancer_and_the_GG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""GT:Patients_with_metastasized_cancer_and_the_GT_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GG_genotype_and_worse_response_as_compared_to_people_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model._""TT:Patients_with_metastasized_cancer_and_the_TT_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.";PGKB_RACE=Asian
7	94923856	rs854547	G	A	.	.	PGKB_INDEX=1;PGKB_GENE="PON1_(PA33529)""PPP1R9A_(PA33661)";PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Rheumatoid_Arthritis_patients_with_the_genotype_AA_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Rheumatoid_Arthritis_patients_with_the_genotype_AG_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Rheumatoid_Arthritis_patients_with_the_genotype_GG_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
7	94925820	rs854548	A	G	.	.	PGKB_INDEX=1;PGKB_GENE="PON1_(PA33529)""PPP1R9A_(PA33661)";PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Rheumatoid_Arthritis_patients_with_the_genotype_AA_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Rheumatoid_Arthritis_patients_with_the_genotype_AG_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Rheumatoid_Arthritis_patients_with_the_genotype_GG_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
7	94930391	rs854555	A	C	.	.	PGKB_INDEX=1;PGKB_GENE="PON1_(PA33529)""PPP1R9A_(PA33661)";PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Rheumatoid_Arthritis_patients_with_the_AA_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AC:Rheumatoid_Arthritis_patients_with_the_AC_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CC:Rheumatoid_Arthritis_patients_with_the_CC_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
7	94937446	rs662	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=PON1_(PA33529),PON1_(PA33529);PGKB_DRUG=clopidogrel_(PA449053),"epirubicin_(PA449476)""fluorouracil_(PA128406956)""oxaliplatin_(PA131285527)";PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Angina_Pectoris_(PA443362)""Coronary_Artery_Disease_(PA443796)""Myocardial_Infarction_(PA445019)""Myocardial_Ischemia_(PA446459)""Thrombosis_(PA445850)","Neoplasms_(PA445062)""Stomach_Neoplasms_(PA445742)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_clopidogrel_1)_may_have_higher_levels_of_active_metabolite_resulting_in_increased_platelet_inhibition_and_better_response_2)_may_have_a_decreased_but_not_absent_risk_of_stent_thrombosis_target_vessel_revascularization_or_cardiovascular_secondary_events_as_compared_to_patients_with_the_CT_or_TT_genotype._A_large_number_of_studies_report_contradictory_findings._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""CT:Patients_with_the_CT_genotype_who_are_treated_with_clopidogrel_1)_may_have_lower_levels_of_active_metabolite_resulting_in_decreased_platelet_inhibition_and_decreased_response_2)_may_have_an_increased_risk_for_stent_thrombosis_target_vessel_revascularization_risk_of_stent_thrombosis_target_vessel_revascularization_or_cardiovascular_secondary_events_as_compared_to_patients_with_the_CC_genotype._A_large_number_of_studies_report_contradictory_findings._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""TT:Patients_with_the_TT_genotype_who_are_treated_with_clopidogrel_1)_may_have_lower_levels_of_active_metabolite_resulting_in_decreased_platelet_inhibition_and_decreased_response_2)_may_have_an_increased_risk_for_stent_thrombosis_target_vessel_revascularization_risk_of_stent_thrombosis_target_vessel_revascularization_or_cardiovascular_secondary_events_as_compared_to_patients_with_the_CC_genotype._A_large_number_of_studies_report_contradictory_findings._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.","CC:Patients_with_the_CC_genotype_and_cancer_including_cancer_of_the_stomach_may_have_an_increased_response_when_treated_with_epirubicin_fluorouracil_and_oxaliplatin_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_epirubicin_fluorouracil_and_oxaliplatin_in_patients_with_cancer._""CT:Patients_with_the_CT_genotype_and_cancer_including_cancer_of_the_stomach_may_have_a_decreased_response_when_treated_with_epirubicin_fluorouracil_and_oxaliplatin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_epirubicin_fluorouracil_and_oxaliplatin_in_patients_with_cancer._""TT:Patients_with_the_TT_genotype_and_cancer_including_cancer_of_the_stomach_may_have_a_decreased_response_when_treated_with_epirubicin_fluorouracil_and_oxaliplatin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_epirubicin_fluorouracil_and_oxaliplatin_in_patients_with_cancer._";PGKB_RACE=NR,Asian
7	94946084	rs854560	A	C,G,N,T	.	.	PGKB_INDEX=1;PGKB_GENE=PON1_(PA33529);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=4;PGKB_DISEASE="Cardiovascular_Diseases_(PA443635)""Myocardial_Infarction_(PA445019)";PGKB_TEXT="AA:The_AA_genotype_is_not_associated_with_differences_in_clopi-H4_formation_or_antiplatelet_response_or_increased_risk_of_major_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""AT:The_AT_genotype_is_not_associated_with_differences_in_clopi-H4_formation_or_antiplatelet_response_or_increased_risk_of_major_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""TT:The_TT_genotype_is_not_associated_with_differences_in_clopi-H4_formation_or_antiplatelet_response_or_increased_risk_of_major_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.";PGKB_RACE=NR
7	99245909	rs17161788	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A5_(PA131);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_atorvastatin_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""CT:Patients_with_the_CT_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_atorvastatin_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""TT:Patients_with_the_TT_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_atorvastatin_treatment_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._";PGKB_RACE=NR
7	99250393	rs41303343	T	TA	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A5_(PA131);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Organ_Transplantation_(PA133888799);PGKB_TEXT="A/del:Transplant_recipients_with_the_A/del_(CYP3A5_*1/*7)_genotype_may_have_decreased_metabolism_of_tacrolimus_and_require_a_lower_dose_of_the_drug_as_compared_to_patients_with_the_del/del_(*1/*1)_genotype_and_have_increased_metabolism_and_require_a_higher_dose_of_the_drug_as_compared_to_patients_with_the_AA_(*7/*7)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_tacrolimus_dose_requirements.""AA:Transplant_recipients_with_the_AA_(CYP3A5_*7/*7)_genotype_may_have_decreased_metabolism_of_tacrolimus_and_require_a_lower_dose_of_the_drug_as_compared_to_patients_with_the_A/del_or_del/del_(*1/*7_or_*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_tacrolimus_dose_requirements.""del/del:Transplant_recipients_with_the_del/del_(CYP3A5_*1/*1)_genotype_may_have_increased_metabolism_of_tacrolimus_and_require_a_higher_dose_of_the_drug_as_compared_to_patients_with_the_A/del_or_AA_(*1/*7_or_*7/*7)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_tacrolimus_dose_requirements.";PGKB_RACE=NR
7	99262835	rs10264272	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A5_(PA131);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Organ_Transplantation_(PA133888799);PGKB_TEXT="CC:Transplant_recipients_with_the_CC_(CYP3A5_*1/*1)_genotype_may_have_increased_metabolism_of_tacrolimus_and_require_a_higher_dose_of_the_drug_as_compared_to_patients_with_the_CT_or_TT_(*1/*6_or_*6/*6)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_tacrolimus_dose_requirements.""CT:Transplant_recipients_with_the_CT_(CYP3A5_*1/*6)_genotype_may_have_decreased_metabolism_of_tacrolimus_and_require_a_lower_dose_of_the_drug_as_compared_to_patients_with_the_CC_(*1/*1)_genotype_and_have_increased_metabolism_and_require_a_higher_dose_of_the_drug_as_compared_to_patients_with_the_TT_(*6/*6)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_tacrolimus_dose_requirements.""TT:Transplant_recipients_with_the_TT_(CYP3A5_*6/*6)_genotype_may_have_decreased_metabolism_of_tacrolimus_and_require_a_lower_dose_of_the_drug_as_compared_to_patients_with_the_CT_or_CC_(*1/*6_or_*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_tacrolimus_dose_requirements.";PGKB_RACE=NR
7	99270539	rs776746	C	T	.	.	PGKB_INDEX=29;PGKB_GENE=CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),"CYP3A_(PA27114)""CYP3A5_(PA131)",CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131),CYP3A5_(PA131);PGKB_DRUG=lovastatin_(PA450272),tacrolimus_(PA451578),simvastatin_(PA451363),nifedipine_(PA450631),amlodipine_(PA448388),sunitinib_(PA162372840),atorvastatin_(PA448500),ondansetron_(PA450705),cyclosporine_(PA449167),paclitaxel_(PA450761),nevirapine_(PA450616),tacrolimus_(PA451578),tacrolimus_(PA451578),sirolimus_(PA451365),tacrolimus_(PA451578),efavirenz_(PA449441),tacrolimus_(PA451578),tacrolimus_(PA451578),cyclosporine_(PA449167),tacrolimus_(PA451578),tacrolimus_(PA451578),quetiapine_(PA451201),tacrolimus_(PA451578),tacrolimus_(PA451578),tacrolimus_(PA451578),vardenafil_(PA10229),tacrolimus_(PA451578),tacrolimus_(PA451578),carbamazepine_(PA448785);PGKB_TYPE=Efficacy,"Dosage""Metabolism/PK",Other,Other,Other,"Dosage""Toxicity/ADR",Efficacy,Other,"Dosage""Metabolism/PK",Toxicity/ADR,Other,Toxicity/ADR,Toxicity/ADR,Dosage,"Dosage""Metabolism/PK",Other,Efficacy,Toxicity/ADR,"Dosage""Metabolism/PK","Dosage""Metabolism/PK",Toxicity/ADR,Metabolism/PK,Efficacy,Efficacy,Toxicity/ADR,Metabolism/PK,Toxicity/ADR,Toxicity/ADR,"Dosage""Metabolism/PK";PGKB_EVIDENCE=3,2A,3,3,3,3,3,3,2B,3,3,3,3,2A,1A,3,2A,3,3,3,3,3,3,3,3,3,3,3,3;PGKB_DISEASE=Arteriosclerosis_(PA443425),liver_transplantation_(PA447247),"Hypercholesterolemia_(PA444516)""Myalgia_unspecified_(PA157379134)",Pregnancy_(PA166048714),NR,Carcinoma_Renal_Cell_(PA443624),NR,NR,"Organ_Transplantation_(PA133888799)""Transplantation_(PA134850491)",NR,"HIV_(PA447230)""HIV_Infections_(PA446213)",Hyperlipidemias_(PA444528),nephrotoxicity_(PA162263533),Transplantation_(PA134850491),"Colitis_Ulcerative_(PA443750)""heart_transplantation_(PA166114458)""hemopoietic_stem_cell_transplant_(PA166122646)""Kidney_Transplantation_(PA165817016)""liver_transplantation_(PA447247)""lung_transplantation_(PA166114457)",HIV_Infections_(PA446213),transplant_rejection_(PA166114454),Neurotoxicity_Syndromes_(PA446975),liver_transplantation_(PA447247),liver_transplantation_(PA447247),Kidney_Failure_(PA446438),NR,transplant_rejection_(PA166114454),Colitis_Ulcerative_(PA443750),Infection_(PA444614),NR,Hypertension_(PA444552),Toxic_liver_disease_(PA164925725),Epilepsy_(PA444065);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Arteriosclerosis_who_are_treated_with_lovastatin_may_have_a_better_response_to_treatment_(measured_by_higher_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment.""CT:Patients_with_the_CT_genotype_and_Arteriosclerosis_who_are_treated_with_lovastatin_may_have_a_reduced_response_to_treatment_(measured_by_lower_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment.""TT:Patients_with_the_TT_genotype_and_Arteriosclerosis_were_not_examined_in_the_study_however__patients_with_the_CT_genotype_who_are_treated_with_lovastatin_may_have_a_reduced_response_to_treatment_(measured_by_lower_reductions_in_total_cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment.","CC:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_CC_(CYP3A5_*3/*3)_genotype_may_have_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_may_require_a_lower_dose_as_compared_to_patients_who_receive_a_liver_transplantation_from_a_donor_with_the_CT_or_TT_(*1/*3_or_*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_recipient_genotype_may_also_influence_a_patient's_tacrolimus_dose_requirement._""CT:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_CT_(CYP3A5_*1/*3)_genotype_may_have_increased_metabolism_of_tacrolimus_resulting_in_decreased_exposure_and_may_require_a_higher_dose_as_compared_to_patients_who_receive_a_liver_transplantation_from_a_donor_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_such_as_recipient_genotype_may_also_influence_a_patient's_tacrolimus_dose_requirement._""TT:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_TT_(CYP3A5_*1/*1)_genotype_may_have_increased_metabolism_of_tacrolimus_resulting_in_decreased_exposure_and_may_require_a_higher_dose_as_compared_to_patients_who_receive_a_liver_transplantation_from_a_donor_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_such_as_recipient_genotype_may_also_influence_a_patient's_tacrolimus_dose_requirement._","CC:Patients_with_the_CC_genotype_may_have_higher_plasma_concentrations_and_reduced_clearance_of_simvastatin_as_compared_to_patients_with_the_TT_genotype._This_does_not_seem_to_affect_response_to_treatment_or_risk_of_myalgia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_simvastatin_and_response_to_treatment._""CT:Patients_with_the_CT_genotype_may_have_higher_plasma_concentrations_and_reduced_clearance_of_simvastatin_as_compared_to_patients_with_the_TT_genotype_or_may_have_lower_plasma_concentrations_and_higher_clearance_of_simvastatin_as_compared_to_patients_with_the_CC_genotype._This_does_not_seem_to_affect_response_to_treatment_or_risk_of_myalgia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_simvastatin_and_response_to_treatment._""TT:Patients_with_the_TT_genotype_may_have_lower_plasma_concentrations_and_higher_clearance_of_simvastatin_as_compared_to_patients_with_the_CC_genotype._This_does_not_seem_to_affect_response_to_treatment_or_risk_of_myalgia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_simvastatin_and_response_to_treatment._","CC:Pregnant_women_with_the_CC_genotype_may_have_decreased_clearance_of_nifedipine_as_compared_to_women_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nifedipine.""CT:Pregnant_women_with_the_CT_genotype_may_have_increased_clearance_of_nifedipine_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nifedipine.""TT:Pregnant_women_with_the_TT_genotype_may_have_increased_clearance_of_nifedipine_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nifedipine.","CC:Healthy_males_with_the_CC_(CYP3A5_*3/*3)_genotype_may_have_increased_metabolism_of_amlodipine_as_compared_to_healthy_males_with_the_CT_or_TT_(*3/*1_or_*1/*1)_genotype._No_significant_associations_were_seen_when_considering_clearance_of_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_amlodipine.""CT:Healthy_males_with_the_CT_(CYP3A5_*3/*1)_genotype_may_have_decreased_metabolism_of_amlodipine_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._No_significant_associations_were_seen_when_considering_clearance_of_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_amlodipine.""TT:Healthy_males_with_the_TT_(CYP3A5_*1/*1)_genotype_may_have_decreased_metabolism_of_amlodipine_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._No_significant_associations_were_seen_when_considering_clearance_of_amlodipine._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_amlodipine.","CC:Patients_with_the_CC_genotype_and_Carcinoma_who_are_treated_with_sunitinib_may_have_a_decreased_but_not_absent_risk_for_dose_reductions_due_to_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.""CT:Patients_with_the_CT_genotype_and_Carcinoma_who_are_treated_with_sunitinib_may_have_a_decreased_but_not_absent_risk_for_dose_reductions_due_to_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.""TT:Patients_with_the_TT_genotype_and_Carcinoma_who_are_treated_with_sunitinib_may_have_an_increased_risk_for_dose_reductions_due_to_toxicity_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sunitinib.","CC:Patients_with_the_CC_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Conflicting_evidence_was_seen_by_population_type._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""CT:Patients_with_the_CT_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Conflicting_evidence_was_seen_by_population_type._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Conflicting_evidence_was_seen_by_population_type._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_ondansetron_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_ondansetron.""CT:Patients_with_the_CT_genotype_may_have_increased_metabolism_of_ondansetron_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_ondansetron.""TT:Patients_with_the_TT_genotype_may_have_decreased_metabolism_of_ondansetron_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_ondansetron.","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_may_require_a_lower_dose_of_cyclosporine_to_reach_target_blood_concentration_as_compared_to_patients_with_the_CT_(CYP3A5_*1/*3)_or_TT_(CYP3A5_*1/*1)_genotype_although_this_is_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_dose_of_cyclosporine.""CT:Patients_with_the_CT_(CYP3A5_*1/*3)_genotype_may_require_a_higher_dose_of_cyclosporine_to_reach_target_blood_concentration_as_compared_to_patients_with_the_CC_(CYP3A5_*3/*3)_genotype_although_this_is_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_dose_of_cyclosporine.""TT:Patients_with_the_TT_genotype_(CYP3A5_*1/*1)_may_require_a_higher_dose_of_cyclosporine_to_reach_target_blood_concentration_as_compared_to_patients_with_the_CC_(CYP3A5_*3/*3)_genotype_although_this_is_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_dose_of_cyclosporine.","CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_of_neurotoxicity_when_treated_with_paclitaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_toxicity_with_paclitaxel.""CT:Patients_with_the_CT_genotype_may_have_decreased_but_not_absent_risk_of_neurotoxicity_when_treated_with_paclitaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_toxicity_with_paclitaxel.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_neurotoxicity_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_toxicity_with_paclitaxel.","CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_nevirapine_may_have_increased_clearance_of_the_drug_as_compared_to_patients_with_the_CT_and_TT_genotype._Association_with_clearance_was_not_found_in_a_larger_cohort_in_a_separate_study._Patients_may_also_have_differences_in_alanine_aminotransferase_levels_but_association_with_toxicity_has_not_been_reported._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nevirapine.""CT:Patients_with_the_CT_genotype_and_HIV_infection_who_are_treated_with_nevirapine_may_have_decreased_clearance_of_the_drug_as_compared_to_patients_with_the_CC_genotype._Association_with_clearance_was_not_found_in_a_larger_cohort_in_a_separate_study._Patients_may_also_have_differences_in_alanine_aminotransferase_levels_but_association_with_toxicity_and_genotype_has_not_been_reported._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nevirapine.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_nevirapine_may_have_decreased_clearance_of_the_drug_as_compared_to_patients_with_the_CC_genotype._Association_with_clearance_was_not_found_in_a_larger_cohort_in_a_separate_study._Patients_may_also_have_differences_in_alanine_aminotransferase_levels_but_association_with_toxicity_and_genotype_has_not_been_reported._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nevirapine.","CC:Patients_with_the_CC_genotype_and_recipients_of_kidney_transplant_who_are_treated_with_tacrolimus_may_have_an_increased_risk_of_developing_hyperlipidemia_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hyperlipidemia.""CT:Patients_with_the_CT_genotype_and_recipients_of_kidney_transplant_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_of_developing_hyperlipidemia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hyperlipidemia.""TT:Patients_with_the_TT_genotype_and_recipients_of_kidney_transplant_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_of_developing_hyperlipidemia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hyperlipidemia.","CC:Patients_with_the_CC_(*3/*3)_genotype_and_are_recipients_of_a_kidney_transplantation_who_are_treated_with_tacrolimus_may_have_an_increased_risk_of_nephrotoxicity_as_compared_to_patients_with_the_CT_or_TT_genotype_(*1/*3_or_*1/*1)._However_some_studies_show_a_decreased_risk_of_nephrotoxicity_for_patients_with_the_CC_genotype_and_the_majority_of_studies_show_no_association_at_all._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_nephrotoxicity.""CT:Patients_with_the_CT_genotype_(*1/*3)_and_are_recipients_of_a_kidney_transplantation_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_nephrotoxicity_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._However_some_studies_show_an_increased_risk_of_nephrotoxicity_for_patients_with_the_CT_genotype_and_the_majority_of_studies_show_no_association_at_all._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_nephrotoxicity.""TT:Patients_with_the_TT_(*1/*1)_genotype_and_are_recipients_of_kidney_transplantation_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_nephrotoxicity_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._However_some_studies_show_an_increased_risk_of_nephrotoxicity_for_patients_with_the_TT_genotype_and_the_majority_of_studies_show_no_association_at_all._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_nephrotoxicity.","CC:Patients_with_the_CC_genotype_(*3/*3)_and_who_are_recipients_of_transplants_may_have_decreased_metabolism_of_sirolimus_and_require_a_lower_dose_as_compared_to_patients_with_the_CT_and_TT_genotype_(*1/*3_and_*3*/3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_sirolimus_dose_requirements.""CT:Patients_with_the_CT_genotype_(*1/*3)_and_who_are_recipients_of_transplants_may_have_increased_metabolism_of_sirolimus_and_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_sirolimus_dose_requirements.""TT:Patients_with_the_TT_genotype_(*1/*1)_and_who_are_recipients_of_transplants_may_have_increased_metabolism_of_sirolimus_and_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_sirolimus_dose_requirements.","CC:Patients_with_the_CC_genotype_(CYP3A5*3/*3)_and_recipients_of_a_liver_kidney_heart_lung_or_hematopoeitic_stem_cell_transplant_or_with_ulcerative_colitis_who_are_treated_with_tacrolimus_may_have_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tacrolimus_dose_requirement.""CT:Patients_with_the_CT_genotype_(CYP3A5*1/*3)_and_recipients_of_a_liver_kidney_heart_lung_or_hematopoeitic_stem_cell_transplant_or_with_ulcerative_colitis_who_are_treated_with_tacrolimus_may_have_increased_metabolism_of_tacrolimus_resulting_in_decreased_exposure_and_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tacrolimus_dose_requirement.""TT:Patients_with_the_TT_genotype_(CYP3A5*1/*1)_and_recipients_of_a_liver_kidney_heart_lung_or_hematopoeitic_stem_cell_transplant_or_with_ulcerative_colitis_who_are_treated_with_tacrolimus_may_have_increased_metabolism_of_tacrolimus_resulting_in_decreased_exposure_and_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_tacrolimus_dose_requirement.","CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_decreased_exposure_to_drug_as_compared_to_patients_with_the_TT_genotype._Please_note__an_association_with_efavirenz_exposure_and_this_genetic_variant_was_not_found_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""CT:Patients_with_the_CT_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_decreased_exposure_to_drug_as_compared_to_patients_with_the_TT_genotype_or_may_have_increased_exposure_to_drug_as_compared_to_patients_with_the_CC_genotype._Please_note__an_association_with_efavirenz_exposure_and_this_genetic_variant_was_not_found_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_increased_exposure_to_drug_as_compared_to_patients_with_the_CC_genotype._Please_note__an_association_with_efavirenz_exposure_and_this_genetic_variant_was_not_found_in_the_majority_of_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.","CC:Patients_with_the_CC_(*3/*3)_genotype_and_recipients_of_kidney_or_hematopoietic_stem_cell_transplant_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_transplant_rejection_as_compared_to_patients_with_the_CT_or_TT_genotype_(*1/*3_or_*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus_treatment_and_risk_of_transplant_rejection.""CT:Patients_with_the_CT_genotype_(*1/*3)_and_recipients_of_kidney_or_hematopoietic_stem_cell_transplant_who_are_treated_with_tacrolimus_may_have_an_increased_risk_of_transplant_rejection_as_compared_to_patients_with_the_CC_genotype_(*3/*3)_or_a_decreased_risk_of_transplant_rejection_as_compared_to_patients_with_the_TT_genotype_(*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus_treatment_and_risk_of_transplant_rejection.""TT:Patients_with_the_TT_(*1/*1)_genotype_and_recipients_of_kidney_or_hematopoietic_stem_cell_transplant_who_are_treated_with_tacrolimus_may_have_an_increased_risk_of_transplant_rejection_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus_treatment_and_risk_of_transplant_rejection.","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_undergoing_organ_transplantation_may_have_a_decreased_risk_for_neurotoxicity_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CT_(*1/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neurotoxicity_in_patients_receiving_tacrolimus._""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_undergoing_organ_transplantation_may_have_an_increased_risk_for_neurotoxicity_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neurotoxicity_in_patients_receiving_tacrolimus._""TT:No_individuals_with_the_TT_genotype_(CYP3A5_*1/*1)_were_available_for_analysis._However_patients_with_the_CT_genotype_(CYP3A5_*1/*3)_undergoing_organ_transplantation_may_have_an_increased_risk_for_neurotoxicity_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neurotoxicity_in_patients_receiving_tacrolimus._","CC:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_CC_(CYP3A5_*3/*3)_genotype_who_is_also_CYP3A4_low_or_intermediate_expressers_may_have_decreased_metabolism_of_cyclosporine_resulting_in_increased_exposure_and_may_require_a_lower_dose_as_compared_to_patients_who_receive_a_liver_transplantation_from_a_donor_with_the_CT_or_TT_(*1/*3_or_*1/*1)_genotype_regardless_of_CYP3A4_expresser_status._Other_genetic_and_clinical_factors_such_as_recipient_genotype_may_also_influence_a_patient's_cyclosporine_dose_requirement.""CT:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_CT_(CYP3A5_*1/*3)_genotype_may_have_increased_metabolism_of_cyclosporine_resulting_in_decreased_exposure_and_may_require_a_higher_dose_as_compared_to_patients_who_receive_a_liver_transplantation_from_a_donor_with_the_CC_(*3/*3)_genotype_who_is_also_a_CYP3A4_low_or_intermediate_expresser._Other_genetic_and_clinical_factors_such_as_recipient_genotype_may_also_influence_a_patient's_cyclosporine_dose_requirement.""TT:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_TT_(CYP3A5_*1/*1)_genotype_may_have_increased_metabolism_of_cyclosporine_resulting_in_decreased_exposure_and_may_require_a_higher_dose_as_compared_to_patients_who_receive_a_liver_transplantation_from_a_donor_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_such_as_recipient_genotype_may_also_influence_a_patient's_cyclosporine_dose_requirement.","CC:Patients_undergoing_a_liver_transplant_who_carry_the_CC_(CYP3A5_*3/*3)_genotype_may_have_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_TT_(*1/*3_or_*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_the_donor_liver_genotype_may_also_influence_a_patient's_tacrolimus_dose_requirement.""CT:Patients_undergoing_a_liver_transplant_who_carry_the_CT_(CYP3A5_*1/*3)_genotype_may_have_increased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_may_require_a_lower_dose_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_such_as_the_donor_liver_genotype_may_also_influence_a_patient's_tacrolimus_dose_requirement.""TT:Patients_undergoing_a_liver_transplant_who_carry_the_CT_(CYP3A5_*1/*3)_genotype_may_have_increased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_may_require_a_lower_dose_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_such_as_the_donor_liver_genotype_may_also_influence_a_patient's_tacrolimus_dose_requirement.","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_undergoing_liver_transplantation_may_have_an_increased_risk_for_renal_dysfunction_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CT_or_TT_genotype_(*1/*3_or_*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_renal_dysfunction._""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_undergoing_liver_transplantation_may_have_a_decreased_risk_for_renal_dysfunction_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_renal_dysfunction._""TT:Patients_with_the_TT_genotype_(CYP3A5_*1/*1)_undergoing_liver_transplantation_may_have_a_decreased_risk_for_renal_dysfunction_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_renal_dysfunction._","CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_quetiapine_as_compared_to_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_quetiapine.""CT:Patients_with_the_CT_genotype_may_have_increased_metabolism_of_quetiapine_as_compared_to_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_quetiapine.""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_quetiapine_as_compared_to_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_quetiapine.","CC:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_CC_(CYP3A5_*3/*3)_genotype_and_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_transplant_rejection_as_compared_to_patients_with_the_CT_or_TT_genotype_(*1/*3_or_*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus_treatment_and_risk_of_transplant_rejection.""CT:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_CT_(CYP3A5_*1/*3)_genotype_and_are_treated_with_tacrolimus_may_have_an_increased_risk_of_transplant_rejection_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus_treatment_and_risk_of_transplant_rejection.""TT:Patients_who_are_recipients_of_a_liver_transplantation_from_a_donor_with_the_TT_(CYP3A5_*1/*1)_genotype_and_are_treated_with_tacrolimus_may_have_an_increased_risk_of_transplant_rejection_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus_treatment_and_risk_of_transplant_rejection.","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_and_ulcerative_colitis_may_have_an_increased_chance_of_achieving_remission_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CT_(*1/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_chance_of_remission_from_ulcerative_colitis._""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_and_ulcerative_colitis_may_have_a_decreased_chance_of_achieving_remission_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_chance_of_remission_from_ulcerative_colitis._""TT:No_patients_with_the_TT_genotype_(CYP3A5_*1/*1)_were_available_for_analysis._However_patients_with_the_CT_genotype_(CYP3A5_*1/*3)_and_ulcerative_colitis_may_have_a_decreased_chance_of_achieving_remission_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_chance_of_remission_from_ulcerative_colitis._","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_undergoing_organ_transplantation_may_have_a_decreased_risk_for_infections_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CT_or_TT_(*1/*3_or_*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_infections_in_patients_receiving_tacrolimus.""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_undergoing_organ_transplantation_may_have_an_increased_risk_for_infections_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_infections_in_patients_receiving_tacrolimus.""TT:Patients_with_the_TT_genotype_(CYP3A5_*1/*1)_undergoing_organ_transplantation_may_have_an_increased_risk_for_infections_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_infections_in_patients_receiving_tacrolimus.","CC:Male_patients_with_the_CC_genotype_may_have_decreased_clearance_of_vardenafil_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vardenafil.""CT:Male_patients_with_the_CT_genotype_may_have_decreased_clearance_of_vardenafil_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vardenafil.""TT:Male_patients_with_the_TT_genotype_may_have_increased_clearance_of_vardenafil_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_vardenafil.","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_undergoing_kidney_transplantation_may_have_decreased_systolic_and_diastolic_blood_pressure_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CT_or_TT_(*1/*3_or_*1/*1)_genotype._However_the_majority_of_studies_show_no_association_between_the_CC_genotype_and_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_changes_in_blood_pressure_in_patients_receiving_tacrolimus.""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_undergoing_kidney_transplantation_may_have_increased_systolic_and_diastolic_blood_pressure_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._However_the_majority_of_studies_show_no_association_between_the_CT_genotype_and_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_changes_in_blood_pressure_in_patients_receiving_tacrolimus.""TT:Patients_with_the_TT_genotype_(CYP3A5_*1/*1)_undergoing_kidney_transplantation_may_have_increased_systolic_and_diastolic_blood_pressure_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._However_the_majority_of_studies_show_no_association_between_the_TT_genotype_and_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_changes_in_blood_pressure_in_patients_receiving_tacrolimus.","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_undergoing_liver_transplantation_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_of_experiencing_calcineurin-inhibitor_induced_hepatic_toxicity_as_compared_to_patients_with_the_CT_or_TT_genotype_(*1/*3_or_*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatic_toxicity._""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_undergoing_liver_transplantation_who_are_treated_with_tacrolimus_may_have_an_increased_risk_of_experiencing_calcineurin-inhibitor_induced_hepatic_toxicity_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatic_toxicity._""TT:Patients_with_the_TT_genotype_(CYP3A5_*1/*1)_undergoing_liver_transplantation_who_are_treated_with_tacrolimus_may_have_an_increased_risk_of_experiencing_calcineurin-inhibitor_induced_hepatic_toxicity_as_compared_to_patients_with_the_CC_genotype_(*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatic_toxicity._","CC:Patients_with_the_CC_genotype_(CYP3A5_*3/*3)_and_epilepsy_may_have_increased_dose-adjusted_trough_concentrations_of_carbamazepine_and_require_lower_doses_of_the_drug_as_compared_to_patients_with_the_CT_(*1/*3)_or_TT_(*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_or_concentrations_of_carbamazepine.""CT:Patients_with_the_CT_genotype_(CYP3A5_*1/*3)_and_epilepsy_may_have_decreased_dose-adjusted_trough_concentrations_of_carbamazepine_and_require_higher_doses_of_the_drug_as_compared_to_patients_with_the_CC_genotype_(CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_dose_or_concentrations_of_carbamazepine.""TT:Patients_with_the_TT_genotype_(CYP3A5_*1/*1)_and_epilepsy_may_have_decreased_dose-adjusted_trough_concentrations_of_carbamazepine_and_require_higher_doses_of_the_drug_as_compared_to_patients_with_the_CC_genotype_(CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_dose_or_concentrations_of_carbamazepine.";PGKB_RACE=White,NR,NR,NR,Asian,NR,White,NR,NR,NR,Black_or_African_American,NR,NR,NR,NR,NR,Asian,NR,White,NR,Asian,Asian,NR,Asian,NR,Asian,NR,Asian,Asian
7	99361466	rs2242480	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=CYP3A4_(PA130),CYP3A4_(PA130),CYP3A4_(PA130);PGKB_DRUG=clopidogrel_(PA449053),carbamazepine_(PA448785),methadone_(PA450401);PGKB_TYPE=Efficacy,Metabolism/PK,Toxicity/ADR;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Epilepsy_(PA444065),Heroin_Dependence_(PA444460);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_less_likely_to_respond_to_clopidogrel_as_compared_to_patients_with_the_CT_or_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""TC:Patients_with_the_TC_genotype_may_be_more_likely_to_respond_to_clopidogrel_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""TT:Patients_with_the_TT_genotype_may_be_more_likely_to_respond_to_clopidogrel_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._","CC:Patients_with_the_CC_genotype_(CYP3A4_*1/*1)_and_epilepsy_may_have_increased_concentrations_of_carbamazepine_as_compared_to_patients_with_the_CT_(*1/*1G)_or_TT_(*1G/*1G)_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_carbamazepine.""CT:Patients_with_the_CT_(CYP3A4_*1/*1G)_genotype_and_epilepsy_may_have_decreased_concentrations_of_carbamazepine_as_compared_to_patients_with_the_CC_(*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_carbamazepine.""TT:Patients_with_the_TT_genotype_(CYP3A4_*1G/*1G)_and_epilepsy_may_have_decreased_concentrations_of_carbamazepine_as_compared_to_patients_with_the_CC_(*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_carbamazepine.","CC:Patients_with_genotype_CC_may_have_decreased_severity_of_opioid_withdrawal_symptoms_and_side_effects_when_treated_with_methadone_in_people_with_Heroin_Dependence_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methadone.""CT:Patients_with_genotype_CT_may_have_increased_severity_of_opioid_withdrawal_symptoms_and_side_effects_when_treated_with_methadone_in_people_with_Heroin_Dependence_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methadone.""TT:Patients_with_genotype_TT_may_have_increased_severity_of_opioid_withdrawal_symptoms_and_side_effects_when_treated_with_methadone_in_people_with_Heroin_Dependence_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methadone.";PGKB_RACE=White,Asian,Asian
7	99361626	rs28371759	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=CYP3A4_(PA130),CYP3A4_(PA130);PGKB_DRUG=tacrolimus_(PA451578),cyclosporine_(PA449167);PGKB_TYPE=Metabolism/PK,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(CYP3A4_*1/*1)_who_underwent_kidney_transplantation_may_have_decreased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_AG_genotype_(*1/*18B)._Other_genetic_and_clinical_factors_such_as_rs776746_(CYP3A5*3)_may_also_influence_metabolism_of_tacrolimus.""AG:Patients_with_the_AG_genotype_(CYP3A4_*1/*18B)_who_underwent_kidney_transplantation_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype_(*1/*1)._Other_genetic_and_clinical_factors_such_as_rs776746_(CYP3A5*3)_may_also_influence_metabolism_of_tacrolimus.""GG:No_patients_with_this_genotype_were_included_in_the_analysis._However_patients_with_the_AG_genotype_(CYP3A4_*1/*18B)_who_underwent_kidney_transplantation_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype_(*1/*1)._Other_genetic_and_clinical_factors_such_as_rs776746_(CYP3A5*3)_may_also_influence_metabolism_of_tacrolimus.","AA:Patients_with_the_AA_genotype_(CYP3A4_*1/*1)_who_underwent_kidney_transplantation_may_have_decreased_metabolism_of_cyclosporine_as_compared_to_patients_with_the_GG_genotype_(*18B/*18B)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_cyclosporine.""AG:Patients_with_the_AG_genotype_(CYP3A4_*1/*1B)_who_underwent_kidney_transplantation_may_have_decreased_metabolism_of_cyclosporine_as_compared_to_patients_with_the_GG_genotype_(*18B/*18B)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_cyclosporine.""GG:Patients_with_the_GG_genotype_(CYP3A4_*18B/*18B)_who_underwent_kidney_transplantation_may_have_increased_metabolism_of_cyclosporine_as_compared_to_patients_with_the_AA_or_AG_genotype_(*1/*1_or_*1/*18B)._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_cyclosporine.";PGKB_RACE=Asian,Asian
7	99365083	rs4646437	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=CYP3A4_(PA130),CYP3A4_(PA130),CYP3A4_(PA130);PGKB_DRUG=tacrolimus_(PA451578),cyclosporine_(PA449167),voriconazole_(PA10233);PGKB_TYPE="Dosage""Metabolism/PK","Efficacy""Metabolism/PK",Metabolism/PK;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),Kidney_Transplantation_(PA165817016),Mycoses_(PA445009);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_decreased_dose-adjusted_trough_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_concentrations_of_tacrolimus.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_may_have_increased_dose-adjusted_trough_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_concentrations_of_tacrolimus.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_may_have_increased_dose-adjusted_trough_concentrations_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_such_as_the_CYP3A5*3_allele_may_also_influence_concentrations_of_tacrolimus.","AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_lower_dose-adjusted_trough_concentrations_of_cyclosporine_and_have_a_greater_likelihood_of_experiencing_biopsy-proven_acute_rejection_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_and_response_to_cyclosporine.""AG:Patients_with_the_AG_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_dose-adjusted_trough_concentrations_of_cyclosporine_and_have_a_lower_likelihood_of_experiencing_biopsy-proven_acute_rejection_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_and_response_to_cyclosporine.""GG:Patients_with_the_GG_genotype_who_are_undergoing_kidney_transplantation_may_have_higher_dose-adjusted_trough_concentrations_of_cyclosporine_and_have_a_lower_likelihood_of_experiencing_biopsy-proven_acute_rejection_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_and_response_to_cyclosporine.","AA:No_patients_with_the_AA_genotype_were_available_for_analysis_but_patients_with_the_AG_genotype_who_have_invasive_fungal_infections_may_have_increased_concentrations_of_voriconazole_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_variants_in_the_CYP2C19_gene_may_also_influence_plasma_concentrations_of_voriconazole.""AG:Patients_with_the_AG_genotype_who_have_invasive_fungal_infections_may_have_increased_concentrations_of_voriconazole_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_such_as_variants_in_the_CYP2C19_gene_may_also_influence_plasma_concentrations_of_voriconazole.""GG:Patients_with_the_GG_genotype_who_have_invasive_fungal_infections_may_have_decreased_concentrations_of_voriconazole_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_such_as_variants_in_the_CYP2C19_gene_may_also_influence_plasma_concentrations_of_voriconazole.";PGKB_RACE=Asian,NR,Asian
7	99365719	rs2246709	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A4_(PA130);PGKB_DRUG=amlodipine_(PA448388);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_decreased_likelihood_of_reaching_a_target_mean_arterial_pressure_of_<=_92_mm_Hg_when_treated_with_amlodipine_as_compared_to_patients_with_the_AG_or_GG_genotype._No_significant_associations_were_seen_when_considering_a_target_mean_arterial_pressure_of_<=_107_mm_Hg_or_when_considering_men_or_women_individually._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_reaching_target_mean_arterial_pressure_in_patients_taking_amlodipine.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_an_increased_likelihood_of_reaching_a_target_mean_arterial_pressure_of_<=_92_mm_Hg_when_treated_with_amlodipine_as_compared_to_patients_with_the_AG_or_GG_genotype._No_significant_associations_were_seen_when_considering_a_target_mean_arterial_pressure_of_<=_107_mm_Hg_or_when_considering_men_or_women_individually._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_reaching_target_mean_arterial_pressure_in_patients_taking_amlodipine.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_an_increased_likelihood_of_reaching_a_target_mean_arterial_pressure_of_<=_92_mm_Hg_when_treated_with_amlodipine_as_compared_to_patients_with_the_AG_or_GG_genotype._No_significant_associations_were_seen_when_considering_a_target_mean_arterial_pressure_of_<=_107_mm_Hg_or_when_considering_men_or_women_individually._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_reaching_target_mean_arterial_pressure_in_patients_taking_amlodipine.";PGKB_RACE=Black_or_African_American
7	99366081	rs4987161	A	G	.	.	PGKB_INDEX=1;PGKB_GENE="CYP3A_(PA27114)""CYP3A4_(PA130)";PGKB_DRUG=nifedipine_(PA450631);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:In_vitro_the_construct_expressing_the_wild_type_allelic_protein_has_average_nifedipine_metabolism.""AG:Expression_study_did_not_included_heterozygous_genotype.""GG:In_vitro_the_recombinant_CYP3A4*17_allelic_protein_exhibits_significantly_decreased_catalytic_activity_for_nifedipine_oxidation_by_98_to_99%_compared_to_wild-type_construct_at_high_concentration_of_nifedipine.";PGKB_RACE=NR
7	99366093	rs12721627	G	C	.	.	PGKB_INDEX=2;PGKB_GENE=CYP3A4_(PA130),"CYP3A_(PA27114)""CYP3A4_(PA130)";PGKB_DRUG=midazolam_(PA450496),paclitaxel_(PA450761);PGKB_TYPE=Other,Dosage;PGKB_EVIDENCE=4,3;PGKB_DISEASE=NR,"Carcinoma_Non-Small-Cell_Lung_(PA443622)""Neoplasms_(PA445062)";PGKB_TEXT="CC:The_expression_of_a_construct_caring_the_C_variant_is_associated_with_decreased_clearance_of_midazolam_in_transfected_cells.""CG:While_the_expression_of_a_construct_caring_the_C_variant_is_associated_with_decreased_clearance_of_midazolam_in_transfected_cells_it_is_not_clear_what_the_influence_of_one_G_allele_with_the_C_allele_is.""GG:The_expression_of_a_construct_caring_the_G_variant_is_not_associated_with_decreased_clearance_of_midazolam_in_transfected_cells.","CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_paclitaxel_metabolism.""CG:Patients_with_the_CG_genotype_may_have_decreased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_paclitaxel_metabolism.""GG:Patients_with_the_GG_genotype_may_have_increased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_CC_or_CG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_paclitaxel_metabolism.";PGKB_RACE=NR,Asian
7	99366316	rs35599367	G	A	.	.	PGKB_INDEX=5;PGKB_GENE=CYP3A4_(PA130),"CYP3A_(PA27114)""CYP3A4_(PA130)",CYP3A4_(PA130),CYP3A4_(PA130),CYP3A4_(PA130);PGKB_DRUG=tacrolimus_(PA451578),erythromycin_(PA449493),midazolam_(PA450496),cyclosporine_(PA449167),simvastatin_(PA451363);PGKB_TYPE=Dosage,Other,Other,Other,Efficacy;PGKB_EVIDENCE=3,3,3,3,3;PGKB_DISEASE=Transplantation_(PA134850491),Neoplasms_(PA445062),Neoplasms_(PA445062),Organ_Transplantation_(PA133888799),Chronic_Disease_(PA443731);PGKB_TEXT="AA:Transplant_recipients_with_the_AA_genotype_(also_known_as_CYP3A4_*22/*22)_may_have_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_a_lower_dose_requirement_(among_other_pharmacokinetic_parameters)_as_compared_to_patients_with_the_GG_genotype_(CYP3A4_*1/*1)._Around_half_of_studies_report_an_association_and_half_report_no_association._One_study_found_an_association_with_liver_transplant_donor_genotype_but_not_recipient_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_metabolism_of_tacrolimus.""AG:Transplant_recipients_with_the_AG_genotype_(also_known_as_CYP3A4_*1/*22)_may_have_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_and_a_lower_dose_requirement_(among_other_pharmacokinetic_parameters)_as_compared_to_patients_with_the_GG_genotype_(CYP3A4_*1/*1)._Around_half_of_studies_report_an_association_and_half_report_no_association._One_study_found_an_association_with_liver_transplant_donor_genotype_but_not_recipient_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_metabolism_of_tacrolimus.""GG:Transplant_recipients_with_the_GG_genotype_(also_known_as_CYP3A4_*1/*1)_may_have_increased_metabolism_of_tacrolimus_resulting_in_decreased_exposure_and_a_higher_dose_requirement_(among_other_pharmacokinetic_parameters)_as_compared_to_patients_with_the_AG_or_AA_genotype_(CYP3A4_*22/*1_and_*22/*22)._Around_half_of_studies_report_an_association_and_half_report_no_association._One_study_found_an_association_with_liver_transplant_donor_genotype_but_not_recipient_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_metabolism_of_tacrolimus.","AA:Patients_with_the_AA_genotype_were_not_studied_however_they_may_have_decreased_metabolism_of_erythromycin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_erythromycin._""AG:Patients_with_the_AG_genotype_and_tumors_may_have_decreased_metabolism_of_erythromycin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_erythromycin._""GG:Patients_with_the_GG_genotype_and_tumors_may_have_increased_metabolism_of_erythromycin_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_erythromycin.","AA:Patients_with_the_AA_genotype_were_not_studied_however_they_may_have_decreased_metabolism_of_midazolam_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_midazolam._""AG:Patients_with_the_AG_genotype_and_tumors_may_have_decreased_metabolism_of_midazolam_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_midazolam._""GG:Patients_with_the_GG_genotype_and_tumors_may_have_increased_metabolism_of_midazolam_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_midazolam._","AA:Patients_with_the_AA_genotype_and_organ_transplantation_administered_cyclosporine_may_have_a_1)_decreased_metabolism_of_cyclosporine_2)_decreased_clearance_of_cyclosporine_and_3)_an_increased_risk_in_adverse_events_(e.g._graft_rejection_or_kidney_function)_all_as_compared_to_patients_with_the_._Other_clinical_and_genetic_factors_may_also_affect_metabolism_and_incidence_of_adverse_events_in_organ_transplant_patients_administered_cyclosporine._""AG:Patients_with_the_AG_genotype_and_organ_transplantation_administered_cyclosporine_may_have_a_1)_decreased_metabolism_of_cyclosporine_2)_decreased_clearance_of_cyclosporine_and_3)_an_increased_risk_in_adverse_events_(e.g._graft_rejection_or_kidney_function)_as_compared_to_patients_with_the_GG_genotype._Patients_with_the_AG_genotype_and_organ_transplantation_administered_cyclosporine_may_have_1)_increased_metabolism_2)_increased_clearance_and_3)_decreased_risk_of_adverse_events_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_affect_metabolism_and_incidence_of_adverse_events_in_organ_transplant_patients_administered_cyclosporine._""GG:Patients_with_the_GG_genotype_and_organ_transplantation_administered_cyclosporine_may_have_a_1)_increased_metabolism_of_cyclosporine_2)_increased_clearance_of_cyclosporine_and_3)_a_decreased_risk_in_adverse_events_(e.g._graft_rejection_or_kidney_function)_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_affect_metabolism_and_incidence_of_adverse_events_in_organ_transplant_patients_administered_cyclosporine._","AA:Patients_with_the_AA_genotype_may_have_increased_reduction_in_total_cholesterol_or_LDL_cholesterol_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin.""AG:Patients_with_the_AG_genotype_may_have_increased_reduction_in_total_cholesterol_or_LDL_cholesterol_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin.""GG:Patients_with_the_GG_genotype_may_have_increased_reduction_in_total_cholesterol_or_LDL_cholesterol_levels_when_treated_with_simvastatin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin.";PGKB_RACE=NR,NR,NR,NR,NR
7	99382096	rs2740574	C	T	.	.	PGKB_INDEX=8;PGKB_GENE=CYP3A4_(PA130),CYP3A4_(PA130),CYP3A4_(PA130),CYP3A4_(PA130),"CYP3A_(PA27114)""CYP3A4_(PA130)",CYP3A4_(PA130),"CYP3A_(PA27114)""CYP3A4_(PA130)",CYP3A4_(PA130);PGKB_DRUG=sirolimus_(PA451365),amlodipine_(PA448388),cyclophosphamide_(PA449165),tacrolimus_(PA451578),docetaxel_(PA449383),indinavir_(PA449977),efavirenz_(PA449441),docetaxel_(PA449383);PGKB_TYPE=Other,Efficacy,Toxicity/ADR,Dosage,Dosage,Other,Other,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,2A,3,3,3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),Hypertension_(PA444552),Breast_Neoplasms_(PA443560),Organ_Transplantation_(PA133888799),Neoplasms_(PA445062),HIV_Infections_(PA446213),HIV_(PA447230),Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Transplant_recipients_with_the_CC_(CYP3A4_*1B/*1B)_genotype_may_require_an_increased_dose_of_sirolimus_as_compared_to_patients_with_the_TT_(*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_dose_requirements.""CT:Transplant_recipients_with_the_CT_(CYP3A4_*1B/*1)_genotype_may_require_an_increased_dose_of_sirolimus_as_compared_to_patients_with_the_TT_(*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_dose_requirements.""TT:Transplant_recipients_with_the_TT_(CYP3A4_*1/*1)_genotype_may_require_a_decreased_dose_of_sirolimus_as_compared_to_patients_with_the_CC_(*1B/*1B)_or_CT_(*1B/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_dose_requirements.","CC:Women_with_the_CC_genotype_and_hypertension_may_have_a_decreased_likelihood_of_reaching_a_target_mean_arterial_pressure_of_<=_107_mm_Hg_when_treated_with_amlodipine_as_compared_to_women_with_the_CT_or_TT_genotype._No_significant_associations_were_seen_when_considering_a_target_mean_arterial_pressure_of_<=_92_mm_Hg_or_when_considering_men_or_men_and_women_together._Other_genetic_and_clinical_factors_may_also_influence_response_to_amlodipine.""CT:Women_with_the_CT_genotype_and_hypertension_may_have_an_increased_likelihood_of_reaching_a_target_mean_arterial_pressure_of_<=_107_mm_Hg_when_treated_with_amlodipine_as_compared_to_women_with_the_CC_genotype._No_significant_associations_were_seen_when_considering_a_target_mean_arterial_pressure_of_<=_92_mm_Hg_or_when_considering_men_or_men_and_women_together._Other_genetic_and_clinical_factors_may_also_influence_response_to_amlodipine.""TT:Women_with_the_TT_genotype_and_hypertension_may_have_an_increased_likelihood_of_reaching_a_target_mean_arterial_pressure_of_<=_107_mm_Hg_when_treated_with_amlodipine_as_compared_to_women_with_the_CC_genotype._No_significant_associations_were_seen_when_considering_a_target_mean_arterial_pressure_of_<=_92_mm_Hg_or_when_considering_men_or_men_and_women_together._Other_genetic_and_clinical_factors_may_also_influence_response_to_amlodipine.","CC:Premenopausal_patients_with_the_CC_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_a_longer_period_of_time_before_chemotherapy-induced_ovarian_failure_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_chemotherapy-induced_ovarian_failure.""CT:Premenopausal_patients_with_the_CT_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_a_longer_period_of_time_before_chemotherapy-induced_ovarian_failure_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_chemotherapy-induced_ovarian_failure.""TT:Premenopausal_patients_with_the_TT_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_a_shorter_period_of_time_before_chemotherapy-induced_ovarian_failure_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_chemotherapy-induced_ovarian_failure.","CC:Transplant_recipients_with_the_CC_(CYP3A4_*1B/*1B)_genotype_may_require_an_increased_dose_of_tacrolimus_as_compared_to_patients_with_the_TT_(*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_dose_requirements.""CT:Transplant_recipients_with_the_CT_(CYP3A4_*1B/*1)_genotype_may_require_an_increased_dose_of_tacrolimus_as_compared_to_patients_with_the_TT_(*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_dose_requirements.""TT:Transplant_recipients_with_the_TT_(CYP3A4_(*1/*1)_genotype_may_require_a_decreased_dose_of_tacrolimus_as_compared_to_patients_with_the_CT_(*1B/*1)_or_CC_(*1/*1)_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5_*3_(rs776746)_may_also_influence_a_patient's_dose_requirements.","CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_docetaxel.""CT:Patients_with_the_CT_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_TT_genotype_or_decreased_clearance_of_docetaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_docetaxel.""TT:Patients_with_the_TT_genotype_may_have_decreased_clearance_of_docetaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_docetaxel.","CC:Patients_with_the_CC_genotype_and_HIV_infection_may_have_decreased_metabolism_of_indinavir_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_indinavir_metabolism.""CT:Patients_with_the_CT_genotype_and_HIV_infection_may_have_increased_metabolism_of_indinavir_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_indinavir_metabolism.""TT:Patients_with_the_TT_genotype_and_HIV_infection_may_have_increased_metabolism_of_indinavir_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_indinavir_metabolism.","CC:Patients_with_the_CC_genotype_may_have_increased_plasma_drug_exposure_when_treated_with_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""CT:Patients_with_the_CT_genotype_may_have_increased_plasma_drug_exposure_when_treated_with_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_drug_exposure_when_treated_with_efavirenz_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.","CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_an_increased_risk_for_an_infusion-related_reaction_when_treated_with_docetaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_an_infusion-related_reaction.""CT:Patients_with_the_CT_genotype_and_breast_cancer_may_have_an_increased_risk_for_an_infusion-related_reaction_when_treated_with_docetaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_an_infusion-related_reaction.""TT:Patients_with_the_TT_genotype_and_breast_cancer_may_have_a_decreased_risk_for_an_infusion-related_reaction_when_treated_with_docetaxel_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_an_infusion-related_reaction.";PGKB_RACE=NR,Black_or_African_American,NR,NR,White,NR,NR,White
7	99460107	rs472660	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP3A43_(PA427);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Schizophrenia_may_have_increased_clearance_of_olanzapine_as_compared_to_patients_with_the_AG_or_GG_genotype._However_contradictory_findings_for_no_association_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_may_have_decreased_clearance_of_olanzapine_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_for_no_association_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_may_have_decreased_clearance_of_olanzapine_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_for_no_association_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=NR
7	100769538	rs2227631	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SERPINE1_(PA261);PGKB_DRUG="antidepressants_(PA452229)""citalopram_(PA449015)""fluoxetine_(PA449673)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_to_citalopram_and_fluoxetine_as_compared_to_patients_with_the_AG_and_GG_genotype_who_also_have_genotype_GG_or_AG_at_rs1799889._Patients_with_the_AA_genotype_may_still_be_at_risk_for_non-response_to_antidepressants_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_non-response_to_antidepressants.""AG:Patients_with_the_AG_genotype_and_genotype_GG_or_AG_at_rs1799889_with_major_depressive_disorder_may_be_less_likely_to_respond_to_citalopram_and_fluoxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_non-response_to_antidepressants.""GG:Patients_with_the_GG_genotype_and_genotype_GG_or_AG_at_rs1799889_with_major_depressive_disorder_may_be_less_likely_to_respond_to_citalopram_and_fluoxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_non-response_to_antidepressants.";PGKB_RACE=Asian
7	100769711	rs1799889	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SERPINE1_(PA261);PGKB_DRUG="antidepressants_(PA452229)""citalopram_(PA449015)""fluoxetine_(PA449673)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_be_more_likely_to_respond_to_citalopram_and_fluoxetine_as_compared_to_patients_with_the_AG_and_GG_genotype_who_also_have_genotype_GG_or_AG_at_rs2227631._Patients_with_the_AA_genotype_may_still_be_at_risk_for_non-response_to_antidepressants_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_non-response_to_antidepressants.""AG:Patients_with_the_AG_genotype_and_genotype_GG_or_AG_at_rs2227631_with_major_depressive_disorder_may_be_less_likely_to_respond_to_citalopram_and_fluoxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_non-response_to_antidepressants.""GG:Patients_with_the_GG_genotype_and_genotype_GG_or_AG_at_rs2227631_with_major_depressive_disorder_may_be_less_likely_to_respond_to_citalopram_and_fluoxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_non-response_to_antidepressants.";PGKB_RACE=Asian
7	101115994	rs17135437	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=COL26A1_(PA134887081);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_decreased_hearing_and_vision-related_side-effects_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_hearing_and_vision-related_side-effects.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_decreased_hearing_and_vision-related_side-effects_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype_or_increased_hearing_and_vision-related_side-effects_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_hearing_and_vision-related_side-effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_increased_hearing_and_vision-related_side-effects_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_hearing_and_vision-related_side-effects.";PGKB_RACE=NR
7	101171028	rs10279545	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=COL26A1_(PA134887081);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_for_asthma_as_compared_to_patients_with_the_TT_gneotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CT:Patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_for_asthma_as_compared_to_patients_with_the_TT_gneotype_or_may_have_increased_risk_for_asthma_as_compared_to_patients_with_the_CC_gneotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_for_asthma_as_compared_to_patients_with_the_CC_gneotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
7	106372219	rs342293	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Coronary_Artery_Disease_may_have_decreased_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""CG:Patients_with_the_CG_genotype_and_Coronary_Artery_Disease_may_have_increased_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""GG:Patients_with_the_GG_genotype_and_Coronary_Artery_Disease_may_have_increased_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._";PGKB_RACE=Asian
7	117174372	rs80282562	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(two_copies_of_the_CFTR_G178R_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G178R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""AG:Patients_with_the_AG_genotype_(one_copy_of_the_CFTR_G178R_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G178R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GG:Patients_with_the_GG_genotype_(do_not_have_a_copy_of_the_CFTR_G178R_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G178R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117199645	rs113993960	TCTT	T	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="CTT/CTT:Indication_of_ivacaftor_in_cystic_fibrosis_patients_with_the_CTT/CTT_genotype_(no_copies_of_the_CFTR_F508del_variant)_is_dependent_on_the_presence_of_other_variants_within_the_CFTR_gene._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""CTT/del:Indication_of_ivacaftor_in_cystic_fibrosis_patients_with_the_CTT/del_genotype_(one_copy_of_the_CFTR_F508del_variant)_is_dependent_on_the_presence_of_other_variants_within_the_CFTR_gene._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""del/del:Ivacaftor_is_not_recommended_in_cystic_fibrosis_patients_with_the_del/del_genotype_(two_copies_of_the_F508del_variant)._A_clinical_trial_of_ivacaftor_in_patients_with_the_del/del_genotype_showed_ivacaftor_was_ineffective_in_these_patients_though_this_study_was_not_powered_to_examine_efficacy._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._";PGKB_RACE=NR
7	117227853	rs121908757	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(do_not_have_a_copy_of_the_CFTR_S549R_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.""AC:Patients_with_the_AC_genotype_(one_copy_of_the_CFTR_S549R_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""CC:Patients_with_the_CC_genotype_(two_copies_of_the_CFTR_S549R_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._";PGKB_RACE=NR
7	117227854	rs121908755	G	A,T	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(two_copies_of_the_CFTR_S549N_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549N._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""AG:Patients_with_the_AG_genotype_(one_copy_of_the_CFTR_S549N_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549N._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GG:Patients_with_the_GG_genotype_(do_not_have_a_copy_of_the_CFTR_S549N_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549N._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117227855	rs121909005	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="GG:Patients_with_the_GG_genotype_(two_copies_of_the_CFTR_S549R_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GT:Patients_with_the_GG_genotype_(one_copy_of_the_CFTR_S549R_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""TT:Patients_with_the_TT_genotype_(do_not_have_a_copy_of_the_CFTR_S549R_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S549R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117227859	rs121909013	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(two_copies_of_the_CFTR_G551S_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_indicates_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G551S._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""AG:Patients_with_the_AG_genotype_(one_copy_of_the_CFTR_G551S_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_indicates_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G551S._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GG:Patients_with_the_GG_genotype_(do_not_have_a_copy_of_the_CFTR_G551S_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_indicates_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G551S._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117227860	rs75527207	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Ivacaftor_is_indicated_in_cystic_fibrosis_patients_with_the_AA_genotype_(two_copies_of_the_CFTR_G551D_variant)._FDA-approved_drug_labeling_information_indicates_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G551D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.""AG:Ivacaftor_is_indicated_in_cystic_fibrosis_patients_with_the_AG_genotype_(one_copy_of_the_CFTR_G551D_variant)._FDA-approved_drug_labeling_information_indicates_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G551D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.""GG:Indication_of_ivacaftor_in_cystic_fibrosis_patients_with_the_GG_genotype_(no_copies_of_the_CFTR_G551D_variant)_is_dependent_on_the_presence_of_other_variants_within_the_CFTR_gene._FDA-approved_drug_labeling_information_indicates_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G551D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._";PGKB_RACE=NR
7	117282505	rs267606723	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(two_copies_of_the_CFTR_G1244E_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G1244E._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""AG:Patients_with_the_AG_genotype_(one_copy_of_the_CFTR_G1244E_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G1244E._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GG:Patients_with_the_GG_genotype_(do_not_have_a_copy_of_the_CFTR_G1244E_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G1244E._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117282526	rs74503330	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(two_copies_of_the_CFTR_S1251N_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S1251N._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""AG:Patients_with_the_AG_genotype_(one_copy_of_the_CFTR_S1251N_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S1251N._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GG:Patients_with_the_GG_genotype_(do_not_have_a_copy_of_the_CFTR_S1251N_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S1251N._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117282537	rs121909041	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=NR;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="CC:Patients_with_the_CC_genotype_(two_copies_of_the_CFTR_S1255P_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S1255P._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""CT:Patients_with_the_CT_genotype_(one_copy_of_the_CFTR_S1255P_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S1255P._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""TT:Patients_with_the_TT_genotype_(do_not_have_a_copy_of_the_CFTR_S1255P_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_S1255P._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	117304824	rs193922525	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CFTR_(PA109);PGKB_DRUG=ivacaftor_(PA165950341);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE=Cystic_Fibrosis_(PA443829);PGKB_TEXT="AA:Patients_with_the_AA_genotype_(two_copies_of_the_CFTR_G1349D_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G1349D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""AG:Patients_with_the_AG_genotype_(one_copy_of_the_CFTR_G1349D_variant)_and_cystic_fibrosis_may_respond_to_ivacaftor_treatment._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G1349D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor._""GG:Patients_with_the_GG_genotype_(do_not_have_a_copy_of_the_CFTR_G1349D_variant)_and_cystic_fibrosis_have_an_unknown_response_to_ivacaftor_treatment_as_response_may_depend_on_the_presence_of_other_CFTR_variants._FDA-approved_drug_labeling_information_and_CPIC_guidelines_indicate_use_of_ivacaftor_in_cystic_fibrosis_patients_with_at_least_one_copy_of_a_list_of_10_CFTR_genetic_variants_including_G1349D._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ivacaftor.";PGKB_RACE=NR
7	127164958	rs6467136	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=PAX4_(PA32958);PGKB_DRUG=rosiglitazone_(PA451283);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_type_2_diabetes_may_have_a_better_response_when_treated_with_rosiglitazone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rosiglitazone.""AG:Patients_with_the_AG_genotype_and_type_2_diabetes_may_have_a_better_response_when_treated_with_rosiglitazone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rosiglitazone""GG:Patients_with_the_GG_genotype_and_type_2_diabetes_may_have_a_poorer_response_when_treated_with_rosiglitazone_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rosiglitazone";PGKB_RACE=Asian
7	127254587	rs114202595	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PAX4_(PA32958);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="AA:Patients_with_AA_+_AG_genotypes_may_have_better_response_for_postprandial_plasma_glucose_in_diabetic_patients_treated_with_repaglinide_when_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""AG:Patients_with_AA_+_AG_genotypes_may_have_better_response_for_postprandial_plasma_glucose_in_diabetic_patients_treated_with_repaglinide_when_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""GG:Patients_with_GG_genotypes_may_have_worse_response_for_postprandial_plasma_glucose_in_diabetic_patients_treated_with_repaglinide_when_compared_to_patients_with_AA_+AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.";PGKB_RACE=Asian
7	127878783	rs7799039	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=LEP_(PA228);PGKB_DRUG="antipsychotics_(PA452233)""risperidone_(PA451257)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Autism_Spectrum_Disorder_(PA153906318)""Mood_Disorders_(PA447209)";PGKB_TEXT="AA:Patients_with_autism_spectrum_disorder_(ASD)_or_mood_disorders_and_the_AA_genotype_may_have_a_decreased_likelihood_of_weight_gain_when_taking_antipsychotics_including_risperidone_as_compared_to_patients_with_the_GG_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_when_taking_antipsychotics_including_risperidone.""AG:Patients_with_autism_spectrum_disorder_(ASD)_or_mood_disorders_and_the_AG_genotype_may_have_a_decreased_likelihood_of_weight_gain_when_taking_antipsychotics_including_risperidone_as_compared_to_patients_with_the_GG_genotype__patients_with_the_AG_genotype_may_have_an_increased_likelihood_of_weight_gain_as_compared_to_patients_with_the_AA_genotype._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_when_taking_antipsychotics_including_risperidone.""GG:Patients_with_autism_spectrum_disorder_(ASD)_or_mood_disorders_and_the_GG_genotype_may_have_an_increased_likelihood_of_weight_gain_when_taking_antipsychotics_including_risperidone_as_compared_to_patients_with_the_AG_or_AA_genotypes_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_when_taking_antipsychotics_including_risperidone.";PGKB_RACE=NR
7	127882070	rs4731426	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=LEP_(PA228);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_extreme_weight_gain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_extreme_weight_gain_with_olanzapine_treatment.""CG:Patients_with_the_CG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_extreme_weight_gain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_extreme_weight_gain_with_olanzapine_treatment.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_extreme_weight_gain_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_extreme_weight_gain_with_olanzapine_treatment.";PGKB_RACE=Asian
7	128040699	rs2278294	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=IMPDH1_(PA29862),IMPDH1_(PA29862);PGKB_DRUG=mycophenolate_mofetil_(PA450566),mycophenolate_mofetil_(PA450566);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Leukopenia_(PA444773),"Kidney_Transplantation_(PA165817016)""Organ_Transplantation_(PA133888799)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_of_leukopenia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_leukopenia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_leukopenia_when_treated_with_mycophenolate_mofetil_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.","CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_acute_kidney_transplant_rejection_when_treated_with_mycophenolate_mofetil_as_compared_to_those_with_the_TT_or_CT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_decreased_but_not_absent_risk_of_acute_kidney_transplant_rejection_when_treated_with_mycophenolate_mofetil_as_compared_to_those_with_the_CC_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_absent_risk_of_acute_kidney_transplant_rejection_when_treated_with_mycophenolate_mofetil_as_compared_to_those_with_the_CC_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.";PGKB_RACE=NR,NR
7	128040752	rs2278293	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=IMPDH1_(PA29862);PGKB_DRUG=mycophenolate_mofetil_(PA450566);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_for_acute_rejection_after_kidney_transplantation_as_compared_to_patients_with_the_CT_or_TT_genotypes_but_the_CC_genotype_influence_is_controversy_discussed_among_different_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_rejection_after_transplantation.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_but_not_absent_risk_for_acute_rejection_after_kidney_transplantation_as_compared_to_patients_with_the_CC_genotype_but_the_CT_genotype_influence_is_controversy_discussed_among_different_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_rejection_after_transplantation.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_but_not_absent_risk_for_acute_rejection_after_kidney_transplantation_as_compared_to_patients_with_the_CC_genotype_but_the_TT_genotype_influence_is_controversy_discussed_among_different_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_acute_rejection_after_transplantation.";PGKB_RACE=NR
7	128399224	rs339097	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CALU_(PA26047);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_require_a_lower_maintenance_dose_as_compared_to_patients_with_the_GA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.""AG:Patients_with_the_AG_genotype_who_are_treated_with_warfarin_may_require_a_higher_maintenance_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_a_higher_maintenance_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.";PGKB_RACE=Black_or_African_American
7	144793834	rs478437	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=tamoxifen_(PA451581);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:In_lymphoblastoid_cell_lines_the_CC_genotype_was_associated_with_increased_sensitivity_to_tamoxifen_as_compared_to_the_CT_or_TT_genotype._Other_genetic_or_clinical_factors_may_affect_sensitivity_to_tamoxifen.""CT:In_lymphoblastoid_cell_lines_the_CT_genotype_was_associated_with_decreased_sensitivity_to_tamoxifen_as_compared_to_the_CC_genotype._Other_genetic_or_clinical_factors_may_affect_sensitivity_to_tamoxifen.""TT:In_lymphoblastoid_cell_lines_the_TT_genotype_was_associated_with_decreased_sensitivity_to_tamoxifen_as_compared_to_the_CC_genotype._Other_genetic_or_clinical_factors_may_affect_sensitivity_to_tamoxifen.";PGKB_RACE=NR
7	150647304	rs12720441	G	C,A	.	.	PGKB_INDEX=1;PGKB_GENE=KCNH2_(PA212);PGKB_DRUG=amiodarone_(PA448383);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Torsades_de_Pointes_(PA446294);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_for_Torsades_de_Point_when_treated_with_amiodarone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_for_Torsades_de_Point_when_treated_with_amiodarone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_for_Torsades_de_Point_when_treated_with_amiodarone_as_compared_to_patients_with_the_AA_or_AG_genotype._Patients_with_the_GG_genotype_may_still_be_at_risk_for_adverse_events_when_taking_amiodarone_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.";PGKB_RACE=NR
7	150648198	rs1137617	A	G,C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNH2_(PA212);PGKB_DRUG="calcium_channel_blockers_(PA10407)""nitrendipine_(PA146096020)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_essential_hypertension_who_are_treated_with_calcium_channel_blockers_may_have_greater_reductions_in_diastolic_blood_pressure_and_mean_arterial_pressure_as_compared_to_patients_with_the_GG_genotype._Male_patients_with_the_AA_genotype_may_also_have_greater_reductions_in_systolic_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antihypertensive_treatments._""AG:Patients_with_the_AG_genotype_with_essential_hypertension_who_are_treated_with_calcium_channel_blockers_may_have_greater_reductions_in_diastolic_blood_pressure_and_mean_arterial_pressure_as_compared_to_patients_with_the_GG_genotype._Male_patients_with_the_AG_genotype_may_also_have_greater_reductions_in_systolic_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antihypertensive_treatments._""GG:Patients_with_the_GG_genotype_with_essential_hypertension_who_are_treated_with_calcium_channel_blockers_may_have_smaller_reductions_in_diastolic_blood_pressure_and_mean_arterial_pressure_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antihypertensive_treatments._";PGKB_RACE=Asian
7	150690079	rs2070744	C	T	.	.	PGKB_INDEX=4;PGKB_GENE=NOS3_(PA254),NOS3_(PA254),NOS3_(PA254),NOS3_(PA254);PGKB_DRUG=Antihypertensives_And_Diuretics_In_Combination_(PA164712446),"cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""fluorouracil_(PA128406956)""methotrexate_(PA450428)","Antihypertensives_(PA164712445)""Antihypertensives_And_Diuretics_In_Combination_(PA164712446)""diuretics_(PA151249535)",sildenafil_(PA451346);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=NR,Breast_Neoplasms_(PA443560),Hypertension_(PA444552),Erectile_Dysfunction_(PA444606);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_antihypertensive_drugs_may_have_an_increased_risk_for_resistance_as_compared_to_patients_with_the_CT_or_TT_genotype.""CT:Patients_with_the_CT_genotype_who_are_treated_with_antihypertensive_drugs_may_have_a_decreased_but_not_absent_risk_for_resistance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistance.""TT:Patients_with_the_TT_genotype_who_are_treated_with_antihypertensive_drugs_may_have_a_decreased_but_not_absent_risk_for_resistance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistance.","CC:Patients_with_the_CC_genotype_and_breast_cancer_who_are_not_treated_with_adjuvant_cyclophophamide-based_regimens_may_have_longer_disease-free_survival_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_disease-free_survival.""CT:Patients_with_the_CT_genotype_and_breast_cancer_who_are_not_treated_with_a_adjuvant_cyclophophamide-based_regimens_may_have_shorter_disease-free_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_disease-free_survival.""TT:Patients_with_the_TT_genotype_and_breast_cancer_who_are_not_treated_with_a_adjuvant_cyclophophamide-based_regimens_may_have_shorter_disease-free_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_disease-free_survival.","CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_resistant_hypertension_when_treated_with_antihypertensive_drugs_including_diuretics_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antihypertensives.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_but_not_absent_risk_of_resistant_hypertension_when_treated_with_antihypertensive_drugs_including_diuretics_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antihypertensives.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_but_not_absent_risk_of_resistant_hypertension_when_treated_with_antihypertensive_drugs_including_diuretics_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antihypertensives.","CC:Patients_with_the_CC_genotype_may_have_increased_response_to_sildenafil_in_men_with_post-operative_Erectile_Dysfunction_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_sildenafil.""CT:Patients_with_the_CT_genotype_may_have_increased_response_to_sildenafil_in_men_with_post-operative_Erectile_Dysfunction_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_sildenafil.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_sildenafil_in_men_with_post-operative_Erectile_Dysfunction_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_sildenafil.";PGKB_RACE=White,NR,White,NR
7	150696111	rs1799983	T	G	.	.	PGKB_INDEX=6;PGKB_GENE=NOS3_(PA254),NOS3_(PA254),NOS3_(PA254),NOS3_(PA254),NOS3_(PA254),NOS3_(PA254);PGKB_DRUG="aspirin_(PA448497)""Beta_Blocking_Agents_(PA164712535)""clopidogrel_(PA449053)""hmg_coa_reductase_inhibitors_(PA133950441)","cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""fluorouracil_(PA128406956)""methotrexate_(PA450428)","anthracyclines_and_related_substances_(PA130620651)""cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""epirubicin_(PA449476)""fluorouracil_(PA128406956)""methotrexate_(PA450428)""oxaliplatin_(PA131285527)""Platinum_compounds_(PA164713176)",salvianolic_acid_b_(PA166128370),daunorubicin_(PA449212),"Ace_Inhibitors_Plain_(PA164712308)""Angiotensin_II_Antagonists_(PA164712372)""Beta_Blocking_Agents_(PA164712535)""digoxin_(PA449319)""diuretics_(PA151249535)""spironolactone_(PA451483)";PGKB_TYPE=Toxicity/ADR,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Breast_Neoplasms_(PA443560),"Neoplasms_(PA445062)""Ovarian_Neoplasms_(PA445204)""Stomach_Neoplasms_(PA445742)",Coronary_Disease_(PA443797),Leukemia_Myeloid_Acute_(PA444760),Heart_Failure_(PA444370);PGKB_TEXT="GG:Male_patients_with_the_GG_genotype_and_Coronary_Artery_Disease_may_have_a_decreased_but_not_absent_risk_of_in-stent_restenosis_when_treated_with_aspirin_Beta_Blocking_Agents_clopidogrel_and_hmg_coa_reductase_inhibitors_as_compared_to_male_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_in-stent_restenosis.""TG:Male_patients_with_the_TG_genotype_and_Coronary_Artery_Disease_may_have_an_increased_risk_of_in-stent_restenosis_when_treated_with_aspirin_Beta_Blocking_Agents_clopidogrel_and_hmg_coa_reductase_inhibitors_as_compared_to_male_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_in-stent_restenosis.""TT:Male_patients_with_the_TT_genotype_and_Coronary_Artery_Disease_may_have_an_increased_risk_of_in-stent_restenosis_when_treated_with_aspirin_Beta_Blocking_Agents_clopidogrel_and_hmg_coa_reductase_inhibitors_as_compared_to_male_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_in-stent_restenosis.","GG:Patients_with_the_GG_genotype_1)_may_have_longer_disease-free_survival_when_treated_with_cyclophosphamide-based_regimens_2)_may_have_shorter_disease-free_survival_when_not_treated_with_cyclophosphamide-based_regimens_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_disease-free_survival.""GT:Patients_with_the_GT_genotype_1)_may_have_longer_disease-free_survival_when_treated_with_cyclophosphamide-based_regimens_2)_may_have_shorter_disease-free_survival_when_not_treated_with_cyclophosphamide-based_regimens_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_disease-free_survival.""TT:Patients_with_the_TT_genotype_1)_may_have_shorter_disease-free_survival_when_treated_with_cyclophosphamide-based_regimens_2)_may_have_longer_disease-free_survival_when_not_treated_with_cyclophosphamide-based_regimens_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_disease-free_survival.","GG:Patients_with_the_GG_genotype_and_breast_cancer_stomach_cancer_or_other_cancer_may_have_an_improved_response_(increased_disease_free_survival_or_overall_survival)_when_treated_with_a_chemotherapy_regimen_that_includes_anthracyclines_and_related_substances_platinum_compounds_nucleoside_inhibitors_or_folate_analog_metabolite_inhibitors_IF_CYCLOPHOSPHAMIDE_IS_GIVEN_AS_AN_ADJUVANT_as_compared_to_patients_with_the_TT_genotype._However_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy_regimens.""GT:Patients_with_the_GT_genotype_and_breast_cancer_stomach_cancer_or_other_cancer_may_have_an_improved_response_(increased_disease_free_survival_or_overall_survival)_when_treated_with_a_chemotherapy_regimen_that_includes_anthracyclines_and_related_substances_platinum_compounds_nucleoside_inhibitors_or_folate_analog_metabolite_inhibitors_IF_CYCLOPHOSPHAMIDE_IS_GIVEN_AS_AN_ADJUVANT_as_compared_to_patients_with_the_TT_genotype._However_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy_regimens.""TT:Patients_with_the_TT_genotype_and_breast_cancer_stomach_cancer_or_other_cancer_may_have_a_improved_response_(decreased_disease_free_survival_or_overall_survival)_when_treated_with_a_chemotherapy_regimen_that_includes_anthracyclines_and_related_substances_platinum_compounds_nucleoside_inhibitors_or_folate_analog_metabolite_inhibitors_IF_CYCLOPHOSPHAMIDE_IS_NOT_GIVEN_AS_AN_ADJUVANT_as_compared_to_patients_with_the_GG_and_GT_genotypes._However_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy_regimens.","GG:Patients_with_the_GG_genotype_and_coronary_heart_disease_may_have_a_better_response_to_treatment_with_salvianolate_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_salvianolate.""GT:Patients_with_the_GT_genotype_and_coronary_heart_disease_may_have_a_poorer_response_to_treatment_with_salvianolate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_salvianolate.""TT:Patients_with_the_TT_genotype_and_coronary_heart_disease_may_have_a_poorer_response_to_treatment_with_salvianolate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_salvianolate.","GG:Patients_with_acute_myeloid_leukemia_and_the_GG_genotype_may_have_increased_survival_time_when_treated_with_daunorubicin_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_daunorubicin.""GT:Patients_with_acute_myeloid_leukemia_and_the_GT_genotype_may_have_decreased_survival_time_when_treated_with_daunorubicin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_daunorubicin.""TT:Patients_with_acute_myeloid_leukemia_and_the_TT_genotype_may_have_decreased_survival_time_when_treated_with_daunorubicin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_daunorubicin.","GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_emergency_department_visits_when_treated_with_Ace_Inhibitors_Plain_Angiotensin_II_Antagonists_Beta_Blocking_Agents_digoxin_diuretics_or_spironolactone_in_people_with_Heart_Failureas_compared_to_patients_with_genotype_TT_or_GT._Other_genetic_or_clinical_factors_may_also_influence_the_outcome_of_heart_failure_patients.""GT:Patients_with_the_GT_genotype_may_have_increased_risk_of_emergency_department_visits_when_treated_with_Ace_Inhibitors_Plain_Angiotensin_II_Antagonists_Beta_Blocking_Agents_digoxin_diuretics_or_spironolactone_in_people_with_Heart_Failureas_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_the_outcome_of_heart_failure_patients.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_emergency_department_visits_when_treated_with_Ace_Inhibitors_Plain_Angiotensin_II_Antagonists_Beta_Blocking_Agents_digoxin_diuretics_or_spironolactone_in_people_with_Heart_Failureas_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_or_clinical_factors_may_also_influence_the_outcome_of_heart_failure_patients.";PGKB_RACE=NR,NR,NR,Asian,Asian,NR
7	154072020	rs6977820	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Schizophrenia_(PA447216)""tardive_dyskinesia_(PA447268)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antipsychotics.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antipsychotics.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antipsychotics.";PGKB_RACE=Asian
7	156880398	rs6966038	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""AG:Patients_with_the_GG_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=NR
8	2809581	rs11993031	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=CSMD1_(PA26947);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""AT:Patients_with_the_AT_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AA_genotype_and_an_increased_response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""TT:Patients_with_the_TT_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AT_and_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._";PGKB_RACE=White
8	2903020	rs7387065	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CSMD1_(PA26947);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""AG:Patients_with_the_AG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_GG_genotype_and_an_increased_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""GG:Patients_with_the_GG_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.";PGKB_RACE=White
8	11612381	rs13273672	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GATA4_(PA28587);PGKB_DRUG=Drugs_used_in_alcohol_dependence_(PA164712718);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Alcoholism_(PA443309);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_time_to_relapse_when_treated_with_Drugs_used_in_alcohol_dependence_in_people_with_Alcoholism_as_compared_to_patients_with_genotypes_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_increased_time_to_relapse_when_treated_with_Drugs_used_in_alcohol_dependence_in_people_with_Alcoholism_as_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_increased_time_to_relapse_when_treated_with_Drugs_used_in_alcohol_dependence_in_people_with_Alcoholism_as_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
8	18071907	rs13253389	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NAT1_(PA17);PGKB_DRUG=cotinine_(PA166114414);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_concentrations_of_cotinine_when_exposed_to_secondhand_smoke_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_levels_of_cotinine_in_patients_exposed_to_secondhand_smoke.""AG:Patients_with_the_AG_genotype_may_have_increased_concentrations_of_cotinine_when_exposed_to_secondhand_smoke_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_levels_of_cotinine_in_patients_exposed_to_secondhand_smoke.""GG:Patients_with_the_GG_genotype_may_have_increased_concentrations_of_cotinine_when_exposed_to_secondhand_smoke_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_levels_of_cotinine_in_patients_exposed_to_secondhand_smoke.";PGKB_RACE=White
8	18257854	rs1801280	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NAT2_(PA18);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_similar_risk_of_grade_2-4_anemia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_grade_2-4_anemia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_reduced_but_not_absent_risk_of_grade_2-4_anemia_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._";PGKB_RACE=NR
8	18258370	rs1799931	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NAT2_(PA18);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
8	18272881	rs1495741	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="Drugs_For_Treatment_Of_Tuberculosis_(PA164712708)""isoniazid_(PA450112)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Tuberculosis_(PA445941);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_drugs_for_treatment_of_tuberculosis_may_have_increased_risk_for_toxic_liver_disease_abnormal_liver-function_tests_and_decreased_mean_cumulative_doses_of_isoniazid_before_the_development_of_abnormal_liver-function_tests_as_compared_to_patients_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxic_liver_disease._""AG_:Patients_with_the_AG_genotype_who_are_treated_with_drugs_for_treatment_of_tuberculosis_may_have_increased_risk_for_toxic_liver_disease_abnormal_liver-function_tests_and_decreased_mean_cumulative_doses_of_isoniazid_before_the_development_of_abnormal_liver-function_tests_as_compared_to_patients_with_GG_genotype_or_may_have_decreased_risk_for_toxic_liver_disease_abnormal_liver-function_tests_and_increased_mean_cumulative_doses_of_isoniazid_before_the_development_of_abnormal_liver-function_tests_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxic_liver_disease._""GG:Patients_with_the_GG_genotype_who_are_treated_with_drugs_for_treatment_of_tuberculosis_may_have_decreased_risk_for_toxic_liver_disease_abnormal_liver-function_tests_and_increased_mean_cumulative_doses_of_isoniazid_before_the_development_of_abnormal_liver-function_tests_as_compared_to_patients_with_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxic_liver_disease._";PGKB_RACE=Asian
8	19819724	rs328	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=LPL_(PA232);PGKB_DRUG=pravastatin_(PA451089);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_(less_decrease_in_total_cholesterol)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""CG:Patients_with_the_CG_genotype_who_are_treated_with_pravastatin_may_have_a_reduced_response_(less_decrease_in_total_cholesterol)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_pravastatin_may_have_a_better_response_(higher_decreases_in_total_cholesterol)_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._";PGKB_RACE=White
8	22228828	rs17060812	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC39A14_(PA134863701);PGKB_DRUG=nortriptyline_(PA450657);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_response_to_nortriptyline_in_people_with_Depression_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""CT:Patients_with_the_CT_genotype_may_have_increased_response_to_nortriptyline_in_people_with_Depression_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_nortriptyline_in_people_with_Depression_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.";PGKB_RACE=White
8	23059324	rs20575	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF10A_(PA36597);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_(PA443430);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_rheumatoid_or_psoriatic_arthritis_may_have_a_better_response_when_treated_with_anti-TNF_therapy_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapies._""CG:Patients_with_the_CG_genotype_and_rheumatoid_or_psoriatic_arthritis_may_have_a_poorer_response_when_treated_with_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapies._""GG:Patients_with_the_GG_genotype_and_rheumatoid_or_psoriatic_arthritis_may_have_a_poorer_response_when_treated_with_anti-TNF_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapies._";PGKB_RACE=White
8	28478892	rs352428	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_may_be_less_likely_to_respond_to_citalopram_or_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram._""AG:Patients_with_the_AG_genotype_and_depression_may_be_less_likely_to_respond_to_citalopram_or_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram._""GG:Patients_with_the_GG_genotype_and_depression_may_be_more_likely_to_respond_to_citalopram_or_escitalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram.";PGKB_RACE=White
8	30535660	rs3594	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=GSR_(PA29014);PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="AA:Women_with_ovarian_cancer_and_the_AA_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""AC:Women_with_ovarian_cancer_and_the_AC_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""CC:Women_with_ovarian_cancer_and_the_CC_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_AA_or_AC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._";PGKB_RACE=NR
8	32317917	rs17716295	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NRG1_(PA31776);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_genotype_AA_and_schizophrenia_may_have_decreased_response_to_antipsychotics_compared_to_patients_with_AC_or_CC_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_antipsychotics.""AC:Patients_with_genotype_AC_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_AA_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_antipsychotics.""CC:Patients_with_genotype_CC_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_AA_or_AC_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_antipsychotics.";PGKB_RACE=Asian
8	32392809	rs13250975	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NRG1_(PA31776);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_AA_genotype_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_the_AG_and_GG_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_antipsychotics.""AG:Patients_with_AG_genotype_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_antipsychotics.""GG:Patients_with_GG_genotype_and_schizophrenia_may_have_increased_response_to_antipsychotics_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_antipsychotics.";PGKB_RACE=Asian
8	37823798	rs4994	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADRB3_(PA24598);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Schizophrenia_(PA447216)""Weight_gain_(PA128406954)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.""AG:Patients_with_the_AG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.";PGKB_RACE=Asian
8	39765848	rs9657182	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=IDO1_(PA29869);PGKB_DRUG="interferon_alfa-2a_recombinant_(PA164779048)""peginterferon_alfa-2b_(PA164784024)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_for_moderate_or_severe_depression_when_treated_with_peginterferon_alfa-2b_or_recombinant_interferon_alfa-2a_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug_side_effects.""CT:Patients_with_the_CT_genotype_may_have_decreased_but_not_absent_risk_for_moderate_or_severe_depression_when_treated_with_peginterferon_alfa-2b_or_recombinant_interferon_alfa-2a_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug_side_effects.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_absent_risk_for_moderate_or_severe_depression_when_treated_with_peginterferon_alfa-2b_or_recombinant_interferon_alfa-2a_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug_side_effects.";PGKB_RACE=White
8	40402374	rs1367094	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ZMAT4_(PA142670525);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_genotype_CC_and_hypertension_have_increased_response_to_atenolol_compared_to_patients_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_affect_patient_response_to_atenolol._""CT:Patients_with_genotype_CT_and_hypertension_have_increased_response_to_atenolol_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_affect_patient_response_to_atenolol._""TT:Patients_with_genotype_TT_and_hypertension_have_increased_response_to_atenolol_compared_to_patients_with_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_affect_patient_response_to_atenolol._";PGKB_RACE=Black_or_African_American
8	59412924	rs3808607	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP7A1_(PA132);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_atorvastatin_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin.""GT:Patients_with_the_GT_genotype_may_have_a_decreased_response_to_atorvastatin_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin.""TT:Patients_with_the_TT_genotype_may_have_an_increased_response_to_atorvastatin_as_compared_to_patients_with_the_GG_or_GT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin.";PGKB_RACE=NR
8	63938764	rs11545078	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=GGH_(PA432),GGH_(PA432);PGKB_DRUG=methotrexate_(PA450428),pemetrexed_(PA10810);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_methotrexate:_1)_may_have_higher_accumulation_of_active_methotrexate_metabolites_2)_may_have_an_increased_risk_for_thrombocytopenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_clearance_and_toxicity.""AG:Patients_with_the_AG_genotype_who_are_treated_with_methotrexate:_1)_may_have_higher_accumulation_of_active_methotrexate_metabolites_2)_may_have_an_increased_risk_for_thrombocytopenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_clearance_and_toxicity.""GG:Patients_with_the_GG_genotype_who_are_treated_with_methotrexate:_1)_may_have_reduced_accumulation_of_active_methotrexate_metabolites_2)_may_have_a_decreased_risk_for_thrombocytopenia_as_compared_to_patients_with_the_AA_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_clearance_and_toxicity.","AA:Patients_with_the_AA_genotype_and_lung_cancer_may_have_a_decreased_risk_of_experiencing_drug_toxicity_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity_in_patients_receiving_pemetrexed.""AG:Patients_with_the_AG_genotype_and_lung_cancer_may_have_a_decreased_risk_of_experiencing_drug_toxicity_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype_or_an_increased_risk_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity_in_patients_receiving_pemetrexed.""GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_an_increased_risk_of_experiencing_drug_toxicity_when_treated_with_pemetrexed_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_drug_toxicity_in_patients_receiving_pemetrexed.";PGKB_RACE=NR,NR
8	63951312	rs1800909	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=GGH_(PA432);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_less_improvement_in_disease_symptoms_at_3_months_but_not_at_6_months_of_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_therapy.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_better_improvement_in_disease_symptoms_at_3_months_but_not_at_6_months_of_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_therapy.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_better_improvement_in_disease_symptoms_at_3_months_but_not_at_6_months_of_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_therapy.";PGKB_RACE=NR
8	63951728	rs3758149	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GGH_(PA432);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_1)_may_have_decreased_conversion_of_the_drug_to_active_polyglutamates_2)_may_have_decreased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_metabolism_and_response.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_1)_may_have_increased_conversion_of_the_drug_to_active_polyglutamates_as_compared_to_the_AA_genotype_2)_may_have_decreased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_metabolism_and_response.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_1)_may_have_increased_conversion_of_the_drug_to_active_polyglutamates_2)_may_have_increased_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_metabolism_and_response.";PGKB_RACE=NR
8	69389217	rs1517114	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=C8orf34_(PA142672353);PGKB_DRUG=irinotecan_(PA450085);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_severity_of_Diarrhea_when_treated_with_irinotecan_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""CG:Patients_with_the_CG_genotype_may_have_increased_severity_of_Diarrhea_when_treated_with_irinotecan_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_decreased_severity_of_Diarrhea_when_treated_with_irinotecan_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=Asian
8	103200036	rs1265138	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=RRM2B_(PA34866);PGKB_DRUG="cladribine_(PA449027)""cytarabine_(PA449177)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_be_more_likely_to_have_a_complete_response_to_first_remission_induction_therapy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""AG:Patients_with_the_AG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_be_less_likely_to_have_a_complete_response_to_first_remission_induction_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""GG:Patients_with_the_GG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_be_less_likely_to_have_a_complete_response_to_first_remission_induction_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._";PGKB_RACE=NR
8	118184783	rs13266634	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=SLC30A8_(PA134915546),SLC30A8_(PA134915546);PGKB_DRUG=repaglinide_(PA451234),"insulin_recombinant_(PA164744571)""zinc_acetate_(PA451961)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_repaglinide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_repaglinide.""CT:Patients_with_the_CT_genotype_may_have_increased_response_to_repaglinide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_repaglinide.""TT:Patients_with_the_TT_genotype_may_have_increased_response_to_repaglinide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_repaglinide.","CC:Individuals_with_the_CC_genotype_may_have_a_decreased_response_to_insulin_supplemented_with_zinc_acetate_as_compared_to_individuals_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_insulin_and_zinc_acetate._""CT:Individuals_with_the_CT_genotype_may_have_an_increased_response_to_insulin_supplemented_with_zinc_acetate_as_compared_to_individuals_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_insulin_and_zinc_acetate._""TT:Individuals_with_the_TT_genotype_may_have_an_increased_response_to_insulin_supplemented_with_zinc_acetate_as_compared_to_individuals_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_insulin_and_zinc_acetate._";PGKB_RACE=Asian,White
8	119964052	rs2073618	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF11B_(PA36602);PGKB_DRUG="anastrozole_(PA448432)""letrozole_(PA450196)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_breast_cancer_and_the_CC_genotype_may_have_an_increased_likelihood_of_aromatase_inhibitor-associated_musculoskeletal_syndrome_metabolic_bone_disease_or_osteoporosis_when_treated_with_anastrozole_or_letrozole_as_compared_to_genotypes_CG_and_GG._Other_clinical_and_genetic_factors_may_also_affect_risk_of_musculoskeletal_syndromes_and_bone_diseases_who_are_taking_anastrozole_or_letrozole.""CG:Patients_with_breast_cancer_and_the_CG_genotype_may_have_a_decreased_likelihood_of_aromatase_inhibitor-associated_musculoskeletal_syndrome_metabolic_bone_disease_or_osteoporosis_when_treated_with_anastrozole_or_letrozole_as_compared_to_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_musculoskeletal_syndromes_and_bone_diseases_in_patients_who_are_taking_anastrozole_or_letrozole.""GG:Patients_with_breast_cancer_and_the_GG_genotype_may_have_a_decreased_likelihood_of_aromatase_inhibitor-associated_musculoskeletal_syndrome_metabolic_bone_disease_or_osteoporosis_when_treated_with_anastrozole_or_letrozole_as_compared_to_genotypes_CC._Other_clinical_and_genetic_factors_may_also_affect_risk_of_musculoskeletal_syndromes_and_bone_diseases_in_patients_who_are_taking_anastrozole_or_letrozole.";PGKB_RACE=Asian
8	139884509	rs6988229	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=COL22A1_(PA134914705);PGKB_DRUG=salbutamol_(PA448068);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_CC_genotypes_may_have_decreased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_asthma_when_compared_to_patients_with_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""TC:Patients_with_TC_genotypes_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_asthma_when_compared_to_patients_with_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""TT:Patients_with_TT_genotypes_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_asthma_when_compared_to_patients_with_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.";PGKB_RACE=NR
8	143999600	rs1799998	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=CYP11B2_(PA134),CYP11B2_(PA134);PGKB_DRUG="benazepril_(PA448561)""imidapril_(PA452640)",candesartan_(PA448765);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Essential_hypertension_(PA447288),Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_or_imidapril_as_compared_to_patients_with_the_GG_genotype._No_significant_effects_on_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_diastolic_blood_pressure_response.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_or_imidapril_as_compared_to_patients_with_the_GG_genotype._No_significant_effects_on_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_diastolic_blood_pressure_response.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_benazepril_or_imidapril_as_compared_to_patients_with_the_AA_or_AG_genotype._No_significant_effects_on_systolic_blood_pressure_were_seen._Other_genetic_and_clinical_factors_may_also_influence_diastolic_blood_pressure_response.","AA:Patients_with_the_AA_genotype_and_hypertension_may_be_less_likely_to_respond_to_treatment_with_candesartan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_candesartan.""AG:Patients_with_the_AG_genotype_and_hypertension_may_be_less_likely_to_respond_to_treatment_with_candesartan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_candesartan.""GG:Patients_with_the_GG_genotype_and_hypertension_may_be_more_likely_to_respond_to_treatment_with_candesartan_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_candesartan.";PGKB_RACE=Asian,NR
9	4582082	rs301434	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC1A1_(PA35826);PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Obsessive-Compulsive_Disorder_(PA447211);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Obsessive-Compulsive_Disorder_may_have_decreased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""CT:Patients_with_the_CT_genotype_and_Obsessive-Compulsive_Disorder_may_have_increased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""TT:Patients_with_the_TT_genotype_and_Obsessive-Compulsive_Disorder_may_have_increased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.";PGKB_RACE=White
9	4582843	rs301435	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC1A1_(PA35826);PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Obsessive-Compulsive_Disorder_(PA447211);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Obsessive-Compulsive_Disorder_may_have_increased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""CT:Patients_with_the_CT_genotype_and_Obsessive-Compulsive_Disorder_may_have_increased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_TT_genotype_or_may_have_decreased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""TT:Patients_with_the_TT_genotype_and_Obsessive-Compulsive_Disorder_may_have_decreased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.";PGKB_RACE=White
9	4586808	rs3087879	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC1A1_(PA35826);PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Obsessive-Compulsive_Disorder_(PA447211);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Obsessive-Compulsive_Disorder_may_have_increased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""CG:Patients_with_the_CG_genotype_and_Obsessive-Compulsive_Disorder_may_have_increased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""GG:Patients_with_the_GG_genotype_and_Obsessive-Compulsive_Disorder_may_have_decreased_severity_of_pharmacological_resistance_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.";PGKB_RACE=White
9	6556839	rs10975641	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=GLDC_(PA28716);PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_may_have_decreased_response_to_citalopram_and_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_and_escitalopram.""CG:Patients_with_the_CG_genotype_and_major_depression_may_have_increased_response_to_citalopram_and_escitalopram_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_response_to_citalopram_and_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_and_escitalopram.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_increased_response_to_citalopram_and_escitalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_and_escitalopram.";PGKB_RACE=NR
9	8176226	rs10739150	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_increased_response_to_atenolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.""GT:Patients_with_the_GT_genotype_may_have_increased_response_to_atenolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_atenolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.";PGKB_RACE=Black_or_African_American
9	9687487	rs4742610	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PTPRD_(PA34013);PGKB_DRUG="trandolapril_(PA451737)""verapamil_(PA451868)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_for_resistant_hypertension_in_whites_and_Hispanics_patients_treated_with_verapamil_and_trandolapril_as_compared_to_patients_with_genotype_TT_or_TC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_verapamil.""TC:Patients_with_the_TC_genotype_may_have_higher_risk_for_resistant_hypertension_in_whites_and_Hispanics_patients_treated_with_verapamil_and_trandolapril_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_verapamil.""TT:Patients_with_the_TT_genotype_may_have_higher_risk_for_resistant_hypertension_in_whites_and_Hispanics_patients_treated_with_verapamil_and_trandolapril_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_verapamil.";PGKB_RACE=NR
9	11018077	rs12346562	C	A	.	.	PGKB_INDEX=2;PGKB_GENE=NR,NR;PGKB_DRUG="atenolol_(PA448499)""bisoprolol_(PA448641)",hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Hypertension_(PA444552),Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_atenolol_pr_bisoprolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.""AC:Patients_with_the_AC_genotype_may_have_increased_response_to_atenolol_pr_bisoprolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.""CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_atenolol_pr_bisoprolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.","AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_hydrochlorothiazide_in_hypertensive_patients_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_hydrochlorothiazide.""AC:Patients_with_the_AC_genotype_may_have_decreased_response_to_hydrochlorothiazide_in_hypertensive_patients_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_hydrochlorothiazide.""CC:Patients_with_the_CC_genotype_may_have_increased_response_to_hydrochlorothiazide_in_hypertensive_patients_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_hydrochlorothiazide.";PGKB_RACE=White,White
9	11028275	rs1104514	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_atenolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_atenolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_atenolol_in_hypertensive_patients_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_atenolol.";PGKB_RACE=White
9	20497142	rs6475448	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MLLT3_(PA30852);PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_an_increased_response_to_montelukast_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma.";PGKB_RACE=NR
9	22096055	rs10757274	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CDKN2B-AS1_(PA164717802);PGKB_DRUG=Antiinflammatory_agents_non-steroids_(PA164712462);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acute_coronary_syndrome_(PA165108401);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_in_people_with_Acute_coronary_syndrome_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_NSAIDs.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_in_people_with_Acute_coronary_syndrome_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_NSAIDs.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_in_people_with_Acute_coronary_syndrome_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_NSAIDs.";PGKB_RACE=NR
9	22134094	rs10811661	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=troglitazone_(PA451799);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_at_high-risk_for_type_II_diabetes_who_are_treated_with_troglitazone_may_have_increased_beta_cell_function_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_and_at_high_risk_for_type_II_diabetes_who_are_treated_with_troglitazone_may_have_increased_beta_call_function_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_troglitazone.""TT:Patients_with_the_TT_genotype_and_at_high_risk_for_type_II_diabetes_who_are_treated_with_troglitazone_may_have_decreased_beta_cell_function_as_compared_to_patients_with_the_CT_and_CC_genotype.";PGKB_RACE=NR
9	27489251	rs868856	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=MOB3B_(PA134886513);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Rheumatoid_Arthritis_patients_with_the_AA_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Rheumatoid_Arthritis_patients_with_the_AG_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Rheumatoid_Arthritis_patients_with_the_GG_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
9	27490967	rs7046653	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=MOB3B_(PA134886513);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Rheumatoid_Arthritis_patients_with_the_AA_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Rheumatoid_Arthritis_patients_with_the_AG_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_a_patient_with_the_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Rheumatoid_Arthritis_patients_with_the_GG_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
9	27536397	rs2814707	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=MOB3B_(PA134886513);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Rheumatoid_Arthritis_patients_with_the_CC_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Rheumatoid_Arthritis_patients_with_the_CT_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_the_TT_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
9	27543281	rs3849942	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=C9orf72_(PA134908144);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Rheumatoid_Arthritis_patients_with_the_CC_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Rheumatoid_Arthritis_patients_with_the_CT_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_the_TT_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
9	27561049	rs774359	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=C9orf72_(PA134908144);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Rheumatoid_Arthritis_patients_with_the_CC_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Rheumatoid_Arthritis_patients_with_the_CT_genotype_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_the_TT_genotype_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_to_patients_with_genotypes_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
9	75568383	rs6151031	G	GCTGGTGAGGAGAGAACC	.	.	PGKB_INDEX=1;PGKB_GENE=ALDH1A1_(PA24692);PGKB_DRUG="carboplatin_(PA448803)""cyclophosphamide_(PA449165)""thiotepa_(PA451668)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC:Patients_with_the_CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC_genotype_may_have_decreased_severity_of_Drug_Toxicity_when_treated_with_carboplatin_cyclophosphamide_and_thiotepa_in_people_with_Neoplasms_as_compared_to_genotype_CTGGTGAGGAGAGAACC/del_or_del/del._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_carboplatin_cyclophosphamide_and_thiotepa.""CTGGTGAGGAGAGAACC/del:Patients_with_the_CTGGTGAGGAGAGAACC/del_genotype_may_have_increased_severity_of_Drug_Toxicity_when_treated_with_carboplatin_cyclophosphamide_and_thiotepa_in_people_with_Neoplasms_as_compared_to_genotype_CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_carboplatin_cyclophosphamide_and_thiotepa.""del/del:Patients_with_the_del/del_genotype_may_have_increased_severity_of_Drug_Toxicity_when_treated_with_carboplatin_cyclophosphamide_and_thiotepa_in_people_with_Neoplasms_as_compared_to_genotype_CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_carboplatin_cyclophosphamide_and_thiotepa.";PGKB_RACE=White
9	86900926	rs7853758	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC28A3_(PA426);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.";PGKB_RACE=NR
9	86909550	rs885004	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC28A3_(PA426);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines_and_related_substance.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines_and_related_substance.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines_and_related_substance.";PGKB_RACE=NR
9	86920236	rs7867504	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC28A3_(PA426);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_formation_of_gemcitabine_triphosphate_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_formation_of_gemcitabine_triphosphate_in_patients_administered_gemcitabine._""CT:Patients_with_the_CT_genotype_may_have_decreased_formation_of_gemcitabine_triphosphate_as_compared_to_patients_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_formation_of_gemcitabine_triphosphate_in_patients_administered_gemcitabine._""TT:Patients_with_the_TT_genotype_may_have_decreased_formation_of_gemcitabine_triphosphate_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_affect_formation_of_gemcitabine_triphosphate_in_patients_administered_gemcitabine._";PGKB_RACE=NR
9	87322540	rs1778929	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_to_clozapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_to_clozapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_decreased_response_to_clozapine_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.";PGKB_RACE=White
9	87392582	rs10465180	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_decreased_response_to_clozapine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_to_clozapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_to_clozapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.";PGKB_RACE=White
9	87456351	rs2120266	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AG:Patients_with_the_AG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
9	87563370	rs2289658	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""CT:Patients_with_the_CT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""TT:Patients_with_the_TT_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
9	87600969	rs4358872	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""GT:Patients_with_the_GT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""TT:Patients_with_the_TT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
9	87616257	rs1948308	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AG:Patients_with_the_AG_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
9	87619423	rs2378676	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AC:Patients_with_the_AC_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""CC:Patients_with_the_CC_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
9	87632318	rs4877900	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NTRK2_(PA31818);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""CT:Patients_with_the_CT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""TT:Patients_with_the_TT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
9	87640636	rs1387923	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Bipolar_disorder_may_have_increased_response_to_lithium_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""AG:Patients_with_the_AG_genotype_and_Bipolar_disorder_may_have_decreased_response_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""GG:Patients_with_the_GG_genotype_and_Bipolar_disorder_may_have_decreased_response_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.";PGKB_RACE=White
9	87912671	rs2769605	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="lithium_(PA450243)""valproic_acid_(PA451846)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_or_valproic_acid_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""CT:Patients_with_the_CT_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_or_valproic_acid_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""TT:Patients_with_the_TT_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_or_valproic_acid_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=Asian
9	90235794	rs11141915	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=DAPK1_(PA27142);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_leukopenia.""AC:Patients_with_the_AC_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_genotype_and_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_leukopenia.""CC:Patients_with_the_CC_genotype_and_Neoplasms_who_are_treated_with_gemcitabine_may_have_a_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_leukopenia.";PGKB_RACE=Asian
9	98786276	rs238	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_slightly_decreased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_AG_or_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""AG:Patients_with_the_AG_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_slightly_increased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_AA_genotype_and_slightly_decreased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""GG:Patients_with_the_GG_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_slightly_increased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_AA_or_the_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.";PGKB_RACE=White
9	100459578	rs1800975	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=XPA_(PA368);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small-cell_lung_cancer_may_have_a_better_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""CT:Patients_with_the_CT_genotype_and_non-small-cell_lung_cancer_may_have_a_poorer_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""TT:Patients_with_the_TT_genotype_and_non-small-cell_lung_cancer_may_have_a_poorer_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.";PGKB_RACE=NR
9	104378003	rs10121600	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=GRIN3A_(PA28983);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_with_increased_risk_for_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""CT:Patients_with_the_CC_genotype_may_have_with_increased_risk_for_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_TT_genotype_or_may_have_with_decreased_risk_for_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""TT:Patients_with_the_TT_genotype_may_have_with_decreased_risk_for_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.";PGKB_RACE=NR
9	107562804	rs2230808	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCA1_(PA24373);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertriglyceridemia_(PA446120);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""CT:Patients_with_the_CT_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype_or_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""TT:Patients_with_the_TT_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.";PGKB_RACE=White
9	107620867	rs2230806	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=ABCA1_(PA24373),ABCA1_(PA24373);PGKB_DRUG=fenofibrate_(PA449594),pravastatin_(PA451089);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Hypertriglyceridemia_(PA446120),Coronary_Disease_(PA443797);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""CT:Patients_with_the_CT_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""TT:Patients_with_the_TT_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.","CC:Patients_with_the_CC_genotype_and_Coronary_Disease_who_are_treated_with_pravastatin_may_have_a_reduced_response_(lower_increases_in_HDL-cholesterol)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""CT:Patients_with_the_CT_genotype_and_Coronary_Disease_who_are_treated_with_pravastatin_may_have_a_better_response_(increased_HDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_reduced_response_(lower_increases_in_HDL-cholesterol)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Patients_with_the_TT_genotype_and_Coronary_Disease_who_are_treated_with_pravastatin_may_have_a_better_response_(increased_HDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._";PGKB_RACE=White,Asian
9	107645477	rs12003906	G	C,T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCA1_(PA24373);PGKB_DRUG="atorvastatin_(PA448500)""pravastatin_(PA451089)""simvastatin_(PA451363)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hyperlipidemias_(PA444528);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Hyperlipidemia_who_are_treated_with_atorvastatin_pravastatin_or_simvastatin_may_have_a_reduced_response_(less_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""CG:Patients_with_the_CG_genotype_and_Hyperlipidemia_who_are_treated_with_atorvastatin_pravastatin_or_simvastatin_may_have_a_reduced_response_(less_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_better_response_(a_higher_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_and_Hyperlipidemia_who_are_treated_with_atorvastatin_pravastatin_or_simvastatin_may_have_a_better_response_(a_higher_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._";PGKB_RACE=NR
9	115986409	rs10981694	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC31A1_(PA118);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_NSCLC_who_are_treated_with_cisplatin_may_have_an_increased_risk_of_severe_ototoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._""GT:Patients_with_the_GT_genotype_and_NSCLC_who_are_treated_with_cisplatin_may_have_an_increased_risk_of_severe_ototoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._""TT:Patients_with_the_TT_genotype_and_NSCLC_who_are_treated_with_cisplatin_may_have_an_reduced_risk_of_severe_ototoxicity_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cisplatin-induced_ototoxicity._";PGKB_RACE=Asian
9	116002464	rs7851395	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC31A1_(PA118);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_overall_survival_when_treated_with_carboplatin_or_cisplatin_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_genotypes_AG_or_GG._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_carboplatin_or_cisplatin.""AG:Patients_with_the_AG_genotype_may_have_decreased_overall_survival_when_treated_with_carboplatin_or_cisplatin_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_genotypes_AA._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_carboplatin_or_cisplatin.""GG:Patients_with_the_GG_genotype_may_have_decreased_overall_survival_when_treated_with_carboplatin_or_cisplatin_in_people_with_Non-Small-Cell_Lung_Carcinoma_as_compared_to_patients_with_genotypes_AA._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_carboplatin_or_cisplatin.";PGKB_RACE=Asian
9	117103973	rs2250242	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ORM2_(PA32818);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_prostate_cancer_may_have_increased_clearance_of_docetaxel_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_docetaxel.""AG:Patients_with_the_AG_genotype_and_prostate_cancer_may_have_decreased_clearance_of_docetaxel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_docetaxel.""GG:Patients_with_the_GG_genotype_and_prostate_cancer_may_have_decreased_clearance_of_docetaxel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_docetaxel.";PGKB_RACE=NR
9	120472764	rs1927907	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TLR4_(PA36552);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Organ_Transplantation_(PA133888799);PGKB_TEXT="CC:Organ_transplant_patients_with_the_CC_genotype_who_are_administered_tacrolimus_may_have_increased_dose_adjusted_trough_concentration_of_tacrolimus_as_compared_to_organ_transplant_patients_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_dose_adjusted_trough_concentration_of_tacrolimus_in_organ_transplant_patients._""CT:Organ_transplant_patients_with_the_CT_genotype_who_are_administered_tacrolimus_may_have_decreased_dose_adjusted_trough_concentration_of_tacrolimus_as_compared_to_organ_transplant_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_dose_adjusted_trough_concentration_of_tacrolimus_in_organ_transplant_patients._""TT:Organ_transplant_patients_with_the_TT_genotype_who_are_administered_tacrolimus_may_have_decreased_dose_adjusted_trough_concentration_of_tacrolimus_as_compared_to_organ_transplant_patients_with_the_CT_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_dose_adjusted_trough_concentration_of_tacrolimus_in_organ_transplant_patients._";PGKB_RACE=Asian
9	120474282	rs5030728	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TLR4_(PA36552);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Inflammatory_Bowel_Diseases_(PA446116);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_diseases_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AG:Patients_with_the_AG_genotype_and_inflammatory_bowel_diseases_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""GG:Patients_with_the_GG_genotype_and_inflammatory_bowel_diseases_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
9	120475302	rs4986790	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=TLR4_(PA36552),TLR4_(PA36552),TLR4_(PA36552);PGKB_DRUG=pravastatin_(PA451089),"folic_acid_(PA449692)""methotrexate_(PA450428)",Pertussis_vaccines_(PA164713160);PGKB_TYPE=Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Arthritis_Rheumatoid_(PA443434),NR;PGKB_TEXT="AA:Patients_with_AA_genotype_and_Coronary_Artery_Disease_who_are_treated_with_pravastatin_may_have_a_higher_risk_of_cardiovascular_events_as_compared_to_patients_with_the_AG_or_GG_genotype._Changes_in_angiographic_measurements_and_lipid/_lipoprotein_levels_were_not_significantly_different_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AG:Patients_with_AG_genotype_and_Coronary_Artery_Disease_who_are_treated_with_pravastatin_may_have_a_lower_risk_of_cardiovascular_events_as_compared_to_patients_with_the_AA_genotype._Changes_in_angiographic_measurements_and_lipid/_lipoprotein_levels_were_not_significantly_different_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Coronary_Artery_Disease_who_are_treated_with_pravastatin_may_have_a_lower_risk_of_cardiovascular_events_as_compared_to_patients_with_the_AA_genotype._Changes_in_angiographic_measurements_and_lipid/_lipoprotein_levels_were_not_significantly_different_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_folic_acid_and_methotrexate_may_have_a_decreased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_folic_acid_and_methotrexate_treatment._""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_folic_acid_and_methotrexate_may_have_a_decreased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_GG_genotype_or_may_have_an_increased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_folic_acid_and_methotrexate_treatment._""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_folic_acid_and_methotrexate_may_have_an_increased_risk_of_adverse_drug_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_folic_acid_and_methotrexate_treatment._","AA:Patients_with_the_AA_genotype_may_have_a_better_response_to_the_pertussis_vaccine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_efficacy_of_the_pertussis_vaccine.""AG:Patients_with_the_AG_genotype_may_have_a_poorer_response_to_the_pertussis_vaccine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_efficacy_of_the_pertussis_vaccine.""GG:Patients_with_the_GG_genotype_may_have_a_poorer_response_to_the_pertussis_vaccine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_efficacy_of_the_pertussis_vaccine.";PGKB_RACE=NR,NR,NR
9	120480812	rs1554973	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CNPY4_(PA162382618);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Inflammatory_Bowel_Diseases_(PA446116);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_inflammatory_bowel_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_inflammatory_bowel_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
9	123690239	rs3761847	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TRAF1_(PA36708);PGKB_DRUG="adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)""Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_anti-Tumor_necrosis_factor_alpha_(TNF-alpha)_treatments_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_anti-TNF_treatments.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_anti-Tumor_necrosis_factor_alpha_(TNF-alpha)_treatments_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_anti-TNF_treatments.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_anti-Tumor_necrosis_factor_alpha_(TNF-alpha)_treatments_in_people_with_Arthritis_Rheumatoid_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_anti-TNF_treatments.";PGKB_RACE=White
9	123759961	rs56040400	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=C5_(PA25911);PGKB_DRUG=eculizumab_(PA164776637);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_paroxysmal_nocturnal_hemoglobinuria_who_are_treated_with_eculizumab_may_have_an_increased_response_to_eculizumab_as_compared_with_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_eculizumab.""CT:Patients_with_the_CT_genotype_and_paroxysmal_nocturnal_hemoglobinuria_who_are_treated_with_eculizumab_may_have_a_decreased_response_to_eculizumab_as_compared_with_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_eculizumab.""TT:Patients_with_the_TT_genotype_were_not_part_of_the_study._But_patients_with_the_CT_genotype_and_paroxysmal_nocturnal_hemoglobinuria_who_are_treated_with_eculizumab_may_have_a_decreased_response_to_eculizumab_as_compared_with_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_eculizumab.";PGKB_RACE=Asian
9	125132522	rs10306114	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=PTGS1_(PA24346),PTGS1_(PA24346),PTGS1_(PA24346);PGKB_DRUG="aspirin_(PA448497)""clopidogrel_(PA449053)",aspirin_(PA448497),latanoprost_(PA164774763);PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,2B,3;PGKB_DISEASE=Myocardial_Infarction_(PA445019),"Coronary_Artery_Disease_(PA443796)""Myocardial_Infarction_(PA445019)",Glaucoma_Open-Angle_(PA444282);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_but_not_absent_risk_for_cardiovascular_events_(cardiac_death_and_recurrent_myocardial_infarction)_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_cardiovascular_events_(cardiac_death_and_recurrent_myocardial_infarction)_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_cardiovascular_events_(cardiac_death_and_recurrent_myocardial_infarction)_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.","AA:Patients_with_the_AA_genotype_who_are_treated_with_aspirin_may_have_a_decreased_but_not_absent_risk_for_non-response_to_aspirin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_for_non-response_to_aspirin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_for_non-response_to_aspirin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.","AA:Patients_with_the_AA_genotype_and_open-angle_glaucoma_may_have_an_increased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_latanoprost._*Please_note:_in_the_single_study_listed_below_individuals_of_genotype_GG_were_not_analyzed._""AG:Patients_with_the_AG_genotype_and_open-angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_latanoprost.""GG:Patients_with_the_GG_genotype_and_open-angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_latanoprost._*Please_note:_in_the_single_study_listed_below_individuals_of_genotype_GG_were_not_analyzed._";PGKB_RACE=NR,NR,Asian
9	125137695	rs10306135	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=PTGS1_(PA24346);PGKB_DRUG=Antiinflammatory_agents_non-steroids_(PA164712462);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acute_coronary_syndrome_(PA165108401);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_(NSAIDs)_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_NSAIDs.""AT:Patients_with_the_AT_genotype_may_have_decreased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_(NSAIDs)_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_NSAIDs.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Acute_coronary_syndrome_when_exposed_to_Antiinflammatory_agents_non-steroids_(NSAIDs)_as_compared_to_patients_with_genotype_AA_or_AT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_NSAIDs.";PGKB_RACE=NR
9	128001119	rs430397	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HSPA5_(PA29504);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_decreased_resistance_decreased_likelihood_of_early_relapse_increased_progression_free_survival_and_decreased_risk_of_non-small_cell_lung_cancer-related_death_when_treated_with_platinum_compounds_(cisplatin_or_carboplatin)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_platinum_compounds_relapse_progression-free_survival_or_non-small_cell_lung_cancer-related_death._""CT:Patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_have_decreased_resistance_decreased_likelihood_of_early_relapse_increased_progression_free_survival_and_decreased_risk_of_non-small_cell_lung_cancer-related_death_when_treated_with_platinum_compounds_(cisplatin_or_carboplatin)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_platinum_compounds_relapse_progression-free_survival_or_non-small_cell_lung_cancer-related_death._""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_increased_resistance_increased_likelihood_of_early_relapse_decreased_progression_free_survival_and_increased_risk_of_non-small_cell_lung_cancer-related_death_when_treated_with_platinum_compounds_(cisplatin_or_carboplatin)_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_platinum_compounds_relapse_progression-free_survival_or_carcinoma_non-smal_cell_lung_cancer-related_death._";PGKB_RACE=Asian
9	130562725	rs1544105	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=FPGS_(PA167);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_respond_to_methotrexate_as_compared_to_patients_with_the_TC_and_TT_genotype._Patients_with_the_CC_genotype_may_still_be_at_risk_for_non-response_to_methotrexate_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""CT:Patients_with_the_TC_genotype_and_rheumatoid_arthritis_may_be_less_likely_to_respond_to_methotrexate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_and_rheumatoid_arthritis_may_be_less_likely_to_respond_to_methotrexate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian
9	132501881	rs2302821	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=PTGES_(PA33948);PGKB_DRUG=celecoxib_(PA448871);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Colorectal_Neoplasms_who_are_treated_with_celecoxib_may_have_decreased_but_not_absent_risk_for_cardiovascular_toxicity_and_symptoms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""AC:Patients_with_the_AC_genotype_and_Colorectal_Neoplasms_who_are_treated_with_celecoxib_may_have_increased_risk_for_cardiovascular_toxicity_and_symptoms_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_but_not_absent_risk_for_cardiovascular_toxicity_and_symptoms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""CC:Patients_with_the_CC_genotype_and_Colorectal_Neoplasms_who_are_treated_with_celecoxib_may_have_increased_risk_for_cardiovascular_toxicity_and_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.";PGKB_RACE=NR
9	135782221	rs7862221	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TSC1_(PA37034);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="CC:Patients_with_asthma_and_the_CC_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""CT:Patients_with_asthma_and_the_CT_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""TT:Patients_with_asthma_and_the_TT_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
9	136154867	rs495828	G	T	.	.	PGKB_INDEX=2;PGKB_GENE=ABO_(PA24415),NR;PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308),enalapril_(PA449456);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Hypertension_(PA444552);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_TT_or_TG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough.""TG:Patients_with_the_TG_genotype_may_have_an_increased_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough_when_treated_with_Ace_Inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough.","GG:Patients_with_the_GG_genotype_and_Hypertension_who_are_treated_with_enalapril_may_have_decreased_but_not_absent_risk_for_Cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril.""GT:Patients_with_the_GT_genotype_and_Hypertension_who_are_treated_with_enalapril_may_have_decreased_but_not_absent_risk_for_Cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril.""TT:Patients_with_the_TT_genotype_and_Hypertension_who_are_treated_with_enalapril_may_have_increased_risk_for_Cough_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril.";PGKB_RACE=White,Asian
9	136500515	rs1611115	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=DBH_(PA136),DBH_(PA136),DBH_(PA136);PGKB_DRUG=naltrexone_(PA450588),"Analgesics_(PA164712362)""Antiinflammatory_agents_non-steroids_(PA164712462)""Ergot_alkaloids_(PA164712741)""opioids_(PA452618)""sumatriptan_(PA451566)",levodopa_(PA450213);PGKB_TYPE=Efficacy,Other,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Alcoholism_(PA443309),Substance_Withdrawal_Syndrome_(PA445768),Cocaine-Related_Disorders_(PA446878);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_alcohol-dependent_may_have_a_poorer_response_to_treatment_with_naltrexone_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_naltrexone._""CT:Patients_with_the_CT_genotype_who_are_alcohol-dependent_may_have_a_better_response_to_treatment_with_naltrexone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_naltrexone.""TT:Patients_with_the_TT_genotype_who_are_alcohol-dependent_may_have_a_better_response_to_treatment_with_naltrexone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_naltrexone.","CC:Patients_with_the_CC_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""CT:Patients_with_the_CT_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""TT:Patients_with_the_TT_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.","CC:Patients_with_the_CC_genotype_may_have_a_decreased_response_to_levodopa_in_people_with_cocaine-related_disorders_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_levodopa.""CT:Patients_with_the_CT_genotype_may_have_an_increased_response_to_levodopa_in_people_with_cocaine-related_disorders_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_levodopa.""TT:Patients_with_the_TT_genotype_may_have_an_increased_response_to_levodopa_in_people_with_cocaine-related_disorders_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_levodopa.";PGKB_RACE=White,NR,NR
9	140051376	rs1126442	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GRIN1_(PA28978);PGKB_DRUG=methamphetamine_(PA450403);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="AA:Individuals_with_the_AA_genotype_who_are_addicted_to_methamphetamine_may_be_less_likely_to_experience_psychosis_when_taking_methamphetamine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_psychosis_when_taking_methamphetamine.""AG:Individuals_with_the_AG_genotype_who_are_addicted_to_methamphetamine_may_be_less_likely_to_experience_psychosis_when_taking_methamphetamine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_psychosis_when_taking_methamphetamine.""GG:Individuals_with_the_GG_genotype_who_are_addicted_to_methamphetamine_may_be_more_likely_to_experience_psychosis_when_taking_methamphetamine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_psychosis_when_taking_methamphetamine.";PGKB_RACE=Asian
10	4240870	rs11252394	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=salbutamol_(PA448068);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_AA_genotypes_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_asthma_when_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._""AG:Patients_with_AG_genotypes_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_asthma_when_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""GG:Patients_with_GG_genotypes_may_have_decreased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_asthma_when_compared_to_patients_with_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.";PGKB_RACE=NR
10	4810561	rs1901633	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_may_have_increased_response_to_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_methotrexate_as_compared_to_patients_with_the_AA_genotype_or_may_have_increased_response_to_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_may_have_decreased_response_to_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian
10	8104208	rs3824662	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=GATA3_(PA28586);PGKB_DRUG="asparaginase_(PA448492)""cyclophosphamide_(PA449165)""cytarabine_(PA449177)""daunorubicin_(PA449212)""dexamethasone_(PA449247)""doxorubicin_(PA449412)""leucovorin_(PA450198)""mercaptopurine_(PA450379)""methotrexate_(PA450428)""pegaspargase_(PA164760860)""prednisone_(PA451100)""thioguanine_(PA451663)""vincristine_(PA451879)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Children_with_the_AA_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_combination_chemotherapy_may_have_a_worse_treatment_response_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""AC:Children_with_the_AC_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_combination_chemotherapy_may_have_a_worse_treatment_response_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_better_treatment_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""CC:Children_with_the_CC_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_combination_chemotherapy_may_have_a_better_treatment_response_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.";PGKB_RACE=NR
10	12704191	rs10752271	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CAMK1D_(PA134992438);PGKB_DRUG=losartan_(PA450268);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_smaller_decrease_in_blood_pressure_when_treated_with_losartan_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_greater_decrease_in_blood_pressure_when_treated_with_losartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_greater_decrease_in_blood_pressure_when_treated_with_losartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure.";PGKB_RACE=White
10	12732743	rs10737062	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CAMK1D_(PA134992438);PGKB_DRUG=losartan_(PA450268);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_a_smaller_decrease_in_blood_pressure_when_treated_with_losartan_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure.""AG:Patients_with_the_AG_genotype_and_hypertension_may_have_a_greater_decrease_in_blood_pressure_when_treated_with_losartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_greater_decrease_in_blood_pressure_when_treated_with_losartan_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure.";PGKB_RACE=White
10	37790412	rs11819745	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=THRA_(PA36507);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="aspirin-induced_asthma_(PA131285571)""Asthma_(PA443450)";PGKB_TEXT="AA:Patients_with_asthma_and_the_AA_genotype_may_have_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""AG:Patients_with_asthma_and_the_AG_genotype_may_have_an_increased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_of_aspirin_induced_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.""GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_increased_risk_of_aspirin_induced_asthma_as_compared_to_people_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma.";PGKB_RACE=Asian
10	45901089	rs2115819	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ALOX5_(PA46);PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Asthma_may_not_have_an_increased_response_to_montelukast_treatment_based_on_no_change_in_Forced_expiratory_volume_in_one_second_(FEV1)_response_to_montelukast_at_6_month_of_treatment_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.""AG:Patients_with_the_AG_genotype_and_Asthma_may_not_have_an_increased_response_to_montelukast_treatment_based_on_no_change_in_Forced_expiratory_volume_in_one_second_(FEV1)_response_to_montelukast_at_6_month_of_treatment_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.""GG:Patients_with_the_GG_genotype_and_Asthma_may_have_an_increased_response_to_montelukast_treatment_based_on_an_increased_Forced_expiratory_volume_in_one_second_(FEV1)_response_to_montelukast_at_6_month_of_treatment_compared_to_patients_with_the_AA_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.";PGKB_RACE=White
10	50824117	rs1880676	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHAT_(PA26448);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_as_compared_to_patients_with_the_GG_genotype.or_may_have_decreased_response_to_olanzapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_may_have_decreased_response_to_olanzapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=White
10	50824619	rs3810950	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHAT_(PA26448);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_response_to_olanzapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_may_have_decreased_response_to_olanzapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=White
10	50838874	rs2177370	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=CHAT_(PA26448),CHAT_(PA26448),CHAT_(PA26448);PGKB_DRUG=galantamine_(PA449726),donepezil_(PA449394),rivastigmine_(PA451262);PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Alzheimer_Disease_(PA443319),Alzheimer_Disease_(PA443319),Alzheimer_Disease_(PA443319);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Alzheimer's_disease_may_have_increased_response_to_galantamine_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_galantamine_.""AG:Patients_with_the_AG_genotype_and_Alzheimer's_disease_may_have_increased_response_to_galantamine_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_galantamine.""GG:Patients_with_the_GG_genotype_and_Alzheimer's_disease_may_have_decreased_response_to_galantamine_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_galantamine.","AA:Patients_with_the_AA_genotype_and_Alzheimer's_disease_may_have_increased_response_to_donepezil_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_donezepil.""AG:Patients_with_the_AG_genotype_and_Alzheimer's_disease_may_have_increased_response_to_donepezil_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_donezepil.""GG:Patients_with_the_GG_genotype_and_Alzheimer's_disease_may_have_decreased_response_to_donepezil_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_donezepil.","AA:Patients_with_the_AA_genotype_and_Alzheimer's_disease_may_have_increased_response_to_rivastigmine_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_rivastigmine.""AG:Patients_with_the_AG_genotype_and_Alzheimer's_disease_may_have_increased_response_to_rivastigmine_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_rivastigmine.""GG:Patients_with_the_GG_genotype_and_Alzheimer's_disease_may_have_decreased_response_to_rivastigmine_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_impact_the_metabolism_of_rivastigmine.";PGKB_RACE=Asian,Asian,Asian
10	50840736	rs3793790	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHAT_(PA26448);PGKB_DRUG="donepezil_(PA449394)""galantamine_(PA449726)""rivastigmine_(PA451262)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Alzheimer_Disease_(PA443319);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Alzheimer_Disease_may_have_decreased_response_to_donepezil_galantamine_or_rivastigmine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_donezepil_galantamine_and_rivastigmine.""AG:Patients_with_the_AG_genotype_and_Alzheimer_Disease_may_have_decreased_response_to_donepezil_galantamine_or_rivastigmine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_donezepil_galantamine_and_rivastigmine.""GG:Patients_with_the_GG_genotype_and_Alzheimer_Disease_may_have_increased_response_to_donepezil_galantamine_or_rivastigmine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_donezepil_galantamine_and_rivastigmine.";PGKB_RACE=Asian
10	62554474	rs10711	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=CDK1_(PA99);PGKB_DRUG=radiotherapy_(PA166122986);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=pneumonitis_(PA166124223);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_pneumonitis_when_treated_with_radiotherapy_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_radiotherapy.""GT:Patients_with_the_GT_genotype_may_have_increased_risk_of_pneumonitis_when_treated_with_radiotherapy_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_radiotherapy.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_pneumonitis_when_treated_with_radiotherapy_as_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_radiotherapy.";PGKB_RACE=NR
10	63723577	rs10821936	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ARID5B_(PA134943193);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Pediatric_patients_with_the_CC_genotype_and_B-hyperdiploid_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_greater_methotrexate_polyglutamate_accumulation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_polyglutamate_accumulation.""CT:Pediatric_patients_with_the_CT_genotype_and_B-hyperdiploid_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_greater_methotrexate_polyglutamate_accumulation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_polyglutamate_accumulation.""TT:Pediatric_patients_with_the_TT_genotype_and_B-hyperdiploid_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_lower_methotrexate_polyglutamate_accumulation_as_compared_to_patients_with_the_CC_and_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methotrexate_polyglutamate_accumulation.";PGKB_RACE=White
10	63805617	rs4948496	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ARID5B_(PA134943193);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_acute_lymphoblastic_leukemia_may_have_increased_concentrations_of_methotrexate_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_methotrexate.""CT:Patients_with_the_CT_genotype_and_acute_lymphoblastic_leukemia_may_have_decreased_concentrations_of_methotrexate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_methotrexate.""TT:Patients_with_the_TT_genotype_and_acute_lymphoblastic_leukemia_may_have_decreased_concentrations_of_methotrexate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_methotrexate.";PGKB_RACE=White
10	63915972	rs7912580	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=NR,NR;PGKB_DRUG=haloperidol_(PA449841),"olanzapine_(PA450688)""quetiapine_(PA451201)""risperidone_(PA451257)""ziprasidone_(PA451974)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=4,4;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_were_not_studied._However_patients_with_the_AG_genotype_and_Schizophrenia_may_have_decreased_response_to_haloperidol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_may_have_decreased_response_to_haloperidol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_may_have_increased_response_to_haloperidol_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.","AA:Patients_with_the_AA_genotype_were_not_studied._However_patients_with_the_AG_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_may_have_decreased_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone.";PGKB_RACE=White,NR
10	67679048	rs1786929	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="fluticasone_propionate_(PA449686)""montelukast_(PA450546)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_better_response_to_treatment_with_fluticasone_propionate_or_montelukast_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluticasone_propionate_or_montelukast.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_better_response_to_treatment_with_fluticasone_propionate_or_montelukast_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluticasone_propionate_or_montelukast.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_poorer_response_to_treatment_with_fluticasone_propionate_or_montelukast_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluticasone_propionate_or_montelukast.";PGKB_RACE=NR
10	70158869	rs7917432	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="ABCC2_(PA116)""RUFY2_(PA134935922)";PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_increased_creatinine_clearance_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.""CT_:Patients_with_the_CT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_decreased_creatinine_clearance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.""TT:Patients_with_the_TT_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_decreased_creatinine_clearance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.";PGKB_RACE=NR
10	73769507	rs4148943	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	73769590	rs4148945	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_1)_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_increased_risk_of_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_1)_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_increased_risk_of_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_a_1)_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	73770117	rs4148947	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	73771706	rs4148950	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_1)_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_1)_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_a_1)_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	73772014	rs1871450	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_1)_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AA_genotype_may_have_an_1)_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_a_1)_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_2)_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	73772762	rs730720	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	73773014	rs12418	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CHST3_(PA26503);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_chance_of_response_to_treatment_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
10	79570873	rs2289310	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=DLG5_(PA27360);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="GG:Patients_with_metastasized_cancer_and_the_GG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""GT:Patients_with_metastasized_cancer_and_the_GT_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GG_genotype_and_worse_response_as_compared_to_people_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""TT:Patients_with_metastasized_cancer_and_the_TT_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.";PGKB_RACE=Asian
10	83819125	rs4933824	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NRG3_(PA31778);PGKB_DRUG=iloperidone_(PA161199368);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acquired_Long_QT_Syndrome_(aLQTS)_(PA447300);PGKB_TEXT="GG:Patients_with_the_GG_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_TT_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Patients_with_the_GT_genotype_who_are_treated_with_iloperidone_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_who_are_treated_with_iloperidone_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
10	89720251	rs17431184	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PTEN_(PA33942);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="CC:Patients_with_metastasized_cancer_and_the_CC_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""CT:Patients_with_metastasized_cancer_and_the_CT_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_CC_genotype_and_improved_response_as_compared_to_people_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""TT:Patients_with_metastasized_cancer_and_the_TT_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.";PGKB_RACE=Asian
10	92594343	rs1935349	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HTR7_(PA29561);PGKB_DRUG="atorvastatin_(PA448500)""hmg_coa_reductase_inhibitors_(PA133950441)""pravastatin_(PA451089)""simvastatin_(PA451363)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Myalgia_unspecified_(PA157379134);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_non-existent_risk_for_statin-related_myalgia_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_responses_to_statins.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_for_statin-related_myalgia_as_compared_to_patients_with_the_CC_genotypes_or_may_have_a_decreased_risk_for_statin-related_myalgia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_responses_to_statins.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_for_statin-related_myalgia_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_responses_to_statins.";PGKB_RACE=NR
10	96405502	rs12777823	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_a_lower_dose_of_warfarin_(may_require_a_dose_reduction_of_934_mg/week)_in_African_Americans_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""AG:Patients_with_the_AG_genotype_may_require_a_lower_dose_of_warfarin_(may_require_a_dose_reduction_of_692_mg/week)_in_African_Americans_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_may_require_a_higher_dose_of_warfarin_in_African_Americans_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.";PGKB_RACE=Black_or_African_American
10	96519061	rs11188072	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=CYP2C19_(PA124),NR,CYP2C19_(PA124);PGKB_DRUG=escitalopram_(PA10074),imipramine_(PA449969),mephenytoin_(PA450373);PGKB_TYPE=Dosage,Other,Dosage;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Mental_Disorders_(PA447208),Depressive_Disorder_Major_(PA447321),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_escitalopram_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""CT:Patients_with_the_CT_genotype_who_are_treated_with_escitalopram_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""TT:Patients_with_the_TT_genotype_who_are_treated_with_escitalopram_may_require_an_increased_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.","CC:Patients_with_the_CC_genotype_(CYP2C19*1/*1)_and_major_depressive_disorder_may_have_higher_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_CT_or_TT_genotype_(CYP2C19*1/*17_or_*17/*17)._In_this_case_*17_was_defined_by_2_variants_rs11188072_and_rs12248560._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""CT:Patients_with_the_CT_genotype_(CYP2C19*1/*17)_and_major_depressive_disorder_may_have_lower_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_CC_genotype_(CYP2C19*1/*1)._In_this_case_*17_was_defined_by_2_variants_rs11188072_and_rs12248560._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""TT:Patients_with_the_TT_genotype_(CYP2C19*17/*17)_and_major_depressive_disorder_may_have_lower_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_CC_genotype_(CYP2C19*1/*1)._In_this_case_*17_was_defined_by_2_variants_rs11188072_and_rs12248560._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._","CC:Patients_with_the_CC_genotype_who_are_treated_with_mephenytoin_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""CT:Patients_with_the_CT_genotype_who_are_treated_with_mephenytoin_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""TT:Patients_with_the_TT_genotype_who_are_treated_with_mephenytoin_may_require_an_increased_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.";PGKB_RACE=White,NR,Black_or_African_American
10	96521657	rs12248560	C	A,T	.	.	PGKB_INDEX=8;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=amitriptyline_(PA448385),"citalopram_(PA449015)""escitalopram_(PA10074)",imipramine_(PA449969),clopidogrel_(PA449053),escitalopram_(PA10074),mephenytoin_(PA450373),prasugrel_(PA154410481),busulfan_(PA448691);PGKB_TYPE=Efficacy,Metabolism/PK,Other,"Dosage""Efficacy""Toxicity/ADR",Dosage,Dosage,Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=3,2A,3,1A,3,3,3,3;PGKB_DISEASE=NR,NR,Depressive_Disorder_Major_(PA447321),"Acute_coronary_syndrome_(PA165108401)""Coronary_Artery_Disease_(PA443796)""Myocardial_Infarction_(PA445019)",Mental_Disorders_(PA447208),NR,Acute_coronary_syndrome_(PA165108401),hemopoietic_stem_cell_transplant_(PA166122646);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_amitriptyline_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration._""TC:Patients_with_the_TC_genotype_may_have_decreased_metabolism_of_amitriptyline_as_compared_to_patients_with_the_CC_genotype_or_may_have_increased_metabolism_of_amitriptyline_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration._""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_amitriptyline_levels_as_compared_to_patients_with_the_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration._","CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_citalopram_or_escitalopram_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_citalopram_or_escitalopram_metabolism._""CT:Patients_with_the_CT_genotype_(CYP2C19*1/*17)_may_have_an_increased_metabolism_of_citalopram_or_escitalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_citalopram_or_escitalopram_metabolism._""TT:Patients_with_the_TT_genotype_(CYP2C19*17/*17)_may_have_an_increased_metabolism_of_citalopram_or_escitalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_citalopram_or_escitalopram_metabolism._","CC:Patients_with_the_CC_genotype_(CYP2C19*1/*1)_and_major_depressive_disorder_may_have_higher_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_CT_or_TT_genotype_(CYP2C19*1/*17_or_*17/*17)._In_this_case_*17_was_defined_by_2_variants_rs11188072_and_rs12248560._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""CT:Patients_with_the_CT_genotype_(CYP2C19*1/*17)_and_major_depressive_disorder_may_have_lower_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_CC_genotype_(CYP2C19*1/*1)._In_this_case_*17_was_defined_by_2_variants_rs11188072_and_rs12248560._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._""TT:Patients_with_the_TT_genotype_(CYP2C19*17/*17)_and_major_depressive_disorder_may_have_lower_dose-corrected_plasma_concentrations_of_imipramine_as_compared_to_patients_with_the_CC_genotype_(CYP2C19*1/*1)._In_this_case_*17_was_defined_by_2_variants_rs11188072_and_rs12248560._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_imipramine._","CC:Patients_with_the_CC_genotype_(*1/*1):_1)_may_have_decreased_activation_of_clopidogrel_2)_may_have_a_decreased_but_not_absent_risk_for_bleeding_with_clopidogrel_as_compared_to_patients_with_the_CT_or_TT_genotype_3)_may_have_an_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_a_CT_or_TT_genotype._Other_genetic_including_CYP2C19_loss-of-function_alleles_e.g._*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding_and_adverse_cardiovascular_events.""CT:Patients_with_the_CT_(*1/*17)_genotype:_1)_may_have_increased_activation_of_clopidogrel_2)_may_have_an_increased_risk_of_bleeding_with_clopidogrel_as_compared_to_patients_with_the_CC_genotype_3)_may_have_a_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_a_CC_genotype._Current_CPIC_guidelines_recommend_no_change_in_clopidogrel_dosing_based_on_*1/*17_genotype_as_of_yet._Other_genetic_including_CYP2C19_loss-of-function_alleles_e.g._*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding_and_adverse_cardiovascular_events.""TT:Patients_with_the_TT_(*17/*17)_genotype:_1)_may_have_increased_activation_of_clopidogrel_2)_may_have_an_increased_risk_of_bleeding_with_clopidogrel_as_compared_to_patients_with_a_CC_genotype_3)_may_have_a_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_a_CC_genotype._Current_CPIC_guidelines_recommend_no_change_in_clopidogrel_dosing_based_on_*17/*17_genotype_as_of_yet._Other_genetic_including_CYP2C19_loss-of-function_alleles_e.g._*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding_and_adverse_cardiovascular_events.","CC:Patients_with_the_CC_genotype_who_are_treated_with_escitalopram_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""CT:Patients_with_the_CT_genotype_who_are_treated_with_escitalopram_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""TT:Patients_with_the_TT_genotype_who_are_treated_with_escitalopram_may_require_an_increased_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.","CC:Patients_with_the_CC_genotype_who_are_treated_with_mephenytoin_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""CT:Patients_with_the_CT_genotype_who_are_treated_with_mephenytoin_may_require_a_decreased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""TT:Patients_with_the_TT_genotype_who_are_treated_with_mephenytoin_may_require_an_increased_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_*2_rs4244285*3_rs4986893_and_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.","CC:Patients_with_the_CC_genotype_and_acute_coronary_syndrome_who_are_treated_with_prasugrel_may_have_an_decreased_but_not_absent_risk_for_bleeding_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding.""CT:Patients_with_the_CT_genotype_and_acute_coronary_syndrome_who_are_treated_with_prasugrel_may_have_an_increased_risk_for_bleeding_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding.""TT:Patients_with_the_TT_genotype_and_acute_coronary_syndrome_who_are_treated_with_prasugrel_may_have_an_increased_risk_for_bleeding_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding.","CC:Patients_with_the_CC_genotype_(CYP2C19_*1/*1)_undergoing_transplantation_may_have_decreased_metabolism_of_busulfan_as_compared_to_patients_with_the_CT_(*1/*17)_or_TT_(*17/*17)_genotype._However_some_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_busulfan.""CT:Patients_with_the_CT_(CYP2C19_*1/*17)_genotype_undergoing_transplantation_may_have_increased_metabolism_of_busulfan_as_compared_to_patients_with_the_CC_(*1/*1)_genotype._However_some_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_busulfan.""TT:Patients_with_the_TT_(CYP2C19_*17/*17)_genotype_undergoing_transplantation_may_have_increased_metabolism_of_busulfan_as_compared_to_patients_with_the_CC_(*1/*1)_genotype._However_some_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_busulfan.";PGKB_RACE=NR,NR,NR,NR,White,Black_or_African_American,NR,NR
10	96522463	rs28399504	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=1A;PGKB_DISEASE="Acute_coronary_syndrome_(PA165108401)""Cardiovascular_Diseases_(PA443635)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_1)_may_have_increased_metabolism_of_clopidogrel_and_2)_may_have_a_decreased_but_not_absent_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_and_AG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""AG:Patients_with_the_AG_genotype_1)_may_have_poor_metabolism_of_clopidogrel_and_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""GG:Patients_with_the_GG_genotype_1)_may_have_poor_metabolism_of_clopidogrel_and_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.";PGKB_RACE=NR
10	96525865	rs12768009	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C19_(PA124);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_who_are_treated_with_nevirapine_may_have_decreased_clearance_of_nevirapine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nevirapine.""AG:Patients_with_the_AG_genotype_and_HIV_who_are_treated_with_nevirapine_may_have_increased_clearance_of_nevirapine_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nevirapine.""GG:Patients_with_the_GG_genotype_and_HIV_who_are_treated_with_nevirapine_may_have_increased_clearance_of_nevirapine_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nevirapine.";PGKB_RACE=NR
10	96540410	rs4986893	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=clopidogrel_(PA449053),escitalopram_(PA10074);PGKB_TYPE="Efficacy""Toxicity/ADR",Metabolism/PK;PGKB_EVIDENCE=1A,3;PGKB_DISEASE="Acute_coronary_syndrome_(PA165108401)""Coronary_Artery_Disease_(PA443796)",Mental_Disorders_(PA447208);PGKB_TEXT="AA:Patients_with_the_AA_genotype_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""AG:Patients_with_the_AG_genotype_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""GG:Patients_with_the_GG_genotype_1)_may_have_increased_metabolism_of_clopidogrel_and_formation_of_active_drug_metabolite_resulting_in_increased_response_2)_may_have_a_decreased_but_not_absent_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.","AA:Patients_with_the_AA_genotype_and_Mental_disorders_may_have_increased_serum_concentration_of_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.""AG:Patients_with_the_AG_genotype_and_Mental_disorders_may_have_increased_serum_concentration_of_escitalopram_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_serum_concentration_of_escitalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.""GG:Patients_with_the_GG_genotype_and_Mental_disorders_may_have_decreased_serum_concentration_of_escitalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.";PGKB_RACE=NR,White
10	96541616	rs4244285	G	A,C	.	.	PGKB_INDEX=10;PGKB_GENE=CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124),CYP2C19_(PA124);PGKB_DRUG=clomipramine_(PA449048),citalopram_(PA449015),amitriptyline_(PA448385),doxepin_(PA449409),prasugrel_(PA154410481),clopidogrel_(PA449053),cyclophosphamide_(PA449165),"cyclophosphamide_(PA449165)""doxorubicin_(PA449412)",venlafaxine_(PA451866),etravirine_(PA166014703);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Other,Efficacy,"Efficacy""Toxicity/ADR",Toxicity/ADR,Efficacy,Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=2A,2A,1A,3,3,1A,3,4,4,3;PGKB_DISEASE=NR,NR,NR,NR,Acute_coronary_syndrome_(PA165108401),"Acute_coronary_syndrome_(PA165108401)""Cardiovascular_Diseases_(PA443635)""Thrombosis_(PA445850)",Lupus_Erythematosus_Systemic_(PA444822),Breast_Neoplasms_(PA443560),Depression_(PA447278),HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_metabolism_of_clomipramine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._""AG:Patients_with_the_AG_genotype_may_have_a_decreased_metabolism_of_clomipramine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._""GG:Patients_with_the_GG_genotype_may_have_an_increased_metabolism_of_clomipramine_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clomipramine_metabolism._","AA:Patients_with_AA_genotype_may_have_a_decreased_metabolism_of_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_citalopram_metabolism._""AG:Patients_with_AG_genotype_may_have_a_decreased_metabolism_of_citalopram_as_compared_to_patients_with_the_GG_genotype_or_an_increased_metabolism_of_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_citalopram_metabolism._""GG:Patients_with_GG_genotype_may_have_an_increased_metabolism_of_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_citalopram_metabolism._","AA:Patients_with_the_AA_genotype_who_are_treated_with_amitriptyline_may_have_decreased_metabolism_of_amitriptyline_(increased_amitriptyline_plasma_concentrations_and_decreased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_and_*3_rs4986893_along_with_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""GA:Patients_with_the_AG_genotype_who_are_treated_with_amitriptyline_may_have_decreased_metabolism_of_amitriptyline_(increased_amitriptyline_plasma_concentrations_and_decreased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_and_*3_rs4986893_along_with_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.""GG:Patients_with_the_GG_genotype_who_are_treated_with_amitriptyline_may_have_increased_metabolism_of_amitriptyline_(decreased_amitriptyline_plasma_concentrations_and_increased_nortriptyline_plasma_concentrations)_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_factors_including_other_CYP2C19_alleles_*17_rs12248560_and_*3_rs4986893_along_with_clinical_factors_may_also_influence_a_patient's_required_dose_and_should_be_taken_into_consideration.","AA:Patients_with_the_AA_genotype_(CYP2C19*2/*2)_may_have_a_decreased_clearance_of_doxepin_as_compared_to_patients_with_the_GG_genotype_(CYP2C19*1/*1)._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_doxepin_metabolism.""AG:Patients_with_the_AG_genotype_(CYP2C19*1/*2)_may_have_a_decreased_clearance_of_doxepin_as_compared_to_patients_with_the_GG_genotype_(CYP2C19*1/*1)._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_doxepin_metabolism.""GG:Patients_with_the_GG_genotype_(CYP2C19*1/*1)_may_have_an_increased_clearance_of_doxepin_as_compared_to_patients_with_the_AA_genotype_(CYP2C19*2/*2)._The_number_of_studies_for_doxepin_pharmacogenomics_is_limited._However_since_tricyclics_have_comparable_pharmacokinetic_properties_see_also_annotations_for_amitriptyline_imipramine_trimipramine_and_clomipramine_for_further_evidence._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_doxepin_metabolism.","AA:Patients_with_the_AA_genotype_who_are_treated_with_prasugrel_may_have_a_higher_rate_of_high_on-treatment_platelet_reactivity_at_1_month_of_treatment_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel._""AG:Patients_with_the_AG_genotype_who_are_treated_with_prasugrel_may_have_a_higher_rate_of_high_on-treatment_platelet_reactivity_at_1_month_of_treatment_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel._""GG:Patients_with_the_GG_genotype_who_are_treated_with_prasugrel_may_have_a_lower_rate_of_high_on-treatment_platelet_reactivity_at_1_month_of_treatment_as_compared_to_patients_with_the_AG_or_AA_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_prasugrel._","AA:Patients_with_the_AA_genotype:_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""AG:Patients_with_the_AG_genotype:_1)_may_have_poor_metabolism_of_clopidogrel_and_decreased_formation_of_active_drug_metabolite_resulting_in_decreased_response_2)_may_have_an_increased_risk_for_secondary_cardiovascular_events_when_treated_with_clopidogrel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.""GG:Patients_with_the_GG_genotype:_1)_may_have_sufficient_metabolism_of_clopidogrel_and_increased_formation_of_active_drug_metabolite_2)_may_have_a_decreased_risk_for_secondary_cardiovascular_events_with_clopidogrel_as_compared_to_patients_with_the_AA_or_AG_genotype._Patients_with_the_GG_genotype_may_still_be_at_risk_for_secondary_cardiovascular_events_when_taking_clopidogrel_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_secondary_cardiovascular_events_and_response_to_clopidogrel.","AA:Patients_with_the_AA_genotype_and_Systemic_Lupus_Erythematosus_who_are_treated_with_cyclophosphamide_may_have_decreased_metabolism_of_cyclophosphamide_leading_to_lower_concentrations_of_the_active_metabolite_and_a_decreased_risk_of_toxicity_(ovarian_gastrointestinal_or_hematological)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cyclophosphamide-induced_toxicity.""AG:Patients_with_the_AG_genotype_and_Systemic_Lupus_Erythematosus_who_are_treated_with_cyclophosphamide_may_have_decreased_metabolism_of_cyclophosphamide_leading_to_lower_concentrations_of_the_active_metabolite_and_a_decreased_risk_of_toxicity_(ovarian_gastrointestinal_or_hematological)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cyclophosphamide-induced_toxicity.""GG:Patients_with_the_GG_genotype_and_Systemic_Lupus_Erythematosus_who_are_treated_with_cyclophosphamide_may_have_increased_metabolism_of_cyclophosphamide_leading_to_higher_concentrations_of_the_active_metabolite_and_an_increased_risk_of_toxicity_(ovarian_gastrointestinal_or_hematological)_as_compared_to_patients_with_the_AA_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cyclophosphamide-induced_toxicity.","AA:Patients_with_the_AA_genotype_and_Breast_Cancer_who_are_treated_with_cyclophosphamide_and_doxorubicin_may_have_an_increased_risk_of_poorer_outcome_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""AG:Patients_with_the_AG_genotype_and_Breast_Cancer_who_are_treated_with_cyclophosphamide_and_doxorubicin_may_have_a_decreased_risk_of_poorer_outcome_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""GG:Patients_with_the_AG_genotype_and_Breast_Cancer_who_are_treated_with_cyclophosphamide_and_doxorubicin_may_have_a_decreased_risk_of_poorer_outcome_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.","AA:Patients_with_the_AA_genotype_were_not_studied._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment_side_effects.""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_venlafaxine_may_have_an_increased_risk_for_agitation_and_dysphoria_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment_side_effects.""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_venlafaxine_may_have_a_decreased_but_not_absent_risk_for_agitation_and_dysphoria_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment_side_effects.","AA:Patients_with_the_AA_genotype_who_are_treated_with_etravirine_may_have_a_decreased_etravirine_clearance_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_etravirine_clearance.""AG:Patients_with_the_AG_genotype_who_are_treated_with_etravirine_may_have_a_decreased_etravirine_clearance_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_etravirine_clearance.""GG:Patients_with_the_GG_genotype_who_are_treated_with_etravirine_may_have_an_increased_etravirine_clearance_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_etravirine_clearance.";PGKB_RACE=NR,NR,NR,White,NR,NR,Asian,NR,Asian,NR
10	96695351	rs12782374	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=phenytoin_(PA450947);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_decreased_dose_of_phenytoin_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GG._The_Allele_A_is_associated_with_decreased_expression_of_CYP2C9_when_treated_with_phenytoin_in_HepG2_cells._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_dose_of_phenytoin.""AG:Patients_with_the_AG_genotype_may_1)_require_decreased_dose_of_phenytoin_2)_have_increase_metabolism_of_phenytoin_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GG._The_Allele_A_is_associated_with_decreased_expression_of_CYP2C9_when_treated_with_phenytoin_in_HepG2_cells._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_dose_of_phenytoin.""GG:Patients_with_the_GG_genotype_may_1)_require_increased_dose_of_phenytoin_2)_have_decrease_metabolism_of_phenytoin_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_AA_or_AG._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_dose_of_phenytoin.";PGKB_RACE=White
10	96695775	rs71486745	TGT	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=phenytoin_(PA450947);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GT/GT:Patients_with_the_GT/GT_genotype_may_have_increased_dose_of_phenytoin_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_del/del_or_GT/del._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_phenytoin.""GT/del:Patients_with_the_GT/del_genotype_may_have_decreased_dose_of_phenytoin_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GT/GT._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_phenytoin.""del/del:Patients_with_the_del/del_genotype_may_have_decreased_dose_of_phenytoin_in_people_with_Epilepsy_as_compared_to_patients_with_genotype_GT/GT._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_phenytoin.";PGKB_RACE=White
10	96696875	rs9332096	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_increased_warfarin_dose_requirement_in_mechanical_heart_valve_replacement_patients_when_treated_with_warfarin_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_dose_of_warfarin.""CT:Patients_with_the_CT_genotype_may_require_decreased_warfarin_dose_requirement_in_mechanical_heart_valve_replacement_patients_when_treated_with_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_may_require_decreased_warfarin_dose_requirement_in_mechanical_heart_valve_replacement_patients_when_treated_with_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_dose_of_warfarin.";PGKB_RACE=Asian
10	96702047	rs1799853	C	T	.	.	PGKB_INDEX=7;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG=phenytoin_(PA450947),acenocoumarol_(PA452632),clopidogrel_(PA449053),sulfonamides_urea_derivatives_(PA10390),warfarin_(PA451906),celecoxib_(PA448871),busulfan_(PA448691);PGKB_TYPE="Efficacy""Toxicity/ADR",Toxicity/ADR,Efficacy,Efficacy,Dosage,Efficacy,Metabolism/PK;PGKB_EVIDENCE=3,3,3,3,1A,3,3;PGKB_DISEASE=Epilepsy_(PA444065),NR,NR,Diabetes_Mellitus_Type_2_(PA443890),NR,NR,hemopoietic_stem_cell_transplant_(PA166122646);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Epilepsy_who_are_treated_with_phenytoin_may_have_an_increased_metabolism_of_phenytoin_decreased_plasma_free_phenytoin_concentration_and_a_decreased_but_not_absent_risk_of_drug_toxicity_as_compared_to_patients_with_the_CT_and_TT_genotype._These_associations_have_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.""CT:Patients_with_the_CT_genotype_and_Epilepsy_who_are_treated_with_phenytoin_may_have_a_decreased_metabolism_of_phenytoin_increased_plasma_free_phenytoin_concentration_and_an_increased_risk_of_drug_toxicity_as_compared_to_patients_with_the_CC_genotype._These_associations_have_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.""TT:Patients_with_the_TT_genotype_and_Epilepsy_who_are_treated_with_phenytoin_may_have_a_decreased_metabolism_of_phenytoin_increased_plasma_free_phenytoin_concentration_and_an_increased_risk_of_drug_toxicity_as_compared_to_patients_with_the_CC_genotype._These_associations_have_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.","CC:Patients_with_the_CC_genotype_who_are_taking_acenocoumarol_may_have_a_decreased_risk_of_a_gastrointestinal_hemorrhage_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_gastrointestinal_hemorrhage.""CT:Patients_with_the_CT_genotype_who_are_taking_acenocoumarol_may_have_an_increased_risk_of_a_gastrointestinal_hemorrhage_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_gastrointestinal_hemorrhage.""TT:Patients_with_the_TT_genotype_who_are_taking_acenocoumarol_may_have_an_increased_risk_of_a_gastrointestinal_hemorrhage_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_gastrointestinal_hemorrhage.","CC:Patients_with_the_CC_genotype_may_have_1)_increased_exposure_to_clopidogrel_active_metabolite_and_2)_decreased_but_not_absent_risk_of_poor_responder_status_as_compared_to_patients_with_the_CT_or_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""CT:Patients_with_the_CT_genotype_may_have_1)_decreased_exposure_to_clopidogrel_active_metabolite_and_2)_an_increased_risk_of_poor_responder_status_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""TT:Patients_with_the_TT_genotype_may_have_1)_decreased_exposure_to_clopidogrel_active_metabolite_and_2)_an_increased_risk_of_poor_responder_status_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.","CC:Patients_with_the_CC_genotype_and_type_II_diabetes_who_are_treated_with_sulfonylureas:_1)_May_be_less_likely_to_achieve_a_HbA1c_level_of_<7%_as_compared_to_patients_with_the_TT_genotype_2)_May_be_more_likely_to_experience_treatment_failure_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylureas.""CT:Results_from_patients_with_the_CT_genotype_were_not_statistically_significant.""TT:Patients_with_the_TT_genotype_and_type_II_diabetes_who_are_treated_with_sulfonylureas:_1)_May_be_more_likely_to_achieve_a_HbA1c_level_of_<7%_as_compared_to_patients_with_the_CC_genotype_2)_May_be_less_likely_to_experience_treatment_failure_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylureas.","CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""CT:Patients_with_the_CT_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.","CC:Patients_with_the_CC_genotype_who_are_treated_with_celecoxib_may_have_an_increased_metabolism_of_celecoxib_and_as_compared_to_patients_with_the_CT_and_TT_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""CT:Patients_with_the_CT_genotype_who_are_treated_with_celecoxib_may_have_a_decreased_metabolism_of_celecoxib_and_as_compared_to_patients_with_the_CC_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.""TT:Patients_with_the_TT_genotype_who_are_treated_with_celecoxib_may_have_a_decreased_metabolism_of_celecoxib_and_as_compared_to_patients_with_the_CC_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_celecoxib.","CC:Patients_with_the_CC_(CYP2C9_*1/*1)_genotype_undergoing_hemopoietic_stem_cell_transplant_may_have_increased_metabolism_of_busulfan_as_compared_to_patients_with_the_CT_(*1/*2)_or_TT_(*2/*2)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_busulfan.""CT:Patients_with_the_CT_(CYP2C9_*1/*2)_genotype_undergoing_hemopoietic_stem_cell_transplant_may_have_decreased_metabolism_of_busulfan_as_compared_to_patients_with_the_CC_(*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_busulfan.""TT:Patients_with_the_TT_(CYP2C9_*2/*2)_genotype_undergoing_hemopoietic_stem_cell_transplant_may_have_decreased_metabolism_of_busulfan_as_compared_to_patients_with_the_CC_(*1/*1)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_busulfan.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR
10	96702066	rs7900194	G	A,T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=2A;PGKB_DISEASE="Atrial_Fibrillation_(PA443459)""Pulmonary_Embolism_(PA445465)""Stroke_(PA447054)""Venous_Thrombosis_(PA446969)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_require_the_lowest_maintenance_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""AG:Patients_with_the_AG_genotype_who_are_treated_with_warfarin_may_require_a_lower_maintenance_dose_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_a_higher_maintenance_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.";PGKB_RACE=Black_or_African_American
10	96705223	rs7089580	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_lower_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.""TA:Patients_with_the_TA_genotype_may_require_higher_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.""TT:Patients_with_the_TT_genotype_may_require_higher_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.";PGKB_RACE=Black_or_African_American
10	96707202	rs4086116	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG=acenocoumarol_(PA452632),phenprocoumon_(PA450921);PGKB_TYPE=Dosage,Dosage;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_an_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_acenocoumarol_dose.""CT:Patients_with_the_CT_genotype_may_require_a_lower_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_acenocoumarol_dose.""TT:Patients_with_the_TT_genotype_may_require_the_lowest_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_acenocoumarol_dose.","CC:Patients_with_the_CC_genotype_may_require_an_increased_dose_of_phenprocoumon_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_phenprocoumon_dose.""CT:Patients_with_the_CT_genotype_may_require_a_lower_dose_of_phenprocoumon_as_compared_to_patients_with_the_CC_genotype_and_may_require_an_increased_dose_of_phenprocoumon_as_compared_to_patients_with_the_TT._Other_genetic_and_clinical_factors_may_also_influence_phenprocoumon_dose.""TT:Patients_with_the_TT_genotype_may_require_the_lowest_dose_of_phenprocoumon_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_phenprocoumon_dose.";PGKB_RACE=White,NR
10	96709038	rs9332131	GA	G	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906),phenytoin_(PA450947);PGKB_TYPE=Dosage,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Atrial_Fibrillation_(PA443459)""Pulmonary_Embolism_(PA445465)""Stroke_(PA447054)""Venous_Thrombosis_(PA446969)",NR;PGKB_TEXT="A/del:Patients_with_A/del_genotype_may_require_a_lower_daily_warfarin_maintenance_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_require_a_higher_maintenance_dose_as_compared_to_patients_with_the_del/A_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.""del/del:Patients_with_del/del_genotype_may_require_significantly_lower_daily_warfarin_maintenance_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_warfarin.","A/del:Patients_with_the_A/del_genotype_may_have_decreased_metabolism_of_phenytoin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_phenytoin.""AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_phenytoin_as_compared_to_patients_with_the_A/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_phenytoin.""del/del:Patients_with_the_del/del_genotype_may_have_decreased_metabolism_of_phenytoin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_phenytoin.";PGKB_RACE=Black_or_African_American,Black_or_African_American
10	96725535	rs4917639	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_or_CA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""CA:Patients_with_the_CA_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""CC:Patients_with_the_CC_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.";PGKB_RACE="Asian""White"
10	96734339	rs10509680	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_require_increased_dose_of_warfarin_when_treated_with_warfarin_as_compared_to_patients_with_the_TT_or_TG_genotype._Other_clinical_or_genetic_factors_may_also_influence_the_dose_of_warfarin.""TG:Patients_with_the_TG_genotype_may_require_decreased_dose_of_warfarin_when_treated_with_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_the_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_may_require_decreased_dose_of_warfarin_when_treated_with_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_the_dose_of_warfarin.";PGKB_RACE=Asian
10	96740981	rs28371685	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Atrial_Fibrillation_(PA443459)""Pulmonary_Embolism_(PA445465)""Stroke_(PA447054)""Venous_Thrombosis_(PA446969)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_an_increased_dose_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""CT:Patients_with_the_CT_genotype_who_are_treated_with_warfarin_may_require_a_decreased_dose_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_warfarin_may_require_the_lowest_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.";PGKB_RACE=Black_or_African_American
10	96741053	rs1057910	A	C	.	.	PGKB_INDEX=10;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG="Antiinflammatory_agents_non-steroids_(PA164712462)""celecoxib_(PA448871)""diclofenac_(PA449293)",fluvastatin_(PA449688),clopidogrel_(PA449053),phenytoin_(PA450947),"simvastatin_(PA451363)""warfarin_(PA451906)",sulfonamides_urea_derivatives_(PA10390),acenocoumarol_(PA452632),warfarin_(PA451906),losartan_(PA450268),celecoxib_(PA448871);PGKB_TYPE=Toxicity/ADR,Other,Efficacy,Toxicity/ADR,Dosage,Efficacy,"Dosage""Toxicity/ADR","Dosage""Toxicity/ADR",Efficacy,Dosage;PGKB_EVIDENCE=2A,3,3,3,3,3,2A,1A,3,2A;PGKB_DISEASE=NR,NR,"Acute_coronary_syndrome_(PA165108401)""Coronary_Artery_Disease_(PA443796)",Epilepsy_(PA444065),NR,Diabetes_Mellitus_Type_2_(PA443890),NR,NR,NR,NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_non-steroid_antiinflammatory_agents_celecoxib_or_diclofenac_may_have_a_decreased_but_not_absent_risk_of_gastrointestinal_bleeding_as_compared_to_patients_with_the_AC_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Antiinflammatory_agents_non-steroids_celecoxib_or_diclofenac.""AC:Patients_with_the_AC_genotype_who_are_treated_with_non-steroids_antiinflammatory_agents_celecoxib_or_diclofenac_may_have_an_increased_risk_of_gastrointestinal_bleeding_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Antiinflammatory_agents_non-steroids_celecoxib_or_diclofenac.""CC:Patients_with_the_CC_genotype_who_are_treated_with_non-steroids_antiinflammatory_agents_celecoxib_or_diclofenac_may_have_an_increased_risk_of_gastrointestinal_bleeding_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Antiinflammatory_agents_non-steroids_celecoxib_or_diclofenac.","AA:Patients_with_the_AA_(CYP2C9*1/*1)_genotype_may_have_lower_plasma_levels_of_fluvastatin_as_compared_to_patients_with_the_AC_(CYP2C9*1/*3)_or_CC_(CYP2C9*3/*3)_genotype._This_association_does_not_seem_to_affect_response_to_fluvastatin_treatment_or_risk_of_myopathy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment_and_pharmacokinetics._""AC:Patients_with_the_AC_(CYP2C9*1/*3)_genotype_may_have_higher_plasma_levels_of_fluvastatin_as_compared_to_patients_with_the_AA_(CYP2C9*1/*1)_genotype._This_association_does_not_seem_to_affect_response_to_fluvastatin_treatment_or_risk_of_myopathy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment_and_pharmacokinetics._""CC:Patients_with_the_CC_(CYP2C9*3/*3)_genotype_may_have_higher_plasma_levels_of_fluvastatin_as_compared_to_patients_with_the_AC_(CYP2C9*1/*3)_or_AA_(CYP2C9*1/*1)_genotype._This_association_does_not_seem_to_affect_response_to_fluvastatin_treatment_or_risk_of_myopathy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment_and_pharmacokinetics._","AA:Patients_with_the_AA_genotype_may_have_1)_increased_inhibition_of_platelet_aggregation_and_2)_decreased_but_not_absent_risk_of_high_on-clopidogrel_platelet_reactivity_and_poor_responder_status_as_compared_to_patients_with_the_AC_or_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""AC:Patients_with_the_AC_genotype_may_have_1)_decreased_inhibition_of_platelet_aggregation_and_2)_increased_risk_of_high_on-clopidogrel_platelet_reactivity_and_poor_responder_status_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""CC:Patients_with_the_CC_genotype_may_have_1)_decreased_inhibition_of_platelet_aggregation_and_2)_increased_risk_of_high_on-clopidogrel_platelet_reactivity_and_poor_responder_status_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._","AA:Patients_with_the_AA_genotype_and_with_Epilepsy_who_are_treated_with_phenytoin_may_have_an_increased_metabolism_decreased_plasma_free_phenytoin_concentration_and_decreased_but_not_absent_risk_of_Drug_Toxicity_as_compared_to_patients_with_the_AC_and_CC_genotype._However_these_associations_are_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.""AC:Patients_with_the_AC_genotype_and_with_Epilepsy_who_are_treated_with_phenytoin_may_have_a_decreased_metabolism_increased_plasma_free_phenytoin_concentration_and_increased_likelihood_of_Drug_Toxicity_as_compared_to_patients_with_the_AA_genotype._However_these_associations_are_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.""CC:Patients_with_the_CC_genotype_and_with_Epilepsy_who_are_treated_with_phenytoin_may_have_a_decreased_metabolism_increased_plasma_free_phenytoin_concentration_and_increased_likelihood_of_Drug_Toxicity_as_compared_to_patients_with_the_AA_genotype._However_these_associations_are_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_phenytoin.","AA:Patients_with_the_AA_genotype_who_are_treated_with_simvastatin_and_warfarin_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_or_AC_genotype_(patients_with_the_CYP2C9*3_allele)._Simvastatin_did_not_seem_to_affect_warfarin_dose_in_patients_who_did_not_have_the_C_allele_(CYP2C9*3)._This_variant_does_not_seem_to_be_associated_with_response_to_simvastatin_treatment_or_risk_of_myopathy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_warfarin_dosage_and_response_to_simvastatin._""AC:Patients_with_the_AC_genotype_(carriers_of_CYP2C9*3)_who_are_treated_with_simvastatin_and_warfarin_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype_(patients_who_do_not_have_the_CYP2C9*3_allele)._This_variant_does_not_seem_to_be_associated_with_response_to_simvastatin_treatment_or_risk_of_myopathy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_warfarin_dosage_and_response_to_simvastatin._""CC:Patients_with_the_CC_genotype_(CYP2C9*3/*3)_who_are_treated_with_simvastatin_and_warfarin_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype_(patients_who_do_not_have_the_CYP2C9*3_allele)._This_variant_does_not_seem_to_be_associated_with_response_to_simvastatin_treatment_or_risk_of_myopathy._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_warfarin_dosage_and_response_to_simvastatin._","AA:Patients_with_the_AA_genotype_who_are_treated_with_sulfonylurea:_1)_May_be_less_likely_to_achieve_a_HbA1c_level_of_<7%_as_compared_to_patients_with_the_CC_genotype_2)_May_be_more_likely_to_have_failure_of_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylurea_therapy.""AC:Results_from_patients_with_the_AC_genotype_were_not_statistically_significant.""CC:Patients_with_the_CC_genotype_who_are_treated_with_sulfonylurea:_1)_May_be_more_likely_to_achieve_a_HbA1c_level_of_<7%_as_compared_to_patients_with_the_AA_genotype_2)_May_be_less_likely_to_have_failure_of_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylurea_therapy.","AA:Patients_with_the_AA_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_acenocoumarol_dose.""AC:Patients_with_the_AC_genotype_may_require_decreased_dose_of_acenocoumarol_or_closer_INR_monitoring_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_acenocoumarol_dose.""CC:Patients_with_the_CC_genotype_may_require_decreased_dose_of_acenocoumarol_or_closer_INR_monitoring_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_acenocoumarol_dose.","AA:Patients_with_the_AA_genotype:_1)_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AC_or_CC_genotype_2)_may_have_a_decreased_risk_for_adverse_events_as_compared_to_patients_with_the_AC_or_CC_genotype._Patients_with_the_AA_genotype_may_still_be_at_risk_for_adverse_events_when_taking_warfarin_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""AC:Patients_with_the_AC_genotype:_1)_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype_2)_may_have_an_increased_risk_for_adverse_events_as_compared_to_patients_with_the_AA_genotype.""CC:Patients_with_the_CC_genotype:_1)_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype_2)_may_have_an_increased_risk_for_adverse_events_as_compared_to_patients_with_the_AA_genotype.","AA:Subjects_with_the_AA_genotype_who_are_treated_with_losartan_may_have_increased_metabolism_of_losartan_as_compared_to_subjects_with_the_CA_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_losartan.""AC:Subjects_with_the_AC_genotype_who_are_treated_with_losartan_may_have_decreased_metabolism_of_losartan_as_compared_to_subjects_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_losartan.""CC:Subjects_with_the_CC_genotype_who_are_treated_with_losartan_may_have_decreased_metabolism_of_losartan_as_compared_to_subjects_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_losartan.","AA:Patients_with_the_AA_(CYP2C9_*1/*1)_genotype_may_have_increased_metabolism_of_celecoxib_as_compared_to_patients_with_the_AC_or_CC_(*1/*3_or_*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_metabolism_of_celecoxib._""AC:Patients_with_the_AC_(CYP2C9_*1/*3)_genotype_may_have_reduced_metabolism_of_celecoxib_as_compared_to_patients_with_the_AA_(*1/*1)_genotype_and_increased_metabolism_as_compared_to_patients_with_the_CC_(*3/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_celecoxib._""CC:Patients_with_the_CC_(CYP2C9_*3/*3)_genotype_may_have_reduced_metabolism_of_celecoxib_as_compared_to_patients_with_the_AA_or_AC_(*1/*1_or_*1/*3)_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_celecoxib._";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR,NR,White,NR
10	96741054	rs56165452	T	A,C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_required_reduced_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose._This_variant_rs56165452_defines_CYP2C9*4.""CT:Patients_with_the_CT_genotype_may_required_reduced_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose._This_variant_rs56165452_defines_CYP2C9*4.""TT:Patients_with_the_TT_genotype_may_required_higher_dose_of_warfarin_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose._This_variant_rs56165452_defines_CYP2C9*4.";PGKB_RACE=NR
10	96741058	rs28371686	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE="Atrial_Fibrillation_(PA443459)""Pulmonary_Embolism_(PA445465)""Stroke_(PA447054)""Venous_Thrombosis_(PA446969)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_an_increased_dose_as_compared_to_patients_with_the_CG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""CG:Patients_with_the_CG_genotype_who_are_treated_with_warfarin_may_require_a_decreased_dose_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_the_lowest_does_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.";PGKB_RACE=Black_or_African_American
10	96748495	rs1934969	A	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C9_(PA126),CYP2C9_(PA126);PGKB_DRUG=losartan_(PA450268),phenytoin_(PA450947);PGKB_TYPE=Other,Metabolism/PK;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_losartan_as_compared_to_patients_with_the_AT_or_TT_genotype._No_association_was_seen_in_Korean_subjects_and_a_seperate_study_in_Ecuadorian_subjects_found_contradictory_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_losartan_metabolism.""AT:Patients_with_the_AT_genotype_may_have_decreased_metabolism_of_losartan_as_compared_to_patients_with_the_AA_genotype._No_association_was_seen_in_Korean_subjects_and_a_seperate_study_in_Ecuadorian_subjects_found_contradictory_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_losartan_metabolism.""TT:Patients_with_the_TT_genotype_may_have_decreased_metabolism_of_losartan_as_compared_to_patients_with_the_AA_genotype._No_association_was_seen_in_Korean_subjects_and_a_seperate_study_in_Ecuadorian_subjects_found_contradictory_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_losartan_metabolism.","AA:Patients_with_the_AA_genotype_and_epilepsy_may_have_decreased_dose-adjusted_trough_concentrations_of_phenytoin_as_compared_to_patients_with_the_AT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_trough_concentrations_of_phenytoin.""AT:Patients_with_the_AT_genotype_and_epilepsy_may_have_increased_dose-adjusted_trough_concentrations_of_phenytoin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_trough_concentrations_of_phenytoin.""TT:Patients_with_the_TT_genotype_and_epilepsy_may_have_increased_dose-adjusted_trough_concentrations_of_phenytoin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose-adjusted_trough_concentrations_of_phenytoin.";PGKB_RACE=NR,Hispanic_or_Latino
10	96748777	rs9332239	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C9_(PA126);PGKB_DRUG=tolbutamide_(PA451718);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_tolbutamide_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_tolbutamide_metabolism.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_tolbutamide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_tolbutamide_metabolism.""TT:Patients_with_the_TT_genotype_may_have_decreased_metabolism_of_tolbutamide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_tolbutamide_metabolism.";PGKB_RACE=NR
10	96798548	rs1934951	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C8_(PA125),CYP2C8_(PA125);PGKB_DRUG="Bisphosphonates_(PA164712563)""pamidronate_(PA450767)""zoledronate_(PA10235)",paclitaxel_(PA450761);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Multiple_Myeloma_(PA444985)""Osteonecrosis_(PA445187)",Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_non-existent_risk_for_osteonecrosis_of_the_jaw_in_response_to_bisphosphonates_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_adverse_responses_to_bisphosphonates.""CT:Patients_with_the_CT_genotype_may_have_decreased_but_not_non-existent_risk_for_osteonecrosis_of_the_jaw_in_response_to_bisphosphonates_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_adverse_responses_to_bisphosphonates.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_for_osteonecrosis_of_the_jaw_in_response_to_bisphosphonates_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_adverse_responses_to_bisphosphonates.","CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_a_decreased_risk_for_anemia_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_anemia.""CT:Patients_with_the_CT_genotype_and_breast_cancer_may_have_an_increased_risk_for_anemia_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_anemia.""TT:Patients_with_the_TT_genotype_and_breast_cancer_may_have_an_increased_risk_for_anemia_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_anemia.";PGKB_RACE=White,White
10	96798749	rs10509681	T	C	.	.	PGKB_INDEX=4;PGKB_GENE=CYP2C8_(PA125),CYP2C8_(PA125),CYP2C8_(PA125),CYP2C8_(PA125);PGKB_DRUG=amodiaquine_(PA448404),rosiglitazone_(PA451283),paclitaxel_(PA450761),repaglinide_(PA451234);PGKB_TYPE=Toxicity/ADR,Dosage,Other,Other;PGKB_EVIDENCE=4,3,4,3;PGKB_DISEASE=NR,NR,NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_side_effects_to_amodiaquine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_side_effects_to_amodiaquine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_non-existent_risk_of_side_effects_to_amodiaquine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects.","CC:Patients_with_the_CC_genotype_(CYP2C8*3/*3)_may_have_increased_metabolism_of_rosiglitazone_compared_to_patients_with_the_TT_genotype_(CYP2C8*1/*1)_but_this_is_not_associated_with_differences_in_blood_glucose_lowering_efficacy_compared_to_patients_with_the_TT_genotype._Please_note_the_study_supporting_this_annotation_was_carried_out_in_healthy_volunteers._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rosiglitazone_and_blood_glucose_levels.""CT:Patients_with_the_CT_(CYP2C8*3/*1)_genotype_may_have_increased_metabolism_of_rosiglitazone_compared_to_patients_with_the_TT_genotype_(CYP2C8*1/*1)_or_may_have_decreased_metabolism_of_rosiglitazone_compared_to_patients_with_the_CC_genotype_(CYP2C8*3/*3)._This_is_not_associated_with_differences_in_blood_glucose_lowering_efficacy._Please_note_the_study_supporting_this_annotation_was_carried_out_in_healthy_volunteers._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rosiglitazone_and_blood_glucose_levels.""TT:Patients_with_the_TT_(CYP2C8*1/*1)_genotype_may_have_decreased_metabolism_of_rosiglitazone_compared_to_patients_with_the_CC_genotype_(CYP2C8*3/*3)_but_this_is_not_associated_with_differences_in_blood_glucose_lowering_efficacy_compared_to_patients_with_the_CC_genotype._Please_note_the_study_supporting_this_annotation_was_carried_out_in_healthy_volunteers._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_rosiglitazone_and_blood_glucose_levels.","CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_TT_genotype_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_TT_genotype_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_CT_or_CC_genotypes_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.","CC:Individuals_with_the_CC_genotype_were_not_studied_however_individuals_with_the_CT_(CYP2C8*3/*1)_genotype_may_have_increased_metabolism_of_repaglinide_compared_to_patients_with_the_TT_genotype_(CYP2C8*1/*1)._No_association_was_found_with_differences_in_blood_glucose_lowering_efficacy._Please_note_the_study_supporting_this_annotation_was_carried_out_in_healthy_volunteers._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_repaglinide_and_blood_glucose_levels.""CT:Individuals_with_the_CT_(CYP2C8*3/*1)_genotype_may_have_increased_metabolism_of_repaglinide_compared_to_patients_with_the_TT_genotype_(CYP2C8*1/*1)._No_association_was_found_with_differences_in_blood_glucose_lowering_efficacy._Please_note_the_study_supporting_this_annotation_was_carried_out_in_healthy_volunteers._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_repaglinide.""TT:Individuals_with_the_TT_(CYP2C8*1/*1)_genotype_may_have_decreased_metabolism_of_repaglinide_compared_to_patients_with_the_CT_genotype_(CYP2C8*3/*1)._No_association_was_found_with_differences_in_blood_glucose_lowering_efficacy._Please_note_the_study_supporting_this_annotation_was_carried_out_in_healthy_volunteers._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_repaglinide.";PGKB_RACE=NR,White,NR,White
10	96811045	rs1113129	G	C	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2C8_(PA125),CYP2C8_(PA125);PGKB_DRUG=paclitaxel_(PA450761),paclitaxel_(PA450761);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_neurotoxicity_in_people_with_neoplasms_treated_with_paclitaxel_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""CG:Patients_with_the_CG_genotype_may_have_decreased_risk_of_neurotoxicity_in_people_with_neoplasms_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_neurotoxicity_in_people_with_neoplasms_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_a_decreased_risk_for_anemia_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_anemia.""CG:Patients_with_the_CG_genotype_and_breast_cancer_may_have_an_increased_risk_for_anemia_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_anemia.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_an_increased_risk_for_anemia_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_anemia.";PGKB_RACE=NR,White
10	96818106	rs11572103	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C8_(PA125);PGKB_DRUG=paclitaxel_(PA450761);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_clearance_of_paclitaxel_as_compared_to_patients_with_the_TT_genotype_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.""AT:Patients_with_the_AT_genotype_may_have_decreased_clearance_of_paclitaxel_as_compared_to_patients_with_the_TT_genotype_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.""TT:Patients_with_the_TT_genotype_may_have_increased_clearance_of_paclitaxel_as_compared_to_patients_with_the_AA_or_AT_genotypes_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.";PGKB_RACE=White
10	96827030	rs11572080	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=CYP2C8_(PA125),CYP2C8_(PA125),CYP2C8_(PA125);PGKB_DRUG=amodiaquine_(PA448404),paclitaxel_(PA450761),paclitaxel_(PA450761);PGKB_TYPE=Toxicity/ADR,Other,Toxicity/ADR;PGKB_EVIDENCE=4,4,3;PGKB_DISEASE=NR,NR,"Drug_Toxicity_(PA443937)""Neurotoxicity_Syndromes_(PA446975)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_side_effects_with_amodiaquine_as_compared_to_patients_with_the_CT_or_TT_genotype._Patients_with_the_CC_genotype_may_still_be_at_risk_for_adverse_events_when_taking_amodiaquine_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_side_effects_with_amodiaquine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_side_effects_with_amodiaquine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.","CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_paclitaxel_as_compared_to_patients_with_the_CT_or_TT_genotypes_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_CC_genotype_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.""TT:Patients_with_the_TT_genotype_may_have_decreased_metabolism_of_paclitaxel_as_compared_to_patients_with_the_CC_genotype_however_this_has_not_been_shown_in_vivo._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_paclitaxel.","CC:Patients_with_the_CC_genotype_may_be_at_decreased_but_not_absent_risk_of_neurotoxicity_when_treated_with_paclitaxel_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neurotoxicity.""CT:Patients_with_the_CT_genotype_may_be_at_decreased_but_not_absent_risk_of_neurotoxicity_when_treated_with_paclitaxel_compared_to_patients_with_the_TT_genotype_or_may_be_at_increased_risk_of_neurotoxicity_when_treated_with_paclitaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neurotoxicity.""TT:Patients_with_the_TT_genotype_may_be_at_increased_risk_of_neurotoxicity_when_treated_with_paclitaxel_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_neurotoxicity.";PGKB_RACE=NR,NR,White
10	96827150	rs11572076	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2C8_(PA125);PGKB_DRUG=mycophenolate_mofetil_(PA450566);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_a_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia.""CT:Patients_with_the_CT_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia.""TT:Patients_with_the_TT_genotype_were_not_studied_but_patients_with_the_CT_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia.";PGKB_RACE=NR
10	98911936	rs11189015	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLIT1_(PA35938);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hypertension_as_compared_to_patients_with_the_CG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""CG:Patients_with_the_CG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hypertension_as_compared_to_patients_with_the_GG_genotype_and_an_increased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""GG:Patients_with_the_GG_genotype_and_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hypertension_as_compared_to_patients_with_the_CG_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.";PGKB_RACE=White
10	98928942	rs2784917	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLIT1_(PA35938);PGKB_DRUG=etoposide_(PA449552);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_toxicity_with_etoposide_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_may_have_lower_risk_of_toxicity_with_etoposide_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_lower_risk_of_toxicity_with_etoposide_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=Black_or_African_American
10	99563198	rs11189381	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SFRP5_(PA35695);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""TC:Patients_with_the_TC_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.";PGKB_RACE=White
10	101542578	rs717620	C	T	.	.	PGKB_INDEX=10;PGKB_GENE=ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116);PGKB_DRUG=erythromycin_(PA449493),"fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)","fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)",tenofovir_(PA10204),antiepileptics_(PA143485705),"atorvastatin_(PA448500)""simvastatin_(PA451363)",methotrexate_(PA450428),methotrexate_(PA450428),deferasirox_(PA164760843),efavirenz_(PA449441);PGKB_TYPE=Other,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Efficacy,Dosage,Metabolism/PK,Metabolism/PK,Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=3,3,3,3,3,3,3,3,4,4;PGKB_DISEASE=NR,Colonic_Neoplasms_(PA443756),Colorectal_Neoplasms_(PA446108),HIV_(PA447230),Epilepsy_(PA444065),NR,Leukemia_Lymphoid_(PA444756),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),beta-Thalassemia_(PA446432),HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_erythromycin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_erythromycin.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_erythromycin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_erythromycin.""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_erythromycin_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_erythromycin.","CC:Patients_with_the_CC_genotype_and_colon_cancer_may_have_an_increased_risk_of_thrombocytopenia_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_thrombocytopenia.""CT:Patients_with_the_CT_genotype_and_colon_cancer_may_have_a_decreased_risk_of_thrombocytopenia_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_thrombocytopenia.""TT:Patients_with_the_TT_genotype_and_colon_cancer_may_have_a_decreased_risk_of_thrombocytopenia_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_thrombocytopenia.","CC:Patients_with_the_CC_genotype_and_colorectal_cancer_may_have_decreased_severity_of_neurotoxicity_syndromes_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_neurotoxicity_syndromes.""CT:Patients_with_the_CT_genotype_and_colorectal_cancer_may_have_decreased_severity_of_neurotoxicity_syndromes_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_neurotoxicity_syndromes.""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_increased_severity_of_neurotoxicity_syndromes_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_severity_of_neurotoxicity_syndromes.","CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_tenofovir_may_have_an_increased_risk_of_kidney_tubular_dysfunction_but_may_not_be_associated_with_changes_in_glomerular_filtration_rate_as_compared_to_patients_with_the_CT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_kidney_tubular_dysfunction.""CT:Patients_with_the_CT_genotype_and_HIV_infection_who_are_treated_with_tenofovir_may_have_a_decreased_risk_of_kidney_tubular_dysfunction_but_may_not_be_associated_with_changes_in_glomerular_filtration_rate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_kidney_tubular_dysfunction.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_tenofovir_may_have_a_decreased_risk_of_kidney_tubular_dysfunction_but_may_not_be_associated_with_changes_in_glomerular_filtration_rate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_kidney_tubular_dysfunction.","CC:Patients_with_the_CC_genotype_and_Epilepsy_who_are_treated_with_antiepileptics_may_be_less_likely_to_be_resistant_to_treatment_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.""CT:Patients_with_the_CT_genotype_and_Epilepsy_who_are_treated_with_antiepileptics_may_be_more_likely_to_be_resistant_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.""TT:Patients_with_the_TT_genotype_and_Epilepsy_who_are_treated_with_antiepileptics_may_be_more_likely_to_be_resistant_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.","CC:Patients_with_the_CC_genotype_may_have_increased_dose_of_simvastatin_and_atorvastatin_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_simvastatin.""CT:Patients_with_the_CT_genotype_may_have_decreased_dose_of_simvastatin_and_atorvastatin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_simvastatin.""TT:Patients_with_the_TT_genotype_may_have_decreased_dose_of_simvastatin_and_atorvastatin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_simvastatin.","CC:Patients_with_the_CC_genotype_may_have_decreased_clearance_and_distribution_of_volume_of_methotrexate_as_compared_to_patients_with_the_TT_genotype._Please_note:_the_opposite_effect_was_observed_in_a_study_done_in_an_Asian_population_with_various_types_of_lymphomas._The_T_allele_was_associated_with_decreased_clearance_of_methotrexate._Other_clinical_and_genetic_factors_may_also_affect_clearance_and_distribution_of_volume_of_methotrexate._""CT:Patients_with_the_CT_genotype_may_have_increased_clearance_and_distribution_of_volume_of_methotrexate_as_compared_to_patients_with_the_CC_genotype._Please_note:_the_opposite_effect_was_observed_in_a_study_done_in_an_Asian_population_with_various_types_of_lymphomas._The_T_allele_was_associated_with_decreased_clearance_of_methotrexate._Other_clinical_and_genetic_factors_may_also_affect_clearance_and_distribution_of_volume_of_methotrexate._""TT:Patients_with_the_TT_genotype_may_have_increased_clearance_and_distribution_of_volume_of_methotrexate_as_compared_to_patients_with_the_CC_genotype._Please_note:_the_opposite_effect_was_observed_in_a_study_done_in_an_Asian_population_with_various_types_of_lymphomas._The_C_allele_was_associated_with_increased_clearance_of_methotrexate._Other_clinical_and_genetic_factors_may_also_affect_clearance_and_distribution_of_volume_of_methotrexate._","CC:Patients_with_lymphoblastic_leukemia-lymphoma_and_the_CC_genotype_may_have_a_decreased_risk_of_drug_toxicity_and_increased_clearance_of_methotrexate_when_treated_with_methotrexate_as_compared_to_patients_with_the_TT_genotype._Please_note:_the_opposite_effect_was_observed_in_a_study_done_in_a_French_population_with_various_types_of_lymphomas._The_C_allele_was_associated_with_decreased_clearance_of_methotrexate._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug_toxicity_when_treated_with_methotrexate._""CT:Patients_with_lymphoblastic_leukemia-lymphoma_and_the_CT_genotype_may_have_an_increased_risk_of_drug_toxicity_and_decreased_clearance_of_methotrexate_when_treated_with_methotrexate_as_compared_to_patients_with_the_CC_genotype._Please_note:_the_opposite_effect_was_observed_in_a_study_done_in_a_French_population_with_various_types_of_lymphomas._The_C_allele_was_associated_with_decreased_clearance_of_methotrexate._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug_toxicity_when_treated_with_methotrexate._""TT:Patients_with_lymphoblastic_leukemia-lymphoma_and_the_TT_genotype_may_have_an_increased_risk_of_drug_toxicity_and_decreased_clearance_of_methotrexate_when_treated_with_methotrexate_as_compared_to_patients_with_the_CC_genotype._Please_note:_the_opposite_effect_was_observed_in_a_study_done_in_a_French_population_with_various_types_of_lymphomas._The_C_allele_was_associated_with_decreased_clearance_of_methotrexate._Other_clinical_and_genetic_factors_may_also_influence_risk_of_drug_toxicity_when_treated_with_methotrexate._","CC:Pediatric_patients_with_major_thalassemia_and_the_CC_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_CT_or_TT_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_CT_therefore_there_is_no_information_for_patients_with_the_CC_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""CT:Pediatric_patients_with_major_thalassemia_and_the_CT_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_CC_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_CT_therefore_there_is_no_information_for_patients_with_the_CC_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""TT:Pediatric_patients_with_major_thalassemia_and_the_TT_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_CC_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_CT_therefore_there_is_no_information_for_patients_with_the_CC_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.","CC:Patients_with_the_CC_genotype_and_HIV_may_have_decreased_concentrations_of_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_circulating_concentrations_of_efavirenz.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_decreased_concentrations_of_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_circulating_concentrations_of_efavirenz.""TT:Patients_with_the_TT_genotype_and_HIV_may_have_increased_concentrations_of_efavirenz_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_circulating_concentrations_of_efavirenz.";PGKB_RACE=White,Asian,White,NR,Asian,White,NR,Asian,NR,NR
10	101563815	rs2273697	G	A	.	.	PGKB_INDEX=7;PGKB_GENE=ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116);PGKB_DRUG=irinotecan_(PA450085),"mycophenolate_mofetil_(PA450566)""mycophenolic_acid_(PA164748728)","antiepileptics_(PA143485705)""carbamazepine_(PA448785)""oxcarbazepine_(PA450732)",talinolol_(PA146123005),tenofovir_(PA10204),deferasirox_(PA164760843),carbamazepine_(PA448785);PGKB_TYPE=Other,"Efficacy""Toxicity/ADR",Toxicity/ADR,NR,Toxicity/ADR,Metabolism/PK,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3,3,3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),Kidney_Transplantation_(PA165817016),Epilepsy_(PA444065),NR,"HIV_(PA447230)""Kidney_Diseases_(PA444682)",beta-Thalassemia_(PA446432),Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_increased_metabolism_of_irinotecan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_irinotecan.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_increased_metabolism_of_irinotecan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_irinotecan.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_decreased_metabolism_of_irinotecan_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_irinotecan.","AA:Patients_with_the_AA_genotype_were_not_studied._However_patients_with_AG_genotype_and_Kidney_Transplantation_may_have_a_decreased_metabolism_of_mycophenolic_acid_as_compared_to_patients_with_the_GG_genotype._However_no_association_is_reported_regarding_increased_risk_of_adverse_drug_reactions_and_this_has_been_contradicted_in_at_least_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""AG:Patients_with_AG_genotype_and_Kidney_Transplantation_may_have_a_decreased_metabolism_of_mycophenolic_acid_as_compared_to_patients_with_the_GG_genotype._However_no_association_is_reported_regarding_increased_risk_of_adverse_drug_reactions_and_this_has_been_contradicted_in_at_least_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""GG:Patients_with_GG_genotype_and_Kidney_Transplantation_may_have_an_increased_metabolism_of_mycophenolic_acid_as_comapred_to_patients_with_the_AG_genotype._However_no_association_is_reported_regarding_increased_risk_of_adverse_drug_reactions_and_this_has_been_contradicted_in_at_least_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.","AA:Patients_with_the_AA_genotype_and_epilepsy_who_are_treated_with_antiepileptic_drugs_may_have_an_increased_likelihood_of_resistance_to_treatment_as_compared_to_patients_with_the_GG_genotype._Note__most_studies_find_no_association_with_response_and_one_study_finds_the_A_allele_to_be_associated_with_better_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""AG:Patients_with_the_AG_genotype_and_epilepsy_who_are_treated_with_antiepileptic_drugs_may_have_an_increased_likelihood_of_resistance_to_treatment_as_compared_to_patients_with_the_GG_genotype._Note__most_studies_find_no_association_with_response_and_one_study_finds_the_A_allele_to_be_associated_with_better_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""GG:Patients_with_the_GG_genotype_and_epilepsy_who_are_treated_with_antiepileptic_drugs_may_be_less_likely_to_be_resistant_to_treatment_as_compared_to_patients_with_the_AG_genotype._Note__most_studies_find_no_association_with_response_and_one_study_finds_the_A_allele_to_be_associated_with_better_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.","AA:People_with_the_AA_genotype_may_have_increased_residual_clearance_of_intravenous_talinolol_and_lower_bioavailablilty_of_orally_administered_talinolol_as_compared_to_people_with_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_talinolol.""AG:People_with_the_AG_genotype_may_have_increased_residual_clearance_of_intravenous_talinolol_and_lower_bioavailablilty_of_orally_administered_talinolol_as_compared_to_people_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_talinolol.""GG:People_with_the_GG_genotype_may_have_higher_bioavailablilty_of_orally_administered_talinolol_as_compared_to_people_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_talinolol.","AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_renal_proximal_tubulopathy_but_may_not_be_associated_with_changes_in_glomerular_filtration_rate_or_risk_of_Fanconi_syndrome_when_treated_with_tenofovir_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_renal_proximal_tubulopathy_but_may_not_be_associated_with_changes_in_glomerular_filtration_rate_or_risk_of_Fanconi_syndrome_when_treated_with_tenofovir_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""GG:Patients_with_the_GG_genotype_may_have_decreased_but_not_absent_risk_of_renal_proximal_tubulopathy_but_may_not_be_associated_with_changes_in_glomerular_filtration_rate_or_risk_of_Fanconi_syndrome_when_treated_with_tenofovir_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.","AA:No_patients_with_the_AA_genotype_were_available_for_analysis._However_patients_with_the_AG_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""AG:Patients_with_the_AG_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""GG:Patients_with_the_GG_genotype_and_beta-thalassemia_may_have_decreased_concentrations_of_deferasirox_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.","AA:Patients_with_the_AA_genotype_and_epilepsy_who_are_treated_with_carbamazepine_may_have_an_increased_risk_of_neurological_adverse_drug_reactions_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions._""AG:Patients_with_the_AG_genotype_and_epilepsy_who_are_treated_with_carbamazepine_may_have_an_increased_risk_of_neurological_adverse_drug_reactions_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions._""GG:Patients_with_the_GG_genotype_and_epilepsy_who_are_treated_with_carbamazepine_may_have_a_reduced_but_not_absent_risk_of_neurological_adverse_drug_reactions_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_carbamazepine-induced_adverse_reactions._";PGKB_RACE=Asian,Asian,NR,White,NR,NR,Asian
10	101595996	rs17222723	T	A	.	.	PGKB_INDEX=2;PGKB_GENE=ABCC2_(PA116),ABCC2_(PA116);PGKB_DRUG=doxorubicin_(PA449412),tenofovir_(PA10204);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Arrhythmias_Cardiac_(PA443421)""Drug_Toxicity_(PA443937)""Lymphoma_Non-Hodgkin_(PA444845)",HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_of_cardiotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""AT:Patients_with_the_AT_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_of_cardiotoxicity_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_decreased_but_not_absent_risk_of_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""TT:Patients_with_the_TT_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_a_decreased_but_not_absent_risk_of_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.","AA:Patients_with_the_AA_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_a_decreased_risk_of_renal_proximal_tubulopathy_as_compared_to_patients_with_the_TT_genotype._This_association_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_tenofovir_treatment.""AT:Patients_with_the_AT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_a_decreased_risk_of_renal_proximal_tubulopathy_as_compared_to_patients_with_the_TT_genotype._This_association_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_tenofovir_treatment.""TT:Patients_with_the_TT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_an_increased_risk_of_renal_proximal_tubulopathy_as_compared_to_patients_with_the_AT_and_AA_genotype._This_association_has_been_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_tenofovir_treatment.";PGKB_RACE=White,NR
10	101604207	rs3740066	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116);PGKB_DRUG=irinotecan_(PA450085),antiepileptics_(PA143485705),carbamazepine_(PA448785);PGKB_TYPE=Toxicity/ADR,Efficacy,Metabolism/PK;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622),Epilepsy_(PA444065),Epilepsy_(PA444065);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_an_increased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CT_or_TT_genotype._No_association_has_been_seen_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.""CT:Patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype._No_association_has_been_seen_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_risk_of_diarrhea_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_genotype._No_association_has_been_seen_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_risk_of_diarrhea.","CC:Patients_with_the_CC_genotype_and_Epilepsy_who_are_treated_with_antiepileptics_may_have_a_decreased_risk_of_drug_resistance_as_compared_to_patients_with_the_CT_or_TT_genotype._Most_studies_find_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.""CT:Patients_with_the_CT_genotype_and_Epilepsy_who_are_treated_with_antiepileptics_may_have_an_increased_risk_of_drug_resistance_as_compared_to_patients_with_the_CC_genotype._Most_studies_find_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.""TT:Patients_with_the_TT_genotype_and_Epilepsy_who_are_treated_with_antiepileptics_may_have_an_increased_risk_of_drug_resistance_as_compared_to_patients_with_the_CC_genotype._Most_studies_find_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antiepileptics.","CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_carbamazepine_in_men_with_Epilepsy_as_compared_to_patients_with_genotype_TT_or_CT._This_association_was_only_significant_in_male_patients._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_carbamazepine.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_carbamazepine_in_men_with_Epilepsy_as_compared_to_patients_with_genotype_CC._This_association_was_only_significant_in_male_patients._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_carbamazepine.""TT:Patients_with_the_TT_genotype_may_have_decreased_metabolism_of_carbamazepine_in_men_with_Epilepsy_as_compared_to_patients_with_genotype_CC._This_association_was_only_significant_in_male_patients._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_carbamazepine.";PGKB_RACE=Asian,NR,NR
10	101605693	rs3740065	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC2_(PA116);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE="Toxicity/ADR""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_B-Cell_Acute_(PA446157);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_leukemia_who_are_treated_with_methotrexate_may_have_decreased_plasma_level_and_decreased_but_not_absent_risk_for_toxicity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_leukemia_who_are_treated_with_methotrexate_may_have_increased_plasma_level_and_increased_risk_for_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_leukemia_who_are_treated_with_methotrexate_may_have_increased_plasma_level_and_increased_risk_for_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=White
10	101610533	rs8187707	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC2_(PA116);PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_increased_creatinine_clearance_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.""CT:Patients_with_the_CT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_decreased_creatinine_clearance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.""TT:Patients_with_the_TT_genotype_and_HIV_who_are_treated_with_tenofovir_may_have_decreased_creatinine_clearance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tenofovir.";PGKB_RACE=NR
10	101611294	rs8187710	G	A	.	.	PGKB_INDEX=4;PGKB_GENE=ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116),ABCC2_(PA116);PGKB_DRUG=lopinavir_(PA450264),"calcein_(PA132595336)""lopinavir_(PA450264)",doxorubicin_(PA449412),deferasirox_(PA164760843);PGKB_TYPE=Efficacy,Other,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,4,3,4;PGKB_DISEASE=HIV_(PA447230),NR,Lymphoma_Non-Hodgkin_(PA444845),beta-Thalassemia_(PA446432);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_lopinavir_may_have_a_higher_accumulation_of_lopinavir_in_peripheral_blood_mononuclear_cells_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lopinavir.""AG:Patients_with_the_AG_genotype_who_are_treated_with_lopinavir_may_have_a_higher_accumulation_of_lopinavir_in_peripheral_blood_mononuclear_cells_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lopinavir.""GG:Patients_with_the_GG_genotype_who_are_treated_with_lopinavir_may_have_a_lower_accumulation_of_lopinavir_in_peripheral_blood_mononuclear_cells_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lopinavir.","AA:Patients_with_the_AA_genotype_may_have_higher_accumulation_of_lopinavir_or_calcein_and_reduced_ABCC2-mediated_efflux_of_lopinavir_as_compared_to_the_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_lopinavir_or_calcein.""AG:The_AG_genotype_was_not_studied.""GG:Patients_with_the_GG_genotype_may_have_lower_accumulation_of_lopinavir_or_calcein_and_increased_ABCC2-mediated_efflux_of_lopinavir_as_compared_to_the_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_lopinavir_or_calcein.","AA:Patients_with_the_AA_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_of_cardiotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cardiotoxicity.""AG:Patients_with_the_AG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_of_cardiotoxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_but_not_absent_risk_of_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cardiotoxicity.""GG:Patients_with_the_GG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_a_decreased_but_not_absent_risk_of_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cardiotoxicity.","AA:Pediatric_patients_with_major_thalassemia_and_the_AA_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_GG_or_AA_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""AG:Pediatric_patients_with_major_thalassemia_and_the_AG_genotype_may_have_an_increased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_GG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_GG_or_AA_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.""GG:Pediatric_patients_with_major_thalassemia_and_the_GG_genotype_may_have_a_decreased_risk_of_adverse_reactions_when_administered_deferasirox_as_compared_to_patients_with_the_AA_or_AG_genotype._Please_note_the_evidence_comes_solely_from_a_single_case_study_report_of_a_single_individual_a_3_year_old_female_patient_with_major_thalassemia_of_genotype_AG_therefore_there_is_no_information_for_patients_with_the_GG_or_AA_genotypes.Other_clinical_and_genetic_factors_may_also_influence_risk_of_adverse_reactions_in_patients_with_major_thalassemia_who_are_administered_deferasirox.";PGKB_RACE=NR,NR,White,NR
10	101620771	rs12762549	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC2_(PA116);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE="Toxicity/ADR""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_docetaxel_may_have_an_increased_clearance_and_decreased_risk_of_leukopenia_as_compared_to_patients_with_the_GG_genotype._However_the_association_for_clearance_of_docetaxel_was_not_significant_and_no_association_was_found_with_risk_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_docetaxel.""CG:Patients_with_the_CG_genotype_who_are_treated_with_docetaxel_may_have_a_decreased_clearance_and_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_genotype._However_the_association_for_clearance_of_docetaxel_was_not_significant_and_no_association_was_found_with_risk_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_docetaxel.""GG:Patients_with_the_GG_genotype_who_are_treated_with_docetaxel_may_have_a_decreased_clearance_and_increased_risk_of_leukopenia_as_compared_to_patients_with_the_CC_genotype._However_the_association_for_clearance_of_docetaxel_was_not_significant_and_no_association_was_found_with_risk_for_neutropenia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_docetaxel.";PGKB_RACE=NR
10	104869531	rs11191561	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NT5C2_(PA31801);PGKB_DRUG=didanosine_(PA449301);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_reduced_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""CG:Patients_with_the_CG_genotype_and_HIV_may_have_an_increased_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""GG:Patients_with_the_GG_genotype_and_HIV_may_have_an_increased_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.";PGKB_RACE=NR
10	104897985	rs11598702	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=NT5C2_(PA31801),NT5C2_(PA31801);PGKB_DRUG=didanosine_(PA449301),gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR,Other;PGKB_EVIDENCE=3,2B;PGKB_DISEASE=HIV_(PA447230),Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_have_a_increased_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_a_increased_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.""TT:Patients_with_the_TT_genotype_and_HIV_may_have_a_reduced_risk_of_developing_noncirrhotic_portal_hypertension_when_treated_with_didanosine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_noncirrhotic_portal_hypertension.","CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_gemcitabine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_affect_clearance_of_gemcitabine.""CT:Patients_with_the_CT_genotype_may_have_increased_clearance_of_gemcitabine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_affect_clearance_of_gemcitabine.""TT:Patients_with_the_TT_genotype_may_have_decreased_clearance_of_gemcitabine_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_affect_clearance_of_gemcitabine.";PGKB_RACE=NR,NR
10	112836503	rs1800544	G	C	.	.	PGKB_INDEX=2;PGKB_GENE=ADRA2A_(PA35),ADRA2A_(PA35);PGKB_DRUG=dexmedetomidine_(PA449256),methylphenidate_(PA450464);PGKB_TYPE=Other,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,"Attention_Deficit_Disorder_with_Hyperactivity_(PA447197)""Autism_Spectrum_Disorder_(PA153906318)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_sedative_response_to_dexmedetomidine_as_compared_to_patients_with_the_GG_or_GC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dexmedetomidine.""GC:Patients_with_the_GC_genotype_may_have_a_decreased_sedative_response_to_dexmedetomidine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dexmedetomidine.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_sedative_response_to_dexmedetomidine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dexmedetomidine.","CC:Pediatric_patients_with_the_CC_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_poorer_response_to_methylphenidate_treatment_as_compared_to_pediatric_patients_with_the_CG_or_GG_genotype._However_patients_with_the_CC_genotype_and_autism_spectrum_disorder_(ASD)_were_found_to_have_a_better_response_to_methylphenidate_though_this_was_a_non-significant_result_after_correction_for_multiple_testing._Other_genetic_and_clinical_factors_may_also_influence_response_to_methylphenidate.""CG:Pediatric_patients_with_the_CG_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_better_response_to_methylphenidate_treatment_as_compared_to_pediatric_patients_with_the_CC_genotype._However_patients_with_the_CG_genotype_and_autism_spectrum_disorder_(ASD)_were_found_to_have_a_poorer_response_to_methylphenidate_though_this_was_a_non-significant_result_after_correction_for_multiple_testing._Other_genetic_and_clinical_factors_may_also_influence_response_to_methylphenidate.""GG:Pediatric_patients_with_the_GG_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_better_response_to_methylphenidate_treatment_as_compared_to_pediatric_patients_with_the_CC_genotype._However_patients_with_the_GG_genotype_and_autism_spectrum_disorder_(ASD)_were_found_to_have_a_poorer_response_to_methylphenidate_though_this_was_a_non-significant_result_after_correction_for_multiple_testing._Other_genetic_and_clinical_factors_may_also_influence_response_to_methylphenidate.";PGKB_RACE=White,NR
10	112837538	rs1800545	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ADRA2A_(PA35);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertrophy_Left_Ventricular_(PA446479);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_left_ventricular_hypertrophy_may_have_a_decreased_response_when_treated_with_atenolol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atenolol.""AG:Patients_with_the_AG_genotype_and_left_ventricular_hypertrophy_may_have_a_decreased_response_when_treated_with_atenolol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atenolol.""GG:Patients_with_the_GG_genotype_and_left_ventricular_hypertrophy_may_have_an_increased_response_when_treated_with_atenolol_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atenolol.";PGKB_RACE=NR
10	114732882	rs7917983	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TCF7L2_(PA36394);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Hypertension_who_are_treated_with_hydrochlorothiazide_may_have_decreased_but_not_absent_risk_for_diabetes_mellitus_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_diabetes_mellitus.""CT:Patients_with_the_CT_genotype_and_Hypertension_who_are_treated_with_hydrochlorothiazide_may_have_increased_risk_for_diabetes_mellitus_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_but_not_absent_risk_for_diabetes_mellitus_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_diabetes_mellitus.""TT:Patients_with_the_TT_genotype_and_Hypertension_who_are_treated_with_hydrochlorothiazide_may_have_increased_risk_for_diabetes_mellitus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_diabetes_mellitus.";PGKB_RACE=White
10	114756041	rs4506565	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=TCF7L2_(PA36394);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypertension_may_have_decreased_but_not_absent_risk_for_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""AT:Patients_with_the_TT_genotype_and_Hypertension_may_have_increased_risk_for_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_but_not_absent_risk_for_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""TT:Patients_with_the_TT_genotype_and_Hypertension_may_have_increased_risk_for_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.";PGKB_RACE=White
10	114758349	rs7903146	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=TCF7L2_(PA36394),TCF7L2_(PA36394);PGKB_DRUG=sulfonamides_urea_derivatives_(PA10390),"cyclosporine_(PA449167)""sirolimus_(PA451365)""tacrolimus_(PA451578)";PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=NR,Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_response_(reductions_in_haemoglobin_A1c_(HbA1c)_and_fasting_plasma_glucose_(FPG)_levels)_when_treated_with_sulfonamides_urea_derivatives_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_CT_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sulfonamides_urea_derivatives.""CT:Patients_with_the_CT_genotype_may_have_decreased_response_(reductions_in_haemoglobin_A1c_(HbA1c)_and_fasting_plasma_glucose_(FPG)_levels)_when_treated_with_sulfonamides_urea_derivatives_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sulfonamides_urea_derivatives.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_(reductions_in_haemoglobin_A1c_(HbA1c)_and_fasting_plasma_glucose_(FPG)_levels)_when_treated_with_sulfonamides_urea_derivatives_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_sulfonamides_urea_derivatives.","CC:Patients_with_the_CC_genotype_who_undergo_kidney_transplantation_may_have_a_decreased_likelihood_of_developing_new-onset_diabetes_after_transplantation_(NODAT)_when_treated_with_tacrolimus_sirolimus_or_cyclosporine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_development_of_NODAT.""CT:Patients_with_the_CT_genotype_who_undergo_kidney_transplantation_may_have_a_decreased_likelihood_of_developing_new-onset_diabetes_after_transplantation_(NODAT)_when_treated_with_tacrolimus_sirolimus_or_cyclosporine_as_compared_to_patients_with_the_TT_genotype_or_an_increased_likelihood_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_development_of_NODAT.""TT:Patients_with_the_TT_genotype_who_undergo_kidney_transplantation_may_have_an_increased_likelihood_of_developing_new-onset_diabetes_after_transplantation_(NODAT)_when_treated_with_tacrolimus_sirolimus_or_cyclosporine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_development_of_NODAT.";PGKB_RACE=NR,White
10	114767771	rs4132670	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TCF7L2_(PA36394);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypertension_may_have_increased_risk_of_diabetes_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""AG:Patients_with_the_AG_genotype_and_Hypertension_may_have_increased_risk_of_diabetes_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_but_not_absent_risk_of_diabetes_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""GG:Patients_with_the_GG_genotype_and_Hypertension_may_have_decreased_but_not_absent_risk_of_diabetes_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.";PGKB_RACE=White
10	114808902	rs12255372	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=TCF7L2_(PA36394);PGKB_DRUG=sulfonamides_urea_derivatives_(PA10390);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_type_II_diabetes_who_are_treated_with_sulfonylureas_may_be_more_likely_to_achieve_a_HbA1c_level_of_<7%_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Patients_with_the_GT_genotype_and_type_II_diabetes_who_are_treated_with_sulfonylureas_may_be_less_likely_to_achieve_a_target_HbA1c_level_of_<7%_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_and_type_II_diabetes_who_are_treated_with_sulfonylureas_may_be_less_likely_to_achieve_a_target_HbA1c_level_of_<7%_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
10	114909731	rs290487	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TCF7L2_(PA36394);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_lower_response_to_repaglinide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repsonse.""CT:Patients_with_the_CT_genotype_may_have_lower_response_to_repaglinide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repsonse.""TT:Patients_with_the_TT_genotype_may_have_better_response_to_repaglinide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_repsonse.";PGKB_RACE=Asian
10	115438204	rs12415607	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CASP7_(PA26091);PGKB_DRUG="docetaxel_(PA449383)""gemcitabine_(PA449748)""paclitaxel_(PA450761)""Platinum_compounds_(PA164713176)""vinorelbine_(PA451881)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small_cell_lung_cancer_may_have_increased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CC_genotype._No_significant_association_between_this_SNP_and_overall_survival_time_was_seen_when_considering_patients_taking_gemcitabine_only._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""AC:Patients_with_the_AC_genotype_and_non-small_cell_lung_cancer_may_have_increased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CC_genotype._No_significant_association_between_this_SNP_and_overall_survival_time_was_seen_when_considering_patients_taking_gemcitabine_only._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_decreased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_AA_or_AC_genotype._No_significant_association_between_this_SNP_and_overall_survival_time_was_seen_when_considering_patients_taking_gemcitabine_only._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=Asian
10	115439569	rs7921977	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CASP7_(PA26091);PGKB_DRUG="docetaxel_(PA449383)""gemcitabine_(PA449748)""paclitaxel_(PA450761)""Platinum_compounds_(PA164713176)""vinorelbine_(PA451881)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_show_no_significant_differences_in_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_TT_genotype._However_patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_have_reduced_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""CT:Patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_have_reduced_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_increased_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=Asian
10	115489152	rs2227310	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=CASP7_(PA26091);PGKB_DRUG="docetaxel_(PA449383)""gemcitabine_(PA449748)""paclitaxel_(PA450761)""Platinum_compounds_(PA164713176)""vinorelbine_(PA451881)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_decreased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""CG:Patients_with_the_CG_genotype_and_non-small_cell_lung_cancer_may_have_increased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""GG:Patients_with_the_GG_genotype_and_non-small_cell_lung_cancer_may_have_increased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=Asian
10	115489589	rs4353229	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CASP7_(PA26091);PGKB_DRUG="docetaxel_(PA449383)""gemcitabine_(PA449748)""paclitaxel_(PA450761)""Platinum_compounds_(PA164713176)""vinorelbine_(PA451881)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_increased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_TT_genotype._No_significant_association_between_this_SNP_and_overall_survival_time_was_seen_when_considering_patients_taking_gemcitabine_only._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""CT:Patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_have_increased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_TT_genotype._No_significant_association_between_this_SNP_and_overall_survival_time_was_seen_when_considering_patients_taking_gemcitabine_only._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_decreased_overall_survival_time_when_treated_with_platinum_compounds_in_combination_with_either_docetaxel_gemcitabine_paclitaxel_or_vinorelbine_as_compared_to_patients_with_the_CC_or_CT_genotype._No_significant_association_between_this_SNP_and_overall_survival_time_was_seen_when_considering_patients_taking_gemcitabine_only._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=Asian
10	115490109	rs1127687	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CASP7_(PA26091),CASP7_(PA26091);PGKB_DRUG="paclitaxel_(PA450761)""Platinum_compounds_(PA164713176)","gemcitabine_(PA449748)""Platinum_compounds_(PA164713176)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622),Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small_cell_lung_cancer_may_have_reduced_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_paclitaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AG:Patients_with_the_AG_genotype_and_non-small_cell_lung_cancer_may_have_reduced_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_paclitaxel_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GG:Patients_with_the_GG_genotype_and_non-small_cell_lung_cancer_may_have_increased_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_paclitaxel_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.","AA:Patients_with_the_AA_genotype_and_non-small_cell_lung_cancer_may_have_reduced_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_gemcitabine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AG:Patients_with_the_AG_genotype_and_non-small_cell_lung_cancer_may_have_reduced_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_gemcitabine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GG:Patients_with_the_GG_genotype_and_non-small_cell_lung_cancer_may_have_increased_progression-free_survival_time_when_treated_with_platinum_compounds_in_combination_with_gemcitabine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=Asian,Asian
10	115804036	rs1801252	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=ADRB1_(PA38),ADRB1_(PA38);PGKB_DRUG="Antihypertensives_(PA164712445)""atenolol_(PA448499)""Beta_Blocking_Agents_(PA164712535)""bisoprolol_(PA448641)""metoprolol_(PA450480)""verapamil_(PA451868)",timolol_(PA451690);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Death_(PA443842)""Heart_Failure_(PA444370)",NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_1)_experience_more_benefit_from_beta_blocking_agents_(such_as_atenolol)_than_verapamil_2)_require_additional_heart_failure_medications_(such_as_diuretics)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response_in_particular_ADRB1_Arg389_(rs1801253).""AG:Patients_with_the_AG_genotype_may_1)_experience_more_benefit_from_beta_blocking_agents_(such_as_atenolol)_than_verapamil_2)_not_require_additional_heart_failure_medications_(such_as_diuretics)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response_in_particular_ADRB1_Arg389_(rs1801253).""GG:People_with_the_GG_genotype_may_1)_not_experience_more_benefit_from_beta_blocking_agents_(such_as_atenolol)_than_verapamil_2)_not_require_additional_heart_failure_medications_(such_as_diuretics)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response_in_particular_ADRB1_Arg389_(rs1801253).","AA:Patients_with_the_AA_genotype_who_are_treated_with_timolol_may_have_increased_systolic_(SAP)_and_diastolic_(DAP)_arterial_pressure_responses_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_timolol.""AG:Patients_with_the_AG_genotype_who_are_treated_with_timolol_may_have_decreased_systolic_(SAP)_and_diastolic_(DAP)_arterial_pressure_responses_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_timolol.""GG:Patients_with_the_GG_genotype_who_are_treated_with_timolol_may_have_decreased_systolic_(SAP)_and_diastolic_(DAP)_arterial_pressure_responses_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_timolol.";PGKB_RACE=NR,NR
10	115805056	rs1801253	G	C	.	.	PGKB_INDEX=5;PGKB_GENE=ADRB1_(PA38),ADRB1_(PA38),ADRB1_(PA38),ADRB1_(PA38),ADRB1_(PA38);PGKB_DRUG=dobutamine_(PA449381),verapamil_(PA451868),muraglitazar_(PA162356187),metoprolol_(PA450480),"atenolol_(PA448499)""Beta_Blocking_Agents_(PA164712535)""bucindolol_(PA165945764)""carvedilol_(PA448817)""metoprolol_(PA450480)";PGKB_TYPE=Efficacy,Efficacy,Toxicity/ADR,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,4,3,3;PGKB_DISEASE=NR,Atrial_Fibrillation_(PA443459),"Diabetes_Mellitus_(PA443886)""Edema_(PA443994)""Hyperlipidemias_(PA444528)",Hypertension_(PA444552),NR;PGKB_TEXT="CC:Healthy_males_with_the_CC_genotype_may_have_a_greater_increase_in_fractional_shortening_and_systolic_blood_pressure_when_given_dobutamine_as_compared_to_healthy_males_with_the_CG_or_GG_genotype._No_significant_differences_were_seen_for_heart_rate._Other_genetic_and_clinical_factors_may_also_influence_fractional_shortening_and_systolic_blood_pressure.""CG:Healthy_males_with_the_CG_genotype_may_have_smaller_increases_in_fractional_shortening_and_systolic_blood_pressure_when_given_dobutamine_as_compared_to_healthy_males_with_the_CC_genotype._No_significant_differences_were_seen_for_heart_rate._Other_genetic_and_clinical_factors_may_also_influence_fractional_shortening_and_systolic_blood_pressure.""GG:Healthy_males_with_the_GG_genotype_may_have_smaller_increases_in_fractional_shortening_and_systolic_blood_pressure_when_given_dobutamine_as_compared_to_healthy_males_with_the_CC_genotype._No_significant_differences_were_seen_for_heart_rate._Other_genetic_and_clinical_factors_may_also_influence_fractional_shortening_and_systolic_blood_pressure.","CC:Patients_with_the_CC_genotype_and_Atrial_Fibrillation_may_have_a_decreased_response_to_verapamil_treatment_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.""CG:Patients_with_the_CG_genotype_and_Atrial_Fibrillation_may_have_an_increased_response_to_verapamil_treatment_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.""GG:Patients_with_the_GG_genotype_and_Atrial_Fibrillation_may_have_an_increased_response_to_verapamil_treatment_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.","CC:Patients_with_the_CC_genotype_and_Diabetes_Mellitus_who_are_treated_with_muraglitazar_may_have_a_decreased_but_not_absent_risk_of_edema_as_compared_to_patients_with_the_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_edema_with_muraglitazar_treatment.""CG:Patients_with_the_CG_genotype_and_Diabetes_Mellitus_who_are_treated_with_muraglitazar_may_have_an_increased_risk_of_edema_as_compared_to_patients_with_the_CC_genotype.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_edema_with_muraglitazar_treatment.""GG:Patients_with_the_GG_genotype_and_Diabetes_Mellitus_who_are_treated_with_muraglitazar_may_have_an_increased_risk_of_edema_as_compared_to_patients_with_the_CC_genotype_but_the_results_were_not_statistically_significant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_edema_with_muraglitazar_treatment.","CC:Patients_with_the_CC_(Arg389)_genotype_may_have_a_stronger_DBP_response_to_metoprolol_with_a_significantly_greater_reduction_in_24-hour_and_daytime_DBP_than_was_found_in_carriers_of_a_G(Gly389)_allele._Other_genetic_and_clinical_factors_may_also_influence_the_patient's_response_to_metoprolol.""CG:Patients_with_the_CG_genotype_may_have_weaker_response_to_metoprolol_compared_to_CC_genotype_carriers._Other_genetic_and_clinical_factors_may_also_influence_the_patient's_response_to_metoprolol.""GG:Patients_with_the_GG_genotype_may_have_weaker_response_to_metoprolol_compared_to_CC_genotype_carriers._Other_genetic_and_clinical_factors_may_also_influence_the_patient's_response_to_metoprolol.","CC:Patients_with_the_CC_genotype_1)_may_have_an_increased_response_to_Beta_Blocking_Agents_(this_association_has_not_been_found_in_all_studies_and_has_been_contradicted)_2)_may_have_a_decreased_likelihood_for_requiring_increases_in_other_heart_failure_medication_(for_example_diuretics)_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Beta_Blocking_Agents.""CG:Patients_with_the_CG_genotype_1)_may_have_a_decreased_response_to_Beta_Blocking_Agents_(this_association_has_not_been_found_in_all_studies_and_has_been_contradicted)_2)_may_have_an_increased_likelihood_for_requiring_increases_in_other_heart_failure_medication_(for_example_diuretics)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Beta_Blocking_Agents.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_Beta_Blocking_Agents_(this_association_has_not_been_found_in_all_studies_and_has_been_contradicted)_2)_may_have_an_increased_likelihood_for_requiring_increases_in_other_heart_failure_medication_(for_example_diuretics)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Beta_Blocking_Agents.";PGKB_RACE=NR,White,NR,NR,NR
10	120840195	rs3740556	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=EIF3A_(PA27699);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Lung_Neoplasms_(PA444818);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_lung_cancer_may_have_a_better_response_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_and_lung_cancer_may_have_a_better_response_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_a_poorer_response_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.";PGKB_RACE=Asian
10	121086097	rs2230345	A	T	.	.	PGKB_INDEX=2;PGKB_GENE=GRK5_(PA180),GRK5_(PA180);PGKB_DRUG=Beta_Blocking_Agents_(PA164712535),"Antihypertensives_(PA164712445)""Beta_Blocking_Agents_(PA164712535)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=4,3;PGKB_DISEASE=Heart_Failure_(PA444370),Heart_Diseases_(PA444368);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heart_failure_may_have_an_elevated_risk_for_death_as_compared_to_patients_with_the_TT_genotype_and_may_benefit_more_from_beta_blocker_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_cardiovascular_events.""AT:Patients_with_the_AT_genotype_and_heart_failure_may_have_lower_but_not_absent_risk_for_death_as_compared_to_patients_with_the_AA_genotype_and_may_benefit_more_from_beta_blocker_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_cardiovascular_events.""TT:Patients_with_the_TT_genotype_and_heart_failure_may_have_lower_but_not_absent_risk_for_death_as_compared_to_patients_with_the_AA_genotype_regardless_of_beta_blocker._treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_cardiovascular_events.","AA:Patients_with_the_AA_genotype_and_heart_conditions_may_have_a_poorer_response_to_treatment_with_beta-blockers_or_antihypertensives_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_beta-blockers_or_antihypertensives.""AT:Patients_with_the_AT_genotype_and_heart_conditions_may_have_a_better_response_to_treatment_with_beta-blockers_or_antihypertensives_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_beta-blockers_or_antihypertensives.""TT:Patients_with_the_TT_genotype_and_heart_conditions_may_have_a_better_response_to_treatment_with_beta-blockers_or_antihypertensives_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_beta-blockers_or_antihypertensives.";PGKB_RACE=Black_or_African_American,NR
10	121190113	rs915120	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GRK5_(PA180);PGKB_DRUG="citalopram_(PA449015)""escitalopram_(PA10074)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_(PA447207);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_remission_at_8_weeks_when_treated_with_citalopram_or_escitalopram_in_people_with_depression_as_compared_to_patients_with_the_TT_genotype._However_this_association_did_not_reach_genome-wide_level_of_significance_in_the_GWAS_study_(P<10-7)._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram._""CT:Patients_with_the_CT_genotype_may_have_decreased_likelihood_of_remission_at_8_weeks_when_treated_with_citalopram_or_escitalopram_in_people_with_depression_as_compared_to_patients_with_the_TT_genotype._However_this_association_did_not_reach_genome-wide_level_of_significance_in_the_GWAS_study_(P<10-7)._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram._""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_remission_at_8_weeks_when_treated_with_citalopram_or_escitalopram_in_people_with_depression_as_compared_to_patients_with_the_CC_or_CT_genotype._However_this_association_did_not_reach_genome-wide_level_of_significance_in_the_GWAS_study_(P<10-7)._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_citalopram_or_escitalopram._";PGKB_RACE=White
10	124214448	rs10490924	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=ARMS2_(PA162376896);PGKB_DRUG=bevacizumab_(PA130232992);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Macular_Degeneration_(PA134850558);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_age-related_macular_degeneration_who_are_treated_with_bevacizumab_may_have_poorer_improvement_in_visual_acuity_as_compared_to_patients_with_the_GT_or_TT_genotype._However_another_study_finds_that_those_with_the_GG_genotype_have_better_improvement_in_visual_acuity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bevacizumab_treatment.""GT:Patients_with_the_GT_genotype_and_age-related_macular_degeneration_who_are_treated_with_bevacizumab_may_have_better_improvement_in_visual_acuity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bevacizumab_treatment.""TT:Patients_with_the_TT_genotype_and_age-related_macular_degeneration_who_are_treated_with_bevacizumab_may_have_better_improvement_in_visual_acuity_as_compared_to_patients_with_the_GG_genotype._However_another_study_finds_that_those_with_the_TT_genotype_have_poorer_improvement_in_visual_acuity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bevacizumab_treatment.";PGKB_RACE=Asian
10	135340567	rs2070673	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2E1_(PA129);PGKB_DRUG="cytarabine_(PA449177)""fludarabine_(PA449655)""gemtuzumab_ozogamicin_(PA164749431)""idarubicin_(PA449961)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""AT:Patients_with_the_AT_genotype_may_have_a_decreased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype_and_an_increased_likelihood_of_toxic_liver_disease_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""TT:Patients_with_the_TT_genotype_may_have_an_increased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.";PGKB_RACE=NR
10	135348544	rs6413432	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2E1_(PA129);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="AA:The_AA_genotype_was_not_studied_but_female_patients_with_the_AT_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_a_decreased_likelihood_of_progression-free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_progression-free_survival.""AT:Female_patients_with_the_AT_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_a_decreased_likelihood_of_progression-free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_progression-free_survival.""TT:Female_patients_with_the_TT_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_an_increased_likelihood_of_progression-free_survival_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_progression-free_survival.";PGKB_RACE=NR
10	135351137	rs2070676	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2E1_(PA129);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Female_patients_with_the_CC_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_a_decreased_risk_for_severe_emesis_as_compared_to_patients_with_the_GC_genotype._However_no_association_was_found_with_progression-free_survival_or_overall_survival._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_severe_emesis.""CG:Female_patients_with_the_CG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_for_severe_emesis_as_compared_to_patients_with_the_CC_genotype._However_no_association_was_found_with_progression-free_survival_or_overall_survival._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_severe_emesis.""GG:Patients_with_the_GG_genotype_were_not_studied_but_female_patients_with_the_CG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_for_severe_emesis_as_compared_to_patients_with_the_CC_genotype._However_no_association_was_found_with_progression-free_survival_or_overall_survival._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_severe_emesis.";PGKB_RACE=NR
10	135351362	rs2515641	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="cytarabine_(PA449177)""fludarabine_(PA449655)""gemtuzumab_ozogamicin_(PA164749431)""idarubicin_(PA449961)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_genotype_and_an_increased_likelihood_of_toxic_liver_disease_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.";PGKB_RACE=NR
11	2839751	rs2237892	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=KCNQ1_(PA223);PGKB_DRUG=repaglinide_(PA451234);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_type_2_diabetes_may_have_a_decreased_response_when_treated_with_repaglinide_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_repaglinide.""CT:Patients_with_the_CT_genotype_and_type_2_diabetes_may_have_an_increased_response_when_treated_with_repaglinide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_repaglinide.""TT:Patients_with_the_TT_genotype_and_type_2_diabetes_may_have_an_increased_response_when_treated_with_repaglinide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_repaglinide.";PGKB_RACE=Asian
11	2857194	rs2237895	A	C	.	.	PGKB_INDEX=2;PGKB_GENE=KCNQ1_(PA223),KCNQ1_(PA223);PGKB_DRUG=repaglinide_(PA451234),tacrolimus_(PA451578);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890),Kidney_Transplantation_(PA165817016);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_type_2_diabetes_may_have_a_decreased_response_when_treated_with_repaglinide_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_repaglinide.""AC:Patients_with_the_AC_genotype_an_type_2_diabetes_may_have_an_increased_response_when_treated_with_repaglinide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_repaglinide.""CC:Patients_with_the_CC_genotype_and_type_2_diabetes_may_have_an_increased_response_when_treated_with_repaglinide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_repaglinide.","AA:Patients_with_the_AA_genotype_who_are_undergoing_kidney_transplantation_may_have_a_decreased_risk_of_experiencing_new-onset_diabetes_after_transplantation_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_new-onset_diabetes_after_transplantation.""AC:Patients_with_the_AC_genotype_who_are_undergoing_kidney_transplantation_may_have_a_decreased_risk_of_experiencing_new-onset_diabetes_after_transplantation_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_genotype_or_an_increased_risk_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_new-onset_diabetes_after_transplantation.""CC:Patients_with_the_CC_genotype_who_are_undergoing_kidney_transplantation_may_have_an_increased_risk_of_experiencing_new-onset_diabetes_after_transplantation_when_treated_with_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_new-onset_diabetes_after_transplantation.";PGKB_RACE=Asian,White
11	4104060	rs2898950	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG="cladribine_(PA449027)""cytarabine_(PA449177)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_be_less_likely_to_have_a_complete_response_to_the_first_course_of_remission_induction_therapy_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""AC:Patients_with_the_AC_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_be_more_likely_to_have_a_complete_response_to_the_first_course_of_remission_induction_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""CC:Patients_with_the_CC_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_be_more_likely_to_have_a_complete_response_to_the_first_course_of_remission_induction_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._";PGKB_RACE=NR
11	4113395	rs1561876	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG="cladribine_(PA449027)""cytarabine_(PA449177)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""AG:Patients_with_the_AG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""GG:Patients_with_the_GG_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._";PGKB_RACE=NR
11	4115487	rs11030918	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG="gemcitabine_(PA449748)""Platinum_compounds_(PA164713176)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Mesothelioma_(PA444937);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_gemcitabine_and_platinum_compounds_may_have_a_decreased_risk_for_nausea_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nausea.""CT:Patients_with_the_CT_genotype_who_are_treated_with_gemcitabine_and_platinum_compounds_may_have_a_decreased_risk_for_nausea_as_compared_to_patients_with_the_TT_genotype_or_may_have_an_increased_risk_for_nausea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nausea.""TT:Patients_with_the_TT_genotype_who_are_treated_with_gemcitabine_and_platinum_compounds_may_have_an_increased_risk_for_nausea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_nausea.";PGKB_RACE=White
11	4115974	rs12806698	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG="gemcitabine_(PA449748)""Platinum_compounds_(PA164713176)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Mesothelioma_(PA444937);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_gemcitabine_and_platinum_compounds_may_have_decreased_risk_for_nausea_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nausea.""AC:Patients_with_the_AC_genotype_who_are_treated_gemcitabine_and_platinum_compounds_may_have_decreased_risk_for_nausea_as_compared_to_patients_with_the_CC_genotype_or_may_have_increased_risk_for_nausea_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nausea.""CC:Patients_with_the_CC_genotype_who_are_treated_gemcitabine_and_platinum_compounds_may_have_increased_risk_for_nausea_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nausea.";PGKB_RACE=White
11	4159457	rs9937	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_advanced_breast_cancer_who_are_treated_with_gemcitabine_1)_may_be_more_likely_to_experience_toxicity_such_as_neutropenia_as_compared_to_a_patient_with_genotype_GG_or_GA_and_the_A_allele_at_rs1042858_2)_may_have_a_tendency_though_not_a_statistically_significant_one_towards_better_progression-free_survival_as_compared_to_patients_with_the_GG_genotype_and_the_A_allele_at_rs1042858._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_and_response_to_gemcitabine.""AG:Patients_with_the_AG_genotype_and_the_A_allele_of_rs1042858_with_advanced_breast_cancer_who_are_treated_with_gemcitabine_1)_may_be_less_likely_to_experience_toxicity_such_as_neutropenia_2)_may_have_a_tendency_though_not_a_statistically_significant_one_towards_poorer_progression-free_survival_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_and_response_to_gemcitabine.""GG:Patients_with_the_GG_genotype_and_the_A_allele_of_rs1042858_with_advanced_breast_cancer_who_are_treated_with_gemcitabine_1)_may_be_less_likely_to_experience_toxicity_such_as_neutropenia_2)_may_have_a_tendency_though_not_a_statistically_significant_one_towards_poorer_progression-free_survival_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_and_response_to_gemcitabine.";PGKB_RACE=Asian
11	4159466	rs1042858	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_combined_with_the_G_allele_at_rs9937_and_breast_cancer_who_are_treated_with_gemcitabine_may_have_a_reduced_risk_of_side_effects_including_neutropenia_as_compared_to_patients_with_the_GG_genotype._This_association_was_not_seen_in_a_seperate_study_in_patients_with_pancreatic_cancer._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine_treatment._""AG:Patients_with_the_AG_genotype_combined_with_the_G_allele_at_rs9937_and_breast_cancer_who_are_treated_with_gemcitabine_may_have_a_reduced_risk_of_side_effects_including_neutropenia_as_compared_to_patients_with_the_GG_genotype._This_association_was_not_seen_in_a_seperate_study_in_patients_with_pancreatic_cancer._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine_treatment._""GG:Patients_with_the_GG_genotype_and_breast_cancer_who_are_treated_with_gemcitabine_may_have_an_increased_risk_of_side_effects_including_neutropenia_as_compared_to_patients_with_the_AA_or_AG_genotype_combined_with_the_G_allele_at_rs9937._This_association_was_not_seen_in_a_seperate_study_in_patients_with_pancreatic_cancer.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_gemcitabine_treatment._";PGKB_RACE=Asian
11	4159764	rs1042919	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG="cladribine_(PA449027)""cytarabine_(PA449177)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_better_event-free_survival_as_compared_to_patients_with_the_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""AT:Patients_with_the_AT_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_poorer_event-free_survival_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._""TT:Patients_with_the_TT_genotype_were_not_studied._Patients_with_the_AT_genotype_and_acute_myeloid_leukemia_who_are_treated_with_cytarabine_and_cladribine_may_have_poorer_event-free_survival_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_and_cladribine_treatment._";PGKB_RACE=NR
11	4159929	rs1042927	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=RRM1_(PA298);PGKB_DRUG="gemcitabine_(PA449748)""Platinum_compounds_(PA164713176)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Mesothelioma_(PA444937);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Mesothelioma_who_are_treated_with_gemcitabine_and_Platinum_compounds_may_have_an_increased_overall_survival_probability_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_survival_probability.""CA:Patients_with_the_CA_genotype_and_Mesothelioma_who_are_treated_with_gemcitabine_and_Platinum_compounds_may_have_a_decreased_overall_survival_probability_as_compared_to_patients_with_the_AA_genotype_and_increased_overall_survival_probability_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_survival_probability.""CC:Patients_with_the_CC_genotype_and_Mesothelioma_who_are_treated_with_gemcitabine_and_Platinum_compounds_may_have_a_decreased_overall_survival_probability_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_survival_probability.";PGKB_RACE=White
11	5061541	rs2499984	A	G	.	.	PGKB_INDEX=1;PGKB_GENE="OR52J2P_(PA32415)""OR52J3_(PA32416)";PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""AG:Patients_with_the_AG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=NR
11	10325325	rs11042725	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=ADM_(PA24580);PGKB_DRUG=paroxetine_(PA450801);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_an_increased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""AC:Patients_with_the_AC_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_an_increased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_decreased_response_as_compared_to_patients_with_the_AC_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.";PGKB_RACE=NR
11	14380998	rs11023197	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RRAS2_(PA34862);PGKB_DRUG=tamoxifen_(PA451581);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_breast_neoplasms_may_have_an_increased_frequency_of_relapse_when_treated_with_tamoxifen_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_frequency_of_relapse.""AG:Patients_with_the_AG_genotype_and_breast_neoplasms_may_have_an_increased_frequency_of_relapse_when_treated_with_tamoxifen_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_frequency_of_relapse_when_treated_with_tamoxifen_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_frequency_of_relapse.""GG:Patients_with_the_GG_genotype_and_breast_neoplasms_may_have_a_decreased_frequency_of_relapse_when_treated_with_tamoxifen_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_frequency_of_relapse.";PGKB_RACE=NR
11	17409572	rs5219	T	C	.	.	PGKB_INDEX=3;PGKB_GENE="ABCC8_(PA24395)""KCNJ11_(PA217)",KCNJ11_(PA217),KCNJ11_(PA217);PGKB_DRUG=repaglinide_(PA451234),sulfonamides_urea_derivatives_(PA10390),"metformin_(PA450395)""sulfonamides_urea_derivatives_(PA10390)";PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890),Diabetes_Mellitus_Type_2_(PA443890),Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_are_less_likely_to_respond_to_repaglinide_than_patients_with_the_CT_or_TT_genotype_in_T2DM_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_are_more_likely_to_respond_to_repaglinide_than_patients_with_the_CC_genotype_in_T2DM_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_are_more_likely_to_respond_to_repaglinide_than_patients_with_the_CC_genotype_in_T2DM_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_CC_genotype_and_Type_2_diabetes_may_have_a_poorer_response_(smaller_decrease_in_HbA1c)_when_receiving_treatment_with_sulfonylureas_as_compared_to_patients_with_genotype_CT_or_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylureas.""CT:Patients_with_CT_genotype_and_Type_2_diabetes_may_have_better_response_(higher_decrease_in_HbA1c)_when_receiving_treatment_with_sulfonylureas_as_compared_to_patients_with_genotype_CC_or_a_poorer_response_(smaller_decrease_in_HbA1c)_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylureas.""TT:Patients_with_TT_genotype_and_Type_2_diabetes_may_have_better_response_(higher_decrease_in_HbA1c)_when_receiving_treatment_with_sulfonylureas_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_sulfonylureas.","CC:Patients_with_the_CC_genotype_and_Type_2_Diabetes_who_are_treated_with_metformin_and_sulfonamides_urea_derivatives_may_have_a_decreased_likelihood_of_treatment_failure_as_compared_to_patients_with_the_TT_genotype._This_association_with_response_was_not_seen_in_a_separate_study_in_patients_treated_with_sulfonamides_urea_derivatives._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""CT:Patients_with_the_CT_genotype_and_Type_2_Diabetes_who_are_treated_with_metformin_and_sulfonamides_urea_derivatives_may_have_a_decreased_likelihood_of_treatment_failure_as_compared_to_patients_with_the_TT_genotype_or_may_have_an_increased_likelihood_of_treatment_failure_as_compared_to_patients_with_the_CC_genotype._This_association_with_response_was_not_seen_in_a_separate_study_in_patients_treated_with_sulfonamides_urea_derivatives._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TT:Patients_with_the_TT_genotype_and_Type_2_Diabetes_who_are_treated_with_metformin_and_sulfonamides_urea_derivatives_may_have_an_increased_likelihood_of_treatment_failure_as_compared_to_patients_with_the_CC_genotype._This_association_with_response_was_not_seen_in_a_separate_study_in_patients_treated_with_sulfonamides_urea_derivatives._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.";PGKB_RACE=Asian,White,White
11	18047816	rs1800532	G	T	.	.	PGKB_INDEX=2;PGKB_GENE=TPH1_(PA355),TPH1_(PA355);PGKB_DRUG=lithium_(PA450243),"antidepressants_(PA452229)""citalopram_(PA449015)""fluoxetine_(PA449673)""paroxetine_(PA450801)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Bipolar_Disorder_(PA447199),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""GT:Patients_with_the_GT_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""TT:Patients_with_the_TT_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.","GG:Patients_with_the_GG_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_citalopram_treatment_as_compared_to_patients_with_the_GT_or_TT_genotype._However_no_association_has_been_reported_in_studies_that_determined_response_using_several_antidepressants_including_citalopram._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant_treatment._""GT:Patients_with_the_GT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_citalopram_treatment_as_compared_to_patients_with_the_GG_genotype._However_no_association_has_been_reported_in_studies_that_determined_response_using_several_antidepressants_including_citalopram._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_citalopram_treatment_as_compared_to_patients_with_the_GG_genotype._However_no_association_has_been_reported_in_studies_that_determined_response_using_several_antidepressants_including_citalopram._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant_treatment._";PGKB_RACE=White,NR
11	20659757	rs2298826	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC6A5_(PA35911);PGKB_DRUG=haloperidol_(PA449841);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Schizophrenia_who_are_treated_with_haloperidol_may_have_an_increased_risk_for_rapid_rise_of_motor_side_effects_at_the_beginning_of_the_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment_side_effects.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_who_are_treated_with_haloperidol_may_have_a_decreased_risk_for_rapid_rise_of_motor_side_effects_at_the_beginning_of_the_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment_side_effects.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_who_are_treated_with_haloperidol_may_have_a_decreased_risk_for_rapid_rise_of_motor_side_effects_at_the_beginning_of_the_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_treatment_side_effects.";PGKB_RACE=NR
11	27670108	rs10501087	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF-AS_(PA134953249);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_show_greater_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics._""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_show_greater_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics._""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_show_less_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics._";PGKB_RACE=White
11	27677041	rs7124442	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_a_better_response_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_a_better_response_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_a_poorer_response_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.";PGKB_RACE=White
11	27679916	rs6265	C	T	.	.	PGKB_INDEX=8;PGKB_GENE=BDNF_(PA31891),BDNF_(PA31891),BDNF_(PA31891),BDNF_(PA31891),BDNF_(PA31891),BDNF_(PA31891),BDNF_(PA31891),BDNF_(PA31891);PGKB_DRUG=paroxetine_(PA450801),"heroin_(PA452619)""methamphetamine_(PA450403)",fluoxetine_(PA449673),"antidepressants_(PA452229)""citalopram_(PA449015)""paroxetine_(PA450801)",antipsychotics_(PA452233),olanzapine_(PA450688),antipsychotics_(PA452233),"Analgesics_(PA164712362)""Antiinflammatory_agents_non-steroids_(PA164712462)""Ergot_alkaloids_(PA164712741)""opioids_(PA452618)""sumatriptan_(PA451566)";PGKB_TYPE=Efficacy,Other,Toxicity/ADR,Efficacy,Efficacy,Efficacy,Toxicity/ADR,Other;PGKB_EVIDENCE=3,3,4,3,3,3,3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),Substance-Related_Disorders_(PA446876),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_(PA447207),Schizophrenia_(PA447216),Schizophrenia_(PA447216),Schizophrenia_(PA447216),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Depressive_Disorder_may_be_more_likely_to_respond_to_paroxetine_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""CT:Patients_with_the_CT_genotype_and_Depressive_Disorder_may_be_more_likely_to_respond_to_paroxetine_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""TT:Patients_with_the_TT_genotype_and_Depressive_Disorder_may_be_less_likely_to_respond_to_paroxetine_as_compared_to_patients_with_the_CT_or_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._","CC:Patients_with_the_CC_genotype_may_have_a_lower_risk_of_dependence_on_methamphetamine_or_heroin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_addiction_to_methamphetamine_or_heroin._""CT:Patients_with_the_CT_genotype_may_have_a_greater_risk_of_dependence_on_methamphetamine_or_heroin_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_lower_risk_of_dependence_on_methamphetamine_or_heroin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_addiction_to_methamphetamine_or_heroin._""TT:Patients_with_the_TT_genotype_may_have_a_greater_risk_of_dependence_on_methamphetamine_or_heroin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_addiction_to_methamphetamine_or_heroin._","CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_fluoxetine_may_have_a_higher_likelihood_of_side_effects_as_compared_to_patients_with_the_TT_genotype._This_SNP_was_not_associated_with_response_to_fluoxetine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluoxetine-induced_side_effects.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_who_are_treated_with_fluoxetine_may_have_a_higher_likelihood_of_side_effects_as_compared_to_patients_with_the_TT_genotype_or_may_have_a_reduced_likelihood_of_side_effects_as_compared_to_patients_with_the_CC_genotype._This_SNP_was_not_associated_with_response_to_fluoxetine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluoxetine-induced_side_effects.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_fluoxetine_may_have_a_reduced_likelihood_of_side_effects_as_compared_to_patients_with_the_CC_genotype._This_SNP_was_not_associated_with_response_to_fluoxetine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_fluoxetine-induced_side_effects._","CC:Patients_with_the_CC_genotype_and_Depressive_Disorder_may_be_more_likely_to_respond_to_paroxetine_but_less_likely_to_respond_to_citalopram_or_antidepressants_as_compared_to_patients_with_the_CT_or_TT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressants.""CT:Patients_with_the_CT_genotype_and_Depressive_Disorder_may_be_more_likely_to_respond_to_paroxetine_or_antidepressants_as_compared_to_patients_with_the_CC_or_TT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressants.""TT:Patients_with_the_TT_genotype_and_Depressive_Disorder_may_be_less_likely_to_respond_to_paroxetine_or_antidepressants_but_more_likely_to_respond_to_citalopram_as_compared_to_patients_with_the_CT_or_TT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressants.","CC:Patients_with_the_CC_genotype_and_schizophrenia_may_show_less_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_show_greater_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_show_greater_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics.","CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_olanzapine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine.","CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_greater_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_lower_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain_in_patients_taking_antipsychotics._","CC:Patients_with_the_CC_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""CT:Patients_with_the_CT_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""TT:Patients_with_the_TT_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.";PGKB_RACE=NR,Asian,Asian,NR,White,White,NR,NR
11	27684517	rs11030104	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_show_less_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_show_greater_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_show_greater_resistance_to_treatment_with_antipsychotics_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_antipsychotics.";PGKB_RACE=White
11	27695910	rs10835210	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AC:Patients_with_the_AC_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""CC:Patients_with_the_CC_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
11	27700125	rs7103411	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_a_better_response_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_a_better_response_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype_or_a_poorer_response_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_a_poorer_response_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.";PGKB_RACE=White
11	27722278	rs61888800	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG="antidepressants_(PA452229)""desipramine_(PA449233)""fluoxetine_(PA449673)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Depression_(PA447278)""Depressive_Disorder_Major_(PA447321)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_with_major_depressive_disorder_may_experience_a_greater_response_when_treated_with_desipramine_or_fluoxetine_compared_to_patients_with_the_GT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""GT:Patients_with_the_GT_genotype_with_major_depressive_disorder_may_experience_a_lesser_response_when_treated_with_desipramine_or_fluoxetine_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""TT:Patients_with_the_TT_genotype_with_major_depressive_disorder_may_experience_a_lesser_response_when_treated_with_desipramine_or_fluoxetine_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.";PGKB_RACE=Hispanic_or_Latino
11	27731983	rs7934165	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AG:Patients_with_the_AG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
11	27734420	rs962369	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG="escitalopram_(PA10074)""nortriptyline_(PA450657)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depression_may_have_increased_likelihood_of_suicide_ideation_with_escitalopram_or_nortriptyline_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""CT:Patients_with_the_CT_genotype_and_depression_may_have_increased_likelihood_of_suicide_ideation_with_escitalopram_or_nortriptyline_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""TT:Patients_with_the_TT_genotype_and_depression_may_have_decreased_likelihood_of_suicide_ideation_with_escitalopram_or_nortriptyline_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.";PGKB_RACE=White
11	27749725	rs1491850	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=BDNF_(PA31891);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""CT:Patients_with_the_CT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""TT:Patients_with_the_TT_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
11	34460231	rs1001179	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CAT_(PA26099);PGKB_DRUG=ethanol_(PA448073);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Alcoholism_(PA443309);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_at_decreased_risk_for_alcoholism_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_alcoholism._""CT:Patients_with_the_CT_genotype_may_be_at_increased_risk_for_alcoholism_as_compared_to_patients_with_the_CC_genotype_or_decreased_risk_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_alcoholism._""TT:Patients_with_the_TT_genotype_may_be_at_increased_risk_for_alcoholism_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_alcoholism._";PGKB_RACE=NR
11	34460704	rs10836235	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CAT_(PA26099);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_cardiac_damage_after_anthracycline_exposure_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""CT:Patients_with_the_CT_genotype_may_have_decreased_risk_of_cardiac_damage_after_anthracycline_exposure_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_CT_genotype_may_still_be_at_risk_for_adverse_events_when_exposed_to_anthracyclines_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_cardiac_damage_after_anthracycline_exposure_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_TT_genotype_may_still_be_at_risk_for_adverse_events_when_exposed_to_anthracyclines_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.";PGKB_RACE=White
11	46761055	rs1799963	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=F2_(PA157);PGKB_DRUG=hormonal_contraceptives_for_systemic_use_(PA452637);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Stroke_(PA447054)""Venous_Thrombosis_(PA446969)";PGKB_TEXT="AA:No_evidence_available.""AG:Patients_with_the_AG_genotype_who_are_taking_oral_contraceptives_(OCs)_may_have_an_increased_risk_for_deep_vein_thrombosis_(DVT)_as_compared_to_patients_with_the_GG_genotype_who_are_not_taking_oral_contraceptives._Current_evidence_suggests_that_patients_with_the_AG_mutation_who_are_taking_oral_contraceptives_experience_an_increase_risk_for_DVT_due_to_the_cumulative_effect_of_both_the_contraceptives_and_the_AG_genotype._At_the_time_of_writing_there_are_no_studies_that_show_a_significant_increase_in_risk_for_DVT_when_considering_only_the_AG_genotype._Additionally_some_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_risk_for_DVT_in_patients_taking_oral_contraceptives.""GG:Patients_with_the_GG_genotype_who_are_not_taking_oral_contraceptives_(OCs)_may_have_a_decreased_risk_for_deep_vein_thrombosis_(DVT)_as_compared_to_patients_with_the_AG_genotype_who_are_taking_oral_contraceptives._Current_evidence_suggests_that_patients_with_the_AG_mutation_who_are_taking_oral_contraceptives_experience_an_increase_risk_for_DVT_due_to_the_cumulative_effect_of_both_the_contraceptives_and_the_AG_genotype._At_the_time_of_writing_there_are_no_studies_that_show_a_significant_increase_in_risk_for_DVT_when_considering_only_the_AG_genotype._Additionally_some_contradictory_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_risk_for_DVT_in_patients_taking_oral_contraceptives.";PGKB_RACE=NR
11	47276675	rs11039149	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR1H3_(PA31751);PGKB_DRUG="atenolol_(PA448499)""verapamil_(PA451868)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Hypertension_(PA444552)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_and_coronary_artery_disease_who_are_treated_with_atenolol_and_verapamil_may_have_a_decreased_but_not_absent_risk_for_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiovascular_events.""GA:Patients_with_the_GA_genotype_and_hypertension_and_coronary_artery_disease_who_are_treated_with_atenolol_and_verapamil_may_have_an_increased_risk_for_cardiovascular_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiovascular_events.""GG:Patients_with_the_GG_genotype_and_hypertension_and_coronary_artery_disease_who_are_treated_with_atenolol_and_verapamil_may_have_an_increased_risk_for_cardiovascular_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiovascular_events.";PGKB_RACE=NR
11	47280653	rs12221497	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR1H3_(PA31751);PGKB_DRUG=verapamil_(PA451868);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_who_are_treated_with_verapamil_may_have_decreased_risk_for_primary_outcome_as_defined_by_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.""AG:Patients_with_the_AG_genotype_and_hypertension_who_are_treated_with_verapamil_may_have_decreased_risk_for_primary_outcome_as_defined_by_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_GG_genotype_or_may_have_increased_risk_for_primary_outcome_as_defined_by_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.""GG:Patients_with_the_GG_genotype_and_hypertension_who_are_treated_with_verapamil_may_have_increased_risk_for_primary_outcome_as_defined_by_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.";PGKB_RACE=NR
11	47282024	rs2279238	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR1H3_(PA31751);PGKB_DRUG=verapamil_(PA451868);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_and_coronary_artery_disease_who_are_treated_with_verapamil_may_have_decreased_but_not_absent_risk_for_the_primary_outcome_defined_as_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.""CT:Patients_with_the_CT_genotype_and_hypertension_and_coronary_artery_disease_who_are_treated_with_verapamil_may_have_increased_risk_for_the_primary_outcome_defined_as_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_but_not_absent_risk_for_the_primary_outcome_defined_as_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.""TT:Patients_with_the_TT_genotype_and_hypertension_and_coronary_artery_disease_who_are_treated_with_verapamil_may_have_increased_risk_for_the_primary_outcome_defined_as_first_occurrence_of_all-cause_death_nonfatal_myocardial_infarction_or_nonfatal_stroke_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_verapamil.";PGKB_RACE=NR
11	62758799	rs10792367	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_more_blood_pressure_(BP)_reduction_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GG_or_GC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients_response_to_hydrochlorothiazide.""CG:Patients_with_the_CG_genotype_and_hypertension_may_have_less_blood_pressure_(BP)_reduction_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients_response_to_hydrochlorothiazide.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_less_blood_pressure_(BP)_reduction_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients_response_to_hydrochlorothiazide.";PGKB_RACE=Asian
11	64302950	rs11231809	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A11_(PA38295);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_TT_or_AT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""AT:Patients_with_the_AT_genotype_may_have_decreased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.";PGKB_RACE=NR
11	64360274	rs11231825	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC22A12_(PA38478);PGKB_DRUG="cytarabine_(PA449177)""fludarabine_(PA449655)""gemtuzumab_ozogamicin_(PA164749431)""idarubicin_(PA449961)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_likelihood_of_fever_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_likelihood_of_fever_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""TT:Patients_with_the_TT_genotype_may_have_an_increased_likelihood_of_fever_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_and_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.";PGKB_RACE=NR
11	67352689	rs1695	A	G	.	.	PGKB_INDEX=8;PGKB_GENE=GSTP1_(PA29028),GSTP1_(PA29028),GSTP1_(PA29028),GSTP1_(PA29028),GSTP1_(PA29028),GSTP1_(PA29028),NR,GSTP1_(PA29028);PGKB_DRUG=fluorouracil_(PA128406956),"oxaliplatin_(PA131285527)""Platinum_compounds_(PA164713176)",Platinum_compounds_(PA164713176),Platinum_compounds_(PA164713176),"cisplatin_(PA449014)""cyclophosphamide_(PA449165)","fluorouracil_(PA128406956)""oxaliplatin_(PA131285527)","cyclophosphamide_(PA449165)""epirubicin_(PA449476)",methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Efficacy,Efficacy,Efficacy,"Efficacy""Toxicity/ADR",Toxicity/ADR;PGKB_EVIDENCE=3,3,2A,3,3,2A,2A,3;PGKB_DISEASE=Rectal_Neoplasms_(PA445503),"Carcinoma_Non-Small-Cell_Lung_(PA443622)""Colorectal_Neoplasms_(PA446108)""Gastrointestinal_Neoplasms_(PA444257)""Ovarian_Neoplasms_(PA445204)",Neoplasms_(PA445062),Neoplasms_(PA445062),Ovarian_Neoplasms_(PA445204),Colorectal_Neoplasms_(PA446108),Breast_Neoplasms_(PA443560),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_cancer_who_are_treated_with_fluorouracil_may_have_a_higher_risk_of_hematological_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hematological_toxicity_when_exposed_to_fluorouracil.""AG:Patients_with_the_AG_genotype_and_cancer_who_are_treated_with_fluorouracil_may_have_a_lower_but_not_absent_risk_of_hematological_toxicity_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_higher_risk_of_hematological_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hematological_toxicity_when_exposed_to_fluorouracil.""GG:Patients_with_the_GG_genotype_and_cancer_who_are_treated_with_fluorouracil_may_have_a_lower_but_not_absent_risk_of_hematological_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hematological_toxicity_when_exposed_to_flourouracil.","AA:Patients_with_the_AA_genotype_and_cancer_who_are_treated_with_oxaliplatin_or_platinum_compounds_may_have_an_increased_risk_for_hematological_toxicity_neurotoxicity_neutropenia_and_discontinuation_of_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Conflicting_data_exist_for_the_neurotoxicity_risk_showing_that_patients_with_the_AA_might_have_a_decreased_but_not_absent_risk._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_oxaliplatin_or_platinum_compounds_treatment.""AG:Patients_with_the_AG_genotype_and_cancer_who_are_treated_with_oxaliplatin_or_platinum_compounds_may_have_a_decreased_but_not_absent_risk_for_hematological_toxicity_neurotoxicity_neutropenia_and_discontinuation_of_treatment_as_compared_to_patients_with_the_AA_genotype._Conflicting_data_exist_for_the_neurotoxicity_risk_showing_that_patients_with_the_AG_might_have_an_increased_risk._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_oxaliplatin_or_platinum_compounds_treatment.""GG:Patients_with_the_GG_genotype_and_cancer_who_are_treated_with_oxaliplatin_or_platinum_compounds_may_have_a_decreased_but_not_absent_risk_for_hematological_toxicity_neurotoxicity_neutropenia_and_discontinuation_of_treatment_as_compared_to_patients_with_the_AA_genotype._Conflicting_data_exist_for_the_neurotoxicity_risk_showing_that_patients_with_the_GG_might_have_an_increased_risk._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_oxaliplatin_or_platinum_compounds_treatment.","AA:Patients_with_the_AA_genotype_and_cancer_who_are_treated_with_platinum-based_drugs_may_have_the_highest_risk_of_toxicity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_and_cancer_who_are_treated_with_platinum-based_drugs_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_and_cancer_who_are_treated_with_platinum-based_drugs_may_have_a_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_AG_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","AA:Patients_with_the_AA_genotype_may_have_increased_risk_for_progression_and_decreased_survival_with_platinum-based_treatments_with_colorectal_cancer_as_compared_to_patients_with_the_GG_genotype_but_studies_of_ovarian_cancer_found_increased_survival_and_studies_of_non-small_cell_lung_cancer_found_no_association_with_survival._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_may_have_average_risk_for_progression_with_platinum-based_treatments_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_for_progression_with_platinum-based_treatments_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Patients_with_the_AA_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_an_increased_likelihood_of_progression_free_survival_as_compared_to_patients_with_the_AG_and_GG_genotype._However_this_association_was_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin_and_cyclophosphamide_treatment.""AG:Patients_with_the_AG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_a_decreased_likelihood_of_progression_free_survival_as_compared_to_patients_with_the_AA_genotype._However_this_association_was_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin_and_cyclophosphamide_treatment.""GG:Patients_with_the_GG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_a_decreased_likelihood_of_progression_free_survival_as_compared_to_patients_with_the_AA_genotype._However_this_association_was_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin_and_cyclophosphamide_treatment.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_who_are_treated_with_fluorouracil_and_oxaliplatin_may_have_poorer_treatment_outcome_(reduced_responsiveness_lower_overall_survival_time_increased_risk_of_death)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_and_oxaliplatin_treatment.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_who_are_treated_with_fluorouracil_and_oxaliplatin_may_have_better_treatment_outcome_as_compared_to_patients_with_the_AA_genotype_or_may_have_poorer_treatment_outcome_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_and_oxaliplatin_treatment.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_who_are_treated_with_fluorouracil_and_oxaliplatin_may_have_a_better_treatment_outcome_(increased_response_increased_overall_survival_time_reduced_risk_of_death)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_and_oxaliplatin_treatment.","AA:Patients_with_the_AA_genotype_and_Breast_Neoplasms_who_are_treated_with_cyclophosphamide_and_epirubicin_may_have_1)_increased_drug_response_2)_decreased_severity_of_toxicity_as_compared_to_patients_with_GG_genotype._Some_patients_were_additionally_treated_with_fluorouracil._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_cyclophosphamide_epirubicin_and_fluorouracil.""AG:Patients_with_the_AG_genotype_and_Breast_Neoplasms_who_are_treated_with_cyclophosphamide_and_epirubicin_may_have_1)_increased_drug_response_2)_decreased_severity_of_toxicity_as_compared_to_patients_with_GG_genotype._Some_patients_were_additionally_treated_with_fluorouracilOther_genetic_and_clinical_factors_may_influence_a_patient's_response_to_cyclophosphamide_epirubicin_and_fluorouracil.""GG:Patients_with_the_GG_genotype_and_Breast_Neoplasms_who_are_treated_with_cyclophosphamide_and_epirubicin_may_have_1)_decreased_drug_response_2)_increased_severity_of_toxicity_as_compared_to_patients_with_AG_and_AA_genotype._Some_patients_were_additionally_treated_with_fluorouracil._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_cyclophosphamide_epirubicin_and_fluorouracil.","AA:Patients_with_the_AA_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_a_decreased_likelihood_of_Drug_Toxicity_as_compared_to_patients_with_the_GG_genotype._This_finding_is_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methotrexate_induced_toxicity.""AG:Patients_with_the_AG_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_a_decreased_likelihood_of_Drug_Toxicity_as_compared_to_patients_with_the_GG_genotype._This_finding_is_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methotrexate_induced_toxicity.""GG:Patients_with_the_GG_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_an_increased_likelihood_of_Drug_Toxicity_as_compared_to_patients_with_the_AG_and_AA_genotype._This_finding_is_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methotrexate_induced_toxicity.";PGKB_RACE=White,NR,NR,NR,NR,NR,NR,NR
11	67353579	rs1138272	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=GSTP1_(PA29028),GSTP1_(PA29028);PGKB_DRUG=thiotepa_(PA451668),cisplatin_(PA449014);PGKB_TYPE=NR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Neoplasms_(PA445062),Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_clearance_of_thiotepa_as_compared_to_patients_with_the_TT_genotype.""CT:Patients_with_the_CT_genotype_may_have_decreased_clearance_of_thiotepa_as_compared_to_patients_with_the_TT_genotype.""TT:Patients_with_the_TT_genotype_may_have_increased_clearance_of_thiotepa_as_compared_to_patients_with_the_CT_or_TT_genotype.","CC:Patients_with_the_CC_genotype_and_cancer_may_have_longer_survival_times_when_treated_with_cisplatin_as_compared_to_patients_with_the_CT_or_TT_genotype._However_conflicting_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_survival_time.""CT:Patients_with_the_CT_genotype_and_cancer_may_have_shorter_survival_times_when_treated_with_cisplatin_as_compared_to_patients_with_the_CC_genotype._However_conflicting_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_survival_time.""TT:Patients_with_the_TT_genotype_and_cancer_may_have_shorter_survival_times_when_treated_with_cisplatin_as_compared_to_patients_with_the_CC_genotype._However_conflicting_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_survival_time.";PGKB_RACE=White,NR
11	68450203	rs948854	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=GAL_(PA28529),GAL_(PA28529);PGKB_DRUG="antidepressants_(PA452229)""benzodiazepine_derivatives_(PA10402)""mirtazapine_(PA450522)""Selective_serotonin_reuptake_inhibitors_(PA164713257)",opioids_(PA452618);PGKB_TYPE=Efficacy,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),Opioid-Related_Disorders_(PA445043);PGKB_TEXT="CC:Female_patients_with_the_CC_genotype_and_depression_who_are_treated_with_antidepressants_benzodiazepine_derivatives_mirtazapine_or_selective_serotonin_reuptake_inhibitors_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants._""CT:Female_patients_with_the_CT_genotype_and_depression_who_are_treated_with_antidepressants_benzodiazepine_derivatives_mirtazapine_or_selective_serotonin_reuptake_inhibitors_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants._""TT:Female_patients_with_the_TT_genotype_and_depression_who_are_treated_with_antidepressants_benzodiazepine_derivatives_mirtazapine_or_selective_serotonin_reuptake_inhibitors_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants._","CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_opioid_dependence_upon_exposure_to_opioids._""CT:Patients_with_the_CT_genotype_may_have_a_decreased_risk_of_opioid_dependence_when_exposed_to_opioids_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_opioid_dependence_upon_exposure_to_opioids._""TT:The_TT_genotype_was_not_evaluated_for_its_influence_on_risk_of_opioid_dependence_upon_exposure_to_opioids.Other_clinical_and_genetic_factors_may_also_influence_the_risk_of_opioid_dependence_upon_exposure_to_opioids._";PGKB_RACE=White,White
11	69462910	rs9344	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=CCND1_(PA75),CCND1_(PA75),CCND1_(PA75);PGKB_DRUG=fluorouracil_(PA128406956),cetuximab_(PA10040),methotrexate_(PA450428);PGKB_TYPE=NR,Efficacy,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Colonic_Neoplasms_(PA443756),Colorectal_Neoplasms_(PA446108),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_time-to-tumor_recurrence_when_treated_with_fluorouracil_as_compared_to_patients_with_the_AG_or_GG_genotypes_in_Colonic_Neoplasms_however_the_data_is_from_one_study_including_evaluation_and_validation_cohorts_._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._""AG:Patients_with_the_AG_or_GG_genotypes_may_have_increased_time-to-tumor_recurrence_when_treated_with_fluorouracil_as_compared_to_patients_with_the_AA_genotypes_in_Colonic_Neoplasms_however_the_data_is_from_one_study_including_evaluation_and_validation_cohorts_._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil.""GG:Patients_with_the_AG_or_GG_genotypes_may_have_increased_time-to-tumor_recurrence_when_treated_with_fluorouracil_as_compared_to_patients_with_the_AA_genotypes_in_Colonic_Neoplasms_however_the_data_is_from_one_study_including_evaluation_and_validation_cohorts_._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil.","AA:Patients_with_the_AA_genotype_may_have_increased_survival_when_treated_with_cetuximab_as_compared_to_patients_with_the_AG_or_GG_genotypes_however_the_data_is_from_small_studies_and_there_is_contradictory_data._Other_genetic_and_clinical_factors_may_also_influence_response_to_cetuximab.""AG:Patients_with_the_AG_genotype_may_have_decreased_survival_when_treated_with_cetuximab_as_compared_to_patients_with_the_AA_genotypes_however_the_data_is_from_small_studies_and_there_is_contradictory_data._Other_genetic_and_clinical_factors_may_also_influence_response_to_cetuximab.""GG:Patients_with_the_GG_genotype_may_have_decreased_survival_when_treated_with_cetuximab_as_compared_to_patients_with_the_AA_genotypes_however_the_data_is_from_small_studies_and_there_is_contradictory_data._Other_genetic_and_clinical_factors_may_also_influence_response_to_cetuximab.","AA:Patients_with_the_AA_genotype_may_have_1)_decreased_but_not_absent_risk_for_drug_toxicity_2)_decreased_event_free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_particularly_rs34743033.""AG:Patients_with_the_AG_genotype_may_have_1)_increased_risk_for_drug_toxicity_2)_increased_event_free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_particularly_rs34743033.""GG:Patients_with_the_GG_genotype_may_have_1)_increased_risk_for_drug_toxicity_2)_increased_event_free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_particularly_rs34743033.";PGKB_RACE=NR,NR,White
11	71850130	rs61734430	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=FOLR3_(PA28211);PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_lung_cancer_may_have_a_better_response_to_treatment_with_pemetrexed_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pemetrexed.""CT:Patients_with_the_CT_genotype_and_lung_cancer_may_have_a_poorer_response_to_treatment_with_pemetrexed_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pemetrexed.""TT:Patients_with_the_TT_genotype_and_lung_cancer_may_have_a_poorer_response_to_treatment_with_pemetrexed_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pemetrexed.";PGKB_RACE=NR
11	74883577	rs12422149	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO2B1_(PA35845);PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:No_AA_genotype_carrier_was_found_in_the_study._But_patients_with_the_AG_genotype_and_Asthma_treated_with_montelukast_may_have_significantly_reduced_plasma_concentration_of_montelukast_and_poorer_response_to_montelukast_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.""AG:Patients_with_the_AG_genotype_and_asthma_treated_with_montelukast_may_have_significantly_reduced_plasma_concentration_of_montelukast_and_poorer_response_to_montelukast_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.""GG:Patients_with_the_GG_genotype_and_Asthma_treated_with_montelukast_may_have_higher_plasma_concentration_of_montelukast_and_better_response_to_montelukast_compared_to_patients_with_the_GA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.";PGKB_RACE=NR
11	74907582	rs2306168	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO2B1_(PA35845);PGKB_DRUG=fexofenadine_(PA449621);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_fexofenadine_may_have_increased_area_under_the_plasma_concentration-time_curve_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fexofenadine.""CT:Patients_with_the_CT_genotype_who_are_treated_with_fexofenadine_may_have_decreased_area_under_the_plasma_concentration-time_curve_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fexofenadine.""TT:Patients_with_the_TT_genotype_who_are_treated_with_fexofenadine_may_have_decreased_area_under_the_plasma_concentration-time_curve_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_fexofenadine.";PGKB_RACE=NR
11	82564294	rs2229437	T	G,A	.	.	PGKB_INDEX=1;PGKB_GENE=PRCP_(PA33705);PGKB_DRUG=benazepril_(PA448561);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_decreased_response_when_treated_with_benazepril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril.""GT:Patients_with_the_GT_genotype_and_hypertension_may_have_a_decreased_response_when_treated_with_benazepril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_an_increased_response_when_treated_with_benazepril_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril.";PGKB_RACE=Asian
11	94132139	rs3758785	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=GPR83_(PA28927),GPR83_(PA28927);PGKB_DRUG=hydrochlorothiazide_(PA449899),candesartan_(PA448765);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Essential_hypertension_(PA447288),Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_hydrochlorothiazide_in_people_with_essential_hypertension_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_hydrochlorothiazide.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_hydrochlorothiazide_in_people_with_essential_hypertension_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_hydrochlorothiazide.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_hydrochlorothiazide_in_people_with_essential_hypertension_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_hydrochlorothiazide.","AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_candesartan_in_people_with_essential_hypertension_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_candesartan.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_candesartan_in_people_with_essential_hypertension_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_candesartan.""GG:Patients_with_the_GG_genotype_may_have_increased_response_to_candesartan_in_people_with_essential_hypertension_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_candesartan.";PGKB_RACE=White,White
11	102715947	rs3025058	G	GA	.	.	PGKB_INDEX=2;PGKB_GENE=MMP3_(PA30886),MMP3_(PA30886);PGKB_DRUG=pravastatin_(PA451089),"chlorthalidone_(PA448970)""lisinopril_(PA450242)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796),Hypertension_(PA444552);PGKB_TEXT="A/del:Patients_with_the_A/del_genotype_and_Coronary_Artery_Disease_may_be_more_likely_to_benefit_from_pravastatin_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""AA:Patients_with_the_AA_genotype_and_Coronary_Artery_Disease_may_be_more_likely_to_benefit_from_pravastatin_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""del/del:Patients_with_the_del/del_genotype_and_Coronary_Artery_Disease_may_be_less_likely_to_benefit_from_pravastatin_treatment_as_compared_to_patients_with_the_AA_or_A/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","A/del:Patients_with_the_A/del_genotype_and_hypertension_may_have_a_decreased_risk_of_stroke_when_treated_with_lisinopril_as_compared_to_patients_with_the_AA_genotype_who_are_treated_with_chlorthalidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_of_stroke._""AA:Patients_with_the_AA_genotype_and_hypertension_may_have_an_increased_risk_of_stroke_when_treated_with_lisinopril_as_compared_to_patients_with_the_AA_genotype_treated_with_chlorthalidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_of_stroke._""del/del:Patients_with_the_del/del_genotype_and_hypertension_may_have_a_decreased_risk_of_stroke_when_treated_with_lisinopril_as_compared_to_patients_with_the_AA_genotype_who_are_treated_with_chlorthalidone._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_and_risk_of_stroke._";PGKB_RACE=NR,NR
11	103418158	rs716274	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=DYNC2H1_(PA27433);PGKB_DRUG="etoposide_(PA449552)""Platinum_compounds_(PA164713176)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_Death_when_treated_with_etoposide_and_Platinum_compounds_in_people_with_Carcinoma_Small_Cell_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_etoposide_and_Platinum_compounds.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Death_when_treated_with_etoposide_and_Platinum_compounds_in_people_with_Carcinoma_Small_Cell_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_etoposide_and_Platinum_compounds.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_Death_when_treated_with_etoposide_and_Platinum_compounds_in_people_with_Carcinoma_Small_Cell_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_etoposide_and_Platinum_compounds.";PGKB_RACE=Asian
11	108283161	rs11212617	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=C11orf65_(PA144596484);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_CC_genotype._An_association_with_increased/decreased_response_to_metformin_was_not_seen_in_people_with_impaired_glucose_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""AC:Patients_with_the_AC_genotype_with_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_an_increased_response_to_metformin_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_decreased_response_to_metformin_as_compared_to_patients_with_the_CC_genotype._An_association_with_increased/decreased_response_to_metformin_was_not_seen_in_people_with_impaired_glucose_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""CC:Patients_with_the_CC_genotype_with_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_an_increased_response_to_metformin_as_compared_to_patients_with_the_AA_genotype._An_association_with_increased/decreased_response_to_metformin_was_not_seen_in_people_with_impaired_glucose_tolerance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.";PGKB_RACE=NR
11	112026156	rs5744247	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL18_(PA29802);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=liver_transplantation_(PA447247);PGKB_TEXT="CC:Patients_who_are_undergoing_liver_transplant_and_receive_a_liver_with_the_CC_genotype_may_have_decreased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_concentration_of_tacrolimus.""CG:Patients_who_are_undergoing_liver_transplant_and_receive_a_liver_with_the_CG_genotype_may_have_increased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_concentration_of_tacrolimus.""GG:Patients_who_are_undergoing_liver_transplant_and_receive_a_liver_with_the_GG_genotype_may_have_increased_concentrations_of_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_such_as_CYP3A5*3_may_also_influence_concentration_of_tacrolimus.";PGKB_RACE=Asian
11	112035458	rs1946518	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=IL18_(PA29802);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_kidney_transplantation_may_experience_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_tacrolimus._""GT:Patients_with_the_GT_genotype_and_kidney_transplantation_may_experience_decreased_metabolism_of_tacrolimus_resulting_in_increased_exposure_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_tacrolimus._""TT:Patients_with_the_TT_genotype_and_kidney_transplantation_may_experience_increased_metabolism_of_tacrolimus_resulting_in_decreased_exposure_as_compared_to_patients_with_the_GG_and_GT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_tacrolimus._";PGKB_RACE=Asian
11	113266821	rs7118900	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ANKK1_(PA134872551);PGKB_DRUG=methadone_(PA450401);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AG:Patients_with_the_AG_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""GG:Patients_with_the_GG_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._";PGKB_RACE=NR
11	113270828	rs1800497	G	A	.	.	PGKB_INDEX=9;PGKB_GENE=ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551),ANKK1_(PA134872551);PGKB_DRUG="Drugs_used_in_nicotine_dependence_(PA164712720)""nicotine_(PA450626)",disulfiram_(PA449376),bupropion_(PA448687),"antipsychotics_(PA452233)""clozapine_(PA449061)""olanzapine_(PA450688)""risperidone_(PA451257)",nemonapride_(PA151186253),risperidone_(PA451257),ethanol_(PA448073),olanzapine_(PA450688),valproic_acid_(PA451846);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Toxicity/ADR,Toxicity/ADR,Efficacy,Toxicity/ADR,Metabolism/PK,Toxicity/ADR;PGKB_EVIDENCE=3,3,1B,2B,3,3,2B,3,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),Cocaine-Related_Disorders_(PA446878),Tobacco_Use_Disorder_(PA445876),"Hyperprolactinemia_(PA444545)""Weight_gain_(PA128406954)",Schizophrenia_(PA447216),Schizophrenia_(PA447216),Alcoholism_(PA443309),NR,Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_an_increased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.""AG:Patients_with_AG_genotype_may_have_an_increased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.""GG:Patients_with_GG_genotype_may_have_a_decreased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_as_compared_to_patients_with_the_AG_and_AA_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.","AA:Patients_with_the_AA_genotype_may_have_an_increased_likelihood_of_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_disulfiram._""AG:Patients_with_the_AG_genotype_may_have_an_increased_likelihood_of_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_disulfiram.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_likelihood_of_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_AG_or_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_disulfiram.","AA:Patients_with_the_AA_genotype_who_are_treated_with_bupropion_may_be_less_likely_to_quit_smoking_as_compared_to_patients_with_the_GG_genotype_although_this_has_been_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_quitting_smoking.""AG:Patients_with_the_AG_genotype_who_are_treated_with_bupropion_may_be_less_likely_to_quit_smoking_as_compared_to_patients_with_the_GG_genotype_although_this_has_been_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_quitting_smoking.""GG:Patients_with_the_GG_genotype_who_are_treated_with_bupropion_may_be_more_likely_to_quit_smoking_as_compared_to_patients_with_the_AA_or_AG_genotypes_although_this_has_been_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_quitting_smoking.","AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_side_effects_including_hyperprolactinemia_and_weight_gain_during_treatment_with_antipsychotic_drugs_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_side_effects_including_hyperprolactinemia_and_weight_gain_during_treatment_with_antipsychotic_drugs_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects.""GG:Patients_with_the_GG_genotype_may_have_decreased_but_not_non-existent_risk_of_side_effects_including_hyperprolactinemia_and_weight_gain_during_treatment_with_antipsychotic_drugs_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects.","AA:Female_patients_with_the_AA_genotype_and_schizophrenia_treated_with_nemonapride_may_have_a_greater_prolactin_response_to_nemonapride_compared_to_female_patients_with_the_GG_genotype_and_male_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nemonapride.""AG:Female_patients_with_the_AG_genotype_and_schizophrenia_treated_with_nemonapride_may_have_a_greater_prolactin_response_to_nemonapride_compared_to_female_patients_with_the_GG_genotype_and_male_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nemonapride.""GG:Female_patients_with_the_GG_genotype_and_schizophrenia_treated_with_nemonapride_may_have_a_decreased_but_not_absent_prolactin_response_to_nemonapride_compared_to_female_patients_with_the_AG_and_AA_genotype_and_male_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nemonapride.","AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""AG:Patients_with_the_AG_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype_or_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.","AA:Patients_with_AA_genotype_may_have_an_increased_risk_for_Alcoholism_when_exposed_to_ethanol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_alcohol_dependency.""AG:Patients_with_AG_genotype_may_have_an_increased_risk_for_Alcoholism_when_exposed_to_ethanol_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_alcohol_dependency.""GG:Patients_with_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_Alcoholism_when_exposed_to_ethanol_as_compared_to_patients_with_the_AG_and_AA_genotype._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_alcohol_dependency.","AA:Individuals_with_the_AA_genotype_may_have_increased_area_under_the_curve_(AUC)_of_olanzapine_as_compared_to_individuals_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_AUC_of_olanzapine.""AG:Individuals_with_the_AG_genotype_may_have_increased_area_under_the_curve_(AUC)_of_olanzapine_as_compared_to_individuals_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_AUC_of_olanzapine.""GG:Individuals_with_the_GG_genotype_may_have_decreased_area_under_the_curve_(AUC)_of_olanzapine_as_compared_to_individuals_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_AUC_of_olanzapine.","AA:Patients_with_the_AA_genotype_and_epilepsy_may_have_lower_weight_gain_when_treated_with_valproic_acid_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""AG:Patients_with_the_AG_genotype_and_epilepsy_may_have_greater_weight_gain_when_treated_with_valproic_acid_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""GG:Patients_with_the_GG_genotype_and_epilepsy_may_have_greater_weight_gain_when_treated_with_valproic_acid_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.";PGKB_RACE=White,NR,NR,NR,Asian,Asian,NR,White,Asian
11	113280274	rs2734842	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Female_patients_with_the_CC_genotype_may_have_decreased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""CG:Female_patients_with_the_CG_genotype_may_have_increased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""GG:Female_patients_with_the_GG_genotype_may_have_increased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=White
11	113281776	rs2734841	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Female_patients_with_the_AA_genotype_may_have_increased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""AC:Female_patients_with_the_AC_genotype_may_have_increased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""CC:Female_patients_with_the_CC_genotype_may_have_decreased_prolactin_when_treated_with_olanzapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=White
11	113282295	rs1124493	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Female_patients_with_the_GG_genotype_may_have_decreased_prolactin_serum_concentration_when_treated_with_olanzapine_as_compared_to_female_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""GT:Female_patients_with_the_GT_genotype_may_have_increased_prolactin_serum_concentration_when_treated_with_olanzapine_as_compared_to_female_patients_with_the_GG_genotype_and_decreased_prolactin_serum_concentration_when_treated_with_olanzapine_as_compared_to_female_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""TT:Female_patients_with_the_TT_genotype_may_have_increased_prolactin_serum_concentration_when_treated_with_olanzapine_as_compared_to_female_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=White
11	113283459	rs6277	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=DRD2_(PA27478),DRD2_(PA27478);PGKB_DRUG="antipsychotics_(PA452233)""clozapine_(PA449061)""olanzapine_(PA450688)",aripiprazole_(PA10026);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_for_weight_gain_when_treated_with_clozapine_or_olanzepine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_side-effects.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_weight_gain_when_treated_with_clozapine_or_olanzepine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_side-effects.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_weight_gain_when_treated_with_clozapine_or_olanzepine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_side-effects.","AA:Patients_with_the_genotype_AA_may_have_increased_response_to_aripiprazole_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_aripiprazole.""GA:Patients_with_the_genotype_GG_may_have_decreased_response_to_aripiprazole_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_AA._Though_this_association_was_found_not_statistically_significant._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_aripiprazole.""GG:Patients_with_the_genotype_GG_may_have_decreased_response_to_aripiprazole_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_aripiprazole.";PGKB_RACE=White,Asian
11	113283477	rs6275	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=DRD2_(PA27478),DRD2_(PA27478),DRD2_(PA27478);PGKB_DRUG=methadone_(PA450401),methadone_(PA450401),"Analgesics_(PA164712362)""Antiinflammatory_agents_non-steroids_(PA164712462)""Ergot_alkaloids_(PA164712741)""opioids_(PA452618)""sumatriptan_(PA451566)";PGKB_TYPE=Dosage,Dosage,Other;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Heroin_Dependence_(PA444460),Heroin_Dependence_(PA444460),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Heroin_Dependence_may_require_an_increased_dose_of_methadone_as_compared_to_patients_with_the_GG_genotype._This_was_seen_in_White_patients_-_the_opposite_association_was_seen_in_a_different_study_with_Asian_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.""AG:Patients_with_the_AG_genotype_and_Heroin_Dependence_may_require_an_increased_dose_of_methadone_as_compared_to_patients_with_the_GG_genotype._This_was_seen_in_White_patients_-_the_opposite_association_was_seen_in_a_different_study_with_Asian_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.""GG:Patients_with_the_GG_genotype_and_Heroin_Dependence_may_require_a_decreased_dose_of_methadone_as_compared_to_patients_with_the_AA_genotype._This_was_seen_in_White_patients_-_the_opposite_association_was_seen_in_a_different_study_with_Asian_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.","AA:Patients_with_the_AA_genotype_and_Heroin_Dependence_may_require_a_decreased_dose_of_methadone_as_compared_to_patients_with_the_GG_genotype._This_was_seen_in_Asian_patients_-_the_opposite_association_was_seen_in_a_different_study_with_White_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.""AG:Patients_with_the_AG_genotype_and_Heroin_Dependence_may_require_a_decreased_dose_of_methadone_as_compared_to_patients_with_the_GG_genotype_or_may_require_an_increased_dose_of_methadone_as_compared_to_patients_with_the_AA_genotype._This_was_seen_in_Asian_patients_-_the_opposite_association_was_seen_in_a_different_study_with_White_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.""GG:Patients_with_the_GG_genotype_and_Heroin_Dependence_may_require_an_increased_dose_of_methadone_as_compared_to_patients_with_the_AA_genotype._This_was_seen_in_Asian_patients_-_the_opposite_association_was_seen_in_a_different_study_with_White_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.","AA:Patients_with_the_AA_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""AG:Patients_with_the_AG_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""GG:Patients_with_the_GG_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.";PGKB_RACE=White,Asian,NR
11	113283688	rs1076560	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_genotype_AA_and_schizophrenia_may_have_increased_response_to_olanzapine_compared_to_patients_with_CC_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_olanzapine.""AC:Patients_with_genotype_AC_and_schizophrenia_may_have_increased_response_to_olanzapine_compared_to_patients_with_CC_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_olanzapine.""CC:Patients_with_genotype_CC_and_schizophrenia_may_have_decreased_response_to_olanzapine_compared_to_patients_with_AA_or_AC_genotype._Other_clinical_and_genetic_factors_may_affect_a_patient's_response_to_olanzapine.";PGKB_RACE=NR
11	113285536	rs2283265	C	A	.	.	PGKB_INDEX=2;PGKB_GENE=DRD2_(PA27478),DRD2_(PA27478);PGKB_DRUG=methadone_(PA450401),disulfiram_(PA449376);PGKB_TYPE=Dosage,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Heroin_Dependence_(PA444460)""Opioid-Related_Disorders_(PA445043)",Cocaine-Related_Disorders_(PA446878);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""AC:Patients_with_the_AC_genotype_and_heroin_addiction_may_require_a_lower_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._""CC:Patients_with_the_CC_genotype_and_heroin_addiction_may_require_a_higher_dose_of_methadone_when_undergoing_methadone_maintenance_treatment_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_methadone_dose_required_for_effective_treatment._","AA:Patients_with_the_AA_genotype_may_have_an_increased_likelihood_of_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_disulfiram.""AC:Patients_with_the_AC_genotype_may_have_an_increased_likelihood_of_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_disulfiram.""CC:Patients_with_the_CC_genotype_may_have_a_decreased_likelihood_of_response_when_treated_with_disulfiram_as_compared_to_patients_with_the_AC_or_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_disulfiram.";PGKB_RACE=NR,NR
11	113286878	rs2440390	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Mental_Disorders_(PA447208);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_mental_disorders_may_have_decreased_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""CT:Patients_with_the_CT_genotype_and_mental_disorders_may_have_increased_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype_or_decreased_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""TT:Patients_with_the_TT_genotype_and_mental_disorders_may_have_increased_weight_gain_when_treated_with_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.";PGKB_RACE=White
11	113292920	rs2734833	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_late_decrease_in_the_percentage_of_HAMD_scores_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""AG:Patients_with_the_AG_genotype_and_major_depression_may_have_early_decrease_in_the_percentage_of_HAMD_scores_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_AA_genotype_or_may_have_late_decrease_in_the_percentage_of_HAMD_scores_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_early_decrease_in_the_percentage_of_HAMD_scores_when_treated_with_Selective_serotonin_reuptake_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.";PGKB_RACE=Asian
11	113296274	rs1079598	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG="antipsychotics_(PA452233)""clozapine_(PA449061)""olanzapine_(PA450688)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_for_weight_gain_when_treated_with_clozapine_or_olanzepine_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_side-effects.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_weight_gain_when_treated_with_clozapine_or_olanzepine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_side-effects.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_weight_gain_when_treated_with_clozapine_or_olanzepine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_side-effects.";PGKB_RACE=White
11	113296286	rs1079597	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG=amisulpride_(PA162565877);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_an_increased_response_according_to_the_PANSS_negative_symptoms_scale_when_treated_with_amisulpride_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_amisulpride.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_decreased_response_according_to_the_PANSS_negative_symptoms_scale_when_treated_with_amisulpride_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_amisulpride.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_decreased_response_according_to_the_PANSS_negative_symptoms_scale_when_treated_with_amisulpride_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_amisulpride.";PGKB_RACE=Asian
11	113306765	rs4436578	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG="clozapine_(PA449061)""olanzapine_(PA450688)""risperidone_(PA451257)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Schizophrenia_may_have_increased_risk_for_body_weight_gain_when_treated_with_clozapine_olanzapine_or_risperidone_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine_olanzapine_or_risperidone.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_may_have_decreased_risk_for_body_weight_gain_when_treated_with_clozapine_olanzapine_or_risperidone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine_olanzapine_or_risperidone.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_may_have_decreased_risk_for_body_weight_gain_when_treated_with_clozapine_olanzapine_or_risperidone_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine_olanzapine_or_risperidone.";PGKB_RACE=Asian
11	113321796	rs4460839	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="DRD2_(PA27478)""MIR4301_(PA165543477)";PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_who_are_treated_with_Selective_serotonin_reuptake_inhibitors_may_have_early_decrease_in_the_percentage_of_HAMD_scores_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""CT:Patients_with_the_CT_genotype_and_major_depression_who_are_treated_with_Selective_serotonin_reuptake_inhibitors_may_have_early_decrease_in_the_percentage_of_HAMD_scores_as_compared_to_patients_with_the_TT_genotype_or_may_have_late_decrease_in_the_percentage_of_HAMD_scores_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""TT:Patients_with_the_TT_genotype_and_major_depression_who_are_treated_with_Selective_serotonin_reuptake_inhibitors_may_have_late_decrease_in_the_percentage_of_HAMD_scores_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.";PGKB_RACE=Asian
11	113346251	rs1799732	T	TG	.	.	PGKB_INDEX=1;PGKB_GENE=DRD2_(PA27478);PGKB_DRUG="antipsychotics_(PA452233)""aripiprazole_(PA10026)""bromperidol_(PA165282097)""chlorpromazine_(PA448964)""clozapine_(PA449061)""nemonapride_(PA151186253)""olanzapine_(PA450688)""risperidone_(PA451257)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="G/G:Patients_with_the_G/G_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_1)_may_have_an_increased_response_2)_may_have_decreased_time_until_response_compared_to_patients_with_the_del/del_or_G/del_genotype._Please_note_that_there_is_contradictory_evidence_from_studies_that_report_no_association_with_this_allele_and_response_to_antipsychotics._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""G/del:Patients_with_the_G/del_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_1)_may_have_decreased_response_2)_may_have_increased_time_until_response_compared_to_patients_with_the_GG_genotype._Please_note_that_there_is_contradictory_evidence_from_studies_that_report_no_association_with_these_alleles_and_response_to_antipsychotics._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""del/del:Patients_with_the_del/del_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_1)_may_have_decreased_response_2)_may_have_increased_time_until_response_compared_to_patients_with_the_GG_genotype._Please_note_that_there_is_contradictory_evidence_from_studies_that_report_no_association_with_this_allele_and_response_to_antipsychotics._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.";PGKB_RACE=NR
11	113346351	rs1799978	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=DRD2_(PA27478),DRD2_(PA27478),DRD2_(PA27478);PGKB_DRUG=risperidone_(PA451257),risperidone_(PA451257),"olanzapine_(PA450688)""risperidone_(PA451257)";PGKB_TYPE=Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=2A,3,3;PGKB_DISEASE=Schizophrenia_(PA447216),NR,Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_less_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_TC_And_TT_genotype.""CT:Patients_with_the_TC_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.","CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Hyperprolactinemia_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Hyperprolactinemia_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_absent_risk_of_Hyperprolactinemia_when_treated_with_risperidone_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","CC:Patients_with_the_CC_genotype_and_Schizophrenia_who_are_treated_with_olanzapine_or_risperidone_may_have_decreased_time_until_response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_or_risperidone.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_who_are_treated_with_olanzapine_or_risperidone_may_have_decreased_time_until_response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_or_risperidone.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_who_are_treated_with_olanzapine_or_risperidone_may_have_increased_time_until_response_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_or_risperidone.";PGKB_RACE=Asian,White,NR
11	113803028	rs1176744	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=HTR3B_(PA29556);PGKB_DRUG=paroxetine_(PA450801);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Mental_Disorders_(PA447208);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Mental_Disorders_who_are_treated_with_paroxetine_may_have_an_increased_risk_of_nausea_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""AC:Patients_with_the_AC_genotype_and_Mental_Disorders_who_are_treated_with_paroxetine_may_have_a_decreased_risk_of_nausea_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""CC:Patients_with_the_CC_genotype_and_Mental_Disorders_who_are_treated_with_paroxetine_may_have_a_decreased_risk_of_nausea_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.";PGKB_RACE=Asian
11	113803887	rs2276307	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HTR3B_(PA29556);PGKB_DRUG="atorvastatin_(PA448500)""pravastatin_(PA451089)""simvastatin_(PA451363)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Myalgia_unspecified_(PA157379134);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_may_have_a_decreased_but_not_absent_risk_of_statin-related_myalgia_as_compared_to_patients_with_the_GG_or_GA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_myalgia.""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_may_have_an_increased_risk_of_statin-related_myalgia_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_decreased_but_not_absent_risk_statin-related_myalgia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_myalgia.""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_may_have_an_increased_risk_of_statin-related_myalgia_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_myalgia.";PGKB_RACE=NR
11	113845541	rs1150226	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HTR3A_(PA29555);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_as_part_of_a_haplotype_rs2276302-rs1062613-rs1150226_and_Schizophrenia_who_are_treated_with_clozapine_may_have_a_decreased_response_as_compared_to_patients_with_the_GG_genotype_as_part_of_a_haplotype_rs2276302-rs1062613-rs1150226._However_only_a_trend_of_association_is_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""GA:Patients_with_the_GA_genotype_as_part_of_a_haplotype_rs2276302-rs1062613-rs1150226_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_as_compared_to_patients_with_the_AA_genotype_as_part_of_a_haplotype_rs2276302-rs1062613-rs1150226._However_only_a_trend_of_association_is_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.""GG:Patients_with_the_GG_genotype_as_part_of_a_haplotype_rs2276302-rs1062613-rs1150226_and_Schizophrenia_who_are_treated_with_clozapine_may_have_an_increased_response_as_compared_to_patients_with_the_AA_genotype_as_part_of_a_haplotype_rs2276302-rs1062613-rs1150226._However_only_a_trend_of_association_is_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clozapine.";PGKB_RACE=NR
11	113846006	rs1062613	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=HTR3A_(PA29555);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_be_less_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_be_less_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_TT_genotype_or_may_be_more_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_be_more_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.";PGKB_RACE=NR
11	113850140	rs2276302	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=HTR3A_(PA29555);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_may_be_less_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_be_less_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_GG_genotype_or_more_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_be_more_likely_to_respond_to_treatment_with_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.";PGKB_RACE=NR
11	116648917	rs964184	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=APOA1_(PA49);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertriglyceridemia_(PA446120);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""CG:Patients_with_the_CG_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype_or_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.""GG:Patients_with_the_GG_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate.";PGKB_RACE=NR
11	116663707	rs662799	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=APOA5_(PA24888);PGKB_DRUG="atorvastatin_(PA448500)""lovastatin_(PA450272)""simvastatin_(PA451363)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hyperlipidemias_(PA444528);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hyperlipidemia_who_are_treated_with_atorvastatin_lovastatin_or_simvastatin_may_have_a_higher_reduction_in_LDL-cholesterol_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""AG:Patients_with_the_AG_genotype_and_Hyperlipidemia_who_are_treated_with_atorvastatin_lovastatin_or_simvastatin_may_have_less_reduction_in_LDL-cholesterol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_and_Hyperlipidemia_who_are_treated_with_atorvastatin_lovastatin_or_simvastatin_may_have_less_reduction_in_LDL-cholesterol_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._";PGKB_RACE=White
11	116700142	rs2854117	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="APOA4_(PA24887)""APOC3_(PA53)";PGKB_DRUG=ritonavir_(PA451260);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)""Hyperlipidemias_(PA444528)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_lower_triglyceride_levels_(lower_risk_of_Hypertriglyceridemia)_as_compared_to_patients_with_the_TC_or_TT_genotype._Patients_with_the_CC_genotype_may_still_be_at_risk_for_toxicity_when_taking_ritonavir._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.""CT:Patients_with_the_TC_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_higher_triglyceride_(increased_risk_of_Hypertriglyceridemia)_levels_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""TT:Patients_with_the_TT_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_higher_triglyceride_levels_(increased_risk_of_Hypertriglyceridemia)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=NR
11	116700169	rs2854116	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="APOA4_(PA24887)""APOC3_(PA53)";PGKB_DRUG=ritonavir_(PA451260);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)""Hyperlipidemias_(PA444528)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_decreased_severity_of_triglyceride_elevation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.""CT:Patients_with_the_CT_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_decreased_severity_of_triglyceride_elevation_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.""TT:Patients_with_the_TT_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_increased_severity_of_triglyceride_elevation_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.";PGKB_RACE=NR
11	116703640	rs5128	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=APOC3_(PA53);PGKB_DRUG=ritonavir_(PA451260);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)""Hyperlipidemias_(PA444528)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_an_increased_risk_of_triglyceride_elevation_as_compared_to_patients_with_the_CG_or_GG_genotype.""CG:Patients_with_the_CG_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_a_decreased_but_not_absent_risk_of_triglyceride_elevation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_triglyceride_elevation.""GG:Patients_with_the_GG_genotype_and_HIV_who_are_treated_with_ritonavir_may_have_a_decreased_but_not_absent_risk_of_triglyceride_elevation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_triglyceride_elevation.";PGKB_RACE=White
11	120663363	rs1954787	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=GRIK4_(PA28976),GRIK4_(PA28976);PGKB_DRUG=antidepressants_(PA452229),citalopram_(PA449015);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=2B,1B;PGKB_DISEASE="Depression_(PA447278)""Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)",Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Depressive_Disorder_or_Depression_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressants._""CT:Patients_with_the_CT_genotype_and_Depressive_Disorder_or_Depression_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressants._""TT:Patients_with_the_TT_genotype_and_Depressive_Disorder_or_Depression_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressants._","CC:Patients_with_the_CC_genotype_may_have_an_increased_chance_of_response_to_citalopram_treatment_as_compared_to_patients_with_the_TT_genotype._Patients_with_the_CC_genotype_may_still_be_at_risk_for_non-response_to_citalopram_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_chance_of_response_to_citalopram_treatment_as_compared_to_patients_with_the_TT_genotype._Patients_with_the_CT_genotype_may_still_be_at_risk_for_non-response_to_citalopram_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_chance_of_response_to_citalopram_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.";PGKB_RACE=NR,NR
11	128728067	rs658903	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=KCNJ1_(PA213);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Diabetes_Mellitus_(PA443886)""Hypertension_(PA444552)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_hydrochlorothiazide.""AT:Patients_with_the_AT_genotype_may_have_decreased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_hydrochlorothiazide.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_genotype_AA_or_AT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_hydrochlorothiazide.";PGKB_RACE=Hispanic_or_Latino
11	128730876	rs12795437	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNJ1_(PA213);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Diabetes_Mellitus_(PA443886)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""CG:Patients_with_the_CG_genotype_may_have_increased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.";PGKB_RACE=NR
11	128733314	rs11600347	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=KCNJ1_(PA213);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_genotype_CC._This_association_is_more_significant_in_white_than_in_Hispanic._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_hydrochlorothiazide.""AC:Patients_with_the_AC_genotype_may_have_increased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_genotype_CC._This_association_is_more_significant_in_white_than_in_Hispanic._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_hydrochlorothiazide.""CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Diabetes_Mellitus_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_genotype_AA_or_AC._This_association_is_more_significant_in_white_than_in_Hispanic._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_hydrochlorothiazide.";PGKB_RACE=NR
12	988558	rs880054	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=WNK1_(PA33782);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_reduction_in_systolic_blood_pressure_(SBP)_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""CT:Patients_with_the_CT_genotype_may_have_increased_reduction_in_systolic_blood_pressure_(SBP)_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""TT:Patients_with_the_TT_genotype_may_have_decreased_reduction_in_systolic_blood_pressure_(SBP)_when_treated_with_hydrochlorothiazide_in_people_with_Hypertension_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.";PGKB_RACE=NR
12	1021813	rs11226	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RAD52_(PA34180);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_similar_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""AG:Patients_with_the_AG_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""GG:Patients_with_the_GG_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._";PGKB_RACE=NR
12	1756665	rs12819505	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=WNT5B_(PA38104);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.";PGKB_RACE=NR
12	2222732	rs2238032	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1C_(PA83);PGKB_DRUG=calcium_channel_blockers_(PA10407);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_calcium_channel_blockers.""GT:Patients_with_the_GT_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_calcium_channel_blockers.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_a_better_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_calcium_channel_blockers.";PGKB_RACE=White
12	2316195	rs10848635	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1C_(PA83);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_increased_risk_of_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""AT:Patients_with_the_AT_genotype_and_major_depression_may_have_increased_risk_of_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype_or_may_have_decreased_but_not_absent_risk_of_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""TT:Patients_with_the_TT_genotype_and_major_depression_may_have_decreased_but_not_absent_risk_of_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=White
12	2345295	rs1006737	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1C_(PA83);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_increased_risk_for_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_citalopram._""AG:Patients_with_the_AG_genotype_and_major_depression_may_have_increased_risk_for_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_but_not_absent_risk_for_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_citalopram._""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_decreased_but_not_absent_risk_for_suicide_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_citalopram._";PGKB_RACE=White
12	2447414	rs2239050	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1C_(PA83);PGKB_DRUG=calcium_channel_blockers_(PA10407);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_GG_genotype._However_no_significant_association_was_seen_in_a_subpopulation_of_patients_taking_only_losartan_nifedipine_or_nitrendipine._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.""CG:Patients_with_the_CG_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_GG_genotype._However_no_significant_association_was_seen_in_a_subpopulation_of_patients_taking_only_losartan_nifedipine_or_nitrendipine._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.""GG:Patients_with_the_GG_genotype_and_hypertension_may_have_a_better_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.";PGKB_RACE=White
12	2757769	rs2239128	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1C_(PA83);PGKB_DRUG=calcium_channel_blockers_(PA10407);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_may_have_a_better_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_TT_genotype._However_no_significant_association_was_seen_in_a_subpopulation_of_patients_taking_only_losartan_nifedipine_or_nitrendipine._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.""CT:Patients_with_the_CT_genotype_and_hypertension_may_have_a_better_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_TT_genotype_or_a_poorer_blood_pressure_response_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_calcium_channel_blockers_including_amlodipine_felodipine_losartan_nifedipine_or_nitrendipine_as_compared_to_patients_with_the_CC_genotype._However_no_significant_association_was_seen_in_a_subpopulation_of_patients_taking_only_losartan_nifedipine_or_nitrendipine._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.";PGKB_RACE=White
12	2788879	rs1051375	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CACNA1C_(PA83);PGKB_DRUG="atenolol_(PA448499)""verapamil_(PA451868)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Hypertension_(PA444552)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_hypertension_and_stable_coronary_artery_disease_are_more_likely_to_benefit_from_treatment_with_verapamil_compared_to_treatment_with_atenolol._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""AG:Patients_with_the_AG_genotype_hypertension_and_stable_coronary_artery_disease_may_respond_similarily_to_treatment_with_atenolol_or_verapamil._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""GG:Patients_with_the_GG_genotype_hypertension_and_stable_coronary_artery_disease_are_more_likely_to_benefit_from_treatment_with_atenolol_compared_to_treatment_with_verapamil._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.";PGKB_RACE=NR
12	6450945	rs767455	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=TNFRSF1A_(PA36609),TNFRSF1A_(PA36609);PGKB_DRUG="adalimumab_(PA10004)""etanercept_(PA449515)""infliximab_(PA452639)",Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Arthritis_Psoriatic_(PA446198),Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_psoriatic_arthritis_may_have_a_decreased_response_after_3_months_of_treatment_with_adalimumab_etanercept_or_infliximab_as_compared_to_patients_with_the_TT_genotype._No_significant_associations_were_seen_after_6_months_of_treatment._Other_genetic_and_clinical_factors_may_also_influence_response_to_adalimumab_etanercept_or_infliximab.""CT:Patients_with_the_CT_genotype_and_psoriatic_arthritis_may_have_a_decreased_response_after_3_months_of_treatment_with_adalimumab_etanercept_or_infliximab_as_compared_to_patients_with_the_TT_genotype._No_significant_associations_were_seen_after_6_months_of_treatment._Other_genetic_and_clinical_factors_may_also_influence_response_to_adalimumab_etanercept_or_infliximab.""TT:Patients_with_the_TT_genotype_and_psoriatic_arthritis_may_have_an_increased_response_after_3_months_of_treatment_with_adalimumab_etanercept_or_infliximab_as_compared_to_patients_with_the_CC_or_CT_genotype._No_significant_associations_were_seen_after_6_months_of_treatment._Other_genetic_and_clinical_factors_may_also_influence_response_to_adalimumab_etanercept_or_infliximab.","CC:Patients_with_the_CC_genotype_and_rheumatoid_arthritis_may_have_an_increased_response_to_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CT:Patients_with_the_CT_genotype_and_rheumatoid_arthritis_may_have_an_increased_response_to_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_rheumatoid_arthritis_may_have_a_decreased_response_to_treatment_with_anti-TNF_therapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=White,White
12	6451590	rs4149570	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF1A_(PA36609);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Crohn_Disease_(PA443815)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AC:Patients_with_the_AC_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""CC:Patients_with_the_CC_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
12	6953257	rs11064426	A	C,T	.	.	PGKB_INDEX=1;PGKB_GENE=GNB3_(PA176);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Women_with_the_AA_genotype_and_hypertension_may_have_a_better_blood_pressure_response_when_treated_with_atenolol_as_compared_to_those_with_the_AC_or_CC_genotype._No_significant_results_were_seen_when_considering_men_only._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.""AC:Women_with_the_AC_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_atenolol_as_compared_to_women_with_the_AA_genotype._No_significant_results_were_seen_when_considering_men_only._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.""CC:Women_with_the_CC_genotype_and_hypertension_may_have_a_poorer_blood_pressure_response_when_treated_with_atenolol_as_compared_to_patients_with_the_AA_genotype._No_significant_results_were_seen_when_considering_men_only._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_response.";PGKB_RACE=White
12	6954624	rs2301339	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GNB3_(PA176);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Women_with_the_AA_genotype_and_hypertension_may_have_smaller_decreases_in_systolic_or_diastolic_blood_pressure_when_treated_with_atenolol_as_compared_to_women_with_the_GG_genotype._No_significant_results_were_seen_in_men._When_considering_systolic_blood_pressure_only_significant_results_were_seen_for_men_and_women_combined._Other_genetic_and_clinical_factors_may_also_influence_systolic_and_diastolic_blood_pressure_response_to_atenolol._""AG:Women_with_the_AG_genotype_and_hypertension_may_have_smaller_decreases_in_systolic_blood_pressure_when_treated_with_atenolol_as_compared_to_women_with_the_GG_genotype._The_same_result_was_seen_for_women_and_men_combined__no_significant_results_were_seen_in_men._Other_genetic_and_clinical_factors_may_also_influence_systolic_blood_pressure_response_to_atenolol._""GG:Women_with_the_GG_genotype_and_hypertension_may_have_greater_decreases_in_systolic_or_diastolic_blood_pressure_when_treated_with_atenolol_as_compared_to_women_with_the_AA_or_AG_genotype._No_significant_results_were_seen_in_men._When_considering_systolic_blood_pressure_only_significant_results_were_seen_for_men_and_women_combined._Other_genetic_and_clinical_factors_may_also_influence_systolic_and_diastolic_blood_pressure_response_to_atenolol._";PGKB_RACE=White
12	6954875	rs5443	C	T	.	.	PGKB_INDEX=12;PGKB_GENE=GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176),GNB3_(PA176);PGKB_DRUG=atenolol_(PA448499),antidepressants_(PA452229),"bumetanide_(PA448682)""furosemide_(PA449719)""torasemide_(PA451733)",hmg_coa_reductase_inhibitors_(PA133950441),sumatriptan_(PA451566),olanzapine_(PA450688),sildenafil_(PA451346),nortriptyline_(PA450657),Beta_Blocking_Agents_(PA164712535),"hydralazine_(PA449894)""isosorbide_dinitrate_(PA450125)",telmisartan_(PA451605),clonidine_(PA449051);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Toxicity/ADR,Efficacy,"Efficacy""Toxicity/ADR",Other,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,4,3,3,2B,3,3,3,3,3;PGKB_DISEASE=Essential_hypertension_(PA447288),Depressive_Disorder_Major_(PA447321),NR,"Hypercholesterolemia_(PA444516)""Myocardial_Infarction_(PA445019)",Cluster_Headache_(PA443742),"Schizophrenia_(PA447216)""Weight_gain_(PA128406954)",Erectile_Dysfunction_(PA444606),Depressive_Disorder_Major_(PA447321),NR,Heart_Failure_(PA444370),Essential_hypertension_(PA447288),Liver_Cirrhosis_(PA444797);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_essential_hypertension_who_are_treated_with_atenolol_may_have_an_increased_response_as_compared_to_patients_with_the_TT_or_CT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atenolol.""CT:Patients_with_the_CT_genotype_and_essential_hypertension_who_are_treated_with_atenolol_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atenolol.""TT:Patients_with_the_TT_genotype_and_essential_hypertension_who_are_treated_with_atenolol_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atenolol.","CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CT_or_CC_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._","CC:Healthy_males_with_the_CC_genotype_may_have_an_increased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_and_torasemide.""CT:Healthy_males_with_the_CT_genotype_may_have_an_increased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_TT_genotype_or_a_decreased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_and_torasemide.""TT:Healthy_males_with_the_TT_genotype_have_have_a_decreased_response_when_given_bumetanide_furosemide_and_torasemide_as_compared_to_healthy_males_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_and_torasemide.","CC:Patients_with_the_CC_genotype_and_hypercholesterolemia_who_are_treated_with_antihypertensive_drugs_and_exposed_to_statins_may_have_a_smaller_reduction_in_risk_of_myocardial_infarction_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antihypertensive_drugs.""CT:Patients_with_the_TT_genotype_and_hypercholesterolemia_who_are_treated_with_antihypertensive_drugs_and_exposed_to_statins_may_have_a_greater_reduction_in_risk_of_myocardial_infarction_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antihypertensive_drugs.""TT:Patients_with_the_TT_genotype_and_hypercholesterolemia_who_are_treated_with_antihypertensive_drugs_and_exposed_to_statins_may_have_a_greater_reduction_in_risk_of_myocardial_infarction_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antihypertensive_drugs.","CC:Patients_with_the_CC_genotype_and_cluster_headache_who_are_treated_with_triptans_may_be_less_likely_to_have_reduced_pain_or_attack_frequency_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sumatriptan.""CT:Patients_with_the_CT_genotype_and_cluster_headache_who_are_treated_with_triptans_may_be_more_likely_to_have_reduced_pain_or_attack_frequency_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sumatriptan.""TT:Patients_with_the_TT_genotype_and_cluster_headache_who_are_treated_with_triptans_may_be_more_likely_to_have_reduced_pain_or_attack_frequency_as_compared_to_patients_with_the_CC_genotype._However_patients_with_this_genotype_were_not_studied_directly._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sumatriptan.","CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_weight_gain_with_olanzapine.""CT:Patients_with_the_CT_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_weight_gain_with_olanzapine.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_weight_gain_with_olanzapine.","CC:Patients_with_the_CC_genotype_and_erectile_dysfunction_who_are_treated_with_sildenafil_may_be_less_likely_to_have_positive_erectile_response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sildenafil.""CT:Patients_with_the_CT_genotype_and_erectile_dysfunction_who_are_treated_with_sildenafil_may_be_less_likely_to_have_positive_erectile_response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sildenafil.""TT:Patients_with_the_TT_genotype_and_erectile_dysfunction_who_are_treated_with_sildenafil_may_be_more_likely_to_have_positive_erectile_response_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sildenafil.","CC:Patients_with_the_CC_genotype_and_major_depression_who_are_treated_with_nortriptyline_may_have_less_improvement_in_neurovegetative_symptoms_increased_likelihood_of_Sleep_Initiation_and_Maintenance_Disorders_but_decreased_risk_for_weight_gain_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""CT:Patients_with_the_CT_genotype_and_major_depression_who_are_treated_with_nortriptyline_may_have_less_improvement_in_neurovegetative_symptoms_increased_likelihood_of_Sleep_Initiation_and_Maintenance_Disorders_but_decreased_risk_for_weight_gain_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.""TT:Patients_with_the_TT_genotype_and_major_depression_who_are_treated_with_nortriptyline_may_have_more_improvement_in_neurovegetative_symptoms_decreased_likelihood_of_Sleep_Initiation_and_Maintenance_Disorders_but_increased_risk_for_weight_gain_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nortriptyline.","CC:Patients_with_the_CC_genotype_may_have_increased_heart_rate_when_treated_with_Beta_Blocking_Agents_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_Beta_Blocking_Agents.""CT:Patients_with_the_CT_genotype_may_have_decreased_heart_rate_when_treated_with_Beta_Blocking_Agents_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_Beta_Blocking_Agents.""TT:Patients_with_the_TT_genotype_may_have_decreased_heart_rate_when_treated_with_Beta_Blocking_Agents_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_Beta_Blocking_Agents.","CC:Patients_with_the_CC_genotype_and_heart_failure_may_have_decreased_response_to_hydralazine_and_isosorbide_dinitrate_compared_with_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment_and_isosorbide_dinitrate.""CT:Patients_with_the_CT_genotype_and_heart_failure_may_have_decreased_response_to_hydralazine_and_isosorbide_dinitrate_compared_with_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment_and_isosorbide_dinitrate.""TT:Patients_with_the_TT_genotype_and_heart_failure_may_have_increased_response_to_hydralazine_and_isosorbide_dinitrate_compared_with_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydralazine_treatment_and_isosorbide_dinitrate.","CC:Patients_with_CC_genotype_and_essential_hypertension_may_have_increased_response_to_telmisartan_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_telmisartan._""CT:Patients_with_CT_genotype_and_essential_hypertension_may_have_increased_response_to_telmisartan_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_telmisartan._""TT:Patients_with_TT_genotype_and_essential_hypertension_may_have_decreased_response_to_telmisartan_compared_to_patients_with_genotype_CC_and_CT._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_telmisartan._","CC:Patients_with_the_CC_genotype_may_have_a_poorer_response_to_treatment_with_clonidine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clonidine.""CT:Patients_with_the_CT_genotype_may_have_a_better_response_to_treatment_with_clonidine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clonidine.""TT:Patients_with_the_TT_genotype_may_have_a_betterr_response_to_treatment_with_clonidine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clonidine.";PGKB_RACE=NR,NR,White,NR,White,Asian,White,NR,NR,Black_or_African_American,Asian,NR
12	9232268	rs669	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=A2M_(PA24357);PGKB_DRUG=Enzymes_(PA164712734);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Stroke_(PA447054);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_have_had_a_stroke_may_be_at_decreased_risk_for_hemorrhagic_transformation_when_treated_with_tissue_plasminogen_activator_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_hemorrhagic_transformation.""CT:Patients_with_the_CT_genotype_who_have_had_a_stroke_may_be_at_decreased_risk_for_hemorrhagic_transformation_when_treated_with_tissue_plasminogen_activator_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_hemorrhagic_transformation.""TT:Patients_with_the_TT_genotype_who_have_had_a_stroke_may_be_at_increased_risk_for_hemorrhagic_transformation_when_treated_with_tissue_plasminogen_activator_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_hemorrhagic_transformation.";PGKB_RACE=White
12	13717508	rs1806201	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=GRIN2B_(PA28980),GRIN2B_(PA28980);PGKB_DRUG=risperidone_(PA451257),quetiapine_(PA451201);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Drug_Toxicity_(PA443937),Drug_Toxicity_(PA443937);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_risperidone_may_have_a_decreased_likelihood_of_adverse_reactions_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_risperidone._""AG:Patients_with_the_AG_genotype_who_are_treated_with_risperidone_may_have_a_decreased_likelihood_of_adverse_reactions_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_risperidone._""GG:Patients_with_the_GG_genotype_who_are_treated_with_risperidone_may_have_an_increased_likelihood_of_adverse_reactions_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_risperidone._","AA:Patients_with_the_AA_genotype_who_are_treated_with_quetiapine_may_have_an_increased_likelihood_of_neurological_adverse_reactions_and_sleepiness_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_quetiapine.""AG:Patients_with_the_AG_genotype_who_are_treated_with_quetiapine_may_have_a_decreased_likelihood_of_neurological_adverse_reactions_and_sleepiness_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_quetiapine.""GG:Patients_with_the_GG_genotype_who_are_treated_with_quetiapine_may_have_a_decreased_likelihood_of_neurological_adverse_reactions_and_sleepiness_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_quetiapine.";PGKB_RACE=White,White
12	13953118	rs2058878	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=GRIN2B_(PA28980);PGKB_DRUG=acamprosate_(PA10344);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Alcoholism_(PA443309);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_alcoholism_may_have_an_increased_response_to_acamprosate_as_compared_to_patients_with_the_AT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_acamprosate_in_patients_with_alcoholism._""AT:Patients_with_the_AT_genotype_and_alcoholism_may_have_an_increased_response_to_acamprosate_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_response_as_compared_to_patients_with_the_AT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_acamprosate_in_patients_with_alcoholism._""TT:Patients_with_the_TT_genotype_and_alcoholism_may_have_an_increased_response_to_acamprosate_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_acamprosate_in_patients_with_alcoholism._";PGKB_RACE=White
12	20860093	rs3794271	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1C1_(PA37815);PGKB_DRUG="etanercept_(PA449515)""infliximab_(PA452639)""Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_may_be_more_likely_to_respond_to_anti-TNF_treatment_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""AG:Patients_with_the_AG_genotype_and_Rheumatoid_Arthritis_may_be_more_likely_to_respond_to_anti-TNF_treatment_as_compared_to_patients_with_the_GG_genotype_but_may_be_less_likely_to_respond_to_anti-TNF_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""GG:Patients_with_the_GG_genotype_and_Rheumatoid_Arthritis_may_be_less_likely_to_respond_to_anti-TNF_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._";PGKB_RACE=White
12	21011480	rs4149117	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B3_(PA35844);PGKB_DRUG=mycophenolate_mofetil_(PA450566);PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=4;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="GG:Patients_with_the_GG_genotype_who_are_renal_transplant_recipients_and_are_treated_with_mycophenolate_mofetil:_1)_may_have_an_increased_risk_of_adverse_drug_reactions_2)_may_have_decreased_exposure_to_active_mycophenolic_acid_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity_and_exposure_to_mycophenolic_acid.""GT:Patients_with_the_GT_genotype_who_are_renal_transplant_recipients_and_are_treated_with_mycophenolate_mofetil:_1)_may_have_an_increased_risk_of_adverse_drug_reactions_2)_may_have_decreased_exposure_to_active_mycophenolic_acid_as_compared_to_patients_with_the_TT_genotype_or_1)_may_have_a_decreased_risk_of_adverse_drug_reactions_2)_may_have_increased_exposure_to_active_mycophenolic_acid_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity_and_exposure_to_mycophenolic_acid.""TT:Patients_with_the_TT_genotype_who_are_renal_transplant_recipients_and_are_treated_with_mycophenolate_mofetil:_1)_may_have_a_decreased_risk_of_adverse_drug_reactions_2)_may_have_increased_exposure_to_active_mycophenolic_acid_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_drug-induced_toxicity_and_exposure_to_mycophenolic_acid.";PGKB_RACE=NR
12	21015760	rs7311358	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=SLCO1B3_(PA35844),SLCO1B3_(PA35844);PGKB_DRUG=mycophenolate_mofetil_(PA450566),docetaxel_(PA449383);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_may_have_a_decreased_clearance_of_mycophenolate_mofetil_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""AG:Patients_with_the_AG_genotype_and_Kidney_Transplantation_may_have_a_decreased_clearance_of_mycophenolate_mofetil_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.""GG:Patients_with_the_GG_genotype_and_Kidney_Transplantation_may_have_an_increased_clearance_of_mycophenolate_mofetil_as_compared_to_patients_with_the_AG_or_AA_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_mycophenolate_mofetil.","AA:Patients_with_the_AA_genotype_may_have_increased_AUC_and_decreased_clearance_of_docetaxel_in_people_with_Nasopharyngeal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_docetaxel.""AG:Patients_with_the_AG_genotype_may_have_increased_AUC_and_decreased_clearance_of_docetaxel_in_people_with_Nasopharyngeal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_docetaxel.""GG:Patients_with_the_GG_genotype_may_have_decreased_AUC_and_increased_clearance_of_docetaxel_in_people_with_Nasopharyngeal_Neoplasms_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_docetaxel.";PGKB_RACE=NR,Asian
12	21045694	rs11045585	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B3_(PA35844);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Neoplasms_who_are_treated_with_docetaxel_may_have_1)_a_decreased_but_not_absent_risk_of_leukopenia_2)_an_increased_clearance_of_docetaxel_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_docetaxel.""AG:Patients_with_the_AG_genotype_and_Neoplasms_who_are_treated_with_docetaxel_may_have_1)_an_increased_risk_of_leukopenia_2)_a_decreased_clearance_of_docetaxel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_docetaxel.""GG:Patients_with_the_GG_genotype_and_Neoplasms_who_are_treated_with_docetaxel_may_have_1)_an_increased_risk_of_leukopenia_2)_a_decreased_clearance_of_docetaxel_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_docetaxel.";PGKB_RACE=Asian
12	21283322	rs4149015	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=SLCO1B1_(PA134865839),SLCO1B1_(PA134865839);PGKB_DRUG=irinotecan_(PA450085),pravastatin_(PA451089);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,2A;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small_cell_lung_cancer_may_have_an_increased_risk_of_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_GG_genotype._No_association_has_been_seen_for_diarrhea._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia.""AG:Patients_with_the_AG_genotype_and_non-small_cell_lung_cancer_may_have_an_increased_risk_of_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_GG_genotype._No_association_has_been_seen_for_diarrhea._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia.""GG:Patients_with_the_GG_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_risk_of_neutropenia_when_treated_with_irinotecan_as_compared_to_patients_with_the_AG_or_GG_genotype._No_association_has_been_seen_for_diarrhea._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia.","AA:Patients_carrying_the_AA_genotype_may_have_increased_pravastatin_plasma_AUC_and_decreased_response_to_pravastatin_compared_with_patients_carrying_the_GG_genotype._This_variant_is_part_of_the_SLCO1B1*17_haplotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_carrying_the_AG_genotype_may_have_increased_pravastatin_plasma_AUC_and_decreased_response_to_pravastatin_compared_with_patients_carrying_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_carrying_the_GG_genotype_may_have_increased_chance_of_response_to_pravastatin_compared_to_patients_carrying_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=Asian,White
12	21327740	rs4149036	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_atorvastatin_as_compared_to_patients_with_the_CC_or_AC_genotypes._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_atorvastatin_response.""AC:Patients_with_the_AC_genotype_may_have_increased_response_to_atorvastatin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_atorvastatin_response.""CC:Patients_with_the_CC_genotype_may_have_increased_response_to_atorvastatin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_atorvastatin_response.";PGKB_RACE=White
12	21329738	rs2306283	A	G	.	.	PGKB_INDEX=8;PGKB_GENE=SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839);PGKB_DRUG=methotrexate_(PA450428),irinotecan_(PA450085),pitavastatin_(PA142650384),hmg_coa_reductase_inhibitors_(PA133950441),atorvastatin_(PA448500),repaglinide_(PA451234),pravastatin_(PA451089),rocuronium_(PA164754992);PGKB_TYPE=Other,Efficacy,Other,Toxicity/ADR,Efficacy,Other,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3,3,3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Colorectal_Neoplasms_(PA446108),NR,"Diabetes_Mellitus_(PA443886)""Hypercholesterolemia_(PA444516)",Hypercholesterolemia_(PA444516),NR,NR,NR;PGKB_TEXT="AA:Pediatric_patients_with_the_AA_genotype_and_acute_lymphoblastic_leukemia_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate._""AG:Pediatric_patients_with_the_AG_genotype_and_acute_lymphoblastic_leukemia_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate._""GG:Pediatric_patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate._","AA:Patients_with_the_AA_genotype_and_metastatic_colorectal_cancer_may_have_1)_increased_rapid_response_to_treatment_containing_irinotecan_2)_longer_progression_free_survival_and_3)_greater_irinotecan-related_time_to_treatment_failure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irinotecan_based_treatment.""AG:Patients_with_the_AG_genotype_and_metastatic_colorectal_cancer_may_have_1)_increased_rapid_response_to_treatment_containing_irinotecan_2)_longer_progression_free_survival_and_3)_greater_irinotecan-related_time_to_treatment_failure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irinotecan_based_treatment.""GG:Patients_with_the_GG_genotype_and_metastatic_colorectal_cancer_may_have_1)_decreased_rapid_response_to_treatment_containing_irinotecan_2)_shorter_progression_free_survival_and_3)_lower_irinotecan-related_time_to_treatment_failure_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irinotecan_based_treatment.","AA:Patients_with_the_AA_genotype_may_have_decreased_pitavastatin_plasma_concentrations_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_pitavastatin_pharmacokinetics._""AG:Patients_with_the_AG_genotype_may_have_increased_pitavastatin_plasma_concentrations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_pitavastatin_pharmacokinetics._""GG:Patients_with_the_GG_genotype_may_have_increased_pitavastatin_plasma_concentrations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_pitavastatin_pharmacokinetics.","AA:Patients_with_the_AA_genotype_who_are_treated_with_statins_(hmg_coa_reductase_inhibitors)_may_have_increased_creatine_kinase_levels_and_increased_risk_of_intolerance_to_treatment_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment.""AG:Patients_with_the_AG_genotype_who_are_treated_with_statins_(hmg_coa_reductase_inhibitors)_may_have_increased_creatine_kinase_levels_and_higher_a_higher_risk_of_intolerance_to_treatment_as_compared_to_patients_with_the_GG_genotype_but_a_lower_creatine_kinase_levels_and_lower_risk_of_intolerance_as_compared_to_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_who_are_treated_with_statins_(hmg_coa_reductase_inhibitors)_may_have_decreased_creatine_kinase_levels_and_may_have_a_lower_risk_of_intolerance_to_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._","AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_less_reduction_in_LDL_as_compared_to_patients_with_the_GG_genotype._However_one_study_found_no_association_with_LDL_levels._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_less_reduction_in_LDL_as_compared_to_patients_with_the_GG_genotype._However_one_study_found_no_association_with_LDL_levels._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_who_are_treated_with_atorvastatin_may_a_larger_reduction_in_LDL_as_compared_to_patients_with_the_AA_or_AG_genotype._However_one_study_found_no_association_with_LDL_levels._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","AA:Patients_with_the_AA_genotype_may_have_higher_plasma_concentrations_of_repaglinide_in_people_with_no_health_problems_compared_to_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:While_the_GG_genotype_is_associated_with_reduced_plasma_concentrations_of_repaglinide_no_results_are_shown_for_the_GA_genotype.""GG:Patients_with_the_GG_genotype_may_have_reduced_plasma_concentrations_of_repaglinide_and_higher_blood_glucose_concentrations_after_repaglinide_intake_in_people_with_no_health_problems_compared_to_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Patients_with_the_AA_genotype_may_have_increased_pravastatin_plasma_concentrations_as_compared_to_patients_with_the_GG_genotype._This_does_not_seem_to_have_an_affect_on_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_pravastatin_pharmacokinetics._""AG:Patients_with_the_AG_genotype_may_have_decreased_pravastatin_plasma_concentrations_as_compared_to_patients_with_the_AA_genotype_or_may_have_increased_pravastatin_plasma_concentrations_as_compared_to_patients_with_the_GG_genotype._This_does_not_seem_to_have_an_affect_on_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_pravastatin_pharmacokinetics._""GG:Patients_with_the_GG_genotype_may_have_decreased_pravastatin_plasma_concentrations_as_compared_to_patients_with_the_AA_genotype._This_does_not_seem_to_have_an_affect_on_response._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_pravastatin_pharmacokinetics._","AA:Patients_with_the_AA_genotype_who_are_placed_under_anesthesia_may_have_a_decreased_response_to_rocuronium_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rocuronium.""AG:Patients_with_the_AG_genotype_who_are_placed_under_anesthesia_may_have_an_increased_response_to_rocuronium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rocuronium.""GG:Patients_with_the_GG_genotype_who_are_placed_under_anesthesia_may_have_an_increased_response_to_rocuronium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rocuronium.";PGKB_RACE=NR,Asian,Asian,NR,NR,White,White,Asian
12	21329813	rs11045819	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=fluvastatin_(PA449688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_fluvastatin_may_have_a_greater_reduction_in_LDL-C_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_response_to_fluvastatin.""AC:Patients_with_the_AC_genotype_who_are_treated_with_fluvastatin_may_have_a_greater_reduction_in_LDL-C_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin.""CC:Patients_with_the_CC_genotype_who_are_treated_with_fluvastatin_may_have_a_lesser_reduction_in_LDL-C_as_compared_to_patients_with_the_AC_and_AA_genotype.";PGKB_RACE=White
12	21331549	rs4149056	T	C	.	.	PGKB_INDEX=16;PGKB_GENE=SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839);PGKB_DRUG=pravastatin_(PA451089),"cytarabine_(PA449177)""fludarabine_(PA449655)""gemtuzumab_ozogamicin_(PA164749431)""idarubicin_(PA449961)",atorvastatin_(PA448500),irinotecan_(PA450085),SN-38_(PA165110775),methotrexate_(PA450428),simvastatin_(PA451363),repaglinide_(PA451234),nateglinide_(PA450600),cerivastatin_(PA448897),pravastatin_(PA451089),"atorvastatin_(PA448500)""rifampin_(PA451250)",hmg_coa_reductase_inhibitors_(PA133950441),rosuvastatin_(PA134308647),lopinavir_(PA450264),mycophenolate_mofetil_(PA450566);PGKB_TYPE=Efficacy,Toxicity/ADR,"Toxicity/ADR""Metabolism/PK",Toxicity/ADR,Dosage,Other,Toxicity/ADR,Efficacy,NR,Toxicity/ADR,Other,Metabolism/PK,Toxicity/ADR,Other,Metabolism/PK,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3,3,3,1A,3,4,2A,2A,3,2A,2A,4,3;PGKB_DISEASE=NR,Leukemia_Myeloid_Acute_(PA444760),NR,Neoplasms_(PA445062),Carcinoma_Non-Small-Cell_Lung_(PA443622),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),"Muscular_Diseases_(PA444997)""Myopathy_Central_Core_(PA447048)",NR,NR,Rhabdomyolysis_(PA445549),NR,NR,"Muscular_Diseases_(PA444997)""Rhabdomyolysis_(PA445549)",Hypercholesterolemia_(PA444516),NR,Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_pravastatin_may_have_a_smaller_reduction_in_total_cholesterol_as_compared_to_patients_with_the_TT_genotype._This_has_not_been_found_in_all_studies_and_the_association_between_this_variant_and_pravastatin_response_remains_unclear._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""CT:Patients_with_the_CT_genotype_who_are_treated_with_pravastatin_may_have_a_smaller_reduction_in_total_cholesterol_as_compared_to_patients_with_the_TT_genotype._This_has_not_been_found_in_all_studies_and_the_association_between_this_variant_and_pravastatin_response_remains_unclear._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_pravastatin_may_have_a_larger_reduction_in_total_cholesterol_as_compared_to_patients_with_the_CC_or_CT_genotype._This_has_not_been_found_in_all_studies_and_the_association_between_this_variant_and_pravastatin_response_remains_unclear._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","CC:Patients_with_the_CC_genotype_may_have_an_increased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.gemtuzumab_ozogamicin_and_idarubicin.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_genotype_and_an_increased_likelihood_of_toxic_liver_disease_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_likelihood_of_toxic_liver_disease_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.","CC:Patients_with_the_CC_genotype_and_who_are_treated_with_atorvastatin_may_have_1)_lower_oral_clearance_and_higher_plasma_concentrations_of_atorvastatin_2)_an_increased_risk_of_composite_adverse_events_but_not_an_increased_risk_of_myalgia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment_and_atorvastatin_pharmacokinetics._""CT:Patients_with_the_CT_genotype_and_who_are_treated_with_atorvastatin_may_have_1)_lower_oral_clearance_and_higher_plasma_concentrations_of_atorvastatin_2)_an_increased_risk_of_composite_adverse_events_but_not_an_increased_risk_of_myalgia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment_and_atorvastatin_pharmacokinetics._""TT:Patients_with_the_TT_genotype_and_who_are_treated_with_atorvastatin_may_have_1)_higher_oral_clearance_and_lower_plasma_concentrations_of_atorvastatin_2)_a_decreased_risk_of_composite_adverse_events_but_not_a_decreased_risk_of_myalgia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment_and_atorvastatin_pharmacokinetics._","CC:Patients_with_the_CC_genotype_and_cancer_may_have_an_increased_risk_of_neutropenia_when_treated_with_irinotecan_or_irinotecan-based_regimens_as_compared_to_patients_with_the_TT_genotype._No_significant_results_have_been_seen_for_diarrhea._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia_or_diarrhea.""CT:Patients_with_the_CT_genotype_and_cancer_may_have_an_increased_risk_of_neutropenia_when_treated_with_irinotecan_or_irinotecan-based_regimens_as_compared_to_patients_with_the_TT_genotype._However_a_different_study_of_similar_size_found_no_association_between_the_CT_genotype_and_neutropenia._No_significant_results_have_been_seen_for_diarrhea._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia_or_diarrhea.""TT:Patients_with_the_TT_genotype_and_cancer_may_have_a_decreased_risk_of_neutropenia_when_treated_with_irinotecan_or_irinotecan-based_regimens_as_compared_to_patients_with_the_CC_or_CT_genotype._However_a_different_study_of_similar_size_found_no_association_between_the_TT_genotype_and_neutropenia._No_significant_results_have_been_seen_for_diarrhea._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia_or_diarrhea.","CC:Patients_with_the_CC_genotype_and_non-small_cell_lung_cancer_may_have_receive_an_increased_dose_of_SN-38_(as_shown_by_an_increased_area_under_the_concentration_curve)_when_treated_with_irinotecan_as_compared_to_patients_with_the_TT_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_may_also_influence_dose_of_SN-38._""CT:Patients_with_the_CT_genotype_and_non-small_cell_lung_cancer_may_receive_an_increased_dose_of_SN-38_(as_shown_by_an_increased_area_under_the_concentration_curve)_when_treated_with_irinotecan_as_compared_to_patients_with_the_TT_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_may_also_influence_dose_of_SN-38._""TT:Patients_with_the_TT_genotype_and_non-small_cell_lung_cancer_may_have_a_decreased_dose_of_SN-38_(as_shown_by_an_increased_area_under_the_concentration_curve)_when_treated_with_irinotecan_as_compared_to_patients_with_the_CC_or_CT_genotype._SN-38_is_the_active_metabolite_of_irinotecan._Other_genetic_and_clinical_factors_may_also_influence_dose_of_SN-38._","CC:Pediatric_patients_with_the_CC_genotype_and_acute_lymphoblastic_leukemia_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate.""CT:Pediatric_patients_with_the_CT_genotype_and_acute_lymphoblastic_leukemia_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate.""TT:Pediatric_patients_with_the_TT_genotype_and_acute_lymphoblastic_leukemia_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate.","CC:Patients_with_the_CC_genotype_may_have_a_higher_risk_of_simvastatin-related_myopathy_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""CT:Patients_with_the_CT_genotype_may_have_a_higher_risk_of_simvastatin-related_myopathy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""TT:Patients_with_the_TT_genotype_may_have_a_lower_risk_of_simvastatin-related_myopathy_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","CC:Patients_with_the_CC_genotype_may_have_increased_mean_plasma_AUC_of_repaglinide_and_greater_blood_glucose-lowering_effect_in_response_to_repaglinide_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_decreased_mean_plasma_AUC_of_repaglinide_and_lower_blood_glucose-lowering_effect_in_response_to_repaglinide_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_mean_plasma_AUC_of_repaglinide_and_lower_blood_glucose-lowering_effect_in_response_to_repaglinide_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:This_genotype_has_no_significant_effect_on_the_PK_or_PD_of_nateglinide.""CT:This_genotype_has_no_significant_effect_on_the_PK_or_PD_of_nateglinide.""TT:This_genotype_has_no_significant_effect_on_the_PK_or_PD_of_nateglinide.","CC:Patients_with_the_CC_genotype_may_have_a_higher_risk_of_cerivastatin-related_rhabdomyolysis_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity._Cerivastatin_was_withdrawn_from_the_market_because_of_52_deaths_attributed_to_drug-related_rhabdomyolysis_that_lead_to_kidney_failure.""CT:Patients_with_the_CT_genotype_may_have_a_higher_risk_of_cerivastatin-related_rhabdomyolysis_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity._Cerivastatin_was_withdrawn_from_the_market_because_of_52_deaths_attributed_to_drug-related_rhabdomyolysis_that_lead_to_kidney_failure.""TT:Patients_with_the_TT_genotype_may_have_a_lower_risk_of_cerivastatin-related_rhabdomyolysis_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity._Cerivastatin_was_withdrawn_from_the_market_because_of_52_deaths_attributed_to_drug-related_rhabdomyolysis_that_lead_to_kidney_failure.","CC:Patients_with_the_CC_genotype_may_have_increased_plasma_concentrations_of_pravastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_pravastatin.""CT:Patients_with_the_CT_genotype_may_have_increased_plasma_concentrations_of_pravastatin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_pravastatin.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_concentrations_of_pravastatin_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_pravastatin.","CC:Patients_with_the_CC_genotype_may_have_decreased_plasma_concentration_of_atorvastatin_when_treated_concomitantly_with_rifampin_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_atorvastatin.""CT:Patients_with_the_CT_genotype_may_have_decreased_plasma_concentration_of_atorvastatin_when_treated_concomitantly_with_rifampin_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_atorvastatin.""TT:Patients_with_the_TT_genotype_may_have_increased_plasma_concentration_of_atorvastatin_when_treated_concomitantly_with_rifampin_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_atorvastatin.","CC:Patients_with_the_CC_genotype_may_have_increased_plasma_drug_concentrations_of_particular_statins_as_compared_to_patients_with_the_TT_genotype._For_some_statins_this_is_associated_with_increased_risk_of_adverse_events_-_see_individual_drug_annotations_particularly_for_simvastatin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_statins.""CT:Patients_with_the_CT_genotype_may_have_increased_plasma_drug_concentrations_of_particular_statins_as_compared_to_patients_with_the_TT_genotype._For_some_statins_this_is_associated_with_increased_risk_of_adverse_events_-_see_individual_drug_annotations_particularly_for_simvastatin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_statins.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_drug_concentrations_of_particular_statins_as_compared_to_patients_with_the_CC_or_CT_genotype._For_some_statins_this_is_associated_with_decreased_risk_of_adverse_events_-_see_individual_drug_annotations_particularly_for_simvastatin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_statins.","CC:Patients_with_the_CC_genotype_may_have_higher_plasma_concentrations_of_rosuvastatin_as_compared_to_patients_with_the_TT_genotype._No_association_is_seen_between_genotypes_of_this_variant_and_change_in_LDL-cholesterol_levels_in_response_to_rosuvastatin_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_rosuvastatin.""CT:Patients_with_the_CT_genotype_may_have_higher_plasma_concentrations_of_rosuvastatin_as_compared_to_patients_with_the_TT_genotype._No_association_is_seen_between_genotypes_of_this_variant_and_change_in_LDL-cholesterol_levels_in_response_to_rosuvastatin_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_rosuvastatin.""TT:Patients_with_the_TT_genotype_may_have_lower_plasma_concentrations_of_rosuvastatin_as_compared_to_patients_with_the_CC_genotype._No_association_is_seen_between_genotypes_of_this_variant_and_change_in_LDL-cholesterol_levels_in_response_to_rosuvastatin_treatment._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_and_response_to_rosuvastatin.","CC:Patients_with_the_CC_genotype_may_have_increased_plasma_level_of_lopinavir_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lopinavir.""CT:Patients_with_the_CT_genotype_may_have_decreased_plasma_level_of_lopinavir_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lopinavir.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_level_of_lopinavir_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lopinavir.","CC:Patients_with_the_CC_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_a_decreased_risk_of_adverse_drug_reaction_as_compared_to_patients_with_the_TT_genotype._However_no_association_is_found_with_increased_risk_of_diarrhea_or_leukopenia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_drug_reaction.""CT:Patients_with_the_CT_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_an_increased_risk_of_adverse_drug_reaction_as_compared_to_patients_with_the_CC_genotype_and_may_have_a_decreased_risk_of_adverse_drug_reaction_as_compared_to_patients_with_the_TT_genotype._However_no_association_is_found_with_increased_risk_of_diarrhea_or_leukopenia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_drug_reaction.""TT:Patients_with_the_TT_genotype_and_Kidney_Transplantation_who_are_treated_with_mycophenolate_mofetil_may_have_an_increased_risk_of_adverse_drug_reaction_as_compared_to_patients_with_the_CC_genotype._However_no_association_is_found_with_increased_risk_of_diarrhea_or_leukopenia._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_drug_reaction.";PGKB_RACE=NR,NR,NR,Asian,Asian,NR,NR,White,White,NR,NR,NR,NR,Asian,NR,NR
12	21332423	rs11045821	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Pediatric_patients_with_ALL_and_the_AA_genotype_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_clearance_of_methotrexate.""AG:Pediatric_patients_with_ALL_and_the_AG_genotype_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_clearance_of_methotrexate.""GG:Pediatric_patients_with_ALL_and_the_GG_genotype_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_clearance_of_methotrexate.";PGKB_RACE=NR
12	21368797	rs2900478	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors._""AT:Patients_with_the_AT_genotype_may_have_a_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_TT_genotypes_and_an_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors._""TT:Patients_with_the_TT_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AT_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors._";PGKB_RACE=NR
12	21372344	rs11045872	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Pediatric_patients_with_ALL_and_the_AA_genotype_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_clearance_of_methotrexate.""AG:Pediatric_patients_with_ALL_and_the_AG_genotype_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_clearance_of_methotrexate.""GG:Pediatric_patients_with_ALL_and_the_GG_genotype_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_influence_also_a_patient's_clearance_of_methotrexate.";PGKB_RACE=NR
12	21378021	rs4149081	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=SLCO1B1_(PA134865839),SLCO1B1_(PA134865839),SLCO1B1_(PA134865839);PGKB_DRUG=rosuvastatin_(PA134308647),methotrexate_(PA450428),simvastatin_(PA451363);PGKB_TYPE=Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Coronary_Disease_(PA443797),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Coronary_Disease_(PA443797);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Coronary_Disease_may_have_an_increased_response_to_rosuvastatin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin.""AG:Patients_with_the_AG_genotype_and_Coronary_Disease_may_have_an_increased_response_to_rosuvastatin_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_response_to_rosuvastatin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin.""GG:Patients_with_the_GG_genotype_and_Coronary_Disease_may_have_a_decreased_response_to_rosuvastatin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_rosuvastatin.","AA:Patients_with_the_AA_genotype_and_precursor_cell_lymphoblastic_leukemia-lymphoma_who_are_treated_with_methotrexate:_1)_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_AG_or_GG_genotype_2)_may_have_a_decreased_but_not_absent_risk_of_GI_toxicity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_GI_toxicity.""AG:Patients_with_the_AG_genotype_and_precursor_cell_lymphoblastic_leukemia-lymphoma_who_are_treated_with_methotrexate:_1)_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_genotype_2)_may_have_an_increased_risk_of_GI_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_GI_toxicity.""GG:Patients_with_the_GG_genotype_and_precursor_cell_lymphoblastic_leukemia-lymphoma_who_are_treated_with_methotrexate:_1)_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_AA_genotype_2)_may_have_an_increased_risk_of_GI_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_GI_toxicity.","AA:Patients_with_the_AA_genotype_and_Coronary_Disease_who_are_treated_with_simvastatin_may_have_higher_LDL-C_reduction_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin.""AG:Patients_with_the_AG_genotype_and_Coronary_Disease_who_are_treated_with_simvastatin_may_have_higher_LDL-C_reduction_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin.""GG:Patients_with_the_GG_genotype_and_Coronary_Disease_who_are_treated_with_simvastatin_may_have_less_LDL-C_reduction_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin";PGKB_RACE=Asian,NR,NR
12	21382619	rs11045879	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1B1_(PA134865839);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_precursor_cell_lymphoblastic_leukemia-lymphoma_who_are_treated_with_methotrexate:_1)_may_have_decreased_clearance_of_methotrexate_as_compared_to_patients_with_the_CT_or_TT_genotype_2)_may_have_a_decreased_but_not_absent_risk_for_GI_toxicity_(mucositis)_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_GI_toxicity_when_treated_with_methotrexate.""CT:Patients_with_the_CT_genotype_and_precursor_cell_lymphoblastic_leukemia-lymphoma_who_are_treated_with_methotrexate:_1)_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_CC_genotype_2)_may_have_an_increased_risk_for_GI_toxicity_(mucositis)_when_treated_with_methotrexate_as_compared_to_patients_with_the_CC_genotype.""TT:Patients_with_the_TT_genotype_and_precursor_cell_lymphoblastic_leukemia-lymphoma_who_are_treated_with_methotrexate:_1)_may_have_increased_clearance_of_methotrexate_as_compared_to_patients_with_the_CC_genotype_2)_may_have_an_increased_risk_for_GI_toxicity_(mucositis)_when_treated_with_methotrexate_as_compared_to_patients_with_the_CC_genotype.";PGKB_RACE=NR
12	21488004	rs3764043	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLCO1A2_(PA328);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_imatinib_clearance_when_treated_with_imatinib_as_compared_to_patients_with_genotype_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_imatinib.""CT:Patients_with_the_CT_genotype_may_have_increased_imatinib_clearance_when_treated_with_imatinib_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_imatinib.""TT:Patients_with_the_TT_genotype_may_have_increased_imatinib_clearance_when_treated_with_imatinib_as_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_the_clearance_of_imatinib.";PGKB_RACE=Asian
12	25360224	rs61764370	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=KRAS_(PA30196);PGKB_DRUG="cetuximab_(PA10040)""panitumumab_(PA162373091)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Adenocarcinoma_(PA443265);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Adenocarcinoma_may_have_a_decreased_but_not_absent_risk_for_nonresponse_to_anti-EGFR-based_treatment_when_treated_with_cetuximab_and_panitumumab_as_compared_to_patients_with_the_CC_or_CA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nonresponse_to_anti-EGFR-based_treatment.""CA:Patients_with_the_CA_genotype_and_Adenocarcinoma_may_have_an_increased_risk_for_nonresponse_to_anti-EGFR-based_treatment_when_treated_with_cetuximab_and_panitumumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nonresponse_to_anti-EGFR-based_treatment.""CC:Patients_with_the_CC_genotype_and_Adenocarcinoma_may_have_an_increased_risk_for_nonresponse_to_anti-EGFR-based_treatment_when_treated_with_cetuximab_and_panitumumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nonresponse_to_anti-EGFR-based_treatment.";PGKB_RACE=White
12	32792974	rs10771973	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=FGD4_(PA134907925);PGKB_DRUG=paclitaxel_(PA450761);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_sensory_peripheral_neuropathy_when_treated_with_paclitaxel_in_women_with_breast_cancer_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_paclitaxel.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_sensory_peripheral_neuropathy_when_treated_with_paclitaxel_in_women_with_breast_cancer_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_paclitaxel.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_sensory_peripheral_neuropathy_when_treated_with_paclitaxel_in_women_with_breast_cancer_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_paclitaxel.";PGKB_RACE=NR
12	34174756	rs1705772	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ALG10_(PA134732019);PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_gemcitabine_may_have_a_decreased_but_not_absent_risk_for_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_who_are_treated_with_gemcitabine_may_have_a_decreased_but_not_absent_risk_for_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_toxicity_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=Asian
12	48238757	rs731236	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=VDR_(PA37301),VDR_(PA37301);PGKB_DRUG=calcium_(PA164712582),clodronate_(PA10239);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Osteitis_Deformans_(PA445172);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_bone_fractures_when_treated_with_Calcium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_calcium.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_bone_fractures_when_treated_with_Calcium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_calcium.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_bone_fractures_when_treated_with_Calcium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_calcium.","AA:Patients_with_the_AA_genotype_and_Osteitis_Deformans_may_have_increased_likelihood_of_resistance_when_treated_with_clodronate_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_clodronate.""AG:Patients_with_the_AG_genotype_and_Osteitis_Deformans_may_have_increased_likelihood_of_resistance_when_treated_with_clodronate_compared_to_patients_with_genotype_GG_or_may_have_decreased_likelihood_of_resistance_when_treated_with_clodronate_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_clodronate.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_resistance_when_treated_with_clodronate_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_resistance_to_clodronate.";PGKB_RACE=NR,White
12	48239835	rs1544410	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=VDR_(PA37301),VDR_(PA37301);PGKB_DRUG="alendronate_(PA448082)""Bisphosphonates_(PA164712563)""calcium_(PA164712582)""clodronate_(PA10239)""etidronic_acid_(PA449548)""raloxifene_(PA451221)","peginterferon_alfa-2a_(PA164749390)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Osteitis_Deformans_(PA445172)""Osteoporosis_(PA445190)",Hepatitis_C_(PA444445);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_bisphosphonates_may_have_greater_improvement_in_bone_mineral_density_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bisphosphonates.""CT:The_response_of_patients_with_the_CT_genotype_who_are_treated_with_bisphosphonates_is_not_clear_compared_to_that_of_patients_with_the_CC_or_the_TT_genotype.""TT:Patients_with_the_TT_genotype_who_are_treated_with_bisphosphonates_may_have_less_improvement_in_bone_mineral_density_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bisphosphonates.","CC:Patients_with_the_CC_genotype_and_Hepatitis_C_may_have_a_decreased_but_not_absent_risk_for_anemia_when_treated_with_peginterferon_alfa-2a_and_ribavirin_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_anemia.""CT:Patients_with_the_CT_genotype_and_Hepatitis_C_may_have_a_decreased_but_not_absent_risk_for_anemia_when_treated_with_peginterferon_alfa-2a_and_ribavirin_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_anemia.""TT:Patients_with_the_TT_genotype_and_Hepatitis_C_may_have_an_increased_risk_for_anemia_when_treated_with_peginterferon_alfa-2a_and_ribavirin_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_anemia.";PGKB_RACE=White,NR
12	50350953	rs296766	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=AQP2_(PA24920);PGKB_DRUG=thiazolidinediones_(PA452631);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_thiazolidinediones_may_have_decreased_but_not_absent_risk_for_edema_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_thiazolidinediones.""CT:Patients_with_the_CT_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_thiazolidinediones_may_have_increased_risk_for_edema_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_but_not_absent_risk_for_edema_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_thiazolidinediones.""TT:Patients_with_the_TT_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_thiazolidinediones_may_have_increased_risk_for_edema_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_thiazolidinediones.";PGKB_RACE=Asian
12	53605545	rs2229774	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RARG_(PA34227);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="cardiotoxicity_(PA166128121)""Neoplasms_(PA445062)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_anthracycline-induced_cardiotoxicity_in_childhood_cancer_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_anthracycline-induced_cardiotoxicity_in_childhood_cancer_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_anthracycline-induced_cardiotoxicity_in_childhood_cancer_as_compared_to_patients_with_genotype_AG_or_AA._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.";PGKB_RACE=White
12	53755212	rs10747673	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="AA:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_AA_genotype_may_be_associated_with_an_increased_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_which_is_indicative_of_decreased_metformin_efficacy_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.""AG:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_AG_genotype_may_be_associated_with_an_increased_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_indicative_of_a_decreased_metformin_efficacy_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_secretory_clearance_of_metformin_and_a_corresponding_decrease_in_HbA1c_levels_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.""GG:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_GG_genotype_may_be_associated_with_a_decreased_secretory_clearance_of_metformin_leading_to_increased_exposure_and_a_corresponding_decrease_in_HbA1c_levels_which_is_indicative_of_improved_metformin_efficacy_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.";PGKB_RACE=NR
12	53804490	rs2683511	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SP1_(PA36042);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE="Efficacy""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="CC:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_CC_genotype_may_be_associated_with_a_decreased_secretory_clearance_of_metformin_leading_to_increased_exposure_and_a_corresponding_decrease_in_HbA1c_levels_which_is_indicative_of_improved_metformin_efficacy_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus._""CT:Patients_with_the_CT_genotype_and_diabetes_mellitus_may_have_a_higher_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_indicative_of_a_decreased_metformin_efficacy_as_compared_to_patients_with_the_CC_genotype_and_a_lower_secretory_clearance_of_metformin_and_a_corresponding_decrease_in_HbA1c_levels_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus._""TT:Patients_with_the_TT_genotype_and_diabetes_mellitus_may_have_a_higher_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_which_is_indicative_of_decreased_metformin_efficacy_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.";PGKB_RACE=NR
12	53822884	rs784892	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=metformin_(PA450395);PGKB_TYPE="Efficacy""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="AA:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_AA_genotype_may_be_associated_with_decreased_secretory_clearance_of_metformin_leading_to_increased_exposure_and_a_corresponding_decrease_in_HbA1c_levels_which_is_indicative_of_improved_metformin_efficacy_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.""AG:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_AG_genotype_may_be_associated_with_increased_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_indicative_of_a_decreased_metformin_efficacy_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_secretory_clearance_of_metformin_and_a_corresponding_decrease_in_HbA1c_levels_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.""GG:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_GG_genotype_may_be_associated_with_a_increased_secretory_clearance_of_metformin_leading_to_decreased_exposure_and_a_corresponding_increase_in_HbA1c_levels_which_is_indicative_of_decreased_metformin_efficacy_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.";PGKB_RACE=NR
12	58144665	rs2069502	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="AGAP2_(PA26411)""CDK4_(PA102)""MARCH9_(PA134920045)""TSPAN31_(PA34949)";PGKB_DRUG=somatropin_recombinant_(PA451446);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Turner_Syndrome_(PA445968);PGKB_TEXT="CC:Patient_with_CC_genotype_may_have_decreased_IGH-I_response_when_treated_with_somatropin_recombinant_in_children_with_Turner_Syndrome_as_compared_to_patients_with_CT_+_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._""CT:Patient_with_CT_+_TT_genotypes_may_have_increased_IGH-I_response_when_treated_with_somatropin_recombinant_in_children_with_Turner_Syndrome_as_compared_to_patients_with_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._""TT:Patient_with_CT_+_TT_genotypes_may_have_increased_IGH-I_response_when_treated_with_somatropin_recombinant_in_children_with_Turner_Syndrome_as_compared_to_patients_with_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._";PGKB_RACE=NR
12	58145156	rs2270777	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CDK4_(PA102);PGKB_DRUG=somatropin_recombinant_(PA451446);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patient_with_CC_+_CT_genotypes_may_have_a_decreased_IGH-I_response_when_treated_with_somatropin_recombinant_in_children_with_growth_hormone_deficiency_as_compared_to_patients_with_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._""CT:Patient_with_CT_+_CC_genotypes_may_have_a_decreased_IGH-I_response_when_treated_with_somatropin_recombinant_in_children_with_growth_hormone_deficiency_as_compared_to_patients_with_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._""TT:Patient_with_TT_genotypes_may_have_an_increased_IGH-I_response_when_treated_with_somatropin_recombinant_in_children_with_growth_hormone_deficiency_as_compared_to_patients_with_CC_+_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy._";PGKB_RACE=NR
12	60173356	rs3763980	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC16A7_(PA35819);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Juvenile_Rheumatoid_(PA443433);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_methotrexate_as_compared_to_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AT:Patients_with_the_AA_genotype_may_have_decreased_response_to_methotrexate_as_compared_to_TT_genotype_or_may_have_increased_response_to_methotrexate_as_compared_to_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_may_have_increased_response_to_methotrexate_as_compared_to_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=White
12	65522647	rs10878232	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=WIF1_(PA38291);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""GT:Patients_with_the_GT_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""TT:Patients_with_the_TT_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.";PGKB_RACE=NR
12	68552522	rs2430561	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=IFNG_(PA29674);PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Crohn_Disease_(PA443815)""Inflammatory_Bowel_Diseases_(PA446116)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""AT:Patients_with_the_AT_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_better_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.""TT:Patients_with_the_TT_genotype_and_inflammatory_bowel_disease_or_specifically_Crohn's_disease_may_have_a_poorer_response_to_anti-TNF_therapy_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_anti-TNF_therapy.";PGKB_RACE=NR
12	69824024	rs7297610	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=YEATS4_(PA134992686);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE="Essential_hypertension_(PA447288)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_an_increased_response_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""CT:Patients_with_the_CT_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""TT:Patients_with_the_TT_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.";PGKB_RACE=Black_or_African_American
12	71977787	rs17109924	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=LGR5_(PA28894);PGKB_DRUG=fluorouracil_(PA128406956);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Colonic_Neoplasms_(PA443756);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_colon_cancer_may_have_a_longer_time_to_tumor_recurrence_when_treated_with_fluorouracil-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._""CT:Patients_with_the_CT_genotype_and_colon_cancer_may_have_a_longer_time_to_tumor_recurrence_when_treated_with_fluorouracil-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._""TT:Patients_with_the_TT_genotype_and_colon_cancer_may_have_a_shorter_time_to_tumor_recurrence_when_treated_with_fluorouracil-based_chemotherapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluorouracil._";PGKB_RACE=NR
12	72331923	rs4570625	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=TPH2_(PA128747823);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_(PA447207);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_TT_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""GT:Patients_with_the_GT_genotype_and_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""TT:Patients_with_the_TT_genotype_and_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=NR
12	72351835	rs10879346	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TPH2_(PA128747823);PGKB_DRUG="antidepressants_(PA452229)""mirtazapine_(PA450522)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_antidepressants_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""CT:Patients_with_the_CT_genotype_who_are_treated_with_antidepressants_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""TT:Patients_with_the_TT_genotype_who_are_treated_with_antidepressants_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_CT_and_CC_genotype.";PGKB_RACE=White
12	72400851	rs1487278	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=TPH2_(PA128747823);PGKB_DRUG="mirtazapine_(PA450522)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_respond_better_to_antidepressant_treatments_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant._(The_frequency_for_CC_allele_is_very_low_homozygous_minor_allele_carriers_were_pooled_together_with_the_heterozygous_samples_and_compared_with_the_homozygous_major_allele_(T)_carrier.)""CT:Patients_with_the_CT_genotype_may_respond_better_to_antidepressant_treatments_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant.""TT:Patients_with_the_TT_genotype_may_be_less_likely_to_respond_to_antidepressant_treatments_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressant.";PGKB_RACE=White
12	77436148	rs310786	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=E2F7_(PA134894421),E2F7_(PA134894421);PGKB_DRUG=tamoxifen_(PA451581),tamoxifen_(PA451581);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=4,3;PGKB_DISEASE=NR,Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:In_lymphoblastoid_cell_lines_the_CC_genotype_was_associated_with_increased_sensitivity_to_tamoxifen_as_compared_to_the_CT_or_TT_genotype._Other_genetic_or_clinical_factors_may_affect_sensitivity_to_tamoxifen.""CT:In_lymphoblastoid_cell_lines_the_CT_genotype_was_associated_with_decreased_sensitivity_to_tamoxifen_as_compared_to_the_CC_genotype._Other_genetic_or_clinical_factors_may_affect_sensitivity_to_tamoxifen.""TT:In_lymphoblastoid_cell_lines_the_TT_genotype_was_associated_with_decreased_sensitivity_to_tamoxifen_as_compared_to_the_CC_genotype._Other_genetic_or_clinical_factors_may_affect_sensitivity_to_tamoxifen.","CC:Women_with_the_CC_genotype_and_breast_cancer_may_have_increased_lumbar_bone_loss_when_treated_with_tamoxifen_as_compared_to_women_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_lumbar_bone_loss_in_women_taking_tamoxifen.""CT:Women_with_the_CT_genotype_and_breast_cancer_may_have_decreased_lumbar_bone_loss_when_treated_with_tamoxifen_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_lumbar_bone_loss_in_women_taking_tamoxifen.""TT:Women_with_the_TT_genotype_and_breast_cancer_may_have_decreased_lumbar_bone_loss_when_treated_with_tamoxifen_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_lumbar_bone_loss_in_women_taking_tamoxifen.";PGKB_RACE=NR,White
12	85243681	rs6539870	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=etoposide_(PA449552);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_lower_risk_of_toxicity_with_etoposide_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""AG:Patients_with_the_AG_genotype_may_have_lower_risk_of_toxicity_with_etoposide_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_toxicity_with_etoposide_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.";PGKB_RACE=White
12	90039326	rs12817819	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ATP2B1_(PA25107);PGKB_DRUG=Antihypertensives_(PA164712445);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_antihypertensives_may_have_a_lower_risk_for_resistant_hypertension_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistant_hypertension._""CT:Patients_with_the_CT_genotype_who_are_treated_with_antihypertensives_may_have_an_increased_risk_for_resistant_hypertension_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistant_hypertension._""TT:Patients_with_the_TT_genotype_who_are_treated_with_antihypertensives_may_have_an_increased_risk_for_resistant_hypertension_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_resistant_hypertension._";PGKB_RACE=NR
12	96438553	rs2660845	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=LTA4H_(PA24345);PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_montelukast_may_have_a_decreased_but_not_absent_risk_of_asthma_exacerbations_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma_exacerbations_with_montelukast_treatment.""AG:Patients_with_the_AG_genotype_and_asthma_who_are_treated_with_montelukast_may_have_an_increased_risk_of_asthma_exacerbations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma_exacerbations_with_montelukast_treatment.""GG:Patients_with_the_GG_genotype_and_asthma_who_are_treated_with_montelukast_may_have_an_increased_risk_of_asthma_exacerbations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_asthma_exacerbations_with_montelukast_treatment.";PGKB_RACE=White
12	107395106	rs8192440	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CRY1_(PA26904);PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GA:Patients_with_the_GA_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=White
12	110042348	rs10161126	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=alendronate_(PA448082);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bone_Diseases_(PA443532);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_osteoporosis_or_osteopenia_may_have_a_poorer_response_when_treated_with_alendronate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_alendronate.""AG:Patients_with_the_AG_genotype_and_osteoporosis_or_osteopenia_may_have_a_poorer_response_when_treated_with_alendronate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_alendronate.""GG:Patients_with_the_GG_genotype_and_osteoporosis_or_osteopenia_may_have_a_better_response_when_treated_with_alendronate_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_alendronate.";PGKB_RACE=Asian
12	121458400	rs12819210	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=OASL_(PA31879);PGKB_DRUG="peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_(PA444445);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_SVR_(sustained_virological_response)_when_treated_with_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peg-interferons.""CT:Patients_with_the_CT_genotype_may_have_decreased_SVR_(sustained_virological_response)_when_treated_with_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peg-interferons.""TT:Patients_with_the_TT_genotype_may_have_increased_SVR_(sustained_virological_response)_when_treated_with_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peg-interferons.";PGKB_RACE=White
12	125284748	rs5888	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SCARB1_(PA97);PGKB_DRUG=atorvastatin_(PA448500);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_who_are_treated_with_atorvastatin_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._";PGKB_RACE=NR
12	125348263	rs4238001	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SCARB1_(PA97);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertriglyceridemia_(PA446120);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertriglyceridemia_may_have_a_decreased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate._""CT:Patients_with_the_CT_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate._""TT:Patients_with_the_TT_genotype_and_hypertriglyceridemia_may_have_an_increased_response_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate._";PGKB_RACE=White
13	23231920	rs9552679	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=salbutamol_(PA448068);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.""CT:Patients_with_the_CT_genotype_may_have_decreased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_TT_genotype._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.""TT:Patients_with_the_TT_genotype_may_have_increased_bronchodilator_response_(FEV1)_when_treated_with_salbutamol_in_Asthma_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_response_to_salbutamol.";PGKB_RACE=NR
13	28624294	rs1933437	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=FLT3_(PA28181);PGKB_DRUG=sunitinib_(PA162372840);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Renal_Cell_(PA443624);PGKB_TEXT="AA:Patients_with_renal_cell_carcinoma_and_the_AA_genotype_who_are_treated_with_sunitinib_may_have_an_increased_risk_of_experiencing_adverse_events_such_as_neutropenia_and_leukopenia_as_compared_to_patients_with_the_AG_and_GG_genotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_risk_of_leukopenia_neutropenia_or_other_toxicities_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib.""AG:Patients_with_renal_cell_carcinoma_and_the_AG_genotype_who_are_treated_with_sunitinib_may_have_a_decreased_risk_of_experiencing_adverse_events_such_as_neutropenia_and_leukopenia_as_compared_to_patients_with_the_AA_genotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_risk_of_leukopenia_neutropenia_or_other_toxicities_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib.""GG:Patients_with_renal_cell_carcinoma_and_the_GG_genotype_who_are_treated_with_sunitinib_may_have_a_decreased_risk_of_experiencing_adverse_events_such_as_neutropenia_and_leukopenia_as_compared_to_patients_with_the_AA_genotypes._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_risk_of_leukopenia_neutropenia_or_other_toxicities_in_patients_with_renal_cell_carcinoma_who_are_administered_sunitinib.";PGKB_RACE=Asian
13	40700622	rs953977	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="GG:Patients_with_asthma_and_the_GG_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_GT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma._""GT:Patients_with_asthma_and_the_GT_genotype_may_have_a_decreased_response_to_montelukast_as_compared_to_patients_with_the_TT_genotype_and_an_increased_response_as_compared_to_patients_with_the_GG_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma._""TT:Patients_with_asthma_and_the_TT_genotype_may_have_an_increased_response_to_montelukast_as_compared_to_patients_with_the_GT_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_affect_response_to_montelukast_in_patients_with_asthma._";PGKB_RACE=NR
13	40818284	rs7325568	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="fluorouracil_(PA128406956)""oxaliplatin_(PA131285527)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Drug_Toxicity_when_treated_with_fluorouracil_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_fluorouracil_and_oxaliplatin.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_fluorouracil_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_fluorouracil_and_oxaliplatin.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Drug_Toxicity_when_treated_with_fluorouracil_and_oxaliplatin_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_fluorouracil_and_oxaliplatin.";PGKB_RACE=White
13	43146482	rs7984870	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=TNFSF11_(PA36619);PGKB_DRUG="anastrozole_(PA448432)""letrozole_(PA450196)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_breast_cancer_and_the_CC_genotype_may_have_an_increased_likelihood_of_Aromatase_inhibitor-associated_musculoskeletal_syndrome_metabolic_bone_diseases_and_osteoporosis_when_treated_with_anastrozole_or_letrozole_as_compared_to_patients_with_the_CG_and_GG_genotypes._""CG:Patients_with_breast_cancer_and_the_genotype_CG_may_have_a_decreased_likelihood_of_Aromatase_inhibitor-associated_musculoskeletal_syndrome_metabolic_bone_diseases_and_osteoporosis_when_treated_with_anastrozole_or_letrozole_as_compared_to_patients_with_the_CC_genotype._""GG:Patients_with_breast_cancer_and_the_genotype_GG_may_have_a_decreased_likelihood_of_Aromatase_inhibitor-associated_musculoskeletal_syndrome_metabolic_bone_diseases_and_osteoporosis_when_treated_with_anastrozole_or_letrozole_as_compared_to_patients_with_the_CC_genotype._";PGKB_RACE=Asian
13	47056399	rs585719	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_(PA447207);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""CT:Patients_with_the_CT_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""TT:Patients_with_the_TT_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=Black_or_African_American
13	47409034	rs6314	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=HTR2A_(PA193),HTR2A_(PA193);PGKB_DRUG=paroxetine_(PA450801),antidepressants_(PA452229);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depression_(PA447278),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_paroxetine_may_have_a_reduced_response_and_reduced_likelihood_of_remission_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment_and_likelihood_of_remission._""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_paroxetine_may_have_a_better_response_and_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment_and_likelihood_of_remission._""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_paroxetine_may_have_a_reduced_response_and_reduced_likelihood_of_remission_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment_and_likelihood_of_remission._","AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_who_are_treated_with_antidepressants_and_other_treatments_may_have_a_reduced_response_and_reduced_likelihood_of_remission_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_for_major_depressive_disorder_and_likelihood_of_remission._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_who_are_treated_with_antidepressants_and_other_treatments_may_have_a_better_response_and_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_for_major_depressive_disorder_and_likelihood_of_remission._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_who_are_treated_with_antidepressants_and_other_treatments_may_have_a_better_response_and_an_increased_likelihood_of_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_for_major_depressive_disorder_and_likelihood_of_remission._";PGKB_RACE=White,White
13	47411985	rs7997012	A	G	.	.	PGKB_INDEX=3;PGKB_GENE=HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193);PGKB_DRUG=venlafaxine_(PA451866),olanzapine_(PA450688),"antidepressants_(PA452229)""citalopram_(PA449015)""Selective_serotonin_reuptake_inhibitors_(PA164713257)";PGKB_TYPE=Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,2B;PGKB_DISEASE=Anxiety_Disorders_(PA447196),NR,"Depression_(PA447278)""Depressive_Disorder_(PA447207)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_less_likely_to_respond_to_venlafaxine_as_compared_to_patients_with_the_GA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine._""GA:Patients_with_the_GA_genotype_may_be_more_likely_to_respond_to_venlafaxine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine._""GG_:Patients_with_the_GG_genotype_may_be_more_likely_to_respond_to_venlafaxine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine._","AA:Patients_with_the_AA_genotype_and_psychiatric_disorders_who_are_treated_with_olanzapine_may_have_an_increased_risk_for_more_side_effects_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects_with_olanzapine_treatment.""AG:Patients_with_the_AG_genotype_and_psychiatric_disorders_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_for_more_side_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects_with_olanzapine_treatment.""GG:Patients_with_the_GG_genotype_and_psychiatric_disorders_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_for_more_side_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_side_effects_with_olanzapine_treatment.","AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_citalopram_or_antidepressants_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._However_no_association_has_been_reported_in_studies_that_determined_response_to_different_Selective_serotonin_reuptake_inhibitors_(SSRIs)_or_antidepressants_as_a_drug_class._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_citalopram_may_be_more_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._However_no_association_has_been_reported_in_studies_that_determined_response_to_different_Selective_serotonin_reuptake_inhibitors_(SSRIs)_or_antidepressants_as_a_drug_class._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_citalopram_may_be_less_likely_to_have_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._However_no_association_has_been_reported_in_studies_that_determined_response_to_different_Selective_serotonin_reuptake_inhibitors_(SSRIs)_or_antidepressants_as_a_drug_class._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antidepressants.";PGKB_RACE=White,White,NR
13	47433355	rs9316233	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=HTR2A_(PA193);PGKB_DRUG=escitalopram_(PA10074);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_(PA447207);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_antidepressant_response_to_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_escitalopram.""CG:Patients_with_the_CG_genotype_may_have_increased_antidepressant_response_to_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_escitalopram.""GG:Patients_with_the_GG_genotype_may_have_decreased_antidepressant_response_to_escitalopram_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_escitalopram.";PGKB_RACE=White
13	47466622	rs6305	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=HTR2A_(PA193);PGKB_DRUG="Analgesics_(PA164712362)""Antiinflammatory_agents_non-steroids_(PA164712462)""Ergot_alkaloids_(PA164712741)""opioids_(PA452618)""sumatriptan_(PA451566)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""AG:Patients_with_the_AG_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""GG:Patients_with_the_GG_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.";PGKB_RACE=NR
13	47469940	rs6313	G	A	.	.	PGKB_INDEX=9;PGKB_GENE=HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193);PGKB_DRUG=efavirenz_(PA449441),risperidone_(PA451257),paroxetine_(PA450801),olanzapine_(PA450688),"olanzapine_(PA450688)""risperidone_(PA451257)",antidepressants_(PA452229),"fluvoxamine_(PA449690)""paroxetine_(PA450801)","fluvoxamine_(PA449690)""paroxetine_(PA450801)",citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Toxicity/ADR,Efficacy,Efficacy,Efficacy,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=4,3,3,3,3,3,4,4,3;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)",Drug_Toxicity_(PA443937),Depression_(PA447278),"Schizophrenia_(PA447216)""Weight_gain_(PA128406954)",Alzheimer_Disease_(PA443319),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321),Depressive_Disorder_(PA447207);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_a_decreased_risk_of_sadness_as_a_side_effect_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_efavirenz-induced_side_effects.""AG:Patients_with_the_AG_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_a_decreased_risk_of_sadness_as_a_side_effect_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_efavirenz-induced_side_effects.""GG:Patients_with_the_GG_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_an_increased_risk_of_sadness_as_a_side_effect_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_efavirenz-induced_side_effects.","AA:Patients_with_the_AA_genotype_who_are_treated_with_risperidone_may_have_an_increased_likelihood_of_cardiovascular_adverse_events_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_risperidone-induced_adverse_reactions._""AG:Patients_with_the_AG_genotype_who_are_treated_with_risperidone_may_have_a_reduced_but_not_absent_risk_of_cardiovascular_adverse_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_risperidone-induced_adverse_reactions._""GG:Patients_with_the_GG_genotype_who_are_treated_with_risperidone_may_have_a_reduced_but_not_absent_risk_of_cardiovascular_adverse_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_risperidone-induced_adverse_reactions._","AA:Patients_with_the_AA_genotype_and_depression_who_are_treated_with_paroxetine_may_have_a_reduced_risk_of_adverse_drug_reactions_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions._""AG:Patients_with_the_AG_genotype_and_depression_who_are_treated_with_paroxetine_may_have_a_reduced_risk_of_adverse_drug_reactions_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions._""GG:Patients_with_the_GG_genotype_and_depression_who_are_treated_with_paroxetine_may_have_an_increased_risk_of_adverse_drug_reactions_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions._","AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.""AG:Patients_with_the_GA_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_GA_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.","AA:Patients_with_the_AA_genotype_and_Alzheimer_disease_may_have_increased_risk_for_treatment-resistance_to_olanzapine_or_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine_or_risperidone.""AG:Patients_with_the_AG_genotype_and_Alzheimer_disease_may_have_increased_risk_for_treatment-resistance_to_olanzapine_or_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine_or_risperidone.""GG:Patients_with_the_GG_genotype_and_Alzheimer_disease_may_have_decreased_but_not_non-existent_risk_for_treatment-resistance_to_olanzapine_or_risperidone_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_olanzapine_or_risperidone.","AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_have_a_better_response_to_treatment_with_antidepressants_as_compared_to_patients_with_the_GG_genotype._However_some_studies_show_no_association_with_response_or_remission._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_may_have_a_better_response_to_treatment_with_antidepressants_as_compared_to_patients_with_the_GG_genotype._However_some_studies_show_no_association_with_response_or_remission._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_have_a_poorer_response_to_treatment_with_antidepressants_as_compared_to_patients_with_the_AA_or_AG_genotype._However_some_studies_show_no_association_with_response_or_remission._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants._","AA:Patients_with_the_AA_genotype_who_are_treated_with_fluvoxamine_or_paroxetine_may_have_a_faster_score_reduction_for_the_in_Somatic_anxiety_item_of_HAM-D_as_compared_to_patients_with_the_GG_genotype._However_no_association_regarding_response_was_found_with_the_overall_HAM-D_score._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine_or_paroxetine.""AG:Patients_with_the_AG_genotype_who_are_treated_with_fluvoxamine_or_paroxetine_may_have_a_slower_score_reduction_for_the_in_Somatic_anxiety_item_of_HAM-D_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_faster_score_reduction_for_the_in_Somatic_anxiety_item_of_HAM-D_as_compared_to_patients_with_the_GG_genotype._However_no_association_regarding_response_was_found_with_the_overall_HAM-D_score._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine_or_paroxetine.""GG:Patients_with_the_GG_genotype_who_are_treated_with_fluvoxamine_or_paroxetine_may_have_a_slower_score_reduction_for_the_in_Somatic_anxiety_item_of_HAM-D_as_compared_to_patients_with_the_AA_genotype._However_no_association_regarding_response_was_found_with_the_overall_HAM-D_score._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine_or_paroxetine.","AA:Patients_with_the_AA_genotype_who_are_treated_with_fluvoxamine_or_paroxetine_may_have_a_slower_score_reduction_for_the_in_Delusion_and_Activity_scores_item_of_HAM-D_as_compared_to_patients_with_the_GG_genotype._However_no_association_regarding_response_was_found_with_the_overall_HAM-D_score._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine_or_paroxetine.""AG:Patients_with_the_GG_genotype_who_are_treated_with_fluvoxamine_or_paroxetine_may_have_a_faster_score_reduction_for_the_in_Delusion_and_Activity_scores_item_of_HAM-D_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_slower_score_reduction_for_the_in_Delusion_and_Activity_scores_item_of_HAM-D_as_compared_to_patients_with_the_GG_genotype._However_no_association_regarding_response_was_found_with_the_overall_HAM-D_score._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine_or_paroxetine.""GG:Patients_with_the_GG_genotype_who_are_treated_with_fluvoxamine_or_paroxetine_may_have_a_faster_score_reduction_for_the_in_Delusion_and_Activity_scores_item_of_HAM-D_as_compared_to_patients_with_the_AA_genotype._However_no_association_regarding_response_was_found_with_the_overall_HAM-D_score._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine_or_paroxetine.","AA:Patients_with_the_AA_genotype_and_major_depression_may_have_decreased_but_not_absent_risk_of_heart_palpitations_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""AG:Patients_with_the_AG_genotype_and_major_depression_may_have_decreased_but_not_absent_risk_of_heart_palpitations_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype_or_may_have_increased_risk_of_heart_palpitations_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_increased_risk_of_heart_palpitations_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=White,White,White,Asian,White,NR,White,Asian,NR
13	47471478	rs6311	C	T	.	.	PGKB_INDEX=4;PGKB_GENE=HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193),HTR2A_(PA193);PGKB_DRUG=risperidone_(PA451257),antipsychotics_(PA452233),fluvoxamine_(PA449690),escitalopram_(PA10074);PGKB_TYPE=Efficacy,Efficacy,"Efficacy""Toxicity/ADR",Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Autistic_Disorder_(PA447198),tardive_dyskinesia_(PA447268),Depressive_Disorder_Major_(PA447321),Anxiety_Disorders_(PA447196);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_poorer_response_to_risperidone_in_children_with_autism_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_lower_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_than_CC_homozygotes_indicating_improved_symptoms_and_response_to_risperidone_in_children_with_autism_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_lower_Autism_Treatment_Evaluation_Checklist_(ATEC)_scores_than_CC_homozygotes_indicating_improved_symptoms_and_response_to_risperidone_in_children_with_autism_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_genotypes_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antipsychotics.""CT:Patients_with_the_CT_genotype_may_have_decreased_risk_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_genotypes_TT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antipsychotics.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_genotypes_CC_+_CT._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_antipsychotics.","CC:Patients_with_the_CC_genotype_who_are_treated_with_fluvoxamine_may_have_an_increased_risk_of_gastrointestinal_side_effects_and_increased_response_as_compared_to_patients_with_the_TC_or_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.""CT:Patients_with_the_CT_genotype_who_are_treated_with_fluvoxamine_may_have_an_increased_risk_of_gastrointestinal_side_effects_and_decreased_response_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.""TT:Patients_with_the_TT_genotype_who_are_treated_with_fluvoxamine_may_have_a_decreased_but_not_absent_risk_of_gastrointestinal_side_effects_and_decreased_response_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.","CC:Patients_with_the_CC_genotype_and_anxiety_disorder_who_are_treated_with_escitalopram_may_have_decreased_but_not_absent_risk_of_adverse_cognitive_effects_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_escitalopram._""CT:Patients_with_the_CT_genotype_and_anxiety_disorder_who_are_treated_with_escitalopram_may_have_increased_risk_of_adverse_cognitive_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_escitalopram._""TT:Patients_with_the_TT_genotype_and_anxiety_disorder_who_are_treated_with_escitalopram_may_have_increased_risk_of_adverse_cognitive_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_escitalopram._";PGKB_RACE=NR,White,Asian,White
13	48619855	rs116855232	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NUDT15_(PA134963132);PGKB_DRUG="azathioprine_(PA448515)""mercaptopurine_(PA450379)";PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=1B;PGKB_DISEASE="Inflammatory_Bowel_Diseases_(PA446116)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_thiopurines_for_inflammatory_bowel_diseases_(IBD)_or_acute_lymphoblastic_leukemia_(ALL)_may_have_a_reduced_but_not_absent_risk_of_developing_leukopenia_or_alopecia_as_compared_to_patients_with_the_CT_or_TT_genotype._Patients_may_also_tolerate_higher_doses_of_thiopurines_and_be_less_likely_to_discontinue_thiopurine_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype_possibly_due_to_the_reduced_risk_for_adverse_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia_alopecia_or_treatment_discontinuation._""CT:Patients_with_the_CT_genotype_who_are_treated_with_thiopurines_for_inflammatory_bowel_diseases_(IBD)_or_acute_lymphoblastic_leukemia_(ALL)_may_have_an_increased_risk_of_developing_leukopenia_or_alopecia_as_compared_to_patients_with_the_CC_genotype._Patients_may_also_require_lower_doses_of_thiopurines_and_be_more_likely_to_discontinue_thiopurine_treatment_as_compared_to_patients_with_the_CC_genotype_possibly_due_to_the_increased_risk_for_adverse_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia_alopecia_or_treatment_discontinuation._""TT:Patients_with_the_TT_genotype_who_are_treated_with_thiopurines_for_inflammatory_bowel_diseases_(IBD)_or_acute_lymphoblastic_leukemia_(ALL)_may_have_an_increased_risk_of_developing_leukopenia_or_alopecia_as_compared_to_patients_with_the_CC_genotype._Patients_may_also_require_lower_doses_of_thiopurines_and_be_more_likely_to_discontinue_thiopurine_treatment_as_compared_to_patients_with_the_CC_genotype_possibly_due_to_the_increased_risk_for_adverse_effects._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_leukopenia_alopecia_or_treatment_discontinuation._";PGKB_RACE=NR
13	52515354	rs1801249	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ATP7B_(PA73);PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="AA:Women_with_ovarian_cancer_and_the_AA_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes.""AG:Women_with_ovarian_cancer_and_the_AG_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""GG:Women_with_ovarian_cancer_and_the_GG_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_such_as_paclitaxel_and_docetaxel_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._";PGKB_RACE=NR
13	52524488	rs1061472	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ATP7B_(PA73);PGKB_DRUG="carboplatin_(PA448803)""taxanes_(PA150481189)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Women_with_ovarian_cancer_and_the_CC_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""CT:Women_with_ovarian_cancer_and_the_CT_genotype_may_have_a_decreased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_as_compared_to_women_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._""TT:Women_with_ovarian_cancer_and_the_TT_genotype_may_have_an_increased_likelihood_of_gastrointestinal_toxicity_when_exposed_to_carboplatin_and_taxanes_as_compared_to_women_with_the_CC_or_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_likelihood_of_gastrointestinal_toxicity_in_women_with_ovarian_cancer_who_are_administered_carboplatin_and_taxanes._";PGKB_RACE=NR
13	52566126	rs9535826	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=ATP7B_(PA73);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Lung_Neoplasms_(PA444818);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_an_increased_response_to_platinum_compounds_as_compared_to_patients_with_the_GT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_response_to_platinum_compounds_in_patients_with_lung_cancer._""GT:Patients_with_the_GT_genotype_and_lung_cancer_may_have_a_decreased_response_to_platinum_compounds_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_platinum_compounds_in_patients_with_lung_cancer._""TT:Patients_with_the_TT_genotype_and_lung_cancer_may_have_a_decreased_response_to_platinum_compounds_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_platinum_compounds_in_patients_with_lung_cancer._";PGKB_RACE=Asian
13	52573422	rs9535828	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ATP7B_(PA73);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Lung_Neoplasms_(PA444818);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_lung_cancer_may_have_an_improved_response_to_platinum_compounds_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_affect_response_to_platinum_compounds_in_patients_with_lung_cancer._""AG:Patients_with_the_AG_genotype_and_lung_cancer_may_have_a_decreased_response_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_platinum_compounds_in_patients_with_lung_cancer._""GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_a_decreased_response_to_platinum_compounds_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_affect_response_to_platinum_compounds_in_patients_with_lung_cancer._";PGKB_RACE=Asian
13	60319019	rs77876672	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=DIAPH3_(PA27335);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""CT:Patients_with_the_CT_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_TT_genotypes_and_an_increased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._""TT:Patients_with_the_TT_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension._";PGKB_RACE=White
13	95672457	rs9516519	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_B-Cell_Acute_(PA446157);PGKB_TEXT="GG:Patients_with_the_GG_genotype_who_are_treated_with_methotrexate_may_have_decreased_risk_for_toxicity_and_decreased_plasma_level_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GT:Patients_with_the_GT_genotype_who_are_treated_with_methotrexate_may_have_decreased_risk_for_toxicity_and_decreased_plasma_level_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_who_are_treated_with_methotrexate_may_have_increased_risk_for_toxicity_and_increased_plasma_level_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=White
13	95672950	rs1059751	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Individuals_with_the_AA_genotype_and_HIV_may_have_a_decreased_risk_of_developing_Kidney_disease_when_treated_with_tenofovir_as_compared_to_those_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_may_affect_risk_of_developing_kidney_disease_in_individuals_with_HIV_who_are_taking_tenofovir._""AG:Individuals_with_the_AG_genotype_and_HIV_may_have_a_decreased_risk_of_developing_Kidney_disease_when_treated_with_tenofovir_as_compared_to_those_with_the_GG_genotype_and_an_increased_risk_as_compared_to_those_with_the_AA_genotype._Other_clinical_and_genetic_may_affect_risk_of_developing_kidney_disease_in_individuals_with_HIV_who_are_taking_tenofovir._""GG:Individuals_with_the_GG_genotype_and_HIV_may_have_a_increased_risk_of_developing_Kidney_disease_when_treated_with_tenofovir_as_compared_to_those_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_may_affect_risk_of_developing_kidney_disease_in_individuals_with_HIV_who_are_taking_tenofovir._";PGKB_RACE=Asian
13	95673791	rs3742106	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_decreased_mean_plasma_concentrations_of_tenofovir_in_people_with_HIV_as_compared_to_patients_with_genotype_CC_or_AC._Other_genetic_and_clinical_factors_may_also_affect_tenofovir_plasma_concentrations.""AC:Patients_with_genotype_AC_may_have_increased_mean_plasma_concentrations_of_tenofovir_in_people_with_HIV_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_affect_tenofovir_plasma_concentrations.""CC:Patients_with_genotype_CC_may_have_increased_mean_plasma_concentrations_of_tenofovir_in_people_with_HIV_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_affect_tenofovir_plasma_concentrations.";PGKB_RACE=Asian
13	95683243	rs9561765	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=imatinib_(PA10804);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Gastrointestinal_Stromal_Tumors_(PA151958383);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_gastrointestinal_stromal_tumors_may_have_a_shorter_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.""AG:Patients_with_the_AG_genotype_and_gastrointestinal_stromal_tumors_may_have_prolonged_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.""GG:No_patients_with_the_GG_genotype_were_present_in_this_study._However_patients_with_the_AG_genotype_and_gastrointestinal_stromal_tumors_may_have_prolonged_time_to_progression_when_treated_with_imatinib_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_time_to_progression.";PGKB_RACE=White
13	95696540	rs11568695	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=zidovudine_(PA451954);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_who_are_treated_with_indinavir_lamivudine_or_zidovudine_may_have_a_decreased_median_zidovudine-triphosphate_concentration_at_a_marginally_significance_after_gender_adjustment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""TC:Patients_with_the_TC_genotype_and_HIV_who_are_treated_with_indinavir_lamivudine_or_zidovudine_may_have_an_increased_median_zidovudine-triphosphate_concentration_at_a_marginally_significance_after_gender_adjustment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""TT:Patients_with_the_TT_genotype_and_HIV_who_are_treated_with_indinavir_lamivudine_or_zidovudine_may_have_an_increased_median_zidovudine-triphosphate_concentration_at_a_marginally_significance_after_gender_adjustment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.";PGKB_RACE=Black_or_African_American
13	95713715	rs9561778	G	A,T	.	.	PGKB_INDEX=2;PGKB_GENE=ABCC4_(PA397),ABCC4_(PA397);PGKB_DRUG=cyclophosphamide_(PA449165),"cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""fluorouracil_(PA128406956)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Drug_Toxicity_(PA443937)","Breast_Neoplasms_(PA443560)""Neoplasms_(PA445062)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_a_decreased_but_not_absent_risk_of_adverse_drug_reactions_in_particular_neutropenia/_leukopenia_and_gastrointestinal_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_cyclophosphamide_treatment.""GT:Patients_with_the_GT_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_an_increased_risk_of_adverse_drug_reactions_in_particular_neutropenia/_leukopenia_and_gastrointestinal_toxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_but_not_absent_risk_of_adverse_drug_reactions_in_particular_neutropenia/_leukopenia_and_gastrointestinal_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_cyclophosphamide_treatment.""TT:Patients_with_the_GT_genotype_and_breast_cancer_who_are_treated_with_cyclophosphamide_may_have_an_increased_risk_of_adverse_drug_reactions_in_particular_neutropenia/_leukopenia_and_gastrointestinal_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_cyclophosphamide_treatment.","GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_of_ADR_when_treated_with_CAF_(cyclophosphamide_doxorubicin_and_fluorouracil)_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_ADRs.""GT:Patients_with_the_GT_genotype_may_have_an_increased_risk_of_ADR_when_treated_with_CAF_(cyclophosphamide_doxorubicin_and_fluorouracil)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_ADRs.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_ADR_when_treated_with_CAF_(cyclophosphamide_doxorubicin_and_fluorouracil)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_ADRs.";PGKB_RACE=Asian,Asian
13	95714976	rs1751034	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=NR;PGKB_EVIDENCE=2B;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)";PGKB_TEXT="CC:The_CC_genotype_carriers_had_lower_tenofovir_renal_clearance_and_higher_AUC_than_TT_genotype.""CT:The_TC_genotype_carriers_had_lower_tenofovir_renal_clearance_and_higher_AUC_than_TT_genotype.""TT:The_TT_genotype_is_associated_with_higher_tenofovir_renal_clearance_and_lower_AUC_compared_to_TC_and_CC_cariers.";PGKB_RACE=White
13	95717906	rs1678387	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.";PGKB_RACE=White
13	95775432	rs16950650	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG="cisplatin_(PA449014)""irinotecan_(PA450085)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Small_Cell_(PA446661);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Small_Cell_Carcinoma_as_compared_to_patients_with_genotype_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_decreased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Small_Cell_Carcinoma_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Small_Cell_Carcinoma_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=Asian
13	95863008	rs11568658	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=latanoprost_(PA164774763);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Glaucoma_Open-Angle_(PA444282);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_open-angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_latanoprost._*Please_note:_in_the_single_study_listed_below_individuals_of_genotype_AA_were_not_analyzed.""AC:Patients_with_the_AC_genotype_and_open-angle_glaucoma_may_have_a_decreased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_latanoprost._*Please_note:_in_the_single_study_listed_below_individuals_of_genotype_AA_were_not_analyzed.""CC:Patients_with_the_CC_genotype_and_open-angle_glaucoma_may_have_an_increased_response_to_latanoprost_(as_determined_by_a_reduction_in_intraocular_pressure)_as_compared_to_patients_with_the_AA_or_AC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_latanoprost._*Please_note:_in_the_single_study_listed_below_individuals_of_genotype_AA_were_not_analyzed.";PGKB_RACE=Asian
13	95923523	rs7317112	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC4_(PA397);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_lymphoblastic_leukemia_may_have_an_increased_risk_for_mucositis_when_treated_with_methotrexate_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_mucositis.""AG:Patients_with_the_AG_genotype_and_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_for_mucositis_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_mucositis.""GG:Patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_may_have_a_decreased_risk_for_mucositis_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_mucositis.";PGKB_RACE=NR
13	96631221	rs9590353	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=UGGT2_(PA38015);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""GT:Patients_with_the_GT_genotype_and_essential_hypertension_may_have_a_decreased_response_as_compared_to_patients_with_the_TT_genotype_and_an_increased_response_as_compared_to_patients_with_the_GG_genotype_when_treated_with_hydrochlorothiazide._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""TT:Patients_with_the_TT_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_GT_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.";PGKB_RACE=White
13	101797840	rs7992226	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NALCN_(PA162396840);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_childhood_acute_lymphoblastic_leukemia_(ALL)_may_have_reduced_exposure_to_methotrexate_and_higher_likelihood_of_minimal_residual_disease_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate.""AG:Patients_with_the_AG_genotype_and_childhood_acute_lymphoblastic_leukemia_(ALL)_may_have_increased_exposure_to_methotrexate_and_lower_likelihood_of_minimal_residual_disease_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate.""GG:Patients_with_the_GG_genotype_and_childhood_acute_lymphoblastic_leukemia_(ALL)_may_have_increased_exposure_to_methotrexate_and_lower_likelihood_of_minimal_residual_disease_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_methotrexate.";PGKB_RACE=NR
13	103528002	rs17655	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=ERCC5_(PA27851);PGKB_DRUG=platinum_(PA150595617);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_the_CC_genotype_and_early_stage_ovarian_cancer_may_have_increased_progression-free_survival_and_overall_survival_whereas_patients_with_the_CC_genotype_and_late_stage_ovarian_cancer_may_have_decreased_progression-free_survival_and_overall_survival_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._""CG:Patients_the_CG_genotype_and_early_stage_ovarian_cancer_may_have_increased_progression-free_survival_and_overall_survival_whereas_patients_with_the_CC_genotype_and_late_stage_ovarian_cancer_may_have_decreased_progression-free_survival_and_overall_survival_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._""GG:Patients_the_GG_genotype_and_early_stage_ovarian_cancer_may_have_decreased_progression-free_survival_and_overall_survival_whereas_patients_with_the_GG_genotype_and_late_stage_ovarian_cancer_may_have_increased_progression-free_survival_and_overall_survival_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_chemotherapy._";PGKB_RACE=NR
13	103697728	rs2301159	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC10A2_(PA318);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
13	103714254	rs9514091	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC10A2_(PA318);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_for_cardiotoxicity_when_exposed_to_anthracyclines_for_pediatric_cancer_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_cardiotoxicity.""AG:Patients_with_the_AG_genotype_may_have_decreased_but_not_absent_risk_for_cardiotoxicity_when_exposed_to_anthracyclines_for_pediatric_cancer_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_cardiotoxicity.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_cardiotoxicity_when_exposed_to_anthracyclines_for_pediatric_cancer_as_compared_to_patients_with_the_AA_or_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_risk_for_cardiotoxicity.";PGKB_RACE=NR
13	103723722	rs7319981	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""GG:Patients_with_the_GG_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.";PGKB_RACE=NR
13	105807023	rs16965962	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_may_have_an_increased_general_side-effect_burden_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_general_side-effect_burden.""AC:Patients_with_the_AC_genotype_and_major_depressive_disorder_may_have_an_increased_general_side-effect_burden_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype_or_a_decreased_general_side-effect_burden_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_general_side-effect_burden.""CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_a_decreased_general_side-effect_burden_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_general_side-effect_burden.";PGKB_RACE=NR
14	32093548	rs7142881	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NUBPL_(PA134907818);PGKB_DRUG=iloperidone_(PA161199368);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acquired_Long_QT_Syndrome_(aLQTS)_(PA447300);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_who_are_treated_with_iloperidone_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
14	34526819	rs4982133	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""AC:Patients_with_the_AC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=Asian
14	48015982	rs1160351	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=MDGA2_(PA162395090);PGKB_DRUG="fluvoxamine_(PA449690)""milnacipran_(PA164752812)""paroxetine_(PA450801)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_who_are_treated_with_fluvoxamine_milnacipran_or_paroxetine_may_have_an_increased_risk_of_sexsual_dysfunction_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_fluvoxamine_milnacipran_or_paroxetine._""AC:Patients_with_the_AA_genotype_and_major_depression_who_are_treated_with_fluvoxamine_milnacipran_or_paroxetine_may_have_an_increased_risk_of_sexsual_dysfunction_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_of_sexsual_dysfunction_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_fluvoxamine_milnacipran_or_paroxetine._""CC:Patients_with_the_CC_genotype_and_major_depression_who_are_treated_with_fluvoxamine_milnacipran_or_paroxetine_may_have_a_decreased_but_not_absent_risk_of_sexsual_dysfunction_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_fluvoxamine_milnacipran_or_paroxetine._";PGKB_RACE=Asian
14	52780651	rs2075797	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=PTGER2_(PA287);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_of_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CG:Patients_with_the_GG_genotype_and_asthma_who_are_treated_with_aspirin_may_have_decreased_risk_of_aspirin-intolerant_asthma_as_compared_to_patients_with_the_CC_genotype_or_may_have_increased_risk_of_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""GG:Patients_with_the_GG_genotype_and_asthma_who_are_treated_with_aspirin_may_have_decreased_risk_of_aspirin-intolerant_asthma_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
14	52781101	rs1353411	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PTGER2_(PA287);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_when_exposed_to_aspirin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_when_exposed_to_aspirin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_when_exposed_to_aspirin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
14	64699816	rs4986938	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ESR2_(PA27886);PGKB_DRUG=tamoxifen_(PA451581);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_higher_tamoxifen-induced_increase_in_triglycerides_in_postmenopausal_woman_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_influence_the_response_to_tamoxifen.""CT:Patients_with_the_CT_genotype_may_have_lower_tamoxifen-induced_increase_in_triglycerides_in_postmenopausal_woman_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_influence_the_response_to_tamoxifen.""TT:Patients_with_the_TT_genotype_may_have_lower_tamoxifen-induced_increase_in_triglycerides_in_postmenopausal_woman_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_influence_the_response_to_tamoxifen.";PGKB_RACE=NR
14	64700045	rs944050	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Pancreatic_Neoplasms_(PA445218);PGKB_TEXT="CC:Patients_with_genotype_CC_may_have_decreased_response_to_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_gemcitabine.""CT:Patients_with_genotype_CT_may_have_decreased_response_to_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_gemcitabine.""TT:Patients_with_genotype_TT_may_have_increased_response_to_gemcitabine_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_gemcitabine.";PGKB_RACE=Asian
14	64716693	rs10140457	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=letrozole_(PA450196);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Women_with_the_AA_genotype_were_not_studied._However_women_with_the_AC_genotype_and_breast_neoplasms_may_have_a_decreased_risk_of_bone_density_loss_when_exposed_to_letrozole_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_bone_density_loss.""AC:Women_with_the_AC_genotype_and_breast_neoplasms_may_have_a_decreased_risk_of_bone_density_loss_when_exposed_to_letrozole_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_bone_density_loss.""CC:Women_with_the_CC_genotype_and_breast_neoplasms_may_have_an_increased_risk_of_bone_density_loss_when_exposed_to_letrozole_as_compared_to_patients_with_the_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_bone_density_loss.";PGKB_RACE=NR
14	64908845	rs2236225	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MTHFD1_(PA31236);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_event_free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_response_to_therapy.""AG:Patients_with_the_AG_genotype_may_have_decreased_event_free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_response_to_therapy.""GG:Patients_with_the_GG_genotype_may_have_increased_event_free_survival_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_response_to_therapy.";PGKB_RACE=White
14	65453063	rs11623866	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="carboplatin_(PA448803)""lonafarnib_(PA166129466)""paclitaxel_(PA450761)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_ovarian_cancer_and_the_CC_genotype_may_have_an_increased_response_to_carboplatin_lonafarnib_and_paclitaxel_as_compared_to_patients_with_the_GG_genotype._In_a_single_study_the_authors_compared_outcomes_between_genotypes_between_treatments._Other_clinical_and_genetic_factors_may_also_influence_response_to_carboplatin_lonafarnib_and_paclitaxel_in_patients_with_ovarian_cancer._Please_note_the_treatment_arm_that_included_paclitaxel_and_carboplatin_WITHOUT_lonafarnib_showed_no_significant_differences_in_treatment_outcome_when_comparing_between_genotypes.""CG:Patients_with_ovarian_cancer_and_the_CG_genotype_may_have_an_increased_response_to_carboplatin_lonafarnib_and_paclitaxel_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_carboplatin_lonafarnib_and_paclitaxel_in_patients_with_ovarian_cancer._Please_note_the_treatment_arm_that_included_paclitaxel_and_carboplatin_WITHOUT_lonafarnib_showed_no_significant_differences_in_treatment_outcome_when_comparing_between_genotypes.""GG:Patients_with_ovarian_cancer_and_the_GG_genotype_may_have_a_decreased_response_to_carboplatin_lonafarnib_and_paclitaxel_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_carboplatin_lonafarnib_and_paclitaxel_in_patients_with_ovarian_cancer._Please_note_the_treatment_arm_that_included_paclitaxel_and_carboplatin_WITHOUT_lonafarnib_showed_no_significant_differences_in_treatment_outcome_when_comparing_between_genotypes.";PGKB_RACE=NR
14	73394614	rs7160796	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=DCAF4_(PA165478762);PGKB_DRUG=corticosteroids_(PA10832);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_who_are_treated_with_corticosteroids_may_have_increased_change_in_forced_expiratory_volume_in_1_s_(FEV1)_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids.""CG:Patients_with_the_CG_genotype_and_asthma_who_are_treated_with_corticosteroids_may_have_a_decreased_change_in_forced_expiratory_volume_in_1_s_(FEV1)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids.""GG:Patients_with_the_GG_genotype_and_asthma_who_are_treated_with_corticosteroids_may_have_a_decreased_change_in_forced_expiratory_volume_in_1_s_(FEV1)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_corticosteroids.";PGKB_RACE=Asian
14	73721775	rs11628713	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PAPLN_(PA134914395);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depression_who_are_treated_with_citalopram_may_have_a_decreased_but_not_absent_risk_for_suicidal_ideation_as_compared_to_patients_with_the_CC_genotype.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_suicidal_ideation.""CT:Patients_with_the_TT_genotype_and_major_depression_who_are_treated_with_citalopram_may_have_an_increased_risk_for_suicidal_ideation_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_for_suicidal_ideation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_suicidal_ideation.""TT:Patients_with_the_TT_genotype_and_major_depression_who_are_treated_with_citalopram_may_have_an_increased_risk_for_suicidal_ideation_as_compared_to_patients_with_the_CC_genotype.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_suicidal_ideation.";PGKB_RACE=White
14	87628156	rs2776546	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_greater_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_AC_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""AC:Patients_with_the_AC_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_smaller_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_AA_genotype_and_greater_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""CC:Patients_with_the_CC_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_smaller_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_AA_or_AC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.";PGKB_RACE=White
14	95089232	rs17091162	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=SERPINA3_(PA35020);PGKB_DRUG=antineoplastic_agents_(PA452621);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Pancreatic_Neoplasms_(PA445218);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_survival_when_treated_with_antineoplastic_agents_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_AC_or_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.""AC:Patients_with_the_AC_genotype_may_have_decreased_survival_when_treated_with_antineoplastic_agents_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.""CC:Patients_with_the_CC_genotype_may_have_decreased_survival_when_treated_with_antineoplastic_agents_in_people_with_Pancreatic_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.";PGKB_RACE=NR
14	96175978	rs11849538	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=estradiol_(PA449503);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_expression_of_TCL1A_IL17RA_and_increased_expression_of_IL17A_IL12RB2_and_IL1R2_when_treated_with_estradiol_as_compared_to_patients_with_the_GG_genotype_based_on_in-vitro_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_estradiol.""CG:Patients_with_the_GG_genotype_may_have_increased_expression_of_TCL1A_IL17RA_and_decreased_expression_of_IL17A_IL12RB2_and_IL1R2_when_treated_with_estradiol_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_expression_of_TCL1A_IL17RA_and_increased_expression_of_IL17A_IL12RB2_and_IL1R2_when_treated_with_estradiol_as_compared_to_patients_with_the_GG_genotype_based_on_in-vitro_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_estradiol.""GG:Patients_with_the_GG_genotype_may_have_increased_expression_of_TCL1A_IL17RA_and_decreased_expression_of_IL17A_IL12RB2_and_IL1R2_when_treated_with_estradiol_as_compared_to_patients_with_the_CC_genotype_based_on_in-vitro_results._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_estradiol.";PGKB_RACE=White
14	96671139	rs1799722	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=BDKRB2_(PA80),BDKRB2_(PA80),BDKRB2_(PA80);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308),enalapril_(PA449456),"enalapril_(PA449456)""imidapril_(PA452640)""lisinopril_(PA450242)";PGKB_TYPE=Toxicity/ADR,Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Cough_(PA443803),NR,"Cough_(PA443803)""Essential_hypertension_(PA447288)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_for_cough_as_compared_to_patients_with_the_CT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.""CT:Patients_with_the_CT_genotype_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_for_cough_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.""TT:Patients_with_the_TT_genotype_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_for_cough_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.","CC:Patients_with_the_CC_genotype_may_have_increased_response_to_enalapril_in_people_with_Hypertension_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_efficacy_of_enalapril.""CT:Patients_with_the_CT_genotype_may_have_increased_response_to_enalapril_in_people_with_Hypertension_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_efficacy_of_enalapril.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_enalapril_in_people_with_Hypertension_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_efficacy_of_enalapril.","CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Cough_when_treated_with_enalapril_imidapril_and_lisinopril_in_people_with_Essential_hypertension_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_enalapril_imidapril_and_lisinopril.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Cough_when_treated_with_enalapril_imidapril_and_lisinopril_in_people_with_Essential_hypertension_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_enalapril_imidapril_and_lisinopril.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Cough_when_treated_with_enalapril_imidapril_and_lisinopril_in_people_with_Essential_hypertension_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_enalapril_imidapril_and_lisinopril.";PGKB_RACE=Asian,NR,Asian
14	96675933	rs8016905	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=BDKRB2_(PA80);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Cough_(PA443803);PGKB_TEXT="AA:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough_when_treated_with_Ace_Inhibitors_Plain_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough_when_treated_with_Ace_Inhibitors_Plain_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough_when_treated_with_Ace_Inhibitors_Plain_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_angiotensin-converting_enzyme_inhibitors-induced_cough.";PGKB_RACE=White
14	96688767	rs8012552	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=BDKRB2_(PA80);PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Cough_(PA443803)""Hypertension_(PA444552)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_who_are_treated_with_ACE-inhibitors_may_have_an_increased_risk_of_cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cough_with_ACE-inhibitors.""CT:Patients_with_the_CT_genotype_and_hypertension_who_are_treated_with_ACE-inhibitors_may_have_an_increased_risk_of_cough_as_compared_to_patients_with_the_TT_genotype._(please_note_that_patients_with_this_genotype_were_not_studied_directly)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cough_with_ACE-inhibitors.""TT:Patients_with_the_TT_genotype_and_hypertension_who_are_treated_with_ACE-inhibitors_may_have_a_decreased_but_not_absent_risk_of_cough_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_cough_with_ACE-inhibitors.";PGKB_RACE=NR
14	96728753	rs12050217	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=BDKRB1_(PA79);PGKB_DRUG=perindopril_(PA450877);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_perindopril_may_have_a_decreased_but_not_absent_risk_for_cardiac_events_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiac_events_when_taking_perindopril.""AG:Patients_with_the_AG_genotype_who_are_treated_with_perindopril_may_have_an_increased_risk_for_cardiac_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiac_events_when_taking_perindopril.""GG:Patients_with_the_GG_genotype_who_are_treated_with_perindopril_may_have_an_increased_risk_for_cardiac_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiac_events_when_taking_perindopril.";PGKB_RACE=White
14	104165753	rs861539	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=NR,"KLC1_(PA162393424)""XRCC3_(PA37422)";PGKB_DRUG="docetaxel_(PA449383)""irinotecan_(PA450085)""Platinum_compounds_(PA164713176)","fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Neoplasms_(PA445062),Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_response_when_treated_with_platinum_compounds_docetaxel_and_irinotecan_in_people_with_Neoplasms_as_compared_to_patients_with_genotypes_AG_or_GG._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_platinum_compounds_docetaxel_or_irinotecan_in_people_with_Neoplasms.""AG:Patients_with_the_AG_genotype_may_have_increased_response_when_treated_with_platinum_compounds_docetaxel_and_irinotecan_in_people_with_Neoplasms_as_compared_to_patients_with_genotypes_AA._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_platinum_compounds_docetaxel_or_irinotecan_in_people_with_Neoplasms.""GG:Patients_with_the_GG_genotype_may_have_increased_response_when_treated_with_platinum_compounds_docetaxel_and_irinotecan_in_people_with_Neoplasms_as_compared_to_patients_with_genotypes_AA._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_platinum_compounds_docetaxel_or_irinotecan_in_people_with_Neoplasms.","AA:Patients_with_the_AG_genotype_may_have_increased_progression_free_survival_in_people_with_colorectal_cancer_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_may_have_increased_progression_free_survival_in_people_with_colorectal_cancer_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_progression_free_survival_in_people_with_colorectal_cancer_when_treated_with_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR,White
14	105239192	rs2494732	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=AKT1_(PA24684);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_less_likely_to_have_an_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""CT:Patients_with_the_CT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_less_likely_to_have_an_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_more_likely_to_have_an_improvement_in_symptoms_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.";PGKB_RACE=Asian
14	105259734	rs1130214	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=AKT1_(PA24684);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Lung_Neoplasms_(PA444818);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_lung_cancer_who_are_treated_with_carboplatin_or_cisplatin_may_have_a_reduced_but_not_absent_risk_of_distant_disease_progression_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_chemotherapy.""AC:Patients_with_the_AC_genotype_and_lung_cancer_who_are_treated_with_carboplatin_or_cisplatin_may_have_a_reduced_but_not_absent_risk_of_distant_disease_progression_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_chemotherapy.""CC:Patients_with_the_CC_genotype_and_lung_cancer_who_are_treated_with_carboplatin_or_cisplatin_may_have_a_higher_risk_of_distant_disease_progression_as_compared_to_patients_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_chemotherapy.";PGKB_RACE=White
14	105263608	rs2494752	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=AKT1_(PA24684);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_carboplatin_or_cisplatin_may_have_decreased_risk_of_progression_of_disease_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_carboplatin_or_cisplatin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_carboplatin_or_cisplatin_may_have_increased_risk_of_progression_of_disease_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_carboplatin_or_cisplatin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_carboplatin_or_cisplatin_may_have_decreased_risk_of_progression_of_disease_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_carboplatin_or_cisplatin.";PGKB_RACE=Asian
14	105269779	rs3803300	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=AKT1_(PA24684);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_less_likely_to_have_an_improvement_in_symptoms_as_compared_to_patients_with_the_CT_or_GG_genotype._Please_note_this_did_not_reach_statistical_significance._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""CT:Patients_with_the_CT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_more_likely_to_have_an_improvement_in_symptoms_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_be_less_likely_to_have_an_improvement_in_symptoms_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.";PGKB_RACE=Asian
15	27520811	rs2061051	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GABRG3_(PA28502);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""AG:Patients_with_the_AG_genotype_may_have_increased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""GG:Patients_with_the_GG_genotype_may_have_decreased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_with_Schizophrenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.";PGKB_RACE=White
15	32396457	rs6494223	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CHRNA7_(PA114);PGKB_DRUG="donepezil_(PA449394)""galantamine_(PA449726)""rivastigmine_(PA451262)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Alzheimer_Disease_(PA443319);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Alzheimer's_disease_may_be_less_likely_to_respond_to_treatment_with_cholinesterase_inhibitors_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_cholinesterase_inhibitors.""CT:Patients_with_the_CT_genotype_and_Alzheimer's_disease_may_be_less_likely_to_respond_to_treatment_with_cholinesterase_inhibitors_as_compared_to_patients_with_the_TT_genotype_or_more_likely_to_respond_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_cholinesterase_inhibitors.""TT:Patients_with_the_TT_genotype_and_Alzheimer's_disease_may_be_more_likely_to_respond_to_treatment_with_cholinesterase_inhibitors_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_cholinesterase_inhibitors.";PGKB_RACE=NR
15	40063053	rs7179742	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=FSIP1_(PA142671750);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.";PGKB_RACE=Asian
15	40295959	rs2412459	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=EIF2AK4_(PA134947616),EIF2AK4_(PA134947616);PGKB_DRUG="olanzapine_(PA450688)""quetiapine_(PA451201)""risperidone_(PA451257)""ziprasidone_(PA451974)",haloperidol_(PA449841);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=4,4;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_may_have_increased_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_may_have_decreased_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine_quetiapine_risperidone_or_ziprasidone.","CC:Patients_with_the_CC_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_Schizophrenia_may_have_decreased_response_to_haloperidol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""CT:Patients_with_the_CT_genotype_and_Schizophrenia_may_have_decreased_response_to_haloperidol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.""TT:Patients_with_the_TT_genotype_and_Schizophrenia_may_have_increased_response_to_haloperidol_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_haloperidol.";PGKB_RACE=NR,White
15	45620985	rs1719247	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="hmg_coa_reductase_inhibitors_(PA133950441)""simvastatin_(PA451363)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_more_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins.""CT:Patients_with_the_CT_genotype_may_be_less_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_CC_genotype_and_more_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins.""TT:Patients_with_the_TT_genotype_may_be_less_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins.";PGKB_RACE=White
15	45673029	rs1346268	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="hmg_coa_reductase_inhibitors_(PA133950441)""simvastatin_(PA451363)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_less_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins.""CT:Patients_with_the_CT_genotype_may_be_less_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_TT_genotype_and_more_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins.""TT:Patients_with_the_TT_genotype_may_be_more_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins.";PGKB_RACE=White
15	45740392	rs9806699	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="hmg_coa_reductase_inhibitors_(PA133950441)""simvastatin_(PA451363)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Myocardial_Infarction_(PA445019);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_less_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_AG_or_GG_genotype._This_association_has_not_been_found_consistently_in_replication_studies._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins._""AG:Patients_with_the_AG_genotype_may_be_less_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_GG_genotype_and_more_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_AA_genotype._This_association_has_not_been_found_consistently_in_replication_studies._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins._""GG:Patients_with_the_GG_genotype_may_be_more_likely_to_experience_myopathy_when_treated_with_statins_as_compared_to_patients_with_the_AA_or_AG_genotype._This_association_has_not_been_found_consistently_in_replication_studies._Other_genetic_and_clinical_factors_may_also_influence_the_likelihood_of_myopathy_when_a_patient_is_treated_with_statins._";PGKB_RACE=White
15	51478777	rs934635	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=exemestane_(PA449563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_significantly_higher_odds_of_Musculoskeletal_adverse_events_(MSAEs)_and_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.""AG:Patients_with_the_AG_genotype_may_have_a_lower_odds_of_Musculoskeletal_adverse_events_(MSAEs)_and_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.""GG:Patients_with_the_GG_genotype_may_have_a_lower_odds_of_Musculoskeletal_adverse_events_(MSAEs)_and_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.";PGKB_RACE=NR
15	51494237	rs16964189	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=exemestane_(PA449563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_lower_odds_of_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.""CT:Patients_with_the_CT_genotype_may_have_a_lower_odds_of_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.""TT:Patients_with_the_TT_genotype_may_have_a_higher_odds_of_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.";PGKB_RACE=NR
15	51502844	rs4646	A	C	.	.	PGKB_INDEX=3;PGKB_GENE=CYP19A1_(PA27091),CYP19A1_(PA27091),CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196),letrozole_(PA450196),"anastrozole_(PA448432)""cyclophosphamide_(PA449165)""docetaxel_(PA449383)""doxorubicin_(PA449412)""epirubicin_(PA449476)""exemestane_(PA449563)""fluorouracil_(PA128406956)""letrozole_(PA450196)""paclitaxel_(PA450761)""radiotherapy_(PA166122986)""tamoxifen_(PA451581)";PGKB_TYPE=Efficacy,Other,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=Breast_Neoplasms_(PA443560),"Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)","Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_letrozole_may_have_improved_treatment_efficacy_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AC:Patients_with_the_AC_genotype_who_are_treated_with_letrozole_may_have_improved_treatment_efficacy_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CC:Patients_with_the_CC_genotype_who_are_treated_with_letrozole_may_have_decreased_treatment_efficacy_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Post-menopausal_women_with_the_AA_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AC_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin._""AC:Post-menopausal_women_with_the_AC_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_CC_genotype_and_increased_plasma_concentrations_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin._""CC:Post-menopausal_women_with_the_CC_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AA_or_AC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin._","AA:Post-menopausal_women_with_breast_cancer_and_the_AA_genotype_may_have_a_reduced_response_to_anastrozole_cyclophosphamide_docetaxel_doxorubicin_epirubicin_exemestane_fluorouracil_letrozole_paclitaxel_tamoxifen_or_radiotherapy_as_compared_to_post-menopausal_women_with_the_AC_and_CC_genotypes._""AC:Post-menopausal_women_with_breast_cancer_and_the_AC_genotype_may_have_an_improved_response_to_anastrozole_cyclophosphamide_docetaxel_doxorubicin_epirubicin_exemestane_fluorouracil_letrozole_paclitaxel_tamoxifen_or_radiotherapy_as_compared_to_post-menopausal_women_with_the_AA_genotypes._""CC:Post-menopausal_women_with_breast_cancer_and_the_CC_genotype_may_have_an_improved_response_to_anastrozole_cyclophosphamide_docetaxel_doxorubicin_epirubicin_exemestane_fluorouracil_letrozole_paclitaxel_tamoxifen_or_radiotherapy_as_compared_to_post-menopausal_women_with_the_AA_genotypes._";PGKB_RACE=NR,NR,Asian
15	51502986	rs10046	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CYP19A1_(PA27091),CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196),"hmg_coa_reductase_inhibitors_(PA133950441)""letrozole_(PA450196)";PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)","Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="AA:Post-menopausal_women_with_the_AA_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.""AG:Post-menopausal_women_with_the_AG_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_GG_genotypes_and_increased_levels_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.""GG:Post-menopausal_women_with_the_GG_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_increased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_AA_or_AG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.","AA:Post-menopausal_women_with_the_AA_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.""AG:Post-menopausal_women_with_the_AG_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_GG_genotypes_and_decreased_concentrations_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_in_combination_with_a_statin.""GG:Post-menopausal_women_with_the_GG_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_decreased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.";PGKB_RACE=NR,NR
15	51507508	rs2289105	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=CYP19A1_(PA27091),CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196),"hmg_coa_reductase_inhibitors_(PA133950441)""letrozole_(PA450196)";PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)","Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="CC:Post-menopausal_women_with_the_CC_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.""CT:Post-menopausal_women_with_the_CT_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_TT_genotypes_and_increased_levels_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.""TT:Post-menopausal_women_with_the_TT_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_increased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.","CC:Post-menopausal_women_with_the_CC_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.""CT:Post-menopausal_women_with_the_CT_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_TT_genotypes_and_decreased_concentrations_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_in_combination_with_a_statin.""TT:Post-menopausal_women_with_the_TT_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_decreased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_CT_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.";PGKB_RACE=NR,NR
15	51529112	rs700518	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="AA:Post-menopausal_women_with_breast_cancer_and_the_AA_genotype_may_have_increased_concentrations_of_plasma_triglycerides_when_taking_letrozole_alone_or_with_a_statin_as_compared_to_women_with_the_AC_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_triglyceride_levels_in_post-menopausal_women_with_breast_cancer._""AC:Post-menopausal_women_with_breast_cancer_and_the_AC_genotype_may_have_decreased_concentrations_of_plasma_triglycerides_when_taking_letrozole_alone_or_with_a_statin_as_compared_to_women_with_the_AA_genotypes_and_increased_concentrations_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_plasma_triglyceride_levels_in_post-menopausal_women_with_breast_cancer._""CC:Post-menopausal_women_with_breast_cancer_and_the_CC_genotype_may_have_decreased_concentrations_of_plasma_triglycerides_when_taking_letrozole_alone_or_with_a_statin_as_compared_to_women_with_the_AC_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_triglyceride_levels_in_post-menopausal_women_with_breast_cancer._";PGKB_RACE=NR
15	51529265	rs3759811	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="CC:Post-menopausal_women_with_breast_cancer_and_the_CC_genotype_who_are_taking_letrozole_with_or_without_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_triglycerides_in_post-menopausal_women_with_breast_cancer.""CT:Post-menopausal_women_with_breast_cancer_and_the_CT_genotype_who_are_taking_letrozole_with_or_without_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_TT_genotypes_and_increased_concentrations_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_triglycerides_in_post-menopausal_women_with_breast_cancer.""TT:Post-menopausal_women_with_breast_cancer_and_the_TT_genotype_who_are_taking_letrozole_with_or_without_a_statin_may_have_increased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_CT_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_triglycerides_in_post-menopausal_women_with_breast_cancer.";PGKB_RACE=NR
15	51534995	rs2236722	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Neoplasm_Metastasis_(PA445058);PGKB_TEXT="AA:Patients_with_metastasized_cancer_and_the_AA_genotype_may_have_improved_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""AG:Patients_with_metastasized_cancer_and_the_AG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AA_genotype_and_improved_response_as_compared_to_people_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.""GG:Patients_with_metastasized_cancer_and_the_GG_genotype_may_have_worse_response_to_capecitabine_or_fluorouracil_as_compared_to_people_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_capecitabine_and_fluorouracil._Please_note:_the_single_statistically_significant_association_was_for_a_haplotype_that_included_five_SNPs_(rs2289310_G>T__rs1047840_G>A__rs17431184_T>C__rs17160359_G>T__rs2236722_A>G)_that_distinguished_the_"non-responder"_phenotype_from_the_"responder"_phenotype_when_using_a_logistic_regression_multivariate_model.";PGKB_RACE=Asian
15	51536022	rs4775936	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="CC:Post-menopausal_women_with_the_CC_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.""CT:Post-menopausal_women_with_the_CT_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_TT_genotypes_and_increased_levels_as_compared_to_women_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.""TT:Post-menopausal_women_with_the_TT_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_increased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin.";PGKB_RACE=NR
15	51547938	rs1062033	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG="hmg_coa_reductase_inhibitors_(PA133950441)""letrozole_(PA450196)";PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="CC:Post-menopausal_women_with_breast_cancer_and_the_CC_genotype_may_have_decreased_concentrations_of_plasma_HDL_cholesterol_when_taking_letrozole_in_combination_with_a_statin_as_compared_to_women_with_the_CG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_triglyceride_levels_in_post-menopausal_women_with_breast_cancer.""CG:Post-menopausal_women_with_breast_cancer_and_the_CG_genotype_may_have_increased_concentrations_of_plasma_HDL_cholesterol_when_taking_letrozole_in_combination_with_a_statin_as_compared_to_women_with_the_CC_genotypes_and_decreased_concentrations_as_compared_to_women_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_plasma_triglyceride_levels_in_post-menopausal_women_with_breast_cancer.""GG:Post-menopausal_women_with_breast_cancer_and_the_GG_genotype_may_have_increased_concentrations_of_plasma_HDL_cholesterol_when_taking_letrozole_in_combination_with_a_statin_as_compared_to_women_with_the_CC_or_CG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_plasma_triglyceride_levels_in_post-menopausal_women_with_breast_cancer.";PGKB_RACE=NR
15	51549599	rs1008805	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG=letrozole_(PA450196);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="AA:Post-menopausal_women_with_the_AA_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.""AG:Post-menopausal_women_with_the_AG_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_GG_genotype_and_decreased_concentrations_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.""GG:Post-menopausal_women_with_the_GG_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_decreased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AA_or_AG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.";PGKB_RACE=NR
15	51558731	rs749292	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CYP19A1_(PA27091),CYP19A1_(PA27091);PGKB_DRUG="hmg_coa_reductase_inhibitors_(PA133950441)""letrozole_(PA450196)",letrozole_(PA450196);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)","Breast_Neoplasms_(PA443560)""Menopause_(PA166048848)";PGKB_TEXT="AA:Post-menopausal_women_with_the_AA_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.""AG:Post-menopausal_women_with_the_AG_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_increased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_GG_genotypes_and_decreased_concentrations_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.""GG:Post-menopausal_women_with_the_GG_genotype_and_breast_cancer_who_are_taking_letrozole_with_a_statin_may_have_decreased_plasma_concentrations_of_hdl_cholesterol_as_compared_to_women_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_hdl_cholesterol_levels_in_post-menopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_in_combination_with_a_statin.","AA:Post-menopausal_women_with_the_AA_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin._""AG:Post-menopausal_women_with_the_AG_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_decreased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_GG_genotypes_and_increased_concentrations_as_compared_to_women_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin._""GG:Post-menopausal_women_with_the_GG_genotype_and_breast_cancer_who_are_taking_letrozole_alone_or_with_a_statin_may_have_increased_plasma_concentrations_of_triglycerides_as_compared_to_women_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_triglyceride_levels_in_postmenopausal_women_with_breast_cancer_who_are_taking_letrozole_alone_or_in_combination_with_a_statin._";PGKB_RACE=NR,NR
15	51631279	rs7176005	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP19A1_(PA27091);PGKB_DRUG=exemestane_(PA449563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_lower_odds_of_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.""CT:Patients_with_the_CT_genotype_may_have_a_lower_odds_of_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.""TT:Patients_with_the_TT_genotype_may_have_a_higher_odds_of_vasomotor_symptoms_(VMSs)_in_postmenopausal_hormone_receptor_(HR)-positive_breast_cancer_patients_when_treated_with_exemestane_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_exemestane.";PGKB_RACE=NR
15	58306793	rs12903202	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ALDH1A2_(PA24693);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates._""AG:Patients_with_the_AG_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates._""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates._";PGKB_RACE=White
15	61329788	rs809736	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=RORA_(PA34630);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""AG:Patients_with_the_AG_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=NR
15	63623463	rs4984241	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CA12_(PA25987);PGKB_DRUG="topiramate_(PA451728)""zonisamide_(PA451978)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_topiramate_or_zonisamide_may_have_decreased_serum_bicarbonate_levels_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_topiramate_or_zonisamide.""AG:Patients_with_the_AG_genotype_who_are_treated_with_topiramate_or_zonisamide_may_have_decreased_serum_bicarbonate_levels_as_compared_to_patients_with_the_GG_genotype_or_may_have_increased_serum_bicarbonate_levels_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_topiramate_or_zonisamide.""GG:Patients_with_the_GG_genotype_who_are_treated_with_topiramate_or_zonisamide_may_have_increased_serum_bicarbonate_levels_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_topiramate_or_zonisamide.";PGKB_RACE=NR
15	63633238	rs2306719	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CA12_(PA25987);PGKB_DRUG="topiramate_(PA451728)""zonisamide_(PA451978)";PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_were_not_studied._However_patients_with_the_CT_genotype_who_are_treated_with_topiramate_or_zonisamide_may_have_increased_serum_bicarbonate_levels_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_topiramate_or_zonisamide.""CT:Patients_with_the_CT_genotype_who_are_treated_with_topiramate_or_zonisamide_may_have_increased_serum_bicarbonate_levels_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_topiramate_or_zonisamide.""TT:Patients_with_the_TT_genotype_who_are_treated_with_topiramate_or_zonisamide_may_have_decreased_serum_bicarbonate_levels_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_topiramate_or_zonisamide.";PGKB_RACE=NR
15	75012985	rs1048943	T	G,C,A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP1A1_(PA27092);PGKB_DRUG="capecitabine_(PA448771)""docetaxel_(PA449383)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Women_with_the_AA_genotype_and_breast_cancer_may_have_decreased_progression-free_survival_time_when_treated_with_capecitabine_and_docetaxel_as_compared_to_women_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""AG:Women_with_the_AG_genotype_and_breast_cancer_may_have_increased_progression-free_survival_time_when_treated_with_capecitabine_and_docetaxel_as_compared_to_women_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.""GG:Women_with_the_GG_genotype_and_breast_cancer_may_have_increased_progression-free_survival_time_when_treated_with_capecitabine_and_docetaxel_as_compared_to_women_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_progression-free_survival_time.";PGKB_RACE=Asian
15	75017176	rs2606345	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP1A1_(PA27092);PGKB_DRUG=deferasirox_(PA164760843);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=beta-Thalassemia_(PA446432);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_beta-thalassemia_may_have_decreased_concentrations_of_deferasirox_possibly_to_levels_below_therapeutic_efficacy_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""AC:Patients_with_the_AC_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""CC:Patients_with_the_CC_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.";PGKB_RACE=NR
15	75027880	rs2472297	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Psychotic_Disorders_(PA447215);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_olanzapine_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_olanzapine.""CT:Patients_with_the_CT_genotype_may_have_increased_metabolism_of_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_olanzapine.""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_olanzapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_olanzapine.";PGKB_RACE=White
15	75038220	rs2069514	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP1A2_(PA27093);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Schizophrenia_patients_with_the_AA_genotype_may_have_increased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_who_were_smokers_as_compared_to_patients_with_the_GG_genotype._Genotype_AA_is_not_associated_with_increased_QT_interval_in_Schizophrenia_patients_treated_with_antipsychotics_as_compared_to_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_to_antipsychotics.""AG:Schizophrenia_patients_with_the_AG_genotype_may_have_increased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_who_were_smokers_as_compared_to_patients_with_the_GG_genotype._Genotype_AG_is_not_associated_with_increased_QT_interval_in_Schizophrenia_patients_treated_with_antipsychotics_as_compared_to_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_to_antipsychotics.""GG:Schizophrenia_patients_with_the_GG_genotype_may_have_decreased_severity_of_tardive_dyskinesia_when_treated_with_antipsychotics_in_people_who_were_smokers_as_compared_to_patients_with_the_AA_or_AG_genotype._Genotype_GG_is_not_associated_with_increased_QT_interval_in_Schizophrenia_patients_treated_with_antipsychotics_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_to_antipsychotics.";PGKB_RACE=Asian
15	75038967	rs2069521	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=escitalopram_(PA10074);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_may_1)_have_increased_metabolism_of_escitalopram_at_week_2_of_treatment_2)_experience_more_severe_side_effects_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_may_1)_have_reduced_metabolism_of_escitalopram_at_week_2_of_treatment_2)_experience_less_severe_side_effects_as_compared_to_patients_with_the_AA_genotype_or_may_1)_have_increased_metabolism_of_escitalopram_at_week_2_of_treatment_2)_experience_more_severe_side_effects_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_may_1)_have_reduced_metabolism_of_escitalopram_at_week_2_of_treatment_2)_experience_less_severe_side_effects_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._";PGKB_RACE=Asian
15	75041341	rs2069526	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP1A2_(PA27093);PGKB_DRUG=escitalopram_(PA10074);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_may_have_increased_metabolism_of_escitalopram_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram._""GT:Patients_with_the_GT_genotype_and_major_depressive_disorder_may_have_increased_metabolism_of_escitalopram_as_compared_to_patients_with_the_TT_genotype_or_may_have_reduced_metabolism_of_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_reduced_metabolism_of_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram._";PGKB_RACE=Asian
15	75041917	rs762551	C	A	.	.	PGKB_INDEX=7;PGKB_GENE=CYP1A2_(PA27093),CYP1A2_(PA27093),CYP1A2_(PA27093),CYP1A2_(PA27093),CYP1A2_(PA27093),CYP1A2_(PA27093),CYP1A2_(PA27093);PGKB_DRUG=clopidogrel_(PA449053),paroxetine_(PA450801),"antipsychotics_(PA452233)""chlorpromazine_(PA448964)""fluphenazine_(PA449676)""thioridazine_(PA451666)""trifluoperazine_(PA451771)",caffeine_(PA448710),olanzapine_(PA450688),leflunomide_(PA450192),deferasirox_(PA164760843);PGKB_TYPE=Efficacy,"Dosage""Toxicity/ADR",Toxicity/ADR,Toxicity/ADR,Efficacy,Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=3,3,3,3,3,3,3;PGKB_DISEASE=NR,Depressive_Disorder_Major_(PA447321),Schizophrenia_(PA447216),Myocardial_Infarction_(PA445019),NR,Arthritis_Rheumatoid_(PA443434),beta-Thalassemia_(PA446432);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_CC_genotype._However_another_study_found_no_association_with_risk_of_major_adverse_cardiac_events._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_clopidogrel.""AC:Patients_with_the_AC_genotype_may_have_decreased_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_CC_genotype._However_another_study_found_no_association_with_risk_of_major_adverse_cardiac_events._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_clopidogrel.""CC:Patients_with_the_CC_genotype_may_have_increased_on-treatment_platelet_reactivity_when_treated_with_clopidogrel_as_compared_to_patients_with_the_AC_+_CC_genotype._However_another_study_found_no_association_with_risk_of_major_adverse_cardiac_events._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_clopidogrel.","AA:Patients_with_AA_genotype_may_require_an_increased_dose_of_paroxetine_and_may_have_an_increased_risk_of_fatigue_when_treated_with_paroxetine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_paroxetine.""AC:Patients_with_AT_genotype_may_require_an_increased_dose_of_paroxetine_and_may_have_an_increased_risk_of_fatigue_when_treated_with_paroxetine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_paroxetine.""CC:Patients_with_CC_genotype_may_require_a_decreased_dose_of_paroxetine_and_may_have_an_decreased_risk_of_fatigue_when_treated_with_paroxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_paroxetine.","AA:Patients_with_the_AA_genotype_may_have_decreased_QT_interval_when_treated_with_antipsychotics_chlorpromazine_fluphenazine_thioridazine_and_trifluoperazine_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_CC_or_AC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""AC:Patients_with_the_AC_genotype_may_have_increased_QT_interval_when_treated_with_antipsychotics_chlorpromazine_fluphenazine_thioridazine_and_trifluoperazine_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.""CC:Patients_with_the_CC_genotype_may_have_increased_QT_interval_when_treated_with_antipsychotics_chlorpromazine_fluphenazine_thioridazine_and_trifluoperazine_in_people_with_Schizophrenia_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antipsychotics.","AA:Patients_with_the_AA_genotype_may_have_a_decreased_but_not_absent_risk_of_nonfatal_myocardial_infarction_with_increased_coffee_consumption_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_myocardial_infarction.""AC:Patients_with_the_AC_genotype_may_have_an_increased_risk_of_nonfatal_myocardial_infarction_with_increased_coffee_consumption_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_myocardial_infarction.""CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_of_nonfatal_myocardial_infarction_with_increased_coffee_consumption_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_myocardial_infarction.","AA:Patients_with_the_AA_genotype_and_psychiatric_disorders_who_are_treated_with_olanzapine_may_have_decreased_response_to_olanzapine_based_on_decreased_mean_dose-/body_weight-normalized_olanzapine_serum_concentrations_as_compared_to_patients_with_the_AC_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""AC:Patients_with_the_AC_genotype_and_psychiatric_disorders_who_are_treated_with_olanzapine_may_have_an_increased_response_to_olanzapine_based_on_not_decreased_mean_dose-/body_weight-normalized_olanzapine_serum_concentrations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""CC:Patients_with_the_CC_genotype_and_psychiatric_disorders_who_are_treated_with_olanzapine_may_have_an_increased_response_to_olanzapine_based_on_not_decreased_mean_dose-/body_weight-normalized_olanzapine_serum_concentrations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.","AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_who_are_treated_with_leflunomide_may_have_a_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_with_leflunomide_treatment.""AC:Patients_with_the_AC_genotype_and_rheumatoid_arthritis_who_are_treated_with_leflunomide_may_have_a_decreased_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_with_leflunomide_treatment.""CC:Patients_with_the_CC_genotype_and_rheumatoid_arthritis_who_are_treated_with_leflunomide_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_AC_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_with_leflunomide_treatment.","AA:Patients_with_the_AA_genotype_and_beta-thalassemia_may_have_decreased_concentrations_of_deferasirox_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""AC:Patients_with_the_AC_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""CC:Patients_with_the_CC_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.";PGKB_RACE=NR,Asian,Asian,Hispanic_or_Latino,White,White,NR
15	75043281	rs4646425	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP1A2_(PA27093),CYP1A2_(PA27093);PGKB_DRUG=escitalopram_(PA10074),paroxetine_(PA450801);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_1)_may_have_reduced_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_less_severe_side_effects_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._""TC:Patients_with_the_TC_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_1)_may_have_reduced_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_less_severe_side_effects_as_compared_to_patients_with_the_TT_genotype_or_1)_may_have_increased_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_more_severe_side_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_1)_may_have_increased_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_more_severe_side_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._","CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_slower_response_time_but_an_increased_likelihood_of_experiencing_remission_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_faster_response_time_but_a_decreased_likelihood_of_experiencing_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_faster_response_time_but_a_decreased_likelihood_of_experiencing_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._";PGKB_RACE=Asian,Asian
15	75044238	rs2472304	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CYP1A2_(PA27093),CYP1A2_(PA27093);PGKB_DRUG=paroxetine_(PA450801),erlotinib_(PA134687924);PGKB_TYPE=Efficacy,Metabolism/PK;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment._""AG:Patients_with_the_AG_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_GG_genotype_or_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment._""GG:Patients_with_the_GG_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment._","AA:Patients_with_the_AA_genotype_may_have_increased_concentrations_of_erlotinib_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_erlotinib.""AG:Patients_with_the_AG_genotype_may_have_increased_concentrations_of_erlotinib_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_erlotinib.""GG:Patients_with_the_GG_genotype_may_have_decreased_concentrations_of_erlotinib_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_erlotinib.";PGKB_RACE=Asian,Asian
15	75044578	rs72547516	A	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP1A2_(PA27093);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_metabolism_of_clozapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clozapine_metabolism.""AT:The_AT_genotype_was_not_studied.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_metabolism_of_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clozapine_metabolism.";PGKB_RACE=NR
15	75045692	rs4646427	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=CYP1A2_(PA27093),CYP1A2_(PA27093);PGKB_DRUG=paroxetine_(PA450801),escitalopram_(PA10074);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_faster_response_time_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_faster_response_time_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_have_a_slower_response_time_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine._","CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_1)_may_have_increased_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_more_severe_side_effects_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_1)_may_have_reduced_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_less_severe_side_effects_as_compared_to_patients_with_the_CC_genotype_or_1)_may_have_increased_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_more_severe_side_effects_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_escitalopram_1)_may_have_reduced_metabolism_of_escitalopram_at_week_2_of_treatment_2)_may_experience_less_severe_side_effects_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_escitalopram_and_severity_of_drug-induced_side_effects._";PGKB_RACE=Asian,Asian
15	75047245	rs72547517	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP1A2_(PA27093);PGKB_DRUG=clozapine_(PA449061);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_decreased_metabolism_of_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clozapine_metabolism.""AG:The_AG_genotype_was_not_studied.""GG:Patients_with_the_GG_genotype_may_have_an_increased_metabolism_of_clozapine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_clozapine_metabolism.";PGKB_RACE=NR
15	75047426	rs2470890	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP1A2_(PA27093),CYP1A2_(PA27093);PGKB_DRUG=paroxetine_(PA450801),deferasirox_(PA164760843);PGKB_TYPE=Efficacy,Metabolism/PK;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),beta-Thalassemia_(PA446432);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment._""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_be_less_likely_to_experience_remission_as_compared_to_patients_with_the_TT_genotype_or_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment._""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_who_are_treated_with_paroxetine_may_be_more_likely_to_experience_remission_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine_treatment._","CC:Patients_with_the_CC_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""CT:Patients_with_the_CT_genotype_and_beta-thalassemia_may_have_increased_concentrations_of_deferasirox_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.""TT:Patients_with_the_TT_genotype_and_beta-thalassemia_may_have_decreased_concentrations_of_deferasirox_possibly_to_levels_below_therapeutic_efficacy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_concentrations_of_deferasirox.";PGKB_RACE=Asian,NR
15	78865425	rs588765	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CHRNA5_(PA26491);PGKB_DRUG="Drugs_used_in_nicotine_dependence_(PA164712720)""nicotine_(PA450626)""varenicline_(PA164781343)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_chance_of_achieving_6_month_abstinence_if_prescribed_NRT_(nicotine_replacement_therapy)_when_treated_with_Drugs_used_in_nicotine_dependence_as_compared_to_patients_with_the_TT_genotype._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_response_to_smoking_cessation_therapies.""CT:Patients_with_the_CT_genotype_may_have_increased_chance_of_achieving_6_month_abstinence_if_prescribed_NRT_(nicotine_replacement_therapy)_when_treated_with_Drugs_used_in_nicotine_dependence_as_compared_to_patients_with_the_CC_genotype._However_this_has_been_contradicted_in_some_studies.Other_clinical_and_genetic_factors_may_also_influence_response_to_smoking_cessation_therapies.""TT:Patients_with_the_TT_genotype_may_have_increased_chance_of_achieving_6_month_abstinence_if_prescribed_NRT_(nicotine_replacement_therapy)_when_treated_with_Drugs_used_in_nicotine_dependence_as_compared_to_patients_with_the_CC_genotype._However_this_has_been_contradicted_in_some_studies._Other_clinical_and_genetic_factors_may_also_influence_response_to_smoking_cessation_therapies.";PGKB_RACE=White
15	78882925	rs16969968	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CHRNA5_(PA26491),CHRNA5_(PA26491);PGKB_DRUG=Drugs_used_in_nicotine_dependence_(PA164712720),nicotine_(PA450626);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="AA:Patients_with_AA_genotype_may_have_an_increased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_(transdermal_nicotine_patch)_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_have_been_reported_with_the_AA_genotype_may_be_associated_with_a_decreased_likelihood_of_smoking_cessation_compared_to_GG_genotype._Finding_are_based_on_haplotype_analysis_of_rs16969968_and_rs680244._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.""AG:Patients_with_AG_genotype_may_have_a_decreased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_(transdermal_nicotine_patch)_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_have_been_reported_with_the_AG_genotype_may_be_associated_with_an_increased_likelihood_of_smoking_cessation_compared_to_AA_genotype._Finding_are_based_on_haplotype_analysis_of_rs16969968_and_rs680244._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.""GG:Patients_with_GG_genotype_may_have_a_decreased_likelihood_of_smoking_cessation_when_treated_with_nicotine_replacement_therapy_(transdermal_nicotine_patch)_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_have_been_reported_with_the_GG_genotype_may_be_associated_with_an_increased_likelihood_of_smoking_cessation_compared_to_AA_genotype._Finding_are_based_on_haplotype_analysis_of_rs16969968_and_rs680244._Other_genetic_and_clinical_factors_may_influence_a_patient's_likelihood_of_smoking_cessation.","AA:Patients_with_AA_genotype_may_have_an_increased_risk_for_nicotine_dependence_when_exposed_to_nicotine_as_compared_to_patients_with_the_GG_genotype._Findings_are_based_on_haplotype_studies_with_either_rs680244_or_rs680244_rs569207_rs578776_and_rs1051730._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_nicotine_dependency.""AG:Patients_with_AG_genotype_may_have_an_increased_risk_for_nicotine_dependence_when_exposed_to_nicotine_as_compared_to_patients_with_the_GG_genotype._Findings_are_based_on_haplotype_studies_with_either_rs680244_or_rs680244_rs569207_rs578776_and_rs1051730._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_nicotine_dependency.""GG:Patients_with_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_nicotine_dependence_when_exposed_to_nicotine_as_compared_to_patients_with_the_AG_and_AA_genotype._Findings_are_based_on_haplotype_studies_with_either_rs680244_or_rs680244_rs569207_rs578776_and_rs1051730._Other_genetic_and_clinical_factors_may_influence_a_patient's_risk_for_nicotine_dependency.";PGKB_RACE=NR,NR
15	78894339	rs1051730	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=CHRNA3_(PA113),CHRNA3_(PA113),CHRNA3_(PA113);PGKB_DRUG=Drugs_used_in_nicotine_dependence_(PA164712720),nicotine_(PA450626),Opium_alkaloids_and_derivatives_(PA164712950);PGKB_TYPE=Efficacy,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,2B,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),NR,Pain_(PA445208);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_chance_of_achieving_6_month_abstinence_if_prescribed_NRT_(nicotiene_replacement_therapy)_when_treated_with_Drugs_used_in_nicotine_dependence_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_smoking_cessation_therapies.""AG:Patients_with_the_AG_genotype_may_have_increased_chance_of_achieving_6_month_abstinence_if_prescribed_NRT_(nicotiene_replacement_therapy)_when_treated_with_Drugs_used_in_nicotine_dependence_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_smoking_cessation_therapies.""GG:Patients_with_the_GG_genotype_may_have_decreased_chance_of_achieving_6_month_abstinence_if_prescribed_NRT_(nicotiene_replacement_therapy)_when_treated_with_Drugs_used_in_nicotine_dependence_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_smoking_cessation_therapies.","AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_for_nicotine_dependency_decreased_lung_function_when_exposed_to_nicotine_but_may_experience_an_increased_chance_of_achieving_6_month_abstinence_if_prescribed_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_nicotine_dependency_decreased_lung_function_when_exposed_to_nicotine_but_may_experience_an_increased_chance_of_achieving_6_month_abstinence_if_prescribed_nicotine_replacement_therapy_as_compared_to_patients_with_the_GG_genotype_or_a_decreased_risk_for_nicotine_dependency_and_decreased_chance_of_achieving_6_month_abstinence_if_prescribed_nicotine_replacement_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""GG:Patients_with_the_GG_genotype_may_have_an_decreased_risk_for_nicotine_dependency_increased_lung_function_when_exposed_to_nicotine_but_may_experience_decreased_chance_of_achieving_6_month_abstinence_if_prescribed_nicotine_replacement_therapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.","AA:Patients_with_the_AA_genotype_and_pain_who_are_receiving_Opium_alkaloids_and_derivatives_may_have_an_increased_severity_of_Substance-Related_Disorders_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Substance-Related_Disorders.""AG:Patients_with_the_AG_genotype_and_pain_who_are_receiving_Opium_alkaloids_and_derivatives_may_have_a_decreased_severity_of_Substance-Related_Disorders_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Substance-Related_Disorders.""GG:Patients_with_the_GG_genotype_and_pain_who_are_receiving_Opium_alkaloids_and_derivatives_may_have_a_decreased_severity_of_Substance-Related_Disorders_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Substance-Related_Disorders.";PGKB_RACE=White,NR,NR
15	85447635	rs2290271	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC28A1_(PA387);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_CC_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""AC:Patients_with_genotype_AC_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.""CC:Patients_with_genotype_CC_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_anthracyclines.";PGKB_RACE=NR
15	89859994	rs3087374	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=POLG_(PA33500);PGKB_DRUG=valproic_acid_(PA451846);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Toxic_liver_disease_(PA164925725);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_valproic_acid_may_have_an_increased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_CC_genotype._This_variation_is_commonly_referred_to_as_Q1236H_within_the_literature._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hepatotoxicity._""AC:Patients_with_the_AC_genotype_who_are_treated_with_valproic_acid_may_have_an_increased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_CC_genotype_or_a_decreased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_AA_genotype._This_variation_is_commonly_referred_to_as_Q1236H_within_the_literature._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hepatotoxicity._""CC:Patients_with_the_CC_genotype_who_are_treated_with_valproic_acid_may_have_a_decreased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_AA_genotype._This_variation_is_commonly_referred_to_as_Q1236H_within_the_literature._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hepatotoxicity._";PGKB_RACE=NR
15	99613173	rs1703794	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_may_have_an_increased_response_to_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_may_have_a_decreased_response_to_methotrexate_as_compared_to_patients_with_the_CC_genotype_or_may_have_an_increased_response_to_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_may_have_a_decreased_response_to_methotrexate_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian
16	1374951	rs9597	C	G	.	.	PGKB_INDEX=1;PGKB_GENE="BAIAP3_(PA25252)""RPS20P2_(PA34809)""UBE2I_(PA37134)";PGKB_DRUG="cisplatin_(PA449014)""irinotecan_(PA450085)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_response_to_cisplatin_and_irinotecan_as_compared_to_patients_with_the_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin_and_irinotecan_treatment.""CG:Patients_with_the_CG_genotype_may_have_an_increased_response_to_cisplatin_and_irinotecan_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin_and_irinotecan_treatment.""GG:Patients_with_the_GG_genotype_may_have_an_increased_response_to_cisplatin_and_irinotecan_as_compared_to_patients_with_the_CC_genotype_although_the_GG_genotype_was_not_observed_in_the_supporting_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin_and_irinotecan_treatment.";PGKB_RACE=Asian
16	4065583	rs1967309	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADCY9_(PA30);PGKB_DRUG=dalcetrapib_(PA166131581);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acute_coronary_syndrome_(PA165108401);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_major_adverse_cardiac_events_(MACE)_when_treated_with_delcetrapib_in_people_with_acute_coronary_syndrome_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity._These_results_are_from_a_stratified_analysis_of_a_trial_that_found_patients_taking_dalcetrapib_at_increased_risk_for_MACE_compared_to_patients_on_placebo._""AG:Patients_with_the_AG_genotype_may_have_decreased_risk_of_major_adverse_cardiac_events_(MACE)_when_treated_with_delcetrapib_in_people_with_acute_coronary_syndrome_as_compared_to_patients_with_the_GG_genotype_but_increased_risk_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity._These_results_are_from_a_stratified_analysis_of_a_trial_that_found_patients_taking_dalcetrapib_at_increased_risk_for_MACE_compared_to_patients_on_placebo._""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_major_adverse_cardiac_events_(MACE)_when_treated_with_delcetrapib_in_people_with_acute_coronary_syndrome_as_compared_to_patients_with_the_AA_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity._These_results_are_from_a_stratified_analysis_of_a_trial_that_found_patients_taking_dalcetrapib_at_increased_risk_for_MACE_compared_to_patients_on_placebo._";PGKB_RACE=White
16	14041958	rs1799801	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ERCC4_(PA27850);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small-cell_lung_cancer_may_have_a_better_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""CT:Patients_with_the_CT_genotype_and_non-small-cell_lung_cancer_may_have_a_better_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""TT:Patients_with_the_TT_genotype_and_non-small-cell_lung_cancer_may_have_a_poorer_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.";PGKB_RACE=NR
16	16086833	rs119774	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG=montelukast_(PA450546);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Asthma_may_not_have_an_increased_response_to_montelukast_treatment_based_on_no_change_in_Forced_expiratory_volume_in_one_second_(FEV1)_response_to_montelukast_at_6_month_of_treatment_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.""CT:Patients_with_the_CT_genotype_and_Asthma_may_have_an_increased_response_to_montelukast_treatment_based_on_an_increased_Forced_expiratory_volume_in_one_second_(FEV1)_response_to_montelukast_at_6_month_of_treatment_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.""TT:Patients_with_the_TT_genotype_were_not_studied._But_patients_with_the_CT_genotype_and_Asthma_may_have_an_increased_response_to_montelukast_treatment_based_on_an_increased_Forced_expiratory_volume_in_one_second_(FEV1)_response_to_montelukast_at_6_month_of_treatment_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_montelukast.";PGKB_RACE=White
16	16119024	rs246240	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=ABCC1_(PA244),ABCC1_(PA244);PGKB_DRUG=methotrexate_(PA450428),methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Psoriasis_(PA445451)",Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_toxicity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_toxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity_to_methotrexate.","AA:Patients_with_the_AA_genotype_may_have_increased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.";PGKB_RACE=NR,NR
16	16125325	rs3784864	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_GG_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_may_have_decreased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_to_methotrexate_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_methotrexate.";PGKB_RACE=NR
16	16141823	rs35592	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Psoriasis_(PA445451);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""CT:Patients_with_the_CT_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=NR
16	16173232	rs45511401	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG=doxorubicin_(PA449412);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Arrhythmias_Cardiac_(PA443421)""Drug_Toxicity_(PA443937)""Lymphoma_Non-Hodgkin_(PA444845)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_a_decreased_but_not_absent_risk_for_cardiotoxocity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""GT:Patients_with_the_GT_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxocity_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_but_not_absent_risk_for_cardiotoxocity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""TT:Patients_with_the_TT_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.";PGKB_RACE=White
16	16213872	rs2238476	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Psoriasis_(PA445451);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_psoriasis_who_are_treated_with_methotrexate:_1)_may_be_less_likely_to_have_a_reduction_in_psoriasis_area_or_disease_severity_2)_may_have_a_reduced_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_risk_of_toxicity.""AG:Patients_with_the_AG_genotype_and_psoriasis_who_are_treated_with_methotrexate:_1)_may_be_less_likely_to_have_a_reduction_in_psoriasis_area_or_disease_severity_2)_may_have_a_reduced_but_not_absent_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_risk_of_toxicity.""GG:Patients_with_the_GG_genotype_and_psoriasis_who_are_treated_with_methotrexate:_1)_may_be_more_likely_to_have_a_reduction_in_psoriasis_area_or_disease_severity_2)_may_have_an_increased_risk_of_toxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_risk_of_toxicity.";PGKB_RACE=NR
16	16228249	rs28364006	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Psoriasis_(PA445451);PGKB_TEXT="AA:Patients_with_the_AA_genotype_were_not_studied_and_so_conclusions_cannot_be_made_in_regard_to_response_to_methotrexate._However_patients_with_the_GA_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_GA_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_psoriasis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_improvement_in_psoriasis_area_and_severity_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=NR
16	16236650	rs212091	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC1_(PA244);PGKB_DRUG="lamivudine_(PA450163)""lopinavir_(PA450264)""ritonavir_(PA451260)""zidovudine_(PA451954)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_have_an_increased_risk_for_virological_failure_when_treated_with_highly_active_antiretroviral_therapy_(HAART)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_virological_failure.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_an_increased_risk_for_virological_failure_when_treated_with_highly_active_antiretroviral_therapy_(HAART)_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_virological_failure.""TT:Patients_with_the_TT_genotype_and_HIV_may_have_a_decreased_risk_for_virological_failure_when_treated_with_highly_active_antiretroviral_therapy_(HAART)_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_virological_failure.";PGKB_RACE=NR
16	16251599	rs2238472	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC6_(PA58);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""TT:Patients_with_the_TT_genotype_may_have_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
16	16957915	rs7186128	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="cisplatin_(PA449014)""irinotecan_(PA450085)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Carcinoma_Small_Cell_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cisplatin_and_irinotecan.""AG:Patients_with_the_AG_genotype_may_have_decreased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Carcinoma_Small_Cell_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cisplatin_and_irinotecan.""GG:Patients_with_the_GG_genotype_may_have_decreased_overall_survival_when_treated_with_cisplatin_and_irinotecan_in_people_with_Carcinoma_Small_Cell_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_cisplatin_and_irinotecan.";PGKB_RACE=Asian
16	23381914	rs889299	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SCNN1B_(PA306);PGKB_DRUG="Farglitazar_(PA165815771)""glibenclamide_(PA449782)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_increased_risk_of_oedema_when_treated_with_Farglitazar_and_glibenclamide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_Farglitazar.""AG:Patients_with_genotype_AG_may_have_increased_risk_of_oedema_when_treated_with_Farglitazar_and_glibenclamide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_Farglitazar.""GG:Patients_with_genotype_GG_may_have_decreased_risk_of_oedema_when_treated_with_Farglitazar_and_glibenclamide_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_Farglitazar.";PGKB_RACE=White
16	23909952	rs9922316	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=PRKCB_(PA33761);PGKB_DRUG=dexmedetomidine_(PA449256);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_dexmedetomidine_ED50_values_for_drug-induced_dorsal_hand_vein_constriction_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dexmedetomidine.""TG:Patients_with_the_TG_genotype_may_have_increased_dexmedetomidine_ED50_values_for_drug-induced_dorsal_hand_vein_constriction_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dexmedetomidine.""TT_:Patients_with_the_TT_genotype_may_have_increased_dexmedetomidine_ED50_values_for_drug-induced_dorsal_hand_vein_constriction_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_dexmedetomidine.";PGKB_RACE=White
16	27336427	rs1110470	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=pitrakinra_(PA165983754);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_reduced_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.";PGKB_RACE=White
16	27350687	rs3024530	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=pitrakinra_(PA165983754);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_reduced_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.";PGKB_RACE=White
16	27356203	rs1805010	A	C,G,T	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=pitrakinra_(PA165983754);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_reduced_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.";PGKB_RACE=White
16	27359021	rs2239347	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=pitrakinra_(PA165983754);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_reduced_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""AC:Patients_with_the_AC_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbationswhen_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.";PGKB_RACE=White
16	27374180	rs1805015	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=Hepatitis_vaccines_(PA164712789);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_at_decreased_risk_for_non-immune_response_to_the_hepatitis_B_vaccine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_in_patients_receiving_the_hepatitis_B_vaccine.""CT:Patients_with_the_CT_genotype_may_be_at_decreased_risk_for_non-immune_response_to_the_hepatitis_B_vaccine_as_compared_to_patients_with_the_TT_genotype_or_at_increased_risk_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_in_patients_receiving_the_hepatitis_B_vaccine.""TT:Patients_with_the_TT_genotype_may_be_at_increased_risk_for_non-immune_response_to_the_hepatitis_B_vaccine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_non-immune_response_in_patients_receiving_the_hepatitis_B_vaccine.";PGKB_RACE=Asian
16	27375787	rs8832	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=pitrakinra_(PA165983754);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Asthma_may_be_less_likely_to_respond_when_treated_with_pitrakinra_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pitrakinra._""AG:Patients_with_the_AG_genotype_and_Asthma_may_be_less_likely_to_respond_when_treated_with_pitrakinra_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pitrakinra._""GG:Patients_with_the_GG_genotype_and_Asthma_may_be_more_likely_to_respond_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pitrakinra._";PGKB_RACE=White
16	27376217	rs1029489	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=IL4R_(PA29832);PGKB_DRUG=pitrakinra_(PA165983754);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_higher_frequency_of_asthma_exacerbations_when_treated_with_pitrakinra_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_reduced_frequency_of_asthma_exacerbationse_when_treated_with_pitrakinra_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pitrakinra.";PGKB_RACE=White
16	28617514	rs9282861	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="SULT1A1_(PA343)""SULT1A2_(PA341)";PGKB_DRUG=conjugated_estrogens_(PA164754789);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Endometrial_Neoplasms_(PA446411);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_but_not_absent_risk_for_endometrial_neoplasms_when_treated_with_estrogen_replacement_therapy_for_greater_than_3_years_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_responses_to_hormone_replacement_therapy.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_for_endometrial_neoplasms_when_treated_with_estrogen_replacement_therapy_for_greater_than_3_years_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_responses_to_hormone_replacement_therapy.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_for_endometrial_neoplasms_when_treated_with_estrogen_replacement_therapy_for_greater_than_3_years_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_responses_to_hormone_replacement_therapy.";PGKB_RACE=NR
16	31048079	rs10871454	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=STX4_(PA36236),STX4_(PA36236);PGKB_DRUG=warfarin_(PA451906),phenprocoumon_(PA450921);PGKB_TYPE=Dosage,Dosage;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_an_increased_dose_as_compared_to_patients_with_the_CT_or_TT_genotype.""CT:Patients_with_the_CT_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_CC_genotype.""TT:Patients_with_the_TT_genotype_who_are_treated_with_warfarin_may_require_the_lowest_dose_as_compared_to_patients_with_the_CT_or_CC_genotype.","CC:Patients_with_the_CC_genotype_who_are_treated_with_phenprocoumon_may_require_a_increased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_phenprocoumon_dosage._""CT:Patients_with_the_CT_genotype_who_are_treated_with_phenprocoumon_may_require_a_increased_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_phenprocoumon_dosage._""TT:Patients_with_the_TT_genotype_who_are_treated_with_phenprocoumon_may_require_a_decreased_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_phenprocoumon_dosage._";PGKB_RACE=White,NR
16	31099011	rs11150606	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="PRSS53_(PA165450635)""VKORC1_(PA133787052)";PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=NR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""CT:Patients_with_the_CT_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""TT:Patients_with_the_TT_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.";PGKB_RACE=White
16	31102321	rs7294	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=VKORC1_(PA133787052),VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906),"acenocoumarol_(PA452632)""phenprocoumon_(PA450921)";PGKB_TYPE=Dosage,Dosage;PGKB_EVIDENCE=1B,2A;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_TC_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""CT:Patients_with_the_CT_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.","CC:Patients_with_the_CC_genotype_may_require_a_decreased_dose_of_phenprocoumon_or_acenocoumarol_as_compared_to_patients_with_the_CT_or_TT_genotypes_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_phenprocoumon_or_acenocoumarol_dose_requirement._""CT:Patients_with_the_CT_genotype_may_require_a_increased_dose_of_phenprocoumon_or_acenocoumarol_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_dose_as_compared_to_the_TT_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_phenprocoumon_or_acenocoumarol_dose_requirement.""TT:Patients_with_the_TT_genotype_may_require_an_increased_dose_of_phenprocoumon_or_acenocoumarol_as_compared_to_patients_with_the_CT_or_CC_genotypes_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_phenprocoumon_or_acenocoumarol_dose_requirement._";PGKB_RACE=NR,NR
16	31102564	rs104894542	A	T,G,C	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_are_unlikely_to_be_resistant_to_warfarin_and_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""AC:Patients_with_the_AC_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""CC:Patients_with_the_CC_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.";PGKB_RACE=NR
16	31102589	rs7200749	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=VKORC1_(PA133787052),VKORC1_(PA133787052);PGKB_DRUG=acenocoumarol_(PA452632),warfarin_(PA451906);PGKB_TYPE=Dosage,Dosage;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""AG:Patients_with_the_AG_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""GG:Patients_with_the_GG_genotype_may_require_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.","AA:_Patients_with_the_AA_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose""AG:_Patients_with_the_AG_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose""GG:_Patients_with_the_GG_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose";PGKB_RACE=White,Black_or_African_American
16	31103796	rs2359612	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_require_the_lowest_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.";PGKB_RACE=NR
16	31104447	rs17886199	A	G	.	.	PGKB_INDEX=1;PGKB_GENE="PRSS53_(PA165450635)""VKORC1_(PA133787052)";PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""AG:Patients_with_the_AG_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""GG:Patients_with_the_GG_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.";PGKB_RACE=Black_or_African_American
16	31104509	rs8050894	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""CG:Patients_with_the_CG_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_the_lowest_dose_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.";PGKB_RACE=NR
16	31104878	rs9934438	G	A	.	.	PGKB_INDEX=4;PGKB_GENE="PRSS53_(PA165450635)""VKORC1_(PA133787052)",VKORC1_(PA133787052),VKORC1_(PA133787052),VKORC1_(PA133787052);PGKB_DRUG=fluindione_(PA165980614),warfarin_(PA451906),"acenocoumarol_(PA452632)""phenprocoumon_(PA450921)",warfarin_(PA451906);PGKB_TYPE=Efficacy,Dosage,Dosage,Efficacy;PGKB_EVIDENCE=3,1B,2A,3;PGKB_DISEASE=Thromboembolism_(PA445848),"Arteriosclerosis_(PA443425)""Heart_Diseases_(PA444368)""Hemorrhage_(PA444417)""Intracranial_Hemorrhages_(PA446997)""Myocardial_Infarction_(PA445019)""Peripheral_Vascular_Diseases_(PA153619833)""Pulmonary_Embolism_(PA445465)""Stroke_(PA447054)""Thromboembolism_(PA445848)""venous_thromboembolism_(PA447298)""Venous_Thrombosis_(PA446969)",NR,NR;PGKB_TEXT="AA:Patients_with_AA_genotypes_may_have_decreased_the_time_to_achieve_a_first_INR_within_the_therapeutic_range_and_shorter_time_to_have_over-anticoagulation_(INR_>4)_risk_when_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""AG:Patients_with_AG_genotypes_may_have_decreased_the_time_to_achieve_a_first_INR_within_the_therapeutic_range_and_shorter_time_to_have_over-anticoagulation_(INR_>4)_risk_when_compared_to_patients_with_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.""GG:Patients_with_GG_genotypes_may_have_increased_the_time_to_achieve_a_first_INR_within_the_therapeutic_range_and_longer_time_to_have_over-anticoagulation_(INR_>4)_risk_when_compared_to_patients_with_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_therapy.","AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_GG_genotype_and_a_higher_dose_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patients_required_dose_of_warfarin._""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_higher_dose_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.","AA:Patients_with_the_AA_genotype_may_have_decreased_dose_of_acenocoumarol_or_phenprocoumon_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_acenocoumarol_or_phenprocoumon.""AG:Patients_with_the_AG_genotype_may_have_decreased_dose_of_acenocoumarol_or_phenprocoumon_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_acenocoumarol_or_phenprocoumon.""GG:Patients_with_the_GG_genotype_may_have_increased_dose_of_acenocoumarol_or_phenprocoumon_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_acenocoumarol_or_phenprocoumon.","AA:Patients_with_the_AA_genotype_may_have_decreased_time_in_therapeutic_range_of_INR_(TTR)_when_treated_with_warfarin_as_compared_to_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""AG:Patients_with_the_AG_genotype_may_have_decreased_time_in_therapeutic_range_of_INR_(TTR)_when_treated_with_warfarin_as_compared_to_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""GG:Patients_with_the_GG_genotype_may_have_increased_time_in_therapeutic_range_of_INR_(TTR)_when_treated_with_warfarin_as_compared_to_genotype_AG_or_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.";PGKB_RACE=NR,NR,NR,NR
16	31105353	rs17708472	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_(homozygous_for_VKORC1*4)_may_require_a_higher_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Some_studies_have_not_found_a_significant_association_between_this_variant_and_warfarin_dose_however_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""AG:Patients_with_the_AG_genotype_(heterozygous_for_VKORC1*4)_may_require_a_higher_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Some_studies_have_not_found_a_significant_association_between_this_variant_and_warfarin_dose_however_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_AG_and_AA_genotype._Some_studies_have_not_found_a_significant_association_between_this_variant_and_warfarin_dose_however_the_majority_report_an_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_dose_of_warfarin.";PGKB_RACE=White
16	31105554	rs2884737	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2A;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_higher_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_warfarin_dose._""AC:Patients_with_the_AC_genotype_may_require_higher_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_warfarin_dose._""CC:Patients_with_the_CC_genotype_may_require_lower_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_warfarin_dose._";PGKB_RACE=NR
16	31105879	rs104894541	T	G,C,A	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""CT:Patients_with_the_CT_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""TT:Patients_with_the_TT_genotype_are_unlikely_to_be_resistant_to_warfarin_and_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.";PGKB_RACE=NR
16	31105917	rs104894540	A	T,G,C	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_are_unlikely_to_be_resistant_to_warfarin_and_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""AG:Patients_with_the_AG_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""GG:Patients_with_the_GG_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.";PGKB_RACE=NR
16	31105945	rs61742245	C	A	.	.	PGKB_INDEX=2;PGKB_GENE=VKORC1_(PA133787052),VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906),acenocoumarol_(PA452632);PGKB_TYPE=Dosage,Dosage;PGKB_EVIDENCE=2A,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_dose_of_warfarin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.""AC:Patients_with_the_AC_genotype_may_have_increased_dose_of_warfarin_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.""CC:Patients_with_the_CC_genotype_may_have_decreased_dose_of_warfarin_as_compared_to_patients_with_genotype_AA_or_AC._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_warfarin.","AA:Patients_with_the_AA_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""AC:Patients_with_the_AC_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""CC:Patients_with_the_CC_genotype_may_require_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.";PGKB_RACE=White,White
16	31105966	rs104894539	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""AC:Patients_with_the_AC_genotype_may_be_resistant_to_warfarin_requiring_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.""CC:Patients_with_the_CC_genotype_are_unlikely_to_be_resistant_to_warfarin_and_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose.";PGKB_RACE=NR
16	31106015	rs55894764	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=acenocoumarol_(PA452632);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""CT:Patients_with_the_CT_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""TT:Patients_with_the_TT_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.";PGKB_RACE=White
16	31107689	rs9923231	C	A,G,T	.	.	PGKB_INDEX=5;PGKB_GENE=VKORC1_(PA133787052),VKORC1_(PA133787052),VKORC1_(PA133787052),VKORC1_(PA133787052),VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906),"acenocoumarol_(PA452632)""phenprocoumon_(PA450921)",warfarin_(PA451906),warfarin_(PA451906),warfarin_(PA451906);PGKB_TYPE=Dosage,Dosage,Efficacy,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=1A,1B,2A,2A,3;PGKB_DISEASE=NR,NR,NR,over-anticoagulation_(PA166123298),time_in_therapeutic_range_(PA166129531);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose_requirement.""AG:Patients_with_the_AG_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_GG_genotype_or_may_require_a_higher_dose_as_compared_to_patients_with_the_AA_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose_requirement.""CC:Patients_with_the_CC_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_CT_or_TT_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose_requirement.""CT:Patients_with_the_CT_genotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype_or_may_require_a_higher_dose_as_compared_to_patients_with_the_TT_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose_requirement.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_AG_or_AA_genotypes._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose_requirement.""TT:Patients_with_the_TT_genotype_may_require_a_lower_dose_of_warfarin_as_compared_to_patients_with_the_CC_or_CT_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose_requirement.","AA:Patients_with_the_AA_genotype_who_are_treated_with_acenocoumarol_or_phenprocoumon_may_require_a_lower_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_acenocoumarol_or_phenprocoumon_maintenance_dose_requirement.""AG:Patients_with_the_AG_genotype_who_are_treated_with_acenocoumarol_or_phenprocoumon_may_require_a_lower_dose_as_compared_to_patients_with_the_GG_genotype_or_may_require_a_higher_dose_as_compared_to_patients_with_the_AA_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_acenocoumarol_or_phenprocoumon_maintenance_dose_requirement.""CC:Patients_with_the_CC_genotype_who_are_treated_with_acenocoumarol_or_phenprocoumon_may_require_a_higher_dose_as_compared_to_patients_with_the_CT_or_TT_genotypes._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_acenocoumarol_or_phenprocoumon_maintenance_dose_requirement.""CT:Patients_with_the_CT_genotype_who_are_treated_with_acenocoumarol_or_phenprocoumon_may_require_a_lower_dose_as_compared_to_patients_with_the_CC_genotype_or_may_require_a_higher_dose_as_compared_to_patients_with_the_TT_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_acenocoumarol_or_phenprocoumon_maintenance_dose_requirement.""GG:Patients_with_the_GG_genotype_who_are_treated_with_acenocoumarol_or_phenprocoumon_may_require_a_higher_dose_as_compared_to_patients_with_the_AG_or_AA_genotypes._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_acenocoumarol_or_phenprocoumon_maintenance_dose_requirement.""TT:Patients_with_the_TT_genotype_who_are_treated_with_acenocoumarol_or_phenprocoumon_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Patients_with_the_AT_AC_GT_or_CG_genotypes_were_not_observed_in_these_studies.Other_genetic_and_clinical_factors_may_also_influence_a_patient's_acenocoumarol_or_phenprocoumon_maintenance_dose_requirement.","CC:Patients_with_genotype_CC_may_require_longer_time_to_therapeutic_INR_when_treated_with_warfarin_as_compared_with_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin._""CT:Patients_with_genotype_CT_may_require_shorter_time_to_therapeutic_INR_when_treated_with_warfarin_as_compared_with_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin._""TT:Patients_with_genotype_TT_may_require_shorter_time_to_therapeutic_INR_when_treated_with_warfarin_as_compared_with_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin._","CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_with_patients_with_genotype_TT_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_with_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_over-anticoagulation_when_treated_with_warfarin_as_compared_with_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_toxicity_to_warfarin.","CC:Patients_with_the_CC_genotype_may_spent_more_time_in_INR_therapeutic_range_(TTR)_when_treated_with_warfarin_as_compared_with_patients_with_genotype_TT_or_CT._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""CT:Patients_with_the_CT_genotype_may_spent_less_time_in_INR_therapeutic_range_(TTR)_when_treated_with_warfarin_as_compared_with_patients_with_genotype_CC._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.""TT:Patients_with_the_TT_genotype_may_spent_less_time_in_INR_therapeutic_range_(TTR)_when_treated_with_warfarin_as_compared_with_patients_with_genotype_CC._Contradictory_findings_have_also_been_reported._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_warfarin.";PGKB_RACE=NR,NR,NR,NR,NR
16	31107927	rs17878544	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=acenocoumarol_(PA452632);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""CT:Patients_with_the_CT_genotype_may_require_increased_dose_of_acenocoumarol_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.""TT:Patients_with_the_TT_genotype_may_require_decreased_dose_of_acenocoumarol_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_clinical_or_genetic_factors_may_also_influence_acenocoumarol_dose.";PGKB_RACE=White
16	31110501	rs17880887	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_require_lower_dose_of_warfarin_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose._This_variant_rs17880887_is_part_of_VKORC1_H8_and_H9_haplotypes.""GT:Patients_with_the_GT_genotype_may_require_higher_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose._This_variant_rs17880887_is_part_of_VKORC1_H8_and_H9_haplotypes.""TT:Patients_with_the_TT_genotype_may_require_higher_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_warfarin_dose._This_variant_rs17880887_is_part_of_VKORC1_H8_and_H9_haplotypes.";PGKB_RACE=Asian
16	31110981	rs7196161	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_the_dose_of_warfarin._""AG:Patients_with_the_AG_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype_and_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_the_dose_of_warfarin._""GG:Patients_with_the_GG_genotype_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_the_dose_of_warfarin._";PGKB_RACE=Asian
16	31114234	rs61162043	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=VKORC1_(PA133787052);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""AG:Patients_with_the_AG_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""GG:Patients_with_the_GG_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.";PGKB_RACE=Black_or_African_American
16	48242898	rs7194667	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC11_(PA24393);PGKB_DRUG=fluorouracil_(PA128406956);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Leukopenia_(PA444773)""Neoplasms_(PA445062)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_cancer_who_are_treated_with_fluorouracil_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_fluorouracil._""GT:Patients_with_the_GT_genotype_and_cancer_who_are_treated_with_fluorouracil_may_have_an_increased_risk_of_leukopenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_fluorouracil._""TT:Patients_with_the_TT_genotype_and_cancer_who_are_treated_with_fluorouracil_may_have_an_reduced_risk_of_leukopenia_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_adverse_reactions_when_treated_with_fluorouracil._";PGKB_RACE=NR
16	49830204	rs8060157	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ZNF423_(PA134903681);PGKB_DRUG="raloxifene_(PA451221)""tamoxifen_(PA451581)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_occurrence_of_breast_cancer_during_SERM_(selective_estrogen_receptor_modulators)_therapy_when_treated_with_raloxifene_or_tamoxifen_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_SERM_therapy.""AG:Patients_with_the_AG_genotype_may_have_decreased_risk_of_occurrence_of_breast_cancer_during_SERM_(selective_estrogen_receptor_modulators)_therapy_when_treated_with_raloxifene_or_tamoxifen_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_SERM_therapy.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_occurrence_of_breast_cancer_during_SERM_(selective_estrogen_receptor_modulators)_therapy_when_treated_with_raloxifene_or_tamoxifen_in_people_with_Breast_Neoplasms_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_SERM_therapy.";PGKB_RACE=NR
16	50745926	rs2066844	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NOD2_(PA26074);PGKB_DRUG=tacrolimus_(PA451578);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Kidney_Transplantation_(PA165817016);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_underwent_kidney_transplantation_may_have_a_longer_post-transplantation_hospital_stay_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_post-transplantation_hospital_stay.""CT:Patients_with_the_CT_genotype_who_underwent_kidney_transplantation_may_have_a_shorter_post-transplantation_hospital_stay_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_post-transplantation_hospital_stay.""TT:Patients_with_the_TT_genotype_who_underwent_kidney_transplantation_may_have_a_shorter_post-transplantation_hospital_stay_when_treated_with_tacrolimus_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_length_of_post-transplantation_hospital_stay.";PGKB_RACE=White
16	53820527	rs9939609	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=FTO_(PA152208656);PGKB_DRUG="interferon_alfa-2a_recombinant_(PA164779048)""interferon_alfa-2b_recombinant_(PA164783990)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Hepatitis_C_Chronic_(PA446863)""HIV_(PA447230)";PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_lower_likelihood_of_achieving_successful_virologic_response_to_pegylated-interferon-alpha_plus_ribavirin_in_patients_coinfected_with_HIV/HCV_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_pegylated-interferon-alpha_plus_ribavirin_therapy.""AT:Patients_with_genotype_AT_may_have_lower_likelihood_of_achieving_successful_virologic_response_to_pegylated-interferon-alpha_plus_ribavirin_in_patients_coinfected_with_HIV/HCV_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_pegylated-interferon-alpha_plus_ribavirin_therapy.""TT:Patients_with_genotype_TT_may_have_higher_likelihood_of_achieving_successful_virologic_response_to_pegylated-interferon-alpha_plus_ribavirin_in_patients_coinfected_with_HIV/HCV_as_compared_to_patients_with_genotype_AA_or_AT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_pegylated-interferon-alpha_plus_ribavirin_therapy.";PGKB_RACE=NR
16	53876751	rs12595985	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=FTO_(PA152208656);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_genotype_AA_and_hypertension_may_have_an_increased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AC_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""AC:Patients_with_genotype_AC_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""CC:Patients_with_genotype_CC_and_hypertension_may_have_a_decreased_risk_of_hypercholesteremia_when_administered_atenolol_as_compared_to_patients_with_the_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=Black_or_African_American
16	54004811	rs9940629	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=FTO_(PA152208656);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_genotype_AA_and_hypertension_may_have_a_smaller_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""AG:Patients_with_genotype_AG_and_hypertension_may_have_a_smaller_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_the_GG_genotype_and_an_greater_reduction_in_HDL-C_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.""GG:Patients_with_genotype_GG_and_hypertension_may_have_a_greater_reduction_in_HDL-C_when_administered_atenolol_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_hypercholesteremia_upon_administration_of_atenolol_in_patients_with_hypertension.";PGKB_RACE=White
16	55171874	rs9936750	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_capecitabine_may_have_an_increased_risk_for_capecitabine-induced_toxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_severe_capecitabine_toxicity.""CT:Patients_with_the_CT_genotype_who_are_treated_with_capecitabine_may_have_an_increased_risk_for_capecitabine-induced_toxicity_as_compared_to_patients_with_the_TT_genotype_and_may_have_a_decreased_but_not_absent_risk_for_capecitabine-induced_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_severe_capecitabine_toxicity.""TT:Patients_with_the_TT_genotype_who_are_treated_with_capecitabine_may_have_a_decreased_but_not_absent_risk_for_capecitabine-induced_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_severe_capecitabine_toxicity.";PGKB_RACE=NR
16	55695106	rs3785143	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC6A2_(PA310);PGKB_DRUG=atomoxetine_(PA134688071);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Attention_Deficit_Disorder_with_Hyperactivity_(PA447197);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_better_response_to_treatment_with_atomoxetine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atomoxetine.""CT:Patients_with_the_CT_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_better_response_to_treatment_with_atomoxetine_as_compared_to_patients_with_the_TT_genotype_or_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atomoxetine.""TT:Patients_with_the_TT_genotype_and_attention_deficit_hyperactivity_disorder_(ADHD)_may_have_a_poorer_response_to_treatment_with_atomoxetine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_atomoxetine.";PGKB_RACE=Asian
16	55731599	rs12708954	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC6A2_(PA310);PGKB_DRUG=atomoxetine_(PA134688071);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Attention_Deficit_Disorder_with_Hyperactivity_(PA447197);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Attention_Deficit_Disorder_with_Hyperactivity_who_are_treated_with_atomoxetine_may_have_increased_response_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine.""AC:Patients_with_the_AC_genotype_and_Attention_Deficit_Disorder_with_Hyperactivity_who_are_treated_with_atomoxetine_may_have_increased_response_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine.._""CC:Patients_with_the_CC_genotype_and_Attention_Deficit_Disorder_with_Hyperactivity_who_are_treated_with_atomoxetine_may_have_decreased_response_as_compared_to_patients_with_the_AA_genotype._However_contradictory_findings_exist._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atomoxetine.";PGKB_RACE=NR
16	55793695	rs3785161	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=CES1P1_(PA134906523);PGKB_DRUG=clopidogrel_(PA449053);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Coronary_Disease_(PA443797);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Coronary_Disease_who_are_treated_with_clopidogrel_may_have_a_decreased_on-treatment_platelet_activity_as_compared_to_patients_with_the_CC_or_CA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_high_on-treatment_platelet_activity.""CA:Patients_with_the_CA_genotype_and_Coronary_Disease_who_are_treated_with_clopidogrel_may_have_an_increased_on-treatment_platelet_activity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_high_on-treatment_platelet_activity.""CC:Patients_with_the_CC_genotype_and_Coronary_Disease_who_are_treated_with_clopidogrel_may_have_an_increased_on-treatment_platelet_activity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_high_on-treatment_platelet_activity.";PGKB_RACE=Asian
16	55844609	rs2244613	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=CES1_(PA107);PGKB_DRUG=Dabigatran_(PA165110351);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Atrial_Fibrillation_(PA443459);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Atrial_Fibrillation_who_are_treated_with_dabigatran_may_have_1)_a_decreased_adjusted_trough_concentrations_of_dabigatran_2)_a_decreased_but_not_absent_risk_for_bleeding_when_treated_with_dabigatran_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding.""GT:Patients_with_the_GT_genotype_and_Atrial_Fibrillation_who_are_treated_with_dabigatran_may_have_1)_a_decreased_adjusted_trough_concentrations_of_dabigatran_2)_a_decreased_but_not_absent_risk_for_bleeding_when_treated_with_dabigatran_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding.""TT:Patients_with_the_TT_genotype_and_Atrial_Fibrillation_may_have_an_increased_risk_for_bleeding_when_treated_with_dabigatran_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bleeding.";PGKB_RACE=NR
16	55857570	rs71647871	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=CES1_(PA107),CES1_(PA107),CES1_(PA107);PGKB_DRUG=clopidogrel_(PA449053),methylphenidate_(PA450464),enalapril_(PA449456);PGKB_TYPE=Efficacy,Dosage,Metabolism/PK;PGKB_EVIDENCE=2B,3,3;PGKB_DISEASE=NR,Attention_Deficit_Disorder_with_Hyperactivity_(PA447197),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_clopidogrel_may_have_higher_on-treatment_ADP-induced_platelet_aggregation_and_lower_levels_of_clopidogrel_active_metabolite_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""CT:Patients_with_the_CT_genotype_who_are_treated_with_clopidogrel_may_have_lower_on-treatment_ADP-induced_platelet_aggregation_and_higher_levels_of_clopidogrel_active_metabolite_as_compared_to_patients_with_the_CC_genotype._The_T_allele_is_associated_with_impaired_catalytic_activity_towards_hydrolysis_of_clopidogrel_and_2-oxo-clopidogrel._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.""TT:Patients_with_the_TT_genotype_who_are_treated_with_clopidogrel_may_have_lower_on-treatment_ADP-induced_platelet_aggregation_and_higher_levels_of_clopidogrel_active_metabolite_as_compared_to_patients_with_the_CC_genotype._The_T_allele_is_associated_with_impaired_catalytic_activity_towards_hydrolysis_of_clopidogrel_and_2-oxo-clopidogrel._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel.","CC:Patients_with_the_CC_genotype_and_Attention_Deficit_Disorder_may_require_an_increased_dose_of_methylphenidate_as_compared_to_patients_with_the_CT_genotype._This_was_not_associated_with_response._Other_genetic_and_clinical_factors_may_also_influence_methylphenidate_dose_and_response.""CT:Patients_with_the_CT_genotype_and_Attention_Deficit_Disorder_may_require_a_decreased_dose_of_methylphenidate_as_compared_to_patients_with_the_CC_genotype._This_was_not_associated_with_response._Other_genetic_and_clinical_factors_may_also_influence_methylphenidate_dose_and_response.""TT:Patients_with_the_TT_genotype_were_not_studied_however_patients_with_the_CT_genotype_and_Attention_Deficit_Disorder_may_require_a_decreased_dose_of_methylphenidate_as_compared_to_patients_with_the_CC_genotype._This_was_not_associated_with_response._Other_genetic_and_clinical_factors_may_also_influence_methylphenidate_dose_and_response.","CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_enalapril_as_compared_to_patients_with_the_CT_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_enalapril.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_enalapril_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_enalapril.";PGKB_RACE=NR,White,White
16	56900931	rs13306673	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC12A3_(PA321);PGKB_DRUG=Thiazides_plain_(PA164713347);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_reduction_in_mean_blood_pressure_when_treated_with_Thiazides_in_people_with_Essential_hypertension_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_thiazides.""CT:Patients_with_the_CT_genotype_may_have_decreased_reduction_in_mean_blood_pressure_when_treated_with_Thiazides_in_people_with_Essential_hypertension_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_thiazides.""TT:Patients_with_the_TT_genotype_may_have_decreased_reduction_in_mean_blood_pressure_when_treated_with_Thiazides_in_people_with_Essential_hypertension_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_thiazides.";PGKB_RACE=Asian
16	56904587	rs1529927	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="bumetanide_(PA448682)""furosemide_(PA449719)""torasemide_(PA451733)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_better_response_to_treatment_with_loop_diuretics_as_compared_to_those_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_loop_diuretics._""CG:Patients_with_the_CG_genotype_may_have_a_better_response_to_treatment_with_loop_diuretics_as_compared_to_those_with_the_GG_genotype_or_a_poorer_response_to_treatment_as_compared_to_those_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_loop_diuretics._""GG:Patients_with_the_GG_genotype_may_have_a_poorer_response_to_treatment_with_loop_diuretics_as_compared_to_those_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_loop_diuretics._";PGKB_RACE=White
16	56994894	rs4783961	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CETP_(PA108);PGKB_DRUG=fluvastatin_(PA449688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypercholesterolemia_(PA444516);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_fluvastatin_treatment_(determined_by_a_lower_change_in_HDL-C_levels)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_fluvastatin_treatment_(determined_by_a_lower_change_in_HDL-C_levels)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_fluvastatin_treatment_(determined_by_higher_change_in_HDL-C_levels)_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._";PGKB_RACE=NR
16	56996288	rs708272	G	A	.	.	PGKB_INDEX=5;PGKB_GENE=CETP_(PA108),CETP_(PA108),CETP_(PA108),CETP_(PA108),CETP_(PA108);PGKB_DRUG=lovastatin_(PA450272),pravastatin_(PA451089),simvastatin_(PA451363),atorvastatin_(PA448500),hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy,Efficacy,Efficacy,"Efficacy""Toxicity/ADR","Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3,3,3,3,3;PGKB_DISEASE=NR,Coronary_Artery_Disease_(PA443796),"Hypercholesterolemia_(PA444516)""Hyperlipoproteinemia_Type_II_(PA444517)",NR,Coronary_Artery_Disease_(PA443796);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_response_to_lovastatin_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_response_to_lovastatin_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lovastatin_treatment._""AG:Patients_with_the_AG_genotype_may_have_an_increased_response_to_lovastatin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lovastatin_treatment._""GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_lovastatin_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lovastatin_treatment._","AA:Patients_with_the_AA_genotype_and_Coronary_Artery_Disease_may_be_less_likely_to_benefit_from_treatment_with_pravastatin_and_have_an_increased_risk_of_death_or_cardiovascular_disease_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""AG:Patients_with_the_AG_genotype_and_Coronary_Artery_Disease_may_be_more_likely_to_benefit_from_treatment_with_pravastatin_and_have_a_reduced_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_and_Coronary_Artery_Disease_may_be_more_likely_to_benefit_from_treatment_with_pravastatin_and_have_a_reduced_risk_of_death_or_cardiovascular_disease_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._","AA:Patients_with_the_AA_genotype_and_hypercholesterolemia_who_are_treated_with_simvastatin_may_have_an_increased_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_AG_or_GG_genotype._Another_study_found_no_association_with_response_to_simvastatin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""AG:Patients_with_the_AG_genotype_and_hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_decreased_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_AA_genotype._Another_study_found_no_association_with_response_to_simvastatin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_and_hypercholesterolemia_who_are_treated_with_simvastatin_may_have_a_decreased_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_AA_genotype._Another_study_found_no_association_with_response_to_simvastatin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._","AA:Patients_with_the_AA_genotype_who_are_treated_with_atorvastatin_may_have_a_decreased_response_to_treatment_and_an_increased_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_GG_genotype._However_these_results_were_not_statistically_significant_and_there_are_contradictory_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment.""AG:Patients_with_the_AG_genotype_who_are_treated_with_atorvastatin_may_have_a_decreased_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_AA_genotype._However_these_results_were_not_statistically_significant_and_there_are_contradictory_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment.""GG:Patients_with_the_GG_genotype_who_are_treated_with_atorvastatin_may_have_an_increased_response_to_treatment_and_a_decreased_risk_of_cardiovascular_disease_events_as_compared_to_patients_with_the_AA_genotype._However_these_results_were_not_statistically_significant_and_there_are_contradictory_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment.","AA:Patients_with_the_AA_genotype_and_Coronary_Artery_Disease_who_are_treated_with_statins_may_have_a_greater_reduction_in_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""AG:Patients_with_the_AA_genotype_and_Coronary_Artery_Disease_who_are_treated_with_statins_may_have_a_greater_reduction_in_cardiovascular_events_as_compared_to_patients_with_the_GG_genotype_or_may_have_less_of_a_reduction_in_cardiovascular_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._""GG:Patients_with_the_GG_genotype_and_Coronary_Artery_Disease_who_are_treated_with_statins_may_have_less_of_a_reduction_in_cardiovascular_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_statin_treatment._";PGKB_RACE=White,NR,NR,NR,NR
16	57005479	rs1532624	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CETP_(PA108);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Hyperlipidemias_(PA444528);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_response_to_hmg_coa_reductase_inhibitors_in_people_with_Hyperlipidemias_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.""AC:Patients_with_the_AC_genotype_may_have_decreased_response_to_hmg_coa_reductase_inhibitors_in_people_with_Hyperlipidemias_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.""CC:Patients_with_the_CC_genotype_may_have_increased_response_to_hmg_coa_reductase_inhibitors_in_people_with_Hyperlipidemias_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.";PGKB_RACE=NR
16	57016092	rs5882	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CETP_(PA108),CETP_(PA108);PGKB_DRUG=fluvastatin_(PA449688),simvastatin_(PA451363);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=4,3;PGKB_DISEASE=Hypercholesterolemia_(PA444516),Hypercholesterolemia_(PA444516);PGKB_TEXT="AA:Patients_with_the_AA_genotype_were_not_studied_however_patients_with_the_AG_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_fluvastatin_(a_higher_change_in_triglycerides)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_may_have_a_better_response_to_fluvastatin_(a_higher_change_in_triglycerides)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_may_have_a_reduced_response_to_fluvastatin_(a_lower_change_in_triglycerides)_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._","AA:Patients_with_the_AA_genotype_who_have_Hypercholesterolemia_may_have_a_better_response_to_simvastatin_(a_greater_decrease_in_triglyceride_levels_and_higher_increase_in_HDL-cholesterol_levels)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AG:Patients_with_the_AG_genotype_who_have_Hypercholesterolemia_may_have_a_better_response_to_simvastatin_(a_greater_decrease_in_triglyceride_levels_and_higher_increase_in_HDL-cholesterol_levels)_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_reduced_response_to_simvastatin_(a_lower_decrease_in_triglyceride_levels_and_lower_increase_in_HDL-cholesterol_levels)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""GG:Patients_with_the_GG_genotype_who_have_Hypercholesterolemia_may_have_a_reduced_response_to_simvastatin_(a_lower_decrease_in_triglyceride_levels_and_lower_increase_in_HDL-cholesterol_levels)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._";PGKB_RACE=NR,NR
16	69143577	rs2232228	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=HAS3_(PA29196);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Cardiomyopathies_(PA445018);PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_increased_cardiomyopathy_risk_when_exposed_to_high-dose_(>_250_mg/m2)_anthracyclines_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_anthracyclines.""AG:Patients_with_genotype_AG_may_have_increased_cardiomyopathy_risk_when_exposed_to_high-dose_(>_250_mg/m2)_anthracyclines_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_anthracyclines.""GG:Patients_with_genotype_GG_may_have_decreased_cardiomyopathy_risk_when_exposed_to_high-dose_(>_250_mg/m2)_anthracyclines_in_children_with_Neoplasms_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_anthracyclines.";PGKB_RACE=NR
16	69743760	rs10517	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NQO1_(PA31744);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_dose_of_warfarin.""AG:Patients_with_the_AG_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_dose_of_warfarin.""GG:Patients_with_the_GG_genotype_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AA_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_dose_of_warfarin.";PGKB_RACE=Asian
16	69745145	rs1800566	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=NQO1_(PA31744),NQO1_(PA31744),NQO1_(PA31744);PGKB_DRUG=warfarin_(PA451906),"Alkylating_Agents_(PA164712331)""anthracyclines_and_related_substances_(PA130620651)""fluorouracil_(PA128406956)""Platinum_compounds_(PA164713176)",warfarin_(PA451906);PGKB_TYPE=Dosage,Efficacy,NR;PGKB_EVIDENCE=3,2A,3;PGKB_DISEASE=NR,"Breast_Neoplasms_(PA443560)""Carcinoma_Non-Small-Cell_Lung_(PA443622)""Neoplasms_(PA445062)""Ovarian_Neoplasms_(PA445204)""Stomach_Neoplasms_(PA445742)",NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""AG:Patients_with_the_AG_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.""GG:Patients_with_the_GG_genotype_may_require_an_decreased_dose_of_warfarin_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose.","AA:Patients_with_the_AA_genotype_and_cancer_who_are_treated_with_chemotherapy_regimes_that_include_platinum_compounds_anthracyclines_and_related_substances_and_nucleoside_inhibitors_may_have_worse_outcome_(overall_survival_and_progression-free_survival)_as_compared_to_patients_with_the_GG_genotype._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_treatment_outcome.""AG:Patients_with_the_AG_genotype_and_cancer_who_are_treated_with_chemotherapy_regimes_that_include_platinum_compounds_anthracyclines_and_related_substances_and_nucleoside_inhibitors_may_have_a_a_better_outcome_(overall_survival_and_progression-free_survival)_as_compared_to_patients_with_the_AA_genotype_and_a_worse_outcome_as_compared_to_patients_with_the_GG_genotype._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_treatment_outcome.""GG:Patients_with_the_GG_genotype_and_Breast_Neoplasms_and_cancer_who_are_treated_with_chemotherapy_regimes_that_include_platinum_compounds_anthracyclines_and_related_substances_and_nucleoside_inhibitors_may_have_a_better_outcome_(overall_survival_and_progression-free_survival)_as_compared_to_patients_with_the_AA_genotype._However_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_treatment_outcome.","AA:Patients_with_the_AA_genotype_may_require_a_decreased_dose_of_warfarin_as_compared_to_patients_with_the_GG_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose._""AG:Patients_with_the_AG_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose._""GG:Patients_with_the_GG_genotype_may_require_an_increased_dose_of_warfarin_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_warfarin_dose._";PGKB_RACE=Hispanic_or_Latino,NR,Asian
16	72042682	rs3213422	A	C	.	.	PGKB_INDEX=1;PGKB_GENE="ATP5A1P3_(PA25121)""DHODH_(PA27327)""PKD1L3_(PA134907578)";PGKB_DRUG=leflunomide_(PA450192);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_leflunomide_may_be_less_likely_to_respond_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AC:It_is_not_clear_how_patients_with_the_AC_genotype_who_are_treated_with_leflunomide_respond_as_compared_to_patients_with_the_AA_or_the_CC_genotype.""CC:Patients_with_the_CC_genotype_who_are_treated_with_leflunomide_may_be_more_likely_to_respond_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
16	79439374	rs4888024	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Neoplasm_Residual_(PA446714)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_childhood_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_end-of-induction_minimal_residual_disease_(MRD)_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_MRD.""AG:Patients_with_the_AG_genotype_and_childhood_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_end-of-induction_minimal_residual_disease_(MRD)_as_compared_to_patients_with_the_AA_genotype.""GG:Patients_with_the_GG_genotype_and_childhood_acute_lymphoblastic_leukemia_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_end-of-induction_minimal_residual_disease_(MRD)_as_compared_to_patients_with_the_AA_genotype.";PGKB_RACE=NR
16	87889203	rs4240803	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC7A5_(PA35923);PGKB_DRUG=melphalan_(PA450354);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Multiple_Myeloma_(PA444985);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_multiple_myeloma_may_have_a_decreased_risk_of_gastrointestinal_toxicity_when_treated_with_melphalan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_melphalan-induced_toxicity.""AG:Patients_with_the_AG_genotype_and_multiple_myeloma_may_have_a_decreased_risk_of_gastrointestinal_toxicity_when_treated_with_melphalan_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_melphalan-induced_toxicity.""GG:Patients_with_the_GG_genotype_and_multiple_myeloma_may_have_an_increased_risk_of_gastrointestinal_toxicity_when_treated_with_melphalan_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_melphalan-induced_toxicity.";PGKB_RACE=White
16	88713236	rs4673	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=CYBA_(PA27075),CYBA_(PA27075);PGKB_DRUG=simvastatin_(PA451363),doxorubicin_(PA449412);PGKB_TYPE=Other,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Hypercholesterolemia_(PA444516),"Arrhythmias_Cardiac_(PA443421)""Drug_Toxicity_(PA443937)""Lymphoma_Non-Hodgkin_(PA444845)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hypercholesterolemia_may_benefit_more_from_simvastatin_treatment_due_to_an_increased_reduction_in_DNA_damage_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AG:Patients_with_the_AG_genotype_and_Hypercholesterolemia_may_benefit_more_from_simvastatin_treatment_due_to_an_increased_reduction_in_DNA_damage_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""GG:Patients_with_the_GG_genotype_and_Hypercholesterolemia_may_benefit_less_from_simvastatin_treatment_due_to_a_lower_reduction_in_DNA_damage_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","AA:Patients_with_the_AA_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""AG:Patients_with_the_AG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxicity_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_but_not_absent_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""GG:Patients_with_the_GG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_a_decreased_but_not_absent_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.";PGKB_RACE=NR,White
16	89613123	rs2292954	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SPG7_(PA36067);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
16	89620328	rs12960	G	A	.	.	PGKB_INDEX=1;PGKB_GENE="RPL13_(PA34670)""SNORD68_(PA145007789)""SPG7_(PA36067)";PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
16	89985940	rs2228479	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=MC1R_(PA30673);PGKB_DRUG=desipramine_(PA449233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Depressive_Disorder_may_have_an_increased_likelihood_of_remission_when_treated_with_desipramine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_desipramine.""AG:Patients_with_the_AG_genotype_and_Depressive_Disorder_may_have_an_increased_likelihood_of_remission_when_treated_with_desipramine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_desipramine.""GG:Patients_with_the_GG_genotype_and_Depressive_Disorder_may_have_a_decreased_likelihood_of_remission_when_treated_with_desipramine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_desipramine.";PGKB_RACE=NR
16	89986608	rs2228478	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=MC1R_(PA30673);PGKB_DRUG=desipramine_(PA449233);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Depressive_Disorder_may_have_a_decreased_likelihood_of_remission_when_treated_with_desipramine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_desipramine.""AG:Patients_with_the_AG_genotype_and_Depressive_Disorder_may_have_an_increased_likelihood_of_remission_when_treated_with_desipramine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_desipramine.""GG:Patients_with_the_GG_genotype_and_Depressive_Disorder_may_have_an_increased_likelihood_of_remission_when_treated_with_desipramine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_desipramine.";PGKB_RACE=NR
17	3466596	rs879207	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="carboplatin_(PA448803)""docetaxel_(PA449383)""paclitaxel_(PA450761)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""AG:Patients_with_the_AG_genotype_and_ovarian_cancer_may_have_an_increased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""GG:Patients_with_the_GG_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._";PGKB_RACE=NR
17	4622638	rs1045280	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ARRB2_(PA60);PGKB_DRUG=methamphetamine_(PA450403);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Substance-Related_Disorders_(PA446876);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_Substance-Related_Disorders_when_exposed_to_methamphetamine_as_compared_to_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methamphetamine.""CT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Substance-Related_Disorders_when_exposed_to_methamphetamine_as_compared_to_CC_genotype_or_may_have_decreased_likelihood_of_Substance-Related_Disorders_when_exposed_to_methamphetamine_as_compared_to_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methamphetamine.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_Substance-Related_Disorders_when_exposed_to_methamphetamine_as_compared_to_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methamphetamine.";PGKB_RACE=Asian
17	4836381	rs6065	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=GP1BA_(PA178);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_risk_for_aspirin_resistance_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_but_not_absent_risk_for_aspirin_resistance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_but_not_absent_risk_for_aspirin_resistance_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
17	6903944	rs11078659	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ALOX12_(PA45);PGKB_DRUG=celecoxib_(PA448871);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="AA:Patients_with_the_AA_genotype_with_colorectal_neoplasms_who_are_treated_with_celecoxib_may_have_an_increased_risk_of_adenoma_recurrence_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_adenoma_recurrence.""AG:Patients_with_the_AG_genotype_with_colorectal_neoplasms_who_are_treated_with_celecoxib_may_have_an_increased_risk_of_adenoma_recurrence_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_risk_of_adenoma_recurrence_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_adenoma_recurrence.""GG:Patients_with_the_GG_genotype_with_colorectal_neoplasms_who_are_treated_with_celecoxib_may_have_a_decreased_risk_of_adenoma_recurrence_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_risk_for_adenoma_recurrence.";PGKB_RACE=NR
17	7579472	rs1042522	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=TP53_(PA36679);PGKB_DRUG="antineoplastic_agents_(PA452621)""cisplatin_(PA449014)""cyclophosphamide_(PA449165)""fluorouracil_(PA128406956)""paclitaxel_(PA450761)";PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=2B;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Neoplasms_(PA445062)""Neutropenia_(PA445113)""Ovarian_Neoplasms_(PA445204)""Stomach_Neoplasms_(PA445742)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_1)_decreased_but_not_absent_risk_for_toxicity_2)_increased_survival_when_treated_with_antineoplastic_agents_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.""CG:Patients_with_the_CG_genotype_may_have_1)_increased_risk_for_toxicity_2)_decreased_survival_when_treated_with_antineoplastic_agents_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.""GG:Patients_with_the_GG_genotype_may_have_1)_increased_risk_for_toxicity_2)_decreased_survival_when_treated_with_antineoplastic_agents_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_antineoplastic_agents.";PGKB_RACE=NR
17	17740164	rs60282872	GC	G	.	.	PGKB_INDEX=1;PGKB_GENE=SREBF1_(PA335);PGKB_DRUG=fluvastatin_(PA449688);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="C/del:Patients_with_the_CC/del_genotype_who_are_treated_with_fluvastatin_may_have_a_smaller_change_in_apolipoprotein_A1_and_C3_levels_as_compared_to_patients_with_the_C/C_genotype_or_may_have_a_larger_change_in_apolipoprotein_A1_and_C3_levels_as_compared_to_patients_with_the_del/del_genotype._Changes_with_treatment_in_other_lipids_were_not_significantly_different_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""CC:Patients_with_the_CC_genotype_who_are_treated_with_fluvastatin_may_have_a_larger_change_in_apolipoprotein_A1_and_C3_levels_as_compared_to_patients_with_the_C/del_or_del/del_genotype._Changes_with_treatment_in_other_lipids_were_not_significantly_different_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_fluvastatin_may_have_a_smaller_change_in_apolipoprotein_A1_and_C3_levels_as_compared_to_patients_with_the_CC_or_C/del_genotype._Changes_with_treatment_in_other_lipids_were_not_significantly_different_between_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._";PGKB_RACE=White
17	18232096	rs1979277	G	A	.	.	PGKB_INDEX=4;PGKB_GENE=SHMT1_(PA35753),SHMT1_(PA35753),SHMT1_(PA35753),SHMT1_(PA35753);PGKB_DRUG="bevacizumab_(PA130232992)""fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)",methotrexate_(PA450428),methotrexate_(PA450428),"capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy,Other,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),Arthritis_Rheumatoid_(PA443434),Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Colorectal_Neoplasms_may_have_1)_increased_response_2)_increased_progression-free_survival_and_overall_survival_when_treated_with_bevacizumab_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bevacizumab_fluorouracil_irinotecan_and_leucovorin.""AG:Patients_with_the_AG_genotype_and_Colorectal_Neoplasms_may_have_1)_increased_response_2)_increased_progression-free_survival_and_overall_survival_when_treated_with_bevacizumab_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bevacizumab_fluorouracil_irinotecan_and_leucovorin.""GG:Patients_with_the_GG_genotype_and_Colorectal_Neoplasms_may_have_1)_decreased_response_2)_decreased_progression-free_survival_and_overall_survival_when_treated_with_bevacizumab_fluorouracil_irinotecan_and_leucovorin_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_bevacizumab_fluorouracil_irinotecan_and_leucovorin.","AA:Patients_with_the_AA_genotype_and_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_increased_red_blood_cell_folate_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_increased_red_blood_cell_folate_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_red_blood_cell_folate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_decreased_red_blood_cell_folate_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.","AA:Pediatric_patients_with_the_AA_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_increased_catalytic_activity_of_TYMS_as_compared_to_pediatric_patients_with_the_AG_and_GG_genotype._Patients_with_the_AA_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_increased_likelihood_of_Toxic_liver_disease_as_compared_to_patients_with_the_AG_genotype._However_this_association_is_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Pediatric_patients_with_the_AG_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_decreased_catalytic_activity_of_TYMS_as_compared_to_pediatric_patients_with_the_AA_genotype._Patients_with_the_AG_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_a_decreased_likelihood_of_Toxic_liver_disease_as_compared_to_patients_with_the_AA_and_GG_genotype._However_this_association_is_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Pediatric_patients_with_the_GG_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_decreased_catalytic_activity_of_TYMS_as_compared_to_pediatric_patients_with_the_AA_genotype._Patients_with_the_GG_genotype_and_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_methotrexate_may_have_increased_likelihood_of_Toxic_liver_disease_as_compared_to_patients_with_the_AG_genotype._However_this_association_is_contradicted_in_other_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.","AA:Patients_with_the_AA_genotype_and_cancer_may_have_an_increased_risk_of_drug_toxicity_when_administered_capecitabine_and/or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity_in_patients_with_cancer.""AG:Patients_with_the_AG_genotype_and_cancer_may_have_a_decreased_risk_of_drug_toxicity_when_administered_capecitabine_and/or_fluorouracil_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity_in_patients_with_cancer.""GG:Patients_with_the_GG_genotype_and_cancer_may_have_a_decreased_risk_of_drug_toxicity_when_administered_capecitabine_and/or_fluorouracil_as_compared_to_patients_with_the_AA_and_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity_in_patients_with_cancer.";PGKB_RACE=NR,White,NR,NR
17	19437187	rs2252281	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC47A1_(PA162403808);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_an_increased_response_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_metformin.""CT:Patients_with_the_CT_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_metformin.""TT:Patients_with_the_TT_genotype_and_Diabetes_Mellitus_Type_2_who_are_treated_with_metformin_may_have_a_decreased_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_patient's_response_to_metformin.";PGKB_RACE=NR
17	19463343	rs2289669	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="AA:Patients_with_the_genotype_AA_may_have_better_response_to_metformin_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_genotype_AG_or_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_metformin.""AG:Patients_with_genotype_AG_may_have_decreased_response_to_metformin_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_metformin.""GG:Patients_with_genotype_GG_may_have_decreased_response_to_metformin_in_people_with_Diabetes_Mellitus_Type_2_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_metformin.";PGKB_RACE=White
17	19619998	rs12943590	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=SLC47A2_(PA162403847),SLC47A2_(PA162403847);PGKB_DRUG=metformin_(PA450395),metformin_(PA450395);PGKB_TYPE=Efficacy,Metabolism/PK;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_1)_decreased_response_to_metformin_in_people_with_Diabetes_Mellitus_2)_increased_renal_and_secretory_clearance_of_metformin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin._""AG:Patients_with_the_AG_genotype_may_have_1)_increased_response_to_metformin_in_people_with_Diabetes_Mellitus_2)_decreased_renal_and_secretory_clearance_of_metformin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin._""GG:Patients_with_the_GG_genotype_may_have_1)_increased_response_to_metformin_in_people_with_Diabetes_Mellitus_2)_decreased_renal_and_secretory_clearance_of_metformin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin._","AA:Individuals_with_the_AA_genotype_may_have_increased_renal_and_secretory_clearance_of_metformin_as_compared_to_individuals_with_the_GG_genotype._However_current_evidence_is_contradictory._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin._""AG:Individuals_with_the_AG_genotype_may_have_increased_renal_and_secretory_clearance_of_metformin_as_compared_to_individuals_with_the_GG_genotype_however_current_evidence_is_contradictory._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin._""GG:Individuals_with_the_GG_genotype_may_have_decreased_renal_and_secretory_clearance_of_metformin_as_compared_to_individuals_with_the_AA_genotype_however_current_evidence_is_contradictory._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin._";PGKB_RACE=White,NR
17	19620264	rs34834489	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC47A2_(PA162403847);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_metformin_may_have_increased_renal_clearance_and_secretion_clearance_of_metformin_but_no_differences_in_the_plasma_metformin_concentration_and_no_association_with_glucose-lowering_effect_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_metformin_may_have_increased_renal_clearance_and_secretion_clearance_of_metformin_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_renal_clearance_and_secretion_clearance_of_metformin_but_no_differences_in_the_plasma_metformin_concentration_and_no_association_with_glucose-lowering_effect_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_metformin_may_have_decreased_renal_clearance_and_secretion_clearance_of_metformin_but_no_differences_in_the_plasma_metformin_concentration_and_no_association_with_glucose-lowering_effect_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metformin.";PGKB_RACE=Asian
17	26104511	rs11080344	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NOS2_(PA164724093);PGKB_DRUG="isoniazid_(PA450112)""rifampin_(PA451250)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Toxic_liver_disease_(PA164925725);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_Toxic_liver_disease_when_treated_with_isoniazid_and_rifampin_in_people_with_Tuberculosis_as_compared_to_patients_with_the_TT_or_TC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_isoniazid_and_rifampin.""TC:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_Toxic_liver_disease_when_treated_with_isoniazid_and_rifampin_in_people_with_Tuberculosis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_isoniazid_and_rifampin.""TT:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_Toxic_liver_disease_when_treated_with_isoniazid_and_rifampin_in_people_with_Tuberculosis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_isoniazid_and_rifampin.";PGKB_RACE=Asian
17	28525011	rs1042173	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC6A4_(PA312);PGKB_DRUG=ondansetron_(PA450705);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Alcoholism_(PA443309);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_ondansetron_may_have_increased_treatment_response_among_patients_carrying_the_SLC6A4_promoter_length_polymorphism_long/long_genotype_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""AC:Patients_with_the_AC_genotype_who_are_treated_with_ondansetron_may_have_decreased_treatment_response_among_patients_carrying_the_SLC6A4_promoter_length_polymorphism_long/long_genotype_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.""CC:Patients_with_the_CC_genotype_who_are_treated_with_ondansetron_may_have_decreased_treatment_response_among_patients_carrying_the_SLC6A4_promoter_length_polymorphism_long/long_genotype_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_ondansetron.";PGKB_RACE=NR
17	28564346	rs25531	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=SLC6A4_(PA312),SLC6A4_(PA312);PGKB_DRUG=fluoxetine_(PA449673),citalopram_(PA449015);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=4,3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluoxetine_may_be_less_likely_to_respond_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluoxetine_may_be_less_likely_to_respond_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_who_are_treated_with_fluoxetine_may_be_more_likely_to_respond_compared_to_patients_with_genotype_CC_or_CT_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_side_effects_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype._No_association_was_found_with_response_or_remission._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_side_effects_when_treated_with_citalopram_as_compared_to_patients_with_the_TT_genotype_or_may_have_decreased_likelihood_of_side_effects_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._No_association_was_found_with_response_or_remission._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""TT:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_side_effects_when_treated_with_citalopram_as_compared_to_patients_with_the_CC_genotype._No_association_was_found_with_response_or_remission._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=NR,NR
17	32574448	rs4795893	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CCL2_(PA130413151);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.";PGKB_RACE=Asian
17	32583132	rs2857657	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=CCL2_(PA130413151);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""CG:Patients_with_the_CG_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.";PGKB_RACE=Asian
17	32583269	rs4586	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CCL2_(PA130413151);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.";PGKB_RACE=Asian
17	33331575	rs1052536	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=LIG3_(PA30374);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_similar_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_who_are_treated_with_chemotherapy_involving_cisplatin_and_cyclophosphamide_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_when_treated_with_chemotherapy._";PGKB_RACE=NR
17	37879588	rs1136201	A	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=ERBB2_(PA27844);PGKB_DRUG=trastuzumab_(PA451743);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Drug_Toxicity_(PA443937)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_cardiotoxicity_in_breast_cancer_patients_treated_with_trastuzumab_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_cardiotoxicity_in_breast_cancer_patients_treated_with_trastuzumab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity.""GG:Cardiotox_was_not_not_found_in_GG_group_in_this_small_study._The_GG_genotype_(Val_form)_is_more_sensitive_to_trastuzamab_in_vitro._There_was_no_link_between_tumor_response_or_survival_and_HER2_genotype_in_clinical_study.";PGKB_RACE=White
17	38253212	rs2314339	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="NR1D1_(PA31748)""THRA_(PA36507)";PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""TC:Patients_with_the_TC_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""TT:Patients_with_the_TT_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=White
17	38254492	rs2071427	C	T	.	.	PGKB_INDEX=1;PGKB_GENE="NR1D1_(PA31748)""THRA_(PA36507)";PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""CT:Patients_with_the_CT_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""TT:Patients_with_the_TT_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=White
17	43208121	rs12946454	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=PLCD3_(PA33389);PGKB_DRUG=diltiazem_(PA449334);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_reduction_in_blood_pressure_when_treated_with_diltiazem_in_people_with_Hypertension_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diltiazem._""AT:Patients_with_the_AT_genotype_may_have_increased_reduction_in_blood_pressure_when_treated_with_diltiazem_in_people_with_Hypertension_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diltiazem._""TT:Patients_with_the_TT_genotype_may_have_decreased_reduction_in_blood_pressure_when_treated_with_diltiazem_in_people_with_Hypertension_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_diltiazem._";PGKB_RACE=White
17	43892520	rs242941	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR1_(PA26874);PGKB_DRUG=fluoxetine_(PA449673);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Anxiety_Disorders_(PA447196)""Depressive_Disorder_Major_(PA447321)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_and_high_anxiety_may_have_a_decreased_response_to_fluoxetine_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""AC:Patients_with_the_AC_genotype_and_major_depression_and_high_anxiety_may_have_a_decreased_response_to_fluoxetine_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.""CC:Patients_with_the_CC_genotype_and_major_depression_and_high_anxiety_may_have_an_increased_response_to_fluoxetine_treatment_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluoxetine.";PGKB_RACE=Asian
17	43911525	rs1876828	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR1_(PA26874);PGKB_DRUG="budesonide_(PA448681)""corticosteroids_(PA10832)""fluticasone_propionate_(PA449686)""fluticasone/salmeterol_(PA165290926)""triamcinolone_(PA451749)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_1)_decreased_short_term_response_to_inhaled_corticosteroids_(as_measured_by_FEV_after_6_weeks_of_treatment)_and_2)_increased_endogenous_cortisol_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_hypothalamic_pituitary_adrenal_axis_and_response_to_corticosteroids.""CT:Patients_with_the_CT_genotype_may_have_decreased_short_term_response_to_inhaled_corticosteroids_(as_measured_by_FEV_after_6_weeks_of_treatment)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_hypothalamic_pituitary_adrenal_axis_and_response_to_corticosteroids.""TT:Patients_with_the_TT_genotype_may_have_1)_increased_short_term_response_to_inhaled_corticosteroids_(as_measured_by_FEV_after_6_weeks_of_treatment)_and_2)_altered_hypothalamic_pituitary_adrenal_axis_and_decreased_endogenous_cortisol_compared_to_patients_with_the_CT_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_hypothalamic_pituitary_adrenal_axis_and_response_to_corticosteroids.";PGKB_RACE=NR
17	43912342	rs28364032	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CRHR1_(PA26874);PGKB_DRUG=antidepressants_(PA452229);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_major_depressive_disorder_may_have_a_poorer_response_to_antidepressant_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""CT:Patients_with_the_CT_genotype_and_major_depressive_disorder_may_have_a_better_response_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.""TT:Patients_with_the_TT_genotype_and_major_depressive_disorder_may_have_a_better_response_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_antidepressants.";PGKB_RACE=Asian
17	45360730	rs5918	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=ITGB3_(PA205),ITGB3_(PA205);PGKB_DRUG=clopidogrel_(PA449053),aspirin_(PA448497);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Coronary_Artery_Disease_(PA443796)""Myocardial_Infarction_(PA445019)","Acute_coronary_syndrome_(PA165108401)""Coronary_Artery_Disease_(PA443796)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_antiplatelet_effect_to_a_300_or_600_mg_loading_dose_clopiodgrel_as_compared_to_patients_with_TT_genotype._Other_studies_found_no_association_with_differences_in_platelet_inhibition._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""CT:Patients_with_the_CT_genotype_may_have_a_decreased_antiplatelet_effect_to_a_300_or_600_mg_loading_dose_clopiodgrel_as_compared_to_patients_with_TT_genotype._Other_studies_found_no_association_with_differences_in_platelet_inhibition._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._""TT:Patients_with_the_TT_genotype_may_have_an_increased_antiplatelet_effect_to_a_300_or_600_mg_loading_dose_clopiodgrel_as_compared_to_patients_with_CC_or_CT_genotype._Other_studies_found_no_association_with_differences_in_platelet_inhibition._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_clopidogrel._","CC:Patients_with_the_CC_genotype_may_be_less_likely_to_respond_to_aspirin_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""CT:Patients_with_the_CT_genotype_may_be_less_likely_to_respond_to_aspirin_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._""TT:Patients_with_the_TT_genotype_may_be_more_likely_to_respond_to_aspirin_as_compared_to_patients_with_the_CC_or_CT_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin._";PGKB_RACE=NR,NR
17	48712038	rs9895420	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC3_(PA376);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_1)_decreased_event_free_survival_2)_increased_risk_of_central_nervous_system_relapse_3)_decreased_risk_of_thrombocytopenia_when_treated_with_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AT:Patients_with_the_AT_genotype_may_have_1)_decreased_event_free_survival_2)_increased_risk_of_central_nervous_system_relapse_3)_decreased_risk_of_thrombocytopenia_when_treated_with_methotrexate_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_may_have_1)_increased_event_free_survival_2)_decreased_but_not_non-existent_risk_of_central_nervous_system_relapse_3)_increased_risk_of_thrombocytopenia_when_treated_with_methotrexate_as_compared_to_patients_with_the_AA_or_AT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=White
17	48712087	rs4793665	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC3_(PA376);PGKB_DRUG=morphine_(PA450550);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_(PA445208);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_morphine_may_have_higher_levels_of_morphine-3-glucuronide_and_morphine-6-glucuronide_metabolite_formation_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_morphine._""CT:Patients_with_the_CT_genotype_who_are_treated_with_morphine_may_have_lower_levels_of_morphine-3-glucuronide_and_morphine-6-glucuronide_metabolite_formation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_morphine._""TT:Patients_with_the_TT_genotype_who_are_treated_with_morphine_may_have_lower_levels_of_morphine-3-glucuronide_and_morphine-6-glucuronide_metabolite_formation_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_morphine._";PGKB_RACE=NR
17	48753423	rs4148416	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC3_(PA376);PGKB_DRUG="cisplatin_(PA449014)""cyclophosphamide_(PA449165)""doxorubicin_(PA449412)""methotrexate_(PA450428)""vincristine_(PA451879)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteosarcoma_(PA445601);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_osteosarcoma_may_have_a_decreased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_and_osteosarcoma_may_have_an_increased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_and_osteosarcoma_have_not_been_studied._However_patients_carrying_the_T_allele_(CT_genotype)_may_have_an_increased_risk_of_death_when_treated_with_cisplatin_cyclophosphamide_doxorubicin_methotrexate_and_vincristine_as_compared_to_patients_homozygous_for_the_C_allele._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
17	48768486	rs1051640	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ABCC3_(PA376);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Neoplasms_(PA445062)""Ototoxicity_(PA162263534)";PGKB_TEXT="AA:Children_with_the_AA_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_a_lower_but_not_absent_risk_for_hearing_loss_as_compared_to_children_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""AG:Children_with_the_AG_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_AA_genotype_or_may_have_a_lower_but_not_absent_risk_for_hearing_loss_as_compared_to_children_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""GG:Children_with_the_GG_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.";PGKB_RACE=NR
17	49960309	rs967676	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CA10_(PA25985);PGKB_DRUG="fluticasone_propionate_(PA449686)""montelukast_(PA450546)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_a_better_response_to_treatment_with_fluticasone_propionate_or_montelukast_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluticasone_propionate_or_montelukast.""CT:Patients_with_the_CT_genotype_and_asthma_may_have_a_better_response_to_treatment_with_fluticasone_propionate_or_montelukast_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluticasone_propionate_or_montelukast.""TT:Patients_with_the_TT_genotype_and_asthma_may_have_a_poorer_response_to_treatment_with_fluticasone_propionate_or_montelukast_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fluticasone_propionate_or_montelukast.";PGKB_RACE=NR
17	54433211	rs9915451	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ANKFN1_(PA142672624);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Essential_hypertension_(PA447288);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_essential_hypertension_may_have_an_increased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""AG:Patients_with_the_AG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AA_genotype_and_an_increased_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.""GG:Patients_with_the_GG_genotype_and_essential_hypertension_may_have_a_decreased_response_when_treated_with_hydrochlorothiazide_as_compared_to_patients_with_the_AG_and_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_hydrochlorothiazide_in_patients_with_essential_hypertension.";PGKB_RACE=White
17	61393816	rs2429427	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TANC2_(PA142670837);PGKB_DRUG=calcium_channel_blockers_(PA10407);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_genotype_AA_may_have_decreased_response_to_calcium_channel_blockers_in_people_with_Hypertension_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_calcium_channel_blockers.""AG:Patients_with_genotype_AG_may_have_increased_response_to_calcium_channel_blockers_in_people_with_Hypertension_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_calcium_channel_blockers.""GG:Patients_with_genotype_GG_may_have_increased_response_to_calcium_channel_blockers_in_people_with_Hypertension_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_calcium_channel_blockers.";PGKB_RACE=Asian
17	61554194	rs4291	T	A	.	.	PGKB_INDEX=2;PGKB_GENE=ACE_(PA139),ACE_(PA139);PGKB_DRUG="amlodipine_(PA448388)""chlorthalidone_(PA448970)""lisinopril_(PA450242)",aspirin_(PA448497);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Hypertension_(PA444552),Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_may_have_decreased_fasting_glucose_levels_when_treated_with_amlodipine_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_fasting_glucose_levels.""AT:Patients_with_the_AT_genotype_and_hypertension_may_have_decreased_fasting_glucose_levels_when_treated_with_amlodipine_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_fasting_glucose_levels.""TT:Patients_with_the_TT_genotype_and_hypertension_may_have_increased_fasting_glucose_levels_when_treated_with_amlodipine_chlorthalidone_or_lisinopril_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_fasting_glucose_levels.","AA:Patients_with_the_AA_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_aspirin_intolerance_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AT:Patients_with_the_AT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_aspirin_intolerance_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_decreased_but_not_absent_risk_for_aspirin_intolerance_as_compared_to_patients_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=NR,Asian
17	61554341	rs4292	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ACE_(PA139);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_aspirin_intolerance_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""CT:Patients_with_the_CT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_increased_risk_for_aspirin_intolerance_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""TT:Patients_with_the_TT_genotype_and_asthma_who_are_treated_with_aspirin_may_have_decreased_but_not_absent_risk_for_aspirin_intolerance_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=Asian
17	61565890	rs1799752	T	TATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	.	.	PGKB_INDEX=15;PGKB_GENE=ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139),ACE_(PA139);PGKB_DRUG=spironolactone_(PA451483),"atorvastatin_(PA448500)""quinapril_(PA451205)",enalapril_(PA449456),lisinopril_(PA450242),acetylcholine_(PA448031),nitroprusside_(PA451406),hydrochlorothiazide_(PA449899),fluvastatin_(PA449688),pravastatin_(PA451089),"bumetanide_(PA448682)""furosemide_(PA449719)""torasemide_(PA451733)","benazepril_(PA448561)""perindopril_(PA450877)",captopril_(PA448780),"antidepressants_(PA452229)""antiepileptics_(PA143485705)""Beta_Blocking_Agents_(PA164712535)""calcium_channel_blockers_(PA10407)",Ace_Inhibitors_Plain_(PA164712308),irbesartan_(PA450084);PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Other,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3,3,3,4,3,3,2A,3,3,3;PGKB_DISEASE=Heart_Failure_(PA444370),Coronary_Artery_Disease_(PA443796),"Arteriosclerosis_(PA443425)""Coronary_Disease_(PA443797)""Essential_hypertension_(PA447288)""glomerular_disease_(PA447283)""Glomerulonephritis_IGA_(PA444288)""Kidney_Diseases_(PA444682)","Diabetes_Mellitus_Type_1_(PA443888)""Heart_Failure_(PA444370)",NR,NR,Essential_hypertension_(PA447288),Coronary_Artery_Disease_(PA443796),NR,NR,Diabetes_Mellitus_(PA443886),"Diabetes_Mellitus_Type_2_(PA443890)""Heart_Failure_(PA444370)""Pulmonary_Disease_Chronic_Obstructive_(PA447178)","Headache_Disorders_(PA447076)""Migraine_with_Aura_(PA447004)""Migraine_without_Aura_(PA444949)",NR,"Hypertension_(PA444552)""Hypertrophy_Left_Ventricular_(PA446479)";PGKB_TEXT="ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_may_be_associated_with_improvement_in_left_ventricular_ejection_fraction_end-systolic_and_end-diastolic_volume_in_people_with_chronic_heart_failure_treated_with_spironolactone_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_genotype_may_be_associated_with_improvement_in_left_ventricular_ejection_fraction_end-systolic_and_end-diastolic_volume_in_people_with_chronic_heart_failure_treated_with_spironolactone_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""del/del:Patients_with_the_del/del_genotype_may_have_less_improvement_in_left_ventricular_ejection_fraction_end-systolic_and_end-diastolic_volume_in_people_with_chronic_heart_failure_treated_with_spironolactone_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_or_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_insert/insert_genotype_and_Coronary_Artery_Disease_may_be_more_likely_to_benefit_from_atorvastatin_and_quinapril_treatment_(due_to_an_increased_reduction_in_the_fibrinolytic_marker_D-dimer)_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_insert/del_genotype_and_Coronary_Artery_Disease_may_be_more_likely_to_benefit_from_atorvastatin_and_quinapril_treatment_(due_an_increased_reduction_in_the_fibrinolytic_marker_D-dimer)_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._""del/del:Patients_with_the_del/del_genotype_and_Coronary_Artery_Disease_may_benefit_less_from_atorvastatin_and_quinapril_treatment_(due_to_less_of_a_reduction_in_the_fibrinolytic_marker_D-dimer)_as_compared_to_patients_with_the_insert/del_or_insert/insert_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment._","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATAC.../ATAC..._genotype_and_conditions_such_as_kidney_disease_heart_disease_hypertension_and_arteriosclerosis_may_have_an_increased_response_when_treated_with_enalapril_as_compared_to_patients_with_the_del/del_or_ATAC.../del_genotype._However_evidence_is_highly_contradictory_with_almost_half_the_studies_showing_a_decreased_response_to_enalapril_for_this_genotype._Some_patients_were_also_treated_with_losartan_or_atenolol._One_study_found_an_increased_risk_of_kidney_failure_for_this_genotype_(compared_to_the_del/del_or_ATAC.../del_genotypes)_and_another_a_decreased_response_in_bone_mineral_density_(compared_to_the_del/del_genotype)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril_risk_of_kidney_failure_or_response_in_bone_mineral_density.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATAC.../del_genotype_and_conditions_such_as_kidney_disease_heart_disease_hypertension_and_arteriosclerosis_may_have_an_increased_response_when_treated_with_enalapril_as_compared_to_patients_with_the_del/del_genotype._However_evidence_is_highly_contradictory_with_one_study_showing_a_decreased_response_for_this_genotype_compared_to_the_del/del_genotype_one_showing_an_increased_response_compared_to_the_ATAC.../ATAC..._genotype_and_another_a_decreased_response_compared_to_the_ATAC.../ATAC..._genotype._Some_patients_were_also_treated_with_losartan_or_atenolol._One_study_found_a_decreased_risk_of_kidney_failure_for_this_genotype_compared_to_ATAC.../ATAC..._and_another_a_decreased_response_in_bone_mineral_density_compared_to_del/del._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril_risk_of_kidney_failure_or_response_in_bone_mineral_density.""del/del:Patients_with_the_del/del_genotype_and_conditions_such_as_kidney_disease_heart_disease_hypertension_and_arteriosclerosis_may_have_a_decreased_response_when_treated_with_enalapril_as_compared_to_patients_with_the_ATAC.../del_or_ATAC.../ATAC..._genotype._However_evidence_is_highly_contradictory_with_almost_half_the_studies_showing_an_increased_response_to_enalapril_for_this_genotype._Some_patients_were_also_treated_with_losartan_or_atenolol._One_study_found_a_decreased_risk_of_kidney_failure_for_this_genotype_and_another_an_increased_response_in_bone_mineral_density_both_compared_to_the_ATAC.../ATAC..._genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_enalapril_risk_of_kidney_failure_or_response_in_bone_mineral_density.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATAC.../ATAC..._genotype_may_have_an_increased_response_when_treated_with_lisinopril_as_compared_to_patients_with_the_del/del_genotype._However_contradictory_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_response_to_lisinopril.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATAC.../del_genotype_may_have_an_increased_response_when_treated_with_lisinopril_as_compared_to_patients_with_the_del/del_genotype_or_a_decreased_response_when_treated_with_lisinopril_as_compared_to_patients_with_the_ATAC.../ATAC..._genotype._However_contradictory_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_response_to_lisinopril.""del/del:Patients_with_the_del/del_genotype_may_have_a_decreased_response_when_treated_with_lisinopril_as_compared_to_patients_with_the_ATAC.../ATAC..._genotype._However_contradictory_evidence_exists._Other_genetic_and_clinical_factors_may_also_influence_response_to_lisinopril.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_may_experience_greater_vasodilation_when_treated_with_acetylcholine_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_acetylcholine.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_genotype_may_experience_greater_vasodilation_as_compared_to_patients_with_the_del/del_genotype_but_lesser_vasodilation_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_when_treated_with_acetylcholine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_acetylcholine.""del/del:Patients_with_the_del/del_genotype_may_experience_less_vasodilation_when_treated_with_acetylcholine_as_compared_to_patients_with_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_or_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_acetylcholine.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_may_experience_greater_vasodilation_when_treated_with_nitroprusside_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nitroprusside.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_genotype_may_experience_greater_vasodilation_as_compared_to_patients_with_the_del/del_genotype_but_lesser_vasodilation_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_when_treated_with_nitroprusside._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nitroprusside.""del/del:Patients_with_the_del/del_genotype_may_experience_less_vasodilation_when_treated_with_nitroprusside_as_compared_to_patients_with_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_or_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nitroprusside.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_and_essential_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_decreased_reduction_in_blood_pressure_as_compared_to_patients_with_the_del/del_genotype._The_opposite_association_is_found_for_females_in_some_studies_where_female_patients_carrying_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_may_have_an_increased_reduction_in_blood_pressure_as_compared_to_female_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_genotype_and_essential_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_decreased_reduction_in_blood_pressure_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.""del/del:Patients_with_the_del/del_genotype_and_essential_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_an_increased_reduction_in_blood_pressure_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_+_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del_genotype._The_opposite_association_is_found_for_females_in_some_studies_where_female_patients_carrying_the_del/del_genotype_may_have_a_decreased_reduction_in_blood_pressure_as_compared_to_female_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_insert/insert_genotype_and_Coronary_Artery_Disease_may_be_less_responsive_to_fluvastatin_treatment_as_compared_to_patients_with_the_del/del_or_del/insert_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_del/insert_genotype_and_Coronary_Artery_Disease_may_be_less_responsive_to_fluvastatin_treatment_as_compared_to_patients_with_the_del/del_genotype_or_may_have_a_better_response_to_fluvastatin_treatment_as_compared_to_patients_with_the_insert/insert_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._""del/del:Patients_with_the_del/del_genotype_and_Coronary_Artery_Disease_may_have_a_better_response_to_fluvastatin_treatment_as_compared_to_patients_with_the_insert/del_or_insert/insert_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvastatin_treatment._","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_:Patients_with_the_insert/insert_genotype_may_be_less_likely_to_benefit_from_pravastatin_treatment_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_insert/del_genotype_may_be_less_likely_to_benefit_from_pravastatin_treatment_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""del/del:Patients_with_the_del/del_genotype_may_be_more_likely_to_benefit_from_pravastatin_treatment_as_compared_to_patients_with_the_insert/del_or_insert/insert_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Healthy_males_with_the_ATAC.../ATAC..._genotype_may_have_a_decreased_response_when_given_bumetanide_furosemide_or_torasemide_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_torasemide._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Healthy_males_with_the_ATAC.../del_genotype_may_have_an_increased_response_when_given_bumetanide_furosemide_or_torasemide_as_compared_to_patients_with_the_ATAC.../ATAC..._genotype_or_a_decreased_response_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_torasemide._""del/del:Healthy_males_with_the_del/del_genotype_may_have_an_increased_response_when_given_bumetanide_furosemide_or_torasemide_as_compared_to_patients_with_the_ATAC.../ATAC..._genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_bumetanide_furosemide_torasemide._","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATAC.../ATAC..._genotype_and_diabetes_or_hypertension_may_have_a_poorer_response_when_treated_with_benazepril_or_perindopril_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril_or_perindopril._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATAC.../del_genotype_and_diabetes_or_hypertension_may_have_a_poorer_response_when_treated_with_benazepril_or_perindopril_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril_or_perindopril._""del/del:Patients_with_the_del/del_genotype_and_diabetes_or_hypertension_may_have_a_better_response_when_treated_with_benazepril_or_perindopril_as_compared_to_patients_with_the_ATAC.../del_or_ATAC.../ATAC..._genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_benazepril_or_perindopril._","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATAC.../ATAC..._genotype_and_conditions_such_as_heart_failure_chronic_obstructive_pulmonary_disease_and_Type_2_diabetes_may_have_an_increased_response_when_treated_with_captopril_as_compared_to_patients_with_the_del/del_genotype._Responses_were_also_tested_within_healthy_individuals_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_captopril.""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_ATAC.../del_genotype_and_conditions_such_as_heart_failure_chronic_obstructive_pulmonary_disease_and_Type_2_diabetes_may_have_an_increased_response_when_treated_with_captopril_as_compared_to_patients_with_the_del/del_genotype_or_a_decreased_response_compared_to_patients_with_the_ATAC.../ATAC..._genotype._Responses_were_also_tested_within_healthy_individuals_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_captopril.""del/del:Patients_with_the_del/del_genotype_and_conditions_such_as_heart_failure_chronic_obstructive_pulmonary_disease_and_Type_2_diabetes_may_have_a_decreased_response_when_treated_with_captopril_as_compared_to_patients_with_the_ATAC.../del_or_ATAC.../ATAC..._genotype._Responses_were_also_tested_within_healthy_individuals_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_captopril.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_insert/insert_genotype_and_Migraine_with_Aura_or_Chronic_Migraine_may_be_less_likely_to_use_pharmacological_prophylaxis_as_compared_to_patients_with_the_ins/del_or_del/del_genotype._No_association_was_seen_for_patients_with_Migraine_without_Aura._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_use_of_pharmacological_prophylaxis._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Patients_with_the_insert/del_genotype_and_Migraine_with_Aura_or_Chronic_Migraine_may_be_more_likely_to_use_pharmacological_prophylaxis_as_compared_to_patients_with_the_ins/ins_genotype._No_association_was_seen_for_patients_with_Migraine_without_Aura._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_use_of_pharmacological_prophylaxis._""del/del:Patients_with_the_del/del_genotype_and_Migraine_with_Aura_or_Chronic_Migraine_may_be_more_likely_to_use_pharmacological_prophylaxis_as_compared_to_patients_with_the_ins/ins_genotype._No_association_was_seen_for_patients_with_Migraine_without_Aura._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_use_of_pharmacological_prophylaxis._","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_who_are_treated_with_Ace_Inhibitors_may_have_a_decreased_but_not_absent_risk_for_major_cardiovascular_events_or_mortality_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Ace_Inhibitors.""del/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC:Patients_with_the_del/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_who_are_treated_with_Ace_Inhibitors_may_have_an_increased_risk_for_major_cardiovascular_events_or_mortality_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype_or_may_have_a_decreased_but_not_absent_risk_for_major_cardiovascular_events_or_mortality_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Ace_Inhibitors.""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_Ace_Inhibitors_may_have_an_increased_risk_for_major_cardiovascular_events_or_mortality_as_compared_to_patients_with_the_ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Ace_Inhibitors.","ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC_:Hypertensive_patients_with_the_ATAC.../ATAC..._genotype_may_have_a_greater_reduction_in_diastolic_blood_pressure_when_treated_with_irbesartan_as_compared_to_patients_with_the_ATAC.../del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_diastolic_blood_pressure_response._""ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del:Hypertensive_patients_with_the_ATAC.../del_genotype_may_have_a_smaller_reduction_in_diastolic_blood_pressure_when_treated_with_irbesartan_as_compared_to_patients_with_the_ATAC.../ATAC..._genotype._Other_genetic_and_clinical_factors_may_also_influence_diastolic_blood_pressure_response._""_del/del:Hypertensive_patients_with_the_del/del_genotype_may_have_a_smaller_reduction_in_diastolic_blood_pressure_when_treated_with_irbesartan_as_compared_to_patients_with_the_ATAC.../ATAC..._genotype._Other_genetic_and_clinical_factors_may_also_influence_diastolic_blood_pressure_response._";PGKB_RACE=NR,NR,NR,NR,White,White,NR,NR,NR,White,Asian,NR,NR,NR,White
17	61566031	rs4343	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=ACE_(PA139),ACE_(PA139);PGKB_DRUG=spironolactone_(PA451483),sildenafil_(PA451346);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Erectile_Dysfunction_(PA444606);PGKB_TEXT="AA:Patients_with_the_AA_genotype_are_associated_with_improvement_in_left_ventricular_ejection_fraction_end-systolic_and_end-diastolic_volume_in_people_with_chronic_heart_failure_treated_with_spironolactone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_are_associated_with_improvement_in_left_ventricular_ejection_fraction_end-systolic_and_end-diastolic_volume_in_people_with_chronic_heart_failure_treated_with_spironolactone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_may_have_less_improvement_in_left_ventricular_ejection_fraction_end-systolic_and_end-diastolic_volume_in_people_with_chronic_heart_failure_treated_with_spironolactone_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","AA:Patients_with_the_AA_genotype_and_erectile_dysfunction_who_are_treated_with_sildenafil_may_have_an_increased_chance_of_positive_erectile_response_as_compared_to_patient's_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sildenafil.""AG:Patients_with_the_AG_genotype_and_erectile_dysfunction_who_are_treated_with_sildenafil_may_have_a_decreased_chance_of_positive_erectile_response_as_compared_to_patient's_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sildenafil.""GG:Patients_with_the_GG_genotype_and_erectile_dysfunction_who_are_treated_with_sildenafil_may_have_a_decreased_chance_of_positive_erectile_response_as_compared_to_patient's_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_sildenafil.";PGKB_RACE=NR,White
17	61583756	rs4267385	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Cough_(PA443803);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_homozygous_carrier_for_the_GG_genotype_for_rs4343_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_for_cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.""CT:Patients_with_the_CT_genotype_and_homozygous_carrier_for_the_GG_genotype_for_rs4343_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_for_cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.""TT:Patients_with_the_TT_genotype_and_homozygous_carrier_for_the_GG_genotype_for_rs4343_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_for_cough_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.";PGKB_RACE=White
17	61584720	rs4459610	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Ace_Inhibitors_Plain_(PA164712308);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Cough_(PA443803);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_for_cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.""AT:Patients_with_the_AT_genotype_who_are_treated_with_ACE_inhibitors_may_have_a_decreased_but_not_absent_risk_for_cough_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.""TT:Patients_with_the_TT_genotype_who_are_treated_with_ACE_inhibitors_may_have_an_increased_risk_for_cough_as_compared_to_patients_with_the_AT_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cough.";PGKB_RACE=White
17	62021206	rs80338792	C	T,G,A	.	.	PGKB_INDEX=1;PGKB_GENE=SCN4A_(PA35006);PGKB_DRUG="flecainide_(PA449646)""mexiletine_(PA450488)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Myotonia_(PA445030);PGKB_TEXT="CC:No_patients_with_this_genotype_were_present_in_the_population._However_patients_with_the_CT_genotype_and_myotonia_permanens_may_respond_better_to_treatment_with_flecainide_than_to_treatment_with_mexiletine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""CT:Patients_with_the_CT_genotype_and_myotonia_permanens_may_respond_better_to_treatment_with_flecainide_than_to_treatment_with_mexiletine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TT:Patients_with_the_TT_genotype_and_myotonia_permanens_may_respond_better_to_treatment_with_flecainide_than_to_treatment_with_mexiletine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.";PGKB_RACE=NR
17	63523603	rs11868547	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=AXIN2_(PA25196);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""CG:Patients_with_the_CG_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_or_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.";PGKB_RACE=NR
17	63534538	rs4541111	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=AXIN2_(PA25196);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""AC:Patients_with_the_AC_genotype_and_non-small-cell_lung_cancer_may_have_a_longer_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.""CC:Patients_with_the_CC_genotype_and_non-small-cell_lung_cancer_may_have_a_shorter_survival_time_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_in_patients_receiving_platinum-based_chemotherapy.";PGKB_RACE=NR
17	64787573	rs4791040	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PRKCA_(PA33759);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_increased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""CT:Patients_with_the_CT_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_decreased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_CC_genotype_and_increased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""TT:Patients_with_the_TT_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_decreased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.";PGKB_RACE=White
17	64788827	rs16960228	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=PRKCA_(PA33759);PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_increased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""AG:Patients_with_the_AG_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_increased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_GG_genotype_and_decreased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""GG:Patients_with_the_GG_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_decreased_reduction_of_diastolic_blood_pressure_as_compared_to_patients_with_the_AA_or_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.";PGKB_RACE=White
17	74499400	rs12948783	G	A,T	.	.	PGKB_INDEX=1;PGKB_GENE=RHBDF2_(PA134980674);PGKB_DRUG="fentanyl_(PA449599)""morphine_(PA450550)""opioids_(PA452618)""oxycodone_(PA450741)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_lower_pain_relief_to_opioids_in_cancer_patients_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_opioids.""AG:Patients_with_the_AG_genotype_may_have_lower_pain_relief_to_opioids_in_cancer_patients_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_opioids.""GG:Patients_with_the_GG_genotype_may_have_better_pain_relief_to_opioids_in_cancer_patients_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_opioids.";PGKB_RACE=NR
17	79478007	rs1135989	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ACTG1_(PA24468);PGKB_DRUG=vincristine_(PA451879);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neurotoxicity_Syndromes_(PA446975);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_an_increased_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._""AG:Patients_with_the_AG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_AA_genotype_or_may_have_an_increased_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._""GG:Patients_with_the_GG_genotype_and_acute_lymphoblastic_leukemia_who_are_treated_with_vincristine_may_have_a_reduced_but_not_absent_risk_of_grade_3-4_neurotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_neurotoxicity._";PGKB_RACE=White
18	659829	rs2853539	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=TYMS_(PA359);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_less_likely_to_have_improvement_in_disease_activity_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AG:Patients_with_the_AG_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_improvement_in_disease_activity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""GG:Patients_with_the_GG_genotype_and_rheumatoid_arthritis_who_are_treated_with_methotrexate_may_be_more_likely_to_have_improvement_in_disease_activity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian
18	673443	rs151264360	TTTAAAG	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Mesothelioma_(PA444937);PGKB_TEXT="TTAAAG/TTAAAG:Patients_with_the_TTAAAG/TTAAAG_genotype_and_mesothelioma_may_have_shorter_progression-free_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TTAAAG/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pemetrexed._""TTAAAG/del:Patients_with_the_TTAAAG/del_genotype_and_mesothelioma_may_have_longer_progression-free_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pemetrexed._""del/del:Patients_with_the_del/del_genotype_and_mesothelioma_may_have_longer_progression-free_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_pemetrexed._";PGKB_RACE=NR
18	673450	rs34489327	TT	T,TTTAAAG	.	.	PGKB_INDEX=5;PGKB_GENE="ENOSF1_(PA134897613)""TYMS_(PA359)",TYMS_(PA359),TYMS_(PA359),TYMS_(PA359),ENOSF1_(PA134897613);PGKB_DRUG=methotrexate_(PA450428),"fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)",methotrexate_(PA450428),fluorouracil_(PA128406956),"capecitabine_(PA448771)""paclitaxel_(PA450761)";PGKB_TYPE=Efficacy,Efficacy,Toxicity/ADR,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,3,3;PGKB_DISEASE="Arthritis_Rheumatoid_(PA443434)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)",Colorectal_Neoplasms_(PA446108),"Drug_Toxicity_(PA443937)""Toxic_liver_disease_(PA164925725)",Colorectal_Neoplasms_(PA446108),Stomach_Neoplasms_(PA445742);PGKB_TEXT="TTAAAG/TTAAAG:Patients_with_the_TTAAAG/TTAAAG_genotype_who_are_treated_with_methotrexate_may_have_a_lower_response_to_treatment_as_compared_to_patients_with_the_del/del_genotype_and_the_3/3_genotype_at_rs34743033._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TTAAAG/del:Patients_with_the_TTAAAG/del_genotype_and_the_3/3_genotype_at_rs34743033_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Patients_with_the_TTAAAG/del_genotype_may_have_a_lower_response_to_treatment_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""del/del:Patients_with_the_del/del_genotype_and_the_3/3_genotype_at_rs34743033_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.","TTAAAG/TTAAAG:Patients_with_the_TTAAAG/TTAAAG_genotype_and_Colorectal_Cancer_who_are_treated_with_the_drug_combination_fluorouracil_leucovorin_and_irinotecan_may_have_an_increased_risk_of_disease_progression_as_compared_to_patients_with_the_TTAAAG/del_or_del/del_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TTAAAG/del:Patients_with_the_TTAAAG/del_genotype_and_Colorectal_Cancer_who_are_treated_with_the_drug_combination_fluorouracil_leucovorin_and_irinotecan_may_have_a_decreased_risk_of_disease_progression_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""del/del:Patients_with_the_del/del_genotype_and_Colorectal_Cancer_who_are_treated_with_the_drug_combination_fluorouracil_leucovorin_and_irinotecan_may_have_a_decreased_risk_of_disease_progression_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.","TTAAAG/TTAAAG:Patients_with_the_TTAAAG/TTAAAG_genotype_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_hepatotoxicity_and_may_develop_less_severe_oral_mucositis_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_methotrexate-induced_toxicity.""TTAAAG/del:Patients_with_the_TTAAAG/del_genotype_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_hepatotoxicity_and_may_develop_less_severe_oral_mucositis_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_methotrexate-induced_toxicity.""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_hepatotoxicity_and_may_develop_more_severe_oral_mucositis_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_methotrexate-induced_toxicity.","TTAAAG/TTAAAG:Patients_with_the_TTAAAG/TTAAAG_genotype_and_Colorectal_Cancer_who_are_treated_with_fluorouracil-based_adjuvant_therapy_may_have_a_better_response_as_compared_to_patients_with_the_TTAAAG/del_or_del/del_genotype_who_also_have_rs45445694_genotype_2R/2R._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TTAAAG/del:Patients_with_the_TTAAAG/del_genotype_who_also_have_rs45445694_genotype_2R/2R_and_Colorectal_Cancer_who_are_treated_with_fluorouracil_may_have_a_decreased_response_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""del/del:Patients_with_the_del/del_genotype_who_also_have_rs45445694_genotype_2R/2R_and_Colorectal_Cancer_who_are_treated_with_fluorouracil_may_have_a_decreased_response_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.","TTAAAG/TTAAAG:Patients_with_the_TTAAAG/TTAAAG_genotype_and_gastric_cancer_may_have_a_shorter_overall_and_progression-free_survival_time_when_treated_with_capecitabine_and_paclitaxel_as_compared_to_patients_with_the_TTAAAG/del_or_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine_and_paclitaxel_treatment.""TTAAAG/del:Patients_with_the_TTAAAG/del_genotype_and_gastric_cancer_may_have_a_longer_overall_and_progression-free_survival_time_when_treated_with_capecitabine_and_paclitaxel_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine_and_paclitaxel_treatment.""del/del:Patients_with_the_del/del_genotype_and_gastric_cancer_may_have_a_longer_overall_and_progression-free_survival_time_when_treated_with_capecitabine_and_paclitaxel_as_compared_to_patients_with_the_TTAAAG/TTAAAG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine_and_paclitaxel_treatment.";PGKB_RACE=White,White,NR,NR,Asian
18	683607	rs2612091	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ENOSF1_(PA134897613);PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.""CT:Patients_with_the_CT_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_TT_genotype_or_a_decreased_risk_for_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.";PGKB_RACE=White
18	700687	rs2741171	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ENOSF1_(PA134897613);PGKB_DRUG=capecitabine_(PA448771);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.""CT:Patients_with_the_CT_genotype_and_colorectal_cancer_may_have_a_decreased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_TT_genotype_or_an_increased_risk_for_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.""TT:Patients_with_the_TT_genotype_and_colorectal_cancer_may_have_an_increased_risk_for_experiencing_drug_toxicity_particularly_hand-foot_syndrome_when_treated_with_capecitabine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_experiencing_drug_toxicity_when_treated_with_capecitabine.";PGKB_RACE=White
18	8275857	rs6506569	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PTPRM_(PA34020);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=Asian
18	22044400	rs4483927	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=HRH4_(PA134982275);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""GT:Patients_with_the_GT_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.";PGKB_RACE=Asian
18	34928639	rs4799915	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CELF4_(PA25428);PGKB_DRUG=iloperidone_(PA161199368);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Acquired_Long_QT_Syndrome_(aLQTS)_(PA447300);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_iloperidone_may_have_decreased_but_not_absent_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_who_are_treated_with_iloperidone_may_have_increased_risk_for_adverse_cardiovascular_events_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
18	43252883	rs1123617	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC14A2_(PA35811);PGKB_DRUG=nifedipine_(PA450631);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_nifedipine_may_have_larger_changes_in_systolic_and_diastolic_blood_pressure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nifedipine.""AG:Patients_with_the_GA_genotype_who_are_treated_with_nifedepine_may_have_larger_changes_in_systolic_and_diastolic_blood_pressures_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nifedipine.""GG:Patients_with_the_GG_genotype_who_are_treated_with_nifediping_may_have_smaller_changes_in_systolic_and_diastolic_blood_pressure_as_compared_to_patients_with_the_GA_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nifedipine.";PGKB_RACE=Asian
18	43262359	rs3745009	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC14A2_(PA35811);PGKB_DRUG=nifedipine_(PA450631);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_nifedipine_may_have_smaller_mean_changes_in_systolic_and_diastolic_blood_pressure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nifedipine_treatment.""AG:Patients_with_the_GA_genotype_who_are_treated_with_nifedipine_may_have_smaller_mean_changes_in_systolic_and_diastolic_blood_pressure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nifedipine_treatment.""GG:Patients_with_the_GG_genotype_who_are_treated_with_nifedipine_may_have_larger_mean_changes_in_systolic_and_diastolic_blood_pressure_as_compared_to_patients_with_the_GA_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nifedipine_treatment.";PGKB_RACE=Asian
18	49201814	rs17751934	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=MEX3C_(PA162395821);PGKB_DRUG=Bisphosphonates_(PA164712563);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Osteonecrosis_(PA445187);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.""TT:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_Osteonecrosis_when_treated_with_Bisphosphonates_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_bisphosphonates.";PGKB_RACE=White
18	55808073	rs520210	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NEDD4L_(PA31534);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_depression_may_have_a_better_response_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.""AG:Patients_with_the_AG_genotype_and_depression_may_have_a_better_response_when_treated_with_citalopram_as_compared_to_patients_with_the_GG_genotype_or_a_poorer_response_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.""GG:Patients_with_the_GG_genotype_and_depression_may_have_a_poorer_response_when_treated_with_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_citalopram.";PGKB_RACE=NR
18	55816791	rs4149601	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=NEDD4L_(PA31534),NEDD4L_(PA31534);PGKB_DRUG="diuretics_(PA151249535)""hydrochlorothiazide_(PA449899)",hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=Hypertension_(PA444552),Hypertension_(PA444552);PGKB_TEXT="AA:White_patients_with_the_AA_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_poorer_response_as_compared_with_patients_with_genotype_GG._The_opposite_result_has_been_seen_in_Asians_(at_a_lower_level_of_evidence)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_or_other_diuretic_treatment.""AG:White_patients_with_the_AG_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_better_response_as_compared_with_patients_with_genotype_AA._The_opposite_result_has_been_seen_in_Asians_(at_a_lower_level_of_evidence)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_or_other_diuretic_treatment.""GG:White_patients_with_the_GG_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_better_response_as_compared_with_patients_with_genotype_AA._The_opposite_result_has_been_seen_in_Asians_(at_a_lower_level_of_evidence)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_or_other_diuretic_treatment.","AA:Asian_patients_with_the_AA_genotype_and_Hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_GG_genotype._The_opposite_has_been_found_in_White_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""AG:Asian_patients_with_the_AG_genotype_and_Hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_GG_genotype._The_opposite_has_been_found_in_White_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""GG:Asian_patients_with_the_GG_genotype_and_Hypertension_who_are_treated_with_hydrochlorothiazide_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_AA_or_AG_genotype._The_opposite_has_been_found_in_White_patients._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.";PGKB_RACE=White,Asian
18	57851097	rs17782313	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=MC4R_(PA30676);PGKB_DRUG=antipsychotics_(PA452233);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_disorders_requiring_antipsychotic_treatment_(amisulpride_clozapine_olanzapine_paliperidone_quetiapine_or_risperidone)_may_have_an_increased_risk_of_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_weight_gain.""CT:Patients_with_the_CT_genotype_and_disorders_requiring_antipsychotic_treatment_(amisulpride_clozapine_olanzapine_paliperidone_quetiapine_or_risperidone)_may_have_an_increased_risk_of_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_weight_gain.""TT:Patients_with_the_TT_genotype_and_disorders_requiring_antipsychotic_treatment_(amisulpride_clozapine_olanzapine_paliperidone_quetiapine_or_risperidone)_may_have_a_decreased_risk_of_weight_gain_when_treated_with_antipsychotics_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_weight_gain.";PGKB_RACE=NR
18	57882787	rs489693	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG="amisulpride_(PA162565877)""aripiprazole_(PA10026)""clozapine_(PA449061)""haloperidol_(PA449841)""olanzapine_(PA450688)""paliperidone_(PA163518919)""quetiapine_(PA451201)""risperidone_(PA451257)""ziprasidone_(PA451974)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Autism_Spectrum_Disorder_(PA153906318)""schizoaffective_disorder_(PA166123368)""Schizophrenia_(PA447216)";PGKB_TEXT="AA:Patients_with_schizophrenia_schizoaffective_disorder_or_autism_spectrum_disorder_and_genotype_AA_may_have_an_increased_likelihood_of_weight_gain_and_hypertriglyceridemia_when_taking_amisulpride_aripiprazole_clozapine_olanzapine_haloperidol_paliperidone_quetiapine_ziprasidone_or_risperidone_as_compared_to_patients_with_the_AC_and_CC_genotypes_although_this_is_contradicted_in_one_study._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_weight_gain_in_patients_taking_amisulpride_aripiprazole_clozapine_olanzapine_haloperidol_paliperidone_quetiapine_ziprasidone_or_risperidone._""AC:Patients_with_schizophrenia_schizoaffective_disorder_or_autism_spectrum_disorder_and_genotype_AC_may_have_a_decreased_likelihood_of_weight_gain_and_hypertriglyceridemia_when_taking_amisulpride_aripiprazole_clozapine_olanzapine_haloperidol_paliperidone_quetiapine_ziprasidone_or_risperidone_as_compared_to_patients_with_the_AA_genotypes_although_this_is_contradicted_in_one_study._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_weight_gain_in_patients_taking_amisulpride_aripiprazole_clozapine_olanzapine_haloperidol_paliperidone_quetiapine_ziprasidone_or_risperidone._""CC:Patients_with_schizophrenia_schizoaffective_disorder_or_autism_spectrum_disorder_and_genotype_CC_may_have_a_decreased_likelihood_of_weight_gain_and_hypertriglyceridemia_when_taking_amisulpride_aripiprazole_clozapine_olanzapine_haloperidol_paliperidone_quetiapine_ziprasidone_or_risperidone_as_compared_to_patients_with_the_AA_genotypes_although_this_is_contradicted_in_one_study._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_weight_gain_in_patients_taking_amisulpride_aripiprazole_clozapine_olanzapine_haloperidol_paliperidone_quetiapine_ziprasidone_or_risperidone._";PGKB_RACE=NR
18	58040587	rs11872992	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=MC4R_(PA30676),MC4R_(PA30676);PGKB_DRUG="clozapine_(PA449061)""olanzapine_(PA450688)","clozapine_(PA449061)""olanzapine_(PA450688)";PGKB_TYPE=NR,Toxicity/ADR;PGKB_EVIDENCE=4,3;PGKB_DISEASE=Schizophrenia_(PA447216),Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Schizophrenia_may_have_a_decreased_but_not_absent_risk_for_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_GG_genotype._However_the_association_was_found_as_trend_only_and_was_not_statistically_significant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_may_have_an_increased_risk_for_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_but_not_absent_risk_for_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_GG_genotype._However_the_association_was_found_as_trend_only_and_was_not_statistically_significant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_may_have_an_increased_risk_for_weight_gain_when_treated_with_clozapine_or_olanzapine_as_compared_to_patients_with_the_AA_genotype._However_the_association_was_found_as_trend_only_and_was_not_statistically_significant._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain.","AA:Patients_with_schizophrenia_with_the_AA_genotype_may_have_a_decreased_likelihood_of_weight_gain_when_taking_clozapine_or_olanzapine_as_compared_to_patients_the_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_weight_gain_in_patients_taking_clozapine_or_olanzapine._""AG:Patients_with_schizophrenia_with_the_AG_genotype_may_have_a_decreased_likelihood_of_weight_gain_when_taking_clozapine_or_olanzapine_as_compared_to_patients_the_the_GG_genotypes_and_an_increased_likelihood_of_weight_when_as_compared_to_patients_with_the_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_weight_gain_in_patients_taking_clozapine_or_olanzapine._""GG:Patients_with_schizophrenia_with_the_GG_genotype_may_have_an_increased_likelihood_of_weight_gain_when_taking_clozapine_or_olanzapine_as_compared_to_patients_the_the_AA_and_AG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_weight_gain_in_patients_taking_clozapine_or_olanzapine._";PGKB_RACE=White,White
18	60027241	rs1805034	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TNFRSF11A_(PA36601);PGKB_DRUG="acetaminophen_(PA448015)""aspirin_(PA448497)""diclofenac_(PA449293)""propionic_acid_derivatives_(PA451140)""Pyrazolones_(PA164713217)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_an_increased_risk_of_urticaria_and_Angioedema_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria_and_Angioedema.""CT:Patients_with_the_CT_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_an_increased_risk_of_urticaria_and_Angioedema_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria_and_Angioedema.""TT:Patients_with_the_TT_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_a_decreased_but_not_absent_risk_of_urticaria_and_Angioedema_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria_and_Angioedema.";PGKB_RACE=NR
18	60979360	rs2849380	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=BCL2_(PA25302);PGKB_DRUG="carboplatin_(PA448803)""docetaxel_(PA449383)""paclitaxel_(PA450761)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""CT:Patients_with_the_CT_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""TT:Patients_with_the_TT_genotype_and_ovarian_cancer_may_have_an_increased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._";PGKB_RACE=NR
18	60985773	rs1800477	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=BCL2_(PA25302);PGKB_DRUG="interferons_(PA451999)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_(PA444445);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Hepatitis_C_who_are_treated_with_interferons_and_ribavirin_may_have_decreased_but_not_absent_risk_for_non-response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_interferons_and_ribavirin.""CT:Patients_with_the_CT_genotype_and_Hepatitis_C_who_are_treated_with_interferons_and_ribavirin_may_have_increased_risk_for_non-response_as_compared_to_patients_with_the_CC_genotype_or_may_have_decreased_but_not_absent_risk_for_non-response_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_interferons_and_ribavirin.""TT:Patients_with_the_TT_genotype_and_Hepatitis_C_who_are_treated_with_interferons_and_ribavirin_may_have_increased_risk_for_non-response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_interferons_and_ribavirin.";PGKB_RACE=White
19	3595794	rs4523	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=TBXA2R_(PA348);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_for_aspirin_resistance_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_resistance.""AG:Patients_with_the_AG_genotype_may_have_a_decreased_but_not_absent_risk_for_aspirin_resistance_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_resistance.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_aspirin_resistance_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin_resistance.";PGKB_RACE=Asian
19	3595923	rs1131882	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TBXA2R_(PA348);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_a_decreased_but_not_absent_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_an_increased_risk_for_aspirin-intolerant_asthma_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_aspirin-intolerant_asthma.";PGKB_RACE=Asian
19	11227602	rs688	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=LDLR_(PA227);PGKB_DRUG=atenolol_(PA448499);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_more_effective_lowering_of_systolic_blood_pressure_with_atenolol_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response.""CT:Patients_with_the_CT_genotype_may_have_more_effective_lowering_of_systolic_blood_pressure_with_atenolol_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response.""TT:Patients_with_the_TT_genotype_may_have_less_effective_lowering_of_systolic_blood_pressure_with_atenolol_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response.";PGKB_RACE=White
19	15959200	rs2189784	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_warfarin_may_have_increased_time_to_achieve_therapeutic_international_normalized_ratio_as_compared_to_patients_with_the_GG_genotype._However_another_study_reported_no_association_with_dose_of_warfarin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_warfarin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_warfarin_may_have_decreased_time_to_achieve_therapeutic_international_normalized_ratio_as_compared_to_patients_with_the_AA_genotype_or_may_have_increased_time_to_achieve_therapeutic_international_normalized_ratio_as_compared_to_patients_with_the_GG_genotype._However_another_study_reported_no_association_with_dose_of_warfarin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_warfarin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_warfarin_may_have_decreased_time_to_achieve_therapeutic_international_normalized_ratio_as_compared_to_patients_with_the_AA_genotype._However_another_study_reported_no_association_with_dose_of_warfarin._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_warfarin.";PGKB_RACE=NR
19	15990431	rs2108622	C	T	.	.	PGKB_INDEX=5;PGKB_GENE=CYP4F2_(PA27121),CYP4F2_(PA27121),CYP4F2_(PA27121),CYP4F2_(PA27121),CYP4F2_(PA27121);PGKB_DRUG=warfarin_(PA451906),phenprocoumon_(PA450921),vitamin_e_(PA451900),acenocoumarol_(PA452632),"aspirin_(PA448497)""clopidogrel_(PA449053)";PGKB_TYPE=Dosage,Dosage,Metabolism/PK,Dosage,Other;PGKB_EVIDENCE=1B,2A,3,2B,3;PGKB_DISEASE="Heart_Diseases_(PA444368)""Hemorrhage_(PA444417)""Intracranial_Hemorrhages_(PA446997)""Myocardial_Infarction_(PA445019)""Peripheral_Vascular_Diseases_(PA153619833)""Thromboembolism_(PA445848)""venous_thromboembolism_(PA447298)",NR,NR,Atrial_Fibrillation_(PA443459),Acute_coronary_syndrome_(PA165108401);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_warfarin_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_TT_genotype._Some_studies_have_not_found_an_association_between_genotypes_of_this_SNP_and_warfarin_dose_or_report_finding_a_trend_that_was_not_statistically_significant._This_SNP_is_not_currently_associated_with_time_to_INR_risk_of_hemorrhage_or_risk_of_over-coagulation._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_warfarin_dose.""CT:Patients_with_the_CT_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Some_studies_have_not_found_an_association_between_genotypes_of_this_SNP_and_warfarin_dose_or_report_finding_a_trend_that_was_not_statistically_significant._This_SNP_is_not_currently_associated_with_time_to_INR_risk_of_hemorrhage_or_risk_of_over-coagulation._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_warfarin_dose.""TT:Patients_with_the_TT_genotype_who_are_treated_with_warfarin_may_require_a_higher_dose_as_compared_to_patients_with_the_CT_or_CC_genotype._Some_studies_have_not_found_an_association_between_genotypes_of_this_SNP_and_warfarin_dose_or_report_finding_a_trend_that_was_not_statistically_significant._This_SNP_is_not_currently_associated_with_time_to_INR_risk_of_hemorrhage_or_risk_of_over-coagulation._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_warfarin_dose.","CC:Patients_with_the_CC_genotype_who_are_treated_with_phenprocoumon_may_require_a_lower_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_phenprocoumon_dose.""CT:Patients_with_the_CT_genotype_who_are_treated_with_phenprocoumon_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype_or_a_lower_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_phenprocoumon_dose.""TT:Patients_with_the_TT_genotype_who_are_treated_with_phenprocoumon_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_phenprocoumon_dose.","CC:Patients_with_the_CC_genotype_may_have_decreased_steady-state_levels_of_vitamin_E_when_taking_vitamin_E_supplements_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_steady-state_levels_of_vitamin_E_in_patients_taking_vitamin_E_supplements.""CT:Patients_with_the_CT_genotype_may_have_decreased_steady-state_levels_of_vitamin_E_when_taking_vitamin_E_supplements_as_compared_to_patients_with_the_TT_genotypes_and_increased_steady-state_levels_as_compared_to_patients_with_the_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_steady-state_levels_of_vitamin_E_in_patients_taking_vitamin_E_supplements.""TT:_Patients_with_the_TT_genotype_may_have_increased_steady-state_levels_of_vitamin_E_when_taking_vitamin_E_supplements_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_steady-state_levels_of_vitamin_E_in_patients_taking_vitamin_E_supplements.","CC:Patients_with_the_CC_genotype_who_are_treated_with_acenocoumarol_may_require_a_lower_dose_as_compared_to_patients_with_the_CT_or_TT_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dose.""CT:Patients_with_the_CT_genotype_who_are_treated_with_acenocoumarol_may_require_a_lower_dose_as_compared_to_patients_with_the_TT_genotype_or_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dose.""TT:Patients_with_the_TT_genotype_who_are_treated_with_acenocoumarol_may_require_a_higher_dose_as_compared_to_patients_with_the_CC_genotype_although_this_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_required_acenocoumarol_dose.","CC:Patients_with_the_CC_genotype_and_acute_coronary_syndrome_may_have_decreased_platelet_aggregation_with_epinephrine_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_CT_genotype_and_a_decreased_response_to_aspirin_and_clopidogrel_in_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.""CT:Patients_with_the_CT_genotype_and_acute_coronary_syndrome_may_have_increased_platelet_aggregation_with_epinephrine_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_CC_or_TT_genotype_and_and_a_decreased_response_to_aspirin_and_clopidogrel_in_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.""TT:Patients_with_the_TT_genotype_and_acute_coronary_syndrome_may_have_decreased_platelet_aggregation_with_epinephrine_when_treated_with_aspirin_and_clopidogrel_as_compared_to_patients_with_the_CT_genotype_and_and_an_increased_response_to_aspirin_and_clopidogrel_in_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin_and_clopidogrel.";PGKB_RACE=NR,NR,NR,NR,NR
19	38931442	rs193922747	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CT_and_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.";PGKB_RACE=NR
19	38934851	rs118192161	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Malignant_Hyperthermia_(PA444863)""Myopathy_Central_Core_(PA447048)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._""CT:_Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._The_T_allele_is_also_associated_with_central_core_myopathy.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._The_T_allele_is_also_associated_with_central_core_myopathy._Please_note:_the_T_allele_is_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known.";PGKB_RACE=NR
19	38934852	rs193922753	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GT_and_TT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""GT:Patients_with_the_GT_genotype_may_have_increase_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""TT:Patients_with_the_TT_genotype_may_have_increase_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_T_allele_is_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.";PGKB_RACE=NR
19	38937350	rs1801086	G	A,C	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_C_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_CC_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38939352	rs121918592	G	A,C	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._Please_note:_the_A_allele_is_considered_to_be_inherited_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._""CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._Please_note:_the_C_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_CC_genotype_is_not_known.""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC_CG_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._";PGKB_RACE=NR
19	38942490	rs118192116	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Individuals_with_the_CC_genotype_may_have_a_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_CG_or_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""CG:Individuals_with_the_CG_genotype_may_have_an_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""GG:Individuals_with_the_GG_genotype_may_have_an_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_CC_genotype._Please_note:_the_G_allele_is_thought_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_GG_genotype_is_not_known._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.";PGKB_RACE=White
19	38945999	rs118192162	A	C,G	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Malignant_Hyperthermia_(PA444863)""Myopathy_Central_Core_(PA447048)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AC_or_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""AC:Patients_with_the_AC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA._The_C_allele_is_also_associated_with_central_core_myopathy.""CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._The_C_allele_is_also_associated_with_increased_risk_of_central_core_myopathy._Please_note:_the_C_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_CC_genotype_is_not_known.";PGKB_RACE=NR
19	38946103	rs111888148	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_(MH)_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._The_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.";PGKB_RACE=NR
19	38948185	rs118192172	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=RYR1_(PA34896),RYR1_(PA34896);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441),"desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Muscular_Diseases_(PA444997),Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_CC_genotype_may_have_decreased_risk_to_statin-related_myopathy_as_compared_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_statins.""CT:Patients_with_CT_genotype_may_have_increased_risk_to_statin-related_myopathy_as_compared_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_statins._""TT:Patients_with_TT_genotype_may_have_increased_risk_to_statin-related_myopathy_as_compared_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_toxicity_to_statins._","CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._";PGKB_RACE=NR,NR
19	38948186	rs193922772	G	A,T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""GT:Patients_with_the_GT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38985204	rs118192175	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CT_:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._The_T_allele_is_also_associated_with_central_core_myopathy._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._The_T_allele_is_also_associated_with_central_core_myopathy._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._";PGKB_RACE=NR
19	38985205	rs118192163	G	A,C	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Malignant_Hyperthermia_(PA444863)""Myopathy_Central_Core_(PA447048)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._The_A_allele_is_also_associated_with_central_core_myopathy._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._The_A_allele_is_also_associated_with_central_core_myopathy.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._";PGKB_RACE=NR
19	38985219	rs118192176	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._";PGKB_RACE=NR
19	38986923	rs118192177	C	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CG:_Patients_with_the_CG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_G_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_GG_genotype_is_not_known._""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._";PGKB_RACE=NR
19	38989863	rs112563513	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG_although_this_is_contradicted_in_some_studies._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG_although_this_is_contradicted_in_some_studies._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG_although_this_is_contradicted_in_some_studies._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38990295	rs193922802	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38990310	rs193922803	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known.";PGKB_RACE=NR
19	38990371	rs193922807	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_C_allele_is_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_CC_genotype_is_not_known.Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_dereased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38990615	rs193922809	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._The_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.";PGKB_RACE=NR
19	38990633	rs121918593	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._";PGKB_RACE=NR
19	38990637	rs28933396	G	A,T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38991276	rs118192124	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.The_T_allele_is_also_associated_with_central_core_myopathy._""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._The_T_allele_is_also_associated_with_central_core_myopathy._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38991282	rs193922816	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Malignant_Hyperthermia_(PA444863)""Myopathy_Central_Core_(PA447048)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._The_T_allele_is_also_associated_with_central_core_myopathy.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._The_T_allele_is_also_associated_with_central_core_myopathy.";PGKB_RACE=NR
19	38991283	rs118192122	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._The_A_allele_is_also_associated_with_central_core_myopathy._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia._The_A_allele_is_also_associated_with_central_core_myopathy.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_Hyperthermia.";PGKB_RACE=NR
19	38991294	rs28933397	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._";PGKB_RACE=NR
19	38991295	rs121918594	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known.Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._";PGKB_RACE=NR
19	38991538	rs118192178	C	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._The_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.";PGKB_RACE=NR
19	38991539	rs193922818	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_(MH)_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._The_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.";PGKB_RACE=NR
19	39070644	rs118192167	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Malignant_Hyperthermia_(PA444863)""Myopathy_Central_Core_(PA447048)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG_or_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._The_G_allele_is_also_associated_with_central_core_myopathy.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AA._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_G_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_GG_genotype_is_not_known._The_G_allele_is_also_associated_with_central_core_myopathy.";PGKB_RACE=NR
19	39070734	rs121918595	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known._";PGKB_RACE=NR
19	39070754	rs193922876	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_a_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_the_CT_genotype._Other_clinical_and_genetic_factors_also_influence_risk_of_malignant_hyperthermia._""CT:Patients_with_the_CT_genotype_may_have_an_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_the_the_CC_genotype._Other_clinical_and_genetic_factors_also_influence_risk_of_malignant_hyperthermia._""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._Please_note:_the_T_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_TT_genotype_is_not_known.";PGKB_RACE=Native_Hawaiian_or_Other_Pacific_Islander
19	39071010	rs193922878	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""CG:Patients_with_the_CG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._The_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_(MH)_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC._Please_note:_the_G_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes._Based_on_the_classification_as_Malignant_Hyperthermia_susceptible_the_use_of_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_or_succinylcholine_is_contraindicated._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_Malignant_Hyperthermia.";PGKB_RACE=NR
19	39071080	rs63749869	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Malignant_Hyperthermia_(PA444863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._The_A_allele_is_also_associated_with_central_core_myopathy._Please_note:_the_A_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_AA_genotype_is_not_known._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_GG._The_A_allele_is_also_associated_with_central_core_myopathy._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.""GG:Patients_with_the_GG_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_AG._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia.";PGKB_RACE=NR
19	39075629	rs118192170	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=RYR1_(PA34896);PGKB_DRUG="desflurane_(PA164749136)""enflurane_(PA449461)""halothane_(PA449845)""isoflurane_(PA450106)""methoxyflurane_(PA450434)""sevoflurane_(PA451341)""succinylcholine_(PA451522)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Malignant_Hyperthermia_(PA444863)""Myopathy_Central_Core_(PA447048)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT._Please_note:_the_C_allele_is_considered_to_confer_MH_in_an_autosomal_dominant_manner_and_is_almost_always_reported_in_heterozygotes_therefore_the_phenotype_of_an_individual_with_CC_genotype_is_not_known._The_C_allele_is_also_associated_with_central_core_myopathy._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""CT:Patients_with_the_CT_genotype_may_have_increased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_TT._The_C_allele_is_also_associated_with_central_core_myopathy._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._""TT:Patients_with_the_TT_genotype_may_have_decreased_risk_of_Malignant_Hyperthermia_when_treated_with_inhalational_anaesthetics_(desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane)_either_alone_or_in_conjunction_with_a_depolarizing_muscle_relaxant_(specifically_succinylcholine)_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_or_clinical_factors_may_also_influence_a_patient's_risk_of_developing_malignant_hyperthermia._";PGKB_RACE=NR
19	39735106	rs8103142	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=IFNL3_(PA134952671);PGKB_DRUG="peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_(PA444445);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_peginterferon_alfa-2a_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_peginterferon_and_ribavirin_therapy.""CT:Patients_with_the_CT_genotype_may_have_decreased_response_to_peginterferon_alfa-2a_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_peginterferon_and_ribavirin_therapy.""TT:Patients_with_the_TT_genotype_may_have_increased_response_to_peginterferon_alfa-2a_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_or_clinical_factors_may_also_influence_the_response_to_peginterferon_and_ribavirin_therapy.";PGKB_RACE=NR
19	39738787	rs12979860	C	T	.	.	PGKB_INDEX=7;PGKB_GENE=NR,"IFNL3_(PA134952671)""IFNL4_(PA166049147)",IFNL3_(PA134952671),"IFNL3_(PA134952671)""IFNL4_(PA166049147)","IFNL3_(PA134952671)""IFNL4_(PA166049147)","IFNL3_(PA134952671)""IFNL4_(PA166049147)","IFNL3_(PA134952671)""IFNL4_(PA166049147)";PGKB_DRUG="boceprevir_(PA165948902)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)","peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)","peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)""telaprevir_(PA165958354)",simeprevir_(PA166122590),"ledipasvir_(PA166128166)""sofosbuvir_(PA166122593)","daclatasvir_(PA166128167)""peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)","deleobuvir_(PA166128130)""faldaprevir_(PA166128132)";PGKB_TYPE=Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=3,1A,1A,3,3,3,3;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863),Hepatitis_C_(PA444445),Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_better_response_to_triple_therapy_(boceprevir_peginterferon_alfa-2b_and_ribavirin)_in_people_with_Hepatitis_C_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Patients_with_the_CT_genotype_may_have_poorer_response_to_triple_therapy_(boceprevir_peginterferon_alfa-2b_and_ribavirin)_in_people_with_Hepatitis_C_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Patients_with_the_TT_genotype_may_have_poorer_response_to_triple_therapy_(boceprevir_peginterferon_alfa-2b_and_ribavirin)_in_people_with_Hepatitis_C_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_and_Hepatitis_C_genotype_1_may_have_increased_response_(sustained_virological_response_SVR)_when_administered_peg_interferon_alpha_(2a_2b)_and_ribavirin_as_compared_to_patients_with_the_CT_or_TT_genotype._Patients_with_the_CC_genotype_may_also_have_higher_spontaneous_clearance_in_acute_HCV_infections_than_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peg_interferon_and_ribavirin.""CT:Patients_with_the_CT_genotype_and_Hepatitis_C_genotype_1_may_have_decreased_response_(sustained_virological_response_SVR)_when_administered_peg_interferon_alpha_(2a_2b)_and_ribavirin_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_CT_genotype_may_also_have_lower_spontaneous_clearance_in_acute_HCV_infections_than_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peg_interferon_and_ribavirin.""TT:Patients_with_the_TT_genotype_and_Hepatitis_C_genotype_1_may_have_decreased_response_(sustained_virological_response_SVR)_when_administered_peg_interferon_alpha_(2a_2b)_and_ribavirin_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_TT_genotype_may_also_have_lower_spontaneous_clearance_in_acute_HCV_infections_than_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peg_interferon_and_ribavirin.","CC:Patients_with_the_CC_genotype_may_have_higher_response_rates_(SVR)_to_triple_therapy_(telaprevir_peginterferon_alfa-2a/b_and_ribavirin)_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_the_CT_or_TT_genotype._Patients_with_the_CC_genotype_may_also_more_likely_to_be_eligible_for_shortened_therapy_(24_weeks_instead_of_standard_48_weeks)._The_impact_of_IL28B_genotype_maybe_dampened_in_patients_with_prior_PegIFN/RBV_treatment_failure._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_HCV_triple_therapy.""CT:Patients_with_the_CT_genotype_may_have_lower_response_rates_(SVR)_to_triple_therapy_(telaprevir_peginterferon_alfa-2a/b_and_ribavirin)_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_the_CC_genotype._The_impact_of_IL28B_genotype_maybe_dampened_in_patients_with_prior_PegIFN/RBV_treatment_failure._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_HCV_triple_therapy.""TT:Patients_with_the_TT_genotype_may_have_lower_response_rates_(SVR)_to_triple_therapy_(telaprevir_peginterferon_alfa-2a/b_and_ribavirin)_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_the_CC_genotype._The_impact_of_IL28B_genotype_maybe_dampened_in_patients_with_prior_PegIFN/RBV_treatment_failure._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_HCV_triple_therapy.","CC:Patients_with_CC_genotype_may_have_increased_response_to_simeprevir_and_peginterferon_alfa-2a_peginterferon_alfa-2b_ribavirin_therapy_in_people_with_Hepatitis_C_Chronic_as_compared_to_patients_with_genotype_CT_or_TT._However_RVR_and_SVR_rates_were_higher_in_simeprevir_treatment_group_than_placebo_for_each_of_the_CC_CT_and_TT_genotypes_suggesting_the_role_of_IFNL3_genotype_is_modest_for_simeprevir_therapy_as_compare_to_PEG-IFN/RBV_therapy._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_simeprevir_based_therapy.""CT:Patients_with_CT_genotype_may_have_decreased_response_to_simeprevir_and_peginterferon_alfa-2a_peginterferon_alfa-2b_ribavirin_therapy_in_people_with_Hepatitis_C_Chronic_as_compared_to_patients_with_genotype_CC._However_RVR_and_SVR_rates_were_higher_in_simeprevir_treatment_group_than_placebo_for_each_of_the_CC_CT_and_TT_genotypes_suggesting_the_role_of_IFNL3_genotype_is_modest_for_simeprevir_therapy_as_compare_to_PEG-IFN/RBV_therapy._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_simeprevir_based_therapy.""TT:Patients_with_TT_genotype_may_have_decreased_response_to_simeprevir_and_peginterferon_alfa-2a_peginterferon_alfa-2b_ribavirin_therapy_in_people_with_Hepatitis_C_Chronic_as_compared_to_patients_with_genotype_CC._However_RVR_and_SVR_rates_were_higher_in_simeprevir_treatment_group_than_placebo_for_each_of_the_CC_CT_and_TT_genotypes_suggesting_the_role_of_IFNL3_genotype_is_modest_for_simeprevir_therapy_as_compare_to_PEG-IFN/RBV_therapy._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_simeprevir_based_therapy.","CC:Patients_with_genotype_CC_may_have_increased_response_to_ledipasvir_and_sofosbuvir_in_people_with_Hepatitis_C_as_compared_to_patients_with_genotypes_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_ledipasvir_and_sofosbuvir.""CT:Patients_with_genotype_CT_may_have_decreased_response_to_ledipasvir_and_sofosbuvir_in_people_with_Hepatitis_C_as_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_ledipasvir_and_sofosbuvir.""TT:Patients_with_genotype_TT_may_have_decreased_response_to_ledipasvir_and_sofosbuvir_in_people_with_Hepatitis_C_as_compared_to_patients_with_genotypes_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_ledipasvir_and_sofosbuvir.","CC:Patients_with_genotype_CC_may_have_increased_response_to_daclatasvir_peginterferon_alfa-2a_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_Chronic_as_compared_to_genotypes_CT_+_TT._SVR24_rates_are_higher_in_patients_treated_with_the_combination_of_daclatasvir_and_pegIFN-alfa/RBV_than_those_receiving_pegIFN-alfa/RBV_alone_across_all_IL28B_genotypes_(CC_CT_or_TT)_regardless_of_viral_subtypes._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_daclatasvir_therapy.""CT:Patients_with_genotype_CT_may_have_decreased_response_to_daclatasvir_peginterferon_alfa-2a_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_Chronic_as_compared_to_genotypes_CC._SVR24_rates_are_higher_in_patients_treated_with_the_combination_of_daclatasvir_and_pegIFN-alfa/RBV_than_those_receiving_pegIFN-alfa/RBV_alone_across_all_IL28B_genotypes_(CC_CT_or_TT)_regardless_of_viral_subtypes._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_daclatasvir_therapy.""TT:Patients_with_genotype_TT_may_have_decreased_response_to_daclatasvir_peginterferon_alfa-2a_peginterferon_alfa-2b_and_ribavirin_in_people_with_Hepatitis_C_Chronic_as_compared_to_genotypes_CC._SVR24_rates_are_higher_in_patients_treated_with_the_combination_of_daclatasvir_and_pegIFN-alfa/RBV_than_those_receiving_pegIFN-alfa/RBV_alone_across_all_IL28B_genotypes_(CC_CT_or_TT)_regardless_of_viral_subtypes._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_daclatasvir_therapy.","CC:Patients_with_the_CC_genotype_may_have_increased_response_to_deleobuvir_and_faldaprevir_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_genotype_CT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_deleobuvir_and_faldaprevir.""CT:Patients_with_the_CT_genotype_may_have_decreased_response_to_deleobuvir_and_faldaprevir_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_deleobuvir_and_faldaprevir.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_deleobuvir_and_faldaprevir_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_deleobuvir_and_faldaprevir.";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR
19	39739153	rs368234815	CTT	CG	.	.	PGKB_INDEX=2;PGKB_GENE=IFNL4_(PA166049147),IFNL4_(PA166049147);PGKB_DRUG="peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)""telaprevir_(PA165958354)","ribavirin_(PA451241)""sofosbuvir_(PA166122593)";PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=2B,3;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="G/TT:Patients_with_the_G/TT_genotype_may_have_decreased_response_or_treatment_failure_with_pegIFN-alpha/ribavirin_treatment_(with_and_without_telaprevir)_in_people_with_chronic_Hepatitis_C_as_compared_to_patients_with_genotype_TT/TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_pegIFN-alpha_based_therapy.""GG:Patients_with_the_GG_genotype_may_have_decreased_response_or_treatment_failure_with_pegIFN-alpha/ribavirin_treatment_(with_and_without_telaprevir)_in_people_with_chronic_Hepatitis_C_as_compared_to_patients_with_genotype_TT/TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_pegIFN-alpha_based_therapy.""TT/TT:Patients_with_the_TT/TT_genotype_may_have_increased_response_or_treatment_failure_with_pegIFN-alpha/ribavirin_treatment_(with_and_without_telaprevir)_in_people_with_chronic_Hepatitis_C_as_compared_to_patients_with_genotype_GG_or_G/TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_pegIFN-alpha_based_therapy.","G/TT:Patients_with_the_G/TT_genotype_may_have_faster_viral_clearance_and_increased_drug_efficacy_in_hepatitis_C_genotype-1_patients_treated_with_sofosbuvir_and_ribavirin_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sofosbuvir_and_ribavirin.""GG:Patients_with_the_GG_genotype_may_have_slower_viral_clearance_and_decreased_drug_efficacy_in_hepatitis_C_genotype-1_patients_treated_with_sofosbuvir_and_ribavirin_as_compared_to_patients_with_genotype_G/TT_+_TT/TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sofosbuvir_and_ribavirin.""TT/TT:Patients_with_the_TT/TT_genotype_may_have_faster_viral_clearance_and_increased_drug_efficacy_in_hepatitis_C_genotype-1_patients_treated_with_sofosbuvir_and_ribavirin_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_sofosbuvir_and_ribavirin.";PGKB_RACE=NR,NR
19	39743165	rs8099917	T	G	.	.	PGKB_INDEX=3;PGKB_GENE=IFNL3_(PA134952671),IFNL3_(PA134952671),"IFNL3_(PA134952671)""IFNL4_(PA166049147)";PGKB_DRUG="interferons_(PA451999)""peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)","peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)""telaprevir_(PA165958354)","peginterferon_alfa-2a_(PA164749390)""peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)""simeprevir_(PA166122590)";PGKB_TYPE=Efficacy,Efficacy,Efficacy;PGKB_EVIDENCE=1B,1B,3;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863),Hepatitis_C_(PA444445);PGKB_TEXT="GG:Patients_with_the_GG_genotype_may_have_decreased_response_(lower_SVR)_to_peginterferon_alfa_and_ribavirin_therapy_in_people_with_HCV_genotype_1_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_peginterferon_alfa_and_ribavirin_therapy._This_association_is_significant_in_HCV_genotype_1_patients_but_may_not_be_significant_in_HCV_genotype_2_genotype_3_or_genotype_5_patients._""GT:Patients_with_the_GT_genotype_may_have_decreased_response_(lower_SVR)_to_peginterferon_alfa_and_ribavirin_therapy_in_people_with_HCV_genotype_1_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_peginterferon_alfa_and_ribavirin_therapy._This_association_is_significant_in_HCV_genotype_1_patients_but_may_not_be_significant_in_HCV_genotype_2_genotype_3_or_genotype_5_patients._""TT:Patients_with_the_TT_genotype_may_have_increased_response_(higher_SVR)_to_peginterferon_alfa_and_ribavirin_therapy_in_people_with_HCV_genotype_1_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_peginterferon_alfa_and_ribavirin_therapy._This_association_is_significant_in_HCV_genotype_1_patients_but_may_not_be_significant_in_HCV_genotype_2_genotype_3_or_genotype_5_patients._","GG:Patients_with_the_GG_genotype_may_have_lower_response_rates_(SVR)_to_triple_therapy_(telaprevir_peginterferon_alfa-2a/b_and_ribavirin)_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_HCV_triple_therapy.""GT:Patients_with_the_GT_genotype_may_have_lower_response_rates_(SVR)_to_triple_therapy_(telaprevir_peginterferon_alfa-2a/b_and_ribavirin)_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_HCV_triple_therapy.""TT:Patients_with_the_TT_genotype_may_have_higher_response_rates_(SVR)_to_triple_therapy_(telaprevir_peginterferon_alfa-2a/b_and_ribavirin)_in_people_with_Hepatitis_C_genotype_1_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_HCV_triple_therapy.","GG:Patients_with_genotype_GG_may_have_decreased_response_to_simeprevir_plus_peginterferon_and_ribavirin_therapy_in_treatment-nave_patients_and_relapsers_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_simeprevir/pegintron_therapy.""GT:Patients_with_genotype_GT_may_have_decreased_response_to_simeprevir_plus_peginterferon_and_ribavirin_therapy_in_treatment-nave_patients_and_relapsers_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_simeprevir/pegintron_therapy.""TT:Patients_with_genotype_TT_may_have_increased_response_to_simeprevir_plus_peginterferon_and_ribavirin_therapy_in_treatment-nave_patients_and_relapsers_as_compared_to_patients_with_genotype_GG_or_GT._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_simeprevir/pegintron_therapy.";PGKB_RACE=NR,NR,Asian
19	41341229	rs12461964	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="AA:Individuals_who_smoke_and_have_the_AA_genotype_may_have_decreased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_less_when_compared_to_individuals_who_smoke_and_have_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers.""AG:Individuals_who_smoke_and_have_the_AG_genotype_may_have_decreased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_less_when_compared_to_individuals_who_smoke_and_have_the_GG_genotypes_and_increased_rates_of_metabolism_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers.""GG:Individuals_who_smoke_and_have_the_GG_genotype_may_have_increased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_more_when_compared_to_individuals_who_smoke_and_have_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers.";PGKB_RACE=White
19	41349732	rs28399468	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism_in_particular_other_tag_SNPs_for_alleles_of_CYP2A6_should_be_cross_checked.""AC:Patients_with_the_AC_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism_in_particular_other_tag_SNPs_for_alleles_of_CYP2A6_should_be_cross_checked.""CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_or_AC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism_in_particular_other_tag_SNPs_for_alleles_of_CYP2A6_should_be_cross_checked.";PGKB_RACE=NR
19	41349774	rs5031016	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_GG_or_AG_genotype._Other_variants_within_the_CYP2A6_gene_should_be_considered_-_allele_G_of_this_SNP_is_part_of_the_*7_*10_*19_*36_*37_CYP2A6_alleles._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""AG:Patients_with_the_AG_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_variants_within_the_CYP2A6_gene_should_be_considered_-_allele_G_of_this_SNP_is_part_of_the_*7_*10_*19_*36_*37_CYP2A6_alleles._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.""GG:Patients_with_the_GG_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_variants_within_the_CYP2A6_gene_should_be_considered_-_allele_G_of_this_SNP_is_part_of_the_*7_*10_*19_*36_*37_CYP2A6_alleles._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_nicotine.";PGKB_RACE=Asian
19	41350671	rs376817657	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""TC:Patients_with_the_CT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.";PGKB_RACE=Black_or_African_American
19	41351267	rs28399454	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=efavirenz_(PA449441);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_plasma_drug_concentration_when_treated_with_efavirenz_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism_in_particular_CYP2A6*9_(rs8192726)_should_be_cross_checked.""CT:Patients_with_the_CT_genotype_may_have_increased_plasma_drug_concentration_when_treated_with_efavirenz_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism_in_particular_CYP2A6*9_(rs8192726)_should_be_cross_checked.""TT:Patients_with_the_TT_genotype_may_have_increased_plasma_drug_concentration_when_treated_with_efavirenz_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism_in_particular_CYP2A6*9_(rs8192726)_should_be_cross_checked.";PGKB_RACE=NR
19	41352817	rs140471703	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.";PGKB_RACE=Black_or_African_American
19	41353107	rs56113850	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="CC:Individuals_who_smoke_and_have_the_CC_genotype_may_have_increased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_more_when_compared_to_individuals_who_smoke_and_have_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers._""CT:Individuals_who_smoke_and_have_the_CT_genotype_may_have_increased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_more_when_compared_to_individuals_who_smoke_and_have_the_TT_genotypes_and_decreased_rates_of_metabolism_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers._""TT:Individuals_who_smoke_and_have_the_TT_genotype_may_have_decreased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_less_when_compared_to_individuals_who_smoke_and_have_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers._";PGKB_RACE=White
19	41354496	rs8192726	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=efavirenz_(PA449441);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_Infections_(PA446213);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_lower_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_AC_or_CC_genotype._The_association_with_risk_of_side_effects_is_currently_unclear._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_efavirenz._""AC:Patients_with_the_AC_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_higher_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_AA_genotype._The_association_with_risk_of_side_effects_is_currently_unclear._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_efavirenz._""CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_efavirenz_may_have_higher_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_AA_genotype._The_association_with_risk_of_side_effects_is_currently_unclear._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_efavirenz._";PGKB_RACE=Black_or_African_American
19	41354533	rs1801272	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=coumarin_(PA134521193);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_7-hydroxylation_of_coumarin_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_coumarin.""AT:Patients_with_the_AT_genotype_may_have_increased_7-hydroxylation_of_coumarin_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_coumarin.""TT:Patients_with_the_TT_genotype_may_have_minimal_7-hydroxylation_of_coumarin_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_of_coumarin.";PGKB_RACE=NR
19	41355864	rs143690364	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2A6_(PA121);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.";PGKB_RACE=Black_or_African_American
19	41356379	rs28399433	A	C	.	.	PGKB_INDEX=3;PGKB_GENE=CYP2A6_(PA121),CYP2A6_(PA121),CYP2A6_(PA121);PGKB_DRUG=efavirenz_(PA449441),nicotine_(PA450626),coumarin_(PA134521193);PGKB_TYPE=Other,Other,Other;PGKB_EVIDENCE=3,4,4;PGKB_DISEASE=HIV_(PA447230),NR,NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_may_have_decreased_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_AC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_plasma_concentrations_of_efavirenz.""AC:Patients_with_the_AC_genotype_and_HIV_may_have_increased_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_plasma_concentrations_of_efavirenz.""CC:Patients_with_the_CC_genotype_and_HIV_may_have_increased_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_plasma_concentrations_of_efavirenz.","AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_AC_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""AC:Patients_with_the_AC_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.","AA:Patients_with_the_AA_genotype_may_have_increased_metabolism_of_coumarin_as_compared_to_patients_with_the_AC_or_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""AC:Patients_with_the_AC_genotype_may_have_decreased_metabolism_of_coumarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_coumarin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.";PGKB_RACE=Black_or_African_American,NR,NR
19	41362293	rs113288603	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="CC:Individuals_who_smoke_and_have_the_CC_genotype_may_have_increased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_more_when_compared_to_individuals_who_smoke_and_have_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers.""CT:Individuals_who_smoke_and_have_the_CT_genotype_may_have_increased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_more_when_compared_to_individuals_who_smoke_and_have_the_TT_genotypes_and_decreased_rates_of_metabolism_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers.""TT:Individuals_who_smoke_and_have_the_TT_genotype_may_have_decreased_rates_of_nicotine_clearance_and_as_a_consequence_may_smoke_less_when_compared_to_individuals_who_smoke_and_have_the_CC_or_CT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_nicotine_clearance_rates_in_smokers.";PGKB_RACE=White
19	41494891	rs7254579	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=cyclophosphamide_(PA449165);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Lupus_erythematosus_(PA444819);PGKB_TEXT="CC:Patients_with_lupus_and_the_CC_genotype_may_have_decreased_metabolism_of_cyclophosphamide_resulting_in_decreased_concentrations_of_active_cyclophosphamide_metabolite_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cyclophosphamide_in_patients_with_lupus._""CT:Patients_with_lupus_and_the_CT_genotype_may_have_decreased_metabolism_of_cyclophosphamide_resulting_in_decreased_concentrations_of_active_cyclophosphamide_metabolite_as_compared_to_patients_with_the_TT_genotypes_and_increased_metabolism_of_cyclophosphamide_and_increased_concentrations_of_cyclophosphide_metabolite_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cyclophosphamide_in_patients_with_lupus._""TT:Patients_with_lupus_and_the_TT_genotype_may_have_increased_metabolism_of_cyclophosphamide_resulting_in_increased_concentrations_of_cyclophosphamide_metabolites_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cyclophosphamide_in_patients_with_lupus._";PGKB_RACE=Asian
19	41495755	rs2054675	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_be_at_an_increased_risk_for_experiencing_severe_cutaneous_adverse_events_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_nevirapine-related_adverse_reactions.""CT:Patients_with_the_CT_genotype_and_HIV_may_be_at_an_increased_risk_for_experiencing_severe_cutaneous_adverse_events_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype_or_a_decreased_risk_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_nevirapine-related_adverse_reactions.""TT:Patients_with_the_TT_genotype_and_HIV_may_be_at_a_decreased_risk_for_experiencing_severe_cutaneous_adverse_events_when_treated_with_nevirapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_nevirapine-related_adverse_reactions.";PGKB_RACE=NR
19	41496461	rs4802101	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=cyclophosphamide_(PA449165);PGKB_TYPE="Toxicity/ADR""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Lupus_erythematosus_(PA444819);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_metabolism_of_cyclophosphamide_resulting_in_decreased_concentrations_of_active_cyclophosphamide_metabolites_and_decreased_risk_of_gastrointestinal_toxicity_or_leukopenia_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cyclophosphamide_as_well_as_risk_of_toxicity_in_patients_with_lupus.""CT:Patients_with_the_CT_genotype_may_have_decreased_metabolism_of_cyclophosphamide_resulting_in_decreased_concentrations_of_active_cyclophosphamide_metabolites_and_decreased_risk_of_gastrointestinal_toxicity_or_leukopenia_as_compared_to_patients_with_the_TT_genotypes_and_increased_metabolism_and_increased_risk_of_toxicity_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cyclophosphamide_as_well_as_risk_of_toxicity_in_patients_with_lupus.""TT:Patients_with_the_TT_genotype_may_have_increased_metabolism_of_cyclophosphamide_resulting_in_increased_concentrations_of_active_cyclophosphamide_metabolites_and_increased_risk_of_gastrointestinal_toxicity_or_leukopenia_as_compared_to_patients_with_the_CT_or_CC_genotypes._Other_clinical_and_genetic_factors_may_also_influence_metabolism_of_cyclophosphamide_as_well_as_risk_of_toxicity_in_patients_with_lupus.";PGKB_RACE=Asian
19	41497274	rs8192709	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG=cyclophosphamide_(PA449165),efavirenz_(PA449441);PGKB_TYPE=Toxicity/ADR,Metabolism/PK;PGKB_EVIDENCE=3,3;PGKB_DISEASE="Cystitis_(PA443833)""Transplantation_(PA134850491)",NR;PGKB_TEXT="CC:Recipients_of_HLA-identical_hematopoietic_stem_cell_transplantation_with_the_CC_genotype_and_leukemia_may_have_a_decreased_but_not_absent_risk_for_hemorrhagic_cystitis_when_treated_with_cyclophosphamide_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hemorrhagic_cystitis.""CT:Recipients_of_HLA-identical_hematopoietic_stem_cell_transplantation_with_the_CT_genotype_and_leukemia_may_have_an_increased_risk_for_hemorrhagic_cystitis_when_treated_with_cyclophosphamide_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hemorrhagic_cystitis.""TT:Recipients_of_HLA-identical_hematopoietic_stem_cell_transplantation_with_the_TT_genotype_and_leukemia_may_have_an_increased_risk_for_hemorrhagic_cystitis_when_treated_with_cyclophosphamide_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hemorrhagic_cystitis.","CC:Patients_with_genotype_CC_may_have_decreased_metabolism_of_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_genotype_CT._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_efavirenz.""CT:Patients_with_genotype_CT_may_have_increased_metabolism_of_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_efavirenz.""TT:Patients_with_genotype_TT_may_have_increased_metabolism_of_efavirenz_in_people_with_HIV_Infections_as_compared_to_patients_with_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_the_metabolism_of_efavirenz.";PGKB_RACE=NR,Asian
19	41497346	rs35303484	A	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=efavirenz_(PA449441);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_who_are_treated_with_efavirenz_may_have_decreased_efavirenz_plasma_concentrations_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_efavirenz._""AG:Patients_with_the_AG_genotype_and_HIV_who_are_treated_with_efavirenz_may_have_decreased_efavirenz_plasma_concentrations_as_compared_to_patients_with_the_GG_genotype_or_may_have_increased_efavirenz_plasma_concentrations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_efavirenz._""GG:Patients_with_the_GG_genotype_and_HIV_who_are_treated_with_efavirenz_may_have_increased_efavirenz_plasma_concentrations_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_efavirenz._";PGKB_RACE=Black_or_African_American
19	41506191	rs3786547	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_be_at_an_increased_risk_for_experiencing_severe_cutaneous_adverse_events_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_nevirapine-related_adverse_reactions.""CT:Patients_with_the_CT_genotype_and_HIV_may_be_at_an_increased_risk_for_experiencing_severe_cutaneous_adverse_events_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype_or_a_decreased_risk_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_nevirapine-related_adverse_reactions.""TT:Patients_with_the_TT_genotype_and_HIV_may_be_at_a_decreased_risk_for_experiencing_severe_cutaneous_adverse_events_when_treated_with_nevirapine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_nevirapine-related_adverse_reactions.";PGKB_RACE=NR
19	41510282	rs12721655	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG="cyclophosphamide_(PA449165)""doxorubicin_(PA449412)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_survival_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_genotype_AG_or_GG._Authors_caution_"the_relevance_of_these_data_is_uncertain_given_the_low_number_of_rare_alleles"._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_may_have_decreased_survival_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_genotype_AA._Authors_caution_"the_relevance_of_these_data_is_uncertain_given_the_low_number_of_rare_alleles"._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_may_have_decreased_survival_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_genotype_AA._Authors_caution_"the_relevance_of_these_data_is_uncertain_given_the_low_number_of_rare_alleles"._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
19	41512792	rs4803419	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=efavirenz_(PA449441);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=2B;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_HIV_and_the_CC_genotype_may_have_lower_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_efavirenz_in_patients_with_HIV.""CT:Patients_with_HIV_and_the_CT_genotype_may_have_higher_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_CC_genotype_and_lower_plasma_concentrations_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_efavirenz_in_patients_with_HIV._""TT:Patients_with_HIV_and_the_TT_genotype_may_have_higher_plasma_concentrations_of_efavirenz_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_plasma_concentrations_of_efavirenz_in_patients_with_HIV.";PGKB_RACE=NR
19	41512841	rs3745274	G	T	.	.	PGKB_INDEX=9;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG=mitotane_(PA164746157),efavirenz_(PA449441),efavirenz_(PA449441),"cyclophosphamide_(PA449165)""doxorubicin_(PA449412)",nevirapine_(PA450616),cyclophosphamide_(PA449165),methadone_(PA450401),imatinib_(PA10804),propofol_(PA451141);PGKB_TYPE=Other,Dosage,Toxicity/ADR,Dosage,Other,Toxicity/ADR,Dosage,"Efficacy""Toxicity/ADR",Dosage;PGKB_EVIDENCE=3,1B,2A,3,2A,3,2A,3,3;PGKB_DISEASE=Adrenocortical_Carcinoma_(PA446644),HIV_(PA447230),HIV_(PA447230),Breast_Neoplasms_(PA443560),HIV_Infections_(PA446213),"Hepatic_Veno-Occlusive_Disease_(PA444434)""Transplantation_(PA134850491)",Heroin_Dependence_(PA444460),Leukemia_Myelogenous_Chronic_BCR-ABL_Positive_(PA446171),NR;PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Adrenocortical_Carcinoma_who_are_treated_with_mitotane_may_have_lower_mitotane_plasma_concentrations_as_compared_to_patients_with_the_TT_or_TG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mitotane.""TG:Patients_with_the_TG_genotype_and_Adrenocortical_Carcinoma_who_are_treated_with_mitotane_may_have_higher_mitotane_plasma_concentrations_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mitotane.""TT:Patients_with_the_TT_genotype_and_Adrenocortical_Carcinoma_who_are_treated_with_mitotane_may_have_higher_mitotane_plasma_concentrations_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_mitotane.","GG:Patients_with_the_GG_genotype_and_HIV_infection_may_have_decreased_plasma_concentrations_and_increased_clearance_of_efavirenz_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""GT:Patients_with_the_GT_genotype_and_HIV_infection_may_have_increased_plasma_concentrations_and_decreased_clearance_of_efavirenz_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""TT:Patients_with_the_TT_genotype_and_HIV_infection_may_have_increased_plasma_concentrations_and_decreased_clearance_of_efavirenz_as_compared_to_patients_with_the_GT_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.","GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_of_efavirenz-induced_side_effects_including_sleep-_and_central_nervous_system-related_side_effects_as_compared_to_patients_with_the_GT_or_TT_genotype._However_patients_with_the_GG_genotype_may_also_have_an_increased_risk_for_immunological_failure_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""GT:Patients_with_the_GT_genotype_may_have_a_decreased_risk_of_efavirenz-induced_side_effects_including_sleep-_and_central_nervous_system-related_side_effects_as_compared_to_patients_with_the_TT_genotype._One_study_shows_an_increased_risk_for_sleep_disorders_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""TT:Patients_with_the_TT_genotype_may_have_an_increased_risk_for_efavirenz-induced_side_effects_including_sleep-_and_central_nervous_system-related_side_effects_as_compared_to_patients_with_the_GG_or_GT_genotype._However_patients_with_the_TT_genotype_may_also_have_a_decreased_risk_for_immunological_failure_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","GG:Patients_with_the_GG_genotype_and_Breast_Cancer_who_are_treated_with_cyclophosphamide_and_doxorubicin_may_be_more_likely_to_require_a_reduction_in_dose_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.""GT:Patients_with_the_GT_genotype_and_Breast_Cancer_who_are_treated_with_cyclophosphamide_and_doxorubicin_may_be_more_likely_to_require_a_reduction_in_dose_as_compared_to_patients_with_the_TT_genotype_or_may_be_less_likely_to_require_a_reduction_in_dose_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.""TT:Patients_with_the_TT_genotype_and_Breast_Cancer_who_are_treated_with_cyclophosphamide_and_doxorubicin_may_be_less_likely_to_require_a_reduction_in_dose_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirements.","GG:Patients_with_the_GG_genotype_and_HIV_infection_may_have_increased_clearance_of_and_decreased_exposure_to_nevirapine_as_compared_to_patients_with_the_TT_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nevirapine_and_exposure_to_drug.""GT:Patients_with_the_GT_genotype_and_HIV_infection_may_have_decreased_clearance_of_and_increased_exposure_to_nevirapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nevirapine_and_exposure_to_drug.""TT:Patients_with_the_TT_genotype_and_HIV_infection_may_have_decreased_clearance_of_and_increased_exposure_to_nevirapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_of_nevirapine_and_exposure_to_drug.","GG:Leukemia_patients_who_are_recipients_of_HLA-identical_hematopoietic_stem_cell_transplantation_from_donors_with_the_GG_genotype_may_have_an_increased_risk_of_developing_veno-occlusive_disease_of_the_liver_when_treated_with_cyclophosphamide_as_compared_to_donor_cells_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_venoocclusive_disease_of_the_liver.""GT:Leukemia_patients_who_are_recipients_of_HLA-identical_hematopoietic_stem_cell_transplantation_from_donors_with_the_GT_genotype_may_have_a_decreased_risk_of_developing_veno-occlusive_disease_of_the_liver_when_treated_with_cyclophosphamide_as_compared_to_donor_cells_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_venoocclusive_disease_of_the_liver.""TT:Leukemia_patients_who_are_recipients_of_HLA-identical_hematopoietic_stem_cell_transplantation_from_donors_with_the_TT_genotype_may_have_a_decreased_risk_of_developing_veno-occlusive_disease_of_the_liver_when_treated_with_cyclophosphamide_as_compared_to_donor_cells_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_venoocclusive_disease_of_the_liver.","GG:Patients_with_the_GG_genotype_who_are_being_treated_with_methadone_for_heroin_addiction_may_require_an_increased_dose_of_the_drug_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_methadone.""GT:Patients_with_the_GT_genotype_who_are_being_treated_with_methadone_for_heroin_addiction_may_require_an_increased_dose_of_the_drug_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_methadone.""TT:Patients_with_the_TT_genotype_who_are_being_treated_with_methadone_for_heroin_addiction_may_require_a_decreased_dose_of_the_drug_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_dose_of_methadone.","GG:Patients_with_the_GG_genotype_and_chronic_myeloid_leukemia_may_have_a_1)_a_better_response_to_treatment_with_imatinib_as_compared_to_patients_with_the_TT_genotype_2)_an_increased_risk_of_developing_cytogenetic_resistance_to_imatinib_as_compared_to_patients_with_the_GT_genotype_and_3)_a_greater_risk_for_side_effects_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_resistance_and_risk_of_side_effects_in_patients_taking_imatinib.""GT:Patients_with_the_GT_genotype_and_chronic_myeloid_leukemia_may_have_a_1)_a_better_response_to_treatment_with_imatinib_as_compared_to_patients_with_the_TT_genotype_2)_a_decreased_risk_of_developing_cytogenetic_resistance_to_imatinib_as_compared_to_patients_with_the_GG_or_TT_genotype_and_3)_a_decreased_risk_for_side_effects_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_resistance_and_risk_of_side_effects_in_patients_taking_imatinib.""TT:Patients_with_the_TT_genotype_and_chronic_myeloid_leukemia_may_have_a_1)_a_poorer_response_to_treatment_with_imatinib_as_compared_to_patients_with_the_GG_or_GT_genotype_2)_an_increased_risk_of_developing_cytogenetic_resistance_to_imatinib_as_compared_to_patients_with_the_GT_genotype_and_3)_a_decreased_risk_for_side_effects_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_resistance_and_risk_of_side_effects_in_patients_taking_imatinib.","GG:Patients_under_general_anaesthesia_with_genotypes_GG_may_need_increased_dose_of_propofol_as_compared_to_patients_with_genotype_TT_or_GT._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_propofol._""GT:Patients_under_general_anaesthesia_with_genotypes_GT_may_need_decreased_dose_of_propofol_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_propofol._""TT:Patients_under_general_anaesthesia_with_genotypes_TT_may_need_decreased_dose_of_propofol_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_dose_of_propofol._";PGKB_RACE=NR,NR,NR,NR,NR,NR,NR,NR,NR
19	41514965	rs58425034	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=nevirapine_(PA450616);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_nevirapine_may_have_an_increased_alanine_aminotransferase_levels_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_alanine_aminotransferase_levels.""CG:Patients_with_the_CG_genotype_who_are_treated_with_nevirapine_may_have_an_increased_alanine_aminotransferase_levels_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_alanine_aminotransferase_levels.""GG:Patients_with_the_GG_genotype_who_are_treated_with_nevirapine_may_have_a_decreased_alanine_aminotransferase_levels_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_alanine_aminotransferase_levels.";PGKB_RACE=Black_or_African_American
19	41515263	rs2279343	A	G	.	.	PGKB_INDEX=4;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG=efavirenz_(PA449441),cyclophosphamide_(PA449165),methadone_(PA450401),nicotine_(PA450626);PGKB_TYPE=Metabolism/PK,Toxicity/ADR,Dosage,Metabolism/PK;PGKB_EVIDENCE=2A,3,3,4;PGKB_DISEASE=HIV_(PA447230),Transplantation_(PA134850491),Heroin_Dependence_(PA444460),Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_HIV_may_have_increased_clearance_and_decreased_plasma_concentration_of_efavirenz_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""AG:Patients_with_the_AG_genotype_and_HIV_may_have_increased_clearance_and_decreased_plasma_concentration_of_efavirenz_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.""GG:Patients_with_the_GG_genotype_and_HIV_may_have_decreased_clearance_and_increased_plasma_concentration_of_efavirenz_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_exposure_to_efavirenz.","AA:Patients_with_the_AA_genotype_who_have_received_a_hematopoietic_stem_cell_transplant_and_are_treated_with_cyclophosphamide_may_have_a_decreased_but_not_absent_risk_for_oral_mucositis_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_oral_mucositis.""AG:Patients_with_the_AG_genotype_who_have_received_a_hematopoietic_stem_cell_transplant_and_are_treated_with_cyclophosphamide_may_have_an_increased_risk_for_oral_mucositis_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_oral_mucositis.""GG:Patients_with_the_GG_genotype_who_have_received_a_hematopoietic_stem_cell_transplant_and_are_treated_with_cyclophosphamide_may_have_an_increased_risk_for_oral_mucositis_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_oral_mucositis.","AA:Patients_with_the_AA_genotype_who_are_being_treated_with_methadone_for_heroin_addiction_may_require_an_increased_dose_of_the_drug_as_compared_to_patients_with_the_GG_genotype._However_one_study_found_no_association_between_this_variant_and_methadone_dose._Other_genetic_and_clinical_factors_may_also_influence_dose_of_methadone.""AG:Patients_with_the_AG_genotype_who_are_being_treated_with_methadone_for_heroin_addiction_may_require_an_increased_dose_of_the_drug_as_compared_to_patients_with_the_GG_genotype._However_one_study_found_no_association_between_this_variant_and_methadone_dose._Other_genetic_and_clinical_factors_may_also_influence_dose_of_methadone.""GG:Patients_with_the_GG_genotype_who_are_being_treated_with_methadone_for_heroin_addiction_may_require_a_decreased_dose_of_the_drug_as_compared_to_patients_with_the_AA_or_AG_genotype._However_one_study_found_no_association_between_this_variant_and_methadone_dose._Other_genetic_and_clinical_factors_may_also_influence_dose_of_methadone.","AA:Patients_with_the_AA_genotype_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_nicotine.""AG:Patients_with_the_AG_genotype_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_metabolism_of_nicotine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_nicotine.""GG:Patients_with_the_GG_genotype_may_have_increased_metabolism_of_nicotine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_nicotine.";PGKB_RACE=Asian,NR,NR,NR
19	41515702	rs2279345	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2B6_(PA123);PGKB_DRUG=efavirenz_(PA449441);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=2A;PGKB_DISEASE="HIV_(PA447230)""Tuberculosis_(PA445941)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_have_increased_metabolism_of_efavirenz_resulting_in_lower_efavirenz_plasma_levels_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_and_plasma_concentrations_of_efavirenz.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_increased_metabolism_of_efavirenz_resulting_in_lower_efavirenz_plasma_levels_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_and_plasma_concentrations_of_efavirenz.""TT:Patients_with_the_TT_genotype_and_HIV_may_have_decreased_metabolism_of_efavirenz_resulting_in_higher_efavirenz_plasma_levels_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_metabolism_and_plasma_concentrations_of_efavirenz.";PGKB_RACE=Asian
19	41518221	rs28399499	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG=efavirenz_(PA449441),nevirapine_(PA450616),nevirapine_(PA450616);PGKB_TYPE=Metabolism/PK,Other,Toxicity/ADR;PGKB_EVIDENCE=2A,2A,3;PGKB_DISEASE=HIV_(PA447230),HIV_(PA447230),"Epidermal_Necrolysis_Toxic_(PA444059)""Stevens-Johnson_Syndrome_(PA445738)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_plasma_drug_exposure_when_treated_with_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""CT:Patients_with_the_CT_genotype_may_have_increased_plasma_drug_exposure_when_treated_with_efavirenz_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_drug_exposure_when_treated_with_efavirenz_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.","CC:Patients_with_the_CC_genotype_may_have_increased_plasma_drug_exposure_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""CT:Patients_with_the_CT_genotype_may_have_increased_plasma_drug_exposure_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_drug_exposure_when_treated_with_nevirapine_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_drug_metabolism.","CC:Patients_with_the_CC_genotype_and_HIV_may_have_an_increased_risk_for_Stevens-Johnson_Syndrome/toxic_epidermal_necrolysis_(SJS/TEN)_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_developing_SJS/TEN_when_receiving_nevirapine.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_an_increased_risk_for_Stevens-Johnson_Syndrome/toxic_epidermal_necrolysis_(SJS/TEN)_when_treated_with_nevirapine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_developing_SJS/TEN_when_receiving_nevirapine.""TT:Patients_with_the_TT_genotype_and_HIV_may_have_a_decreased_risk_for_Stevens-Johnson_Syndrome/toxic_epidermal_necrolysis_(SJS/TEN)_when_treated_with_nevirapine_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_developing_SJS/TEN_when_receiving_nevirapine.";PGKB_RACE=NR,NR,Black_or_African_American
19	41522715	rs3211371	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2B6_(PA123),CYP2B6_(PA123);PGKB_DRUG="cyclophosphamide_(PA449165)""doxorubicin_(PA449412)",bupropion_(PA448687);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Breast_Neoplasms_(PA443560),Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="CC:Patients_withe_the_CC_genotype_may_have_decreased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_TT_or_TC_genotype._Leucopenia_and_neutropenia_were_the_most_common_reasons_for_dose_delay._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.""TC:Patients_withe_the_TC_genotype_may_have_increased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_CC_genotype._Leucopenia_and_neutropenia_were_the_most_common_reasons_for_dose_delay._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.""TT:Patients_withe_the_TT_genotype_may_have_increased_likelihood_of_dose_delay_when_treated_with_cyclophosphamide_and_doxorubicin_in_women_with_Breast_Neoplasms_as_compared_to_patients_with_the_CC_genotype._Leucopenia_and_neutropenia_were_the_most_common_reasons_for_dose_delay._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response.","CC:Patients_with_the_CC_genotype_who_are_smokers_may_have_a_lower_chance_of_smoking_cessation_when_treated_with_bupropion_as_compared_to_patients_with_the_CT_or_TT_genotype_although_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_smoking_cessation.""CT:Patients_with_the_CT_genotype_who_are_smokers_may_have_a_better_chance_of_smoking_cessation_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype_although_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_smoking_cessation.""TT:Patients_with_the_TT_genotype_who_are_smokers_may_have_a_better_chance_of_smoking_cessation_when_treated_with_bupropion_as_compared_to_patients_with_the_CC_genotype_although_this_is_contradicted_in_one_study._Other_genetic_and_clinical_factors_may_also_influence_likelihood_of_smoking_cessation.";PGKB_RACE=NR,White
19	41858876	rs1800471	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=TGFB1_(PA350);PGKB_DRUG=rituximab_(PA451261);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:No_patients_with_the_CC_genotype_were_present_in_this_study._However_patients_with_the_CG_genotype_and_rheumatoid_arthritis_may_be_more_likely_to_respond_to_rituximab_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab.""CG:Patients_with_the_CG_genotype_and_rheumatoid_arthritis_may_be_more_likely_to_respond_to_rituximab_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab.""GG:Patients_with_the_GG_genotype_and_rheumatoid_arthritis_may_be_less_likely_to_respond_to_rituximab_treatment_as_compared_to_patients_with_the_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab.";PGKB_RACE=White
19	41858921	rs1800470	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TGFB1_(PA350);PGKB_DRUG=rituximab_(PA451261);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_rheumatoid_arthritis_may_have_a_poorer_response_when_treated_with_rituximab_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab.""AG:Patients_with_the_AG_genotype_and_rheumatoid_arthritis_may_have_a_better_response_when_treated_with_rituximab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab.""GG:No_patients_with_the_GG_genotype_were_present_in_the_population._However_patients_with_the_AG_genotype_and_rheumatoid_arthritis_may_have_a_better_response_when_treated_with_rituximab_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_rituximab.";PGKB_RACE=White
19	41860296	rs1800469	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_aspirin-intolerant_chronic_urticaria_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.""AG:Patients_with_the_AG_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_aspirin-intolerant_chronic_urticaria_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.""GG:Patients_with_the_GG_genotype_who_are_treated_with_aspirin_may_have_a_decreased_risk_of_aspirin-intolerant_chronic_urticaria_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_urticaria.";PGKB_RACE=Asian
19	44055726	rs25487	T	C	.	.	PGKB_INDEX=3;PGKB_GENE=XRCC1_(PA369),XRCC1_(PA369),XRCC1_(PA369);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)""oxaliplatin_(PA131285527)""platinum_(PA150595617)""Platinum_compounds_(PA164713176)",fluorouracil_(PA128406956),cyclophosphamide_(PA449165);PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy,"Efficacy""Toxicity/ADR";PGKB_EVIDENCE=2B,3,3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Colorectal_Neoplasms_(PA446108)""Neoplasms_(PA445062)""Ovarian_Neoplasms_(PA445204)""Pancreatic_Neoplasms_(PA445218)""Uterine_Cervical_Neoplasms_(PA443685)","Colonic_Neoplasms_(PA443756)""Colorectal_Neoplasms_(PA446108)""Neoplasms_(PA445062)""Rectal_Neoplasms_(PA445503)""Uterine_Cervical_Neoplasms_(PA443685)","Neoplasms_(PA445062)""Ovarian_Neoplasms_(PA445204)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_1)_increased_survival_and_response_and_2)_increased_risk_of_severe_neutropenia_when_treated_with_platinum-based_regimens_as_compared_to_patients_with_the_CT_or_TT_genotype._However_one_study_found_decreased_survival_and_response_for_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_regimens.""CT:Patients_with_the_CT_genotype_may_have_1)_decreased_survival_and_2)_decreased_risk_of_severe_neutropenia_when_treated_with_platinum-based_regimens_as_compared_to_patients_with_the_CC_genotype._However_one_study_found_increased_survival_as_compared_to_patients_with_the_CC_genotype._Conflicting_results_exist_for_the_relationship_between_the_CT_genotype_and_response_to_platinum-based_treatment._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_regimens.""TT:Patients_with_the_TT_genotype_may_have_1)_decreased_survival_and_response_and_2)_decreased_risk_of_severe_neutropenia_when_treated_with_platinum-based_regimens_as_compared_to_patients_with_the_CC_genotype._However_one_study_found_increased_survival_and_response_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_regimens.","CC:Patients_with_the_CC_genotype_and_cancer_may_have_increased_response_to_fluorouracil-containing_chemotherapy_regimens_as_well_as_a_decreased_risk_for_and_a_later_onset_of_sensory_neuropathy_as_compared_to_patients_with_the_CT_or_TT_genotype._However_all_studies_evaluated_also_included_other_treatments_(platinum_drugs_or_radiotherapy)_which_may_interact_with_this_variant._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.""CT:Patients_with_the_CT_genotype_and_cancer_may_have_decreased_response_to_fluorouracil-containing_chemotherapy_regimens_as_well_as_an_increased_risk_for_and_an_earlier_onset_of_sensory_neuropathy_as_compared_to_patients_with_the_CC_genotype._However_all_studies_evaluated_also_included_other_treatments_(platinum_drugs_or_radiotherapy)_which_may_interact_with_this_variant._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.""TT:Patients_with_the_TT_genotype_and_cancer_may_have_decreased_response_to_fluorouracil-containing_chemotherapy_regimens_as_well_as_an_increased_risk_for_and_an_earlier_onset_of_sensory_neuropathy_as_compared_to_patients_with_the_CC_genotype._However_all_studies_evaluated_also_included_other_treatments_(platinum_drugs_or_radiotherapy)_which_may_interact_with_this_variant._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.","CC:Patients_with_the_CC_genotype_may_have_1)_increased_survival_and_2)_increased_risk_of_severe_neutropenia_when_treated_with_cyclophosphamide-containing_chemotherapy_regimens_as_compared_to_patients_with_the_CT_or_TT_genotype._However_all_studies_evaluated_also_included_platinum_drugs_which_may_interact_with_this_variant._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.""CT:Patients_with_the_CT_genotype_may_have_1)_decreased_survival_and_2)_decreased_risk_of_severe_neutropenia_when_treated_with_cyclophosphamide-containing_chemotherapy_regimens_as_compared_to_patients_with_the_CC_genotype._However_all_studies_evaluated_also_included_platinum_drugs_which_may_interact_with_this_variant._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.""TT:Patients_with_the_TT_genotype_may_have_1)_decreased_survival_and_2)_decreased_risk_of_severe_neutropenia_when_treated_with_cyclophosphamide-containing_chemotherapy_regimens_as_compared_to_patients_with_the_CC_genotype._However_all_studies_evaluated_also_included_platinum_drugs_which_may_interact_with_this_variant._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment.";PGKB_RACE=NR,Asian,White
19	44057574	rs1799782	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=XRCC1_(PA369);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small-cell_lung_cancer_may_be_more_likely_to_respond_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._However_conflicting_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_and_non-small-cell_lung_cancer_may_be_more_likely_to_respond_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._However_conflicting_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_be_less_likely_to_respond_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._However_conflicting_evidence_exists_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_response_to_treatment_with_platinum-based_chemotherapy.";PGKB_RACE=NR
19	44081059	rs3213239	G	GGGCC	.	.	PGKB_INDEX=1;PGKB_GENE=APLF_(PA164715842);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CCGG/CCGG:Patients_with_the_CCGG/CCGG_genotype_and_non-small-cell_lung_cancer_may_have_shorter_overall_and_progression-free_survival_times_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_and_progression-free_survival_time.""CCGG/del:Patients_with_the_CCGG/del_genotype_and_non-small-cell_lung_cancer_may_have_shorter_overall_and_progression-free_survival_times_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_and_progression-free_survival_time.""del/del:Patients_with_the_del/del_genotype_and_non-small-cell_lung_cancer_may_have_longer_overall_and_progression-free_survival_times_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CCGG/CCGG_or_CCGG/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_and_progression-free_survival_time.";PGKB_RACE=NR
19	45411941	rs429358	T	C	.	.	PGKB_INDEX=1;PGKB_GENE="APOC1_(PA51)""APOE_(PA55)""TOMM40_(PA38274)";PGKB_DRUG="Antivirals_for_treatment_of_HIV_infections_combinations_(PA164712505)""ritonavir_(PA451260)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="HIV_(PA447230)""HIV_Infections_(PA446213)""Hyperlipidemias_(PA444528)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_antiretrovirals_for_HIV_such_as_ritonavir_may_have_an_increased_risk_for_elevated_plasma_lipids_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_in_particular_rs7412_may_also_influence_a_patient's_risk_for_adverse_events_with_ritonavir_treatment.""CT:Patients_with_the_CT_genotype_who_are_treated_with_antiretrovirals_for_HIV_such_as_ritonavir_may_have_an_increased_risk_for_elevated_plasma_lipids_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_in_particular_rs7412_may_also_influence_a_patient's_risk_for_adverse_events_with_ritonavir_treatment.""TT:Patients_with_the_TT_genotype_who_are_treated_with_antiretrovirals_for_HIV_such_as_ritonavir_may_have_a_decreased_but_not_non-existent_risk_for_elevated_plasma_lipids_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_in_particular_rs7412_may_also_influence_a_patient's_risk_for_adverse_events_with_ritonavir_treatment.";PGKB_RACE=NR
19	45412079	rs7412	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=APOE_(PA55),"APOC1_(PA51)""APOE_(PA55)",APOE_(PA55);PGKB_DRUG=atorvastatin_(PA448500),ritonavir_(PA451260),"Antivirals_for_treatment_of_HIV_infections_combinations_(PA164712505)""ritonavir_(PA451260)";PGKB_TYPE=Efficacy,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2A,3,4;PGKB_DISEASE="Coronary_Disease_(PA443797)""Hyperlipidemias_(PA444528)","HIV_(PA447230)""HIV_Infections_(PA446213)""Hyperlipidemias_(PA444528)""Hypertriglyceridemia_(PA446120)","HIV_Infections_(PA446213)""Hypertriglyceridemia_(PA446120)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_atorvastatin_may_have_a_reduced_response_(less_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""CT:Patients_with_the_CT_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(higher_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._""TT:Patients_with_the_TT_genotype_who_are_treated_with_atorvastatin_may_have_a_better_response_(higher_reduction_in_LDL-cholesterol)_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_atorvastatin_treatment._","CC:Patients_with_the_CC_genotype_may_have_decreased_risk_for_elevated_triglycerides_in_response_to_ritonavir_containing_antiretroviral_therapy_as_compared_to_patients_with_the_TT_or_CT_genotype._Patients_with_the_CC_genotype_may_still_be_at_risk_for_toxicity_when_taking_ritonavir._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""CT:Patients_with_the_CT_genotype_may_have_increased_risk_for_elevated_triglycerides_in_response_to_ritonavir_containing_antiretroviral_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_for_elevated_triglycerides_in_response_to_ritonavir_containing_antiretroviral_therapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_toxicity.","CC:Patients_with_the_CC_genotype_and_HIV_infection_who_are_treated_with_antiretroviral_regimens_containing_ritonavir_may_have_a_decreased_risk_of_hypertriglyceridemia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.""CT:Patients_with_the_CT_genotype_and_HIV_infection_who_are_treated_with_antiretroviral_regimens_containing_ritonavir_may_have_an_increased_risk_of_hypertriglyceridemia_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_risk_of_hypertriglyceridemia_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.""TT:Patients_with_the_TT_genotype_and_HIV_infection_who_are_treated_with_antiretroviral_regimens_containing_ritonavir_may_have_an_increased_risk_of_hypertriglyceridemia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_triglyceride_levels.";PGKB_RACE=White,NR,NR
19	45415640	rs445925	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors._""AG:Patients_with_the_AG_genotype_may_have_an_increased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_GG_genotypes_and_a_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors._""GG:Patients_with_the_GG_genotype_may_have_a_decreased_response_to_hmg_coa_reductase_inhibitors_as_compared_to_patients_with_the_AG_or_AA_genotypes._Other_clinical_and_genetic_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors._";PGKB_RACE=NR
19	45854919	rs13181	T	G	.	.	PGKB_INDEX=4;PGKB_GENE=ERCC2_(PA27848),"ERCC2_(PA27848)""KLC3_(PA142671588)",ERCC2_(PA27848),ERCC2_(PA27848);PGKB_DRUG="fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)","cisplatin_(PA449014)""oxaliplatin_(PA131285527)""platinum_(PA150595617)""Platinum_compounds_(PA164713176)",Platinum_compounds_(PA164713176),docetaxel_(PA449383);PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108),"Colorectal_Neoplasms_(PA446108)""Esophageal_Neoplasms_(PA444101)""Osteosarcoma_(PA445601)""Ovarian_Neoplasms_(PA445204)""Pancreatic_Neoplasms_(PA445218)",Carcinoma_Non-Small-Cell_Lung_(PA443622),Breast_Neoplasms_(PA443560);PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_and_leucovorin_or_fluorouracil_leucovorin_and_oxaliplatin_may_have_1)_an_increased_risk_of_Drug_Toxicity_2)_an_increased_risk_of_early_relapse_and_3)_decreased_progression_free_survival_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_leucovorin_and_oxaliplatin.""GT:Patients_with_the_GT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_and_leucovorin_or_fluorouracil_leucovorin_and_oxaliplatin_may_have_1)_an_increased_risk_of_Drug_Toxicity_as_compared_to_patients_with_the_TT_genotype_2)_an_increased_risk_of_early_relapse_as_compared_to_patients_with_the_TT_genotype._However_a_trend_of_an_association_is_found_for_the_GT_genotype_with_increased_progression_free_survival_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_leucovorin_and_oxaliplatin.""TT:Patients_with_the_TT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_and_leucovorin_or_fluorouracil_leucovorin_and_oxaliplatin_may_have_1)_a_decreased_but_not_absent_risk_of_Drug_Toxicity_2)_a_decreased_but_not_absent_risk_of_early_relapse_and_3)_increased_progression_free_survival_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluorouracil_leucovorin_and_oxaliplatin.","GG:Patients_with_the_GG_genotype_may_have_decreased_survival_when_treated_with_platinum_compounds_as_compared_to_patients_with_the_GT_or_TT_genotypes_however_evidence_is_highly_contradictory._Other_genetic_and_clinical_factors_may_also_influence_survival.""GT:Patients_with_the_GT_genotype_may_have_increased_survival_when_treated_with_platinum_compounds_as_compared_to_patients_with_the_GG_genotypes_however_evidence_is_highly_contradictory._Other_genetic_and_clinical_factors_may_also_influence_survival.""TT:Patients_with_the_TT_genotype_may_have_increased_survival_when_treated_with_platinum_compounds_as_compared_to_patients_with_the_GG_genotypes_however_evidence_is_highly_contradictory._Other_genetic_and_clinical_factors_may_also_influence_survival.","GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_an_increased_risk_for_pneumonitis_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_pneumonitis.""GT:Patients_with_the_GT_genotype_and_non-small-cell_lung_cancer_may_have_a_decreased_risk_for_pneumonitis_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_pneumonitis.""TT:Patients_with_the_TT_genotype_and_non-small-cell_lung_cancer_may_have_a_decreased_risk_for_pneumonitis_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_pneumonitis.","GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_decreased_risk_for_neutropenia_when_treated_with_docetaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neutropenia.""GT:Patients_with_the_GT_genotype_and_breast_cancer_may_have_a_decreased_risk_for_neutropenia_when_treated_with_docetaxel_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neutropenia.""TT:Patients_with_the_TT_genotype_and_breast_cancer_may_have_an_increased_risk_for_neutropenia_when_treated_with_docetaxel_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neutropenia.";PGKB_RACE=NR,NR,NR,White
19	45855524	rs1052555	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=ERCC2_(PA27848);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-small-cell_lung_cancer_may_have_a_poorer_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_and_non-small-cell_lung_cancer_may_have_a_poorer_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_a_better_response_to_treatment_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_chemotherapy.";PGKB_RACE=NR
19	45867259	rs1799793	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=ERCC2_(PA27848),ERCC2_(PA27848);PGKB_DRUG=cisplatin_(PA449014),Platinum_compounds_(PA164713176);PGKB_TYPE="Efficacy""Toxicity/ADR",Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Neoplasms_(PA445062),Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_shorter_survival_times_as_compared_to_patients_with_the_CT_or_TT_genotype._This_has_been_contradicted_in_another_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin.""CT:Patients_with_the_CT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_longer_survival_times_as_compared_to_patients_with_the_CC_genotype._This_has_been_contradicted_in_another_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin.""TT:Patients_with_the_TT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_longer_survival_times_as_compared_to_patients_with_the_CC_genotype._This_has_been_contradicted_in_another_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cisplatin.","CC:Patients_with_the_CC_genotype_and_non-small-cell_lung_cancer_may_have_a_decreased_risk_for_pneumonitis_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_pneumonitis._""CT:Patients_with_the_CT_genotype_and_non-small-cell_lung_cancer_may_have_an_increased_risk_for_pneumonitis_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_pneumonitis._""TT:Patients_with_the_TT_genotype_and_non-small-cell_lung_cancer_may_have_an_increased_risk_for_pneumonitis_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_pneumonitis._";PGKB_RACE=NR,NR
19	45912002	rs735482	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=ERCC1_(PA155);PGKB_DRUG=thalidomide_(PA451644);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Multiple_Myeloma_(PA444985);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_overall_survival_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_CC_or_AC_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.""AC:Patients_with_the_AC_genotype_may_have_increased_overall_survival_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.""CC:Patients_with_the_CC_genotype_may_have_increased_overall_survival_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.";PGKB_RACE=NR
19	45912736	rs3212986	C	A	.	.	PGKB_INDEX=5;PGKB_GENE=ERCC1_(PA155),"CD3EAP_(PA142672156)""ERCC1_(PA155)""PPP1R13L_(PA34195)",NR,"CD3EAP_(PA142672156)""ERCC1_(PA155)",ERCC1_(PA155);PGKB_DRUG="cisplatin_(PA449014)""platinum_(PA150595617)""Platinum_compounds_(PA164713176)",Platinum_compounds_(PA164713176),"cisplatin_(PA449014)""Platinum_compounds_(PA164713176)",docetaxel_(PA449383),paclitaxel_(PA450761);PGKB_TYPE=Toxicity/ADR,Efficacy,Efficacy,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=2B,3,3,3,3;PGKB_DISEASE="Neoplasms_(PA445062)""Ovarian_Neoplasms_(PA445204)",Ovarian_Neoplasms_(PA445204),"Carcinoma_Non-Small-Cell_Lung_(PA443622)""Esophageal_Neoplasms_(PA444101)",Breast_Neoplasms_(PA443560),Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_for_nephrotoxicity_with_platinum-based_regimens_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_regimens.""AC:Patients_with_the_AC_genotype_may_have_increased_risk_for_nephrotoxicity_with_platinum-based_regimens_as_compared_to_patients_with_the_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_regimens.""CC:Patients_with_the_CC_genotype_may_have_increased_risk_for_nephrotoxicity_with_platinum-based_regimens_as_compared_to_patients_with_the_AA_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_platinum-based_regimens.","AA:Patients_with_the_AA_genotype_and_ovarian_cancer_who_are_treated_with_platinum_compounds_may_have_decreased_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_with_platinum_compounds.""AC:Patients_with_the_CA_genotype_and_ovarian_cancer_who_are_treated_with_platinum_compounds_may_have_decreased_survival_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_with_platinum_compounds.""CC:Patients_with_the_CC_genotype_and_ovarian_cancer_who_are_treated_with_platinum_compounds_may_have_increased_survival_as_compared_to_patients_with_the_CA_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_survival_with_platinum_compounds.","AA:Patients_with_the_AA_genotype_may_have_better_overall_survival_rate_when_treated_with_platinum_in_people_with_Non-Small-Cell_Lung_Carcinoma_or_esophageal_cancer_or_Ovarian_Neoplasms_as_compared_to_patients_with_CC_genotype._However_contradictory_findings_(better_and_poorer_responses_or_no_association)_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Platinum_compounds.""AC:Patients_with_the_AC_genotype_may_have_better_overall_survival_rate_when_treated_with_platinum_in_people_with_Non-Small-Cell_Lung_Carcinoma_or_esophageal_cancer_or_Ovarian_Neoplasms_as_compared_to_patients_with_CC_genotype._However_contradictory_findings_(better_and_poorer_responses_or_no_association)_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Platinum_compounds.""CC:Patients_with_the_CC_genotype_may_have_worse_overall_survival_rate_when_treated_with_platinum_in_people_with_Non-Small-Cell_Lung_Carcinoma_or_esophageal_cancer_or_Ovarian_Neoplasms_as_compared_to_patients_with_AA_and_AC_genotypes._However_contradictory_findings_(better_and_poorer_responses_or_no_association)_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Platinum_compounds.","AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_an_decreased_risk_for_mucositis_when_treated_with_docetaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_mucositis.""AC:Patients_with_the_AC_genotype_and_breast_cancer_may_have_an_decreased_risk_for_mucositis_when_treated_with_docetaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_mucositis.""CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_an_increased_risk_for_mucositis_when_treated_with_docetaxel_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_mucositis.","AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_an_increased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.""AC:Patients_with_the_AC_genotype_and_breast_cancer_may_have_an_increased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.""CC:Patients_with_the_CC_genotype_and_breast_cancer_may_have_an_decreased_risk_for_neuropathy_when_treated_with_paclitaxel_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_neuropathy.";PGKB_RACE=White,Asian,NR,White,White
19	45923653	rs11615	A	G	.	.	PGKB_INDEX=6;PGKB_GENE=ERCC1_(PA155),ERCC1_(PA155),ERCC1_(PA155),ERCC1_(PA155),ERCC1_(PA155),ERCC1_(PA155);PGKB_DRUG="fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)","fluorouracil_(PA128406956)""leucovorin_(PA450198)""oxaliplatin_(PA131285527)","cisplatin_(PA449014)""cyclophosphamide_(PA449165)","carboplatin_(PA448803)""cisplatin_(PA449014)""oxaliplatin_(PA131285527)""platinum_(PA150595617)""Platinum_compounds_(PA164713176)","capecitabine_(PA448771)""radiotherapy_(PA166122986)",docetaxel_(PA449383);PGKB_TYPE=Toxicity/ADR,Efficacy,Toxicity/ADR,"Efficacy""Toxicity/ADR",Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,2B,3,3;PGKB_DISEASE=Colonic_Neoplasms_(PA443756),Colorectal_Neoplasms_(PA446108),Ovarian_Neoplasms_(PA445204),"Carcinoma_Non-Small-Cell_Lung_(PA443622)""Colorectal_Neoplasms_(PA446108)""Esophageal_Neoplasms_(PA444101)""Mesothelioma_(PA444937)""Neoplasms_(PA445062)""Ovarian_Neoplasms_(PA445204)""Pancreatic_Neoplasms_(PA445218)",Rectal_Neoplasms_(PA445503),Breast_Neoplasms_(PA443560);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_colon_cancer_may_have_an_increased_risk_of_neutropenia_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia.""AG:Patients_with_the_AG_genotype_and_colon_cancer_may_have_a_decreased_risk_of_neutropenia_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia.""GG:Patients_with_the_GG_genotype_and_colon_cancer_may_have_a_decreased_risk_of_neutropenia_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neutropenia.","AA:Patients_with_the_AA_genotype_and_colorectal_cancer_may_have_decreased_overall_and_progression-free_survival_time_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_and_progression-free_survival_time.""AG:Patients_with_the_AG_genotype_and_colorectal_cancer_may_have_decreased_overall_and_progression-free_survival_time_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_and_progression-free_survival_time.""GG:Patients_with_the_GG_genotype_and_colorectal_cancer_may_have_increased_overall_and_progression-free_survival_time_when_treated_with_FOLFOX_(fluorouracil_leucovorin_oxaliplatin)_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_and_progression-free_survival_time.","AA:Genotype_AA_is_not_associated_with_decreased_risk_of_Drug_Toxicity_when_treated_with_cisplatin_and_cyclophosphamide_as_compared_to_genotypes_AG_and_GG._Please_note_patients_with_the_AG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_nephrotoxicity_as_compared_to_patients_with_the_GG_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_cisplatin_and_cyclophosphamide_treatment.No_result""AG:Patients_with_the_AG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_an_increased_risk_of_nephrotoxicity_as_compared_to_patients_with_the_GG_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_cisplatin_and_cyclophosphamide_treatment.""GG:Patients_with_the_GG_genotype_and_Ovarian_Neoplasms_who_are_treated_with_cisplatin_and_cyclophosphamide_may_have_a_decreased_but_not_absent_risk_of_nephrotoxicity_as_compared_to_patients_with_the_AG_genotype._This_association_has_been_contradicted_in_some_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_cisplatin_and_cyclophosphamide_treatment.","AA:Patients_with_the_AA_genotype_may_have_1)_an_increased_risk_for_nephrotoxicity_2)_decreased_survival_and_3)_a_poorer_response_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AG_or_GG_genotype._However_some_studies_find_no_association_with_drug_toxicity_and_one_study_found_a_better_response_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_chemotherapy.""AG:Patients_with_the_AG_genotype_who_are_treated_with_platinum-based_chemotherapy_may_have_an_increased_risk_for_nephrotoxicity_as_compared_to_patients_with_the_GG_genotype._The_findings_for_response_and_overall_survival_are_inconclusive._Patients_with_the_AG_genotype_may_have_an_increased_response_compared_to_patients_with_the_AA_genotype._However_another_study_showed_an_increased_response_compared_to_patients_with_the_GG_genotype._Additionally_some_studies_find_no_association_with_drug_toxicity_or_survival._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_chemotherapy.""GG:Patients_with_the_GG_genotype_may_have_1)_decreased_but_not_absent_risk_for_toxicity_2)_increased_survival_and_3)_a_better_response_when_treated_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_AA_or_AG_genotype._However_some_studies_find_no_association_with_drug_toxicity_and_one_study_found_a_poorer_response_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_chemotherapy.","AA:Patients_with_the_AA_genotype_and_rectal_cancer_may_have_a_better_response_to_capecitabine-based_chemoradiotherapy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine-based_chemoradiotherapy.""AG:Patients_with_the_AG_genotype_and_rectal_cancer_may_have_a_poorer_response_to_capecitabine-based_chemoradiotherapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine-based_chemoradiotherapy.""GG:Patients_with_the_GG_genotype_and_rectal_cancer_may_have_a_poorer_response_to_capecitabine-based_chemoradiotherapy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_capecitabine-based_chemoradiotherapy.","AA:Patients_with_the_AA_genotype_and_breast_cancer_may_have_an_increased_risk_for_mucositis_when_treated_with_docetaxel_as_compared_to_patients_with_the_AG_or_GG_genotype._This_association_was_only_found_in_individuals_who_are_CYP3A4_and_CYP3A5_non-expressers_(CYP3A4_*1/*1_and_CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_mucositis.""AG:Patients_with_the_AG_genotype_and_breast_cancer_may_have_a_decreased_risk_for_mucositis_when_treated_with_docetaxel_as_compared_to_patients_with_the_AA_genotype._This_association_was_only_found_in_individuals_who_are_CYP3A4_and_CYP3A5_non-expressers_(CYP3A4_*1/*1_and_CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_mucositis.""GG:Patients_with_the_GG_genotype_and_breast_cancer_may_have_a_decreased_risk_for_mucositis_when_treated_with_docetaxel_as_compared_to_patients_with_the_AA_genotype._This_association_was_only_found_in_individuals_who_are_CYP3A4_and_CYP3A5_non-expressers_(CYP3A4_*1/*1_and_CYP3A5_*3/*3)._Other_genetic_and_clinical_factors_may_also_influence_risk_for_mucositis.";PGKB_RACE=Asian,Asian,NR,NR,NR,White
19	46182304	rs10423928	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=GIPR_(PA28682);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_plasma_insulin_levels_when_treated_with_olanzapine_in_people_with_Schizophrenia_as_compared_to_patients_with_the_genotype_AT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""AT:Patients_with_the_AT_genotype_may_have_decreased_plasma_insulin_levels_when_treated_with_olanzapine_in_people_with_Schizophrenia_as_compared_to_patients_with_the_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.""TT:Patients_with_the_TT_genotype_may_have_decreased_plasma_insulin_levels_when_treated_with_olanzapine_in_people_with_Schizophrenia_as_compared_to_patients_with_the_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_olanzapine.";PGKB_RACE=Asian
19	47123783	rs1126510	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=PTGIR_(PA291);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_increased_risk_of_aspirin-intolerant_asthma_when_exposed_to_aspirin_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_aspirin.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_decreased_but_not_absent_risk_of_aspirin-intolerant_asthma_when_exposed_to_aspirin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_aspirin.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_decreased_but_not_absent_risk_of_aspirin-intolerant_asthma_when_exposed_to_aspirin_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_response_to_aspirin.";PGKB_RACE=Asian
19	49092234	rs10426377	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=SULT2B1_(PA36249);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines.""AC:Patients_with_the_AC_genotype_may_have_decreased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines.""CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_cardiotoxicity_when_exposed_to_anthracyclines_and_related_substances_in_children_with_Neoplasms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anthracyclines.";PGKB_RACE=NR
19	49096065	rs2302948	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SULT2B1_(PA36249);PGKB_DRUG="cytarabine_(PA449177)""fludarabine_(PA449655)""gemtuzumab_ozogamicin_(PA164749431)""idarubicin_(PA449961)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Leukemia_Myeloid_Acute_(PA444760);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_an_increased_likelihood_of_fever_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""CT:Patients_with_the_CT_genotype_may_have_a_decreased_likelihood_of_fever_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_genotype_and_an_increased_likelihood_of_fever_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.""TT:Patients_with_the_TT_genotype_may_have_a_decreased_likelihood_of_fever_when_treated_with_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_cytarabine_fludarabine_gemtuzumab_ozogamicin_and_idarubicin.";PGKB_RACE=NR
19	55536595	rs1613662	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GP6_(PA28824);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Coronary_Artery_Disease_(PA443796);PGKB_TEXT="AA_:Patients_with_the_AA_genotype_were_not_studied_but_patients_with_the_AG_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_for_non-response_to_aspirin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""AG:Patients_with_the_AG_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_for_non-response_to_aspirin_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.""GG:Patients_with_the_GG_genotype_who_are_treated_with_aspirin_may_have_a_decreased_but_not_absent_risk_for_non-response_to_aspirin_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_aspirin.";PGKB_RACE=NR
19	55879872	rs1126757	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=IL11_(PA29781);PGKB_DRUG=escitalopram_(PA10074);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depression_(PA447278);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_depression_may_not_respond_as_well_to_treatment_with_escitalopram_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_escitalopram.""CT:Patients_with_the_CT_genotype_and_depression_may_respond_better_to_treatment_with_escitalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_escitalopram.""TT:Patients_with_the_TT_genotype_and_depression_may_respond_better_to_treatment_with_escitalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_escitalopram.";PGKB_RACE=White
20	2500871	rs4815273	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=hydrochlorothiazide_(PA449899);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_decreased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_CT_or_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""CT:Patients_with_the_CT_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_decreased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_TT_genotype_and_increased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.""TT:Patients_with_the_TT_genotype_and_hypertension_who_are_treated_with_hydrochlorothiazide_may_have_increased_reduction_of_systolic_blood_pressure_as_compared_to_patients_with_the_CC_or_the_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hydrochlorothiazide_treatment.";PGKB_RACE=White
20	3193842	rs1127354	C	A,G,T	.	.	PGKB_INDEX=5;PGKB_GENE=ITPA_(PA29973),ITPA_(PA29973),"DDRGK1_(PA164718734)""ITPA_(PA29973)",ITPA_(PA29973),ITPA_(PA29973);PGKB_DRUG=methotrexate_(PA450428),azathioprine_(PA448515),azathioprine_(PA448515),"interferon_alfa-2b_recombinant_(PA164783990)""ribavirin_(PA451241)","peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)";PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy,Efficacy,"Dosage""Toxicity/ADR",Toxicity/ADR;PGKB_EVIDENCE=3,3,3,2B,2B;PGKB_DISEASE="Arthritis_Rheumatoid_(PA443434)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)",Lupus_Erythematosus_Systemic_(PA444822),Inflammatory_Bowel_Diseases_(PA446116),Hepatitis_C_Chronic_(PA446863),Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_1)_an_increased_risk_for_gastrointestinal_toxicities_2)_a_decreased_response_to_folic_acid_and_methotrexate_as_compared_to_patients_with_the_CC_genotype._However_this_association_is_contradicted_in_other_studies_that_show_the_AA_genotype_may_have_an_increased_response_to_methotrexate_as_compared_to_patients_with_the_CC_genotype_or_or_show_no_association_of_the_allele_with_response_to_methotrexate._Children_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphomathe_and_the_AA_genotype_may_have_decreased_event_free_survival_when_treated_with_mercaptopurine_and_methotrexate_as_compared_to_children_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""AC:Patients_with_the_AC_genotype_and_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_1)_an_increased_risk_for_gastrointestinal_toxicities_2)_a_decreased_response_to_folic_acid_and_methotrexate_as_compared_to_patients_with_the_CC_genotype._However_this_association_is_contradicted_in_other_studies_that_show_the_AC_genotype_may_have_an_increased_response_to_methotrexate_as_compared_to_patients_with_the_CC_genotype_or_or_show_no_association_of_the_allele_with_response_to_methotrexate._Children_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphomathe_and_the_AC_genotype_may_have_decreased_event_free_survival_when_treated_with_mercaptopurine_and_methotrexate_as_compared_to_children_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""CC:Patients_with_the_CC_genotype_and_with_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_1)_a_decreased_but_not_absent_risk_for_gastrointestinal_toxicities_2)_an_increased_response_to_folic_acid_and_methotrexate_as_compared_to_patients_with_the_AA_and_AC_genotype._However_this_association_is_contradicted_in_other_studies_that_show_the_CC_genotype_may_have_decreased_response_to_methotrexate_as_compared_to_patients_with_the_AC_and_AA_genotype_or_show_no_association_of_the_allele_with_response_to_methotrexate._Children_with_Precursor_Cell_Lymphoblastic_Leukemia-Lymphomathe_and_the_CC_genotype_may_have_increased_event_free_survival_when_treated_with_mercaptopurine_and_methotrexate_as_compared_to_children_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.","AA:Patients_with_the_AA_genotype_may_experience_a_greater_response_to_azathiopurine_treatment_for_SLE_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_AA_genotype_may_still_be_at_risk_for_non-response_to_azathioprine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""AC:Patients_with_the_AC_genotype_may_experience_a_greater_response_to_azathiopurine_treatment_for_SLE_as_compared_to_patients_with_the_CC_genotype._Patients_with_the_AC_genotype_may_still_be_at_risk_for_non-response_to_azathioprine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""CC:Patients_with_the_CC_genotype_may_experience_less_response_to_azathiopurine_treatment_for_SLE_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_likelihood_of_response.","AA:Patients_with_the_AA_genotype_may_experience_less_response_to_azathiopurine_treatment_for_inflammatory_bowel_disease_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""AC:Patients_with_the_AC_genotype_may_experience_less_response_to_azathiopurine_treatment_for_inflammatory_bowel_disease_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""CC:Patients_with_the_CC_genotype_may_experience_a_greater_response_to_azathiopurine_treatment_for_inflammatory_bowel_disease_as_compared_to_patients_with_the_AA_or_AC_genotype._Patients_with_the_CC_genotype_may_still_be_at_risk_for_non-response_to_azathioprine._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.","AA:Patients_with_the_AA_genotype_and_Hepatitis_C_Chronic_may_have_a_decreased_but_not_absent_risk_of_1)_dose_reduction_of_ribavirin_2)_rapid_decrease_in_hemoglobin_levels_when_treated_with_interferon_alfa-2b_recombinant_and_ribavirin_or_interferon_alfa-2b_recombinant_and_ribavirin_and_telaprevir_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_response_to_ribavirin.""AC:Patients_with_the_AC_genotype_and_Hepatitis_C_Chronic_may_have_a_decreased_but_not_absent_risk_of_1)_dose_reduction_of_ribavirin_2)_rapid_decrease_in_hemoglobin_levels_when_treated_with_interferon_alfa-2b_recombinant_and_ribavirin_or_interferon_alfa-2b_recombinant_and_ribavirin_and_telaprevir_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_response_to_ribavirin.""CC:Patients_with_the_CC_genotype_and_Hepatitis_C_Chronic_may_have_an_increased_risk_of_1)_dose_reduction_of_ribavirin_2)_rapid_decrease_in_hemoglobin_levels_when_treated_with_interferon_alfa-2b_recombinant_and_ribavirin_or_interferon_alfa-2b_recombinant_and_ribavirin_and_telaprevir_as_compared_to_patients_with_the_AC_and_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_response_to_ribavirin.","AA:Patients_with_chronic_hepatitis_C_and_the_AA_genotype_may_have_a_decreased_risk_of_anemia_but_an_increased_risk_of_thrombocytopenia_when_compared_to_patients_with_the_CC_genotype_who_are_taking_peg_interferon_alfa-2b_and_ribavirin._Other_clinical_and_genetic_factors_may_influence_risk_of_anemia_in_patients_with_hepatitis_C_who_are_taking_peg_interferon_alfa-2b_and_ribavirin.""AC:Patients_with_chronic_hepatitis_C_and_the_AC_genotype_may_have_a_decreased_risk_of_anemia_but_an_increased_risk_of_thrombocytopenia_when_compared_to_patients_with_the_CC_genotype_who_are_taking_peg_interferon_alfa-2b_and_ribavirin._Other_clinical_and_genetic_factors_may_influence_risk_of_anemia_in_patients_with_hepatitis_C_who_are_taking_peg_interferon_alfa-2b_and_ribavirin.""CC:Patients_with_chronic_hepatitis_C_and_the_CC_genotype_may_have_an_increased_risk_of_anemia_but_a_decreased_risk_of_thrombocytopenia_as_compared_to_patients_with_the_AA_or_AC_genotype_who_are_taking_peg_interferon_alfa-2b_and_ribavirin._Other_clinical_and_genetic_factors_may_influence_risk_of_anemia_in_patients_with_hepatitis_C_who_are_taking_peg_interferon_alfa-2b_and_ribavirin.";PGKB_RACE=NR,Asian,NR,Asian,NR
20	3193893	rs7270101	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=ITPA_(PA29973);PGKB_DRUG="peginterferon_alfa-2b_(PA164784024)""ribavirin_(PA451241)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Hepatitis_C_Chronic_(PA446863);PGKB_TEXT="AA:Patients_with_chronic_hepatitis_C_and_the_AA_genotype_may_have_an_increased_risk_of_anemia_but_a_decreased_risk_of_thrombocytopenia_when_compared_to_patients_with_the_CC_genotype_who_are_taking_peg_interferon_alfa-2b_and_ribavirin._Other_clinical_and_genetic_factors_may_influence_risk_of_anemia_in_patients_with_hepatitis_C_who_are_taking_peg_interferon_alfa-2b_and_ribavirin.""AC:Patients_with_chronic_hepatitis_C_and_the_AC_genotype_may_have_an_increased_risk_of_anemia_but_a_decreased_risk_of_thrombocytopenia_when_compared_to_patients_with_the_CC_genotype_who_are_taking_peg_interferon_alfa-2b_and_ribavirin._Other_clinical_and_genetic_factors_may_influence_risk_of_anemia_in_patients_with_hepatitis_C_who_are_taking_peg_interferon_alfa-2b_and_ribavirin.""CC:Patients_with_chronic_hepatitis_C_and_the_CC_genotype_may_have_an_increased_risk_of_anemia_but_a_decreased_risk_of_thrombocytopenia_when_compared_to_patients_with_the_AA_or_AC_genotype_who_are_taking_peg_interferon_alfa-2b_and_ribavirin._Other_clinical_and_genetic_factors_may_influence_risk_of_anemia_in_patients_with_hepatitis_C_who_are_taking_peg_interferon_alfa-2b_and_ribavirin.";PGKB_RACE=NR
20	3251924	rs6051702	A	C	.	.	PGKB_INDEX=1;PGKB_GENE="C20orf194_(PA134905007)""ITPA_(PA29973)";PGKB_DRUG="peginterferon_alfa-2a_(PA164749390)""ribavirin_(PA451241)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Hepatitis_C_(PA444445);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Hepatitis_C_who_are_treated_with_peginterferon_alfa-2a_and_ribavirin_may_have_increased_risk_of_anemia_as_compared_to_patients_with_the_CC_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peginterferon_alfa-2a_and_ribavirin.""AC:Patients_with_the_AC_genotype_and_Hepatitis_C_who_are_treated_with_peginterferon_alfa-2a_and_ribavirin_may_have_decreased_but_not_absent_risk_of_anemia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peginterferon_alfa-2a_and_ribavirin.""CC:Patients_with_the_CC_genotype_and_Hepatitis_C_who_are_treated_with_peginterferon_alfa-2a_and_ribavirin_may_have_decreased_but_not_absent_risk_of_anemia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_peginterferon_alfa-2a_and_ribavirin.";PGKB_RACE=NR
20	6783274	rs2650972	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_poorer_response_to_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=Asian
20	23027621	rs1042580	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=THBD_(PA36496);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_risk_of_Hemorrhage_in_patients_with_mechanical_cardiac_valves_treated_with_warfarin_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_warfarin.""CT:Patients_with_the_CT_genotype_may_have_decreased_risk_of_Hemorrhage_in_patients_with_mechanical_cardiac_valves_treated_with_warfarin_as_compared_to_patients_with_genotype_TT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_warfarin.""TT:Patients_with_the_TT_genotype_may_have_increased_risk_of_Hemorrhage_in_patients_with_mechanical_cardiac_valves_treated_with_warfarin_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_or_clinical_factors_may_also_influence_the_risk_of_toxicity_to_warfarin.";PGKB_RACE=Asian
20	23847009	rs6138150	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Rheumatoid_Arthritis_patients_with_the_genotype_CC_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_with_patients_with_genotypes_TT_or_CT_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Rheumatoid_Arthritis_patients_with_the_genotype_CT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_with_a_patient_with_the_genotype_CC_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_the_genotype_TT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_with_a_patient_with_the_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
20	38820805	rs6028945	G	T	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="GG:Rheumatoid_Arthritis_patients_with_the_genotype_GG_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_with_patients_with_the_genotypes_GT_or_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GT:Rheumatoid_Arthritis_patients_with_the_genotype_GT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_with_a_patient_with_the_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_the_genotype_TT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_with_a_patient_with_the_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
20	38868576	rs6071980	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=Tumor_necrosis_factor_alpha_(TNF-alpha)_inhibitors_(PA164713366);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Rheumatoid_Arthritis_patients_with_the_genotype_CC_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_with_a_patient_with_the_genotype_TT_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""CT:Rheumatoid_Arthritis_patients_with_the_genotype_CT_may_be_less_likely_to_respond_to_TNF_inhibitors_compared_with_a_patient_with_the_genotype_TT_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""TT:Rheumatoid_Arthritis_patients_with_the_genotype_TT_may_be_more_likely_to_respond_to_TNF_inhibitors_compared_with_patients_with_genotypes_CC_or_CT_._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=White
20	39704995	rs6072262	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TOP1_(PA353);PGKB_DRUG=irinotecan_(PA450085);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_severity_of_Neutropenia_when_treated_with_irinotecan_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_irinotecan.""GA:Patients_with_the_GA_genotype_may_have_decreased_severity_of_Neutropenia_when_treated_with_irinotecan_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_irinotecan.""GG:Patients_with_the_GG_genotype_may_have_decreased_severity_of_Neutropenia_when_treated_with_irinotecan_in_people_with_Colorectal_Neoplasms_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_toxicity_to_irinotecan.";PGKB_RACE=White
20	39792063	rs2228246	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=PLCG1_(PA33392);PGKB_DRUG="acetaminophen_(PA448015)""aspirin_(PA448497)""diclofenac_(PA449293)""propionic_acid_derivatives_(PA451140)""Pyrazolones_(PA164713217)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_a_decreased_but_not_absent_risk_of_Angioedema_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Angioedema.""AG:Patients_with_the_AG_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_an_increased_risk_of_Angioedema_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Angioedema.""GG:Patients_with_the_GG_genotype_who_are_treated_with_acetaminophen_aspirin_diclofenac_propionic_acid_derivatives_or_Pyrazolones_may_have_an_increased_risk_of_Angioedema_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Angioedema.";PGKB_RACE=NR
20	43030435	rs2071197	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=HNF4A_(PA29349);PGKB_DRUG=carbamazepine_(PA448785);PGKB_TYPE=Metabolism/PK;PGKB_EVIDENCE=3;PGKB_DISEASE=Epilepsy_(PA444065);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_may_have_decreased_concentration-to-dose_ratios_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""AG:Patients_with_the_AG_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_may_have_decreased_concentration-to-dose_ratios_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.""GG:Patients_with_the_GG_genotype_and_Epilepsy_who_are_treated_with_carbamazepine_may_have_increased_concentration-to-dose_ratios_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_carbamazepine.";PGKB_RACE=Asian
20	43044362	rs3212198	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HNF4A_(PA29349);PGKB_DRUG=warfarin_(PA451906);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_rs2501873_TT_genotype_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.""CT:Patients_with_the_CT_genotype_and_rs2501873_TT_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype_or_may_require_decreased_dose_of_warfarin_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.""TT:Patients_with_the_TT_genotype_and_rs2501873_TT_genotype_may_require_increased_dose_of_warfarin_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_warfarin_dose.";PGKB_RACE=Asian
20	45076909	rs446112	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=etoposide_(PA449552);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_resistance_to_etoposide_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_etoposide.""AG:Patients_with_the_AG_genotype_may_have_decreased_resistance_to_etoposide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_etoposide.""GG:Patients_with_the_GG_genotype_may_have_decreased_resistance_to_etoposide_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_etoposide.";PGKB_RACE=NR
20	50036237	rs6021191	A	T	.	.	PGKB_INDEX=1;PGKB_GENE=NFATC2_(PA31583);PGKB_DRUG=asparaginase_(PA448492);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155);PGKB_TEXT="AA:Pediatric_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma_and_the_AA_genotype_may_have_a_decreased_risk_of_hypersensitivity_to_asparaginase_as_compared_to_patients_with_the_AT_and_TT_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_hypersensitivity_to_asparaginase_in_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma.""AT:Pediatric_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma_and_the_AT_genotype_may_have_an_increased_risk_of_hypersensitivity_to_asparaginase_as_compared_to_patients_with_the_AA_genotype_and_a_decreased_risk_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_affect_risk_of_hypersensitivity_to_asparaginase_in_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma.""TT:Pediatric_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma_and_the_TT_genotype_may_have_an_increased_risk_of_hypersensitivity_to_asparaginase_as_compared_to_patients_with_the_AT_and_AA_genotypes._Other_clinical_and_genetic_factors_may_also_affect_risk_of_hypersensitivity_to_asparaginase_in_patients_with_precursor_cell_lymphoblastic_leukemia-lymphoma.";PGKB_RACE=NR
20	55480277	rs6064463	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_response_to_methotrexate_as_compared_to_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""CT:Patients_with_the_CC_genotype_may_have_decreased_response_to_methotrexate_as_compared_to_TT_genotype_or_may_have_increased_response_to_methotrexate_as_compared_to_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.""TT:Patients_with_the_TT_genotype_may_have_increased_response_to_methotrexate_as_compared_to_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate.";PGKB_RACE=Asian
20	55638750	rs6127921	A	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_major_depression_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""AC:Patients_with_the_CC_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype_or_may_have_increased_response_to_citalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.""CC:Patients_with_the_CC_genotype_and_major_depression_may_have_decreased_response_to_citalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_citalopram.";PGKB_RACE=NR
20	57478193	rs62205366	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GNAS_(PA175);PGKB_DRUG=dobutamine_(PA449381);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Healthy_males_with_the_CC_genotype_may_have_an_increased_response_when_given_dobutamine_as_compared_to_healthy_males_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_dobutamine.""CT:Healthy_males_with_the_CT_genotype_may_have_an_increased_response_when_given_dobutamine_as_compared_to_healthy_males_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_dobutamine.""TT:Healthy_males_with_the_TT_genotype_may_have_a_decreased_response_when_given_dobutamine_as_compared_to_healthy_males_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_dobutamine.";PGKB_RACE=Asian
20	57600655	rs10485828	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=TUBB1_(PA38100);PGKB_DRUG="anastrozole_(PA448432)""exemestane_(PA449563)";PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_a_decreased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CG_or_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.""CG:Patients_with_the_CG_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_an_increased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CC_genotype_and_a_decreased_risk_of_bone_fractures_as_compared_to_patients_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.""GG:Patients_with_the_GG_genotype_and_ER_and/or_PR_positive_breast_cancer_may_have_an_increased_risk_of_bone_fractures_when_exposed_to_the_aromatase_inhibitors_anastrazole_and_exemestane_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_risk_of_bone_fractures_in_people_with_ER_and/or_PR_positive_breast_cancer_when_exposed_to_exemestane_or_anastrazole.";PGKB_RACE=NR
20	60791404	rs3787429	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HRH3_(PA29458);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.";PGKB_RACE=Asian
20	60791422	rs3787430	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HRH3_(PA29458);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Schizophrenia_(PA447216);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""CT:Patients_with_the_CT_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_risperidone_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.""TT:Patients_with_the_TT_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_risperidone_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_risperidone.";PGKB_RACE=Asian
20	61977556	rs2236196	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CHRNA4_(PA26490),CHRNA4_(PA26490);PGKB_DRUG=nicotine_(PA450626),nicotine_(PA450626);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_risk_for_nicotine_dependence_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_nicotine_dependence_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_but_not_absent_risk_for_nicotine_dependence_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.","AA:Patients_with_the_AA_genotype_may_have_a_decreased_but_not_absent_risk_for_nicotine_dependence_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.""AG:Patients_with_the_AG_genotype_may_have_an_increased_risk_for_nicotine_dependence_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_for_nicotine_dependence_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.";PGKB_RACE=Black_or_African_American,White
20	61981104	rs1044397	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CHRNA4_(PA26490);PGKB_DRUG=nicotine_(PA450626);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="CC:Male_patients_with_the_CC_genotype_may_have_increased_likelihood_of_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""CT:Male_patients_with_the_CT_genotype_may_have_increased_likelihood_of_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_the_TT_genotype_or_may_have_decreased_likelihood_of_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.""TT:Male_patients_with_the_TT_genotype_may_have_decreased_likelihood_of_Tobacco_Use_Disorder_when_exposed_to_nicotine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine.";PGKB_RACE=Asian
20	61981134	rs1044396	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CHRNA4_(PA26490),CHRNA4_(PA26490);PGKB_DRUG=nicotine_(PA450626),varenicline_(PA164781343);PGKB_TYPE=Other,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),Tobacco_Use_Disorder_(PA445876);PGKB_TEXT="AA:The_AA_genotype_was_found_less_often_in_smokers_as_compared_to_the_GG_genotype._In_the_White_population_the_association_with_nicotine_dependence_based_on_the_Fagerstrom_test_for_nicotine_dependence_was_not_significant_and_only_included_male_subjects_in_the_study_with_Asian_population._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.""AG:The_AG_genotype_was_found_more_often_in_smokers_as_compared_to_the_AA_genotype_(smoker_OR_:_1.13)._In_the_White_population_the_association_with_nicotine_dependence_based_on_the_Fagerstrom_test_for_nicotine_dependence_was_not_significant_and_only_included_male_subjects_in_the_study_with_Asian_population._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.""GG:The_GG_genotype_was_found_more_often_in_smokers_as_compared_to_the_AA_genotype_(smoker_OR_:_1.28)._In_the_White_population_the_association_with_nicotine_dependence_based_on_the_Fagerstrom_test_for_nicotine_dependence_was_not_significant_and_only_included_male_subjects_in_the_study_with_Asian_population._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_nicotine_dependence.","AA:Patients_with_the_AA_genotype_and_Tobacco_Use_Disorder_who_are_treated_with_varenicline_may_have_an_increased_response_to_varenicline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_varenicline.""AG:Patients_with_the_AG_genotype_and_Tobacco_Use_Disorder_who_are_treated_with_varenicline_may_have_an_increased_response_to_varenicline_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_varenicline.""GG:Patients_with_the_GG_genotype_and_Tobacco_Use_Disorder_who_are_treated_with_varenicline_may_have_a_decreased_response_to_varenicline_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_varenicline.";PGKB_RACE=NR,NR
21	20310893	rs79663003	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Individuals_with_the_CC_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_CT_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder.""CT:Individuals_with_the_CT_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_TT_genotype_and_an_improved_response_as_compared_to_individuals_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder.""TT:Individuals_with_the_TT_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_CT_or_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder.";PGKB_RACE=NR
21	20312612	rs78015114	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Individuals_with_the_CC_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_CT_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder._""CT:Individuals_with_the_CT_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_TT_genotype_and_an_improved_response_as_compared_to_individuals_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder._""TT:Individuals_with_the_TT_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_CT_or_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder._";PGKB_RACE=NR
21	20327427	rs75222709	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="GG:Individuals_with_the_GG_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_G_or_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder._""GT:Individuals_with_the_GT_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_TT_genotype_and_an_improved_response_as_compared_to_individuals_with_the_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder._""TT:Individuals_with_the_TT_genotype_and_bipolar_disorder_may_have_a_worse_response_to_lithium_as_compared_to_individuals_with_the_GT_or_GG_genotype._Other_clinical_and_genetic_factors_may_also_influence_response_to_lithium_in_individuals_with_bipolar_disorder._";PGKB_RACE=NR
21	22104695	rs2826494	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GC:Patients_with_the_GC_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""GG:Patients_with_the_GG_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=NR
21	23140523	rs1155463	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=gemcitabine_(PA449748);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_gemcitabine_may_have_a_decreased_but_not_absent_risk_for_neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_neutropenia._""AC:Patients_with_the_AC_genotype_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_neutropenia_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_decreased_but_not_absent_risk_for_neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_neutropenia.""CC:Patients_with_the_CC_genotype_who_are_treated_with_gemcitabine_may_have_an_increased_risk_for_neutropenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_neutropenia._";PGKB_RACE=Asian
21	28216595	rs428785	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADAMTS1_(PA24536);PGKB_DRUG=pravastatin_(PA451089);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Coronary_Disease_(PA443797)""Myocardial_Infarction_(PA445019)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_benefit_less_from_pravastatin_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""CG:Patients_with_the_CG_genotype_may_benefit_less_from_pravastatin_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._""GG:Patients_with_the_GG_genotype_may_benefit_more_from_pravastatin_treatment_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_pravastatin_treatment._";PGKB_RACE=White
21	28217320	rs402007	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=ADAMTS1_(PA24536);PGKB_DRUG=hmg_coa_reductase_inhibitors_(PA133950441);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_hmg_coa_reductase_inhibitors_may_have_more_benefit_from_statin_treatment_in_reducing_the_risk_of_myocardial_infarction_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.""CG:Patients_with_the_CG_genotype_who_are_treated_with_hmg_coa_reductase_inhibitors_may_have_more_benefit_from_statin_treatment_in_reducing_the_risk_of_myocardial_infarction_as_compared_to_patients_with_the_GG_genotype_or_may_have_less_benefit_from_statin_treatment_in_reducing_the_risk_of_myocardial_infarction_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.""GG:Patients_with_the_GG_genotype_who_are_treated_with_hmg_coa_reductase_inhibitors_may_have_less_benefit_from_statin_treatment_in_reducing_the_risk_of_myocardial_infarction_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_hmg_coa_reductase_inhibitors.";PGKB_RACE=White
21	30967508	rs2832407	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=GRIK1_(PA28973);PGKB_DRUG=topiramate_(PA451728);PGKB_TYPE="Efficacy""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Alcohol-Related_Disorders_(PA446879);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_who_are_heavy_drinkers_or_have_an_alcohol-use_disorder_may_have_higher_concentrations_of_topiramate_and_a_poorer_response_to_treatment_with_the_drug_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_concentrations_of_topiramate._""AC:Patients_with_the_AC_genotype_and_who_are_heavy_drinkers_or_have_an_alcohol-use_disorder_may_have_higher_concentrations_of_topiramate_and_a_poorer_response_to_treatment_with_the_drug_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_concentrations_of_topiramate._""CC:Patients_with_the_CC_genotype_and_who_are_heavy_drinkers_or_have_an_alcohol-use_disorder_may_have_lower_concentrations_of_topiramate_and_a_better_response_to_treatment_with_the_drug_as_compared_to_patients_with_the_AA_or_AC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_or_concentrations_of_topiramate._";PGKB_RACE=NR
21	37444973	rs20572	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=CBR1_(PA26121),CBR1_(PA26121);PGKB_DRUG=doxorubicin_(PA449412),"doxorubicin_(PA449412)""doxorubicinol_(PA165291922)";PGKB_TYPE=Dosage,Dosage;PGKB_EVIDENCE=3,4;PGKB_DISEASE=Breast_Neoplasms_(PA443560),Breast_Neoplasms_(PA443560);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_1)_increased_clearance_of_doxorubicin_and_decreased_exposure_2)_decreased_plasma_concentration_of_doxorubicinol_in_people_with_breast_cancer_as_compared_to_patients_with_the_CT_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_pharmacokinetics_of_doxorubicin.""CT:Patients_with_the_CT_genotype_may_have_1)_decreased_clearance_of_doxorubicin_and_increased_exposure_2)_increased_plasma_concentration_of_doxorubicinol_in_people_with_breast_cancer_as_compared_to_patients_with_the_CC_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_pharmacokinetics_of_doxorubicin.""TT:Patients_with_the_TT_genotype_may_have_1)_decreased_clearance_of_doxorubicin_and_increased_exposure_2)_increased_plasma_concentration_of_doxorubicinol_in_people_with_breast_cancer_as_compared_to_patients_with_the_CC_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_pharmacokinetics_of_doxorubicin.","CC:Patients_with_the_CC_genotype_may_have_1)_increased_clearance_of_doxorubicin_2)_decreased_exposure_to_doxorubicin_and_its_metabolite_doxorubicinol_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_doxorubicin_clearance_and_exposure.""CT:Patients_with_the_CT_genotype_may_have_1)_decreased_clearance_of_doxorubicin_2)_increased_exposure_to_doxorubicin_and_its_metabolite_doxorubicinol_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_doxorubicin_clearance_and_exposure.""TT:Patients_with_the_TT_genotype_1)_may_have_similar_levels_of_clearance_of_doxorubicin_2)_may_have_similar_exposure_to_doxorubicin_and_its_metabolite_doxorubicinol_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_doxorubicin_clearance_and_exposure.";PGKB_RACE=Asian,Asian
21	37445313	rs9024	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=CBR1_(PA26121),CBR1_(PA26121),CBR1_(PA26121);PGKB_DRUG="doxorubicin_(PA449412)""doxorubicinol_(PA165291922)",doxorubicin_(PA449412),anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Dosage,Dosage,Toxicity/ADR;PGKB_EVIDENCE=3,4,3;PGKB_DISEASE=Breast_Neoplasms_(PA443560),Breast_Neoplasms_(PA443560),"Cardiomyopathies_(PA445018)""Neoplasms_(PA445062)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_1)_decreased_clearance_of_doxorubicin_and_increased_exposure_2)_increased_plasma_concentration_of_doxorubicinol_in_people_with_breast_cancer_as_compared_to_patients_with_the_GG_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_pharmacokinetics_of_doxorubicin.""AG:Patients_with_the_AG_genotype_may_have_1)_decreased_clearance_of_doxorubicin_and_increased_exposure_2)_increased_plasma_concentration_of_doxorubicinol_in_people_with_breast_cancer_as_compared_to_patients_with_the_GG_genotype._Other_genetic_or_clinical_factors_may_also_influence_the_pharmacokinetics_of_doxorubicin.""GG:Patients_with_the_GG_genotype_may_have_1)_increased_clearance_of_doxorubicin_and_decreased_exposure_2)_decreased_plasma_concentration_of_doxorubicinol_in_people_with_breast_cancer_as_compared_to_patients_with_the_AG_genotype._Genotype_GG_is_also_associated_with_increased_catalytic_activity_of_CBR1._Other_genetic_or_clinical_factors_may_also_influence_the_pharmacokinetics_of_doxorubicin.","AA:In_patients_with_the_AA_genotype_the_levels_of_clearance_and_exposure_to_doxorubicin_may_be_similar_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_and_exposure_to_doxorubicin.""AG:Patients_with_the_AG_genotype_1)_may_have_decreased_clearance_of_doxorubicin_2)_increased_exposure_to_doxorubicin_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_and_exposure_to_doxorubicin.""GG:Patients_with_the_GG_genotype_1)_may_have_increased_clearance_of_doxorubicin_2)_decreased_exposure_to_doxorubicin_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_clearance_and_exposure_to_doxorubicin.","AA:Patients_with_the_AA_genotype_and_Cancer_who_are_treated_with_anthracyclines_and_related_substances_may_have_a_decreased_but_not_absent_risk_of_developing_Cardiomyopathies_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_Cardiomyopathies.""AG:Patients_with_the_AG_genotype_and_Cancer_who_are_treated_with_anthracyclines_and_related_substances_may_have_a_decreased_but_not_absent_risk_of_developing_Cardiomyopathies_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_Cardiomyopathies.""GG:Patients_with_the_GG_genotype_and_Cancer_who_are_treated_with_anthracyclines_and_related_substances_may_have_an_increased_risk_of_developing_Cardiomyopathies_as_compared_to_patients_with_the_AA_and_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_Cardiomyopathies.";PGKB_RACE=Asian,NR,NR
21	37507501	rs8133052	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CBR3_(PA26122);PGKB_DRUG=doxorubicin_(PA449412);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE="Breast_Neoplasms_(PA443560)""Neutropenia_(PA445113)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_breast_cancer_who_are_treated_with_doxorubicin:_1)_may_have_decreased_metabolism_of_doxorubicin_2)_may_have_greater_tumor_reduction_3)_may_have_increased_severity_of_neutropenia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxorubicin_treatment_and_risk_of_toxicity.""AG:Patients_with_the_AG_genotype_and_breast_cancer_who_are_treated_with_doxorubicin:_1)_may_have_decreased_metabolism_of_doxorubicin_2)_may_have_greater_tumor_reduction_3)_may_have_increased_severity_of_neutropenia_as_compared_to_patients_with_the_GG_genotype_or_1)_may_have_increased_metabolism_of_doxorubicin_2)_may_have_less_tumor_reduction_3)_may_have_decreased_severity_of_neutropenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxorubicin_treatment_and_risk_of_toxicity.""GG:Patients_with_the_GG_genotype_and_breast_cancer_who_are_treated_with_doxorubicin:_1)_may_have_increased_metabolism_of_doxorubicin_2)_may_have_less_tumor_reduction_3)_may_have_decreased_severity_of_neutropenia_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_doxorubicin_treatment_and_risk_of_toxicity.";PGKB_RACE=Asian
21	37518706	rs1056892	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=CBR3_(PA26122);PGKB_DRUG=anthracyclines_and_related_substances_(PA130620651);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Heart_Failure_(PA444370)""Neoplasms_(PA445062)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_cardiac_damage_after_anthracycline_exposure_as_compared_to_patients_with_the_GG_genotype._Patients_with_the_AA_genotype_may_still_be_at_risk_for_adverse_events_when_exposed_to_anthracyclines_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_cardiac_damage_after_anthracycline_exposure_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_cardiac_damage_after_anthracycline_exposure_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events.";PGKB_RACE=NR
21	39018162	rs2835859	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNJ6_(PA30049);PGKB_DRUG=fentanyl_(PA449599);PGKB_TYPE=Dosage;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_Postoperative_(PA445210);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_post-operative_pain_may_require_a_decreased_dose_of_fentanyl_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_dose_of_fentanyl_in_people_with_post-operative_pain.""CT:Patients_with_the_CT_genotype_and_post-operative_pain_may_require_a_decreased_dose_of_fentanyl_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_dose_of_fentanyl_in_people_with_post-operative_pain.""TT:Patients_with_the_TT_genotype_and_post-operative_pain_may_require_an_increased_dose_of_fentanyl_as_compared_to_patients_with_the_CT_and_CC_genotypes._Other_genetic_and_clinical_factors_may_also_influence_dose_of_fentanyl_in_people_with_post-operative_pain.";PGKB_RACE=Asian
21	39086965	rs2070995	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=KCNJ6_(PA30049);PGKB_DRUG=Analgesics_(PA164712362);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_(PA445208);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_post-operative_pain_may_be_less_likely_to_require_rescue_analgesic_administration_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_requiring_a_rescue_analgesic.""CT:Patients_with_the_TC_genotype_and_post-operative_pain_may_be_less_likely_to_require_rescue_analgesic_administration_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_requiring_a_rescue_analgesic.""TT:Patients_with_the_TT_genotype_and_post-operative_pain_may_be_more_likely_to_require_rescue_analgesic_administration_as_compared_to_patients_with_the_TC_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_for_requiring_a_rescue_analgesic.";PGKB_RACE=Asian
21	41415044	rs9981861	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=DSCAM_(PA27491);PGKB_DRUG="carboplatin_(PA448803)""paclitaxel_(PA450761)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Neoplasms_(PA445062)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_survival_when_treated_with_carboplatin_and_paclitaxel_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_survival.""CT:Patients_with_the_CT_genotype_may_have_increased_survival_when_treated_with_carboplatin_and_paclitaxel_as_compared_to_patients_with_the_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_survival.""TT:Patients_with_the_TT_genotype_may_have_decreased_survival_when_treated_with_carboplatin_and_paclitaxel_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_survival.";PGKB_RACE=Asian
21	43653053	rs225440	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=ABCG1_(PA24408);PGKB_DRUG="fluorouracil_(PA128406956)""irinotecan_(PA450085)""leucovorin_(PA450198)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Colorectal_Neoplasms_(PA446108);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_a_decreased_but_not_absent_risk_for_Neutropenia_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Neutropenia.""CT:Patients_with_the_CT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_Neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Neutropenia.""TT:Patients_with_the_TT_genotype_and_Colorectal_Neoplasms_who_are_treated_with_fluorouracil_irinotecan_and_leucovorin_may_have_an_increased_risk_for_Neutropenia_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_Neutropenia.";PGKB_RACE=White
21	46907287	rs9977268	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=SLC19A1_(PA327);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=4;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_likelihood_of_treatment_being_effective_as_compared_to_patients_with_the_TT_genotype._This_association_was_not_statistically_significant_after_Bonferroni_correction._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_likelihood_of_treatment_being_ineffective_as_compared_to_patients_with_the_CC_genotype_or_may_have_an_increased_likelihood_of_treatment_being_effective_as_compared_to_patients_with_the_TT_genotype._This_association_was_not_statistically_significant_after_Bonferroni_correction._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_increased_likelihood_of_treatment_being_ineffective_as_compared_to_patients_with_the_CC_genotype._This_association_was_not_statistically_significant_after_Bonferroni_correction._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_treatment.";PGKB_RACE=White
21	46934826	rs1051298	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=SLC19A1_(PA327);PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""AG:Patients_with_the_AG_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_a_longer_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=NR
21	46936583	rs3788189	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC19A1_(PA327);PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""GT:Patients_with_the_GT_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""TT:Patients_with_the_TT_genotype_and_lung_cancer_may_have_a_longer_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_GG_or_GT_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=NR
21	46951556	rs12659	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=SLC19A1_(PA327);PGKB_DRUG="carboplatin_(PA448803)""cisplatin_(PA449014)""fluorouracil_(PA128406956)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Uterine_Cervical_Neoplasms_(PA443685);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_cervical_cancer_who_are_treated_with_carboplatin_cisplatin_and_fluorouracil_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_neoadjuvant_treatment._""AG:Patients_with_the_AG_genotype_and_cervical_cancer_who_are_treated_with_carboplatin_cisplatin_and_fluorouracil_may_have_a_reduced_response_to_treatment_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_neoadjuvant_treatment._""GG:Patients_with_the_GG_genotype_and_cervical_cancer_who_are_treated_with_carboplatin_cisplatin_and_fluorouracil_may_have_a_better_response_to_treatment_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_platinum-based_neoadjuvant_treatment._";PGKB_RACE=Asian
21	46952750	rs914232	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=SLC19A1_(PA327);PGKB_DRUG=pemetrexed_(PA10810);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE="Carcinoma_Non-Small-Cell_Lung_(PA443622)""Mesothelioma_(PA444937)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_lung_cancer_may_have_a_longer_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""CT:Patients_with_the_CT_genotype_and_lung_cancer_may_have_a_longer_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.""TT:Patients_with_the_TT_genotype_and_lung_cancer_may_have_a_shorter_overall_survival_time_when_treated_with_pemetrexed_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_overall_survival_time.";PGKB_RACE=NR
21	46957794	rs1051266	T	C	.	.	PGKB_INDEX=6;PGKB_GENE=SLC19A1_(PA327),SLC19A1_(PA327),SLC19A1_(PA327),SLC19A1_(PA327),SLC19A1_(PA327),SLC19A1_(PA327);PGKB_DRUG="leucovorin_(PA450198)""mercaptopurine_(PA450379)""methotrexate_(PA450428)",irinotecan_(PA450085),"methotrexate_(PA450428)""prednisone_(PA451100)",methotrexate_(PA450428),methotrexate_(PA450428),methotrexate_(PA450428);PGKB_TYPE="Efficacy""Toxicity/ADR",Efficacy,Efficacy,Toxicity/ADR,Efficacy,Efficacy;PGKB_EVIDENCE=3,3,3,3,3,3;PGKB_DISEASE=Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155),Colorectal_Neoplasms_(PA446108),Arthritis_Rheumatoid_(PA443434),"Drug_Toxicity_(PA443937)""Toxic_liver_disease_(PA164925725)",Arthritis_Rheumatoid_(PA443434),"Osteosarcoma_(PA445601)""Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_(PA446155)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_mercaptopurine_and_methotrexate_or_leucovorin_mercaptopurine_and_methotrexate_may_have_1)_increased_likelihood_of_Toxic_liver_disease_2)_decreased_but_not_absent_risk_of_Drug_Toxicity_3)_decreased_likelihood_of_treatment_interruptions_as_compared_to_patients_with_the_CT_and_TT_genotype._Further_patients_with_the_CC_genotype_may_have_4)_decreased_likelihood_of_Myelosuppression_and_5)_decreased_likelihood_of_staying_in_remission_when_treated_with_leucovorin_mercaptopurine_and_methotrexate_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_(association_with_drug_toxicity)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_leucovorin_mercaptopurine_and_methotrexate.""CT:Patients_with_the_CT_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_mercaptopurine_and_methotrexate_or_leucovorin_mercaptopurine_and_methotrexate_may_have_1)_decreased_but_not_absent_risk_of_Toxic_liver_disease_2)_increased_risk_of_Drug_Toxicity_3)_increased_likelihood_of_treatment_interruptions_as_compared_to_patients_with_the_CC_genotype._Further_patients_with_the_CT_genotype_may_have_4)_decreased_likelihood_of_Myelosuppression_and_5)_decreased_likelihood_of_staying_in_remission_when_treated_with_leucovorin_mercaptopurine_and_methotrexate_as_compared_to_patients_with_the_TT_genotype._However_contradictory_findings_(association_with_drug_toxicity)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_leucovorin_mercaptopurine_and_methotrexate.""TT:Patients_with_the_TT_genotype_and_Precursor_Cell_Lymphoblastic_Leukemia-Lymphoma_who_are_treated_with_mercaptopurine_and_methotrexate_or_leucovorin_mercaptopurine_and_methotrexate_may_have_1)_decreased_but_not_absent_risk_of_Toxic_liver_disease_2)_increased_risk_of_Drug_Toxicity_3)_increased_likelihood_of_treatment_interruptions_as_compared_to_patients_with_the_CC_genotype._Further_patients_with_the_TT_genotype_may_have_4)_increased_likelihood_of_Myelosuppression_and_5)_increased_likelihood_of_staying_in_remission_when_treated_with_leucovorin_mercaptopurine_and_methotrexate_as_compared_to_patients_with_the_CT_and_CC_genotype._However_contradictory_findings_(association_with_drug_toxicity)_have_been_reported._Other_genetic_and_clinical_factors_may_influence_a_patient's_response_to_leucovorin_mercaptopurine_and_methotrexate.","CC:Patients_with_the_CC_genotype_and_metastatic_colorectal_cancer_may_have_increased_rapid_response_to_treatment_containing_irinotecan_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irinotecan_based_treatment.""CT:Patients_with_the_CT_genotype_and_metastatic_colorectal_cancer_may_have_decreased_rapid_response_to_treatment_containing_irinotecan_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irinotecan_based_treatment.""TT:Patients_with_the_TT_genotype_and_metastatic_colorectal_cancer_may_have_decreased_rapid_response_to_treatment_containing_irinotecan_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_irinotecan_based_treatment.","CC:Patients_with_the_CC_genotype_may_have_decreased_likelihood_of_remission_when_treated_with_methotrexate_and_prednisone_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_prednisone.""CT:Patients_with_the_CT_genotype_may_have_increased_likelihood_of_remission_when_treated_with_methotrexate_and_prednisone_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_prednisone.""TT:Patients_with_the_TT_genotype_may_have_increased_likelihood_of_remission_when_treated_with_methotrexate_and_prednisone_in_people_with_Arthritis_Rheumatoid_as_compared_to_genotype_CC._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_and_prednisone.","CC:Patients_with_the_CC_genotype_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_hepatotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatoxicity.""CT:Patients_with_the_TC_genotype_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_of_hepatotoxicity_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatoxicity.""TT:Patients_with_the_TT_genotype_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_hepatotoxicity_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hepatoxicity.","CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_less_symptom_improvement_as_compared_to_patients_with_the_TT_genotype._This_association_has_not_been_found_in_all_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_therapy.""CT:Patients_with_the_TC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_less_symptom_improvement_as_compared_to_patients_with_the_TT_genotype_or_may_have_more_symptom_improvement_as_compared_to_patients_with_the_CC_genotype._This_association_has_not_been_found_in_all_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_therapy.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_more_symptom_improvement_as_compared_to_patients_with_the_CC_genotype._This_association_has_not_been_found_in_all_studies._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_methotrexate_therapy.","CC:Patients_with_the_CC_genotype_and_osteosarcoma_or_acute_lymphoblastic_leukemia_who_are_receiving_methotrexate_may_have_increased_survival_times_and_reduced_risk_of_metastasis_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_and_risk_of_metastasis_in_patients_receiving_methotrexate.""CT:Patients_with_the_CT_genotype_and_osteosarcoma_or_acute_lymphoblastic_leukemia_who_are_receiving_methotrexate_may_have_decreased_survival_times_as_compared_to_patients_with_the_CC_genotype_and_decreased_risk_of_metastasis_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_and_risk_of_metastasis_in_patients_receiving_methotrexate.""TT:Patients_with_the_TT_genotype_and_osteosarcoma_or_acute_lymphoblastic_leukemia_who_are_receiving_methotrexate_may_have_decreased_survival_times_and_increased_risk_of_metastasis_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_survival_time_and_risk_of_metastasis_in_patients_receiving_methotrexate.";PGKB_RACE=NR,Asian,White,NR,NR,White
22	19929027	rs13306278	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=TXNRD2_(PA38302);PGKB_DRUG=Selective_serotonin_reuptake_inhibitors_(PA164713257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=2B;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_likelihood_of_remission_when_treated_with_Selective_serotonin_reuptake_inhibitors_in_people_with_Depressive_Disorder_as_compared_to_patients_with_the_TT_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""CT:Patients_with_the_CT_genotype_may_have_decreased_likelihood_of_remission_when_treated_with_Selective_serotonin_reuptake_inhibitors_in_people_with_Depressive_Disorder_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.""TT:Patients_with_the_TT_genotype_may_have_decreased_likelihood_of_remission_when_treated_with_Selective_serotonin_reuptake_inhibitors_in_people_with_Depressive_Disorder_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_Selective_serotonin_reuptake_inhibitors.";PGKB_RACE=White
22	19949952	rs6269	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=COMT_(PA117);PGKB_DRUG=opioids_(PA452618);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_(PA445208);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_be_less_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""AG:Patients_with_the_AG_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""GG:Patients_with_the_GG_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._";PGKB_RACE=NR
22	19950235	rs4633	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=COMT_(PA117);PGKB_DRUG=opioids_(PA452618);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_(PA445208);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""CT:Patients_with_the_CT_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""TT:Patients_with_the_TT_genotype_may_be_less_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._";PGKB_RACE=NR
22	19951207	rs4818	C	G,T	.	.	PGKB_INDEX=1;PGKB_GENE=COMT_(PA117);PGKB_DRUG=opioids_(PA452618);PGKB_TYPE=Other;PGKB_EVIDENCE=3;PGKB_DISEASE=Pain_(PA445208);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_be_less_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_CG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""CG:Patients_with_the_CG_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""GG:Patients_with_the_GG_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._";PGKB_RACE=NR
22	19951271	rs4680	G	A	.	.	PGKB_INDEX=14;PGKB_GENE=COMT_(PA117),COMT_(PA117),NR,COMT_(PA117),COMT_(PA117),COMT_(PA117),COMT_(PA117),COMT_(PA117),COMT_(PA117),COMT_(PA117),COMT_(PA117),COMT_(PA117),NR,COMT_(PA117);PGKB_DRUG=venlafaxine_(PA451866),fluvoxamine_(PA449690),morphine_(PA450550),antipsychotics_(PA452233),nicotine_(PA450626),antipsychotics_(PA452233),opioids_(PA452618),clozapine_(PA449061),entacapone_(PA164748726),antipsychotics_(PA452233),antipsychotics_(PA452233),paroxetine_(PA450801),"Analgesics_(PA164712362)""Antiinflammatory_agents_non-steroids_(PA164712462)""Ergot_alkaloids_(PA164712741)""opioids_(PA452618)""sumatriptan_(PA451566)",haloperidol_(PA449841);PGKB_TYPE=Efficacy,Efficacy,Dosage,Toxicity/ADR,Efficacy,Other,Other,Efficacy,Efficacy,Toxicity/ADR,Toxicity/ADR,Efficacy,Other,Toxicity/ADR;PGKB_EVIDENCE=3,3,3,3,2A,4,3,3,3,3,3,3,3,3;PGKB_DISEASE="Anxiety_Disorders_(PA447196)""Depressive_Disorder_(PA447207)",Depressive_Disorder_Major_(PA447321),Pain_(PA445208),tardive_dyskinesia_(PA447268),Tobacco_Use_Disorder_(PA445876),Schizophrenia_(PA447216),Pain_(PA445208),Schizophrenia_(PA447216),Parkinson_Disease_(PA445254),NR,NR,Depressive_Disorder_Major_(PA447321),NR,Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_response_to_venlafaxine_in_people_with_Anxiety_Disorder_but_a_decreased_response_to_venlafaxine_in_people_with_Depressive_Disorders_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment.""AG:Patients_with_the_AG_genotype_may_have_increased_response_to_venlafaxine_in_people_with_Anxiety_Disorder_but_a_decreased_response_to_venlafaxine_in_people_with_Depressive_Disorders_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment.""GG:Patients_with_the_GG_genotype_may_have_increased_response_to_venlafaxine_in_people_with_Depressive_Disorder_but_a_decreased_response_to_venlafaxine_in_people_with_Anxiety_Disorders_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment.","AA:Patients_with_the_AA_genotype_and_major_Depressive_Disorder_may_have_an_increased_response_to_fluvoxamine_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.""AG:Patients_with_the_AG_genotype_and_major_Depressive_Disorder_may_have_an_increased_response_to_fluvoxamine_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.""GG:Patients_with_the_GG_genotype_and_major_Depressive_Disorder_may_have_a_decreased_response_to_fluvoxamine_treatment_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fluvoxamine.","AA:Patients_with_the_AA_genotype_who_are_treated_with_morphine_may_require_a_lower_dose_as_compared_to_patients_with_the_AG_or_GG_genotype._Contradictory_studies_exist_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_morphine._""AG:Patients_with_the_AG_genotype_who_are_treated_with_morphine_may_require_a_higher_dose_as_compared_to_patients_with_the_AA_genotype._Contradictory_studies_exist_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_morphine._""GG:Patients_with_the_GG_genotype_who_are_treated_with_morphine_may_require_a_higher_dose_as_compared_to_patients_with_the_AA_genotype._Contradictory_studies_exist_for_this_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_when_treated_with_morphine.","AA:Patients_with_the_AA_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_may_have_a_decreased_risk_of_tardive_dyskinesia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_tardive_dyskinesia.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_may_have_a_decreased_risk_of_tardive_dyskinesia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_tardive_dyskinesia.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_may_have_an_increased_risk_of_tardive_dyskinesia_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_tardive_dyskinesia.","AA:Patients_with_the_AA_genotype_who_are_treated_with_nicotine_replacement_therapy_may_have_an_increased_likelihood_of_smoking_cessation_and_decreased_risk_of_relapse_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine_replacement_therapy.""AG:Patients_with_the_AG_genotype_who_are_treated_with_nicotine_replacement_therapy_may_have_a_decreased_likelihood_of_smoking_cessation_and_increased_risk_of_relapse_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine_replacement_therapy.""GG:Patients_with_the_GG_genotype_who_are_treated_with_nicotine_replacement_therapy_may_have_a_decreased_likelihood_of_smoking_cessation_and_increased_risk_of_relapse_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_nicotine_replacement_therapy.","AA:Patients_with_the_AA_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_may_have_increased_methylation_at_sites_within_the_COMT_gene_promoter_as_compared_to_patients_with_the_GG_genotype._Metabolic_syndrome_was_also_associated_with_increased_methylation._No_significant_difference_was_seen_in_levels_of_methylation_of_the_COMT_gene_promoter_in_patients_with_or_without_metabolic_syndrome_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methylation_of_the_COMT_gene_promoter_when_treated_with_antipsychotics.""AG:Patients_with_the_AG_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_may_have_increased_methylation_at_sites_within_the_COMT_gene_promoter_as_compared_to_patients_with_the_GG_genotype_or_decreased_methylation_at_sites_within_the_COMT_gene_promoter_as_compared_to_patients_with_the_AA_genotype._Metabolic_syndrome_was_associated_with_increased_methylation._No_significant_difference_was_seen_in_levels_of_methylation_of_the_COMT_gene_promoter_in_patients_with_or_without_metabolic_syndrome_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methylation_of_the_COMT_gene_promoter_when_treated_with_antipsychotics.""GG:Patients_with_the_GG_genotype_and_Schizophrenia_who_are_treated_with_antipsychotics_may_have_decreased_methylation_at_sites_within_the_COMT_gene_promoter_as_compared_to_patients_with_the_AA_genotype._Metabolic_syndrome_was_associated_with_increased_methylation._Patients_with_the_GG_genotype_who_are_treated_with_antipsychotics_and_have_metabolic_syndrome_may_have_similar_levels_of_methylation_at_sites_within_the_COMT_gene_promoter_to_those_seen_in_patients_with_the_AA_genotype_without_metabolic_syndrome._Other_genetic_and_clinical_factors_may_also_influence_methylation_of_the_COMT_gene_promoter._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_level_of_methylation_of_the_COMT_gene_promoter_when_treated_with_antipsychotics.","AA:Patients_with_the_AA_genotype_may_be_less_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""AG:Patients_with_the_AG_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._""GG:Patients_with_the_GG_genotype_may_be_more_likely_to_require_postoperative_intervention_with_opioids_after_adenotonsillectomy_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_requirement_for_pain_management._","AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_a_poorer_response_when_treated_with_clozapine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_better_response_when_treated_with_clozapine_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_clozapine.","AA:Patients_with_the_AA_genotype_and_Parkinson_Disease_may_have_decreased_response_to_entacapone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_entacapone.""AG:Patients_with_the_AG_genotype_and_Parkinson_Disease_may_have_increased_response_to_entacapone_as_compared_to_patients_with_the_AA_genotype_or_may_have_decreased_response_to_entacapone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_entacapone.""GG:Patients_with_the_GG_genotype_and_Parkinson_Disease_may_have_increased_response_to_entacapone_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_entacapone.","AA:Patients_with_the_AA_genotype_may_have_increased_blood_pressure_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_in_patients_receiving_antipsychotics.""AG:Patients_with_the_AG_genotype_may_have_increased_blood_pressure_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_in_patients_receiving_antipsychotics.""GG:Patients_with_the_GG_genotype_may_have_decreased_blood_pressure_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_blood_pressure_in_patients_receiving_antipsychotics.","AA:Patients_with_the_AA_genotype_may_have_increased_fasting_glucose_levels_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_fasting_glucose_in_patients_taking_antipsychotics.""AG:Patients_with_the_AG_genotype_may_have_increased_fasting_glucose_levels_when_treated_with_antipsychotics_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_fasting_glucose_in_patients_taking_antipsychotics.""GG:Patients_with_the_GG_genotype_may_have_reduced_fasting_glucose_levels_when_treated_with_antipsychotics_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_fasting_glucose_in_patients_taking_antipsychotics.","AA:Patients_with_the_AA_genotype_and_major_depression_may_have_an_increased_response_to_paroxetine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""AG:Patients_with_the_AG_genotype_and_major_depression_may_have_an_increased_response_to_paroxetine_as_compared_to_patients_with_the_GG_genotype_or_may_have_a_decreased_response_to_paroxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.""GG:Patients_with_the_GG_genotype_and_major_depression_may_have_a_decreased_response_to_paroxetine_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_paroxetine.","AA:Patients_with_the_AA_genotype_with_substance_withdrawal_syndrome_may_have_a_decreased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""AG:Patients_with_the_AG_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.""GG:Patients_with_the_GG_genotype_with_substance_withdrawal_syndrome_may_have_an_increased_likelihood_of_headache_when_discontinuing_the_use_of_analgesics_(such_as_opioids_NSAIDs_triptans_ergot)_as_compared_to_patients_with_the_AA_genotype._Other_clinical_and_genetic_factors_may_also_influence_likelihood_of_headache_in_patients_with_withdrawal_syndrome_who_discontinue_the_use_of_analgesics.","AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_a_decreased_risk_for_developing_extrapyramidal_symptoms_when_treated_with_haloperidol_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_extrapyramidal_symptoms_when_taking_haloperidol.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_an_increased_risk_for_developing_extrapyramidal_symptoms_when_treated_with_haloperidol_as_compared_to_patients_with_the_AA_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_extrapyramidal_symptoms_when_taking_haloperidol.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_a_decreased_risk_for_developing_extrapyramidal_symptoms_when_treated_with_haloperidol_as_compared_to_patients_with_the_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_for_extrapyramidal_symptoms_when_taking_haloperidol.";PGKB_RACE=White,NR,White,NR,White,NR,NR,NR,NR,NR,NR,White,NR,White
22	19952132	rs4646316	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=COMT_(PA117);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Neoplasms_(PA445062)""Ototoxicity_(PA162263534)";PGKB_TEXT="CC:Children_with_the_CC_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_TT_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""CT:Children_with_the_CT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_TT_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""TT:Children_with_the_TT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_a_lower_but_not_absent_risk_for_hearing_loss_as_compared_to_children_with_the_TC_or_CC_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.";PGKB_RACE=NR
22	19955692	rs9332377	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=COMT_(PA117);PGKB_DRUG=cisplatin_(PA449014);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Drug_Toxicity_(PA443937)""Neoplasms_(PA445062)""Ototoxicity_(PA162263534)";PGKB_TEXT="CC:Children_with_the_CC_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_lower_but_not_absent_risk_for_hearing_loss_as_compared_to_children_with_the_TT_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""CT:Children_with_the_CT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_CC_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.""TT:Children_with_the_TT_genotype_and_cancer_who_are_treated_with_cisplatin_may_have_an_increased_risk_for_hearing_loss_as_compared_to_children_with_the_CC_genotype._A_separate_independent_study_found_no_association_between_this_SNP_and_risk_of_cisplatin-induced_ototoxicity._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_hearing_loss_with_cisplatin_treatment.";PGKB_RACE=NR
22	19956781	rs165599	G	A	.	.	PGKB_INDEX=2;PGKB_GENE="ARVCF_(PA25018)""COMT_(PA117)",COMT_(PA117);PGKB_DRUG=bupropion_(PA448687),risperidone_(PA451257);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Tobacco_Use_Disorder_(PA445876),Schizophrenia_(PA447216);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_an_increased_chance_of_response_to_bupropion_treatment_for_smoking_cessation_as_compared_to_patients_with_the_GG_genotype._Patients_with_the_AA_genotype_may_still_be_at_risk_for_non-response_to_bupropion_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""AG:Patients_with_the_AG_genotype_may_have_an_increased_chance_of_response_to_bupropion_treatment_for_smoking_cessation_as_compared_to_patients_with_the_GG_genotype._Patients_with_the_AG_genotype_may_still_be_at_risk_for_non-response_to_bupropion_treatment_based_on_their_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.""GG:Patients_with_the_GG_genotype_may_have_a_decreased_chance_of_response_to_bupropion_treatment_for_smoking_cessation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_chance_of_response.","AA:Patients_with_the_AA_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""AG:Patients_with_the_AG_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_less_improvement_in_symptoms_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_risperidone_may_have_more_improvement_in_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_risperidone.";PGKB_RACE=White,NR
22	24376322	rs4630	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GSTT1_(PA183);PGKB_DRUG=thalidomide_(PA451644);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Multiple_Myeloma_(PA444985);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_increased_likelihood_of_Neurotoxicity_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AG_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.""AG:Patients_with_the_AG_genotype_may_have_decreased_likelihood_of_Neurotoxicity_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.""GG:Patients_with_the_GG_genotype_may_have_decreased_likelihood_of_Neurotoxicity_when_treated_with_thalidomide_in_people_with_Multiple_Myeloma_as_compared_to_patients_with_the_AA_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_thalidomide.";PGKB_RACE=NR
22	24815406	rs5760410	G	A	.	.	PGKB_INDEX=1;PGKB_GENE="ADORA2A_(PA24584)""SPECC1L_(PA164718673)";PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_adverse_events_as_compared_to_patients_with_the_AG_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.""AG:Patients_with_the_AG_genotype_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_gastrointestinal_adverse_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.""GG:Patients_with_the_GG_genotype_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_adverse_events_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_with_methotrexate_treatment.";PGKB_RACE=NR
22	24825511	rs2298383	C	T	.	.	PGKB_INDEX=2;PGKB_GENE=ADORA2A_(PA24584),ADORA2A_(PA24584);PGKB_DRUG=methotrexate_(PA450428),caffeine_(PA448710);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,2B;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434),NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_adverse_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_adverse_events_as_compared_to_patients_with_the_TT_genotype_or_may_have_an_increased_risk_for_adverse_events_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_adverse_events_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.","CC:Patients_with_the_CC_genotype_may_have_increased_anxiety_when_exposed_to_caffeine_as_compared_to_patients_with_the_CT_or_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_caffeine.""CT:Patients_with_the_CT_genotype_may_have_decreased_anxiety_when_exposed_to_caffeine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_caffeine.""TT:Patients_with_the_TT_genotype_may_have_decreased_anxiety_when_exposed_to_caffeine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_response_to_caffeine.";PGKB_RACE=White,NR
22	24826672	rs3761422	T	C	.	.	PGKB_INDEX=2;PGKB_GENE=ADORA2A_(PA24584),ADORA2A_(PA24584);PGKB_DRUG=methotrexate_(PA450428),caffeine_(PA448710);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434),Anxiety_Disorders_(PA447196);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_of_adverse_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_adverse_events_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_of_adverse_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_of_adverse_events_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.","CC:People_with_the_CT_genotype_may_have_decreased_Anxiety_Disorders_when_exposed_to_caffeine_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_anxiogenic_effect_of_caffeine.""CT:People_with_the_CT_genotype_may_have_decreased_Anxiety_Disorders_when_exposed_to_caffeine_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_the_anxiogenic_effect_of_caffeine.""TT:People_with_the_TT_genotype_may_have_increased_Anxiety_Disorders_when_exposed_to_caffeine_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_the_anxiogenic_effect_of_caffeine.";PGKB_RACE=White,NR
22	24830595	rs2267076	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ADORA2A_(PA24584);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_adverse_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_adverse_events_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_for_adverse_events_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_adverse_events_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_adverse_events_when_treated_with_methotrexate.";PGKB_RACE=White
22	24836024	rs2236624	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ADORA2A_(PA24584);PGKB_DRUG=methotrexate_(PA450428);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Arthritis_Rheumatoid_(PA443434);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_a_decreased_but_not_absent_risk_for_an_adverse_event_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_an_adverse_event.""CT:Patients_with_the_CT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_an_adverse_event_as_compared_to_patients_with_the_CC_genotype_or_may_have_a_decreased_but_not_absent_risk_for_an_adverse_event_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_an_adverse_event.""TT:Patients_with_the_TT_genotype_and_Rheumatoid_Arthritis_who_are_treated_with_methotrexate_may_have_an_increased_risk_for_an_adverse_event_as_compared_to_patients_with_the_CC_genotype.";PGKB_RACE=White
22	24837301	rs5751876	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=ADORA2A_(PA24584);PGKB_DRUG=caffeine_(PA448710);PGKB_TYPE="Dosage""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Individuals_with_the_CC_genotype_1)_may_be_less_sensitive_to_caffeine_and_less_likely_to_experience_anxiety_2)_may_consume_more_caffeine_as_compared_to_individuals_with_the_TT_genotype._Please_note_contradictory_results_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_an_individual's_response_to_caffeine.""CT:Individuals_with_the_CT_genotype_1)_may_be_less_sensitive_to_caffeine_and_less_likely_to_experience_anxiety_2)_may_consume_more_caffeine_as_compared_to_individuals_with_the_TT_genotype._Please_note_contradictory_results_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_an_individual's_response_to_caffeine.""TT:Individuals_with_the_TT_genotype_1)_may_be_more_sensitive_to_caffeine_and_more_likely_to_experience_anxiety_2)_may_consume_less_caffeine_as_compared_to_individuals_with_the_CC_genotype._Please_note_contradictory_results_have_been_reported._Other_genetic_and_clinical_factors_may_also_influence_an_individual's_response_to_caffeine.";PGKB_RACE=NR
22	29196757	rs2269577	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=XBP1_(PA37400);PGKB_DRUG=Platinum_compounds_(PA164713176);PGKB_TYPE="Efficacy""Toxicity/ADR";PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_non-small-cell_lung_cancer_may_have_a_decreased_risk_for_nausea_or_vomiting_and_be_more_likely_to_be_responders_to_treatment_when_receiving_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_nausea_or_vomiting_and_likelihood_of_being_a_responder_when_receiving_platinum-based_chemotherapy.""CG:No_significant_findings_available._""GG:Patients_with_the_GG_genotype_and_non-small-cell_lung_cancer_may_have_an_increased_risk_for_nausea_or_vomiting_and_be_less_likely_to_be_responders_to_treatment_when_receiving_with_platinum-based_chemotherapy_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_nausea_or_vomiting_and_likelihood_of_being_a_responder_when_receiving_platinum-based_chemotherapy.";PGKB_RACE=Asian
22	37096927	rs2284017	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=CACNG2_(PA26016);PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_response_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""CT:Patients_with_the_CT_genotype_may_have_increased_response_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.""TT:Patients_with_the_TT_genotype_may_have_decreased_response_to_lithium_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment.";PGKB_RACE=White
22	37097564	rs2284018	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CACNG2_(PA26016);PGKB_DRUG=lithium_(PA450243);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Bipolar_Disorder_(PA447199);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium.""CT:Patients_with_the_CT_genotype_and_Bipolar_Disorder_may_be_more_likely_to_respond_to_lithium_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._""TT:Patients_with_the_TT_genotype_and_Bipolar_Disorder_may_be_less_likely_to_respond_to_lithium_as_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_lithium._";PGKB_RACE=White
22	37256846	rs1883112	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=NCF4_(PA31465);PGKB_DRUG=doxorubicin_(PA449412);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Arrhythmias_Cardiac_(PA443421)""Drug_Toxicity_(PA443937)""Lymphoma_Non-Hodgkin_(PA444845)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""AG:Patients_with_the_AG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_a_decreased_but_not_absent_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""GG:Patients_with_the_GG_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubcin_may_have_a_decreased_but_not_absent_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.";PGKB_RACE=White
22	37632770	rs13058338	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=RAC2_(PA34163);PGKB_DRUG=doxorubicin_(PA449412);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Arrhythmias_Cardiac_(PA443421)""Drug_Toxicity_(PA443937)""Lymphoma_Non-Hodgkin_(PA444845)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_a_decreased_but_not_absent_risk_for_cardiotoxicity_as_compared_to_patients_with_the_TT_genotype._Please_note_the_risk_allele_reported_in_the_study_has_been_complemented_to_the_positive_chromosomal_strand_here._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""AT:Patients_with_the_AT_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype_or_may_have_a_decreased_but_not_absent_risk_for_cardiotoxicity_as_compared_to_patients_with_the_TT_genotype._Please_note_the_risk_allele_reported_in_the_study_has_been_complemented_to_the_positive_chromosomal_strand_here._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.""TT:Patients_with_the_TT_genotype_and_non-Hodgkin_lymphoma_who_are_treated_with_doxorubicin_may_have_an_increased_risk_for_cardiotoxicity_as_compared_to_patients_with_the_AA_genotype._Please_note_the_risk_allele_reported_in_the_study_has_been_complemented_to_the_positive_chromosomal_strand_here._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_cardiotoxicity.";PGKB_RACE=White
22	38371396	rs139887	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=SOX10_(PA36027);PGKB_DRUG="carboplatin_(PA448803)""docetaxel_(PA449383)""paclitaxel_(PA450761)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Ovarian_Neoplasms_(PA445204);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""CG:Patients_with_the_CG_genotype_and_ovarian_cancer_may_have_an_increased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_CC_or_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._""GG:Patients_with_the_GG_genotype_and_ovarian_cancer_may_have_a_decreased_risk_of_neurotoxicity_when_treated_with_carboplatin_in_combination_with_either_docetaxel_or_paclitaxel_as_compared_to_patients_with_the_CG_genotype._Other_genetic_and_clinical_factors_may_also_influence_risk_of_neurotoxicity._";PGKB_RACE=NR
22	38463652	rs2076369	T	G	.	.	PGKB_INDEX=1;PGKB_GENE=PICK1_(PA33760);PGKB_DRUG=methamphetamine_(PA450403);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Psychotic_Disorders_(PA447215)""Substance-Related_Disorders_(PA446876)";PGKB_TEXT="GG:Patients_with_the_GG_genotype_who_are_methamphetamine_abusers_may_have_a_decreased_but_not_absent_risk_for_spontaneous_relapse_of_psychosis_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_spontaneous_relapse_of_psychosis_with_methamphetamine_abuse.""GT:Patients_with_this_genotype_were_not_studied.""TT:Patients_with_the_TT_genotype_who_are_methamphetamine_abusers_may_have_an_increased_risk_for_spontaneous_relapse_of_psychosis_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_spontaneous_relapse_of_psychosis_with_methamphetamine_abuse.";PGKB_RACE=Asian
22	41227086	rs138335	C	G	.	.	PGKB_INDEX=1;PGKB_GENE=ST13_(PA36167);PGKB_DRUG=corticosteroids_(PA10832);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_asthma_may_have_an_increased_response_when_treated_with_inhaled_corticosteroids_as_compared_to_patients_with_the_CG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.""CG:Patients_with_the_CG_genotype_and_asthma_may_have_an_increased_response_when_treated_with_inhaled_corticosteroids_as_compared_to_patients_with_the_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_decreased_response_when_treated_with_inhaled_corticosteroids_as_compared_to_patients_with_the_CC_and_CG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.";PGKB_RACE=NR
22	41231053	rs138337	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ST13_(PA36167);PGKB_DRUG=corticosteroids_(PA10832);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Asthma_(PA443450);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_asthma_may_have_an_increased_response_when_treated_with_inhaled_corticosteroids_as_compared_to_patients_with_the_AG_and_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.""AG:Patients_with_the_AG_genotype_and_asthma_may_have_an_increased_response_when_treated_with_inhaled_corticosteroids_as_compared_to_patients_with_the_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.""GG:Patients_with_the_GG_genotype_and_asthma_may_have_a_decreased_response_when_treated_with_inhaled_corticosteroids_as_compared_to_patients_with_the_AA_and_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_response_to_corticosteroids_in_asthmatics.";PGKB_RACE=NR
22	42523943	rs16947	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=NR;PGKB_DRUG=timolol_(PA451690);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Bradycardia_(PA443548);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_open-angle_glaucoma_who_are_treated_with_timolol_may_have_an_increased_risk_for_bradycardia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bradycardia.""AG:Patients_with_the_AG_genotype_and_open-angle_glaucoma_who_are_treated_with_timolol_may_have_an_increased_risk_for_bradycardia_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bradycardia.""GG:Patients_with_the_GG_genotype_and_open-angle_glaucoma_who_are_treated_with_timolol_may_have_a_decreased_risk_for_bradycardia_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_bradycardia.";PGKB_RACE=Asian
22	42524947	rs3892097	C	T	.	.	PGKB_INDEX=5;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG="amitriptyline_(PA448385)""antidepressants_(PA452229)""clomipramine_(PA449048)""desipramine_(PA449233)""doxepin_(PA449409)""imipramine_(PA449969)""nortriptyline_(PA450657)""trimipramine_(PA451791)","citalopram_(PA449015)""escitalopram_(PA10074)""fluoxetine_(PA449673)""fluvoxamine_(PA449690)""paroxetine_(PA450801)""sertraline_(PA451333)",tamoxifen_(PA451581),venlafaxine_(PA451866),metoprolol_(PA450480);PGKB_TYPE="Dosage""Toxicity/ADR",Dosage,"Efficacy""Toxicity/ADR",Toxicity/ADR,Efficacy;PGKB_EVIDENCE=1A,3,2A,3,3;PGKB_DISEASE=Depression_(PA447278),Depression_(PA447278),Breast_Neoplasms_(PA443560),"Depression_(PA447278)""Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)""Diarrhea_(PA443899)""Drug_Toxicity_(PA443937)""Nausea_(PA445048)""Vomiting_(PA446051)",NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_(CYP2D6*1/*1)_and_depression_who_are_treated_with_tricyclic_antidepressants_1)_may_have_a_decreased_likelihood_of_switching_treatment_indicating_a_reduced_risk_of_side_effects_2)_may_require_an_increased_dose_of_drug_as_compared_to_patients_with_the_TT_genotype_(CYP2D6*4/*4)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_tricyclic_antidepressants_and_risk_of_adverse_effects._""CT:Patients_with_the_CT_genotype_(CYP2D6*1/*4)_and_depression_who_are_treated_with_tricyclic_antidepressants_1)_may_have_an_increased_likelihood_of_switching_treatment_indicating_an_increased_risk_of_side_effects_as_compared_to_patients_with_the_CC_genotype_(CYP2D6*1/*1)_2)_may_require_an_increased_dose_of_drug_as_compared_to_patients_with_the_TT_genotype_(CYP2D6*4/*4)_or_may_require_a_decreased_dose_of_drug_as_compared_to_patients_with_the_CC_genotype_(CYP2D6*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_tricyclic_antidepressants_and_risk_of_adverse_effects._""TT:Patients_with_the_TT_genotype_(CYP2D6*4/*4)_and_depression_who_are_treated_with_tricyclic_antidepressants_1)_may_have_an_increased_likelihood_of_switching_treatment_indicating_an_increased_risk_of_side_effects_2)_may_require_a_decreased_dose_of_drug_as_compared_to_patients_with_the_CC_genotype_(CYP2D6*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_tricyclic_antidepressants_and_risk_of_adverse_effects._","CC:Patients_with_the_CC_genotype_(CYP2D6*1/*1)_and_depression_may_require_a_higher_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_TT_genotype_(CYP2D6*4/*4)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirement._""CT:Patients_with_the_CT_genotype_(CYP2D6*1/*4)_and_depression_may_require_a_lower_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_CC_genotype_(CYP2D6*1/*1)_or_may_require_a_higher_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_TT_genotype_(CYP2D6*4/*4)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirement._""TT:Patients_with_the_TT_genotype_(CYP2D6*4/*4)_and_depression_may_require_a_lower_dose_of_citalopram_escitalopram_fluoxetine_fluvoxamine_paroxetine_or_sertraline_as_compared_to_patients_with_the_CC_genotype_(CYP2D6*1/*1)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_requirement._","CC:Patients_with_the_CC_genotype_who_are_treated_with_tamoxifen:_1)_may_have_a_decreased_but_not_absent_risk_of_relapse_as_compared_to_patients_with_the_TT_genotype_2)_may_have_an_increased_severity_in_hot_flashes_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_relapse.""CT:Patients_with_the_CT_genotype_who_are_treated_with_tamoxifen:_1)_may_have_a_decreased_but_not_absent_risk_of_relapse_as_compared_to_patients_with_the_TT_genotype_2)_may_have_an_increased_severity_in_hot_flashes_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_relapse.""TT:Patients_with_the_TT_genotype_who_are_treated_with_tamoxifen:_1)_may_have_an_increased_risk_of_relapse_as_compared_to_patients_with_the_CT_or_CC_genotype_2)_may_have_a_decreased_severity_in_hot_flashes_as_compared_to_patients_with_the_CT_or_CC_genotype.","CC:Patients_with_the_CC_genotype_who_are_treated_with_venlafaxine_may_have_1)_average_venlafaxine_plasma_concentration_2)_an_average_risk_of_adverse_effects_(but_check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_CT_or_TT_genotype._Contradictory_findings_have_been_reported_in_the_literature._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.""CT:Patients_with_the_CT_genotype_who_are_treated_with_venlafaxine_may_have_an_increased_risk_of_adverse_effects_(but_check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_CC_genotype._Contradictory_findings_have_been_reported_in_the_literature._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.""TT:Patients_with_the_TT_genotype_who_are_treated_with_venlafaxine_may_have_1)_increased_venlafaxine_plasma_concentration_2)_an_increased_risk_of_adverse_effects_(but_check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_CC_genotype._Contradictory_findings_have_been_reported_in_the_literature._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.","CC:Patients_with_CC_genotype_may_have_lower_plasma_concentrations_of_metoprolol_and_have_smaller_reductions_in_heart_rate_diastolic_blood_pressure_and_mean_arterial_pressure_when_treated_with_metoprolol_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol._Please_check_other_variants_for_PM_phenotype.""CT:Patients_with_CT_genotype_may_have_higher_plasma_concentrations_of_metoprolol_and_have_greater_reductions_in_heart_rate_diastolic_blood_pressure_and_mean_arterial_pressure_when_treated_with_metoprolol_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol._Please_check_other_variants_for_PM_phenotype.""TT:Patients_with_TT_genotype_may_have_higher_plasma_concentrations_of_metoprolol_and_have_greater_reductions_in_heart_rate_diastolic_blood_pressure_and_mean_arterial_pressure_when_treated_with_metoprolol_as_compared_to_patients_with_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol._Please_check_other_variants_for_PM_phenotype.";PGKB_RACE=White,White,NR,NR,White
22	42525085	rs5030655	CA	C	.	.	PGKB_INDEX=3;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=antipsychotics_(PA452233),venlafaxine_(PA451866),metoprolol_(PA450480);PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=NR,"Depression_(PA447278)""Depressive_Disorder_(PA447207)""Depressive_Disorder_Major_(PA447321)""Diarrhea_(PA443899)""Drug_Toxicity_(PA443937)""Nausea_(PA445048)""Vomiting_(PA446051)",NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_who_are_treated_with_antipsychotics_may_have_a_decreased_but_not_absent_risk_for_antipsychotic-induced_extrapyramidal_symptoms_as_compared_to_patients_with_the_DEL/A_or_DEL/DEL_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_with_antipsychotics.""DEL/A:Patients_with_the_DEL/A_genotype_who_are_treated_with_antipsychotics_may_have_an_increased_risk_for_antipsychotic-induced_extrapyramidal_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_with_antipsychotics.""DEL/DEL:Patients_with_the_DEL/DEL_genotype_who_are_treated_with_antipsychotics_may_have_an_increased_risk_for_antipsychotic-induced_extrapyramidal_symptoms_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_treatment_with_antipsychotics.","A/del:Patients_with_the_A/del_genotype_who_are_treated_with_venlafaxine_may_have_an_increased_risk_of_adverse_effects_(check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_A/A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.""AA:Patients_with_the_A/A_genotype_who_are_treated_with_venlafaxine_may_have_average_risk_of_adverse_effects_(check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_del/del_or_A/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_venlafaxine_may_have_an_increased_risk_of_adverse_effects_(check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_A/A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine.","A/del:Patients_with_the_A/del_genotype_who_are_treated_with_metoprolol_may_have_average_reponse_to_metoprolol_(check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol.""AA:Patients_with_the_AA_genotype_who_are_treated_with_metoprolol_may_have_average_reponse_to_metoprolol_(check_other_variants_for_PM_phenotype)_as_compared_to_patients_with_the_del/del_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol.""del/del:Patients_with_the_del/del_genotype_who_are_treated_with_metoprolol_may_have_an_greater_reduction_in_heart_rate_diastolic_blood_pressure_and_mean_arterial_pressure_as_compared_to_patients_with_the_A/del_or_A/A_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_metoprolol.";PGKB_RACE=White,White,White
22	42526694	rs1065852	G	A	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=iloperidone_(PA161199368),escitalopram_(PA10074);PGKB_TYPE=Toxicity/ADR,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Schizophrenia_(PA447216),Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_schizophrenia_may_have_a_decreased_QTc_interval_when_treated_with_iloperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_QTc_interval.""AG:Patients_with_the_AG_genotype_and_schizophrenia_may_have_a_decreased_QTc_interval_when_treated_with_iloperidone_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_QTc_interval.""GG:Patients_with_the_GG_genotype_and_schizophrenia_may_have_an_increased_QTc_interval_when_treated_with_iloperidone_as_compared_to_patients_with_the_AA_or_AG_genotype._Other_genetic_and_clinical_factors_may_also_influence_QTc_interval.","AA:Patients_with_the_AA_genotype_and_depression_may_have_a_decreased_response_and_remission_rate_when_treated_with_escitalopram_as_compared_to_patients_with_the_AG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients_response.""AG:Patients_with_the_AG_genotype_and_depression_may_have_a_increased_response_and_remission_rate_when_treated_with_escitalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients_response.""GG:Patients_with_the_GG_genotype_and_depression_may_have_a_increased_response_and_remission_rate_when_treated_with_escitalopram_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients_response.";PGKB_RACE=NR,Asian
22	42528382	rs1080985	C	G	.	.	PGKB_INDEX=2;PGKB_GENE=CYP2D6_(PA128),CYP2D6_(PA128);PGKB_DRUG=debrisoquine_(PA452616),thioridazine_(PA451666);PGKB_TYPE=Other,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_metabolism_of_debrisoquine_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_debrisoquine._""CG:Patients_with_the_CG_genotype_may_have_increased_metabolism_of_debrisoquine_as_compared_to_patients_with_the_GG_genotype_or_may_have_decreased_metabolism_of_debrisoquine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_debrisoquine._""GG:Patients_with_the_GG_genotype_may_have_decreased_metabolism_of_debrisoquine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_debrisoquine._","CC:Patients_with_the_CC_genotype_may_have_a_higher_thioridazine:mesoridazine_ratio_when_treated_with_thioridazine_as_compared_to_patients_with_the_CG_and_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_thioridazine.""CG_:Patients_with_the_CG_genotype_may_have_a_lower_thioridazine:mesoridazine_ratio_when_treated_with_thioridazine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_thioridazine.""GG:Patients_with_the_GG_genotype_may_have_a_lower_thioridazine:mesoridazine_ratio_when_treated_with_thioridazine_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_metabolism_of_thioridazine.";PGKB_RACE=NR,White
22	42528976	rs28360521	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=CYP2D6_(PA128);PGKB_DRUG=aspirin_(PA448497);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_gastrointestinal_bleeding_as_compared_to_patients_with_the_CT_and_TT_genotypes._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_gastrointestinal_bleeding_when_administered_aspirin.""CT:Patients_with_the_CT_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_gastrointestinal_bleeding_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_gastrointestinal_bleeding_when_administered_aspirin.""TT:Patients_with_the_TT_genotype_who_are_treated_with_aspirin_may_have_an_increased_risk_of_gastrointestinal_bleeding_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_gastrointestinal_bleeding_when_administered_aspirin.";PGKB_RACE=Asian
22	46553234	rs135550	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=PPARA_(PA280);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_reduction_in_fasting_LDL-C_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fenofibrate.""CT:Patients_with_the_CT_genotype_may_have_decreased_reduction_in_fasting_LDL-C_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fenofibrate.""TT:Patients_with_the_TT_genotype_may_have_increased_reduction_in_fasting_LDL-C_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fenofibrate.";PGKB_RACE=White
22	46555321	rs135543	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PPARA_(PA280);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_reduction_in_fasting_LDL-C_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotypes._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fenofibrate.""CT:Patients_with_the_CT_genotype_may_have_decreased_reduction_in_fasting_LDL-C_when_treated_with_fenofibrate_as_compared_to_patients_with_the_TT_genotypes._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fenofibrate.""TT:Patients_with_the_TT_genotype_may_have_increased_reduction_in_fasting_LDL-C_when_treated_with_fenofibrate_as_compared_to_patients_with_the_CC_or_CT_genotypes._Other_clinical_or_genetic_factors_may_also_influence_a_patient's_response_to_fenofibrate.";PGKB_RACE=White
22	46562183	rs9626730	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PPARA_(PA280);PGKB_DRUG=fenofibrate_(PA449594);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=NR;PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_reduction_in_fasting_IL-2_when_treated_with_fenofibrate_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fenofibrate.""CT:Patients_with_the_CT_genotype_may_have_decreased_reduction_in_fasting_IL-2_when_treated_with_fenofibrate_as_compared_to_patients_with_genotype_TT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fenofibrate.""TT:Patients_with_the_TT_genotype_may_have_decreased_reduction_in_fasting_IL-2_when_treated_with_fenofibrate_as_compared_to_patients_with_genotype_CC_or_CT._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_fenofibrate.";PGKB_RACE=White
22	46594035	rs149711321	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PPARA_(PA280);PGKB_DRUG=metformin_(PA450395);PGKB_TYPE="Efficacy""Metabolism/PK";PGKB_EVIDENCE=3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886);PGKB_TEXT="CC:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_CC_genotype_may_be_associated_with_an_increased_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_which_is_indicative_of_decreased_metformin_efficacy_as_compared_to_patients_with_the_TT_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.""CT:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_CT_genotype_may_be_associated_with_an_increased_secretory_clearance_of_metformin_leading_to_reduced_exposure_and_a_corresponding_increase_in_HbA1c_levels_indicative_of_a_decreased_metformin_efficacy_as_compared_to_patients_with_the_TT_genotype_and_a_decreased_secretory_clearance_of_metformin_and_a_corresponding_decrease_in_HbA1c_levels_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus._""TT:In_healthy_volunteers_as_well_as_patients_with_diabetes_mellitus_the_TT_genotype_may_be_associated_with_a_decreased_secretory_clearance_of_metformin_leading_to_increased_exposure_and_a_corresponding_decrease_in_HbA1c_levels_which_is_indicative_of_improved_metformin_efficacy_as_compared_to_patients_with_the_CC_genotype._Other_clinical_and_genetic_factors_may_also_influence_metformin_clearance_and_efficacy_in_patients_with_diabetes_mellitus.";PGKB_RACE=NR
22	46598307	rs4823613	A	G	.	.	PGKB_INDEX=2;PGKB_GENE=PPARA_(PA280),PPARA_(PA280);PGKB_DRUG=simvastatin_(PA451363),tacrolimus_(PA451578);PGKB_TYPE=Efficacy,Other;PGKB_EVIDENCE=3,3;PGKB_DISEASE=NR,Organ_Transplantation_(PA133888799);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(a_lower_reduction_in_total_cholesterol_and_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._A_separate_larger_study_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AG:Patients_with_the_AG_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(a_lower_reduction_in_total_cholesterol_and_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._A_separate_larger_study_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""GG:Patients_with_the_GG_genotype_may_have_a_better_response_to_simvastatin_treatment_(an_increased_reduction_in_total_cholesterol_and_LDL-cholesterol)_as_compared_to_patients_with_the_AA_genotype._A_seperate_larger_study_found_no_association._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","AA:Patients_with_the_AA_genotype_and_organ_transplantation_administered_tacrolimus_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_affect_metabolism_of_tacrolimus_in_organ_transplant_patients_administered_tacrolimus._""AG:Patients_with_the_AG_genotype_and_organ_transplantation_administered_tacrolimus_may_have_increased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_GG_genotype_and_decreased_metabolism_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_affect_metabolism_of_tacrolimus_in_organ_transplant_patients_administered_tacrolimus._""GG:Patients_with_the_GG_genotype_and_organ_transplantation_administered_tacrolimus_may_have_decreased_metabolism_of_tacrolimus_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_affect_metabolism_of_tacrolimus_in_organ_transplant_patients_administered_tacrolimus._";PGKB_RACE=NR,NR
22	46610067	rs4253728	G	A	.	.	PGKB_INDEX=3;PGKB_GENE=PPARA_(PA280),PPARA_(PA280),PPARA_(PA280);PGKB_DRUG=simvastatin_(PA451363),tacrolimus_(PA451578),phenprocoumon_(PA450921);PGKB_TYPE=Efficacy,Toxicity/ADR,Dosage;PGKB_EVIDENCE=3,3,3;PGKB_DISEASE=NR,Kidney_Transplantation_(PA165817016),NR;PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_a_better_response_to_simvastatin_treatment_(an_increased_reduction_in_total_cholesterol_and_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""AG:Patients_with_the_AG_genotype_may_have_a_better_response_to_simvastatin_treatment_(an_increased_reduction_in_total_cholesterol_and_LDL-cholesterol)_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._""GG:Patients_with_the_GG_genotype_may_have_a_reduced_response_to_simvastatin_treatment_(a_lower_reduction_in_total_cholesterol_and_LDL-cholesterol)_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_simvastatin_treatment._","AA:Patients_with_the_AA_genotype_and_Kidney_Transplantation_who_are_treated_with_tacrolimus_may_have_an_increased_risk_for_developing_new-onset_diabetes_after_transplantation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus._""AG:Patients_with_the_AG_genotype_and_Kidney_Transplantation_who_are_treated_with_tacrolimus_may_have_an_increased_risk_for_developing_new-onset_diabetes_after_transplantation_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus._""GG:Patients_with_the_GG_genotype_and_Kidney_Transplantation_who_are_treated_with_tacrolimus_may_have_a_decreased_but_not_absent_risk_for_developing_new-onset_diabetes_after_transplantation_as_compared_to_patients_with_the_AG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_tacrolimus._","AA:Patients_with_the_AA_genotype_who_are_treated_with_phenprocoumon_may_require_a_higher_dose_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_phenprocoumon.""AG:Patients_with_the_AG_genotype_who_are_treated_with_phenprocoumon_may_require_a_higher_dose_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_phenprocoumon.""GG:Patients_with_the_AG_genotype_who_are_treated_with_phenprocoumon_may_require_a_lower_dose_as_compared_to_patients_with_the_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_dose_of_phenprocoumon.";PGKB_RACE=NR,NR,NR
22	46630634	rs4253778	G	C	.	.	PGKB_INDEX=2;PGKB_GENE=PPARA_(PA280),PPARA_(PA280);PGKB_DRUG=fenofibrate_(PA449594),Beta_Blocking_Agents_(PA164712535);PGKB_TYPE=Efficacy,Efficacy;PGKB_EVIDENCE=3,3;PGKB_DISEASE=Diabetes_Mellitus_(PA443886),Coronary_Disease_(PA443797);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_diabetes_may_be_less_likely_to_respond_to_fenofibrate_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate._""CG:Patients_with_the_CG_genotype_and_diabetes_may_be_less_likely_to_respond_to_fenofibrate_treatment_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate._""GG:Patients_with_the_GG_genotype_and_diabetes_may_be_more_likely_to_respond_to_fenofibrate_treatment_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_response_to_fenofibrate._","CC:Patients_with_the_CC_genotype_and_acute_coronary_artery_syndrome_who_are_treated_with_beta_blockers_may_have_an_increased_chance_of_rehospitalization_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_rehospitalization.""CG:Patients_with_the_CG_genotype_and_acute_coronary_artery_syndrome_who_are_treated_with_beta_blockers_may_have_an_increased_chance_of_rehospitalization_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_rehospitalization.""GG:Patients_with_the_GG_genotype_and_acute_coronary_artery_syndrome_who_are_treated_with_beta_blockers_may_have_a_decreased_but_not_absent_chance_of_rehospitalization_as_compared_to_patients_with_the_CG_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_rehospitalization.";PGKB_RACE=NR,NR
22	50964236	rs11479	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=TYMP_(PA162407502);PGKB_DRUG="capecitabine_(PA448771)""fluorouracil_(PA128406956)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Neoplasms_(PA445062);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_cancer_may_have_an_increased_risk_of_drug_toxicity_when_administered_capecitabine_and/or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity_in_patients_with_cancer._""AG:Patients_with_the_AG_genotype_and_cancer_may_have_an_increased_risk_of_drug_toxicity_when_administered_capecitabine_and/or_fluorouracil_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity_in_patients_with_cancer._""GG:Patients_with_the_GG_genotype_and_cancer_may_have_a_decreased_risk_of_drug_toxicity_when_administered_capecitabine_and/or_fluorouracil_as_compared_to_patients_with_the_AA_and_AG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_the_risk_of_drug_toxicity_in_patients_with_cancer._";PGKB_RACE=NR
MT	1095	rs267606618	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=MT-RNR1_(PA31274);PGKB_DRUG=aminoglycoside_antibacterials_(PA452167);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Ototoxicity_(PA162263534);PGKB_TEXT="C:Patients_with_the_1095C_allele_may_have_a_greater_risk_of_experiencing_aminoglycoside-induced_hearing_loss_as_compared_to_patients_with_the_1095T_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_of_aminoglycoside-induced_hearing_loss""T:Patients_with_the_1095T_allele_may_have_a_lower_but_not_absent_risk_of_experiencing_aminoglycoside-induced_hearing_loss_as_compared_to_patients_with_the_1095C_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_of_aminoglycoside-induced_hearing_loss.";PGKB_RACE=NR
MT	1494	rs267606619	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=MT-RNR1_(PA31274);PGKB_DRUG=aminoglycoside_antibacterials_(PA452167);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE=Ototoxicity_(PA162263534);PGKB_TEXT="C:Patients_with_the_1494C_allele_may_have_a_lower_but_not_absent_risk_of_experiencing_aminoglycoside-induced_hearing_loss_as_compared_to_patients_with_the_1494T_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_of_aminoglycoside-induced_hearing_loss.""T:Patients_with_the_1494T_allele_may_have_a_greater_risk_of_experiencing_aminoglycoside-induced_hearing_loss_as_compared_to_patients_with_the_1494C_allele._In_the_majority_of_studies_every_individual_who_carried_the_1494T_allele_developed_hearing_loss_after_receiving_aminoglycoside_antibiotics._Almost_all_individuals_studied_were_homoplasmic_for_the_T_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_of_aminoglycoside-induced_hearing_loss.";PGKB_RACE=NR
MT	1555	rs267606617	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=MT-RNR1_(PA31274);PGKB_DRUG=aminoglycoside_antibacterials_(PA452167);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=1B;PGKB_DISEASE=Ototoxicity_(PA162263534);PGKB_TEXT="A:Patients_with_the_1555A_allele_may_have_a_lower_but_not_absent_risk_of_experiencing_aminoglycoside-induced_hearing_loss_as_compared_to_patients_with_the_1555G_allele._Other_genetic_and_clinical_factors_may_also_influence_risk_of_aminoglycoside-induced_hearing_loss.""G:Patients_with_the_1555G_allele_may_have_a_greater_risk_of_experiencing_aminoglycoside-induced_hearing_loss_as_compared_to_patients_with_the_1555A_allele._In_the_majority_of_studies_every_individual_who_carried_the_1555G_allele_developed_hearing_loss_after_receiving_aminoglycoside_antibiotics._Most_individuals_studied_were_homoplasmic_for_the_G_allele__it_is_unclear_how_heteroplasmy_affects_the_severity_or_occurrence_of_aminoglycoside-induced_hearing_loss._Other_genetic_and_clinical_factors_may_also_influence_risk_of_hearing_loss.";PGKB_RACE=NR
X	12903659	rs179008	A	C,T	.	.	PGKB_INDEX=1;PGKB_GENE=TLR7_(PA38008);PGKB_DRUG=imiquimod_(PA449972);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Carcinoma_Basal_Cell_(PA443613);PGKB_TEXT="A:Males_with_basal_cell_carcinoma_who_are_hemizygous_for_the_A_allele_may_have_a_better_response_to_treatment_with_imiquimod_as_compared_to_males_hemizygous_for_the_T_allele._Other_genetic_and_clinical_factors_may_also_influence_response_to_imiquimod_treatment._""T:Males_with_basal_cell_carcinoma_who_are_hemizygous_for_the_T_allele_may_have_a_poorer_response_to_treatment_with_imiquimod_as_compared_to_males_hemizygous_for_the_A_allele._Other_genetic_and_clinical_factors_may_also_influence_response_to_imiquimod_treatment._";PGKB_RACE=NR
X	15618061	rs2106809	A	G	.	.	PGKB_INDEX=1;PGKB_GENE=ACE2_(PA425);PGKB_DRUG=captopril_(PA448780);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Hypertension_(PA444552);PGKB_TEXT="AA:Women_with_the_AA_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_captopril_as_compared_to_women_with_the_GG_genotype._No_significant_differences_were_seen_when_considering_systolic_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_blood_pressure.""AG:Women_with_the_AG_genotype_and_hypertension_may_have_a_smaller_decrease_in_diastolic_blood_pressure_when_treated_with_captopril_as_compared_to_women_with_the_GG_genotype._No_significant_differences_were_seen_when_considering_systolic_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_blood_pressure.""GG:Women_with_the_GG_genotype_and_hypertension_may_have_a_greater_decrease_in_diastolic_blood_pressure_when_treated_with_captopril_as_compared_to_women_with_the_AA_or_AG_genotype._No_significant_differences_were_seen_when_considering_systolic_blood_pressure._Other_genetic_and_clinical_factors_may_also_influence_change_in_diastolic_blood_pressure.";PGKB_RACE=Asian
X	23695236	rs518329	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=PRDX4_(PA33725);PGKB_DRUG=docetaxel_(PA449383);PGKB_TYPE=Dosage;PGKB_EVIDENCE=4;PGKB_DISEASE=Carcinoma_Non-Small-Cell_Lung_(PA443622);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""CT:Patients_with_the_CT_genotype_may_have_increased_clearance_of_docetaxel_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.""TT:Patients_with_the_TT_genotype_may_have_decreased_clearance_of_docetaxel_compared_to_patients_with_the_CT_or_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_docetaxel_clearance.";PGKB_RACE=White
X	77268502	rs2227291	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=ATP7A_(PA72);PGKB_DRUG="docetaxel_(PA449383)""thalidomide_(PA451644)";PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Prostatic_Neoplasms_(PA445425);PGKB_TEXT="CC:Patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CG_or_GG_genotypes._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""CG:Patients_with_the_CG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.""GG:Patients_with_the_GG_genotype_may_have_an_increased_risk_of_toxicity_with_docetaxel_and_thalidomide_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_treatment_response.";PGKB_RACE=NR
X	113818282	rs3813928	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=HTR2C_(PA194);PGKB_DRUG=risperidone_(PA451257);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Autistic_Disorder_(PA447198);PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_worse_symptoms_and_a_poorer_response_to_risperidone_as_compared_to_patients_with_the_GG_genotype_in_autistic_children._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""AG:Patients_with_the_AG_genotype_may_have_worse_symptoms_and_a_poorer_response_to_risperidone_as_compared_to_patients_with_the_GG_genotype_in_autistic_children._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.""GG:Patients_with_the_GG_genotype_may_have_better_response_to_risperidone_as_compared_to_patients_with_the_AA_or_AG_genotype_in_autistic_children._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response.";PGKB_RACE=NR
X	113818520	rs3813929	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=HTR2C_(PA194);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=2B;PGKB_DISEASE="Schizophrenia_(PA447216)""Weight_gain_(PA128406954)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_psychiatric_disorders_or_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.""CT:Patients_with_the_CT_genotype_and_psychiatric_disorders_or_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.""TT:Patients_with_the_TT_genotype_and_psychiatric_disorders_or_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_weight_gain_with_olanzapine_treatment.";PGKB_RACE=White
X	113818582	rs518147	G	C	.	.	PGKB_INDEX=1;PGKB_GENE=HTR2C_(PA194);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Schizophrenia_(PA447216)""Weight_gain_(PA128406954)";PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_a_decreased_but_not_absent_risk_of_weight_gain_as_compared_to_patients_with_the_GG_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_weight_gain_with_olanzapine_treatment.""CG:Patients_with_the_CG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_weight_gain_with_olanzapine_treatment.""GG:Patients_with_the_GG_genotype_and_schizophrenia_who_are_treated_with_olanzapine_may_have_an_increased_risk_of_weight_gain_as_compared_to_patients_with_the_CC_genotype._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_weight_gain_with_olanzapine_treatment.";PGKB_RACE=White
X	113965735	rs6318	G	C	.	.	PGKB_INDEX=2;PGKB_GENE=HTR2C_(PA194),HTR2C_(PA194);PGKB_DRUG=escitalopram_(PA10074),olanzapine_(PA450688);PGKB_TYPE=Efficacy,Toxicity/ADR;PGKB_EVIDENCE=3,3;PGKB_DISEASE=neuropathic_pain_(PA162263525),"Schizophrenia_(PA447216)""Weight_gain_(PA128406954)";PGKB_TEXT="CC:Male_patients_with_neuropathic_pain_and_the_CC_genotype_may_have_increased_pain_relief_when_treated_with_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.""CG:Male_patients_with_the_CG_genotype_and_neuropathic_pain_may_have_increased_pain_relief_when_treated_with_escitalopram_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.""GG:Male_patients_with_the_GG_genotype_and_neuropathic_pain_may_have_decreased_pain_relief_when_treated_with_escitalopram_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_escitalopram.","CC:Patients_with_the_CC_genotype_and_schizophrenia_treated_with_olanzapine_may_have_an_increased_likelihood_for_tendency_of_olanzapine-induced_weight_as_compared_to_patients_the_genotype_GG._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_olanzapine-induced_weight_gain.""CG:Patients_with_the_CG_genotype_and_schizophrenia_treated_with_olanzapine_may_have_an_increased_likelihood_for_tendency_of_olanzapine-induced_weight_as_compared_to_patients_the_genotype_GG._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_olanzapine-induced_weight_gain.""GG:Patients_with_the_GG_genotype_and_schizophrenia_treated_with_olanzapine_may_have_decreased_likelihood_for_tendency_of_olanzapine-induced_weight_as_compared_to_patients_the_genotype_GG._However_contradictory_findings_are_reported._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_olanzapine-induced_weight_gain.";PGKB_RACE=NR,NR
X	113968341	rs2497538	C	A	.	.	PGKB_INDEX=1;PGKB_GENE=HTR2C_(PA194);PGKB_DRUG=olanzapine_(PA450688);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE=Weight_gain_(PA128406954);PGKB_TEXT="AA:Women_with_the_AA_genotype_and_mental_disorders_may_have_decreased_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_CC_genotype._No_significant_results_were_seen_for_men._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""AC:Women_with_the_AC_genotype_and_mental_disorders_may_have_increased_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_AA_genotype_or_decreased_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_CC_genotype._No_significant_results_were_seen_for_men._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""CC:Women_with_the_CC_genotype_and_mental_disorders_may_have_increased_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_AA_genotype._No_significant_results_were_seen_for_men._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.";PGKB_RACE=White
X	114138144	rs1414334	C	G	.	.	PGKB_INDEX=2;PGKB_GENE=HTR2C_(PA194),HTR2C_(PA194);PGKB_DRUG=olanzapine_(PA450688),"antipsychotics_(PA452233)""clozapine_(PA449061)""risperidone_(PA451257)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=3,2B;PGKB_DISEASE=Mental_Disorders_(PA447208),"Metabolic_Syndrome_X_(PA447159)""Schizophrenia_(PA447216)";PGKB_TEXT="CC:Women_with_the_CC_genotype_and_mental_disorders_(excluding_schizophrenia)_may_have_smaller_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""CG:Women_with_the_CG_genotype_and_mental_disorders_(excluding_schizophrenia)_may_have_greater_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_CC_genotype_or_smaller_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.""GG:Women_with_the_GG_genotype_and_mental_disorders_(excluding_schizophrenia)_may_have_greater_weight_gain_when_treated_with_olanzapine_as_compared_to_women_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_weight_gain.","CC:Patients_with_the_CC_genotype_who_are_treated_with_antipsychotics_may_have_an_increased_risk_of_developing_metabolic_syndrome_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_developing_metabolic_syndrome.""CG:Patients_with_the_CG_genotype_who_are_treated_with_antipsychotics_may_have_an_increased_risk_of_developing_metabolic_syndrome_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_developing_metabolic_syndrome.""GG:Patients_with_the_GG_genotype_who_are_treated_with_antipsychotics_may_have_a_decreased_but_not_absent_risk_of_developing_metabolic_syndrome_as_compared_to_patients_with_the_CG_and_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_for_developing_metabolic_syndrome.";PGKB_RACE=White,White
X	122316437	rs3761555	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GRIA3_(PA28968);PGKB_DRUG="antidepressants_(PA452229)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._";PGKB_RACE=Asian
X	122317244	rs3761554	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GRIA3_(PA28968);PGKB_DRUG="antidepressants_(PA452229)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_or_CT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._";PGKB_RACE=Asian
X	122441479	rs4825476	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=GRIA3_(PA28968);PGKB_DRUG=citalopram_(PA449015);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=3;PGKB_DISEASE="Depression_(PA447278)""suicide_(PA165374639)";PGKB_TEXT="AA:Patients_with_the_AA_genotype_may_have_decreased_risk_of_treatment-emergent_suicidal_ideation_when_treated_with_citalopram_in_people_with_depression_as_compared_to_patients_with_genotype_GG._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_citalopram.""AG:Patients_with_the_AG_genotype_may_have_increased_risk_of_treatment-emergent_suicidal_ideation_when_treated_with_citalopram_in_people_with_depression_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_citalopram.""GG:Patients_with_the_GG_genotype_may_have_increased_risk_of_treatment-emergent_suicidal_ideation_when_treated_with_citalopram_in_people_with_depression_as_compared_to_patients_with_genotype_AA._Other_genetic_and_clinical_factors_may_also_influence_the_response_to_citalopram.";PGKB_RACE=NR
X	122537277	rs502434	T	C	.	.	PGKB_INDEX=1;PGKB_GENE=GRIA3_(PA28968);PGKB_DRUG="antidepressants_(PA452229)""Selective_serotonin_reuptake_inhibitors_(PA164713257)""venlafaxine_(PA451866)";PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""CT:Patients_with_the_CT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_antidepressant_treatment_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_anti-depressant_treatment._";PGKB_RACE=Asian
X	128710213	rs113165732	C	T	.	.	PGKB_INDEX=1;PGKB_GENE=OCRL_(PA31896);PGKB_DRUG=tenofovir_(PA10204);PGKB_TYPE=Other;PGKB_EVIDENCE=4;PGKB_DISEASE=HIV_(PA447230);PGKB_TEXT="CC:Patients_with_the_CC_genotype_and_HIV_may_have_an_increased_creatinine_clearance_when_treated_with_tenofovir_as_compared_to_patients_with_the_CT_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_creatinine_clearance.""CT:Patients_with_the_CT_genotype_and_HIV_may_have_a_decreased_creatinine_clearance_when_treated_with_tenofovir_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_creatinine_clearance.""TT:Patients_with_the_TT_genotype_were_not_studied._However_patients_with_the_CT_genotype_and_HIV_may_have_a_decreased_creatinine_clearance_when_treated_with_tenofovir_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_effect_patients'_creatinine_clearance.";PGKB_RACE=NR
X	151821277	rs3810651	T	A	.	.	PGKB_INDEX=1;PGKB_GENE=GABRQ_(PA28504);PGKB_DRUG=venlafaxine_(PA451866);PGKB_TYPE=Efficacy;PGKB_EVIDENCE=3;PGKB_DISEASE=Depressive_Disorder_Major_(PA447321);PGKB_TEXT="AA:Patients_with_the_AA_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_venlafaxine_treatment_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""AT:Patients_with_the_AT_genotype_and_Major_Depressive_Disorder_may_be_more_likely_to_respond_to_venlafaxine_treatment_as_compared_to_those_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._""TT:Patients_with_the_TT_genotype_and_Major_Depressive_Disorder_may_be_less_likely_to_respond_to_venlafaxine_treatment_as_compared_to_those_with_the_AA_or_AT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_venlafaxine_treatment._";PGKB_RACE=Asian
X	153762634	rs5030868	G	A	.	.	PGKB_INDEX=1;PGKB_GENE=G6PD_(PA28469);PGKB_DRUG=glibenclamide_(PA449782);PGKB_TYPE=Toxicity/ADR;PGKB_EVIDENCE=4;PGKB_DISEASE=Diabetes_Mellitus_Type_2_(PA443890);PGKB_TEXT="A:Male_patients_with_the_A_genotype_(hemizygous_for_the_G6PD_Mediterranean_variant)_and_Type_2_diabetes_who_are_treated_with_glibenclamide_may_have_an_increased_risk_of_hemolysis_as_compared_to_patients_with_the_G_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""AA:Female_patients_with_the_AA_genotype_(homozygous_for_the_G6PD_Mediterranean_variant)_and_Type_2_diabetes_who_are_treated_with_glibenclamide_may_have_an_increased_risk_of_hemolysis_as_compared_to_patients_with_the_GG_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""AG:Female_patients_with_the_AG_genotype_(heterozygous_for_the_G6PD_Mediterranean_variant)_and_Type_2_diabetes_who_are_treated_with_glibenclamide_may_have_a_varying_degree_of_G6PD_deficient_red_blood_cells_and_an_unknown_risk_of_hemolysis_as_compared_to_patients_with_the_GG_or_AA_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""G:Male_patients_with_the_G_genotype_and_Type_2_diabetes_who_are_treated_with_glibenclamide_may_have_a_reduced_risk_of_hemolysis_as_compared_to_patients_with_the_A_genotype_(hemizygous_for_the_G6PD_Mediterranean_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._""GG:Female_patients_with_the_GG_genotype_and_Type_2_diabetes_who_are_treated_with_glibenclamide_may_have_a_reduced_risk_of_hemolysis_as_compared_to_patients_with_the_AA_genotype_(homozygous_for_the_G6PD_Mediterranean_variant)._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_drug-induced_hemolysis._";PGKB_RACE=NR
X	153764217	rs1050828	C	T	.	.	PGKB_INDEX=3;PGKB_GENE=G6PD_(PA28469),"G6PD_(PA28469)""IKBKG_(PA29777)",G6PD_(PA28469);PGKB_DRUG="amodiaquine_(PA448404)""pyrimethamine_(PA451193)""sulfadoxine_(PA451540)","artesunate_(PA165111697)""primaquine_(PA451103)""pyrimethamine_(PA451193)""sulfadoxine_(PA451540)","chlorproguanil_(PA165857067)""dapsone_(PA449211)";PGKB_TYPE=Toxicity/ADR,Toxicity/ADR,Toxicity/ADR;PGKB_EVIDENCE=4,3,1B;PGKB_DISEASE="Malaria_(PA444859)""Malaria_Falciparum_(PA446390)",NR,Malaria_(PA444859);PGKB_TEXT="CC:Children_with_the_CC_genotype_and_malaria_who_are_treated_with_amodiaquine_pyrimethamine_and_sulfadoxine_may_have_an_reduced_risk_of_requiring_a_blood_transfusion_as_compared_to_children_with_the_CT_or_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_severe_hemolysis._""CT:Children_with_the_CT_genotype_and_malaria_who_are_treated_with_amodiaquine_pyrimethamine_and_sulfadoxine_may_have_an_increased_risk_of_requiring_a_blood_transfusion_as_compared_to_children_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_severe_hemolysis._""TT:Children_with_the_TT_genotype_and_malaria_who_are_treated_with_amodiaquine_pyrimethamine_and_sulfadoxine_may_have_an_increased_risk_of_requiring_a_blood_transfusion_as_compared_to_children_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_risk_of_severe_hemolysis._","CC:Pediatric_patients_with_the_CC_genotype_may_have_decreased_but_not_absent_risk_of_moderate_anemia_when_treated_with_artesunate_primaquine_pyrimethamine_and_sulfadoxine_as_compared_to_pediatric_patients_with_the_CT_and_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_risk_of_toxicity_to_artesunate_primaquine_pyrimethamine_and_sulfadoxine.""CT:Pediatric_patients_with_the_CT_genotype_may_have_an_increased_risk_of_moderate_anemia_when_treated_with_artesunate_primaquine_pyrimethamine_and_sulfadoxine_as_compared_to_pediatric_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_risk_of_toxicity_to_artesunate_primaquine_pyrimethamine_and_sulfadoxine.""TT:Pediatric_patients_with_the_TT_genotype_may_have_an_increased_risk_of_moderate_anemia_when_treated_with_artesunate_primaquine_pyrimethamine_and_sulfadoxine_as_compared_to_pediatric_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patients_risk_of_toxicity_to_artesunate_primaquine_pyrimethamine_and_sulfadoxine.","CC:Patients_with_the_CC_genotype_with_Malaria_who_are_treated_with_artesunate_chlorproguanil_and_dapsone_may_have_1)_a_decreased_but_not_absent_risk_of_hemolysis_and_severe/_unsafe_hemoglobin_decreases_2)_decreased_but_not_absent_risk_of_requiring_a_blood_transfusion_as_compared_to_patients_with_the_TT_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_artesunate_chlorproguanil_and_dapsone.""CT:Patients_with_the_CT_genotype_with_Malaria_who_are_treated_with_artesunate_chlorproguanil_and_dapsone_may_have_an_increased_risk_of_requiring_a_blood_transfusion_as_compared_to_patients_with_the_CC_genotype._This_association_was_contradicted_in_another_study_showing_no_association_of_the_CT_genotype_with_increased_risk_of_unsafe_hemoglobin_decreases_or_requirement_for_a_blood_transfusion_when_treated_with_artesunate_chlorproguanil_and_dapsone_compared_to_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_artesunate_chlorproguanil_and_dapsone.""TT:Patients_with_the_TT_genotype_with_Malaria_who_are_treated_with_artesunate_chlorproguanil_and_dapsone_may_have_1)_an_increased_risk_of_hemolysis_and_severe/_unsafe_hemoglobin_decreases_2)_an_increased_risk_of_requiring_a_blood_transfusion_as_compared_to_patients_with_the_CC_genotype._Other_genetic_and_clinical_factors_may_also_influence_a_patient's_response_to_artesunate_chlorproguanil_and_dapsone.";PGKB_RACE=Black_or_African_American,Black_or_African_American,Black_or_African_American
